PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Canaan, S; Zadori, Z; Ghomashchi, F; Bollinger, J; Sadilek, M; Moreau, ME; Tijssen, P; Gelb, MH				Canaan, S; Zadori, Z; Ghomashchi, F; Bollinger, J; Sadilek, M; Moreau, ME; Tijssen, P; Gelb, MH			Interfacial enzymology of parvovirus phospholipases A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; PORCINE PARVOVIRUS; CAPSID PROTEIN; VIRUS TYPE-2; GROUP-II; GROUP-V; GROUP-X; BINDING; INFECTIVITY; VESICLES	The capsid of parvoviruses proteins were recently shown to contain secreted phospholipase A(2) (sPLA(2))-like activity that is required during host cell entry. Parvoviral PLA(2) domains have little sequence identity with sPLA(2)s and lack disulfide bonds. In the present study, after bacterial expression and purification, the biochemical characterizations of these first PLA(2)s identified in viruses have been investigated, and a comparison has been made with other known PLA(2)s. The specific activities of three viral PLA(2)s differed by 3 orders of magnitude, with porcine parvovirus PLA(2) displaying a specific activity similar to that of the most active sPLA(2)s (e.g. human group IIA) and the human AAV2 and B19 parvoviral enzymes displaying approximately 10(3) lower specific activities (similar to human sPLA(2) groups IIE and XIIA). These differences were not caused by weaker Ca2+ or interfacial binding. The specific activities of the viral PLA(2)s on zwitterionic or anionic phospholipid vesicles were comparable. The viral PLA(2)s did not display a preference for unsaturated versus saturated sn-2 fatty acyl chains and hydrolyzed all major classes of glycero-phospholipids except phosphatidylinositol. Incubation of mammalian cells with porcine parvovirus PLA(2) led to the release of arachidonic acid into the culture medium. Interestingly, among nine previously known sPLA(2) inhibitors, only a subset showed inhibition of the viral PLA(2)s and with weak potency, indicating that the active sites of these new enzymes are structurally distinct from those of sPLA(2)s. Based on these distinct enzymatic and structural properties, we propose to classify the parvovirus PLA(2)s within the PLA(2) superfamily as group XIII enzymes.	Univ Washington, Dept Chem & Biochem, Seattle, WA 98195 USA; CNRS, UMR Architecture & Fonct Macromol Biol 6098, Dept Chem & Biochem, F-13402 Marseille 20, France; Univ Quebec, Inst Armand Frappier, INRS, Dept Chem & Biochem, Laval, PQ H7V 1B7, Canada	University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Quebec; Institut national de la recherche scientifique (INRS)	Tijssen, P (corresponding author), Univ Washington, Dept Chem & Biochem, Box 351700, Seattle, WA 98195 USA.	peter.tijssen@inrs-iaf.uquebec.ca; gelb@chem.washington.edu		gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL36235] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036235, R37HL036235, R23HL036235] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; Beers SA, 2002, J BIOL CHEM, V277, P1788, DOI 10.1074/jbc.M109777200; Bergeron J, 1996, J VIROL, V70, P2508, DOI 10.1128/JVI.70.4.2508-2515.1996; Bezzine S, 2002, J BIOL CHEM, V277, P48523, DOI 10.1074/jbc.M203137200; BROWN KE, 1989, BRIT J OBSTET GYNAEC, V96, P764, DOI 10.1111/j.1471-0528.1989.tb03313.x; Canaan S, 2002, J BIOL CHEM, V277, P30984, DOI 10.1074/jbc.M203649200; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; Girod A, 2002, J GEN VIROL, V83, P973, DOI 10.1099/0022-1317-83-5-973; HERMONAT PL, 1984, J VIROL, V51, P329, DOI 10.1128/JVI.51.2.329-339.1984; KAWASE M, 1995, VIROLOGY, V211, P359, DOI 10.1006/viro.1995.1418; Kinkaid Adrian R., 1997, Biochemical Society Transactions, V25, p497S; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Koprivnjak T, 2002, J BIOL CHEM, V277, P47636, DOI 10.1074/jbc.M205104200; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Rouault M, 2003, BIOCHEMISTRY-US, V42, P11494, DOI 10.1021/bi0349930; Simpson AA, 2002, J MOL BIOL, V315, P1189, DOI 10.1006/jmbi.2001.5319; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; TELERMAN A, 1993, P NATL ACAD SCI USA, V90, P8702, DOI 10.1073/pnas.90.18.8702; TSAO FHC, 1991, BIOCHIM BIOPHYS ACTA, V1081, P141, DOI 10.1016/0005-2760(91)90019-E; TULLIS GE, 1993, J VIROL, V67, P131, DOI 10.1128/JVI.67.1.131-141.1993; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; Weinrauch Y, 1996, J CLIN INVEST, V97, P250, DOI 10.1172/JCI118399; YU BZ, 1993, BIOCHEMISTRY-US, V32, P6485, DOI 10.1021/bi00076a024; Zadori Z, 2001, DEV CELL, V1, P291, DOI 10.1016/S1534-5807(01)00031-4	29	93	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14502	14508		10.1074/jbc.M312630200	http://dx.doi.org/10.1074/jbc.M312630200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14726513	hybrid			2022-12-25	WOS:000220594700007
J	Hagner-McWhirter, A; Li, JP; Oscarson, S; Lindahl, U				Hagner-McWhirter, A; Li, JP; Oscarson, S; Lindahl, U			Irreversible glucuronyl C5-epimerization in the biosynthesis of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN/HEPARAN SULFATE; SUBSTRATE-SPECIFICITY; C-5 EPIMERASE; ACID; PROTEOGLYCANS; DOMAIN; UNITS	Glucuronyl C5-epimerase catalyzes the conversion of D-glucuronic acid to L-iduronic acid units in heparan sulfate biosynthesis. Substrate recognition depends on the N-substituent pattern of the heparan sulfate precursor polysaccharide and requires the adjacent glucosamine residue toward the non-reducing end to be N-sulfated. Epimerization of an appropriately N-sulfated substrate is freely reversible in a soluble system, with equilibrium favoring retention of D-gluco configuration (Hagner-McWhirter, Angstrom., Lindahl, U., and Li, J.- P. ( 2000) Biochem. J. 347, 69 - 75). We studied the reversibility of the epimerase reaction in a cellular system, by incubating human embryonic kidney 293 cells with D-[5-H-3] galactose. The label was incorporated with glucuronic acid units into the heparan sulfate precursor polysaccharide and was lost upon subsequent C5-epimerization to iduronic acid. However, analysis of oligosaccharides obtained by deaminative cleavage of the mature heparan sulfate chains indicated that all glucuronic acid units retained their C5-H-3 label, irrespective of whether they had occurred in sequences susceptible or resistant to the epimerase. All H-3-labels of the final products resisted incubation with epimerase in a soluble system, apparently due to blocking O-sulfate groups. These results indicate that glucuronic acid C5-epimerization is effectively irreversible in vivo and argue for a stringent organization of the biosynthetic machinery.	Univ Uppsala, Ctr Biomed, Dept Med Biochem & Biochem, S-75123 Uppsala, Sweden; Stockholm Univ, Arrhenius Lab, Dept Organ Chem, S-10691 Stockholm, Sweden	Uppsala University; Stockholm University	Li, JP (corresponding author), Univ Uppsala, Ctr Biomed, Dept Med Biochem & Biochem, Box 582, S-75123 Uppsala, Sweden.	jin-ping.li@imbim.uu.se		Oscarson, Stefan/0000-0002-8273-4918				Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; CONRAD HE, 1998, HEPARIN BINDING PROT, P22; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Hagner-McWhirter A, 2000, BIOCHEM J, V347, P69, DOI 10.1042/0264-6021:3470069; ISUDA Y, 1989, CHEM PHARM BULL, V37, P2344; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MALMSTROM A, 1981, BIOCHEM J, V198, P669, DOI 10.1042/bj1980669; MORGENLIE S, 1973, ACTA CHEM SCAND, V27, P3609, DOI 10.3891/acta.chem.scand.27-3609; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; SHIVELY JE, 1970, BIOCHEMISTRY-US, V9, P33, DOI 10.1021/bi00803a005; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Smeds E, 2003, BIOCHEM J, V372, P371, DOI 10.1042/BJ20021665; SMITS NC, 2003, AM J RESP CELL MOL B; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303	32	31	33	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14631	14638		10.1074/jbc.M313760200	http://dx.doi.org/10.1074/jbc.M313760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14718527	hybrid			2022-12-25	WOS:000220594700021
J	Misevic, GN; Guerardel, Y; Sumanovski, LT; Slomianny, MC; Demarty, M; Ripoll, C; Karamanos, Y; Maes, E; Popescu, O; Strecker, G				Misevic, GN; Guerardel, Y; Sumanovski, LT; Slomianny, MC; Demarty, M; Ripoll, C; Karamanos, Y; Maes, E; Popescu, O; Strecker, G			Molecular recognition between glyconectins as an adhesion self-assembly pathway to multicellularity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGE MICROCIONA-PROLIFERA; GAS-LIQUID-CHROMATOGRAPHY; AGGREGATION FACTOR; CELL-ADHESION; MASS SPECTROMETRY; METHYL-GLYCOSIDES; PROTEOGLYCANS; PROTEIN; BINDING; AFFINITY	The appearance of multicellular forms of life has been tightly coupled to the ability of an organism to retain its own anatomical integrity and to distinguish self from non-self. Large glycoconjugates, which make up the outermost cell surface layer of all Metazoans, are the primary candidates for the primordial adhesion and recognition functions in biological self-assembly systems. Atomic force microscopy experiments demonstrated that the binding strength between a single pair of Porifera cell surface glyconectin 1 glycoconjugates from Microciona prolifera can hold the weight of 1600 cells, proving their adhesion functions. Here, measurement of molecular self-recognition of glyconectins (GNs) purified from three Porifera species was used as an experimental model for primordial xenogeneic self/non-self discrimination. Physicochemical and biochemical characterization of the three glyconectins, their glycans, and peptides using gel electrophoresis, ultracentrifugation, NMR, mass spectrometry, glycosaminoglycan-degrading enzyme treatment, amino acid and carbohydrate analyses, and peptide mapping showed that GNs define a new family of proteoglycan-like molecules exhibiting species-specific structures with complex and repetitive acidic carbohydrate motives different from the classical proteoglycans and mucins. In functional self-assembly color-coded bead, cell, and blotting assays, glyconectins displayed species-specific recognition and adhesion. Affinity-purified monospecific polyclonal antibodies prepared against GN1, -2, and -3 glycans selectively inhibited cell adhesion of the respective sponge species. These results together with species-specific coaggregation of GN carbohydrate-coated beads with cells showed that GN glycans are functional in cell recognition and adhesion. The specificity of carbohydrate-mediated homophilic GN interactions in Porifera approaches the binding selectivity of the evolutionarily advanced immunoglobulin superfamily. Xenoselectivity of primordial glyconectin to glyconectin recognition may be a new paradigm in the self-assembly and non-self discrimination pathway of cellular adhesion leading to multicellularity.	Fac Sci & Tech Rouen, CNRS, UMR 6037, Lab Proc Integrat Cellulaires, F-76821 Mont St Aignan, France; Univ Sci & Technol Lille, CNRS, UMR 8576, Unite Glycobiol Struct & Fonct, F-59655 Villeneuve Dascq, France; Univ Basel Hosp, Dept Res, CH-4058 Basel, Switzerland; Univ Artois, Fac J Perrin, Lab Biochim Mol & Cellulaire, F-62307 Lens, France; Univ Babes Bolyai, Ctr Mol Biol, Cluj Napoca 400006, Romania; Univ Babes Bolyai, Inst Interdisciplinary Expt Res, Cluj Napoca 400006, Romania	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; University of Basel; Universite d'Artois; Babes Bolyai University from Cluj; Babes Bolyai University from Cluj	Misevic, GN (corresponding author), Fac Sci & Tech Rouen, CNRS, UMR 6037, Lab Proc Integrat Cellulaires, F-76821 Mont St Aignan, France.	gradimir@gradimir.com	Karamanos, Yannis/AAE-9379-2020; Popescu, Octavian/E-4942-2010; Popescu, Octavian/O-2134-2019; Misevic, Gradimir/D-8294-2016; Popescu, Octavian/C-4027-2011	Karamanos, Yannis/0000-0002-2411-6636; Popescu, Octavian/0000-0002-2597-7155; Popescu, Octavian/0000-0002-2597-7155; Misevic, Gradimir/0000-0001-5047-2936; Guerardel, Yann/0000-0003-4967-9512				BRUNE DC, 1992, ANAL BIOCHEM, V207, P285, DOI 10.1016/0003-2697(92)90013-W; CAULDWELL CB, 1973, BIOCHEMISTRY-US, V12, P3051, DOI 10.1021/bi00740a017; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; CURTIS ASG, 1962, NATURE, V196, P245, DOI 10.1038/196245a0; DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599; DUDMAN WF, 1986, CARBOHYD RES, V145, P175, DOI 10.1016/S0008-6215(00)90428-2; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; FernandezBusquets X, 1996, J BIOL CHEM, V271, P23558, DOI 10.1074/jbc.271.38.23558; GALLAGHER JT, 1995, ADV EXP MED BIOL, V376, P125; GALSTOFF PS, 1925, J EXP ZOOL, V42, P183; Guerardel Y, 2004, J BIOL CHEM, V279, P15591, DOI 10.1074/jbc.M308928200; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; Haseley SR, 2001, P NATL ACAD SCI USA, V98, P9419, DOI 10.1073/pnas.151111298; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Jarchow J, 2000, J STRUCT BIOL, V132, P95, DOI 10.1006/jsbi.2000.4309; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; Maes E, 1999, ANAL BIOCHEM, V267, P300, DOI 10.1006/abio.1998.2967; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1982, J BIOL CHEM, V257, P6931; MISEVIC GN, 1995, J MOL RECOGNIT, V8, P100, DOI 10.1002/jmr.300080118; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; MISEVIC GN, 1989, METHOD ENZYMOL, V179, P95; MISEVIC GN, 1991, TRENDS GLYCOSCI GLYC, V3, P400; MOSCONA AA, 1968, DEV BIOL, V18, P250, DOI 10.1016/0012-1606(68)90035-3; MULLER WEG, 1973, EXP CELL RES, V80, P95, DOI 10.1016/0014-4827(73)90279-6; Popescu O, 1997, NATURE, V386, P231, DOI 10.1038/386231b0; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; SPILLMANN D, 1995, J BIOL CHEM, V270, P5089, DOI 10.1074/jbc.270.10.5089; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wilson H.V., 1910, B BUR FISH, V30, P1; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204; Zanetta JP, 1999, GLYCOBIOLOGY, V9, P255, DOI 10.1093/glycob/9.3.255	40	23	26	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15579	15590		10.1074/jbc.M308927200	http://dx.doi.org/10.1074/jbc.M308927200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14701844	hybrid			2022-12-25	WOS:000220594700130
J	Rakhit, R; Crow, JP; Lepock, JR; Kondejewski, LH; Cashman, NR; Chakrabartty, A				Rakhit, R; Crow, JP; Lepock, JR; Kondejewski, LH; Cashman, NR; Chakrabartty, A			Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU/ZN-SUPEROXIDE-DISMUTASE; ASTROCYTIC HYALINE INCLUSIONS; BODY-LIKE INCLUSIONS; TRANSGENIC MICE; PROTEIN AGGREGATION; MOTOR-NEURONS; MUTANT SOD1; COPPER; ENZYME; SUPEROXIDE-DISMUTASE-1	Proteinacious intracellular aggregates in motor neurons are a key feature of both sporadic and familial amyotrophic lateral sclerosis (ALS). These inclusion bodies are often immunoreactive for Cu, Zn-superoxide dismutase (SOD1) and are implicated in the pathology of ALS. On the basis of this and a similar clinical presentation of symptoms in the familial (fALS) and sporadic forms of ALS, we sought to investigate the possibility that there exists a common disease-related aggregation pathway for fALS-associated mutant SODs and wild type SOD1. We have previously shown that oxidation of fALS-associated mutant SODs produces aggregates that have the same morphological, structural, and tinctorial features as those found in SOD1 inclusion bodies in ALS. Here, we show that oxidative damage of wild type SOD at physiological concentrations (similar to 40 muM) results in destabilization and aggregation in vitro. Oxidation of either mutant or wild type SOD1 causes the enzyme to dissociate to monomers prior to aggregation. Only small changes in secondary and tertiary structure are associated with monomer formation. These results indicate a common aggregation prone monomeric intermediate for wild type and fALS-associated mutant SODs and provides a link between sporadic and familial ALS.	Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 2M9, Canada; Univ Arkansas Med Sci, Coll Med, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; Caprion Pharmaceut Inc, St Laurent, PQ H4S 2C8, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Sunnybrook & Womens Coll Hosp, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Arkansas System; University of Arkansas Medical Sciences; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Chakrabartty, A (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.	chakrab@uhnres.utoronto.ca		Chakrabartty, Avi/0000-0001-7002-8381				Andrus PK, 1998, J NEUROCHEM, V71, P2041; Banci L, 1998, BIOCHEMISTRY-US, V37, P11780, DOI 10.1021/bi9803473; Battistoni A, 1998, J BIOL CHEM, V273, P5655, DOI 10.1074/jbc.273.10.5655; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Borchelt DR, 1998, NEUROBIOL DIS, V5, P27, DOI 10.1006/nbdi.1998.0178; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chou SM, 1999, J NEUROL SCI, V169, P87, DOI 10.1016/S0022-510X(99)00222-1; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Crow JP, 1997, J NEUROCHEM, V69, P1936; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Kato S, 2001, NEUROPATHOLOGY, V21, P67, DOI 10.1046/j.1440-1789.2001.00359.x; Kato S, 1999, HISTOL HISTOPATHOL, V14, P973, DOI 10.14670/HH-14.973; Kato S, 1997, AM J PATHOL, V151, P611; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; Koide T, 1998, NEUROSCI LETT, V257, P29, DOI 10.1016/S0304-3940(98)00800-3; KUROBE N, 1990, CLIN CHIM ACTA, V187, P11, DOI 10.1016/0009-8981(90)90257-S; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Liu HB, 2000, BIOCHEMISTRY-US, V39, P8125, DOI 10.1021/bi000846f; Majoor-Krakauer D, 2003, CLIN GENET, V63, P83, DOI 10.1046/j.0009-9163.2002.00001.x; Matsumoto S, 1996, CLIN NEUROPATHOL, V15, P41; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; NOBLE J, 2001, NOBLE TXB PRIMARY CA, P1089; OKAMOTO K, 1991, NEUROSCI LETT, V129, P233, DOI 10.1016/0304-3940(91)90469-A; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Peterson SA, 1998, P NATL ACAD SCI USA, V95, P12956, DOI 10.1073/pnas.95.22.12956; Piao YS, 2003, BRAIN PATHOL, V13, P10; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; SHIBATA N, 1994, NEUROSCI LETT, V179, P149, DOI 10.1016/0304-3940(94)90956-3; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; UCHINO M, 1994, J NEUROL SCI, V127, P61, DOI 10.1016/0022-510X(94)90136-8; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	40	259	269	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15499	15504		10.1074/jbc.M313295200	http://dx.doi.org/10.1074/jbc.M313295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14734542	hybrid			2022-12-25	WOS:000220594700121
J	Jarving, R; Jarving, I; Kurg, R; Brash, AR; Samel, N				Jarving, R; Jarving, I; Kurg, R; Brash, AR; Samel, N			On the evolutionary origin of cyclooxygenase (COX) isozymes - Characterization of marine invertebrate COX genes points to independent duplication events in vertebrate and invertebrate lineages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; MESSENGER-RNA; 3'-UNTRANSLATED REGION; POSTTRANSCRIPTIONAL REGULATION; CIONA-INTESTINALIS; PLEXAURA-HOMOMALLA; MOLECULAR-CLONING; BINDING PROTEIN; H SYNTHASE-1; G/H SYNTHASE	In vertebrates, COX-1 and COX-2, two cyclooxygenase isozymes with different physiological functions and gene regulation, catalyze identical reactions in prostaglandin synthesis. It is still not understood why there are multiple forms of COX enzyme in the same cell type and when the evolutionary duplication of the COX gene occurred. Here we report the structure of two genes encoding for COX isozymes in the coral Gersemia fruticosa, the first non-vertebrate organism from which a cyclooxygenase was characterized. Both genes are about 20 kb in size and consist of nine exons. Intron/exon boundaries are well conserved between coral and mammalian COX genes. mRNAs of the previously reported G. fruticosa COX-A (GenBank(TM) accession number AY004222) and the novel COX-B share 94% sequence identity in the coding regions and less than 30% in the 5'- and 3'-untranslated region. Transcripts of both COX genes are detectable in coral cells, although the transcriptional level of COX-A is 2 orders of magnitude higher than COX-B. Expression of both coral genes in mammalian cells gave functional proteins with similar catalytic properties. By data base analyses we also detected and constructed different pairs of COX genes from the primitive chordates, Ciona savignyi and Ciona intestinalis. These two gene pairs encode proteins with 50% intra-species and only 70% cross-species sequence identity. Our results suggest that invertebrate COX gene pairs do not correspond to vertebrate COX-1 and COX-2 and are consistent with duplication of the COX gene having occurred independently in corals, ascidians, and vertebrates. It is evident that due to the importance and complexity of its regulatory role, COX has multiple isoforms in all organisms known to express it, and the genes encoding for the isozymes may to be regulated differently.	Tallinn Univ Technol, Dept Chem, EE-12618 Tallinn, Estonia; Univ Tartu, Inst Technol, EE-51010 Tartu, Estonia; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Tallinn University of Technology; University of Tartu; Vanderbilt University	Samel, N (corresponding author), Tallinn Univ Technol, Dept Chem, Akad Tee 15, EE-12618 Tallinn, Estonia.	samel@chemnet.ee	Samel, Nigulas/A-1420-2019; Kurg, Reet/J-2829-2015	Kurg, Reet/0000-0001-7188-9693	NIGMS NIH HHS [GM-53638] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Bandyopadhyay PK, 2002, P NATL ACAD SCI USA, V99, P1264, DOI 10.1073/pnas.022637099; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Boerboom D, 1998, ENDOCRINOLOGY, V139, P1662, DOI 10.1210/en.139.4.1662; BRASH AR, 1987, J BIOL CHEM, V262, P15829; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; COREY EJ, 1973, J AM CHEM SOC, V95, P2054, DOI 10.1021/ja00787a079; Dean JLE, 2002, BIOCHEM J, V366, P709, DOI 10.1042/BJ20020402; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Deutsch M, 1999, NUCLEIC ACIDS RES, V27, P3219, DOI 10.1093/nar/27.15.3219; DEWITT DL, 1989, ADV PROSTAG THROMB L, V19, P454; Duquette M, 2002, J BIOL CHEM, V277, P44631, DOI 10.1074/jbc.M207007200; Faour WH, 2003, J BIOL CHEM, V278, P26897, DOI 10.1074/jbc.M212790200; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Garavito RM, 2002, PROSTAG OTH LIPID M, V68-9, P129; Grosser T, 2002, P NATL ACAD SCI USA, V99, P8418, DOI 10.1073/pnas.112217799; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Hla T, 1996, PROSTAG OTH LIPID M, V51, P81, DOI 10.1016/0090-6980(95)00158-1; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13; Kaldalu N, 2000, BIOTECHNIQUES, V28, P456, DOI 10.2144/00283st02; Knight J, 1999, BBA-MOL CELL BIOL L, V1436, P467, DOI 10.1016/S0005-2760(98)00153-2; Koljak R, 2001, J BIOL CHEM, V276, P7033, DOI 10.1074/jbc.M009803200; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; Kulmacz RJ, 2003, PROG LIPID RES, V42, P377, DOI 10.1016/S0163-7827(03)00023-7; Kurg R, 1999, J VIROL, V73, P4670, DOI 10.1128/JVI.73.6.4670-4677.1999; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai EC, 1997, DEVELOPMENT, V124, P4847; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MARNETT LJ, 1999, COMPREHENSIVE NATURA, V5, P225; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Muller WEG, 2002, GENE, V295, P299, DOI 10.1016/S0378-1119(02)00690-X; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Pesole G, 2002, NUCLEIC ACIDS RES, V30, P335, DOI 10.1093/nar/30.1.335; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Pope EC, 2002, J EXP BIOL, V205, P1577; Reed DW, 1996, PROSTAGLANDINS, V52, P269, DOI 10.1016/S0090-6980(96)00089-5; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; Scott BT, 2002, BLOOD COAGUL FIBRIN, V13, P519, DOI 10.1097/00001721-200209000-00007; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; SU X, 1988, ANAL BIOCHEM, V174, P650, DOI 10.1016/0003-2697(88)90068-1; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; Valmsen K, 2001, P NATL ACAD SCI USA, V98, P7700, DOI 10.1073/pnas.131022398; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Varvas K, 1999, J BIOL CHEM, V274, P9923, DOI 10.1074/jbc.274.15.9923; WEISING K, 1995, DNA FINGERPRINTING P, P251; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; Yuasa HJ, 2001, GENE, V279, P205, DOI 10.1016/S0378-1119(01)00755-7	61	53	54	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13624	13633		10.1074/jbc.M313258200	http://dx.doi.org/10.1074/jbc.M313258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732711	hybrid			2022-12-25	WOS:000220478500043
J	Jiang, YF; Minet, E; Zhang, ZX; Silver, PA; Bai, M				Jiang, YF; Minet, E; Zhang, ZX; Silver, PA; Bai, M			Modulation of interprotomer relationships is important for activation of dimeric calcium-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; INTERMOLECULAR INTERACTIONS; BRAIN-FUNCTION; SWISS-MODEL; DIMERIZATION; DOMAIN; MUTAGENESIS; INTERFACE; CELLS; SITE	The extracellular calcium-sensing receptor (CaR) forms a disulfide-linked dimer through cysteine residues within its N-terminal extracellular domain (ECD). However, these disulfide linkages are dispensable for the formation of the dimeric CaR and for the functional reconstitution of two inactive CaRs. In this study, using molecular modeling, mutagenesis, and biochemical and biophysical analyses, we examined the importance of two leucine residues, Leu-112 and Leu-156, in the ECD of the CaR for the non-covalent dimerization and functional reconstitution. We found that the mutant receptor carrying L112S and L156S still exists mostly as a covalently linked dimer and has a significantly higher apparent affinity for calcium than the wild-type receptor. However, a combination of four mutations, L112S, L156S, C129S, and C131S, significantly reduces receptor dimerization and markedly inactivates the CaR. We also found that L112S and L156S mediate the non-covalent intermolecular interactions important for functional reconstitution. Because mutating either the two cysteines or the two leucines enhances the apparent ligand affinity of the CaR, it is likely that the changes in intermolecular relationships between two receptor protomers linked by these leucines and cysteines are essential for receptor activation. Moreover, these mutations are unlikely to have negative effects on the secondary structure of each protomer of the dimeric receptor. Thus, the detrimental effects of the combined mutations on the function of the CaR further suggest that CaR dimerization through its ECD is essential for the formation of a functional tertiary structure of the CaR.	Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Bai, M (corresponding author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, 221 Longwood Ave, Boston, MA 02115 USA.	mbai@rics.bwh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054934] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54934] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; FAJTOVA VT, 1991, AM J PHYSIOL, V261, pE151, DOI 10.1152/ajpendo.1991.261.1.E151; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Jin TQ, 2001, J BIOL CHEM, V276, P12879, DOI 10.1074/jbc.M010513200; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Sato T, 2003, J BIOL CHEM, V278, P4314, DOI 10.1074/jbc.M210278200; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; Yamauchi M, 2002, J BONE MINER RES, V17, P2174, DOI 10.1359/jbmr.2002.17.12.2174; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200	23	29	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14147	14156		10.1074/jbc.M307422200	http://dx.doi.org/10.1074/jbc.M307422200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729680	hybrid			2022-12-25	WOS:000220478500105
J	Sheader, K; Vruchte, DT; Rudenko, G				Sheader, K; Vruchte, DT; Rudenko, G			Bloodstream form-specific up-regulation of silent VSG expression sites and procyclin in Trypanosoma brucei after inhibition of DNA synthesis or DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; RNA-POLYMERASE-I; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; ANTIGENIC VARIATION; AFRICAN TRYPANOSOMES; STRAND BREAKS; SIR PROTEINS; HUMAN NUCLEI; HUMAN SERUM	The African trypanosome Trypanosoma brucei transcribes the active variant surface glycoprotein (VSG) gene from one of about 20 VSG expression sites (ESs). In order to study ES control, we made reporter lines with a green fluorescent protein gene inserted behind the promoter of different ESs. We attempted to disrupt the silencing machinery, and we used fluorescence-activated cell sorter analysis for the rapid and sensitive detection of ES up-regulation. We find that a range of treatments that either block nuclear DNA synthesis, like aphidicolin, or modify DNA-like cisplatin and 1-methyl-3-nitro-1-nitrosoguanidine results in up-regulation of silent ESs. Aphidicolin treatment was the most effective, with almost 80% of the cells expressing green fluorescent protein from a silent ES. All of these treatments blocked the cells in S phase. In contrast, a range of toxic chemicals had little or no effect on expression. These included berenil and pentamidine, which selectively cleave the mitochondrial kinetoplast DNA, the metabolic inhibitors suramin and difluoromethylornithine, and the mitotic inhibitor rhizoxin. Up-regulation also affected other RNA polymerase I (pol I) transcription units, as procyclin genes were also up-regulated after cells were treated with either aphidicolin or DNA-modifying agents. Strikingly, this up-regulation of silent pol I transcription units was bloodstream form-specific and was not observed in insect form T. brucei. We postulate that the redistribution of a limiting bloodstream form-specific factor involved in both silencing and DNA repair results in the derepression of normally silenced pol I transcription units after DNA damage.	Univ Oxford, Oxford OX1 3SY, England	University of Oxford	Rudenko, G (corresponding author), Univ Oxford, Peter Medawar Bldg Pathogen Res,S Parks Rd, Oxford OX1 3SY, England.	gloria.rudenko@medawar.ox.ac.uk		Rudenko, Gloria/0000-0003-1884-4933	Wellcome Trust [095161] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALBER AE, 1985, EXP PARASITOL, V59, P74, DOI 10.1016/0014-4894(85)90059-1; Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BERNARDS A, 1984, CELL, V36, P163, DOI 10.1016/0092-8674(84)90085-0; Berriman M, 2002, MOL BIOCHEM PARASIT, V122, P131, DOI 10.1016/S0166-6851(02)00092-0; Biebinger S, 1996, NUCLEIC ACIDS RES, V24, P1202, DOI 10.1093/nar/24.7.1202; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; Bitter W, 1998, NATURE, V391, P499, DOI 10.1038/35166; Boibessot I, 2002, ACTA TROP, V84, P219, DOI 10.1016/S0001-706X(02)00188-2; Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; Borst P, 2001, MOL BIOCHEM PARASIT, V114, P17, DOI 10.1016/S0166-6851(01)00243-2; Breidbach T, 2002, EXP PARASITOL, V101, P223, DOI 10.1016/S0014-4894(02)00133-9; BRUN R, 1979, ACTA TROP, V36, P289; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; Chaves I, 1999, EMBO J, V18, P4846, DOI 10.1093/emboj/18.17.4846; Conway C, 2002, J BIOL CHEM, V277, P21269, DOI 10.1074/jbc.M200550200; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; Donelson JE, 2003, ACTA TROP, V85, P391, DOI 10.1016/S0001-706X(02)00237-1; FAIRLAMB AH, 1980, MOL BIOCHEM PARASIT, V1, P315, DOI 10.1016/0166-6851(80)90050-X; Feuerbach F, 2002, NAT CELL BIOL, V4, P214, DOI 10.1038/ncb756; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Garcia-Salcedo JA, 2003, EMBO J, V22, P5851, DOI 10.1093/emboj/cdg553; Gerrits H, 2002, MOL BIOCHEM PARASIT, V119, P237, DOI 10.1016/S0166-6851(01)00417-0; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Hediger F, 2002, CURR BIOL, V12, P2076, DOI 10.1016/S0960-9822(02)01338-6; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Hoogstraten D, 2002, MOL CELL, V10, P1163, DOI 10.1016/S1097-2765(02)00709-8; Horn D, 1997, EMBO J, V16, P7422, DOI 10.1093/emboj/16.24.7422; HORN D, 1995, CELL, V83, P555, DOI 10.1016/0092-8674(95)90095-0; Iben S, 2002, CELL, V109, P297, DOI 10.1016/S0092-8674(02)00729-8; Isobe T, 2003, J MOL EVOL, V56, P377, DOI 10.1007/s00239-002-2408-z; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lau A, 2002, GENE DEV, V16, P2935, DOI 10.1101/gad.764102; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Mutomba MC, 1996, MOL BIOCHEM PARASIT, V80, P89, DOI 10.1016/0166-6851(96)02675-8; Navarro M, 1996, MOL CELL BIOL, V16, P3615; Navarro M, 2001, NATURE, V414, P759, DOI 10.1038/414759a; Navarro M, 1998, MOL BIOCHEM PARASIT, V94, P53, DOI 10.1016/S0166-6851(98)00049-8; Navarro M, 1999, EMBO J, V18, P2265, DOI 10.1093/emboj/18.8.2265; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Pays E, 2001, MOL BIOCHEM PARASIT, V114, P1, DOI 10.1016/S0166-6851(01)00242-0; PEDRALINOY G, 1980, J VIROL, V36, P457, DOI 10.1128/JVI.36.2.457-464.1980; Perez-Morga D, 2001, J EUKARYOT MICROBIOL, V48, P221, DOI 10.1111/j.1550-7408.2001.tb00306.x; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; Ploubidou A, 1999, J CELL SCI, V112, P4641; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; Rudenko G, 1998, MOL BIOCHEM PARASIT, V95, P97, DOI 10.1016/S0166-6851(98)00099-1; RUDENKO G, 1995, CELL, V83, P547, DOI 10.1016/0092-8674(95)90094-2; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; Ruepp S, 1997, J CELL BIOL, V137, P1369, DOI 10.1083/jcb.137.6.1369; Sambrook J, 2001, MOL CLONING LAB MANU; SHAPIRO TA, 1990, P NATL ACAD SCI USA, V87, P950, DOI 10.1073/pnas.87.3.950; Sheader K, 2003, MOL BIOCHEM PARASIT, V128, P147, DOI 10.1016/S0166-6851(03)00056-2; SHEAFF R, 1991, BIOCHEMISTRY-US, V30, P8590, DOI 10.1021/bi00099a014; Shore D, 2001, CURR BIOL, V11, pR816, DOI 10.1016/S0960-9822(01)00493-6; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Ulbert S, 2002, MOL BIOCHEM PARASIT, V120, P225, DOI 10.1016/S0166-6851(02)00003-8; van de Vaart PJM, 2000, INT J CANCER, V89, P160, DOI 10.1002/(SICI)1097-0215(20000320)89:2<160::AID-IJC10>3.0.CO;2-J; van Leeuwen F, 1998, MOL CELL BIOL, V18, P5643, DOI 10.1128/MCB.18.10.5643; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vanhamme L, 2001, INT J PARASITOL, V31, P523, DOI 10.1016/S0020-7519(01)00143-6; Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461; Vanhamme L, 2000, MOL MICROBIOL, V36, P328, DOI 10.1046/j.1365-2958.2000.01844.x; Vassella E, 1997, J CELL SCI, V110, P2661; Vruchte DT, 2003, MOL BIOCHEM PARASIT, V128, P123, DOI 10.1016/S0166-6851(03)00053-7; WOODWARD R, 1990, J CELL SCI, V95, P49; Xong HV, 1998, CELL, V95, P839, DOI 10.1016/S0092-8674(00)81706-7; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zurita M, 2003, TRENDS GENET, V19, P578, DOI 10.1016/j.tig.2003.08.005; ZWEYGARTH E, 1991, ACTA TROP, V48, P223, DOI 10.1016/0001-706X(91)90050-T	81	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13363	13374		10.1074/jbc.M312307200	http://dx.doi.org/10.1074/jbc.M312307200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726511	hybrid			2022-12-25	WOS:000220478500013
J	Gamero, AM; Sakamoto, S; Montenegro, J; Larner, AC				Gamero, AM; Sakamoto, S; Montenegro, J; Larner, AC			Identification of a novel conserved motif in the STAT family that is required for tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INTERFERON; GENE-EXPRESSION; V-ABL; ACTIVATION; PROTEINS; PATHWAY; MUTATIONS; CELLS; DNA; PROLIFERATION	The rapid transcriptional activation of cellular genes by either type 1 interferons (IFNalpha/beta) or type 2 interferon (IFNgamma) is responsible for many of the pleiotropic effects of these cytokines, including their antiviral, antigrowth, and immunomodulatory activities. Interferon-stimulated gene expression is mediated by transcription factors termed Stats, which upon being tyrosine-phosphorylated, translocate to the nucleus and bind enhancers of interferon-activated genes. We have recently characterized a new Jurkat cell variant, named H123, where IFNalpha stimulates programmed cell death. H123 clones that are resistant to the apoptotic actions of IFNalpha have been selected. One of these clones (Clone 8) is defective in its responses to IFNalpha with regard to activation of genes that require tyrosine phosphorylation of Stat2. Stimulation of Clone 8 cells with IFNalpha induces normal tyrosine phosphorylation of Stat1 and Stat3. Sequencing of Stat2 RNA reveals a substitution of proline 630 located within the Src homology 2 domain of Stat2 to leucine (P630L). Pro-630 and its adjacent amino acids are conserved in all Stat family members but are absent in other proteins that contain Src homology 2 domains. Expression of Stat2 P630L in cells inhibits IFNalpha-stimulated gene expression. These results not only define a critical motif in Stat2 required for its transcriptional activity, but they also provide evidence that resistance to type one IFNs can be mediated by mutations in Stat2 as well as those previously described for Stat1.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; NCI, Expt Immunol Lab, NIH, Frederick, MD 21702 USA	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Larner, AC (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, NB-3-30,9500 Euclid Ave, Cleveland, OH 44195 USA.	larnera@ccf.org			NCI NIH HHS [CA 77366] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAI H, 1989, J BIOL CHEM, V264, P3252; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Gamero AM, 2001, J BIOL CHEM, V276, P13547, DOI 10.1074/jbc.M007948200; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Lau JF, 2003, MOL CELL BIOL, V23, P620, DOI 10.1128/MCB.23.2.620-628.2003; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	23	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12379	12385		10.1074/jbc.M310787200	http://dx.doi.org/10.1074/jbc.M310787200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722125	hybrid			2022-12-25	WOS:000220334900046
J	Kariko, K; Ni, HP; Capodici, J; Lamphier, M; Weissman, D				Kariko, K; Ni, HP; Capodici, J; Lamphier, M; Weissman, D			mRNA is an endogenous ligand for Toll-like receptor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CYTOTOXIC T-LYMPHOCYTES; HEAT-SHOCK PROTEINS; MHC CLASS-I; NF-KAPPA-B; DENDRITIC CELLS; CROSS-PRESENTATION; TRANSCRIPTION FACTORS; ADAPTER MOLECULE; GENE-EXPRESSION	Toll-like receptors (TLRs) are the basic signaling receptors of the innate immune system. They are activated by molecules associated with pathogens or injured host cells and tissue. TLR3 has been shown to respond to double stranded (ds) RNA, a replication intermediary for many viruses. Here we present evidence that heterologous RNA released from or associated with necrotic cells or generated by in vitro transcription also stimulates TLR3 and induces immune activation. To assess RNA-mediated TLR3 activation, human embryonic kidney 293 cells stably expressing TLR3 and containing a nuclear factor-kappaB-dependent luciferase reporter were generated. Exposing these cells to in vitro transcribed RNA resulted in a TLR3-dependent induction of luciferase activity and interleukin-8 secretion. Treatment with in vitro transcribed mRNA activated nuclear factor-kappaB via TLR3 through a process that was dose-dependent and involved tyrosine phosphorylation. Furthermore, in vitro transcribed natural or 2'-fluoro-substituted mRNA induced the expression of TLR3, interferon regulatory factor-1, tumor necrosis factor-alpha, and interleukin-1 receptor-associated kinase-M mRNA in human dendritic cells (DCs). DCs responded to mRNA treatment by expressing activation markers, and this maturation was inhibited by antagonistic TLR3-specific antibody. Endogenous RNA released from or associated with necrotic cells also stimulated DCs, leading to interferon-alpha secretion, which could be abolished by pretreatment of necrotic cells with RNase. These results demonstrate that RNA, likely through secondary structure, is a potent host-derived activator of TLR3. This finding has potential physiologic relevance because RNA escaping from damaged tissue or contained within endocytosed cells could serve as an endogenous ligand for TLR3 that induces or otherwise modulates immune responses.	Univ Penn, Div Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA; Eisai Res Inst, Andover, MA 01810 USA	University of Pennsylvania; University of Pennsylvania; Eisai Co Ltd	Kariko, K (corresponding author), Univ Penn, Div Neurosurg, 3610 Hamilton Walk, Philadelphia, PA 19104 USA.	kariko@mail.med.upenn.edu			NHLBI NIH HHS [HL 62060-04] Funding Source: Medline; NIAID NIH HHS [AI 50484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Armant MA, 2002, GENOME BIOL, V3; Barton GM, 2002, CURR TOP MICROBIOL, V270, P81; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Beg AA, 2002, TRENDS IMMUNOL, V23, P509, DOI 10.1016/S1471-4906(02)02317-7; Belz GT, 2002, CRIT REV IMMUNOL, V22, P439; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Datta SK, 2003, J IMMUNOL, V170, P4102, DOI 10.4049/jimmunol.170.8.4102; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Doyle SE, 2003, J IMMUNOL, V170, P3565, DOI 10.4049/jimmunol.170.7.3565; EILAT D, 1994, MOL IMMUNOL, V31, P1377, DOI 10.1016/0161-5890(94)90154-6; Ginsberg SD, 1999, ANN NEUROL, V45, P174, DOI 10.1002/1531-8249(199902)45:2<174::AID-ANA7>3.0.CO;2-E; Ginsberg SD, 1998, ACTA NEUROPATHOL, V96, P487, DOI 10.1007/s004010050923; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Grentzmann G, 1998, RNA, V4, P479; Guillot L, 2002, J IMMUNOL, V168, P5989, DOI 10.4049/jimmunol.168.12.5989; Heiser A, 2002, J CLIN INVEST, V109, P409, DOI 10.1172/JCI14364; Heiser A, 2001, J IMMUNOL, V166, P2953, DOI 10.4049/jimmunol.166.5.2953; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kariko K, 1998, BBA-BIOMEMBRANES, V1369, P320, DOI 10.1016/S0005-2736(97)00238-1; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; Larsson M, 2003, CURR TOP MICROBIOL, V276, P261; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Marcinkiewicz M, 2002, J NEUROPATH EXP NEUR, V61, P815, DOI 10.1093/jnen/61.9.915; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Matzinger P, 2002, ANN NY ACAD SCI, V961, P341, DOI 10.1111/j.1749-6632.2002.tb03118.x; Maurer T, 2002, EUR J IMMUNOL, V32, P2356, DOI 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO;2-Z; Miettinen M, 2001, GENES IMMUN, V2, P349, DOI 10.1038/sj.gene.6363791; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; Nair SK, 2002, ANN SURG, V235, P540, DOI 10.1097/00000658-200204000-00013; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; Ni HP, 2002, J BIOL CHEM, V277, P12689, DOI 10.1074/jbc.M110729200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; Sarkar SN, 2003, J BIOL CHEM, V278, P4393, DOI 10.1074/jbc.C200655200; Sato M, 2001, CYTOKINE GROWTH F R, V12, P133, DOI 10.1016/S1359-6101(00)00032-0; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Shinobu N, 2002, FEBS LETT, V517, P251, DOI 10.1016/S0014-5793(02)02636-4; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Smith CL, 2000, MOL ENDOCRINOL, V14, P956, DOI 10.1210/me.14.7.956; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Vabulas RM, 2002, CURR TOP MICROBIOL, V270, P169; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168; Weissman D, 2000, J IMMUNOL, V165, P4710, DOI 10.4049/jimmunol.165.8.4710; Werling D, 2003, VET IMMUNOL IMMUNOP, V91, P1, DOI 10.1016/S0165-2427(02)00228-3; Williams B.R., 2001, SCI STKE, V2001, pre2; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yasutomo K, 2001, NAT GENET, V28, P313, DOI 10.1038/91070; Zinkernagel RM, 2002, EUR J IMMUNOL, V32, P2385, DOI 10.1002/1521-4141(200209)32:9<2385::AID-IMMU2385>3.0.CO;2-V; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	64	777	868	6	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12542	12550		10.1074/jbc.M310175200	http://dx.doi.org/10.1074/jbc.M310175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14729660	hybrid			2022-12-25	WOS:000220334900066
J	Pauwels, F; Vergauwen, B; Van Beeumen, JJ				Pauwels, F; Vergauwen, B; Van Beeumen, JJ			Physiological characterization of Haemophilus influenzae Rd deficient in its glutathione-dependent peroxidase PGdx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; OXIDATIVE STRESS DEFENSE; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; CATALASE; GENE; SURVIVAL; MUTANTS; OPERON; DNA	The chimeric peroxidase PGdx of Haemophilus influenzae Rd belongs to a recently identified family of thiol peroxidases capable of reducing hydrogen peroxide as well as alkylhydroperoxides by means of glutathione redox cycling. In the present study, we constructed a H. influenzae Rd strain, deficient in its PGdx encoding gene ( open reading frame HI0572). The mutant was shown by disk inhibition and liquid culture growth assays to exhibit increased susceptibility to organic hydroperoxides. The hampered growth was restored by complementing the interrupted gene on the genome with a replicating plasmid bearing an intact copy of the gene, hereby rejecting the possible influences of polar effects. Elevated levels of hydrogen peroxide scavenging activity, due to the catalase HktE, were measured in the absence of a functional pgdx gene rendering the mutant more resilient against hydrogen peroxide. On the other hand, after initiation of the stationary phase, aerobic cultures of the pgdx mutant were practically devoid of living cells, whereas wild-type counterparts retained viability. This observed feature was alleviated by complementation with the functional gene or with the addition of catalase.	Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	Ghent University	Van Beeumen, JJ (corresponding author), Univ Ghent, Lab Prot Biochem & Prot Engn, KL Ledeganckstr 95, B-9000 Ghent, Belgium.	Jozef.vanbeeumen@UGent.be						Bandyopadhyay P, 1998, J BACTERIOL, V180, P5369, DOI 10.1128/JB.180.20.5369-5374.1998; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BISHAI WR, 1994, INFECT IMMUN, V62, P4855, DOI 10.1128/IAI.62.11.4855-4860.1994; BISHAI WR, 1994, J BACTERIOL, V176, P2914, DOI 10.1128/JB.176.10.2914-2921.1994; Bsat N, 1996, J BACTERIOL, V178, P6579, DOI 10.1128/jb.178.22.6579-6586.1996; Craig JE, 2001, FEMS MICROBIOL LETT, V203, P55, DOI 10.1016/S0378-1097(01)00328-7; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; GonzalezFlecha B, 1997, J BACTERIOL, V179, P382, DOI 10.1128/jb.179.2.382-388.1997; Herbert M, 2003, INT J MED MICROBIOL, V293, P145, DOI 10.1078/1438-4221-00261; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEWEN PC, 1994, ANNU REV MICROBIOL, V48, P53, DOI 10.1146/annurev.mi.48.100194.000413; Mongkolsuk S, 2000, J BACTERIOL, V182, P6845, DOI 10.1128/JB.182.23.6845-6849.2000; Ochsner UA, 2000, J BACTERIOL, V182, P4533, DOI 10.1128/JB.182.16.4533-4544.2000; Pauwels F, 2003, J BIOL CHEM, V278, P16658, DOI 10.1074/jbc.M300157200; Pericone CD, 2000, INFECT IMMUN, V68, P3990, DOI 10.1128/IAI.68.7.3990-3997.2000; Rocha ER, 1999, J BACTERIOL, V181, P5701, DOI 10.1128/JB.181.18.5701-5710.1999; Rouhier N, 2003, FEBS LETT, V554, P149, DOI 10.1016/S0014-5793(03)01156-6; SAMBROOK J, 1989, MOL CLONING, V2, P9; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Steinman HM, 1997, J BACTERIOL, V179, P6831, DOI 10.1128/jb.179.21.6831-6836.1997; Vergauwen B, 2003, J BACTERIOL, V185, P5555, DOI 10.1128/JB.185.18.5555-5562.2003; Vergauwen B, 2003, J BACTERIOL, V185, P1572, DOI 10.1128/JB.185.5.1572-1581.2003; Vergauwen B, 2001, J BIOL CHEM, V276, P20890, DOI 10.1074/jbc.M102026200; [No title captured]	24	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12163	12170		10.1074/jbc.M312037200	http://dx.doi.org/10.1074/jbc.M312037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701867	hybrid			2022-12-25	WOS:000220334900022
J	Romsicki, Y; Reece, M; Gauthier, JY; Asante-Appiah, E; Kennedy, BP				Romsicki, Y; Reece, M; Gauthier, JY; Asante-Appiah, E; Kennedy, BP			Protein tyrosine phosphatase-1B dephosphorylation of the insulin receptor occurs in a perinuclear endosome compartment in human embryonic kidney 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; QUANTITATIVE-ANALYSIS; INTERNALIZATION; IDENTIFICATION; SENSITIVITY; ENDOCYTOSIS; BINDING; PTP-1B; GRB2	Protein tyrosine phosphatase-1B (PTP-1B) is a negative regulator of insulin signaling. It is thought to carry out this role by interacting with and dephosphorylating the activated insulin receptor (IR). However, little is known regarding the nature of the cellular interaction between these proteins, especially because the IR is localized to the plasma membrane and PTP-1B to the endoplasmic reticulum. Using confocal microscopy and fluorescence resonance energy transfer (FRET), the interaction between PTP-1B and the IR was examined in co-transfected human embryonic kidney 293 cells. Biological activities were not significantly affected for either PTP-1B or the IR with the fusion of W1B-green fluorescent protein (GFP) to the N terminus of PTP-1B (W1B-PTP-1B) or the fusion of Topaz-GFP to the C terminus of the IR (Topaz-IR). FRET between W1B and Topaz was monitored in cells transfected with either wild type PTP-1B (W1B-PTP-1B) or the substrate-trapping form PTP-1B(D181A) (W1B-PTP-1B(D181A)) and Topaz-IR. Co-expression of W1B-PTP-1B with Topaz-IR resulted in distribution of Topaz-IR to the plasma membrane, but no FRET was obtained upon insulin treatment. In contrast, co-expression of W1B-PTP-1B(D181A) with Topaz-IR caused an increase in cytosolic Topaz-IR fluorescence and, in some cells, a significant basal FRET signal, suggesting that PTP-1B is interacting with the IR during its synthesis. Stimulation of these cells with insulin resulted in a rapid induction of FRET that increased over time and was localized to a perinuclear spot. Co-expression of Topaz-IR with a GFP-labeled RhoB endosomal marker and treatment of the cells with insulin identified a perinuclear endosome compartment as the site of localization. Furthermore, the insulin-induced FRET could be prevented by the treatment of the cells with a specific PTP-1B inhibitor. These results suggest that PTP-1B appears not only to interact with and dephosphorylate the insulin-stimulated IR in a perinuclear endosome compartment but is also involved in maintaining the IR in a dephosphorylated state during its biosynthesis.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Ctr Therapeut Res, Dept Chem, Pointe Claire, PQ H9R 4P8, Canada	Merck & Company; Merck & Company	Kennedy, BP (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.	Brian_Kennedy@merck.com						ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Asante-Appiah E, 2002, BIOCHEMISTRY-US, V41, P9043, DOI 10.1021/bi0259554; Asante-Appiah E, 2003, AM J PHYSIOL-ENDOC M, V284, pE663, DOI 10.1152/ajpendo.00462.2002; Bass J, 1998, J CELL BIOL, V141, P637, DOI 10.1083/jcb.141.3.637; Bevan AP, 2000, MOL CELL ENDOCRINOL, V164, P145, DOI 10.1016/S0303-7207(00)00224-0; Boute N, 2003, EMBO REP, V4, P313, DOI 10.1038/sj.embor.embor767; Conway RR, 2001, J CELL PHYSIOL, V189, P341, DOI 10.1002/jcp.10028; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Di Guglielmo GM, 1998, MOL CELL BIOCHEM, V182, P59, DOI 10.1023/A:1006883311233; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAURE R, 1992, J BIOL CHEM, V267, P11215; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Ghosh RN, 2000, BIOTECHNIQUES, V29, P170, DOI 10.2144/00291pf01; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Lu KH, 1996, MOL BIOL CELL, V7, P679, DOI 10.1091/mbc.7.5.679; OLSON TS, 1988, J BIOL CHEM, V263, P7342; Romsicki Y, 2003, ARCH BIOCHEM BIOPHYS, V414, P40, DOI 10.1016/S0003-9861(03)00178-4; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SING LC, 2001, Patent No. 200170753; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Tawa P, 2001, CELL DEATH DIFFER, V8, P30, DOI 10.1038/sj.cdd.4400769; Weiss TS, 2001, P NATL ACAD SCI USA, V98, P14961, DOI 10.1073/pnas.261572098; Youvan D. C., 1997, BIOTECHNOLOGY, V3, P1	30	64	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12868	12875		10.1074/jbc.M309600200	http://dx.doi.org/10.1074/jbc.M309600200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722096	hybrid			2022-12-25	WOS:000220334900103
J	Yadava, N; Houchens, T; Potluri, P; Scheffler, IE				Yadava, N; Houchens, T; Potluri, P; Scheffler, IE			Development and characterization of a conditional mitochondrial complex I assembly system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; HAMSTER CELL MUTANTS; 3-DIMENSIONAL STRUCTURE; QUINONE OXIDOREDUCTASE; NEUROSPORA-CRASSA; KDA SUBUNIT; PROTEIN; DEFICIENT; GENE; IDENTIFICATION	We developed a conditional complex I assembly system in a Chinese hamster fibroblast mutant line, CCL16-B2, that does not express the NDUFA1 gene (encoding the MWFE protein). In this mutant, a hemagglutinin (HA) epitope-tagged MWFE protein was expressed from a doxycycline-inducible promoter. The expression of the protein was absolutely dependent on the presence of doxycycline, and the gene could be turned off completely by removal of doxycycline. These experiments demonstrated a key role of MWFE in the pathway of complex I assembly. Upon induction the MWFE.HA protein reached steady-state levels within 24 h, but the appearance of fully active complex I was delayed by another similar to24 h. The MWFE appeared in a precomplex that probably includes one or more subunits encoded by mtDNA. The fate of MWFE and the stability of complex I were themselves very tightly linked to the activity of mitochondrial protein synthesis and to the assembly of subunits encoded by mtDNA (ND1-6 and ND4L). This novel conditional system can shed light not only on the mechanism of complex I assembly but emphasizes the role of subunits previously thought of as "accessory." It promises to have broader applications in the study of cellular energy metabolism and production of reactive oxygen species and related processes.	Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Scheffler, IE (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA.	ischeffler@ucsd.edu						Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200; Au HC, 1999, P NATL ACAD SCI USA, V96, P4354, DOI 10.1073/pnas.96.8.4354; Au HC, 1997, SOMAT CELL MOLEC GEN, V23, P27, DOI 10.1007/BF02679953; BAI Y, 2001, EMBO J, V17, P4848; BREEN GAM, 1979, SOMAT CELL GENET, V5, P441, DOI 10.1007/BF01538879; BURNETT KG, 1981, J CELL BIOL, V90, P108, DOI 10.1083/jcb.90.1.108; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961; Dabbeni-Sala F, 2001, FASEB J, V15, P164, DOI 10.1096/fj.00-0129com; DITTA G, 1976, SOMAT CELL GENET, V2, P331, DOI 10.1007/BF01538838; DITTA G, 1977, NATURE, V268, P64, DOI 10.1038/268064a0; Ferreirinha F, 1999, BIOCHEM J, V342, P551, DOI 10.1042/0264-6021:3420551; Gong X, 2003, J BIOL CHEM, V278, P25731, DOI 10.1074/jbc.M302361200; Green-Willms NS, 2001, J BIOL CHEM, V276, P6392, DOI 10.1074/jbc.M009856200; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; HALL RE, 1990, J BIOL CHEM, V265, P16484; HARE JF, 1982, J BIOL CHEM, V257, P3575; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Kuffner R, 1998, J MOL BIOL, V283, P409, DOI 10.1006/jmbi.1998.2114; Marques I, 2003, J MOL BIOL, V329, P283, DOI 10.1016/S0022-2836(03)00443-1; Nakamaru-Ogiso E, 2003, BIOCHEMISTRY-US, V42, P746, DOI 10.1021/bi0269660; Nargang FE, 2002, J BIOL CHEM, V277, P12846, DOI 10.1074/jbc.M112099200; NEHLS U, 1992, J MOL BIOL, V227, P1032, DOI 10.1016/0022-2836(92)90519-P; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Papa S, 2001, FEBS LETT, V489, P259, DOI 10.1016/S0014-5793(00)02334-6; Petruzzella V, 2002, GENE, V286, P149, DOI 10.1016/S0378-1119(01)00810-1; Saracco SA, 2002, MOL BIOL CELL, V13, P1122, DOI 10.1091/mbc.01-12-0580; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Scheffler IE, 2001, J BIOENERG BIOMEMBR, V33, P243, DOI 10.1023/A:1010739120891; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; Schulte U, 2001, J BIOENERG BIOMEMBR, V33, P205, DOI 10.1023/A:1010730919074; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; SODERBERG K, 1979, SOMAT CELL GENET, V5, P225, DOI 10.1007/BF01539163; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Videira A, 2001, J BIOENERG BIOMEMBR, V33, P197, DOI 10.1023/A:1010778802236; Yadava N, 2002, J BIOL CHEM, V277, P21221, DOI 10.1074/jbc.M202016200	43	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12406	12413		10.1074/jbc.M313588200	http://dx.doi.org/10.1074/jbc.M313588200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722084	hybrid			2022-12-25	WOS:000220334900049
J	van Meeteren, LA; Frederiks, F; Giepmans, BNG; Pedrosa, MFF; Billington, SJ; Jost, BH; Tambourgi, DV; Moolenaar, WH				van Meeteren, LA; Frederiks, F; Giepmans, BNG; Pedrosa, MFF; Billington, SJ; Jost, BH; Tambourgi, DV; Moolenaar, WH			Spider and bacterial sphingomyelinases D target cellular lysophosphatidic acid receptors by hydrolyzing lysophosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN RECLUSE SPIDER; PHOSPHOLIPASE-D; CORYNEBACTERIUM-PSEUDOTUBERCULOSIS; LYSOPHOSPHOLIPASE-D; ACTIVATION; CERAMIDE; CLONING; VENOM; IDENTIFICATION; LYMPHADENITIS	Bites by Loxosceles spiders can produce severe clinical symptoms, including dermonecrosis, thrombosis, vascular leakage, hemolysis, and persistent inflammation. The causative factor is a sphingomyelinase D (SMaseD) that cleaves sphingomyelin into choline and ceramide 1-phosphate. A similar enzyme, showing comparable bioactivity, is secreted by certain pathogenic corynebacteria and acts as a potent virulence factor. However, the molecular basis for SMaseD toxicity is not well understood, which hampers effective therapy. Here we show that the spider and bacterial SMases D hydrolyze albumin-bound lysophosphatidylcholine (LPC), but not sphingosylphosphorylcholine, with K-m values (similar to20-40 muM) well below the normal LPC levels in blood. Thus, toxic SMases D have intrinsic lysophospholipase D activity toward LPC. LPC hydrolysis yields the lipid mediator lysophosphatidic acid (LPA), a known inducer of platelet aggregation, endothelial hyperpermeability, and pro-inflammatory responses. Introduction of LPA(1) receptor cDNA into LPA receptor-negative cells renders non-susceptible cells susceptible to SmaseD, but only in LPC-containing media. Degradation of circulating LPC to LPA with consequent activation of LPA receptors may have a previously unappreciated role in the pathophysiology of secreted SMases D.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Inst Butantan, Lab Imunoquim, BR-05503900 Sao Paulo, Brazil; Univ Arizona, Dept Vet Sci & Microbiol, Tucson, AZ 85721 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Instituto Butantan; University of Arizona	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	w.moolenaar@nki.nl	Fernandes-Pedrosa, Matheus/C-6398-2014; van Meeteren, Laurens/A-9890-2008; Van Meeteren, Laurens A./AGQ-6139-2022; Tambourgi, Denise/H-7114-2016; Giepmans, Ben N.G./R-4564-2016	Fernandes-Pedrosa, Matheus/0000-0003-4221-9580; van Meeteren, Laurens/0000-0001-9885-0668; Tambourgi, Denise/0000-0003-1896-9074; Giepmans, Ben N.G./0000-0001-5105-5915				Amerongen GPV, 2000, ARTERIOSCL THROM VAS, V20, pE127, DOI 10.1161/01.ATV.20.12.e127; BATEY RG, 1986, AUST VET J, V63, P269, DOI 10.1111/j.1751-0813.1986.tb08064.x; BERNHEIMER AW, 1985, SCIENCE, V228, P590, DOI 10.1126/science.3983643; CARNE HR, 1978, NATURE, V271, P246, DOI 10.1038/271246a0; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; Feldhaus MJ, 2002, J BIOL CHEM, V277, P4285, DOI 10.1074/jbc.M106653200; FORRESTER LJ, 1978, ARCH BIOCHEM BIOPHYS, V187, P355, DOI 10.1016/0003-9861(78)90046-2; Fueller M, 2003, CELL SIGNAL, V15, P367, DOI 10.1016/S0898-6568(02)00117-1; FUTRELL JM, 1992, AM J MED SCI, V304, P261, DOI 10.1097/00000441-199210000-00008; Geng D, 1998, J BIOL CHEM, V273, P12195, DOI 10.1074/jbc.273.20.12195; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; HASERUECK N, 2004, IN PRESS BLOOD; Hashimoto T, 2003, J PHARMACOL SCI, V91, P8, DOI 10.1254/jphs.91.8; KURPIEWSKI G, 1981, BIOCHIM BIOPHYS ACTA, V678, P467, DOI 10.1016/0304-4165(81)90128-8; LILIOM K, 2004, BIOCHEM J, V355, P189; LIPSKY BA, 1982, REV INFECT DIS, V4, P1220; MCNAMARA PJ, 1995, GENE, V156, P113, DOI 10.1016/0378-1119(95)00002-N; MCNAMARA PJ, 1994, MOL MICROBIOL, V12, P921, DOI 10.1111/j.1365-2958.1994.tb01080.x; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; Pedrosa MD, 2002, BIOCHEM BIOPH RES CO, V298, P638, DOI 10.1016/S0006-291X(02)02521-4; Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200; REES RS, 1983, J SURG RES, V35, P1, DOI 10.1016/0022-4804(83)90119-1; Sams HH, 2001, J AM ACAD DERMATOL, V44, P561, DOI 10.1067/mjd.2001.112385; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Siess W, 2002, BBA-MOL CELL BIOL L, V1582, P204, DOI 10.1016/S1388-1981(02)00173-7; Songer JG, 1997, TRENDS MICROBIOL, V5, P156, DOI 10.1016/S0966-842X(97)01005-6; SOUCEK A, 1967, BIOCHIM BIOPHYS ACTA, V144, P180; SOUCEK A, 1971, BIOCHIM BIOPHYS ACTA, V227, P116, DOI 10.1016/0005-2744(71)90173-2; Subbaiah PV, 2003, J LIPID RES, V44, P1574, DOI 10.1194/jlr.M300103-JLR200; SUBBAIAH PV, 1985, J BIOL CHEM, V260, P5308; Tachedjian M, 1995, VACCINE, V13, P1785, DOI 10.1016/0264-410X(95)00144-P; Tambourgi DV, 1998, BIOCHEM BIOPH RES CO, V251, P366, DOI 10.1006/bbrc.1998.9474; Tambourgi DV, 2002, IMMUNOLOGY, V107, P93, DOI 10.1046/j.1365-2567.2002.01483.x; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; TRUETT AP, 1993, ADV LIPID RES, V26, P275; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; van Dijk MCM, 1998, CURR BIOL, V8, P386, DOI 10.1016/S0960-9822(98)70157-5; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Yang HY, 2002, PROTEIN SCI, V11, P2958, DOI 10.1110/ps.0225302; Yang L, 2000, BLOOD, V95, P2420, DOI 10.1182/blood.V95.7.2420.007k12_2420_2425	45	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10833	10836		10.1074/jbc.C300563200	http://dx.doi.org/10.1074/jbc.C300563200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14732720	hybrid			2022-12-25	WOS:000220157600002
J	Wang, HB; Ma, WG; Tejada, L; Zhang, H; Morrow, JD; Das, SK; Dey, SK				Wang, HB; Ma, WG; Tejada, L; Zhang, H; Morrow, JD; Das, SK; Dey, SK			Rescue of female infertility from the loss of cyclooxygenase-2 by compensatory up-regulation of cyclooxygenase-1 is a function of genetic makeup	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MOUSE UTERUS; EMBRYO IMPLANTATION; EGF-RECEPTOR; IN-VITRO; MICE; DISRUPTION; OVULATION; PROSTAGLANDINS; INFLAMMATION	Cyclooxygenase-2 (COX-2), an inducible rate-limiting enzyme in prostaglandin biosynthesis, is implicated in various physiological and pathological processes including female fertility, renal function, angiogenesis, inflammation, and tumorigenesis. We showed previously that targeted deletion of Ptgs2 encoding COX-2, but not Ptgs1 encoding COX-1, in C57BL/6J/129 mice produces complete female infertility resulting from multiple reproductive failures spanning ovulation, fertilization, and implantation. Here we show that Ptgs2 null mice on a CD1 background have dramatically improved female fertility including ovulation, fertilization, and implantation, giving rise to live births. We provide evidence that this improved fertility in CD1 Ptgs2 null mice is the result of a compensatory up-regulation of Ptgs1 which does not occur in C57BL/6J/129 mice missing Ptgs2. These results clearly demonstrate for the first time that COX-1 can replace specific functions of COX-2 in vivo in the context of genetic disparity. In light of this finding, the therapeutic use and efficacy of COX-2-specific inhibitors among human populations without regard for genetic and ethnic diversities should be revisited.	Vanderbilt Univ, Med Ctr, Dept Pediat, Div Reprod & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Clin Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Dev & Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Dey, SK (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Div Reprod & Dev Biol, MCN-D4100, Nashville, TN 37232 USA.	sk.dey@vanderbilt.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012304, R01HD037830, R37HD012304] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA006668, R01DA006668] Funding Source: NIH RePORTER; NCI NIH HHS [CA77839] Funding Source: Medline; NICHD NIH HHS [HD37830, HD33994, HD12304] Funding Source: Medline; NIDA NIH HHS [DA06668] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIEHS NIH HHS [ES07814] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonyadi M, 1997, NAT GENET, V15, P207, DOI 10.1038/ng0297-207; Cambria-Kiely JA, 2002, J THROMB THROMBOLYS, V14, P51, DOI 10.1023/A:1022066305399; Chakraborty I, 1996, J MOL ENDOCRINOL, V16, P107, DOI 10.1677/jme.0.0160107; DAS SK, 1994, DEVELOPMENT, V120, P1071; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Ewart-Toland A, 1999, ENDOCRINOLOGY, V140, P732, DOI 10.1210/en.140.2.732; Flower RJ, 2003, NAT REV DRUG DISCOV, V2, P179, DOI 10.1038/nrd1034; Fowler KJ, 2000, GENOME RES, V10, P30; Gupta RA, 2003, CANCER RES, V63, P906; Joyce IM, 2001, ENDOCRINOLOGY, V142, P3187, DOI 10.1210/en.142.7.3187; Kaji K, 2000, NAT GENET, V24, P279, DOI 10.1038/73502; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Li DK, 2003, BRIT MED J, V327, P368, DOI 10.1136/bmj.327.7411.368; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Ma WG, 2003, P NATL ACAD SCI USA, V100, P2963, DOI 10.1073/pnas.0530162100; Matsumoto H, 2001, BIOL REPROD, V64, P1557, DOI 10.1095/biolreprod64.5.1557; Matzuk MM, 2002, SCIENCE, V296, P2178, DOI 10.1126/science.1071965; Nielsen GL, 2001, BRIT MED J, V322, P266, DOI 10.1136/bmj.322.7281.266; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; Reese J, 2001, ENDOCRINOLOGY, V142, P3198, DOI 10.1210/en.142.7.3198; Reese J, 2000, P NATL ACAD SCI USA, V97, P9759, DOI 10.1073/pnas.97.17.9759; SIROIS J, 1992, J BIOL CHEM, V267, P11586; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Song H, 2002, DEVELOPMENT, V129, P2879; Spearow JL, 1999, BIOL REPROD, V61, P851, DOI 10.1095/biolreprod61.4.851; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; VIGGIANO JM, 1995, PROSTAG LEUKOTR ESS, V53, P261, DOI 10.1016/0952-3278(95)90125-6; Wilcox AJ, 1999, NEW ENGL J MED, V340, P1796, DOI 10.1056/NEJM199906103402304	33	89	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10649	10658		10.1074/jbc.M312203200	http://dx.doi.org/10.1074/jbc.M312203200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701858	hybrid			2022-12-25	WOS:000220050400119
J	Cheng, BK; Feng, JY; Gadgil, S; Tse-Dinh, YC				Cheng, BK; Feng, JY; Gadgil, S; Tse-Dinh, YC			Flexibility at Gly-194 is required for DNA cleavage and relaxation activity of Escherichia coli DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; MECHANISM; MUTATIONS; RESIDUES; PROTEIN; REGION	The proposed mechanism of type IA DNA topoisomerase I includes conformational changes by the single enzyme polypeptide to allow binding of the G strand of the DNA substrate at the active site, and the opening or closing of the "gate" created on the G strand of DNA to the passing single or double DNA strand(s) through the cleaved G strand DNA. The shifting of an alpha helix upon G strand DNA binding has been observed from the comparison of the type IA DNA topoisomerase crystal structures (Changela, A., DiGate, R. J., and Mondragon, A. ( 2001) Nature 411, 1077 - 1081). Site-directed mutagenesis of the strictly conserved Gly-194 at the N terminus of this alpha helix in Escherichia coli DNA topoisomerase I showed that flexibility around this glycine residue is required for DNA cleavage and relaxation activity and supports a functional role for this hinge region in the enzyme conformational change.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Tse-Dinh, YC (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	yuk-ching_tse-dinh@nymc.edu			NIGMS NIH HHS [R01 GM054226, GM54226] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahumada A, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-13; Caron PR, 1999, METH MOL B, V94, P279; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Champoux JJ, 2002, TRENDS PHARMACOL SCI, V23, P199, DOI 10.1016/S0165-6147(02)01997-1; Changela A, 2001, NATURE, V411, P1077, DOI 10.1038/35082615; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; Grant GA, 2001, J BIOL CHEM, V276, P17844, DOI 10.1074/jbc.M009957200; Keck JL, 1999, NAT STRUCT BIOL, V6, P900; KIRKEGAARD K, 1984, COLD SPRING HARB SYM, V49, P411, DOI 10.1101/SQB.1984.049.01.047; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; McCormack EA, 2001, J STRUCT BIOL, V135, P198, DOI 10.1006/jsbi.2001.4385; Mondragon A, 1999, STRUCTURE, V7, P1373, DOI 10.1016/S0969-2126(00)80027-1; Perry K, 2002, J BIOL CHEM, V277, P13237, DOI 10.1074/jbc.M112019200; Rafferty JA, 1997, BBA-PROTEIN STRUCT M, V1342, P90, DOI 10.1016/S0167-4838(97)00095-2; Rodriguez AC, 2002, EMBO J, V21, P418, DOI 10.1093/emboj/21.3.418; TSE YC, 1980, J BIOL CHEM, V255, P5560; Tse-Dinh YC, 1998, BBA-GENE STRUCT EXPR, V1400, P19, DOI 10.1016/S0167-4781(98)00125-0; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; ZHANG HL, 1995, J BIOL CHEM, V270, P23700, DOI 10.1074/jbc.270.40.23700; ZHAO GP, 1993, J BIOL CHEM, V268, P14921; Zhu CX, 1999, METH MOL B, V94, P145; Zhu CX, 1998, J BIOL CHEM, V273, P8783, DOI 10.1074/jbc.273.15.8783	25	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8648	8654		10.1074/jbc.M312095200	http://dx.doi.org/10.1074/jbc.M312095200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14711811	hybrid			2022-12-25	WOS:000189265900017
J	Kim, EH; Kim, SU; Shin, DY; Choi, KS				Kim, EH; Kim, SU; Shin, DY; Choi, KS			Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP	ONCOGENE			English	Article						TRAIL; roscovitine; apoptosis; glioma	X-LINKED INHIBITOR; CYCLIN-DEPENDENT KINASES; PROSTATE-CANCER CELLS; GLIAL-CELLS; PHASE-II; EXPRESSION; PROTEIN; LIGAND; CLEAVAGE; FAMILY	The cytotoxic effect of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is limited in many glioma cell lines. However, treatment with TRAIL in combination with subtoxic doses of roscovitine, a specific inhibitor of Cdc2 and Cdk2, induced rapid apoptosis in TRAIL-resistant glioma cells. Roscovitine could sensitize Bcl-2- or Bcl-xL-overexpressing glioma cells, but not human astrocytes, to TRAIL-induced apoptosis, offering an attractive strategy for safely treating resistant gliomas. Treatment with roscovitine significantly inhibited Cdc2 activity, and expression of a dominant-negative Cdc2 mutant sensitized glioma cells to TRAIL-induced apoptosis. While the proteolytic processing of procaspase-3 by TRAIL was partially blocked in U87MG and T98 glioma cells, treatment with roscovitine recovered TRAIL-induced activation of caspases very efficiently in these cells. We found that treatment with roscovitine or expression of a dominant-negative Cdc2 mutant downregulated the protein levels of survivin and XIAP, two major caspase inhibitors. Overexpression of survivin or XIAP attenuated the apoptosis induced by roscovitine and TRAIL. Taken together, these results suggest that downregulation of survivin and XIAP by subtoxic doses of roscovitine contributes to the amplification of caspase cascades, thereby overcoming glioma cell resistance to TRAIL-mediated apoptosis.	Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea; Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 442749, South Korea; Dankook Univ Coll Med, Dept Microbiol, Cheonan 330714, South Korea	Ajou University; Ajou University; Dankook University	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Kim, Eunhee/AAK-3650-2020; Kim, Eunhee/Q-9162-2016	Kim, Eunhee/0000-0001-7143-7769; Choi, Kyeong Sook/0000-0003-2331-0856				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Asselin E, 2001, CANCER RES, V61, P1862; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Gazzaniga P, 2003, ANN ONCOL, V14, P85, DOI 10.1093/annonc/mdg002; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Grant S, 2003, DRUG RESIST UPDATE, V6, P15, DOI 10.1016/S1368-7646(02)00141-3; Griffith TS, 2002, CANCER RES, V62, P3093; Hao CH, 2001, CANCER RES, V61, P1162; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; KIM SU, 1986, J NEUROSCI RES, V15, P303, DOI 10.1002/jnr.490150303; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Nagane M, 2000, CANCER RES, V60, P847; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Schwartz GK, 2001, J CLIN ONCOL, V19, P1985, DOI 10.1200/JCO.2001.19.7.1985; Sehgal A, 1998, SEMIN SURG ONCOL, V14, P3; Shapiro GI, 2001, CLIN CANCER RES, V7, P1590; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Weber RG, 2001, INT J CANCER, V91, P213, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1036>3.3.CO;2-D; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3; Zhang XD, 2001, CANCER RES, V61, P7339; Zhao J, 2000, J CELL SCI, V113, P4363; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	44	116	124	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					446	456		10.1038/sj.onc.1207025	http://dx.doi.org/10.1038/sj.onc.1207025			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724573				2022-12-25	WOS:000188098300015
J	Conlan, LA; McNees, CJ; Heierhorst, J				Conlan, LA; McNees, CJ; Heierhorst, J			Proteasome-dependent dispersal of PML nuclear bodies in response to alkylating DNA damage	ONCOGENE			English	Article						PML; Sp100; DNA alkylation; proteasome	PROTEIN; LOCALIZATION; P53	Promyelocytic leukemia protein (PML) nuclear bodies (NBs) are present in variable number in most human cell types and have been linked to various cellular functions, including roles as depots for DNA repair proteins. Here, we show that treatment of human cells with DNA methylating agents leads to redistribution of PML from NBs to a diffuse nuclear localization. Biochemically, this correlates with a specific reduction of PML levels in the nuclear matrix fraction without affecting total PML levels. Similar results were obtained for the other major PML NB component, the Sp100 protein, indicating that DNA methylating agents lead to a general disassembly of PML NBs. Similar to the dispersal of PML NBs in response to some viral infections, PML redistribution after DNA damage was inhibited by the proteasome inhibitor MG132. We propose that the regulated dispersal of PML NBs may facilitate the enhanced release of DNA repair proteins from NB depots in order to respond adequately to extensive DNA damage.	Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia	St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne	Heierhorst, J (corresponding author), Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	heier@ariel.its.unimelb.edu.au						Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; De Lucia F, 2001, BIOCHEM J, V358, P447, DOI 10.1042/0264-6021:3580447; Everett RD, 1999, J CELL SCI, V112, P3443; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seker H, 2003, ONCOGENE, V22, P1620, DOI 10.1038/sj.onc.1206140; Venere M, 2002, NAT CELL BIOL, V4, pE255, DOI 10.1038/ncb1102-e255; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Xu ZX, 2003, MOL CELL BIOL, V23, P4247, DOI 10.1128/MCB.23.12.4247-4256.2003; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869	16	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					307	310		10.1038/sj.onc.1207119	http://dx.doi.org/10.1038/sj.onc.1207119			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712236				2022-12-25	WOS:000187895300033
J	Wright, KO; Messing, EM; Reeder, JE				Wright, KO; Messing, EM; Reeder, JE			DBCCR1 mediates death in cultured bladder tumor cells	ONCOGENE			English	Article						bladder neoplasm; DBCCR1; tumor suppressor gene; chromosme 9	HOMOZYGOUS DELETION; SUPPRESSOR REGION; CANCER; 9Q32-33; GENE; DEFINITION; EXPRESSION; CARCINOMA; GROWTH; LOCUS	Chromosome 9, which is often partially or fully reduced to homozygosity in bladder cancer cells, harbors several tumor suppressor loci including deleted in bladder cancer chromosome region 1 (DBCCR1) at 9q32-33. To study DBCCR1 function, stable cell lines, inducible for DBCCR1 expression by tetracycline, were made, but the DBCCR1 protein was not expressed at detectable levels. To understand the fate of DBCCR1-expressing cells, human bladder tumor cells were transiently transfected with an expression vector containing DBCCR1 fused to enhanced green fluorescent protein (EGFP). Initially, DBCCR1-expressing cells demonstrated diffuse cytoplasmic green fluorescence with nuclear exclusion patterns. After time, the intensity level of green fluorescence increased and a granular distribution of protein became visible in the cells. At this point, cells rounded up and detached from the tissue culture dish. Cells transfected with a control vector, containing only EGFP, and partial DBCCR1-EGFP fusion constructs did not demonstrate this behavior. DBCCR1-mediated cell death in cultured tumor cells was independent of caspase-3 activation and did not result in detectable DNA strand breaks by TUNEL staining that are hallmarks of the classical apoptotic pathway.	Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, Rochester, NY USA	University of Rochester; University of Rochester	Reeder, JE (corresponding author), Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA.	Jay_Reeder@urmc.patholo-gy.rochester.edu		Reeder, Jay/0000-0002-7125-6893	NCI NIH HHS [CA33148-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1993, ONCOGENE, V8, P1083; COMPTON M, 1992, CANCER METAST REV, V2, P105; CREAGH E, 2001, BIOCH SOC T, V29; DEVLIN J, 1994, ONCOGENE, V9, P2757; Easton RM, 1997, J NEUROSCI, V17, P9656; Fujiwara H, 2001, J HUM GENET, V46, P372, DOI 10.1007/s100380170056; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Habuchi T, 2001, ONCOGENE, V20, P531, DOI 10.1038/sj.onc.1204122; Howard CM, 2000, CANCER RES, V60, P2737; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; KEEN AJ, 1994, ONCOGENE, V9, P2083; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li WW, 1997, CANCER RES, V57, P2193; MICKEY D, 1982, J UROLOGY, V27, P23307; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Nishiyama H, 2001, ONCOGENE, V20, P2956, DOI 10.1038/sj.onc.1204432; RUPPERT JM, 1993, CANCER RES, V53, P5093; Sowden MP, 1998, NUCLEIC ACIDS RES, V26, P1644, DOI 10.1093/nar/26.7.1644; Stadler WM, 2001, CLIN CANCER RES, V7, P1676; Tang Dean G, 1996, Pathol Oncol Res, V2, P117; Weng LP, 1999, CANCER RES, V59, P5808	25	28	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					82	90		10.1038/sj.onc.1206642	http://dx.doi.org/10.1038/sj.onc.1206642			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712213				2022-12-25	WOS:000187895300009
J	Santos, AD; McIntosh, JM; Hillyard, DR; Cruz, LJ; Olivera, BM				Santos, AD; McIntosh, JM; Hillyard, DR; Cruz, LJ; Olivera, BM			The A-superfamily of conotoxins - Structural and functional divergence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONUS-VENOM PEPTIDES; ALPHA-CONOTOXIN; RECEPTOR; TARGETS; SNAILS; LYASE	The generation of functional novelty in proteins encoded by a gene superfamily is seldom well documented. In this report, we define the A-conotoxin superfamily, which is widely expressed in venoms of the predatory cone snails (Conus), and show how gene products that diverge considerably in structure and function have arisen within the same superfamily. A cDNA clone encoding alpha-conotoxin GI, the first conotoxin characterized, provided initial data that identified the A-superfamily. Conotoxin precursors in the A-superfamily were identified from six Conus species: most (11/16) encoded alpha-conotoxins, but some (5/16) belong to a family of excitatory peptides, the kappaA-conotoxins that target voltage-gated ion channels. alpha-Conotoxins are two-disulfide-bridged nicotinic antagonists, 13-19 amino acids in length; kappaA-conotoxins are larger (31-36 amino acids) with three disulfide bridges. Purification and biochemical characterization of one peptide, kappaA-conotoxin MIVA is reported; five of the other predicted conotoxins were previously venom-purified. A comparative analysis of conotoxins purified from venom, and their precursors reveal novel post-translational processing, as well as mutational events leading to polymorphism. Patterns of sequence divergence and Cys codon usage define the major superfamily branches and suggest how these separate branches arose.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Philippines, Inst Mol Biol & Biotechnol, Quezon City 1101, Philippines; Univ Philippines, Inst Marine Sci, Quezon City 1101, Philippines	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Diliman; University of the Philippines System; University of the Philippines Diliman	Olivera, BM (corresponding author), Univ Utah, Dept Biol, 257 S 1400 E, Salt Lake City, UT 84112 USA.	olivera@biology.utah.edu			NIGMS NIH HHS [GM-48677] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Champtiaux N, 2002, J NEUROSCI, V22, P1208, DOI 10.1523/JNEUROSCI.22-04-01208.2002; Conticello SG, 2001, MOL BIOL EVOL, V18, P120, DOI 10.1093/oxfordjournals.molbev.a003786; Craig AG, 1998, BIOCHEMISTRY-US, V37, P16019, DOI 10.1021/bi981690a; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; Espiritu DJD, 2001, TOXICON, V39, P1899, DOI 10.1016/S0041-0101(01)00175-1; Favreau P, 1999, BIOCHEMISTRY-US, V38, P6317, DOI 10.1021/bi982817z; GRAY WR, 1981, J BIOL CHEM, V256, P4734; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KAHN AJ, 1994, LIFE HIST BIOGEOGRAP; Lirazan MB, 2000, BIOCHEMISTRY-US, V39, P1583, DOI 10.1021/bi9923712; Lu BS, 1999, PEPTIDES, V20, P1139; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Miles LA, 2002, J BIOL CHEM, V277, P43033, DOI 10.1074/jbc.M206690200; Olivera BM, 1999, ANN NY ACAD SCI, V870, P223, DOI 10.1111/j.1749-6632.1999.tb08883.x; Olivera BM, 2002, ANNU REV ECOL SYST, V33, P25, DOI 10.1146/annurev.ecolsys.33.010802.150424; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; OLIVERA BM, 1996, Patent No. 5589340; PING DS, 1995, J BIOL CHEM, V270, P29250, DOI 10.1074/jbc.270.49.29250; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; Sambrook J, 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS AD, 1993, THESIS U PHILIPPINES; Shon KJ, 1997, BIOCHEMISTRY-US, V36, P15693, DOI 10.1021/bi971443r; Shon KJ, 1998, J NEUROSCI, V18, P4473; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664; WOODWARD SR, 1990, EMBO J, V9, P1015, DOI 10.1002/j.1460-2075.1990.tb08204.x; YOSHIKAMI D, 1989, ANN NY ACAD SCI, V560, P230, DOI 10.1111/j.1749-6632.1989.tb24100.x; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065; Zoli M, 2002, J NEUROSCI, V22, P8785	32	108	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17596	17606		10.1074/jbc.M309654200	http://dx.doi.org/10.1074/jbc.M309654200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14701840	hybrid			2022-12-25	WOS:000220870400088
J	Vinci, F; Catharino, S; Frey, S; Buchner, J; Marino, G; Pucci, P; Ruoppolo, M				Vinci, F; Catharino, S; Frey, S; Buchner, J; Marino, G; Pucci, P; Ruoppolo, M			Hierarchical formation of disulfide bonds in the immunoglobulin Fc fragment is assisted by protein-disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; CONSTANT FRAGMENT; DOMAIN; PDI; RENATURATION; STABILITY; CHAIN	Antibodies provide an excellent system to study the folding and assembly of all beta-sheet proteins and to elucidate the hierarchy of intra/inter chain disulfide bonds formation during the folding process of multimeric and multidomain proteins. Here, the folding process of the Fc fragment of the heavy chain of the antibody MAK33 was investigated. The Fc fragment consists of the C(H)3 and C(H)2 domains of the immunoglobulin heavy chain, both containing a single S-S bond. The folding process was investigated both in the absence and presence of the folding catalyst protein-disulfide isomerase (PDI), monitoring the evolution of intermediates by electrospray mass spectrometry. Moreover, the disulfide bonds present at different times in the folding mixture were identified by mass mapping to determine the hierarchy of disulfide bond formation. The analysis of the uncatalyzed folding showed that the species containing one intramolecular disulfide predominated throughout the entire process, whereas the fully oxidized Fc fragment never accumulated in significant amounts. This result suggests the presence of a kinetic trap during the Fc folding, preventing the one-disulfide-containing species (1S2H) to reach the fully oxidized protein (2S). The assignment of disulfide bonds revealed that 1S2H is a homogeneous species characterized by the presence of a single disulfide bond (Cys-130-Cys-188) belonging to the CH3 domain. When the folding experiments were carried out in the presence of PDI, the completely oxidized species accumulated and predominated at later stages of the process. This species contained the two native S-S bonds of the Fc protein. Our results indicate that the two domains of the Fc fragment fold independently, with a precise hierarchy of disulfide formation in which the disulfide bond, especially, of the CH2 domain requires catalysis by PDI.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Fac Med & Chirurg, I-80131 Naples, Italy; Univ Monte S Angelo, Dipartimento Chim Organ & Biochim, I-80126 Naples, Italy; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Munich, Germany; CEINGE, I-80131 Naples, Italy; Univ Naples Federico II, Sch Biotechnol Sci, I-80126 Naples, Italy	University of Naples Federico II; Technical University of Munich; CEINGE Biotecnologie Avanzate; University of Naples Federico II	Ruoppolo, M (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Fac Med & Chirurg, Via Pansini 5, I-80131 Naples, Italy.	ruoppolo@dbbm.unina.it	Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737; PUCCI, Pietro/0000-0002-5885-1495				Augustine JG, 2001, J BIOL CHEM, V276, P3287, DOI 10.1074/jbc.M005221200; Bolivar F, 1979, Methods Enzymol, V68, P245; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; CHOWDHURY SK, 1990, J AM CHEM SOC, V112, P9012, DOI 10.1021/ja00180a074; Clark PL, 1997, NAT STRUCT BIOL, V4, P883, DOI 10.1038/nsb1197-883; Creighton Thomas E., 1992, P301; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; FREEDMAN RB, 1995, METHOD ENZYMOL, V251, P397, DOI 10.1016/0076-6879(95)51143-1; Frisch C, 1996, FOLD DES, V1, P431, DOI 10.1016/S1359-0278(96)00059-4; GARCIA GM, 1986, CELL, V45, P453, DOI 10.1016/0092-8674(86)90331-4; GOTO Y, 1979, J BIOCHEM-TOKYO, V86, P1433, DOI 10.1093/oxfordjournals.jbchem.a132661; GOTO Y, 1982, J MOL BIOL, V156, P911, DOI 10.1016/0022-2836(82)90147-4; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; HUBER R, 1976, NATURE, V264, P415, DOI 10.1038/264415a0; Iwaoka M, 1998, BIOCHEMISTRY-US, V37, P4490, DOI 10.1021/bi9725327; KATTA V, 1991, RAPID COMMUN MASS SP, V5, P214, DOI 10.1002/rcm.1290050415; KIM PS, 1992, ANNU REV BIOCHEM, V51, P247; LILIE H, 1994, J BIOL CHEM, V269, P14290; LOO JA, 1991, RAPID COMMUN MASS SP, V62, P693; Mayer M, 2000, J BIOL CHEM, V275, P29421, DOI 10.1074/jbc.M002655200; Navon A, 2002, BIOCHEMISTRY-US, V41, P14225, DOI 10.1021/bi020506p; Rudolph R, 1997, PROTEIN FUNCTION PRA, P57; RUDOLPH R, MODERN METHODS PROTE, P14990; Ruoppolo M, 2000, BIOCHEMISTRY-US, V39, P12033, DOI 10.1021/bi001044n; Ruoppolo M, 1998, BIOCHEMISTRY-US, V37, P16060, DOI 10.1021/bi981492j; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Thies MJW, 1999, J MOL BIOL, V293, P67, DOI 10.1006/jmbi.1999.3128; Thies MJW, 2002, J MOL BIOL, V319, P1267, DOI 10.1016/S0022-2836(02)00375-3; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Vinci F, 2000, PROTEIN SCI, V9, P525; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	34	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15059	15066		10.1074/jbc.M311480200	http://dx.doi.org/10.1074/jbc.M311480200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14729662	hybrid			2022-12-25	WOS:000220594700070
J	Huang, MD; Furie, BC; Furie, B				Huang, MD; Furie, BC; Furie, B			Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BINDING SITE; CARBOXYGLUTAMIC ACID DOMAIN; ELECTRON-DENSITY MAPS; K-DEPENDENT PROTEINS; BLOOD-COAGULATION; MEMBRANE-BINDING; HEMOPHILIA-B; PROTHROMBIN FRAGMENT-1; BOVINE PROTHROMBIN; POINT MUTATIONS	The binding of Factor IX to membranes during blood coagulation is mediated by the N-terminal gamma-carboxyglutamic acid-rich (Gla) domain, a membrane-anchoring domain found on vitamin K-dependent blood coagulation and regulatory proteins. Conformation-specific anti-Factor IX antibodies are directed at the calcium-stabilized Gla domain and interfere with Factor IX-membrane interaction. One such antibody, 10C12, recognizes the calcium-stabilized form of the Gla domain of Factor IX. We prepared the fully carboxylated Gla domain of Factor IX by solid phase peptide synthesis and crystallized Factor IX-(1- 47) in complex with Fab fragments of the 10C12 antibody. The overall structure of the Gla domain in the Factor IX-(1 - 47)-antibody complex at 2.2 Angstrom is similar to the structure of the Factor IX Gla domain in the presence of calcium ions as determined by NMR spectroscopy (Freedman, S. J., Furie, B. C., Furie, B., and Baleja, J. D. (1995) Biochemistry 34, 12126 - 12137) and by x-ray crystallography (Shikamoto, Y., Morita, T., Fujimoto, Z., and Mizuno, H. (2003) J. Biol. Chem. 278, 24090 - 24094). The complex structure shows that the complementarity determining region loops of the 10C12 antibody form a hydrophobic pocket to accommodate the hydrophobic patch of the Gla domain consisting of Leu-6, Phe-9, and Val-10. Polar interactions also play an important role in the antibody-antigen recognition. Furthermore, the calcium coordination network of the Factor IX Gla domain is different than in Gla domain structures of other vitamin K-dependent proteins. We conclude that this antibody is directed at the membrane binding site in the omega loop of Factor IX and blocks Factor IX function by inhibiting its interaction with membranes.	Beth Israel Deaconess Med Ctr, Ctr Hemostasis Thrombosis & Vasc Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Furie, B (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Hemostasis Thrombosis & Vasc Biol, 330 Brookline Ave, Boston, MA 02215 USA.		Huang, Mingdong/J-4278-2017	Huang, Mingdong/0000-0003-0085-9141				Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FREEDMAN SJ, 1995, J BIOL CHEM, V270, P7980, DOI 10.1074/jbc.270.14.7980; FURIE B, 1979, J BIOL CHEM, V254, P9766; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GIANNELLI F, 1993, NUCLEIC ACIDS RES, V21, P3075, DOI 10.1093/nar/21.13.3075; Giannelli F, 1998, NUCLEIC ACIDS RES, V26, P265, DOI 10.1093/nar/26.1.265; Gillis S, 1997, PROTEIN SCI, V6, P185; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gui T, 2002, BLOOD, V100, P153, DOI 10.1182/blood.V100.1.153; Huang MD, 1998, J MOL BIOL, V275, P873, DOI 10.1006/jmbi.1997.1512; Huang MD, 2003, NAT STRUCT BIOL, V10, P751, DOI 10.1038/nsb971; Jalbert LR, 1996, BIOCHEMISTRY-US, V35, P7093, DOI 10.1021/bi960290p; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEWIS RM, 1983, BIOCHEMISTRY-US, V22, P948, DOI 10.1021/bi00273a037; Li LP, 1997, BIOCHEMISTRY-US, V36, P2132, DOI 10.1021/bi962250r; LIEBMAN HA, 1987, J BIOL CHEM, V262, P7605; LIEBMAN HA, 1985, P NATL ACAD SCI USA, V82, P3879, DOI 10.1073/pnas.82.11.3879; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P5120, DOI 10.1021/bi9626160; MERRITT EA, 1997, METHOD ENZYMOL, V277, P502; Mizuno H, 2001, P NATL ACAD SCI USA, V98, P7230, DOI 10.1073/pnas.131179698; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Refino CJ, 2002, ARTERIOSCL THROM VAS, V22, P517, DOI 10.1161/hq0302.105375; Refino CJ, 1999, THROMB HAEMOSTASIS, V82, P1188; Rowley G, 1995, GENOMICS, V30, P574, DOI 10.1006/geno.1995.1279; Shikamoto Y, 2003, J BIOL CHEM, V278, P24090, DOI 10.1074/jbc.M300650200; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; Suggett S, 2000, BLOOD COAGUL FIBRIN, V11, P27, DOI 10.1097/00001721-200011010-00004; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; TAI MM, 1980, J BIOL CHEM, V255, P2790; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; Wojcik EGC, 1998, BBA-PROTEIN STRUCT M, V1382, P91, DOI 10.1016/S0167-4838(97)00149-0; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	48	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14338	14346		10.1074/jbc.M314011200	http://dx.doi.org/10.1074/jbc.M314011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722079	hybrid, Green Published			2022-12-25	WOS:000220478500129
J	Jeanneau, C; Chazalet, V; Auge, C; Soumpasis, DM; Harduin-Lepers, A; Delannoy, P; Imberty, A; Breton, C				Jeanneau, C; Chazalet, V; Auge, C; Soumpasis, DM; Harduin-Lepers, A; Delannoy, P; Imberty, A; Breton, C			Structure-function analysis of the human sialyltransferase ST3Gal I - Role of N-glycosylation and a novel conserved sialylmotif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND; LOCALIZATION; RECOGNITION; MECHANISM; RESIDUES; HOMOLOGY; MOUSE; DONOR; DIMER	All eukaryotic sialyltransferases have in common the presence in their catalytic domain of several conserved peptide regions (sialylmotifs L, S, and VS). Functional analysis of sialylmotifs L and S previously demonstrated their involvement in the binding of donor and acceptor substrates. The region comprised between the sialylmotifs S and VS contains a stretch of four highly conserved residues, with the following consensus sequence (H/ y) Y(Y/F/W/h)(E/D/q/g). (Capital letters and lowercase letters indicate a strong or low occurrence of the amino acid, respectively.) The functional importance of these residues and of the conserved residues of motif VS (HX4E) was assessed using as a template the human ST3Gal I. Mutational analysis showed that residues His(299) and Tyr(300) of the new motif, and His(316) of the VS motif, are essential for activity since their substitution by alanine yielded inactive enzymes. Our results suggest that the invariant Tyr residue (Tyr(300)) plays an important conformational role mainly attributable to the aromatic ring. In contrast, the mutants W301F, E302Q, and E321Q retained significant enzyme activity (25 - 80% of the wild type). Kinetic analyses and CDP binding assays showed that none of the mutants tested had any significant effect in nucleotide donor binding. Instead the mutant proteins were affected in their binding to the acceptor and/or demonstrated lower catalytic efficiency. Although the human ST3Gal I has four N-glycan attachment sites in its catalytic domain that are potentially glycosylated, none of them was shown to be necessary for enzyme activity. However, N-glycosylation appears to contribute to the proper folding and trafficking of the enzyme.	Univ Grenoble 1, Ctr Rech Macromol Vegetales, CNRS, GDR 2590, F-38041 Grenoble, France; Univ Paris 11, CNRS, UMR 8614, F-91405 Orsay, France; Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark; USTL, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Technical University of Denmark; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Breton, C (corresponding author), CNRS, CERMAV, BP 53, F-38041 Grenoble 9, France.	Christelle.Breton@cermav.cnrs.fr	Anne, Harduin-Lepers/O-7503-2017; Imberty, Anne/P-6451-2018	Anne, Harduin-Lepers/0000-0002-1233-3799; Imberty, Anne/0000-0001-6825-9527; Delannoy, Philippe/0000-0001-6467-7553				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; Breton C, 2002, BIOCHEM SOC SYMP, V69, P23; Breton C, 1998, J BIOCHEM, V123, P1000; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Chen C, 2000, GLYCOBIOLOGY, V10, P531, DOI 10.1093/glycob/10.5.531; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; Datta AK, 2001, J BIOL CHEM, V276, P15200, DOI 10.1074/jbc.M010542200; Datta AK, 1997, INDIAN J BIOCHEM BIO, V34, P157; Donadio S, 2003, BIOCHIMIE, V85, P311, DOI 10.1016/S0300-9084(03)00080-4; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Kapitonov D, 1999, GLYCOCONJUGATE J, V16, P337, DOI 10.1023/A:1007091926413; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; Laroy W, 2001, GLYCOBIOLOGY, V11, P175, DOI 10.1093/glycob/11.3.175; Legaigneur P, 2001, J BIOL CHEM, V276, P21608, DOI 10.1074/jbc.M100860200; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Martina JA, 1998, J BIOL CHEM, V273, P3725, DOI 10.1074/jbc.273.6.3725; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Qian R, 2001, J BIOL CHEM, V276, P28641, DOI 10.1074/jbc.M103664200; Sarkar M, 1998, GLYCOCONJUGATE J, V15, P193, DOI 10.1023/A:1006928624913; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Vallejo-Ruiz V, 2001, BBA-PROTEIN STRUCT M, V1549, P161, DOI 10.1016/S0167-4838(01)00257-6; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wrabl JO, 2001, J MOL BIOL, V314, P365, DOI 10.1006/jmbi.2001.5151	32	95	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13461	13468		10.1074/jbc.M311764200	http://dx.doi.org/10.1074/jbc.M311764200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722111	hybrid			2022-12-25	WOS:000220478500024
J	Saito, K; Ohara, N; Hotokezaka, H; Fukumoto, S; Yuasa, K; Naito, M; Fujiwara, T; Nakayama, K				Saito, K; Ohara, N; Hotokezaka, H; Fukumoto, S; Yuasa, K; Naito, M; Fujiwara, T; Nakayama, K			Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; FACTOR LIGAND FAMILY; BONE-RESORPTION; OSTEOPROTEGERIN LIGAND; PARATHYROID-HORMONE; IMMUNE-RESPONSES; ANABOLIC ACTIONS; MICE LACKING	Bacterial infection sometimes impairs bone metabolism. In this study, we infected the osteoblastic cell line MC3T3-E1 with Mycobacterium bovis bacillus Calmette-Guerin (BCG) and identified genes that were up-regulated in the BCG-infected cells by the suppression subtractive hybridization method. A gene encoding 4-1BB (CD137), a member of the tumor necrosis factor-alpha receptor family, was found to be one of the up-regulated genes. Up-regulation of 4-1BB was also observed by infection with Escherichia coli, Salmonella typhimurium, and Staphylococcus aureus, and by treatment with lipopolysaccharides and heat-killed BCG. Bone marrow cells and the macrophage-like cell lines J774 and RAW264.7 were found to express 4-1BB ligand (4-1BBL). Recombinant 4-1BB (r4-1BB) that was immobilized on culture plates strongly inhibited macrophage colony stimulating factor (M-CSF)/receptor activator of nuclear factor-kappaB ligand (RANKL)-induced in vitro osteoclast formation from bone marrow cells. Anti-4-1BBL antibody also inhibited osteoclast formation to a lesser extent, indicating involvement of reverse signaling through 4-1BBL during inhibition of osteoclast formation. A casein kinase I (CKI) inhibitor markedly suppressed the inhibitory effect of r4-1BB on M-CSF/ RANKL-induced osteoclast formation, suggesting that CKI might be involved in 4-1BB/4-1BBL reverse signaling. r4-1BB showed no effects on M-CSF- or RANKL-induced phosphorylation of I-kappaB, ERK1/2, p38, or JNK, whereas RANKL-induced phosphorylation of Akt, a downstream target of phosphatidylinositol 3-kinase (PI3K), was completely abolished by r4-1BB, suggesting that 4-1BB/4-1BBL reverse signaling may interfere with PI3K/Akt pathway. r4-1BB also abolished RANKL-mediated induction of nuclear factor of activated T cells-2. This study may elucidate a novel role of 4-1BB in cell metabolism, especially osteoclastogenesis.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Microbiol & Oral Infect, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Pediat Dent, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Orthodont & Biomed Engn, Nagasaki 8528588, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Nakayama, K (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Microbiol & Oral Infect, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	knak@net.nagasaki-u.ac.jp	Saito, Kan/AFS-5564-2022; OHARA, Naoya/B-2481-2011; Saito, Kan/AAG-3507-2020	Saito, Kan/0000-0002-2151-6204; Saito, Kan/0000-0002-2151-6204; Fukumoto, Satoshi/0000-0002-5046-6891				Abu-Nader R, 2002, MAYO CLIN PROC, V77, P393, DOI 10.4065/77.4.393; ALDERSON MR, 1994, EUR J IMMUNOL, V24, P2219, DOI 10.1002/eji.1830240943; ANBIN JE, 1996, PRINCIPLES BONE BIOL, P51; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Boyce BF, 1999, LAB INVEST, V79, P83; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cannons JL, 2001, J IMMUNOL, V167, P1313, DOI 10.4049/jimmunol.167.3.1313; Chambers TJ, 2000, J PATHOL, V192, P4; Chu NR, 1997, J IMMUNOL, V158, P3081; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; DeBenedette MA, 1999, J IMMUNOL, V163, P4833; DELANY AM, 1994, J CELL BIOCHEM, V56, P295, DOI 10.1002/jcb.240560304; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; DEMPSTER DW, 1995, ENDOCRINE REV MONOGR, V4, P247; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200; Hotokezaka H, 1998, SCAND J IMMUNOL, V47, P453; Hurtado JC, 1997, J IMMUNOL, V158, P2600; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822; Iwamoto T, 2001, J BIOL CHEM, V276, P46031, DOI 10.1074/jbc.M104464200; Kawabata Y, 1998, FEMS IMMUNOL MED MIC, V22, P293, DOI 10.1016/S0928-8244(98)00100-X; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kong YY, 2000, IMMUNOL TODAY, V21, P495, DOI 10.1016/S0167-5699(00)01718-7; Kwon BS, 2002, J IMMUNOL, V168, P5483, DOI 10.4049/jimmunol.168.11.5483; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Langstein J, 1999, BLOOD, V94, P3161, DOI 10.1182/blood.V94.9.3161.421k31_3161_3168; Langstein J, 1999, J LEUKOCYTE BIOL, V65, P829, DOI 10.1002/jlb.65.6.829; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006-291X(03)00695-8; Lian JB, 1999, VITAM HORM, V55, P443; Lin CJ, 1999, J BONE JOINT SURG AM, V81A, P1305, DOI 10.2106/00004623-199909000-00012; Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBEN RA, 1976, ENDOCRINOLOGY, V99, P526, DOI 10.1210/endo-99-2-526; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Meghji S, 1997, J EXP MED, V186, P1241, DOI 10.1084/jem.186.8.1241; Melero I, 1998, CELL IMMUNOL, V190, P167, DOI 10.1006/cimm.1998.1396; Moon MS, 1997, SPINE, V22, P1791, DOI 10.1097/00007632-199708010-00022; Nau GJ, 1999, INFECT IMMUN, V67, P4223, DOI 10.1128/IAI.67.8.4223-4230.1999; Nau GJ, 1997, P NATL ACAD SCI USA, V94, P6414, DOI 10.1073/pnas.94.12.6414; Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293; POLLOK KE, 1994, EUR J IMMUNOL, V24, P367, DOI 10.1002/eji.1830240215; POLLOK KE, 1993, J IMMUNOL, V150, P771; Sakai H, 2000, BIOCHEM BIOPH RES CO, V270, P550, DOI 10.1006/bbrc.2000.2485; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tsurukai T, 1998, J CELL PHYSIOL, V177, P26, DOI 10.1002/(SICI)1097-4652(199810)177:1<26::AID-JCP3>3.0.CO;2-G; TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275; ULSTRUP JC, 1995, INFECT IMMUN, V63, P672, DOI 10.1128/IAI.63.2.672-675.1995; Valledor AF, 1999, J IMMUNOL, V163, P2452; Vinay DS, 1998, SEMIN IMMUNOL, V10, P481, DOI 10.1006/smim.1998.0157; Watts AD, 1999, EMBO J, V18, P2119, DOI 10.1093/emboj/18.8.2119; Watts TH, 1999, CURR OPIN IMMUNOL, V11, P286, DOI 10.1016/S0952-7915(99)80046-6; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhang ZY, 2003, J IMMUNOL, V171, P3620, DOI 10.4049/jimmunol.171.7.3620	68	42	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13555	13563		10.1074/jbc.M303791200	http://dx.doi.org/10.1074/jbc.M303791200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729681	hybrid			2022-12-25	WOS:000220478500035
J	Silvennoinen, L; Myllyharju, J; Ruoppolo, M; Orru, S; Caterino, M; Kivirikko, KI; Koivunen, P				Silvennoinen, L; Myllyharju, J; Ruoppolo, M; Orru, S; Caterino, M; Kivirikko, KI; Koivunen, P			Identification and characterization of structural domains of human ERp57 - Association with calreticulin requires several domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; THIOL-DEPENDENT REDUCTASE; PROLYL 4-HYDROXYLASES; ENDOPLASMIC-RETICULUM; N-15 RESONANCES; TERMINAL DOMAIN; SUBUNIT; ASSIGNMENT; A'; EXPRESSION	The amino acid sequence of ERp57, which functions in the endoplasmic reticulum together with the lectins calreticulin and calnexin to achieve folding of newly synthesized glycoproteins, is highly similar to that of protein disulfide isomerase (PDI), but they have their own distinct roles in protein folding. We have characterized the domain structure of ERp57 by limited proteolysis and N-terminal sequencing and have found it to be similar but not identical to that of PDI. ERp57 had three major protease-sensitive regions, the first of which was located between residues 120 and 150, the second between 201 and 215, and the third between 313 and 341, the data thus being consistent with a four-domain structure abb 'a'. Recombinant expression in Escherichia coli was used to verify the domain boundaries. Each single domain and a b 'a' double domain could be produced in the form of soluble, folded polypeptides, as verified by circular dichroism spectra and urea gradient gel electrophoresis. When the ability of ERp57 and its a and a' domains to fold denatured RNase A was studied by electrospray mass analyses, ERp57 markedly enhanced the folding rate at early time points, although less effectively than PDI, but was an ineffective catalyst of the overall process. The a and a' domains produced only minor, if any, increases in the folding rate at the early stages and no increase at the late stages. Interaction of the soluble ERp57 domains with the P domain of calreticulin was studied by chemical cross-linking in vitro. None of the single ERp57 domains nor the b' a' double domain could be cross-linked to the P domain, whereas cross-linking was obtained with a hybrid ERpabb' PDIa' c polypeptide but not with ERpabPDIb' a' c, indicating that multiple domains are involved in this protein-protein interaction and that the b' domain of ERp57 cannot be replaced by that of PDI.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Naples Federico II, Dept Biochem & Med Biotechnol, I-80138 Naples, Italy; Ctr Ingn Genet Biotecnol Avanzate, Scrl, I-80138 Naples, Italy	University of Oulu; University of Oulu; University of Naples Federico II	Koivunen, P (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	peppi.koivunen@oulu.fi	Caterino, Marianna/AAR-3526-2020; Orrù, Stefania/A-2895-2015; Caterino, Marianna/K-4531-2016; Stefania, Orrù/ABH-2178-2020	Caterino, Marianna/0000-0001-6035-8213				Alanen HI, 2003, ANTIOXID REDOX SIGN, V5, P367, DOI 10.1089/152308603768295096; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; Dijkstra K, 1999, J BIOMOL NMR, V14, P195, DOI 10.1023/A:1008331225208; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Freedman RB, 1998, BIOL CHEM, V379, P321, DOI 10.1515/bchm.1998.379.3.321; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; GRUENWALD S, 1994, BACULOVIRUS EXPRESSI; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Koivunen P, 1997, GENOMICS, V42, P397, DOI 10.1006/geno.1997.4750; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; Koivunen P, 1996, BIOCHEM J, V316, P599, DOI 10.1042/bj3160599; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Peterson JR, 1999, J CELL SCI, V112, P2775; Pirneskoski A, 2001, J BIOL CHEM, V276, P11287, DOI 10.1074/jbc.M010656200; Ruoppolo M, 1997, BIOCHEMISTRY-US, V36, P12259, DOI 10.1021/bi970851s; Ruoppolo M, 2000, BIOCHEMISTRY-US, V39, P12033, DOI 10.1021/bi001044n; Ruoppolo M, 2003, PROTEIN SCI, V12, P939, DOI 10.1110/ps.0242803; Silvennoinen L, 2001, J BIOMOL NMR, V20, P385, DOI 10.1023/A:1011291316810; SRIVASTAVA SP, 1993, BIOCHEM BIOPH RES CO, V193, P971, DOI 10.1006/bbrc.1993.1720; TORELLA C, 1994, FEBS LETT, V352, P301; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	38	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13607	13615		10.1074/jbc.M313054200	http://dx.doi.org/10.1074/jbc.M313054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732712	hybrid			2022-12-25	WOS:000220478500041
J	Goumon, Y; Angelone, T; Schoentgen, FO; Chasserot-Golaz, S; Almas, B; Fukami, MM; Langley, K; Welters, ID; Tota, B; Aunis, D; Metz-Boutigue, MH				Goumon, Y; Angelone, T; Schoentgen, FO; Chasserot-Golaz, S; Almas, B; Fukami, MM; Langley, K; Welters, ID; Tota, B; Aunis, D; Metz-Boutigue, MH			The hippocampal cholinergic neurostimulating peptide, the N-terminal fragment of the secreted phosphatidylethanolamine-binding protein, possesses a new biological activity on cardiac physiology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; DOPAMINE-BETA-HYDROXYLASE; CHROMOGRANIN-A; CHROMAFFIN GRANULES; ENDOCARDIAL ENDOTHELIUM; CARBOXYPEPTIDASE-Y; PROCESSING ENZYME; CRYSTAL-STRUCTURE; PROENKEPHALIN-A; CELLS	Phosphatidylethanolamine- binding protein ( PEBP), alternatively named Raf- 1 kinase inhibitor protein, is the precursor of the hippocampal cholinergic neurostimulating peptide ( HCNP) corresponding to its natural N- terminal fragment, previously described to be released by hippocampal neurons. PEBP is a soluble cytoplasmic protein, also associated with plasma and reticulum membranes of numerous cell types. In the present report, using biochemistry and cell biology techniques, we report for the first time the presence of PEBP in bovine chromaffin cell, a well described secretion model. We have examined its presence at the subcellular level and characterized this protein on both secretory granule membranes and intragranular matrix. In addition, its presence in bovine chromaffin cell and platelet exocytotic medium, as well as in serum, was reported showing that it is secreted. Like many other proteins that lack signal sequence, PEBP may be secreted through non- classic signal secretory mechanisms, which could be due to interactions with granule membrane lipids and lipid rafts. By two- dimensional liquid chromatography- tandem mass spectrometry, HCNP was detected among the intragranular matrix components. The observation that PEBP and HCNP were secreted with catecholamines into the circulation prompted us to investigate endocrine effects of this peptide on cardiovascular system. By using as bioassay an isolated and perfused frog ( Rana esculenta) heart preparation, we show here that HCNP acts on the cardiac mechanical performance exerting a negative inotropism and counteracting the adrenergic stimulation of isoproterenol. All together, these data suggest that PEBP and HCNP might be considered as new endocrine factors involved in cardiac physiology.	INSERM, U575, F-67084 Strasbourg, France; Univ Calabria, Dept Cell Biol, Lab Cardiovasc Physiol, I-87030 Arcavacata Di Rende, Italy; CNRS, UPR 4301, Ctr Biophys Mol, F-45071 Orleans, France; CNRS, UPR 2356, F-67084 Strasbourg, France; Dept Biochem & Mol Biol, N-5009 Bergen, Norway; Univ Giessen, Dept Anaesthesiol Intens Care & Pain Med, D-35385 Giessen, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Calabria; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Justus Liebig University Giessen	Metz-Boutigue, MH (corresponding author), INSERM, U575, IFR 37, F-67084 Strasbourg, France.	metz@neurochem.u-strasbg.fr	Langley, Keith/M-7516-2014; Dominique, Aunis/W-1419-2019; Chasserot-Golaz, Sylvette/K-7625-2017; Angelone, Tommaso/AAM-1230-2020	Angelone, Tommaso/0000-0001-7797-7862; Chasserot-Golaz, Sylvette/0000-0002-7437-2558; Welters, Ingeborg/0000-0002-3408-8798; Goumon, Yannick/0000-0003-4336-3437				Ayala-Sanmartin J, 2001, BBA-BIOMEMBRANES, V1510, P18, DOI 10.1016/S0005-2736(00)00262-5; AZARYAN AV, 1995, J BIOL CHEM, V270, P8201, DOI 10.1074/jbc.270.14.8201; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; BERNIER I, 1984, BIOCHIM BIOPHYS ACTA, V790, P174, DOI 10.1016/0167-4838(84)90221-8; Bond J. S., 1989, PROTEOLYTIC ENZYMES, P240; Bruun AW, 1998, BIOCHEMISTRY-US, V37, P3351, DOI 10.1021/bi971286w; Carvalho AL, 2002, J MOL BIOL, V322, P325, DOI 10.1016/S0022-2836(02)00705-2; Chasserot-Golaz S, 1998, J NEUROCHEM, V70, P2347; Dahl A, 2003, RAPID COMMUN MASS SP, V17, P2195, DOI 10.1002/rcm.1183; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; DREYFUS H, 1977, BIOCHIM BIOPHYS ACTA, V489, P89, DOI 10.1016/0005-2760(77)90235-1; EIDEN LE, 1987, J NEUROCHEM, V49, P65, DOI 10.1111/j.1471-4159.1987.tb03395.x; EVANGELISTA R, 1982, BIOCHEM BIOPH RES CO, V106, P895, DOI 10.1016/0006-291X(82)91795-8; Frayne J, 1999, CELL TISSUE RES, V298, P415, DOI 10.1007/s004419900113; FUKAMI MH, 2001, HEMOSTASIS THROMBOSI, P561; FURIE B, 1992, NEW ENGL J MED, V326, P800; Gattuso A, 1999, AM J PHYSIOL-HEART C, V276, pH633, DOI 10.1152/ajpheart.1999.276.2.H633; Goumon Y, 2000, J BIOL CHEM, V275, P38355, DOI 10.1074/jbc.M007557200; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; HELLE KB, 1971, BIOCHIM BIOPHYS ACTA, V245, P94, DOI 10.1016/0005-2728(71)90011-9; HELLE KB, 1969, PHARMACOL RES COMMUN, V1, P25; Hengst U, 2001, J BIOL CHEM, V276, P535, DOI 10.1074/jbc.M002524200; Hook VYH, 1996, ANN NY ACAD SCI, V780, P121, DOI 10.1111/j.1749-6632.1996.tb15116.x; HORTNAGL H, 1974, J NEUROCHEM, V22, P197, DOI 10.1111/j.1471-4159.1974.tb12201.x; Hwang SR, 1999, J BIOL CHEM, V274, P34164, DOI 10.1074/jbc.274.48.34164; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Katada E, 2000, J NEUROCYTOL, V29, P199, DOI 10.1023/A:1026555107647; Kieffer AE, 2003, FASEB J, V17, P776, DOI 10.1096/fj.02-0699fje; Kratchmarova I, 2002, MOL CELL PROTEOMICS, V1, P213, DOI 10.1074/mcp.M200006-MCP200; KUHN DM, 1990, J BIOL CHEM, V265, P5780; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leone Marc, 2002, Curr Opin Crit Care, V8, P395, DOI 10.1097/00075198-200210000-00005; LINDBERG I, 1982, LIFE SCI, V31, P1713, DOI 10.1016/0024-3205(82)90192-8; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; Mima J, 2003, J BIOL CHEM, V278, P29792, DOI 10.1074/jbc.M301859200; MIZUNO K, 1985, BIOCHEM BIOPH RES CO, V128, P884, DOI 10.1016/0006-291X(85)90129-9; Ojika K, 2000, PROG NEUROBIOL, V60, P37, DOI 10.1016/S0301-0082(99)00021-0; Otsuka Y, 1996, NEUROCHEM RES, V21, P369, DOI 10.1007/BF02531654; Parmer RJ, 2000, J CLIN INVEST, V106, P907, DOI 10.1172/JCI7394; PERRY ACF, 1994, BIOCHEM J, V301, P235, DOI 10.1042/bj3010235; ROUSSEL G, 1988, DEV NEUROSCI-BASEL, V10, P65, DOI 10.1159/000111957; Rubartelli A., 1997, UNUSUAL SECRETORY PA, P87, DOI [10.1007/978-3-662-22581-3_3, DOI 10.1007/978-3-662-22581-3_3]; RUSH RA, 1980, CRC CR REV CL LAB SC, V12, P241, DOI 10.3109/10408368009108731; SABO T, 1992, BIOCHEM BIOPH RES CO, V188, P604, DOI 10.1016/0006-291X(92)91099-C; SAUNDERS PTK, 1995, MOL CELL ENDOCRINOL, V107, P221, DOI 10.1016/0303-7207(94)03447-2; SCHOENTGEN F, 1987, EUR J BIOCHEM, V166, P333, DOI 10.1111/j.1432-1033.1987.tb13519.x; SHEN FS, 1989, J BIOL CHEM, V264, P15600; SIMON JP, 1989, BIOCHEM J, V262, P1; Slimane TA, 2002, FEBS LETT, V529, P54, DOI 10.1016/S0014-5793(02)03183-6; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; SUZUKI H, 1995, EXP MOL PATHOL, V62, P63, DOI 10.1006/exmp.1995.1007; Sys SU, 1997, J EXP BIOL, V200, P3109; TERLAND O, 1980, BIOCHIM BIOPHYS ACTA, V597, P318, DOI 10.1016/0005-2736(80)90109-1; Thiele C, 1998, SEMIN CELL DEV BIOL, V9, P511, DOI 10.1006/scdb.1998.0259; Thiriet N, 2001, EUR J NEUROSCI, V14, P1702, DOI 10.1046/j.0953-816x.2001.01791.x; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Tota B, 2003, REGUL PEPTIDES, V114, P123, DOI 10.1016/S0167-0115(03)00112-5; Towbin H, 1992, Biotechnology, V24, P145; Tsugu Y, 1998, EUR J NEUROL, V5, P561, DOI 10.1046/j.1468-1331.1998.560561.x; Turner KJ, 1996, J ANDROL, V17, P127; Vallee BS, 2001, EUR J BIOCHEM, V268, P5831, DOI 10.1046/j.0014-2956.2001.02528.x; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; Wortsman J, 2002, ENDOCRIN METAB CLIN, V31, P79, DOI 10.1016/S0889-8529(01)00024-X; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; YOO SH, 1994, J BIOL CHEM, V269, P12001; Zhang CF, 2003, BIOCHEM J, V369, P453, DOI 10.1042/BJ20020827	68	46	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13054	13064		10.1074/jbc.M308533200	http://dx.doi.org/10.1074/jbc.M308533200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14724289	Green Published, hybrid			2022-12-25	WOS:000220334900126
J	Kim, MH; Hersh, LB				Kim, MH; Hersh, LB			The vesicular acetylcholine transporter interacts with clathrin-associated adaptor complexes AP-1 and AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; SYNAPTIC VESICLE ENDOCYTOSIS; TAIL SORTING SIGNALS; TRANS-GOLGI NETWORK; FACTOR-II RECEPTOR; PROTEIN COMPLEX; CYTOPLASMIC TAIL; PLASMA-MEMBRANE; RAPID INTERNALIZATION; INVARIANT CHAIN	In neuronal cells the neurotransmitter acetylcholine is transferred from the cytoplasm into synaptic vesicles by the vesicular acetylcholine transporter ( VAChT). The cytoplasmic tail of VAChT has been shown to contain signals that direct its sorting and trafficking. The role of clathrin-associated protein complexes in VAChT sorting to synaptic vesicles has been examined. A fusion protein between the VAChT cytoplasmic tail and glutathione S-transferase was used to identify VAChT-clathrin-associated protein adaptor protein 1, adaptor protein 2 and adaptor protein 180 complexes from a rat brain extract. In vivo coimmunoprecipitation confirmed adaptin alpha and adaptin gamma complexes, but adaptor protein 180 complexes were not detected by this technique. Deletion and site directed mutagenesis show that the VAChT cytoplasmic tail contains multiple trafficking signals. These include a non-classical tyrosine motif that serves as the signal for adaptin alpha and a dileucine motif that serves as the signal for adaptin gamma. A classical tyrosine motif is also involved in VAChT trafficking, but does not interact with any known adaptor proteins. There appear to be two endocytosis motifs, one involving the adaptor protein 1 binding site and the other involving the adaptor protein 2 binding site. These results suggest a complex trafficking pathway for VAChT.	Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky	Hersh, LB (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, 800 Rose St,MS607, Lexington, KY 40536 USA.	lhersh@uky.edu			NIA NIH HHS [AG 05893] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG005893, R55AG005893] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barbosa J, 2002, J NEUROCHEM, V82, P1221, DOI 10.1046/j.1471-4159.2002.01068.x; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Denzer K, 1997, BIOCHEM J, V326, P497, DOI 10.1042/bj3260497; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Eiden LE, 1998, J NEUROCHEM, V70, P2227; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Gilmor ML, 1996, J NEUROSCI, V16, P2179; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JADOT M, 1992, J BIOL CHEM, V267, P11069; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KELLY RB, 1993, ANNU REV NEUROSCI, V16, P95, DOI 10.1146/annurev.ne.16.030193.000523; Kim MH, 1999, J BIOL CHEM, V274, P673, DOI 10.1074/jbc.274.2.673; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kongsvik TL, 2002, J BIOL CHEM, V277, P16484, DOI 10.1074/jbc.M201583200; Krantz DE, 2000, J CELL BIOL, V149, P379, DOI 10.1083/jcb.149.2.379; Lee WS, 2002, J BIOL CHEM, V277, P3544, DOI 10.1074/jbc.M108531200; Liu YJ, 1997, J CELL BIOL, V139, P907, DOI 10.1083/jcb.139.4.907; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Mellman I, 1996, CURR OPIN CELL BIOL, V8, P497, DOI 10.1016/S0955-0674(96)80026-3; Morgan JR, 2000, J NEUROSCI, V20, P8667; Morgan JR, 1999, J NEUROSCI, V19, P10201; NAIM HY, 1994, J BIOL CHEM, V269, P3928; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Nonet ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/mbc.10.7.2343; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V123, P1093; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHULDINER S, 1994, ANN NY ACAD SCI, V733, P174, DOI 10.1111/j.1749-6632.1994.tb17267.x; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SONG JK, 1999, J BIOL CHEM, V274, P3141; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; Sorkina T, 1999, J CELL SCI, V112, P317; Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351; Tao-Cheng J H, 1998, Adv Pharmacol, V42, P250; Teuchert M, 1999, J BIOL CHEM, V274, P8199, DOI 10.1074/jbc.274.12.8199; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; Varoqui H, 1998, J BIOL CHEM, V273, P9094, DOI 10.1074/jbc.273.15.9094; Varoqui H, 1997, MOL NEUROBIOL, V15, P165, DOI 10.1007/BF02740633; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482; Weihe E, 1996, P NATL ACAD SCI USA, V93, P3547, DOI 10.1073/pnas.93.8.3547; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	58	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12580	12587		10.1074/jbc.M310681200	http://dx.doi.org/10.1074/jbc.M310681200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14724281	hybrid			2022-12-25	WOS:000220334900071
J	Yang, SC; Cho, YS; Chennathukuzhi, VM; Underkoffler, LA; Loomes, K; Hecht, NB				Yang, SC; Cho, YS; Chennathukuzhi, VM; Underkoffler, LA; Loomes, K; Hecht, NB			Translin-associated factor X is post-transcriptionally regulated by its partner protein TB-RBP, and both are essential for normal cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; MALE GERM-CELLS; TESTIS-BRAIN; MESSENGER-RNAS; CHROMOSOMAL TRANSLOCATIONS; ENDOPLASMIC-RETICULUM; GENOMIC STRUCTURE; DNA-BINDING; TRAX; GENE	To determine the functions of the DNA/RNA-binding protein TB-RBP in somatic cells, we examined cultured primary mouse embryonic fibroblasts (MEFs) derived from TB-RBP-deficient mice. The TB-RBP-deficient MEFs exhibit a reduced growth rate compared with MEFs from littermates. Reintroduction of TB-RBP remedies this defect. A partner protein of TB-RBP, Translin-associated factor X ( TRAX), was absent in TB-RBP-deficient MEFs, despite normal TRAX mRNA levels. TRAX is dependent upon the presence of TB-RBP and is removed from null MEFs following ubiquitination. Re-introduction of TB-RBP, but not TB-RBP lacking an oligomerization domain, into null MEFs stabilized TRAX protein without changing TRAX mRNA levels. The coordinated expression of TB-RBP and TRAX is also seen in synchronized cells, where the amount of TRAX protein but not TRAX RNA closely parallels TB-RBP levels throughout the cell cycle. In transgenic mice overexpressing TRAX in testis, total TB-RBP and TRAX levels are constant with reductions of endogenous TRAX compensating for exogenous TRAX. Using RNA interference, reductions of either TB-RBP or TRAX ( without affecting TB-RBP) slow cell growth rates. We conclude that TRAX is posttranscriptionally stabilized by TB-RBP and both proteins are needed for normal cell proliferation.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Hecht, NB (corresponding author), Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, 1310 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	nhecht@mail.med.upenn.edu			NICHD NIH HHS [HD 28832] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028832] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aoki K, 1997, FEBS LETT, V401, P109, DOI 10.1016/S0014-5793(96)01444-5; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Aoki K, 1997, GENOMICS, V43, P237, DOI 10.1006/geno.1997.4796; Bray JD, 2002, GENOMICS, V79, P799, DOI 10.1006/geno.2002.6779; Chennathukuzhi V, 2003, P NATL ACAD SCI USA, V100, P15566, DOI 10.1073/pnas.2536695100; Chennathukuzhi V, 2003, MOL CELL BIOL, V23, P6419, DOI 10.1128/MCB.23.18.6419-6434.2003; Chennathukuzhi VM, 2001, J BIOL CHEM, V276, P13256, DOI 10.1074/jbc.M009707200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Erdemir T, 2002, J CELL SCI, V115, P207; Finkenstadt PM, 2000, J NEUROCHEM, V75, P1754, DOI 10.1046/j.1471-4159.2000.0751754.x; Gu W, 1998, MOL REPROD DEV, V49, P219, DOI 10.1002/(SICI)1098-2795(199803)49:3&lt;219::AID-MRD1&gt;3.0.CO;2-R; HAN JR, 1995, BIOL REPROD, V53, P707, DOI 10.1095/biolreprod53.3.707; HAN JR, 1995, P NATL ACAD SCI USA, V92, P9550, DOI 10.1073/pnas.92.21.9550; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Ishida R, 2002, FEBS LETT, V525, P105, DOI 10.1016/S0014-5793(02)03095-8; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kasai M, 1997, J BIOL CHEM, V272, P11402; KWON YK, 1993, MOL CELL BIOL, V13, P6547, DOI 10.1128/MCB.13.10.6547; MCCARREY JR, 1987, GENE, V61, P291, DOI 10.1016/0378-1119(87)90192-2; Millar JK, 2000, GENOMICS, V67, P69, DOI 10.1006/geno.2000.6239; Morales CR, 2002, DEV BIOL, V246, P480, DOI 10.1006/dbio.2002.0679; Nicola AV, 1999, NAT CELL BIOL, V1, P341, DOI 10.1038/14032; Pascal JM, 2002, J MOL BIOL, V319, P1049, DOI 10.1016/S0022-2836(02)00364-9; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; VanLoock MS, 2001, J STRUCT BIOL, V135, P58, DOI 10.1006/jsbi.2001.4383; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wu XQ, 1999, BIOCHEMISTRY-US, V38, P11261, DOI 10.1021/bi990573s; Wu XQ, 2000, BIOL REPROD, V62, P720, DOI 10.1095/biolreprod62.3.720; Wu XQ, 1998, NUCLEIC ACIDS RES, V26, P1675, DOI 10.1093/nar/26.7.1675; Wu XQ, 1997, P NATL ACAD SCI USA, V94, P5640, DOI 10.1073/pnas.94.11.5640; Yang JX, 2003, BIOL REPROD, V68, P853, DOI 10.1095/biolreprod.102.008631; Yang SC, 2001, MOL CELL BIOL, V21, P7807, DOI 10.1128/MCB.21.22.7807-7816.2001; Yang SC, 2001, J BIOL CHEM, V276, P4889, DOI 10.1074/jbc.M004895200; [No title captured]	36	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12605	12614		10.1074/jbc.M313133200	http://dx.doi.org/10.1074/jbc.M313133200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711818	hybrid			2022-12-25	WOS:000220334900074
J	Das, R; Mahabeleshwar, GH; Kundu, GC				Das, R; Mahabeleshwar, GH; Kundu, GC			Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; B-MEDIATED SECRETION; SIGNAL-TRANSDUCTION PATHWAYS; FOCAL ADHESION KINASE; EGF RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PROMATRIX METALLOPROTEINASE-2; MATRIX-METALLOPROTEINASE; CYCLE PROGRESSION; MELANOMA-CELLS	We have recently reported that osteopontin (OPN) stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase-type plasminogen activator (uPA) through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells (Das, R., Mahabeleshwar, G. H., and Kundu, G. C. ( 2003) J. Biol. Chem. 278, 28593 28606). However, the role(s) of OPN on AP-1-mediated uPA secretion and cell motility and the involvement of c-Src/epidermal growth factor receptor ( EGFR) in these processes in breast cancer cells are not well defined. In this study we report that OPN induces alpha(v)beta(3) integrin-mediated c-Src kinase activity in both highly invasive (MDA-MB-231) and low invasive (MCF-7) breast cancer cells. Ligation of OPN with alpha(v)beta(3) integrin induces kinase activity and tyrosine phosphorylation of EGFR in MDA-MB-231 and wild type EGFR-transfected MCF-7 cells, and this was inhibited by the dominant negative form of c-Src (dn c-Src) indicating that c-Src kinase plays a crucial role in this process. OPN induces association between alpha(v)beta(3) integrin and EGFR on the cell membrane in a macromolecular form with c-Src. Furthermore, OPN induces alpha(v)beta(3) integrin/ EGFR-mediated ERK1/2 phosphorylation and AP-1 activation. Moreover, dn c-Src also suppressed the OPN-induced phosphatidylinositol ( PI) 3-kinase activity in these cells indicating that c-Src acts as master switch in regulating MEK/ERK1/2 and phosphatidylinositol 3-kinase/ Akt signaling pathways. OPN-induced ERK phosphorylation, AP-1 activation, uPA secretion, and cell motility were suppressed when cells were transfected with dn c-Src or pretreated with alpha(v)beta(3) integrin antibody, c-Src kinase inhibitor (pp2), EGFR tyrosine kinase inhibitor (PD153035), and MEK-1 inhibitor (PD98059). To our knowledge, this is the first report that OPN induces alpha(v)beta(3) integrin-mediated AP-1 activity and uPA secretion by activating c-Src/EGFR/ERK signaling pathways and further demonstrates a functional molecular link between OPN-induced integrin/ c-Src-dependent EGFR phosphorylation and ERK/AP-1-mediated uPA secretion, and all of these ultimately control the motility of breast cancer cells.	NCCS, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), NCCS, NCCS Complex, Pune 411007, Maharashtra, India.	gopalkundu@hotmail.com	Kundu, Gopal C./ABA-9897-2020					Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BROWN LF, 1994, AM J PATHOL, V145, P610; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chen J, 2001, J BIOL CHEM, V276, P47901, DOI 10.1074/jbc.M107574200; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; DECESARE D, 1995, ONCOGENE, V11, P365; DEFILIPPI P, 1997, MOL B INT U, P1; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HRUSKA KA, 1995, ENDOCRINOLOGY, V136, P2984, DOI 10.1210/en.136.7.2984; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Liaw L, 1998, J CLIN INVEST, V101, P1468; Lui VWY, 2002, ANTICANCER RES, V22, P1; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P52598, DOI 10.1074/jbc.M308941200; Malik RK, 1996, BBA-REV CANCER, V1287, P73, DOI 10.1016/0304-419X(96)00008-X; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Price JT, 1999, CANCER RES, V59, P5475; PRINCE CW, 1989, CONNECT TISSUE RES, V21, P345, DOI 10.3109/03008208909049991; RADINSKY R, 1995, CLIN CANCER RES, V216, P261; Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; Shih WL, 2003, J BIOL CHEM, V278, P31807, DOI 10.1074/jbc.M302580200; Teti A, 1998, INT J CANCER, V77, P82; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	58	97	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11051	11064		10.1074/jbc.M310256200	http://dx.doi.org/10.1074/jbc.M310256200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14704150	hybrid			2022-12-25	WOS:000220157600028
J	Li, SY; Gomelsky, M; Duan, JH; Zhang, ZJ; Gomelsky, L; Zhang, XC; Epstein, PN; Ren, J				Li, SY; Gomelsky, M; Duan, JH; Zhang, ZJ; Gomelsky, L; Zhang, XC; Epstein, PN; Ren, J			Overexpression of aldehyde dehydrogenase-2 (ALDH2) transgene prevents acetaldehyde-induced cell injury in human umbilical vein endothelial cells - Role of ERK and p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; LIPID-PEROXIDATION; XANTHINE-OXIDASE; GENE-EXPRESSION; ETHANOL; ALCOHOL; METABOLISM; EXPOSURE; COLLAGEN; BLOOD	Acetaldehyde, the major ethanol metabolite that is far more toxic and reactive than ethanol, has been postulated to be responsible for alcohol-induced tissue and cell injury. This study was to examine whether facilitated acetaldehyde metabolism affects acetaldehyde-induced oxidative stress and apoptosis. Transgene-encoding human aldehyde dehydrogenase-2 (ALDH2), which converts acetaldehyde into acetate, was constructed under chicken beta-actin promoter and transfected into human umbilical vein endothelial cells (HUVECs). Efficacy of ALDH2 transfection was verified using green fluorescent protein and ALDH2 enzymatic assay. Generation of reactive oxygen species (ROS) was measured using chloromethyl-2 ', 7'-dichlorodihydrofluorescein diacetate. Apoptosis was evaluated by 4', 6'-diamidino-2'-phenylindoladihydrochloride fluorescence microscopy, quantitative DNA fragmentation, and caspase-3 assay. Acetaldehyde (0 - 200 muM) elicited ROS generation and apoptosis in HUVECs in a time- and concentration-dependent manner, associated with activation of the stress signal molecules ERK1/2 and p38 mitogen-activated protein ( MAP) kinase. A close liner correlation was observed between the acetaldehyde-induced ROS generation and apoptosis. Interestingly, the acetaldehyde-induced ROS generation, apoptosis, activation of ERK1/2, and p38 MAP kinase were prevented by the ALDH2 transgene or antioxidant alpha-tocopherol. The involvement of ERK1/2 and p38 MAP kinase in acetaldehyde-induced apoptosis was confirmed by selective kinase inhibitors U0126, SB203580, and SB202190. Collectively, our data revealed that facilitation of acetaldehyde metabolism by ALDH2 transgene overexpression may prevent acetaldehyde-induced cell injury and activation of stress signals. These results indicated therapeutic potential of ALDH2 enzyme in the prevention and detoxification of acetaldehyde or alcohol-induced cell injury.	Univ Wyoming, Coll Hlth Sci, Div Pharmaceut Sci, Laramie, WY 82071 USA; Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA; Univ Wyoming, Microscop Facil, Laramie, WY 82071 USA; Univ Louisville, Dept Pediat, Louisville, KY 40202 USA	University of Wyoming; University of Wyoming; University of Wyoming; University of Louisville	Ren, J (corresponding author), Univ Wyoming, Coll Hlth Sci, Div Pharmaceut Sci, Laramie, WY 82071 USA.	jren@uwyo.edu	Ren, Jun/ACG-5366-2022; gomelsky, mark/F-6209-2010	Ren, Jun/0000-0002-0275-0783; Epstein, Paul/0000-0002-7006-8954; Gomelsky, Mark/0000-0003-4077-3932	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R15AA013575] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR15640] Funding Source: Medline; NIAAA NIH HHS [1R15AA/HL13575-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aberle NS, 2003, ALCOHOL CLIN EXP RES, V27, P577, DOI 10.1097/01.ALC.0000060522.40447.8E; AGARWAL DP, 1990, PHARMACOL THERAPEUT, V45, P69, DOI 10.1016/0163-7258(90)90008-P; Bailey SM, 1999, FREE RADICAL BIO MED, V27, P891, DOI 10.1016/S0891-5849(99)00138-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGUNDER JM, 1988, EUR J CLIN INVEST, V18, P420, DOI 10.1111/j.1365-2362.1988.tb01034.x; Cao Q, 2002, BIOCHEM BIOPH RES CO, V299, P459, DOI 10.1016/S0006-291X(02)02672-4; Cederbaum AI, 2001, FREE RADICAL BIO MED, V31, P1539, DOI 10.1016/S0891-5849(01)00743-2; Chen AP, 2000, MOL CELL BIOL, V20, P2818, DOI 10.1128/MCB.20.8.2818-2826.2000; Duan JH, 2002, AM J PHYSIOL-HEART C, V282, pH1216, DOI 10.1152/ajpheart.00780.2001; ESPINET C, 1984, IRCS MED SCI-BIOCHEM, V12, P830; FERNANDEZSOLA J, 1994, ANN INTERN MED, V120, P529, DOI 10.7326/0003-4819-120-7-199404010-00001; GUERRI C, 1994, ADV EXP MED BIOL, V366, P291; Hill GE, 1998, ATHEROSCLEROSIS, V141, P107, DOI 10.1016/S0021-9150(98)00153-1; Hintz KK, 2003, ALCOHOL CLIN EXP RES, V27, P1090, DOI 10.1097/01.ALC.0000075823.73536.DD; Kawarabayashi T, 1996, NEUROBIOL AGING, V17, P215, DOI 10.1016/0197-4580(95)02061-6; LAPOSATA EA, 1986, SCIENCE, V231, P497, DOI 10.1126/science.3941913; Lee YJ, 2002, J PHARMACOL EXP THER, V301, P908, DOI 10.1124/jpet.301.3.908; Liang QR, 1999, J PHARMACOL EXP THER, V291, P766; Lieber CS, 1999, ALCOHOL CLIN EXP RES, V23, P991, DOI 10.1111/j.1530-0277.1999.tb04217.x; LIEBER CS, 1988, BIOCHEM SOC T, V16, P241, DOI 10.1042/bst0160241; Masamune A, 2002, J PHARMACOL EXP THER, V302, P36, DOI 10.1124/jpet.302.1.36; McDonough Kathleen H., 1999, Frontiers in Bioscience, V4, pd601, DOI 10.2741/mcdonoug; OEI HHH, 1986, RES COMMUN CHEM PATH, V51, P195; PREEDY VR, 1999, FRONT BIOSCI, V4, P58; Ren J, 2003, CARDIOVASC RES, V57, P738, DOI 10.1016/S0008-6363(02)00788-5; Ren J, 1997, CELL MOL BIOL, V43, P825; Ren J, 2002, ALCOHOL ALCOHOLISM, V37, P30, DOI 10.1093/alcalc/37.1.30; Ren T, 2000, ALCOHOL ALCOHOLISM, V35, P554, DOI 10.1093/alcalc/35.6.554; SHAW S, 1990, BIOCHEM J, V268, P579, DOI 10.1042/bj2680579; SIDDIQ T, 1993, CELL BIOCHEM FUNCT, V11, P45, DOI 10.1002/cbf.290110106; Svegliati-Baroni G, 2001, HEPATOLOGY, V33, P1130, DOI 10.1053/jhep.2001.23788; TSUKAMOTO S, 1989, ALCOHOL ALCOHOLISM, V24, P101, DOI 10.1093/oxfordjournals.alcalc.a044872; VINA J, 1980, BIOCHEM J, V188, P549, DOI 10.1042/bj1880549; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Weng YI, 2000, EUR J PHARMACOL, V398, P323, DOI 10.1016/S0014-2999(00)00313-7; Ye G, 2003, DIABETES, V52, P777, DOI 10.2337/diabetes.52.3.777; YOSHIDA A, 1992, PHARMACOGENETICS, V2, P139, DOI 10.1097/00008571-199208000-00001; Yuan Q, 2002, AM J PHYSIOL-CELL PH, V282, pC1290, DOI 10.1152/ajpcell.00351.2001; Zima T, 2001, J BIOMED SCI, V8, P59, DOI 10.1159/000054014	39	99	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11244	11252		10.1074/jbc.M308011200	http://dx.doi.org/10.1074/jbc.M308011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722101	hybrid			2022-12-25	WOS:000220157600051
J	Tchurikov, NA; Kretova, OV; Chernov, BK; Golova, YB; Zhimulev, IF; Zykov, IA				Tchurikov, NA; Kretova, OV; Chernov, BK; Golova, YB; Zhimulev, IF; Zykov, IA			SuUR protein binds to the boundary regions separating forum domains in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRITHORAX GROUP PROTEINS; CHROMATIN-STRUCTURE; BITHORAX COMPLEX; RESPONSE ELEMENT; POLYCOMB; GENE; HETEROCHROMATIN; UNDERREPLICATION; SUPPRESSOR; INTERACTS	Forum domains are 50-150 kb DNA fragments that are released during spontaneous fragmentation of chromosomes. They are separated by islands of putative heterochromatin boundary regions. The SuUR protein, which is involved in the control of chromosome organization, is localized exclusively in heterochromatin and often co-localizes on chromosomes with Polycomb group proteins. To test whether the SuUR protein is associated with boundary regions, we used gel retardation assays and found that the SuUR protein binds specifically to boundary regions and that boundary regions are under-replicated. These results suggest that the regular distribution of boundary regions in chromosomes may represent the dispersion of sites designed for chromosomal silencing.	Russian Acad Sci, VA Engelhardt Mol Biol Inst, Dept Genome Org, Moscow 119991, Russia; Russian Acad Sci, Inst Cytol & Genet, Siberian Div, Dept Mol Cytogenet, Novosibirsk 630090, Russia	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS	Tchurikov, NA (corresponding author), Russian Acad Sci, VA Engelhardt Mol Biol Inst, Dept Genome Org, Vavilov St 32, Moscow 119991, Russia.	tchurikov@eimb.ru	Tchurikov, Nickolai A./R-4850-2016; Zhimulev, Igor F/N-7978-2015; Zykov, Ivan/N-7973-2015	Zhimulev, Igor/0000-0002-6220-3028				ANANEV EV, 1985, ELEKTRONNOMIKROSKOPI, P1; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; Grewal SIS, 2002, CURR OPIN GENET DEV, V12, P178, DOI 10.1016/S0959-437X(02)00284-8; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Hodgson JW, 2001, MOL CELL BIOL, V21, P4528, DOI 10.1128/MCB.21.14.4528-4543.2001; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002; Makunin IV, 2002, GENETICS, V160, P1023; Moshkin YM, 2002, CHROMOSOMA, V111, P114, DOI 10.1007/s00412-002-0190-8; Moshkin YM, 2001, P NATL ACAD SCI USA, V98, P570, DOI 10.1073/pnas.021353598; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Orlando V, 1998, EMBO J, V17, P5141, DOI 10.1093/emboj/17.17.5141; Pagans S, 2002, NUCLEIC ACIDS RES, V30, P4406, DOI 10.1093/nar/gkf570; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TCHURIKOV NA, 1992, P NATL ACAD SCI USA, V89, P6751, DOI 10.1073/pnas.89.15.6751; Tchurikov NA, 1998, NUCLEIC ACIDS RES, V26, P3221, DOI 10.1093/nar/26.13.3221; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Vazquez M, 1999, DEVELOPMENT, V126, P733; Zhimulev IF, 2003, CHROMOSOMA, V111, P377, DOI 10.1007/s00412-002-0218-0; ZHIMULEV IF, 1998, ADV GENET, V37, P11	29	20	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11705	11710		10.1074/jbc.M306191200	http://dx.doi.org/10.1074/jbc.M306191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702350	hybrid			2022-12-25	WOS:000220157600106
J	Yan, FF; Lin, CW; Weisiger, E; Cartier, EA; Taschenberger, G; Shyng, SL				Yan, FF; Lin, CW; Weisiger, E; Cartier, EA; Taschenberger, G; Shyng, SL			Sulfonylureas correct trafficking defects of ATP-sensitive potassium channels caused by mutations in the sulfonylurea receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; NEPHROGENIC DIABETES-INSIPIDUS; LONG QT SYNDROME; INSULIN-SECRETION; K+ CHANNEL; CHEMICAL CHAPERONES; CYSTIC-FIBROSIS; PHARMACOLOGICAL CHAPERONES; FAMILIAL HYPERINSULINISM; INTRACELLULAR-TRANSPORT	The pancreatic ATP-sensitive potassium (K-ATP) channel, a complex of four sulfonylurea receptor 1 (SUR1) and four potassium channel Kir6.2 subunits, regulates insulin secretion by linking metabolic changes to beta-cell membrane potential. Sulfonylureas inhibit K-ATP channel activities by binding to SUR1 and are widely used to treat type II diabetes. We report here that sulfonylureas also function as chemical chaperones to rescue K-ATP channel trafficking defects caused by two SUR1 mutations, A116P and V187D, identified in patients with congenital hyperinsulinism. Sulfonylureas markedly increased cell surface expression of the A116P and V187D mutants by stabilizing the mutant SUR1 proteins and promoting their maturation. By contrast, diazoxide, a potassium channel opener that also binds SUR1, had no effect on surface expression of either mutant. Importantly, both mutant channels rescued to the cell surface have normal ATP, MgADP, and diazoxide sensitivities, demonstrating that SUR1 harboring either the A116P or the V187D mutation is capable of associating with Kir6.2 to form functional K-ATP channels. Thus, sulfonylureas may be used to treat congenital hyperinsulinism caused by certain K-ATP channel trafficking mutations.	Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA	Oregon Health & Science University	Shyng, SL (corresponding author), Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, 3181 SW Sam JAckson Pk Rd, Portland, OR 97239 USA.	shyngs@ohsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057699] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK057699, DK57699] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Ashcroft FM, 1996, HORM METAB RES, V28, P456, DOI 10.1055/s-2007-979837; Ashcroft SJH, 2000, J MEMBRANE BIOL, V176, P187, DOI 10.1007/s002320001095; Babenko AP, 2003, J BIOL CHEM, V278, P41577, DOI 10.1074/jbc.C300363200; Cartier EA, 2003, J BIOL CHEM, V278, P7081, DOI 10.1074/jbc.M211395200; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Chan KW, 2003, EMBO J, V22, P3833, DOI 10.1093/emboj/cdg376; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2002, J BIOL CHEM, V277, P25416, DOI 10.1074/jbc.M203109200; Conti LR, 2001, J BIOL CHEM, V276, P41270, DOI 10.1074/jbc.M106555200; Deschenes SM, 1997, J NEUROSCI, V17, P9077; Doyle ME, 2003, PHARMACOL REV, V55, P105, DOI 10.1124/pr.55.1.7; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Glaser B, 2000, SEMIN PERINATOL, V24, P150, DOI 10.1053/sp.2000.6365; Gribble FM, 1997, J PHYSIOL-LONDON, V504, P35, DOI 10.1111/j.1469-7793.1997.00035.x; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; Huopio H, 2002, AM J PHYSIOL-ENDOC M, V283, pE207, DOI 10.1152/ajpendo.00047.2002; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Kawaki J, 1999, DIABETES, V48, P2001, DOI 10.2337/diabetes.48.10.2001; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 2000, J BIOL CHEM, V275, P41184, DOI 10.1074/jbc.M006503200; Mikhailov MV, 2002, BIOCHEM SOC T, V30, P323, DOI 10.1042/BST0300323; Mikhailov MV, 2001, FEBS LETT, V499, P154, DOI 10.1016/S0014-5793(01)02538-8; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Otonkoski T, 1999, DIABETES, V48, P408, DOI 10.2337/diabetes.48.2.408; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Perlmutter DH, 2002, PEDIATR RES, V52, P832, DOI 10.1203/01.PDR.0000036878.28942.14; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Reimann F, 2003, DIABETOLOGIA, V46, P241, DOI 10.1007/s00125-002-1014-3; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Sharma N, 2000, KIDNEY INT, V57, P803, DOI 10.1046/j.1523-1755.2000.00918.x; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Stanley CA, 2002, J CLIN ENDOCR METAB, V87, P4857, DOI 10.1210/jc.2002-021403; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	56	79	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11096	11105		10.1074/jbc.M312810200	http://dx.doi.org/10.1074/jbc.M312810200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707124	hybrid			2022-12-25	WOS:000220157600033
J	Dohoney, KM; Guillerm, C; Whiteford, C; Elbi, C; Lambert, PF; Hager, GL; Brady, JN				Dohoney, KM; Guillerm, C; Whiteford, C; Elbi, C; Lambert, PF; Hager, GL; Brady, JN			Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage	ONCOGENE			English	Article						p53; PP2A; phosphatase; DNA damage; serine 37	PROTEIN PHOSPHATASE 2A; CELL-CYCLE CHECKPOINT; CATALYTIC SUBUNIT; BINDING-SITE; OKADAIC ACID; T-ANTIGEN; MDM2; TRANSACTIVATION; INHIBITION; EXPRESSION	The p53 tumor suppressor protein plays a critical role in mediating cellular response to stress. Upon DNA damage, post-translational modifications stabilize and activate this nuclear phosphoprotein. To determine the effect of phosphorylation site mutants in the context of the whole p53 protein, we performed reporter assays in p53 and MDM2 knockout mouse embryonic fibroblasts transfected with full-length p53 constructs. We show that mutation of S37 causes a decrease in p53 transcriptional activity compared to wild-type p53. Our data further suggest that the dephosphorylation of p53 at S37 is a regulated event involving protein phosphatase 2A (PP2A). Coimmunoprecipitation and immunofluorescence microscopy studies demonstrate that PP2A and p53 associate with one another in vivo following gamma-irradiation. Consistent with these observations, phosphorylated S37 accumulates in cell extracts prepared from gamma-irradiated Molt-4 cells in the presence of okadaic acid. Furthermore, in vitro phosphatase assays show that PP2A dephosphorylates p53 at S37. These results suggest that dephosphorylation of p53 at S37 plays a role in the transcriptional regulation of the p53 protein in response to DNA damage.	NCI, Basic Res Lab, Virus Tumor Biol Sect, NIH, Bethesda, MD 20892 USA; NCI, Ctr Adv Technol, Ctr Canc Res, Gaithersburg, MD 20892 USA; NCI, Lab Receptor Biol & Gene Express, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Flinders Univ S Australia, Sch Med, Bedford Pk, SA 5042, Australia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Flinders University South Australia	Brady, JN (corresponding author), NCI, Basic Res Lab, Virus Tumor Biol Sect, NIH, Bldg 41,Room B 201,41 Lib Dr MSC 5055, Bethesda, MD 20892 USA.	bradyj@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010308, Z01BC005450, ZIABC005450, ZIABC005691, Z01BC005691, Z01BC010308] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1989, J BIOL CHEM, V264, P21435; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Elbi C, 2002, MOL BIOL CELL, V13, P2001, DOI 10.1091/mboc.13.6.mk0602002001; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GUY GR, 1992, J BIOL CHEM, V267, P1846; HARPER JW, 1993, CELL, V75, P805; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; MIYASHITA T, 1995, CELL, V80, P293; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHONTHAL AH, 1998, FRONT BIOSCI, V3, P1262; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; vanSteensel B, 1996, J CELL SCI, V109, P787; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Wilson NJ, 1999, BIOCHEM J, V339, P517, DOI 10.1042/0264-6021:3390517; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	47	53	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					49	57		10.1038/sj.onc.1207005	http://dx.doi.org/10.1038/sj.onc.1207005			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712210				2022-12-25	WOS:000187895300006
J	Liu, YN; Kang, BB; Chen, JH				Liu, YN; Kang, BB; Chen, JH			Transcriptional regulation of human osteopontin promoter by C/EBP alpha and AML-1 in metastatic cancer cells	ONCOGENE			English	Article						gene expression; metastasis; OPN; C/EBP alpha; AML-1	BINDING; EXPRESSION; PROTEINS; FUSION; DOMAIN	Osteopontin (OPN) is a secreted glycoprotein produced by osteoclasts, macrophages, T cells, hematopoietic cells, and vascular smooth muscle cells. It contributes to macrophage homing and cellular immunity. It also mediates neovascularization, inhibits apoptosis, and plays important roles in extracellular matrix remodeling and angiogenesis. These properties are also characteristics of metastatic cancer cells. Consequently, the OPN gene was found to be upregulated among various metastatic cancer cells. This suggests that OPN is involved in tumor metastasis. How the OPN gene is upregulated in metastatic cancer cells remains to be illustrated. Thus, we investigated the transcriptional activation of the OPN promoter in the human metastatic cancer cell line A2058. We cloned the OPN promoter, and serial deletion analysis of the OPN promoter showed that the region between -170 and -127 may act as an enhancer to control the OPN gene in metastatic tumor cells. This region was found to contain overlapped AML-1 and C/EBP binding site motifs. Gel-mobility-shift assays using the A2058 nuclear extract and AML-1a or C/EBPalpha (CCAAT/enhancer binding protein alpha) recombinant protein indicated that these two transcription factors can bind to the overlapped AML-1/C/EBP binding site motifs on the OPN regulatory sequence from -147 to -127. Surprisingly, the gel-shift experiments did not show supershift complex formation between AML-1 and C/EBPalpha. Functional analysis showed that the C/EBPalpha was more potent than the complex of AML-1 and its cofactor CBFbeta to upregulate the OPN promoter. In addition, AML-1 and C/EBPalpha did not exhibit transactivation additively or synergistically. Our results suggest that AML-1 and C/EBPalpha play an important role in the upregulation of the OPN gene in metastatic tumor cells.	Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien, Taiwan; Tzu Chi Univ, Grad Inst Human Genet, Hualien, Taiwan; Tzu Chi Univ, Coll Med, Dept Med Technol, Hualien, Taiwan	Tzu Chi University; Tzu Chi University; Tzu Chi University	Chen, JH (corresponding author), Tzu Chi Univ, Grad Inst Mol & Cell Biol, 701 Chung Yang Rd Sec 3, Hualien, Taiwan.	jhc@mail.tcu.edu.tw						ANNA T, 1998, INT J CANCER, V77, P82; Baiker A, 2000, NAT CELL BIOL, V2, P182, DOI 10.1038/35004061; BROWN LF, 1994, AM J PATHOL, V145, P610; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Crawford HC, 1998, CANCER RES, V58, P5206; DIPAK PR, 2002, BIOCHEM J, V365, P561; DONGYAN W, 2000, ONCOGENE, V19, P5801; FUMIYUKI T, 2002, INT J CANCER, V98, P707; Gang X, 2001, AM J KIDNEY DIS, V37, P374, DOI 10.1053/ajkd.2001.21316; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HELMUT P, 2003, NAT REV MOL CELL BIO, V4, P33; JOHN DD, 1983, NUCLEIC ACIDS RES, V11, P1475; Kaartinen MT, 1999, J BIOL CHEM, V274, P1729, DOI 10.1074/jbc.274.3.1729; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lorsbach RB, 2001, INT J HEMATOL, V74, P258, DOI 10.1007/BF02982058; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; MIKALA E, 2002, NAT REV CANCER, V2, P163; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Nau GJ, 1999, INFECT IMMUN, V67, P4223, DOI 10.1128/IAI.67.8.4223-4230.1999; PER A, 1995, BIOCHEM BIOPH RES CO, V215, P106; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Rudland PS, 2002, CANCER RES, V62, P3417; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Shi XM, 2001, J BIOL CHEM, V276, P850, DOI 10.1074/jbc.M005955200; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; SUBHA P, 2001, J BIOL CHEM, V276, P44926; Tomizawa M, 2002, INT J MOL MED, V9, P597; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	38	31	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					278	288		10.1038/sj.onc.1207022	http://dx.doi.org/10.1038/sj.onc.1207022			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712233				2022-12-25	WOS:000187895300029
J	Pak, BJ; Lee, J; Thai, BL; Fuchs, SY; Shaked, Y; Ronai, Z; Kerbel, RS; Ben-David, Y				Pak, BJ; Lee, J; Thai, BL; Fuchs, SY; Shaked, Y; Ronai, Z; Kerbel, RS; Ben-David, Y			Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase	ONCOGENE			English	Article						radiation resistance; malignant melanoma; DOPAchrome tautomerase; mitogen-activated protein kinase	TYROSINASE-RELATED PROTEIN-2; CISPLATIN-INDUCED APOPTOSIS; JUN NH2-TERMINAL KINASE; DNA MISMATCH REPAIR; DRUG-RESISTANCE; CANCER CELLS; FRIEND-VIRUS; ACTIVATION; EXPRESSION; CIS-DIAMMINEDICHLOROPLATINUM(II)	While melanomas are resistant to the cytotoxic effects of radiotherapy, little is known about the molecular mechanisms underlying this intrinsic resistance. Here, we describe the utilization of retroviral insertional mutagenesis to facilitate the analysis of genetic changes that are associated with radioresistance in human melanoma. A radial growth phase human melanoma cell line, WM35, was infected with a replication-defective amphotropic murine retrovirus and subsequently selected for X-ray radiation-resistant variants. Several radiation-resistant clones were independently isolated and characterized. Interestingly, these clones also displayed resistance to ultraviolet radiation and to the chemotherapeutic drug cis-diamminedichloroplatinum(II) (CDDP). By Northern and Western analyses, we showed that the expression of DOPAchrome tautomerase (DCT), also known as tyrosinase-related protein 2 (TYRP2), an enzyme that functions in eumelanin synthesis, was significantly elevated in the radiation-resistant clones relative to the parental WM35 cells. Moreover, the levels of DCT in a variety of human melanoma cell lines correlated with their relative levels of radioresistance and the enforced expression of DCT conferred increased resistance to UV(B) treatment. An analysis of stress signaling induced by radiation as well other cytotoxic stressors showed that resistance associated with DCT overexpression applied specifically to treatments that activate the ERK/MAPK pathway. Indeed, DCT overexpression in a melanoma cell line resulted in increased ERK activity. Moreover, ectopic expression of dominant-active MEK in this melanoma cell line conferred UV(B) resistance suggesting that the ERK/MAPK pathway downstream of DCT may play a critical role in radiation and drug resistance. Overall, given that each gamma- and UV(B)-resistant cell line also exhibited resistance to CDDP and that CDDP-resistant clones showed increased resistance to UV(B) irradiation, these results suggest a common mechanism underlying radio- and chemoresistance, which is mediated by DCT expression.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada; Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY USA; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Icahn School of Medicine at Mount Sinai; University of Toronto	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Res Bldg,S Wing Rm S-218,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	bendavid@srcl.sunnybrook.utoronto.ca		RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bani MR, 1996, CANCER RES, V56, P3075; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHEN F, 1995, BIOCHEM J, V312, P341, DOI 10.1042/bj3120341; Chu W, 2000, ONCOGENE, V19, P395, DOI 10.1038/sj.onc.1203315; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; DACQUISTO F, 1995, LIFE SCI, V57, pPL401, DOI 10.1016/0024-3205(95)02244-2; DAVID YB, 1988, ONCOGENE, V3, P179; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; Fang D, 2001, PIGM CELL RES, V14, P132, DOI 10.1034/j.1600-0749.2001.140209.x; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Hayakawa J, 2003, J BIOL CHEM, V278, P20582, DOI 10.1074/jbc.M210992200; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; JARA JR, 1990, BIOCHIM BIOPHYS ACTA, V1035, P276, DOI 10.1016/0304-4165(90)90089-F; KUBODA H, 1991, INT J CANCER, V47, P732; Lin XJ, 1999, MOL PHARMACOL, V56, P390, DOI 10.1124/mol.56.2.390; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; LU SJ, 1995, CANCER RES, V55, P1139; Mandic A, 2001, MELANOMA RES, V11, P11, DOI 10.1097/00008390-200102000-00002; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MAZZONI A, 1990, ONCOLOGY, V47, P488; Memoli S, 1997, BBA-LIPID LIPID MET, V1346, P61, DOI 10.1016/S0005-2760(97)00018-0; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Nehme A, 1997, CANCER RES, V57, P3253; Nishioka E, 1999, MELANOMA RES, V9, P433, DOI 10.1097/00008390-199910000-00002; Olivares C, 2001, BIOCHEM J, V354, P131, DOI 10.1042/0264-6021:3540131; Pak BJ, 2000, MELANOMA RES, V10, P499, DOI 10.1097/00008390-200010000-00013; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; Rosengren E, 1998, MELANOMA RES, V8, P469, DOI 10.1097/00008390-199810000-00013; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; WOLF CR, 1987, INT J CANCER, V39, P695, DOI 10.1002/ijc.2910390607; YAN MH, 1994, J BIOL CHEM, V269, P19067	36	55	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					30	38		10.1038/sj.onc.1207007	http://dx.doi.org/10.1038/sj.onc.1207007			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712208				2022-12-25	WOS:000187895300004
J	Mair, GR; Niciu, MJ; Stewart, MT; Brennan, G; Omar, H; Halton, DW; Mains, R; Eipper, BA; Maule, AG; Day, TA				Mair, GR; Niciu, MJ; Stewart, MT; Brennan, G; Omar, H; Halton, DW; Mains, R; Eipper, BA; Maule, AG; Day, TA			A functionally atypical amidating enzyme from the human parasite Schistosoma mansoni	FASEB JOURNAL			English	Article						peptidylglycine alpha-hydroxylating monooxygenase; neuropeptide F; FMRFamide; schistosome; helminth	ALPHA-HYDROXYLATING MONOOXYGENASE; FMRFAMIDE-RELATED PEPTIDES; HUMAN BLOOD FLUKE; NEUROPEPTIDE-F; PROCESSING ENZYME; MONIEZIA-EXPANSA; NERVOUS-SYSTEM; CLONING; PROTEIN; MUSCLE	Many neuropeptide transmitters require the presence of a carboxy-terminal alpha-amide group for biological activity. Amidation requires conversion of a glycine-extended peptide intermediate into a C-terminally amidated product. This post-translational modification depends on the sequential action of two enzymes (peptidylglycine alpha-hydroxylating monooxygenase or PHM, and peptidyl-alpha-hydroxyglycine alpha-amidating lyase or PAL) that in most eukaryotes are expressed as separate domains of a single protein (peptidylglycine alpha-amidating monooxygenase or PAM). We identified a cDNA encoding PHM in the human parasite Schistosoma mansoni. Transient expression of schistosome PHM (smPHM) revealed functional properties that are different from other PHM proteins; smPHM displays a lower pH-optimum and, when expressed in mammalian cells, is heavily N-glycosylated. In adult worms, PHM is found in the trans-Golgi network and secretory vesicles of both central and peripheral nerves. The widespread occurrence of PHM in the nervous system confirms the important role of amidated neuropeptides in these parasitic flatworms. The differences between schistosome and mammalian PHM suggest that it could be a target for new chemotherapeutics.	Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA; Queens Univ Belfast, Ctr Med Biol, Sch Biol & Biochem, Parasitol Res Grp, Belfast BT9 7BL, Antrim, North Ireland; Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA	Iowa State University; Queens University Belfast; University of Connecticut	Day, TA (corresponding author), Iowa State Univ, Dept Biomed Sci, 2036 Vet Med Bldg, Ames, IA 50011 USA.	day@iastate.edu	Niciu, Mark J/J-1766-2014	Niciu, Mark J/0000-0002-5612-3021; Mair, Gunnar/0000-0002-5187-3691; Day, Tim/0000-0002-9037-6540; Maule, Aaron/0000-0003-0862-2667	NIAID NIH HHS [R01-AI49162, N01-AI-55270] Funding Source: Medline; NIDDK NIH HHS [DK-32949] Funding Source: Medline; NIGMS NIH HHS [GM08607] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI055270, R01AI049162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032949, R01DK032949, R56DK032949] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1992, P NATL ACAD SCI USA, V89, P1105, DOI 10.1073/pnas.89.3.1105; Armstrong EP, 1997, J COMP NEUROL, V377, P41, DOI 10.1002/(SICI)1096-9861(19970106)377:1&lt;41::AID-CNE5&gt;3.0.CO;2-J; Bolkenius FN, 1998, GEN PHARMACOL, V31, P655, DOI 10.1016/S0306-3623(98)00192-X; Caldwell BD, 1999, J BIOL CHEM, V274, P34646, DOI 10.1074/jbc.274.49.34646; Cioli D, 2000, CURR OPIN INFECT DIS, V13, P659, DOI 10.1097/00001432-200012000-00014; CURRY WJ, 1992, COMP BIOCHEM PHYS C, V101, P269, DOI 10.1016/0742-8413(92)90272-9; Day TA, 1997, PEPTIDES, V18, P917, DOI 10.1016/S0196-9781(97)00073-9; DAY TA, 1994, PARASITOLOGY, V109, P455, DOI 10.1017/S0031182000080707; Day TA, 1999, PEPTIDES, V20, P999, DOI 10.1016/S0196-9781(99)00093-5; Dougan PM, 2002, J COMP NEUROL, V454, P58, DOI 10.1002/cne.10440; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Fairweather I, 1995, ACTA BIOL HUNG, V46, P211; Fan XM, 2000, MOL BRAIN RES, V82, P25, DOI 10.1016/S0169-328X(00)00173-X; Geary TG, 1999, ANN NY ACAD SCI, V897, P212, DOI 10.1111/j.1749-6632.1999.tb07893.x; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; Hauser F, 1997, BIOCHEM BIOPH RES CO, V241, P509, DOI 10.1006/bbrc.1997.7854; HUSTEN EJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P487, DOI 10.1006/abbi.1994.1336; Ismail M, 1999, AM J TROP MED HYG, V60, P932, DOI 10.4269/ajtmh.1999.60.932; Jiang N, 2000, DEV BIOL, V226, P118, DOI 10.1006/dbio.2000.9832; Johnston RN, 1996, J NEUROCHEM, V67, P814; JOHNSTON RN, 1995, BIOCHEM BIOPH RES CO, V209, P689, DOI 10.1006/bbrc.1995.1554; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; Kolhekar AS, 1998, J BIOL CHEM, V273, P23012, DOI 10.1074/jbc.273.36.23012; LACKEY DB, 1992, J BIOL CHEM, V267, P17508; Mair GR, 1998, PARASITOL TODAY, V14, P73, DOI 10.1016/S0169-4758(97)01182-4; Mair GR, 2000, PARASITOLOGY, V121, P163, DOI 10.1017/S0031182099006174; Mair GR, 2000, PARASITOLOGY, V120, P71, DOI 10.1017/S0031182099005296; MARKS NJ, 1995, PARASITOLOGY, V110, P371, DOI 10.1017/S0031182000064714; Maule Aaron G., 2002, Current Topics in Medicinal Chemistry, V2, P733, DOI 10.2174/1568026023393697; MAULE AG, 1991, PARASITOLOGY, V102, P309, DOI 10.1017/S0031182000062648; Milgram SL, 1997, J CELL SCI, V110, P695; MIYAZONO K, 1992, J BIOL CHEM, V267, P5668; NAIR PM, 1985, INDIAN J BIOCHEM BIO, V22, P339; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Oyarce AM, 2000, J BIOL CHEM, V275, P3270, DOI 10.1074/jbc.275.5.3270; Prigge ST, 1999, NAT STRUCT BIOL, V6, P976; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; Remme JHF, 2002, TRENDS PARASITOL, V18, P421, DOI 10.1016/S1471-4922(02)02387-5; Skelly PJ, 2001, PARASITOLOGY, V123, P277, DOI 10.1017/S0031182001008484; SKUCE PJ, 1990, CELL TISSUE RES, V261, P573, DOI 10.1007/BF00313537; SKUCE PJ, 1990, PARASITOLOGY, V101, P227, DOI 10.1017/S0031182000063277; SOLISSOTO JM, 1994, PARASITOLOGY, V108, P301, DOI 10.1017/S0031182000076149; Spijker S, 1999, FASEB J, V13, P735, DOI 10.1096/fasebj.13.6.735	45	31	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					114	121		10.1096/fj.03-0429com	http://dx.doi.org/10.1096/fj.03-0429com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718392				2022-12-25	WOS:000188829300045
J	Harada, K; Potter, JD				Harada, K; Potter, JD			Familial hypertrophic cardiomyopathy mutations from different functional regions of troponin T result in different effects on the pH and Ca2+ sensitivity of cardiac muscle contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; PROTEIN-C GENE; ALTERED REGULATION; ALPHA-TROPOMYOSIN; SUDDEN-DEATH; SKELETAL; BINDING; IDENTIFICATION; DISEASE; DOMAIN	To understand the molecular function of troponin T (TnT) in the Ca2+ regulation of muscle contraction as well as the molecular pathogenesis of familial hypertrophic cardiomyopathy (FHC), eight FHC-linked TnT mutations, which are located in different functional regions of human cardiac TnT (HCTnT), were produced, and their structural and functional properties were examined. Circular dichroism spectroscopy demonstrated different secondary structures of these TnT mutants. Each of the recombinant HCTnTs was incorporated into porcine skinned fibers along with human cardiac troponin I (HCTnI) and troponin C (HCTnC), and the Ca2+ dependent isometric force development of these troponin-replaced fibers was determined at pH 7.0 and 6.5. All eight mutants altered the contractile properties of skinned cardiac fibers. E244D potentiated the maximum force development without changing Ca2+ sensitivity. In contrast, the other seven mutants increased the Ca2+ sensitivity of force development but not the maximal force. R92L, R92W, and R94L also decreased the change in Ca2+ sensitivity of force development observed on lowering the pH from 7 to 6.5, when compared with wild type TnT. The examination of additional mutants, H91Q and a double mutant H91Q/R92W, suggests that mutations in a region including residues 91-94 in HCTnT can perturb the proper response of cardiac contraction to changes in pH. These results suggest that different regions of TnT may contribute to the pathogenesis of TnT-linked FHC through different mechanisms.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA	University of Miami	Potter, JD (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.	jdpotter@miami.edu			NHLBI NIH HHS [HL-674154, HL-42325] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042325, R01HL042325] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; BRISSON JR, 1986, BIOCHEMISTRY-US, V25, P4548, DOI 10.1021/bi00364a014; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Dargis R, 2002, J BIOL CHEM, V277, P34662, DOI 10.1074/jbc.C200419200; DONALDSON SKB, 1978, PFLUG ARCH EUR J PHY, V376, P55; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; Forissier JF, 1996, CIRCULATION, V94, P3069, DOI 10.1161/01.CIR.94.12.3069; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GOMES AV, 2004, IN PRESS MOL CELL BI; Harada K, 2002, BIOPHYS J, V82, p391A; Harada K, 2000, J BIOCHEM-TOKYO, V127, P263, DOI 10.1093/oxfordjournals.jbchem.a022603; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; Hinkle A, 2003, J BIOL CHEM, V278, P506, DOI 10.1074/jbc.M209194200; Ho CY, 2000, CIRCULATION, V102, P1950, DOI 10.1161/01.CIR.102.16.1950; Hoffmann B, 2001, Hum Mutat, V17, P524, DOI 10.1002/humu.1143; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; Knollmann BC, 2001, TRENDS CARDIOVAS MED, V11, P206, DOI 10.1016/S1050-1738(01)00115-3; Knollmann BC, 2001, J BIOL CHEM, V276, P10039, DOI 10.1074/jbc.M006745200; KOGA Y, 1996, J CARD FAIL, V2, P97; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; Lin TL, 2000, CARDIOLOGY, V93, P155, DOI 10.1159/000007020; LYNCH GS, 1994, EXP PHYSIOL, V79, P47, DOI 10.1113/expphysiol.1994.sp003741; Marian A J, 2001, Minerva Med, V92, P435; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; Moolman JC, 1997, J AM COLL CARDIOL, V29, P549, DOI 10.1016/S0735-1097(96)00530-X; Moolman-Smook JC, 1999, AM J HUM GENET, V65, P1308, DOI 10.1086/302623; Morimoto S, 1998, AM J PHYSIOL-CELL PH, V275, pC200, DOI 10.1152/ajpcell.1998.275.1.C200; Morimoto S, 1999, J BIOCHEM-TOKYO, V126, P121, DOI 10.1093/oxfordjournals.jbchem.a022412; Morimoto S, 2002, P NATL ACAD SCI USA, V99, P913, DOI 10.1073/pnas.022628899; NakajimaTaniguchi C, 1997, J MOL CELL CARDIOL, V29, P839, DOI 10.1006/jmcc.1996.0322; Nakaura H, 1999, J BIOCHEM-TOKYO, V126, P457, DOI 10.1093/oxfordjournals.jbchem.a022473; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; Palm T, 2001, BIOPHYS J, V81, P2827, DOI 10.1016/S0006-3495(01)75924-3; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Richard P, 1999, J MED GENET, V36, P542; Satoh M, 1999, BIOCHEM BIOPH RES CO, V262, P411, DOI 10.1006/bbrc.1999.1221; Sola Francesco, 1997, Angiogenesis, V1, P102, DOI 10.1023/A:1018309200629; Stefancsik R, 1998, P NATL ACAD SCI USA, V95, P957, DOI 10.1073/pnas.95.3.957; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Varnava A, 1999, HEART, V82, P621, DOI 10.1136/hrt.82.5.621; Varnava AM, 2001, CIRCULATION, V104, P1380, DOI 10.1161/hc3701.095952; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; Yanaga F, 1999, J BIOL CHEM, V274, P8806, DOI 10.1074/jbc.274.13.8806; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	51	71	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14488	14495		10.1074/jbc.M309355200	http://dx.doi.org/10.1074/jbc.M309355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722098	hybrid			2022-12-25	WOS:000220594700005
J	Ahuatzi, D; Herrero, P; de la Cera, T; Moreno, F				Ahuatzi, D; Herrero, P; de la Cera, T; Moreno, F			The glucose-regulated nuclear localization of hexokinase 2 in Saccharomyces cerevisiae is Mig1-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNF1 PROTEIN-KINASE; CARBON CATABOLITE REPRESSION; ATOMIC-FORCE MICROSCOPY; HXK2 GENES; YEAST HEXOKINASE; MIG1 REPRESSOR; PHOSPHORYLATION; PII; EXPRESSION; SUC2	Two major mediators of glucose repression in Saccharomyces cerevisiae are the proteins Mig1 and Hxk2. The mechanism of Hxk2-dependent glucose repression pathway is not well understood, but the Mig1-dependent part of the pathway has been elucidated in great detail. Here we report that Hxk2 has a glucose-regulated nuclear localization and that Mig1, a transcriptional repressor responsible for glucose repression of many genes, is required to sequester Hxk2 into the nucleus. Mig1 and Hxk2 interacted in vivo in a yeast two-hybrid assay and in vitro in immunoprecipitation and glutathione S-transferase pull-down experiments. We found that the Lys(6)-Met(15) decapeptide of Hxk2, which is necessary for nuclear localization of the protein, is also essential for interaction with the Mig1 protein. Our results also show that the Hxk2-Mig1 interaction is of physiological significance because both proteins have been found interacting together in a cluster with DNA fragments containing the MIG1 site of SUC2 promoter. We conclude that Hxk2 operates by interacting with Mig1 to generate a repressor complex located in the nucleus of S. cerevisiae during growth in glucose medium.	Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	University of Oviedo	Moreno, F (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Campus Cristo,Edificio Santiago Gascon, E-33006 Oviedo, Spain.	fmoreno@correo.uniovi.es		de la Cera, Tamara/0000-0002-0124-5718				Alms GR, 1999, EMBO J, V18, P4157, DOI 10.1093/emboj/18.15.4157; Ashrafi K, 2000, GENE DEV, V14, P1872; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chaves RS, 1999, BIOCHEM BIOPH RES CO, V254, P345, DOI 10.1006/bbrc.1998.9954; de la Cera T, 2002, J MOL BIOL, V319, P703, DOI 10.1016/S0022-2836(02)00377-7; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; DeWinde JH, 1996, EUR J BIOCHEM, V241, P633; ENTIAN KD, 1980, MOL GEN GENET, V178, P633, DOI 10.1007/BF00337871; ENTIAN KD, 1992, TRENDS BIOCHEM SCI, V17, P506, DOI 10.1016/0968-0004(92)90341-6; ENTIAN KD, 1977, MOL GEN GENET, V156, P99, DOI 10.1007/BF00272258; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GASCON S, 1968, J BIOL CHEM, V243, P1567; GUELMAN R, 2002, BONE, V30, P23; Herrero P, 1998, FEBS LETT, V434, P71, DOI 10.1016/S0014-5793(98)00872-2; Hohmann S, 1999, MICROBIOL-UK, V145, P703, DOI 10.1099/13500872-145-3-703; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Kraakman LS, 1999, BIOCHEM J, V343, P159, DOI 10.1042/0264-6021:3430159; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; MA H, 1989, MOL CELL BIOL, V9, P5643, DOI 10.1128/MCB.9.12.5643; MA H, 1986, MOL CELL BIOL, V6, P4046, DOI 10.1128/MCB.6.11.4046; Mayordomo I, 2001, YEAST, V18, P923, DOI 10.1002/yea.737; Menezes RA, 2003, J MOL BIOL, V333, P479, DOI 10.1016/j.jmb.2003.08.034; Moreno F, 2002, FEMS MICROBIOL REV, V26, P83, DOI 10.1111/j.1574-6976.2002.tb00600.x; Moreno-Herrero F, 2001, BIOCHEM BIOPH RES CO, V280, P151, DOI 10.1006/bbrc.2000.4074; Moreno-Herrero F, 1999, FEBS LETT, V459, P427, DOI 10.1016/S0014-5793(99)01289-2; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; Ostling J, 1998, EUR J BIOCHEM, V252, P162, DOI 10.1046/j.1432-1327.1998.2520162.x; Randez-Gil F, 1998, FEBS LETT, V425, P475, DOI 10.1016/S0014-5793(98)00289-0; Rodriguez A, 2001, BIOCHEM J, V355, P625, DOI 10.1042/bj3550625; ROSE M, 1991, EUR J BIOCHEM, V199, P511, DOI 10.1111/j.1432-1033.1991.tb16149.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanz P, 1996, J BACTERIOL, V178, P4721, DOI 10.1128/jb.178.15.4721-4723.1996; Tettelin H, 1997, NATURE, V387, P81, DOI 10.1038/387s081; Tomas-Cobos L, 2002, BIOCHEM J, V368, P657, DOI 10.1042/BJ20020984; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; VALLIER LG, 1994, GENETICS, V137, P49; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Wray LV, 2001, CELL, V107, P427, DOI 10.1016/S0092-8674(01)00572-4; Zenke FT, 1996, SCIENCE, V272, P1662, DOI 10.1126/science.272.5268.1662	44	98	100	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14440	14446		10.1074/jbc.M313431200	http://dx.doi.org/10.1074/jbc.M313431200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14715653	hybrid			2022-12-25	WOS:000220478500140
J	Huang, HJ; Muddiman, DC; Tindall, DJ				Huang, HJ; Muddiman, DC; Tindall, DJ			Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTEN TUMOR-SUPPRESSOR; PROTEIN-KINASE B/AKT; CYCLE ARREST; PHOSPHATIDYLINOSITOL 3'-KINASE; PROTEASOME INHIBITORS; PHOSPHATASE-ACTIVITY; SIGNALING PATHWAY; CARCINOMA-CELLS; GENE-EXPRESSION; APOPTOSIS	The ability of androgens to inhibit apoptosis in both normal and malignant prostatic cells has been well documented. However, the underlying mechanisms are understood poorly. Here we demonstrated that forkhead transcription factor FKHR (FOXO1)-induced death of LNCaP cells was blocked by a synthetic androgen R1881. Androgen treatment also resulted in a reduction in transcriptional activity of FKHR in these cells. Moreover, treatment of LNCaP cells with R1881 led to a decrease in the intact FKHR protein (70 kDa) and an increase in a faster migrating protein band (60 kDa). Androgen-enhanced appearance of the 60-kDa protein was diminished specifically by lysosomal acidic cysteine protease inhibitors. Mass spectrometry analyses of the purified FLAG-tagged 70- and 60-kDa proteins demonstrated that the 60-kDa species is a FKHR protein product that lacks about 120 amino acid residues of the C-terminal end. Mutagenesis of the basic amino acid Arg(537) in the protease cleavage region, as suggested by mass spectrometry, abrogated both the androgen-induced accumulation of the 60-kDa product and decrease in cell death induced by FKHR, suggesting that the residue Arg(537) is a potential protease cleavage site. Finally, ectopic expression of the first 537 amino acids of FKHR produced an inhibitory effect on transcriptional activity of the intact protein. Together, these results suggest that androgens induce increased activity of an acidic cysteine protease, which in turn cleaves FKHR. This provides a mechanism by which androgens protect prostate cancer cells from the killing effect of FKHR.	Mayo Clin & Mayo Fdn, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Urol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Mayo Proteom Res Ctr, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Tindall, DJ (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Biochem Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	tindall.donald@mayo.edu		Muddiman, David/0000-0003-2216-499X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065236] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065236] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; BERCHEM GJ, 1995, CANCER RES, V55, P735; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; BRANDSTROM A, 1994, CANCER RES, V54, P3594; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardillo M, 1997, J UROLOGY, V158, P212, DOI 10.1097/00005392-199707000-00073; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carson JP, 1999, CANCER RES, V59, P1449; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Georgescu MM, 2000, CANCER RES, V60, P7033; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Huang HJ, 1999, CANCER RES, V59, P2981; ISAACS JT, 1994, VITAM HORM, V49, P433; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; Kimura K, 2001, CANCER RES, V61, P5611; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kuratsukuri K, 1999, PROSTATE, V41, P121; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Lin JQ, 1999, CANCER RES, V59, P2891; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McMenamin ME, 1999, CANCER RES, V59, P4291; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Musial A, 2001, J BIOL CHEM, V276, P24268, DOI 10.1074/jbc.M100725200; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Steinhilb ML, 2001, J BIOL CHEM, V276, P4476, DOI 10.1074/jbc.M008793200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WESTIN P, 1995, AM J PATHOL, V146, P1368; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	66	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13866	13877		10.1074/jbc.M314143200	http://dx.doi.org/10.1074/jbc.M314143200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726521	hybrid			2022-12-25	WOS:000220478500073
J	Sato, M; Gettys, TW; Lanier, SM				Sato, M; Gettys, TW; Lanier, SM			AGS3 and signal integration by G alpha(s)- and G alpha(i)-coupled receptors - AGS3 blocks the sensitization of adenylyl cyclase following prolonged stimulation of a G alpha(i)-coupled receptor by influencing processing of G alpha(i)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; HETEROTRIMERIC G-PROTEINS; REGULATORY MOTIF; ACTIVATION; IDENTIFICATION; EXPRESSION; BINDING; PHOSPHORYLATION; DISSOCIATION; POLARITY	AGS3-LONG and AGS3-SHORT contain G-protein regulatory motifs that interact with and stabilize the GDP-bound conformation of Galpha(i) > Galpha(o). AGS3 and related proteins may influence signal strength or duration as well as the adaptation of the signaling system associated with sustained stimulation. To address these issues, we determined the effect of AGS3 on the integration of stimulatory (Galpha(s)-mediated vasoactive intestinal peptide receptor) and inhibitory (Galpha(i)-mediated alpha(2)-adrenergic receptor (alpha(2)-AR)) signals to adenylyl cyclase in Chinese hamster ovary cells. AGS3-SHORT and AGS3-LONG did not alter the VIP-induced increase in cAMP or the inhibitory effect of alpha(2)-AR activation. System adaptation was addressed by determining the influence of AGS3 on the sensitization of adenylyl cyclase that occurs following prolonged activation of a Galpha(i)-coupled receptor. Incubation of cells with the alpha(2)-AR agonist UK14304 ( 1 muM) for 18 h resulted in a similar to 1.8-fold increase in the vasoactive intestinal peptide-induced activation of adenylyl cyclase, and this was associated with a decrease in membrane-associated Galpha(i3). Both effects were blocked by AGS3-SHORT. AGS3-SHORT also decreased the rate of Galpha(i3) decay. A mutant AGS3-SHORT incapable of binding G-protein was inactive. These data suggest that AGS3 and perhaps other G-protein regulatory motif-containing proteins increase the stability of Galpha(i) in the membrane, which influences the adaptation of the cell to prolonged activation of Galpha(i)-coupled receptors.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Lanier, SM (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, 1901 Perdido St, New Orleans, LA 70112 USA.	slanie@lsuhsc.edu	Gettys, Thomas W/N-1964-2017	Gettys, Thomas W/0000-0001-7125-7995; Lanier, Stephen/0000-0002-2740-7607	NIMH NIH HHS [MH55391] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adhikari A, 2003, J BIOL CHEM, V278, P51825, DOI 10.1074/jbc.M306300200; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; Bayewitch ML, 2000, MOL PHARMACOL, V57, P820, DOI 10.1124/mol.57.4.820; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Blumer JB, 2003, RECEPTOR CHANNEL, V9, P195, DOI 10.1080/10606820390203839; Blumer JB, 2003, J BIOL CHEM, V278, P23217, DOI 10.1074/jbc.C200686200; Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Colombo K, 2003, SCIENCE, V300, P1957, DOI 10.1126/science.1084146; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; GETTYS TW, 1994, ANAL BIOCHEM, V220, P82, DOI 10.1006/abio.1994.1302; Ghosh M, 2003, J BIOL CHEM, V278, P34747, DOI 10.1074/jbc.C300271200; Gotta M, 2003, CURR BIOL, V13, P1029, DOI 10.1016/S0960-9822(03)00371-3; GRABER SG, 1992, J BIOL CHEM, V267, P1271; Hollinger S, 2003, BIOCHEMISTRY-US, V42, P811, DOI 10.1021/bi026664y; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Kroslak T, 2001, J BIOL CHEM, V276, P39772, DOI 10.1074/jbc.M106991200; Lundberg P, 2001, ENDOCRINOLOGY, V142, P339, DOI 10.1210/en.142.1.339; Ma HZ, 2003, BIOCHEMISTRY-US, V42, P8085, DOI 10.1021/bi034561p; Makhlouf M, 1996, BBA-MOL CELL RES, V1312, P163, DOI 10.1016/0167-4889(96)00019-5; Marty C, 2003, MOL CELL BIOL, V23, P3847, DOI 10.1128/MCB.23.11.3847-3858.2003; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Pattingre S, 2003, J BIOL CHEM, V278, P20995, DOI 10.1074/jbc.M300917200; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Peterson YK, 2002, J BIOL CHEM, V277, P6767, DOI 10.1074/jbc.C100699200; Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; Watts VJ, 2002, J PHARMACOL EXP THER, V302, P1, DOI 10.1124/jpet.302.1.1; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	38	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13375	13382		10.1074/jbc.M312660200	http://dx.doi.org/10.1074/jbc.M312660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726514	hybrid			2022-12-25	WOS:000220478500014
J	Wallis, R; Shaw, JM; Uitdehaag, J; Chen, CB; Torgersen, D; Drickamer, K				Wallis, R; Shaw, JM; Uitdehaag, J; Chen, CB; Torgersen, D; Drickamer, K			Localization of the serine protease-binding sites in the collagen-like domain of mannose-binding protein - Indirect effects of naturally occurring mutations on protease binding and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT ACTIVATION; CRYSTAL-STRUCTURE; TRIPLE-HELIX; I COLLAGEN; LECTIN; PATHWAY; ASSOCIATION; ASYMMETRY; COMPLEXES; SEQUENCE	Mutations in the collagen-like domain of serum mannose-binding protein (MBP) interfere with the ability of the protein to initiate complement fixation through the MBP-associated serine proteases (MASPs). The resulting deficiency in the innate immune response leads to susceptibility to infections. Studies have been undertaken to define the region of MBP that interacts with MASPs and to determine how the naturally occurring mutations affect this interaction. Truncated and modified MBPs and synthetic peptides that represent segments of the collagen-like domain of MBP have been used to demonstrate that MASPs bind on the C-terminal side of the hinge region formed by an interruption in the Gly-X-Y repeat pattern of the collagen-like domain. The binding sites for MASP-2 and for MASP-1 and - 3 overlap but are not identical. The two most common naturally occurring mutations in MBP result in substitution of acidic amino acids for glycine residues in Gly-X-Y triplets on the N-terminal side of the hinge. Circular dichroism analysis and differential scanning calorimetry demonstrate that the triple helical structure of the collagen-like domain is largely intact in the mutant proteins, but it is more easily unfolded than in wild-type MBP. Thus, the effect of the mutations is to destabilize the collagen-like domain, indirectly disrupting the binding sites for MASPs. In addition, at least one of the mutations has a further effect on the ability of MBP to activate MASPs.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Drickamer, K (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.	kd@glycob.ox.ac.uk		Wallis, Russell/0000-0002-8705-5295				Baum Jean, 1999, Current Opinion in Structural Biology, V9, P122, DOI 10.1016/S0959-440X(99)80016-5; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; COLLEY KJ, 1987, J BIOL CHEM, V262, P10290; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; DRICKAMER K, 1986, J BIOL CHEM, V261, P1034; Feinberg H, 2003, EMBO J, V22, P2348, DOI 10.1093/emboj/cdg236; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Gadjeva M, 2001, CURR OPIN IMMUNOL, V13, P74, DOI 10.1016/S0952-7915(00)00185-0; Heise CT, 2000, J IMMUNOL, V165, P1403, DOI 10.4049/jimmunol.165.3.1403; Hirs C. H. W., 1967, METHOD ENZYMOL, V11, P325; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; Lesage A, 1996, BIOCHEMISTRY-US, V35, P9647, DOI 10.1021/bi952666p; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; LU J, 1990, J IMMUNOL, V144, P2287; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; McAlinden A, 2003, J BIOL CHEM, V278, P42200, DOI 10.1074/jbc.M302429200; Mogues T, 1996, GLYCOBIOLOGY, V6, P543, DOI 10.1093/glycob/6.5.543; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; Rossi V, 2001, J BIOL CHEM, V276, P40880, DOI 10.1074/jbc.M105934200; SASTRY K, 1991, J IMMUNOL, V147, P692; SCHUMAKER VN, 1981, J MOL BIOL, V148, P191, DOI 10.1016/0022-2836(81)90511-8; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; Slatter DA, 2003, J MOL BIOL, V329, P175, DOI 10.1016/S0022-2836(03)00380-2; Sugimoto R, 1998, J BIOL CHEM, V273, P20721, DOI 10.1074/jbc.273.33.20721; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Tiktopulo EI, 1998, BIOCHEMISTRY-US, V37, P8147, DOI 10.1021/bi980360n; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Vorup-Jensen T, 2000, J IMMUNOL, V165, P2093, DOI 10.4049/jimmunol.165.4.2093; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1999, J IMMUNOL, V163, P4953; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Wallis R, 2002, IMMUNOBIOLOGY, V205, P433, DOI 10.1078/0171-2985-00144; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3	40	67	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14065	14073		10.1074/jbc.M400171200	http://dx.doi.org/10.1074/jbc.M400171200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724269	hybrid			2022-12-25	WOS:000220478500096
J	Kawasaki, J; Davis, GE; Davis, MJ				Kawasaki, J; Davis, GE; Davis, MJ			Regulation of Ca2+-dependent K+ current by alpha(v)beta(3) integrin engagement in vascular endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CURRENT I-CRAC; TYROSINE KINASE; CALCIUM CURRENT; CA2+ ENTRY; CHANNEL ACTIVATION; CEREBRAL-ARTERIES; SMOOTH-MUSCLE; SHEAR-STRESS; CELLS; ADHESION	Interactions between endothelial cells and extracellular matrix proteins are important determinants of endothelial cell signaling. Endothelial adhesion to fibronectin through alpha(v)beta(3) integrins or the engagement and aggregation of luminal alpha(v)beta(3) receptors by vitronectin triggers Ca2+ influx. However, the underlying signaling mechanisms are unknown. The electrophysiological basis of alpha(v)beta(3) integrin- mediated changes in endothelial cell Ca2+ signaling was studied using whole cell patch clamp and microfluorimetry. The resting membrane potential of bovine pulmonary artery endothelial cells averaged - 60 +/- 3 mV. In the absence of intracellular Ca2+ buffering, the application of soluble vitronectin ( 200 mug/ml) resulted in activation of an outwardly rectifying K+ current at holding potentials from - 50 to + 50 mV. Neither a significant shift in reversal potential ( in voltage clamp mode) nor a change in membrane potential ( in current clamp mode) occurred in response to vitronectin. Vitronectin- activated current was significantly inhibited by pretreatment with the alpha(v)beta(3) integrin antibody LM609 by exchanging extracellular K+ with Cs+ or by the application of iberiotoxin, a selective inhibitor of large- conductance, Ca2+- activated K+ channels. With intracellular Ca2+ buffered by EGTA in the recording pipette, vitronectin- activated K+ current was abolished. Fura- 2 microfluorimetry revealed that vitronectin induced a significant and sustained increase in intracellular Ca2+ concentration, although vitronectin- induced Ca2+ current could not be detected. This is the first report to show that an endothelial cell ion channel is regulated by integrin activation, and this K+ current likely plays a crucial role in maintaining membrane potential and a Ca2+ driving force during engagement and activation of endothelial cell alpha(v)beta(3) integrin.	Texas A&M Univ, Syst Hlth Sci Ctr, Coll Med, Dept Med Physiol, College Stn, TX 77845 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Coll Med, Dept Pathol & Lab Med, College Stn, TX 77845 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Davis, MJ (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Coll Med, Dept Med Physiol, Rm 346,Reynolds Med Bldg, College Stn, TX 77845 USA.	mjd@tamu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060180, R01HL059971] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 59971, HL 60180] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCANGELI A, 1991, BIOCHEM BIOPH RES CO, V177, P1266, DOI 10.1016/0006-291X(91)90678-Z; Battistella-Patterson AS, 1997, CAN J PHYSIOL PHARM, V75, P1287, DOI 10.1139/cjpp-75-12-1287; BECCHETTI A, 1992, P ROY SOC B-BIOL SCI, V248, P235, DOI 10.1098/rspb.1992.0067; Bhattacharya S, 2000, CIRC RES, V86, P456, DOI 10.1161/01.RES.86.4.456; Brough GH, 2001, FASEB J, V15, P1727, DOI 10.1096/fj.01-0108com; Bryan RM, 2001, AM J PHYSIOL-HEART C, V280, pH2011, DOI 10.1152/ajpheart.2001.280.5.H2011; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; Clemetson KJ, 1998, CELL MOL LIFE SCI, V54, P499, DOI 10.1007/s000180050178; CONFORTI G, 1992, BLOOD, V80, P437; DAUT J, 1988, J PHYSIOL-LONDON, V402, P237, DOI 10.1113/jphysiol.1988.sp017202; DESMET P, 1994, PFLUG ARCH EUR J PHY, V428, P94, DOI 10.1007/BF00374757; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; Fierro L, 2000, PFLUG ARCH EUR J PHY, V440, P580, DOI 10.1007/s004240050009; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; FUJIMOTO T, 1991, J BIOL CHEM, V266, P16370; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Germer M, 1998, EUR J BIOCHEM, V253, P669, DOI 10.1046/j.1432-1327.1998.2530669.x; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIMMEL HM, 1994, AM J PHYSIOL-CELL PH, V267, pC1338; HIMMEL HM, 1993, HYPERTENSION, V21, P112, DOI 10.1161/01.HYP.21.1.112; Hofmann G, 2001, J BIOL CHEM, V276, P4923, DOI 10.1074/jbc.M005682200; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; Intengan HD, 2000, HYPERTENSION, V36, P312, DOI 10.1161/01.HYP.36.3.312; Kawasaki J, 1999, EUR J PHARMACOL, V373, P111, DOI 10.1016/S0014-2999(99)00257-5; Kelly JJ, 1998, AM J PHYSIOL-LUNG C, V274, pL810, DOI 10.1152/ajplung.1998.274.5.L810; Kramar EA, 2003, J BIOL CHEM, V278, P10722, DOI 10.1074/jbc.M210225200; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; Lin B, 2003, J NEUROPHYSIOL, V89, P2874, DOI 10.1152/jn.00783.2002; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; Madden JA, 1999, AM J PHYSIOL-HEART C, V277, pH2264, DOI 10.1152/ajpheart.1999.277.6.H2264; Millward-Sadler SJ, 1999, J CELL BIOL, V145, P183, DOI 10.1083/jcb.145.1.183; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; NELSON MT, 1995, AM J PHYSIOL, V268, P799; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PREVARSKAYA NB, 1995, J BIOL CHEM, V270, P24292, DOI 10.1074/jbc.270.41.24292; Rosado JA, 2000, BIOCHEM J, V351, P429, DOI 10.1042/0264-6021:3510429; Salter DM, 1997, J BONE MINER RES, V12, P1133, DOI 10.1359/jbmr.1997.12.7.1133; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SHARMA NR, 1994, AM J PHYSIOL, V266, pH156, DOI 10.1152/ajpheart.1994.266.1.H156; Sharma NR, 1996, AM J PHYSIOL-HEART C, V270, pH267, DOI 10.1152/ajpheart.1996.270.1.H267; SHARMA NR, 1995, AM J PHYSIOL-HEART C, V268, pH962, DOI 10.1152/ajpheart.1995.268.3.H962; Singh B, 2000, AM J PHYSIOL-LUNG C, V278, pL217, DOI 10.1152/ajplung.2000.278.1.L217; SJAASTAD MD, 1994, P NATL ACAD SCI USA, V91, P8214, DOI 10.1073/pnas.91.17.8214; Sjaastad MD, 1996, MOL BIOL CELL, V7, P1025, DOI 10.1091/mbc.7.7.1025; Vaca L, 1996, AM J PHYSIOL-CELL PH, V270, pC819, DOI 10.1152/ajpcell.1996.270.3.C819; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wildering WC, 2002, J NEUROSCI, V22, P2419, DOI 10.1523/JNEUROSCI.22-07-02419.2002; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; ZAR JH, 1984, BIOSTAT ANAL, P196	54	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12959	12966		10.1074/jbc.M313791200	http://dx.doi.org/10.1074/jbc.M313791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14724272	hybrid			2022-12-25	WOS:000220334900114
J	Yerlikaya, A; Stanley, BA				Yerlikaya, A; Stanley, BA			S-Adenosylmethionine decarboxylase degradation by the 26 S proteasome is accelerated by substrate-mediated transamination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; N-END RULE; ORNITHINE-DECARBOXYLASE; ESCHERICHIA-COLI; IN-VIVO; LYMPHOCYTE MITOGENESIS; RAT PROSTATE; TUMOR-CELLS; PROTEIN; MECHANISM	The short-lived enzyme S-adenosylmethionine decarboxylase uses a covalently bound pyruvoyl cofactor to catalyze the formation of decarboxylated S-adenosylmethionine, which then donates an aminopropyl group for polyamine biosynthesis. Here we demonstrate that S-adenosylmethionine decarboxylase is ubiquitinated and degraded by the 26 S proteasome in vivo, a process that is accelerated by inactivation of S-adenosylmethionine decarboxylase by substrate-mediated transamination of its pyruvoyl cofactor. Proteasome inhibition in COS-7 cells prevents the degradation of S-adenosylmethionine decarboxylase antigen; however, even brief inhibition of the 26 S proteasome caused substantial losses of S-adenosylmethionine decarboxylase activity despite accumulation of S-adenosylmethionine decarboxylase antigen. Levels of the enzyme's substrate (S-adenosylmethionine) increased rapidly after 26 S proteasome inhibition, and this increase in substrate level is consistent with the observed loss of activity arising from an increased rate of inactivation by substrate-mediated transamination. Evidence is also presented that this substrate-mediated transamination accelerates normal degradation of S-adenosylmethionine decarboxylase, as the rate of degradation of the enzyme was increased in the presence of AbeAdo (5'-([(Z)-4-amino-2-butenyl] methylamino]-5'-deoxyadenosine) ( a substrate analogue that transaminates the enzyme); conversely, when the intracellular substrate level was reduced by methionine deprivation, the rate of degradation of the enzyme was decreased. Ubiquitination of S-adenosylmethionine decarboxylase is demonstrated by isolation of His-tagged AdoMetDC (S-adenosylmethionine decarboxylase) from COS-7 cells co-transfected with hemagglutinin-tagged ubiquitin and showing bands that were immunoreactive to both anti-AdoMetDC antibody and anti-hemagglutinin antibody. This is the first study to demonstrate that AdoMetDC is ubiquitinated and degraded by the 26 S proteasome, and substrate-mediated acceleration of degradation is a unique finding.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Sect Res Resources, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Stanley, BA (corresponding author), Penn State Coll Med, Sect Res Resources H093, 500 Univ Dr, Hershey, PA 17033 USA.	bstanley@psu.edu	Stanley, Bruce/R-9856-2019; Yerlikaya, Azmi/AAS-9289-2020	Yerlikaya, Azmi/0000-0002-0678-0701; Stanley, Bruce/0000-0003-1338-2928				ANTON DL, 1987, BIOCHEMISTRY-US, V26, P6444, DOI 10.1021/bi00394a022; AUTELLI R, 1991, EUR J BIOCHEM, V196, P551, DOI 10.1111/j.1432-1033.1991.tb15849.x; Benanti JA, 2002, MOL CELL BIOL, V22, P7385, DOI 10.1128/MCB.22.21.7385-7397.2002; Berntsson PSH, 1999, BIOCHEM BIOPH RES CO, V263, P13, DOI 10.1006/bbrc.1999.1293; Bohley P, 1996, BIOL CHEM, V377, P425; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Ekstrom JL, 1999, STRUCTURE, V7, P583, DOI 10.1016/S0969-2126(99)80074-4; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FREDLUND JO, 1995, EXP CELL RES, V216, P86, DOI 10.1006/excr.1995.1011; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOLM I, 1989, BIOCHEM J, V261, P205, DOI 10.1042/bj2610205; JANNE J, 1971, J BIOL CHEM, V246, P1725; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KRAMER DL, 1988, BIOCHEM J, V249, P581, DOI 10.1042/bj2490581; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YF, 2001, P NATL ACAD SCI USA, V98, P10578, DOI 10.1073/pnas.181341198; MACH M, 1986, J BIOL CHEM, V261, P1697; MADHUBALA R, 1988, BIOCHEM J, V254, P45, DOI 10.1042/bj2540045; MANN K, 1977, J VIROL, V24, P151, DOI 10.1128/JVI.24.1.151-169.1977; Mitchison JM, 2003, INT REV CYTOL, V226, P165, DOI 10.1016/S0074-7696(03)01004-0; MORRIS DR, 1981, MED BIOL, V59, P314; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Nasizadeh S, 2003, FEBS LETT, V553, P131, DOI 10.1016/S0014-5793(03)00986-4; PEGG AE, 1973, BIOCHEM BIOPH RES CO, V52, P696, DOI 10.1016/0006-291X(73)90768-7; PEGG AE, 1979, J BIOL CHEM, V254, P3249; PEGG AE, 1988, BIOCHEM BIOPH RES CO, V150, P788, DOI 10.1016/0006-291X(88)90460-3; Pegg AE, 1998, BIOCHEM SOC T, V26, P580, DOI 10.1042/bst0260580; PEGG AE, 1987, BIOCHEM J, V244, P49, DOI 10.1042/bj2440049; PEGG AE, 1982, AM J PHYSIOL, V243, P212; POSO H, 1981, BIOCHEM J, V200, P629; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Saito T, 2002, J BIOL CHEM, V277, P33624, DOI 10.1074/jbc.M201909200; Sasajima H, 2002, EUR J BIOCHEM, V269, P3596, DOI 10.1046/j.1432-1033.2002.03052.x; SEYFRIED CE, 1982, BIOCHIM BIOPHYS ACTA, V716, P169, DOI 10.1016/0304-4165(82)90265-3; SHANTZ LM, 1992, BIOCHEM J, V288, P511, DOI 10.1042/bj2880511; SHANTZ LM, 1992, BIOCHEMISTRY-US, V31, P6848, DOI 10.1021/bi00144a027; SHIRAHATA A, 1985, BIOCHEMISTRY-US, V24, P4417, DOI 10.1021/bi00337a024; SHIRAHATA A, 1985, J BIOL CHEM, V260, P9583; Siepmann TJ, 2003, J BIOL CHEM, V278, P9448, DOI 10.1074/jbc.M211240200; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; STANLEY BA, 1994, J BIOL CHEM, V269, P7901; STANLEY BA, 1995, POLYAMINES REGULATIO, P27; STJERNBORG L, 1993, BIOCHEM PHARMACOL, V45, P1174, DOI 10.1016/0006-2952(93)90266-Y; Svensson F, 1997, BIOCHEM J, V322, P297, DOI 10.1042/bj3220297; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TISDALE MJ, 1981, BIOCHIM BIOPHYS ACTA, V675, P366, DOI 10.1016/0304-4165(81)90027-1; Tolbert WD, 2001, BIOCHEMISTRY-US, V40, P9484, DOI 10.1021/bi010735w; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Xiong HS, 1999, BIOCHEMISTRY-US, V38, P2462, DOI 10.1021/bi9825201	53	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12469	12478		10.1074/jbc.M312625200	http://dx.doi.org/10.1074/jbc.M312625200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718534	hybrid			2022-12-25	WOS:000220334900057
J	Arimura, Y; Shiroki, F; Kuwahara, S; Kato, H; Dianzani, U; Uchiyama, T; Yagi, J				Arimura, Y; Shiroki, F; Kuwahara, S; Kato, H; Dianzani, U; Uchiyama, T; Yagi, J			Akt is a neutral amplifier for Th cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE GENE-EXPRESSION; TRANSCRIPTION FACTOR; MOLECULE ICOS; PHOSPHATIDYLINOSITOL 3-KINASE; COSTIMULATORY MOLECULE; CD28-DEFICIENT MICE; IL-4 GENE; CYTOPLASMIC DOMAIN; IN-VIVO; ACTIVATION	Both CD28 and its relative, inducible costimulator ( ICOS), have a binding motif for phosphatidylinositol 3-kinase (PI3K) in their cytoplasmic tail, and the binding of PI3K leads to activation of a serine/threonine kinase, Akt. The role of Akt in cytokine production and helper T (Th) cell differentiation remains obscure. In this study, we found that enforced expression of the constitutively active form (E40K) of Akt rendered CD4(+) T cells activated. Wild-type of Akt and E40K promoted Th1 cell differentiation in C57BL/6-derived and Th1-polarized BALB/c-derived CD4(+) T cells, while both promoted Th2 cell differentiation in BALB/c-derived and Th2-polarized C57BL/6 CD4(+) T cells. E40K also facilitated Th1 differentiation in CD4(+) T cells from IL-4-deficient mice with the BALB/c background. E40K up-regulated expression of NF-AT and c-Myb, which may be related to the augmentation of cytokine production by E40K. These findings indicate that the mechanism by which Akt augments cytokine production via CD28 and ICOS is Th cell type-specific and reflects the intracellular status affected by the cytokine milieu. We conclude that Akt is a neutral amplifier of T cell activation and Th differentiation.	Tokyo Womens Med Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1628666, Japan; A Avogadro Univ Eastern Piedmont, IRCAD, I-28100 Novara, Italy; A Avogadro Univ Eastern Piedmont, Dept Med Sci, I-28100 Novara, Italy	Tokyo Women's Medical University; University of Eastern Piedmont Amedeo Avogadro; University of Eastern Piedmont Amedeo Avogadro	Arimura, Y (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	arimura@research.twmu.ac.jp	Dianzani, Umberto/K-1952-2016	DIANZANI, Umberto/0000-0001-6723-3931				Arimura Y, 2002, INT IMMUNOL, V14, P555, DOI 10.1093/intimm/dxf022; Arimura Y, 2001, J BIOL CHEM, V276, P8550, DOI 10.1074/jbc.M009242200; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brown DR, 1996, J EXP MED, V184, P803, DOI 10.1084/jem.184.3.803; Buonfiglio D, 2000, EUR J IMMUNOL, V30, P3463, DOI 10.1002/1521-4141(2000012)30:12<3463::AID-IMMU3463>3.0.CO;2-5; Chen LQ, 2002, J IMMUNOL, V168, P3817, DOI 10.4049/jimmunol.168.8.3817; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; CROOKS MEC, 1995, MOL CELL BIOL, V15, P6820; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; El-Deiry WS, 2001, NAT CELL BIOL, V3, pE71, DOI 10.1038/35060148; Filippi C, 2003, J EXP MED, V198, P201, DOI 10.1084/jem.20021893; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; GROSS JA, 1992, J IMMUNOL, V149, P380; Harada Y, 2003, J EXP MED, V197, P257, DOI 10.1084/jem.20021305; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Khattri R, 1999, J IMMUNOL, V162, P5784; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; King CL, 1996, EUR J IMMUNOL, V26, P2448, DOI 10.1002/eji.1830261027; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; Lauder A, 2001, MOL CELL BIOL, V21, P5797, DOI 10.1128/MCB.21.17.5797-5805.2001; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Lenschow DJ, 1996, IMMUNITY, V5, P285, DOI 10.1016/S1074-7613(00)80323-4; McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Monticelli S, 2002, EUR J IMMUNOL, V32, P2971, DOI 10.1002/1521-4141(2002010)32:10<2971::AID-IMMU2971>3.0.CO;2-G; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; NobenTrauth N, 1996, TRANSGENIC RES, V5, P487, DOI 10.1007/BF01980214; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Ogawa S, 2001, J IMMUNOL, V167, P5741, DOI 10.4049/jimmunol.167.10.5741; Riley JL, 2002, P NATL ACAD SCI USA, V99, P11790, DOI 10.1073/pnas.162359999; Rodriguez-Palmero M, 1999, EUR J IMMUNOL, V29, P3914; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; Rottman JB, 2001, NAT IMMUNOL, V2, P605, DOI 10.1038/89750; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Shi J, 1997, J IMMUNOL, V158, P4688; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Tamatani T, 2000, INT IMMUNOL, V12, P51, DOI 10.1093/intimm/12.1.51; TRUITT KE, 1995, J IMMUNOL, V155, P4702; WARD SG, 1995, EUR J IMMUNOL, V25, P526, DOI 10.1002/eji.1830250233; Watanabe N, 2003, NAT IMMUNOL, V4, P670, DOI 10.1038/ni944; YAGI J, 1994, J IMMUNOL, V152, P3833; Yagi J, 2003, J IMMUNOL, V171, P783, DOI 10.4049/jimmunol.171.2.783; Yagi J, 1999, J IMMUNOL, V163, P3083; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	58	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11408	11416		10.1074/jbc.M309063200	http://dx.doi.org/10.1074/jbc.M309063200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707136	hybrid			2022-12-25	WOS:000220157600071
J	Matsuura, K; Nagai, T; Nishigaki, N; Oyama, T; Nishi, J; Wada, H; Sano, M; Toko, H; Akazawa, H; Sato, T; Nakaya, H; Kasanuki, H; Komuro, I				Matsuura, K; Nagai, T; Nishigaki, N; Oyama, T; Nishi, J; Wada, H; Sano, M; Toko, H; Akazawa, H; Sato, T; Nakaya, H; Kasanuki, H; Komuro, I			Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; SIDE POPULATION CELLS; BONE-MARROW-CELLS; TRANSCRIPTION FACTOR; OXYTOCIN RECEPTORS; MYOGENIC SPECIFICATION; MYOCYTE PROLIFERATION; PROGENITOR CELLS; IN-VITRO; EXPRESSION	Although somatic stem cells have been reported to exist in various adult organs, there have been few reports concerning stem cells in the heart. We here demonstrate that Sca-1-positive (Sca-1+) cells in adult hearts have some of the features of stem cells. Sca-1+ cells were isolated from adult murine hearts by a magnetic cell sorting system and cultured on gelatin-coated dishes. A fraction of Sca-1+ cells stuck to the culture dish and proliferated slowly. When treated with oxytocin, Sca-1+ cells expressed genes of cardiac transcription factors and contractile proteins and showed sarcomeric structure and spontaneous beating. Isoproterenol treatment increased the beating rate, which was accompanied by the intracellular Ca2+ transients. The cardiac Sca-1+ cells expressed oxytocin receptor mRNA, and the expression was up-regulated after oxytocin treatment. Some of the Sca-1+ cells expressed alkaline phosphatase after osteogenic induction and were stained with Oil-Red O after adipogenic induction. These results suggest that Sca-1+ cells in the adult murine heart have potential as stem cells and may contribute to the regeneration of injured hearts.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba 2608670, Japan; Tokyo Womens Med Univ, Heart Inst Japan, Dept Cardiol, Tokyo 1620054, Japan; Takeda Chem Ind Ltd, Osaka 5408645, Japan; Chiba Univ, Grad Sch Med, Dept Pharmacol, Chiba 2608670, Japan	Chiba University; Tokyo Women's Medical University; Takeda Chemical Industries; Chiba University	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	komuro-tky@umin.ac.jp	Nishigaki, Nobuhiro/AAZ-3584-2021	Nishigaki, Nobuhiro/0000-0002-7524-1429; Akazawa, Hiroshi/0000-0002-3574-9607				Anversa P, 2002, NATURE, V415, P240, DOI 10.1038/415240a; Asakura A, 2002, EXP HEMATOL, V30, P1339, DOI 10.1016/S0301-472X(02)00954-2; Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432-0436.2001.680412.x; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Brunskill EW, 2001, DEV BIOL, V235, P507, DOI 10.1006/dbio.2001.0313; Cassoni P, 2001, ENDOCRINOLOGY, V142, P1130, DOI 10.1210/en.142.3.1130; Cassoni P, 1997, INT J CANCER, V72, P340, DOI 10.1002/(SICI)1097-0215(19970717)72:2<340::AID-IJC23>3.0.CO;2-I; Cassoni P, 1998, INT J CANCER, V77, P695, DOI 10.1002/(SICI)1097-0215(19980831)77:5<695::AID-IJC6>3.0.CO;2-Q; Cassoni P, 2000, J PATHOL, V190, P470, DOI 10.1002/(SICI)1096-9896(200003)190:4<470::AID-PATH550>3.0.CO;2-G; Eisenberg CA, 1997, DEVELOPMENT, V124, P525; Gojo S, 2003, EXP CELL RES, V288, P51, DOI 10.1016/S0014-4827(03)00132-0; Hakuno D, 2002, CIRCULATION, V105, P380, DOI 10.1161/hc0302.102593; Hierlihy AM, 2002, FEBS LETT, V530, P239, DOI 10.1016/S0014-5793(02)03477-4; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Hoare S, 1999, J BIOL CHEM, V274, P28682, DOI 10.1074/jbc.274.40.28682; Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; Leri A, 2001, P NATL ACAD SCI USA, V98, P8626, DOI 10.1073/pnas.151013298; Limana F, 2002, P NATL ACAD SCI USA, V99, P6257, DOI 10.1073/pnas.092672899; Lu S, 2000, J MOL CELL CARDIOL, V32, P143, DOI 10.1006/jmcc.1999.1063; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Mukaddam-Daher S, 2002, J ENDOCRINOL, V175, P211, DOI 10.1677/joe.0.1750211; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; OHMICHI M, 1995, ENDOCRINOLOGY, V136, P2082, DOI 10.1210/en.136.5.2082; Okumoto K, 2003, BIOCHEM BIOPH RES CO, V304, P691, DOI 10.1016/S0006-291X(03)00637-5; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Paquin J, 2002, P NATL ACAD SCI USA, V99, P9550, DOI 10.1073/pnas.152302499; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Strakova Z, 1998, AM J PHYSIOL-ENDOC M, V274, pE634, DOI 10.1152/ajpendo.1998.274.4.E634; SUGI Y, 1995, DEV BIOL, V168, P567, DOI 10.1006/dbio.1995.1102; Swanson BJ, 1998, MOL IMMUNOL, V35, P445, DOI 10.1016/S0161-5890(98)00058-3; Tahara A, 2000, BRIT J PHARMACOL, V129, P131, DOI 10.1038/sj.bjp.0702996; Tahara M, 2002, ENDOCRINOLOGY, V143, P920, DOI 10.1210/en.143.3.920; Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106; Thibonnier M, 1999, ENDOCRINOLOGY, V140, P1301, DOI 10.1210/en.140.3.1301; Torrente Y, 2001, J CELL BIOL, V152, P335, DOI 10.1083/jcb.152.2.335; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; Wei L, 2001, DEVELOPMENT, V128, P2953; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; Yao A, 1998, AM J PHYSIOL-HEART C, V275, pH1441, DOI 10.1152/ajpheart.1998.275.4.H1441; Yao A, 2003, CIRC J, V67, P83, DOI 10.1253/circj.67.83; zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432-0436.2003.700602.x	57	483	527	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11384	11391		10.1074/jbc.M310822200	http://dx.doi.org/10.1074/jbc.M310822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702342	hybrid			2022-12-25	WOS:000220157600068
J	Kumar, D; Gokhale, P; Broustas, C; Chakravarty, D; Ahmad, I; Kasid, U				Kumar, D; Gokhale, P; Broustas, C; Chakravarty, D; Ahmad, I; Kasid, U			Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells	ONCOGENE			English	Article						SCC-S2; subcellular localization; cell growth regulation in vitro and in vivo	NF-KAPPA-B; DEATH-EFFECTOR DOMAIN; NECROSIS-FACTOR-ALPHA; FLICE-INHIBITORY PROTEIN; DISEASE TUMOR-CELLS; C-FLIP; PANCREATIC ADENOCARCINOMA; CONSTITUTIVE ACTIVATION; MEDIATED APOPTOSIS; RADIATION RESPONSE	SCC-S2/GG2-1/NDED is a recently discovered antiapoptotic molecule induced by the activation of the transcription factor NF-kappaB. Here we have examined a role of SCC-S2 in cell growth regulation in vitro and in vivo. Western blotting using an antipeptide antibody revealed endogenous SCC-S2 as a similar to21kDa cytosolic protein in human breast cancer cells (MDA-MB 231) and renal carcinoma cells (RCC-RS). The immunofluorescence detection method showed the cytosolic localization of FLAG-tagged human SCC-S2 in COS-1 transfectants. MDA-MB 435 human cancer cells stably transfected with the FLAG-tagged SCC-S2 cDNA exhibited increased growth rate as compared to control vector transfectants, as measured by the cell viability (>twofold; n=3; P<0.005) and thymidine-labeling procedures (similar to sixfold; n=3; P<0.0001). SCC-S2 transfectants also displayed an increase in cell migration in collagen I as compared to control transfectants (similar totwofold; n=3; P<0.005). In athymic mice, SCC-S2 transfectants showed significantly enhanced tumor growth as compared to control transfectants (mean tumor volumes, day 16: control, 56.86 +/- 19.82 mm(3); SCC-S2, 127.54 +/- 18.78 mm(3); n=5; P<0.03). The examination of a limited number of clinical specimens revealed higher expression levels of SCC-S2 protein in certain human tumor tissues as compared to the matched normal adjacent tissues. Taken together, the present studies demonstrate SCC-S2 as a novel oncogenic factor in cancer cells.	Georgetown Univ, Med Ctr, Dept Radiat Med, Lombardi Canc Ctr, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Lombardi Canc Ctr, Washington, DC 20057 USA; Neopharm Inc, Lake Forest, IL 60045 USA	Georgetown University; Georgetown University	Kasid, U (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Lombardi Canc Ctr, E208,Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	kasidu@georgetown.edu		Chakravarty, Debyani/0000-0001-8629-5732; Broustas, Constantinos/0000-0001-7169-807X	NCI NIH HHS [P01 CA74175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Hackam AS, 2000, J BIOL CHEM, V275, P41299, DOI 10.1074/jbc.M008408200; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; Kaufmann M, 2002, FEBS LETT, V527, P250, DOI 10.1016/S0014-5793(02)03146-0; Keleg Shereen, 2003, Mol Cancer, V2, P14, DOI 10.1186/1476-4598-2-14; Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LEUNG SW, 1993, CANCER-AM CANCER SOC, V71, P2276, DOI 10.1002/1097-0142(19930401)71:7<2276::AID-CNCR2820710718>3.0.CO;2-7; Lim JW, 2002, J BIOL CHEM, V277, P46093, DOI 10.1074/jbc.M206603200; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Mori N, 1999, BLOOD, V93, P2360; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; Nair A, 2003, ONCOGENE, V22, P50, DOI 10.1038/sj.onc.1206043; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; Patel S, 1997, ORAL ONCOL, V33, P197, DOI 10.1016/S0964-1955(96)00065-6; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Scaife CL, 2002, CANCER RES, V62, P6870; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Xiao CW, 2003, ENDOCRINOLOGY, V144, P623, DOI 10.1210/en.2001-211024; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	39	100	117	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					612	616		10.1038/sj.onc.1207123	http://dx.doi.org/10.1038/sj.onc.1207123			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724590				2022-12-25	WOS:000188098300033
J	Chikumi, H; Barac, A; Behbahani, B; Gao, Y; Teramoto, H; Zheng, Y; Gutkind, JS				Chikumi, H; Barac, A; Behbahani, B; Gao, Y; Teramoto, H; Zheng, Y; Gutkind, JS			Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential	ONCOGENE			English	Article						Rho; guanine-nucleotide exchange factor; transformation; GTPases; G proteins	NUCLEOTIDE EXCHANGE FACTORS; VAV PROTOONCOGENE PRODUCT; HETEROTRIMERIC G-PROTEINS; LEUKEMIA-ASSOCIATED RHO; TYROSINE PHOSPHORYLATION; GUANOSINE TRIPHOSPHATASES; CELLULAR-TRANSFORMATION; DEPENDENT ACTIVATION; P115 RHOGEF; DBL FAMILY	PDZ-RhoGEF, LARG, and p115RhoGEF are members of a newly identified family of Rho-guanine nucleotide exchange factors (GEFs) exhibiting a unique structural feature consisting of the presence of an area of similarity to regulators of G protein signaling (RGS). This RGS-like (RGL) domain provides a functional motif by which Galpha(12) and Galpha(13) can bind and regulate the activity of these RhoGEFs, thus providing a direct link from these heterotrimeric G proteins to Rho. PDZ-RhoGEF and LARG can also be phosphorylated by tyrosine kinases, including FAK, and associate with Plexin B, a semaphorin receptor, which controls axon guidance during development, through their PDZ domain, thereby stimulating Rho. Interestingly, while characterizing a PDZ-RhoGEF antiserum, we found that a transfected PDZ-RhoGEF construct associated with the endogenous PDZ-RhoGEF. Indeed, we observed that PDZ-RhoGEF and LARG can form homo- and hetero-oligomers, whereas p115RhoGEF can only homo-oligomerize, and that this intermolecular interaction was mediated by their unique C-terminal regions. Deletion of the C-terminal tail of PDZ-RhoGEF had no significant effect on the GEF catalytic activity towards Rho in vitro, but resulted in a drastic increase in the ability to stimulate a serum response element reporter and the accumulation of the GTP-bound Rho in vivo. Furthermore, removal of the C-termini of each of the three RGL-containing GEFs unleashed their full transforming potential. Together, these findings suggest the existence of a novel mechanism controlling the activity of PDZ-RhoGEF, LARG, and p115RhoGEF, which involves homo- and hetero-oligomerization through their inhibitory C-terminal region.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Room 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Zheng, Yi/J-7235-2015	Gutkind, J. Silvio/0000-0002-5150-4482; Zheng, Yi/0000-0001-7089-6074; Barac, Ana/0000-0002-9935-8904	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sakabe K, 2002, FEBS LETT, V511, P15, DOI 10.1016/S0014-5793(01)03264-1; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhu KJ, 2001, MOL CELL BIOL, V21, P425, DOI 10.1128/MCB.21.2.425-437.2001; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	36	83	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					233	240		10.1038/sj.onc.1207012	http://dx.doi.org/10.1038/sj.onc.1207012			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712228				2022-12-25	WOS:000187895300024
J	Rengifo-Cam, W; Konishi, A; Morishita, N; Matsuoka, H; Yamori, T; Nada, S; Okada, M				Rengifo-Cam, W; Konishi, A; Morishita, N; Matsuoka, H; Yamori, T; Nada, S; Okada, M			Csk defines the ability of integrin-mediated cell adhesion and migration in human colon cancer cells: implication for a potential role in cancer metastasis	ONCOGENE			English	Article						Src; Csk; colon cancer; integrin	PROTEIN-TYROSINE KINASE; TERMINAL SRC KINASE; ADVANCED COLORECTAL CANCERS; C-SRC; FAMILY KINASES; CODON 531; E-CADHERIN; ACTIVATION; PP60C-SRC; GENE	Progression of human colon cancer is often associated with elevated expression and activity of the Src family tyrosine kinase (SFK). SFK is ordinarily in equilibrium between inactive and primed states by a balance of negative regulatory kinase Csk and its counteracting tyrosine phosphatase(s), both of which act on the regulatory C-terminal tyrosine of SFK. To evaluate the contribution of the regulatory system of SFK in cancer progression, we here modulated the equilibrium status of SFK by introducing wild-type or dominant-negative Csk in human epithelial colon cancer cells, HCT15 and HT29. Overexpression of wild-type Csk induced decreased SFK activation, increased cell-cell contacts mediated by E-cadherin, decreased the number of focal contacts and decreased cell adhesion/migration and in vitro invasiveness. Conversely, expression of a dominant-negative Csk resulted in elevated SFK activation, enhanced phosphorylation of FAK and paxilllin, enhanced cell scattering, an increased number of focal contacts, dramatic rearrangement of actin cytoskeleton and increased cell adhesion/migration and in vitro invasiveness. In these scattered cells, however, localization, expression and phosphorylation of either E-cadherin or beta-catenin were not significantly affected, suggesting that the E-cadherin-mediated cell-cell contact is indirectly regulated by SFK. Furthermore, all these events occurred absolutely dependent on integrin-mediated cell adhesion. These findings demonstrate that Csk defines the ability of integrin-SFK-mediated cell adhesion signaling that influences the metastatic potential of cancer cells.	Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, Osaka 5650871, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Pharmacol, Toshima Ku, Tokyo 1708455, Japan	Osaka University; Japanese Foundation for Cancer Research	Okada, M (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, 3-1 Yamadaoka, Osaka 5650871, Japan.	okadam@biken.osaka-u.ac.jp						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; BOARDMAN LA, 1995, GASTROENTEROLOGY, V108, P291, DOI 10.1016/0016-5085(95)90037-3; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Daigo Y, 1999, CANCER RES, V59, P4222; Dan S, 2002, CANCER RES, V62, P1139; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; HYAFIL F, 1980, CELL, V21, P927, DOI 10.1016/0092-8674(80)90456-0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Irby RB, 2002, CANCER RES, V62, P2669; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Laghi L, 2001, BRIT J CANCER, V84, P196, DOI 10.1054/bjoc.2000.1560; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nakagawa T, 2000, INT J CANCER, V88, P384, DOI 10.1002/1097-0215(20001101)88:3<384::AID-IJC10>3.3.CO;2-2; Nam JS, 2002, CLIN CANCER RES, V8, P2430; Nilbert M, 2000, CANCER GENET CYTOGEN, V121, P94, DOI 10.1016/S0165-4608(00)00226-0; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; RENGIFOCAM W, 2001, CANCER, V92, P61; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Suen PW, 1999, J CELL SCI, V112, P4067; Takayama Y, 1999, J BIOL CHEM, V274, P2291, DOI 10.1074/jbc.274.4.2291; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; Wang NM, 2000, CANCER LETT, V150, P201, DOI 10.1016/S0304-3835(99)00398-5	36	36	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					289	297		10.1038/sj.onc.1207041	http://dx.doi.org/10.1038/sj.onc.1207041			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712234				2022-12-25	WOS:000187895300030
J	Ahmad, N				Ahmad, N			Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer	FASEB JOURNAL			English	Article						Plk inhibitor; gene therapy; apoptosis; cell cycle	CYCLIN B1; CELLS; CENTROSOMES; INHIBITION; MARKER	Second only to skin cancer, cancer of the prostate gland (CaP) is the most commonly occurring cancer in American men. Existing treatment approaches and surgical intervention have been unable to effectively manage this dreaded cancer; therefore, efforts are ongoing to explore novel targets and strategies for the management of CaP. A complete understanding of the genetic control of the processes of cellular proliferation and programmed cell death, or "apoptosis," may provide the basis for the rational design of novel therapeutic strategies against CaP. Key regulators for the mitotic progression in mammalian cells are the polo-like kinases (Plks). The activity of Plk1 is elevated in tissues and cells with a high mitotic index, including cancer cells. An increasing body of evidence suggests that the level of Plk1 expression has prognostic value for predicting outcomes in patients with some cancers such as lung cancer, squamous cell carcinomas of the head and neck, melanomas, and ovarian and endometrial carcinomas. However, the role of Plk1 in CaP is not known. Here, a hypothesis is put forward that Plk1 plays a critical role in the development of Prostate cancer; and the silencing of Plk1 will result in elimination of human CaP cells via an inactivation of cyclin-dependent kinase 1 (Cdc2)/cyclin B 1-mediated mitotic arrest followed by apoptosis. A corollary to this hypothesis is that Plk1 could serve as a target for the intervention of CaP in humans. Therefore, if the hypothesis is tested to be true, it is conceivable that gene therapeutic approaches aimed at Plk1 or the pharmacological inhibitors of Plk1 may be developed for the treatment/management of CaP.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Ctr Comprehens Canc, Madison, WI 53706 USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahmad, N (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Ctr Comprehens Canc, 1300 Univ Ave, Madison, WI 53706 USA.	nahmad@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887				Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Donaldson MM, 2001, J CELL SCI, V114, P2357; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Pihan GA, 2001, CANCER RES, V61, P2212; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 1997, AM J PATHOL, V150, P1165	14	28	51	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					5	7		10.1096/fj.03-0848hyp	http://dx.doi.org/10.1096/fj.03-0848hyp			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718382				2022-12-25	WOS:000188829300035
J	Cuzzocrea, S; Mazzon, E; Dugo, L; Di Paola, R; Caputi, AP; Salvemini, D				Cuzzocrea, S; Mazzon, E; Dugo, L; Di Paola, R; Caputi, AP; Salvemini, D			Superoxide: a key player in hypertension	FASEB JOURNAL			English	Article						superoxide dismutase; M40403; F-2-isoprostane	NITRIC-OXIDE SYNTHESIS; PEROXYNITRITE DECOMPOSITION CATALYSTS; SPLANCHNIC ARTERY-OCCLUSION; BLOOD-PRESSURE; RAT MODEL; IN-VIVO; ENDOTHELIUM; DISMUTASE; ACETYLCHOLINE; ACTIVATION	Superoxide is increased in the vessel wall of spontaneously hypertensive rats (SHR) where, if "blocked," potentiates endothelium-dependent vasodilation. The purpose of this study was to determine the role of superoxide anion in hypertension and its interaction with nitric oxide (NO). For this purpose we used a low molecular weight synthetic superoxide dismutase mimetic (M40403), known to remove selectively superoxide anion. Baseline mean arterial pressure (MAP) was significantly elevated in the SHR compared with its normal counterpart, Wistar Kyoto (WKY). M40403 at a dose (2 mg.kg(-1).h(-1)), which had no effect in the WKY, significantly decreased MAP in SHR rats. To determine whether superoxide anion increases MAP by inactivating NO, NO synthesis was blocked with N-G nitroarginine methyl ester (L-NAME, 3 mg/kg i.v.), a nonselective nitric oxide synthase inhibitor. L-NAME (3 mg/kg, i.v) blocked the anti-hypertensive effect of M40403 (2 mg/kg over 30 min). When used at a dose that yielded similar increases in MAP, norepinephrine (2.1 mug/kg) failed to alter the anti-hypertensive effects of M40403 in the SHR. To investigate whether the antihypertensive effect of M40403 was associated with an improvement of the alterations in vascular reactivity, a separate group of experiments was carried out ex vivo. Endothelium-dependent vasorelaxation to acetylcholine (10 nM-10 muM), an index of endothelial function, was reduced in aortic rings taken from SHR rats when compared with WKY rats. In vivo treatment with M40403 caused an improvement of the degree of the endothelial dysfunction in SHR rats. Furthermore, immunohistochemical analysis for nitrotyrosine (the product formed from the interaction of nitric oxide with superoxide) revealed a positive staining in aorta from SHR rats. The degree of staining for nitrotyrosine was markedly reduced in tissue sections obtained from SHR rats treated with M40403. Our data suggest that overt production of superoxide in SHR couples with nitric oxide, reducing its function and leading to a loss of blood vessel tone and hypertension. Another important effect appears to be at the level of endothelial cellular integrity, where by interacting with nitric oxide, superoxide anion forms peroxynitrite and subsequent endothelial cell dysfunction. By removing superoxide, M40403 restores blood pressure to near-to-normal values.	MetaPhore Pharmaceut, Dept Biol & Pharmacol Res, St Louis, MO 63114 USA; Univ Messina, Inst Pharmacol, I-98100 Messina, Italy; Univ Messina, Sch Med, Dept Biomorphol, I-98100 Messina, Italy	University of Messina; University of Messina	Salvemini, D (corresponding author), MetaPhore Pharmaceut, Dept Biol & Pharmacol Res, 1910 Innerbelt Business Ctr Dr, St Louis, MO 63114 USA.	dsalvemini@metaphore.com	di paola, rosanna/U-4356-2019; Mazzon, Emanuela/AAL-4334-2020	di paola, rosanna/0000-0001-6725-8581; mazzon, emanuela/0000-0002-5073-717X; Dugo, Laura/0000-0001-5527-0364				ANGUS JA, 1992, KIDNEY INT, V41, pS73; Balazy M, 1998, J BIOL CHEM, V273, P32009, DOI 10.1074/jbc.273.48.32009; BAYLIS C, 1992, J CLIN INVEST, V90, P278, DOI 10.1172/JCI115849; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Bouloumie A, 1997, HYPERTENSION, V30, P934, DOI 10.1161/01.HYP.30.4.934; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CARLOS R, 1999, HYPERTENSION, V34, P943; COCKCROFT JR, 1994, NEW ENGL J MED, V330, P1036, DOI 10.1056/NEJM199404143301502; Cosentino F, 1998, J CLIN INVEST, V101, P1530, DOI 10.1172/JCI650; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Cuzzocrea S, 2001, BRIT J PHARMACOL, V132, P19, DOI 10.1038/sj.bjp.0703775; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; Davidson C. A., 1997, AM J PHYSIOL, V273, P437; DOHI Y, 1995, HYPERTENSION, V15, P170; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; GRANGER JP, 1992, J CARDIOVASC PHARM, V20, pS160, DOI 10.1097/00005344-199204002-00045; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Grover AK, 2003, AM J PHYSIOL-CELL PH, V284, pC294, DOI 10.1152/ajpcell.00297.2002; GRUNFELD S, 1995, HYPERTENSION, V26, P854, DOI 10.1161/01.HYP.26.6.854; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HAYNES WG, 1993, J HYPERTENS, V11, P1375, DOI 10.1097/00004872-199312000-00009; HU LF, 1994, HYPERTENSION, V23, P185, DOI 10.1161/01.HYP.23.2.185; Kerr S, 1999, HYPERTENSION, V33, P1353, DOI 10.1161/01.HYP.33.6.1353; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; LAURENT S, 1990, AM J PHYSIOL, V258, pH1004, DOI 10.1152/ajpheart.1990.258.4.H1004; Laursen JB, 1997, CIRCULATION, V95, P588, DOI 10.1161/01.CIR.95.3.588; LINDER L, 1990, CIRCULATION, V81, P1762, DOI 10.1161/01.CIR.81.6.1762; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V194, P654, DOI 10.1006/bbrc.1993.1871; MARUYAMA J, 1994, AM J PHYSIOL, V266, pH2476, DOI 10.1152/ajpheart.1994.266.6.H2476; McIntyre M, 1999, HYPERTENSION, V34, P539, DOI 10.1161/01.HYP.34.4.539; McIntyre M, 1997, HYPERTENSION, V30, P1517, DOI 10.1161/01.HYP.30.6.1517; Miyamoto Y, 1996, P SOC EXP BIOL MED, V211, P366; MIYAMOTO Y, 1991, P SOC EXP BIOL MED, V21, P366; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rees D, 1996, HYPERTENSION, V28, P367, DOI 10.1161/01.HYP.28.3.367; RIBEIRO MO, 1992, HYPERTENSION, V20, P298, DOI 10.1161/01.HYP.20.3.298; Riley DP, 1996, INORG CHEM, V35, P5213, DOI 10.1021/ic960262v; Riley L, 1997, INFECT DIS CLIN N AM, V11, P119, DOI 10.1016/S0891-5520(05)70346-9; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; Salvemini D, 1999, SCIENCE, V286, P304, DOI 10.1126/science.286.5438.304; Salvemini D, 1999, BRIT J PHARMACOL, V127, P685, DOI 10.1038/sj.bjp.0702604; Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659; Salvemini D, 2001, ARTHRITIS RHEUM, V44, P2909, DOI 10.1002/1529-0131(200112)44:12<2909::AID-ART479>3.0.CO;2-#; Salvemini D, 1996, EUR J PHARMACOL, V303, P217, DOI 10.1016/0014-2999(96)00140-9; Salvemini D, 2001, BRIT J PHARMACOL, V132, P815, DOI 10.1038/sj.bjp.0703841; SAMUNI A, 1991, J CLIN INVEST, V87, P1526, DOI 10.1172/JCI115163; Schnackenberg CG, 1998, HYPERTENSION, V32, P59, DOI 10.1161/01.HYP.32.1.59; SUZUKI H, 1995, HYPERTENSION, V25, P1083, DOI 10.1161/01.HYP.25.5.1083; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Szabo C, 1996, CIRC RES, V78, P1051, DOI 10.1161/01.RES.78.6.1051; TADDEI S, 1993, HYPERTENSION, V21, P929, DOI 10.1161/01.HYP.21.6.929; TREASURE CB, 1992, CIRC RES, V71, P776, DOI 10.1161/01.RES.71.4.776; Tschudi MR, 1996, HYPERTENSION, V27, P32, DOI 10.1161/01.HYP.27.1.32; VALLANCE P, 1989, LANCET, V2, P997; VILLA LM, 1994, P NATL ACAD SCI USA, V91, P12383, DOI 10.1073/pnas.91.26.12383; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781	60	73	77	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					94	101		10.1096/fj.03-0428com	http://dx.doi.org/10.1096/fj.03-0428com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718390				2022-12-25	WOS:000188829300043
J	Graler, MH; Goetzl, EJ				Graler, MH; Goetzl, EJ			The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors	FASEB JOURNAL			English	Article						receptor internalization; calcium signaling; lymphocyte; immunity; transplantation	CIRCULATING MATURE LYMPHOCYTES; ALLOGRAFT SURVIVAL; INDUCED ARTHRITIS; SEQUESTRATION; ACCELERATION; RATS; TRANSPLANTATION; TRAFFICKING; INDUCTION; DRUG	FTY720 is an immunosuppressant that reduces circulating levels of naive lymphocytes by increasing their localization and sequestration in secondary lymphoid organs. It is considered to be an agonist for sphingosine 1-phosphate (S1P) G protein-coupled receptors (GPCRs) after phosphorylation at micromolar concentrations. We now describe its nonagonist and noncompetitive inhibitory activity at low nanomolar concentrations for types 1 and 5 S1P-GPCRs and of moderate potency for type 2 S1P-GPCRs. FTY720 blocks S1P signaling through S1P(1,2,5) by inducing their internalization and intracellular partial degradation without affecting S1P(3) or S1P(4). S1P-R internalization is maximal several hours after only seconds of incubation with FTY720 at 37degreesC and washing, and continues for days before recovery of surface expression and functions. The timing and extent of S1P-R internalization are highly dependent on FTY720 concentration. FTY720 is therefore an S1P-GPCR-selective and noncompetitive inhibitor with a unique mechanism of action.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Graler, MH (corresponding author), Univ Calif San Francisco, Dept Med, Room UB-8B,UC Box 0711,533 Parnassus Ave, San Francisco, CA 94143 USA.	graeler@itsa.ucsf.edu	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849				An SZ, 1998, J CELL BIOCHEM, P147; Bohler T, 2000, Transpl Int, V13 Suppl 1, pS311, DOI 10.1007/s001470050350; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2001, TRANSPLANT P, V33, P3078, DOI 10.1016/S0041-1345(01)02312-0; Brinkmann V, 2002, CURR OPIN IMMUNOL, V14, P569, DOI 10.1016/S0952-7915(02)00374-6; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Budde K, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341073; Chen S, 2001, TRANSPLANT P, V33, P3057, DOI 10.1016/S0041-1345(01)02306-5; Chiba K, 1999, TRANSPLANT P, V31, P1230, DOI 10.1016/S0041-1345(98)01975-7; Chiba K, 1998, J IMMUNOL, V160, P5037; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Fujino M, 2003, J PHARMACOL EXP THER, V305, P70, DOI 10.1124/jpet.102.045658; FUJITA T, 1994, J ANTIBIOT, V47, P208, DOI 10.7164/antibiotics.47.208; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Graeler MH, 2003, J BIOL CHEM, V278, P27737, DOI 10.1074/jbc.C300147200; Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; Hozumi Y, 1999, LIFE SCI, V65, P1739, DOI 10.1016/S0024-3205(99)00426-9; Kitabayashi H, 2000, J CARDIOVASC PHARM, V35, P410, DOI 10.1097/00005344-200003000-00010; Kiuchi M, 2000, J MED CHEM, V43, P2946, DOI 10.1021/jm000173z; Kiuchi M, 1998, BIOORG MED CHEM LETT, V8, P101, DOI 10.1016/S0960-894X(97)10188-3; KLUEPFEL D, 1972, J ANTIBIOT, V25, P109, DOI 10.7164/antibiotics.25.109; Kurose S, 2000, EXP EYE RES, V70, P7, DOI 10.1006/exer.1999.0777; Li HS, 2002, J PHARMACOL EXP THER, V301, P519, DOI 10.1124/jpet.301.2.519; Luo ZJ, 1999, IMMUNOPHARMACOLOGY, V41, P199, DOI 10.1016/S0162-3109(99)00004-1; Maki T, 2002, TRANSPLANTATION, V74, P1684, DOI 10.1097/01.TP.0000038969.72218.0F; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matsuura M, 2000, INFLAMM RES, V49, P404, DOI 10.1007/s000110050608; Matsuura M, 2000, INT J IMMUNOPHARMACO, V22, P323, DOI 10.1016/S0192-0561(99)00088-0; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Okazaki H, 2002, J RHEUMATOL, V29, P707; Olivera A, 2000, METHOD ENZYMOL, V311, P215; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; Suzuki S, 1996, TRANSPLANT P, V28, P2049; Welsch CA, 2003, J BIOL CHEM, V278, P26976, DOI 10.1074/jbc.M213144200; Yan H, 1998, TRANSPLANT P, V30, P3436, DOI 10.1016/S0041-1345(98)01092-6; Yanagawa Y, 1998, J IMMUNOL, V160, P5493; Yanagawa Y, 1998, IMMUNOLOGY, V95, P591; Yang ZD, 2003, CLIN IMMUNOL, V107, P30, DOI 10.1016/S1521-6616(02)00054-2; Yatomi Y, 1997, J BIOCHEM, V121, P969	41	433	461	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					551	+		10.1096/fj.03-0910fje	http://dx.doi.org/10.1096/fj.03-0910fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715694				2022-12-25	WOS:000188829300033
J	Marquez, S; Crespo, P; Carlini, V; Garbarino-Pico, E; Baler, R; Caputto, BL; Guido, ME				Marquez, S; Crespo, P; Carlini, V; Garbarino-Pico, E; Baler, R; Caputto, BL; Guido, ME			The metabolism of phospholipids oscillates rhythmically in cultures of fibroblasts and is regulated by the clock protein PERIOD 1	FASEB JOURNAL			English	Article						circadian rhythms; phospholipid synthesis; cell cultures; Per1; CLOCK/CLOCK mutants	CIRCADIAN GENE-EXPRESSION; NIH 3T3 FIBROBLASTS; SUPRACHIASMATIC NUCLEUS; PERIPHERAL-TISSUES; RAT-1 FIBROBLASTS; MESSENGER-RNA; BIOLOGICAL CLOCK; GANGLION-CELLS; LIGHT; RHYTHMS	The mammalian circadian timing system is composed of countless cell oscillators distributed throughout the body and central pacemakers regulating temporal physiology and behavior. Peripheral clocks display circadian rhythms in gene expression both in vivo and in culture. We examined the biosynthesis of phospholipids as well as the expression of the clock gene period 1 (Per1) and its potential involvement in the regulation of the phospholipid metabolism in cultured quiescent NIH 3T3 cells synchronized by a 2 h serum shock. A 30 min pulse of radiolabeled precursor was given at phases ranging from 0.5 to 62 h after serum treatment. We observed a daily rhythm in the phospholipid labeling that persisted at least for two cycles, with levels significantly decreasing 29 and 58 h after treatment. Per1 expression exhibited a rapid and transient induction and a daily rhythmicity in antiphase to the lipid labeling. After Per1 expression knockdown, the rhythm of phospholipid labeling was lost. Furthermore, in cultures of CLOCK mutant fibroblasts-cells with a clock mechanism impairment-PERI was equally expressed at all times examined and the phospholipid labeling did not oscillate. The results demonstrate that the biosynthesis of phospholipids oscillates daily in cultured fibroblasts by an endogenous clock mechanism involving Per1 expression.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, RA-5000 Cordoba, Argentina; NIMH, Unit Temporal Gene Express, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA	National University of Cordoba; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Guido, ME (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, Ciudad Univ, RA-5000 Cordoba, Argentina.	mguido@dqb.fcq.unc.edu.ar		Garbarino Pico, Eduardo/0000-0002-2931-2038				Akiyama M, 1999, J NEUROSCI, V19, P1115; Albrecht U, 2001, J BIOL RHYTHM, V16, P100, DOI 10.1177/074873001129001791; Allen G, 2001, J NEUROSCI, V21, P7937, DOI 10.1523/JNEUROSCI.21-20-07937.2001; ASCHOFF J, 1976, FED PROC, V35, P2326; Balsalobre A, 2000, CURR BIOL, V10, P1291, DOI 10.1016/S0960-9822(00)00758-2; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 2002, CELL TISSUE RES, V309, P193, DOI 10.1007/s00441-002-0585-0; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown SA, 2002, CURR BIOL, V12, P1574, DOI 10.1016/S0960-9822(02)01145-4; Bussolino DF, 2001, FASEB J, V15, P556; Bussolino DF, 1998, MOL BRAIN RES, V58, P10, DOI 10.1016/S0169-328X(98)00065-5; Caputto BL, 2002, BBA-MOL CELL BIOL L, V1583, P1, DOI 10.1016/S1388-1981(02)00209-3; Caputto BL, 2000, NEUROCHEM RES, V25, P153, DOI 10.1023/A:1007508020173; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; Deguchi A, 2002, JPN J CANCER RES, V93, P157, DOI 10.1111/j.1349-7006.2002.tb01254.x; Duffield GE, 2002, CURR BIOL, V12, P551, DOI 10.1016/S0960-9822(02)00765-0; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Grundschober C, 2001, J BIOL CHEM, V276, P46751, DOI 10.1074/jbc.M107499200; Guido ME, 1999, NEUROSCIENCE, V90, P555, DOI 10.1016/S0306-4522(98)00467-9; Guido ME, 2001, J NEUROCHEM, V76, P835, DOI 10.1046/j.1471-4159.2001.00081.x; GUIDO ME, 1990, J NEUROCHEM, V55, P1855, DOI 10.1111/j.1471-4159.1990.tb05768.x; Guido ME, 1996, J NEUROSCI RES, V43, P93, DOI 10.1002/jnr.490430112; Hastings J.W., 1991, NEURAL INTEGRATIVE A, P435; Hirota T, 2002, J BIOL CHEM, V277, P44244, DOI 10.1074/jbc.M206233200; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; JAY TM, 1985, BRAIN RES, V342, P297, DOI 10.1016/0006-8993(85)91129-1; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; KISS Z, 1992, ARCH BIOCHEM BIOPHYS, V296, P457, DOI 10.1016/0003-9861(92)90597-P; Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128; Leloup JC, 2003, P NATL ACAD SCI USA, V100, P7051, DOI 10.1073/pnas.1132112100; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Momchilova A, 1999, CELL BIOL INT, V23, P603, DOI 10.1006/cbir.1999.0430; Morre DJ, 2002, BIOCHEMISTRY-US, V41, P11941, DOI 10.1021/bi020392h; Oishi K, 2000, BIOCHEM BIOPH RES CO, V268, P164, DOI 10.1006/bbrc.1999.2054; Okamura H, 2002, CELL TISSUE RES, V309, P47, DOI 10.1007/s00441-002-0572-5; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rutter J, 2002, ANNU REV BIOCHEM, V71, P307, DOI 10.1146/annurev.biochem.71.090501.142857; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; SCHWARTZ WJ, 1977, SCIENCE, V197, P1089, DOI 10.1126/science.887940; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WEISS SJ, 1982, BIOCHEM J, V204, P587, DOI 10.1042/bj2040587; Yagita K, 2000, FEBS LETT, V465, P79, DOI 10.1016/S0014-5793(99)01724-X; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; Yamaguchi S, 2000, MOL CELL BIOL, V20, P4773, DOI 10.1128/MCB.20.13.4773-4781.2000; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Zerpa GAD, 1999, J NEUROCHEM, V73, P1228, DOI 10.1046/j.1471-4159.1999.0731228.x; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	56	31	31	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					519	+		10.1096/fj.03-0417fje	http://dx.doi.org/10.1096/fj.03-0417fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715703				2022-12-25	WOS:000188829300021
J	Meredith, D				Meredith, D			Site-directed mutation of arginine 282 to glutamate uncouples the movement of peptides and protons by the rabbit proton-peptide cotransporter PepT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDE TRANSPORTER; LACTOSE PERMEASE; STOICHIOMETRY; DEPENDENCE; MECHANISM; HPEPT1	A conserved positive residue in the seventh transmembrane domain of the mammalian proton-coupled di- and tripeptide transporter PepT1 has been shown by site-directed mutagenesis to be a key residue for protein function. Substitution of arginine 282 with a glutamate residue (R282E-PepT1) gave a protein at the plasma membrane of Xenopus laevis oocytes that was able to transport the non-hydrolyzable dipeptide [H-3]D-Phe-LGln, although unlike the wild type, the rate of transport by R282E-PepT1 was independent of the extracellular pH level, and the substrate could not be accumulated above equilibrium. The binding affinity of the mutant transport protein was unchanged from the wild type. Thus, R282E-Pept1 appears to have been changed from a proton-driven to a facilitated transporter for peptides. In addition, peptide transport by R282E-PepT1 still induced depolarization as measured by microelectrode recordings of membrane potential. A more detailed study by two-electrode voltage clamping revealed that R282E-PepT1 behaved as a peptide-gated non-selective cation channel with the ion selectivity series lithium > sodium > N-methyl-D-glucamine at pH 7.4. There was also a proton conductance (comparing pH 7.4 and 8.4), and at pH 5.5 the predominant conductance was for potassium ions. Therefore, it can be concluded that changing arginine 282 to a glutamate not only uncouples the cotransport of protons and peptides of the wild-type PepT1 but also creates a peptide-gated cation channel in the protein.	Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England	University of Oxford	Meredith, D (corresponding author), Univ Oxford, Dept Human Anat & Genet, S Parks Rd, Oxford OX1 3QX, England.	david.meredith@anat.ox.ac.uk	Meredith, David/F-3664-2010					Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Bailey PD, 2000, ANGEW CHEM INT EDIT, V39, P506; BEATTIE LA, 2001, THESIS U OXFORD; Bolger MB, 1998, J PHARM SCI-US, V87, P1286, DOI 10.1021/js980090u; Borre L, 2004, J BIOL CHEM, V279, P2513, DOI 10.1074/jbc.M311446200; Covitz KMY, 1998, BIOCHEMISTRY-US, V37, P15214, DOI 10.1021/bi981128k; Daniel H, 2004, PFLUG ARCH EUR J PHY, V447, P610, DOI 10.1007/s00424-003-1101-4; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Kulkarni AA, 2003, BIOCHEM BIOPH RES CO, V306, P177, DOI 10.1016/S0006-291X(03)00926-4; MATZKE EA, 1992, J BIOL CHEM, V267, P19095; Meredith D, 1998, J PHYSIOL-LONDON, V512, P629, DOI 10.1111/j.1469-7793.1998.629bd.x; Meredith D, 2000, CELL MOL LIFE SCI, V57, P754, DOI 10.1007/s000180050040; MEREDITH D, 2003, J PHYSIOL-LONDON, V552, P130; MEREDITH D, 1996, J PHYSIOL-LONDON, V493, P65; Sahin-Toth M, 2001, P NATL ACAD SCI USA, V98, P6068, DOI 10.1073/pnas.111139698; Steel A, 1997, J PHYSIOL-LONDON, V498, P563, DOI 10.1113/jphysiol.1997.sp021883; TEMPLE CS, 1995, PFLUG ARCH EUR J PHY, V430, P825, DOI 10.1007/BF00386182	17	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15795	15798		10.1074/jbc.M313922200	http://dx.doi.org/10.1074/jbc.M313922200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14715671	hybrid			2022-12-25	WOS:000220747900014
J	Blayney, LM; Zissimopoulos, S; Ralph, E; Abbot, E; Matthews, L; Lai, FA				Blayney, LM; Zissimopoulos, S; Ralph, E; Abbot, E; Matthews, L; Lai, FA			Ryanodine receptor oligomeric interaction - Identification of a putative binding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; CA2+ RELEASE; CRYOELECTRON MICROSCOPY; CARDIAC-MUSCLE; COILED COILS; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; MOLECULAR-CLONING	Specific interactions between adjacent ryanodine receptor (RyR) molecules to form ordered two-dimensional arrays in the membrane have been demonstrated using electron microscopy both in situ, in tissues and cells, and in vitro, with the purified protein. RyR interoligomeric association has also been inferred from observations of simultaneous channel gating during multiRyR channel recordings in lipid bilayers. In this study, we report experiments designed to identify the region(s) of the RyR molecule, participating in this reciprocal interaction. Using epitope-specific antibodies, we identified a RyR tryptic fragment that specifically bound the intact immobilized RyR. Three overlapping RyR fragments encompassing this epitope, expressed using an in vitro mammalian expression system, were immunoprecipitated by RyR. To refine the binding regions, smaller RyR fragments were expressed as glutathione S-transferase (GST) fusion proteins, and their binding to RyR was monitored using a "sandwich" enzyme-linked immunosorbent assay. Three GST-RyR fusion proteins demonstrated specific binding, dependent upon ionic strength. Binding was greatest at 50 - 150 mM NaCl for two GST-RyR constructs, and a third GST-RyR construct demonstrated maximum binding between 150 and 450 mM NaCl. The binding at high NaCl concentration suggested involvement of a hydrophobic interaction. In silico analysis of secondary structure showed evidence of coil regions in two of these RyR fragment sequences, which might explain these data. In GST pull-down assays, these same three fragments captured RyR2, and two of them retained RyR1. These results identify a region at the center of the linear RyR ( residues 2540 - 3207 of human RyR2) which is able to bind to the RyR oligomer. This region may constitute a specific subdomain participating in RyR-RyR interaction.	Univ Wales Coll Med, Dept Cardiol, Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Blayney, LM (corresponding author), Univ Wales Coll Med, Dept Cardiol, Wales Heart Res Inst, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	blayney@cf.ac.uk	Zissimopoulos, Spyros/GSD-9824-2022	Lai, Tony/0000-0003-2852-8547; Zissimopoulos, Spyros/0000-0001-5196-9450				ANDERSON K, 1989, J BIOL CHEM, V264, P1329; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; Cannell MB, 1998, TRENDS PHARMACOL SCI, V19, P16, DOI 10.1016/S0165-6147(97)01149-8; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dargan SL, 2002, BIOCHEM J, V361, P401, DOI 10.1042/0264-6021:3610401; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Franzini-Armstrong C, 1999, BIOPHYS J, V77, P1528, DOI 10.1016/S0006-3495(99)77000-1; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; Harlow E., 1999, USING ANTIBODIES LAB; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1989, J BIOL CHEM, V264, P16776; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARKS AR, 1990, J BIOL CHEM, V265, P13143; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Marx SO, 2001, CIRC RES, V88, P1151, DOI 10.1161/hh1101.091268; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MITCHELL RD, 1983, J CELL BIOL, V96, P1017, DOI 10.1083/jcb.96.4.1017; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Oakley MG, 2001, CURR OPIN STRUC BIOL, V11, P450, DOI 10.1016/S0959-440X(00)00232-3; OTSU K, 1990, J BIOL CHEM, V265, P13472; Pollastri G, 2002, PROTEINS, V47, P228, DOI 10.1002/prot.10082; Protasi F, 2000, BIOPHYS J, V79, P2494, DOI 10.1016/S0006-3495(00)76491-5; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; Rice JJ, 1999, BIOPHYS J, V77, P1871, DOI 10.1016/S0006-3495(99)77030-X; Rios E, 1999, J GEN PHYSIOL, V114, P31, DOI 10.1085/jgp.114.1.31; Rios E, 1997, ANNU REV BIOPH BIOM, V26, P47, DOI 10.1146/annurev.biophys.26.1.47; Samso M, 1998, J STRUCT BIOL, V121, P172, DOI 10.1006/jsbi.1997.3955; Serysheva II, 1999, BIOPHYS J, V77, P1936, DOI 10.1016/S0006-3495(99)77035-9; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; Sharma MR, 2000, J BIOL CHEM, V275, P9485, DOI 10.1074/jbc.275.13.9485; Sharma MR, 1998, J BIOL CHEM, V273, P18429, DOI 10.1074/jbc.273.29.18429; Stern MD, 1999, J GEN PHYSIOL, V113, P469, DOI 10.1085/jgp.113.3.469; Stern MD, 1997, J GEN PHYSIOL, V110, P415, DOI 10.1085/jgp.110.4.415; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; WAGENKNECHT T, 1995, FEBS LETT, V369, P43, DOI 10.1016/0014-5793(95)00581-S; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; Willis L, 1997, CHEMTECH, V27, P35; Yin CC, 2000, NAT CELL BIOL, V2, P669, DOI 10.1038/35023625; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	55	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14639	14648		10.1074/jbc.M308014200	http://dx.doi.org/10.1074/jbc.M308014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722100	hybrid			2022-12-25	WOS:000220594700022
J	Matsuda, S; Harries, JC; Viskaduraki, M; Troke, PJF; Kindle, KB; Ryan, C; Heery, DM				Matsuda, S; Harries, JC; Viskaduraki, M; Troke, PJF; Kindle, KB; Ryan, C; Heery, DM			A conserved alpha-helical motif mediates the binding of diverse nuclear proteins to the SRC1 interaction domain of CBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; STRUCTURAL BASIS; HISTONE ACETYLTRANSFERASE; HORMONE RECEPTORS; POINTED DOMAIN; RETINOIC ACID; CANCER CELLS; CBP/P300	CREB-binding protein (CBP) and p300 contain modular domains that mediate protein-protein interactions with a wide variety of nuclear factors. A C-terminal domain of CBP ( referred to as the SID) is responsible for interaction with the alpha-helical AD1 domain of p160 coactivators such as the steroid receptor coactivator (SRC1), and also other transcriptional regulators such as E1A, Ets-2, IRF3, and p53. Here we show that the pointed (PNT) domain of Ets-2 mediates its interaction with the CBP SID, and describe the effects of mutations in the SID on binding of Ets-2, E1A, and SRC1. In vitro binding studies indicate that SRC1, Ets-2 and E1A display mutually exclusive binding to the CBP SID. Consistent with this, we observed negative cross-talk between ERalpha/ SRC1, Ets-2, and E1A proteins in reporter assays in transiently transfected cells. Transcriptional inhibition of Ets-2 or GAL4-AD1 activity by E1A was rescued by cotransfection with a CBP expression plasmid, consistent with the hypothesis that the observed inhibition was due to competition for CBP in vivo. Sequence comparisons revealed that SID-binding proteins contain a leucine-rich motif similar to the alpha-helix Aalpha1 of the SRC1 AD1 domain. Deletion mutants of E1A and Ets-2 lacking the conserved motif were unable to bind the CBP SID. Moreover, a peptide corresponding to this sequence competed the binding of full-length SRC1, Ets-2, and E1A proteins to the CBP SID. Thus, a leucine-rich amphipathic alpha-helix mediates mutually exclusive interactions of functionally diverse nuclear proteins with CBP.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Heery, DM (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	dh37@le.ac.uk		Heery, David/0000-0002-5035-2392; Garrie, Karin/0000-0003-2204-9975				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Benbow U, 1999, BRIT J CANCER, V79, P221, DOI 10.1038/sj.bjc.6690037; Boyd JM, 2002, J VIROL, V76, P1461, DOI 10.1128/JVI.76.3.1461-1474.2002; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; De Guzman RN, 2000, J MOL BIOL, V303, P243, DOI 10.1006/jmbi.2000.4141; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kitamura S, 1999, BIOCHEM BIOPH RES CO, V265, P453, DOI 10.1006/bbrc.1999.1715; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Le Douarin B, 2001, METH MOL B, V176, P227; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Legler J, 1999, TOXICOL SCI, V48, P55, DOI 10.1093/toxsci/48.1.55; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; Livengood JA, 2002, J BIOL CHEM, V277, P9054, DOI 10.1074/jbc.M108870200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; O'Connor MJ, 1999, J VIROL, V73, P3574; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Yang BS, 1996, MOL CELL BIOL, V16, P538	43	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14055	14064		10.1074/jbc.M310188200	http://dx.doi.org/10.1074/jbc.M310188200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722092	hybrid			2022-12-25	WOS:000220478500095
J	Namekata, K; Enokido, Y; Iwasawa, K; Kimura, H				Namekata, K; Enokido, Y; Iwasawa, K; Kimura, H			MOCA induces membrane spreading by activating Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESENILIN-BINDING-PROTEIN; SIGNALING PATHWAY; SMALL GTPASES; SH3 DOMAIN; RHO; CELLS; COMPLEX; GROWTH; KINASE; RAS	The modifier of cell adhesion protein ( MOCA), or Dock3, initially identified as presenilin-binding protein (PBP), belongs to the Dock180 family of proteins and is localized specifically in neurons. Here we demonstrate that MOCA binds to Rac1 and enhances its activity, which leads to the activation of c-Jun NH2-terminal kinase (JNK) and causes changes in cell morphology. Farnesylated MOCA, which is localized in the plasma membrane, enhances the activation of Rac1 and JNK more markedly than wild-type MOCA, and cells expressing farnesylated MOCA show flattened morphology similar to those expressing a constitutive active mutant of Rac1, Rac1Q61L. On poly-D-lysine-coated dishes, endogenous MOCA is concentrated on the leading edge of broad membrane protrusions (lamellipodia) where actin filaments are co-localized. MOCA is also concentrated with actin on the growth cone in primary cultures of cortical neurons. These observations suggest that MOCA may induce cytoskeletal reorganization and changes in cell adhesion by regulating the activity of Rac1.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo 1878551, Japan	National Center for Neurology & Psychiatry - Japan	Kimura, H (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, 4-1-1 Ogawahigashi, Tokyo 1878551, Japan.	kimura@ncnp.go.jp	Kimura, Hideo/AGK-0606-2022; Kimura, Hideo/J-6811-2016	Kimura, Hideo/0000-0002-6069-0475; Enokido, Yasushi/0000-0003-3252-504X				ABE K, 1990, JPN J PHARMACOL, V54, P45, DOI 10.1254/jjp.54.45; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Albertinazzi C, 1998, J CELL BIOL, V142, P815, DOI 10.1083/jcb.142.3.815; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Chen Q, 2002, J CELL BIOL, V158, P79, DOI 10.1083/jcb.200110151; Chen Q, 2001, AM J PATHOL, V159, P1597, DOI 10.1016/S0002-9440(10)63005-2; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kashiwa A, 2000, J NEUROCHEM, V75, P109, DOI 10.1046/j.1471-4159.2000.0750109.x; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MEIRI H, 1987, P NATL ACAD SCI USA, V84, P5058, DOI 10.1073/pnas.84.14.5058; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Namekata K, 2002, J NEUROCHEM, V82, P819, DOI 10.1046/j.1471-4159.2002.01039.x; Nishihara H, 1999, BBA-MOL CELL RES, V1452, P179, DOI 10.1016/S0167-4889(99)00133-0; Nishihara H, 2002, BLOOD, V100, P3968, DOI 10.1182/blood-2001-11-0032; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Scott MP, 2002, J BIOL CHEM, V277, P28238, DOI 10.1074/jbc.M202783200; Yamaguchi Y, 2000, J NEUROCHEM, V75, P708, DOI 10.1046/j.1471-4159.2000.0750708.x	37	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14331	14337		10.1074/jbc.M311275200	http://dx.doi.org/10.1074/jbc.M311275200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14718541	hybrid			2022-12-25	WOS:000220478500128
J	Petrolonis, AJ; Yang, Q; Tummino, PJ; Fish, SM; Prack, AE; Jain, S; Parsons, TF; Li, P; Dales, NA; Ge, L; Langston, SP; Schuller, AGP; An, WF; Tartaglia, LA; Chen, H; Hong, SB				Petrolonis, AJ; Yang, Q; Tummino, PJ; Fish, SM; Prack, AE; Jain, S; Parsons, TF; Li, P; Dales, NA; Ge, L; Langston, SP; Schuller, AGP; An, WF; Tartaglia, LA; Chen, H; Hong, SB			Enzymatic characterization of the pancreatic islet-specific glucose-6-phosphatase-related protein (IGRP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SMALL-INTESTINE; INSULIN-SECRETION; IDENTIFICATION; PHOSPHATASES; METABOLISM; INHIBITORS; ACID; GENE	Glucose is the main physiological stimulus for insulin biosynthesis and secretion by pancreatic beta-cells. Glucose-6-phosphatase (G-6-Pase) catalyzes the dephosphorylation of glucose-6-phosphate to glucose, an opposite process to glucose utilization. G-6-Pase activity in pancreatic islets could therefore be an important factor in the control of glucose metabolism and, consequently, of glucose-dependent insulin secretion. While G-6-Pase activity has been shown to be present in pancreatic islets, the gene responsible for this activity has not been conclusively identified. A homolog of liver glucose-6-phosphatase (LG-6-Pase) specifically expressed in islets was described earlier; however, the authors could not demonstrate enzymatic activity for this protein. Here we present evidence that the previously identified islet-specific glucose-6-phosphatase-related protein ( IGRP) is indeed the major islet glucose-6-phosphatase. IGRP overexpressed in insect cells possesses enzymatic activity comparable to the previously described G-6-Pase activity in islets. The K-m and V-max values determined using glucose-6-phosphate as the substrate were 0.45 mM and 32 nmol/mg/min by malachite green assay, and 0.29 mM and 77 nmol/mg/min by glucose oxidase/peroxidase coupling assay, respectively. High-throughput screening of a small molecule library led to the identification of an active compound that specifically inhibits IGRP enzymatic activity. Interestingly, this inhibitor did not affect LG-6-Pase activity, while conversely LG-6-Pase inhibitors did not affect IGRP activity. These data demonstrate that IGRP is likely the authentic islet-specific glucose-6-phosphatase catalytic subunit, and selective inhibitors to this molecule can be obtained. IGRP inhibitors may be an attractive new approach for the treatment of insulin secretion defects in type 2 diabetes.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Hong, SB (corresponding author), Wyeth Res, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	shong@wyeth.com						Arden SD, 1999, DIABETES, V48, P531, DOI 10.2337/diabetes.48.3.531; ASHCROFT SJ, 1968, NATURE, V219, P857, DOI 10.1038/219857a0; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; BURCHELL A, 1982, BIOCHEM J, V205, P567, DOI 10.1042/bj2050567; Croset M, 2001, DIABETES, V50, P740, DOI 10.2337/diabetes.50.4.740; Ebert DH, 1999, DIABETES, V48, P543, DOI 10.2337/diabetes.48.3.543; Foster JD, 1998, ARCH BIOCHEM BIOPHYS, V354, P125, DOI 10.1006/abbi.1998.0695; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; Ghosh A, 2002, J BIOL CHEM, V277, P32837, DOI 10.1074/jbc.M201853200; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; Iizuka K, 2000, J ENDOCRINOL, V164, P307, DOI 10.1677/joe.0.1640307; KHAN A, 1990, ENDOCRINOLOGY, V126, P2413, DOI 10.1210/endo-126-5-2413; KHAN A, 1989, J BIOL CHEM, V264, P9732; KHAN A, 1990, DIABETES, V39, P456, DOI 10.2337/diabetes.39.4.456; Khan A, 1998, EUR J PHARMACOL, V349, P325, DOI 10.1016/S0014-2999(98)00188-5; KHAN A, 1994, DIABETOLOGIA, V37, pA135; KHAN A, 1995, ENDOCRINOLOGY, V136, P1934, DOI 10.1210/en.136.5.1934; Laybutt DR, 2002, J BIOL CHEM, V277, P10912, DOI 10.1074/jbc.M111751200; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Madsen P, 2000, BIOORGAN MED CHEM, V8, P2277, DOI 10.1016/S0968-0896(00)00153-X; Mao HB, 2002, ANAL CHEM, V74, P379, DOI 10.1021/ac010822u; Martin CC, 2001, J BIOL CHEM, V276, P25197, DOI 10.1074/jbc.M101549200; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; OSTENSON CG, 1993, DIABETOLOGIA, V36, P3, DOI 10.1007/BF00399086; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; PERALES MA, 1991, MOL CELL BIOCHEM, V101, P67; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Sambrook J., 2001, MOL CLONING LAB MANU; SPETH M, 1986, FEBS LETT, V202, P32, DOI 10.1016/0014-5793(86)80643-3; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Stukey J, 1997, PROTEIN SCI, V6, P469; WADDELL ID, 1988, BIOCHEM J, V255, P471, DOI 10.1042/bj2550471; Westergaard N, 2002, DIABETES OBES METAB, V4, P96, DOI 10.1046/j.1463-1326.2002.00179.x	38	38	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13976	13983		10.1074/jbc.M307756200	http://dx.doi.org/10.1074/jbc.M307756200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722102	hybrid			2022-12-25	WOS:000220478500085
J	Rostovtseva, TK; Antonsson, B; Suzuki, M; Youle, RJ; Colombini, M; Bezrukov, SM				Rostovtseva, TK; Antonsson, B; Suzuki, M; Youle, RJ; Colombini, M; Bezrukov, SM			Bid, but not Bax, regulates VDAC channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; CYTOCHROME-C RELEASE; DEPENDENT ANION CHANNEL; BCL-2 FAMILY-MEMBER; NEUROSPORA-CRASSA; CONTACT SITES; ION-CHANNEL; CONFORMATIONAL-CHANGE; ANTIAPOPTOTIC BCL-2; BRAIN MITOCHONDRIA	During apoptosis, cytochrome c is released from mitochondria into the cytosol, where it participates in caspase activation. Various and often conflicting mechanisms have been proposed to account for the increased permeability of the mitochondrial outer membrane that is responsible for this process. The voltage-dependent anion channel (VDAC) is the major permeability pathway for metabolites in the mitochondrial outer membrane and therefore is a very attractive candidate for cytochrome c translocation. Here, we report that properties of VDAC channels reconstituted into planar phospholipid membranes are unaffected by addition of the pro-apoptotic protein Bax under a variety of conditions. Contrary to other reports (Shimizu, S., Narita, M., and Tsujimoto, Y. (1999) Nature 399, 483 - 487; Shimizu, S., Ide, T., Yanagida, T., and Tsujimoto, Y. (2000) J. Biol. Chem. 275, 12321 - 12325; Shimizu, S., Konishi, A., Kodama, T., and Tsujimoto, Y. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 3100 - 3105), we found no electrophysiologically detectable interaction between VDAC channels isolated from mammalian mitochondria and either monomeric or oligomeric forms of Bax. We conclude that Bax does not induce cytochrome c release by acting on VDAC. In contrast to Bax, another pro-apoptotic protein ( Bid) proteolytically cleaved with caspase-8 affected the voltage gating of VDAC by inducing channel closure. We speculate that by decreasing the probability of VDAC opening, Bid reduces metabolite exchange between mitochondria and the cytosol, leading to mitochondrial dysfunction.	NICHD, Lab Phys & Struct Biol, NIH, Bethesda, MD 20892 USA; NICHD, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Univ Maryland, Dept Biol, College Pk, MD 20742 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University System of Maryland; University of Maryland College Park	Rostovtseva, TK (corresponding author), NICHD, Lab Phys & Struct Biol, NIH, Bldg 9,Rm 1E-106, Bethesda, MD 20892 USA.	rostovts@helix.nih.gov	Colombini, Marco/A-1540-2014		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000072] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002859, Z01NS002859] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Bezrukov SM, 2000, CURR OPIN COLLOID IN, V5, P237, DOI 10.1016/S1359-0294(00)00061-3; BEZRUKOV SM, 1993, BIOPHYS J, V64, P16, DOI 10.1016/S0006-3495(93)81336-5; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; COLOMBINI M, 1980, J MEMBRANE BIOL, V53, P79, DOI 10.1007/BF01870576; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DEKROON AIP, 1997, BIOCHIM BIOPHYS ACTA, V1325, pA108; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Goforth RL, 2003, J GEN PHYSIOL, V121, P477, DOI 10.1085/jgp.200308797; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; MANNELLA CA, 1989, FEBS LETT, V253, P231, DOI 10.1016/0014-5793(89)80965-2; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Montessuit S, 1999, PROTEIN EXPRES PURIF, V15, P202, DOI 10.1006/prep.1998.1010; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; Polster BM, 2003, J NEUROSCI, V23, P2735; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Rostovtseva TK, 2002, BIOPHYS J, V82, P160, DOI 10.1016/S0006-3495(02)75383-6; Rostovtseva TK, 2002, J MEMBRANE BIOL, V187, P147, DOI 10.1007/s00232-001-0159-1; Roucou X, 2002, BIOCHEM J, V363, P547, DOI 10.1042/0264-6021:3630547; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; Siskind LJ, 2003, BIOPHYS J, V85, P1560, DOI 10.1016/S0006-3495(03)74588-3; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Song JM, 1998, J BIOL CHEM, V273, P24406, DOI 10.1074/jbc.273.38.24406; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; Wei MC, 2000, GENE DEV, V14, P2060; Xu XF, 1996, J BIOL CHEM, V271, P23675, DOI 10.1074/jbc.271.39.23675; Xu XF, 1997, BIOPHYS J, V72, P2129, DOI 10.1016/S0006-3495(97)78855-6; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; ZALMAN LS, 1980, J BIOL CHEM, V255, P1771; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zhai DY, 2000, FEBS LETT, V472, P293, DOI 10.1016/S0014-5793(00)01471-X	69	158	166	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13575	13583		10.1074/jbc.M310593200	http://dx.doi.org/10.1074/jbc.M310593200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729675	hybrid			2022-12-25	WOS:000220478500037
J	Sondag, CM; Combs, CK				Sondag, CM; Combs, CK			Amyloid precursor protein mediates proinflammatory activation of monocytic lineage cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; SIGNAL-TRANSDUCTION; ALZHEIMERS-DISEASE; TYROSINE PHOSPHORYLATION; BETA(1) INTEGRIN; CDNA CLONING; FE65 PROTEIN; KINASE; COLLAGEN; INDUCTION	Alzheimer's disease is a progressive neurodegenerative disorder characterized by extracellular deposition of beta-amyloid (Abeta) peptide containing neuritic plaques. Abeta peptides are proteolytically derived from the membrane-bound amyloid precursor protein (APP). Although the function of APP is not entirely clear, previous studies demonstrate that neuronal APP colocalizes with beta(1) integrin receptors at sites of focal adhesion, suggesting that APP is involved in mediating neuronal process adhesion. Integrin-dependent adhesion is also a well-characterized component of immune cell proinflammatory activation. Using primary mouse microglia and the human monocytic cell line, THP-1, we have begun investigating the role of APP in integrin-dependent activation. Co-immunoprecipitation studies demonstrate that APP is recruited into a multi-receptor signaling complex during beta(1) integrin-mediated adhesion of monocytes. Stimulation induces a subsequent, specific recruitment of tyrosine phosphorylated proteins to APP, including Lyn and Syk. Antibody cross-linking of cell surface APP leads to a similar response characterized by activation and recruitment of tyrosine kinases to APP as well as subsequent activation of mitogen-activated protein kinases and increased proinflammatory protein levels. These data demonstrate that APP can act as a proinflammatory receptor in monocytic lineage cells and provide insight into the contribution of this protein to the inflammatory conditions described in Alzheimer's disease.	Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58202 USA	University of North Dakota Grand Forks	Combs, CK (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, 501 N Columbia Rd, Grand Forks, ND 58202 USA.	ccombs@medicine.nodak.edu			NCRR NIH HHS [1 P20 RR17699-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017699] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; Brouillet E, 1999, J NEUROSCI, V19, P1717; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howell BW, 1999, MOL CELL BIOL, V19, P5179; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Jung SS, 1999, NEUROBIOL AGING, V20, P249, DOI 10.1016/S0197-4580(99)00051-2; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; McGilvray ID, 1997, J BIOL CHEM, V272, P10287; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miller LA, 1999, EUR J IMMUNOL, V29, P1426, DOI 10.1002/(SICI)1521-4141(199905)29:05<1426::AID-IMMU1426>3.0.CO;2-J; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MONNING U, 1992, J BIOL CHEM, V267, P23950; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Reyes-Reyes M, 2002, BIOCHEM J, V363, P273, DOI 10.1042/0264-6021:3630273; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Russo C, 2002, J BIOL CHEM, V277, P35282, DOI 10.1074/jbc.M110785200; SELKOE DJ, 1991, NATURE, V354, P432, DOI 10.1038/354432a0; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Wang JF, 2001, J BIOL CHEM, V276, P41950, DOI 10.1074/jbc.M101370200; Yamazaki T, 1997, J NEUROSCI, V17, P1004; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200	40	44	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14456	14463		10.1074/jbc.M313747200	http://dx.doi.org/10.1074/jbc.M313747200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732706	hybrid			2022-12-25	WOS:000220478500142
J	Wujek, P; Kida, E; Walus, M; Wisniewski, KE; Golabek, AA				Wujek, P; Kida, E; Walus, M; Wisniewski, KE; Golabek, AA			N-glycosylation is crucial for folding, trafficking, and stability of human tripeptidyl-peptidase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; PEPSTATIN-INSENSITIVE PROTEINASE; MANNOSE 6-PHOSPHATE RECEPTOR; SITE-DIRECTED MUTAGENESIS; ER QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; LYSOSOMAL-ENZYME; CATHEPSIN-L; MISFOLDED GLYCOPROTEINS; HYDROPHOBIC PROTEIN	Tripeptidyl-peptidase I (TPP I) is a lysosomal serine-carboxyl peptidase that sequentially removes tripeptides from polypeptides. Naturally occurring mutations in TPP I are associated with the classic late infantile neuronal ceroid lipofuscinosis. Human TPP I has five potential N-glycosylation sites at Asn residues 210, 222, 286, 313, and 443. To analyze the role of N-glycosylation in the function of the enzyme, we obliterated each N-glycosylation consensus sequence by substituting Gln for Asn, either individually or in combinations, and expressed mutated cDNAs in Chinese hamster ovary and human embryonic kidney 293 cells. Here, we demonstrate that human TPP I in vivo utilizes all five N-glycosylation sites. Elimination of one of these sites, at Asn-286, dramatically affected the folding of the enzyme. However, in contrast to other misfolded proteins that are retained in the endoplasmic reticulum, only a fraction of misfolded TPP I mutant expressed in Chinese hamster ovary cells, but not in human embryonic kidney 293 cells, was arrested in the ER, whereas its major portion was secreted. Secreted proenzyme formed non-native, interchain disulfide bridges and displayed only residual TPP I activity upon acidification. A small portion of TPP I missing Asn-286-linked glycan reached the lysosome and was processed to an active species; however, it showed low thermal and pH stability. N-Glycans at Asn-210, Asn-222, Asn-313, and Asn-443 contributed slightly to the specific activity of the enzyme and its resistance to alkaline pH-induced inactivation. Phospholabeling experiments revealed that N-glycans at Asn-210 and Asn-286 of TPP I preferentially accept a phosphomannose marker. Thus, a dual role of oligosaccharide at Asn-286 in folding and lysosomal targeting could contribute to the unusual, but cell type-dependent, fate of misfolded TPP I conformer and represent the molecular basis of the disease process in subjects with naturally occurring missense mutation at Asn-286.	New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, Staten Isl, NY 10314 USA	Institute for Basic Research in Developmental Disabilities	Golabek, AA (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	a.golabek@att.net			NINDS NIH HHS [NS 047335] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047335] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BERGFUSSMAN A, 1993, J BIOL CHEM, V268, P14861; Bernardini F, 2001, Eur J Paediatr Neurol, V5 Suppl A, P69, DOI 10.1053/ejpn.2000.0438; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; Comellas-Bigler M, 2002, STRUCTURE, V10, P865, DOI 10.1016/S0969-2126(02)00772-4; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; Du PG, 2001, BIOL CHEM, V382, P1715, DOI 10.1515/BC.2001.207; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Ezaki J, 2000, BIOCHEM BIOPH RES CO, V268, P904, DOI 10.1006/bbrc.2000.2207; Ezaki J, 1999, J NEUROCHEM, V72, P2573, DOI 10.1046/j.1471-4159.1999.0722573.x; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; Ferlinz K, 2001, J BIOL CHEM, V276, P35352, DOI 10.1074/jbc.M103066200; Frenkel Z, 2003, J BIOL CHEM, V278, P34119, DOI 10.1074/jbc.M305929200; Golabek AA, 2003, J BIOL CHEM, V278, P7135, DOI 10.1074/jbc.M211872200; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; Hardesty Boyd, 1999, Current Opinion in Structural Biology, V9, P111, DOI 10.1016/S0959-440X(99)80014-1; HERMANS MMP, 1993, BIOCHEM J, V289, P681, DOI 10.1042/bj2890681; Herscovics A, 2002, GLYCOBIOLOGY, V12, p14G; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horwich A, 2002, J CLIN INVEST, V110, P1221, DOI 10.1172/JCI200216781; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Ioannou YA, 1998, BIOCHEM J, V332, P789, DOI 10.1042/bj3320789; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Junaid MA, 2000, J NEUROCHEM, V74, P287, DOI 10.1046/j.1471-4159.2000.0740287.x; Junaid MA, 1999, CLIN CHIM ACTA, V281, P169, DOI 10.1016/S0301-2115(98)00333-9; KANE SE, 1993, J BIOL CHEM, V268, P11456; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kida E, 2001, ADV GENET, V45, P35, DOI 10.1016/S0065-2660(01)45003-6; Kida E, 2001, J NEUROPATH EXP NEUR, V60, P280, DOI 10.1093/jnen/60.3.280; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1984, J BIOL CHEM, V259, P4663; Lin L, 2001, J BIOL CHEM, V276, P2249, DOI 10.1074/jbc.M008562200; Lin L, 2001, BIOCHEM J, V357, P49, DOI 10.1042/0264-6021:3570049; Liu CG, 1998, GENOMICS, V50, P206, DOI 10.1006/geno.1998.5328; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Marcus NY, 2000, J BIOL CHEM, V275, P1987, DOI 10.1074/jbc.275.3.1987; MCDONALD JK, 1985, BIOCHEM BIOPH RES CO, V126, P63, DOI 10.1016/0006-291X(85)90571-6; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Olson LJ, 2002, J BIOL CHEM, V277, P10156, DOI 10.1074/jbc.M112230200; PAGE AE, 1993, ARCH BIOCHEM BIOPHYS, V306, P354, DOI 10.1006/abbi.1993.1523; Palmer DN, 1997, NEUROPEDIATRICS, V28, P45, DOI 10.1055/s-2007-973666; Park H, 2001, P NATL ACAD SCI USA, V98, P11163, DOI 10.1073/pnas.201393498; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SHIPLEY JM, 1993, J BIOL CHEM, V268, P12193; Sleat DE, 1999, AM J HUM GENET, V64, P1511, DOI 10.1086/302427; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; STEARNS NA, 1990, ARCH BIOCHEM BIOPHYS, V283, P447, DOI 10.1016/0003-9861(90)90666-M; Steinfeld R, 2002, AM J MED GENET, V112, P347, DOI 10.1002/ajmg.10660; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vines D, 1998, BBA-PROTEIN STRUCT M, V1384, P233, DOI 10.1016/S0167-4838(98)00012-0; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; Warner JB, 2002, J BIOL CHEM, V277, P41897, DOI 10.1074/jbc.M203097200; WEITZ G, 1992, J BIOL CHEM, V267, P10039; Wisniewski KE, 2001, ADV GENET, V45, P1, DOI 10.1016/S0065-2660(01)45002-4; WISNIEWSKI KE, 2001, EUR J PAED NEUROL SA, V5, P61; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; Wlodawer A, 2003, ACTA BIOCHIM POL, V50, P81; Wlodawer A, 2001, NAT STRUCT BIOL, V8, P442, DOI 10.1038/87610	70	84	85	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12827	12839		10.1074/jbc.M313173200	http://dx.doi.org/10.1074/jbc.M313173200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14702339	hybrid			2022-12-25	WOS:000220334900098
J	Yue, YZ; Lypowy, J; Hedhli, N; Abdellatif, M				Yue, YZ; Lypowy, J; Hedhli, N; Abdellatif, M			Ras GTPase-activating protein binds to Akt and is required for its activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SH3 DOMAIN; GENE-EXPRESSION; KINASE-ACTIVITY; PHOSPHORYLATION; HYPERTROPHY; GROWTH; CELLS; GAP; APOPTOSIS	RasGAP ( Ras GTPase- activating protein) is a negative regulator as well as a downstream effector of Ras. To identify partners of RasGAP we used it as the bait in a yeast two- hybrid screen. This resulted in discovering its interaction with Akt. Overexpression of RasGAP or a mutant lacking the GTPase- activating domain ( nGAP) enhanced phosphorylation and activity of Akt, which was dependent on the upstream integrin- linked kinase. Also, nGAP protected the cells against staurosporin- induced apoptosis through an Akt- dependent pathway. To determine the role of RasGAP in receptor- mediated activation of Akt, we used short hairpin RNA interference to knock out endogenous RasGAP expression. Although this procedure resulted in enhanced Ras activity, it inhibited Akt phosphorylation. Thus, we propose that RasGAP interacts with Akt and is necessary for its activation, possibly via integrin- linked kinase- mediated phosphorylation of Ser- 473. The data suggest that this effect is independent of Ras activity.	Univ Med & Dent New Jersey, Inst Cardiovasc Res, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Abdellatif, M (corresponding author), Univ Med & Dent New Jersey, Inst Cardiovasc Res, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA.	abdellma@umdnj.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057970] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL 57970] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdellatif M, 1997, J BIOL CHEM, V272, P525; ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; Abdellatif M, 1998, MOL CELL BIOL, V18, P6729, DOI 10.1128/MCB.18.11.6729; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; GRAHAM FL, 1991, METHODS MOL BIOL, V7; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Leblanc V, 1999, ONCOGENE, V18, P4884, DOI 10.1038/sj.onc.1202855; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; MATSUI T, 2002, J BIOL CHEM, V9, P9; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001	31	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12883	12889		10.1074/jbc.M312308200	http://dx.doi.org/10.1074/jbc.M312308200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707121	hybrid			2022-12-25	WOS:000220334900105
J	Hattori, M; Suzuki, AZ; Higo, T; Miyauchi, H; Michikawa, T; Nakamura, T; Inoue, T; Mikoshiba, K				Hattori, M; Suzuki, AZ; Higo, T; Miyauchi, H; Michikawa, T; Nakamura, T; Inoue, T; Mikoshiba, K			Distinct roles of inositol 1,4,5-trisphosphate receptor types 1 and 3 in Ca2+ signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III INSP(3) RECEPTOR; SMOOTH-MUSCLE-CELLS; TRISPHOSPHATE RECEPTORS; GENE-EXPRESSION; IP3 RECEPTOR; FUNCTIONAL-PROPERTIES; INTERFERING RNAS; CHANNEL FUNCTION; CYTOSOLIC CA2+; CALCIUM PUFFS	Three subtypes of inositol 1,4,5-trisphosphate receptor (IP(3)R1, IP(3)R2, and IP(3)R3) Ca2+ release channel share basic properties but differ in terms of regulation. To what extent they contribute to complex Ca2+ signaling, such as Ca2+ oscillations, remains largely unknown. Here we show that HeLa cells express comparable amounts of IP(3)R1 and IP(3)R3, but knockdown by RNA interference of each subtype results in dramatically distinct Ca2+ signaling patterns. Knockdown of IP(3)R1 significantly decreases total Ca2+ signals and terminates Ca2+ oscillations. Conversely, knockdown of IP(3)R3 leads to more robust and long lasting Ca2+ oscillations than in controls. Effects of IP(3)R3 knockdown are surprisingly similar in COS-7 cells that predominantly (> 90% of total IP3R) express IP(3)R3, suggesting that IP(3)R3 functions as an anti-Ca2+-oscillatory unit without contributing to peak amplitude of Ca2+ signals, irrespective of its relative expression level. Therefore, differential expression of the IP3R subtype is critical for various forms of Ca2+ signaling, and, particularly, IP(3)R1 and IP(3)R3 have opposite roles in generating Ca2+ oscillations.	Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Tokyo 1088639, Japan; JST, ICORP, Calcium Oscillat Project, Tokyo, Japan; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan	Japan Science & Technology Agency (JST); University of Tokyo; Japan Science & Technology Agency (JST); RIKEN	Hattori, M (corresponding author), Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, 4-1-8 Honmachi, Kawaguchi, Saitama 3320012, Japan.	mhattori@ims.u-tokyo.ac.jp	Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015; Hattori, Mitsuharu/F-3859-2010	Inoue, Takafumi/0000-0002-2728-0060; Hattori, Mitsuharu/0000-0002-0503-4969				Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Cardy TJA, 1997, BIOCHEM J, V328, P785, DOI 10.1042/bj3280785; Davis RJ, 1999, BIOCHEM J, V341, P813, DOI 10.1042/0264-6021:3410813; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; Delmas P, 2002, NEURON, V36, P787, DOI 10.1016/S0896-6273(02)01097-8; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hagar RE, 2000, BIOPHYS J, V79, P271, DOI 10.1016/S0006-3495(00)76289-8; Hirota J, 1998, BIOCHEM J, V333, P615, DOI 10.1042/bj3330615; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Mackrill JJ, 1996, BIOCHEM J, V318, P871, DOI 10.1042/bj3180871; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; Mak DOD, 2001, J GEN PHYSIOL, V117, P435, DOI 10.1085/jgp.117.5.435; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Mathias RS, 1998, AM J PHYSIOL-CELL PH, V274, pC1456, DOI 10.1152/ajpcell.1998.274.6.C1456; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ramos-Franco J, 2000, BIOPHYS J, V79, P1388, DOI 10.1016/S0006-3495(00)76391-0; Shuai JW, 2003, P NATL ACAD SCI USA, V100, P506, DOI 10.1073/pnas.0236032100; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Sorrentino V, 2000, CURR OPIN GENET DEV, V10, P662, DOI 10.1016/S0959-437X(00)00139-8; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; Swatton JE, 1999, BIOCHEM J, V344, P55, DOI 10.1042/0264-6021:3440055; Swillens S, 1999, P NATL ACAD SCI USA, V96, P13750, DOI 10.1073/pnas.96.24.13750; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Thrower EC, 2001, TRENDS PHARMACOL SCI, V22, P580, DOI 10.1016/S0165-6147(00)01809-5; Tomida T, 2003, EMBO J, V22, P3825, DOI 10.1093/emboj/cdg381; Tovey SC, 2001, J CELL SCI, V114, P3979; Uchida K, 2003, J BIOL CHEM, V278, P16551, DOI 10.1074/jbc.M300646200; Van Acker K, 2002, CELL CALCIUM, V32, P71, DOI 10.1016/S0143-4160(02)00092-1; Vermassen E, 2003, J CELL SCI, V116, P1269, DOI 10.1242/jcs.00354; Wang YP, 2001, CIRC RES, V88, P202; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678	43	104	105	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11967	11975		10.1074/jbc.M311456200	http://dx.doi.org/10.1074/jbc.M311456200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707143	hybrid			2022-12-25	WOS:000220157600134
J	Karalis, KP; Venihaki, M; Zhao, J; van Vlerken, LE; Chandras, C				Karalis, KP; Venihaki, M; Zhao, J; van Vlerken, LE; Chandras, C			NF-kappa B participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPAIRED STRESS-RESPONSE; GLUCOCORTICOID REPRESSION; OXIDATIVE STRESS; TRANSCRIPTION; EXPRESSION; ACTIVATION; MECHANISM; RECEPTOR; DEFICIENCY; ANTAGONISM	Corticotropin-releasing hormone is a main regulator of mammalian stress response by stimulating pituitary proopiomelanocortin (POMC) gene expression, and thus adrenocorticotropic hormone (ACTH) secretion, which then causes glucocorticoid release from the adrenal. In a recent study in the pituitary corticotroph cell line AtT20, oxidative stress stimulated the activity of nuclear transcription factor B (NF-kappaB), whereas corticotropin-releasing hormone (CRH) inhibited both the constitutive and the oxidative stress-induced NF-kappaB DNA-binding activity. To further investigate the role of NF-kappaB on the CRH-induced pituitary POMC gene activation, AtT20 cells were transiently transfected with a POMC-luciferase construct mutated at an NF-kappaB binding site. After treatment with CRH, intracellular POMC-luciferase activity was significantly higher from the stimulation observed with transfection of the parental POMC-luciferase construct. In agreement with a previous report, CRH inhibited the constitutive NF-kappaB DNA-binding activity in AtT20 cells, as shown by electrophoretic mobility-shift assay, as soon as within 15 min of treatment. These effects of CRH were blocked by the CRH-R1 antagonist CP154,256. Our findings provide evidence that the regulation of corticotroph NF-kappaB activity by CRH is related to the activation of the pituitary POMC gene and, thus, may play an important role in stress response.	Harvard Univ, Childrens Hosp, Sch Med, Div Endocrinol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Karalis, KP (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Div Endocrinol, 416 Enders,300 Longwood Ave, Boston, MA 02115 USA.	katia.karalis@tch.harvard.edu			NIDDK NIH HHS [R01 DK04777] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Autelitano DJ, 1998, BRAIN RES BULL, V45, P75, DOI 10.1016/S0361-9230(97)00303-1; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bousquet C, 2000, J CLIN INVEST, V106, P1417, DOI 10.1172/JCI11182; Bousquet C, 1999, J BIOL CHEM, V274, P10723, DOI 10.1074/jbc.274.16.10723; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; Bozinovski S, 2002, J BIOL CHEM, V277, P42808, DOI 10.1074/jbc.M207840200; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; DROUIN J, 1987, J CELL BIOCHEM, V35, P293, DOI 10.1002/jcb.240350404; DROUIN J, 1989, J STEROID BIOCHEM, V34, P63, DOI 10.1016/0022-4731(89)90066-6; Drouin J, 1998, J STEROID BIOCHEM, V65, P59, DOI 10.1016/S0960-0760(97)00180-5; Karalis K, 1996, NAT MED, V2, P556, DOI 10.1038/nm0596-556; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lezoualc'h F, 2000, MOL ENDOCRINOL, V14, P147, DOI 10.1210/me.14.1.147; MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; Ray DW, 1996, J CLIN INVEST, V97, P1852, DOI 10.1172/JCI118615; Ray DW, 1998, ANN NY ACAD SCI, V840, P162, DOI 10.1111/j.1749-6632.1998.tb09560.x; REISINE T, 1987, MOL PHARMACOL, V32, P488; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; TACCHINI L, 1995, BIOCHEM J, V309, P453, DOI 10.1042/bj3090453; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VALE W, 1983, RECENT PROG HORM RES, V39, P245; Weninger SC, 2000, ENDOCRINOLOGY, V141, P256, DOI 10.1210/en.141.1.256; Zhao J, 2002, MOL ENDOCRINOL, V16, P2561, DOI 10.1210/me.2001-0334	26	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10837	10840		10.1074/jbc.M313063200	http://dx.doi.org/10.1074/jbc.M313063200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711817	hybrid			2022-12-25	WOS:000220157600003
J	Parkin, ET; Watt, NT; Turner, AJ; Hooper, NM				Parkin, ET; Watt, NT; Turner, AJ; Hooper, NM			Dual mechanisms for shedding of the cellular prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-PRECURSOR-PROTEIN; ANGIOTENSIN-CONVERTING ENZYME; CULTURED-CELLS; CAVEOLAE-LIKE; SCRAPIE; MEMBRANE; ENDOCYTOSIS; INSERTION; DOMAINS; DISEASE	The cellular prion protein ( PrPC) is essential for the pathogenesis and transmission of prion diseases. Whereas the majority of PrPC is bound to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor, a secreted form of the protein has been identified. Here we show that PrPC can be shed into the medium of human neuroblastoma SH-SY5Y cells by both protease- and phospholipase-mediated mechanisms. The constitutive shedding of PrPC was inhibited by a range of hydroxamate-based zinc metalloprotease inhibitors in a manner identical to the alpha-secretase-mediated shedding of the amyloid precursor protein, indicating a proteolytic shedding mechanism. Like amyloid precursor protein, this zinc metalloprotease-mediated shedding of PrPC could be stimulated by phorbol myristate acetate and by copper ions. The lipid raft-disrupting agents filipin and methyl-beta-cyclodextrin promoted the shedding of PrPC via a distinct mechanism that was not inhibited by hydroxamate-based inhibitors. Filipin-mediated shedding of PrPC is likely to occur via phospholipase cleavage of the GPI anchor, since a transmembrane polypeptide-anchored PrP construct was not shed in response to filipin treatment. Collectively, our data indicate that shedding of PrPC can occur via both secretase-like proteolytic cleavage of the protein and phospholipase cleavage of the GPI anchor moiety.	Univ Leeds, Sch Biochem & Mol Biol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Hooper, NM (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England.	n.m.hooper@leeds.ac.uk		Parkin, Edward/0000-0003-3270-3184; Hooper, Nigel/0000-0002-5811-3484				Borchardt T, 1999, BIOCHEM J, V344, P461, DOI 10.1042/0264-6021:3440461; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Canet-Aviles RM, 2002, MOL BRAIN RES, V102, P62, DOI 10.1016/S0169-328X(02)00184-5; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1993, BRIT MED BULL, V49, P860, DOI 10.1093/oxfordjournals.bmb.a072651; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; DUCHEN LW, 1993, BRAIN, V116, P555, DOI 10.1093/brain/116.3.555; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HOOPER NM, 1987, BIOCHEM J, V241, P625, DOI 10.1042/bj2410625; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; Kahl S, 2000, J IMMUNOL, V165, P4463, DOI 10.4049/jimmunol.165.8.4463; KRASEMANN S, 1995, MOL BRAIN RES, V34, P173, DOI 10.1016/0169-328X(95)00175-R; Kretzschmar HA, 1997, J NEURAL TRANSM-SUPP, P191; Leclerc E, 2001, EMBO J, V20, P1547, DOI 10.1093/emboj/20.7.1547; Lehmann S, 1999, BIOMED PHARMACOTHER, V53, P39, DOI 10.1016/S0753-3322(99)80059-6; Li RL, 2003, BIOCHEM BIOPH RES CO, V303, P446, DOI 10.1016/S0006-291X(03)00354-1; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Marella M, 2002, J BIOL CHEM, V277, P25457, DOI 10.1074/jbc.M203248200; McMahon HEM, 2001, J BIOL CHEM, V276, P2286, DOI 10.1074/jbc.M007243200; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; OWEN F, 1992, MOL BRAIN RES, V13, P155, DOI 10.1016/0169-328X(92)90056-H; Parizek P, 2001, J BIOL CHEM, V276, P44627, DOI 10.1074/jbc.M107458200; Parkin ET, 2003, J CELL SCI, V116, P3079, DOI 10.1242/jcs.00626; Parkin ET, 2002, BIOCHEMISTRY-US, V41, P4972, DOI 10.1021/bi015936e; Parkin ET, 1997, J NEUROCHEM, V69, P2179; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Perini F, 1996, BIOCHEM BIOPH RES CO, V223, P572, DOI 10.1006/bbrc.1996.0936; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; TAGLIAVINI F, 1992, BIOCHEM BIOPH RES CO, V184, P1398, DOI 10.1016/S0006-291X(05)80038-5; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Walmsley AR, 2003, J BIOL CHEM, V278, P37241, DOI 10.1074/jbc.M302036200; Walmsley AR, 2001, EMBO J, V20, P703, DOI 10.1093/emboj/20.4.703; Yang XY, 1996, J BIOL CHEM, V271, P11493, DOI 10.1074/jbc.271.19.11493; Zeng FN, 2003, J NEUROCHEM, V84, P480, DOI 10.1046/j.1471-4159.2003.01529.x	48	113	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11170	11178		10.1074/jbc.M312105200	http://dx.doi.org/10.1074/jbc.M312105200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711812	hybrid			2022-12-25	WOS:000220157600042
J	Efimova, EV; Al-Zoubi, AM; Martinez, O; Kaithamana, S; Lu, SF; Arima, T; Prabhakar, BS				Efimova, EV; Al-Zoubi, AM; Martinez, O; Kaithamana, S; Lu, SF; Arima, T; Prabhakar, BS			IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs	ONCOGENE			English	Article						IG20; MADD; DENN-SV; apoptosis; mRNA splicing; tumor	NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; DEATH DOMAIN PROTEIN; KINASE RIP; SIGNALING COMPLEX; NEOPLASTIC-CELLS; TNF; ACTIVATION; ALPHA; MECHANISM	We identified seven putative splice variants of the human IG20 gene. Four variants namely, IG20, MADD, IG20-SV2 and DENN-SV are expressed in human tissues. While DENN-SV is constitutively expressed in all tissues, expression of IG20 appears to be regulated. Interestingly, overexpression of DENN-SV enhanced cell replication and resistance to treatments with TNFalpha, vinblastine, etoposide and gamma-radiation. In contrast, IG20 expression suppressed cell replication and increased susceptibility to the above treatments. Moreover, cells that were resistant and susceptible to TNFalpha-induced apoptosis exclusively expressed endogenous DENN-SV and IG20, respectively. When PA-1 ovarian cancer cells that are devoid of endogenous IG20 variant, but express higher levels of DENN-SV, were transfected with IG20, they showed reduced cell proliferation and increased susceptibility to apoptosis induced by TNFalpha, TRAIL and gamma-radiation. This indicated that overexpression of IG20 can override endogenous DENN-SV function. CrmA reversed the effects of IG20, but not DENN-SV. In contrast, dominant-negative-I-kappa B reversed the effects of DENN-SV, but not IG20, and showed that DENN-SV most likely exerted its effects through NFkappaB activation. Together, our data show that IG20 gene can play a novel and significant role in regulating cell proliferation, survival and death through alternative mRNA splicing.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Miltenyi Biotec Inc, Div Mol Biol, Auburn, CA 95602 USA; Human Genome Sci Inc, Dept Lead Dev & Characterizat, Gaithersburg, MD 20878 USA; MeridianLink Inc, Costa Mesa, CA 92626 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; GlaxoSmithKline; Human Genome Sciences Inc	Prabhakar, BS (corresponding author), Univ Illinois, Dept Microbiol & Immunol, M-C 790,Room E-709,Bldg 935,835 S Wolcott Ave, Chicago, IL 60612 USA.	bprabhak@uic.edu		Martinez, Osvaldo/0000-0001-7335-4342				Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brown TL, 1998, CURR BIOL, V8, pR191; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chow VTK, 1998, GENOME, V41, P543, DOI 10.1139/gen-41-4-543; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Cunningham SJ, 1996, THESIS U TEXAS MED B; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Herbert A, 1999, NAT GENET, V21, P265, DOI 10.1038/6780; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Iwasaki K, 2000, EMBO J, V19, P4806, DOI 10.1093/emboj/19.17.4806; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Levivier E, 2001, BIOCHEM BIOPH RES CO, V287, P688, DOI 10.1006/bbrc.2001.5652; Lim KM, 2002, MOL CARCINOGEN, V35, P110, DOI 10.1002/mc.10082; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Murakami-Mori K, 1999, J IMMUNOL, V162, P3672; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Smrcka M, 2003, PHYSIOL RES, V52, P117; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586	38	33	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1076	1087		10.1038/sj.onc.1207210	http://dx.doi.org/10.1038/sj.onc.1207210			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14716293				2022-12-25	WOS:000188749900006
J	Cuenco, GM; Ren, RB				Cuenco, GM; Ren, RB			Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice	ONCOGENE			English	Article						acute myelogenous leukemia (AML); AML1/MDS1/EVI1; BCR/ABL; EVI1; RUNX1	ACUTE MYELOID-LEUKEMIA; T(3/21) FUSION PRODUCT; TRANSCRIPTION FACTOR; BCR-ABL; MYELOPROLIFERATIVE DISEASE; GROWTH-INHIBITION; GENE CBFB-MYH11; RAPID INDUCTION; PR DOMAIN; EXPRESSION	We have previously shown that BCR/ABL, a fusion protein generated by the t(9;22)(q34;q11) translocation found in the vast majority of chronic myelogenous leukemia (CML), cooperates with AML1/MDS1/EVI1 (AME), a fusion transcription factor generated by a t(3;21)(q26;q22) translocation identified as a secondary mutation in some cases of CML during the blast phase (CML-BC), in the rapid induction of an acute myelogenous leukemia (AML) in mice. In this study, we evaluated the leukemogenic potential of EVI1-, MDS1/EVI1- and AML1-related oncoproteins (AML1Delta, AML1/MDS1). We found that ectopic expression of either EVI1 or MDS1/EVI1 impaired hematopoiesis. However, neither EVI1 nor MDS1/EVI1 was sufficient for inducing AML in mice, although EVI1 did induce some hematologic neoplasia other than AML with a low efficiency. In addition, unlike AME, none of the EVI1- or AML1-related oncoproteins examined were capable of fully cooperating with BCR/ABL in the induction of AML. The results indicate that both the AML1 and EVI1 oncogenic components are required for the leukemogenic potential of AME and for the cooperation of AME and BCR/ABL in the induction of AML.	Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Brandeis University	Ren, RB (corresponding author), Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.	ren@brandeis.edu			NATIONAL CANCER INSTITUTE [R01CA068008] Funding Source: NIH RePORTER; NCI NIH HHS [CA68008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Cuenco GM, 2001, ONCOGENE, V20, P8236, DOI 10.1038/sj.onc.1205095; ERICKSON PF, 1994, CANCER RES, V54, P1782; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FIALKOW PJ, 1991, BLOOD, V77, P1415; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Izutsu K, 2002, ONCOGENE, V21, P2695, DOI 10.1038/sj.onc.1205356; JACOBS A, 1991, LEUKEMIA, V5, P277; Kojima K, 1999, BRIT J HAEMATOL, V106, P720, DOI 10.1046/j.1365-2141.1999.01588.x; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Langabeer SE, 2001, BRIT J HAEMATOL, V112, P208, DOI 10.1046/j.1365-2141.2001.02569.x; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Louz D, 2000, LEUKEMIA, V14, P1876, DOI 10.1038/sj.leu.2401887; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; Myint H, 1997, LEUKEMIA RES, V21, P473, DOI 10.1016/S0145-2126(97)00070-2; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; Nucifora G, 1997, LEUKEMIA, V11, P2022, DOI 10.1038/sj.leu.2400880; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; Scandura JM, 2002, ONCOGENE, V21, P3422, DOI 10.1038/sj.onc.1205315; Senyuk V, 2002, ONCOGENE, V21, P3232, DOI 10.1038/sj.onc.1205436; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	41	40	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					569	579		10.1038/sj.onc.1207143	http://dx.doi.org/10.1038/sj.onc.1207143			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724585				2022-12-25	WOS:000188098300028
J	Carrillo-Vico, A; Calvo, JR; Abreu, P; Lardone, PJ; Garcia-Maurino, S; Reiter, RJ; Guerrero, JM				Carrillo-Vico, A; Calvo, JR; Abreu, P; Lardone, PJ; Garcia-Maurino, S; Reiter, RJ; Guerrero, JM			Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance	FASEB JOURNAL			English	Article						neuroimmunology; NAT; HIOMT; IL-2	BLOOD MONONUCLEAR-CELLS; NATURAL-KILLER ACTIVITY; RAT PINEAL-GLAND; LYMPHOID-CELLS; INTERFERON-GAMMA; HUMAN MONOCYTES; BONE-MARROW; IFN-GAMMA; IN-VITRO; PROLIFERATION	It has been historically assumed that the pineal gland is the major source of melatonin (N-acetyl-5-methoxytryptamine) in vertebrates. Melatonin plays a central role in fine-tuning circadian rhythms in vertebrate physiology. In addition, melatonin shows a remarkable functional versatility exhibiting antioxidant, oncostatic, antiaging, and immunomodulatory properties. Melatonin has been identified in a wide range of organisms from bacteria to human beings. Its biosynthesis from tryptophan involves four well-defined intracellular steps catalyzed by tryptophan hydroxylase, aromatic amino acid decarboxylase, serotonin-N-acetyltransferase, and hydroxyndole-O-methyltransferase. Here, for the first time, we document that both resting and phytohemagglutinin-stimulated human lymphocytes synthesize and release large amounts of melatonin, with the melatonin concentration in the medium increasing up to five times the nocturnal physiological levels in human serum. Moreover, we show that the necessary machinery to synthesize melatonin is present in human lymphocytes. Furthermore, melatonin released to the culture medium is synthesized in the cells, because blocking the enzymes required for its biosynthesis or inhibiting protein synthesis in general produced a significant reduction in melatonin release. Moreover, this inhibition caused a decrease in IL-2 production, which was restored by adding exogenous melatonin. These findings indicate that in addition to pineal gland, human lymphoid cells are an important physiological source of melatonin and that this melatonin could be involved in the regulation of the human immune system, possibly by acting as an intracrine, autocrine, and/or paracrine substance.	Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, E-41009 Seville, Spain; Virgen Macarena Hosp, Seville, Spain; Univ La Laguna, Sch Med, Dept Physiol, Tenerife, Spain; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA	University of Sevilla; Hospital Universitario Virgen Macarena; Universidad de la Laguna; University of Texas System; University of Texas Health San Antonio	Guerrero, JM (corresponding author), Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, Avda Sanchez Pizjuan 4, E-41009 Seville, Spain.	guerrero@us.es	Carrillo-Vico, Antonio/K-5265-2014; IBIS, NEUROINMUNO/O-9306-2015; Calvo, Juan R./A-7338-2017; García-Mauriño, Sofía/E-6707-2010; Lardone, Patricia J/H-1959-2015	Carrillo-Vico, Antonio/0000-0002-8516-0999; Calvo, Juan R./0000-0002-4854-2963; García-Mauriño, Sofía/0000-0002-7698-5112; Lardone, Patricia J/0000-0003-1793-3985; Guerrero, Juan Miguel/0000-0001-7553-0119				ARZT ES, 1988, J CLIN IMMUNOL, V8, P513, DOI 10.1007/BF00916958; Barjavel MJ, 1998, J IMMUNOL, V160, P1191; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bubenik GA, 1997, BIOL SIGNAL, V6, P40; Butcher NJ, 2000, MOL PHARMACOL, V57, P468, DOI 10.1124/mol.57.3.468; CALVO JR, 1995, J PINEAL RES, V18, P119, DOI 10.1111/j.1600-079X.1995.tb00149.x; Carrillo-Vico A, 2003, FASEB J, V17, P755, DOI 10.1096/fj.02-0501fje; CHAMPNEY TH, 1984, J NEUROSCI RES, V11, P59, DOI 10.1002/jnr.490110107; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOMBO LL, 1992, IMMUNOL LETT, V33, P123, DOI 10.1016/0165-2478(92)90035-M; Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600-079X.2000.280401.x; Cos S, 1998, CANCER RES, V58, P4383; CSABA G, 1975, ENDOCRINOL EXP, V9, P59; DELGOBBO V, 1989, INT J IMMUNOPHARMACO, V11, P567, DOI 10.1016/0192-0561(89)90187-2; DISTEFANO A, 1994, J PINEAL RES, V17, P164; FINOCCHIARO LME, 1991, BIOCHEM J, V280, P727, DOI 10.1042/bj2800727; FINOCCHIARO LME, 1988, J INTERFERON RES, V8, P705, DOI 10.1089/jir.1988.8.705; Garcia-Chaumont C, 2000, PHARMACOL THERAPEUT, V87, P255, DOI 10.1016/S0163-7258(00)00062-0; Garcia-Maurino S, 1999, LIFE SCI, V65, P2143, DOI 10.1016/S0024-3205(99)00479-8; GarciaMaurino S, 1997, J IMMUNOL, V159, P574; GarciaPerganeda A, 1997, J IMMUNOL, V159, P3774; GIORDANO M, 1991, J PINEAL RES, V10, P117, DOI 10.1111/j.1600-079X.1991.tb00827.x; GONZALEZHABA MG, 1995, FASEB J, V9, P1331, DOI 10.1096/fasebj.9.13.7557023; GUERRERO JM, 1992, ENDOCR RES, V18, P91, DOI 10.1080/07435809209035401; Guerrero JM, 2002, CURR TOP MED CHEM, V2, P67; JANKOVIC BD, 1970, IMMUNOLOGY, V18, P1; Konakchieva R, 1995, J NEUROIMMUNOL, V63, P125, DOI 10.1016/0165-5728(95)00135-2; Kronenwett R, 1998, BLOOD, V91, P852, DOI 10.1182/blood.V91.3.852.852_852_862; LEWINSKI A, 1989, J PINEAL RES, V7, P153, DOI 10.1111/j.1600-079X.1989.tb00663.x; Manchester LC, 1995, CELL MOL BIOL RES, V41, P391; Markowska M, 2001, J PINEAL RES, V30, P220, DOI 10.1034/j.1600-079X.2001.300405.x; MORREY KM, 1994, J IMMUNOL, V153, P2671; Nelson RJ, 2000, ANN NY ACAD SCI, V917, P404; Pahlavani MA, 1997, IMMUNOPHARM IMMUNOT, V19, P327, DOI 10.3109/08923979709046979; PERSENGIEV SP, 1993, INT J BIOCHEM, V25, P441, DOI 10.1016/0020-711X(93)90637-T; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1992, BIOESSAYS, V14, P169, DOI 10.1002/bies.950140307; RODRIGUEZ IR, 1994, J BIOL CHEM, V269, P31969; RUBIO A, 1993, ENDOCRINOLOGY, V132, P393, DOI 10.1210/en.132.1.393; Simonneaux V, 2003, PHARMACOL REV, V55, P325, DOI 10.1124/pr.55.2.2; SUGDEN D, 1989, EXPERIENTIA, V45, P922, DOI 10.1007/BF01953049; Tan DX, 1999, BBA-GEN SUBJECTS, V1472, P206, DOI 10.1016/S0304-4165(99)00125-7; WAKABAYASHI H, 1986, J CHROMATOGR, V381, P21, DOI 10.1016/S0378-4347(00)83561-6; Wiechmann AF, 1999, J PINEAL RES, V27, P116, DOI 10.1111/j.1600-079X.1999.tb00605.x; Wolfler A, 1998, LIFE SCI, V63, P835, DOI 10.1016/S0024-3205(98)00340-3; YOUNG MRI, 1993, IMMUNOLOGY, V80, P395	48	335	354	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					537	+		10.1096/fj.03-0694fje	http://dx.doi.org/10.1096/fj.03-0694fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715696				2022-12-25	WOS:000188829300026
J	Itano, N; Sawai, T; Atsumi, F; Miyaishi, O; Taniguchi, S; Kannagi, R; Hamaguchi, M; Kimata, K				Itano, N; Sawai, T; Atsumi, F; Miyaishi, O; Taniguchi, S; Kannagi, R; Hamaguchi, M; Kimata, K			Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; RAT 3Y1 FIBROBLASTS; GROWTH-FACTOR; ENDOTHELIAL-CELLS; MESSENGER-RNA; CARCINOMA; INVASION; CANCER; MATRIX; ACID	Malignant transformation of fibroblasts and epithelial cells is often accompanied by increased hyaluronan production and accumulation. Despite recent progress in the study of hyaluronan biosynthesis, the mechanisms underlying the transformation-induced overproduction of hyaluronan have not been elucidated. Here we report that activity and transcriptional levels of hyaluronan synthase ( HAS) significantly increased after oncogenic malignant transformation of a rat 3Y1 fibroblast cell line. Of three HAS isoforms (HAS1, HAS2, and HAS3), only HAS2 gene expression was increased in the v-Ha-ras transformed 3Y1 cells, which show less malignancy. In contrast, both HAS1 and HAS2 expressions were elevated in the highly malignant cells transformed with v-src and/or v-fos. To assess the contribution of HAS expression to the oncogenic malignant transformation, we established stable cell transfectants expressing sense and antisense HAS genes. Antisense suppression of the HAS2 expression significantly decreased hyaluronan production in the cells transformed by the oncogenic v-Ha-ras and eventually led to a reduction in tumorigenicity in the rat peritoneum. The introduction of the HAS1 and HAS2 genes promoted the growth of subcutaneous tumors in a manner dependent on the levels of hyaluronan synthesis. Significant growth promotion was observed within a wide range of HAS1 expression. In contrast, the growth stimulation was only seen within a narrow range of HAS2 expression, and high levels of HAS2 expression even inhibited tumor growth. These results suggest that proper regulation of the expression of each HAS isoform is required for optimal malignant transformation and tumor growth.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Aichi 4801195, Japan; Aichi Med Univ, Lab Anim Res Ctr, Aichi 4801195, Japan; Aichi Med Univ, Dept Pathol 2, Aichi 4801195, Japan; Shinshu Univ, Sch Med, Res Ctr Aging & Adaptat, Dept Mol Oncol & Angiol,Angioaging Div, Nagano 3908621, Japan; Aichi Canc Ctr, Res Inst, Program Mol Pathol, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Nagoya, Aichi 466, Japan	Aichi Medical University; Japan Science & Technology Agency (JST); Aichi Medical University; Aichi Medical University; Shinshu University; Aichi Cancer Center; Nagoya University	Itano, N (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	itano@amugw.aichi-med-u.ac.jp	Kannagi, Reiji/Q-6459-2018	Kannagi, Reiji/0000-0003-4202-2921				Ashley DM, 1998, CANCER RES, V58, P302; Csoka TB, 1997, INVAS METAST, V17, P297; DICK SJ, 1983, SCIENCE, V220, P739, DOI 10.1126/science.6220469; Enegd B, 2002, NEUROSURGERY, V50, P1311, DOI 10.1097/00006123-200206000-00023; HAMERMAN D, 1965, BIOCHIM BIOPHYS ACTA, V101, P343, DOI 10.1016/0926-6534(65)90013-8; HOPWOOD JJ, 1977, J BIOL CHEM, V252, P4777; ISHIMOTO N, 1966, J BIOL CHEM, V241, P2052; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1999, CANCER RES, V59, P2499; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1998, TRENDS GLYCOSCI GLYC, V10, P23, DOI 10.4052/tigg.10.23; Jacobson A, 2000, BIOCHEM J, V348, P29, DOI 10.1042/0264-6021:3480029; Jacobson A, 2002, INT J CANCER, V102, P212, DOI 10.1002/ijc.10683; KIMATA K, 1983, CANCER RES, V43, P1347; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; Knudson W, 1996, AM J PATHOL, V148, P1721; Kosaki R, 1999, CANCER RES, V59, P1141; Kuroda K, 2001, J DERMATOL SCI, V26, P156, DOI 10.1016/S0923-1811(00)00155-9; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; LEONARD JG, 1978, CANCER RES, V38, P185; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Liu NF, 2001, CANCER RES, V61, P5207; Ohkawa T, 1999, BBA-MOL CELL RES, V1448, P416, DOI 10.1016/S0167-4889(98)00155-4; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; Recklies AD, 2001, BIOCHEM J, V354, P17, DOI 10.1042/0264-6021:3540017; Ropponen K, 1998, CANCER RES, V58, P342; Sayo T, 2002, J INVEST DERMATOL, V118, P43, DOI 10.1046/j.0022-202x.2001.01613.x; SHIMURA H, 1988, CANCER RES, V48, P578; Simpson MA, 2002, AM J PATHOL, V161, P849, DOI 10.1016/S0002-9440(10)64245-9; Simpson MA, 2002, J BIOL CHEM, V277, P10050, DOI 10.1074/jbc.M110069200; Spicer AP, 1999, BIOCHEM SOC T, V27, P109, DOI 10.1042/bst0270109; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Sugiyama Y, 1998, J INVEST DERMATOL, V110, P116, DOI 10.1046/j.1523-1747.1998.00093.x; TANAKA H, 1988, J CELL PHYSIOL, V136, P421, DOI 10.1002/jcp.1041360305; TANIGUCHI S, 1989, CANCER RES, V49, P6738; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; TOOLE BP, 1979, P NATL ACAD SCI USA, V76, P6299, DOI 10.1073/pnas.76.12.6299; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; TURLEY EA, 1985, CANCER RES, V45, P5098; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; Usui T, 2000, INVEST OPHTH VIS SCI, V41, P3261; Wang XD, 1998, INT J ONCOL, V12, P1097; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Yamada Y, 1998, BIOCHEM J, V330, P1223, DOI 10.1042/bj3301223; YAMADA Y, 2004, IN PRESS CLIN EXP ME; ZAITSU H, 1984, J CELL PHYSIOL, V119, P82, DOI 10.1002/jcp.1041190114; ZHANG LR, 1995, CANCER RES, V55, P428	51	122	125	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18679	18687		10.1074/jbc.M313178200	http://dx.doi.org/10.1074/jbc.M313178200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14724275	hybrid			2022-12-25	WOS:000221041500073
J	Gov, Y; Borovok, I; Korem, M; Singh, VK; Jayaswal, RK; Wilkinson, BJ; Rich, SM; Balaban, N				Gov, Y; Borovok, I; Korem, M; Singh, VK; Jayaswal, RK; Wilkinson, BJ; Rich, SM; Balaban, N			Quorum sensing in staphylococci is regulated via phosphorylation of three conserved histidine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNAIII-INHIBITING PEPTIDE; GRAM-POSITIVE BACTERIA; ESCHERICHIA-COLI; VIRULENCE DETERMINANTS; TRANSMEMBRANE TOPOLOGY; AUTOINDUCING PEPTIDES; SIGNAL-TRANSDUCTION; AUREUS PATHOGENESIS; BACILLUS-SUBTILIS; BIOFILM FORMATION	Staphylococcus aureus cause infections by producing toxins, a process regulated by cell-cell communication ( quorum sensing) through the histidine-phosphorylation of the target of RNAIII-activating protein ( TRAP). We show here that TRAP is highly conserved in staphylococci and contains three completely conserved histidine residues (His-66, His-79, His-154) that are phosphorylated and essential for its activity. This was tested by constructing a TRAP(-) strain with each of the conserved histidine residues changed to alanine by site-directed mutagenesis. All mutants were tested for pathogenesis in vitro ( expression of RNAIII and hemolytic activity) and in vivo ( murine cellulitis model). Results show that RNAIII is not expressed in the TRAP(-) strain, that it is non hemolytic, and that it does not cause disease in vivo. These pathogenic phenotypes could be rescued in the strain containing the recovered traP, confirming the importance of TRAP in S. aureus pathogenesis. The phosphorylation of TRAP mutated in any of the conserved histidine residues was significantly reduced, and mutants defective in any one of these residues were non-pathogenic in vitro or in vivo, whereas those mutated in a non-conserved histidine residue (His-124) were as pathogenic as the wild type. These results confirm the importance of the three conserved histidine residues in TRAP activity. The phosphorylation pattern, structure, and gene organization of TRAP deviates from signaling molecules known to date, suggesting that TRAP belongs to a novel class of signal transducers.	Tufts Univ, Sch Vet Med, Dept Biomed Sci, North Grafton, MA 01536 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; Illinois State Univ, Dept Biol Sci, Microbiol Grp, Normal, IL 61790 USA	Tufts University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Illinois State University	Balaban, N (corresponding author), Tufts Univ, Sch Vet Med, Dept Biomed Sci, 200 Westboro Rd, North Grafton, MA 01536 USA.	naomi.balaban@tufts.edu	BOROVOK, ILYA/ABB-7370-2022; Rich, Stephen/AAX-6953-2020	BOROVOK, ILYA/0000-0003-1602-4499	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI043970] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43970] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arvidson S, 2001, INT J MED MICROBIOL, V291, P159, DOI 10.1078/1438-4221-00112; Baba T, 2002, LANCET, V359, P1819, DOI 10.1016/S0140-6736(02)08713-5; Balaban N, 2000, PEPTIDES, V21, P1301, DOI 10.1016/S0196-9781(00)00272-2; BALABAN N, 1995, FEMS MICROBIOL LETT, V133, P155, DOI 10.1016/0378-1097(95)00356-A; Balaban N, 2003, J INFECT DIS, V187, P625, DOI 10.1086/345879; Balaban N, 2003, KIDNEY INT, V63, P340, DOI 10.1046/j.1523-1755.2003.00733.x; Balaban N, 1998, SCIENCE, V280, P438, DOI 10.1126/science.280.5362.438; Balaban N, 2001, J BIOL CHEM, V276, P2658, DOI 10.1074/jbc.M005446200; Benito Y, 2000, RNA, V6, P668, DOI 10.1017/S1355838200992550; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; Chen Q, 1998, BIOCHEMISTRY-US, V37, P8714, DOI 10.1021/bi9731652; Cirioni O, 2003, CIRCULATION, V108, P767, DOI 10.1161/01.CIR.0000083717.85060.16; DERBISE A, 1994, PLASMID, V31, P251, DOI 10.1006/plas.1994.1027; Giacometti A, 2003, ANTIMICROB AGENTS CH, V47, P1979, DOI 10.1128/AAC.47.6.1979-1983.2003; Gilot P, 2002, J CLIN MICROBIOL, V40, P4060, DOI 10.1128/JCM.40.11.4060-4067.2002; Gov Y, 2001, PEPTIDES, V22, P1609, DOI 10.1016/S0196-9781(01)00496-X; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hoch JA, 2001, J BACTERIOL, V183, P4941, DOI 10.1128/JB.183.17.4941-4949.2001; Hong-Geller E, 2003, J MOL RECOGNIT, V16, P91, DOI 10.1002/jmr.612; Ivanova N, 2003, NATURE, V423, P87, DOI 10.1038/nature01582; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x; Korem M, 2003, FEMS MICROBIOL LETT, V223, P167, DOI 10.1016/S0378-1097(03)00326-4; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Lina G, 1998, MOL MICROBIOL, V28, P655, DOI 10.1046/j.1365-2958.1998.00830.x; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Lyon GJ, 2002, BIOCHEMISTRY-US, V41, P10095, DOI 10.1021/bi026049u; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Morfeldt E, 1996, FEMS MICROBIOL LETT, V143, P195, DOI 10.1016/0378-1097(96)00310-2; Nei M., 1987, MOL EVOLUTIONARY GEN; NOVICK RP, 1995, MOL GEN GENET, V248, P446, DOI 10.1007/BF02191645; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; Perraud AL, 1999, TRENDS MICROBIOL, V7, P115, DOI 10.1016/S0966-842X(99)01458-4; Saenz HL, 2000, ARCH MICROBIOL, V174, P452, DOI 10.1007/s002030000223; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAFER WM, 1979, INFECT IMMUN, V25, P909; Singh VK, 2001, FEMS MICROBIOL LETT, V199, P79, DOI 10.1016/S0378-1097(01)00163-X; Stephenson K., 2002, Current Drug Targets - Infectious Disorders, V2, P235, DOI 10.2174/1568005023342443; Stephenson K, 2002, CURR OPIN PHARMACOL, V2, P507, DOI 10.1016/S1471-4892(02)00194-7; Sturme MHJ, 2002, ANTON LEEUW INT J G, V81, P233, DOI 10.1023/A:1020522919555; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; Throup JP, 2001, BIOCHEMISTRY-US, V40, P10392, DOI 10.1021/bi0102959; Tortosa P, 1997, J BIOL CHEM, V272, P17230, DOI 10.1074/jbc.272.27.17230; Varughese KL, 2002, CURR OPIN MICROBIOL, V5, P142, DOI 10.1016/S1369-5274(02)00305-3; Vieira-da-Motta O, 2001, PEPTIDES, V22, P1621, DOI 10.1016/S0196-9781(01)00497-1; Zhang LS, 2002, J BIOL CHEM, V277, P34736, DOI 10.1074/jbc.M205367200	49	49	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14665	14672		10.1074/jbc.M311106200	http://dx.doi.org/10.1074/jbc.M311106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14726534	hybrid			2022-12-25	WOS:000220594700025
J	Castell, L; Vance, C; Abbott, R; Marquez, J; Eggleton, P				Castell, L; Vance, C; Abbott, R; Marquez, J; Eggleton, P			Granule localization of glutaminase in human neutrophils and the consequence of glutamine utilization for neutrophil activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IN-VITRO; POSTOPERATIVE-PATIENTS; EXHAUSTIVE EXERCISE; CYTOKINE PRODUCTION; RAT NEUTROPHILS; IMMUNE-RESPONSE; EXPRESSION; GLUCOSE; PHAGOCYTOSIS	The provision of glutamine in vivo has been observed to reduce to normal levels the neutrophilia observed after exhaustive exercise and to decrease the neutrophil chemoattractant, interleukin-8. Thus, the role for glutamine in the regulation of inflammatory mediators of human neutrophil activation was investigated. The study sought to establish whether glutamine supplementation in vitro affects neutrophil function at rest and whether glutaminase, the major enzyme that metabolizes glutamine, is present in human polymorphonuclear neutrophils (PMN). During in vitro studies, the addition of 2 mM glutamine increased the respiratory burst of human PMN stimulated with both phorbol myristate acetate (PMA) and formyl-methionyl-leucyl-phenylalanine. These observations were made using a highly sensitive, real time chemiluminescent probe, Pholasin(R). Glutamine alone did not stimulate the release of reactive oxygen species. In a novel finding using glutaminase-specific antibodies in combination with flow cytometry and confocal microscopy, glutaminase was shown to be present on the surface of human PMN. Subcellular fractionation revealed that the enzyme was enriched in the secondary granules and could be released into cell culture medium upon stimulation with PMA. In conclusion, human PMN appeared to utilize glutamine and possess the appropriate glutaminase enzyme for metabolizing glutamine. This may depress some pro-inflammatory factors that occur during prolonged, exhaustive exercise.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter EX1 2LU, Devon, England; Univ Malaga, Dept Mol Biol & Biochem, E-29071 Malaga, Spain	University of Oxford; University of Oxford; University of Exeter; Universidad de Malaga	Castell, L (corresponding author), Univ Oxford, Radcliffe Infirm, Nuffield Dept Anaesthet, Oxford OX2 6HE, England.	lindy.castell@nda.ox.ac.uk	marquez, javier/K-3289-2012; Vance, Caroline/Q-2633-2019; Vance, Caroline/C-3047-2012	marquez, javier/0000-0003-3317-3963; Vance, Caroline/0000-0001-5780-6951; Vance, Caroline/0000-0001-5780-6951; Eggleton, Paul/0000-0001-8244-2125; Abbott, Rachel/0000-0003-1902-1429				ARDAWI MSM, 1985, ESSAYS BIOCHEM, V21, P1; Blannin AK, 1998, J PHYSIOL-LONDON, V506P, p121P; CANNISTRA SA, 1988, SEMIN HEMATOL, V25, P173; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Castell LM, 2003, SPORTS MED, V33, P323, DOI 10.2165/00007256-200333050-00001; Castell LM, 1996, EUR J APPL PHYSIOL O, V73, P488, DOI 10.1007/BF00334429; Castell LM, 1998, CAN J PHYSIOL PHARM, V76, P524, DOI 10.1139/cjpp-76-5-524; CASTELL LM, 1996, THESIS U OXFORD OXFO; Coeffier M, 2003, CLIN NUTR, V22, P407, DOI 10.1016/S0261-5614(03)00040-2; Curi TCP, 1997, AM J PHYSIOL-CELL PH, V273, pC1124, DOI 10.1152/ajpcell.1997.273.4.C1124; de Beaux AC, 1998, NUTRITION, V14, P261, DOI 10.1016/S0899-9007(97)00477-2; DUFAUX B, 1989, INT J SPORTS MED, V10, P434, DOI 10.1055/s-2007-1024939; EGGLETON P, 1995, ANN RHEUM DIS, V54, P916, DOI 10.1136/ard.54.11.916; Eggleton P, 1999, ANTICANCER RES, V19, P3711; Furukawa S, 2000, NUTRITION, V16, P323, DOI 10.1016/S0899-9007(00)00228-8; Furukawa S, 1997, NUTRITION, V13, P863, DOI 10.1016/S0899-9007(97)00271-2; Gomez-Fabre PM, 2000, BIOCHEM J, V345, P365, DOI 10.1042/0264-6021:3450365; HANSEN JB, 1991, EUR J APPL PHYSIOL O, V62, P157, DOI 10.1007/BF00643735; Healy DA, 2002, CLIN SCI, V103, P179, DOI 10.1042/cs1030179; Huang Y, 2003, CYTOKINE, V22, P77, DOI 10.1016/S1043-4666(03)00115-7; Hunt JF, 2002, AM J RESP CRIT CARE, V165, P101, DOI 10.1164/ajrccm.165.1.2104131; Kjeldsen L, 1999, J IMMUNOL METHODS, V232, P131, DOI 10.1016/S0022-1759(99)00171-4; KNOX WE, 1967, CANCER RES, V27, P1456; LARRABEE RC, 1902, J MED RES, V2, P76; Lin MT, 2001, JPEN-PARENTER ENTER, V25, P346, DOI 10.1177/0148607101025006346; MCCARTHY DA, 1988, SPORTS MED, V6, P333, DOI 10.2165/00007256-198806060-00002; NEWSHOLME P, 1989, BIOCHEM J, V261, P211, DOI 10.1042/bj2610211; Nieman DC, 2001, J APPL PHYSIOL, V91, P109, DOI 10.1152/jappl.2001.91.1.109; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OGLE CK, 1994, JPEN-PARENTER ENTER, V18, P128, DOI 10.1177/0148607194018002128; Olalla L, 2002, J BIOL CHEM, V277, P38939, DOI 10.1074/jbc.C200373200; ORIORDAIN MG, 1996, NUTRITION, V12, P82; Pithon-Curi TC, 2002, CELL BIOCHEM FUNCT, V20, P81, DOI 10.1002/cbf.954; Pithon-Curi TC, 2002, CLIN SCI, V103, P403, DOI 10.1042/cs1030403; POWELL H, 1994, CLIN PHYSIOL, V14, P569, DOI 10.1111/j.1475-097X.1994.tb00415.x; Searl TJ, 1998, J PHARMACOL EXP THER, V285, P247; SEGURA JA, 1995, PROTEIN EXPRES PURIF, V6, P343, DOI 10.1006/prep.1995.1045; Suzuki K, 2000, EUR J APPL PHYSIOL, V81, P281, DOI 10.1007/s004210050044; Suzuki K, 1996, J APPL PHYSIOL, V81, P1213, DOI 10.1152/jappl.1996.81.3.1213; Turner A, 2003, BIOCHEM J, V370, P403, DOI 10.1042/BJ20021360; VOETMAN AA, 1980, BLOOD, V55, P741; Wirthmueller U, 1997, J IMMUNOL, V158, P4444; Wood-Harper AT, 1999, AUST COMPUT J, V31, P66	43	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13305	13310		10.1074/jbc.M309520200	http://dx.doi.org/10.1074/jbc.M309520200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722097	hybrid			2022-12-25	WOS:000220478500006
J	Couve, A; Restituito, S; Brandon, JM; Charles, KJ; Bawagan, H; Freeman, KB; Pangalos, MN; Calver, AR; Moss, SJ				Couve, A; Restituito, S; Brandon, JM; Charles, KJ; Bawagan, H; Freeman, KB; Pangalos, MN; Calver, AR; Moss, SJ			Marlin-1, a novel RNA-binding protein associates with GABA(B) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INTRACELLULAR-LOCALIZATION; HIPPOCAMPAL-NEURONS; MAMMALIAN STAUFEN; SYNAPTIC SITES; GENE; DENDRITES; COMPLEXES; TRANSPORT; REPRESSOR	GABA(B) receptors are heterodimeric G protein-coupled receptors that mediate slow synaptic inhibition in the central nervous system. Whereas heterodimerization between GABA(B) receptor GABA(B)R1 and GABA(B)R2 subunits is essential for functional expression, how neurons coordinate the assembly of these critical receptors remains to be established. Here we have identified Marlin-1, a novel GABA(B) receptor-binding protein that associates specifically with the GABABR1 subunit in yeast, tissue culture cells, and neurons. Marlin-1 is expressed in the brain and exhibits a granular distribution in cultured hippocampal neurons. Marlin-1 binds different RNA species including the 3'-untranslated regions of both the GABA(B)R1 and GABA(B)R2 mRNAs in vitro and also associates with RNA in cultured neurons. Inhibition of Marlin-1 expression via small RNA interference technology results in enhanced intracellular levels of the GABA(B)R2 receptor subunit without affecting the level of GABA(B)R1. Together our results suggest that Marlin-1 functions to regulate the cellular levels of GABA(B) R2 subunits, which may have significant effects on the production of functional GABA(B) receptor heterodimers. Therefore, our observations provide an added level of regulation for the control of GABA(B) receptor expression and for the efficacy of inhibitory synaptic transmission.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; GlaxoSmithKline, Neurol & Gl Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Genet Res, Dept Comparat Genet, King Of Prussia, PA 19406 USA	University of Pennsylvania; University of London; University College London; University of London; University College London; GlaxoSmithKline; GlaxoSmithKline	Moss, SJ (corresponding author), Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA.	sjmoss@mail.med.upenn.edu	couve, andres/I-2249-2013	couve, andres/0000-0003-4216-8672				Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Aoki K, 1999, FEBS LETT, V443, P363, DOI 10.1016/S0014-5793(99)00010-1; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Charles KJ, 2003, MOL CELL NEUROSCI, V24, P214, DOI 10.1016/S1044-7431(03)00162-3; Cheng CK, 2002, ENDOCRINOLOGY, V143, P4693, DOI 10.1210/en.2002-220576; Couve A, 2000, MOL CELL NEUROSCI, V16, P296, DOI 10.1006/mcne.2000.0908; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Couve A, 2002, NAT NEUROSCI, V5, P415, DOI 10.1038/nn833; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Craig AM, 2001, NAT NEUROSCI, V4, P569, DOI 10.1038/88388; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; El Far O, 2002, BIOCHEM J, V365, P329, DOI 10.1042/BJ20020481; Filippov AK, 2000, J NEUROSCI, V20, P2867; Fitzgerald LR, 1996, J NEUROCHEM, V67, P490; Grant SGN, 2001, TRENDS BIOTECHNOL, V19, pS49, DOI 10.1016/S0167-7799(01)01799-1; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Job C, 2001, NAT REV NEUROSCI, V2, P889, DOI 10.1038/35104069; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Kittler JT, 2000, J NEUROSCI, V20, P7972; Knowles RB, 1996, J NEUROSCI, V16, P7812; Krichevsky AM, 2001, NEURON, V32, P683, DOI 10.1016/S0896-6273(01)00508-6; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Lee YC, 2003, MOL BRAIN RES, V111, P61, DOI 10.1016/S0169-328X(02)00670-8; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; Miyashiro KY, 2003, NEURON, V37, P417, DOI 10.1016/S0896-6273(03)00034-5; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; MOTT DD, 1994, INT REV NEUROBIOL, V36, P97, DOI 10.1016/S0074-7742(08)60304-9; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; Ou XM, 2003, J NEUROSCI, V23, P7415; Palacios IM, 2001, ANNU REV CELL DEV BI, V17, P569, DOI 10.1146/annurev.cellbio.17.1.569; Pierce JP, 2001, CURR BIOL, V11, P351, DOI 10.1016/S0960-9822(01)00077-X; Prosser HM, 2001, MOL CELL NEUROSCI, V17, P1059, DOI 10.1006/mcne.2001.0995; Roberts DCS, 1997, PSYCHOPHARMACOLOGY, V131, P271, DOI 10.1007/s002130050293; Roegiers F, 2000, TRENDS CELL BIOL, V10, P220, DOI 10.1016/S0962-8924(00)01767-0; Sapru MK, 1996, J BIOL CHEM, V271, P7203, DOI 10.1074/jbc.271.12.7203; Schuler V, 2001, NEURON, V31, P47, DOI 10.1016/S0896-6273(01)00345-2; Shahied-Milam L, 1998, J BIOL CHEM, V273, P21359, DOI 10.1074/jbc.273.33.21359; Steward O, 2001, P NATL ACAD SCI USA, V98, P7062, DOI 10.1073/pnas.131146398; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; Vernon E, 2001, MOL CELL NEUROSCI, V17, P637, DOI 10.1006/mcne.2000.0960; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Zhang HL, 1999, J CELL BIOL, V147, P59, DOI 10.1083/jcb.147.1.59	51	45	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13934	13943		10.1074/jbc.M311737200	http://dx.doi.org/10.1074/jbc.M311737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14718537	hybrid			2022-12-25	WOS:000220478500080
J	Park, IY; Cho, JH; Kim, KS; Kim, YB; Kim, MS; Kim, SC				Park, IY; Cho, JH; Kim, KS; Kim, YB; Kim, MS; Kim, SC			Helix stability confers salt resistance upon helical antimicrobial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BUFORIN II; MECHANISM; MEMBRANE; MODEL; ANTIBIOTICS	Salt sensitivity of antimicrobial peptides poses a major obstacle in their development as novel antibiotics. Here we report the use of helix-capping motifs to confer salt resistance upon helical antimicrobial peptides. The helical content of the template peptide [RLLR](5) was almost completely destroyed at salt concentrations over 200 mM NaCl, leading to a 8-32-fold decrease in antimicrobial activity. However, the introduction of helix-capping motifs at the helix termini resulted in a structurally stable peptide, which retained membrane-permeabilizing and antimicrobial activities upon exposure to salt. Furthermore, the peptide with helix-capping motifs directly inhibited the in vivo growth of Streptococcus pyogenes, which causes localized fasciitis in mice, and prevented the necrosis of the epidermis, dermis, and subcutaneous muscle layers. Results indicate that the adoption of helix-capping motifs into salt-sensitive antimicrobial peptides provides the necessary structural stability for the peptides to permeabilize cell membranes and cause cell death at physiological salt concentrations.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 130650, South Korea; Chungbuk Natl Univ, Dept Toxicol, Cheongju 361763, South Korea; Korea Inst Energy Res, Biomass Team, Taejon 305343, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Institute of Science & Technology (KIST); Chungbuk National University; Korea Institute of Energy Research (KIER)	Kim, SC (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Yusong Gu Kusong Dong, Taejon 305701, South Korea.	sunkim@kaist.ac.kr	Kim, Sun Chang/C-2026-2011; Kim, Sun/GSN-4867-2022					Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; Friedrich C, 1999, ANTIMICROB AGENTS CH, V43, P1542, DOI 10.1128/AAC.43.7.1542; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Kuo CF, 1998, INFECT IMMUN, V66, P3931, DOI 10.1128/IAI.66.8.3931-3935.1998; Lee IH, 1997, INFECT IMMUN, V65, P2898, DOI 10.1128/IAI.65.7.2898-2903.1997; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8; MOR A, 1994, J BIOL CHEM, V269, P1934; MUNOZ V, 1995, NAT STRUCT BIOL, V2, P380, DOI 10.1038/nsb0595-380; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Park CB, 2000, P NATL ACAD SCI USA, V97, P8245, DOI 10.1073/pnas.150518097; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; PAULING L, 1951, P NATL ACAD SCI USA, V37, P241, DOI 10.1073/pnas.37.5.241; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; Steinberg D A, 1997, Methods Mol Biol, V78, P169; Tam JP, 2000, BIOCHEMISTRY-US, V39, P7159, DOI 10.1021/bi0003487; Tossi A, 2000, BIOPOLYMERS, V55, P4; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299	25	97	104	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13896	13901		10.1074/jbc.M311418200	http://dx.doi.org/10.1074/jbc.M311418200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14718539	hybrid			2022-12-25	WOS:000220478500076
J	Szczesna-Skorupa, E; Chen, CD; Liu, H; Kemper, B				Szczesna-Skorupa, E; Chen, CD; Liu, H; Kemper, B			Gene expression changes associated with the endoplasmic reticulum stress response induced by microsomal cytochrome P450 overproduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN-RESPONSE; NF-KAPPA-B; SIGNAL-TRANSDUCTION; MESSENGER-RNA; CELL-DEATH; PROLIFERATION; TRANSMEMBRANE; RETENTION; IRE1; ACTIVATION	Induction of drug-metabolizing microsomal cytochromes P450 (P450s) results in a striking proliferation of the smooth endoplasmic reticulum (ER). Overexpression of P450s in yeast and cultured cells produces a similar response. The signals mediating this process are not known but probably involve signal transduction pathways involved in the unfolded protein response (UPR) or the ER overload response (EOR). We have examined the temporal response of specific genes in these pathways and genes globally to overexpression of P450 in cultured cells. Activity of NFkappaB, an EOR component, was substantially increased by overexpression of full-length P450 2C2 or a chimera with the 28-amino acid signal anchor sequence of P450 2C2 in HepG2 cells, and the activation correlated temporally with the accumulation of P450 in the cells. In the UPR pathway, activation of the transcription factor XBP1 by IRE1 also correlated with the accumulation of P450 in the cells, and in contrast, maximum activation of the BiP/grp78 promoter preceded the accumulation. Differential effects of expression of P450 on apoptosis were observed in nonhepatic COS1 and hepatic HepG2 cells. In COS1 cells, apoptosis was induced, and this correlated with sustained activation of the pro-apoptotic JNK pathway, induction of CHOP, and an absence of the increased NFkappaB activity. In HepG2 cells, JNK was only transiently activated, and CHOP expression was not induced. As assessed by DNA microarray analysis, up-regulation of signaling genes was predominant including those involved in anti-apoptosis and ER stress. These results suggest that both the EOR and UPR pathways are involved in the cellular response to induction of P450 expression and that in hepatic cells genes are also induced to block apoptosis, which may be a physiologically relevant response to prevent cell death during xenobiotic induced expression of P450 in the liver.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA; Aventis Pharmaceut Inc, Bridgewater, NJ 08807 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Minnesota System; University of Minnesota Twin Cities; Sanofi-Aventis	Kemper, B (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 407 S Goodwin Ave, Urbana, IL 61801 USA.	byronkem@life.uiuc.edu	Longo, Kenneth A/A-5631-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35897] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Cudna RE, 2003, BIOTECHNOL BIOENG, V81, P56, DOI 10.1002/bit.10445; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fu LW, 2003, J CELL BIOL, V160, P157, DOI 10.1083/jcb.200210086; Higashio H, 2002, BIOCHEM BIOPH RES CO, V296, P568, DOI 10.1016/S0006-291X(02)00923-3; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; JONES AL, 1966, J HISTOCHEM CYTOCHEM, V14, P215, DOI 10.1177/14.3.215; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Larson LL, 2002, YEAST, V19, P373, DOI 10.1002/yea.839; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Leonardi A, 2002, ENDOCRINOLOGY, V143, P2169, DOI 10.1210/en.143.6.2169; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Menzel R, 1996, ARCH BIOCHEM BIOPHYS, V330, P97, DOI 10.1006/abbi.1996.0230; Menzel R, 1997, YEAST, V13, P1211, DOI 10.1002/(SICI)1097-0061(199710)13:13<1211::AID-YEA168>3.0.CO;2-8; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Reimold AM, 2000, GENE DEV, V14, P152; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; SCHUNCK WH, 1991, EUR J CELL BIOL, V55, P336; Szczesna-Skorupa E, 2003, J BIOL CHEM, V278, P31269, DOI 10.1074/jbc.M301489200; Szczesna-Skorupa E, 2000, ARCH BIOCHEM BIOPHYS, V374, P128, DOI 10.1006/abbi.1999.1628; Szczesna-Skorupa E, 2000, J BIOL CHEM, V275, P19409, DOI 10.1074/jbc.M002394200; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; Szczesna-Skorupa E, 2001, J BIOL CHEM, V276, P45009, DOI 10.1074/jbc.M104676200; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; Takewaka T, 1999, J BIOCHEM-TOKYO, V125, P507, DOI 10.1093/oxfordjournals.jbchem.a022314; Theilhaber J, 2001, J COMPUT BIOL, V8, P585, DOI 10.1089/106652701753307502; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, J CELL SCI, V113, P3697; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Anken E, 2003, IMMUNITY, V18, P243, DOI 10.1016/S1074-7613(03)00024-4; VERGERES G, 1993, J CELL SCI, V106, P249; Yamamoto A, 1996, J CELL SCI, V109, P1727; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang C, 2001, BIOCHEM BIOPH RES CO, V289, P718, DOI 10.1006/bbrc.2001.6044	48	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13953	13961		10.1074/jbc.M312170200	http://dx.doi.org/10.1074/jbc.M312170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14718536	hybrid			2022-12-25	WOS:000220478500082
J	Taneja, SS; Ha, S; Swenson, NK; Torra, IP; Rome, S; Walden, PD; Huang, HY; Shapiro, E; Garabedian, MJ; Logan, SK				Taneja, SS; Ha, S; Swenson, NK; Torra, IP; Rome, S; Walden, PD; Huang, HY; Shapiro, E; Garabedian, MJ; Logan, SK			ART-27, an androgen receptor coactivator regulated in prostate development and cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIF; CREB-BINDING-PROTEIN; RAT VENTRAL PROSTATE; GLUCOCORTICOID-RECEPTOR; TERMINAL DOMAIN; GENE-EXPRESSION; MOLECULAR-BASIS; ACTIVATION; CELLS; IDENTIFICATION	Androgen receptor trapped clone-27 (ART-27) is a newly described transcriptional coactivator that binds to the N terminus of the androgen receptor (AR). Given the vital importance of AR signaling in prostate growth and differentiation, we investigated the role of ART-27 in these processes. Immunohistochemical studies indicate that ART-27 protein is expressed in differentiated epithelial cells of adult human prostate and breast tissue. In prostate, ART-27 is abundant in AR-positive prostate luminal epithelial cells, in contrast to the stroma, where cells express AR but not ART-27. The use of a rat model of androgen depletion/ reconstitution indicates that ART-27 expression is associated with the elaboration of differentiated prostate epithelial cells. Interestingly, regulated expression of ART-27 in the androgen-sensitive LNCaP prostate cancer cell line inhibits androgen-mediated cellular proliferation and enhances androgen-mediated transcription of the prostate-specific antigen (PSA) gene. Consistent with a growth suppressive function, we show that ART-27 expression levels are negligible in human prostate cancer. Importantly, examination of ART-27 protein expression in early fetal prostate development demonstrates that ART-27 is detected only when the developing prostate gland has proceeded from a solid mass of undifferentiated cells to a stage in which differentiated luminal epithelial cells are evident. Thus, ART-27 is an AR cofactor shown to be subject to both cell type and developmental regulation in humans. Overall, the results suggest that decreased levels of ART-27 protein in prostate cancer tissue may occur as a result of de-differentiation, and indicate that ART-27 is likely to regulate a subset of AR-responsive genes important to prostate growth suppression and differentiation.	NYU, Sch Med, Dept Urol, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Logan, SK (corresponding author), NYU, VAMC, 423 E 23rd St,Room 18064 S, New York, NY 10010 USA.	logans02@med.nyu.edu		Logan, Susan/0000-0002-7904-5927; Pineda Torra, Ines/0000-0002-7349-2208	NIDDK NIH HHS [K08 DK02577-01, DK58024] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058024, K08DK002577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Adachi M, 2000, NEW ENGL J MED, V343, P856, DOI 10.1056/NEJM200009213431205; Astancolle S, 2000, J ENDOCRINOL, V167, P197, DOI 10.1677/joe.0.1670197; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Beitel LK, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290041; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Cinar B, 2001, CANCER RES, V61, P7310; Cleutjens CBJM, 1997, ENDOCRINOLOGY, V138, P5293, DOI 10.1210/en.138.12.5293; COLOMBEL MC, 1995, METHOD CELL BIOL, V46, P369; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gregory CW, 2001, CANCER RES, V61, P4315; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Lakins J, 1998, J BIOL CHEM, V273, P27887, DOI 10.1074/jbc.273.43.27887; LANGELER EG, 1993, PROSTATE, V23, P213, DOI 10.1002/pros.2990230304; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Li P, 2002, AM J PATHOL, V161, P1467, DOI 10.1016/S0002-9440(10)64422-7; Markus SM, 2002, MOL BIOL CELL, V13, P670, DOI 10.1091/mbc.01-10-0513; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Park JJ, 2000, CANCER RES, V60, P5946; Reid J, 2002, J BIOL CHEM, V277, P41247, DOI 10.1074/jbc.M205220200; Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Schroer A, 1999, GENOMICS, V56, P340, DOI 10.1006/geno.1998.5712; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Stanbrough M, 2001, P NATL ACAD SCI USA, V98, P10823, DOI 10.1073/pnas.191235898; Takahashi T, 1999, INT J UROL, V6, P526, DOI 10.1046/j.1442-2042.1999.00104.x; Walden PD, 1998, PROSTATE, V34, P241, DOI 10.1002/(SICI)1097-0045(19980301)34:4<241::AID-PROS1>3.0.CO;2-K; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	46	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13944	13952		10.1074/jbc.M306576200	http://dx.doi.org/10.1074/jbc.M306576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14711828	hybrid			2022-12-25	WOS:000220478500081
J	Appenzeller-Herzog, C; Roche, AC; Nufer, O; Hauri, HP				Appenzeller-Herzog, C; Roche, AC; Nufer, O; Hauri, HP			pH-induced conversion of the transport lectin ERGIC-53 triggers glycoprotein release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI INTERMEDIATE COMPARTMENT; CARBOHYDRATE-RECOGNITION DOMAIN; RECEPTOR-ASSOCIATED PROTEIN; VACUOLAR H+-ATPASE; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; ASIALOGLYCOPROTEIN RECEPTOR; LEGUMINOUS LECTINS; RECYCLING PATHWAY; CRYSTAL-STRUCTURE	The recycling mannose lectin ERGIC- 53 operates as a transport receptor by mediating efficient endoplasmic reticulum ( ER) export of some secretory glycoproteins. Binding of cargo to ERGIC- 53 in the ER requires Ca2+. Cargo release occurs in the ERGIC, but the molecular mechanism is unknown. Here we report efficient binding of purified ERGIC- 53 to immobilized mannose at pH 7.4, the pH of the ER, but not at slightly lower pH. pH sensitivity of the lectin was more prominent when Ca2+ concentrations were low. A conserved histidine in the center of the carbohydrate recognition domain was required for lectin activity suggesting it may serve as a molecular pH/Ca2+ sensor. Acidification of cells inhibited the association of ERGIC- 53 with the known cargo cathepsin Z- related protein and dissociation of this glycoprotein in the ERGIC was impaired by organelle neutralization that did not impair the transport of a control protein. The results elucidate the molecular mechanism underlying reversible lectin/ cargo interaction and establish the ERGIC as the earliest low pH site of the secretory pathway.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; CNRS, Ctr Biophys Mol, F-45071 Orleans, France	University of Basel; Centre National de la Recherche Scientifique (CNRS)	Hauri, HP (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Hans-Peter.Hauri@unibas.ch	Appenzeller-Herzog, Christian/A-2894-2014	Appenzeller-Herzog, Christian/0000-0001-7430-294X				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; ANTUSCH D, 1990, J IMMUNOL, V145, P885; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Belden WJ, 2001, SCIENCE, V294, P1528, DOI 10.1126/science.1065224; BONIFACINO JS, 1988, J BIOL CHEM, V263, P8965; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Elgavish S, 1998, J MOL BIOL, V277, P917, DOI 10.1006/jmbi.1998.1664; Feinberg H, 2000, J BIOL CHEM, V275, P21539, DOI 10.1074/jbc.M002366200; Feinberg H, 2000, J BIOL CHEM, V275, P35176, DOI 10.1074/jbc.M005557200; Fiedler K, 1996, J CELL SCI, V109, P271; Gilbert A, 1998, EXP CELL RES, V242, P144, DOI 10.1006/excr.1998.4101; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Hauri HP, 2000, J CELL SCI, V113, P587; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Klumperman J, 1998, J CELL SCI, V111, P3411; Loris R, 2002, BBA-GEN SUBJECTS, V1572, P198, DOI 10.1016/S0304-4165(02)00309-4; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nufer O, 2003, J BIOL CHEM, V278, P15886, DOI 10.1074/jbc.M211199200; Palokangas H, 1998, MOL BIOL CELL, V9, P3561, DOI 10.1091/mbc.9.12.3561; Pezzati R, 1997, MOL BIOL CELL, V8, P1501, DOI 10.1091/mbc.8.8.1501; PIMPANEAU V, 1991, CARBOHYD RES, V213, P95, DOI 10.1016/S0008-6215(00)90601-3; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Scheel AA, 1996, BIOCHEMISTRY-US, V35, P10203, DOI 10.1021/bi960807x; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; Solovyova N, 2002, J NEUROSCI METH, V122, P1, DOI 10.1016/S0165-0270(02)00300-X; Velloso LM, 2003, J MOL BIOL, V334, P845, DOI 10.1016/j.jmb.2003.10.031; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Warren G, 1999, CELL, V98, P125, DOI 10.1016/S0092-8674(00)81006-5; Weisz OA, 2003, INT REV CYTOL, V226, P259, DOI 10.1016/S0074-7696(03)01005-2; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wragg S, 1999, J BIOL CHEM, V274, P35400, DOI 10.1074/jbc.274.50.35400; Wu MM, 2000, METHOD ENZYMOL, V327, P546, DOI 10.1016/S0076-6879(00)27301-1; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Ying M, 2000, J CELL SCI, V113, P3623; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153	45	84	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12943	12950		10.1074/jbc.M313245200	http://dx.doi.org/10.1074/jbc.M313245200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718532	hybrid			2022-12-25	WOS:000220334900112
J	Ashikari-Hada, S; Habuchi, H; Kariya, Y; Itoh, N; Reddi, AH; Kimata, K				Ashikari-Hada, S; Habuchi, H; Kariya, Y; Itoh, N; Reddi, AH; Kimata, K			Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; HEPARAN-SULFATE; MOLECULAR-CLONING; CRYSTAL-STRUCTURES; COMPLEXES REVEAL; CDNA CLONING; EXPRESSION; PROTEOGLYCANS; FGF	Heparan sulfate (HS) chains interact with various growth and differentiation factors and morphogens, and the most interactions occur on the specific regions of the chains with certain monosaccharide sequences and sulfation patterns. Here we generated a library of octasaccharides by semienzymatic methods by using recombinant HS 2-O-sulfotransferase and HS 6-O-sulfotransferase, and we have made a systematic investigation of the specific binding structures for various heparin-binding growth factors. An octasaccharide (Octa-I, DeltaHexA-GlcNSO(3)-(HexA-GlcNSO(3))(3)) was prepared by partial heparitinase digestion from completely desulfated N-resulfated heparin. 2-O- and 6-O-sulfated Octa-I were prepared by enzymatically transferring one to three 2-O- sulfate groups and one to three 6-O-sulfate groups per molecule, respectively, to Octa-I. Another octasaccharide containing 3 units of HexA(2SO(4))-GlcNSO(3)(6SO(4)) was prepared also from heparin. This octasaccharide library was subjected to affinity chromatography for interactions with fibroblast growth factor (FGF)-2, -4, -7, -8, -10, and -18, hepatocyte growth factor, bone morphogenetic protein 6, and vascular endothelial growth factor, respectively. Based upon differences in the affinity to those octasaccharides, the growth factors could be classified roughly into five groups: group 1 needed 2-O-sulfate but not 6-O-sulfate (FGF-2); group 2 needed 6-O-sulfate but not 2-O-sulfate (FGF-10); group 3 had the affinity to both 2-O-sulfate and 6-O-sulfate but preferred 2-O-sulfate (FGF-18, hepatocyte growth factor); group 4 required both 2-O-sulfate and 6-O-sulfate (FGF-4, FGF-7); and group 5 hardly bound to any octasaccharides (FGF-8, bone morphogenetic protein 6, and vascular endothelial growth factor). The approach using the oligosaccharide library may be useful to define specific structures required for binding to various heparin-binding proteins. Octasaccharides with the high affinity to FGF-2 and FGF-10 had the activity to release them, respectively, from their complexes with HS. Thus, the library may provide new reagents to specifically regulate bindings of the growth factors to HS.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genet Biochem, Kyoto 6068501, Japan; Univ Calif Davis, Sch Med, Ctr Tissue Regenerat & Repair, Sacramento, CA 95817 USA	Aichi Medical University; Seikagaku Corporation; Kyoto University; University of California System; University of California Davis	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	kimata@aichi-med-u.ac.jp						Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Deakin JA, 1999, J CELL SCI, V112, P1999; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Fujise M, 2001, DEV BIOL, V235, P433, DOI 10.1006/dbio.2001.0290; Fujise M, 2003, DEVELOPMENT, V130, P1515, DOI 10.1242/dev.00379; Grisaru S, 2001, DEV BIOL, V231, P31, DOI 10.1006/dbio.2000.0127; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HajMohammadi S, 2003, J CLIN INVEST, V111, P989, DOI 10.1172/JCI200315809; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; Lietha D, 2001, EMBO J, V20, P5543, DOI 10.1093/emboj/20.20.5543; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Loo BM, 2002, J BIOL CHEM, V277, P32616, DOI 10.1074/jbc.M204961200; Luo YD, 1998, BIOCHEMISTRY-US, V37, P16506, DOI 10.1021/bi9816599; LYON M, 1994, J BIOL CHEM, V269, P11216; Ohkawara B, 2002, CURR BIOL, V12, P205, DOI 10.1016/S0960-9822(01)00684-4; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Raman R, 2003, P NATL ACAD SCI USA, V100, P2357, DOI 10.1073/pnas.0437842100; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	49	239	249	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12346	12354		10.1074/jbc.M313523200	http://dx.doi.org/10.1074/jbc.M313523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707131	hybrid			2022-12-25	WOS:000220334900042
J	Canto, C; Suarez, E; Lizcano, JM; Grino, E; Shepherd, PR; Fryer, LGD; Carling, D; Bertran, J; Palacin, M; Zorzano, A; Guma, A				Canto, C; Suarez, E; Lizcano, JM; Grino, E; Shepherd, PR; Fryer, LGD; Carling, D; Bertran, J; Palacin, M; Zorzano, A; Guma, A			Neuregulin signaling on glucose transport in muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR GENE-EXPRESSION; SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; MAP KINASE; NEUROMUSCULAR-JUNCTION; GLUT4 TRANSLOCATION; INSULIN STIMULATION; GROWTH-FACTORS	Neuregulin-1, a growth factor that potentiates myogenesis induces glucose transport through translocation of glucose transporters, in an additive manner to insulin, in muscle cells. In this study, we examined the signaling pathway required for a recombinant active neuregulin-1 isoform (rhHeregulin-beta(1), 177-244, HRG) to stimulate glucose uptake in L6E9 myotubes. The stimulatory effect of HRG required binding to ErbB3 in L6E9 myotubes. PI3K activity is required for HRG action in both muscle cells and tissue. In L6E9 myotubes, HRG stimulated PKBalpha, PKBgamma, and PKCzeta activities. TPCK, an inhibitor of PDK1, abolished both HRG- and insulin-induced glucose transport. To assess whether PKB was necessary for the effects of HRG on glucose uptake, cells were infected with adenoviruses encoding dominant negative mutants of PKBalpha. Dominant negative PKB reduced PKB activity and insulin-stimulated glucose transport but not HRG- induced glucose transport. In contrast, transduction of L6E9 myotubes with adenoviruses encoding a dominant negative kinase-inactive PKCzeta abolished both HRG- and insulin-stimulated glucose uptake. In soleus muscle, HRG induced PKCzeta, but not PKB phosphorylation. HRG also stimulated the activity of p70S6K, p38MAPK, and p42/p44MAPK and inhibition of p42/p44MAPK partially repressed HRG action on glucose uptake. HRG did not affect AMPKalpha(1) or AMPKalpha(2) activities. In all, HRG stimulated glucose transport in muscle cells by activation of a pathway that requires PI3K, PDK1, and PKCzeta, but not PKB, and that shows cross-talk with the MAPK pathway. The PI3K, PDK1, and PKCzeta pathway can be considered as an alternative mechanism, independent of insulin, to induce glucose uptake.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Barcelona, Parc Cient Barcelona, E-08028 Barcelona, Spain; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland; UCL, Dept Biochem, London WC1E 6BT, England; Hammersmith Hosp, Imperial Coll Med, Sch Med, MRC,Clin Sci Ctr,Cellular Stress Grp, London W12 0NN, England	University of Barcelona; University of Barcelona; University of Dundee; University of London; University College London; Imperial College London	Zorzano, A (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.	azorzano@bio.ub.es	Lizcano, Jose M/E-6080-2010; Zorzano, Antonio/R-5479-2018; Gumà, Anna/C-5165-2017; lizcano, jose m/AAK-3577-2020; Bertran, Joan/AAT-3145-2021; Palacín, Manuel/G-9786-2015; Carling, David/F-1943-2014	Lizcano, Jose M/0000-0002-3154-5383; Gumà, Anna/0000-0001-9390-5252; lizcano, jose m/0000-0002-3154-5383; Bertran, Joan/0000-0002-4276-336X; Carling, David/0000-0002-2316-1830; Canto, Carles/0000-0002-5167-7922; Palacin, Manuel/0000-0002-8670-293X	Medical Research Council [MC_U120027537] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Ballif BA, 2001, J BIOL CHEM, V276, P12466, DOI 10.1074/jbc.M009939200; Bandyopadhyay G, 2002, J CLIN ENDOCR METAB, V87, P716, DOI 10.1210/jc.87.2.716; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Baynes KCR, 2000, DIABETOLOGIA, V43, P321, DOI 10.1007/s001250050050; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167; Goldshmit Y, 2001, J BIOL CHEM, V276, P46379, DOI 10.1074/jbc.M105637200; GOODEARL ADJ, 1993, J BIOL CHEM, V268, P18095; HAN AH, 2002, DIABETOLOGIA, V45, P1475; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; HELLYER NJ, 1995, GENE, V165, P279, DOI 10.1016/0378-1119(95)00436-A; Hill MM, 1999, MOL CELL BIOL, V19, P7771; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KALIMAN P, 1995, BIOCHEM J, V312, P471, DOI 10.1042/bj3120471; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lebrasseur NK, 2003, AM J PHYSIOL-CELL PH, V284, pC1149, DOI 10.1152/ajpcell.00487.2002; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTE BM, 1995, ONCOGENE, V10, P167; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Rimer M, 1998, MOL CELL NEUROSCI, V12, P1, DOI 10.1006/mcne.1998.0695; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Suarez E, 2001, J BIOL CHEM, V276, P18257, DOI 10.1074/jbc.M008100200; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Talukder AH, 2000, CANCER RES, V60, P474; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; Trinidad JC, 2000, J NEUROSCI, V20, P8762; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Wojtaszewski JFP, 1999, AM J PHYSIOL-ENDOC M, V277, pE724, DOI 10.1152/ajpendo.1999.277.4.E724; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x; Zorzano A, 2003, CELL SIGNAL, V15, P141, DOI 10.1016/S0898-6568(02)00081-5	62	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12260	12268		10.1074/jbc.M308554200	http://dx.doi.org/10.1074/jbc.M308554200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711829	hybrid			2022-12-25	WOS:000220334900032
J	Hoppins, SC; Nargang, FE				Hoppins, SC; Nargang, FE			The Tim8-Tim13 complex of Neurospora crassa functions in the assembly of proteins into both mitochondrial membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; DEAFNESS DYSTONIA SYNDROME; PERIPLASMIC CHAPERONE SKP; INNER MEMBRANE; OUTER-MEMBRANE; INTERMEMBRANE SPACE; ESCHERICHIA-COLI; ADP/ATP CARRIER; TOM COMPLEX; MEDIATES INSERTION	The Tim8 and Tim13 proteins in yeast are known to exist in the mitochondrial intermembrane space and to form a hetero-oligomeric complex involved in the import of the mitochondrial inner membrane protein Tim23, the central component of the TIM23 translocase. Here, we have isolated tim8 and tim13 mutants in Neurospora crassa and have shown that mitochondria lacking the Tim8-Tim13 complex were deficient in the import of the outer membrane beta-barrel proteins Tom40 and porin. Cross-linking studies showed that the Tom40 precursor contacts the Tim8-Tim13 complex. The complex is involved at an early point in the Tom40 assembly pathway because cross-links can only be detected during the initial stages of Tom40 import. In mitochondria lacking the Tim8-Tim13 complex, the Tom40 precursor appears in a previously characterized early intermediate of Tom40 assembly more slowly than in wild type mitochondria. Thus, our data suggest a model in which one of the first steps in Tom40 assembly may be interaction with the Tim8-Tim13 complex. As in yeast, the N. crassa Tim23 precursor was imported inefficiently into mitochondria lacking the Tim8-Tim13 complex when the membrane potential was reduced. Tim23 import intermediates could also be cross-linked to the complex, suggesting a dual role for the Tim8-Tim13 intermembrane space complex in the import of proteins found in both the outer and inner mitochondrial membranes.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Nargang, FE (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.	frank.nargang@ualberta.ca	Nargang, Frank/A-2669-2014	Nargang, Frank/0000-0002-1383-4720				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; AUSUBEL RA, 1992, CURRENT PROTOCOLS MO; Bauer MF, 2001, J INHERIT METAB DIS, V24, P166, DOI 10.1023/A:1010314900814; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; Binder J, 2003, BRAIN, V126, P1814, DOI 10.1093/brain/awg174; Chen R, 1996, MOL MICROBIOL, V19, P1287, DOI 10.1111/j.1365-2958.1996.tb02473.x; Curran SP, 2002, J CELL BIOL, V158, P1017, DOI 10.1083/jcb.200205124; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Davis AJ, 1998, MOL BIOL CELL, V9, P2577, DOI 10.1091/mbc.9.9.2577; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; de Cock H, 1999, EUR J BIOCHEM, V259, P96, DOI 10.1046/j.1432-1327.1999.00010.x; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Harms N, 2001, J BIOL CHEM, V276, P18804, DOI 10.1074/jbc.M011194200; Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200; Jensen RE, 2002, BBA-MOL CELL RES, V1592, P25, DOI 10.1016/S0167-4889(02)00261-6; Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177; Kaldi K, 1998, EMBO J, V17, P1569, DOI 10.1093/emboj/17.6.1569; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Koehler CM, 2000, MOL CELL BIOL, V20, P1187, DOI 10.1128/MCB.20.4.1187-1193.2000; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rehling P, 2003, J MOL BIOL, V326, P639, DOI 10.1016/S0022-2836(02)01440-7; Rizzitello AE, 2001, J BACTERIOL, V183, P6794, DOI 10.1128/JB.183.23.6794-6800.2001; Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477; Rothbauer U, 2001, J BIOL CHEM, V276, P37327, DOI 10.1074/jbc.M105313200; Schafer U, 1999, J BIOL CHEM, V274, P24567, DOI 10.1074/jbc.274.35.24567; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; Taylor RD, 2003, J BIOL CHEM, V278, P765, DOI 10.1074/jbc.M208083200; TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257; VASILJEV A, 2003, MOL BIOL CELL    DEC; Vial S, 2002, J BIOL CHEM, V277, P36100, DOI 10.1074/jbc.M202310200; Wendland J., 1996, FUNGAL GENETICS REPO, V43, P54; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951	54	137	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12396	12405		10.1074/jbc.M313037200	http://dx.doi.org/10.1074/jbc.M313037200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722057	hybrid			2022-12-25	WOS:000220334900048
J	Wakabayashi, H; Freas, J; Zhou, Q; Fay, PJ				Wakabayashi, H; Freas, J; Zhou, Q; Fay, PJ			Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-VIII; A2 SUBUNIT; CALCIUM-BINDING; COPPER IONS; LIGHT-CHAIN; FACTOR IXA; FACTOR VA; IDENTIFICATION; CLEAVAGE; RECONSTITUTION	Generation of factor VIII cofactor activity requires divalent metal ions such as Ca2+ or Mn2+. Evaluation of cofactor reconstitution from isolated factor VIIIa subunits revealed the presence of a functional Ca2+ binding site within the A1 subunit. Isothermal titration calorimetry demonstrated at least two Ca2+ binding sites of similar affinity (K-d=0.74 muM) within the A1 subunit. Mutagenesis of an acidic residue-rich region in the A1 domain (residues 110-126) homologous to a putative Ca2+ binding site in factor V (Zeibdawi, A. R., and Pryzdial, E. L. (2001) J. Biol. Chem. 276, 19929-19936) and expression of B-domainless factor VIII molecules yielded reagents to probe Ca2+ and Mn2+ binding in a functional assay. Basal activity observed for wild type factor VIII in a metal ion-free buffer was enhanced similar to2-fold with saturating Ca2+ or Mn2+ and yielded functional K-d values of 1.2 and 1.40 muM, respectively. Ca2+ binding affinity was greatly reduced (or lost) in several mutants including E110A, E110D, D116A, E122A, D125A, and D126A. Alternatively, E113A, D115A, and E124A showed wild type-like activity with little or no reduction in Ca2+ affinity. However, Mn2+ affinity was minimally altered except for mutant D125A (and D116A). These results are consistent with region 110-126 serving a critical role for Ca2+ coordination with selected residues capable of contributing to a partially overlapping site for Mn2+, and that occupancy of either site is required for maximal cofactor activity.	Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, POB 712,601 Elmwood Ave, Rochester, NY 14642 USA.	philip_fay@urmc.rochester.edu			NHLBI NIH HHS [HL 30616, HL 38199] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ababou A, 2001, BIOCHEMISTRY-US, V40, P12719, DOI 10.1021/bi010405b; Anderson PJ, 1997, BIOCHEMISTRY-US, V36, P11648, DOI 10.1021/bi9709598; ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; Bajaj SP, 2001, J BIOL CHEM, V276, P16302, DOI 10.1074/jbc.M011680200; Bertini I., 2001, HDB METALLOPROTEINS; BIHOREAU N, 1994, EUR J BIOCHEM, V222, P41, DOI 10.1111/j.1432-1033.1994.tb18839.x; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; DAVIS J, 1995, COURTS COMMUNITIES C, V1, P6; ESMON CT, 1979, J BIOL CHEM, V254, P964; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; Fay PJ, 1999, J BIOL CHEM, V274, P15401, DOI 10.1074/jbc.274.22.15401; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Jenkins PV, 2002, BLOOD, V100, P501, DOI 10.1182/blood-2001-12-0361; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; Lollar P, 1995, ADV EXP MED BIOL, V386, P3; MEANS AR, 1995, ADV 2 MESSENGER PHOS, V30, P89; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; NORDFANG O, 1988, J BIOL CHEM, V263, P1115; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Rosenblum MEK, 2002, J BIOL CHEM, V277, P11664, DOI 10.1074/jbc.M200037200; Stoilova-McPhie S, 2002, BLOOD, V99, P1215, DOI 10.1182/blood.V99.4.1215; Sudhakar K, 1998, BIOCHEMISTRY-US, V37, P6874, DOI 10.1021/bi980084c; Tagliavacca L, 1997, J BIOL CHEM, V272, P27428, DOI 10.1074/jbc.272.43.27428; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TRIGOGONZALEZ G, 1993, BIOCHEMISTRY-US, V32, P9826, DOI 10.1021/bi00088a038; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Wakabayashi H, 2001, BIOCHEMISTRY-US, V40, P10293, DOI 10.1021/bi010353q; Wakabayashi H, 2003, BIOCHEMISTRY-US, V42, P145, DOI 10.1021/bi026430e; Wakabayashi H, 2002, BIOCHEMISTRY-US, V41, P8485, DOI 10.1021/bi025589o; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; Zeibdawi AR, 2004, BIOCHEM J, V377, P141, DOI 10.1042/BJ20031205; Zeibdawi AR, 2001, J BIOL CHEM, V276, P19929, DOI 10.1074/jbc.M004711200	41	44	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12677	12684		10.1074/jbc.M311042200	http://dx.doi.org/10.1074/jbc.M311042200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722121	hybrid			2022-12-25	WOS:000220334900081
J	Caviglia, JM; Li, LO; Wang, SL; DiRusso, CC; Coleman, RA; Lewin, TM				Caviglia, JM; Li, LO; Wang, SL; DiRusso, CC; Coleman, RA; Lewin, TM			Rat long chain acyl-CoA synthetase 5, but not 1, 2, 3, or 4, complements Escherichia coli fadD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID TRANSPORT; PROTEIN N-MYRISTOYLATION; COENZYME-A SYNTHETASE; SACCHAROMYCES-CEREVISIAE; SIGNATURE MOTIF; PLASMA-MEMBRANE; TRIACSIN-C; EXPRESSION; GENE; METABOLISM	Long chain fatty acids are converted to acyl-CoAs by acyl-CoA synthetase ( fatty acid CoA ligase: AMP forming, E. C. 6.2.1.3; ACS). Escherichia coli has a single ACS, FadD, that is essential for growth when fatty acids are the sole carbon and energy source. Rodents have five ACS isoforms that differ in substrate specificity, tissue expression, and subcellular localization and are believed to channel fatty acids toward distinct metabolic pathways. We expressed rat ACS isoforms 1 - 5 in an E. coli strain that lacked FadD. All rat ACS isoforms were expressed in E. coli fadD or fadDfadR and had ACS specific activities that were 1.6-20-fold higher than the wild type control strain expressing FadD. In the fadD background, the rat ACS isoforms 1, 2, 3, 4 and 5 oxidized [C-14] oleate at 5 to 25% of the wild type levels, but only ACS5 restored growth on oleate as the sole carbon source. To ensure that enzymes of beta-oxidation were not limiting, assays of ACS activity, beta-oxidation, fatty acid transport, and phospholipid synthesis were also examined in a fadD fadR strain, thereby eliminating FadR repression of the transporter FadL and the enzymes of beta-oxidation. In this strain, fatty acid transport levels were low but detectable for ACS1, 2, 3, and 4 and were nearly 50% of wild type levels for ACS5. Despite increases in beta-oxidation, only ACS5 transformants were able to grow on oleate. These studies show that although ACS isoforms 1 - 4 variably supported moderate transport activity, beta-oxidation, and phospholipid synthesis and although their in vitro specific activities were greater than that of chromosomally encoded FadD, they were unable to substitute functionally for FadD regarding growth. Thus, membrane composition and protein-protein interactions may be critical in reconstituting bacterial ACS function.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Ordway Res Inst Inc, Albany, NY 12208 USA	University of North Carolina; University of North Carolina Chapel Hill; Ordway Research Institute	Lewin, TM (corresponding author), Univ N Carolina, Dept Nutr, CB 7461, Chapel Hill, NC 27599 USA.	tal_lewin@unc.edu	DiRusso, Concetta C/M-1884-2014; Li, Lei/B-5164-2010	DiRusso, Concetta/0000-0001-7388-9152	NIDDK NIH HHS [DK59935, DK59931] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059931, R01DK059935] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIS RJ, 1974, BIOCHIM BIOPHYS ACTA, V348, P210, DOI 10.1016/0005-2760(74)90232-X; Basu-Modak S, 1999, J BIOL CHEM, V274, P35881, DOI 10.1074/jbc.274.50.35881; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cho YY, 2000, BIOCHEM BIOPH RES CO, V274, P741, DOI 10.1006/bbrc.2000.3207; Cho YY, 2001, BIOCHEM BIOPH RES CO, V284, P993, DOI 10.1006/bbrc.2001.5065; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; COLEMAN RA, 1983, ENZYMES, V16, P605; DiRusso CC, 1999, PROG LIPID RES, V38, P129, DOI 10.1016/S0163-7827(98)00022-8; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DIRUSSO CC, 1985, J BACTERIOL, V161, P583, DOI 10.1128/JB.161.2.583-588.1985; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; Fulgencio JP, 1996, DIABETES, V45, P1556, DOI 10.2337/diabetes.45.11.1556; Gargiulo CE, 1999, J LIPID RES, V40, P881; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; JOHNSON DR, 1994, J BIOL CHEM, V269, P18037; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; Kansara MS, 1996, AM J PHYSIOL-ENDOC M, V270, pE873, DOI 10.1152/ajpendo.1996.270.5.E873; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KUMAR GB, 1991, J BIOL CHEM, V266, P1348; LERAY C, 1987, J CHROMATOGR-BIOMED, V420, P411, DOI 10.1016/0378-4347(87)80198-6; Lewin TM, 2002, ARCH BIOCHEM BIOPHYS, V404, P263, DOI 10.1016/S0003-9861(02)00247-3; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Longo I, 2003, J MED GENET, V40, P11, DOI 10.1136/jmg.40.1.11; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALOY SR, 1981, J BIOL CHEM, V256, P3735; MANGROO D, 1993, BIOCHEM CELL BIOL, V71, P51, DOI 10.1139/o93-008; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Meloni I, 2002, NAT GENET, V30, P436, DOI 10.1038/ng857; Miller J. H., 1972, EXPT MOL GENETICS, P431; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; OVERATH P, 1967, BIOCHEM BIOPH RES CO, V29, P28, DOI 10.1016/0006-291X(67)90535-9; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; ROCK CO, 1985, J BIOL CHEM, V260, P2720; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Weimar JD, 2002, J BIOL CHEM, V277, P29369, DOI 10.1074/jbc.M107022200; WU XJ, 1994, J BIOL CHEM, V269, P12375	46	22	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11163	11169		10.1074/jbc.M311392200	http://dx.doi.org/10.1074/jbc.M311392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711823	Green Published, hybrid			2022-12-25	WOS:000220157600041
J	Hazra, S; Xiong, SG; Wang, JH; Rippe, RA; Chatterjee, VKK; Tsukamoto, H				Hazra, S; Xiong, SG; Wang, JH; Rippe, RA; Chatterjee, VKK; Tsukamoto, H			Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SMOOTH-MUSCLE CELLS; NF-KAPPA-B; PPAR-GAMMA; RAT-LIVER; DNA-BINDING; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; TISSUE INHIBITOR; EXPRESSION	Depletion of peroxisome proliferator-activated receptor gamma (PPARgamma) accompanies myofibroblastic transdifferentiation of hepatic stellate cells (HSC), the primary cellular event underlying liver fibrogenesis. The treatment of activated HSC in vitro or in vivo with synthetic PPARgamma ligands suppresses the fibrogenic activity of HSC. However, it is uncertain whether PPARgamma is indeed a molecular target of this effect, because the ligands are also known to have receptor-independent actions. To test this question, the present study examined the effects of forced expression of PPARgamma via an adenoviral vector on morphologic and biochemical features of culture-activated HSC. The vector-mediated expression of PPARgamma itself is sufficient to reverse the morphology of activated HSC to the quiescent phenotype with retracted cytoplasm, prominent dendritic processes, reduced stress fibers, and accumulation of retinyl palmitate. These effects are abrogated by concomitant expression of a dominant negative mutant of PPARgamma that prevents transactivation of but not binding to the PPAR response element. PPARgamma expression also inhibits the activation markers such as the expression of alpha-smooth muscle actin, type I collagen, and transforming growth factor beta1; DNA synthesis; and JunD binding to the activator protein-1 (AP-1) site and AP-1 promoter activity. Inhibited JunD activity by PPARgamma is not due to reduced JunD expression or JNK activity or to a competition for p300. But it is due to a JunD-PPARgamma interaction as demonstrated by co-immunoprecipitation and glutathione S-transferase pull-down analysis. Further, the use of deletion constructs reveals that the DNA binding region of PPARgamma is the JunD interaction domain. In summary, our results demonstrate that the restoration of PPARgamma reverses the activated HSC to the quiescent phenotype and suppresses AP-1 activity via a physical interaction between PPARgamma and JunD.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Dept Vet Affairs Greater Los Angeles Healthcare S, Los Angeles, CA 90073 USA	University of Southern California; University of North Carolina; University of North Carolina Chapel Hill; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Tsukamoto, H (corresponding author), Univ So Calif, Keck Sch Med, 1333 San Pablo St,MMR-402, Los Angeles, CA 90089 USA.	htsukamo@usc.edu		Chatterjee, Vengalil Krishna/0000-0002-2654-8854	NIAAA NIH HHS [R37AA06603, R24AA12885, P50AA11999] Funding Source: Medline; NIDDK NIH HHS [P30DK48522] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R24AA012885, P50AA011999, R37AA006603] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Baek SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; BHAT PV, 1983, J CHROMATOGR, V272, P269, DOI 10.1016/S0378-4347(00)86129-0; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Buck M, 2000, AM J PHYSIOL-GASTR L, V278, pG321, DOI 10.1152/ajpgi.2000.278.2.G321; Cassiman D, 1999, AM J PATHOL, V155, P1831, DOI 10.1016/S0002-9440(10)65501-0; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; FRIEDMAN SL, 1993, AM J PHYSIOL, V264, pG947, DOI 10.1152/ajpgi.1993.264.5.G947; Fu MG, 2001, J BIOL CHEM, V276, P45888, DOI 10.1074/jbc.M105490200; Galli A, 2002, GASTROENTEROLOGY, V122, P1924, DOI 10.1053/gast.2002.33666; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; GRESSNER AM, 1990, SEMIN LIVER DIS, V10, P30, DOI 10.1055/s-2008-1040455; Gressner AM, 1996, KIDNEY INT, V49, pS39; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hautekeete ML, 1997, VIRCHOWS ARCH, V430, P195, DOI 10.1007/BF01324802; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Knittel T, 1999, AM J PATHOL, V154, P153, DOI 10.1016/S0002-9440(10)65262-5; Kojima S, 2000, BLOOD, V95, P1309; Lang A, 2000, J HEPATOL, V33, P49, DOI 10.1016/S0168-8278(00)80159-2; Lennon AM, 2002, J BIOL CHEM, V277, P29681, DOI 10.1074/jbc.M201517200; Mann DA, 2002, GUT, V50, P891, DOI 10.1136/gut.50.6.891; Marra F, 2000, GASTROENTEROLOGY, V119, P466, DOI 10.1053/gast.2000.9365; Miyahara T, 2000, J BIOL CHEM, V275, P35715, DOI 10.1074/jbc.M006577200; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; Neubauer K, 1996, J HEPATOL, V24, P719, DOI 10.1016/S0168-8278(96)80269-8; Niki T, 1999, HEPATOLOGY, V29, P520, DOI 10.1002/hep.510290232; Ohata M, 1997, AM J PHYSIOL-GASTR L, V272, pG589, DOI 10.1152/ajpgi.1997.272.3.G589; Potter JJ, 1998, BIOCHEM BIOPH RES CO, V244, P178, DOI 10.1006/bbrc.1997.8193; Saile B, 1999, HEPATOLOGY, V30, P196, DOI 10.1002/hep.510300144; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; Saxena NK, 2002, HEPATOLOGY, V35, P762, DOI 10.1053/jhep.2002.32029; Smart DE, 2001, J BIOL CHEM, V276, P24414, DOI 10.1074/jbc.M101840200; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Sugawara A, 2002, J BIOL CHEM, V277, P9676, DOI 10.1074/jbc.M104560200; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; Vincent KJ, 2001, GUT, V49, P713, DOI 10.1136/gut.49.5.713; Xiong SG, 2001, HEPATOLOGY, V34, p520A; YAMADA M, 1987, HEPATOLOGY, V7, P1224, DOI 10.1002/hep.1840070609	44	251	265	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11392	11401		10.1074/jbc.M310284200	http://dx.doi.org/10.1074/jbc.M310284200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702344	Green Published, hybrid			2022-12-25	WOS:000220157600069
J	Mueller, TD; Kamionka, M; Feigon, J				Mueller, TD; Kamionka, M; Feigon, J			Specificity of the interaction between ubiquitin-associated domains and ubiquitin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR PROTEIN HHR23A; DNA-REPAIR; SUBUNIT S5A; CUE DOMAIN; POLYUBIQUITIN CHAINS; MULTIUBIQUITIN CHAIN; 20S PROTEASOME; 26S PROTEASOME; UBA DOMAINS; HIV-1 VPR	Ubiquitin-associated (UBA) domains are found in a large number of proteins with diverse functions involved in ubiquitination, DNA repair, and signaling pathways. Recent studies have shown that several UBA domain proteins interact with ubiquitin (Ub), specifically p62, the phosphotyrosine-independent ligand of the SH2 domain of p56(lck); HHR23A, a human nucleotide excision repair protein; and DDI1, another damage-inducible protein. NMR chemical shift mapping reveals that Ub binds specifically but weakly to a conserved hydrophobic epitope on HHR23A UBA( 1) and UBA( 2) and that the UBA domains bind on the hydrophobic patch on the surface of the five-stranded beta-sheet of Ub. Models of the UBA( 1)-Ub and UBA(2)-Ub complexes obtained from de novo docking reveal different orientations of the UBA domains on the Ub surface compared with those obtained by homology modeling with the related CUE domains, which also bind Ub. Our results suggest that UBA domains may interact with Ub as well as other proteins in more than one way while utilizing the same binding surface.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Feigon, J (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave,POB 951569, Los Angeles, CA 90095 USA.	feigon@mbi.ucla.edu		Mueller, Thomas/0000-0003-1862-7357	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043190] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43190] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; CHEN L, 2001, EMBO REP, V24, P24; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Glickman MH, 1999, MOL BIOL REP, V26, P21, DOI 10.1023/A:1006928316738; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Madura K, 2002, CELL CYCLE, V1, P233, DOI 10.4161/cc.1.4.130; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; Medek A, 2000, J AM CHEM SOC, V122, P1241, DOI 10.1021/ja993921m; Miao F, 2000, J BIOL CHEM, V275, P28433, DOI 10.1074/jbc.M001064200; Mueller TD, 2003, EMBO J, V22, P4634, DOI 10.1093/emboj/cdg467; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Phillips CL, 2001, ACTA CRYSTALLOGR D, V57, P341, DOI 10.1107/S090744490001800X; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Suzuki T, 2001, J BIOL CHEM, V276, P21601, DOI 10.1074/jbc.M100826200; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; VONARNIM AG, 2001, SCI STKE, pE2; Walters KJ, 2003, P NATL ACAD SCI USA, V100, P12694, DOI 10.1073/pnas.1634989100; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Withers-Ward ES, 2000, BIOCHEMISTRY-US, V39, P14103, DOI 10.1021/bi0017071; WithersWard ES, 1997, J VIROL, V71, P9732, DOI 10.1128/JVI.71.12.9732-9742.1997; Zhu QZ, 2001, CANCER RES, V61, P64	60	89	91	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11926	11936		10.1074/jbc.M312865200	http://dx.doi.org/10.1074/jbc.M312865200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707125	hybrid			2022-12-25	WOS:000220157600130
J	Robu, ME; Inman, RB; Cox, MM				Robu, ME; Inman, RB; Cox, MM			Situational repair of replication forks - Roles of RecG and RecA proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECG; DOUBLE-STRAND BREAKS; HOLLIDAY JUNCTIONS; BRANCH MIGRATION; PARTIAL DENATURATION; NUCLEOTIDE-SEQUENCE; ADAPTIVE MUTATION; ATP HYDROLYSIS; DNA-REPAIR; RECOMBINATION	Replication forks often stall or collapse when they encounter a DNA lesion. Fork regression is part of several major paths to the repair of stalled forks, allowing nonmutagenic bypass of the lesion. We have shown previously that Escherichia coli RecA protein can promote extensive regression of a forked DNA substrate that mimics a possible structure of a replication fork stalled at a leading strand lesion. Using electron microscopy and gel electrophoresis, we demonstrate that another protein, E. coli RecG helicase, promotes extensive fork regression in the same system. The RecG-catalyzed fork regression is very efficient and faster than the RecA-promoted reaction (up to 240 bp s(-1)), despite very limited processivity of the RecG protein. The reaction is dependent upon ATP hydrolysis and is stimulated by single-stranded binding protein. The RecA- and RecG-promoted reactions are not synergistic. In fact, RecG functions poorly under the conditions optimal for the RecA reaction, and vice versa. When both RecA and RecG proteins are incubated with the DNA substrate, high RecG concentrations inhibit the RecA protein-promoted fork regression. The very different reaction profiles may reflect a situational application of these proteins to the rescue of stalled replication forks in vivo.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; Bolt EL, 2002, MOL CELL, V10, P187, DOI 10.1016/S1097-2765(02)00560-9; Chatterji D, 2001, CURR OPIN MICROBIOL, V4, P160, DOI 10.1016/S1369-5274(00)00182-X; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; EDLHOCH H, 1948, BIOCHEMISTRY-US, V6, P1948; Foster PL, 1996, GENETICS, V142, P25; Fukuoh A, 1997, EMBO J, V16, P203, DOI 10.1093/emboj/16.1.203; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; Harris RS, 1996, GENETICS, V142, P681; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; Higuchi K, 2003, GENES CELLS, V8, P437, DOI 10.1046/j.1365-2443.2003.00646.x; HONG XK, 1995, EMBO J, V14, P2385, DOI 10.1002/j.1460-2075.1995.tb07233.x; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; Jaktaji RP, 2003, MOL MICROBIOL, V47, P1091, DOI 10.1046/j.1365-2958.2003.03357.x; KALMAN M, 1992, GENE, V110, P95, DOI 10.1016/0378-1119(92)90449-Y; Layton JC, 2003, MOL MICROBIOL, V50, P549, DOI 10.1046/j.1365-2958.2003.03704.x; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LLOYD RG, 1991, J BACTERIOL, V173, P6837, DOI 10.1128/jb.173.21.6837-6843.1991; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1991, J BACTERIOL, V173, P1004, DOI 10.1128/jb.173.3.1004-1011.1991; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; Mahdi AA, 2003, EMBO J, V22, P724, DOI 10.1093/emboj/cdg043; Maisnier-Patin S, 2001, MOL MICROBIOL, V42, P1371, DOI 10.1046/j.1365-2958.2001.02718.x; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; McGlynn P, 2000, NUCLEIC ACIDS RES, V28, P2324, DOI 10.1093/nar/28.12.2324; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; McGlynn P, 2002, TRENDS GENET, V18, P413, DOI 10.1016/S0168-9525(02)02720-8; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; McGlynn P, 2001, J BIOL CHEM, V276, P41938, DOI 10.1074/jbc.M107945200; McKenzie GJ, 2000, P NATL ACAD SCI USA, V97, P6646, DOI 10.1073/pnas.120161797; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; PHILLIPS RC, 1966, J AM CHEM SOC, V88, P2631, DOI 10.1021/ja00964a002; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; Seigneur M, 2000, MOL MICROBIOL, V38, P565, DOI 10.1046/j.1365-2958.2000.02152.x; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; SMITH KC, 1989, BIOESSAYS, V10, P12, DOI 10.1002/bies.950100104; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; WHITBY MC, 1995, EMBO J, V14, P3302, DOI 10.1002/j.1460-2075.1995.tb07337.x; Whitby MC, 1998, J BIOL CHEM, V273, P19729, DOI 10.1074/jbc.273.31.19729; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x; XIAO H, 1991, J BIOL CHEM, V266, P5980	63	49	51	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10973	10981		10.1074/jbc.M312184200	http://dx.doi.org/10.1074/jbc.M312184200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701860	hybrid			2022-12-25	WOS:000220157600019
J	Yung, TMC; Parent, M; Ho, ELY; Satoh, MS				Yung, TMC; Parent, M; Ho, ELY; Satoh, MS			Camptothecin-sensitive relaxation of supercoiled DNA by the topoisomerase I-like activity associated with poly(ADP-ribose) polymerase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGASE-III; AUTOMODIFICATION DOMAIN; APOPTOTIC FRAGMENT; CELLULAR-RESPONSES; EXCISION-REPAIR; ADP-RIBOSE; TRANSCRIPTION; DAMAGE; CELLS; IDENTIFICATION	Poly( ADP-ribose) polymerase-1 is a highly abundant nuclear enzyme implicated in transcription, DNA replication, and DNA repair through binding of nascent RNA and interactions with various factors. We found that purified fractions of recombinant human poly(ADP-ribose) polymerase-1 expressed in Escherichia coli possess yet another activity, a Mg2+-dependent DNA super-coil relaxation activity. Cleavage of recombinant poly(ADP-ribose) polymerase-1 by caspase-3, an apoptotic protease, reduced this activity, as did the removal of either of the two zinc finger motifs located in the N-terminal DNA-binding domain of poly( ADP-ribose) polymerase-1. In addition, this activity was separated from E. coli topoisomerase I by gel-filtration column chromatography, suggesting that this activity is specifically associated with poly( ADP-ribose) polymerase-1. Because this relaxation activity did not require ATP and was resistant to VP16, a topoisomerase II inhibitor, this activity is closer to that of topoisomerase I. However, the supercoiled DNA relaxation activity associated with poly( ADP-ribose) polymerase-1 is distinct from that of human or E. coli topoisomerase I, as this activity could not completely remove superhelical tensions from plasmid DNA. Thus, we referred to this activity as topoisomerase I-like activity. This Mg2+-dependent DNA supercoil relaxation activity was found to be sensitive to camptothecin, a mammalian topoisomerase I inhibitor.	Univ Laval, Fac Med, Ctr Hosp Univ Quebec,Laval Unv Med Ctr, DNA Repair Grp,Hlth & Environm Unit, Quebec City, PQ G1V 4G2, Canada	Laval University	Satoh, MS (corresponding author), Univ Laval, Fac Med, Ctr Hosp Univ Quebec,Laval Unv Med Ctr, DNA Repair Grp,Hlth & Environm Unit, Quebec City, PQ G1V 4G2, Canada.	Masahiko.sato@crchul.ulaval.ca						Affar EB, 1999, MOL CELL BIOCHEM, V193, P127, DOI 10.1023/A:1006984715891; ALTHAUS FR, 1987, ADP RIBOSYLATION PRO; ATTARDI DG, 1981, J BIOL CHEM, V256, P3654; Bauer PI, 2000, INT J MOL MED, V5, P533; BOOTHMAN DA, 1994, CANCER RES, V54, P4618; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; D'Silva I, 1999, BBA-PROTEIN STRUCT M, V1430, P119, DOI 10.1016/S0167-4838(98)00278-7; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; DARPA P, 1990, CANCER RES, V50, P6919; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; Duriez PJ, 1997, BBA-GEN SUBJECTS, V1334, P65, DOI 10.1016/S0304-4165(96)00077-3; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JONGSTRABILEN J, 1983, EUR J BIOCHEM, V136, P391, DOI 10.1111/j.1432-1033.1983.tb07754.x; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Vispe S, 2000, P NATL ACAD SCI USA, V97, P9886, DOI 10.1073/pnas.170280397; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879; YOSHIDA S, 1994, MOL CELL BIOCHEM, V138, P39, DOI 10.1007/BF00928441; Yung TMC, 2001, J BIOL CHEM, V276, P11279, DOI 10.1074/jbc.M008044200	42	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11992	11999		10.1074/jbc.M312459200	http://dx.doi.org/10.1074/jbc.M312459200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14715657	hybrid			2022-12-25	WOS:000220157600137
J	Ahn, S; Wei, HJ; Garrison, TR; Lefkowitz, RJ				Ahn, S; Wei, HJ; Garrison, TR; Lefkowitz, RJ			Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; CLATHRIN ADAPTER; ENDOCYTOSIS; INTERNALIZATION; SCAFFOLD; TYROSINE; 1A	beta-Arrestin2 not only plays essential roles in seven membrane-spanning receptor desensitization and internalization but also functions as a signal transducer in mitogen-activated protein kinase cascades. Here we show that the angiotensin II type 1A receptor-mediated activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) in HEK-293 cells is increased when the cellular level of beta-arrestin1 is down-regulated by RNA interference but is decreased or eliminated when the cellular level of beta-arrestin2 is diminished. Such reciprocal effects of down-regulated levels of beta-arrestins 1 and 2 are primarily due to differences in the ability of the two forms of beta-arrestins to directly mediate ERK activation. These results are the first to demonstrate reciprocal activity of beta-arrestin isoforms on a signaling pathway and suggest that physiological levels of beta-arrestin1 may act as "dominant-negative" inhibitors of beta-arrestin2-mediated ERK activation.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med & Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [R01 HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Goel R, 2002, ANN NY ACAD SCI, V973, P138, DOI 10.1111/j.1749-6632.2002.tb04622.x; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Holloway AC, 2002, MOL PHARMACOL, V61, P768, DOI 10.1124/mol.61.4.768; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1996, MOL PHARMACOL, V49, P89; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100	30	141	148	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7807	7811		10.1074/jbc.C300443200	http://dx.doi.org/10.1074/jbc.C300443200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14711824	hybrid			2022-12-25	WOS:000189103300055
J	Levchenko, T; Bratt, A; Arbiser, JL; Holmgren, L				Levchenko, T; Bratt, A; Arbiser, JL; Holmgren, L			Angiomotin expression promotes hemangioendothelioma invasion	ONCOGENE			English	Article						angiostatin; angiomotin; angiogenesis; motility	ENDOTHELIAL-CELL MIGRATION; TRACTIONAL FORCES; TUMOR INVASION; ANGIOGENESIS; PROTEIN; PROTEOLYSIS; ANGIOSTATIN; MECHANISMS; GROWTH	Angiomotin was identified by its ability to bind angiostatin and has been shown to mediate its activity in vitro. The family of angiomotin-like protein consists of three members that have coiled-coil domains and conserved c-terminal PDZ-binding motifs. We show here that expression of angiomotin in mouse aortic endothelial (MAE) cells results in stabilization of tubes in the Matrigel assay. Control tubes start to regress after 72 h, whereas MAE-angiomotin ( MAE Amot) tubes were stable for over 30 days. In contrast, cells expressing a functional mutant lacking the PDZ protein interaction motif did not migrate and form tubes. Cells from the established tubes invaded into the solidified matrigel. We therefore tested whether angiomotin promotes endothelial invasion. In microcarrier-based invasion in vitro assay, angiomotin-expressing cells invaded collagen matrix and formed tube-like branches. This was confirmed in vivo as injection of MAE-Amot cells promoted tumor growth and invasion into surrounding muscle tissue. Injection of cells transfected with the functional mutant resulted in establishment of noninvasive tumors surrounded by a capsule of fibrous tissue. These tumors remained in constant size or dormant over 3 weeks. Zymogel analysis of the transfected cells did not reveal any differences in proteolytic activity. However, time-lapse photography showed a significant increase in random motility in MAE-Amot cells. We conclude that angiomotin may promote angiogenesis by both stimulating invasion as well as stabilizing established tubes.	Karolinska Inst, Ctr Canc, Dept Oncol Pathol, S-17176 Stockholm, Sweden; Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA	Karolinska Institutet; Emory University	Holmgren, L (corresponding author), Karolinska Hosp, CCK,R8-03, S-17176 Stockholm, Sweden.	lars.holmgren@cck.ki.se		Tegnebratt, Tetyana/0000-0003-4298-2295	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044947, P30AR042687] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44947, AR42687, AR02030] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; Ballestrem C, 2000, MOL BIOL CELL, V11, P2999, DOI 10.1091/mbc.11.9.2999; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Bratt A, 2002, GENE, V298, P69, DOI 10.1016/S0378-1119(02)00928-9; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; Eriksson K, 2003, FEBS LETT, V536, P19, DOI 10.1016/S0014-5793(03)00003-6; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Holmgren L, 1996, CANCER METAST REV, V15, P241, DOI 10.1007/BF00437478; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x; Levchenko T, 2003, J CELL SCI, V116, P3803, DOI 10.1242/jcs.00694; LIOTTA LA, 1984, AM J PATHOL, V117, P339; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Nyberg P, 2003, J BIOL CHEM, V278, P22404, DOI 10.1074/jbc.M210325200; Parker KK, 2002, FASEB J, V16, DOI 10.1096/fj.02-0038com; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Pintucci Giuseppe, 1996, Seminars in Thrombosis and Hemostasis, V22, P517, DOI 10.1055/s-2007-999054; Serini G, 2003, EMBO J, V22, P1771, DOI 10.1093/emboj/cdg176; Staff AC, 2001, SCAND J CLIN LAB INV, V61, P257, DOI 10.1080/00365510152378978; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; Wang N, 2002, CELL MOTIL CYTOSKEL, V52, P97, DOI 10.1002/cm.10037; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	24	38	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1469	1473		10.1038/sj.onc.1207264	http://dx.doi.org/10.1038/sj.onc.1207264			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14730344				2022-12-25	WOS:000189035800014
J	der-Sarkissian, H; Bacchetti, S; Cazes, L; Londono-Vallejo, JA				der-Sarkissian, H; Bacchetti, S; Cazes, L; Londono-Vallejo, JA			The shortest telomeres drive karyotype evolution in transformed cells	ONCOGENE			English	Article						telomere length heterogeneity; chromosome instability; tumorigenesis	CHROMOSOME INSTABILITY; REPLICATIVE SENESCENCE; LENGTH; IMMORTALIZATION; DYSFUNCTION; CANCER; HETEROGENEITY; DYNAMICS; CRISIS; HUMANS	Maintenance of telomeres is essential for chromosome stability. In the absence of telomerase, telomeres shorten with cell division until they approach a stability threshold, at which point cells enter senescence. When senescence-signaling pathways are inactive, further telomere shortening leads to chromosome instability characterized by telomeric fusions and breakage-fusion-bridge (BFB) cycles. Since the distribution of telomere lengths among chromosome extremities is heterogeneous, we wondered about the impact of such variability on the stability of particular chromosome arms. We correlated the initial length of individual telomeres in telomerase-negative-transformed cells with the stability of the corresponding chromosome arms during the precrisis period. We show that arms carrying the shortest telomeres are the first to become unstable and this instability affects the chromosome homologues with shorter telomeres almost exclusively. The analysis of several postcrisis cell populations, which had stabilized their telomeres by re-expressing telomerase, showed that the karyotypic outcome is strongly influenced by the initial telomere length heterogeneity. The timing of telomerase re-expression also seems to play a role in limiting the extent of karyotypic changes, probably by reducing the frequency of telomeric fusions and hence BFB. Since the distribution of telomere lengths within somatic cells is proper to every individual, our results predict that the risk for a particular chromosome arm of becoming unstable early in tumorigenesis will differ between individuals and contribute directly to the heterogeneity of chromosome aberrations found in tumors.	Ctr Etud Polymorphisme Humain, F-75010 Paris, France; Ist Regina Elena, Lab Oncogenesi Mol, I-00158 Rome, Italy; INSERM, U434, F-75010 Paris, France	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Institut National de la Sante et de la Recherche Medicale (Inserm)	Londono-Vallejo, JA (corresponding author), Ctr Etud Polymorphisme Humain, 27 Rue Julliette Dodu, F-75010 Paris, France.	londono@cephb.fr	Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; CHERIF D, 1993, GENE CHROMOSOME CANC, V6, P107, DOI 10.1002/gcc.2870060207; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Der-Sarkissian H, 2002, GENOME RES, V12, P1673, DOI 10.1101/gr.322802; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; Gisselsson D, 2003, ADV CANCER RES, V87, P1; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Graakjaer J, 2003, MECH AGEING DEV, V124, P629, DOI 10.1016/S0047-6374(03)00081-2; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Henderson S, 1996, J CELL BIOL, V134, P1, DOI 10.1083/jcb.134.1.1; Ishikawa F, 1997, BIOCHEM BIOPH RES CO, V230, P1, DOI 10.1006/bbrc.1996.5928; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Lansdorp PM, 2000, MECH AGEING DEV, V118, P23, DOI 10.1016/S0047-6374(00)00151-2; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Londono-Vallejo JA, 2001, NUCLEIC ACIDS RES, V29, P3164, DOI 10.1093/nar/29.15.3164; Martens UM, 1998, NAT GENET, V18, P76, DOI 10.1038/ng0198-018; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	33	78	80	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1221	1228		10.1038/sj.onc.1207152	http://dx.doi.org/10.1038/sj.onc.1207152			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14716292				2022-12-25	WOS:000188892200006
J	Al Moustafa, AE; Foulkes, WD; Benlimame, N; Wong, A; Yen, L; Bergeron, J; Batist, G; Alpert, L; Alaoui-Jamali, MA				Al Moustafa, AE; Foulkes, WD; Benlimame, N; Wong, A; Yen, L; Bergeron, J; Batist, G; Alpert, L; Alaoui-Jamali, MA			E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells	ONCOGENE			English	Article						ErbB-2; E6/E7 of HPV; oral epithelial cells; transformation	GROWTH-FACTOR RECEPTOR; ADHESION MOLECULE UVOMORULIN; HUMAN-PAPILLOMAVIRUS; BETA-CATENIN; ACTIVATED NEU; E-CADHERIN; CYCLIN D1; CLINICAL-IMPLICATIONS; SIGNALING NETWORK; CANCER	Head and neck squamous cell carcinomas (HNSCC) are characterized by a marked propensity for local invasion and spread to cervical lymph nodes, with distant metastases developing in 30-40% of cases. HPV-16 is an important risk factor for HNSCC. How HPV enhances susceptibility to HNSCC is not fully understood, but seems to involve cofactors. In this study, we examined the effect of the cooperation between HPV-16 and the tyrosine kinase receptor ErbB-2 on E-cadherin/catenin complex patterns and neoplastic transformation of human normal oral epithelial (NOE) cells. We report that overexpression of ErbB-2 or E6/E7 alone does not affect E-cadherin/catenin complex patterns nor does it induce cell transformation of NOE cells. In contrast, coexpression of E6/E7 and ErbB-2 downregulates E-cadherin and catenin expression. This is accompanied by cytoplasmic localization of E-cadherin, as well as nuclear translocation of alpha, beta, and gamma-catenins. Furthermore, we demonstrate that E6/E7 cooperate with overexpressed ErbB-2 to induce tumor formation in nude mice and to upregulate cyclin D1 and c-myc expression. Our data suggest that E6/E7 cooperate with ErbB-2 in head and neck carcinogenesis, at least in part, via the conversion of beta-catenin from a cell adhesion to a nuclear function, that is, to act as a potential transcriptional regulator. This conversion leads to the upregulation of cyclin D1, c-myc and other oncoproteins necessary for alteration of the E-cadherin/catenin complex and cell transformation of NOE cells.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Oncol, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Pathol, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Pharmacol, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Therapeut, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada; McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Oncol, Program Canc Genet, Montreal, PQ, Canada; McGill Univ, Dept Human Genet, Program Canc Genet, Montreal, PQ, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Foulkes, WD (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Room A-803,3755 Chemin Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	william.foulkes@mcgill.ca	Foulkes, William D./AAR-9586-2021	Foulkes, William D./0000-0001-7427-4651				Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Al Moustafa AE, 2002, LUNG CANCER, V37, P49, DOI 10.1016/S0169-5002(02)00025-9; Al Moustafa AE, 1999, CLIN CANCER RES, V5, P681; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eckert RL, 2000, INT J ONCOL, V16, P853; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Franceschi S, 1996, CANCER EPIDEM BIOMAR, V5, P567; Galipeau J, 1999, CANCER RES, V59, P2384; Galloway DA, 1996, SEMIN CANCER BIOL, V7, P309, DOI 10.1006/scbi.1996.0040; Gillison Maura L., 1999, Current Opinion in Oncology, V11, P191, DOI 10.1097/00001622-199905000-00010; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ke LD, 1999, ORAL ONCOL, V35, P415, DOI 10.1016/S1368-8375(99)00015-9; Klapper LN, 2000, ADV CANCER RES, V77, P25; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; McDougall J K, 1994, Curr Top Microbiol Immunol, V186, P101; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Ninomiya I, 2000, INT J CANCER, V85, P757, DOI 10.1002/(SICI)1097-0215(20000315)85:6<757::AID-IJC3>3.0.CO;2-O; Niv A, 2000, J LARYNGOL OTOL, V114, P41, DOI 10.1258/0022215001903870; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orr MS, 2000, J NATL CANCER I, V92, P987, DOI 10.1093/jnci/92.12.987; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Wilding J, 1996, CANCER RES, V56, P5285; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; Xia WY, 1999, CLIN CANCER RES, V5, P4164; XIE YM, 1995, ONCOGENE, V10, P2409; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972	46	87	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					350	358		10.1038/sj.onc.1207148	http://dx.doi.org/10.1038/sj.onc.1207148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724563				2022-12-25	WOS:000188098300004
J	Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE				Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE			CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells	ONCOGENE			English	Article						anoikis; pancreatic cancer; adenocarcinoma; CEACAM6; RNA interference; metastasis	CARCINOEMBRYONIC ANTIGEN FAMILY; INTEGRIN-LINKED KINASE; GPI-ANCHORED PROTEINS; COLON-CANCER CELLS; DUCTAL ADENOCARCINOMA; BILIARY GLYCOPROTEIN; MELANOMA-CELLS; TUMOR-GROWTH; CEA FAMILY; N-DOMAINS	Anoikis is the apoptotic response induced in normal cells by inadequate or inappropriate adhesion to substrate. It is postulated that resistance to anoikis facilitates tumorigenesis and metastasis. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is an immunoglobulin superfamily member overexpressed in a number of human cancers and implicated in anoikis resistance. We tested the effect of CEACAM6 gene silencing on anoikis in pancreatic adenocarcinoma cell lines. Anoikis was induced in PANC1, Capan2, MiaPaCa2 and Mia(AR) (a MiaPaCa2-derived anoikis-resistant subline) by culture in poly-2-hydroxyethylmethacrylate-coated wells. Anoikis was quantified by YO-PRO-1/propidium iodide staining and flow cytometry. The role of caspase activation was determined using fluorometric profiling and the caspase inhibitor Z-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-fmk). CEACAM6 expression was suppressed by RNA interference. Using a nude mouse orthotopic xenograft model, we assessed the effect of this treatment on in vivo metastatic ability. Anoikis resistance was associated with increased CEACAM6 expression. CEACAM6-specific short interfering ribonucleic acid (siRNA), but not control siRNA, increased susceptibility to caspase-mediated anoikis, an effect abrogated by Z-VAD-fmk, and decreased Akt phosphorylation (Ser-473) under anchorage-independent conditions. CEACAM6 gene silencing reversed the acquired anoikis resistance of Mia(AR) and inhibited its in vivo metastatic ability. CEACAM6 warrants further investigation as a novel therapeutic target for the treatment of pancreatic adenocarcinoma.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Whang, EE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.	ewhang1@partners.org						Arvelo Francisco, 2001, Acta Cientifica Venezolana, V52, P304; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Beauchemin N, 1999, EXP CELL RES, V252, P243; Bouvet M, 2002, CANCER RES, V62, P1534; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; CHEVINSKY AH, 1991, SEMIN SURG ONCOL, V7, P162, DOI 10.1002/ssu.2980070309; COURNOYER D, 1988, CANCER RES, V48, P3153; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Farrell TJ, 1997, ANN SURG, V226, P66, DOI 10.1097/00000658-199707000-00009; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gardner-Thorpe J, 2002, BIOCHEM BIOPH RES CO, V293, P391, DOI 10.1016/S0006-291X(02)00237-1; GORELIK E, 1993, CLIN EXP METASTAS, V11, P439, DOI 10.1007/BF00054935; HASEGAWA T, 1993, BRIT J CANCER, V67, P58, DOI 10.1038/bjc.1993.9; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim HRC, 1999, CANCER RES, V59, P4148; KODERA Y, 1993, BRIT J CANCER, V68, P130, DOI 10.1038/bjc.1993.300; Kunath T, 1995, ONCOGENE, V11, P2375; Kuroki M, 2001, J LEUKOCYTE BIOL, V70, P543; Malek T R, 1994, Semin Immunol, V6, P105, DOI 10.1006/smim.1994.1015; MAYNE KM, 1993, BRIT J HAEMATOL, V83, P30, DOI 10.1111/j.1365-2141.1993.tb04627.x; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miknyoczki SJ, 1999, CLIN CANCER RES, V5, P2205; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; Ordonez C, 2000, CANCER RES, V60, P3419; Perugini RA, 2000, J SURG RES, V90, P39, DOI 10.1006/jsre.2000.5833; Qiao L, 1996, CANCER LETT, V107, P83, DOI 10.1016/0304-3835(96)04346-7; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RAZ A, 1983, SCIENCE, V221, P1307, DOI 10.1126/science.6612347; ROBINSON P, 1994, BRAZ J MED BIOL RES, V27, P263; Scholzel S, 2000, AM J PATHOL, V156, P595, DOI 10.1016/S0002-9440(10)64764-5; Semba S, 2003, PANCREAS, V26, P250, DOI 10.1097/00006676-200304000-00008; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Skubitz KM, 2001, J PEPT RES, V58, P515, DOI 10.1034/j.1399-3011.2001.00931.x; Soeth E, 2001, CLIN CANCER RES, V7, P2022; Stanners CP, 1998, CELL ADHES COMMUN S, V5, P57; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; TAN MH, 1985, TUMOUR BIOL, V6, P89; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; Wang WX, 2001, ANTICANCER RES, V21, P1789; Wirth T, 2002, CLIN EXP METASTAS, V19, P155, DOI 10.1023/A:1014566127493; Yao Z, 2002, PANCREAS, V24, P42, DOI 10.1097/00006676-200201000-00006; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zhu ZY, 2001, CANCER RES, V61, P1707	50	151	168	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					465	473		10.1038/sj.onc.1207036	http://dx.doi.org/10.1038/sj.onc.1207036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724575				2022-12-25	WOS:000188098300017
J	Faast, R; White, J; Cartwright, P; Crocker, L; Sarcevic, B; Dalton, S				Faast, R; White, J; Cartwright, P; Crocker, L; Sarcevic, B; Dalton, S			Cdk6-cyclin D3 activity in murine ES cells is resistant to inhibition by p16(INK4a)	ONCOGENE			English	Article						ES cells; cyclin D; p16; differentiation	DEPENDENT KINASE CDK6; CYCLIN D1 EXPRESSION; EMBRYONIC STEM-CELLS; TUMOR-SUPPRESSOR; REPLICATIVE SENESCENCE; STRUCTURAL BASIS; INK4 FAMILY; MOUSE; GENE; PROTEIN	Through a screen aimed at identifying genes that are specifically upregulated in embryomic stem (ES) cells but not primitive ectoderm, we identified cyclin D3. This was surprising since cyclin D activity is generally believed to be inactive in ES cells even though retinoblastoma tumor suppressor protein (pRb) accumulates in a predominantly hyperphosphorylated state. Cdk6 is the major catalytic partner for cyclin D3 in ES cells and exhibits robust pRb kinase activity that is downregulated during the early stages of ES embryoid body differentiation. To investigate the basis underlying the insensitivity of ES cells to ectopic p16 expression, we show that Cdk6-cyclin D3 complexes are not subject to inhibition by p16, similar to Cdk-viral cyclin complexes. These observations show that specificity exists between Cdk4/6-cyclin D complexes and their ability to be targeted by p16. Our data suggest that Cdk6-cyclin D3 activity in other cell types, including tumors, may also be refractory to p16-mediated growth inhibition and raises the possibility of additional specificity within the INK4 family.	Univ Georgia, Rhodes Ctr, Athens, GA 30602 USA; Univ Adelaide, Ctr Mol Genet Dev, Bresagen Cell Therapy Program, Dept Mol Biosci, Adelaide, SA, Australia; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia	University System of Georgia; University of Georgia; University of Adelaide; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Dalton, S (corresponding author), Univ Georgia, Rhodes Ctr, 425 River Rd, Athens, GA 30602 USA.	sdalton@uga.edu		Sarcevic, Boris/0000-0002-8063-1050; Wright, Josephine/0000-0003-4588-8827; Dalton, Stephen/0000-0002-3450-1263				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; GARDNER RL, 1988, J CELL SCI, P11; GARDNER RL, 1979, J EMBRYOL EXP MORPH, V52, P141; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Halaban R, 1999, CANCER METAST REV, V18, P333, DOI 10.1023/A:1006396104073; Hara E, 1996, MOL CELL BIOL, V16, P859; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HAUB O, 1991, DEVELOPMENT, V112, P397; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; JIANG H, 1998, MOL CELL BIOL, V130, P755; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lake JA, 2000, J CELL SCI, V113, P555; Laman H, 2000, CURR OPIN GENET DEV, V10, P70, DOI 10.1016/S0959-437X(99)00045-3; Lin J, 2001, ONCOGENE, V20, P2000, DOI 10.1038/sj.onc.1204375; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pelton TA, 1998, REPROD FERT DEVELOP, V10, P535, DOI 10.1071/RD98084; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Pratt T, 2000, DEV BIOL, V228, P19, DOI 10.1006/dbio.2000.9935; QUELLE DE, 1995, ONCOGENE, V11, P635; Rathjen J, 1999, J CELL SCI, V112, P601; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS MB, 1991, DEVELOPMENT, V113, P815; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Savatier P, 1996, ONCOGENE, V12, P309; SAVATIER P, 1994, ONCOGENE, V9, P809; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SOLTER D, 1971, EXP CELL RES, V64, P331, DOI 10.1016/0014-4827(71)90084-X; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Swanton C, 1999, TRENDS BIOCHEM SCI, V24, P116, DOI 10.1016/S0968-0004(99)01354-7; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Thullberg M, 2000, FEBS LETT, V470, P161, DOI 10.1016/S0014-5793(00)01307-7; Wianny F, 1998, DEV DYNAM, V212, P49, DOI 10.1002/(SICI)1097-0177(199805)212:1<49::AID-AJA5>3.0.CO;2-2; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	60	89	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					491	502		10.1038/sj.onc.1207133	http://dx.doi.org/10.1038/sj.onc.1207133			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724578				2022-12-25	WOS:000188098300020
J	Huang, Y; Rangwala, F; Fulkerson, PC; Ling, B; Reed, E; Cox, AD; Kamholz, J; Ratner, N				Huang, Y; Rangwala, F; Fulkerson, PC; Ling, B; Reed, E; Cox, AD; Kamholz, J; Ratner, N			Role of TC/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells	ONCOGENE			English	Article						Schwann cell; TC21; neurofibromin; chemotaxis; R-Ras; Ras	FARNESYL-PROTEIN TRANSFERASE; NUCLEOTIDE EXCHANGE FACTOR; GTP-BINDING PROTEINS; R-RAS; TYPE-1 GENE; FARNESYLTRANSFERASE INHIBITORS; CYTOPLASMIC DOMAINS; TRANSGENIC MICE; N-RAS; H-RAS	The neurofibromatosis type 1 tumor suppressor protein neurofibromin, is a GTPase activating protein for H-, N-, K-, R-Ras and TC21/R-Ras2 proteins. We demonstrate that Schwann cells derived from Nf1-null mice have enhanced chemokinetic and chemotactic migration in comparison to wild-type controls. Surprisingly, this migratory phenotype is not inhibited by a farnesyltransferase inhibitor or dominant-negative (dn) (N17)H-Ras (which inhibits H-, N-, and K-Ras activation). We postulated that increased activity of R-Ras and/or TC21/R-Ras2, due to loss of Nf1, contributes to increased migration. Mouse Schwann cells (MSCs) express R-Ras and TC21/R-Ras2 and their specific guanine exchange factors, C3G and AND-34. Infection of Nf1-null MSCs with a dn(43N)R-Ras adenovirus (to inhibit both R-Ras and TC21/R-Ras2 activation) decreases migration by approximately 50%. Conversely, expression of activated (72L)TC21/R-Ras2, but not activated (38V)R-Ras, increases migration, suggesting a role of TC21/R-Ras2 activation in the migration of neurofibromin-deficient Schwann cells. TC21/R-Ras2 preferentially couples to the phosphatidylinositol 3-kinase (PI3-kinase) and MAP kinase pathways. Treatment with a PI3-kinase or MAP kinase inhibitor reduces Nf1-null Schwann cell migration, implicating these TC21 effectors in Schwann cell migration. These data reveal a key role for neurofibromin regulation of TC21/R-Ras2 in Schwann cells, a cell type critical to NF1 tumor pathogenesis.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Univ N Carolina, Lineberger Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Wayne State Univ, Dept Neurol, Detroit, MI 48201 USA	University System of Ohio; University of Cincinnati; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University	Ratner, N (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, 3125 Eden Ave, Cincinnati, OH 45267 USA.	nancy.ratner@uc.edu		Cox, Adrienne D./0000-0002-4901-2454; RATNER, NANCY/0000-0001-5030-9354	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS028840, NS-28840, R01 NS028840-09] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CARBONI JM, 1995, ONCOGENE, V10, P1905; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Clark GJ, 1996, ONCOGENE, V12, P169; COX AD, 1994, ONCOGENE, V9, P3281; Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Fahsold R, 2000, AM J HUM GENET, V66, P790, DOI 10.1086/302809; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Graham SM, 2001, METHOD ENZYMOL, V333, P203; Guha A, 1996, ONCOGENE, V12, P507; Gutmann DH, 2001, HUM MOL GENET, V10, P3009, DOI 10.1093/hmg/10.26.3009; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Huson SM, 1994, NEUROFIBROMATOSES; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; KIM HA, 1995, ONCOGENE, V11, P325; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klose A, 1998, HUM MOL GENET, V7, P1261, DOI 10.1093/hmg/7.8.1261; Kluwe L, 1999, GENE CHROMOSOME CANC, V24, P283, DOI 10.1002/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; Movilla N, 1999, ONCOGENE, V18, P5860, DOI 10.1038/sj.onc.1202968; MUIR D, 1995, CLIN EXP METASTAS, V13, P303, DOI 10.1007/BF00133486; Murphy GA, 2002, J BIOL CHEM, V277, P9966, DOI 10.1074/jbc.M109059200; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Omer CA, 2000, CANCER RES, V60, P2680; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; REY I, 1994, ONCOGENE, V9, P685; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Serra E, 2001, NAT GENET, V28, P294, DOI 10.1038/90148; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; Sherman LS, 2000, J BIOL CHEM, V275, P30740, DOI 10.1074/jbc.M001702200; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; YAN N, 1995, CANCER RES, V55, P3569; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	64	30	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					368	378		10.1038/sj.onc.1207075	http://dx.doi.org/10.1038/sj.onc.1207075			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724565	Green Accepted, Green Submitted			2022-12-25	WOS:000188098300006
J	Roos, W; Baumgartner, M; Kaina, B				Roos, W; Baumgartner, M; Kaina, B			Apoptosis triggered by DNA damage O-6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1	ONCOGENE			English	Article						apoptosis; DNA damage; DNA repair; alkyltransferase; lymphocytes; Fas; p53	MISMATCH REPAIR; METHYLTRANSFERASE MGMT; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; CHROMOSOMAL-ABERRATIONS; METHYLATING AGENTS; ALKYLATING-AGENTS; BCL-2 DECLINE; CELL-DEATH; V79 CELLS; EXPRESSION	Various tumor-therapeutic drugs and environmental carcinogens alkylate DNA inducing O-6-methylguanine (O(6)MeG) that provokes cell death by apoptosis. In rodent fibroblasts, apoptosis triggered by O(6)MeG is executed via the mitochondrial damage pathway. Conversion of O(6)MeG into critical downstream lesions requires mismatch repair (MMR). This is thought to signal apoptosis upon binding to O(6)MeG lesions mispaired with thymine. Alternatively, O(6)MeG lesions might be processed by MMR giving rise to DNA double-strand breaks (DSBs) during replication that finally provoke apoptosis. To test this, we examined apoptosis triggered by O(6)MeG in human peripheral lymphocytes in which O-6-methylguanine-DNA methyltransferase (MGMT) had been inactivated by O-6-benzylguanine (O(6)BG) and which were not proliferating or proliferating upon CD3/CD28 stimulation. Treatment with N-methyl-N#8242;-nitro-N-nitrosoguanidine (MNNG) or the anticancer drug temozolomide induced apoptosis only in proliferating, but not resting cells. With exceptional high alkylation doses (greater than or equal to15 muM of MNNG), apoptosis was also observed in resting lymphocytes, albeit at a lower level than in proliferating cells. This response was not affected by O(6)BG, suggesting that replication-independent apoptosis at high dose levels is caused by lesions other than O(6)MeG. O(6)MeG-triggered apoptosis in proliferating lymphocytes was preceded by a wave of DSBs, which coincided with p53 and Fas receptor upregulation, while Fas ligand, Bax and Bcl-2 expression was not altered. Treatment with anti-Fas neutralizing antibody attenuated MNNG-induced apoptosis in MGMT-depleted proliferating lymphocytes. The data suggest that O(6)MeG is converted by MMR and DNA replication into DSBs that trigger apoptosis by p53 stabilization and Fas/CD95/Apo-1 upregulation. This is supported by the finding that ionizing radiation, inducing DSBs on its own, provokes apoptosis in lymphocytes in a replication-independent way. The strict proliferation dependence of apoptosis triggered by O(6)MeG may explain the specific killing response of MGMT-deficient proliferating cells, including tumors, to O(6)MeG generating anticancer drugs and suggests that tumor proliferation rate, Fas responsiveness, MGMT and MMR status are important prognosis parameters.	Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany		Kaina, B (corresponding author), Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	Kaina@mail.uni-mainz.de	Roos, Wynand/B-4846-2008	Roos, Wynand/0000-0002-0474-7414				Becker K, 1996, CANCER RES, V56, P3244; Becker R, 2002, BRIT J CANCER, V86, P130, DOI 10.1038/sj.bjc.6600027; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BRENNAND J, 1986, P NATL ACAD SCI USA, V83, P6292, DOI 10.1073/pnas.83.17.6292; COQUERELLE T, 1995, MUTAT RES-DNA REPAIR, V336, P9, DOI 10.1016/0921-8777(94)00035-5; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dikomey E, 1998, INT J RADIAT BIOL, V73, P269, DOI 10.1080/095530098142365; Dosch J, 1996, ONCOGENE, V13, P1927; Dosch J, 1998, CARCINOGENESIS, V19, P567, DOI 10.1093/carcin/19.4.567; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Dunkern TR, 2002, MOL BIOL CELL, V13, P348, DOI 10.1091/mbc.01-05-0225; Dunkern TR, 2001, MUTAT RES-DNA REPAIR, V486, P249, DOI 10.1016/S0921-8777(01)00095-7; DUNKERN TR, 2003, IN PRESS MUTATION RE; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; GALLOWAY SM, 1995, MUTAT RES LETT, V346, P231, DOI 10.1016/0165-7992(95)90040-3; Gerson SL, 1996, BLOOD, V88, P1649; Hammond LA, 1999, J CLIN ONCOL, V17, P2604, DOI 10.1200/JCO.1999.17.8.2604; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Janssen K, 2001, ARCH TOXICOL, V75, P306, DOI 10.1007/s002040100226; Jones DT, 2001, BLOOD, V98, P2800, DOI 10.1182/blood.V98.9.2800; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; KAINA B, 1985, MUTAT RES, V142, P49, DOI 10.1016/S0165-7992(85)80012-9; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; KARRAN P, 1990, MUTAT RES, V236, P269, DOI 10.1016/0921-8777(90)90010-3; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Margison GP, 2002, BIOESSAYS, V24, P255, DOI 10.1002/bies.10063; Marra G, 2001, P NATL ACAD SCI USA, V98, P7164, DOI 10.1073/pnas.121136498; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; MORITZ T, 1995, CANCER RES, V55, P2608; MOSCHEL RC, 1992, J MED CHEM, V35, P4486, DOI 10.1021/jm00101a028; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Ochs K, 2000, CANCER RES, V60, P5815; Ochs K, 2002, CANCER RES, V62, P1524; OLIVE PL, 1991, CANCER RES, V51, P4671; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Raju U, 2000, INT J RADIAT BIOL, V76, P1045, DOI 10.1080/09553000050111514; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I	46	99	103	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					359	367		10.1038/sj.onc.1207080	http://dx.doi.org/10.1038/sj.onc.1207080			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724564				2022-12-25	WOS:000188098300005
J	Guo, JC; Kleeff, J; Li, JS; Ding, JY; Hammer, J; Zhao, YP; Giese, T; Korc, M; Buchler, MW; Friess, H				Guo, JC; Kleeff, J; Li, JS; Ding, JY; Hammer, J; Zhao, YP; Giese, T; Korc, M; Buchler, MW; Friess, H			Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						cell cycle; cyclin-dependent kinase; CDC25B; pancreatic ductal adenocarcinoma	RANDOMIZED CONTROLLED TRIAL; HUMAN COLORECTAL-CARCINOMA; TGF-BETA RESPONSIVENESS; COLO-357 CELLS; UP-REGULATION; CANCER-CELLS; PHOSPHATASE; OVEREXPRESSION; RECEPTOR; ACTIVATION	Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths. Deregulation of cell-cycle control is thought to be a crucial event in malignant transformation, and CDC25 phosphatases are a family of cyclin-dependent kinase activators, which act at different points of the cell cycle, including G1-S and G2-M transition. Here, we investigated the expression and functional significance of CDC25s in PDAC. CDC25B mRNA expression levels in human pancreatic tissue samples were analysed by cDNA array, quantitative PCR and Northern blotting. Immunohistochemistry was carried out to localize and quantify CDC25B expression. Two specific CDC25B inhibitors were utilized to determine the functional relevance of CDC25B. By quantitative RT-PCR, CDC25B mRNA was overexpressed in pancreatic cancer (7.5-fold) in comparison to the normal pancreas. Strong nuclear CDC25B immunoreactivity was present in both pancreatic and metastatic cancer samples, and there was a marked increase of the percentage of positive cells in primary cancer (48.6+/-16.3%) and metastatic tissues (71.7+/-3.1%) compared to normal samples (8.3+/-1.8%). Two CDC25B inhibitors reduced the growth of pancreatic cancer cell lines, resulting in the accumulation of phosphorylated CDC2 and G2/M arrest. These findings demonstrate an important role of CDC25B in cell-cycle progression, raising the possibility that inhibition of CDC25B may have therapeutic potential in pancreatic cancer.	Univ Heidelberg, Dept Gen Surg, D-69120 Heidelberg, Germany; Beijing Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China; Hoffmann La Roche Inc, Roche Genom & Informat Sci, Nutley, NJ 07110 USA; Univ Heidelberg, Inst Immunol, D-69120 Heidelberg, Germany; Univ Calif Irvine, Dept Med Biol Chem & Pharmacol, Div Endocrinol Diabet & Metab, Irvine, CA USA	Ruprecht Karls University Heidelberg; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Roche Holding; Ruprecht Karls University Heidelberg; University of California System; University of California Irvine	Friess, H (corresponding author), Univ Heidelberg, Dept Gen Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	helmut_friess@med.uni-heidelberg.de	Kleeff, Jorg/B-2124-2009	Kleeff, Jorg/0000-0003-3432-6669; Guo, Junchao/0000-0002-7878-8315	NATIONAL CANCER INSTITUTE [R01CA040162] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40162] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldin V, 2002, J BIOL CHEM, V277, P35176, DOI 10.1074/jbc.M204430200; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Broggini M, 2000, ANTICANCER RES, V20, P4835; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Friess H, 2001, ANN SURG, V234, P769, DOI 10.1097/00000658-200112000-00008; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; GUDJONSSON B, 1987, CANCER, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hernandez S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.0.CO;2-R; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Ito Y, 2002, BRIT J CANCER, V86, P1909, DOI 10.1038/sj.bjc.6600364; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Kleeff J, 1999, PANCREAS, V18, P364, DOI 10.1097/00006676-199905000-00006; Koliopanos A, 2001, CANCER RES, V61, P4655; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; Lal G, 2000, GENE CHROMOSOME CANC, V27, P358, DOI 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O; Lammer C, 1998, J CELL SCI, V111, P2445; Lazo JS, 2001, J MED CHEM, V44, P4042, DOI 10.1021/jm0102046; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Miyata H, 2001, CANCER RES, V61, P3188; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2001, ANN SURG, V234, P758, DOI 10.1097/00000658-200112000-00007; Ngan ESW, 2003, ONCOGENE, V22, P734, DOI 10.1038/sj.onc.1206121; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ozawa F, 2001, TERATOGEN CARCIN MUT, V21, P27, DOI 10.1002/1520-6866(2001)21:1<27::AID-TCM4>3.0.CO;2-9; Sasaki H, 2001, CANCER LETT, V173, P187, DOI 10.1016/S0304-3835(01)00669-3; Sato Y, 2001, JPN J CLIN ONCOL, V31, P428, DOI 10.1093/jjco/hye093; Schutte M, 1996, CANCER RES, V56, P2527; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Takemasa I, 2000, CANCER RES, V60, P3043; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tureci O, 2003, FASEB J, V17, P376, DOI 10.1096/fj.02-0478com; Ulloa L, 2001, J BIOL CHEM, V276, P21397, DOI 10.1074/jbc.M010783200; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; WU S, 1995, DEV BIOL, V170, P195, DOI 10.1006/dbio.1995.1207	50	68	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					71	81		10.1038/sj.onc.1206926	http://dx.doi.org/10.1038/sj.onc.1206926			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712212				2022-12-25	WOS:000187895300008
J	Steinman, HA; Sluss, HK; Sands, AT; Pihan, G; Jones, SN				Steinman, HA; Sluss, HK; Sands, AT; Pihan, G; Jones, SN			Absence of p21 partially rescues Mdm4 loss and uncovers an antiproliferative effect of Mdm4 on cell growth	ONCOGENE			English	Article						Mdm4; p21; Mdm2; p53; mice	EMBRYONIC LETHALITY; TRANSCRIPTION FACTOR; MDM2-DEFICIENT MICE; P53; PROTEIN; DELETION	Mdm4 (MdmX) is a p53-binding protein that shares structural similarities with Mdm2 and has been proposed to be a negative regulator of p53 function. Like Mdm2, the absence of Mdm4 has recently been found to induce embryonic lethality in mice that is rescued by p53 deletion. Mdm4-null embryos are reduced in size and die at mid-gestation, and Mdm4-deficient embryos and embryonic fibroblasts displayed reduced rates of cell proliferation. The p53-induced, cyclin-dependent kinase inhibitor p21 is strongly upregulated in Mdm4-null embryos and cells. Here, we report that deletion of p21 delays the mid-gestation lethality observed in Mdm4-null mice, suggesting that Mdm4 downregulates p53-mediated suppression of cell growth. Surprisingly, the absence of p21 also uncovers an antiproliferative effect of Mdm4 on cell growth in vitro and in Mdm4-heterozygous mice. These results indicate that p21 is a downstream modifier of Mdm4, and provides genetic evidence that Mdm4 can function to regulate cell growth both positively and negatively.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Lexicon Genet, The Woodlands, TX 77381 USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; Lexicon Pharmaceuticals; University of Massachusetts System; University of Massachusetts Worcester	Jones, SN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.	stephen.jones@umassmed.edu			NCI NIH HHS [CA77735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077735, R56CA077735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Finch RA, 2002, CANCER RES, V62, P3221; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; LUNA RMD, 1995, NATURE, V378, P203; Luna RMD, 1997, NAT GENET, V16, P336; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Strachan GD, 2003, J CELL BIOCHEM, V88, P557, DOI 10.1002/jcb.10318; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	17	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					303	306		10.1038/sj.onc.1206925	http://dx.doi.org/10.1038/sj.onc.1206925			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712235				2022-12-25	WOS:000187895300032
J	Voz, ML; Mathys, J; Hensen, K; Pendeville, H; Van Valckenborgh, I; Van Huffel, C; Chavez, M; Van Damme, B; De Moor, B; Moreau, Y; Van de Ven, WJM				Voz, ML; Mathys, J; Hensen, K; Pendeville, H; Van Valckenborgh, I; Van Huffel, C; Chavez, M; Van Damme, B; De Moor, B; Moreau, Y; Van de Ven, WJM			Microarray screening for target genes of the proto-oncogene PLAG1	ONCOGENE			English	Article						PLAG1 gene; oligonucleotide microarray; target genes; pleomorphic adenoma; salivary gland	BINDING PROTEIN-II; PLEOMORPHIC ADENOMAS; SALIVARY-GLANDS; P57/KIP2 PROTEIN; RETINOIC ACID; IGF-II; EXPRESSION; GROWTH; FAMILY; P57(KIP2)	PLAG1 is a proto-oncogene whose ectopic expression can trigger the development of pleomorphic adenomas of the salivary glands and of lipoblastomas. As PLAG1 is a transcription factor, able to activate transcription through the binding to the consensus sequence GRGGC(N)(6-8)GGG, its ectopic expression presumably results in the deregulation of target genes, leading to uncontrolled cell proliferation. The identification of PLAG1 target genes is therefore a crucial step in understanding the molecular mechanisms involved in PLAG1-induced tumorigenesis. To this end, we analysed the changes in gene expression caused by the conditional induction of PLAG1 expression in fetal kidney 293 cell lines. Using oligonucleotide microarray analyses of about 12000 genes, we consistently identified 47 genes induced and 12 genes repressed by PLAG1. One of the largest classes identified as upregulated PLAG1 targets consists of growth factors such as the insulin-like growth factor II and the cytokine-like factor 1. The in silico search for PLAG1 consensus sequences in the promoter of the upregulated genes reveals that a large proportion of them harbor several copies of the PLAG1-binding motif, suggesting that they represent direct PLAG1 targets. Our approach was complemented by the comparison of the expression profiles of pleomorphic adenomas induced by PLAG1 versus normal salivary glands. Concordance between these two sets of experiments pinpointed 12 genes that were significantly and consistently upregulated in pleomorphic adenomas and in PLAG1-expressing cells, identifying them as putative PLAG1 targets in these tumors.	Univ Liege, Lab Biol Mol & Genie Genet, Inst Chim, B-4000 Sart Tilman Par Liege, Belgium; Katholieke Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv, Inst Biotechnol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, ESAT SCD, B-3001 Louvain, Belgium; Starlab NV SA, Dept Gen, B-1180 Brussels, Belgium; Katholieke Univ Leuven, Dept Morphol & Mol Pathol, B-3000 Louvain, Belgium	University of Liege; KU Leuven; KU Leuven; KU Leuven	Voz, ML (corresponding author), Univ Liege, Lab Biol Mol & Genie Genet, Inst Chim, B6, B-4000 Sart Tilman Par Liege, Belgium.	mvoz@ulg.ac.be		Van Huffel, Christophe/0000-0001-6127-3027; Moreau, Yves/0000-0002-4647-6560				Alexander WS, 1999, CURR BIOL, V9, P605, DOI 10.1016/S0960-9822(99)80266-8; Astrom AK, 1999, CANCER RES, V59, P918; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Budhu AS, 2002, MOL CELL BIOL, V22, P2632, DOI 10.1128/MCB.22.8.2632-2641.2002; Burns JL, 2001, DEVELOPMENT, V128, P3819; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Coppock D, 2000, BIOCHEM BIOPH RES CO, V269, P604, DOI 10.1006/bbrc.2000.2324; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Debiec-Rychter M, 2001, LAB INVEST, V81, P1289, DOI 10.1038/labinvest.3780342; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DULL TJ, 1984, NATURE, V310, P777, DOI 10.1038/310777a0; Elson GCA, 1998, J IMMUNOL, V161, P1371; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Frade Gonzalez C., 2001, ACTA OTORRINOLARINGO, V52, P456; Grosso LE, 1996, J ORAL PATHOL MED, V25, P5, DOI 10.1111/j.1600-0714.1996.tb01215.x; Hartmann W, 2000, AM J PATHOL, V157, P1393, DOI 10.1016/S0002-9440(10)64652-4; Hensen K, 2002, CANCER RES, V62, P1510; Hibbard MK, 2000, CANCER RES, V60, P4869; Ito Y, 2002, LIVER, V22, P145, DOI 10.1034/j.1600-0676.2002.01532.x; Ito Y, 2002, INT J MOL MED, V9, P373; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kusafuka K, 1998, VIRCHOWS ARCH, V432, P247, DOI 10.1007/s004280050162; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lelievre E, 2001, J BIOL CHEM, V276, P22476, DOI 10.1074/jbc.M101681200; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Oya M, 2000, BRIT J CANCER, V83, P626, DOI 10.1054/bjoc.2000.1298; Praz V, 2002, NUCLEIC ACIDS RES, V30, P322, DOI 10.1093/nar/30.1.322; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHRESTHA P, 1994, ORAL ONCOL, V30B, P393; SUNARDHIWIDYAPUTRA S, 1993, PATHOL RES PRACT, V189, P138, DOI 10.1016/S0344-0338(11)80083-X; SunardhiWidyaputra S, 1995, PATHOL RES PRACT, V191, P1186, DOI 10.1016/S0344-0338(11)81124-6; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Vo HP, 1998, ANTICANCER RES, V18, P217; Voz ML, 2000, CANCER RES, V60, P106; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; Zhu Q, 1997, ORAL ONCOL, V33B, P29, DOI 10.1016/S0964-1955(96)00038-3	41	88	92	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					179	191		10.1038/sj.onc.1207013	http://dx.doi.org/10.1038/sj.onc.1207013			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712223	Green Submitted			2022-12-25	WOS:000187895300019
J	Axelrad, TW; Deo, DD; Ottino, P; Van Kirk, J; Bazan, NG; Bazan, HEP; Hunt, JD				Axelrad, TW; Deo, DD; Ottino, P; Van Kirk, J; Bazan, NG; Bazan, HEP; Hunt, JD			Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration	FASEB JOURNAL			English	Article						HUVEC; MMP2; MT1-MMP; TIMP2; angiogenesis; PAF; PAF receptor; bFGF	TYPE-1 MATRIX-METALLOPROTEINASE; FIBROBLAST-GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; INDUCED IN-VIVO; GELATINASE-A; 1-MATRIX METALLOPROTEINASE; MOLECULAR-MECHANISMS; TISSUE INHIBITOR; FACTOR RECEPTOR; IV COLLAGENASE	Tumor-induced angiogenic responses lead to complex phenotypic changes in vascular endothelial cells, which must coordinate the expression of both proteases and protease inhibitors prior to the proliferation and invasion of surrounding stroma. Matrix metalloproteinase 2 (MMP2), which degrades Type IV collagen, is produced as proMMP2. proMMP2 is activated in part through its interactions with membrane Type 1 MMP (MT1-MMP) and tissue inhibitor of matrix metalloproteinase 2 (TIMP2). In this study, we demonstrate that platelet-activating factor (PAF) is a potent inducer of human umbilical vein endothelial cell (HUVEC) migration and invasion, which is attenuated by PAF receptor antagonists, and that PAF receptor antagonists inhibit the migration and invasion of HUVEC mediated by medium conditioned by a prostatic carcinoma cell line. We confirm that PAF receptor antagonists inhibit proliferation of HUVEC grown in rich growth medium. We show that PAF increases mRNA levels for MT1-MMP and TIMP2, followed by increased temporal conversion of latent proMMP2 to MMP2. Finally, we demonstrate that the ratio of MT1-MMP to TIMP2 in membrane preparations from PAF-stimulated HUVEC is 1.6:1, approximating the hypothesized ideal ratio of 2:1 necessary for the conversion of proMMP2 to MMP2. Our data support the involvement of PAF in vascular endothelial cell migration and invasion.	Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Ctr Neurosci, Dept Ophthalmol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Hunt, JD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, 533 Bolivar St,CSB-4-18, New Orleans, LA 70112 USA.	jhunt@lsuhsc.edu	Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444; Hunt, Jay/0000-0002-8838-201X				ALI H, 1994, J BIOL CHEM, V269, P24557; BAZAN HEP, 1993, P NATL ACAD SCI USA, V90, P8678, DOI 10.1073/pnas.90.18.8678; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P1253, DOI 10.1038/sj.bjp.0704367; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Brizzi MF, 1999, CIRC RES, V84, P785; Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654; Bussolati B, 2000, AM J PATHOL, V157, P1713, DOI 10.1016/S0002-9440(10)64808-0; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; Camussi G, 1997, J IMMUNOL, V158, P1302; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Colorado PC, 2000, CANCER RES, V60, P2520; Del Sorbo L, 2001, EUR J IMMUNOL, V31, P376, DOI 10.1002/1521-4141(200102)31:2<376::AID-IMMU376>3.0.CO;2-5; Deo DD, 2002, J BIOL CHEM, V277, P21237, DOI 10.1074/jbc.M110955200; DEO DD, 2003, J BIOL CHEM     1114; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; Feldman L, 2002, MICROVASC RES, V63, P41, DOI 10.1006/mvre.2001.2364; Fillmore HL, 2001, J NEURO-ONCOL, V53, P187, DOI 10.1023/A:1012213604731; Flamme I, 1997, J CELL PHYSIOL, V173, P206, DOI 10.1002/(SICI)1097-4652(199711)173:2<206::AID-JCP22>3.0.CO;2-C; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Gaumond F, 1997, J CARDIOVASC PHARM, V30, P169, DOI 10.1097/00005344-199708000-00004; Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; Gourley M, 2000, CURR PHARM DESIGN, V6, P417, DOI 10.2174/1381612003400867; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Itoh T, 1998, CANCER RES, V58, P1048; Jackson JR, 1998, BBA-LIPID LIPID MET, V1392, P145, DOI 10.1016/S0005-2760(98)00012-5; KAIGHN ME, 1980, MODELS PROSTATE CANC, P85; Khoury J, 1996, AM J PHYSIOL-LUNG C, V270, pL298, DOI 10.1152/ajplung.1996.270.2.L298; Ko HM, 2002, CANCER RES, V62, P1809; Kume K, 1997, J BIOL CHEM, V272, P22898, DOI 10.1074/jbc.272.36.22898; LACASSE C, 1991, J LEUKOCYTE BIOL, V49, P245, DOI 10.1002/jlb.49.3.245; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Li ZG, 2000, INT J ONCOL, V17, P453; Lupia E, 1996, EUR J IMMUNOL, V26, P1690, DOI 10.1002/eji.1830260804; Montrucchio G, 1997, AM J PATHOL, V151, P557; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; Montrucchio G, 1998, AM J PATHOL, V153, P1589, DOI 10.1016/S0002-9440(10)65747-1; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; Ottino P, 2002, EXP EYE RES, V74, P393, DOI 10.1006/exer.2001.1135; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SA G, 1994, J BIOL CHEM, V269, P3219; Sato T, 1999, ANN NY ACAD SCI, V878, P713, DOI 10.1111/j.1749-6632.1999.tb07770.x; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Sirois MG, 1997, AM J PHYSIOL-HEART C, V272, pH2746, DOI 10.1152/ajpheart.1997.272.6.H2746; Southall MD, 2001, J BIOL CHEM, V276, P45548, DOI 10.1074/jbc.M105978200; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAO Y, 1995, INVEST OPHTH VIS SCI, V36, P345; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; Wang HM, 2003, ONCOGENE, V22, P2186, DOI 10.1038/sj.onc.1206348; Yoon SO, 2002, J BIOL CHEM, V277, P30271, DOI 10.1074/jbc.M202647200; Zhu ZP, 2002, CURR CANCER DRUG TAR, V2, P135, DOI 10.2174/1568009023333881; Zimmerman GA, 2002, CRIT CARE MED, V30, pS294, DOI 10.1097/00003246-200205001-00020; Zucker S, 2002, LAB INVEST, V82, P1673, DOI 10.1097/01.LAB.0000041713.74852.2A; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	65	45	46	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					568	+		10.1096/fj.03-0479fje	http://dx.doi.org/10.1096/fj.03-0479fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715700				2022-12-25	WOS:000188829300025
J	Pinet, F; Poirier, F; Fuchs, S; Tharaux, PL; Caron, M; Corvol, P; Michel, JB; Joubert-Caron, R				Pinet, F; Poirier, F; Fuchs, S; Tharaux, PL; Caron, M; Corvol, P; Michel, JB; Joubert-Caron, R			Troponin T as a marker of differentiation revealed by proteomic analysis in renal arterioles	FASEB JOURNAL			English	Article						cell differentiation; hypertension; proteomics; renin angiotensin system; smooth muscle	SMOOTH-MUSCLE CELLS; JUXTAGLOMERULAR CELLS; MASS-SPECTROMETRY; GENE-EXPRESSION; ONE-CLIP; RENIN; KIDNEY; HYPERTENSION; PROTEINS; RAT	Renovascular hypertension is characterized by stenosis of the renal artery and high plasma renin levels. The renal phenotype is characterized by high levels of renin in the hypoperfused kidney due to the recruitment of renin-producing cells along the afferent arterioles. This increase in myoepithelioid cells is due mainly to the differentiation of existing smooth muscle cells with acquisition of a secretory phenotype. To understand the molecular mechanisms involved in this recruitment, we used the established rat model of renovascular hypertension known as the two-kidney, one-clip model in the Lewis rat. Renal arterioles were isolated using magnetized iron suspension. Differential proteomic analysis was performed using 2-D polyacrylamide gel electrophoresis followed by mass spectrometry. Comparative analysis of soluble proteins extracted from afferent arterioles of clipped and contralateral kidneys showed 14 proteins significantly differentially expressed by at least a factor of 2. These proteins were identified by mass spectrometry. The most striking protein revealed by proteomics is troponin T, which is down-regulated in the afferent arterioles of the clipped kidney. Confocal microscopy showed that troponin T is specific of the smooth muscle phenotype and absent in the myoepithelioid phenotype. Our data suggest that troponin T is only present in renal smooth muscle cells.	Inst Pasteur, INSERM, U508, F-59019 Lille, France; Univ Paris 13, Prot Biochem & Proteom Lab, UPRES EA 3408, F-93017 Bobigny, France; Coll France, INSERM, U36, F-75005 Paris, France; Hop Tenon, INSERM, U489, F-75020 Paris, France; Hop Bichat Claude Bernard, INSERM, U460, F-75870 Paris 18, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite Paris 13; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pinet, F (corresponding author), Inst Pasteur, INSERM, U508, 1 Rue Professeur Calmette, F-59019 Lille, France.	florence.pinet@pasteur-lille.fr	Michel, Jean-Baptiste/AAH-9336-2020; Tharaux, Pierre-Louis/A-9155-2009; Pinet, Florence/F-2892-2013	Tharaux, Pierre-Louis/0000-0002-6062-5905; Pinet, Florence/0000-0002-5471-1487				Appel RD, 1997, ELECTROPHORESIS, V18, P2735, DOI 10.1002/elps.1150181507; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTIN M, 1977, AM J PATHOL, V87, P581; CHATZIANTONIOU C, 1993, AM J PHYSIOL, V265, pF853, DOI 10.1152/ajprenal.1993.265.6.F853; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corman B, 1995, MECH AGEING DEV, V84, P1, DOI 10.1016/0047-6374(95)01630-I; DESCHEPPER CF, 1986, P NATL ACAD SCI USA, V83, P7552, DOI 10.1073/pnas.83.19.7552; DUBEY RK, 1992, CIRC RES, V71, P1143, DOI 10.1161/01.RES.71.5.1143; GALEN FX, 1984, J CLIN INVEST, V74, P723, DOI 10.1172/JCI111488; Goldblatt H, 1934, J EXP MED, V59, P347, DOI 10.1084/jem.59.3.347; GOMEZ RA, 1990, AM J PHYSIOL, V259, pF660, DOI 10.1152/ajprenal.1990.259.4.F660; Joubert-Caron R, 2000, ELECTROPHORESIS, V21, P2566, DOI 10.1002/1522-2683(20000701)21:12<2566::AID-ELPS2566>3.0.CO;2-F; Joubert-Caron R, 1999, ELECTROPHORESIS, V20, P1017, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<1017::AID-ELPS1017>3.0.CO;2-K; KURTZ A, 1984, BIOCHEM BIOPH RES CO, V124, P359, DOI 10.1016/0006-291X(84)91561-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez MLSS, 2001, AM J PHYSIOL-RENAL, V281, pF345, DOI 10.1152/ajprenal.2001.281.2.F345; Mayer DCG, 1997, J CELL BIOL, V139, P1477, DOI 10.1083/jcb.139.6.1477; Medhora M, 2002, AM J PHYSIOL-HEART C, V282, pH414, DOI 10.1152/ajpheart.00292.2001; MENARD J, 1972, ENDOCRINOLOGY, V90, P422, DOI 10.1210/endo-90-2-422; MICHEL JB, 1986, KIDNEY INT, V29, P1011, DOI 10.1038/ki.1986.101; MIKSCHE L W, 1970, Circulation Research, V27, P973, DOI 10.1161/01.RES.27.6.973; Patterson SD, 2000, PHYSIOL GENOMICS, V2, P59, DOI 10.1152/physiolgenomics.2000.2.2.59; Pickering Thomas G., 1995, P2039; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Taugner R, 1989, JUXTAGLOMERULAR APPA; Thongboonkerd V, 2002, J BIOL CHEM, V277, P34708, DOI 10.1074/jbc.M203799200; Wiesel P, 1997, HYPERTENSION, V29, P1025, DOI 10.1161/01.HYP.29.4.1025; ZANELLATO AMC, 1991, CIRC RES, V68, P1349, DOI 10.1161/01.RES.68.5.1349	29	22	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					585	+		10.1096/fj.03-0939fje	http://dx.doi.org/10.1096/fj.03-0939fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715693				2022-12-25	WOS:000188829300030
J	Yan, CH; Wang, H; Aggarwal, BB; Boyd, DD				Yan, CH; Wang, H; Aggarwal, BB; Boyd, DD			A novel homologous recombination system to study 92 kDa type IV collagenase transcription demonstrates that the NFKB motif drives the transition from a repressed to an activated state of gene expression	FASEB JOURNAL			English	Article						MMP-9; gene expression; chromatin; NF-kappa B	FACTOR-BINDING SITES; MATRIX-METALLOPROTEINASE; KAPPA-B; IN-VITRO; MATRIX-METALLOPROTEINASE-9; GELATINASE; PROMOTER; CANCER; ALPHA; MECHANISM	The 92-kDa type IV collagenase (MMP-9) contributes to tissue remodeling in both physiology and pathology. Previous studies on the transcriptional regulation of this gene have used transiently transfected promoter-reporter constructs. However, this approach suffers from several limitations including (a) multiple copies of the plasmid and (b) the plasmid is not genomically integrated and consequently poorly chromatinized. We developed a novel system for studying MMP-9 transcription in which a single copy of a MMP-9 promoter-luciferase construct(s) is integrated at an identical genomic locus in HT1080 cells by homologous recombination. We report that the activity of a genomic-integrated 2.2 kb MMP-9 promoter sequence mirrors expression of the endogenous MMP-9 gene in response to both physiological and pharmacological (curcumin) cues. Further, when constrained into chromatin, the integrated NF-kappaB-mutated NMP-9 promoter is repressed by PMA, a situation not apparent using nonintegrated plasmids. Thus, we have developed a novel method for studying NMP-9 expression that overcomes some of the limitations associated with transient transfection approaches and which may be of utility in screening for agents that repress the expression of this gene.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Boyd, DD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	dboyd@mdanderson.org	Aggarwal, Bharat B/G-3388-2013	Yan, Chunhong/0000-0002-3974-7991				Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; BERGH PA, 1992, J ASSIST REPROD GEN, V9, P429, DOI 10.1007/BF01204048; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; DAVIS GE, 1990, CANCER RES, V50, P1113; El Kharroubi A, 1998, MOL CELL BIOL, V18, P2535, DOI 10.1128/MCB.18.5.2535; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; FINI ME, 1994, J BIOL CHEM, V269, P28620; FRIDMAN R, 1995, CANCER RES, V55, P2548; Gui CY, 2003, P NATL ACAD SCI USA, V100, P7009, DOI 10.1073/pnas.1236499100; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Haggerty TJ, 2003, P NATL ACAD SCI USA, V100, P5313, DOI 10.1073/pnas.0931346100; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Hua J, 1996, CANCER RES, V56, P5279; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Jiang Y, 2002, CANCER RES, V62, P1910; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kaya M, 1996, ONCOGENE, V12, P221; Legrand C, 1999, J CELL BIOL, V146, P517, DOI 10.1083/jcb.146.2.517; Lin LI, 1998, ONCOLOGY-BASEL, V55, P349, DOI 10.1159/000011876; LYONS JG, 1993, J BIOL CHEM, V268, P19143; Mohan R, 1998, J BIOL CHEM, V273, P25903, DOI 10.1074/jbc.273.40.25903; Moses MA, 1998, CANCER RES, V58, P1395; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; OKADA Y, 1992, J BIOL CHEM, V267, P21712; PUTNINS EE, 1995, J INVEST DERMATOL, V104, P989, DOI 10.1111/1523-1747.ep12606233; RAO JS, 1993, CANCER RES, V53, P2208; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sutter NB, 2003, P NATL ACAD SCI USA, V100, P1105, DOI 10.1073/pnas.242732999; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; Yan CH, 2003, J BIOL CHEM, V278, P2309, DOI 10.1074/jbc.M210369200; Yu Q, 2000, GENE DEV, V14, P163; ZUCKER S, 1993, CANCER RES, V53, P140	44	40	41	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					540	+		10.1096/fj.03-0960fje	http://dx.doi.org/10.1096/fj.03-0960fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715692				2022-12-25	WOS:000188829300023
J	Novitskiy, G; Potter, JJ; Rennie-Tankersley, L; Mezey, E				Novitskiy, G; Potter, JJ; Rennie-Tankersley, L; Mezey, E			Identification of a novel NF-kappa B-binding site with regulation of the murine alpha(2)(I) collagen promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL-DEHYDROGENASE GENE; ALPHA-1(I) COLLAGEN GENE; HEPATIC STELLATE CELLS; GROWTH-FACTOR-BETA; NUCLEAR FACTOR-I; KUPFFER CELLS; ACETALDEHYDE; ACTIVATION; TRANSCRIPTION; EXPRESSION	Hepatic fibrosis is due to the increased synthesis and deposition of type I collagen. Acetaldehyde activates type I collagen promoters. Nuclear factor kappaB (NF-kappaB) was previously shown to inhibit expression of murine alpha(1)(I) and human alpha(2)(I) collagen promoters. The present study identifies binding of NF-kappaB, present in nuclear extracts of stellate cells, to a region between -553 and -537 of the murine alpha(2)(I) collagen promoter. The NF-kappaB (p65) expression vector inhibited promoter activity. Mutation of the promoter at the NF-kappaB-binding site increased basal promoter activity and abrogated the activating and inhibitory effects of transforming growth factor beta and tumor necrosis factor alpha, respectively, on promoter activity. Acetaldehyde increased IkappaB-alpha kinase activity and phosphorylated IkappaB-alpha, NF-kappaB nuclear protein, and its binding to the promoter. However, the activating effect of acetaldehyde was not affected by the mutation of the promoter. In conclusion, although acetaldehyde increases the binding of NF-kappaB to the murine alpha(2)(I) collagen promoter, this binding does not mediate the activating effect of acetaldehyde on promoter activity. The effects of acetaldehyde in increasing the translocation of NF-kappaB to the nucleus with increased DNA binding activity may be important in mediating the effects of acetaldehyde on other genes.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Mezey, E (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 921 Ross Res Bldg, Baltimore, MD 21205 USA.	emezey@jhmi.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA000626] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00626] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANANIA FA, 1995, HEPATOLOGY, V21, P1640, DOI 10.1002/hep.1840210624; Anania FA, 1996, ARCH BIOCHEM BIOPHYS, V331, P187, DOI 10.1006/abbi.1996.0297; Attard FA, 2001, DNA CELL BIOL, V20, P455, DOI 10.1089/104454901316976082; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRENNER DA, 1993, HEPATOLOGY, V17, P287, DOI 10.1016/0270-9139(93)90090-A; CASINI A, 1991, HEPATOLOGY, V13, P758, DOI 10.1016/0270-9139(91)92576-T; Chen A, 2002, BIOCHEM J, V368, P683, DOI 10.1042/BJ20020949; Cheon H, 2002, CLIN EXP IMMUNOL, V127, P547, DOI 10.1046/j.1365-2249.2002.01785.x; DECROMBRUGGHE B, 1990, ANN NY ACAD SCI, V580, P88, DOI 10.1111/j.1749-6632.1990.tb17921.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN SL, 1990, SEMIN LIVER DIS, V10, P20, DOI 10.1055/s-2008-1040454; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Greenwel P, 2000, HEPATOLOGY, V31, P109, DOI 10.1002/hep.510310118; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLT K, 1984, HEPATOLOGY, V4, P843, DOI 10.1002/hep.1840040508; HORN T, 1986, J HEPATOL, V3, P333, DOI 10.1016/S0168-8278(86)80486-X; Jokelainen K, 1998, BIOCHEM BIOPH RES CO, V253, P834, DOI 10.1006/bbrc.1998.9863; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kouba DJ, 1999, J IMMUNOL, V162, P4226; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miao K, 1999, ARCH BIOCHEM BIOPHYS, V361, P7, DOI 10.1006/abbi.1998.0977; Miao K, 1997, ARCH BIOCHEM BIOPHYS, V341, P140, DOI 10.1006/abbi.1997.9948; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; Potter JJ, 2001, ARCH BIOCHEM BIOPHYS, V391, P41, DOI 10.1006/abbi.2001.2393; POTTER JJ, 1991, ARCH BIOCHEM BIOPHYS, V285, P246, DOI 10.1016/0003-9861(91)90356-N; Rippe RA, 1999, DNA CELL BIOL, V18, P751, DOI 10.1089/104454999314890; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; ROJKIND M, 1979, GASTROENTEROLOGY, V76, P710; Roman J, 2000, J BIOL CHEM, V275, P14684, DOI 10.1074/jbc.275.19.14684; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	35	29	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15639	15644		10.1074/jbc.M311499200	http://dx.doi.org/10.1074/jbc.M311499200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722113	hybrid			2022-12-25	WOS:000220594700136
J	Xavier, S; Piek, E; Fujii, M; Javelaud, D; Mauviel, A; Flanders, KC; Samuni, AM; Felici, A; Reiss, M; Yarkoni, S; Sowers, A; Mitchell, JB; Roberts, AB; Russo, A				Xavier, S; Piek, E; Fujii, M; Javelaud, D; Mauviel, A; Flanders, KC; Samuni, AM; Felici, A; Reiss, M; Yarkoni, S; Sowers, A; Mitchell, JB; Roberts, AB; Russo, A			Amelioration of radiation-induced fibrosis - Inhibition of transforming growth factor-beta signaling by halofuginone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PULMONARY FIBROSIS; TGF-BETA; IONIZING-RADIATION; GENE-REGULATION; IN-VIVO; CELLS; SMAD3; FIBROBLASTS; ACTIVATION; SKIN	Radiation-induced fibrosis is an untoward effect of high dose therapeutic and inadvertent exposure to ionizing radiation. Transforming growth factor-beta (TGF-beta) has been proposed to be critical in tissue repair mechanisms resulting from radiation injury. Previously, we showed that interruption of TGF-beta signaling by deletion of Smad3 results in resistance to radiation-induced injury. In the current study, a small molecular weight molecule, halofuginone ( 100 nM), is demonstrated by reporter assays to inhibit the TGF-beta signaling pathway, by Northern blotting to elevate inhibitory Smad7 expression within 15 min, and by Western blotting to inhibit formation of phospho-Smad2 and phospho-Smad3 and to decrease cytosolic and membrane TGF-beta type II receptor (TbetaRII). Attenuation of TbetaRII levels was noted as early as 1 h and down-regulation persisted for 24 h. Halofuginone blocked TGF-beta-induced delocalization of tight junction ZO-1, a marker of epidermal mesenchymal transition, in NMuMg mammary epithelial cells and suggest halofuginone may have in vivo anti-fibrogenesis characteristics. After documenting the in vitro cellular effects, halofuginone (intraperitoneum injection of 1, 2.5, or 5 mug/mouse/day) efficacy was assessed using ionizing radiation-induced ( single dose, 35 or 45 Gy) hind leg contraction in C3H/Hen mice. Halofuginone treatment alone exerted no toxicity but significantly lessened radiation-induced fibrosis. The effectiveness of radiation treatment ( 2 gray/day for 5 days) of squamous cell carcinoma (SCC) tumors grown in C3H/Hen was not affected by halofuginone. The results detail the molecular effects of halofuginone on the TGF-beta signal pathway and show that halofuginone may lessen radiation-induced fibrosis in humans.	NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Hop St Louis, INSERM, U532, F-75010 Paris, France; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Mol Genet & Microbiol, New Brunswick, NJ 08903 USA; Collgard Biopharmaceut Ltd, IL-49170 Petah Tiqwa, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Russo, A (corresponding author), Bldg 10,Rm B3-B69, Bethesda, MD 20892 USA.	russo@helix.nih.gov	Reiss, Michael/A-8314-2009; Wang, Weili/D-1546-2011; Javelaud, Delphine/B-1129-2019; MAUVIEL, Alain/F-6251-2013	Javelaud, Delphine/0000-0002-7674-7739; Mauviel, Alain/0000-0002-0438-2793	DIVISION OF BASIC SCIENCES - NCI [Z01BC010473, Z01BC005051] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIASC006321, Z01SC006321] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALPER T, 1989, EXPERIENTIA, V45, P21, DOI 10.1007/BF01990449; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bitzer M, 2000, GENE DEV, V14, P187; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bruck R, 2001, HEPATOLOGY, V33, P379, DOI 10.1053/jhep.2001.21408; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CLEMENT JJ, 1980, CANCER RES, V40, P4165; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; Dai CS, 2003, J BIOL CHEM, V278, P12537, DOI 10.1074/jbc.M300777200; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Denton CP, 2003, J BIOL CHEM, V278, P25109, DOI 10.1074/jbc.M300636200; Dooley S, 2003, GASTROENTEROLOGY, V125, P178, DOI 10.1016/S0016-5085(03)00666-8; Elkin M, 1999, CLIN CANCER RES, V5, P1982; Flanders KC, 2003, AM J PATHOL, V163, P2247, DOI 10.1016/S0002-9440(10)63582-1; Flanders KC, 2002, AM J PATHOL, V160, P1057, DOI 10.1016/S0002-9440(10)64926-7; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GRANOT I, 1993, BIOCHIM BIOPHYS ACTA, V1156, P107, DOI 10.1016/0304-4165(93)90123-P; Hallahan D E, 1993, Important Adv Oncol, P71; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; ILIAKIS G, 1991, BIOESSAYS, V13, P641; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; Lui WY, 2003, ENDOCRINOLOGY, V144, P1139, DOI 10.1210/en.2002-0211; Martin M, 2000, INT J RADIAT ONCOL, V47, P277, DOI 10.1016/S0360-3016(00)00435-1; MARTIN M, 1993, RADIAT RES, V134, P63, DOI 10.2307/3578502; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; McGaha T, 2002, AUTOIMMUNITY, V35, P277, DOI 10.1080/0891693021000001235; McGaha TL, 2002, J INVEST DERMATOL, V118, P461, DOI 10.1046/j.0022-202x.2001.01690.x; Nagler A, 1997, KIDNEY INT, V52, P1561, DOI 10.1038/ki.1997.486; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Pines A, 2003, BIOL BLOOD MARROW TR, V9, P417, DOI 10.1016/S1083-8791(03)00151-4; Randall K, 1996, INT J RADIAT BIOL, V70, P351, DOI 10.1080/095530096145085; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Roberts Anita B., 1995, Wound Repair and Regeneration, V3, P408, DOI 10.1046/j.1524-475X.1995.30405.x; RONG GH, 1985, J SURG ONCOL, V28, P131, DOI 10.1002/jso.2930280213; Ruifrok ACC, 1999, INT J RADIAT ONCOL, V43, P877, DOI 10.1016/S0360-3016(98)00495-7; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Schiffer M, 2000, KIDNEY INT, V58, pS45, DOI 10.1046/j.1523-1755.2000.07708.x; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schnabl B, 2001, HEPATOLOGY, V34, P89, DOI 10.1053/jhep.2001.25349; Schultze-Mosgau S, 2003, WOUND REPAIR REGEN, V11, P297, DOI 10.1046/j.1524-475X.2003.11410.x; STEWART FA, 1978, BRIT J RADIOL, V51, P307, DOI 10.1259/0007-1285-51-604-307; STONE HB, 1984, INT J RADIAT ONCOL, V10, P1053, DOI 10.1016/0360-3016(84)90177-9; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wells RG, 1997, J BIOL CHEM, V272, P11444; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yang Y, 2001, J BIOL CHEM, V276, P19220, DOI 10.1074/jbc.M100551200; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhao JS, 2002, AM J PHYSIOL-LUNG C, V282, pL585, DOI 10.1152/ajplung.00151.2001; Zhao Y, 2002, BIOCHEM BIOPH RES CO, V294, P319, DOI 10.1016/S0006-291X(02)00471-0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	57	164	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15167	15176		10.1074/jbc.M309798200	http://dx.doi.org/10.1074/jbc.M309798200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14732719	hybrid			2022-12-25	WOS:000220594700083
J	Kawamoto, Y; Takeda, K; Okuno, Y; Yamakawa, Y; Ito, Y; Taguchi, R; Kato, M; Suzuki, H; Takahashi, M; Nakashima, I				Kawamoto, Y; Takeda, K; Okuno, Y; Yamakawa, Y; Ito, Y; Taguchi, R; Kato, M; Suzuki, H; Takahashi, M; Nakashima, I			Identification of RET autophosphorylation sites by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; INSULIN-RECEPTOR; SRC KINASE; NEUROTROPHIC FACTOR; PROTEIN-KINASE; DOCKING SITE; SIGNAL-TRANSDUCTION; NEURONAL SURVIVAL; CRYSTAL-STRUCTURE; IN-VIVO	The catalytic and signaling activities of RET, a receptor-type tyrosine kinase, are regulated by the autophosphorylation of several tyrosine residues in the cytoplasmic region of RET. Some studies have revealed a few possible autophosphorylation sites of RET by [P-32] phosphopeptide mapping or by using specific anti-phosphotyrosine antibodies. To ultimately identify these and other autophosphorylation sites of RET, we performed mass spectrometry analysis of an originally prepared RET recombinant protein. Both the autophosphorylation and kinase activity of myelin basic protein as an external substrate of the recombinant RET protein were substantially elevated in the presence of ATP without stimulation by a glial cell line-derived neurotrophic factor, a natural ligand for RET. Mass spectrometric analysis revealed that RET Tyr(806), Tyr(809), Tyr(900), Tyr(905), Tyr(981), Tyr(1062), Tyr(1090), and Tyr(1096) were autophosphorylation sites. Levels of autophosphorylation and kinase activity of RET-MEN2A ( multiple endocrine neoplasia 2A), a constitutively active form of RET with substitution of Tyr900 by phenylalanine (Y900F), were comparable with those of original RET-MEN2A, whereas those of the mutant Y905F were greatly decreased. Interestingly, those of a double mutant, Y900F/Y905F, were completely abolished. Both the kinase activity and transforming activity were impaired in the mutants Y806F and Y809F. These results provide convincing evidence for both previously suggested and new tyrosine autophosphorylation sites of RET as well as for novel functions of Tyr(806), Tyr(809), and Tyr(900) phosphorylation in both catalytic kinase activities and cell growth. The significance of the identified autophosphorylation sites in various protein-tyrosine kinases registered in a data base is discussed in this paper.	Nagoya Univ, Grad Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Equipment Ctr Res & Educ, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Grad Sch Med, Dept Metabolme, Bunkyo Ku, Tokyo, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Environm & Prevent Med, Kanazawa, Ishikawa 920, Japan	Nagoya University; Nagoya University; Nagoya University; University of Tokyo; Kanazawa University	Nakashima, I (corresponding author), Nagoya Univ, Grad Sch Med, Dept Immunol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	inakashi@med.nagoya-u.ac.jp	Takahashi, Masahide/AAN-4770-2020; Okuno, Yusuke/C-9082-2009; 善之, 川本/GPT-3802-2022; TAKAHASHI, Masahide/I-7244-2014; KATO, Masashi/I-7250-2014	Takahashi, Masahide/0000-0002-2803-2683; Okuno, Yusuke/0000-0003-3139-9272; 				Akhand AK, 1999, J BIOL CHEM, V274, P25821, DOI 10.1074/jbc.274.36.25821; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Coulpier M, 2002, J BIOL CHEM, V277, P1991, DOI 10.1074/jbc.M107992200; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hayashi Y, 2001, BIOCHEM BIOPH RES CO, V281, P682, DOI 10.1006/bbrc.2001.4338; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Kato M, 2002, CANCER RES, V62, P2414; Kato M, 1999, ONCOGENE, V18, P837, DOI 10.1038/sj.onc.1202329; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; Kato M, 2001, ONCOGENE, V20, P7536, DOI 10.1038/sj.onc.1204918; Kato M, 2000, ANTIOXID REDOX SIGN, V2, P841, DOI 10.1089/ars.2000.2.4-841; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Mann M, 2002, TRENDS BIOTECHNOL, V20, P261, DOI 10.1016/S0167-7799(02)01944-3; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Miyauchi A, 1999, JPN J CANCER RES, V90, P1; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS SM, 1995, ONCOGENE, V11, P2039; NAKAMURA K, 1993, ONCOGENE, V8, P3133; Nakashima I, 2002, XI BIENNIAL MEETING OF THE SOCIETY FOR FREE RADICAL RESEARCH INTERNATIONAL, P229; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Pu MY, 1996, J CELL BIOCHEM, V63, P104; Pu MY, 1996, ONCOGENE, V13, P2615; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Takeda K, 2001, ANTIOXID REDOX SIGN, V3, P473, DOI 10.1089/15230860152409103; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHANG B, 1991, J BIOL CHEM, V266, P990	65	62	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14213	14224		10.1074/jbc.M312600200	http://dx.doi.org/10.1074/jbc.M312600200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14711813	hybrid			2022-12-25	WOS:000220478500114
J	Choi, J; Levey, AI; Weintraub, ST; Rees, HD; Gearing, M; Chin, LS; Li, L				Choi, J; Levey, AI; Weintraub, ST; Rees, HD; Gearing, M; Chin, LS; Li, L			Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SULFOXIDE REDUCTASE; NEURODEGENERATIVE DISEASES; MODIFIED PROTEINS; IDENTIFICATION; STRESS; DEGENERATION; DEGRADATION; CATALYSIS; RESIDUES; NEURON	Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative diseases that occur either in relatively rare, familial forms or in common, sporadic forms. The genetic defects underlying several monogenic familial forms of AD and PD have recently been identified, however, the causes of other AD and PD cases, particularly sporadic cases, remain unclear. To gain insights into the pathogenic mechanisms involved in AD and PD, we used a proteomic approach to identify proteins with altered expression levels and/or oxidative modifications in idiopathic AD and PD brains. Here, we report that the protein level of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), a neuronal de-ubiquitinating enzyme whose mutation has been linked to an early-onset familial PD, is down-regulated in idiopathic PD as well as AD brains. By using a combination of two-dimensional gel electrophoresis and mass spectrometry, we have identified three human brain UCH-L1 isoforms, a full-length form and two amino-terminally truncated forms. Our proteomic analyses reveal that the full-length UCH-L1 is a major target of oxidative damage in AD and PD brains, which is extensively modified by carbonyl formation, methionine oxidation, and cysteine oxidation. Furthermore, immunohistochemical studies show that prominent UCH-L1 immunostaining is associated with neurofibrillary tangles and that the level of soluble UCH-L1 protein is inversely proportional to the number of tangles in AD brains. Together, these results provide evidence supporting a direct link between oxidative damage to the neuronal ubiquitination/de-ubiquitination machinery and the pathogenesis of sporadic AD and PD.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Neurodegenerat Disorders, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Emory University; Emory University; Emory University; University of Texas System; University of Texas Health San Antonio	Li, L (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	lianli@pharm.emory.edu	Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X; Chin, Lih-Shen/0000-0002-0817-0368; Li, Lian/0000-0003-4700-1134	NCI NIH HHS [CA 54174] Funding Source: Medline; NIA NIH HHS [AG 10130, AG 021489] Funding Source: Medline; NIEHS NIH HHS [ES 12068] Funding Source: Medline; NINDS NIH HHS [NS 047199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES012068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG010130, R01AG021489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Choi JG, 2002, BIOCHEM BIOPH RES CO, V293, P1566, DOI 10.1016/S0006-291X(02)00420-5; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Conrad CC, 2001, PROTEOMICS, V1, P829, DOI 10.1002/1615-9861(200107)1:7<829::AID-PROT829>3.0.CO;2-R; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Gabbita SP, 1999, J NEUROCHEM, V73, P1660, DOI 10.1046/j.1471-4159.1999.0731660.x; GEARING M, 1995, NEUROLOGY, V45, P1985, DOI 10.1212/WNL.45.11.1985; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; ICHIHARA N, 1995, BRAIN RES, V695, P173, DOI 10.1016/0006-8993(95)00729-A; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Iqbal K, 1998, J NEURAL TRANSM-SUPP, P169; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Layfield R, 2003, AGEING RES REV, V2, P343, DOI 10.1016/S1568-1637(03)00025-4; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Levine RL, 2001, EXP GERONTOL, V36, P1495, DOI 10.1016/S0531-5565(01)00135-8; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Nishikawa K, 2003, BIOCHEM BIOPH RES CO, V304, P176, DOI 10.1016/S0006-291X(03)00555-2; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; van Leeuwen FW, 2002, INT J BIOCHEM CELL B, V34, P1502, DOI 10.1016/S1357-2725(02)00043-2; Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WU J, 1996, ALZHEIMERS RES, V2, P163	39	461	492	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13256	13264		10.1074/jbc.M314124200	http://dx.doi.org/10.1074/jbc.M314124200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722078	hybrid			2022-12-25	WOS:000220334900148
J	Day, JM; Olin, AI; Murdoch, AD; Canfield, A; Sasaki, T; Timpl, R; Hardingham, TE; Aspberg, A				Day, JM; Olin, AI; Murdoch, AD; Canfield, A; Sasaki, T; Timpl, R; Hardingham, TE; Aspberg, A			Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CARTILAGE PROTEOGLYCANS; LECTIN DOMAINS; CORE PROTEIN; VERSICAN; IDENTIFICATION; EXPRESSION; FAMILY; PROLIFERATION; HYALURONATE	The proteoglycans aggrecan, versican, neurocan, and brevican bind hyaluronan through their N-terminal G1 domains, and other extracellular matrix proteins through the C-type lectin repeat in their C-terminal G3 domains. Here we identify tenascin-C as a ligand for the lectins of all these proteoglycans and map the binding site on the tenascin molecule to fibronectin type III repeats, which corresponds to the proteoglycan lectin-binding site on tenascin-R. In the G3 domain, the C-type lectin is flanked by epidermal growth factor (EGF) repeats and a complement regulatory protein-like motif. In aggrecan, these are subject to alternative splicing. To investigate if these flanking modules affect the C-type lectin ligand interactions, we produced recombinant proteins corresponding to aggrecan G3 splice variants. The G3 variant proteins containing the C-type lectin showed different affinities for various ligands, including tenascin-C, tenascin-R, fibulin-1, and fibulin-2. The presence of an EGF motif enhanced the affinity of interaction, and in particular the splice variant containing both EGF motifs had significantly higher affinity for ligands, such as tenascin-R and fibulin-2. The mRNA for this splice variant was shown by reverse transcriptase-PCR to be expressed in human chondrocytes. Our findings suggest that alternative splicing in the aggrecan G3 domain may be a mechanism for modulating interactions and extracellular matrix assembly.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Max Planck Inst Biochem, DE-82152 Martinsried, Germany	University of Manchester; Max Planck Society	Aspberg, A (corresponding author), Lund Univ, BMC-C12, SE-22184 Lund, Sweden.	anders.aspberg@medkem.lu.se		Hardingham, Timothy/0000-0001-8271-6763; Aspberg, Anders/0000-0002-6588-6944; Canfield, Ann/0000-0002-8983-5674				Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; Brissett NC, 1998, BIOCHEM J, V329, P415; Day JM, 1999, J BIOL CHEM, V274, P38107, DOI 10.1074/jbc.274.53.38107; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; Fulop C, 1996, BIOCHEM J, V319, P935; FULOP C, 1993, J BIOL CHEM, V268, P17377; FUSS B, 1991, J NEUROSCI RES, V29, P299, DOI 10.1002/jnr.490290305; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Isogai Z, 1996, CANCER RES, V56, P3902; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Lee V, 2002, J BIOL CHEM, V277, P22279, DOI 10.1074/jbc.M110227200; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; RAUCH U, 1992, J BIOL CHEM, V267, P19536; Rauch U, 1997, J BIOL CHEM, V272, P26905, DOI 10.1074/jbc.272.43.26905; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Sasaki T, 1997, EMBO J, V16, P3035, DOI 10.1093/emboj/16.11.3035; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Xiao ZC, 1996, EUR J NEUROSCI, V8, P766, DOI 10.1111/j.1460-9568.1996.tb01262.x; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamaguchi Y, 1996, PERSPECT DEV NEUROBI, V3, P307; Zhang Y, 1999, J CELL BIOCHEM, V73, P445, DOI 10.1002/(SICI)1097-4644(19990615)73:4<445::AID-JCB3>3.0.CO;2-D; Zhang Y, 1998, J BIOL CHEM, V273, P33054, DOI 10.1074/jbc.273.49.33054; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zhang Y, 2001, EXP CELL RES, V263, P33, DOI 10.1006/excr.2000.5095; Zheng J, 1998, J BIOL CHEM, V273, P12999, DOI 10.1074/jbc.273.21.12999; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	47	93	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12511	12518		10.1074/jbc.M400242200	http://dx.doi.org/10.1074/jbc.M400242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722076	hybrid			2022-12-25	WOS:000220334900062
J	Hebeisen, S; Biela, A; Giese, B; Muller-Newen, G; Hidalgo, P; Fahlke, C				Hebeisen, S; Biela, A; Giese, B; Muller-Newen, G; Hidalgo, P; Fahlke, C			The role of the carboxyl terminus in ClC chloride channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BASIS; MYOTONIA-CONGENITA; MUTATIONS; DOMAINS; DOMINANT; COMMON; LEADS; GENE	The human muscle chloride channel ClC-1 has a 398-mino acid carboxyl-terminal domain that resides in the cytoplasm and contains two CBS (cystathionine-beta-synthase) domains. To examine the role of this region, we studied various carboxyl-terminal truncations by heterologous expression in mammalian cells, whole-cell patch clamp recording, and confocal imaging. Channel constructs lacking parts of the distal CBS domain, CBS2, did not produce functional channels, whereas deletion of CBS1 was tolerated. ClC channels are dimeric proteins with two ion conduction pathways (protopores). In heterodimeric channels consisting of one wild type subunit and one subunit in which the carboxyl terminus was completely deleted, only the wild type protopore was functional, indicating that the carboxyl terminus supports the function of the protopore. All carboxyl-terminal-truncated mutant channels fused to yellow fluorescent protein were translated and the majority inserted into the plasma membrane as revealed by confocal microscopy. Fusion proteins of cyan fluorescent protein linked to various fragments of the carboxyl terminus formed soluble proteins that could be redistributed to the surface membrane through binding to certain truncated channel subunits. Stable binding only occurs between carboxyl-terminal fragments of a single subunit, not between carboxyl termini of different subunits and not between carboxyl-terminal and transmembrane domains. However, an interaction with transmembrane domains can modify the binding properties of particular carboxyl-terminal proteins. Our results demonstrate that the carboxyl terminus of ClC-1 is not necessary for intracellular trafficking but is critical for channel function. Carboxyl termini fold independently and modify individual protopores of the double-barreled channel.	Rhein Westfal TH Aachen, Inst Physiol, D-52074 Aachen, Germany; Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; Ctr Estudios Cient, Valdivia, Chile	RWTH Aachen University; RWTH Aachen University	Fahlke, C (corresponding author), Rhein Westfal TH Aachen, Inst Physiol, Pauwelsstr 30, D-52057 Aachen, Germany.	chfahlke@physiology.rwthaachen.de	Hidalgo, Patricia/I-7506-2013; Fahlke, Christoph/G-3635-2013	Hidalgo, Patricia/0000-0002-4162-6590; Fahlke, Christoph/0000-0001-8602-9952				Accardi A, 2000, J GEN PHYSIOL, V116, P433, DOI 10.1085/jgp.116.3.433; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Beck CL, 1996, P NATL ACAD SCI USA, V93, P11248, DOI 10.1073/pnas.93.20.11248; BRYANT SH, 1971, J PHYSIOL-LONDON, V219, P361; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Estevez R, 2003, NEURON, V38, P47, DOI 10.1016/S0896-6273(03)00168-5; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; FAHLKE C, 1995, NEURON, V15, P463, DOI 10.1016/0896-6273(95)90050-0; Fong PY, 1998, AM J PHYSIOL-CELL PH, V274, pC966, DOI 10.1152/ajpcell.1998.274.4.C966; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; Giese B, 2003, J BIOL CHEM, V278, P39205, DOI 10.1074/jbc.M303347200; Haug K, 2003, NAT GENET, V33, P527, DOI 10.1038/ng1121; Hebeisen S, 2003, BIOPHYS J, V84, P2306, DOI 10.1016/S0006-3495(03)75036-X; HEINEMANN SH, 1992, METHOD ENZYMOL, V207, P131; Hryciw DH, 1998, J BIOL CHEM, V273, P4304, DOI 10.1074/jbc.273.8.4304; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Konrad M, 2000, J AM SOC NEPHROL, V11, P1449, DOI 10.1681/ASN.V1181449; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Maduke M, 1998, BIOCHEMISTRY-US, V37, P1315, DOI 10.1021/bi972418o; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; Mindell JA, 2001, NATURE, V409, P219, DOI 10.1038/35051631; MO L, 2003, AM J PHYSIOL, V286, pC79; Ponting CP, 1997, J MOL MED-JMM, V75, P160; SchmidtRose T, 1997, J BIOL CHEM, V272, P20515, DOI 10.1074/jbc.272.33.20515; Schwappach B, 1998, J BIOL CHEM, V273, P15110, DOI 10.1074/jbc.273.24.15110; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Warnstedt M, 2002, J NEUROSCI, V22, P7462; Wu FF, 2002, BRAIN, V125, P2392, DOI 10.1093/brain/awf246	32	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13140	13147		10.1074/jbc.M312649200	http://dx.doi.org/10.1074/jbc.M312649200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718533	hybrid			2022-12-25	WOS:000220334900135
J	Koike, K; Conseil, GL; Leslie, EM; Deeley, RG; Cole, SPC				Koike, K; Conseil, GL; Leslie, EM; Deeley, RG; Cole, SPC			Identification of proline residues in the core cytoplasmic and transmembrane regions of multidrug resistance protein 1 (MRP1/ABCC1) important for transport function, substrate specificity, and nucleotide interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; LEUKOTRIENE C-4; CYSTIC-FIBROSIS; BINDING DOMAINS; ATP HYDROLYSIS; MRP1 ABCC1; GLUTATHIONE; MUTATION; GENE; CONJUGATE	Multidrug resistance protein 1 (MRP1/ABCC1) is an ATP-binding cassette transporter that confers resistance to drugs and mediates the transport of organic anions. MRP1 has a core structure of two membrane spanning domains (MSDs) each followed by a nucleotide binding domain. This core structure is preceded by a third MSD with five transmembrane (TM) helices, whereas MSD2 and MSD3 each contain six TM helices. We investigated the consequences of Ala substitution of 18 Pro residues in both the non-membrane and TM regions of MSD2 and MSD3 on MRP1 expression and organic anion transport function. All MRP1-Pro mutants except P1113A were expressed in human embryonic kidney cells at levels comparable with wild-type MRP1. In addition, five mutants containing substitutions of Pro residues in or proximal to the TM helices of MSD2 (TM6-Pro(343), TM8-Pro(448), TM10-Pro(557), and TM11-Pro(595)) and MSD3 (TM14-Pro(1088)) exhibited significantly reduced transport of five organic anion substrates. In contrast, mutation of Pro(1150) in the cytoplasmic loop (CL7) linking TM15 to TM16 caused a substantial increase in 17beta-estradiol-17-beta-(D-glucuronide) and methotrexate transport, whereas transport of other organic anions was reduced or unchanged. Significant substrate-specific changes in the ATP dependence of transport and binding by the P1150A mutant were also observed. Our findings demonstrate the importance of TM6, TM8, TM10, TM11, and TM14 in MRP1 transport function and suggest that CL7 may play a differential role in coupling the activity of the nucleotide binding domains to the translocation of different substrates across the membrane.	Queens Univ, Canc Res Lab, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Cole, SPC (corresponding author), Queens Univ, Canc Res Lab, Botterell Hall, Kingston, ON K7L 3N6, Canada.	coles@post.queensu.ca	Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; Leslie, Elaine/0000-0003-1825-348X				Akabas MH, 1998, BIOCHEMISTRY-US, V37, P12233, DOI 10.1021/bi980969o; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Campbell JD, 2004, J BIOL CHEM, V279, P463, DOI 10.1074/jbc.M310711200; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Conrad S, 2002, PHARMACOGENETICS, V12, P321, DOI 10.1097/00008571-200206000-00008; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Deeley RG, 2003, ABC PROTEINS BACTERI, P393; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Haimeur A, 2002, J BIOL CHEM, V277, P41326, DOI 10.1074/jbc.M206228200; HAIMEUR A, 2003, P AM ASSOC CANC RES, V44, P3688; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hooijberg JH, 1999, CANCER RES, V59, P2532; Ito K, 2003, BBA-BIOMEMBRANES, V1615, P103, DOI 10.1016/S0005-2736(03)00228-1; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Jedlitschky G, 1996, CANCER RES, V56, P988; Koike K, 2002, J BIOL CHEM, V277, P49495, DOI 10.1074/jbc.M206896200; KONIG J, 2003, ABC PROTEINS BACTERI, P423; Kulczycki LL, 2003, AM J MED GENET A, V116A, P262, DOI 10.1002/ajmg.a.10886; Lee SH, 2003, BIOCHEM J, V370, P357, DOI 10.1042/BJ20021452; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Leslie EM, 2003, DRUG METAB DISPOS, V31, P11, DOI 10.1124/dmd.31.1.11; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Leslie EM, 2001, MOL PHARMACOL, V59, P1171, DOI 10.1124/mol.59.5.1171; Lin ZC, 2000, FASEB J, V14, P715, DOI 10.1096/fasebj.14.5.715; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LOO TW, 1993, J BIOL CHEM, V268, P3143; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Nilsson I, 1998, J MOL BIOL, V284, P1185, DOI 10.1006/jmbi.1998.2219; Ostedgaard LS, 1999, J CELL SCI, V112, P2091; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Ren XQ, 2003, BRIT J PHARMACOL, V138, P1553, DOI 10.1038/sj.bjp.0705197; Ren XQ, 2002, BIOCHEMISTRY-US, V41, P14132, DOI 10.1021/bi026443s; Ri Y, 1999, BIOPHYS J, V76, P2887, DOI 10.1016/S0006-3495(99)77444-8; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; SANSOM MSP, 1992, PROTEIN ENG, V5, P53, DOI 10.1093/protein/5.1.53; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Sheppard DN, 1996, J BIOL CHEM, V271, P14995, DOI 10.1074/jbc.271.25.14995; Tieleman DP, 2001, PROTEINS, V44, P63, DOI 10.1002/prot.1073; Visiers I, 2000, PROTEIN ENG, V13, P603, DOI 10.1093/protein/13.9.603; Visiers I, 2003, BIOCHEMISTRY-US, V42, P6784, DOI 10.1021/bi0273415; WEBB DC, 1992, J BIOL CHEM, V267, P24661; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; Yang RY, 2003, J BIOL CHEM, V278, P30764, DOI 10.1074/jbc.M304118200; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886; Zeng H, 2000, CANCER RES, V60, P4779; Zhang DW, 2003, J BIOL CHEM, V278, P46052, DOI 10.1074/jbc.M308403200; Zhang DW, 2002, J BIOL CHEM, V277, P20934, DOI 10.1074/jbc.M201311200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	60	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12325	12336		10.1074/jbc.M311435200	http://dx.doi.org/10.1074/jbc.M311435200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722114	hybrid			2022-12-25	WOS:000220334900040
J	Lu, JY; Schneider, RJ				Lu, JY; Schneider, RJ			Tissue distribution of AU-rich mRNA-binding proteins involved in regulation of mRNA decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'-UNTRANSLATED REGION; STABILITY FACTOR; ELAV PROTEIN; HEAT-SHOCK; FACTOR HUR; IN-VITRO; DEGRADATION; EXPRESSION; TRISTETRAPROLIN; ELEMENTS	Short lived cytokine and proto- oncogene mRNAs are destabilized by an A + U- rich element ( ARE) in the 3 '-untranslated region. Several regulatory proteins bind to AREs in cytokine and proto- oncogene mRNAs, participate in inhibiting or promoting their rapid degradation of ARE mRNAs, and influence cytokine expression and cellular transformation in experimental models. The tissue distribution and cellular localization of the different AU- rich binding proteins ( AUBPs), however, have not been uniformly characterized in the mouse, a model for ARE mRNA decay. We therefore carried out immunoblot and immunohistochemical analyses of the different AUBPs using the same mouse tissues. We show that HuR protein, a major AUBP that stabilizes the ARE mRNAs, is most strongly expressed in the thymus, spleen ( predominantly in lymphocytic cells), intestine, and testes. AUF1 protein, a negative regulator of ARE mRNA stability, displayed strong expression in thymus and spleen cells within lymphocytic cells, moderate expression in the epithelial linings of lungs, gonadal tissues, and nuclei of most neurons in the brain, and little expression in the other tissues. Tristetraprolin, a negative regulator of ARE mRNA stability, displayed a largely non- overlapping tissue distribution with AUF1 and was predominantly expressed in the liver and testis. KH- type splicing regulatory protein, a presumptive negative regulator of ARE mRNA stability, was distributed widely in murine organs. These results indicate that HuR and AUF1, which functionally oppose each other, have generally similar distributions, suggesting that the balance between HuR and AUF1 is likely important in control of short lived mRNA degradation, lymphocyte development, and/ or cytokine production, and possibly in certain aspects of neurological function.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University	Schneider, RJ (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	schner01@popmail.med.nyu.edu			NIGMS NIH HHS [GM 60428] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060428] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atasoy U, 1998, J CELL SCI, V111, P3145; Blaxall BC, 2000, MOL CARCINOGEN, V28, P76; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Gouble A, 2000, ONCOGENE, V19, P5377, DOI 10.1038/sj.onc.1203910; Gouble A, 2002, CANCER RES, V62, P1489; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; KING PH, 1994, J NEUROSCI, V14, P1943; Lafon I, 1998, ONCOGENE, V16, P3413, DOI 10.1038/sj.onc.1201895; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Laroia G, 2002, P NATL ACAD SCI USA, V99, P1842, DOI 10.1073/pnas.042575699; Laroia G, 2002, NUCLEIC ACIDS RES, V30, P3052, DOI 10.1093/nar/gkf444; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Nabors LB, 1998, J NEUROIMMUNOL, V92, P152, DOI 10.1016/S0165-5728(98)00196-9; Nabors LB, 2001, CANCER RES, V61, P2154; Okano HJ, 1997, J NEUROSCI, V17, P3024; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611	52	104	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12974	12979		10.1074/jbc.M310433200	http://dx.doi.org/10.1074/jbc.M310433200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711832	hybrid			2022-12-25	WOS:000220334900116
J	Mohler, PJ; Davis, JQ; Davis, LH; Hoffman, JA; Michaely, P; Bennett, V				Mohler, PJ; Davis, JQ; Davis, LH; Hoffman, JA; Michaely, P; Bennett, V			Inositol 1,4,5-trisphosphate receptor localization and stability in neonatal cardiomyocytes requires interaction with ankyrin-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CA2+ RELEASE; T-LYMPHOMA CELLS; TRISPHOSPHATE RECEPTOR; INSP(3) RECEPTORS; ANION-EXCHANGER; PURKINJE-CELLS; BINDING-SITES; RAT-BRAIN; CALCIUM; PROTEIN	The molecular mechanisms required for inositol 1,4,5-trisphosphate receptor ( InsP(3)R) targeting to specialized endoplasmic reticulum membrane domains are unknown. We report here a direct, high affinity interaction between InsP(3)R and ankyrin- B and demonstrate that this association is critical for InsP(3)R post- translational stability and localization in cultures of neonatal cardiomyocytes. Recombinant ankyrin- B membrane- binding domain directly interacts with purified cerebellar InsP(3)R ( K-d = 2 nM). 220- kDa ankyrin- B co- immunoprecipitates with InsP(3)R in tissue extracts from brain, heart, and lung. Alanine- scanning mutagenesis of the ankyrin- B ANK ( ankyrin repeat) repeat beta- hairpin loop tips revealed that consecutive ANK repeat beta- hairpin loop tips ( repeats 22 - 24) are required for InsP(3)R interaction, thus providing the first detailed evidence of how ankyrin polypeptides associate with membrane proteins. Pulse- chase biosynthesis experiments demonstrate that reduction or loss of ankyrin- B in ankyrin- B (+/-) or ankyrin- B (-/-) neonatal cardiomyocytes leads to similar to 3- fold reduction in half- life of newly synthesized InsP3R. Furthermore, interactions with ankyrin- B are required for InsP(3)R stability as abnormal InsP(3)R phenotypes, including mis- localization, and reduced half-life in ankyrin- B (+/-) cardiomyocytes can be rescued by green fluorescent protein ( GFP)- 220- kDa ankyrin- B but not by GFP- 220- kDa ankyrin- B mutants, which do not associate with InsP(3)R. These new results provide the first physiological evidence of a molecular partner required for early post- translational stability of InsP(3)R.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurosci, Durham, NC 27710 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mohler, PJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3892, Durham, NC 27710 USA.	p.mohler@cellbio.duke.edu						Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; DAVIS JQ, 1991, J CELL BIOL, V115, P43; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; KIJIMA Y, 1993, J BIOL CHEM, V268, P3499; Lipp P, 2000, CURR BIOL, V10, P939, DOI 10.1016/S0960-9822(00)00624-2; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; Miyata M, 2000, NEURON, V28, P233, DOI 10.1016/S0896-6273(00)00099-4; Miyata M, 1999, ACTA NEUROPATHOL, V98, P226, DOI 10.1007/s004010051073; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mohler PJ, 2002, J BIOL CHEM, V277, P10599, DOI 10.1074/jbc.M110958200; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; Salanova M, 2002, CELL CALCIUM, V32, P193, DOI 10.1016/S0143416002001549; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SHARP AH, 1993, J NEUROSCI, V13, P3051; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Shin DM, 2003, J CELL BIOL, V162, P293, DOI 10.1083/jcb.200210109; Sienaert I, 1998, PFLUG ARCH EUR J PHY, V436, P40, DOI 10.1007/s004240050602; Takagishi Y, 1996, NEUROSCI LETT, V215, P169, DOI 10.1016/S0304-3940(96)12967-0; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; Zhang SB, 2003, J BIOL CHEM, V278, P4048, DOI 10.1074/jbc.M209960200	35	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12980	12987		10.1074/jbc.M313979200	http://dx.doi.org/10.1074/jbc.M313979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722080	hybrid			2022-12-25	WOS:000220334900117
J	Sulzenbacher, G; Bignon, C; Nishimura, T; Tarling, CA; Withers, SG; Henrissat, B; Bourne, Y				Sulzenbacher, G; Bignon, C; Nishimura, T; Tarling, CA; Withers, SG; Henrissat, B; Bourne, Y			Crystal structure of Thermotoga maritima alpha-L-fucosidase - Insights into the catalytic mechanism and the molecular basis for fucosidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUCOSYL-TRANSFERASE; GLYCOSYLATION; IDENTIFICATION; ENDOGLUCANASE; BIOSYNTHESIS; NUCLEOPHILE; REFINEMENT; EXPRESSION; SPECTRUM; GLYCANS	Fucosylated glycoconjugates are involved in numerous biological events, and alpha-L-fucosidases, the enzymes responsible for their processing, are therefore of crucial importance. Deficiency in alpha-L-fucosidase activity is associated with fucosidosis, a lysosomal storage disorder characterized by rapid neurodegeneration, resulting in severe mental and motor deterioration. To gain insight into alpha-L-fucosidase function at the molecular level, we have determined the crystal structure of Thermotoga maritima alpha-L-fucosidase. This enzyme assembles as a hexamer and displays a two-domain fold, composed of a catalytic (beta/alpha)(8)-like domain and a C-terminal beta-sandwich domain. The structures of an enzyme-product complex and of a covalent glycosyl-enzyme intermediate, coupled with kinetic and mutagenesis studies, allowed us to identify the catalytic nucleophile, Asp(244), and the Bronsted acid/base, Glu(266). Because T. maritima alpha-L-fucosidase occupies a unique evolutionary position, being far more closely related to the mammalian enzymes than to any other prokaryotic homolog, a structural model of the human enzyme was built to document the structural consequences of the genetic mutations associated with fucosidosis.	CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; University of British Columbia	Henrissat, B (corresponding author), CNRS, UMR 6098, 31 Chemin J Aiguier, F-13402 Marseille 20, France.	bernie@afmb.cnrs-mrs.fr; yves@afmb.cnrs-mrs.fr	Henrissat, Bernard/J-2475-2012; Bourne, Yves/AAC-4635-2022; Sulzenbacher, Gerlind/A-6801-2018	Henrissat, Bernard/0000-0002-3434-8588; Bourne, Yves/0000-0003-3850-0548; Sulzenbacher, Gerlind/0000-0003-4844-2820				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; Berteau O, 2002, GLYCOBIOLOGY, V12, P273, DOI 10.1093/glycob/12.4.273; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cobucci-Ponzano B, 2003, BIOCHEMISTRY-US, V42, P9525, DOI 10.1021/bi035036t; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAVIES G, 1997, COMPREHENSIVE BIOL C, V1, P119; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Delves PJ, 1998, AUTOIMMUNITY, V27, P239, DOI 10.3109/08916939808993836; Eneyskaya EV, 2001, GLYCOCONJUGATE J, V18, P827, DOI 10.1023/A:1021163720282; Fox JD, 2003, FEBS LETT, V537, P53, DOI 10.1016/S0014-5793(03)00070-X; Fujimoto Z, 2003, J BIOL CHEM, V278, P20313, DOI 10.1074/jbc.M302292200; Garman SC, 2002, STRUCTURE, V10, P425, DOI 10.1016/S0969-2126(02)00726-8; Greenwell P, 1997, GLYCOCONJUGATE J, V14, P159, DOI 10.1023/A:1018581503164; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIRAISHI K, 1993, GLYCOBIOLOGY, V3, P381, DOI 10.1093/glycob/3.4.381; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Hooper LV, 2001, GLYCOBIOLOGY, V11, p1R, DOI 10.1093/glycob/11.2.1R; HUTCHINSON WL, 1991, CLIN SCI, V81, P177, DOI 10.1042/cs0810177; JOHNSON SW, 1991, COMP BIOCHEM PHYS B, V99, P479, DOI 10.1016/0305-0491(91)90327-A; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600-065X.2002.18603.x; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McIntosh LP, 1996, BIOCHEMISTRY-US, V35, P9958, DOI 10.1021/bi9613234; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; MURAMATSU T, 1993, GLYCOBIOLOGY, V3, P294; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nerinckx W, 2003, FEBS LETT, V538, P1, DOI 10.1016/S0014-5793(03)00148-0; Numao S, 2003, J BIOL CHEM, V278, P48074, DOI 10.1074/jbc.M309249200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ridley BL, 2001, PHYTOCHEMISTRY, V57, P929, DOI 10.1016/S0031-9422(01)00113-3; Roussel A, 1991, SILICON GRAPHICS GEO, P81; Roversi P, 2000, ACTA CRYSTALLOGR D, V56, P1316, DOI 10.1107/S0907444900008490; SANO M, 1992, J BIOL CHEM, V267, P1522; Sinowatz F, 1998, ACTA ANAT, V161, P196; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Staudacher E, 1999, BBA-GEN SUBJECTS, V1473, P216, DOI 10.1016/S0304-4165(99)00181-6; Sulzenbacher G, 1997, BIOCHEMISTRY-US, V36, P16032, DOI 10.1021/bi972407v; Sulzenbacher G, 1999, BIOCHEMISTRY-US, V38, P4826, DOI 10.1021/bi982648i; Tarling CA, 2003, J BIOL CHEM, V278, P47394, DOI 10.1074/jbc.M306610200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tyagarajan K, 1996, GLYCOBIOLOGY, V6, P83, DOI 10.1093/glycob/6.1.83; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Varrot A, 2000, J MOL BIOL, V297, P819, DOI 10.1006/jmbi.2000.3567; Varrot A, 1999, BIOCHEMISTRY-US, V38, P8884, DOI 10.1021/bi9903998; WHITE WJ, 1987, BIOCHIM BIOPHYS ACTA, V912, P132, DOI 10.1016/0167-4838(87)90256-1; Wiese TJ, 1997, BBA-GEN SUBJECTS, V1335, P61, DOI 10.1016/S0304-4165(96)00123-7; WILLEMS PJ, 1991, AM J MED GENET, V38, P111, DOI 10.1002/ajmg.1320380125; Willems PJ, 1999, EUR J HUM GENET, V7, P60, DOI 10.1038/sj.ejhg.5200272; XIANG JM, 1992, BIOCHEM BIOPH RES CO, V189, P27, DOI 10.1016/0006-291X(92)91520-Z	54	131	132	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13119	13128		10.1074/jbc.M313783200	http://dx.doi.org/10.1074/jbc.M313783200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715651	Green Published, hybrid			2022-12-25	WOS:000220334900133
J	Suzuki, S; Ferjani, A; Suzuki, I; Murata, N				Suzuki, S; Ferjani, A; Suzuki, I; Murata, N			The SphS-SphR two component system is the exclusive sensor for the induction of gene expression in response to phosphate limitation in Synechocystis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; SIGNAL-TRANSDUCTION; PHO REGULON; SP PCC-6803; STARVATION; PROMOTER; TRANSCRIPTION; METABOLISM; MUTANTS; OPERON	Living organisms respond to phosphate limitation by expressing various genes whose products maintain an appropriate range of phosphate concentrations within each cell. We identified previously a two component system, which consists of histidine kinase SphS and its cognate response regulator SphR, which regulates the expression of the phoA gene for alkaline phosphatase under phosphate-limiting conditions in the cyanobacterium Synechocystis sp. PCC 6803. In the present study, we used DNA microarrays to investigate the role of SphS and SphR in the regulation of the genome-wide expression of genes in response to phosphate limitation. In wild-type cells, phosphate limitation strongly induced the expression of 12 genes with induction factors greater than 7. These genes were included in three clusters of genes, namely, the pst1 and pst2 clusters that encode phosphate transporters; the phoA gene and the nucH gene for the extracellular nuclease. Phosphate limitation strongly repressed the expression of only the urtA gene with induction factors below 0.2. Inactivation of either of SphS or SphR completely eliminated the phosphate limitation-inducible expression of the 12 genes and the phosphate limitation-repressible expression of the urtA gene. These results suggest that the SphS-SphR two component system in Synechocystis sp. PCC 6803 is the dominant sensory system that controls gene expression in response to phosphate limitation.	Natl Inst Basic Biol, Dept Regulat Biol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan	Murata, N (corresponding author), Natl Inst Basic Biol, Dept Regulat Biol, Okazaki, Aichi 4448585, Japan.	murata@nibb.ac.jp	Suzuki, Shingo/O-3651-2014; Murata, Norio/E-6569-2010; Murata, Norio/O-7945-2019	Suzuki, Shingo/0000-0003-1332-3194; Murata, Norio/0000-0002-6605-5800				AIBA H, 1994, MOL MICROBIOL, V13, P25, DOI 10.1111/j.1365-2958.1994.tb00399.x; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Hammond JP, 2003, PLANT PHYSIOL, V132, P578, DOI 10.1104/pp.103.020941; Hirani TA, 2001, PLANT MOL BIOL, V45, P133, DOI 10.1023/A:1006425214168; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Hulett F. M, 2002, BACILLUS SUBTILIS IT, P193, DOI [10.1128/9781555817992.ch15, DOI 10.1128/9781555817992.CH15]; Kaneko T, 1996, DNA Res, V3, P109; Kanesaki Y, 2002, BIOCHEM BIOPH RES CO, V290, P339, DOI 10.1006/bbrc.2001.6201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu W, 1997, J BACTERIOL, V179, P6302, DOI 10.1128/jb.179.20.6302-6310.1997; Liu W, 1998, MOL MICROBIOL, V28, P119, DOI 10.1046/j.1365-2958.1998.00779.x; MAKINO K, 1994, PHOSPHATE IN MICROORGANISMS, P5; MANN N, 1974, J GEN MICROBIOL, V83, P399; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Qi Y, 1998, MOL MICROBIOL, V28, P1187, DOI 10.1046/j.1365-2958.1998.00882.x; Qi Y, 1997, J BACTERIOL, V179, P2534, DOI 10.1128/jb.179.8.2534-2539.1997; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; Taylor BL, 1998, MOL MICROBIOL, V28, P683, DOI 10.1046/j.1365-2958.1998.00835.x; WADA H, 1989, PLANT CELL PHYSIOL, V30, P971; Wanner BL, 1996, ESCHERICHIA COLI SAL, P1357, DOI DOI 10.1007/978-3-642-75969-7_16; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Wu P, 2003, PLANT PHYSIOL, V132, P1260, DOI 10.1104/pp.103.021022; Yamaguchi K, 2002, PLANT CELL, V14, P2901, DOI 10.1105/tpc.006262; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zinchenko VV, 1999, RUSS J GENET+, V35, P228	27	128	132	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13234	13240		10.1074/jbc.M313358200	http://dx.doi.org/10.1074/jbc.M313358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707128	hybrid			2022-12-25	WOS:000220334900145
J	Zhang, Q; Pangrsic, T; Kreft, M; Krzan, M; Li, NZ; Sul, JY; Halassa, M; Van Bockstaele, E; Zorec, R; Haydon, PG				Zhang, Q; Pangrsic, T; Kreft, M; Krzan, M; Li, NZ; Sul, JY; Halassa, M; Van Bockstaele, E; Zorec, R; Haydon, PG			Fusion-related release of glutamate from astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; MEMBRANE-FUSION; SYNAPTIC-TRANSMISSION; CAPACITANCE STEPS; GLIAL-CELLS; TRANSPORTER; EXOCYTOSIS; SNAP-23; PROTEIN; SINGLE	Although cell culture studies have implicated the presence of vesicle proteins in mediating the release of glutamate from astrocytes, definitive proof requires the identification of the glutamate release mechanism and the localization of this mechanism in astrocytes at synaptic locales. In cultured murine astrocytes we show an array of vesicle proteins, including SNARE proteins, and vesicular glutamate transporters that are required to fill vesicles with glutamate. Using immunocytochemistry and single-cell multiplex reverse transcription-PCR we demonstrate the presence of these proteins and their transcripts within astrocytes freshly isolated from the hippocampus. Moreover, immunoelectron microscopy demonstrates the presence of VGLUT1 in processes of astrocytes of the hippocampus. To determine whether calcium-dependent glutamate release is mediated by exocytosis, we expressed the SNARE motif of synaptobrevin II to prevent the formation of SNARE complexes, which reduces glutamate release from astrocytes. To further determine whether vesicular exocytosis mediates calcium-dependent glutamate release from astrocytes, we performed whole cell capacitance measurements from individual astrocytes and demonstrate an increase in whole cell capacitance, coincident with glutamate release. Together, these data allow us to conclude that astrocytes in situ express vesicle proteins necessary for filling vesicles with the chemical transmitter glutamate and that astrocytes release glutamate through a vesicle- or fusion-related mechanism.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Ljubljana, Fac Med, Ljubljana 1000, Slovenia; Celica Biomed Sci Ctr, Ljubljana 1000, Slovenia; Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Thomas Jefferson Univ, Farber Inst Neurosci, Dept Neurosurg, Philadelphia, PA 19107 USA	University of Pennsylvania; University of Ljubljana; University of Washington; University of Washington Seattle; Jefferson University	Haydon, PG (corresponding author), Univ Penn, Sch Med, Dept Neurosci, Rm 215,Stemmler Hall, Philadelphia, PA 19104 USA.	pghaydon@mail.med.upenn.edu		Zorec, Robert/0000-0002-7478-3875	NINDS NIH HHS [R37 NS 37585, R01 NS 43142] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043142, R37NS037585] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Araque A, 1998, J NEUROSCI, V18, P6822; Araque A, 1998, EUR J NEUROSCI, V10, P2129, DOI 10.1046/j.1460-9568.1998.00221.x; ATTWELL D, 1994, NATURE, V369, P707, DOI 10.1038/369707a0; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Blank U, 2002, MOL IMMUNOL, V38, P1341, DOI 10.1016/S0161-5890(02)00085-8; Boudin H, 2000, J NEUROSCI, V20, P5932, DOI 10.1523/JNEUROSCI.20-16-05932.2000; BRAMHAM CR, 1990, NEUROSCIENCE, V39, P405, DOI 10.1016/0306-4522(90)90277-B; Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002; Castle JD, 2002, MOL IMMUNOL, V38, P1337, DOI 10.1016/S0161-5890(02)00084-6; CHAN J, 1990, J NEUROSCI METH, V33, P113, DOI 10.1016/0165-0270(90)90015-8; Crino PB, 1996, NEURON, V17, P1173, DOI 10.1016/S0896-6273(00)80248-2; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Fremeau RT, 2002, P NATL ACAD SCI USA, V99, P14488, DOI 10.1073/pnas.222546799; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Hepp R, 1999, GLIA, V27, P181, DOI 10.1002/(SICI)1098-1136(199908)27:2<181::AID-GLIA8>3.0.CO;2-9; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; Innocenti B, 2000, J NEUROSCI, V20, P1800; Ishikawa T, 2002, NEURON, V34, P613, DOI 10.1016/S0896-6273(02)00692-X; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jeftinija SD, 1997, BRAIN RES, V750, P41, DOI 10.1016/S0006-8993(96)00610-5; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Kimelberg HK, 2000, J NEUROSCI RES, V61, P577, DOI 10.1002/1097-4547(20000915)61:6<577::AID-JNR1>3.0.CO;2-T; Klyachko VA, 2002, NATURE, V418, P89, DOI 10.1038/nature00852; Kreft M, 1997, PFLUG ARCH EUR J PHY, V434, P212, DOI 10.1007/s004240050387; KREFT M, 2004, IN PRESS GLIA; Lai KC, 2003, J CELL PHYSIOL, V194, P206, DOI 10.1002/jcp.10222; Maienschein V, 1999, GLIA, V26, P233, DOI 10.1002/(SICI)1098-1136(199905)26:3<233::AID-GLIA5>3.0.CO;2-2; Marty A., 1983, SINGLE CHANNEL RECOR, P107; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Nirenberg MJ, 1997, J NEUROSCI, V17, P5255; NUSSER Z, 1995, J NEUROSCI, V15, P2948; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Parpura V, 1995, FEBS LETT, V377, P489, DOI 10.1016/0014-5793(95)01401-2; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Polgar J, 2003, J BIOL CHEM, V278, P44369, DOI 10.1074/jbc.M307864200; Robitaille R, 1998, NEURON, V21, P847, DOI 10.1016/S0896-6273(00)80600-5; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; SCHAFER MK, 2002, J BIOL CHEM; Solsona C, 1998, BIOPHYS J, V74, P1061, DOI 10.1016/S0006-3495(98)74030-5; STORMMATHISEN J, 1992, PROG BRAIN RES, V94, P225; Sun JY, 2002, NATURE, V417, P555, DOI 10.1038/417555a; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Wang CT, 2003, NATURE, V424, P943, DOI 10.1038/nature01857; Zhong PY, 1997, BIOCHEMISTRY-US, V36, P4317, DOI 10.1021/bi9625408; Zhou M, 2001, J NEUROSCI, V21, P7901, DOI 10.1523/JNEUROSCI.21-20-07901.2001; Zhuo L, 1997, DEV BIOL, V187, P36, DOI 10.1006/dbio.1997.8601; ZOREC R, 1991, J GEN PHYSIOL, V97, P473, DOI 10.1085/jgp.97.3.473	56	191	200	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12724	12733		10.1074/jbc.M312845200	http://dx.doi.org/10.1074/jbc.M312845200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722063	hybrid			2022-12-25	WOS:000220334900086
J	Zharova, TV; Vinogradov, AD				Zharova, TV; Vinogradov, AD			Energy-dependent transformation of F-0 center dot F-1-ATPase in Paracoccus denitrificans plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING-SITES; STEADY-STATE KINETICS; APPARENT NEGATIVE COOPERATIVITY; PROTON MOTIVE FORCE; ATP-SYNTHASE; CATALYTIC SITE; OXIDATIVE-PHOSPHORYLATION; EPSILON-SUBUNIT; ESCHERICHIA-COLI	F-0.F-1-ATP synthase in tightly coupled inside-out vesicles derived from Paracoccus denitrificans catalyzes rapid respiration-supported ATP synthesis, whereas their ATPase activity is very low. In the present study, the conditions required to reveal the Deltamu(H+)-generating ATP hydrolase activity of the bacterial enzyme have been elucidated. Energization of the membranes by respiration results in strong activation of the venturicidin-sensitive ATP hydrolysis, which is coupled with generation of Delta(mu) over tilde (H+). Partial uncoupling stimulates the proton-translocating ATP hydrolysis, whereas complete uncoupling results in inhibition of the ATPase activity. The presence of inorganic phosphate is indispensable for the steady-state turnover of the Delta(mu) over tilde (H+)-activated ATPase. The collapse of Delta(mu) over tilde (H+) brings about rapid deactivation of the enzyme, which has been subjected to pre-energization. The rate and extent of the deactivation depend on protein concentration, i.e. the more vesicles are present in the assay mixture, the higher the rate and extent of the deactivation is seen. Sulfite and the ADP-trapping system protect ATPase against the Delta(mu) over tilde (H+) collapse-induced deactivation, whereas phosphate delays the rate of deactivation. A low concentration of ADP (<1 mu M) increases the rate of deactivation. Taken together, the results suggest that latent proton-translocating ATPase in P. denitrificans is kinetically equivalent to the previously characterized ADP(Mg2+)-inhibited, azide-trapped bovine heart mitochondrial F-0 center dot F-1-ATPase (Galkin, M. A., and Vinogradov, A. D. (1999) FEBS Lett. 448, 123-126). A Delta<(mu)over tilde>(H+)-sensitive mechanism operates in P. denitrificans that prevents physiologically wasteful consumption of ATP by F-0.F-1-ATPase (synthase) complex when the latter is unable to maintain certain value of Delta(mu) over tilde (H+).	Moscow MV Lomonosov State Univ, Sch Biol, Dept Biochem, Moscow 119992, Russia	Lomonosov Moscow State University	Vinogradov, AD (corresponding author), Moscow MV Lomonosov State Univ, Sch Biol, Dept Biochem, Moscow 119992, Russia.	adv@biochem.bio.msu.su	Zharova, Tatiana/AAO-4438-2021					Allison WS, 1996, J BIOENERG BIOMEMBR, V28, P433, DOI 10.1007/BF02113985; ASAMI K, 1970, BIOCHIM BIOPHYS ACTA, V205, P307, DOI 10.1016/0005-2728(70)90261-6; Bakels RHA, 1996, ARCH BIOCHEM BIOPHYS, V332, P170, DOI 10.1006/abbi.1996.0329; BAKELS RHA, 1991, BIOCHIM BIOPHYS ACTA, V1058, P225, DOI 10.1016/S0005-2728(05)80241-5; Bald D, 1998, J BIOL CHEM, V273, P865, DOI 10.1074/jbc.273.2.865; Bald D, 1999, EUR J BIOCHEM, V262, P563, DOI 10.1046/j.1432-1327.1999.00410.x; Beharry S, 2001, J BIOENERG BIOMEMBR, V33, P35, DOI 10.1023/A:1005620606871; Bottcher B, 2000, BBA-BIOENERGETICS, V1458, P404, DOI 10.1016/S0005-2728(00)00090-6; Boyer PD, 2000, BBA-BIOENERGETICS, V1458, P252, DOI 10.1016/S0005-2728(00)00077-3; Boyer PD, 1998, BIOSCIENCE REP, V18, P97, DOI 10.1023/A:1020188311092; BULYGIN VV, 1991, BIOCHEM J, V276, P149, DOI 10.1042/bj2760149; BULYGIN VV, 1988, FEBS LETT, V236, P497, DOI 10.1016/0014-5793(88)80085-1; Capaldi RA, 2000, J EXP BIOL, V203, P29; Cappellini P, 1997, EUR J BIOCHEM, V248, P496, DOI 10.1111/j.1432-1033.1997.00496.x; Chance B., 1967, METHODS ENZYMOL, V10, P641; CHERNYAK BV, 1992, ARCH BIOCHEM BIOPHYS, V295, P247, DOI 10.1016/0003-9861(92)90514-W; DU ZY, 1989, BIOCHEMISTRY-US, V28, P873, DOI 10.1021/bi00428a070; EBEL RE, 1975, J BIOL CHEM, V250, P191; FERGUSON SJ, 1977, BIOCHEM SOC T, V5, P1525, DOI 10.1042/bst0051525; FERGUSON SJ, 1976, FEBS LETT, V62, P272, DOI 10.1016/0014-5793(76)80073-7; Fischer S, 2000, J BIOL CHEM, V275, P30157, DOI 10.1074/jbc.275.39.30157; FITIN AF, 1979, BIOCHEM BIOPH RES CO, V86, P434, DOI 10.1016/0006-291X(79)90884-2; Galkin MA, 1999, FEBS LETT, V448, P123, DOI 10.1016/S0014-5793(99)00347-6; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; HARRIS DA, 1991, BIOCHEM J, V280, P561, DOI 10.1042/bj2800561; HARRIS DA, 1977, BIOCHIM BIOPHYS ACTA, V459, P546, DOI 10.1016/0005-2728(77)90053-6; Heytler P G, 1979, Methods Enzymol, V55, P462; JAULT JM, 1993, J BIOL CHEM, V268, P1558; JOHN P, 1970, FEBS LETT, V10, P246, DOI 10.1016/0014-5793(70)80639-1; JOHN P, 1970, BIOCHIM BIOPHYS ACTA, V216, P342, DOI 10.1016/0005-2728(70)90225-2; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Kato-Yamada Y, 2003, J BIOL CHEM, V278, P36013, DOI 10.1074/jbc.M306140200; Lodeyro AF, 2001, BBA-BIOENERGETICS, V1506, P236, DOI 10.1016/S0005-2728(01)00221-3; Lu YM, 2001, J BIOCHEM-TOKYO, V130, P873, DOI 10.1093/oxfordjournals.jbchem.a003060; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MINKOV IB, 1980, BIOCHEM INT, V1, P478; Mitome N, 2002, EUR J BIOCHEM, V269, P53, DOI 10.1046/j.0014-2956.2002.02623.x; MOYLE J, 1975, FEBS LETT, V56, P55, DOI 10.1016/0014-5793(75)80110-4; Muneyuki E, 2000, BBA-BIOENERGETICS, V1458, P467, DOI 10.1016/S0005-2728(00)00095-5; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; Pacheco-Moises F, 2000, EUR J BIOCHEM, V267, P993, DOI 10.1046/j.1432-1327.2000.01088.x; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10503, DOI 10.1021/bi00498a013; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10518, DOI 10.1021/bi00498a014; RECKTENWALD D, 1979, FEBS LETT, V108, P257, DOI 10.1016/0014-5793(79)81223-5; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Schulenberg B, 1999, J BIOL CHEM, V274, P28351, DOI 10.1074/jbc.274.40.28351; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; SYROESHKIN AV, 1995, FEBS LETT, V366, P29, DOI 10.1016/0014-5793(95)00487-T; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; VASIL'EVA E A, 1989, Biokhimiya, V54, P1490; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; VASILYEVA EA, 1980, BIOCHEM J, V188, P807, DOI 10.1042/bj1880807; Vinogradov AD, 2000, J EXP BIOL, V203, P41; Waggoner A S, 1979, Methods Enzymol, V55, P689; YALAMOVA MV, 1982, BIOCHEM INT, V4, P337; Zharova TV, 2003, BIOCHEMISTRY-MOSCOW+, V68, P1101, DOI 10.1023/A:1026306611821	59	46	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12319	12324		10.1074/jbc.M311397200	http://dx.doi.org/10.1074/jbc.M311397200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722115	hybrid			2022-12-25	WOS:000220334900039
J	Krauer, KG; Burgess, A; Buck, M; Flanagan, J; Gabrielli, B				Krauer, KG; Burgess, A; Buck, M; Flanagan, J; Gabrielli, B			The EBNA-3 gene family proteins disrupt the G2/M checkpoint	ONCOGENE			English	Article						EBV; EBNA-3; G2/M checkpoint; chk2	EPSTEIN-BARR-VIRUS; CELL-CYCLE CHECKPOINTS; DNA-DAMAGE CHECKPOINT; NUCLEAR ANTIGEN 3C; HISTONE DEACETYLASE; TYROSINE DEPHOSPHORYLATION; MONOCLONAL-ANTIBODY; B-LYMPHOCYTES; J KAPPA; ACTIVATION	The Epstein - Barr nuclear antigens (EBNA), EBNA-3, -4 and - 6, have previously been shown to act as transcriptional regulators, however, this study identifies another function for these proteins, disruption of the G2/M checkpoint. Lymphoblastoid cell lines (LCLs) treated with a G2/M initiating drug azelaic bishydroxamine ( ABHA) did not show a G2/M checkpoint response, but rather they display an increase in cell death, a characteristic of sensitivity to the cytotoxic effects of the drug. Cell cycle analysis demonstrated that the individual expression of EBNA-3, - 4 or - 6 are capable of disrupting the G2/M checkpoint response induced by ABHA resulting in increased toxicity, whereas EBNA-2, and - 5 were not. EBNA-3 gene family protein expression also disrupted the G2/M checkpoint initiated in response to the genotoxin etoposide and the S phase inhibitor hydroxyurea. The G2 arrest in response to these drugs were sensitive to caffeine, suggesting that ATM/ATR signalling in these checkpoint responses may be blocked by the EBNA-3 family proteins. The function of EBNA-3, - 4 and - 6 proteins appears to be more complex than anticipated and these data suggest a role for these proteins in disrupting the host cell cycle machinery.	Univ Queensland, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Univ Queensland, Joint Oncol Program, Brisbane, Qld 4029, Australia; Univ Queensland, Dept Mol & Cellular Pathol, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland; University of Queensland	Krauer, KG (corresponding author), Univ Queensland, Queensland Inst Med Res, Post Off Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.	keniaK@qimr.edu.au	Burgess, Andrew/H-3339-2019; Burgess, Andrew/C-7952-2009; Gabrielli, Brian G/B-3655-2011	Burgess, Andrew/0000-0003-4536-9226; Burgess, Andrew/0000-0003-4536-9226; Gabrielli, Brian G/0000-0003-3933-1651; Flanagan, James/0000-0003-4955-1383				BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Cannell EJ, 1996, ONCOGENE, V13, P1413; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Cludts I, 1998, J VIROL, V72, P1862, DOI 10.1128/JVI.72.3.1862-1869.1998; Connell M. J. O., 2000, TRENDS CELL BIOL, V10, P296; Darbon JM, 2000, J BIOL CHEM, V275, P15363, DOI 10.1074/jbc.275.20.15363; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Grundhoff AT, 1999, J BIOL CHEM, V274, P19136, DOI 10.1074/jbc.274.27.19136; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kaykas A, 2000, ONCOGENE, V19, P1400, DOI 10.1038/sj.onc.1203365; Kienzle N, 1996, BIOTECHNIQUES, V20, P612; Kienzle N, 1996, VIROLOGY, V224, P167, DOI 10.1006/viro.1996.0518; Krauer KG, 1996, VIROLOGY, V226, P346, DOI 10.1006/viro.1996.0662; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; LOCK RB, 1992, CANCER RES, V52, P1817; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MAUNDERS MJ, 1994, J GEN VIROL, V75, P769, DOI 10.1099/0022-1317-75-4-769; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Parker GA, 1996, ONCOGENE, V13, P2541; Parker GA, 2000, ONCOGENE, V19, P700, DOI 10.1038/sj.onc.1203327; PETTI L, 1990, VIROLOGY, V176, P563, DOI 10.1016/0042-6822(90)90027-O; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Radkov SA, 1999, J VIROL, V73, P5688, DOI 10.1128/JVI.73.7.5688-5697.1999; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCULLEY TB, 1984, J VIROL, V52, P88, DOI 10.1128/JVI.52.1.88-93.1984; Sculley TB, 2002, TRANSPLANTATION, V73, P271, DOI 10.1097/00007890-200201270-00021; Shieh SY, 2000, GENE DEV, V14, P289; SILINS SL, 1994, VIROLOGY, V202, P16, DOI 10.1006/viro.1994.1317; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SINCLAIR AJ, 1992, CELL GROWTH DIFFER, V3, P557; Sinclair AJ, 1998, HISTOL HISTOPATHOL, V13, P461, DOI 10.14670/HH-13.461; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Villa LL, 1997, ADV CANCER RES, V71, P321, DOI 10.1016/S0065-230X(08)60102-5; Wade M, 2000, MOL CELL BIOL, V20, P1344, DOI 10.1128/MCB.20.4.1344-1360.2000; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao B, 1996, J VIROL, V70, P4228, DOI 10.1128/JVI.70.7.4228-4236.1996; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	54	48	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1342	1353		10.1038/sj.onc.1207253	http://dx.doi.org/10.1038/sj.onc.1207253			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14716295				2022-12-25	WOS:000189035800002
J	Gan, DD; Khalili, K				Gan, DD; Khalili, K			Interaction between JCV large T-antigen and beta-catenin	ONCOGENE			English	Article						human polyomavirus; T-antigen; Wnt pathway; beta-catenin; medulloblastoma	BRAIN-TUMORS; VIRUS; IDENTIFICATION; MUTATION; PROTEIN; TARGET; GENE	Expression of the JCV early protein T-antigen in transgenic mice leads to the development of cerebellar primitive neuroectodermal tumors (PNETs). In light of earlier reports on the association of JCV with PNETs in humans and the involvement of the Wnt signaling pathway in the development of cerebellar tumors, we investigated the interplay between T-antigen and beta-catenin, the key protein of the Wnt pathway. Our results demonstrate the physical interaction of T-antigen with beta-catenin through the central domain of T-antigen spanning residues 82-628, and the C-terminus of beta-catenin located between amino acids 695 and 781. The association of T-antigen with beta-catenin elevates the level of beta-catenin in the cells due to increased in the stability of the protein. In the presence of T-antigen, beta-catenin was found in the nuclei of cells, suggesting that the interaction of beta-catenin with T-antigen facilitates its nuclear import. In cells expressing mutant T-antigen with no nuclear localization domain, beta-catenin was found in the cytoplasm. Coexpression of T-antigen with beta-catenin increased the transcription of the c-myc promoter, a known downstream target of beta-catenin, and artificial promoter whose activity is beta-catenin dependent. These observations ascribe a new oncogenic pathway for T-antigen, and offer an alternative mechanism for the deregulation of the Wnt pathway through stabilization of beta-catenin upon its association with the viral oncoprotein.	Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.	kamel.khalili@temple.edu						AGOSTINI HT, 2001, HUMAN POLYOMAVIRUSES, P491; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Berger JR, 1999, SEMIN NEUROL, V19, P193, DOI 10.1055/s-2008-1040837; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Castano J, 2002, J BIOL CHEM, V277, P31541, DOI 10.1074/jbc.M204376200; Del Valle L, 2002, JNCI-J NATL CANCER I, V94, P267, DOI 10.1093/jnci/94.4.267; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; RAJ GV, 1995, INT J ONCOL, V7, P801; Safak M, 2001, J VIROL, V75, P1476, DOI 10.1128/JVI.75.3.1476-1486.2001; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Walker D L, 1983, Prog Clin Biol Res, V105, P99; Weiner HL, 2002, CANCER RES, V62, P6385; Xu LF, 2000, GENE DEV, V14, P585	27	59	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					483	490		10.1038/sj.onc.1207018	http://dx.doi.org/10.1038/sj.onc.1207018			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724577				2022-12-25	WOS:000188098300019
J	Claij, N; Riele, HT				Claij, N; Riele, HT			Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells	ONCOGENE			English	Article						mismatch repair; MSH2; cisplatin; Cre-Lox	DNA MISMATCH REPAIR; TUMOR-CELLS; MICROSATELLITE INSTABILITY; DRUG-RESISTANCE; METHYLATION TOLERANCE; REPLICATIVE BYPASS; IN-VITRO; DAMAGE; P53; CANCER	Several reports have suggested that a defect in the DNA mismatch repair (MMR) system not only causes resistance to methylating agents but also confers low-level resistance to the chemotherapeutic drug cisplatin. Here we report that in a clonogenic assay, mouse embryonic stem (ES) cells deficient for the MMR protein MSH2 respond similarly as wild-type cells to cisplatin. Furthermore, restoring MSH2 expression in a cisplatin-resistant subclone selected from an Msh2(-/-) cell population did not sensitize cells to cisplatin. To ascertain that our observations were not the result of a mutation in the Msh2(-/-) cells that obscured the contribution of a defective MMR machinery to cisplatin resistance, we made use of the Cre-lox system to create a cell line in which the Msh2 gene can be conditionally inactivated. However, while de novo inactivation of Msh2 rendered cells tolerant to the methylating drug N-methyl-N'-nitro-N-nitrosoguanidine as expected, it did not alter the sensitivity to cisplatin. In addition, we were not able to derive cisplatin-resistant subclones from this freshly generated MMR-deficient cell line. Thus, in ES cells we did not find evidence for direct involvement of MMR deficiency in cisplatin resistance.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Riele, HT (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	h.t.riele@nki.nl						Aebi S, 1996, CANCER RES, V56, P3087; Anthoney DA, 1996, CANCER RES, V56, P1374; Aquilina G, 2000, CLIN CANCER RES, V6, P671; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Buermeyer AB, 1999, CANCER RES, V59, P538; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Claij N, 2002, ONCOGENE, V21, P2873, DOI 10.1038/sj.onc.1205395; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; Fink D, 1998, BRIT J CANCER, V77, P703, DOI 10.1038/bjc.1998.116; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1997, CANCER RES, V57, P1841; Gong JG, 1999, NATURE, V399, P806; HAWN MT, 1995, CANCER RES, V55, P3721; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; KOI M, 1994, CANCER RES, V54, P4308; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; MAMENTA EL, 1994, CANCER RES, V54, P3500; Massey A, 2003, DNA REPAIR, V2, P73, DOI 10.1016/S1568-7864(02)00187-8; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Nehme A, 1997, CANCER RES, V57, P3253; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Samimi G, 2000, CLIN CANCER RES, V6, P1415; Sansom OJ, 2002, ONCOGENE, V21, P5934, DOI 10.1038/sj.onc.1205760; Sergent C, 2002, CANCER CHEMOTH PHARM, V49, P445, DOI 10.1007/s00280-002-0450-6; Siddik ZH, 1998, CANCER RES, V58, P698; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Taniguchi M, 1998, NUCLEIC ACIDS RES, V26, P679, DOI 10.1093/nar/26.2.679; Vaisman A, 1998, CANCER RES, V58, P3579; Watanabe Y, 2001, BRIT J CANCER, V85, P1064, DOI 10.1054/bjoc.2001.2037; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; ZHUKOVSKAYA N, 1994, CARCINOGENESIS, V15, P2189, DOI 10.1093/carcin/15.10.2189	37	30	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					260	266		10.1038/sj.onc.1207015	http://dx.doi.org/10.1038/sj.onc.1207015			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712231				2022-12-25	WOS:000187895300027
J	Wu, YZ; Diab, I; Zhang, XP; Izmailova, ES; Zehner, ZE				Wu, YZ; Diab, I; Zhang, XP; Izmailova, ES; Zehner, ZE			Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89	ONCOGENE			English	Article						Stat3; ZBP-89; Sp1; repressor; activator	TRANSCRIPTION FACTOR ZBP-89; BREAST-CANCER CELLS; ZINC-FINGER PROTEIN; C-JUN; GROWTH-REGULATION; TUMOR-CELLS; PROMOTER; ACTIVATION; SP1; IDENTIFICATION	Vimentin exhibits a complex pattern of developmental- and tissue-specific expression and is aberrantly expressed in most metastatic tumors. The human vimentin promoter contains multiple DNA elements, some of which enhance gene expression and one that inhibits. A silencer element (at -319) binds the repressor ZBP-89. Further upstream (at <LF>-757) is an element, which acts positively in the presence of the silencer element and, thus, is referred to as an antisilencer (ASE). Previously, we showed that Stat1alpha binds to this element upon induction by IFN-gamma. However, substantial binding and reporter gene activity was still present in nontreated cells. Here, we have found that Stat3 binds to the ASE element in vitro. Transfection experiments in COS-1 cells with various vimentin promoter-reporter constructs show that gene activity is dependent upon the cotransfection and activation of Stat3. Moreover, activated Stat3 can overcome ZBP-89 repression. Coimmunoprecipitation studies demonstrate that Stat3 and ZBP-89 can interact and confocal microscopy detects these factors to be colocalized in the nucleus. Moreover, a correlation exists between the presence of activated Stat3 and vimentin expression in MDA-MB-231 cells, which is lacking in MCF7 cells where vimentin is not expressed. In the light of these results, we propose that the interaction of Stat3 and ZBP-89 may be crucial for overcoming the effects of the repressor ZBP-89, which suggests a novel mode for Stat3 gene activation.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Zehner, ZE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.	zezehner@vcu.edu		Izmailova, Elena/0000-0002-7150-1748; Diab, Iman/0000-0002-4017-5804	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045422] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45422] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bai LC, 2000, J BIOL CHEM, V275, P30725, DOI 10.1074/jbc.M004249200; Bai LG, 2001, MOL CELL BIOL, V21, P4670, DOI 10.1128/MCB.21.14.4670-4683.2001; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; BUSSEMAKERS MJG, 1992, BIOCHEM BIOPH RES CO, V182, P1254, DOI 10.1016/0006-291X(92)91866-O; CAREY I, 1995, CELL GROWTH DIFFER, V6, P899; Chen JH, 1996, ONCOGENE, V13, P1667; Cheng PY, 2000, BIOCHEMISTRY-US, V39, P4347, DOI 10.1021/bi992298f; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobretsova A, 1999, J NEUROCHEM, V72, P2227, DOI 10.1046/j.1471-4159.1999.0722227.x; DUPREY P, 1995, INT J DEV BIOL, V39, P443; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FRANKE WW, 1979, EXP CELL RES, V123, P25, DOI 10.1016/0014-4827(79)90418-X; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gilles C, 2003, CANCER RES, V63, P2658; GILLES C, 1996, BREAST J, V2, P83; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; HSIEH TC, 1995, EXP CELL RES, V218, P137, DOI 10.1006/excr.1995.1140; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Izmailova ES, 1999, GENE, V235, P69, DOI 10.1016/S0378-1119(99)00209-7; Izmailova ES, 1999, GENE, V230, P111, DOI 10.1016/S0378-1119(99)00046-3; Izmailova ES, 2000, J INTERF CYTOK RES, V20, P13, DOI 10.1089/107999000312694; Keates AC, 2001, J BIOL CHEM, V276, P43713, DOI 10.1074/jbc.M107838200; Law DJ, 1998, MAMM GENOME, V9, P165, DOI 10.1007/s003359900711; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Malone CS, 2001, GENE, V268, P9, DOI 10.1016/S0378-1119(01)00430-9; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; Passantino R, 1998, J BIOL CHEM, V273, P484, DOI 10.1074/jbc.273.1.484; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Remington MC, 1997, BIOCHEM BIOPH RES CO, V237, P230, DOI 10.1006/bbrc.1997.7119; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; SALVETTI A, 1993, MOL CELL BIOL, V13, P89, DOI 10.1128/MCB.13.1.89; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Sehgal PB, 2000, CELL SIGNAL, V12, P525, DOI 10.1016/S0898-6568(00)00098-X; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SOMMERS CL, 1989, CANCER RES, V49, P4258; SOMMERS CL, 1992, CANCER RES, V52, P190; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STOVER DM, 1992, MOL CELL BIOL, V12, P2230, DOI 10.1128/MCB.12.5.2230; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898; Yamada A, 2001, J BIOL CHEM, V276, P18082, DOI 10.1074/jbc.M008387200; Ye S, 1999, FEBS LETT, V450, P268, DOI 10.1016/S0014-5793(99)00509-8; Yoo JY, 2001, J BIOL CHEM, V276, P26421, DOI 10.1074/jbc.M009935200; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang XP, 2003, NUCLEIC ACIDS RES, V31, P2900, DOI 10.1093/nar/gkg380	63	49	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					168	178		10.1038/sj.onc.1207003	http://dx.doi.org/10.1038/sj.onc.1207003			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712222				2022-12-25	WOS:000187895300018
J	Bergmann, M; Schutt, F; Holz, FG; Kopitz, J				Bergmann, M; Schutt, F; Holz, FG; Kopitz, J			Inhibition of the ATP-driven proton pump in RPE lysosomes by the major lipofuscin fluorophore A2-E may contribute to the pathogenesis of age-related macular degeneration	FASEB JOURNAL			English	Article						retinal disease; ATPase; proton transport; phagocytosis; autophagy	RETINAL-PIGMENT EPITHELIUM; DEGRADATIVE FUNCTIONS; MODEL MEMBRANES; OUTER SEGMENTS; CELL-SURFACE; A2E; COMPONENT; AUTOPHAGY; ACCUMULATION; APOPTOSIS	Lipofuscin accumulation in the retinal pigment epithelium (RPE) is associated with various blinding retinal diseases, including age-related macular degeneration (AMD). The major lipofuscin fluorophor A2-E is thought to play an important pathogenetic role. In previous studies A2-E was shown to severely impair lysosomal function of RPE cells. However, the underlying molecular mechanism remained obscure. Using purified lysosomes from RPE cells we now demonstrate that A2-E is a potent inhibitor of the ATP-driven proton pump located in the lysosomal membrane. Such inhibition of proton transport to the lysosomal lumen results in an increase of the lysosomal pH with subsequent inhibition of lysosomal hydrolases. An essential task of the lysosomal apparatus of postmitotic RPE for normal photoreceptor function is phagocytosis and degradation of membranous discs shed from photoreceptor outer segments (POS) and of biomolecules from autophagy. When the lysosomes of cultured RPE cells were experimentally loaded with A2-E, we observed intracellular accumulation of exogenously added POS with subsequent congestion of the phagocytic process. Moreover, the autophagic sequestration of cytoplasmic material was also markedly reduced after A2-E loading. These data support the hypothesis that A2-E-induced lysosomal dysfunction contributes to the pathogenesis of AMD and other retinal diseases associated with excessive lipofuscin accumulation.	Heidelberg Univ, Dept Mol Pathol, D-69120 Heidelberg, Germany; Heidelberg Univ, Dept Ophthalmol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Kopitz, J (corresponding author), Heidelberg Univ, Dept Mol Pathol, Neuenheimer Feld 220, D-69120 Heidelberg, Germany.	juergen-kopitz@med.uni-heidelberg.de						Bahr BA, 2002, J NEUROCHEM, V83, P481, DOI 10.1046/j.1471-4159.2002.01192.x; Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200; Bermann M, 2001, EXP EYE RES, V72, P191; Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141; Brown D, 2002, INT J MED MICROBIOL, V291, P433; Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0; Burke JM, 1998, INVEST OPHTH VIS SCI, V39, P1478; CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x; Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566; DEGUCHI J, 1994, INVEST OPHTH VIS SCI, V35, P568; Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200; ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899; GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x; Glazer LC, 2002, OPHTHALMOL CLIN N AM, V15, pviii; Glazer Liane Clamen, 2002, Ophthalmol Clin North Am, V15, P93, DOI 10.1016/S0896-1549(01)00011-6; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; GORDON AH, 1980, NATURE, V286, P79, DOI 10.1038/286079a0; GORDON PB, 1986, BIOMED BIOCHIM ACTA, V45, P1635; Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051; Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; JONAS AJ, 1989, BIOCHIM BIOPHYS ACTA, V984, P257, DOI 10.1016/0005-2736(89)90290-3; Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; KOPITZ J, 1994, CLIN CHIM ACTA, V227, P121, DOI 10.1016/0009-8981(94)90141-4; la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003; Lamb LE, 2001, ARCH BIOCHEM BIOPHYS, V393, P316, DOI 10.1006/abbi.2001.2492; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199; London E, 2002, CURR OPIN STRUC BIOL, V12, P480, DOI 10.1016/S0959-440X(02)00351-2; LULLMANNRAUCH R, 1981, A GRAEF ARCH KLIN EX, V215, P297, DOI 10.1007/BF00407668; MACKENZIE AH, 1983, AM J MED, V75, P5, DOI 10.1016/0002-9343(83)91264-0; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; MARTINEZ CM, 1990, CELL BIOL INT REP, V14, P255, DOI 10.1016/S0309-1651(05)80008-6; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; Mousavi SA, 2001, BBA-BIOMEMBRANES, V1510, P243, DOI 10.1016/S0005-2736(00)00354-0; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001; Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2; Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1; SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57; SCHNEIDER DL, 2003, METHOD ENZYMOL, V157, P591; Schneider P, 1997, MICROSC RES TECHNIQ, V36, P253; Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339; Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x; Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8; Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4; Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303; SCHUTT F, 2003, IN PRESS INVEST OPHT; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041; Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988; Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1080/02713689808951268; Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200; Taute A, 2002, BIOCHEM BIOPH RES CO, V298, P5, DOI 10.1016/S0006-291X(02)02387-2; Uhlen P, 2003, ANN NY ACAD SCI, V986, P514, DOI 10.1111/j.1749-6632.2003.tb07237.x; Wan FY, 2002, ARCH BIOCHEM BIOPHYS, V404, P285, DOI 10.1016/S0003-9861(02)00280-1; Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828; Winchester B G, 2001, Eur J Paediatr Neurol, V5 Suppl A, P11, DOI 10.1053/ejpn.2000.0428; YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1145/1165387.275645; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401	74	166	180	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					562	+		10.1096/fj.03-0289fje	http://dx.doi.org/10.1096/fj.03-0289fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715704				2022-12-25	WOS:000188829300024
J	Kovari, J; Barabas, O; Takacs, E; Bekesi, A; Dubrovay, F; Pongracz, V; Zagyva, I; Imre, T; Szabo, P; Vertessy, BG				Kovari, J; Barabas, O; Takacs, E; Bekesi, A; Dubrovay, F; Pongracz, V; Zagyva, I; Imre, T; Szabo, P; Vertessy, BG			Altered active site flexibility and a structural metal-binding site in eukaryotic dUTPase - Kinetic characterization, folding, and crystallographic studies of the homotrimeric Drosophila enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS-ANEMIA VIRUS; ESCHERICHIA-COLI DUTPASE; CRYSTAL-STRUCTURE; DEOXYURIDINE TRIPHOSPHATASE; URACIL INCORPORATION; C-TERMINUS; EXPRESSION; PYROPHOSPHATASE; PROTEINS; IDENTIFICATION	dUTPase is responsible for preventive DNA repair via exclusion of uracil. Developmental regulation of the Drosophila enzyme is suggested to be involved in thymine-less apoptosis. Here we show that in addition to conserved dUTPase sequence motifs, the gene of Drosophila enzyme codes for a unique Ala-Pro-rich segment. Kinetic and structural analyses of the recombinant protein and a truncation mutant show that the Ala-Pro segment is flexible and has no regulatory role in vitro. The homotrimer enzyme unfolds reversibly as a trimeric entity with a melting temperature of 54degreesC, 23degreesC lower than Escherichia coli dUTPase. In contrast to the bacterial enzyme, Mg2+ binding modulates conformation of fly dUTPase, as identified by spectroscopy and by increment in melting temperature. A single well folded, but inactive, homotrimeric core domain is generated through three distinct steps of limited trypsinolysis. In fly, but not in bacterial dUTPase, binding of the product dUMP induces protection against proteolysis at the tryptic site reflecting formation of the catalytically competent closed conformer. Crystallographic analysis argues for the presence of a stable monomer of Drosophila dUTPase in crystal phase. The significant differences between prototypes of eukaryotic and prokaryotic dUTPases with respect to conformational flexibility of the active site, substrate specificity, metal ion binding, and oligomerization in the crystal phase are consistent with alteration of the catalytic mechanism and hydropathy of subunit interfaces.	Hungarian Acad Sci, BRC, Inst Enzymol, H-1518 Budapest, Hungary; Eotvos Lorand Univ, Dept Theoret Chem, H-1518 Budapest, Hungary; Hungarian Acad Sci, Chem Res Ctr, Dept Mass Spectrometry, H-1525 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences	Vertessy, BG (corresponding author), Hungarian Acad Sci, BRC, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	vertessy@enzim.hu	Vertessy, Beata G/H-6202-2012; Barabas, Orsolya/F-3961-2012	Barabas, Orsolya/0000-0002-2873-5872; Vertessy, Beata G./0000-0002-1288-2982; Szabo, Pal/0000-0003-2260-4641				Aherne G.W., 1999, ANTICANCER DRUG DEV, P409; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Babu KR, 2000, BIOCHEMISTRY-US, V39, P14702, DOI 10.1021/bi001265t; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barabas O, 2003, J BIOL CHEM, V278, P38803, DOI 10.1074/jbc.M306967200; Begun DJ, 2000, GENETICS, V156, P1879; BENSON M, 1988, EMBO J, V7, P3907, DOI 10.1002/j.1460-2075.1988.tb03277.x; Bergman AC, 1998, FEBS LETT, V441, P327, DOI 10.1016/S0014-5793(98)01575-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; CANMAN CE, 1994, CANCER RES, V54, P2296; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; Chu RY, 1996, J BIOL CHEM, V271, P27670, DOI 10.1074/jbc.271.44.27670; Dauter Z, 1999, J MOL BIOL, V285, P655, DOI 10.1006/jmbi.1998.2332; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988; Evans W, 1997, CHEM BRIT, V33, P22; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; Fiser A, 2000, BIOCHEM BIOPH RES CO, V279, P534, DOI 10.1006/bbrc.2000.3994; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; Gigliotti S, 1998, J CELL BIOL, V142, P1195, DOI 10.1083/jcb.142.5.1195; GIROIR IE, 1987, J BIOL CHEM, V262, P130; Gonzalez A, 2001, ACTA CRYSTALLOGR D, V57, P767, DOI 10.1107/S0907444901004255; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Harding MM, 1999, ACTA CRYSTALLOGR D, V55, P1432, DOI 10.1107/S0907444999007374; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; Kornberg A., 1991, DNA REPLICATION; Ladner RD, 1996, J BIOL CHEM, V271, P7752, DOI 10.1074/jbc.271.13.7752; Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072; Ladner RD, 1996, J BIOL CHEM, V271, P7745, DOI 10.1074/jbc.271.13.7745; Ladner RD, 2000, CANCER RES, V60, P3493; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson G, 1996, J BIOL CHEM, V271, P24010, DOI 10.1074/jbc.271.39.24010; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; LERNER DL, 1995, P NATL ACAD SCI USA, V92, P7480, DOI 10.1073/pnas.92.16.7480; LESLIE AG, 1999, MOSFLM 6 01; Leyden Webb J, 1963, ENZYME METABOLIC INH; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; MORRISON ID, 1985, LANGMUIR, V1, P496, DOI 10.1021/la00064a016; Munoz-Pinedo C, 2001, BIOCHEM J, V353, P101, DOI 10.1042/bj3530101; Mustafi D, 2003, P NATL ACAD SCI USA, V100, P5670, DOI 10.1073/pnas.1031504100; NATION MD, 1989, BIOCHEM J, V259, P593, DOI 10.1042/bj2590593; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nord J, 1997, FEBS LETT, V414, P271, DOI 10.1016/S0014-5793(97)00935-6; Nord J, 2001, FEBS LETT, V492, P228, DOI 10.1016/S0014-5793(01)02257-8; Pearl LH, 1996, NAT STRUCT BIOL, V3, P485, DOI 10.1038/nsb0696-485; Persson R, 2002, PREP BIOCHEM BIOTECH, V32, P157, DOI 10.1081/PB-120004128; Prasad GS, 1996, PROTEIN SCI, V5, P2429, DOI 10.1002/pro.5560051205; Prasad GS, 2000, ACTA CRYSTALLOGR D, V56, P1100, DOI 10.1107/S0907444900009197; Privalov P L, 1986, Methods Enzymol, V131, P4; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; PYLES RB, 1992, J VIROL, V66, P6706, DOI 10.1128/JVI.66.11.6706-6713.1992; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Theopold U, 1999, BIOCHEM BIOPH RES CO, V261, P923, DOI 10.1006/bbrc.1999.1121; THREADGILL DS, 1993, J VIROL, V67, P2592, DOI 10.1128/JVI.67.5.2592-2600.1993; Tinkelenberg BA, 2003, EXP CELL RES, V287, P39, DOI 10.1016/S0014-4827(03)00048-X; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Turelli P, 1997, J VIROL, V71, P4522, DOI 10.1128/JVI.71.6.4522-4530.1997; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; Vertessy BG, 1996, BIOCHEM BIOPH RES CO, V219, P294, DOI 10.1006/bbrc.1996.0226; VERTESSY BG, 1994, BBA-PROTEIN STRUCT M, V1205, P146, DOI 10.1016/0167-4838(94)90103-1; Vertessy BG, 1997, PROTEINS, V28, P568, DOI 10.1002/(SICI)1097-0134(199708)28:4<568::AID-PROT10>3.0.CO;2-E; Vertessy BG, 1998, FEBS LETT, V421, P83, DOI 10.1016/S0014-5793(97)01545-7; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4	68	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17932	17944		10.1074/jbc.M313643200	http://dx.doi.org/10.1074/jbc.M313643200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14724274	hybrid			2022-12-25	WOS:000220870400127
J	Guerardel, Y; Czeszak, X; Sumanovski, LT; Karamanos, Y; Popescu, O; Strecker, G; Misevic, GN				Guerardel, Y; Czeszak, X; Sumanovski, LT; Karamanos, Y; Popescu, O; Strecker, G; Misevic, GN			Molecular fingerprinting of carbohydrate structure phenotypes of three Porifera proteoglycan-like glyconectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGE MICROCIONA-PROLIFERA; MAGNETIC-RESONANCE SPECTROSCOPY; GAS-LIQUID-CHROMATOGRAPHY; CELL-ADHESION; AGGREGATION FACTOR; METHYL-GLYCOSIDES; MELANOMA-CELLS; RECOGNITION; GLYCOPROTEINS; GLYCAN	Glyconectins (GNs) represent a new class of proteoglycan-like cell adhesion and recognition molecules found in several Porifera species. Physico-chemical properties of GN carbohydrate moieties, such as size, composition, and resistance to most glycosaminoglycan-degrading enzymes, distinguish them from any other type of known glycoproteins. The molecular mechanism of GN-mediated self/non-self discrimination function is based on highly species-specific and Ca2+-dependent GN to GN associations that approach the selectivity of the evolutionarily advanced immunoglobulin superfamily. Carbohydrates of glyconectins 1, 2, and 3 are essential for species-specific auto-aggregation properties in three respective Porifera species. To obtain a structural insight into the molecular mechanisms, we performed carbohydrate structural analyses of glyconectins isolated from the three sponge model systems, Microciona prolifera (GN1), Halichondria panicea (GN2), and Cliona celata (GN3). The glycan content of all three GNs ranged between 40 and 60% of their total mass. Our approach using sequential and selective chemical degradation of GN glycans and subsequent mass spectrometric and NMR analyses revealed that each glyconectin presents novel and highly species-specific carbohydrate sequences. All three GNs include distinct acid-resistant and acid-labile carbohydrate domains, the latter composed of novel repetitive units. We have sequenced four short sulfated and one pyruvilated unit in GN1, eight larger and branched pyruvilated oligosaccharides in GN2, which represent a heterogeneous but related family of structures, and four sulfated units in GN3.	Fac Sci & Tech Rouen, CNRS, UMR 6037, Lab Proc Integrat Cellulaires, F-76821 Mont St Aignan, France; Univ Sci & Technol Lille, CNRS, UMR 8576, Unite Glycobiol Struct & Fonct, F-59655 Villeneuve Dascq, France; Univ Basel Hosp, Dept Res, CH-4058 Basel, Switzerland; Univ Artois, Fac J Perrin, Lab Biochim Mol & Cellulaire, F-62307 Lens, France; Univ Babes Bolyai, Ctr Mol Biol, Cluj Napoca 400006, Romania; Univ Babes Bolyai, Inst Interdisciplinary Expt Res, Cluj Napoca 400006, Romania	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; University of Basel; Universite d'Artois; Babes Bolyai University from Cluj; Babes Bolyai University from Cluj	Misevic, GN (corresponding author), Fac Sci & Tech Rouen, CNRS, UMR 6037, Lab Proc Integrat Cellulaires, F-76821 Mont St Aignan, France.	gradimir@gradimir.com	Popescu, Octavian/O-2134-2019; Karamanos, Yannis/AAE-9379-2020; Popescu, Octavian/E-4942-2010; Popescu, Octavian/C-4027-2011; Misevic, Gradimir/D-8294-2016	Popescu, Octavian/0000-0002-2597-7155; Karamanos, Yannis/0000-0002-2411-6636; Popescu, Octavian/0000-0002-2597-7155; Misevic, Gradimir/0000-0001-5047-2936; Guerardel, Yann/0000-0003-4967-9512				BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; Cerantola S, 1996, CARBOHYD RES, V285, P59, DOI 10.1016/0008-6215(96)00014-6; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; EGGENS I, 1989, J BIOL CHEM, V264, P9476; EGGENS I, 1989, BIOCHEM BIOPH RES CO, V158, P913, DOI 10.1016/0006-291X(89)92809-X; FONTAINE T, 1991, EUR J BIOCHEM, V196, P105, DOI 10.1111/j.1432-1033.1991.tb15792.x; Haseley SR, 2001, P NATL ACAD SCI USA, V98, P9419, DOI 10.1073/pnas.151111298; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KOJIMA N, 1994, GLYCOCONJUGATE J, V11, P238, DOI 10.1007/BF00731224; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600-065X.2002.18603.x; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; Misevic GN, 2004, J BIOL CHEM, V279, P15579, DOI 10.1074/jbc.M308927200; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; Rabinovich GA, 2002, BBA-GEN SUBJECTS, V1572, P274, DOI 10.1016/S0304-4165(02)00314-8; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; SPILLMANN D, 1995, J BIOL CHEM, V270, P5089, DOI 10.1074/jbc.270.10.5089; Van Calsteren MR, 2002, BIOCHEM J, V363, P7, DOI 10.1042/0264-6021:3630007; Yang BY, 2001, CARBOHYD RES, V331, P59, DOI 10.1016/S0008-6215(01)00004-0; Zanetta JP, 1999, GLYCOBIOLOGY, V9, P255, DOI 10.1093/glycob/9.3.255	22	27	29	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15591	15603		10.1074/jbc.M308928200	http://dx.doi.org/10.1074/jbc.M308928200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14701843	hybrid			2022-12-25	WOS:000220594700131
J	Holthauzen, LMF; Correa, F; Farah, CS				Holthauzen, LMF; Correa, F; Farah, CS			Ca2+-induced rolling of tropomyosin in muscle thin filaments - The alpha- and beta-band hypothesis revisited	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE SKELETAL-MUSCLE; MYOSIN-ACTIN INTERACTIONS; CRYSTAL-STRUCTURE; TROPONIN-I; 3-DIMENSIONAL RECONSTRUCTION; COOPERATIVE REGULATION; REGULATORY PROPERTIES; ESCHERICHIA-COLI; STRIATED-MUSCLE; MODEL	Tropomyosin is a filamentous coiled-coil protein directly involved in the regulation of the actomyosin interaction responsible for muscle contraction: it transmits the local calcium-induced conformational change in troponin to the helical array of myosin-binding sites on the surface of the actin filament. McLachlan and Stewart (McLachlan, A. D., and Stewart, M. (1976) J. Mol. Biol. 103, 271-298) proposed that the tropomyosin coiled-coil structure can be divided into 14 alternating 19- to 20-residue "alpha- and beta-bands," which could act as alternate 7-fold sets of sites for specific binding to actin in the different conformational states of the regulated thin filament. Here we present the first direct experimental evidence in support of the alpha- and beta-band hypothesis: we analyze the acrylamide quenching of the fluorescence of mutant tropomyosins containing 5-hydroxytryptophan residues at different positions along the coiled-coil structure under a variety of conditions (alone, complexed with actin, and complexed with actin and troponin with or without Ca2+). We show that fluorescent probes placed in the alpha-bands become less solvent-exposed in the absence of calcium, whereas those in the beta-bands become less solvent-exposed in the presence of calcium. A model in which the tropomyosin coiled-coil rolls across the actin surface in response to Ca2+-binding to troponin most easily explains these observations.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil	Universidade de Sao Paulo	Farah, CS (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, Av Prof Lineu Prestes 748, BR-05508900 Sao Paulo, Brazil.	chsfarah@iq.usp.br	Farah, Chuck Shaker/G-5565-2012	Farah, Chuck Shaker/0000-0003-3110-6302; Correa, Fernando/0000-0001-5349-1104				Bacchiocchi C, 2002, BIOPHYS J, V82, P1524, DOI 10.1016/S0006-3495(02)75505-7; COHEN CAROLYN, 1963, JOUR MOLECULAR BIOL, V6, P423; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Das K, 1999, PHOTOCHEM PHOTOBIOL, V70, P719; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EFTINK MR, 1976, J PHYS CHEM-US, V80, P486, DOI 10.1021/j100546a014; Eftink MR, 1991, TOPICS FLUORESCENCE, V2, P53; Farah CS, 1999, BIOCHEMISTRY-US, V38, P10543, DOI 10.1021/bi982813u; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; GOODING C, 1987, NUCLEIC ACIDS RES, V15, P8105, DOI 10.1093/nar/15.19.8105; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HOLMES KC, 1995, BIOPHYS J S, V68, P2; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; ISHII Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P193, DOI 10.1006/abbi.1993.1410; JOHNSON P, 1975, BIOCHEM BIOPH RES CO, V64, P1316, DOI 10.1016/0006-291X(75)90836-0; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; Lehman W, 2001, J MOL BIOL, V307, P739, DOI 10.1006/jmbi.2001.4514; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; Lehrer S S, 1978, Methods Enzymol, V49, P222; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; Li Y, 2002, P NATL ACAD SCI USA, V99, P7378, DOI 10.1073/pnas.102179999; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Narita A, 2001, J MOL BIOL, V308, P241, DOI 10.1006/jmbi.2001.4598; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Palm T, 2003, BIOPHYS J, V84, P3181, DOI 10.1016/S0006-3495(03)70042-3; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PARRY DAD, 1974, BIOCHEM BIOPH RES CO, V57, P216, DOI 10.1016/S0006-291X(74)80379-7; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; Paulucci AA, 2002, J BIOL CHEM, V277, P39574, DOI 10.1074/jbc.M204749200; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; Smith DA, 2003, BIOPHYS J, V84, P3155, DOI 10.1016/S0006-3495(03)70040-X; Smith DA, 2003, BIOPHYS J, V84, P3168, DOI 10.1016/S0006-3495(03)70041-1; Sousa AD, 2002, J BIOL CHEM, V277, P2081, DOI 10.1074/jbc.M109568200; SOUSA AD, 2002, THESIS U SAO PAULO B; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; STEWART M, 1975, NATURE, V257, P331, DOI 10.1038/257331a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WAHL P, 1978, EUR J BIOCHEM, V88, P421, DOI 10.1111/j.1432-1033.1978.tb12464.x; Whitby FG, 2000, PROTEINS, V38, P49; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; Xu C, 1999, BIOPHYS J, V77, P985, DOI 10.1016/S0006-3495(99)76949-3	58	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15204	15213		10.1074/jbc.M308904200	http://dx.doi.org/10.1074/jbc.M308904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14724287	hybrid			2022-12-25	WOS:000220594700087
J	Rousset, M; Cens, T; Gouin-Charnet, A; Scamps, F; Charnet, P				Rousset, M; Cens, T; Gouin-Charnet, A; Scamps, F; Charnet, P			Ca2+ and phosphatidylinositol 4,5-bisphosphate stabilize a G beta gamma-sensitive state of Ca(V)2 Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN INHIBITION; VOLTAGE-DEPENDENT FACILITATION; RECTIFYING K+ CHANNELS; CALCIUM-CHANNELS; CA2+-DEPENDENT INACTIVATION; KINASE-C; N-TYPE; DIFFERENTIAL MODULATION; BINDING; ACTIVATION	Direct interactions between G-protein betagamma subunits and N- or P/Q-type Ca2+ channels mediate the inhibitory action of several neurotransmitters in the brain. Membrane potential, channel phosphorylation, or auxiliary subunit association tightly regulate these interactions and the consequent inhibition of Ca2+ current. We now provide evidence that intracellular Ca2+ concentration and phosphoinositides play a stabilizing role in this direct voltage-dependent inhibition. Lowering resting cytosolic Ca2+ concentration in Xenopus oocytes expressing Ca(V)2 Ca2+ channels strongly decreased basal as well as phasic, agonist-dependent inhibition of Ca2+ channels by G-proteins. Decreasing phosphoinositide levels also suppressed G-protein inhibition and completely occluded the effects of a subsequent injection of Ca2+ chelator. Similar regulations are observed in mouse dorsal root ganglia neurons. Alteration of G-protein block by these agents is independent of protein phosphorylation, cytoskeleton dynamics, and GTPase or GDP/GTP exchange activity, suggesting a direct action at the level of the Ca2+ channel/Gbetagamma-protein interaction. Moreover, affinity binding experiments of intracellular loops of the Ca(V)2.1 Ca2+ channels to different phospholipids revealed specific interactions between the C-terminal tail of the channel and phosphoinositides. Taken together these data indicate that a Ca2+-sensitive interaction of the C-terminal tail of P/Q channels with the plasma membrane is important for G-protein regulation.	CNRS, Ctr Rech Biochim Macromol, F-34293 Montpellier, France; CNRS, INSERM, U469, F-34094 Montpellier, France; INSERM, U583, F-34095 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Charnet, P (corresponding author), CNRS, Ctr Rech Biochim Macromol, FRE 2593,1919 Route Mende, F-34293 Montpellier, France.	charnet@crbm.cnrs-mop.fr	Scamps, Frédérique/M-5268-2018; Cens, Thierry/M-3337-2017	Scamps, Frédérique/0000-0001-9545-407X; Cens, Thierry/0000-0002-4109-2779; Charnet, Pierre/0000-0003-4692-528X; Rousset, Matthieu/0000-0003-2064-2791				Andre S, 2003, NEUROREPORT, V14, P147, DOI 10.1097/01.wnr.0000051545.96524.bb; BEECH DJ, 1991, P NATL ACAD SCI USA, V88, P652, DOI 10.1073/pnas.88.2.652; Bodding M, 1999, PFLUG ARCH EUR J PHY, V439, P27, DOI 10.1007/s004240051124; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Budde T, 2002, NAT REV NEUROSCI, V3, P873, DOI 10.1038/nrn959; Burrone J, 2002, NEURON, V33, P101, DOI 10.1016/S0896-6273(01)00565-7; Canti C, 2000, J PHYSIOL-LONDON, V527, P419, DOI 10.1111/j.1469-7793.2000.t01-1-00419.x; Canti C, 1999, J NEUROSCI, V19, P6855, DOI 10.1523/JNEUROSCI.19-16-06855.1999; Cens T, 1996, PFLUG ARCH EUR J PHY, V431, P771, DOI 10.1007/BF02253842; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Flanagan LA, 1997, BIOPHYS J, V73, P1440, DOI 10.1016/S0006-3495(97)78176-1; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; Hering S, 2000, J PHYSIOL-LONDON, V528, P237, DOI 10.1111/j.1469-7793.2000.t01-1-00237.x; Herlitze S, 2001, P NATL ACAD SCI USA, V98, P4699, DOI 10.1073/pnas.051628998; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Ishii M, 2002, P NATL ACAD SCI USA, V99, P4325, DOI 10.1073/pnas.072073399; JACQUES JP, 1999, J GEN PHYSIOL, V114, P673; Kinoshita M, 2001, J BIOL CHEM, V276, P28731, DOI 10.1074/jbc.M104806200; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lee A, 2002, NAT NEUROSCI, V5, P210, DOI 10.1038/nn805; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; LORENZEN A, 1993, MOL PHARMACOL, V44, P115; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Mirshahi T, 2002, J BIOL CHEM, V277, P36345, DOI 10.1074/jbc.M205359200; MOGUL DJ, 1993, NEURON, V10, P327, DOI 10.1016/0896-6273(93)90322-I; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Page KM, 1998, J NEUROSCI, V18, P4815; Page KM, 1997, J NEUROSCI, V17, P1330; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; ROCHE JP, 1995, FEBS LETT, V371, P43, DOI 10.1016/0014-5793(95)00860-C; Roche JP, 1998, J NEUROSCI, V18, P4883; Roche JP, 1998, J NEUROSCI, V18, P878; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Varnai P, 2002, J BIOL CHEM, V277, P27412, DOI 10.1074/jbc.M109672200; Wu L, 2002, NATURE, V419, P947, DOI 10.1038/nature01118; Xie LH, 1999, J PHYSIOL-LONDON, V514, P655, DOI 10.1111/j.1469-7793.1999.655ad.x; You YD, 1997, BIOPHYS J, V72, P175, DOI 10.1016/S0006-3495(97)78656-9; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	59	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14619	14630		10.1074/jbc.M313284200	http://dx.doi.org/10.1074/jbc.M313284200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722074	hybrid			2022-12-25	WOS:000220594700020
J	Hu, MC; Wasserman, D; Hartwig, S; Rosenblum, ND				Hu, MC; Wasserman, D; Hartwig, S; Rosenblum, ND			p38(MAPK) acts in the BMP7-dependent stimulatory pathway during epithelial cell morphogenesis and is regulated by Smad1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; RENAL BRANCHING MORPHOGENESIS; SIGNALING PATHWAYS; TGF-BETA; I RECEPTORS; EXPRESSION; COMPLEXES; ACTIVIN	Bone morphogenetic protein (BMP)-7 exerts dose-dependent stimulatory and inhibitory effects during renal branching morphogenesis. Previously, we identified an inhibitory role for activin-like kinase receptors and Smad1 in BMP-dependent inhibition (Piscione, T. D., Phan, T., and Rosenblum, N. D. (2001) Am. J. Physiol. 280, F19-F33). Here we demonstrate a novel role for p38 mitogen-activated kinase (p38(MAPK)) in BMP7-dependent stimulatory signaling. Stimulatory doses (0.25 nM) of BMP7 increased p38(MAPK) activity and stimulated phosphorylation of endogenous activating transcription factor 2 (ATF2) in a p38(MAPK)-dependent manner in murine inner medullary collecting duct (mIMCD-3) cells. In contrast, high doses ( 10 nM) of BMP7 inhibited p38(MAPK) activity and phosphorylation of endogenous ATF2. Treatment with BMP7 exerted no significant effect on the levels of the phosphorylated forms of endogenous SAPK/JNK or p44 and p42 (ERK1 and ERK2) protein kinases. To investigate the functional importance of p38(MAPK) signaling, we showed that SB203580, a p38(MAPK) inhibitor, blocked the stimulatory effect of BMP7 on mIMCD-3 cell morphogenesis but had no effect on BMP7-dependent inhibition in a three-dimensional culture model. To identify mechanisms by which BMP7-dependent inhibitory signaling suppresses p38(MAPK) activity, we measured p38(MAPK) activity in ligand independent mIMCD-3 models of enhanced and suppressed Smad signaling. Basal activity of p38(MAPK) was decreased in mIMCD-3 cells and in embryonic kidney tissue expressing a constitutively active activin-like kinase receptor, but was increased in mIMCD-3 cells stably expressing a dominant negative form of Smad1. We conclude that BMP7 stimulates renal epithelial cell morphogenesis via p38(MAPK) and that p38(MAPK) activity is negatively regulated by Smad1.	Univ Toronto, Hosp Sick Children, Div Nephrol, Program Dev Biol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Rosenblum, ND (corresponding author), Univ Toronto, Hosp Sick Children, Div Nephrol, Program Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	norman.rosenblum@sickkids.ca	Rosenblum, Norman D/H-4737-2015	Rosenblum, Norman D/0000-0003-1767-6464				ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Curthoys NP, 2001, AM J PHYSIOL-RENAL, V281, pF381, DOI 10.1152/ajprenal.2001.281.3.F381; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Dudley AT, 1997, DEV DYNAM, V208, P349; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Grisaru S, 2001, DEV BIOL, V231, P31, DOI 10.1006/dbio.2000.0127; Gupta IR, 1999, J BIOL CHEM, V274, P26305, DOI 10.1074/jbc.274.37.26305; Gupta IR, 2000, J CELL SCI, V113, P269; Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02-06-0356; Hayes SA, 2003, ONCOGENE, V22, P4841, DOI 10.1038/sj.onc.1206730; Hida M, 2002, KIDNEY INT, V61, P1252, DOI 10.1046/j.1523-1755.2002.00273.x; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hu MC, 2003, DEVELOPMENT, V130, P2753, DOI 10.1242/dev.00478; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Omori S, 2000, KIDNEY INT, V58, P27, DOI 10.1046/j.1523-1755.2000.00137.x; Piscione TD, 1997, AM J PHYSIOL-RENAL, V273, pF961, DOI 10.1152/ajprenal.1997.273.6.F961; Piscione TD, 2001, AM J PHYSIOL-RENAL, V280, pF19, DOI 10.1152/ajprenal.2001.280.1.F19; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Yamanaka Y, 2001, BIOCHEM BIOPH RES CO, V281, P373, DOI 10.1006/bbrc.2001.4385; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	37	53	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12051	12059		10.1074/jbc.M310526200	http://dx.doi.org/10.1074/jbc.M310526200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718543	hybrid			2022-12-25	WOS:000220334900008
J	Keyel, PA; Watkins, SC; Traub, LM				Keyel, PA; Watkins, SC; Traub, LM			Endocytic adaptor molecules reveal an endosomal population of clathrin by total internal reflection fluorescence microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MEMBRANE-ASSOCIATED CLATHRIN; TRANS-GOLGI NETWORK; MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; LIVING CELLS; FACTOR RECEPTOR; AP-1 COMPLEX; COATED PITS; PROTEIN	Most eukaryotes utilize a single pool of clathrin to assemble clathrin-coated transport vesicles at different intracellular locations. Coat assembly is a cyclical process. Soluble clathrin triskelia are recruited to the membrane surface by compartment-specific adaptor and/or accessory proteins. Adjacent triskelia then pack together to assemble a polyhedral lattice that progressively invaginates, budding off the membrane surface encasing a nascent transport vesicle that is quickly uncoated. Using total internal reflection fluorescence microscopy to follow clathrin dynamics close to the cell surface, we find that the majority of labeled clathrin structures are relatively static, moving vertically in and out of the evanescent field but with little lateral motion. A small minority shows rapid lateral and directed movement over micrometer distances. Adaptor proteins, including the alpha subunit of AP-2, ARH, and Dab2 are also relatively static and exhibit virtually no lateral movement. A fluorescently labeled AP-2 beta2 subunit, incorporated into both AP-2 and AP-1 adaptor complexes, exhibits both types of behavior. This suggests that the highly motile clathrin puncta may be distinct from plasma membrane-associated clathrin structures. When endocytosed cargo molecules, such as transferrin or low density lipoprotein, are followed into cells, they exhibit even more lateral motion than clathrin, and gradually concentrate in the perinuclear region, consistent with classical endosomal trafficking. Importantly, clathrin partially colocalizes with internalized transferrin, but diverges as the structures move longitudinally. Thus, highly motile clathrin structures are apparently distinct from the plasma membrane, accompany transferrin, and contain AP-1, revealing an endosomal population of clathrin structures.	Univ Pittsburgh, Dept Cell Biol & Physiol, Sch Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Traub, LM (corresponding author), Univ Pittsburgh, Dept Cell Biol & Physiol, Sch Med, S325 BSTWR, Pittsburgh, PA 15261 USA.	traub@pitt.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552; Traub, Linton/0000-0002-1303-0298	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053249, T32DK061296] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32 DK 061296-02, R01 DK 53249] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELROD D, 1989, METHOD CELL BIOL, V30, P245; Bennett EM, 2001, MOL BIOL CELL, V12, P2790, DOI 10.1091/mbc.12.9.2790; Blanpied TA, 2003, NEUROBIOL AGING, V24, P1095, DOI 10.1016/j.neurobiolaging.2003.04.004; Blanpied TA, 2002, NEURON, V36, P435, DOI 10.1016/S0896-6273(02)00979-0; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; Conner SD, 2003, J CELL BIOL, V162, P773, DOI 10.1083/jcb.200304069; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Han WP, 1999, P NATL ACAD SCI USA, V96, P14577, DOI 10.1073/pnas.96.25.14577; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Huang FT, 2001, TRAFFIC, V2, P345, DOI 10.1034/j.1600-0854.2001.25020506.x; Jaiswal JK, 2002, J CELL BIOL, V159, P625, DOI 10.1083/jcb.200208154; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Lafer EM, 2002, TRAFFIC, V3, P513, DOI 10.1034/j.1600-0854.2002.30801.x; Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lee TH, 1999, MOL BIOL CELL, V10, P1445, DOI 10.1091/mbc.10.5.1445; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; Presley JF, 2002, NATURE, V417, P187, DOI 10.1038/417187a; Rappoport JZ, 2003, TRAFFIC, V4, P460, DOI 10.1034/j.1600-0854.2003.00100.x; Rappoport JZ, 2003, J CELL SCI, V116, P847, DOI 10.1242/jcs.00289; Rappoport JZ, 2003, J BIOL CHEM, V278, P47357, DOI 10.1074/jbc.C300390200; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; SAKAI T, 1991, J BIOCHEM-TOKYO, V109, P528, DOI 10.1093/oxfordjournals.jbchem.a123415; Santini F, 2002, NAT CELL BIOL, V4, pE230, DOI 10.1038/ncb1002-e230; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; Sorkina T, 2002, J BIOL CHEM, V277, P27433, DOI 10.1074/jbc.M201595200; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Toomre D, 2000, J CELL BIOL, V149, P33, DOI 10.1083/jcb.149.1.33; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Waguri S, 2003, MOL BIOL CELL, V14, P142, DOI 10.1091/mbc.E02-06-0338; Wu XF, 2003, MOL BIOL CELL, V14, P516, DOI 10.1091/mbc.E02-06-0353; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085	55	72	73	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13190	13204		10.1074/jbc.M312717200	http://dx.doi.org/10.1074/jbc.M312717200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722064	hybrid			2022-12-25	WOS:000220334900141
J	Takano, M; Koyama, Y; Ito, H; Hoshino, S; Onogi, H; Hagiwara, M; Furukawa, K; Horigome, T				Takano, M; Koyama, Y; Ito, H; Hoshino, S; Onogi, H; Hagiwara, M; Furukawa, K; Horigome, T			Regulation of binding of lamin B receptor to chromatin by SR protein kinase and cdc2 kinase in Xenopus egg extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ENVELOPE; SPLICING FACTORS; MEMBRANE; LOCALIZATION; LBR; PHOSPHORYLATION; EMERIN; SRPK2	Participation of multiple kinases in regulation of the binding of lamin B receptor (LBR) to chromatin was suggested previously (Takano, M., Takeuchi, M., Ito, H., Furukawa, K., Sugimoto, K., Omata, S., and Horigome, T. (2002) Eur. J. Biochem. 269, 943 - 953). To identify these kinases, regulation of the binding of the nucleoplasmic region (NK, amino acid residues 1 - 211) of LBR to sperm chromatin was studied using a cell cycle-dependent Xenopus egg extract in vitro. The binding was stimulated on specific phosphorylation of the NK fragment by an S-phase egg extract. Protein depletion with beads bearing SF2/ASF, which binds SR protein kinases, abolished this stimulation, suggesting that an SR protein kinase(s) is responsible for the activation of LBR. This was confirmed by direct phosphorylation and activation with recombinant SR protein-specific kinase 1. The binding of the NK fragment to chromatin pretreated with an S-phase extract was suppressed by incubation with an M-phase extract. Enzyme inhibitor experiments revealed that multiple kinases participate in the suppression. One of these kinases was shown to be cdc2 kinase using a specific inhibitor, roscovitine, and protein depletion with beads bearing p13, which specifically binds cdc2 kinase. Experiments involving a mutant NK fragment showed that the phosphorylation of serine 71 by cdc2 kinase is responsible for the suppression.	Niigata Univ, Fac Sci, Dept Chem, Niigata 9502181, Japan; Niigata Univ, Grad Sch Sci & Technol, Course Biosphere Sci, Niigata 9502181, Japan; Niigata Univ, Grad Sch Sci & Technol, Course Funct Biol, Niigata 9502181, Japan; Tokyo Med & Dent Univ, Sch Biomed Sci, Bunkyo Ku, Tokyo 1130034, Japan; Niigata Univ, Ctr Transdisciplinary Res, Niigata 9502181, Japan	Niigata University; Niigata University; Niigata University; Tokyo Medical & Dental University (TMDU); Niigata University	Horigome, T (corresponding author), Niigata Univ, Fac Sci, Dept Chem, Igarashi 2, Niigata 9502181, Japan.	thori@chem.sc.niigata-u.ac.jp						Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Collas P, 1996, J CELL BIOL, V135, P1715, DOI 10.1083/jcb.135.6.1715; Dreger M, 1999, BIOCHEMISTRY-US, V38, P9426, DOI 10.1021/bi990645f; Duband-Goulet I, 2000, BIOCHEMISTRY-US, V39, P6483, DOI 10.1021/bi992908b; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; Furukawa K, 1997, BIOCHEM BIOPH RES CO, V238, P240, DOI 10.1006/bbrc.1997.7235; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Haraguchi T, 2000, J CELL SCI, V113, P779; Hoffmann K, 2002, NAT GENET, V31, P410, DOI 10.1038/ng925; Kawahire S, 1996, EXP CELL RES, V222, P385, DOI 10.1006/excr.1996.0048; Koizumi J, 1999, J BIOL CHEM, V274, P11125, DOI 10.1074/jbc.274.16.11125; Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; Nikolakaki E, 1997, J BIOL CHEM, V272, P6208, DOI 10.1074/jbc.272.10.6208; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; Papoutsopoulou S, 1999, BIOCHEM BIOPH RES CO, V255, P602, DOI 10.1006/bbrc.1999.0249; PFALLER R, 1995, J BIOL CHEM, V270, P19066, DOI 10.1074/jbc.270.32.19066; Pyrpasopoulou A, 1996, EMBO J, V15, P7108, DOI 10.1002/j.1460-2075.1996.tb01102.x; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Takano M, 2002, EUR J BIOCHEM, V269, P943, DOI 10.1046/j.0014-2956.2001.02730.x; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737	23	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13265	13271		10.1074/jbc.M308854200	http://dx.doi.org/10.1074/jbc.M308854200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718546	hybrid			2022-12-25	WOS:000220334900149
J	Wong, GT; Manfra, D; Poulet, FM; Zhang, Q; Josien, H; Bara, T; Engstrom, L; Pinzon-Ortiz, M; Fine, JS; Lee, HJJ; Zhang, LL; Higgins, GA; Parker, EM				Wong, GT; Manfra, D; Poulet, FM; Zhang, Q; Josien, H; Bara, T; Engstrom, L; Pinzon-Ortiz, M; Fine, JS; Lee, HJJ; Zhang, LL; Higgins, GA; Parker, EM			Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; E-CADHERIN; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; FATE; CLEAVAGE; NOTCH1; NEUROPATHOLOGY; RELEASE; APP	Inhibition of gamma-secretase, one of the enzymes responsible for the cleavage of the amyloid precursor protein (APP) to produce the pathogenic beta-amyloid (Abeta) peptides, is an attractive approach to the treatment of Alzheimer disease. In addition to APP, however, several other gamma-secretase substrates have been identified (e.g. Notch), and altered processing of these substrates by gamma-secretase inhibitors could lead to unintended biological consequences. To study the in vivo consequences of gamma-secretase inhibition, the gamma-secretase inhibitor LY-411,575 was administered to C57BL/6 and TgCRND8 APP transgenic mice for 15 days. Although most tissues were unaffected, doses of LY-411,575 that inhibited Abeta production had marked effects on lymphocyte development and on the intestine. LY-411,575 decreased overall thymic cellularity and impaired intrathymic differentiation at the CD4(-)CD8(-)CD44(+)CD25(+) precursor stage. No effects on peripheral T cell populations were noted following LY-411,575 treatment, but evidence for the altered maturation of peripheral B cells was observed. In the intestine, LY-411,575 treatment increased goblet cell number and drastically altered tissue morphology. These effects of LY-411,575 were not seen in mice that were administered LY-D, a diastereoisomer of LY-411,575, which is a very weak gamma-secretase inhibitor. These studies show that inhibition of gamma-secretase has the expected benefit of reducing Abeta in a murine model of Alzheimer disease but has potentially undesirable biological effects as well, most likely because of the inhibition of Notch processing.	Schering Plough Res Inst, Dept CNS Res, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Dept Immunol, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Dept Chem Res, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Dept Drug Safety, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute	Parker, EM (corresponding author), Schering Plough Res Inst, Dept CNS Res, Mail Stop K-15-2-2760,2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	eric.parker@spcorp.com						Allman D, 2002, CELL, V109, pS1, DOI 10.1016/S0092-8674(02)00689-X; Arnold SE, 1991, CEREB CORTEX, V1, P103, DOI 10.1093/cercor/1.1.103; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Berzins SP, 2002, TRENDS MOL MED, V8, P469, DOI 10.1016/S1471-4914(02)02415-2; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; CONLON RA, 1995, DEVELOPMENT, V121, P1533; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DICKSON DW, 1995, NEUROBIOL AGING, V16, P285, DOI 10.1016/0197-4580(95)00013-5; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Ewbank DC, 1999, AM J PUBLIC HEALTH, V89, P90, DOI 10.2105/AJPH.89.1.90; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Garcia-Peydro M, 2003, BLOOD, V102, P2444, DOI 10.1182/blood-2002-10-3261; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Josien H, 2002, CURR OPIN DRUG DI DE, V5, P513; Kuroda K, 2003, IMMUNITY, V18, P301, DOI 10.1016/S1074-7613(03)00029-3; Kutlesa S, 2002, J CELL SCI, V115, P4505, DOI 10.1242/jcs.00142; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lanz TA, 2003, J PHARMACOL EXP THER, V305, P864, DOI 10.1124/jpet.102.048280; Lewis HD, 2003, BIOCHEMISTRY-US, V42, P7580, DOI 10.1021/bi034310g; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; MAY PC, 2001, SOC NEUR 31 ANN M SA, P681; Muller KM, 1997, IMMUNITY, V6, P257, DOI 10.1016/S1074-7613(00)80328-3; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Saito T, 2003, IMMUNITY, V18, P675, DOI 10.1016/S1074-7613(03)00111-0; Sawamura N, 2000, J BIOL CHEM, V275, P27901; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Searfoss GH, 2003, J BIOL CHEM, V278, P46107, DOI 10.1074/jbc.M307757200; Stoop R, 2002, EUR J IMMUNOL, V32, P2532, DOI 10.1002/1521-4141(200209)32:9<2532::AID-IMMU2532>3.0.CO;2-A; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; WU J, 1998, Patent No. [09828268, 9828268]; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	46	600	647	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12876	12882		10.1074/jbc.M311652200	http://dx.doi.org/10.1074/jbc.M311652200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709552	hybrid			2022-12-25	WOS:000220334900104
J	Zaballos, A; Villares, R; Albar, JP; Martinez, C; Marquez, G				Zaballos, A; Villares, R; Albar, JP; Martinez, C; Marquez, G			Identification on mouse chromosome 8 of new beta-defensin genes with regionally specific expression in the male reproductive organ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL ACTIVITY; CHEMOKINE RECEPTOR; DENDRITIC CELLS; IMMUNITY; PURIFICATION; EPIDIDYMIS; MULTIPLE; PEPTIDE; CCR6; MICE	Defensins are important elements in innate immunity that can also trigger adaptive immune responses. The defensins form a family of small cationic antimicrobial peptides with six characteristic cysteine residues, whose pairing pattern in forming three intramolecular disulfide bonds defines the alpha- and beta-defensin subfamilies. In a search for new beta-defensin genes, we performed computational analysis using the Celera mouse genome data base and found exons encoding 23 different beta-defensins, including the eight previously characterized members of this family. Among the new beta-defensins, nine of them form two groups of phylogenetically related sequences that were characterized in greater detail. Northern blot, reverse transcription PCR, and in situ hybridization analysis showed that expression of these genes is restricted to the epididymis, with a specific regional expression pattern. One of the new beta-defensins (Defb38) was chemically synthesized; in in vitro assays on Gram-positive and -negative bacterial strains, Defb38 showed the characteristic salt-dependent antimicrobial activity of beta-defensins. The results demonstrate the existence of a relatively large number of beta-defensins with specific expression in distinct regions of the murine epididymis and suggest complex roles for these proteins in host defense and other physiological processes of the male reproductive tract.	Univ Autonoma Madrid, Dept Inmunol & Oncol, Ctr Nacl Biotecnol, Consejo Super Invest Cient, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Marquez, G (corresponding author), Univ Autonoma Madrid, Dept Inmunol & Oncol, Ctr Nacl Biotecnol, Consejo Super Invest Cient, E-28049 Madrid, Spain.	gmarquez@cnb.uam.es	Villares, Ricardo/AAN-3755-2021; Villares, Ricardo/AAA-7236-2020; Zaballos, Ángel/O-2853-2015	Villares, Ricardo/0000-0001-7562-6700; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Carramolino L, 2001, BLOOD, V97, P850, DOI 10.1182/blood.V97.4.850; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; Ganz T, 1999, SCIENCE, V286, P420, DOI 10.1126/science.286.5439.420; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Hieshima K, 2003, J IMMUNOL, V170, P1452, DOI 10.4049/jimmunol.170.3.1452; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; Latifi A, 1996, MOL MICROBIOL, V21, P1137, DOI 10.1046/j.1365-2958.1996.00063.x; Li P, 2001, SCIENCE, V291, P1783, DOI 10.1126/science.1056545; Perez-Canadillas JM, 2001, J BIOL CHEM, V276, P28372, DOI 10.1074/jbc.M103121200; Rodriguez-Jimenez FJ, 2003, GENOMICS, V81, P175, DOI 10.1016/S0888-7543(02)00034-4; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Yamaguchi Y, 2002, J IMMUNOL, V169, P2516, DOI 10.4049/jimmunol.169.5.2516; Yang D, 2002, TRENDS IMMUNOL, V23, P291, DOI 10.1016/S1471-4906(02)02246-9; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525	22	29	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12421	12426		10.1074/jbc.M307697200	http://dx.doi.org/10.1074/jbc.M307697200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718547	hybrid			2022-12-25	WOS:000220334900051
J	Flandez, M; Cosano, IC; Nombela, C; Martin, H; Molina, M				Flandez, M; Cosano, IC; Nombela, C; Martin, H; Molina, M			Reciprocal regulation between Slt2 MAPK and isoforms of Msg5 dual-specificity protein phosphatase modulates the yeast cell integrity pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHATASES; KINASE PATHWAY; BUDDING YEAST; MESSENGER-RNA; DIFFERENTIAL REGULATION; ESCHERICHIA-COLI; SHUTTLE VECTORS; FUSION PROTEINS	Dual-specificity protein phosphatases (DSPs) are involved in the negative regulation of mitogen-activated protein kinases (MAPKs) by dephosphorylating both threonine- and tyrosine-conserved residues located at the activation loop. Here we show that Msg5 DSP activity is essential for maintaining a low level of signaling through the cell integrity pathway in Saccharomyces cerevisiae. Consistent with a role of this phosphatase on cell wall physiology, cells lacking Msg5 displayed an increased sensitivity to the cell wall-interfering compound Congo Red. We have observed that the N-terminal non-catalytic region of this phosphatase was responsible for binding to the kinase domain of Slt2, the MAPK that operates in this pathway. In vivo and in vitro experiments revealed that both proteins act on each other. Msg5 bound and dephosphorylated activated Slt2. Reciprocally, Slt2 phosphorylated Msg5 as a consequence of the activation of the cell integrity pathway. In addition, alternative use of translation initiation sites at MSG5 resulted in two protein forms that are functional on Slt2 and became equally phosphorylated following activation of this MAPK. Under activating conditions, a decrease in the affinity between Msg5 and Slt2 was observed, leading us to suggest that the mechanism by which Slt2 controls the action of Msg5 was via the modulation of protein-protein interactions. Our results indicate the existence of posttranscriptional mechanisms of regulation of DSPs in yeast and provide new insights into the negative control of the cell integrity pathway.	Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, E-28040 Madrid, Spain	Complutense University of Madrid	Molina, M (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, Pza Ramon & Cajal S-N, E-28040 Madrid, Spain.	molmifa@farm.ucm.es	Brieva, Humberto Martin/E-9254-2016; Canet, Marta Flández/E-2681-2019; Molina, Maria/ABE-7186-2021; Martín, Humberto/Z-3423-2019; Nombela Cano, César/H-2565-2015	Brieva, Humberto Martin/0000-0002-6736-3602; Canet, Marta Flández/0000-0002-9096-2267; Molina, Maria/0000-0003-0074-3309; Martín, Humberto/0000-0002-6736-3602; Nombela Cano, César/0000-0003-0757-4034				Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Collister M, 2002, FEBS LETT, V527, P186, DOI 10.1016/S0014-5793(02)03220-9; Davenport KD, 1999, GENETICS, V153, P1091; de Groot PWJ, 2001, COMP FUNCT GENOM, V2, P124, DOI 10.1002/cfg.85; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hahn JS, 2002, J BIOL CHEM, V277, P21278, DOI 10.1074/jbc.M202557200; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; HUANG KN, 1995, GENETICS, V141, P1275; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Logette E, 2003, ONCOGENE, V22, P935, DOI 10.1038/sj.onc.1206172; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; Masuda K, 2003, J BIOL CHEM, V278, P32448, DOI 10.1074/jbc.M213254200; Mattison CP, 1999, MOL CELL BIOL, V19, P7651; MILLAR JBA, 1992, EMBO J, V11, P4943, DOI 10.1002/j.1460-2075.1992.tb05601.x; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; RONCERO C, 1985, J BACTERIOL, V163, P1180, DOI 10.1128/JB.163.3.1180-1185.1985; SAMROOK J, 1989, MOL CLONING LAB MANU; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; SIKORSKI RS, 1989, GENETICS, V122, P19; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; Sohaskey ML, 2002, MOL BIOL CELL, V13, P454, DOI 10.1091/mbc.01-11-0553; SOLER M, 1995, MOL MICROBIOL, V17, P833, DOI 10.1111/j.1365-2958.1995.mmi_17050833.x; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; Vink E, 2002, MICROBIOL-SGM, V148, P4035, DOI 10.1099/00221287-148-12-4035; Vivier MA, 1999, MOL GEN GENET, V261, P11, DOI 10.1007/s004380050936; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x; Zhan XL, 1997, GENE DEV, V11, P1690, DOI 10.1101/gad.11.13.1690; Zhan XL, 1999, GENE DEV, V13, P2811, DOI 10.1101/gad.13.21.2811; Zhang ZY, 2002, PHARMACOL THERAPEUT, V93, P307, DOI 10.1016/S0163-7258(02)00199-7; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013	51	61	63	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11027	11034		10.1074/jbc.M306412200	http://dx.doi.org/10.1074/jbc.M306412200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14703512	hybrid			2022-12-25	WOS:000220157600025
J	Koonpaew, S; Janssen, E; Zhu, MH; Zhang, WG				Koonpaew, S; Janssen, E; Zhu, MH; Zhang, WG			The importance of three membrane-distal tyrosines in the adaptor protein NTAL/LAB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; PHOSPHOLIPASE C-GAMMA-1 PLC-GAMMA-1; MOLECULAR-CLONING; ANTIGEN RECEPTOR; MEDIATED ACTIVATION; SIGNALING PATHWAYS; LINKER PROTEIN; LAT; SLP-76; REQUIREMENT	NTAL (non-T cell activation linker)/LAB ( linker for activation of B cells) is a LAT ( linker for activation of T cells)-like molecule that is expressed in B cells, mast cells, natural killer cells, and monocytes. Upon engagement of the B cell receptor or Fc receptors, it is phosphorylated and interacts with Grb2. LAB is capable of rescuing thymocyte development in LAT(-/-) mice. In this study, we utilized various LAB Tyr to Phe mutants to map the phosphorylation and Grb2-binding sites of LAB. We also examined the function of these mutants by investigating their ability to rescue signaling defects in LAT-deficient Jurkat cells and thymocyte development in LAT(-/-) mice. Our results indicated that human LAB was primarily phosphorylated on three membrane-distal tyrosines, Tyr(136), Tyr(193), and Tyr(233). Mutation of these three tyrosines abolished Grb2 binding and LAB function. Our data suggested that these tyrosines are the most important tyrosines for LAB function.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University	Zhang, WG (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Jones Bldg Rm 112,Box 3010, Durham, NC 27710 USA.	zhang033@mc.duke.edu	Koonpaew, Surapong/C-8295-2011	Janssen, Erin/0000-0002-0687-2550	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056156, R01AI048674, R56AI056156] Funding Source: NIH RePORTER; NIAID NIH HHS [AI056156, 1 R01 AI048674, R01 AI056156] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aguado E, 2002, SCIENCE, V296, P2036, DOI 10.1126/science.1069057; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Bruyns E, 1998, J EXP MED, V188, P561, DOI 10.1084/jem.188.3.561; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Janssen E, 2003, NAT IMMUNOL, V4, P117, DOI 10.1038/ni882; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Marie-Cardine A, 1999, J EXP MED, V189, P1181, DOI 10.1084/jem.189.8.1181; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Sommers CL, 2002, SCIENCE, V296, P2040, DOI 10.1126/science.1069066; Sommers CL, 2001, J EXP MED, V194, P135, DOI 10.1084/jem.194.2.135; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu MH, 2002, J BIOL CHEM, V277, P46151, DOI 10.1074/jbc.M208946200; Zhu NH, 2003, J IMMUNOL, V170, P325, DOI 10.4049/jimmunol.170.1.325	34	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11229	11235		10.1074/jbc.M311394200	http://dx.doi.org/10.1074/jbc.M311394200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722116	hybrid			2022-12-25	WOS:000220157600049
J	Stoorvogel, W; Kerstens, S; Fritzsche, I; den Hartigh, JC; Oud, R; van der Heyden, MAG; Voortman, J; Henegouwen, PMPVE				Stoorvogel, W; Kerstens, S; Fritzsche, I; den Hartigh, JC; Oud, R; van der Heyden, MAG; Voortman, J; Henegouwen, PMPVE			Sorting of ligand-activated epidermal growth factor receptor to lysosomes requires its actin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE DOMAIN; EGF-RECEPTOR; DOWN-REGULATION; POSTENDOCYTIC TRAFFICKING; COATED PITS; ENDOCYTOSIS; INTERNALIZATION; PROTEIN; GRB2; DEGRADATION	Ligand-induced down-regulation of the epidermal growth factor receptor (EGFR) comprises activation of two sequential transport steps. The first involves endocytic uptake by clathrin-coated vesicles, the second transfer of endocytosed EGFR from endosomes to lysosomes. Here we demonstrate that the second transport step requires a domain of the EGFR that encompasses residues 985-996 and was previously found to interact with actin. Deletion of domain 989-994 (Delta989-994 EGFR) did not interfere with EGFR uptake but completely abrogated its degradation. In contrast, both uptake and degradation were affected for K721A EGFR, a kinase-deficient EGFR mutant. To measure intracellular EGFR sorting, we developed a novel cell fractionation assay toward which cells were co-transfected for chicken hepatic lectin, a receptor for agialoglycoproteins. These cells were incubated with agialofetuin-coupled colloidal gold, which was targeted to lysosomes after receptor-mediated endocytosis. Compartments within the lysosomal pathway gained buoyant density because of the presence of colloidal gold and could be isolated from cell homogenates by ultracentrifugation through a high-density sucrose cushion. In contrast to endocytosed wild type EGFR, both Delta989-994 EGFR and K721A EGFR were largely not retrieved in gold-containing endocytic compartments. These results are supported with morphological data. We conclude that sorting of endocytosed EGFR into the degradation pathway requires both its kinase activity and actin-binding domain.	Univ Med Ctr, Dept Cell Biol, NL-3585 CX Utrecht, Netherlands; Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3585 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, Dept Mol Cell Biol, NL-3585 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University	Stoorvogel, W (corresponding author), Univ Utrecht, Dept Biochem & Cell Biol, Yalelaan 2,POB 80-176, NL-3508 TD Utrecht, Netherlands.	W.Stoorvogel@vet.uu.nl	van Bergen en Henegouwen, Paul/B-8870-2011	van Bergen en Henegouwen, Paul/0000-0001-6050-9042; van der Heyden, Marcel/0000-0002-4225-7942				Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; ENHENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; Holbrook MR, 1999, BIOCHEMISTRY-US, V38, P9348, DOI 10.1021/bi990195r; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HORWICH AL, 1985, J CELL BIOL, V100, P1515, DOI 10.1083/jcb.100.5.1515; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Jones SM, 2002, AM J PHYSIOL-CELL PH, V282, pC420, DOI 10.1152/ajpcell.00253.2001; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; LUND KA, 1990, J BIOL CHEM, V265, P15713; MELLOW TE, 1988, J BIOL CHEM, V263, P5468; Mosesson Y., 2003, J BIOL CHEM; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; Sakaguchi K, 2001, BIOCHEM BIOPH RES CO, V282, P1154, DOI 10.1006/bbrc.2001.4680; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SORKIN A, 1992, J BIOL CHEM, V267, P8672; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; SPIRO RG, 1964, J BIOL CHEM, V239, P567; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; vanderHeyden MAG, 1997, EXP CELL RES, V234, P521, DOI 10.1006/excr.1997.3661; VanderHeyden MAG, 1997, FEBS LETT, V410, P265, DOI 10.1016/S0014-5793(97)00599-1; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WILEY HS, 1991, J BIOL CHEM, V266, P11083; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; WUBBOLTS RW, 2003, J BIOL CHEM	43	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11562	11569		10.1074/jbc.M308449200	http://dx.doi.org/10.1074/jbc.M308449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702346	hybrid			2022-12-25	WOS:000220157600089
J	Celetti, A; Cerrato, A; Merolla, F; Vitagliano, D; Vecchio, G; Grieco, M				Celetti, A; Cerrato, A; Merolla, F; Vitagliano, D; Vecchio, G; Grieco, M			H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization	ONCOGENE			English	Article						H4(D10S170); RET/PTC1; ERK; apoptosis; stress; carcinogenesis; thyroid; TUNEL	FACTOR RECEPTOR-BETA; IN-VIVO; CELLS; PROTOONCOGENE; BAX; ACTIVATION; APOPTOSIS; ONCOGENE; PROTEINS; TUMORS	Human thyroid papillary carcinomas are characterized by rearrangements of the RET protooncogene with a number of heterologous genes, which generate the RET/papillary thyroid carcinoma (PTC) oncogenes. One of the most frequent variants of these recombination events is the fusion of the intracellular kinase-encoding domain of RET to the first 101 amino acids of a gene named H4(D10S170). We have characterized the H4(D10S170) gene product, showing that it is a ubiquitously expressed 55 KDa nuclear and cytosolic protein that is phosphorylated following serum stimulation. This phosphorylation was found to depend on mitogen-activated protein kinase (MAPK) Erk1/2 activity and to be associated to the relocation of H4(D10S170) from the nucleus to the cytosol. Overexpression of the H4(D10S170) gene was able to induce apoptosis of thyroid follicular epithelial cells; conversely a carboxy-terminal truncated H4(D10S170) mutant H4(1-101), corresponding to the portion included in the RET/PTC1 oncoprotein, behaved as dominant negative on the proapoptotic function and nuclear localization of H4(D10S170). Furthermore, conditional expression of the H4(D10S170)-dominant negative truncated mutant protected cells from stress-induced apoptosis. The substitution of serine 244 with alanine abrogated the apoptotic function of H4(D10S170). These data suggest that loss of the H4(D10S170) gene function might have a role in thyroid carcinogenesis by impairing apoptosis.	Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Policlin Materdomini, I-88100 Catanzaro, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, CNR, Ist Endocrinol & Oncol Sperimentale, Naples, Italy	Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Grieco, M (corresponding author), Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Policlin Materdomini, Via T Campanella 115, I-88100 Catanzaro, Italy.	mgrieco@unicz.it	Cerrato, Aniello/AAY-1484-2020; vitagliano, donata/B-8976-2012; Celetti, Angela/AAY-7172-2020	Grieco, Michele/0000-0002-4212-7814				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Bouillet P, 2002, J CELL SCI, V115, P1567; Bounacer A, 1997, BIOCHIMIE, V79, P619, DOI 10.1016/S0300-9084(97)82012-3; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; ITO T, 1993, CANCER RES, V53, P2940; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Jossart GH, 1996, CYTOGENET CELL GENET, V75, P254, DOI 10.1159/000134495; Kulkarni S, 2000, CANCER RES, V60, P3592; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Mitchell KO, 2000, CANCER RES, V60, P6318; Mizuno T, 2000, ONCOGENE, V19, P438, DOI 10.1038/sj.onc.1203343; Moysich KB, 2002, LANCET ONCOL, V3, P269, DOI 10.1016/S1470-2045(02)00727-1; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Portella G, 1996, ONCOGENE, V13, P2021; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; Santoro M, 2002, ANN NY ACAD SCI, V963, P116, DOI 10.1111/j.1749-6632.2002.tb04102.x; Schlumberger M, 1999, CR ACAD SCI III-VIE, V322, P205, DOI 10.1016/S0764-4469(99)80045-6; Schwaller J, 2001, BLOOD, V97, P3910, DOI 10.1182/blood.V97.12.3910; Sheils OM, 2000, J PATHOL, V192, P32; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tong Q, 1997, J BIOL CHEM, V272, P9043; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuttle RM, 2000, SEMIN NUCL MED, V30, P133, DOI 10.1053/nm.2000.5412; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; ZHAN QM, 1994, ONCOGENE, V9, P3743	39	48	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					109	121		10.1038/sj.onc.1206981	http://dx.doi.org/10.1038/sj.onc.1206981			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712216				2022-12-25	WOS:000187895300012
J	Liu, DY; Liu, XY; Robinson, D; Burnett, C; Jackson, C; Seele, L; Veach, RA; Downs, S; Collins, RD; Ballard, DW; Hawiger, J				Liu, DY; Liu, XY; Robinson, D; Burnett, C; Jackson, C; Seele, L; Veach, RA; Downs, S; Collins, RD; Ballard, DW; Hawiger, J			Suppression of staphylococcal enterotoxin B-induced toxicity by a nuclear import inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR-ALPHA GENE; T-CELLS; FUNCTIONAL PEPTIDES; LETHAL SHOCK; SUPERANTIGEN; MICE; INTERFERON; RESISTANT; RECEPTOR	Staphylococcal enterotoxin B and related toxins that target T cells have the capacity to elicit systemic inflammation, tissue injury, and death. Genes that encode mediators of inflammation can be globally inhibited by blocking the nuclear import of stress-responsive transcription factors. Here we show that cell-permeant peptides targeting Rch1/importin alpha/karyopherin alpha 2, a nuclear import adaptor protein, are delivered to T cells where they inhibit the staphylococcal enterotoxin B-induced production of inflammatory cytokines ex vivo in cultured primary spleen cells and in vivo. The systemic production of tumor necrosis factor alpha, interferon gamma, and interleukin-6 was attenuated in mice either by a cell-permeant cyclized form of SN50 peptide or by a transgene whose product suppresses the nuclear import of transcription factor nuclear factor kappaB in T cells. The extent of liver apoptosis and hemorrhagic necrosis was also reduced, which correlated with significantly decreased mortality rates. These findings highlight nuclear import inhibitors as a potentially useful countermeasure for staphylococcal enterotoxin B and other toxins that trigger harmful systemic inflammatory responses.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hawiger, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Med Ctr, 1161 21st Ave S,A-5321 MCN, Nashville, TN 37232 USA.	jacek.hawiger@vanderbilt.edu		Veach, Ruth Ann/0000-0003-0038-8802	NATIONAL CANCER INSTITUTE [P30CA068485, R01CA082556] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068744, R01HL062356, R43HL069542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054072] Funding Source: NIH RePORTER; NCI NIH HHS [CA82556, 2P30 CA 68485-05] Funding Source: Medline; NHLBI NIH HHS [HL62356, HL69542, HL68744] Funding Source: Medline; NIDDK NIH HHS [DK54072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOKI Y, 1995, J IMMUNOL, V155, P3494; Balaban N, 2000, INT J FOOD MICROBIOL, V61, P1, DOI 10.1016/S0168-1605(00)00377-9; BHARDWAJ N, 1993, J EXP MED, V178, P633, DOI 10.1084/jem.178.2.633; Blank C, 1997, EUR J IMMUNOL, V27, P825, DOI 10.1002/eji.1830270405; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; Chen CM, 2001, NAT BIOTECHNOL, V19, P921, DOI 10.1038/nbt1001-921; Chen R, 1999, CLIN CHEM, V45, P1693; Clark Nina M, 2003, Curr Opin Crit Care, V9, P403, DOI 10.1097/00075198-200310000-00011; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Fernandez T, 1998, NAT BIOTECHNOL, V16, P418, DOI 10.1038/nbt0598-418; Fey PD, 2003, ANTIMICROB AGENTS CH, V47, P196, DOI 10.1128/AAC.47.1.196-203.2003; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GREEN SJ, 1993, INFECT IMMUN, V61, P689, DOI 10.1128/IAI.61.2.689-698.1993; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099; HAWIGER J, 2001, WILEY ENCY MOL MED, P2435; Jezek Z, 1988, HUMAN MONKEYPOX; Jo DW, 2001, NAT BIOTECHNOL, V19, P929, DOI 10.1038/nbt1001-929; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu XY, 2000, J BIOL CHEM, V275, P16774; Madsen JM, 2001, CLIN LAB MED, V21, P593; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MATTIX ME, 1995, TOXICOL PATHOL, V23, P262, DOI 10.1177/019262339502300304; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; PEAVY DL, 1970, J IMMUNOL, V105, P1453; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; STILES BG, 1993, INFECT IMMUN, V61, P5333, DOI 10.1128/IAI.61.12.5333-5338.1993; Sundstedt A, 1996, P NATL ACAD SCI USA, V93, P979, DOI 10.1073/pnas.93.3.979; TAUB DD, 1992, CELL IMMUNOL, V141, P263, DOI 10.1016/0008-8749(92)90147-H; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Veach RA, 2004, J BIOL CHEM, V279, P11425, DOI 10.1074/jbc.M311089200; Villinger F, 1999, J INFECT DIS, V179, pS188, DOI 10.1086/514283; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	38	39	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19239	19246		10.1074/jbc.M313442200	http://dx.doi.org/10.1074/jbc.M313442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14732709	hybrid			2022-12-25	WOS:000221041500137
J	Liu, XF; Bagchi, MK				Liu, XF; Bagchi, MK			Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; DNA METHYLATION; BREAST-CANCER; N-COR; MOLECULAR DETERMINANTS; COACTIVATOR COMPLEXES; COREPRESSOR COMPLEX; NUCLEAR RECEPTORS; LIVING CELLS	Tamoxifen, a breast cancer therapeutic, is a tissue-selective estrogen receptor modulator ( SERM), which acts as an antiestrogen in the mammary tissue and displays estrogenic activity in other tissues such as bone and uterus. In order to understand the mechanisms underlying the antiestrogenic effect of this prototype SERM, we performed an analysis of the cofactors that interact with ER complexed with 4-hydroxytamoxifen (OHT) at natural target genes in a human breast tumor cell line MCF-7. Employing chromatin immunoprecipitation (ChIP), we observed that treatment with OHT rapidly induces the binding of ERalpha to the E-responsive promoter regions of pS2 and c-myc genes. Promoter-bound OHT-complexed ERa coordinately recruited the components of a multiprotein complex containing the corepressor NCoR, histone deacetylase 3 (HDAC3), and a WD40-repeat protein TBL1. Surprisingly, the OHT-complexed ERalpha also recruited a chromatin-remodeling NuRD complex in which histone deacetylase 1 (HDAC1) is associated with several polypeptides including metastasis-associated protein 1/2 (MTA1/ 2), and SWI2/SNF2-related ATPase Mi2. Kinetic studies revealed that following OHT addition the recruitment of these HDAC complexes to pS2 or the c-myc promoter occurs in a sequential manner; the NCoR-HDAC3 complex is recruited earlier than the NuRD complex. Serial ChIP experiments indicated that the ER-NCoR- HDAC3 and ER-NuRD complexes are distinct, and they do not occupy the target gene promoter simultaneously. We also established a close temporal link between the appearance of the HDAC complexes at the E-responsive regions of pS2 and c-myc promoters, local hypoacetylation of specific lysine residues in N-terminal tails of histones H3 and H4, and disappearance of RNA polymerase II from the target gene loci. Collectively, our studies indicated that transcriptional repression by tamoxifen-bound ER at E-regulated gene promoters involves a dynamic interplay of multiple distinct chromatin-modifying/remodeling complexes.	Univ Illinois, Dept Mol & Integrat Physiol, Sch Mol & Cellular Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Bagchi, MK (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, Sch Mol & Cellular Biol, 534 Burrill Hall,MC-114,407 S Goodwin Ave, Urbana, IL 61801 USA.	mbagchi@life.uiuc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050257] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 50257-05] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; CLARK GM, 1988, SEMIN ONCOL, V15, P20; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DUBIK D, 1992, ONCOGENE, V7, P1587; Feng Q, 2001, GENE DEV, V15, P827; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Glass CK, 2000, GENE DEV, V14, P121; Guenther MG, 2000, GENE DEV, V14, P1048; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang HJ, 2002, MOL ENDOCRINOL, V16, P1778, DOI 10.1210/me.2002-0089; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jordan VC, 1999, TRENDS ENDOCRIN MET, V10, P312, DOI 10.1016/S1043-2760(99)00181-2; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Katzenellenbogen BS, 2000, J STEROID BIOCHEM, V74, P279, DOI 10.1016/S0960-0760(00)00104-7; Kraus WL, 2002, EUR J BIOCHEM, V269, P2275, DOI 10.1046/j.1432-1033.2002.02889.x; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McDonnell DP, 1999, TRENDS ENDOCRIN MET, V10, P301, DOI 10.1016/S1043-2760(99)00177-0; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rice JC, 2001, NATURE, V414, P258, DOI 10.1038/35104721; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	51	107	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15050	15058		10.1074/jbc.M311932200	http://dx.doi.org/10.1074/jbc.M311932200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722073	hybrid			2022-12-25	WOS:000220594700069
J	Gad, A; Thullberg, M; Dannenberg, JH; Riele, HT; Stromblad, S				Gad, A; Thullberg, M; Dannenberg, JH; Riele, HT; Stromblad, S			Retinoblastoma susceptibility gene product (pRb) and p107 functionally separate the requirements for serum and anchorage in the cell cycle G(1)-phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTION POINT; DEPENDENT KINASES; DEFICIENT CELLS; G(1) CONTROL; G1 PHASE; GROWTH; PROLIFERATION; EXPRESSION; PROTEIN; PROGRESSION	Growth factors and cell anchorage are both required for cell cycle G(1)-phase progression, but it is unclear whether their function is mediated through the same set of cell cycle components and whether they are both required during the same periods of time. We separately analyzed the requirements of serum and anchorage during G(1)-phase progression and found that human dermal fibroblasts as well as wild type, pRb(-/-), and p107(-/-) mouse embryonic fibroblasts needed serum ( growth factors) until mid-G(1)-phase but required cell anchorage until late G(1)-phase to be competent for S-phase entry. Importantly, however, pRb/p107 double-null mouse embryonic fibroblasts lacked serum requirement in mid-G(1)- phase but still required cell anchorage until late G(1)-phase to enter S-phase. Our results indicate that pRb and p107 do not constitute the last control point for extracellular factors during G(1)-phase progression, and they functionally separate the requirements for serum and cell anchorage in terms of involved cell cycle components.	Karolinska Inst, Dept Lab Med, S-14186 Huddinge, Sweden; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Karolinska Institutet; Netherlands Cancer Institute	Stromblad, S (corresponding author), Karolinska Inst, Huddinge Sjukhjus F46, S-14186 Huddinge, Sweden.	Staffan.Stromblad@labmed.ki.se	Gad, Annica/H-8758-2017; Gad, Annica/X-8294-2018	Gad, Annica/0000-0002-1098-9129; Gad, Annica/0000-0002-1098-9129; Stromblad, Staffan/0000-0002-1236-6339				Assoian Richard K., 1997, Cytokine and Growth Factor Reviews, V8, P165, DOI 10.1016/S1359-6101(97)00011-7; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Kang JS, 1996, MOL CELL BIOL, V16, P3370; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schwartz MA, 2001, J CELL SCI, V114, P2553; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	41	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13640	13644		10.1074/jbc.M314300200	http://dx.doi.org/10.1074/jbc.M314300200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732703	hybrid			2022-12-25	WOS:000220478500045
J	Hiruma, T; Togayachi, A; Okamura, K; Sato, T; Kikuchi, N; Kwon, YD; Nakamura, A; Fujimura, K; Gotoh, M; Tachibana, K; Ishizuka, Y; Noce, T; Nakanishi, H; Narimatsu, H				Hiruma, T; Togayachi, A; Okamura, K; Sato, T; Kikuchi, N; Kwon, YD; Nakamura, A; Fujimura, K; Gotoh, M; Tachibana, K; Ishizuka, Y; Noce, T; Nakanishi, H; Narimatsu, H			A novel human beta 1,3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAc beta 1-3GlcNAc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN GLYCAN STRUCTURES; CURATED RELATIONAL DATABASE; BETA-1,3-GALACTOSYLTRANSFERASE FAMILY; MOLECULAR-CLONING; UDP-GALACTOSE; EXPRESSION CLONING; BIOLOGICAL SOURCES; N-GLYCOSYLATION; TYPE-1 CHAIN; O-GLYCANS	We found, using a BLAST search, a novel human gene (GenBank(TM) accession number BC029564) that possesses beta3-glycosyltransferase motifs. The full-length open reading frame consists of 500 amino acids and encodes a typical type II membrane protein. This enzyme has a domain containing beta1,3-glycosyltransferase motifs, which are widely conserved in the beta1,3-galactosyltransferase and beta1,3-N-acetylglucosaminyltransferase families. The putative catalytic domain was expressed in human embryonic kidney 293T cells as a soluble protein. Its N-acetylgalactosaminyltransferase activity was observed when N-acetylglucosamine (GlcNAc) beta1-O-benzyl was used as an acceptor substrate. The enzyme product was determined to have a beta1,3-linkage by NMR spectroscopic analysis, and was therefore named beta1,3-N-acetylgalactosaminyltransferase-II (beta3GalNAc-T2). The acceptor substrate specificity of beta3GalNAc-T2 was examined using various oligosaccharide substrates. Galbeta-1-3(GlcNAc beta1-6) GalNAcalpha1-O-para-nitrophenyl (core 2-pNP) was the best acceptor substrate for beta3GalNAc-T2, followed by GlcNAcbeta1 - 4GlcNAcbeta1-O-benzyl, and GlcN-Ac beta1-6GalNAcalpha1-O-para-nitrophenyl (core 6-pNP), among the tested oligosaccharide substrates. Quantitative real time PCR analysis revealed that the beta3GalNAc-T2 transcripts was restricted in its distribution mainly to the testis, adipose tissue, skeletal muscle, and ovary. Its putative orthologous gene, mbeta3GalNAc-T2, was also found in a data base of mouse expressed sequence tags. In situ hybridization analysis with mouse testis showed that the transcripts are expressed in germ line cells. beta3GalNAc-T2 efficiently transferred GalNAc to N-glycans of fetal calf fetuin, which was treated with neuraminidase and beta-galactosidase. However, it showed no activity toward any glycolipid examined. Although the GalNAcbeta1 3GlcNAcbeta1-R structure has not been reported in humans or other mammals, we have discovered a novel human glycosyltransferase producing this structure on N- and O-glycans.	Natl Inst Adv Ind Sci & Technol, Open Space Lab Cent 2, RCG, Glycogene Funct Team, Tsukuba, Ibaraki 3058568, Japan; Fujirebio Inc, Fundamental Res Dept, Frontier Res Div, Tokyo 1920031, Japan; JGS Japan Genome Solut Inc, Tokyo 1920031, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648721, Japan; Mitsubishi Kagaku Inst Life Sci, Reprod Biol Lab, Machida, Tokyo 1948511, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan; AIST, Biol Informat Res Ctr, Mol Recognit Team, Tsukuba, Ibaraki 3058568, Japan	National Institute of Advanced Industrial Science & Technology (AIST); H.U. Group Holdings Inc; Mitsubishi Kagaku Institute of Life Sciences (MITILS); National Institute of Advanced Industrial Science & Technology (AIST)	Narimatsu, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Open Space Lab Cent 2, RCG, Glycogene Funct Team, 1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.	h.narimatsu@aist.go.jp	Togayachi, Akira/M-4144-2018; Sato, Takashi/M-2577-2018; noce, toshiaki/L-1739-2013; Narimatsu, Hisashi/M-4757-2018	Togayachi, Akira/0000-0003-3600-9149; Sato, Takashi/0000-0002-9973-8923; Narimatsu, Hisashi/0000-0002-8402-133X				Akama TO, 2002, SCIENCE, V295, P124, DOI 10.1126/science.1065570; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Cooper CA, 2003, NUCLEIC ACIDS RES, V31, P511, DOI 10.1093/nar/gkg099; Cooper CA, 2001, NUCLEIC ACIDS RES, V29, P332, DOI 10.1093/nar/29.1.332; Dorscheid DR, 2001, AM J PHYSIOL-LUNG C, V281, pL982, DOI 10.1152/ajplung.2001.281.4.L982; FUJIWARA Y, 1994, P NATL ACAD SCI USA, V91, P12258, DOI 10.1073/pnas.91.25.12258; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GREEN ED, 1988, J BIOL CHEM, V263, P18253; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V270, P630, DOI 10.1016/0003-9861(89)90546-8; HOSOMI O, 1989, JPN J MED SCI BIOL, V42, P77, DOI 10.7883/yoken1952.42.77; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; ISSHIKI S, 2003, J BIOL CHEM; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; JONES CJP, 1992, HISTOCHEM J, V24, P327, DOI 10.1007/BF01046164; Karlsson NG, 2002, ANAL BIOCHEM, V305, P173, DOI 10.1006/abio.2002.5657; Kleene KC, 2001, MECH DEVELOP, V106, P3, DOI 10.1016/S0925-4773(01)00413-0; Kudo K, 1998, EUR J BIOCHEM, V252, P492, DOI 10.1046/j.1432-1327.1998.2520492.x; Ludwig A, 2000, J IMMUNOL, V165, P1044, DOI 10.4049/jimmunol.165.2.1044; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; RECNY MA, 1992, J BIOL CHEM, V267, P22428; Royle L, 2002, ANAL BIOCHEM, V304, P70, DOI 10.1006/abio.2002.5619; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; SUGITA M, 1982, J BIOCHEM-TOKYO, V92, P327, DOI 10.1093/oxfordjournals.jbchem.a133938; TAGA S, 1995, BBA-LIPID LIPID MET, V1254, P56, DOI 10.1016/0005-2760(94)00167-W; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x	29	40	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14087	14095		10.1074/jbc.M310614200	http://dx.doi.org/10.1074/jbc.M310614200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724282	hybrid			2022-12-25	WOS:000220478500098
J	Chakrabarty, P; Sethi, DK; Padhan, N; Kaur, KJ; Salunke, DM; Bhattacharya, S; Bhattacharya, A				Chakrabarty, P; Sethi, DK; Padhan, N; Kaur, KJ; Salunke, DM; Bhattacharya, S; Bhattacharya, A			Identification and characterization of EhCaBP2 - A second member of the calcium-binding protein family of the protozoan parasite Entamoeba histolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOLYTIC ACTIVITY; CALMODULIN GENES; CENTRAL HELIX; EXPRESSION; DENATURATION; ACTIVATION; SECRETION; GRANULES; ENZYMES; GROWTH	Entamoeba histolytica, an early branching eukaryote, is the etiologic agent of amebiasis. Calcium plays a pivotal role in the pathogenesis of amebiasis by modulating the cytopathic properties of the parasite. However, the mechanistic role of Ca2+ and calcium- binding proteins in the pathogenesis of E. histolytica remains poorly understood. We had previously characterized a novel calcium- binding protein ( EhCaBP1) from E. histolytica. Here, we report the identification and partial characterization of an isoform of this protein, EhCaBP2. Both EhCaBPs have four canonical EF- hand Ca2+ binding domains. The two isoforms are encoded by genes of the same size ( 402 bp). Comparison between the two genes showed an overall identity of 79% at the nucleotide sequence level. This identity dropped to 40% in the 75- nucleotide central linker region between the second and third Ca2+ binding domains. Both of these genes are single copy, as revealed by Southern hybridization. Analysis of the available E. histolytica genome sequence data suggested that the two genes are non- allelic. Homology- based structural modeling showed that the major differences between the two EhCaBPs lie in the central linker region, normally involved in binding target molecules. A number of studies indicated that EhCaBP1 and EhCaBP2 are functionally different. They bind different sets of E. histolytica proteins in a Ca2+- dependent manner. Activation of endogenous kinase was also found to be unique for the two proteins and the Ca2+ concentration required for their optimal functionality was also different. In addition, a 12- mer peptide was identified from a random peptide library that could differentially bind the two proteins. Our data suggest that EhCaBP2 is a new member of a class of E. histolytica calcium- binding proteins involved in a novel calcium signal transduction pathway.	Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India; Jawaharlal Nehru Univ, Sch Environm Sci, New Delhi 110067, India; Natl Inst Immunol, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi; Jawaharlal Nehru University, New Delhi; Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Bhattacharya, A (corresponding author), Jawaharlal Nehru Univ, Sch Life Sci, New Mehrauli Rd, New Delhi 110067, India.	alok0200@mail.jnu.ac.in	Gagneja, Kanwalinderjit K/K-3204-2017	Gagneja, Kanwalinderjit K/0000-0001-7844-8583				Atreya HS, 2001, BIOCHEMISTRY-US, V40, P14392, DOI 10.1021/bi0114978; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Bernal RM, 1998, PARASITOL RES, V84, P687, DOI 10.1007/s004360050471; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; CHANDOK MR, 1992, PHYTOCHEMISTRY, V31, P2255, DOI 10.1016/0031-9422(92)83259-2; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; EDMAN CF, 1994, EUR J BIOCHEM, V226, P725, DOI 10.1111/j.1432-1033.1994.tb20101.x; Ganguly A, 2001, MOL BIOCHEM PARASIT, V112, P277, DOI 10.1016/S0166-6851(00)00376-5; Gilchrist CA, 2003, J BIOL CHEM, V278, P4646, DOI 10.1074/jbc.M211271200; Gilchrist CA, 2001, J BIOL CHEM, V276, P11838, DOI 10.1074/jbc.M007375200; Gopal B, 1997, BIOCHEMISTRY-US, V36, P10910, DOI 10.1021/bi9702546; Gopal B, 1998, ACTA CRYSTALLOGR D, V54, P1442, DOI 10.1107/S0907444998001759; JOHNSON JG, 1981, J PROTOZOOL, V28, P160, DOI 10.1111/j.1550-7408.1981.tb02825.x; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEE SH, 1995, J BIOL CHEM, V270, P21806, DOI 10.1074/jbc.270.37.21806; Makioka A, 2001, PARASITOL RES, V87, P833, DOI 10.1007/s004360100453; Manivel V, 2002, J IMMUNOL, V169, P888, DOI 10.4049/jimmunol.169.2.888; MATSUMOTO Y, 1987, EUR J CELL BIOL, V45, P36; Meza I, 2000, PARASITOL TODAY, V16, P23, DOI 10.1016/S0169-4758(99)01586-0; Modha J, 1999, PARASITOLOGY, V118, P509, DOI 10.1017/S0031182099004266; MOORTHY AL, 2001, THESIS INDIAN I SCI; MUNOZ MD, 1991, MOL MICROBIOL, V5, P1707, DOI 10.1111/j.1365-2958.1991.tb01919.x; MUNOZ MD, 1992, COMP BIOCHEM PHYS B, V103, P517, DOI 10.1016/0305-0491(92)90363-V; Nickel R, 2000, FEBS LETT, V486, P112, DOI 10.1016/S0014-5793(00)02245-6; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; Pereira C, 1997, J EUKARYOT MICROBIOL, V44, P155, DOI 10.1111/j.1550-7408.1997.tb05952.x; PRASAD J, 1993, CELL MOL BIOL RES, V39, P167; PRASAD J, 1992, MOL BIOCHEM PARASIT, V52, P137, DOI 10.1016/0166-6851(92)90044-K; Protasevich I, 1997, BIOCHEMISTRY-US, V36, P2017, DOI 10.1021/bi962538g; RAVDIN JI, 1988, INFECT IMMUN, V56, P1505, DOI 10.1128/IAI.56.6.1505-1512.1988; Sahoo N, 2003, MOL BIOCHEM PARASIT, V126, P281, DOI 10.1016/S0166-6851(02)00284-0; Sahoo N, 2000, ARCH MED RES, V31, pS57, DOI 10.1016/S0188-4409(00)00212-5; Sahu SC, 1999, FEBS LETT, V459, P51, DOI 10.1016/S0014-5793(99)01204-1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHEIBEL LW, 1992, INT REV CYTOL, V134, P165, DOI 10.1016/S0074-7696(08)62029-X; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEIN JP, 1983, P NATL ACAD SCI-BIOL, V80, P6485, DOI 10.1073/pnas.80.21.6485; Tabernero L, 1997, STRUCTURE, V5, P613, DOI 10.1016/S0969-2126(97)00217-7; Tanaka T, 1997, BIOCHEM BIOPH RES CO, V236, P611, DOI 10.1006/bbrc.1997.7019; Toutenhoofd SL, 2000, CELL CALCIUM, V28, P83, DOI 10.1054/ceca.2000.0136; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; VanderSpoel D, 1996, PROTEIN SCI, V5, P2044; WEIKEL CS, 1988, INFECT IMMUN, V56, P1485, DOI 10.1128/IAI.56.6.1485-1491.1988; Yadava N, 1997, MOL BIOCHEM PARASIT, V84, P69, DOI 10.1016/S0166-6851(96)02782-X; YAKUBU MA, 1994, MOL BIOCHEM PARASIT, V66, P119, DOI 10.1016/0166-6851(94)90042-6	53	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12898	12908		10.1074/jbc.M304716200	http://dx.doi.org/10.1074/jbc.M304716200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711825	hybrid			2022-12-25	WOS:000220334900107
J	Fischer, R; Kohler, K; Fotin-Mleczek, M; Brock, R				Fischer, R; Kohler, K; Fotin-Mleczek, M; Brock, R			A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-RICH PEPTIDES; PROTEIN TRANSDUCTION; ANTENNAPEDIA HOMEODOMAIN; PLASMA-MEMBRANE; GENE-TRANSFER; BASIC DOMAIN; 3RD HELIX; TAT; DELIVERY; BINDING	The role of endosomal acidification and retrograde transport for the uptake of the highly basic cell-penetrating peptides penetratin, Tat, and oligoarginine was investigated. The effect of a panel of drugs that interfere with discrete steps of endocytosis or Golgi-mediated transport on uptake and cellular distribution of fluorescein-labeled peptide analogues was probed by confocal microscopy, flow cytometry, and fluorescence spectroscopy of whole cell lysates. The analyses were carried out in MC57 fibrosarcoma cells and in HeLa cells. While MC57 fibrosarcoma cells showed some vesicular fluorescence and a pronounced cytoplasmic fluorescence, in HeLa cells little cytoplasmic fluorescence was observed. In MC57 cells the inhibitors of endosomal acidification chloroquine and bafilomycin A1 abolished the release of the peptides into the cytoplasm. Release into the cytosol preserved endosomal integrity. In addition, cellular uptake of the peptides was inhibited by brefeldin A, a compound interfering with trafficking in the trans-Golgi network. In contrast, nordihydroguaiaretic acid, a drug that stimulates the rapid retrograde movement of both Golgi stacks and trans-Golgi network to the endoplasmic reticulum, promoted a cytoplasmic localization of Tat peptides in peptide-pulsed HeLa cells. The effects of these drugs on trafficking shared characteristics with those reported for the trafficking of plant and bacterial toxins, such as cholera toxin, which reach the cytoplasm by means of retrograde transport. A sequence comparison revealed a common stretch of 8 - 10 amino acids with high sequence homology to the Tat peptide. The structural and functional data therefore strongly suggest a common mechanism of import for cationic cell-penetrating peptides and the toxins.	Univ Tubingen, Inst Cell Biol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Brock, R (corresponding author), Univ Tubingen, Inst Cell Biol, Morgenstelle 15, D-72076 Tubingen, Germany.	roland.brock@uni-tuebingen.de	Brock, Roland/O-9411-2019; Brock, Roland/K-2590-2012	Brock, Roland/0000-0003-1395-6127				Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHEN RF, 1988, ANAL BIOCHEM, V172, P61, DOI 10.1016/0003-2697(88)90412-5; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Drecktrah D, 1998, J CELL SCI, V111, P951; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Elmquist A, 2003, BIOL CHEM, V384, P387, DOI 10.1515/BC.2003.044; Fischer PM, 2001, BIOCONJUGATE CHEM, V12, P825, DOI 10.1021/bc0155115; Fischer R, 2003, BIOCONJUGATE CHEM, V14, P653, DOI 10.1021/bc025658b; Fischer R, 2002, BBA-BIOMEMBRANES, V1564, P365, DOI 10.1016/S0005-2736(02)00471-6; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X; GARRED O, 1995, J BIOL CHEM, V270, P10817; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; HOSAKA Y, 1986, J VIROL, V57, P1113, DOI 10.1128/JVI.57.3.1113-1118.1986; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; Kozak SL, 1999, J BIOL CHEM, V274, P23499, DOI 10.1074/jbc.274.33.23499; Langel U., 2002, CELL PENETRATING PEP, V1st ed; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; Lord JM, 1998, J CELL BIOL, V140, P733; Lu J, 2001, J IMMUNOL, V166, P7063, DOI 10.4049/jimmunol.166.12.7063; Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200; Merdan T, 2002, PHARMACEUT RES, V19, P140, DOI 10.1023/A:1014212630566; Nishikawa K, 2000, MOL CELL, V6, P969, DOI 10.1016/S1097-2765(05)00085-7; Persson D, 2003, BIOCHEMISTRY-US, V42, P421, DOI 10.1021/bi026453t; Pietersz GA, 2001, VACCINE, V19, P1397, DOI 10.1016/S0264-410X(00)00373-X; PLANK C, 1994, J BIOL CHEM, V269, P12918; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; SANDOVAL RM, 2004, IN PRESS AM J PHYSL; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; Sandvig K, 2002, FEBS LETT, V529, P49, DOI 10.1016/S0014-5793(02)03182-4; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; Scheller A, 2000, EUR J BIOCHEM, V267, P6043, DOI 10.1046/j.1432-1327.2000.01681.x; SchutzeRedelmeier MP, 1996, J IMMUNOL, V157, P650; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Singh D, 1999, BIOCONJUGATE CHEM, V10, P745, DOI 10.1021/bc980131d; Stephens DJ, 2001, P NATL ACAD SCI USA, V98, P4295, DOI 10.1073/pnas.081065198; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; THEODORE L, 1995, J NEUROSCI, V15, P7158; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wang RF, 2002, NAT BIOTECHNOL, V20, P149, DOI 10.1038/nbt0202-149	59	254	263	1	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12625	12635		10.1074/jbc.M311461200	http://dx.doi.org/10.1074/jbc.M311461200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707144	hybrid			2022-12-25	WOS:000220334900076
J	Fukuda, M; Kanno, E; Yamamoto, A				Fukuda, M; Kanno, E; Yamamoto, A			Rabphilin and Noc2 are recruited to dense-core vesicles through specific interaction with Rab27A in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CALCIUM-DEPENDENT OLIGOMERIZATION; SLP HOMOLOGY DOMAIN; TANDEM C2 DOMAINS; MYOSIN-VA; GRISCELLI-SYNDROME; SYNAPTOTAGMIN FAMILY; MELANOSOME TRANSPORT; REGULATED SECRETION; CA2+-DEPENDENT EXOCYTOSIS	Rabphilin and Noc2 were originally described as Rab3A effector proteins involved in the regulation of secretory vesicle exocytosis, however, recently both proteins have been shown to bind Rab27A in vitro in preference to Rab3A ( Fukuda, M. ( 2003) J. Biol. Chem. 278, 15373 - 15380), suggesting that Rab3A is not their major ligand in vivo. In the present study we showed by means of deletion and mutation analyses that rabphilin and Noc2 are recruited to dense- core vesicles through specific interaction with Rab27A, not with Rab3A, in PC12 cells. Rab3A bindingdefective mutants of rabphilin( E50A) and Noc2( E51A) were still localized in the distal portion of the neurites ( where dense- core vesicles had accumulated) in nerve growth factor- differentiated PC12 cells, the same as the wild- type proteins, whereas Rab27A binding- defective mutants of rabphilin( E50A/ I54A) and Noc2( E51A/ I55A) were present throughout the cytosol. We further showed that expression of the wild- type or the E50A mutant of rabphilin- RBD, but not the E50A/ I54A mutant of rabphilinRBD, significantly inhibited high KCl- dependent neuropeptide Y secretion by PC12 cells. We also found that rabphilin and its binding partner, Rab27 have been highly conserved during evolution ( from nematoda to humans) and that Caenorhabditis elegans and Drosophila rabphilin ( ce/ dm- rabphilin) specifically interact with ce/ dm- Rab27, but not with ce/ dm- Rab3 or ce/ dm- Rab8, suggesting that rabphilin functions as a Rab27 effector across phylogeny. Based on these findings, we propose that the N- terminal Rab binding domain of rabphilin and Noc2 be referred to as " RBD27 ( Rab binding domain for Rab27)", the same as the synaptotagmin- like protein homology domain ( SHD) of Slac2- a/ melanophilin.	RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan; Nagahama Inst Biosci & Technol, Nagahama 5260829, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Adolfsen B, 2001, CELL MOL LIFE SCI, V58, P393, DOI 10.1007/PL00000865; Bahadoran P, 2003, J BIOL CHEM, V278, P11386, DOI 10.1074/jbc.M211996200; Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Barral DC, 2002, J CLIN INVEST, V110, P247, DOI 10.1172/JCI200215058; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Burns ME, 1998, J GEN PHYSIOL, V111, P243, DOI 10.1085/jgp.111.2.243; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; Chen YR, 2003, P NATL ACAD SCI USA, V100, P14012, DOI 10.1073/pnas.2436350100; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; Desnos C, 2003, J CELL BIOL, V163, P559, DOI 10.1083/jcb.200302157; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2003, J BIOL CHEM, V278, P15373, DOI 10.1074/jbc.M212341200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2003, J BIOCHEM, V133, P641, DOI 10.1093/jb/mvg082; Fukuda M, 2003, J BIOL CHEM, V278, P3220, DOI 10.1074/jbc.M208323200; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P39673, DOI 10.1074/jbc.M205349200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, BIOCHEM J, V366, P681, DOI 10.1042/BJ20020484; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, J NEUROCHEM, V77, P730, DOI 10.1046/j.1471-4159.2001.00266.x; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Fukuda M, 2003, J BIOL CHEM, V278, P15390, DOI 10.1074/jbc.M213090200; FUKUDA M, 2003, RECENT RES DEV CHEM, V1, P15; FUKUDA M, 2002, RRD NEUROCHEMISTRY, V5, P297; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Haynes LP, 2001, J BIOL CHEM, V276, P9726, DOI 10.1074/jbc.M006959200; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; IMAI A, 2003, IN PRESS J CELL SCI; Joberty G, 1999, J CELL SCI, V112, P3579; Komuro R, 1996, BIOCHEM BIOPH RES CO, V219, P435, DOI 10.1006/bbrc.1996.0251; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LLEDO PM, 1994, TRENDS NEUROSCI, V17, P426, DOI 10.1016/0166-2236(94)90017-5; Masumoto N, 1996, J CELL BIOL, V135, P1741, DOI 10.1083/jcb.135.6.1741; McKiernan CJ, 1996, MOL CELL BIOL, V16, P4985; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Menasche G, 2003, BLOOD, V101, P2736, DOI 10.1182/blood-2002-09-2789; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGATA K, 1990, FEBS LETT, V275, P29, DOI 10.1016/0014-5793(90)81431-M; NAGATA K, 1989, J BIOL CHEM, V264, P17000; Novak EK, 2002, BLOOD, V100, P128, DOI 10.1182/blood.V100.1.128; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Sasaki T, 1997, ADV SEC MESS PHOSPH, V31, P279; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Serano J, 2003, P NATL ACAD SCI USA, V100, P13368, DOI 10.1073/pnas.1835727100; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Staunton J, 2001, J NEUROSCI, V21, P9255, DOI 10.1523/JNEUROSCI.21-23-09255.2001; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; Tiwari S, 2003, BLOOD, V102, P3970, DOI 10.1182/blood-2003-03-0977; Torii S, 2002, MOL CELL BIOL, V22, P5518, DOI 10.1128/MCB.22.15.5518-5526.2002; Wang XL, 2001, J BIOL CHEM, V276, P32480, DOI 10.1074/jbc.M103337200; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	83	53	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13065	13075		10.1074/jbc.M306812200	http://dx.doi.org/10.1074/jbc.M306812200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722103	hybrid			2022-12-25	WOS:000220334900127
J	Khan, MM; Nomura, T; Chiba, T; Tanaka, K; Yoshida, H; Mori, K; Ishii, S				Khan, MM; Nomura, T; Chiba, T; Tanaka, K; Yoshida, H; Mori, K; Ishii, S			The fusion oncoprotein PML-RAR alpha induces endoplasmic reticulum (ER)-associated degradation of N-CoR and ER stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; NUCLEAR RECEPTOR COREPRESSOR; RING-FINGER DOMAIN; RETINOIC ACID; HISTONE DEACETYLASE; TRANSCRIPTION FACTOR; QUALITY-CONTROL; PROTEIN; UBIQUITIN; TARGET	PML-RARalpha, a fusion protein of promyelocytic leukemia (PML) and the retinoic acid receptor-alpha (RARalpha), causes acute promyelocytic leukemias (APL). Although the role of nuclear PML-RARalpha has been extensively studied, a significant amount of PML-RARalpha is in the cytoplasm. The role cytoplasmic PML-RARalpha plays in leukemogenesis is unknown. Here we report that PML-RARalpha induces the N-CoR accumulation in the endoplasmic reticulum ( ER), leading to the induction of ER stress and the processing of activating transcription factor 6 (ATF6), the unfolded protein response. PML-RARalpha stimulates the ubiquitylation of N-CoR via Ubc6 that is involved in the protein quality control. This ER-associated degradation (ERAD) of N-CoR reduces the soluble NCoR protein levels in the nucleus. The two N-CoR-interacting sites in PML-RARalpha are required for the ERAD of N-CoR, suggesting the aberrant binding of PML-RARalpha to N-CoR may induce the ERAD of N-CoR. Overexpression of N-CoR induces the differentiation of APL-derived NB4 cells, suggesting that the low levels of N-CoR in the nucleus may contribute at least partly to PML-RARalpha mediated leukemogenesis.	RIKEN, Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068304, Japan	RIKEN; Tokyo Metropolitan Institute of Medical Science; Kyoto University	Ishii, S (corresponding author), RIKEN, Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.go.jp	Ishii, Shunsuke/A-5271-2016; Mori, Kazutoshi/K-6106-2015	Ishii, Shunsuke/0000-0002-6530-2478; Yoshida, Hiderou/0000-0002-5773-1408				Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bottomley MJ, 2001, CURR BIOL, V11, P1114, DOI 10.1016/S0960-9822(01)00317-7; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Bussolino DF, 2001, FASEB J, V15, P556; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Khan MM, 2001, J BIOL CHEM, V276, P43491, DOI 10.1074/jbc.C100532200; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lenk U, 2002, J CELL SCI, V115, P3007; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shiraki K, 2002, J BIOCHEM, V132, P591, DOI 10.1093/oxfordjournals.jbchem.a003261; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463	49	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11814	11824		10.1074/jbc.M312121200	http://dx.doi.org/10.1074/jbc.M312121200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701861	hybrid			2022-12-25	WOS:000220157600118
J	Kim, E; Muga, SJ; Fischer, SM				Kim, E; Muga, SJ; Fischer, SM			Identification and characterization of a phorbol ester-responsive element in the murine 8S-lipoxygenase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ORNITHINE DECARBOXYLASE ACTIVITY; ARACHIDONIC-ACID METABOLISM; HUMAN 5-LIPOXYGENASE GENE; MOUSE EPIDERMAL-CELLS; LONG TERMINAL REPEAT; SKIN TUMOR PROMOTION; TRANSCRIPTIONAL ACTIVATION; LIPOXYGENASE INHIBITORS; 12-LIPOXYGENASE GENE	Murine 8S-lipoxygenase (8S-LOX) is a 12-O-tetradecanoylphorbol-13-acetate (TPA)-inducible lipoxygenase. That is, it is not detected in normal mouse skin, however, a significant increase in expression is detected in the skin of TPA promotion-sensitive strains of mice after TPA treatment. In this study, we found TPA-induced 8S-LOX mRNA expression is a result of increased transcription in SSIN primary keratinocytes and further investigated transcriptional regulation of 8S-LOX expression by cloning its promoter. The cloned 8S-LOX promoter (similar to2 kb) in which a transcription initiation site was mapped at -27 from the ATG has neither a TATA box nor a CCAAT box. However, the promoter was highly responsive to TPA in TPA promotion-sensitive SSIN but not in TPA promotion-resistant C57BL/6J primary keratinocytes. We then identified a Sp1 binding site located -77 to -68 from the ATG that is a TPA-responsive element (TRE) of the promoter and that Sp1, Sp2, and Sp3 proteins bind to the TRE. We also found that the binding of these proteins to the TRE was significantly increased by TPA treatment and inhibition of the binding by mithramycin A decreased TPA-induced promoter activity as well as 8S-LOX mRNA expression. These data suggest that increased binding of Sp1, Sp2, and Sp3 to the TRE of the 8S-LOX promoter is a mechanism by which TPA induces 8S-LOX expression in keratinocytes.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; Univ S Carolina, Sch Med, S Carolina Canc Ctr, Columbia, SC 29203 USA	University of Texas System; UTMD Anderson Cancer Center; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Fischer, SM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, POB 389, Smithville, TX 78957 USA.	sa83161@odin.mdacc.tmc.edu			NCI NIH HHS [CA34443, CA83794] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083794, R01CA034443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Burger F, 1999, MOL CARCINOGEN, V24, P108, DOI 10.1002/(SICI)1098-2744(199902)24:2<108::AID-MC5>3.0.CO;2-R; CAREY M, 2000, TRANSCRIPTIONAL REGU, P249; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; FISCHER SM, 1988, CANCER RES, V48, P658; FISCHER SM, 1982, CARCINOGENESIS, V3, P1243, DOI 10.1093/carcin/3.11.1243; FISCHER SM, 1987, CANCER RES, V47, P3174; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; GOLDBERG IH, 1971, ANNU REV BIOCHEM, V40, P775, DOI 10.1146/annurev.bi.40.070171.004015; GSCHWENDT M, 1986, CARCINOGENESIS, V7, P449, DOI 10.1093/carcin/7.3.449; Heidt M, 2000, LIPIDS, V35, P701, DOI 10.1007/s11745-000-0576-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; KATO R, 1983, CARCINOGENESIS, V4, P1301, DOI 10.1093/carcin/4.10.1301; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Kinzig A, 1997, FEBS LETT, V402, P162, DOI 10.1016/S0014-5793(96)01517-7; KRIEG P, 1995, MOL CARCINOGEN, V14, P118, DOI 10.1002/mc.2940140208; Kritzik MR, 1997, BBA-GENE STRUCT EXPR, V1352, P267, DOI 10.1016/S0167-4781(97)00005-5; KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; Liu YW, 1997, BIOCHEM J, V324, P133, DOI 10.1042/bj3240133; Mar PK, 1995, MOL CARCINOGEN, V14, P240, DOI 10.1002/mc.2940140404; Muga SJ, 2000, CELL GROWTH DIFFER, V11, P447; NAKADATE T, 1982, CARCINOGENESIS, V3, P1411, DOI 10.1093/carcin/3.12.1411; Noe V, 2001, EUR J BIOCHEM, V268, P3163, DOI 10.1046/j.1432-1327.2001.02198.x; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RISTOW HJ, 1982, J INVEST DERMATOL, V79, P408, DOI 10.1111/1523-1747.ep12530331; Silverman ES, 2000, AM J RESP CRIT CARE, V161, pS77, DOI 10.1164/ajrccm.161.supplement_1.ltta-16; Silverman ES, 2002, AM J RESP CELL MOL, V26, P475, DOI 10.1165/ajrcmb.26.4.4747; SLAGA TJ, 1984, MECHANISMS TUMOR PRO, V2, P1; Steele VE, 1999, CANCER EPIDEM BIOMAR, V8, P467; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Torgeman A, 1999, VIROLOGY, V254, P279, DOI 10.1006/viro.1998.9556; VERMA AK, 1980, CANCER RES, V40, P308; Wang Jun, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P497; YOSHIMOTO T, 1992, J BIOL CHEM, V267, P24805; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; Zheng XL, 2000, J BIOL CHEM, V275, P31747, DOI 10.1074/jbc.M000621200	42	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11188	11197		10.1074/jbc.M313291200	http://dx.doi.org/10.1074/jbc.M313291200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711820	hybrid			2022-12-25	WOS:000220157600044
J	Laudes, M; Christodoulides, C; Sewter, C; Rochford, JJ; Considine, RV; Sethi, JK; Vidal-Puig, A; O'Rahilly, S				Laudes, M; Christodoulides, C; Sewter, C; Rochford, JJ; Considine, RV; Sethi, JK; Vidal-Puig, A; O'Rahilly, S			Role of the POZ zinc finger transcription factor FBI-1 in human and murine adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; MITOTIC CLONAL EXPANSION; ADIPOCYTE DIFFERENTIATION; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; DOMAIN PROTEIN; GAMMA AGONISTS; PPAR-GAMMA; CELLS; BINDING	Poxvirus zinc finger (POZ) zinc finger domain transcription factors have been shown to play a role in the control of growth arrest and differentiation in several types of mesenchymal cells but not, as yet, adipocytes. We found that a POZ domain protein, factor that binds to inducer of short transcripts-1 (FBI-1), was induced during both murine and human preadipocyte differentiation with maximal expression levels seen at days 2-4. FBI-1 mRNA was expressed in human adipose tissue with the highest levels found in samples from morbidly obese subjects. Murine cell lines constitutively expressing FBI-1 showed evidence for accelerated adipogenesis with earlier induction of markers of differentiation and enhanced lipid accumulation, suggesting that FBI-1 may be an active participant in the differentiation process. Consistent with the properties of this family of proteins in other cell systems, 3T3L1 cells stably overexpressing FBI-1 showed reduced DNA synthesis and reduced expression of cyclin A, cyclin-dependent kinase 2, and p107, proteins known to be involved in the regulation of mitotic clonal expansion. In addition, FBI-1 reduced the transcriptional activity of the cyclin A promoter. Thus, FBI-1, a POZ zinc finger transcription factor, is induced during the early phases of human and murine preadipocyte differentiation where it may contribute to adipogenesis through influencing the switch from cellular proliferation to terminal differentiation.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England; Indiana Univ, Sch Med, Div Endocrinol & Metab, Indianapolis, IN 46202 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Indiana University System; Indiana University-Purdue University Indianapolis	O'Rahilly, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Hills Rd,Box 232, Cambridge CB2 2QR, England.	sorahill@hgmp.mrc.ac.uk	O'Rahilly, Stephen/ABF-6509-2020; Laudes, Matthias/C-8885-2011; Sethi, Jaswinder K./B-1413-2008	O'Rahilly, Stephen/0000-0003-2199-4449; Sethi, Jaswinder K./0000-0003-4157-0475; Rochford, Justin/0000-0002-5020-4939; Vidal-Puig, Antonio/0000-0003-4220-9577	Biotechnology and Biological Sciences Research Council [JF16994] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Albagli-Curiel O, 1998, DIFFERENTIATION, V64, P33, DOI 10.1046/j.1432-0436.1998.6410033.x; Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Digby JE, 1998, DIABETES, V47, P138, DOI 10.2337/diabetes.47.1.138; Entenmann G, 1996, AM J PHYSIOL-CELL PH, V270, pC1011, DOI 10.1152/ajpcell.1996.270.4.C1011; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; Hajra AK, 2000, J BIOL CHEM, V275, P9441, DOI 10.1074/jbc.275.13.9441; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kalli KR, 2002, ENDOCRINOLOGY, V143, P3259, DOI 10.1210/en.2001-211408; KASINRERK W, 1992, J IMMUNOL, V149, P847; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; Kumagai T, 1999, ONCOGENE, V18, P467, DOI 10.1038/sj.onc.1202306; Labbaye C, 2002, ONCOGENE, V21, P6669, DOI 10.1038/sj.onc.1205884; Landsberg RL, 2003, P NATL ACAD SCI USA, V100, P2456, DOI 10.1073/pnas.0138064100; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nugent C, 2001, MOL ENDOCRINOL, V15, P1729, DOI 10.1210/me.15.10.1729; Pendergrast PS, 2002, MOL BIOL CELL, V13, P915, DOI 10.1091/mbc.01-08-0383; Pessler F, 1997, MOL CELL BIOL, V17, P3786, DOI 10.1128/MCB.17.7.3786; Pessler F, 2003, J BIOL CHEM, V278, P29327, DOI 10.1074/jbc.M302980200; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Sewter CP, 2002, DIABETES, V51, P718, DOI 10.2337/diabetes.51.3.718; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tu AY, 2001, DIABETES, V50, P1851, DOI 10.2337/diabetes.50.8.1851; Xu HY, 1999, J BIOL CHEM, V274, P26287, DOI 10.1074/jbc.274.37.26287; Yamochi T, 1997, LEUKEMIA, V11, P694, DOI 10.1038/sj.leu.2400631; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	38	44	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11711	11718		10.1074/jbc.M310240200	http://dx.doi.org/10.1074/jbc.M310240200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701838	Green Accepted, hybrid			2022-12-25	WOS:000220157600107
J	Chien, J; Staub, J; Hu, SI; Erickson-Johnson, MR; Couch, FJ; Smith, DI; Crowl, RM; Kaufmann, SH; Shridhar, V				Chien, J; Staub, J; Hu, SI; Erickson-Johnson, MR; Couch, FJ; Smith, DI; Crowl, RM; Kaufmann, SH; Shridhar, V			A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer	ONCOGENE			English	Article						serine protease; HtrA; ovarian cancer; down-regulation; loss of heterozygosity	SERINE-PROTEASE; EPITHELIAL TUMORS; CELL-DEATH; GENE; DMBT1; IDENTIFICATION; APOPTOSIS; GROWTH; EXPRESSION; INHIBITOR	We report here that HtrA1, a candidate tumor suppressor, is downregulated in ovarian cancer. Expression of HtrA1 is downregulated in five of seven ovarian cancer cell lines. In total, 59% of primary ovarian tumors have either a complete absence or markedly reduced levels of HtrA1 expression compared to the brushings of ovarian surface epithelium. Primary ovarian tumors show high frequencies of loss of an allele at microsatellite markers near htrA1 locus on 10q26. Downregulation of HtrA1 in SKOV3 by antisense transfection promotes anchorage-independent growth, while exogenous expression of HtrA1 in OV202 induces cell death. HtrA1-induced cell death is not inhibited by the broad caspase inhibitor, zVAD(O-Me) fmk, but instead reflects serine protease activity associated with HtrA1. These observations raise the possibility of HtrA1 as a candidate tumor suppressor involved in promoting serine-protease-mediated cell death and that downregulation of HtrA1 in ovarian cancer may contribute to malignant phenotype.	Mayo Clin & Mayo Fdn, Div Expt Pathol, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin Canc Ctr, Rochester, MN 55905 USA; Novartis Pharmaceut, Arthrit Biol Unit, E Hanover, NJ 07936 USA; Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Novartis; Mayo Clinic	Shridhar, V (corresponding author), Mayo Clin & Mayo Fdn, Div Expt Pathol, Dept Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	shridv@exrch.mayo.edu	Chien, Jeremy/AID-8939-2022	Chien, Jeremy/0000-0003-4744-8374; Kaufmann, Scott/0000-0002-4900-7145				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Deichmann M, 2002, ONCOLOGY-BASEL, V63, P166, DOI 10.1159/000063802; ENOMOTO T, 1991, AM J PATHOL, V139, P777; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Kato MV, 2000, MOL MED, V6, P126, DOI 10.1007/BF03401780; KATSAROS D, 1995, ANTICANCER RES, V15, P1501; KOHLER MF, 1993, J NATL CANCER I, V85, P1513, DOI 10.1093/jnci/85.18.1513; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mueller W, 2002, ONCOGENE, V21, P5956, DOI 10.1038/sj.onc.1205733; Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Ross JS, 1999, AM J CLIN PATHOL, V111, P311; Sasaki H, 2002, CANCER RES, V62, P1790; Schwartz DI, 1999, BREAST CANCER RES TR, V58, P25, DOI 10.1023/A:1006237031070; Shridhar V, 2002, CANCER RES, V62, P262; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	32	136	145	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1636	1644		10.1038/sj.onc.1207271	http://dx.doi.org/10.1038/sj.onc.1207271			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716297				2022-12-25	WOS:000189219500019
J	Zhao, WD; Hisamuddin, IM; Nandan, MO; Babbin, BA; Lamb, NE; Yang, VW				Zhao, WD; Hisamuddin, IM; Nandan, MO; Babbin, BA; Lamb, NE; Yang, VW			Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer	ONCOGENE			English	Article						gut-enriched Kruppel-like factor; GKLF; KLF4; loss of heterozygosity; methylation; point mutation; colon cancer; tumor suppressor	KRUPPEL-LIKE FACTOR; COLONIC CELL-GROWTH; ZINC-FINGER PROTEIN; EPITHELIAL-CELLS; MUTATIONS OCCUR; LINE RKO; EXPRESSION; TUMORIGENESIS; FACTOR-4; METHYLATION	Kruppel-like factor 4 (KLF4 or GKLF) is an inhibitor of the cell cycle. The gene encoding KLF4 is localized on chromosome 9q, previously shown to exhibit allelic loss in colorectal cancer (CRC). In this study, we show that the mean level of KLF4 mRNA in a panel of 30 CRC was 52% that of paired normal colonic tissues. Similarly, the levels of KLF4 mRNA and protein in a panel of six established CRC cell lines were significantly lower than those of an untransformed colonic epithelial cell line. Using highly polymorphic DNA markers that flank the KLF4 locus, we found evidence for loss of heterozygosity (LOH) in two of eight surgically resected CRC specimens. In addition, LOH was observed in five of six CRC cell lines with one additional cell line exhibiting hemizygous deletion in the KLF4 gene. We also found that the 5'-untranslated region of KLF4 was hypermethylated in a subset of resected CRC specimens and cell lines. Lastly, the open-reading frame of KLF4 in two of three CRC cell lines examined contained several point mutations that resulted in a diminished ability to activate the p21(WAF1#47;Cip1) promoter. These findings indicate that KLF4 is a potential tumor suppressor gene in CRC.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Human Genet, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu		Mandayam, Nandan/0000-0002-4061-9348	NCI NIH HHS [R01 CA084197, CA84197] Funding Source: Medline; NIDDK NIH HHS [DK64399, R24 DK064399, DK52230, R01 DK052230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R01DK052230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM CANC SOC, 2003, CANC FACTS FIG; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bird AP, 1996, CANCER SURV, V28, P87; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen ZY, 2002, J BIOL CHEM, V277, P46831, DOI 10.1074/jbc.M204816200; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Goel A, 2003, CANCER RES, V63, P1608; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ilyas M, 1999, EUR J CANCER, V35, P1986, DOI 10.1016/S0959-8049(99)00298-1; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jubb AM, 2001, J PATHOL, V195, P111, DOI 10.1002/path.923; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Stone CD, 2002, FEBS LETT, V530, P147, DOI 10.1016/S0014-5793(02)03449-X; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Yang V W, 1999, Curr Gastroenterol Rep, V1, P449, DOI 10.1007/s11894-999-0028-0; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	42	251	278	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					395	402		10.1038/sj.onc.1207067	http://dx.doi.org/10.1038/sj.onc.1207067			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724568	Green Accepted			2022-12-25	WOS:000188098300009
J	Keshamouni, VG; Reddy, RC; Arenberg, DA; Joel, B; Thannickal, VJ; Kalemkerian, GP; Standiford, TJ				Keshamouni, VG; Reddy, RC; Arenberg, DA; Joel, B; Thannickal, VJ; Kalemkerian, GP; Standiford, TJ			Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer	ONCOGENE			English	Article						PPAR-gamma; NSCLC; Erk1/2; differentiation	HUMAN BREAST-CANCER; PROTEASOME-DEPENDENT DEGRADATION; PPAR-GAMMA; ESTROGEN-RECEPTOR; RETINOIC ACID; MAP KINASE; MEDIATED PROTEOLYSIS; PROTEIN-KINASE; COLON-CANCER; OXIDIZED LDL	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors and a crucial regulator of cellular differentiation. Differentiation-inducing and antiproliferative effects of PPAR-gamma suggest that PPAR-gamma agonists might be useful as effective anticancer agents. Few studies have examined the efficacy of these agonists in animal models of tumorigenesis, and their mechanism(s) of action are still not clear. Our studies indicate higher PPAR-gamma expression in primary tumors from non-small-cell lung cancer (NSCLC) patients when compared to normal surrounding tissue. The expression of PPAR-gamma was also observed in several NSCLC lines. The treatment of lung adenocarcinoma cells (A549) with troglitazone (Tro), a PPAR-gamma ligand, enhanced PPAR-gamma transcriptional activity and induced a dose-dependent inhibition of A549 cell growth. The observed growth arrest was predominantly due to the inhibition of cell proliferation without significant induction of apoptosis. Cell cycle analysis of Tro-treated cells revealed a cell cycle arrest at G(0)/G(1) with concomitant downregulation of G(0)/G(1) cyclins D and E. In addition, Tro treatment stimulated sustained Erk1/2 activation in A549 cells, suggesting the activation of a differentiation-inducing pathway. Furthermore, treatment of A549 tumor-bearing SCID mice with Tro or Pio inhibited primary tumor growth by 66.7% and significantly inhibited the number of spontaneous lung metastatic lesions. Collectively, our data demonstrate that activation of PPAR-gamma impedes lung tumor progression and suggest that PPAR-gamma ligands may serve as potential therapeutic agents for NSCLC.	Univ Michigan, Med Ctr, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Standiford, TJ (corresponding author), Univ Michigan, Med Ctr, Div Pulm & Crit Care Med, 6301 MSRB III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	tstandif@med.umich.edu	Arenberg, Douglas/P-7251-2014	Arenberg, Douglas/0000-0001-7707-5092; Keshamouni, Venkateshwar/0000-0003-1947-791X	NCI NIH HHS [R01 CA094121, R01 CA094121-02, R01 CA094121-01A1] Funding Source: Medline; NHLBI NIH HHS [P050 HL60289, HL57243, K08 HL070068] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094121] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057243, K08HL070068, P50HL060289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; BLOCH A, 1984, CANCER TREAT REP, V68, P199; Chang TH, 2000, CANCER RES, V60, P1129; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Gurdon JB, 1998, CELL, V95, P159, DOI 10.1016/S0092-8674(00)81747-X; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Heaney AP, 2002, NAT MED, V8, P1281, DOI 10.1038/nm784; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kassam A, 1998, MOL CELL ENDOCRINOL, V141, P153, DOI 10.1016/S0303-7207(98)00085-9; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KRANENBURG O, 1995, ONCOGENE, V10, P87; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kubota T, 1998, CANCER RES, V58, P3344; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; PIERCE GB, 1988, CANCER RES, V48, P1996; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Syvala H, 1998, LIFE SCI, V63, P1505, DOI 10.1016/S0024-3205(98)00417-2; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Watkins PB, 1998, NEW ENGL J MED, V338, P916, DOI 10.1056/NEJM199803263381314; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	45	173	181	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					100	108		10.1038/sj.onc.1206885	http://dx.doi.org/10.1038/sj.onc.1206885			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712215				2022-12-25	WOS:000187895300011
J	Debril, MB; Gelman, L; Fayard, E; Annicotte, JS; Rocchi, S; Auwerx, J				Debril, MB; Gelman, L; Fayard, E; Annicotte, JS; Rocchi, S; Auwerx, J			Transcription factors and nuclear receptors interact with the SWI/SNF complex through the BAF60c subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING COMPLEX; RETINOIC ACID RECEPTOR; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID-RECEPTOR; PPAR-GAMMA; HISTONE ACETYLTRANSFERASES; ESTROGEN-RECEPTOR; HORMONE RECEPTORS; GENE ACTIVATION; HUMAN HOMOLOGS	Transcriptional activity relies on coregulators that modify chromatin structure or serve as bridging factors between transcription factors and the basal transcription machinery. We identified a new coregulator of peroxisome proliferator-activated receptor gamma, BRG1/Brm-associated factor of 60 kDa, subunit c2 (BAF60c2), in a yeast two-hybrid screen of a human adipose tissue cDNA library. BAF60c2 represents a new isoform of BAF60c, a component of the SWI/SNF (mating type switching/sucrose non-fermenting) chromatin remodeling complex. This new isoform as well as the previously identified protein, renamed BAF60c1, is localized primarily in the cell nucleus and is expressed in a wide variety of tissues. Both BAF60c isoforms bind to several nuclear receptors and transcription factors of various families. BAF60c proteins interact in a ligand-independent manner with peroxisome proliferator-activated receptor gamma and enhance its transcriptional activity. Both isoforms are enriched in the central nervous system and also modulate the transcriptional activity of retinoic acid-related orphan receptor alpha1. In conclusion, BAF60c represents a new coregulator that constitutes an important anchoring point by which the SWI/SNF complex is recruited to nuclear receptors and other transcription factors.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Auwerx, J (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP10142, F-67404 Illkirch Graffenstaden, France.	auwerx@igbmc.u-strasbg.fr	Auwerx, Johan/ABE-9307-2021; Annicotte, Jean-Sébastien/H-4641-2018; Rocchi, Stephane/O-4152-2016	Annicotte, Jean-Sébastien/0000-0002-2109-4849; Rocchi, Stephane/0000-0002-0943-1304; Auwerx, Johan/0000-0002-5065-5393; Gelman, Laurent/0000-0003-3277-3115				Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Brendel C, 2002, MOL ENDOCRINOL, V16, P1367, DOI 10.1210/me.16.6.1367; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Dilworth FJ, 1999, P NATL ACAD SCI USA, V96, P1995, DOI 10.1073/pnas.96.5.1995; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fayard E, 2003, J BIOL CHEM, V278, P35725, DOI 10.1074/jbc.M302370200; Fletcher TM, 2002, MOL CELL BIOL, V22, P3255, DOI 10.1128/MCB.22.10.3255-3263.2002; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Inoue H, 2002, J BIOL CHEM, V277, P41674, DOI 10.1074/jbc.M205961200; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Marshall TW, 2003, J BIOL CHEM, V278, P30605, DOI 10.1074/jbc.M304582200; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Remboutsika E, 1999, J CELL SCI, V112, P1671; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Schoonjans K, 2000, LANCET, V355, P1008, DOI 10.1016/S0140-6736(00)90002-3; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Sheldon LA, 1999, MOL CELL BIOL, V19, P8146; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Urnov FD, 2001, MOL ENDOCRINOL, V15, P1, DOI 10.1210/me.15.1.1; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Yamauchi T, 2002, NAT GENET, V30, P221, DOI 10.1038/ng829; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	55	101	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16677	16686		10.1074/jbc.M312288200	http://dx.doi.org/10.1074/jbc.M312288200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14701856	hybrid			2022-12-25	WOS:000220747900120
J	Caldarola, S; Amaldi, F; Proud, CG; Loreni, F				Caldarola, S; Amaldi, F; Proud, CG; Loreni, F			Translational regulation of terminal oligopyrimidine mRNAs induced by serum and amino acids involves distinct signaling events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; TUMOR-SUPPRESSOR PROTEIN; INHIBITS TRANSLATION; PYRIMIDINE TRACT; LA AUTOANTIGEN; 5 UTR; INITIATION; PHOSPHORYLATION; ACTIVATION; RAPAMYCIN	Various mitogenic or growth inhibitory stimuli induce a rapid change in the association of terminal oligopyrimidine (TOP) mRNAs with polysomes. It is generally believed that such translational control hinges on the mammalian target of rapamycin (mTOR)-S6 kinase pathway. Amino acid availability affects the translation of TOP mRNAs, although the signaling pathway involved in this regulation is less well characterized. To investigate both serum- and amino acid-dependent control of TOP mRNA translation and the signaling pathways involved, HeLa cells were subjected to serum and/or amino acid deprivation and stimulation. Our results indicate the following. 1) Serum and amino acid deprivation had additive effects on TOP mRNA translation. 2) The serum content of the medium specifically affected TOP mRNA translation, whereas amino acid availability affected both TOP and non-TOP mRNAs. 3) Serum signaling to TOP mRNAs involved only a rapamycin-sensitive pathway, whereas amino acid signaling depended on both rapamycin-sensitive and rapamycin-insensitive but wortmannin-sensitive events. 4) Eukaryotic initiation factor-2alpha phosphorylation increased during amino acid deprivation, but not following serum deprivation. Interestingly, rapamycin treatment suggests a novel connection between the mTOR pathway and eukaryotic initiation factor-2alpha phosphorylation in mammalian cells, which may not, however, be involved in TOP mRNA translational regulation.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee, Scotland	University of Rome Tor Vergata; University of Dundee	Loreni, F (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	loreni@uniroma2.it		Proud, Christopher/0000-0003-0704-6442				AGRAWAL MG, 1987, J BIOL CHEM, V262, P4868; Anthony TG, 2001, J NUTR, V131, P1171, DOI 10.1093/jn/131.4.1171; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; Crosio C, 2000, NUCLEIC ACIDS RES, V28, P2927, DOI 10.1093/nar/28.15.2927; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fox Heather L., 1998, American Journal of Physiology, V275, pC1232; Fox HL, 1998, AM J PHYSIOL-CELL PH, V274, pC206, DOI 10.1152/ajpcell.1998.274.1.C206; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Garcia-Barrio M, 2002, J BIOL CHEM, V277, P30675, DOI 10.1074/jbc.M203187200; GEYER PK, 1982, MOL CELL BIOL, V2, P685, DOI 10.1128/MCB.2.6.685; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kimball Sr, 2000, COLD SPRING HARBOR M, V39, P561; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; LANE HA, 1991, METHOD ENZYMOL, V200, P268; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Loreni F, 1997, FEBS LETT, V416, P239, DOI 10.1016/S0014-5793(97)01209-X; LORENI F, 1992, EUR J BIOCHEM, V205, P1027, DOI 10.1111/j.1432-1033.1992.tb16870.x; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; Meyuhas O, 2000, COLD SPRING HARBOR M, V39, P671; Pellizzoni L, 1996, J MOL BIOL, V259, P904, DOI 10.1006/jmbi.1996.0368; Pellizzoni L, 1997, J MOL BIOL, V267, P264, DOI 10.1006/jmbi.1996.0888; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Saitoh M, 1998, BIOCHEM BIOPH RES CO, V253, P470, DOI 10.1006/bbrc.1998.9784; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shigemitsu K, 1999, FEBS LETT, V447, P303, DOI 10.1016/S0014-5793(99)00304-X; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; Zhu JF, 2001, BBA-GENE STRUCT EXPR, V1521, P19, DOI 10.1016/S0167-4781(01)00277-9	52	30	39	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13522	13531		10.1074/jbc.M310574200	http://dx.doi.org/10.1074/jbc.M310574200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726531	hybrid			2022-12-25	WOS:000220478500031
J	Hayashi, H; Campenot, RB; Vance, DE; Vance, JE				Hayashi, H; Campenot, RB; Vance, DE; Vance, JE			Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; APOLIPOPROTEIN-E RECEPTORS; PICK C1-DEFICIENT NEURONS; HUMAN CEREBROSPINAL-FLUID; NEURITE OUTGROWTH; CHOLESTEROL TRANSPORT; HUMAN BRAIN; SYMPATHETIC NEURONS; ALZHEIMERS-DISEASE; SYNAPSE FORMATION	The role of lipoproteins secreted by cortical glial cells in axon growth of central nervous system (CNS) neurons was investigated. We first established compartmented cultures of CNS neurons ( retinal ganglion cells). Addition of glial cell-conditioned medium (GCM) to distal axons increased the rate of axon extension by similar to 50%. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase in glial cells diminished the secretion of cholesterol and apolipoprotein E, and prevented the growth stimulatory effect of GCM. When glia-derived lipoproteins containing apolipoprotein E were provided to distal axons, axon extension was stimulated to the same extent as by GCM. In contrast, addition of lipoproteins to cell bodies failed to enhance growth. The growth stimulatory effect of glial lipoproteins was abrogated in the presence of receptor-associated protein, RAP, indicating involvement of receptor(s) of the low density lipoprotein receptor family in stimulation of axonal extension. These observations suggest that glial cells stimulate axon growth of CNS neurons by providing lipoproteins containing cholesterol and apolipoprotein E to distal axons.	Univ Alberta, Dept Med, Grp Mol & Cell Biol Lipids, HMRC 328, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Dept Med, Grp Mol & Cell Biol Lipids, HMRC 328, Edmonton, AB T6G 2S2, Canada.	jean.vance@ualberta.ca						Araque A, 1999, CAN J PHYSIOL PHARM, V77, P699, DOI 10.1139/cjpp-77-9-699; Barres BA, 2000, CURR OPIN NEUROBIOL, V10, P642, DOI 10.1016/S0959-4388(00)00134-3; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; Beisiegel U, 2001, CURR OPIN LIPIDOL, V12, P243, DOI 10.1097/00041433-200106000-00001; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; BORGHINI I, 1995, BBA-LIPID LIPID MET, V1255, P192, DOI 10.1016/0005-2760(94)00232-N; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; Brown MD, 1997, BRAIN RES, V747, P313, DOI 10.1016/S0006-8993(96)01321-2; CAMPENOT RB, 1977, P NATL ACAD SCI USA, V74, P4516, DOI 10.1073/pnas.74.10.4516; CAMPENOT RB, 1979, METHOD ENZYMOL, V28, P302; CAMPENOT RB, 1992, CELL CELL INTERACTIO, P275; CAMPENOT RB, 2001, PROTOCOLS NEURAL CEL, P49; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; de Chaves EIP, 2000, J BIOL CHEM, V275, P19883, DOI 10.1074/jbc.275.26.19883; DeMattos RB, 1998, J BIOL CHEM, V273, P4206, DOI 10.1074/jbc.273.7.4206; DeMattos RB, 2001, J LIPID RES, V42, P976; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Gong JS, 2002, J BIOL CHEM, V277, P29919, DOI 10.1074/jbc.M203934200; GOODRUM JF, 1990, J NEUROCHEM, V54, P1709, DOI 10.1111/j.1471-4159.1990.tb01225.x; Hering H, 2003, J NEUROSCI, V23, P3262; Hermans-Borgmeyer I, 1998, MECH DEVELOP, V70, P65, DOI 10.1016/S0925-4773(97)00177-9; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Ivins KJ, 1998, NEUROBIOL DIS, V5, P365, DOI 10.1006/nbdi.1998.0228; Karten B, 2002, J NEUROCHEM, V83, P1154, DOI 10.1046/j.1471-4159.2002.01220.x; Karten B, 2003, J BIOL CHEM, V278, P4168, DOI 10.1074/jbc.M205406200; KARTEN B, 2002, APOPTOSIS METHODS TE, V37, P163; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Koch S, 2001, J LIPID RES, V42, P1143; LaDu MJ, 2000, J BIOL CHEM, V275, P33974, DOI 10.1074/jbc.M000602200; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; MacInnis BL, 2002, SCIENCE, V295, P1536, DOI 10.1126/science.1064913; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Motoi Y, 1999, BRAIN RES, V833, P209, DOI 10.1016/S0006-8993(99)01542-5; Mouchel Y, 1995, NEUROREPORT, V7, P205; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nimpf J, 2000, BBA-MOL CELL BIOL L, V1529, P287, DOI 10.1016/S1388-1981(00)00155-4; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; Page KJ, 1998, NEUROSCIENCE, V85, P1161, DOI 10.1016/S0306-4522(97)00661-1; Petegnief V, 2001, NEUROSCIENCE, V104, P223, DOI 10.1016/S0306-4522(01)00046-X; Pfrieger FW, 2003, BBA-BIOMEMBRANES, V1610, P271, DOI 10.1016/S0005-2736(03)00024-5; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; PFRIEGER FW, 2003, BIOESSAYS, V25, P486; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; TOOYAMA I, 1995, BRAIN RES, V691, P235, DOI 10.1016/0006-8993(95)00735-9; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099, DOI 10.1152/ajpendo.1998.274.6.E1099; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; VANCE JE, 1994, J NEUROCHEM, V62, P329; VANCE JE, 1991, J CELL BIOL, V115, P1061, DOI 10.1083/jcb.115.4.1061; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WOLF BB, 1992, AM J PATHOL, V141, P37; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; YOSHINO G, 1988, ATHEROSCLEROSIS, V71, P95, DOI 10.1016/0021-9150(88)90133-5	71	138	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14009	14015		10.1074/jbc.M313828200	http://dx.doi.org/10.1074/jbc.M313828200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14709547	hybrid			2022-12-25	WOS:000220478500089
J	Lewin, TM; Schwerbrock, NMJ; Lee, DP; Coleman, RA				Lewin, TM; Schwerbrock, NMJ; Lee, DP; Coleman, RA			Identification of a new glycerol-3-phosphate acyltransferase isoenzyme, mtGPAT2, in mitochondria*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SN-GLYCEROL 3-PHOSPHATE; RAT-LIVER MITOCHONDRIA; MICROSOMAL GLYCEROPHOSPHATE ACYLTRANSFERASE; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; TRIACYLGLYCEROL-SYNTHESIS; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; MONOACYLGLYCEROL ACYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE; FUNCTIONAL EXPRESSION	Glycerol-3-phosphate acyltransferase (GPAT) catalyzes the initial and rate-limiting step of glycerolipid synthesis. Two distinct GPAT isoenzymes had been identified in mammalian tissues, an N-ethylmaleimide (NEM)-sensitive isoform in the endoplasmic reticulum membrane ( microsomal GPAT) and an NEM-resistant form in the outer mitochondrial membrane (mtGPAT). Although only mtGPAT has been cloned, the microsomal and mitochondrial GPAT isoforms can be distinguished, because they differ in acyl-CoA substrate preference, sensitivity to inhibition by dihydroxyacetone phosphate and polymixin B, temperature sensitivity, and ability to be activated by acetone. The preponderance of evidence supports a role for mtGPAT in synthesizing the precursors for triacylglycerol synthesis. In mtGPAT(-/-) mice, PCR genotyping and Northern analysis showed successful knockout of mtGPAT; however, we detected a novel NEM-sensitive GPAT activity in mitochondrial fractions and an anti-mtGPAT immunoreactive protein in liver mitochondria, but not in microsomes. Rigorous analysis using two-dimensional gel electrophoresis revealed that the anti-mtGPAT immunoreactive proteins in wild type and mtGPAT(-/-) liver mitochondria have different isoelectric points. These results suggested the presence of a second GPAT in liver mitochondria from mtGPAT(-/-) mice. Characterization of this GPAT activity in liver from mtGPAT null mice showed that, unlike the mtGPAT activity in wild type samples, activity in mtGPAT knockout mitochondria did not prefer palmitoyl-CoA, was sensitive to inactivation by NEM, was inhibited by dihydroxyacetone phosphate and polymixin B, was temperature-sensitive, and was not activated by acetone. We conclude that a novel GPAT (mtGPAT2) with antigenic epitopes similar to those of mtGPAT is detectable in mitochondria from the livers of mtGPAT(-/-) mice.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Coleman, RA (corresponding author), Univ N Carolina, Dept Nutr, CB 7400, Chapel Hill, NC 27599 USA.	rcoleman@unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059935, K01DK059931, R01DK056598] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59931, DK56598, DK59935] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal AK, 2002, NAT GENET, V31, P21, DOI 10.1038/ng880; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bhat BG, 1999, BBA-MOL CELL BIOL L, V1439, P415, DOI 10.1016/S1388-1981(99)00103-1; BREMER J, 1976, MOL CELL BIOCHEM, V12, P113, DOI 10.1007/BF01731557; CARROLL MA, 1982, ARCH BIOCHEM BIOPHYS, V214, P17, DOI 10.1016/0003-9861(82)90003-0; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG YY, 1967, J LIPID RES, V8, P447; Cheng D, 2003, J BIOL CHEM, V278, P13611, DOI 10.1074/jbc.C300042200; COLEMAN RA, 1988, BIOCHIM BIOPHYS ACTA, V963, P367, DOI 10.1016/0005-2760(88)90303-7; COLEMAN RA, 1980, J BIOL CHEM, V255, P7681; COLEMAN RA, 1983, J BIOL CHEM, V258, P450; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; DALLNER G, 1966, J CELL BIOL, V30, P97, DOI 10.1083/jcb.30.1.97; DAS SK, 1987, LIPIDS, V22, P757, DOI 10.1007/BF02533977; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; HALDAR D, 1979, J BIOL CHEM, V254, P4502; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; KALMAR GB, 1994, BBA-GENE STRUCT EXPR, V1219, P328, DOI 10.1016/0167-4781(94)90056-6; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; Lewin TM, 2001, ARCH BIOCHEM BIOPHYS, V396, P119, DOI 10.1006/abbi.2001.2604; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; MITCHELL JRD, 1994, INT J BIOCHEM, V26, P181, DOI 10.1016/0020-711X(94)90143-0; MONROY G, 1973, J BIOL CHEM, V248, P2845; MONROY G, 1972, J BIOL CHEM, V247, P6884; SAGGERSON ED, 1987, BIOCHEM J, V243, P289, DOI 10.1042/bj2430289; SCHLOSSMAN DM, 1977, ARCH BIOCHEM BIOPHYS, V182, P732, DOI 10.1016/0003-9861(77)90555-0; SCHLOSSMAN DM, 1976, J BIOL CHEM, V251, P5738; SHIN DH, 1991, J BIOL CHEM, V266, P23834; STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451; Vance JE, 1998, TRENDS BIOCHEM SCI, V23, P423, DOI 10.1016/S0968-0004(98)01297-3; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691; Yen CLE, 2003, J BIOL CHEM, V278, P18532, DOI 10.1074/jbc.M301633200; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029	45	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13488	13495		10.1074/jbc.M314032200	http://dx.doi.org/10.1074/jbc.M314032200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724270	hybrid, Green Published			2022-12-25	WOS:000220478500027
J	Tanaka, S; Maeda, Y; Tashima, Y; Kinoshita, T				Tanaka, S; Maeda, Y; Tashima, Y; Kinoshita, T			Inositol deacylation of glycosylphosphatidylinositol-anchored proteins is mediated by mammalian PGAP1 and yeast Bst1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOLICHOL-PHOSPHATE-MANNOSE; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; GLYCOINOSITOL PHOSPHOLIPID ANCHOR; ENDOPLASMIC-RETICULUM; GLUCOSAMINYL PHOSPHATIDYLINOSITOL; COENZYME-A; BIOSYNTHESIS; ACYLATION; LOCALIZATION; TRANSPORT	The inositol moiety of mammalian glycosylphosphatidylinositol (GPI) is acylated at an early step in GPI biosynthesis. The inositol acylation is essential for the generation of mature GPI capable of attachment to proteins. However, the acyl group is usually absent from GPI-anchored proteins (GPI-APs) on the cell surface due to inositol deacylation that occurs in the endoplasmic reticulum (ER) soon after GPI-anchor attachment. Mammalian GPI inositol-deacylase has not been cloned, and the biological significance of the deacylation has been unclear. Here we report a GPI inositol-deacylase-deficient Chinese hamster ovary cell line established by taking advantage of resistance to phosphatidylinositol-specific phospholipase C and the gene responsible, which was termed PGAP1 for Post GPI Attachment to Proteins 1. PGAP1 encoded an ER-associated, 922-amino acid membrane protein bearing a lipase consensus motif. Substitution of a conserved putative catalytic serine with alanine resulted in a complete loss of function, indicating that PGAP1 is the GPI inositol-deacylase. The mutant cells showed a clear delay in the maturation of GPI-APs in the Golgi and accumulation of GPI-APs in the ER. Thus, the GPI inositol deacylation is important for efficient transport of GPI-APs from the ER to the Golgi.	Osaka Univ, Res Inst Microbial Dis, Dept Immunoregulat, Suita, Osaka 5650871, Japan	Osaka University	Kinoshita, T (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Immunoregulat, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	tkinoshi@biken.osaka-u.ac.jp	Kinoshita, Taroh/C-7353-2009					Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DEEG MA, 1992, J BIOL CHEM, V267, P18573; Doerrler WT, 1996, J BIOL CHEM, V271, P27031, DOI 10.1074/jbc.271.43.27031; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; Guther MLS, 2001, EMBO J, V20, P4923, DOI 10.1093/emboj/20.17.4923; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hong YJ, 2002, EMBO J, V21, P5047, DOI 10.1093/emboj/cdf508; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; Ikezawa H, 2002, BIOL PHARM BULL, V25, P409, DOI 10.1248/bpb.25.409; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maeda Y, 2000, EMBO J, V19, P2475, DOI 10.1093/emboj/19.11.2475; Maeda Y, 1998, EMBO J, V17, P4920, DOI 10.1093/emboj/17.17.4920; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Murakami Y, 2003, MOL BIOL CELL, V14, P4285, DOI 10.1091/mbc.E03-03-0193; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; STEVENS VL, 1994, J BIOL CHEM, V269, P31397; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; TOUTANT JP, 1989, EUR J BIOCHEM, V180, P503, DOI 10.1111/j.1432-1033.1989.tb14674.x; Umemura M, 2003, J BIOL CHEM, V278, P23639, DOI 10.1074/jbc.M301044200; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; WALTER EI, 1990, J IMMUNOL, V144, P1030	31	125	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14256	14263		10.1074/jbc.M313755200	http://dx.doi.org/10.1074/jbc.M313755200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734546	hybrid			2022-12-25	WOS:000220478500119
J	Davis, AJ; Perugini, MA; Smith, BJ; Stewart, JD; Ilg, T; Hodder, AN; Handman, E				Davis, AJ; Perugini, MA; Smith, BJ; Stewart, JD; Ilg, T; Hodder, AN; Handman, E			Properties of GDP-mannose pyrophosphorylase, a critical enzyme and drug target in Leishmania mexicana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRULENCE; PHENOTYPES; PROTEINS	Leishmania parasites synthesize a range of mannose-containing glycoconjugates thought to be essential for virulence in the mammalian host and sandfly vector. A prerequisite for the synthesis of these molecules is the availability of the activated mannose donor, GDP-Man, the product of the catalysis of mannose-1-phosphate and GTP by GDP-mannose pyrophosphorylase (GDP-MP). In contrast to the lethal phenotype in fungi, the deletion of the gene in Leishmania mexicana did not affect parasite viability but led to a total loss of virulence, making GDP-MP an ideal target for anti-Leishmania drug development. We show by immunofluorescence and subcellular fractionation that GDP-MP is a cytoplasmic protein, and we describe a colorimetric activity assay suitable for the high throughput screening of small molecule inhibitors. We expressed recombinant GDP-MP as a fusion with maltose-binding protein and separated the enzyme from maltose-binding protein by thrombin cleavage, ion-exchange, and size exclusion chromatography. Size exclusion chromatography and analytical ultracentrifugation studies demonstrate that GDP-MP self-associates to form an enzymatically active and stable hexamer. However, sedimentation studies show that the GDP-MP hexamer dissociates to trimers and monomers in a time-dependent manner, at low protein concentrations, at low ionic strength, and at alkaline pH. Circular dichroism spectroscopy reveals that GDP-MP is comprised of mixed alpha/beta structure, similar to its closest related homologue, N-acetyl-glucoseamine-1-phosphate uridyltransferase (Glmu) from Streptococcus pneumoniae. Our studies provide insight into the structure of a novel target for the development of anti-Leishmania drugs.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia; Intervet Innovat GmbH, D-55270 Schwabenheim, Germany	Walter & Eliza Hall Institute; University of Melbourne; Merck & Company; Intervet International B.V.	Handman, E (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	handman@wehi.edu.Au	Smith, Brian J/F-8282-2011	Smith, Brian J/0000-0003-0498-1910; Perugini, Matthew/0000-0001-8052-5584; Stewart, James/0000-0002-1774-8619				BORDIER C, 1981, J BIOL CHEM, V256, P1604; Croft SL, 1999, MEM I OSWALDO CRUZ, V94, P215, DOI 10.1590/S0074-02761999000200017; Davis AJ, 2004, TRENDS PARASITOL, V20, P73, DOI 10.1016/j.pt.2003.11.006; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Garami A, 2001, EMBO J, V20, P3657, DOI 10.1093/emboj/20.14.3657; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; HANDMAN E, 1992, ADV MOL CELL BIOL, V5, P133; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Ilg T, 2000, PARASITOL TODAY, V16, P489, DOI 10.1016/S0169-4758(00)01791-9; Ilg T, 1999, TRENDS GLYCOSCI GLYC, V11, P53, DOI 10.4052/tigg.11.53; Ilgoutz SC, 2001, INT J PARASITOL, V31, P899, DOI 10.1016/S0020-7519(01)00197-7; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MCCONVILLE MJ, 1991, LEISHMANIA PARASITES, P38; Ohta A, 2000, BBA-GEN SUBJECTS, V1475, P265, DOI 10.1016/S0304-4165(00)00075-1; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; OUELLETTE M, 1991, RES MICROBIOL, V142, P737, DOI 10.1016/0923-2508(91)90089-S; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; Ralton JE, 2003, J BIOL CHEM, V278, P40757, DOI 10.1074/jbc.M307660200; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Sulzenbacher G, 2001, J BIOL CHEM, V276, P11844, DOI 10.1074/jbc.M011225200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARKI A, 1999, ESSENTIALS GLYCOBIOL, P57; Warit S, 2000, MOL MICROBIOL, V36, P1156, DOI 10.1046/j.1365-2958.2000.01944.x; World Health Organization (WHO), 1998, LEISHM CONTR BURD TR, P1; Yardley V, 2000, INT J ANTIMICROB AG, V13, P243, DOI 10.1016/S0924-8579(99)00133-8	28	56	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12462	12468		10.1074/jbc.M312365200	http://dx.doi.org/10.1074/jbc.M312365200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718535	hybrid			2022-12-25	WOS:000220334900056
J	Ghosh, A; Shieh, JJ; Pan, CJ; Chou, JY				Ghosh, A; Shieh, JJ; Pan, CJ; Chou, JY			Histidine 167 is the phosphate acceptor in glucose-6-phosphatase-beta forming a phosphohistidine enzyme intermediate during catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; SUBUNIT-RELATED PROTEIN; ACTIVE-SITE; MICROSOMAL GLUCOSE-6-PHOSPHATASE; MURINE GLUCOSE-6-PHOSPHATASE; TRANSMEMBRANE TOPOLOGY; GLUCOSE 6-PHOSPHATASE; CURVULARIA-INAEQUALIS; IDENTIFICATION; GENE	The glucose-6-phosphatase (Glc-6-Pase) family comprises two active endoplasmic reticulum (ER)-associated isozymes: the liver/kidney/intestine Glc-6-Pase-alpha and the ubiquitous Glc-6-Pase-beta. Both share similar kinetic properties. Sequence alignments predict the two proteins are structurally similar. During glucose 6-phosphate (Glc-6-P) hydrolysis, Glc-6-Pase-beta, a nine-transmembrane domain protein, forms a covalently bound phosphoryl enzyme intermediate through His(176), which lies on the lumenal side of the ER membrane. We showed that Glc-6-Pase-beta is also a nine-transmembrane domain protein that forms a covalently bound phosphoryl enzyme intermediate during Glc-6-P hydrolysis. However, the intermediate was not detectable in Glc-6-Pase-alpha active site mutants R79A, H114A, and H167A. Using [P-32] Glc-6-P coupled with cyanogen bromide mapping, we demonstrated that the phosphate acceptor in Glc-6-Pase-beta is His(167) and that it lies inside the ER lumen with the active site residues, Arg(79) and His(114). Therefore Glc-6-Pase-alpha and Glc-6-Pase-beta share a similar active site structure, topology, and mechanism of action.	NICHD, Sect Cellular Differentat, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chou, JY (corresponding author), NICHD, Sect Cellular Differentat, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241, Bethesda, MD 20892 USA.	chouja@mail.nih.gov	Shieh, Jeng-Jer/AAX-6903-2020	Shieh, Jeng-Jer/0000-0001-8412-3603	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arden SD, 1999, DIABETES, V48, P531, DOI 10.2337/diabetes.48.3.531; Chou Janice Yang, 2001, Current Molecular Medicine (Hilversum), V1, P25; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; Coligan JE, 1996, CURRENT PROTOCOLS PR; Cordoba OL, 1997, J BIOCHEM BIOPH METH, V35, P1, DOI 10.1016/S0165-022X(97)00018-3; FELDMAN F, 1972, BIOCHIM BIOPHYS ACTA, V268, P698, DOI 10.1016/0005-2744(72)90274-4; FELDMAN F, 1969, BIOCHEM BIOPH RES CO, V36, P119, DOI 10.1016/0006-291X(69)90657-3; Ghosh A, 2002, J BIOL CHEM, V277, P32837, DOI 10.1074/jbc.M201853200; Guionie O, 2003, FEBS LETT, V551, P159, DOI 10.1016/S0014-5793(03)00903-7; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hemrika W, 1999, J BIOL CHEM, V274, P23820, DOI 10.1074/jbc.274.34.23820; Hemrika W, 1997, FEBS LETT, V409, P317, DOI 10.1016/S0014-5793(97)00530-9; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; Kishnani PS, 1997, BIOCHEM MOL MED, V61, P168, DOI 10.1006/bmme.1997.2600; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Martin CC, 2002, J MOL ENDOCRINOL, V29, P205, DOI 10.1677/jme.0.0290205; Martin CC, 2001, J BIOL CHEM, V276, P25197, DOI 10.1074/jbc.M101549200; NORDLIE RC, 1966, J BIOL CHEM, V241, P3136; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; Pan CJ, 1998, J BIOL CHEM, V273, P21658, DOI 10.1074/jbc.273.34.21658; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Pan CJ, 1998, ARCH BIOCHEM BIOPHYS, V358, P17, DOI 10.1006/abbi.1998.0849; PARVIN R, 1969, BIOCHEMISTRY-US, V8, P1748, DOI 10.1021/bi00832a058; Renirie R, 2000, J BIOL CHEM, V275, P11650, DOI 10.1074/jbc.275.16.11650; Scriver C.R., 2001, METABOLIC MOL BASIS, VEighth; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Shieh JJ, 2002, J BIOL CHEM, V277, P5047, DOI 10.1074/jbc.M110486200; Shieh JJ, 2003, J BIOL CHEM, V278, P47098, DOI 10.1074/jbc.M309472200; Stukey J, 1997, PROTEIN SCI, V6, P469; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590	32	44	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12479	12483		10.1074/jbc.M313271200	http://dx.doi.org/10.1074/jbc.M313271200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718531	hybrid			2022-12-25	WOS:000220334900058
J	Nie, YZ; Zhao, QC; Su, YJ; Yang, JH				Nie, YZ; Zhao, QC; Su, YJ; Yang, JH			Subcellular distribution of ADAR1 isoforms is synergistically determined by three nuclear discrimination signals and a regulatory motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-EDITING ENZYME; SEMLIKI-FOREST VIRUS; ADENOSINE-DEAMINASE; BINDING DOMAINS; MESSENGER-RNA; EXPORT SIGNAL; UNWINDING ACTIVITY; IN-VIVO; PROTEIN; RECEPTOR	ADAR1 is an RNA-specific adenosine deaminase that edits RNA sequences. We have demonstrated previously that different ADAR1 isoforms are induced during acute inflammation. Here we show that the mouse ADAR1 isoforms are differentially localized in cellular compartments and that their localization is controlled by several independent signals. Nuclear import of the full-length ADAR1 is predominantly regulated by a nuclear localization signal at the C terminus (NLS-c), which consists of a bipartite basic amino acid motif plus the last 39 residues of ADAR1. Deletion of the NLS-c causes the truncated ADAR1 protein to be retained in the cytoplasm. The addition of this sequence to pyruvate kinase causes the cytoplasmic protein to be localized within the nucleus. The localization of nuclear ADAR1 is determined by a dynamic balance between the nucleolar binding activity of the nucleolar localization signal (NoLS) in the middle of the protein and the exporting activity of the nuclear exporter signal (NES) near the N terminus. The NoLS consists of a typical monopartite cluster of basic residues followed by the third double-stranded RNA-binding domain. These signals act independently; however, NES function can be completely silenced by the NLS-c when a regulatory motif within the catalytic domain and the NoLS are deleted. Thus, the intracellular distribution of the various ADAR1 isoforms is determined by NLS-c, NES, NoLS, and a regulatory motif.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA	Yale University	Yang, JH (corresponding author), Yale Univ, Sch Med, Dept Surg, 333 Cedar St, New Haven, CT 06520 USA.	jinghua.yang@yale.edu			NIGMS NIH HHS [GM 60426] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060426] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Cho DSC, 2003, J BIOL CHEM, V278, P17093, DOI 10.1074/jbc.M213127200; Desterro JMP, 2003, J CELL SCI, V116, P1805, DOI 10.1242/jcs.00371; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Doyle M, 2003, J CELL BIOL, V161, P309, DOI 10.1083/jcb.200301034; Eckmann CR, 1999, J CELL BIOL, V144, P603, DOI 10.1083/jcb.144.4.603; Eckmann CR, 2001, MOL BIOL CELL, V12, P1911, DOI 10.1091/mbc.12.7.1911; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gallo A, 2003, EMBO J, V22, P3421, DOI 10.1093/emboj/cdg327; Herbert A, 2002, MOL CELL, V10, P1235, DOI 10.1016/S1097-2765(02)00737-2; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; JAKOB R, 1993, VIRUS RES, V30, P145, DOI 10.1016/0168-1702(93)90003-6; Kawakubo K, 2000, GENE, V258, P165, DOI 10.1016/S0378-1119(00)00368-1; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; Lei M, 1998, VIROLOGY, V245, P188, DOI 10.1006/viro.1998.9162; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; LOUIS BG, 1988, MOL BIOL REP, V13, P103, DOI 10.1007/BF00539058; Maas S, 1999, P NATL ACAD SCI USA, V96, P8895, DOI 10.1073/pnas.96.16.8895; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; MICHEL MR, 1990, J VIROL, V64, P5123, DOI 10.1128/JVI.64.10.5123-5131.1990; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Palladino MJ, 2000, RNA, V6, P1004, DOI 10.1017/S1355838200000248; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Poulsen H, 2001, MOL CELL BIOL, V21, P7862, DOI 10.1128/MCB.21.22.7862-7871.2001; Rabinovici R, 2001, CIRC RES, V88, P1066, DOI 10.1161/hh1001.090877; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; Slavov D, 2000, GENE, V250, P41, DOI 10.1016/S0378-1119(00)00174-8; Strehblow A, 2002, MOL BIOL CELL, V13, P3822, DOI 10.1091/mbc.E02-03-0161; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; Wong SK, 2003, RNA, V9, P586, DOI 10.1261/rna.5160403; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; Yang JH, 2003, J BIOL CHEM, V278, P45833, DOI 10.1074/jbc.M308612200; Yang JH, 2003, IMMUNOLOGY, V109, P15, DOI 10.1046/j.1365-2567.2003.01598.x; Yang JH, 1997, P NATL ACAD SCI USA, V94, P4354, DOI 10.1073/pnas.94.9.4354	46	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13249	13255		10.1074/jbc.M312753200	http://dx.doi.org/10.1074/jbc.M312753200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711814	hybrid			2022-12-25	WOS:000220334900147
J	Peterson, FC; Elgin, ES; Nelson, TJ; Zhang, FM; Hoeger, TJ; Linhardt, RJ; Volkman, BF				Peterson, FC; Elgin, ES; Nelson, TJ; Zhang, FM; Hoeger, TJ; Linhardt, RJ; Volkman, BF			Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SURFACE; HEPARIN-BINDING; SITE; OLIGOMERIZATION; INHIBITION; MIP-1-BETA; EXPRESSION; STRATEGIES; PROTEIN-1; CYTOKINE	Chemokine-mediated recruitment of leukocytes in vivo depends on interactions with cell surface glycosaminoglycans. Lymphotactin, the unique member of the "C" chemokine subclass, is a highly basic protein that binds heparin, a glycosaminoglycan, with high affinity ( similar to 10 nM). We detected lymphotactin-heparin binding by NMR and mapped this interaction to a narrow surface that wraps around the protein. Substitutions in and around this binding site and surface plasmon resonance analysis of heparin binding affinity identified two arginine residues of lymphotactin as critical for glycosaminoglycan binding. Both arginine mutant proteins and the combined double mutant had dramatically diminished in vivo activity in a leukocyte recruitment assay, suggesting that the lymphotactin-glycosaminoglycan interactions detected in vitro are important for the function of this chemokine. Our results demonstrate that like other chemokines, lymphotactin utilizes highly specific glycosaminoglycan-binding sites that represent potential targets for drug development.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Mugla Univ, Kimya Bolumu, TR-48000 Mugla, Turkey; Rensselaer Polytech Inst, Dept Chem, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Biol & Chem Engn, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Biol, Troy, NY 12180 USA	Medical College of Wisconsin; Mugla Sitki Kocman University; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute	Volkman, BF (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	bvolkman@mcw.edu	Volkman, Brian F./ABE-7306-2020; Volkman, Brian F./ABE-7312-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179; Nelson, Timothy/0000-0002-3862-7023	NIAID NIH HHS [R01 AI045843, R01 AI045843-04, R01 AI045843-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045843] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Blaschke S, 2003, ARTHRITIS RHEUM, V48, P1858, DOI 10.1002/art.11171; Campanella GSV, 2003, J BIOL CHEM, V278, P17066, DOI 10.1074/jbc.M212077200; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chakravarty L, 1998, J BIOL CHEM, V273, P29641, DOI 10.1074/jbc.273.45.29641; Dorner B, 1997, J BIOL CHEM, V272, P8817, DOI 10.1074/jbc.272.13.8817; DOUGHERTY WG, 1989, VIROLOGY, V171, P356, DOI 10.1016/0042-6822(89)90603-X; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Gale LM, 1999, BIOESSAYS, V21, P17, DOI 10.1002/(SICI)1521-1878(199901)21:1<17::AID-BIES3>3.0.CO;2-4; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Hedrick JA, 1997, J IMMUNOL, V158, P1533; Hedrick JA, 1998, CLIN IMMUNOL IMMUNOP, V87, P218, DOI 10.1006/clin.1998.4546; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Keane MP, 2000, CRIT CARE MED, V28, pN13, DOI 10.1097/00003246-200004001-00003; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Koopmann W, 1997, J BIOL CHEM, V272, P10103; Koopmann W, 1999, J IMMUNOL, V163, P2120; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuloglu ES, 2002, J BIOL CHEM, V277, P17863, DOI 10.1074/jbc.M200402200; Kuloglu ES, 2001, BIOCHEMISTRY-US, V40, P12486, DOI 10.1021/bi011106p; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Loetscher P, 2001, J LEUKOCYTE BIOL, V69, P881; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; McCornack MA, 2003, J BIOL CHEM, V278, P1946, DOI 10.1074/jbc.M207440200; McFadden G, 1997, BIOCHEM PHARMACOL, V54, P1271, DOI 10.1016/S0006-2952(97)00182-2; Middel P, 2001, AM J PATHOL, V159, P1751, DOI 10.1016/S0002-9440(10)63022-2; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; Proudfoot AEI, 1998, EUR J DERMATOL, V8, P147; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Proudfoot AEI, 2003, SEMIN IMMUNOL, V15, P57, DOI 10.1016/S1044-5323(02)00128-8; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rousseau RF, 2003, BLOOD, V101, P1718, DOI 10.1182/blood-2002-08-2493; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Wang JD, 1998, IMMUNOLOGY, V95, P56; Yu GL, 2000, THROMB RES, V100, P549, DOI 10.1016/S0049-3848(00)00368-6; Zhang FM, 2002, ANAL BIOCHEM, V304, P271, DOI 10.1006/abio.2002.5617; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	46	69	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12598	12604		10.1074/jbc.M311633200	http://dx.doi.org/10.1074/jbc.M311633200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707146	hybrid			2022-12-25	WOS:000220334900073
J	Yu, XR; Rajala, RVS; McGinnis, JF; Li, F; Anderson, RE; Yan, XR; Li, S; Elias, RV; Knapp, RR; Zhou, XH; Cao, W				Yu, XR; Rajala, RVS; McGinnis, JF; Li, F; Anderson, RE; Yan, XR; Li, S; Elias, RV; Knapp, RR; Zhou, XH; Cao, W			Involvement of insulin/phosphoinositide 3-kinase/Akt signal pathway in 17 beta-estradiol-mediated neuroprotection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; APOPTOTIC CELL-DEATH; HYDROGEN-PEROXIDE; INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; RETINAL NEURONS; LIGHT DAMAGE; IN-VITRO; ACTIVATION	In the present study, we tested the hypothesis that 17beta-estradiol (betaE2) is a neuroprotectant in the retina, using two experimental approaches: 1) hydrogen peroxide (H2O2)-induced retinal neuron degeneration in vitro, and 2) light-induced photoreceptor degeneration in vivo. We demonstrated that both betaE2 and 17alpha-estradiol (alphaE2) significantly protected against H2O2-induced retinal neuron degeneration; however, progesterone had no effect. betaE2 transiently increased the phosphoinositide 3-kinase (PI3K) activity, when phosphoinositide 4,5-bisphosphate and [(32)gammaATP] were used as substrate. Phospho-Akt levels were also transiently increased by betaE2 treatment. Addition of the estrogen receptor antagonist tamoxifen did not reverse the protective effect of betaE2, whereas the PI3K inhibitor LY294002 inhibited the protective effect of betaE2, suggesting that betaE2 mediates its effect through some PI3K-dependent pathway, independent of the estrogen receptor. Pull-down experiments with glutathione S-transferase fused to the N-Src homology 2 domain of p85, the regulatory subunit of PI3K, indicated that betaE2 and alphaE2, but not progesterone, identified phosphorylated insulin receptor beta-subunit (IRbeta) as a binding partner. Pretreatment with insulin receptor inhibitor, HNMPA, inhibited IRbeta activation of PI3K. Systemic administration of betaE2 significantly protected the structure and function of rat retinas against light-induced photoreceptor cell degeneration and inhibited photoreceptor apoptosis. In addition, systemic administration of betaE2 activated retinal IRbeta, but not the insulin-like growth factor receptor-1, and produced a transient increase in PI3K activity and phosphorylation of Akt in rat retinas. The results show that estrogen has retinal neuroprotective properties in vivo and in vitro and suggest that the insulin receptor/PI3K/Akt signaling pathway is involved in estrogen-mediated retinal neuroprotection.	Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Dean A McGee Eye Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Xi An Jiao Tong Univ, Sch Med, Dept Biochem & Mol Biol, Xian 710061, Peoples R China	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Xi'an Jiaotong University	Cao, W (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Dean A McGee Eye Inst, 608 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	wei-cao@ouhsc.edu			NCRR NIH HHS [P20 RR 17703] Funding Source: Medline; NEI NIH HHS [EY 13050, EY 12190, EY 00871, EY 06973, EY 014427, EY 04149] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017703] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013050, R01EY000871, R03EY014427, R01EY004149, P30EY012190] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Banerjee S, 2003, BIOCHEM BIOPH RES CO, V300, P209, DOI 10.1016/S0006-291X(02)02830-9; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; Belcher SM, 2001, J PHARMACOL EXP THER, V299, P408; Bennett J, 2000, CURR OPIN MOL THER, V2, P420; Berglin L, 1997, GRAEF ARCH CLIN EXP, V235, P306, DOI 10.1007/BF01739640; Berson EL, 2000, INT OPHTHALMOL CLIN, V40, P93, DOI 10.1097/00004397-200010000-00008; BLANKS JC, 1992, INVEST OPHTH VIS SCI, V33, P2814; Cambiasso MJ, 2001, J NEUROSCI RES, V66, P475, DOI 10.1002/jnr.1238; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao W, 2003, ADV EXP MED BIOL, V533, P395; Cao W, 2000, J NEUROSCI RES, V60, P195, DOI 10.1002/(SICI)1097-4547(20000415)60:2<195::AID-JNR8>3.0.CO;2-7; Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646; Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.3.CO;2-D; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; Carrer HF, 2002, CELL MOL NEUROBIOL, V22, P479, DOI 10.1023/A:1021825317546; Chen WH, 2001, J NEUROSCI RES, V63, P116, DOI 10.1002/1097-4547(20010115)63:2<116::AID-JNR1003>3.0.CO;2-G; Clement MV, 1998, FEBS LETT, V440, P13, DOI 10.1016/S0014-5793(98)01410-0; Dhandapani KM, 2002, BIOL REPROD, V67, P1379, DOI 10.1095/biolreprod.102.003848; Diaz B, 1999, EUR J NEUROSCI, V11, P1624, DOI 10.1046/j.1460-9568.1999.00577.x; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; Fitzpatrick JL, 2002, J NEUROCHEM, V82, P674, DOI 10.1046/j.1471-4159.2002.01000.x; Gallaher BW, 2001, HORM METAB RES, V33, P511, DOI 10.1055/s-2001-17213; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Gosbell AD, 2000, CLIN EXP OPHTHALMOL, V28, P212, DOI 10.1046/j.1442-9071.2000.00305.x; Guo XX, 1997, INVEST OPHTH VIS SCI, V38, P1873; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hivert B, 1998, NEUROREPORT, V9, P1835, DOI 10.1097/00001756-199806010-00031; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010; Kitamura Y, 1999, GLIA, V25, P154, DOI 10.1002/(SICI)1098-1136(19990115)25:2<154::AID-GLIA6>3.0.CO;2-S; Lawlor MA, 2001, J CELL SCI, V114, P2903; LORENZO A, 1992, J NEUROSCI RES, V33, P418, DOI 10.1002/jnr.490330308; Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Moosmann B, 2002, EXPERT OPIN INV DRUG, V11, P1407, DOI 10.1517/13543784.11.10.1407; Nakamura M, 2001, J BIOL CHEM, V276, P43748, DOI 10.1074/jbc.M108594200; Organisciak DT, 2003, INVEST OPHTH VIS SCI, V44, P486, DOI 10.1167/iovs.02-0708; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Rajala RVS, 2002, J BIOL CHEM, V277, P43319, DOI 10.1074/jbc.M206355200; Rajala RVS, 2001, INVEST OPHTH VIS SCI, V42, P3110; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; Richards RG, 1998, J BIOL CHEM, V273, P11962, DOI 10.1074/jbc.273.19.11962; Rosenbaum DM, 1997, VISION RES, V37, P3445, DOI 10.1016/S0042-6989(96)00328-8; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Sherwin BB, 1999, J PSYCHIATR NEUROSCI, V24, P315; Simoncini T, 2002, STEROIDS, V67, P935, DOI 10.1016/S0039-128X(02)00040-5; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; Skaper SD, 1998, J NEUROCHEM, V70, P1859, DOI 10.1046/j.1471-4159.1998.70051859.x; STOYANOVSKY DA, 1995, CURR EYE RES, V14, P181, DOI 10.3109/02713689509033513; Taguchi H, 1996, INVEST OPHTH VIS SCI, V37, P1444; Toth G, 2002, J NEUROSCI RES, V69, P622, DOI 10.1002/jnr.10358; Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772; Tsai EM, 2001, CANCER RES, V61, P8390; Vaughan DK, 2003, INVEST OPHTH VIS SCI, V44, P848, DOI 10.1167/iovs.02-0709; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Wong JK, 2003, J NEUROSCI, V23, P4984; YAMASHITA H, 1992, RETINA-J RET VIT DIS, V12, P59, DOI 10.1097/00006982-199212010-00012; YU KT, 1985, J BIOL CHEM, V260, P5838	61	139	147	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13086	13094		10.1074/jbc.M313283200	http://dx.doi.org/10.1074/jbc.M313283200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711819	hybrid			2022-12-25	WOS:000220334900129
J	Jimenez-Vidal, M; Gasol, E; Zorzano, A; Nunes, V; Palacin, M; Chillaron, J				Jimenez-Vidal, M; Gasol, E; Zorzano, A; Nunes, V; Palacin, M; Chillaron, J			Thiol modification of cysteine 327 in the eighth transmembrane domain of the light subunit xCT of the heteromeric cystine/glutamate antiporter suggests close proximity to the substrate binding site/permeation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTERS; CONSENSUS AMPHIPATHIC REGION; ESCHERICHIA-COLI; EXCHANGE TRANSPORTER; 4-AMINOBUTYRATE TRANSPORTER; FUNCTIONAL-ANALYSIS; MEMBRANE TOPOLOGY; HEAVY-CHAIN; GXXXG MOTIF; HELIX 8	We measured sensitivity to thiol modification of the heteromeric glutamate/cystine transporter 4F2hc-xCT expressed in Xenopus oocytes. p-Chloromercuribenzoate (pCMB) and p-chloromercuribenzenesulfonate (pCMBS) rapidly blocked transport activity. Cys(327), located in the middle of the eighth transmembrane domain of the light subunit (xCT), was found to be the main target of inactivation. Cysteine, an impermeant reducing reagent, reversed pCMB and pCMBS effects only when applied from the extracellular medium. L-Glutamate and L-cystine, but not L-arginine, protected from the inactivation with an IC50 similar to the K-m. Protection was not temperature-dependent, suggesting that it did not depend on large substrate-induced conformational changes. Mutation of Cys(327) to Ala and Ser slightly modified the K-m and a C327L mutant abolished transport function without compromising transporter expression at the plasma membrane. The results indicate that Cys(327) is a functionally important residue accessible to the aqueous extracellular environment and is structurally linked to the permeation pathway and/or the substrate binding site.	Univ Barcelona, Barcelona Sci Pk, E-08028 Barcelona, Spain; Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Inst Recerca Oncol, Med & Mol Genet Ctr, E-08028 Barcelona, Spain	University of Barcelona; University of Barcelona	Chillaron, J (corresponding author), Univ Barcelona, Barcelona Sci Pk, Josep Samitier 1-5, E-08028 Barcelona, Spain.	chillaro@worldonline.es	Chillaron, Josep/ABF-7663-2021; Palacín, Manuel/G-9786-2015; Zorzano, Antonio/R-5479-2018; Nunes, Virginia/AAD-1014-2019	Chillaron, Josep/0000-0003-3068-7598; Nunes, Virginia/0000-0002-5747-9310; Palacin, Manuel/0000-0002-8670-293X				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; BANNAI S, 1989, J BIOL CHEM, V264, P18480; Bassi MT, 2001, PFLUG ARCH EUR J PHY, V442, P286, DOI 10.1007/s004240100537; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; Boado RJ, 2003, J NEUROCHEM, V84, P1322, DOI 10.1046/j.1471-4159.2003.01622.x; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; Dodd JR, 2001, J BIOL CHEM, V276, P46983, DOI 10.1074/jbc.M107137200; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; Font M, 2001, HUM MOL GENET, V10, P305, DOI 10.1093/hmg/10.4.305; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Habermeier A, 2003, J BIOL CHEM, V278, P19492, DOI 10.1074/jbc.M210254200; Hu LA, 1998, J BIOL CHEM, V273, P20162, DOI 10.1074/jbc.273.32.20162; Hu LA, 1998, BIOCHEM J, V336, P69, DOI 10.1042/bj3360069; Hu LYA, 1998, BIOCHEM J, V330, P771; Hu LYA, 1999, BIOCHEM J, V339, P649, DOI 10.1042/0264-6021:3390649; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; JUNG H, 1994, BIOCHEMISTRY-US, V33, P12160, DOI 10.1021/bi00206a019; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kanai Y, 2001, CURR DRUG METAB, V2, P339, DOI 10.2174/1389200013338324; Kashiwagi K, 2000, J BIOL CHEM, V275, P36007, DOI 10.1074/jbc.M006083200; Lopez-Corcuera B, 2001, J BIOL CHEM, V276, P43463, DOI 10.1074/jbc.M107438200; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; Mykkanen J, 2000, HUM MOL GENET, V9, P431, DOI 10.1093/hmg/9.3.431; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; Sato H, 2002, J NEUROSCI, V22, P8028; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Sato H, 2001, J BIOL CHEM, V276, P10407, DOI 10.1074/jbc.M007216200; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001	39	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11214	11221		10.1074/jbc.M309866200	http://dx.doi.org/10.1074/jbc.M309866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722095	hybrid, Green Published			2022-12-25	WOS:000220157600047
J	Mukhopadhyay, D; Asari, A; Rugg, MS; Day, AJ; Fulop, C				Mukhopadhyay, D; Asari, A; Rugg, MS; Day, AJ; Fulop, C			Specificity of the tumor necrosis factor-induced protein 6-mediated heavy chain transfer from inter-alpha-trypsin inhibitor to hyaluronan - Implications for the assembly of the cumulus extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-DIFFERENTIATION FACTOR-9; FACTOR-STIMULATED GENE-6; CELL-OOCYTE COMPLEX; HUMAN FOLLICULAR-FLUID; CHROMOSOMAL LOCALIZATION; RHEUMATOID-ARTHRITIS; MAMMALIAN OVARY; CODING SEQUENCE; ACID SYNTHESIS; MOUSE OOCYTES	The formation of the hyaluronan-rich cumulus extracellular matrix is crucial for female fertility and accompanied by a transesterification reaction in which the heavy chains (HCs) of inter-alpha-trypsin inhibitor (IalphaI)-related proteins are covalently transferred to hyaluronan. Tumor necrosis factor-induced protein-6 (TNFIP6) is essential for this transfer reaction. Female mice deficient in TNFIP6 are infertile due to the lack of a correctly formed cumulus matrix. In this report, we characterize the specificity of TNFIP6-mediated HC transfer from IalphaI to hyaluronan. Hyaluronan oligosaccharides with eight or more monosaccharide units are potent acceptors in the HC transfer, with longer oligosaccharides being somewhat more efficient. Epimerization of the N-acetylglucosamine residues to N-acetyl-galactosamines (i.e. in chondroitin) still allows the HC transfer although at a significantly lower efficiency. Sulfation of the N-acetylgalactosamines in dermatan-4-sulfate or chondroitin-6- sulfate prevents the HC transfer. Hyaluronan oligosaccharides disperse cumulus cells from expanding cumulus cell-oocyte complexes with the same size specificity as their HC acceptor specificity. This process is accompanied by the loss of hyaluronan-linked HCs from the cumulus matrix and the appearance of oligosaccharide-linked HCs in the culture medium. Chondroitin interferes with the expansion of cumulus cell-oocyte complexes only when added with exogenous TNFIP6 before endogenous hyaluronan synthesis starts, supporting that chondroitin is a weaker HC acceptor than hyaluronan. Our data indicate that TNFIP6-mediated HC transfer to hyaluronan is a prerequisite for the correct cumulus matrix assembly and hyaluronan oligosaccharides and chondroitin interfere with this assembly by capturing the HCs of the IalphaI-related proteins.	Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan	Cleveland Clinic Foundation; University of Oxford; Seikagaku Corporation	Fulop, C (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn ND20, 9500 Euclid Ave, Cleveland, OH 44195 USA.	fulop@bme.ri.ccf.org	Day, Anthony/O-1658-2015	Day, Anthony/0000-0002-1415-3134				BEDFORD JM, 1993, J EXP ZOOL, V265, P321, DOI 10.1002/jez.1402650314; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; Camaioni A, 1996, ARCH BIOCHEM BIOPHYS, V325, P190, DOI 10.1006/abbi.1996.0024; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; Chen L, 1996, J BIOL CHEM, V271, P19409, DOI 10.1074/jbc.271.32.19409; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; DEFELICI M, 1982, GAMETE RES, V6, P107, DOI 10.1002/mrd.1120060203; DEKEL N, 1978, ENDOCRINOLOGY, V102, P1797, DOI 10.1210/endo-102-6-1797; DOWNS SM, 1989, BIOL REPROD, V41, P371, DOI 10.1095/biolreprod41.2.371; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; EPPIG JJ, 1981, BIOL REPROD, V25, P191, DOI 10.1095/biolreprod25.1.191; EPPIG JJ, 1979, NATURE, V281, P483, DOI 10.1038/281483a0; Eriksen GV, 1999, BIOCHEM J, V340, P613, DOI 10.1042/0264-6021:3400613; Fulop C, 1997, ARCH BIOCHEM BIOPHYS, V337, P261, DOI 10.1006/abbi.1996.9793; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Hess KA, 1999, BIOL REPROD, V61, P436, DOI 10.1095/biolreprod61.2.436; HUANG L, 1993, J BIOL CHEM, V268, P26725; Jessen TE, 2003, REPRODUCTION, V125, P27, DOI 10.1530/rep.0.1250027; Kida D, 1999, J RHEUMATOL, V26, P1230; Lam X, 2000, BIOL REPROD, V62, P579, DOI 10.1095/biolreprod62.3.579; Lesley J, 2002, J BIOL CHEM, V277, P26600, DOI 10.1074/jbc.M201068200; MAHIBROWN CA, 1983, GAMETE RES, V8, P1, DOI 10.1002/mrd.1120080102; Matzuk MM, 2002, SCIENCE, V296, P2178, DOI 10.1126/science.1071965; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; POWERS RW, 1995, AM J PHYSIOL-ENDOC M, V269, pE290, DOI 10.1152/ajpendo.1995.269.2.E290; Protin U, 1999, J IMMUNOL, V163, P4917; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; Salustri A, 1999, HUM REPROD UPDATE, V5, P293, DOI 10.1093/humupd/5.4.293; Salustri A, 2000, SERONO SYMP, P67; SALUSTRI A, 1993, OVARY, P209; Sato H, 2001, BIOCHEM BIOPH RES CO, V281, P1154, DOI 10.1006/bbrc.2001.4475; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Stoop R, 2001, ARTHRITIS RHEUM, V44, P2922, DOI 10.1002/1529-0131(200112)44:12<2922::AID-ART480>3.0.CO;2-7; Tawada A, 2002, GLYCOBIOLOGY, V12, P421, DOI 10.1093/glycob/cwf048; UNDERHILL CB, 1979, J CELL BIOL, V82, P475, DOI 10.1083/jcb.82.2.475; UNDERHILL CB, 1985, J BIOL CHEM, V260, P8128; VANDERHYDEN BC, 1989, BIOL REPROD, V40, P720, DOI 10.1095/biolreprod40.4.720; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200; YONEDA M, 1990, J BIOL CHEM, V265, P5247; Yoshioka S, 2000, ENDOCRINOLOGY, V141, P4114, DOI 10.1210/en.141.11.4114; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	50	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11119	11128		10.1074/jbc.M313471200	http://dx.doi.org/10.1074/jbc.M313471200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707130	hybrid			2022-12-25	WOS:000220157600036
J	Nassif, NT; Lobo, GP; Wu, XJ; Henderson, CJA; Morrison, CD; Eng, C; Jalaludin, B; Segelov, E				Nassif, NT; Lobo, GP; Wu, XJ; Henderson, CJA; Morrison, CD; Eng, C; Jalaludin, B; Segelov, E			PTEN mutations are common in sporadic microsatellite stable colorectal cancer	ONCOGENE			English	Article						PTEN; sporadic colorectal cancer; mutation; microsatellite instability; loss of heterozygosity; immunohistochemistry	TUMOR-SUPPRESSOR GENE; PTEN/MMAC1 GENE; COWDEN-DISEASE; SOMATIC MUTATIONS; ADJUVANT CHEMOTHERAPY; PHOSPHATASE-ACTIVITY; GERMLINE MUTATIONS; INSTABILITY; ENDOMETRIAL; EXPRESSION	The tumour suppressor gene PTEN, located at chromosome sub-band 10q23.3, encodes a dual-specificity phosphatase that negatively regulates the phosphatidylinositol 3'-kinase (PI3K)/Akt-dependent cellular survival pathway. PTEN is frequently inactivated in many tumour types including glioblastoma, prostate and endometrial cancers. While initial studies reported that PTEN gene mutations were rare in colorectal cancer, more recent reports have shown an approximate 18% incidence of somatic PTEN mutations in colorectal tumours exhibiting microsatellite instability (MSI+). To verify the role of this gene in colorectal tumorigenesis, we analysed paired normal and tumour DNA from 41 unselected primary sporadic colorectal cancers for PTEN inactivation by mutation and/or allelic loss. We now report PTEN gene mutations in 19.5% (8/41) of tumours and allele loss, including all or part of the PTEN gene, in a further 17% (7/41) of the cases. Both PTEN alleles were affected in over half (9/15) of these cases showing PTEN genetic abnormalities. Using immunohistochemistry, we have further shown that all tumours harbouring PTEN alterations have either reduced or absent PTEN expression and this correlated strongly with later clinical stage of tumour at presentation (P=0.02). In contrast to previous reports, all but one of the tumours with PTEN gene mutations were microsatellite stable (MSI-), suggesting that PTEN is involved in a distinct pathway of colorectal tumorigenesis that is separate from the pathway of mismatch repair deficiency. This work therefore establishes the importance of PTEN in primary sporadic colorectal cancer.	Univ New S Wales, Liverpool Hosp, SW Sydney Clin Sch, Canc Res Labs, Liverpool, NSW 2170, Australia; Liverpool Hosp, Dept Anat Pathol, SW Area Pathol Serv, Liverpool, NSW 2170, Australia; Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA; Univ Cambridge, Canc Res UK Human Canc Genet Res Grp, Cambridge CB2 2XZ, England; Univ New S Wales, Liverpool Hosp, Sch Publ Hlth & Community Med, Epidemiol Unit, Liverpool, NSW 2170, Australia	Liverpool Hospital; University of New South Wales Sydney; Liverpool Hospital; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Cambridge; Liverpool Hospital; University of New South Wales Sydney	Nassif, NT (corresponding author), Univ Technol Sydney, Dept Cell & Mol Biol, St Leonards Campus,Cnr Pacific Hwy & Westbourne S, Gore Hill, NSW 2065, Australia.	Najah.Nassif@uts.edu.au; e.segelov@unsw.edu.au	Segelov, Eva/Q-7611-2019; Nassif, Najah T/G-6214-2012; Lobo, Glenn P./AAI-9736-2020	Segelov, Eva/0000-0002-4410-6144; Nassif, Najah T/0000-0003-2675-8322; Eng, Charis/0000-0002-3693-5145				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; BEAHRS OH, 1997, AM JOINT COMMITTEE C, P83; Biesecker LG, 2001, LANCET, V358, P2079, DOI 10.1016/S0140-6736(01)07109-4; Boland CR, 1998, CANCER RES, V58, P5248; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Cairns P, 1997, CANCER RES, V57, P4997; Chang JG, 1999, EUR J CANCER, V35, P647, DOI 10.1016/S0959-8049(98)00411-0; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Dahia PLM, 1997, CANCER RES, V57, P4710; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dicuonzo G, 2001, CLIN CANCER RES, V7, P4049; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Elsaleh H, 2000, ONCOLOGY-BASEL, V58, P52, DOI 10.1159/000012079; Elsaleh H, 2001, GASTROENTEROLOGY, V121, P230, DOI 10.1053/gast.2001.26044; Elsaleh H, 2001, CLIN CANCER RES, V7, P1343; Elsaleh H, 2001, GASTROENTEROLOGY, V120, P1309; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Eng C, 2000, J MED GENET, V37, P828, DOI 10.1136/jmg.37.11.828; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Frayling IM, 1997, CANCER GENET CYTOGEN, V97, P64, DOI 10.1016/S0165-4608(97)00011-3; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Giraud S, 1997, J CLIN ENDOCR METAB, V82, P3487, DOI 10.1210/jc.82.10.3487; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Guldberg P, 1997, CANCER RES, V57, P3660; Han SY, 2000, CANCER RES, V60, P3147; Hansen L, 2001, DIABETOLOGIA, V44, P237, DOI 10.1007/s001250051605; Ilyas M, 1999, EUR J CANCER, V35, P335, DOI 10.1016/S0959-8049(98)00431-6; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kahnoski K, 2003, J MED GENET, V40, P511, DOI 10.1136/jmg.40.7.511; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kurose K, 1998, JPN J CANCER RES, V89, P842, DOI 10.1111/j.1349-7006.1998.tb00638.x; Kurose K, 2000, GENE CHROMOSOME CANC, V29, P166, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1025>3.3.CO;2-D; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lin WM, 1998, CLIN CANCER RES, V4, P2577; Liu Q, 1994, PCR Methods Appl, V4, P97; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; Maxwell GL, 2000, CLIN CANCER RES, V6, P2999; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Mutter GL, 2001, CANCER RES, V61, P4311; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Negoro K, 2000, DIS COLON RECTUM, V43, pS29, DOI 10.1007/BF02237223; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Okami K, 1998, CANCER RES, V58, P509; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rhei E, 1997, CANCER RES, V57, P3657; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Sato K, 2002, VIRCHOWS ARCH, V440, P160, DOI 10.1007/s004280100499; Shin KH, 2001, CANCER LETT, V174, P189, DOI 10.1016/S0304-3835(01)00691-7; Singh B, 1998, GENE CHROMOSOME CANC, V21, P166, DOI 10.1002/(SICI)1098-2264(199802)21:2<166::AID-GCC13>3.3.CO;2-V; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Taniyama K, 2001, J PATHOL, V194, P341, DOI 10.1002/path.908; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Wang SI, 1997, CANCER RES, V57, P4183; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5; Zhou XP, 1999, INT J CANCER, V84, P150, DOI 10.1002/(SICI)1097-0215(19990420)84:2<150::AID-IJC10>3.0.CO;2-#; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9; Zhou XP, 2002, HUM MOL GENET, V11, P445, DOI 10.1093/hmg/11.4.445	77	114	125	0	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					617	628		10.1038/sj.onc.1207059	http://dx.doi.org/10.1038/sj.onc.1207059			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724591	Green Submitted			2022-12-25	WOS:000188098300034
J	Chopin, V; Toillon, RA; Jouy, N; Le Bourhis, X				Chopin, V; Toillon, RA; Jouy, N; Le Bourhis, X			P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells	ONCOGENE			English	Article						apoptosis; breast cancer; butyrate; cell cycle; PCNA; P21(waf1/cip1)	HISTONE DEACETYLASE INHIBITOR; HUMAN COLON-CANCER; BINDING PROTEIN-3 PROMOTER; NUCLEOTIDE EXCISION-REPAIR; GROWTH ARREST; CARCINOMA CELLS; NUCLEAR ANTIGEN; IN-VIVO; TRANSCRIPTIONAL REPRESSION; INDUCIBLE EXPRESSION	Sodium butyrate (NaB) has been proposed as a potential anticancer agent. However, its mechanism of action is not totally elucidated. Here, we showed that NaB-induced cell cycle arrest and apoptosis were associated with an increase of P21(waf1/cip1) in MCF-7 breast cancer cells. This increase was more important in the nuclei, as revealed by immunofluorescence analysis. Transient transfections of MCF-7 cells with p21 deficient for interaction with CDK, but not with p21 deficient for interaction with PCNA <LF>(p21PCNA-), abrogated NaB-induced cell cycle arrest. This indicated that cell cycle blockage involved the interaction of P21(waf1/cip1) with CDK. However, P21(waf1/cip1) was dispensable, since p21 antisense did not modify cell cycle arrest. On the other hand, NaB-induced apoptosis was abolished by p21 antisense or p21PCNA-. In addition, NaB decreased PCNA levels, but increased the association of PCNA with P21(waf1/cip1). These results suggested that NaB-induced apoptosis required P21(waf1/cip1) and its interaction with PCNA.	Univ Sci & Technol Lille, Equipe Facteurs Croissance, Dev Biol Lab, UPRES 1033, F-59655 Villeneuve Dascq, France; Inst Rech Canc Lille, Inst Rech, Inst Med Predict & Rech Therapeut, IMPRT, F-59045 Lille, France	Universite de Lille - ISITE; Universite de Lille	Le Bourhis, X (corresponding author), Univ Sci & Technol Lille, Equipe Facteurs Croissance, Dev Biol Lab, UPRES 1033, IFR 118, F-59655 Villeneuve Dascq, France.	Xuefen.lebourhis@univ-lille1.fr	Le+Bourhis, Xuefen/AAL-5141-2021; Toillon, Robert-Alain/Q-2286-2018	Toillon, Robert-Alain/0000-0001-5483-2118				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Chopin V, 2002, BRIT J PHARMACOL, V135, P79, DOI 10.1038/sj.bjp.0704456; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Demary K, 2001, CANCER LETT, V163, P103, DOI 10.1016/S0304-3835(00)00676-5; Derjuga A, 2001, J BIOL CHEM, V276, P37815; Detjen KM, 2003, EXP CELL RES, V282, P78, DOI 10.1016/S0014-4827(02)00011-3; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Galfi P, 2002, CANCER LETT, V188, P141, DOI 10.1016/S0304-3835(02)00347-6; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Gilbert J, 2001, CLIN CANCER RES, V7, P2292; Gregory DJ, 2002, CELL CYCLE, V1, P343, DOI 10.4161/cc.1.5.153; HALL PA, 1995, ONCOGENE, V10, P2427; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Ito N, 2001, NEUROSURGERY, V49, P430, DOI 10.1097/00006123-200108000-00031; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Mandal M, 1997, CARCINOGENESIS, V18, P229, DOI 10.1093/carcin/18.1.229; Mattock H, 2001, EXP CELL RES, V265, P234, DOI 10.1006/excr.2001.5160; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Patnaik A, 2002, CLIN CANCER RES, V8, P2142; Pellizzaro C, 2001, INT J CANCER, V91, P654, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1117>3.0.CO;2-I; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Peschiaroli A, 2002, ONCOGENE, V21, P8114, DOI 10.1038/sj.onc.1206010; Qiao L, 2002, HEPATOLOGY, V36, P39, DOI 10.1053/jhep.2002.33899; Qin LF, 2001, CANCER LETT, V172, P7, DOI 10.1016/S0304-3835(01)00701-7; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Ritt MG, 2000, CANCER LETT, V158, P73, DOI 10.1016/S0304-3835(00)00507-3; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sawa H, 2001, Brain Tumor Pathol, V18, P109, DOI 10.1007/BF02479423; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; Scott M, 2001, J CELL SCI, V114, P3455; Shibata MA, 2001, CANCER GENE THER, V8, P23, DOI 10.1038/sj.cgt.7700275; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Takahashi S, 2001, CANCER RES, V61, P1187; Terao Y, 2001, INT J CANCER, V94, P257, DOI 10.1002/ijc.1448; Tian H, 2000, CANCER RES, V60, P679; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Tsubaki J, 2002, ENDOCRINOLOGY, V143, P1778, DOI 10.1210/en.143.5.1778; Tsubaki J, 2001, J ENDOCRINOL, V169, P97, DOI 10.1677/joe.0.1690097; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Velazquez OC, 1996, JPEN-PARENTER ENTER, V20, P243, DOI 10.1177/0148607196020004243; Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817; Wang XM, 1999, ANTICANCER RES, V19, P2901; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	65	84	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					21	29		10.1038/sj.onc.1207020	http://dx.doi.org/10.1038/sj.onc.1207020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712207				2022-12-25	WOS:000187895300003
J	Liu, WL; Tang, L; Zhang, G; Wei, HD; Cui, YF; Guo, LH; Gou, ZK; Chen, XX; Jiang, DF; Zhu, YP; Kang, GF; He, FC				Liu, WL; Tang, L; Zhang, G; Wei, HD; Cui, YF; Guo, LH; Gou, ZK; Chen, XX; Jiang, DF; Zhu, YP; Kang, GF; He, FC			Characterization of a novel C-type lectin-like gene, LSECtin - Demonstration of carbohydrate node	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; DC-SIGN; DENDRITIC CELL; MANNOSE RECEPTOR; ENDOTHELIAL-CELLS; TISSUE EXPRESSION; RAT-LIVER; BINDING; CD23; RECOGNITION	A new C-type lectin-like gene encodes 293 amino acids and maps to chromosome 19p13.3 adjacent to the previously described C-type lectin genes, CD23, dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN), and DC-SIGN-related protein (DC-SIGNR). The four genes form a tight cluster in an insert size of 105 kb and have analogous genomic structures. The new C-type lectin-like molecule, designated liver and lymph node sinusoidal endothelial cell C-type lectin (LSECtin), is a type II integral membrane protein of similar to 40 kDa in size with a single C-type lectin-like domain at the COOH terminus, closest in homology to DC-SIGNR, DC-SIGN, and CD23. LSECtin mRNA was only expressed in liver and lymph node among 15 human tissues tested, intriguingly neither expressed on hematopoietic cell lines nor on monocyte-derived dendritic cells (DCs). Moreover, LSECtin is expressed predominantly by sinusoidal endothelial cells of human liver and lymph node and co-expressed with DC-SIGNR. LSECtin binds to mannose, GlcNAc, and fucose in a Ca2+-dependent manner but not to galactose. Our results indicate that LSECtin is a novel member of a family of proteins comprising CD23, DC-SIGN, and DC-SIGNR and might function in vivo as a lectin receptor.	Beijing Inst Radiat Med, Chinese Human Genome Ctr Beijing, Dept Gen & Prote, Beijing 100850, Peoples R China; Chongqing Univ Med Sci, Fac Med Lab Sci, Chongqing, Peoples R China; Sun Yat Sen Univ, Mol Med Lab, Guangzhou, Peoples R China; Tsinghua Univ, Sch Life Sci & Technol, Beijing 100084, Peoples R China	Academy of Military Medical Sciences - China; Chongqing Medical University; Sun Yat Sen University; Tsinghua University	He, FC (corresponding author), Beijing Inst Radiat Med, Chinese Human Genome Ctr Beijing, Dept Gen & Prote, 27 Taiping Rd, Beijing 100850, Peoples R China.	hefc@nic.bmi.ac.cn		Liu, Wanli/0000-0003-0395-2800				Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; AUBRY JP, 1994, J IMMUNOL, V152, P5806; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; BEAVIL RL, 1995, IMMUNOLOGY, V84, P202; Bonnefoy J Y, 1997, Int Rev Immunol, V16, P113, DOI 10.3109/08830189709045705; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; East L, 2002, J BIOL CHEM, V277, P50469, DOI 10.1074/jbc.M208985200; East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; FARR AG, 1980, AM J ANAT, V157, P265, DOI 10.1002/aja.1001570304; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Fernandes MJ, 1999, CANCER RES, V59, P2709; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Geijtenbeek TBH, 2002, J BIOL CHEM, V277, P11314, DOI 10.1074/jbc.M111532200; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; GOERDT S, 1992, CLIN INVESTIGATOR, V70, P89; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; HARLOW E, 1998, ANTIBODIES LAB MANUA, P72; Irjala H, 2001, J EXP MED, V194, P1033, DOI 10.1084/jem.194.8.1033; Kawai Y, 1998, CELL TISSUE RES, V292, P395, DOI 10.1007/s004410051069; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; Kijimoto-Ochiai S, 2002, CELL MOL LIFE SCI, V59, P648, DOI 10.1007/s00018-002-8455-1; Knolle PA, 2000, IMMUNOL REV, V174, P21, DOI 10.1034/j.1600-0528.2002.017408.x; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LECOANETHENCHOZ S, 1995, IMMUNITY, V3, P119, DOI 10.1016/1074-7613(95)90164-7; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; MORRE DJ, 1989, BIOTECHNIQUES, V7, P946; Mullin NP, 1997, J BIOL CHEM, V272, P5668, DOI 10.1074/jbc.272.9.5668; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Qu XH, 2002, J BIOL CHEM, V277, P35574, DOI 10.1074/jbc.M206451200; Qu XH, 2001, GENE, V264, P37, DOI 10.1016/S0378-1119(01)00324-9; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SAMBROOK J, 1989, MOL CLONING LAB MANU, P852; SEHESTED M, 1981, VIRCHOWS ARCH A, V391, P217, DOI 10.1007/BF00437598; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Soilleux EJ, 2003, CLIN SCI, V104, P437, DOI 10.1042/CS20020092; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Trowsdale J, 2001, IMMUNOL REV, V181, P20, DOI 10.1034/j.1600-065X.2001.1810102.x; van Kooyk Y, 2002, IMMUNOL REV, V186, P47, DOI 10.1034/j.1600-065X.2002.18605.x; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; Yu YT, 2001, GENOME RES, V11, P1392, DOI 10.1101/gr.175501; YUKAWA K, 1987, J IMMUNOL, V138, P2576; Zhang CG, 2000, GENOMICS, V63, P400, DOI 10.1006/geno.1999.6095	59	116	130	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18748	18758		10.1074/jbc.M311227200	http://dx.doi.org/10.1074/jbc.M311227200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14711836	hybrid			2022-12-25	WOS:000221041500082
J	Tashima, Y; Oe, R; Lee, S; Sugihara, G; Chambers, EJ; Takahashi, M; Yamada, T				Tashima, Y; Oe, R; Lee, S; Sugihara, G; Chambers, EJ; Takahashi, M; Yamada, T			The effect of cholesterol and monosialoganglioside (GM1) on the release and aggregation of amyloid beta-peptide from liposomes prepared from brain membrane-like lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; A-BETA; ULTRASTRUCTURAL EVIDENCE; PLASMALOGEN DEFICIENCY; PROTEIN; FIBRILLOGENESIS; GANGLIOSIDE; ASSOCIATION; DOMAIN	In order to investigate the influence of cholesterol (Ch) and monosialoganglioside (GM1) on the release and subsequent deposition/aggregation of amyloid beta peptide (Abeta)-(1-40) and Abeta-(1-42), we have examined Abeta peptide model membrane interactions by circular dichroism, turbidity measurements, and transmission electron microscopy (TEM). Model liposomes containing Abeta peptide and a lipid mixture composition similar to that found in the cerebral cortex membranes (CCM-lipid) have been prepared. In all, four Abeta-containing liposomes were investigated: CCM-lipid; liposomes with no GM1 (GM1-free lipid); those with no cholesterol (Ch-free lipid); liposomes with neither cholesterol nor GM1 (Ch-GM1-free lipid). In CCM liposomes, Abeta was rapidly released from membranes to form a well defined fibril structure. However, for the GM1-free lipid, Abeta was first released to yield a fibril structure about the membrane surface, then the membrane became disrupted resulting in the formation of small vesicles. In Ch-free lipid, a fibril structure with a phospholipid membrane-like shadow formed, but this differed from the well defined fibril structure seen for CCM-lipid. In Ch-GM1-free lipid, no fibril structure formed, possibly because of membrane solubilization by Abeta. The absence of fibril structure was noted at physiological extracellular pH (7.4) and also at liposomal/endosomal pH (5.5). Our results suggest a possible role for both Ch and GM1 in the membrane release of Abeta from brain lipid bilayers.	Fukuoka Univ, Fac Sci, Dept Chem, Fukuoka 8140180, Japan; Fukuoka Univ, Fac Pharmaceut Sci, Fukuoka 8140180, Japan; Fukuoka Univ, Sch Med, Fukuoka 8140180, Japan; Univ So Calif, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA	Fukuoka University; Fukuoka University; Fukuoka University; University of Southern California	Lee, S (corresponding author), Fukuoka Univ, Fac Sci, Dept Chem, Fukuoka 8140180, Japan.	leesan@cis.fukuoka-u.ac.jp	Chambers, Eric J/B-7537-2012; Taylor, Graham/A-4027-2012					BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Bunnell WL, 1998, J BIOL CHEM, V273, P31947, DOI 10.1074/jbc.273.48.31947; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; De Strooper B, 2000, J CELL SCI, V113, P1857; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Ferraretto A, 1997, BIOCHEMISTRY-US, V36, P9232, DOI 10.1021/bi970428j; Furuya T, 2003, BIOPHYS J, V84, P1950, DOI 10.1016/S0006-3495(03)75003-6; GINSBERG L, 1995, BRAIN RES, V698, P223, DOI 10.1016/0006-8993(95)00931-F; Gorman PM, 2003, J MOL BIOL, V325, P743, DOI 10.1016/S0022-2836(02)01279-2; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Han XL, 2001, J NEUROCHEM, V77, P1168, DOI 10.1046/j.1471-4159.2001.00332.x; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Ji SR, 2002, J BIOL CHEM, V277, P6273, DOI 10.1074/jbc.M104146200; Kakio A, 2001, J BIOL CHEM, V276, P24985, DOI 10.1074/jbc.M100252200; Kitamura A, 1999, BIOPHYS J, V76, P1457, DOI 10.1016/S0006-3495(99)77306-6; Lee S, 2001, J BIOL CHEM, V276, P41224, DOI 10.1074/jbc.M104705200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LeVine H, 2002, ARCH BIOCHEM BIOPHYS, V404, P106; Li YH, 1999, J NEUROCHEM, V73, P1477; Matsuzaki K, 1999, BIOCHEMISTRY-US, V38, P4137, DOI 10.1021/bi982345o; McLaurin J, 1998, J BIOL CHEM, V273, P4506, DOI 10.1074/jbc.273.8.4506; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; MORIYAMA Y, 1992, FEBS LETT, V302, P18, DOI 10.1016/0014-5793(92)80274-K; Natte R, 1999, ACTA NEUROPATHOL, V98, P577, DOI 10.1007/s004010051121; ROSSITER RJ, 1962, NEUROCHEMISTRY; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; Shigematsu D, 2002, BBA-BIOMEMBRANES, V1564, P271, DOI 10.1016/S0005-2736(02)00462-5; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Torp R, 2000, NEUROSCIENCE, V96, P495, DOI 10.1016/S0306-4522(99)00568-0; UEDA K, 1994, BRAIN RES, V639, P240, DOI 10.1016/0006-8993(94)91736-1; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Waschuk SA, 2001, J BIOL CHEM, V276, P33561, DOI 10.1074/jbc.M103598200; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yip CM, 2002, J MOL BIOL, V318, P97, DOI 10.1016/S0022-2836(02)00028-1; Yip CM, 2001, J MOL BIOL, V311, P723, DOI 10.1006/jmbi.2001.4881; Yip CM, 2001, BIOPHYS J, V80, P1359, DOI 10.1016/S0006-3495(01)76109-7	43	46	48	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17587	17595		10.1074/jbc.M308622200	http://dx.doi.org/10.1074/jbc.M308622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14709559	hybrid			2022-12-25	WOS:000220870400087
J	Plakoutsi, G; Taddei, N; Stefani, M; Chiti, F				Plakoutsi, G; Taddei, N; Stefani, M; Chiti, F			Aggregation of the acylphosphatase from Sulfolobus solfataricus - The folded and partially unfolded states can both be precursors for amyloid formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIL FORMATION; 3-DIMENSIONAL STRUCTURE; PROTEIN AGGREGATION; CRYSTAL-STRUCTURE; ALPHA-SYNUCLEIN; BETA-PEPTIDE; TRANSTHYRETIN; INTERMEDIATE; STABILITY; TOXICITY	Protein aggregation is associated with a number of human pathologies including Alzheimer's and Creutzfeldt-Jakob diseases and the systemic amyloidoses. In this study, we used the acylphosphatase from the hyperthermophilic Archaea Sulfolobus solfataricus (Sso AcP) to investigate the mechanism of aggregation under conditions in which the protein maintains a folded structure. In the presence of 15 - 25% (v/v) trifluoroethanol, Sso AcP was found to form aggregates able to bind specific dyes such as thioflavine T, Congo red, and 1-anilino-8-naphthalenesulfonic acid. The presence of aggregates was confirmed by circular dichroism and dynamic light scattering. Electron microscopy revealed the presence of small aggregates generally referred to as amyloid protofibrils. The monomeric form adopted by Sso AcP prior to aggregation under these conditions retained enzymatic activity; in addition, folding was remarkably faster than unfolding. These observations indicate that Sso AcP adopts a folded, although possibly distorted, conformation prior to aggregation. Most important, aggregation appeared to be 100-fold faster than unfolding under these conditions. Although aggregation of Sso AcP was faster at higher trifluoroethanol concentrations, in which the protein adopted a partially unfolded conformation, these findings suggest that the early events of amyloid fibril formation may involve an aggregation process consisting of the assembly of protein molecules in their folded state. This conclusion has a biological relevance as globular proteins normally spend most of their lifetime in folded structures.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Florence	Chiti, F (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	fchiti@scibio.unifi.it		STEFANI, MASSIMO/0000-0002-4490-1922; Taddei, Niccolo/0000-0003-2513-1018				BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bousset L, 2003, J STRUCT BIOL, V141, P132, DOI 10.1016/S1047-8477(02)00606-8; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; CAMICI G, 1976, EXPERIENTIA, V32, P535, DOI 10.1007/BF01920843; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 1999, NAT STRUCT BIOL, V6, P380; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199; Fernandez A, 2003, P NATL ACAD SCI USA, V100, P6446, DOI 10.1073/pnas.0731893100; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; Funahashi J, 1996, J BIOCHEM, V120, P1216; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Hamada D, 2000, NAT STRUCT BIOL, V7, P58; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Kremer JJ, 2000, BIOCHEMISTRY-US, V39, P10309, DOI 10.1021/bi0001980; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Laurine E, 2003, J BIOL CHEM, V278, P51770, DOI 10.1074/jbc.M306767200; LeVine H, 1999, METHOD ENZYMOL, V309, P274; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; Munishkina LA, 2003, BIOCHEMISTRY-US, V42, P2720, DOI 10.1021/bi027166s; PASTORE A, 1992, J MOL BIOL, V224, P427, DOI 10.1016/0022-2836(92)91005-A; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Quintas A, 2001, J BIOL CHEM, V276, P27207, DOI 10.1074/jbc.M101024200; Raffen R, 1999, PROTEIN SCI, V8, P509; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Rosano C, 2002, J MOL BIOL, V321, P785, DOI 10.1016/S0022-2836(02)00713-1; Rousseau F, 2001, P NATL ACAD SCI USA, V98, P5596, DOI 10.1073/pnas.101542098; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; Sousa MM, 2001, AM J PATHOL, V159, P1993; Srisailam S, 2003, J BIOL CHEM, V278, P17701, DOI 10.1074/jbc.M300336200; Staniforth RA, 2001, EMBO J, V20, P4774, DOI 10.1093/emboj/20.17.4774; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Stefani M, 1997, CELL MOL LIFE SCI, V53, P141, DOI 10.1007/PL00000585; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Taddei N, 1996, BIOCHEMISTRY-US, V35, P7077, DOI 10.1021/bi952900b; Taddei N, 1996, FEBS LETT, V384, P172, DOI 10.1016/0014-5793(96)00292-X; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Thunnissen MMGM, 1997, STRUCTURE, V5, P69, DOI 10.1016/S0969-2126(97)00167-6; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; VANDEHULST HC, 1957, LIGHT SCATTERING SMA, P1; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a	56	91	93	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14111	14119		10.1074/jbc.M312961200	http://dx.doi.org/10.1074/jbc.M312961200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724277	hybrid			2022-12-25	WOS:000220478500101
J	Belli, G; Molina, MM; Garcia-Martinez, J; Perez-Ortin, JE; Herrero, E				Belli, G; Molina, MM; Garcia-Martinez, J; Perez-Ortin, JE; Herrero, E			Saccharomyces cerevisiae glutaredoxin 5-deficient cells subjected to continuous oxidizing conditions are affected in the expression of specific sets of genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; YEAST FRATAXIN; IRON; PROTEIN; CLUSTER; IDENTIFICATION; MITOCHONDRIA; FAMILIES	The Saccharomyces cerevisiae GRX5 gene codes for a mitochondrial glutaredoxin involved in the synthesis of iron/sulfur clusters. Its absence prevents respiratory growth and causes the accumulation of iron inside cells and constitutive oxidation of proteins. Null Deltagrx5 mutants were used as an example of continuously oxidized cells, as opposed to situations in which oxidative stress is instantaneously caused by addition of external oxidants. Whole transcriptome analysis was carried out in the mutant cells. The set of genes whose expression was affected by the absence of Grx5 does not significantly overlap with the set of genes affected in respiratory petite mutants. Many Aft1-dependent genes involved in iron utilization that are up-regulated in a frataxin mutant were also up-regulated in the absence of Grx5. BIO5 is another Aft1-dependent gene induced both upon iron deprivation and in Deltagrx5 cells; this links iron and biotin metabolism. Other genes are specifically affected under the oxidative conditions generated by the grx5 mutation. One of these is MLP1, which codes for a homologue of the Slt2 kinase. Cells lacking MLP1 and GRX5 are hypersensitive to oxidative stress caused by external agents and exhibit increased protein oxidation in relation to single mutants. This in turn points to a role for Mlp1 in protection against oxidative stress. The genes of the Hap4 regulon, which are involved in respiratory metabolism, are down-regulated in Deltagrx5 cells. This effect is suppressed by HAP4 overexpression. Inhibition of respiratory metabolism during continuous moderately oxidative conditions could be a protective response by the cell.	Univ Lleida, Fac Med, Dept Ciencias Med Basiques, Lleida 25198, Spain; Univ Valencia, Fac Ciencias Biol, Dept Bioquim & Biol Mol, E-46100 Valencia, Spain; Univ Valencia, DNA SCSIE, Serv Chips, E-46100 Valencia, Spain	Universitat de Lleida; University of Valencia; University of Valencia	Herrero, E (corresponding author), Univ Lleida, Fac Med, Dept Ciencias Med Basiques, Rovira Roure 44, Lleida 25198, Spain.	enric.herrero@cmb.udl.es	Garcia-Martinez, Jose/F-6790-2016; belli, gemma/A-7424-2011; Herrero, Enrique/B-5592-2009; Bellí, Gemma/AAD-5325-2019; Garcia-Martinez, Jose/X-4995-2019; Pérez-Ortín, José E./K-8582-2014	Garcia-Martinez, Jose/0000-0001-5866-5994; belli, gemma/0000-0002-4161-3204; Herrero, Enrique/0000-0002-6763-111X; Bellí, Gemma/0000-0002-4161-3204; Garcia-Martinez, Jose/0000-0001-5866-5994; Pérez-Ortín, José E./0000-0002-1992-513X; , Micaela/0000-0002-2103-0351				Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; Belli G, 1998, NUCLEIC ACIDS RES, V26, P942, DOI 10.1093/nar/26.4.942; Bilski P, 2000, PHOTOCHEM PHOTOBIOL, V71, P129, DOI 10.1562/0031-8655(2000)071&lt;0129:SIPVBP&gt;2.0.CO;2; Blom J, 2000, APPL ENVIRON MICROB, V66, P1970, DOI 10.1128/AEM.66.5.1970-1973.2000; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Charizanis C, 1999, MOL GEN GENET, V261, P740, DOI 10.1007/s004380050017; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Hasan R, 2002, MOL MICROBIOL, V45, P233, DOI 10.1046/j.1365-2958.2002.03011.x; Joseph-Horne T, 2001, BBA-BIOENERGETICS, V1504, P179, DOI 10.1016/S0005-2728(00)00251-6; Jung US, 2002, MOL MICROBIOL, V46, P781, DOI 10.1046/j.1365-2958.2002.03198.x; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Karthikeyan G, 2002, HUM MOL GENET, V11, P1351, DOI 10.1093/hmg/11.11.1351; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kwast KE, 1998, J EXP BIOL, V201, P1177; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lascaris R, 2003, GENOME BIOL, V4; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; Park S, 2003, J BIOL CHEM, V278, P31340, DOI 10.1074/jbc.M303158200; Phalip V, 1999, GENE, V232, P43, DOI 10.1016/S0378-1119(99)00117-1; Protchenko O, 2003, J BIOL CHEM, V278, P36582, DOI 10.1074/jbc.M306584200; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Rodriguez-Navarro S, 2002, YEAST, V19, P1261, DOI 10.1002/yea.916; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; Shenton D, 2003, BIOCHEM J, V374, P513, DOI 10.1042/BJ20030414; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stolz J, 1999, J BIOL CHEM, V274, P18741, DOI 10.1074/jbc.274.26.18741; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Toledano MB, 2003, TOP CURR GENET, V1, P241; Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200; Trotter EW, 2003, EMBO REP, V4, P184, DOI 10.1038/sj.embor.embor729; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8343, DOI 10.1021/bi0104625; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Young TA, 2002, ARCH BIOCHEM BIOPHYS, V405, P65, DOI 10.1016/S0003-9861(02)00338-7; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200	61	53	54	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12386	12395		10.1074/jbc.M311879200	http://dx.doi.org/10.1074/jbc.M311879200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722110	hybrid, Green Published			2022-12-25	WOS:000220334900047
J	Guo, Q; Detweiler, CD; Mason, RP				Guo, Q; Detweiler, CD; Mason, RP			Protein radical formation during lactoperoxidase-mediated oxidation of the suicide substrate glutathione - Immunochemical detection of a lactoperoxidase radical-derived 5,5-dimethyl-1-pyrroline N-oxide nitrone adduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE; IRREVERSIBLE ENZYME INACTIVATION; RHO-SIGMA CORRELATION; CYTOCHROME-C-OXIDASE; HORSERADISH-PEROXIDASE; HYDROGEN-PEROXIDE; THYROID PEROXIDASE; THIYL RADICALS; COMPOUND-II; ONE-ELECTRON	A novel anti-5,5-dimethyl-1-pyrroline N-oxide ( DMPO) polyclonal antiserum that specifically recognizes protein radical-derived DMPO nitrone adducts has been developed. In this study, we employed this new approach, which combines the specificity of spin trapping and the sensitivity of antigen-antibody interactions, to investigate protein radical formation from lactoperoxidase (LPO). When LPO reacted with GSH in the presence of DMPO, we detected an LPO radical-derived DMPO nitrone adduct using enzyme-linked immunosorbent assay and Western blotting. The formation of this nitrone adduct depended on the concentrations of GSH, LPO, and DMPO as well as pH values, and GSH could not be replaced by H2O2. The level of this nitrone adduct was decreased significantly by azide, catalase, ascorbate, iodide, thiocyanate, phenol, or nitrite. However, its formation was unaffected by chemical modification of free cysteine, tyrosine, and tryptophan residues on LPO. ESR spectra showed that a glutathiyl radical was formed from the LPO/GSH/DMPO system, but no protein radical adduct could be detected by ESR. Its formation was decreased by azide, catalase, ascorbate, iodide, or thiocyanate, whereas phenol or nitrite increased it. GSH caused marked changes in the spectrum of compound II of LPO, indicating that GSH binds to the heme of compound II, whereas phenol or nitrite prevented these changes and reduced compound II back to the native enzyme. GSH also dose-dependently inhibited the peroxidase activity of LPO as determined by measuring 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) oxidation. Taken together, these results demonstrate that the GSH-dependent LPO radical formation is mediated by the glutathiyl radical, possibly via the reaction of the glutathiyl radical with the heme of compound II to form a heme-centered radical trapped by DMPO.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Guo, Q (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	guo1@niehs.nih.gov	Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050139, Z01ES050139] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUNE TM, 1977, EUR J BIOCHEM, V80, P209, DOI 10.1111/j.1432-1033.1977.tb11873.x; BANDYOPADHYAY U, 1995, BIOCHEM J, V306, P751, DOI 10.1042/bj3060751; BANERJEE RK, 1986, J BIOL CHEM, V261, P592; Bruck TB, 2001, EUR J BIOCHEM, V268, P3214, DOI 10.1046/j.1432-1327.2001.02213.x; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Burner U, 1997, FEBS LETT, V411, P269, DOI 10.1016/S0014-5793(97)00713-8; Burner U, 1999, FEBS LETT, V443, P290, DOI 10.1016/S0014-5793(98)01727-X; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Chen YR, 2000, BIOCHEMISTRY-US, V39, P4415, DOI 10.1021/bi992652+; CLARKE AJ, 1987, BIOCHIM BIOPHYS ACTA, V912, P424, DOI 10.1016/0167-4838(87)90048-3; DAS D, 1995, BIOCHEM J, V305, P59, DOI 10.1042/bj3050059; DAVIDSON B, 1978, BIOCHIM BIOPHYS ACTA, V522, P318, DOI 10.1016/0005-2744(78)90066-9; Dayan FE, 1998, ARCH BIOCHEM BIOPHYS, V351, P27, DOI 10.1006/abbi.1997.0533; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DEMONTELLANO PRO, 1988, BIOCHEMISTRY-US, V27, P5470, DOI 10.1021/bi00415a013; Detweiler CD, 2002, FREE RADICAL BIO MED, V33, P364, DOI 10.1016/S0891-5849(02)00895-X; DROGE W, 1993, PHARMACOLOGY, V46, P61, DOI 10.1159/000139029; DUNFORD HB, 1986, ARCH BIOCHEM BIOPHYS, V251, P536, DOI 10.1016/0003-9861(86)90361-9; DUNFORD HB, 1995, XENOBIOTICA, V25, P725, DOI 10.3109/00498259509061888; EASTMOND DA, 1986, MOL PHARMACOL, V30, P674; EDELHOCH H, 1979, J BIOL CHEM, V254, P1822; Ferrari RP, 1997, J INORG BIOCHEM, V68, P17, DOI 10.1016/S0162-0134(97)00003-2; FERRARI RP, 1995, J INORG BIOCHEM, V58, P109, DOI 10.1016/0162-0134(94)00041-8; Furtmuller PG, 2002, BIOCHEMISTRY-US, V41, P11895, DOI 10.1021/bi026326x; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; Gunther MR, 2000, FREE RADICAL BIO MED, V28, P709, DOI 10.1016/S0891-5849(00)00164-7; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HARMAN LS, 1984, J BIOL CHEM, V259, P5606; HEWSON WD, 1976, J BIOL CHEM, V251, P6043; HUWILER M, 1986, EUR J BIOCHEM, V158, P609, DOI 10.1111/j.1432-1033.1986.tb09798.x; ILLY C, 1991, BIOCHEMISTRY-US, V30, P7135, DOI 10.1021/bi00243a014; JENZER H, 1986, BIOCHEM BIOPH RES CO, V139, P327, DOI 10.1016/S0006-291X(86)80117-6; JENZER H, 1986, J BIOL CHEM, V261, P5550; Jones CM, 2002, FREE RADICAL BIO MED, V32, P982, DOI 10.1016/S0891-5849(02)00791-8; JOYCE DA, 1989, PHARMACOL THERAPEUT, V42, P405, DOI 10.1016/0163-7258(89)90033-8; KIMURA S, 1979, ARCH BIOCHEM BIOPHYS, V198, P580, DOI 10.1016/0003-9861(79)90534-4; KOHLER H, 1988, ARCH BIOCHEM BIOPHYS, V264, P438, DOI 10.1016/0003-9861(88)90309-8; Kolberg M, 2002, ARCH BIOCHEM BIOPHYS, V403, P141, DOI 10.1016/S0003-9861(02)00264-3; Kolberg M, 2002, ARCH BIOCHEM BIOPHYS, V397, P57, DOI 10.1006/abbi.2001.2658; Lardinois OM, 1999, J BIOL CHEM, V274, P35441, DOI 10.1074/jbc.274.50.35441; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; LOVAAS E, 1992, FREE RADICAL BIO MED, V13, P187, DOI 10.1016/0891-5849(92)90014-8; MAGNUSSON RP, 1984, J BIOL CHEM, V259, P197; MAPLES KR, 1990, ARCH BIOCHEM BIOPHYS, V277, P402, DOI 10.1016/0003-9861(90)90596-Q; METODIEWA D, 1989, BIOCHEM BIOPH RES CO, V160, P1183, DOI 10.1016/S0006-291X(89)80128-7; METODIEWA D, 1989, ARCH BIOCHEM BIOPHYS, V274, P601, DOI 10.1016/0003-9861(89)90475-X; MICHOT JL, 1979, J BIOL CHEM, V254, P2205; MISRA HP, 1974, J BIOL CHEM, V249, P2151; MODI S, 1991, BIOCHEMISTRY-US, V30, P118, DOI 10.1021/bi00215a018; Mottley C, 2001, J BIOL CHEM, V276, P42677, DOI 10.1074/jbc.M104889200; MOTTLEY C, 1987, MOL PHARMACOL, V31, P417; MUNDAY R, 1989, BIOCHEM PHARMACOL, V38, P4349, DOI 10.1016/0006-2952(89)90641-2; NAKAMURA M, 1986, J BIOL CHEM, V261, P13923; NAKAMURA S, 1984, J BIOL CHEM, V259, P7080; OHLSSON PI, 1983, ACTA CHEM SCAND B, V37, P917, DOI 10.3891/acta.chem.scand.37b-0917; OLSEN J, 1976, BIOCHIM BIOPHYS ACTA, V445, P324, DOI 10.1016/0005-2744(76)90086-3; Qian SY, 2002, BIOCHEM J, V363, P281, DOI 10.1042/0264-6021:3630281; Ramirez DC, 2003, FREE RADICAL BIO MED, V34, P830, DOI 10.1016/S0891-5849(02)01437-5; RAO DNR, 1990, J BIOL CHEM, V265, P844; Reszka KJ, 1999, FREE RADICAL BIO MED, V26, P669, DOI 10.1016/S0891-5849(98)00244-5; SAEZ G, 1982, BIOCHIM BIOPHYS ACTA, V719, P24, DOI 10.1016/0304-4165(82)90302-6; SCHREIBER J, 1989, J BIOL CHEM, V264, P7936; SCOTT BC, 1994, FREE RADICAL RES, V20, P119, DOI 10.3109/10715769409147509; SERBINOVA E, 1992, FREE RADICAL RES COM, V17, P49, DOI 10.3109/10715769209061088; SHAN XQ, 1990, PHARMACOL THERAPEUT, V47, P61, DOI 10.1016/0163-7258(90)90045-4; STOCK BH, 1986, J BIOL CHEM, V261, P5959; STOCK BH, 1986, J BIOL CHEM, V261, P5915; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V317, P315, DOI 10.1006/abbi.1995.1169; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; SVENSSON BE, 1993, FREE RADICAL BIO MED, V14, P167, DOI 10.1016/0891-5849(93)90007-H; SVENSSON BE, 1988, BIOCHEM J, V256, P757, DOI 10.1042/bj2560757; SVENSSON BE, 1988, BIOCHEM J, V253, P441, DOI 10.1042/bj2530441; SVENSSON BE, 1988, BIOCHEM J, V256, P751, DOI 10.1042/bj2560751; TAUROG A, 1994, ARCH BIOCHEM BIOPHYS, V315, P82, DOI 10.1006/abbi.1994.1474; TAUROG A, 1991, ARCH BIOCHEM BIOPHYS, V287, P288, DOI 10.1016/0003-9861(91)90481-W; THOMAS EL, 1986, J BIOL CHEM, V261, P9694; vanDalen CJ, 1997, BIOCHEM J, V327, P487; WARDMAN P, 1995, METHOD ENZYMOL, V251, P31, DOI 10.1016/0076-6879(95)51108-3; WEFERS H, 1985, Journal of Free Radicals in Biology and Medicine, V1, P311, DOI 10.1016/0748-5514(85)90137-0; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200; Witting PK, 2001, J BIOL CHEM, V276, P16540, DOI 10.1074/jbc.M011707200; YAMAZAKI I, 1973, MOL CELL BIOCHEM, V2, P39, DOI 10.1007/BF01738677; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038; ZHANG HC, 1993, CAN J CHEM, V71, P1990, DOI 10.1139/v93-248	85	25	26	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13272	13283		10.1074/jbc.M310034200	http://dx.doi.org/10.1074/jbc.M310034200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14724284	hybrid			2022-12-25	WOS:000220334900150
J	Kwon, C; Chung, IK				Kwon, C; Chung, IK			Interaction of an Arabidopsis RNA-binding protein with plant single-stranded telomeric DNA modulates telomerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; HNRNP A1; END; LENGTH; YEAST; REPLICATION; DOMAIN; EST1; ASSOCIATION; INHIBITION	Telomeres are the specialized structures at the end of linear chromosomes and terminate with a single-stranded 3' overhang of the G-rich strand. The primary role of telomeres is to protect chromosome ends from recombination and fusion and from being recognized as broken DNA ends. This protective function can be achieved through association with specific telomere-binding proteins. Although proteins that bind single-stranded G-rich overhang regulate telomere length and telomerase activity in mammals and lower eukaryotes, equivalent factors have yet to be identified in plants. Here we have identified proteins capable of interacting with the G-rich single-stranded telomeric repeat from the Arabidopsis extracts by affinity chromatography. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis indicates that the isolated protein is a chloroplast RNA-binding protein (and a truncated derivative). The truncated derivative, which we refer to as STEP1 (single-stranded telomere-binding protein 1), binds specifically the single-stranded G-rich plant telomeric DNA sequences but not double-stranded telomeric DNA. Unlike the chloroplast-localized full-length RNA-binding protein, STEP1 localizes exclusively to the nucleus, suggesting that it plays a role in plant telomere biogenesis. We also demonstrated that the specific binding of STEP1 to single-stranded telomeric DNA inhibits telomerase-mediated telomere extension. The evidence presented here suggests that STEP1 is a telomere-end binding protein that may contribute to telomere length regulation by capping the ends of chromosomes and thereby repressing telomerase activity in plants.	Yonsei Univ, Coll Sci, Dept Biol, Mol Aging Res Ctr, Seoul 120749, South Korea; Yonsei Univ, Prot Network Res Ctr, Seoul 120749, South Korea	Yonsei University; Yonsei University	Chung, IK (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Mol Aging Res Ctr, 134 Shinchon Dong, Seoul 120749, South Korea.	topoviro@yonsei.ac.kr						Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Cesare AJ, 2003, PLANT J, V36, P271, DOI 10.1046/j.1365-313X.2003.01882.x; CHENG SH, 1994, PLANT PHYSIOL, V106, P303, DOI 10.1104/pp.106.1.303; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Eversole A, 2000, MOL CELL BIOL, V20, P5425, DOI 10.1128/MCB.20.15.5425-5432.2000; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Fitzgerald MS, 1996, P NATL ACAD SCI USA, V93, P14422, DOI 10.1073/pnas.93.25.14422; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; Fulneckova J, 2000, FEBS LETT, V467, P305, DOI 10.1016/S0014-5793(00)01178-9; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Greider CW, 1999, CELL, V97, P419, DOI 10.1016/S0092-8674(00)80750-3; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hwang MG, 2001, FEBS LETT, V503, P35, DOI 10.1016/S0014-5793(01)02685-0; Kamma H, 2001, BIOCHEM BIOPH RES CO, V280, P625, DOI 10.1006/bbrc.2000.4173; Killan A, 1998, PLANT MOL BIOL, V37, P621, DOI 10.1023/A:1005994629814; Kim JH, 2003, MOL PHARMACOL, V63, P1117, DOI 10.1124/mol.63.5.1117; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Muniyappa K, 1998, CRIT REV BIOCHEM MOL, V33, P297, DOI 10.1080/10409239891204242; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OHTA M, 1995, PLANT MOL BIOL, V27, P529, DOI 10.1007/BF00019319; PETRACEK ME, 1994, EMBO J, V13, P3648, DOI 10.1002/j.1460-2075.1994.tb06672.x; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; RAGHURAMAN MK, 1989, CELL, V59, P719, DOI 10.1016/0092-8674(89)90018-4; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; Riha K, 1998, PLANT CELL, V10, P1691, DOI 10.1105/tpc.10.10.1691; Riha K, 2000, PLANT J, V23, P633, DOI 10.1046/j.1365-313x.2000.00831.x; SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034; SHENG H, 1995, MOL CELL BIOL, V15, P1144; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Yu EY, 2000, J BIOL CHEM, V275, P24208, DOI 10.1074/jbc.M003250200; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zhou JL, 2000, MOL CELL BIOL, V20, P1947, DOI 10.1128/MCB.20.6.1947-1955.2000	53	45	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12812	12818		10.1074/jbc.M312011200	http://dx.doi.org/10.1074/jbc.M312011200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14703514	hybrid			2022-12-25	WOS:000220334900096
J	Tikhomirov, O; Carpenter, G				Tikhomirov, O; Carpenter, G			Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN-BREAST-CANCER; EGF RECEPTOR; QUANTITATIVE-ANALYSIS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; DOWN-REGULATION; FACTOR-ALPHA; HEAT-SHOCK; C-NEU	Increased expression of the epidermal growth factor ( EGF) receptor ( EGFR) and ErbB- 2 is implicated into the development and progression of breast cancer. Constant ligand- induced activation of EGFR and ErbB- 2 receptor-tyrosine kinases is thought to be involved in the transformation of fibroblasts and mammary epithelial cells. Data herein show that ligand stimulation of cells that express both the EGFR and the ErbB- 2 may result either in cell proliferation or apoptosis depending on the expression levels of EGFR and ErbB- 2. Mammary tumor cells that express low levels of both receptors or high levels of ErbB- 2 and low levels of EGFR survive and proliferate in the presence of EGF. In contrast, fibroblastic cells or mammary tumor cells, which co- express high levels of EGFR and ErbB- 2 invariably undergo apoptosis in response to EGF. In these cells persistent activation of p38 MAPK is an essential element of the apoptotic mechanism. Also, the data implicate a p38- dependent change in mitochondrial membrane permeability as a downstream effector of apoptosis. Ligand- dependent apoptosis in cells co- expressing high levels of EGFR and ErbB- 2 could be a natural mechanism that protects tissues from unrestricted proliferation in response to the sustained activation of receptor- tyrosine kinases.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	Graham.Carpenter@vanderbilt.edu			NATIONAL CANCER INSTITUTE [P30CA068485, R01CA097456] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 68485, CA 97456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baulida J, 1996, J BIOL CHEM, V271, P5251; Bera TK, 1999, CANCER RES, V59, P4018; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Casalini P, 2001, J BIOL CHEM, V276, P12449, DOI 10.1074/jbc.M009732200; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Christensen JG, 2001, CLIN CANCER RES, V7, P4230; COLEMAN S, 1990, DEV BIOL, V137, P425, DOI 10.1016/0012-1606(90)90267-M; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Darcy KM, 1999, EUR J CELL BIOL, V78, P511, DOI 10.1016/S0171-9335(99)80077-6; Darcy KM, 2000, J HISTOCHEM CYTOCHEM, V48, P63, DOI 10.1177/002215540004800107; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; DiAugustine RP, 1997, J MAMMARY GLAND BIOL, V2, P109, DOI 10.1023/A:1026395513038; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Garcia I, 2003, ANN SURG ONCOL, V10, P234, DOI 10.1245/ASO.2003.05.010; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HARRIS RA, 1995, BRIT J CANCER, V72, P386, DOI 10.1038/bjc.1995.343; Hendriks BS, 2003, CANCER RES, V63, P1130; Hendriks BS, 2003, J BIOL CHEM, V278, P23343, DOI 10.1074/jbc.M300477200; Huang GC, 2002, BRIT J CANCER, V86, P1104, DOI 10.1038/sj/bjc/6600219; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Klapper LN, 2000, ADV CANCER RES, V77, P25; KORNILOVA ES, 1992, ONCOGENE, V7, P511; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Mukherjee S, 2000, ONCOGENE, V19, P5982, DOI 10.1038/sj.onc.1203964; Neve RM, 2001, ANN ONCOL, V12, P9, DOI 10.1023/A:1011199404516; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANDGREN EP, 1995, CANCER RES, V55, P3915; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; SORKIN A, 1993, ONCOGENE, V8, P3021; Suo Z, 2002, J PATHOL, V196, P17, DOI 10.1002/path.1003; Suzuki Y, 1997, BIOCHEM BIOPH RES CO, V240, P856, DOI 10.1006/bbrc.1997.7758; Takada E, 2002, IMMUNOL LETT, V81, P93, DOI 10.1016/S0165-2478(02)00002-0; Timms JF, 2002, ONCOGENE, V21, P6573, DOI 10.1038/sj.onc.1205847; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Troyer KL, 2001, J MAMMARY GLAND BIOL, V6, P7, DOI 10.1023/A:1009560330359; Tsutsui S, 2003, SURGERY, V133, P219, DOI 10.1067/msy.2003.32; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	61	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12988	12996		10.1074/jbc.M311655200	http://dx.doi.org/10.1074/jbc.M311655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711810	hybrid			2022-12-25	WOS:000220334900118
J	Usui, S; Sugimoto, N; Takuwa, N; Sakagami, S; Takata, S; Kaneko, S; Takuwa, Y				Usui, S; Sugimoto, N; Takuwa, N; Sakagami, S; Takata, S; Kaneko, S; Takuwa, Y			Blood lipid mediator sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression through S1P(1)-G(i)-Ras-MAPK-dependent induction of Kruppel-like factor 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; ACTIVATED PROTEIN-KINASE; ANGIOTENSIN-II; TRANSCRIPTION FACTOR; GENE-EXPRESSION; RECEPTOR EDG-1; PDGF-B; SPHINGOSINE-1-PHOSPHATE; MIGRATION; PATHWAYS	Platelet-derived growth factors (PDGFs), potent mitogens and chemoattractants for mesenchymal cell types, play essential roles in development of several organs including blood vessels, kidney, and lung, and are also implicated in the pathogenesis of atherosclerosis and malignancies. Blood lipid mediator sphingosine 1-phosphate (S1P) regulates migration, proliferation, and apoptosis in a variety of cell types through multiple G protein-coupled receptors of the Edg family, and is necessary for vascular formation at the developmental stage. We found in the present study that S1P induced severalfold increases in the mRNA and protein levels of PDGF-A and -B chains in vascular smooth muscle cells and neointimal cells. S1P stimulation of PDGF mRNA and protein expression was abolished by the small interfering RNA duplexes targeting S1P(1)/Edg1 receptor subtype. S1P stimulated the small GTPase Ras in a G(i)-dependent manner, and activated ERK and p38 MAPK in G(i)- and Ras-dependent manners. Pertussis toxin pretreatment, adenovirus-mediated Asn(17)Ras expression, the MEK inhibitor PD98059, or the p38 MAPK inhibitor SB203580 markedly suppressed PDGF mRNA and protein up-regulation, indicating the involvement of Gi- Ras-ERK/p38 MAPK in S1P stimulation of PDGF expression. S1P stimulated expression of the transcription factor KLF5 in manners dependent on G(i), Ras, and ERK/p38 MAPK. Down-regulation of KLF5 by small interfering RNA duplexes abolished S1P-induced PDGF-A and -B chain expression. On the other hand, overexpression of KLF5 stimulated basal and S1P-induced PDGF expression. Either S1P stimulation or KLF5 overexpression increased the PDGF-B promoter activity in a cis-element-dependent manner. These results reveal the S1P(1)-triggered, G(i)-Ras-ERK/p38 MAPK-KLF5-dependent, stimulatory regulation of PDGF gene transcription in vascular smooth muscle cells.	Kanazawa Univ, Grad Sch Med, Dept Cellular & Mol Physiol, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Grad Sch Med, Dept Internal Med, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Grad Sch Med, Dept Hlth Sci, Kanazawa, Ishikawa 9208640, Japan	Kanazawa University; Kanazawa University; Kanazawa University	Takuwa, Y (corresponding author), Kanazawa Univ, Grad Sch Med, Dept Physiol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.	ytakuwa@med.kanazawa-u.ac.jp	Sugimoto, Naotoshi/C-4739-2015; USUI, Soichiro/GQH-4849-2022	Sugimoto, Naotoshi/0000-0003-1995-5002; TAKUWA, Noriko/0000-0002-4278-2704; Usui, Soichiro/0000-0003-1752-8082				Abe J, 1997, CIRCULATION, V96, P1906, DOI 10.1161/01.CIR.96.6.1906; Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bischoff A, 2000, BRIT J PHARMACOL, V130, P1871, DOI 10.1038/sj.bjp.0703515; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Deguchi J, 1999, CIRC RES, V85, P565, DOI 10.1161/01.RES.85.7.565; FUKUSHIMA N, 2001, ANNU REV PHARMACOL, V131, P767; Hamada K, 1998, J BIOL CHEM, V273, P6334, DOI 10.1074/jbc.273.11.6334; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; KATAYOSE D, 1993, AM J PHYSIOL, V264, pL100, DOI 10.1152/ajplung.1993.264.2.L100; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Kluk MJ, 2001, CIRC RES, V89, P496, DOI 10.1161/hh1801.096338; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MITUI H, 1997, J BIOL CHEM, V272, P4904; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; NODA M, 1994, J BIOL CHEM, V269, P17911; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Sachinidis A, 1999, ARTERIOSCL THROM VAS, V19, P2412, DOI 10.1161/01.ATV.19.10.2412; Sakurada S, 2001, AM J PHYSIOL-CELL PH, V281, pC571, DOI 10.1152/ajpcell.2001.281.2.C571; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Takuwa Y, 2002, BBA-MOL CELL BIOL L, V1582, P112, DOI 10.1016/S1388-1981(02)00145-2; TAMAMA K, 2001, BIOCHEM J, V352, P809; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yatomi Y, 1997, J BIOCHEM, V121, P969	42	83	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12300	12311		10.1074/jbc.M305025200	http://dx.doi.org/10.1074/jbc.M305025200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711826	hybrid, Green Submitted			2022-12-25	WOS:000220334900037
J	Chang, JD; Field, SJ; Rameh, LE; Carpenter, CL; Cantley, LC				Chang, JD; Field, SJ; Rameh, LE; Carpenter, CL; Cantley, LC			Identification and characterization of a phosphoinositide phosphate kinase homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASES; PROTEIN; FAMILY; MYOTUBULARIN; VESICLES; ALPHA; 3-PHOSPHATASE; REGULATORS; MOVEMENT; PATHWAY	Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2) plays a central role in regulating the actin cytoskeleton as a substrate for phosphoinositide 3-kinase and phospholipase C as well as by binding directly to proteins that control the processes of actin monomer sequestration, filament severing, capping, nucleation, cross-linking, and bundling (Ma, L., Cantley, L. C., Janmey, P. A., and Kirschner, M. W. (1998) J. Cell Biol. 140, 1125 1136; Hinchliffe, K. (2000) Curr. Biol. 10, R104-R1051). Three related phosphatidylinositol 4-phosphate 5-kinases (PI(4)P 5-kinases) have been identified in mammalian cells (types Ialpha, Ibeta, and Igamma) and appear to play distinct roles in actin remodeling. Here we have identified a fourth member of this family by searching the human genome and EST data bases. This new protein, which we have designated phosphatidylinositol phosphate kinase homolog (PIPKH), is expressed at relatively high levels in brain and testis. Immunoprecipitates of PIPKH expressed in mammalian cells contain PI(4)P 5-kinase activity, but this activity is not affected by mutations in residues that inactivate other type I PI(4)P 5-kinases. We show that the PI(4)P 5-kinase activity in PIPKH immunoprecipitates can be explained by the ability of PIPKH to heterodimerize with other type I PI(4)P 5-kinases. Transfection of 293t cells with PIPKH resulted in >8-fold increase in total phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P-3) without a significant net increase in total PI(4,5)P-2. When coexpressed with PIPKH, green fluorescent protein (GFP) fusion construct of the pleckstrin homology domain from Bruton's tyrosine kinase (GFP-BTK-PH) localized in intracellular vesicular structures, suggesting an unusual intracellular site of PI(3,4,5)P-3 production. Finally, expression of PIPKH induced the reorganization of actin from predominantly stress fibers to predominantly foci and comets similar to those observed previously in cells infected with the intracellular pathogen Listeria or transfected with recombinant PIPKIalpha. These results suggest that PIPKH acts as a scaffold to localize and regulate type I PI(4)P 5-kinases and the synthesis of PI(3,4,5)P-3.	Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA; Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Chang, JD (corresponding author), Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA.	jchang@bidmc.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Field, Seth/0000-0002-8893-4806	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03313] Funding Source: Medline; NIGMS NIH HHS [GM36624, GM54389] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balla A, 2002, J BIOL CHEM, V277, P20041, DOI 10.1074/jbc.M111807200; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Guo J, 2003, P NATL ACAD SCI USA, V100, P3995, DOI 10.1073/pnas.0230488100; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Hinchliffe K, 2000, CURR BIOL, V10, pR104, DOI 10.1016/S0960-9822(00)00303-1; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ma L, 1998, J CELL BIOL, V140, P1125; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; Nandurkar HH, 2003, P NATL ACAD SCI USA, V100, P8660, DOI 10.1073/pnas.1033097100; Nandurkar HH, 2002, IUBMB LIFE, V53, P37, DOI 10.1080/15216540210812; Nandurkar HH, 2001, P NATL ACAD SCI USA, V98, P9499, DOI 10.1073/pnas.171306098; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Tolias K, 2000, METHOD ENZYMOL, V325, P190; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1	31	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11672	11679		10.1074/jbc.M309721200	http://dx.doi.org/10.1074/jbc.M309721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701839	hybrid			2022-12-25	WOS:000220157600102
J	Gao, CJ; Guo, HT; Wei, JP; Mi, ZY; Wai, P; Kuo, PC				Gao, CJ; Guo, HT; Wei, JP; Mi, ZY; Wai, P; Kuo, PC			S-nitrosylation of heterogeneous nuclear ribonucleoprotein A/B regulates osteopontin transcription in endotoxin-stimulated murine macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ELEMENT-BINDING PROTEIN; DNA-BINDING; EXPRESSION; CLONING; CELLS; GENE; INHIBITION; IDENTIFICATION; ENHANCER	Osteopontin (OPN) is a highly hydrophilic and negatively charged sialoprotein of similar to 298 amino acids that contains a Gly-Arg-Gly-Asp-Ser sequence. It is a secreted protein with diverse regulatory functions, including cell adhesion and migration, tumor growth and metastasis, atherosclerosis, aortic valve calcification, and repair of myocardial injury. Despite the many recognized functions of OPN, very little is known of the transcriptional regulation of OPN. In this regard, we have previously demonstrated that OPN transcription and promoter activity are significantly up-regulated in response to NO in a system of endotoxin-stimulated murine macrophages. However, the specific cis- and trans-regulatory elements that determine the extent of endotoxin- and NO-mediated induction of OPN synthesis are unknown. In this follow-up study, we demonstrate that: 1) OPN gene transcription is regulated by a constitutive transcriptional repressor protein, heterogeneous nuclear ribonucleoprotein A/B ( hnRNP A/B); 2) inhibition of in vivo hnRNP DNA binding activity is accompanied by increased S-nitrosylation of hnRNP A/B in the setting of lipopolysaccharide (LPS)-mediated NO synthesis; 3) inhibition of LPS mediated NO synthesis restores hnRNP DNA binding and decreases the extent of S-nitrosylation; and 4) S-nitrosylation of hnRNP at cysteine 104 inhibits in vitro DNA binding activity, which is reversed by dithiothreitol. Our findings suggest that LPS induced S-nitrosylation of hnRNP inhibits its activity as a constitutive repressor of the OPN promoter and results in enhanced OPN expression.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Duke University	Kuo, PC (corresponding author), 110 Bell Bldg,Box 3522,DUMC, Durham, NC 27710 USA.	kuo00004@mc.duke.edu		Gao, Chengjiang/0000-0002-9365-4497	NIAID NIH HHS [R01 AI44629] Funding Source: Medline; NIGMS NIH HHS [R01 GM65113] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065113] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; Attur MG, 2001, ARTHRITIS RHEUM-US, V44, P578, DOI 10.1002/1529-0131(200103)44:3<578::AID-ANR106>3.3.CO;2-Z; Calmels S, 1997, CANCER RES, V57, P3365; Chellaiah M, 1996, ENDOCRINOLOGY, V137, P2432, DOI 10.1210/en.137.6.2432; Chen H, 1998, J BIOL CHEM, V273, P31352, DOI 10.1074/jbc.273.47.31352; Chen H, 2003, P NATL ACAD SCI USA, V100, P6109, DOI 10.1073/pnas.1031395100; Chen H, 2000, J BIOL CHEM, V275, P35557, DOI 10.1074/jbc.M007117200; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; delaTorre A, 1999, J IMMUNOL, V162, P4101; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Dreyfuss G, 1996, CELL, V85, P963, DOI 10.1016/S0092-8674(00)81298-2; Guo HT, 2002, J BIOL CHEM, V277, P5054, DOI 10.1074/jbc.M109017200; Guo HT, 2001, J IMMUNOL, V166, P1079, DOI 10.4049/jimmunol.166.2.1079; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255; HWANG S, 1994, J BIOL CHEM, V269, P711; HWANG SM, 1994, J CELL PHYSIOL, V160, P61, DOI 10.1002/jcp.1041600108; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Rollo EE, 1996, J LEUKOCYTE BIOL, V60, P397, DOI 10.1002/jlb.60.3.397; Saitoh Y, 2002, NUCLEIC ACIDS RES, V30, P5205, DOI 10.1093/nar/gkf642; Schneiderhan N, 2003, ONCOGENE, V22, P2857, DOI 10.1038/sj.onc.1206431; SINGH K, 1995, J BIOL CHEM, V270, P28471; Singh K, 1999, HYPERTENSION, V33, P663, DOI 10.1161/01.HYP.33.2.663; SMIDT MP, 1995, NUCLEIC ACIDS RES, V23, P2389, DOI 10.1093/nar/23.13.2389; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; TAY N, 1992, J VIROL, V66, P6841, DOI 10.1128/JVI.66.12.6841-6848.1992; Tolnay M, 1999, BIOCHEM J, V338, P417, DOI 10.1042/0264-6021:3380417; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Vossen Christine, 2002, Med Sci Monit, V8, pRA217; Wang D, 1999, J VIROL, V73, P7761, DOI 10.1128/JVI.73.9.7761-7768.1999; WILSON AB, 1988, CELL IMMUNOL, V113, P130, DOI 10.1016/0008-8749(88)90012-3; Yabuki T, 2001, GENE, V264, P123, DOI 10.1016/S0378-1119(00)00592-8	41	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11236	11243		10.1074/jbc.M313385200	http://dx.doi.org/10.1074/jbc.M313385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722087	hybrid			2022-12-25	WOS:000220157600050
J	Iwase, A; Shen, RQ; Navarro, D; Nanus, DM				Iwase, A; Shen, RQ; Navarro, D; Nanus, DM			Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONIC-ACID-BINDING; PROSTATE-CANCER CELLS; SCHIZOSACCHAROMYCES-POMBE; CYTOPLASMIC DOMAIN; GLYCOPROTEIN CD44; FAMILY MEMBERS; ACTIN-BINDING; IN-VIVO; EXPRESSION; ADHESION	Neutral endopeptidase 24.11 (NEP) is a cell surface peptidase expressed by numerous tissues including prostatic epithelial cells. We reported that NEP inhibits prostate cancer cell proliferation and cell migration by enzymatic inactivation of neuropeptide substrates and through protein-protein interaction independent of catalytic function. The cytoplasmic domain of NEP contains a positively charged amino acid cluster, previously identified as a binding site for ezrin/radixin/moesin (ERM) proteins. We report here that NEP co-immunoprecipitates with ERM proteins in NEP-expressing LNCaP prostate cancer cells and MeWo melanoma cells. Co-immunoprecipitation showed that ERM proteins associate with wild-type NEP protein but not NEP protein containing a truncated cytoplasmic domain or point mutations replacing the positively charged amino acid cluster. In vitro binding assays showed that NEP binds directly to recombinant N terminus fragments of ERM proteins at the positively charged amino acid cluster within the NEP cytoplasmic domain. Binding of ERM proteins to NEP results in decreased binding of ERM proteins to the hyaluronan receptor CD44, a main binding partner of ERM proteins. Moreover, cells expressing wild-type NEP demonstrate decreased adhesion to hyaluronic acid and cell migration. These data suggest that NEP can affect cell adhesion and migration through direct binding to ERM proteins.	Cornell Univ, Weill Med Coll, Dept Urol, Urol Oncol Res Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Hematol & Med Oncol, New York, NY 10021 USA	Cornell University; Cornell University	Nanus, DM (corresponding author), Cornell Univ, Weill Med Coll, Dept Urol, Urol Oncol Res Lab, 525 E 68th St, New York, NY 10021 USA.	dnanus@med.cornell.edu			NATIONAL CANCER INSTITUTE [R01CA080240] Funding Source: NIH RePORTER; NCI NIH HHS [CA80240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; CHECLER F, 1984, J NEUROCHEM, V43, P1295, DOI 10.1111/j.1471-4159.1984.tb05386.x; Cichy J, 2000, J BIOL CHEM, V275, P18061, DOI 10.1074/jbc.M907962199; Dai J, 2001, CLIN CANCER RES, V7, P1370; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Dhir R, 1997, MOL DIAGN, V2, P197, DOI 10.1016/S1084-8592(97)80029-X; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; Fukui M, 2000, CLIN IMMUNOL, V94, P173, DOI 10.1006/clim.1999.4830; Girardi ACC, 2001, J BIOL CHEM, V276, P46671, DOI 10.1074/jbc.M106897200; Goi T, 2002, INT SURG, V87, P130; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; Granes F, 2000, J CELL SCI, V113, P1267; Gschwend JE, 1997, PROSTATE, V33, P166; Harrison GM, 2002, INT J ONCOL, V21, P935; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Herrlich P, 2000, ANN NY ACAD SCI, V910, P106; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hiscox S, 1999, J CELL SCI, V112, P3081; HOOSEIN NM, 1991, CANCER COMMUN, V3, P255, DOI 10.3727/095535491820873146; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Huhn J, 2000, IMMUNOL LETT, V72, P127, DOI 10.1016/S0165-2478(00)00170-X; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Jiang H, 2002, J BIOL CHEM, V277, P10531, DOI 10.1074/jbc.M108654200; JOENSUU H, 1993, AM J PATHOL, V143, P867; KENNY J, 1993, BIOCHEM SOC T, V21, P663, DOI 10.1042/bst0210663; Kim HS, 2002, CLIN ORTHOP RELAT R, P184; Knupfer MM, 1999, CLIN EXP METASTAS, V17, P71; Lang SH, 2002, PROSTATE, V52, P253, DOI 10.1002/pros.10088; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; LOKESHWAR BL, 1995, ANTICANCER RES, V15, P1191; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Lu Q, 1997, GENE, V200, P135, DOI 10.1016/S0378-1119(97)00393-4; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; NANUS DM, 1997, CELL SURFACE PEPTIDA; Noordzij MA, 1999, INT J CANCER, V84, P478, DOI 10.1002/(SICI)1097-0215(19991022)84:5<478::AID-IJC5>3.0.CO;2-N; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Peck D, 1996, CURR BIOL, V6, P884, DOI 10.1016/S0960-9822(02)00612-7; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Shen RQ, 2002, ANTICANCER RES, V22, P2533; SHIPP MA, 1991, P NATL ACAD SCI USA, V88, P10662, DOI 10.1073/pnas.88.23.10662; SHIPP MA, 1988, P NATL ACAD SCI USA, V85, P4819, DOI 10.1073/pnas.85.13.4819; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Sumitomo M, 2001, CANCER RES, V61, P3294; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zohar R, 2000, J CELL PHYSIOL, V184, P118, DOI 10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.3.CO;2-P	54	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11898	11905		10.1074/jbc.M212737200	http://dx.doi.org/10.1074/jbc.M212737200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14704146	hybrid			2022-12-25	WOS:000220157600127
J	Sawamura, N; Ko, MH; Yu, WX; Zou, K; Hanada, K; Suzuki, T; Gong, JS; Yanagisawa, K; Michikawa, M				Sawamura, N; Ko, MH; Yu, WX; Zou, K; Hanada, K; Suzuki, T; Gong, JS; Yanagisawa, K; Michikawa, M			Modulation of amyloid precursor protein cleavage by cellular sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE MEMBRANE COMPARTMENT; BETA-PROTEIN; KINASE-C; LIPID RAFTS; SERINE PALMITOYLTRANSFERASE; CHOLESTEROL DEPLETION; PRION PROTEIN; SIGNAL-TRANSDUCTION; NEUROBLASTOMA-CELLS; ALZHEIMERS-DISEASE	Lipid rafts and their component, cholesterol, modulate the processing of beta-amyloid precursor protein (APP). However, the role of sphingolipids, another major component of lipid rafts, in APP processing remains undetermined. Here we report the effect of sphingolipid deficiency on APP processing in Chinese hamster ovary cells treated with a specific inhibitor of serine palmitoyltransferase, which catalyzes the first step of sphingolipid biosynthesis, and in a mutant LY-B strain defective in the LCB1 subunit of serine palmitoyltransferase. We found that in sphingolipid-deficient cells, the secretion of soluble APPalpha (sAPPalpha) and the generation of C-terminal fragment cleaved at alpha-site dramatically increased, whereas epsilon-cleavage activity remained unchanged, and the epsilon-cleavage activity decreased without alteration of the total APP level. The secretion of amyloid beta-protein 42 increased in sphingolipid-deficient cells, whereas that of amyloid beta-protein 40 did not. All of these alterations were restored in sphingolipid-deficient cells by adding exogenous sphingosine and in LY-B cells by transfection with cLCB1. Sphingolipid deficiency increased MAPK/ERK activity and a specific inhibitor of MAPK kinase, PD98059, restored sAPPalpha level, indicating that sphingolipid deficiency enhances sAPPalpha secretion via activation of MAPK/ERK pathway. These results suggest that not only the cellular level of cholesterol but also that of sphingolipids may be involved in the pathological process of Alzheimer's disease by modulating APP cleavage.	Natl Inst Longev Sci, Dept Dementia Res, Aichi 4748522, Japan; Japan Soc Promot Sci, Tokyo 1028471, Japan; Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Sapporo, Hokkaido 0600812, Japan; Org Pharmaceut Safety & Res Japan, Tokyo 1000013, Japan	Japan Society for the Promotion of Science; National Institute of Infectious Diseases (NIID); Hokkaido University	Michikawa, M (corresponding author), Natl Inst Longev Sci, Dept Dementia Res, 36-3 Gengo, Aichi 4748522, Japan.	michi@nils.go.jp	Suzuki, Toshiharu/B-5342-2013; Sawamura, Naoya/K-1663-2018	Sawamura, Naoya/0000-0003-4753-1119; Hanada, Kentaro/0000-0003-1383-2781				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Avramovich Y, 2002, J BIOL CHEM, V277, P31466, DOI 10.1074/jbc.M201308200; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; De Strooper B, 2000, J CELL SCI, V113, P1857; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HANADA K, 1993, J BIOL CHEM, V268, P13820; Hanada K, 2000, BIOCHEM PHARMACOL, V59, P1211, DOI 10.1016/S0006-2952(00)00251-3; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; Harter D, 2001, BEHAV BRAIN SCI, V24, P45, DOI 10.1017/S0140525X01303916; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; KOO EH, 1994, J BIOL CHEM, V269, P17386; LeBlanc AC, 1998, J NEUROSCI, V18, P2907; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; Mills J, 1997, J NEUROSCI, V17, P9415; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Mudher A, 2001, J NEUROSCI, V21, P4987, DOI 10.1523/JNEUROSCI.21-14-04987.2001; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; Piiper A, 2003, J BIOL CHEM, V278, P7065, DOI 10.1074/jbc.M211234200; Puglielli L, 2003, J BIOL CHEM, V278, P19777, DOI 10.1074/jbc.M300466200; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Sato T, 2003, J BIOL CHEM, V278, P24294, DOI 10.1074/jbc.M211161200; Sawamura N, 2000, J BIOL CHEM, V275, P27901; Sawamura N, 2001, J BIOL CHEM, V276, P10314, DOI 10.1074/jbc.M009733200; Sawamura N, 2003, J NEUROCHEM, V84, P1086, DOI 10.1046/j.1471-4159.2003.01596.x; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 2001, NEUROLOGY, V57, P1089, DOI 10.1212/WNL.57.6.1089; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Stevens VL, 1997, J BIOL CHEM, V272, P18020, DOI 10.1074/jbc.272.29.18020; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wang PY, 2003, EMBO J, V22, P2658, DOI 10.1093/emboj/cdg255; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o	62	69	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11984	11991		10.1074/jbc.M309832200	http://dx.doi.org/10.1074/jbc.M309832200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14715666	hybrid			2022-12-25	WOS:000220157600136
J	Rezk, BM; Haenen, GRMM; van der Vijgh, WJF; Bast, A				Rezk, BM; Haenen, GRMM; van der Vijgh, WJF; Bast, A			Lipoic acid protects efficiently only against a specific form of peroxynitrite-induced damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOCHLOROUS ACID; GLUTATHIONE DISULFIDE; TYROSINE NITRATION; POTENT INHIBITOR; NITRIC-OXIDE; OXIDATION; INACTIVATION; ALPHA(1)-ANTIPROTEINASE; DERIVATIVES; SUPEROXIDE	The ability of the sulfur-containing compounds glutathione (GSH), glutathione disulphide (GSSG), S-methylglutathione ( GSMe), lipoic acid ( LA), and dihydrolipoic acid ( DHLA) to protect against hypochlorous acid (HOCl)-mediated damage and peroxynitrite (ONOOH)induced damage has been compared. Protective activity was assessed in competition assays by monitoring several detectors, i.e. dihydrorhodamine-123 (DHR-123) oxidation, alpha(1)-antiproteinase (alpha(1)-AP) inactivation, and glutathione S-transferase P1-1 (GST-P1-1) inactivation. In addition, nitration of tyrosine was measured to assess protection of the sulfur-containing compounds against ONOOH. For protection against HOCl, the efficacy of the antioxidant was controlled by the ratio of the reaction rates of the antioxidant and the detector molecule with the oxidant. The rank order of the activity of the antioxidants (GSH > DHLA approximate to LA approximate to GSMe > GSSG) appeared to be independent of the detector used. However, the rank order of the antioxidants against ONOOH-induced damage is strongly dependent on the detector. LA was 40 times less active than GSH in the inhibition of ONOOH-induced DHR-123 oxidation, whereas LA was 20 times more active than GSH in preventing the inhibition of GST-P1-1 by ONOOH. This points to different molecular mechanisms of ONOOH damage to DHR-123 compared with ONOOH damage to GST-P1-1. LA is a poor antioxidant in protecting against the form of ONOOH damage involved in DHR-123 oxidation. In the form of ONOOH toxicity involved in GST-P1-1 inhibition, LA is the most potent sulfur-containing antioxidant in our series. It is proposed that an intermediate product in which both sulfur atoms of LA have reacted is involved in the reaction of ONOOH with LA. The high potency of LA to protect GST-P1-1 against ONOOH might be of therapeutic interest.	Univ Maastricht, Fac Med, Dept Pharmacol & Toxicol, NL-6200 MD Maastricht, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands	Maastricht University; Vrije Universiteit Amsterdam	Bast, A (corresponding author), Univ Maastricht, Fac Med, Dept Pharmacol & Toxicol, POB 616, NL-6200 MD Maastricht, Netherlands.	a.bast@farmaco.unimaas.nl	Haenen, Guido/H-9209-2013; Bast, Aalt/I-7809-2013	Haenen, Guido/0000-0001-6986-290X; Bast, Aalt/0000-0002-5383-2789				ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BIEWENGA GP, 1994, ARCH BIOCHEM BIOPHYS, V312, P114, DOI 10.1006/abbi.1994.1288; Chen HJC, 2003, ARCH BIOCHEM BIOPHYS, V415, P109, DOI 10.1016/S0003-9861(03)00220-0; den Hartog GJM, 2002, TOXICOL APPL PHARM, V181, P228, DOI 10.1006/taap.2002.9419; den Hartog GJM, 2002, BIOL CHEM, V383, P709; EVANS MD, 1994, AM J PHYSIOL, V266, P593; HAENEN GRMM, 1991, BIOCHEM PHARMACOL, V42, P2244, DOI 10.1016/0006-2952(91)90363-A; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Jenner AM, 2002, ARTERIOSCL THROM VAS, V22, P574, DOI 10.1161/01.ATV.0000013785.03265.5C; Kirsch M, 2001, CHEM-EUR J, V7, P3313, DOI 10.1002/1521-3765(20010803)7:15<3313::AID-CHEM3313>3.0.CO;2-7; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; Mannervik B, 1981, Methods Enzymol, V77, P231; Nakagawa H, 2000, CHEM PHARM BULL, V48, P261; Priyadarsini KI, 2001, CHEM RES TOXICOL, V14, P567, DOI 10.1021/tx000239t; RADI R, 1991, J BIOL CHEM, V266, P4244; Terentis AC, 2002, CIRC RES, V90, P333, DOI 10.1161/hh0302.104454; Trujillo M, 2002, ARCH BIOCHEM BIOPHYS, V397, P91, DOI 10.1006/abbi.2001.2619; van Haaften RIM, 2001, CHEM-BIOL INTERACT, V138, P77, DOI 10.1016/S0009-2797(01)00262-9; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; Whiteman M, 1997, FEBS LETT, V414, P497, DOI 10.1016/S0014-5793(97)01058-2; Whiteman M, 1996, FEBS LETT, V379, P74, DOI 10.1016/0014-5793(95)01489-6; Wong PSY, 2001, ARCH BIOCHEM BIOPHYS, V394, P216, DOI 10.1006/abbi.2001.2532	23	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9693	9697		10.1074/jbc.M312289200	http://dx.doi.org/10.1074/jbc.M312289200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701855	hybrid			2022-12-25	WOS:000220050400006
J	Dirsch, VM; Kirschke, SO; Estermeier, M; Steffan, B; Vollmar, AM				Dirsch, VM; Kirschke, SO; Estermeier, M; Steffan, B; Vollmar, AM			Apoptosis signaling triggered by the marine alkaloid ascididemin is routed via caspase-2 and JNK to mitochondria	ONCOGENE			English	Article						apoptosis; ascididemin; caspase-2; mitochondria	CYTOCHROME-C RELEASE; HUMAN PROMYELOLEUKEMIC CELLS; DEATH; ACTIVATION; PROTEIN; DNA; INHIBITION; GENERATION; INDUCTION; THYMOCYTE	The marine alkaloid ascididemin (ASC) was shown to exert cytotoxicity even against multidrug-resistant cancer cells. Here, we address the signaling pathways utilized by ASC to trigger apoptosis in Jurkat leukemia T cells. We show that ASC (0.5-20 muM) induces a mitochondrial pathway that requires the activation of the initiator caspase-2 upstream of mitochondria. ASC-triggered apoptosis occurred independent of CD95, but required mitochondrial dysfunction. The activation of caspase-2 was shown to precede the processing of caspase-8, -9 and -3. The specific caspase-2 inhibitor zVDVADfmk abrogated ASC-induced DNA fragmentation almost completely. Overexpression of Bcl-x(L) blocked caspase-8 but not caspase-2 processing. Conversely, caspase-2 inhibition strongly reduced caspase-9 activation. As a possible link between caspase-2 and mitochondrial dysfunction, Bid was found to be cleaved by ASC. In addition, JNK was activated by ASC upstream of mitochondria via reactive oxygen species. The specific JNK inhibitor SP600125 partially inhibited caspase-2 and -9 processing as well as cytochrome c release and DNA fragmentation indicating that JNK contributes to, but is not necessary for ASC-mediated apoptosis. Thus, ASC triggers a pathway in which early activation of caspase-2 provides a possible link between its DNA-damaging activity and the induction of mitochondrial dysfunction. The activation of JNK contributes to this signaling upstream of mitochondria.	Univ Munich, Ctr Drug Res, Dept Pharm, D-81377 Munich, Germany; Univ Munich, Dept Chem, D-81377 Munich, Germany	University of Munich; University of Munich	Dirsch, VM (corresponding author), Univ Munich, Ctr Drug Res, Dept Pharm, Butenandstr 5-13, D-81377 Munich, Germany.	Verena.Dirsch@cup.uni-muenchen.de		Dirsch, Verena/0000-0002-9261-5293				Antlsperger DSM, 2003, ONCOGENE, V22, P582, DOI 10.1038/sj.onc.1206161; Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Beck WT, 2001, BIOCHEM SOC T, V29, P702, DOI 10.1042/0300-5127:0290702; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BONNARD I, 1995, ANTI-CANCER DRUG DES, V10, P333; BRACHER F, 1993, J HETEROCYCLIC CHEM, V30, P157, DOI 10.1002/jhet.5570300128; Bratton SB, 2001, TRENDS PHARMACOL SCI, V22, P306, DOI 10.1016/S0165-6147(00)01718-1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Dassonneville L, 2000, BIOCHEM PHARMACOL, V60, P527, DOI 10.1016/S0006-2952(00)00351-8; Dirsch VM, 2001, CANCER RES, V61, P5817; Dirsch VM, 1998, MOL PHARMACOL, V53, P402, DOI 10.1124/mol.53.3.402; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; KOBAYASHI J, 1988, TETRAHEDRON LETT, V29, P1177, DOI 10.1016/S0040-4039(00)86681-2; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; LINDSAY BS, 1995, BIOORG MED CHEM LETT, V5, P739, DOI 10.1016/0960-894X(95)00106-4; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsumoto SS, 2003, CHEM RES TOXICOL, V16, P113, DOI 10.1021/tx025618w; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stefanis L, 1998, J NEUROSCI, V18, P9204; Walczak H, 2000, CANCER RES, V60, P3051; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	38	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1586	1593		10.1038/sj.onc.1207281	http://dx.doi.org/10.1038/sj.onc.1207281			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716300				2022-12-25	WOS:000189219500012
J	Langley, B; Thomas, M; McFarlane, C; Gilmour, S; Sharma, M; Kambadur, R				Langley, B; Thomas, M; McFarlane, C; Gilmour, S; Sharma, M; Kambadur, R			Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway	ONCOGENE			English	Article						myostatin; NPAT; rhabdomyosarcoma; retinoblastoma; histone	TRANSFORMING-GROWTH-FACTOR; HISTONE GENE-TRANSCRIPTION; CYCLIN-DEPENDENT KINASES; PAX3-FKHR FUSION PROTEIN; BETA SUPERFAMILY MEMBER; ALVEOLAR RHABDOMYOSARCOMA; EMBRYONAL RHABDOMYOSARCOMA; MUSCLE GROWTH; MYOD FAMILY; S-PHASE	Rhabdomyosarcoma (RMS) tumors are the most common soft-tissue sarcomas in childhood. In this investigation, we show that myostatin, a skeletal muscle-specific inhibitor of growth and differentiation is expressed and translated in the cultured RMS cell line, RD. The addition of exogenous recombinant myostatin inhibits the proliferation of RD cells cultured in growth media, consistent with the role of myostatin in normal myoblast proliferation inhibition. However, unlike normal myoblasts, upregulation of p21 was not observed. Rather, myostatin signalling resulted in the specific downregulation of both Cdk2 and its cognate partner, cyclin-E. The analysis of Rb reveals that there was no change in its phosphorylation status with myostatin treatment, consistent with D-type-cyclin-Cdk4/6 complexes being active in the absence of p21. Moreover, the activity of Rb appeared to be unchanged between treated and nontreated RD cells, as determined by the ability of Rb to bind E2F1. The examination of NPAT, a substrate of cyclin-E-Cdk2 involved in the transcriptional activation of replication-dependent histone gene expression, revealed that it undergoes a loss of phosphorylation with myostatin treatment. Supporting this, a downregulation in H4-histone gene expression was observed. These results suggest that myostatin could potentially be used as an inhibitor of RMS proliferation and define a previously uncharacterized, Rb-independent mechanism for the inhibition of muscle precursor cell proliferation by myostatin.	AgRes, Anim Genom, Hamilton, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand	AgResearch - New Zealand; University of Auckland	Kambadur, R (corresponding author), AgRes, Anim Genom, Private Bag 3123,East St, Hamilton, New Zealand.	Ravi.Kambadur@agresearch.co.nz	McFarlane, Craig/R-2968-2019; Langley, Brett C/P-7207-2017	McFarlane, Craig/0000-0002-7056-8887; Langley, Brett C/0000-0003-4009-2109				AGUANNO S, 1990, CANCER RES, V50, P3377; Albig W, 1997, HUM GENET, V101, P284, DOI 10.1007/s004390050630; Arthur PF, 1995, AUST J AGR RES, V46, P1493, DOI 10.1071/AR9951493; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Bouche M, 2000, FASEB J, V14, P1147, DOI 10.1096/fasebj.14.9.1147; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; Dagher R, 1999, Oncologist, V4, P34; DAVIS RJ, 1994, CANCER RES, V54, P2869; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Ewen ME, 2000, GENE DEV, V14, P2265, DOI 10.1101/gad.842100; Feinberg AP, 1999, CANCER RES, V59, p1743S; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Grobet L, 1998, MAMM GENOME, V9, P210, DOI 10.1007/s003359900727; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; HOUGHTON JA, 1981, INT J CANCER, V28, P409, DOI 10.1002/ijc.2910280403; Hu XT, 2001, J HEMATOTH STEM CELL, V10, P67, DOI 10.1089/152581601750098255; Ji SQ, 1998, AM J PHYSIOL-REG I, V275, pR1265, DOI 10.1152/ajpregu.1998.275.4.R1265; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Megeney LA, 1995, BIOCHEM CELL BIOL, V73, P723, DOI 10.1139/o95-080; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; NIGGLI FK, 1994, BRIT J CANCER, V69, P1106, DOI 10.1038/bjc.1994.217; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OLIVER MH, 1989, J CELL SCI, V92, P513; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; Otten AD, 1997, CELL GROWTH DIFFER, V8, P1151; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Pandita Ajay, 1999, Neoplasia (New York), V1, P262, DOI 10.1038/sj.neo.7900036; PAPPO AS, 1993, J CLIN ONCOL, V11, P1901, DOI 10.1200/JCO.1993.11.10.1901; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Puri PL, 2000, GENE DEV, V14, P574; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SHAPIRO DN, 1991, J CLIN ONCOL, V9, P159, DOI 10.1200/JCO.1991.9.1.159; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Sharma M, 1999, J CELL PHYSIOL, V180, P1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEIN G S, 1992, Current Opinion in Cell Biology, V4, P166, DOI 10.1016/0955-0674(92)90028-B; Szabo G, 1998, MAMM GENOME, V9, P671, DOI 10.1007/s003359900843; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Thies RS, 2001, GROWTH FACTORS, V18, P251; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Yang JZ, 2001, MOL REPROD DEV, V60, P351, DOI 10.1002/mrd.1097; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2	61	45	50	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					524	534		10.1038/sj.onc.1207144	http://dx.doi.org/10.1038/sj.onc.1207144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724580				2022-12-25	WOS:000188098300023
J	Surace, EI; Haipek, CA; Gutmann, DH				Surace, EI; Haipek, CA; Gutmann, DH			Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function	ONCOGENE			English	Article						merlin; schwannomin; ERM proteins; FERM; Protein 4.1; phosphorylation	TUMOR-SUPPRESSOR PROTEIN; CELL EXTENSION ACTIVITY; ERM PROTEINS; PLASMA-MEMBRANE; TERMINAL DOMAIN; EZRIN; MOESIN; BINDING; ASSOCIATION; GROWTH	The neurofibromatosis 2 (NF2) tumor suppressor gene product, merlin, belongs to the ezrin-radixin-moesin (ERM) subgroup of the Protein 4.1 family, which links cell surface glycoproteins to the actin cytoskeleton. Previous studies have suggested that phosphorylation of merlin, similar to other ERM proteins, may regulate its function. To determine whether merlin phosphorylation has functional consequences for merlin suppression of cell growth and motility, we generated doxycycline-regulatable RT4 schwannoma cell lines that inducibly express full-length merlin with mutations at two potential phosphorylation sites (amino-acid residues S518 and T576). Whereas a mutation at S518 that mimics constitutive phosphorylation (S518D) abrogates the ability of merlin to suppress cell growth and motility, the S518A merlin mutant, which mimics nonphosphorylated merlin, functions equivalently to wild-type merlin. Similar mutations involving T576, the analogous phosphorylation site in ERM proteins important for regulating their function, had no effect. In contrast to other functionally inactive missense merlin mutants, the regulated overexpression of S518D merlin resulted in dramatic changes in cell shape and the elaboration of filopodial extensions. These results provide the first direct demonstration that the S518D merlin mutation, which mimics merlin phosphorylation, impairs not only merlin growth and motility suppression but also leads to an acquisition of a novel phenotype previously ascribed to ERM proteins.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035848] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35848] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerley S, 2003, J CELL BIOL, V161, P489, DOI 10.1083/jcb.200303138; Baser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/00019052-200302000-00004; Bretscher A, 1995, BIOCHEMISTRY-US, V34, P16830, DOI 10.1021/bi00051a034; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; CHEN J, 1995, P NATL ACAD SCI USA, V92, P7495, DOI 10.1073/pnas.92.16.7495; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Gopalbhai K, 2003, J BIOL CHEM, V278, P8118, DOI 10.1074/jbc.M211870200; Gutmann DH, 1998, HUM MOL GENET, V7, P335, DOI 10.1093/hmg/7.3.335; Gutmann DH, 2001, HUM MOL GENET, V10, P1519, DOI 10.1093/hmg/10.14.1519; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Jabbur JR, 2002, CANCER BIOL THER, V1, P277, DOI 10.4161/cbt.81; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Martin M, 1997, MOL BIOL CELL, V8, P1543, DOI 10.1091/mbc.8.8.1543; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sherman LS, 2001, TRENDS CELL BIOL, V11, P442, DOI 10.1016/S0962-8924(01)02128-6; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497	41	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					580	587		10.1038/sj.onc.1207142	http://dx.doi.org/10.1038/sj.onc.1207142			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724586				2022-12-25	WOS:000188098300029
J	Grant, GA; Xu, XL; Hu, ZQ				Grant, GA; Xu, XL; Hu, ZQ			Quantitative relationships of site to site interaction in Escherichia coli D-3-phosphoglycerate dehydrogenase revealed by asymmetric hybrid tetramers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATED ALLOSTERIC REGULATION; END PRODUCT INHIBITION; EFFECTOR-BINDING; PHOSPHOGLYCERATE DEHYDROGENASE; SERINE BIOSYNTHESIS; DOMAIN INTERFACE; SERA GENE; MECHANISM; PHOSPHOFRUCTOKINASE; COOPERATIVITY	A set of asymmetric hybrid tetramers of Escherichia coli D-3-phosphoglycerate dehydrogenase ( PGDH) have been made by gene co-expression and KSCN-induced dimer exchange. These tetramers contain varied numbers of active sites and effector binding sites arranged in different orientations within the tetramer. They reveal that PGDH displays half-of-the-sites activity with respect to its active sites and that the two sites that are active at any particular time lie in subunits on either side of the nucleotide binding domain interface. Half-of-the-sites functionality is also observed for the effector even though all four sites eventually bind effector. That is, only two effector sites need to be occupied for maximum inhibition. Binding of the last two effector molecules does not contribute functionally to inhibition of activity. Furthermore, positive cooperativity of inhibition of activity by the effector is completely dependent on the positive cooperativity of binding of the effector. Binding of the first effector molecule produces a conformational change that essentially completely inhibits the active site within the subunit to which it binds and produces an approximate 33% inhibition of the active site in the subunit to which it is not bound. Binding of the second effector at the opposite regulatory domain interface completes the inhibition of activity. This simple relationship defines the positional and quantitative influence of effector ligand binding on activity and can be used to predict the maximum level of inhibition of individual hybrid tetramers. In addition, the site-specific quantitative relationship of effector binding to individual active sites can be used to model the inhibition profile with relatively good agreement. These simple rules for the site to site interaction in PGDH provide significant new insight into the mechanism of allostery of this enzyme.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Grant, GA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	ggrant@molecool.wustl.edu			NIGMS NIH HHS [GM 56676] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056676] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlRabiee R, 1996, J BIOL CHEM, V271, P23235, DOI 10.1074/jbc.271.38.23235; AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; BELL JE, 1988, PROTEINS ENZYMES, P465; DEVILLEBONNE D, 1989, BIOCHEMISTRY-US, V28, P1917, DOI 10.1021/bi00430a073; Grant GA, 1999, PROTEIN SCI, V8, P2501; Grant GA, 1996, PROTEIN SCI, V5, P34; Grant GA, 2003, J BIOL CHEM, V278, P18170, DOI 10.1074/jbc.M213050200; Grant GA, 2002, J BIOL CHEM, V277, P39548, DOI 10.1074/jbc.M208019200; Grant GA, 2001, J BIOL CHEM, V276, P17844, DOI 10.1074/jbc.M009957200; Grant GA, 1998, J BIOL CHEM, V273, P22389, DOI 10.1074/jbc.273.35.22389; Grant GA, 2001, J BIOL CHEM, V276, P1078, DOI 10.1074/jbc.M007512200; GRANT GA, BIOCHEMISTRY, V38, P16548; Kimmel JL, 2001, BIOCHEMISTRY-US, V40, P11623, DOI 10.1021/bi010844a; LAZDUNSKI M, 1972, CURRENT TOPICS CELLU, V6, P267; Neet K E, 1980, Methods Enzymol, V64, P139; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	21	15	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13452	13460		10.1074/jbc.M313593200	http://dx.doi.org/10.1074/jbc.M313593200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14718528	hybrid			2022-12-25	WOS:000220478500023
J	Muhlenbein, N; Hofmann, S; Rothbauer, U; Bauer, MF				Muhlenbein, N; Hofmann, S; Rothbauer, U; Bauer, MF			Organization and function of the small Tim complexes acting along the import pathway of metabolite carriers into mammalian mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAFNESS DYSTONIA SYNDROME; ADP ATP CARRIER; INNER MEMBRANE; PROTEIN IMPORT; INTERMEMBRANE SPACE; PREPROTEIN TRANSLOCASE; ADP/ATP CARRIER; MEDIATES INSERTION; PEPTIDE-1 DDP1; COMPONENT	Tim9, Tim10a, and Tim10b are members of the family of small Tim proteins located in the intermembrane space of mammalian mitochondria. In yeast, members of this family act along the TIM22 import pathway during import of metabolite carriers and other integral inner membrane proteins. Here, we show that the human small proteins form two distinct hetero-oligomeric complexes. A 70-kDa complex that contains Tim9 and Tim10a and a Tim9-10a-10b that is part of a higher molecular weight assembly of 450 kDa. This distribution among two complexes suggests Tim10b to be the functional homologue of yeast Tim12. Both human complexes are tightly associated with the inner membrane and, compared with yeast, soluble 70-kDa complexes appear to be completely absent in the intermembrane space. Thus, the function of soluble 70-kDa complexes as trans-site receptors for incoming carrier proteins is not conserved from lower to higher eukaryotes. During import, the small Tim complexes directly interact with human adenine nucleotide translocator (ANT) in transit in a metal-dependent manner. For insertion of carrier preproteins into the inner membrane, the human small Tim proteins directly interact with human Tim22, the putative insertion pore of the TIM22 translocase. However, in contrast to yeast, only a small fraction of Tim9-Tim10a-Tim10b complex is in a stable association with Tim22. We conclude that different mechanisms and specific requirements for import and insertion of mammalian carrier preproteins have evolved in higher eukaryotes.	Akad Krankenhaus Munchen Schwabing, Inst Diabet Forsch, D-80804 Munich, Germany; Akad Krankenhaus Munchen Schwabing, Inst Klin Chem Mol Biol Diagnost & Mitochondriale, D-80804 Munich, Germany		Bauer, MF (corresponding author), KH Munchen Schwabing, Inst Klin Chem Mol Biol Diagnost & Mitochondriale, Kolner Pl 1, D-80804 Munich, Germany.	bauer@bio.med.uni-muenchen.de	Rothbauer, Ulrich/C-7712-2018	Rothbauer, Ulrich/0000-0001-5923-8986				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 1999, J MOL BIOL, V289, P69, DOI 10.1006/jmbi.1999.2751; Bauer MF, 2002, INT REV NEUROBIOL, V53, P57; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Dyall SD, 2003, J BIOL CHEM, V278, P26757, DOI 10.1074/jbc.M302700200; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200; Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9; Jensen RE, 2002, BBA-MOL CELL RES, V1592, P25, DOI 10.1016/S0167-4889(02)00261-6; Jin H, 1999, GENOMICS, V61, P259, DOI 10.1006/geno.1999.5966; Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Koehler CM, 2000, MOL CELL BIOL, V20, P1187, DOI 10.1128/MCB.20.4.1187-1193.2000; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Liu QL, 2003, SCIENCE, V300, P139, DOI 10.1126/science.1083379; Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Murphy MP, 2001, MOL CELL BIOL, V21, P6132, DOI 10.1128/MCB.21.18.6132-6138.2001; Okamoto K, 2002, EMBO J, V21, P3659, DOI 10.1093/emboj/cdf358; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477; Rothbauer U, 2001, J BIOL CHEM, V276, P37327, DOI 10.1074/jbc.M105313200; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	42	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13540	13546		10.1074/jbc.M312485200	http://dx.doi.org/10.1074/jbc.M312485200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726512	hybrid			2022-12-25	WOS:000220478500033
J	Pichiule, P; Chavez, JC; LaManna, JC				Pichiule, P; Chavez, JC; LaManna, JC			Hypoxic regulation of angiopoietin-2 expression in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; GROWTH-FACTOR; GENE-EXPRESSION; TIE2 RECEPTOR; UP-REGULATION; SIGNAL-TRANSDUCTION; MESSENGER-RNA; BINDING-SITE; RAT-BRAIN; ANGIOGENESIS	Exposure of endothelial cells to hypoxia-induced angiopoietin-2 (Ang2) expression. The increase in Ang2 mRNA levels occurred by transcriptional regulation and by post-transcriptional increase in mRNA stability. Induction of Ang2 mRNA resulted in an increase of intracellular and secreted Ang2 protein levels. Since the transcriptional regulation of several genes involved in angiogenesis during hypoxia is mediated by hypoxia-inducible factor-1 (HIF-1), it was conceivable that Ang2 expression might be regulated by the same oxygen-dependent mechanism. However, our data showed that pharmacological HIF inducers, CoCl2 and DFO, did not affect Ang2 expression. Moreover, HIF-1-deficient hepatoma cell ( Hepa1 c4) and its wild-type counterpart (Hepa1 c1c4) up-regulates Ang2 during hypoxia. These results indicated that hypoxia-driven Ang2 expression may be independent of the HIF pathway. Using neutralizing VEGF antibody or pharmacological inhibitors of VEGF receptors, we showed that hypoxia-induced VEGF participates but could not account completely for Ang2 expression during hypoxia. In addition, hypoxia elicited an increase of cyclooxygenase-2 (COX-2) expression and a parallel increase in prostanglandin E-2 (PGE(2)) and prostacyclin (PGI(2)) production. COX-2 inhibitors decreased the hypoxic induction of Ang2 and the hypoxic induction of PGE(2) and PGI(2) in a dose-dependent manner. Similarly, COX-2 but not COX-1 antisense treatment decreased hypoxic induction of Ang2 expression, and this effect was reversed by exogenous PGE(2). Finally, exogenous PGE(2) and PGI(2) were able to stimulate Ang2 under normoxic conditions. These findings suggest that COX-2-dependent prostanoids may play an important role in the regulation of hypoxia-induced Ang2 expression.	Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA	Case Western Reserve University	LaManna, JC (corresponding author), Cornell Univ, Coll Med, Burke Med Res Inst, White Plains, NY 10605 USA.	JCL4@po.cwru.edu	LaManna, Joseph C/C-3347-2012; LaManna, Joseph/D-3860-2013	LaManna, Joseph C/0000-0002-0159-4512; LaManna, Joseph/0000-0002-0159-4512	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038632, R01NS037111] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 37111, NS 38632] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; Bruick RK, 2001, GENE DEV, V15, P2497, DOI 10.1101/gad.931601; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Goede V, 1998, LAB INVEST, V78, P1385; GREENBERG ME, 1994, CURRENT PROTOCOLS 4, V26; Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.3.CO;2-Z; Hofer T, 2003, BLOOD, V101, P348, DOI 10.1182/blood-2002-03-0773; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; Huang YQ, 2002, BLOOD, V99, P1646, DOI 10.1182/blood.V99.5.1646; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Jones MK, 1999, NAT MED, V5, P1418; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185; Kim I, 2000, ONCOGENE, V19, P4549, DOI 10.1038/sj.onc.1203800; Kim I, 2000, J BIOL CHEM, V275, P18550, DOI 10.1074/jbc.M910084199; Kim I, 2000, BIOCHEM BIOPH RES CO, V269, P361, DOI 10.1006/bbrc.2000.2296; Koh GY, 2002, EXP MOL MED, V34, P1; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lobov IB, 2002, P NATL ACAD SCI USA, V99, P11205, DOI 10.1073/pnas.172161899; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mandriota SJ, 2000, AM J PATHOL, V156, P2077, DOI 10.1016/S0002-9440(10)65079-1; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Masferrer JL, 2000, CANCER RES, V60, P1306; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Mezquita J, 2000, BIOCHEM BIOPH RES CO, V275, P643, DOI 10.1006/bbrc.2000.3345; MICHELS C, 1993, AM J PHYSIOL, V264, pC866, DOI 10.1152/ajpcell.1993.264.4.C866; Mochizuki Y, 2002, J CELL SCI, V115, P175; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Otani A, 2001, DIABETES, V50, P867, DOI 10.2337/diabetes.50.4.867; Pai R, 2001, BIOCHEM BIOPH RES CO, V286, P923, DOI 10.1006/bbrc.2001.5494; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; Park YS, 2003, MICROVASC RES, V65, P125, DOI 10.1016/S0026-2862(02)00035-3; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; Pichiule P, 2002, J APPL PHYSIOL, V93, P1131, DOI 10.1152/japplphysiol.00318.2002; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2001, J CLIN INVEST, V108, P39, DOI 10.1172/JCI13374; Stempien-Otero A, 1999, J BIOL CHEM, V274, P8039, DOI 10.1074/jbc.274.12.8039; Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Vajkoczy P, 2002, J CLIN INVEST, V109, P777, DOI 10.1172/JCI200214105; Visconti RP, 2002, P NATL ACAD SCI USA, V99, P8219, DOI 10.1073/pnas.122109599; WANG GL, 1993, BLOOD, V82, P3610; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; XU XP, 1995, CARDIOVASC RES, V30, P345, DOI 10.1016/S0008-6363(95)00037-2; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Zagzag D, 2000, LAB INVEST, V80, P837, DOI 10.1038/labinvest.3780088; Zhang ZG, 2002, TRENDS CARDIOVAS MED, V12, P62, DOI 10.1016/S1050-1738(01)00149-9	63	144	155	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12171	12180		10.1074/jbc.M305146200	http://dx.doi.org/10.1074/jbc.M305146200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14702352	hybrid			2022-12-25	WOS:000220334900023
J	Pili-Floury, S; Leulier, F; Takahashi, K; Saigo, K; Samain, E; Ueda, R; Lemaitre, B				Pili-Floury, S; Leulier, F; Takahashi, K; Saigo, K; Samain, E; Ueda, R; Lemaitre, B			In vivo RNA interference analysis reveals an unexpected role for GNBP1 in the Defense against Gram-positive bacterial infection in Drosophila adults	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDOGLYCAN-RECOGNITION PROTEIN; ANTIMICROBIAL PEPTIDE GENES; INNATE IMMUNE-RESPONSES; NEGATIVE BACTERIA; BOMBYX-MORI; BINDING PROTEIN; HOST-DEFENSE; CDNA CLONING; TOLL; MELANOGASTER	The Drosophila immune system discriminates between different classes of infectious microbes and responds with pathogen-specific defense reactions via the selective activation of the Toll and the immune deficiency (Imd) signaling pathways. The Toll pathway mediates most defenses against Gram-positive bacteria and fungi, whereas the Imd pathway is required to resist Gram-negative bacterial infection. Microbial recognition is achieved through peptidoglycan recognition proteins (PGRPs); Gram-positive bacteria activate the Toll pathway through a circulating PGRP (PGRP-SA), and Gram-negative bacteria activate the Imd pathway via PGRP-LC, a putative transmembrane receptor, and PGRP-LE. Gram-negative binding proteins (GNBPs) were originally identified in Bombyx mori for their capacity to bind various microbial compounds. Three GNBPs and two related proteins are encoded in the Drosophila genome, but their function is not known. Using inducible expression of GNBP1 double-stranded RNA, we now demonstrate that GNBP1 is required for Toll activation in response to Gram-positive bacterial infection; GNBP1 double-stranded RNA expression renders flies susceptible to Gram-positive bacterial infection and reduces the induction of the antifungal peptide encoding gene Drosomycin after infection by Gram-positive bacteria but not after fungal infection. This phenotype induced by GNBP1 inactivation is identical to a loss-of-function mutation in PGRP-SA, and our genetic studies suggest that GNBP1 acts upstream of the Toll ligand Spatzle. Altogether, our results demonstrate that the detection of Gram-positive bacteria in Drosophila requires two putative pattern recognition receptors, PGRP-SA and GNBP1.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Natl Inst Genet, Genet Strains Res Ctr, Shizuoka 4118540, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan; Univ Franche Comte, Ctr Hosp Univ, F-25030 Besancon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; University of Tokyo; Universite de Franche-Comte; CHU Besancon	Lemaitre, B (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.	lemaitre@cgm.cnrs-gif.fr	Lemaitre, Bruno/T-8146-2019	Lemaitre, Bruno/0000-0001-7970-1667				Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; Girardin SE, 2003, EMBO REP, V4, P932, DOI 10.1038/sj.embor.embor940; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hedengren M, 1999, MOL CELL, V4, P827, DOI 10.1016/S1097-2765(00)80392-5; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Kalidas S, 2002, NEURON, V33, P177, DOI 10.1016/S0896-6273(02)00560-3; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Kim YS, 2000, J BIOL CHEM, V275, P32721, DOI 10.1074/jbc.M003934200; Kurata S, 2004, DEV COMP IMMUNOL, V28, P89, DOI 10.1016/S0145-305X(03)00121-6; Lee MH, 2003, J BIOL CHEM; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; Manfruelli P, 1999, EMBO J, V18, P3380, DOI 10.1093/emboj/18.12.3380; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Reichhart JM, 2002, GENESIS, V34, P160, DOI 10.1002/gene.10122; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Rutschmann S, 2002, J IMMUNOL, V168, P1542, DOI 10.4049/jimmunol.168.4.1542; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Tzou P, 2002, CURR OPIN MICROBIOL, V5, P102, DOI 10.1016/S1369-5274(02)00294-1; Tzou P, 2002, METHOD MICROBIOL, V31, P507, DOI 10.1016/S0580-9517(02)31028-6; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	38	129	142	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12848	12853		10.1074/jbc.M313324200	http://dx.doi.org/10.1074/jbc.M313324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722090	Green Submitted, hybrid			2022-12-25	WOS:000220334900100
J	Wang, GY; Woods, A; Sabari, S; Pagnotta, L; Stanton, LA; Beier, F				Wang, GY; Woods, A; Sabari, S; Pagnotta, L; Stanton, LA; Beier, F			RhoA/ROCK signaling suppresses hypertrophic chondrocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GROWTH-FACTOR RECEPTOR-3; BRACHYDACTYLY TYPE-B; RHO FAMILY GTPASES; RECESSIVE ROBINOW-SYNDROME; INTEGRIN-LINKED KINASE; BONE SIALOPROTEIN BSP; EZRIN-LIKE DOMAIN; PARATHYROID-HORMONE; TYROSINE KINASE; CELL-LINE	Coordinated proliferation and differentiation of growth plate chondrocytes is required for normal growth and development of the endochondral skeleton, but little is known about the intracellular signal transduction pathways regulating these processes. We have investigated the roles of the GTPase RhoA and its effector kinases ROCK1/2 in hypertrophic chondrocyte differentiation. RhoA, ROCK1, and ROCK2 are expressed throughout chondrogenic differentiation. RhoA overexpression in chondrogenic ATDC5 cells results in increased proliferation and a marked delay of hypertrophic differentiation, as shown by decreased induction of alkaline phosphatase activity, mineralization, and expression of the hypertrophic markers collagen X, bone sialoprotein, and matrix metalloproteinase 13. These effects are accompanied by activation of cyclin D1 transcription and repression of the collagen X promoter by RhoA. In contrast, inhibition of Rho/ROCK signaling by the pharmacological inhibitor Y27632 inhibits chondrocyte proliferation and accelerates hypertrophic differentiation. Dominant-negative RhoA also inhibits induction of the cyclin D1 promoter by parathyroid hormone-related peptide. Finally, Y27632 treatment partially rescues the effects of RhoA overexpression. In summary, we identify the RhoA/ROCK signaling pathway as a novel and important regulator of chondrocyte proliferation and differentiation.	Univ Western Ontario, Dept Physiol & Pharmacol, Canadian Inst Hlth Res, Grp Skeletal Dev & Remodeling, London, ON N6A 5C1, Canada; Univ Western Ontario, Sch Dent, London, ON N6A 5C1, Canada	Institute for Work & Health; Western University (University of Western Ontario); Western University (University of Western Ontario)	Beier, F (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Canadian Inst Hlth Res, Grp Skeletal Dev & Remodeling, London, ON N6A 5C1, Canada.	fbeier@uwo.ca	Beier, Frank/G-4595-2013; Beier, Frank/T-4734-2019	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537				Adamiak K, 2002, ADV BOUND ELEM SER, V13, P465; Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Aszodi A, 2003, GENE DEV, V17, P2465, DOI 10.1101/gad.277003; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Ballock RT, 2000, ENDOCRINOLOGY, V141, P4552, DOI 10.1210/en.141.12.4552; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Beier F, 1999, MATRIX BIOL, V18, P109, DOI 10.1016/S0945-053X(99)00009-8; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Beier F, 2002, MOL ENDOCRINOL, V16, P2163, DOI 10.1210/me.2001-0103; Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852; Beier F, 1997, J CELL BIOCHEM, V66, P210, DOI 10.1002/(SICI)1097-4644(19970801)66:2<210::AID-JCB8>3.0.CO;2-T; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BENYA PD, 1993, EXP CELL RES, V204, P268, DOI 10.1006/excr.1993.1033; BENYA PD, 1988, PATHOL IMMUNOPATH R, V7, P51, DOI 10.1159/000157093; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bokoch GM, 2000, IMMUNOL RES, V21, P139, DOI 10.1385/IR:21:2-3:139; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; CHEN J, 1991, HISTOCHEM J, V23, P281, DOI 10.1007/BF01045047; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; Church V, 2002, J CELL SCI, V115, P4809, DOI 10.1242/jcs.00152; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Cleverley S, 1999, CURR BIOL, V9, P657, DOI 10.1016/S0960-9822(99)80289-9; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Corre I, 2001, J EXP MED, V194, P903, DOI 10.1084/jem.194.7.903; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955-0674(00)00276-3; DerMardirossian C, 2001, DRUG NEWS PERSPECT, V14, P389, DOI 10.1358/dnp.2001.14.7.858421; Dib K, 2001, J IMMUNOL, V166, P6311, DOI 10.4049/jimmunol.166.10.6311; EnomotoIwamoto M, 1997, J BONE MINER RES, V12, P1124, DOI 10.1359/jbmr.1997.12.7.1124; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Hirsch MS, 1997, DEV DYNAM, V210, P249, DOI 10.1002/(SICI)1097-0177(199711)210:3<249::AID-AJA6>3.0.CO;2-G; Ionescu AM, 2001, J BIOL CHEM, V276, P11639, DOI 10.1074/jbc.M006564200; Karaplis AC, 1998, ENDOCRINOLOGY, V139, P5255, DOI 10.1210/en.139.12.5255; KIELTY CM, 1985, BIOCHEM J, V227, P545, DOI 10.1042/bj2270545; Koyano Y, 2001, OSTEOARTHR CARTILAGE, V9, pS64, DOI 10.1053/joca.2001.0446; Koyano Y, 1997, BIOCHEM BIOPH RES CO, V241, P369, DOI 10.1006/bbrc.1997.7826; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Loeser RF, 2002, BIORHEOLOGY, V39, P119; Long FX, 2001, DEVELOPMENT, V128, P5099; LuValle P, 2000, FRONT BIOSCI-LANDMRK, V5, pD493, DOI 10.2741/LuValle; Magie CR, 1999, DEVELOPMENT, V126, P5353; Marlow F, 2002, CURR BIOL, V12, P876, DOI 10.1016/S0960-9822(02)00864-3; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; Negishi Y, 2000, BIOCHEM BIOPH RES CO, V268, P450, DOI 10.1006/bbrc.2000.2076; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; REICHENBERGER E, 1991, DEV BIOL, V148, P562, DOI 10.1016/0012-1606(91)90274-7; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rossi F, 2002, DEV BIOL, V247, P271, DOI 10.1006/dbio.2002.0691; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Schwabe GC, 2000, AM J HUM GENET, V67, P822, DOI 10.1086/303084; Segat D, 2002, J BIOL CHEM, V277, P31612, DOI 10.1074/jbc.M203471200; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Stanton LA, 2003, DEV BIOL, V263, P165, DOI 10.1016/S0012-1606(03)00321-X; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Thies E, 2003, J NEUROBIOL, V54, P358, DOI 10.1002/neu.10135; Tuckermann JP, 2000, J BONE MINER RES, V15, P1257, DOI 10.1359/jbmr.2000.15.7.1257; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van Bokhoven H, 2000, NAT GENET, V25, P423, DOI 10.1038/78113; Von der Mark K., 1986, RHEUMATOLOGY, V10; VONDERMARK K, 1977, NATURE, V267, P531, DOI 10.1038/267531a0; Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959-437X(00)00228-8; Wei L, 2002, DEVELOPMENT, V129, P1705; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7; Wunnenberg-Stapleton K, 1999, DEVELOPMENT, V126, P5339; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324; Yuan XB, 2003, NAT CELL BIOL, V5, P38, DOI 10.1038/ncb895; Zelzer E, 2003, NATURE, V423, P343, DOI 10.1038/nature01659; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhen XC, 2001, J BIOL CHEM, V276, P4879, DOI 10.1074/jbc.M004990200	103	105	108	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13205	13214		10.1074/jbc.M311427200	http://dx.doi.org/10.1074/jbc.M311427200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14726536	hybrid			2022-12-25	WOS:000220334900142
J	Herr, AJ; Wills, NM; Nelson, CC; Gesteland, RF; Atkins, JF				Herr, AJ; Wills, NM; Nelson, CC; Gesteland, RF; Atkins, JF			Factors that influence selection of coding resumption sites in translational bypassing - Minimal conventional peptidyl-tRNA : mRNA pairing can suffice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN L9; OPEN READING FRAMES; ESCHERICHIA-COLI; NASCENT PEPTIDE; BACTERIOPHAGE-T4; SEQUENCE; GENE-60; ELONGATION; EXPRESSION; SIGNALS	This study investigates bypassing initiated from codons immediately 5' of a stop codon. The mRNA slips and is scanned by the peptidyl-tRNA for a suitable landing site, and standard decoding resumes at the next 3' codon. This work shows that landing sites with potentially strong base pairing between the peptidyl-tRNA anticodon and mRNA are preferred, but sites with little or no potential for Watson-Crick or wobble base pairing can also be utilized. These results have implications for re-pairing in ribosomal frameshifting. Shine-Dalgarno sequences in the mRNA can alter the distribution of landing sites observed. The bacteriophage T4 gene 60 nascent peptide, known to influence take-off in its native context, imposes stringent P-site pairing requirements, thereby limiting the number of suitable landing sites.	Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Atkins, JF (corresponding author), Univ Utah, Dept Human Genet, 15 N 2030 E, Salt Lake City, UT 84112 USA.	john.atkins@genetics.utah.edu		Atkins, John/0000-0001-7933-0165; Herr, Alan/0000-0002-9498-0972	NIGMS NIH HHS [GM48152, 5T32GM07464-024] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048152, T32GM007464] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkins JF, 2001, COLD SPRING HARB SYM, V66, P217, DOI 10.1101/sqb.2001.66.217; Baranov PV, 2002, EMBO REP, V3, P373, DOI 10.1093/embo-reports/kvf065; BRIERLEY I, 1992, J MOL BIOL, V227, P463, DOI 10.1016/0022-2836(92)90901-U; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; CONDRON BG, 1991, NUCLEIC ACIDS RES, V19, P5607, DOI 10.1093/nar/19.20.5607; Gallant J, 2003, P NATL ACAD SCI USA, V100, P13430, DOI 10.1073/pnas.2233745100; Gallant JA, 1998, P NATL ACAD SCI USA, V95, P13771, DOI 10.1073/pnas.95.23.13771; Gao HX, 2003, CELL, V113, P789, DOI 10.1016/S0092-8674(03)00427-6; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; Gong F, 2002, SCIENCE, V297, P1864, DOI 10.1126/science.1073997; HERBST KL, 1994, P NATL ACAD SCI USA, V91, P12525, DOI 10.1073/pnas.91.26.12525; Herr AJ, 2000, ANNU REV BIOCHEM, V69, P343, DOI 10.1146/annurev.biochem.69.1.343; Herr AJ, 1999, EMBO J, V18, P2886, DOI 10.1093/emboj/18.10.2886; Herr AJ, 2000, EMBO J, V19, P2671, DOI 10.1093/emboj/19.11.2671; Herr AJ, 2001, J MOL BIOL, V311, P445, DOI 10.1006/jmbi.2001.4899; Herr AJ, 2001, J MOL BIOL, V309, P1029, DOI 10.1006/jmbi.2001.4717; Hoffman DW, 1996, J MOL BIOL, V264, P1058, DOI 10.1006/jmbi.1996.0696; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; Larsen B, 1995, BIOCHEM CELL BIOL, V73, P1123, DOI 10.1139/o95-121; LARSEN B, 1994, J BACTERIOL, V176, P6842, DOI 10.1128/JB.176.22.6842-6851.1994; Licznar P, 2003, EMBO J, V22, P4770, DOI 10.1093/emboj/cdg465; Lieberman KR, 2000, J MOL BIOL, V297, P1129, DOI 10.1006/jmbi.2000.3621; Lindsley D, 2003, MOL MICROBIOL, V48, P1267, DOI 10.1046/j.1365-2958.2003.03514.x; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Mejlhede N, 1999, J BACTERIOL, V181, P2930, DOI 10.1128/JB.181.9.2930-2937.1999; Miller JH., 1992, SHORT COURSE BACTERI, P72; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; OMAHONY DJ, 1989, P NATL ACAD SCI USA, V86, P7979, DOI 10.1073/pnas.86.20.7979; OPPENHEIM DS, 1980, GENETICS, V95, P785; PAGEL FT, 1992, J BACTERIOL, V174, P4179, DOI 10.1128/jb.174.12.4179-4182.1992; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; Valle M, 2003, CELL, V114, P123, DOI 10.1016/S0092-8674(03)00476-8; WEISS RB, 1990, CELL, V62, P117, DOI 10.1016/0092-8674(90)90245-A; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WEISS RB, 1988, EMBO J, V7, P1503, DOI 10.1002/j.1460-2075.1988.tb02969.x; Yu JS, 2001, MOL MICROBIOL, V42, P821, DOI 10.1046/j.1365-2958.2001.02681.x; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; YUSUPOVA GZ, 1986, FEBS LETT, V206, P142, DOI 10.1016/0014-5793(86)81356-4; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	42	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11081	11087		10.1074/jbc.M311491200	http://dx.doi.org/10.1074/jbc.M311491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707145	hybrid			2022-12-25	WOS:000220157600031
J	Morante, S; Gonzalez-Iglesias, R; Potrich, C; Meneghini, C; Meyer-Klaucke, W; Menestrina, G; Gasset, M				Morante, S; Gonzalez-Iglesias, R; Potrich, C; Meneghini, C; Meyer-Klaucke, W; Menestrina, G; Gasset, M			Inter- and intra-octarepeat Cu(II) site geometries in the prion protein - Implications in Cu(II) binding cooperativity and Cu(II)-mediated assemblies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ABSORPTION; BODY DISTRIBUTION-FUNCTIONS; COPPER-BINDING; QUERCETIN 2,3-DIOXYGENASE; CONDENSED MATTER; TERMINAL DOMAIN; SPECTROSCOPY; CU2+; IDENTIFICATION; TRAFFICKING	Cu(II) binding to the alpha prion protein (alphaPrP) can be both intramolecular and intermolecular. X-ray absorption spectroscopy at the copper K-edge has been used to explore the site geometry under each binding mode using both insoluble polymeric Cu(II).alphaBoPrP-(24-242) (bovine PrP) complexes and soluble Cu(II) complexes of peptides containing one, two, and four copies of the octarepeat. Analysis of the extended region of the spectra using a multiple scattering approach revealed two types of sites differing in the number of His residues in the first coordination shell of Cu(II). Peptides containing one and two-octarepeat copies in sub-stoichiometric Cu(II) complexes showed the direct binding of a single His in accord with crystallographic intra-repeat geometry. Alternatively, the polymeric Cu(II).alphaBoPrP-(24-242) complex and Cu(II) in its soluble complex with a four-octarepeat peptide at half-site-occupancy showed Cu(II) directly bound to two His residues, consistent with an inter-repeat binding mode. Increasing the Cu(II) site occupancy from 0.5 to 0.75 in the peptide containing four octarepeats resulted in spectral features that are intermediate to those of the inter-and intra-repeat modes. The transition from His-Cu-His (inter-repeat) to Cu-His (intra-repeat) on increasing Cu(II) saturation offers a structural basis for the positive cooperativity of the cation binding process and explains the capacity of alphaPrP to participate in Cu(II)-mediated intermolecular interactions.	CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; Univ Roma Tor Vergata, Dept Phys, I-00133 Rome, Italy; Ist Nazl Fis Mat, I-00133 Rome, Italy; CNR, Inst Trentino Cultura, Ist Biofis, Sez Trento, I-38050 Trent, Italy; Dept Phys E Amaldi, I-00146 Rome, Italy; European Synchrotron Radiat Facil, GILDA, Operat Grp Grenoble, F-38043 Grenoble, France; DESY, European Mol Biol Lab, D-22603 Hamburg, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); European Synchrotron Radiation Facility (ESRF); European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Gasset, M (corresponding author), CSIC, Inst Quim Fis Rocasolano, Serrano 119, E-28006 Madrid, Spain.	mgasset@iqfr.csic.es	Meyer-Klaucke, Wolfram/G-1148-2010; Gasset, Maria/K-4339-2012; Gasset, Maria/I-2050-2014; meneghini, carlo/F-7761-2013; Potrich, Cristina/AAR-7812-2020	Gasset, Maria/0000-0001-6436-4055; Gasset, Maria/0000-0001-6436-4055; meneghini, carlo/0000-0003-4846-8422; Potrich, Cristina/0000-0002-0793-7547; Morante, Silvia/0000-0002-3913-5733				Arnesano F, 2003, P NATL ACAD SCI USA, V100, P3814, DOI 10.1073/pnas.0636904100; Aronoff-Spencer E, 2000, BIOCHEMISTRY-US, V39, P13760, DOI 10.1021/bi001472t; BENFATTO M, 1986, PHYS REV B, V34, P5774, DOI 10.1103/PhysRevB.34.5774; Burns CS, 2002, BIOCHEMISTRY-US, V41, P3991, DOI 10.1021/bi011922x; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; Cereghetti GM, 2001, BIOPHYS J, V81, P516, DOI 10.1016/S0006-3495(01)75718-9; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Filipponi A, 1995, PHYS REV B, V52, P15135, DOI 10.1103/PhysRevB.52.15135; Filipponi A, 1995, PHYS REV B, V52, P15122, DOI 10.1103/PhysRevB.52.15122; Filipponi A., 2000, TASK Quarterly, V4, P575; Fusetti F, 2002, STRUCTURE, V10, P259, DOI 10.1016/S0969-2126(02)00704-9; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; Gonzalez-Iglesias R, 2004, FEBS LETT, V556, P161, DOI 10.1016/S0014-5793(03)01397-8; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; Hasnain SS, 2001, J MOL BIOL, V311, P467, DOI 10.1006/jmbi.2001.4795; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; LEE PA, 1981, REV MOD PHYS, V53, P769, DOI 10.1103/RevModPhys.53.769; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; Meneghini C, 1998, BIOPHYS J, V75, P1953, DOI 10.1016/S0006-3495(98)77636-2; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Nunziante M, 2003, J BIOL CHEM, V278, P3726, DOI 10.1074/jbc.M206313200; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Rachidi W, 2003, J BIOL CHEM, V278, P14595, DOI 10.1074/jbc.C300092200; Shaked Y, 2001, J VIROL, V75, P7872, DOI 10.1128/JVI.75.17.7872-7874.2001; Steiner RA, 2002, BIOCHEMISTRY-US, V41, P7963, DOI 10.1021/bi015974y; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; SULKOWSKI E, 1992, FEBS LETT, V307, P129, DOI 10.1016/0014-5793(92)80750-B; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Viles JH, 2001, BIOCHEMISTRY-US, V40, P2743, DOI 10.1021/bi002898a; Whittal RM, 2000, PROTEIN SCI, V9, P332; Wuthrich K, 2001, ADV PROTEIN CHEM, V57, P55	39	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11753	11759		10.1074/jbc.M312860200	http://dx.doi.org/10.1074/jbc.M312860200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14703517	hybrid			2022-12-25	WOS:000220157600112
J	Sommerer, F; Vieth, M; Markwarth, A; Rohrich, K; Vomschloss, S; May, A; Ell, C; Stolte, M; Hengge, UR; Wittekind, C; Tannapfel, A				Sommerer, F; Vieth, M; Markwarth, A; Rohrich, K; Vomschloss, S; May, A; Ell, C; Stolte, M; Hengge, UR; Wittekind, C; Tannapfel, A			Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma	ONCOGENE			English	Article						BRAF; KRAS2; barrett; neoplasia	B-RAF; CANCER; GENE; ACTIVATION; CARCINOMA; ESOPHAGUS; PROGRESSION; MELANOMA; PROTEINS; PATHWAY	Activation of the Raf/MEK/ERK (MAPK) signal transduction cascade by RAS mutations has been found in a variety of human cancers. Mutations of BRAF provide an alternative route for activation of this signalling pathway. To determine the role of mutations in BRAF and KRAS2 in the neoplastic progression of Barrett's adenocarcinoma, we analysed both genes for common mutations. After microdissection, DNA of 19 Barrett's adenocarcinomas, 56 Barrett's intraepithelial neoplasias (n=29 low-grade intraepithelial neoplasia (LGIN) and n=27 high-grade intraepithelial neoplasia (HGIN)), 30 Barrett's mucosa without neoplasia and normal squamous, as well as gastric epithelium, were analysed for BRAF and KRAS2 mutation. Activating BRAF mutations were identified in 2/19 Barrett's adenocarcinomas (11%) and in 1/27 HGIN (4%). KRAS2 mutations were found in four out of 19 (21%) Barrett's adenocarcinomas examined and in three cases of HGIN (11%). In LGIN as well as in normal gastric or oesophageal mucosa, neither BRAF nor KRAS2 mutations were detected. All lesions with KRAS2 mutations had an intact BRAF gene. The status of mismatch-repair proteins was neither related to BRAF nor KRAS2 mutations. These data indicate that RAS or BRAF mutations are detected in about 32% of all Barrett's adenocarcinomas. We conclude that the disruption of the Raf/MEK/ERK (MAPK) kinase pathway is a frequent but also early event in the development of Barrett's adenocarcinoma.	Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany; Otto Von Guericke Univ, Inst Pathol, D-39120 Magdeburg, Germany; HSK Clin Wiesbaden, Clin Internal Med 2, D-65199 Wiesbaden, Germany; Klinikum Bayreuth, Inst Pathol, D-95445 Bayreuth, Germany; Univ Dusseldorf, Dept Dermatol, D-4000 Dusseldorf, Germany	Leipzig University; Otto von Guericke University; Klinikum Bayreuth; Heinrich Heine University Dusseldorf	Tannapfel, A (corresponding author), Univ Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany.	tana@medizin.uni-leipzig.de						Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Arber N, 2000, GASTROENTEROLOGY, V118, P1045, DOI 10.1016/S0016-5085(00)70357-X; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Barrett MT, 1996, ONCOGENE, V13, P1867; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Dunn JR, 2003, ONCOGENE, V22, P4134, DOI 10.1038/sj.onc.1206466; Fitzgerald RC, 2003, GUT, V52, P16, DOI 10.1136/gut.52.1.16; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; HAMILTON SR, 2000, PATHOLOGY GENETICS, P173; Kimura ET, 2003, CANCER RES, V63, P1454; Leder A, 2002, ONCOGENE, V21, P6657, DOI 10.1038/sj.onc.1205795; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Morales CP, 2002, LANCET, V360, P1587, DOI 10.1016/S0140-6736(02)11569-8; Naoki K, 2002, CANCER RES, V62, P7001; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Ruschoff J, 1998, PATHOLOGE, V19, P269, DOI 10.1007/s002920050283; Satyamoorthy K, 2003, CANCER RES, V63, P756; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Spechler SJ, 2002, NEW ENGL J MED, V346, P836, DOI 10.1056/NEJMcp012118; Stahl J, 2000, ADV ANAT PATHOL, V7, P85, DOI 10.1097/00125480-200007020-00003; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Tselepis C, 2002, ONCOGENE, V21, P6071, DOI 10.1038/sj.onc.1205731; Weber A, 2003, ONCOGENE, V22, P4757, DOI 10.1038/sj.onc.1206705; Weber CK, 2001, CANCER RES, V61, P3595; Yuen ST, 2002, CANCER RES, V62, P6451	32	61	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					554	558		10.1038/sj.onc.1207189	http://dx.doi.org/10.1038/sj.onc.1207189			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724583				2022-12-25	WOS:000188098300026
J	Wang, Q; Wieder, R				Wang, Q; Wieder, R			All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells	ONCOGENE			English	Article						apoptosis; JNK; retinoic acid; Taxotere; breast cancer	ACTIVATED PROTEIN-KINASE; RECEPTOR-ALPHA; INDUCED APOPTOSIS; SIGNALING PATHWAYS; GROWTH-INHIBITION; TUMOR-CELLS; LNCAP CELLS; EXPRESSION; PHOSPHORYLATION; PROLIFERATION	Taxotere is a cytotoxin effective in treating breast and prostate cancer. It stabilizes microtubules and causes catastrophic cell cycle arrest in G2/M. Taxanes also initiate apoptosis by activating signal pathways, such as the jun N-terminal kinase (JNK) pathway. Strategies aimed at potentiating cell death signaling may improve their efficacy while lessening the potential side effects. We reported that all-trans retinoic acid (ATRA) potentiated taxane-mediated cell death. Here we investigated whether ATRA potentiates cell death signaling through the JNK pathway. Activation of JNK by Taxotere 0.01, 0.1 and 1.0 muM was observed at 24h in adherent cells and increased at 48h. Taxotere 0.001 muM-induced JNK activation started after 48h and increased at 72h. The timing and intensity of PARP cleavage was similar to that of JNK activation. JNK activation and PARP cleavage induced by 30 nM Taxotere at 48h were reversed by curcumin, PD169316 and SP600125, JNK inhibitors in order of progressive specificity. None of these inhibitors had an effect on p38 or ERK phosphorylation. All three inhibitors reversed Taxotere-induced phosphorylation of Bcl-2. ATRA induced JNK activation at 24, 48 and 72h. Incubating cells with ATRA 0.01 muM for 3 days prior to Taxotere treatment potentiated Taxotere-induced JNK activation 24 and 48h later, an effect sustained for 72h. Cytotoxicities from 3-day ATRA 0.01 muM incubations were synergistic with subsequent 1-h Taxotere 0.01, 0.1 and 1.0 muM incubations in breast cancer cell lines MCF-7 and MDA-MB-231 and in prostate cancer cell lines LNCaP and PC-3, and additive in breast cancer cell line SK-Br-3. These data demonstrate the potentiation of Taxotere-induced cell death by ATRA pretreatment in breast and prostate cancer cells, and support a mechanism through accentuated and sustained JNK activation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Hematol Oncol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Wieder, R (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Hematol Oncol, MSB I-596,185 S Orange Ave, Newark, NJ 07103 USA.	wiederro@umdnj.edu						Aapro M, 1996, ANTI-CANCER DRUG, V7, P33, DOI 10.1097/00001813-199608002-00009; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Consolini R, 1998, J CLIN ONCOL, V16, P907, DOI 10.1200/JCO.1998.16.3.907; Cosulich S, 1996, CURR BIOL, V6, P1586, DOI 10.1016/S0960-9822(02)70779-3; DAWSON MI, 1995, CANCER RES, V55, P4446; Fenig E, 1997, CLIN CANCER RES, V3, P135; Fitzgerald P, 1997, CANCER RES, V57, P2642; Flicker SH, 1997, CANCER LETT, V115, P63, DOI 10.1016/S0304-3835(97)04715-0; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; GRECO WR, 1995, PHARMACOL REV, V47, P331; Grunt TW, 1998, BRIT J CANCER, V78, P79, DOI 10.1038/bjc.1998.446; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Jones HE, 1997, PROSTATE, V30, P174; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Li MT, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-16; Liang JY, 1999, PROSTATE, V38, P228; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Masuda M, 2002, JPN J CANCER RES, V93, P329, DOI 10.1111/j.1349-7006.2002.tb02176.x; Moos PJ, 1998, CELL GROWTH DIFFER, V9, P687; Moreno-Manzano V, 1999, J BIOL CHEM, V274, P20251, DOI 10.1074/jbc.274.29.20251; Nabholtz J M, 2000, Expert Opin Pharmacother, V1, P187, DOI 10.1517/14656566.1.2.187; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Petras J, 2000, LAT AM PERSPECT, V27, P3, DOI 10.1177/0094582X0002700501; Rishi AK, 1996, CANCER RES, V56, P5246; Schneider SM, 2000, CANCER RES, V60, P5479; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Shiah SG, 2001, MOL PHARMACOL, V59, P254, DOI 10.1124/mol.59.2.254; Sommer KM, 1999, P NATL ACAD SCI USA, V96, P8651, DOI 10.1073/pnas.96.15.8651; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Sun SY, 1999, CANCER RES, V59, P2829; Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO;2-3; Torres K, 1998, CANCER RES, V58, P3620; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang H, 2001, FEBS LETT, V503, P91, DOI 10.1016/S0014-5793(01)02699-0; Wang Q, 2000, CANCER RES, V60, P2040; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wanner R, 2002, J MOL MED, V80, P61, DOI 10.1007/s00109-001-0288-0; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Widschwendter M, 1997, CANCER RES, V57, P4158; Wieder R, 1999, PRACT APPROACH SER, V215, P1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu XC, 1997, CANCER RES, V57, P4992; Yang CPH, 2002, BBA-MOL CELL RES, V1590, P76, DOI 10.1016/S0167-4889(02)00200-8; Yokoo T, 1997, AM J PHYSIOL-RENAL, V273, pF206, DOI 10.1152/ajprenal.1997.273.2.F206; YOUNG CYF, 1994, PROSTATE, V25, P39, DOI 10.1002/pros.2990250106; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350; Zheng A, 2000, ACTA HAEMATOL-BASEL, V103, P135, DOI 10.1159/000041036; Zou CP, 1998, CLIN CANCER RES, V4, P1345	56	51	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					426	433		10.1038/sj.onc.1207040	http://dx.doi.org/10.1038/sj.onc.1207040			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724571				2022-12-25	WOS:000188098300013
J	Pan, F; Ye, ZH; Cheng, LZ; Liu, JO				Pan, F; Ye, ZH; Cheng, LZ; Liu, JO			Myocyte enhancer factor 2 mediates calcium-dependent transcription of the interleukin-2 gene in T lymphocytes - A calcium signaling module that is distinct from but collaborates with the nuclear factor of activated T cells (NFAT).	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCINEURIN PHOSPHATASE-ACTIVITY; HISTONE DEACETYLASES; LENTIVIRAL VECTORS; CYCLOSPORINE-A; FACTOR MEF2; EXPRESSION; APOPTOSIS; CYCLOPHILIN; DIFFERENTIATION; ASSOCIATION	The second messenger calcium plays an essential role in the T cell receptor-mediated signal transduction pathways leading to transcription of the interleukin-2 gene. A key mechanism of calcium signaling has been shown to be mediated by calcineurin and NFAT. We report herein that the transcription factor myocyte enhancer factor (MEF)-2 is another calcium signal transducer involved in the regulation of the interleukin (IL)-2 promoter. A MEF2-binding site was identified in proximity to the TATA box of the IL-2 promoter. This site was shown to be bound by MEF2 in both resting and activated T cells. Overexpression of MEF2 enhanced, while overexpression of a dominant negative form of MEF2 or the MEF2-specific transcriptional corepressors Cabin1 and histone deacetylase 4 inhibited, the T cell receptor-dependent activation of an IL-2 reporter gene. Down-regulation of MEF2 by RNA interference in primary human T cells led to the inhibition of endogenous IL-2 transcription. These results suggest that MEF2 is required for the transcriptional activation of IL-2 and likely other cytokine genes in response to calcium signaling and may serve as a novel target for development of immunosuppressants.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Div Immunol & Hematopoiesis, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Liu, JO (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Hunterian Bldg,Rm 516,725 N Wolfe St, Baltimore, MD 21205 USA.	joliu@jhu.edu		Ye, Zhaohui/0000-0001-5272-9168	NIGMS NIH HHS [GM55783] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055783] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Cavalieri S, 2003, BLOOD, V102, P497, DOI 10.1182/blood-2003-01-0297; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cui Y, 2002, BLOOD, V99, P399, DOI 10.1182/blood.V99.2.399; Esau C, 2001, J EXP MED, V194, P1449, DOI 10.1084/jem.194.10.1449; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, EUR J IMMUNOL, V22, P2513, DOI 10.1002/eji.1830221008; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Ornatsky OI, 1997, J BIOL CHEM, V272, P33271, DOI 10.1074/jbc.272.52.33271; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SMITH KA, 1992, CURR OPIN IMMUNOL, V4, P271, DOI 10.1016/0952-7915(92)90076-Q; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Zhou XZ, 2003, HUM GENE THER, V14, P1089, DOI 10.1089/104303403322124800	34	57	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14477	14480		10.1074/jbc.C300487200	http://dx.doi.org/10.1074/jbc.C300487200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722108	hybrid			2022-12-25	WOS:000220594700002
J	Ruotolo, R; Peracchi, A; Bolchi, A; Infusini, G; Amoresano, A; Ottonello, S				Ruotolo, R; Peracchi, A; Bolchi, A; Infusini, G; Amoresano, A; Ottonello, S			Domain organization of phytochelatin synthase - Functional properties of truncated enzyme species identified by limited proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-METAL DETOXIFICATION; ARABIDOPSIS-THALIANA; BINDING PEPTIDES; PLANTS; GLUTATHIONE; TOLERANCE; MUTANTS; GENE	Phytochelatin synthase (PCS) is a major determinant of heavy metal tolerance in plants and other organisms. No structural information on this enzyme is as yet available. It is generally believed, however, that the active site region is located in the more conserved N-terminal portion of PCS, whereas various, as yet unidentified ( but supposedly less critical) roles have been proposed for the C-terminal region. To gain insight into the structural/ functional organization of PCS, we have conducted a limited proteolysis analysis of the enzyme from Arabidopsis (AtPCS1), followed by functional characterization of the resulting polypeptide fragments. Two N-terminal fragments ending at positions 372 (PCS_Nt1) and 283 (PCS_Nt2) were produced sequentially upon V8 protease digestion, without any detectable accumulation of the corresponding C-terminal fragments. As revealed by the results of in vivo and in vitro functional assays, the core PCS_Nt2 fragment is biosynthetically active in the presence of cadmium ions and supports phytochelatin formation at a rate that is only similar to5-fold lower than that of full-length AtPCS1. The loss of the C-terminal region, however, substantially decreases the thermal stability of the enzyme and impairs phytochelatin formation in the presence of certain heavy metals ( e. g. mercury and zinc, but not cadmium or copper). The latter phenotype was shared by PCS_Nt2 and by its precursor fragment PCS_Nt1, which, on the other hand, was almost as stable and biosynthetically active ( in the presence of cadmium) as the full-length enzyme. AtPCS1 thus appears to be composed of a protease-resistant ( and hence presumably highly structured) N-terminal domain, flanked by an intrinsically unstable C-terminal region. The most upstream part of such a region ( positions 284 - 372) is important for enzyme stabilization, whereas its most terminal part ( positions 373 - 485) appears to be required to determine enzyme responsiveness to a broader range of heavy metals.	Univ Parma, Dipartimento Biochim & Biol Mol, I-43100 Parma, Italy; Univ Naples Federico II, Dipartimento Chim Organ & Biochim, I-80134 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); University of Parma; University of Naples Federico II	Ottonello, S (corresponding author), Univ Parma, Dipartimento Biochim & Biol Mol, I-43100 Parma, Italy.	s.ottonello@unipr.it	Bolchi, Angelo/GOJ-9730-2022; Ruotolo, Roberta/GVU-0360-2022; Peracchi, Alessio/G-5167-2012; Peracchi, Alessio/Q-5173-2019	Peracchi, Alessio/0000-0003-3254-4099; Peracchi, Alessio/0000-0003-3254-4099; AMORESANO, Angela/0000-0002-8386-655X				Clemens S, 2001, EUR J BIOCHEM, V268, P3640, DOI 10.1046/j.1432-1327.2001.02293.x; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett C, 2002, ANNU REV PLANT BIOL, V53, P159, DOI 10.1146/annurev.arplant.53.100301.135154; Cobbett CS, 2000, CURR OPIN PLANT BIOL, V3, P211, DOI 10.1016/S1369-5266(00)00066-2; DEKNECHT JA, 1994, PLANT PHYSIOL, V104, P255, DOI 10.1104/pp.104.1.255; Di Toppi LS, 2002, PHYSIOLOGY AND BIOCHEMISTRY OF METAL TOXICITY AND TOLERANCE IN PLANTS, P59; GRILL E, 1989, P NATL ACAD SCI USA, V86, P6838, DOI 10.1073/pnas.86.18.6838; GRILL E, 1987, P NATL ACAD SCI USA, V84, P439, DOI 10.1073/pnas.84.2.439; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; Heiss S, 2003, J EXP BOT, V54, P1833, DOI 10.1093/jxb/erg205; HOWDEN R, 1995, PLANT PHYSIOL, V107, P1059, DOI 10.1104/pp.107.4.1059; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanfranco L, 2002, PLANT PHYSIOL, V130, P58, DOI 10.1104/pp.003525; Maier T, 2003, PLANTA, V218, P300, DOI 10.1007/s00425-003-1091-7; Maitani T, 1996, PLANT PHYSIOL, V110, P1145, DOI 10.1104/pp.110.4.1145; MINET M, 1992, PLANT J, V2, P417; Oven M, 2002, J BIOL CHEM, V277, P4747, DOI 10.1074/jbc.M108254200; Rauser WE, 1999, CELL BIOCHEM BIOPHYS, V31, P19, DOI 10.1007/BF02738153; SCHELLER HV, 1987, PLANT PHYSIOL, V85, P1031, DOI 10.1104/pp.85.4.1031; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vatamaniuk OK, 2001, J BIOL CHEM, V276, P20817, DOI 10.1074/jbc.C100152200; Vatamaniuk OK, 2000, J BIOL CHEM, V275, P31451, DOI 10.1074/jbc.M002997200; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2	25	65	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14686	14693		10.1074/jbc.M314325200	http://dx.doi.org/10.1074/jbc.M314325200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14729665	hybrid			2022-12-25	WOS:000220594700028
J	Decher, N; Chen, J; Sanguinetti, MC				Decher, N; Chen, J; Sanguinetti, MC			Voltage-dependent gating of hyperpolarization-activated, cyclic nucleotide-gated pacemaker channels - Molecular coupling between the S4-S5 and C-linkers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNELS; POTASSIUM CHANNELS; STRUCTURAL BASIS; XENOPUS-OOCYTES; CATION CHANNEL; ION CHANNELS; MODULATION; SENSOR	Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels have a transmembrane topology that is highly similar to voltage-gated K+ channels, yet HCN channels open in response to membrane hyperpolarization instead of depolarization. The structural basis for the "inverted" voltage dependence of HCN gating and how voltage sensing by the S1-S4 domains is coupled to the opening of the intracellular gate formed by the S6 domain are unknown. Coupling could arise from interaction between specific residues or entire transmembrane domains. We previously reported that the mutation of specific residues in the S4-S5 linker of HCN2 (i.e. Tyr-331 and Arg-339) prevented normal channel closure presumably by disruption of a crucial interaction with the activation gate. Here we hypothesized that the Clinker, a carboxyl terminus segment that connects S6 to the cyclic nucleotide binding domain, interacts with specific residues of the S4-S5 linker to mediate coupling. The recently solved structure of the C-linker of HCN2 indicates that an alpha-helix (the A'-helix) is located near the end of each S6 domain, the presumed location of the activation gate. Ala-scanning mutagenesis of the end of S6 and the A'-helix identified five residues that were important for normal gating as mutations disrupted channel closure. However, partial deletion of the C-linker indicated that the presence of only two of these residues was required for normal coupling. Further mutation analyses suggested that a specific electrostatic interaction between Arg-339 of the S4-S5 linker and Asp-443 of the C-linker stabilizes the closed state and thus participates in the coupling of voltage sensing and activation gating in HCN channels.	Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA; Univ Utah, Dept Physiol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Sanguinetti, MC (corresponding author), Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, 95 S 2000 E, Salt Lake City, UT 84112 USA.	michael.sanguinetti@hmbg.utah.edu	Decher, Niels/AAF-5002-2020; Sanguinetti, Michael/AAN-2615-2020		NHLBI NIH HHS [HL65299] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065299] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen J, 2000, J BIOL CHEM, V275, P36465, DOI 10.1074/jbc.M007034200; Chen J, 2001, P NATL ACAD SCI USA, V98, P11277, DOI 10.1073/pnas.201250598; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GOLDIN AL, 1991, METHOD CELL BIOL, V36, P487; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Larsson HP, 2002, J GEN PHYSIOL, V120, P475, DOI 10.1085/jgp.20028657; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Proenza C, 2002, J BIOL CHEM, V277, P5101, DOI 10.1074/jbc.M106974200; Rothberg BS, 2003, J GEN PHYSIOL, V122, P501, DOI 10.1085/jgp.200308928; Rothberg BS, 2002, J GEN PHYSIOL, V119, P83, DOI 10.1085/jgp.119.1.83; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Silverman WR, 2003, P NATL ACAD SCI USA, V100, P2935, DOI 10.1073/pnas.0636603100; STUEHMER W, 1992, METHOD ENZYMOL, V207, P319; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; Tristani-Firouzi M, 2002, J BIOL CHEM, V277, P18994, DOI 10.1074/jbc.M200410200; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922; Zong XG, 1998, EMBO J, V17, P353, DOI 10.1093/emboj/17.2.353	27	98	100	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13859	13865		10.1074/jbc.M313704200	http://dx.doi.org/10.1074/jbc.M313704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726518	hybrid			2022-12-25	WOS:000220478500072
J	Tsujita, K; Itoh, T; Ijuin, T; Yamamoto, A; Shisheva, A; Laporte, J; Takenawa, T				Tsujita, K; Itoh, T; Ijuin, T; Yamamoto, A; Shisheva, A; Laporte, J; Takenawa, T			Myotubularin regulates the function of the late endosome through the GRAM domain-phosphatidylinositol 3,5-bisphosphate interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; HIGH-AFFINITY BINDING; INOSITOL PHOSPHATES; PROTEIN-KINASE; MUTATIONS; GENE; MYOPATHY; PHOSPHOINOSITIDES; PTDINS(3,5)P-2; 3-PHOSPHATE	Myotubularin and related proteins constitute a large and highly conserved family possessing phosphoinositide 3-phosphatase activity, although not all members possess this activity. This family contains a conserved region called the GRAM domain that is found in a variety of proteins associated with membrane-coupled processes and signal transduction. Mutations of myotubularin are found in X-linked myotubular myopathy, a severe muscle disease. Mutations in the GRAM domain are responsible for this condition, suggesting crucial roles for this region. Here, we show that the GRAM domain of myotubularin binds to phosphoinositide with the highest affinity to phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5) P-2). In patients with myotubular myopathy, mutations in the myotubularin GRAM domain eliminate this binding, indicating that the PtdIns(3,5) P-2 binding ability of the GRAM (glucosyltransferases, Rab-like GTPase activators and myotubularin) domain is crucial for the functions of myotubularin in vivo. Stimulation of epidermal growth factor recruits myotubularin to the late endosomal compartment in a manner dependent on the phosphoinositide binding. Overexpression of myotubularin inhibits epidermal growth factor receptor trafficking from late endosome to lysosome and induces the large endosomal vacuoles. Thus, our data suggest that myotubularin phosphatase physiologically functions in late endosomal trafficking and vacuolar morphology through interaction with PtdIns(3,5) P-2.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; JST, Minato Ku, Tokyo 1088639, Japan; Nagahama Inst Biosci & Technol, Dept Biosci, Tamura, Nagahama 5260829, Japan; Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; Inst Genet & Biol Mol & Cellulaire, Equipe Genet Humaine, F-67404 Illkirch Graffenstaden, France	University of Tokyo; Japan Science & Technology Agency (JST); Wayne State University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	takenawa@ims.u-tokyo.ac.jp	Laporte, Jocelyn/H-6801-2016; Ijuin, Takeshi/H-7016-2017; laporte, jocelyn/J-7008-2012; laporte, jocelyn/O-4888-2019	Ijuin, Takeshi/0000-0002-0618-1776; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058058] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-58058] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berger P, 2003, P NATL ACAD SCI USA, V100, P12177, DOI 10.1073/pnas.2132732100; Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Bolino A, 2000, NAT GENET, V25, P17, DOI 10.1038/75542; Buj-Bello A, 2002, P NATL ACAD SCI USA, V99, P15060, DOI 10.1073/pnas.212498399; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; deGouyon BM, 1997, HUM MOL GENET, V6, P1499, DOI 10.1093/hmg/6.9.1499; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P483, DOI 10.1016/S0968-0004(00)01664-9; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Friant S, 2003, DEV CELL, V5, P499, DOI 10.1016/S1534-5807(03)00238-7; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Herman GE, 2002, HUM MUTAT, V19, P114, DOI 10.1002/humu.10033; Ikonomov OC, 2002, J BIOL CHEM, V277, P46785, DOI 10.1074/jbc.M208068200; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Laporte J, 1997, HUM MOL GENET, V6, P1505, DOI 10.1093/hmg/6.9.1505; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Laporte J, 2001, TRENDS GENET, V17, P221, DOI 10.1016/S0168-9525(01)02245-4; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Misra S, 2001, CELL, V107, P559, DOI 10.1016/S0092-8674(01)00594-3; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; Shaw JD, 2003, TRAFFIC, V4, P479, DOI 10.1034/j.1600-0854.2003.t01-1-00106.x; Shisheva A, 2001, J BIOL CHEM, V276, P11859, DOI 10.1074/jbc.M008437200; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Stenmark H, 2001, SEMIN CELL DEV BIOL, V12, P193, DOI 10.1006/scdb.2000.0236; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	34	118	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13817	13824		10.1074/jbc.M312294200	http://dx.doi.org/10.1074/jbc.M312294200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722070	hybrid			2022-12-25	WOS:000220478500067
J	Charles, N; Monteiro, RC; Benhamou, M				Charles, N; Monteiro, RC; Benhamou, M			p28, a novel IgE receptor-associated protein, is a sensor of receptor occupation by its ligand in mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; HIGH-AFFINITY RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; TYROSINE PHOSPHORYLATION; PHOSPHOLIPID SCRAMBLASE; IMMUNOGLOBULIN-E; MONOCLONAL-ANTIBODIES; UP-REGULATION; GAMMA-CHAIN; BINDING	Mast cells express the high affinity receptor for IgE (FcepsilonRI). Aggregation of this receptor by IgE and antigen leads to a signaling cascade resulting in the secretion of histamine, in the synthesis of other pro-inflammatory mediators such as leukotrienes and prostaglandins, and in the production of various cytokines, all of which participate in the development of the allergic reaction. In the last years, growing evidence accumulated that binding of IgEs to FcepsilonRI in itself induces active signals leading to mast cell survival, increased expression of FcepsilonRI, transient induction of histidine decarboxylase synthesis, and increased cell adhesion. The mechanisms underlying monomeric IgE signaling in the absence of receptor aggregation are still poorly understood. Here, we show that a protein of 28 kDa (p28) is physically and constitutively associated with FcepsilonRI in mast cells. Coimmunoprecipitation studies from I-125 surface-labeled cells demonstrated that this association involves at least 50% of membrane-expressed FcepsilonRI. After the addition of monomeric IgE to the cells, the p28.FcepsilonRI complex dissociates almost completely in less than 2 min. This dissociation is temperature-sensitive and is not due to the recruitment of additional proteins to the complex. Stripping bound IgE from the cells by acidic treatment promotes a rapid reassociation between p28 and FcepsilonRI. Altogether, these data are consistent with a conformational regulation of the complex. Thus, p28 is a sensor for FcepsilonRI occupation by IgE on mast cells, and its dissociation from the receptor could represent an early step of monomeric IgE signaling.	Fac Xavier Bichat, INSERM, EMI0225, F-75870 Paris 18, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Benhamou, M (corresponding author), Fac Xavier Bichat, INSERM, EMI0225, 16 Rue Henri Huchard, F-75870 Paris 18, France.	benhamou@bichat.inserm.fr	Monteiro, Renato C/U-8633-2017; CHARLES, Nicolas/P-5430-2014; CHARLES, Nicolas/S-2214-2019	Monteiro, Renato C/0000-0001-5202-5646; CHARLES, Nicolas/0000-0002-5416-5834; CHARLES, Nicolas/0000-0002-5416-5834; Benhamou, Marc/0000-0001-7763-3795				Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; EISEMAN E, 1992, NATURE, V355, P78; FRANDJI P, 1995, CELL IMMUNOL, V163, P37, DOI 10.1006/cimm.1995.1096; FURUICHI K, 1985, P NATL ACAD SCI USA, V82, P1522, DOI 10.1073/pnas.82.5.1522; Garman SC, 2001, J MOL BIOL, V311, P1049, DOI 10.1006/jmbi.2001.4929; GERMANO P, 1994, J BIOL CHEM, V269, P23102; Hsu C, 1996, IMMUNOL LETT, V52, P129, DOI 10.1016/0165-2478(96)02599-0; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; ISERSKY C, 1979, J IMMUNOL, V122, P1926; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kimura T, 1997, J IMMUNOL, V159, P4426; Kubo S, 2001, J IMMUNOL, V167, P3427, DOI 10.4049/jimmunol.167.6.3427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam V, 2003, BLOOD, V102, P1405, DOI 10.1182/blood-2002-10-3176; LIU FT, 1980, J IMMUNOL, V124, P2728; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; Mecheri S, 1997, IMMUNOL TODAY, V18, P212; Mekori YA, 2000, IMMUNOL REV, V173, P131, DOI 10.1034/j.1600-065X.2000.917305.x; Nadler M J, 2000, Adv Immunol, V76, P325; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Pastorelli C, 2002, MOL IMMUNOL, V38, P1235, DOI 10.1016/S0161-5890(02)00069-X; Pastorelli C, 2001, J BIOL CHEM, V276, P20407, DOI 10.1074/jbc.M100790200; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; STRACKE ML, 1987, MOL IMMUNOL, V24, P347, DOI 10.1016/0161-5890(87)90176-3; Tanaka S, 2002, J EXP MED, V196, P229, DOI 10.1084/jem.20012037; Tkaczyk C, 2000, J ALLERGY CLIN IMMUN, V105, P134, DOI 10.1016/S0091-6749(00)90188-X; Wan T, 2002, NAT IMMUNOL, V3, P681, DOI 10.1038/ni811; Wang HW, 1998, J CLIN INVEST, V102, P1617, DOI 10.1172/JCI3704; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; Williamson P, 2002, BBA-MOL CELL BIOL L, V1585, P53, DOI 10.1016/S1388-1981(02)00324-4; Wurzburg BA, 2002, MOL IMMUNOL, V38, P1063, DOI 10.1016/S0161-5890(02)00035-4; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; Yano K, 1997, LAB INVEST, V77, P185	41	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12312	12318		10.1074/jbc.M309456200	http://dx.doi.org/10.1074/jbc.M309456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715661	hybrid			2022-12-25	WOS:000220334900038
J	Forouhar, F; Lee, I; Benach, J; Kulkarni, K; Xiao, R; Acton, TB; Montelione, GT; Tong, L				Forouhar, F; Lee, I; Benach, J; Kulkarni, K; Xiao, R; Acton, TB; Montelione, GT; Tong, L			A novel NAD-binding protein revealed by the crystal structure of 2,3-diketo-L-gulonate reductase (YiaK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CARBOHYDRATE UTILIZATION; PROGRAM; DIFFRACTION; METABOLISM; EXPRESSION; SEQUENCE; OPERON; ACID; SITE	Escherichia coli YiaK catalyzes the reduction of 2,3-diketo-L-gulonate in the presence of NADH. It belongs to a large family of oxidoreductases that is conserved in archaea, bacteria, and eukaryotes but shows no sequence homology to other proteins. We report here the crystal structures at up to 2.0-Angstrom resolution of YiaK alone and in complex with NAD-tartrate. YiaK has a new polypeptide backbone fold and a novel mode of recognizing the NAD cofactor. In addition, NAD is bound in an unusual conformation, at the interface of a dimer of the enzyme. The crystallographic analysis unexpectedly revealed the binding of tartrate in the active site. Enzyme kinetics studies confirm that tartrate and the related D-malate are inhibitors of YiaK. In contrast to most other enzymes where substrate binding produces a more closed conformation, the binding of NAD-tartrate to YiaK produces a more open active site. The free enzyme conformation is incompatible with NAD binding. His(44) is likely the catalytic residue of the enzyme.	Columbia Univ, Dept Biol Sci, NE Struct Genom Consortium, New York, NY 10027 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, NE Struct Genom Consortium, Piscataway, NJ 08854 USA	Columbia University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, NE Struct Genom Consortium, New York, NY 10027 USA.	tong@como.bio.columbia.edu		Montelione, Gaetano/0000-0002-9440-3059; Tong, Liang/0000-0002-0563-6468	NIGMS NIH HHS [P50 GM 62413] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Badia J, 1998, J BIOL CHEM, V273, P8376, DOI 10.1074/jbc.273.14.8376; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; Doublie S, 1996, FEBS LETT, V384, P219, DOI 10.1016/0014-5793(96)00316-X; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ibanez E, 2000, J BACTERIOL, V182, P4617, DOI 10.1128/JB.182.16.4617-4624.2000; Ibanez E, 2000, J BACTERIOL, V182, P4625, DOI 10.1128/JB.182.16.4625-4627.2000; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Saridakis V, 2003, J BIOL CHEM, V278, P34356, DOI 10.1074/jbc.M205369200; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VOLK WA, 1962, J BIOL CHEM, V237, P2454; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Yew WS, 2002, J BACTERIOL, V184, P302, DOI 10.1128/JB.184.1.302-306.2002	25	9	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13148	13155		10.1074/jbc.M313580200	http://dx.doi.org/10.1074/jbc.M313580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718529	hybrid			2022-12-25	WOS:000220334900136
J	Wernimont, AK; Yatsunyk, LA; Rosenzweig, AC				Wernimont, AK; Yatsunyk, LA; Rosenzweig, AC			Binding of copper(I) by the Wilson disease protein and its copper chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; TRANSPORTING ATPASE ATP7B; P-TYPE ATPASES; MENKES-DISEASE; SACCHAROMYCES-CEREVISIAE; ATX1 METALLOCHAPERONE; FUNCTIONAL EXPRESSION; SUPEROXIDE-DISMUTASE; CATALYTIC-ACTIVITY; GENE	The Wilson disease protein (WND) is a transport ATPase involved in copper delivery to the secretory pathway. Mutations in WND and its homolog, the Menkes protein, lead to genetic disorders of copper metabolism. The WND and Menkes proteins are distinguished from other P-type ATPases by the presence of six soluble N-terminal metal-binding domains containing a conserved CXXC metal-binding motif. The exact roles of these domains are not well established, but possible functions include exchanging copper with the metallochaperone Atox1 and mediating copper-responsive cellular relocalization. Although all six domains can bind copper, genetic and biochemical studies indicate that the domains are not functionally equivalent. One way the domains could be tuned to perform different functions is by having different affinities for Cu(I). We have used isothermal titration calorimetry to measure the association constant (K-a) and stoichiometry (n) values of Cu(I) binding to the WND metal-binding domains and to their metallochaperone Atox1. The association constants for both the chaperone and target domains are similar to10(5) to 10(6) M-1, suggesting that the handling of copper by Atox1 and copper transfer between Atox1 and WND are under kinetic rather than thermodynamic control. Although some differences in both n and K-a values are observed for variant proteins containing less than the full complement of six metal-binding domains, the data for domains 1-6 were best fitted with a single site model. Thus, the individual functions of the six WND metal-binding domains are not conferred by different Cu(I) affinities but instead by fold and electrostatic surface properties.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Rosenzweig, AC (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	amyr@northwestern.edu			NIGMS NIH HHS [GM 008061, GM 58518] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058518] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Banci L, 2001, BIOCHEMISTRY-US, V40, P15660, DOI 10.1021/bi0112715; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; DASILVA JJR, 2001, BIOL CHEM ELEMENTS, P431; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Elam JS, 2002, ADV PROTEIN CHEM, V60, P151; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HIROSE J, 1982, ARCH BIOCHEM BIOPHYS, V218, P179, DOI 10.1016/0003-9861(82)90334-4; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; Jensen PY, 1999, BBA-PROTEIN STRUCT M, V1434, P103, DOI 10.1016/S0167-4838(99)00161-2; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Llanos RM, 2002, DNA CELL BIOL, V21, P259, DOI 10.1089/104454902753759681; Lutsenko S, 2002, J BIOENERG BIOMEMBR, V34, P351, DOI 10.1023/A:1021297919034; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; OBRIEN R, 2001, PROTEIN LIGAND INTER, P263; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; Pierce MM, 1999, METHODS, V19, P213, DOI 10.1006/meth.1999.0852; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ralle M, 2003, J BIOL CHEM, V278, P23163, DOI 10.1074/jbc.M303474200; Ralle M, 1998, J AM CHEM SOC, V120, P13525, DOI 10.1021/ja982990i; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Strausak D, 2003, J BIOL CHEM, V278, P20821, DOI 10.1074/jbc.M212437200; SYVERTSEN C, 1986, J INORG BIOCHEM, V26, P63, DOI 10.1016/0162-0134(86)80037-X; Tao TY, 2003, J BIOL CHEM, V278, P41593, DOI 10.1074/jbc.C300391200; Terada K, 1998, J BIOL CHEM, V273, P1815, DOI 10.1074/jbc.273.3.1815; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	48	70	71	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12269	12276		10.1074/jbc.M311213200	http://dx.doi.org/10.1074/jbc.M311213200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709553	hybrid			2022-12-25	WOS:000220334900033
J	Davidson, L; Pawson, AJ; de Maturana, RL; Freestone, SH; Barran, P; Millar, RP; Maudsley, S				Davidson, L; Pawson, AJ; de Maturana, RL; Freestone, SH; Barran, P; Millar, RP; Maudsley, S			Gonadotropin-releasing hormone-induced activation of diacylglycerol kinase-zeta and its association with active c-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PHOSPHOLIPASE-C; PHORBOL ESTER; SH3 DOMAIN; CELLS; ACID; BINDING; TRANSLOCATION; INHIBITION; MECHANISM	Gonadotropin-releasing hormone (GnRH)-induced receptor activation has been demonstrated to entrain a wide variety of signaling modalities. Most signaling pathways are concerned with the control of serine, threonine, or tyrosine-protein kinases, however, in the current article we demonstrate that in both a model cell line and in gonadotropes, GnRH additionally mediates the activation of lipid-directed kinases. We have shown that there is a functional connection between protein-tyrosine kinase modulation and lipid kinase activation. In HEK293 cells stably expressing the Type I mammalian GnRH receptor, we employed a proteomic approach to identify novel protein binding partners for GnRH-activated c-Src. Using matrix-assisted laser desorption ionization time-of-flight mass spectrometry we identified a GnRH-induced association between c-Src and the lipid kinase, diacylglycerol kinase-zeta (DGK-zeta). Using reciprocal co-immunoprecipitation we show that there is a significant elevation of the association between catalytically active c-Src with DGK-zeta in both HEK293 cells and murine gonadotrope LbetaT2 cells. Employing lipid kinase assays we have shown that the catalytic activity of DGK-zeta is significantly heightened in both HEK293 and LbetaT2 cells by GnRH. In addition, we demonstrate that the activation of DGK-zeta exerts a functional role in the murine gonadotrope LbetaT2 cell line. Elevated expression of DGK-zeta resulted in a shortening of the time scale of ERK activation in these cells suggesting a potential role of endogenous DGK-zeta in controlling the induction of LHbeta transcription by ERK1/2.	Univ Edinburgh, Royal Infirm Edinburgh, MRC, Human Reprod Sci Unit, Edinburgh EH16 4SB, Midlothian, Scotland; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; Ardana Biosci, Edinburgh EH2 3NS, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Maudsley, S (corresponding author), Univ Edinburgh, Royal Infirm Edinburgh, MRC, Human Reprod Sci Unit, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.	s.maudsley@hrsu.mrc.ac.uk	Millar, Robert P/A-4853-2012; Maudsley, Stuart/Q-4782-2019; Barran, Perdita/AAY-6303-2021; Pawson, Adam J/Q-5678-2016; Maudsley, Stuart/AAV-9929-2021	Pawson, Adam J/0000-0003-2280-845X; Maudsley, Stuart/0000-0002-1868-184X; Millar, Robert P/0000-0003-3606-2708	Medical Research Council [U.1276.00.005.00002.01 (85842), MC_U127685842] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDERSON L, 1995, ENDOCRINOLOGY, V136, P5228, DOI 10.1210/en.136.11.5228; ARNOLD S, 1998, BIOCHEMISTRY-US, V37, P14683; Badola P, 1997, J BIOL CHEM, V272, P24176, DOI 10.1074/jbc.272.39.24176; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; CHOI KY, 1994, CELL, V78, P499; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; Davidson L, 2004, J BIOL CHEM, V279, P1980, DOI 10.1074/jbc.M309827200; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; Ebinu JO, 2000, BLOOD, V95, P3199; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Fukami Y, 2002, PHARMACOL THERAPEUT, V93, P263, DOI 10.1016/S0163-7258(02)00195-X; HARDEN N, 1993, BIOCHEM J, V289, P439, DOI 10.1042/bj2890439; Harris BZ, 2001, J CELL SCI, V114, P3219; ISHITOYA J, 1987, BIOCHEM BIOPH RES CO, V144, P1025, DOI 10.1016/S0006-291X(87)80066-9; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee S, 2003, MOL CELLS, V15, P313; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; OHANIAN J, 1994, BIOCHEM J, V300, P51, DOI 10.1042/bj3000051; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Santos T, 2002, J BIOL CHEM, V277, P30300, DOI 10.1074/jbc.M200999200; Schnapp BJ, 2003, J CELL SCI, V116, P2125, DOI 10.1242/jcs.00488; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; SUDOL M, 1993, ONCOGENE, V8, P823; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Tsuganezawa H, 2002, KIDNEY INT, V62, P41, DOI 10.1046/j.1523-1755.2002.00418.x; VANDERBEND RL, 1994, J BIOL CHEM, V269, P4098; Willars GB, 2001, J BIOL CHEM, V276, P3123, DOI 10.1074/jbc.M008916200	41	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11906	11916		10.1074/jbc.M310784200	http://dx.doi.org/10.1074/jbc.M310784200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707140	hybrid			2022-12-25	WOS:000220157600128
J	Hambrock, HO; Kaufmann, B; Muller, S; Hanisch, FG; Nose, K; Paulsson, M; Maurer, P; Hartmann, U				Hambrock, HO; Kaufmann, B; Muller, S; Hanisch, FG; Nose, K; Paulsson, M; Maurer, P; Hartmann, U			Structural characterization of TSC-36/Flik - Analysis of two charge isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLISTATIN-RELATED PROTEIN; CALCIUM-BINDING PROTEIN; MOLECULAR-CLONING; COLLAGEN-IV; BM-40 SPARC; GENE; EXPRESSION; OSTEONECTIN; TRANSCRIPTION; RECOMBINANT	Recombinant forms of the glycoprotein TSC-36/Flik were expressed in human cells and used to compare their structural and functional properties with those described for other members of the BM-40/SPARC/osteonectin protein family. TSC-36 was found to occur in two charge isoforms that differ in the extent of sialylation of otherwise identical N-linked, complex type oligosaccharides. Conformational analysis with both circular dichroism and intrinsic fluorescence spectroscopy showed a lack of significant structural changes upon calcium addition or depletion. This finding is in contrast to results obtained for several other BM-40 family members and indicates that the extracellular calcium-binding domain in TSC-36 is non-functional. The lack of conservation of important functional features common to several other members of the BM-40 family indicates that TSC-36, despite its sequence homology to BM-40, has evolved clearly distinct properties.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med, D-50931 Cologne, Germany; Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Tokyo 1428555, Japan	University of Cologne; University of Cologne; Showa University	Hartmann, U (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	ursula.hartmann@uni-koeln.de						ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; Amthor H, 1996, DEV BIOL, V178, P343, DOI 10.1006/dbio.1996.0223; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; Hambrock HO, 2003, J BIOL CHEM, V278, P11351, DOI 10.1074/jbc.M212291200; Hartmann U, 2001, MATRIX BIOL, V20, P23, DOI 10.1016/S0945-053X(00)00137-2; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mashimo J, 1997, CANCER LETT, V113, P213, DOI 10.1016/S0304-3835(97)04700-9; MAURER P, 1992, EUR J BIOCHEM, V205, P233, DOI 10.1111/j.1432-1033.1992.tb16773.x; Maurer P, 1997, CELL MOL LIFE SCI, V53, P478, DOI 10.1007/s000180050059; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; Nakada M, 2001, CANCER RES, V61, P8896; Okabayashi K, 1999, BIOCHEM BIOPH RES CO, V254, P42, DOI 10.1006/bbrc.1998.9892; Patel K, 1996, DEV BIOL, V178, P327, DOI 10.1006/dbio.1996.0222; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Sumitomo K, 2000, CANCER LETT, V155, P37, DOI 10.1016/S0304-3835(00)00407-9; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; Tochitani S, 2001, EUR J NEUROSCI, V13, P297, DOI 10.1046/j.0953-816X.2000.01390.x; Towers P, 1999, DEV BIOL, V214, P298, DOI 10.1006/dbio.1999.9421; Vannahme C, 2003, BIOCHEM J, V373, P805, DOI 10.1042/BJ20030532; Vannahme C, 2002, J BIOL CHEM, V277, P37977, DOI 10.1074/jbc.M203830200; Vannahme C, 1999, J NEUROCHEM, V73, P12, DOI 10.1046/j.1471-4159.1999.0730012.x; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; ZWIJSEN A, 1994, EUR J BIOCHEM, V225, P937, DOI 10.1111/j.1432-1033.1994.0937b.x	32	63	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11727	11735		10.1074/jbc.M309318200	http://dx.doi.org/10.1074/jbc.M309318200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701841	hybrid			2022-12-25	WOS:000220157600109
J	Sheng, SH; Bruns, JB; Kleyman, TR				Sheng, SH; Bruns, JB; Kleyman, TR			Extracellular histidine residues crucial for Na+ self-inhibition of epithelial Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMILORIDE BINDING DOMAIN; SIDE-CHAIN INTERACTIONS; XENOPUS-LAEVIS OOCYTES; SODIUM-CHANNEL; ALPHA-SUBUNIT; ION CHANNELS; FROG-SKIN; CONCENTRATION-DEPENDENCE; GAMMA-SUBUNIT; CYTOSOLIC NA+	Epithelial Na+ channels ( ENaC) participate in the regulation of extracellular fluid volume homeostasis and blood pressure. Channel activity is regulated by both extracellular and intracellular Na+. The down- regulation of ENaC activity by external Na+ is referred to as Na+ self-inhibition. We investigated the structural determinants of Na+ self-inhibition by expressing wildtype or mutant ENaCs in Xenopus oocytes and analyzing changes in whole-cell Na+ currents following a rapid increase of bath Na+ concentration. Our results indicated that wild-type mouse alphabetagammaENaC has intrinsic Na+ self-inhibition similar to that reported for human, rat, and Xenopus ENaCs. Mutations at His(239) (gammaH239R, gammaH239D, and gammaH239C) in the extracellular loop of the gammaENaC subunit prevented Na+ self- inhibition whereas mutations of the corresponding His(282) in alphaENaC (alphaH282D, alphaH282R, alphaH282W, and alphaH282C) significantly enhanced Na+ self-inhibition. These results suggest that these two histidine residues within the extracellular loops are crucial structural determinants for Na+ self-inhibition.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sheng, SH (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, 3550 Terrace St, Pittsburgh, PA 15261 USA.	shaohu@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J PHYSIOL-LONDON, V516, P31, DOI 10.1111/j.1469-7793.1999.031aa.x; Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Askwith CC, 2001, P NATL ACAD SCI USA, V98, P6459, DOI 10.1073/pnas.111155398; Awayda MS, 2000, AM J PHYSIOL-CELL PH, V279, pC1896, DOI 10.1152/ajpcell.2000.279.6.C1896; Babini E, 2003, J BIOL CHEM, V278, P28418, DOI 10.1074/jbc.M301315200; Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; Bhattacharyya R, 2003, J PROTEOME RES, V2, P255, DOI 10.1021/pr025584d; Bruns JB, 2003, AM J PHYSIOL-RENAL, V285, pF600, DOI 10.1152/ajprenal.00095.2003; Chraibi A, 2002, J GEN PHYSIOL, V120, P133, DOI 10.1085/jgp.20028612; CREIGHTON TE, 1983, PROTEINS STRUCTURES, P14; Cucu D, 2003, J MEMBRANE BIOL, V194, P33, DOI 10.1007/s00232-003-2023-y; Firsov D, 1999, J BIOL CHEM, V274, P2743, DOI 10.1074/jbc.274.5.2743; FUCHS W, 1977, J PHYSIOL-LONDON, V267, P137, DOI 10.1113/jphysiol.1977.sp011805; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Gilbertson TA, 1998, J GEN PHYSIOL, V111, P667, DOI 10.1085/jgp.111.5.667; GORDON SE, 1995, NEURON, V14, P177; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Hummler E, 2003, CURR HYPERTENS REP, V5, P11, DOI 10.1007/s11906-003-0005-1; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Kelly O, 2003, AM J PHYSIOL-RENAL, V285, pF1279, DOI 10.1152/ajprenal.00094.2003; Kieber-Emmons T, 1999, J BIOL CHEM, V274, P9648, DOI 10.1074/jbc.274.14.9648; Komwatana P, 1998, J MEMBRANE BIOL, V162, P225, DOI 10.1007/s002329900360; Komwatana P, 1996, P NATL ACAD SCI USA, V93, P8107, DOI 10.1073/pnas.93.15.8107; KOSSIAKOFF AA, 1980, NATURE, V288, P414, DOI 10.1038/288414a0; LI JHY, 1983, J MEMBRANE BIOL, V75, P179, DOI 10.1007/BF01871949; Meurisse R, 2003, BBA-PROTEINS PROTEOM, V1649, P85, DOI 10.1016/S1570-9639(03)00161-4; Okada A, 2001, BIOCHEMISTRY-US, V40, P6053, DOI 10.1021/bi0028441; Palmer LG, 1998, J PHYSIOL-LONDON, V509, P151, DOI 10.1111/j.1469-7793.1998.151bo.x; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Satlin LM, 2001, AM J PHYSIOL-RENAL, V280, pF1010, DOI 10.1152/ajprenal.2001.280.6.F1010; Schafer JA, 2002, AM J PHYSIOL-RENAL, V283, pF221, DOI 10.1152/ajprenal.00068.2002; SCHULZ AR, 1984, ENZYME KINETICS DIS, P38; Segal A, 2002, FEBS LETT, V515, P177, DOI 10.1016/S0014-5793(02)02464-X; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Sherwood AL, 2002, GLYCOBIOLOGY, V12, P599, DOI 10.1093/glycob/cwf075; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Thomas A, 2002, PROTEINS, V48, P628, DOI 10.1002/prot.10190; TURNHEIM K, 1991, PHYSIOL REV, V71, P429, DOI 10.1152/physrev.1991.71.2.429; VANDRIESSCHE W, 1985, PHYSIOL REV, V65, P833, DOI 10.1152/physrev.1985.65.4.833; VANDRIESSCHE W, 1979, NATURE, V282, P519, DOI 10.1038/282519a0	43	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9743	9749		10.1074/jbc.M311952200	http://dx.doi.org/10.1074/jbc.M311952200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701851	hybrid			2022-12-25	WOS:000220050400012
J	Eyers, PA; Maller, JL				Eyers, PA; Maller, JL			Regulation of Xenopus aurora A activation by TPX2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIPOLAR MITOTIC SPINDLE; CENTROSOME AMPLIFICATION; SIGNALING PATHWAY; KINASE-ACTIVITY; IMPORTIN-ALPHA; CELL-DIVISION; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; MICROTUBULES	The oncogenic protein kinase Aurora A is a critical regulator of meiotic and mitotic cell cycles in eukaryotic cells. Aurora A autoactivation by autophosphorylation is promoted by specific non-catalytic binding proteins. One such protein is TPX2, a required spindle assembly factor in higher eukaryotes whose ability to activate Aurora A by direct binding to the kinase catalytic domain has been established by biochemical and structural analysis. In this report we clarify the autoactivation mechanism of Aurora A by demonstrating that of seven amino acids which become autophosphorylated by Aurora A, only Thr-295 is required for activity. Association of Aurora A with TPX2 leads to activation of the kinase, in parallel with phosphorylation of TPX2. We identify the sites as three Ser residues in the N terminus of TPX2; however, mutation of these residues does not affect Aurora A activation by TPX2. In contrast, the mutation of a putative Aurora A-binding motif in TPX2 abolishes both phosphorylation of TPX2 and activation of Aurora A. We have also investigated the interaction between Xenopus p53 and Xenopus Aurora A. p53 blocks the activity of either full-length Aurora A or the isolated catalytic domain. Interestingly, inhibition is blocked by TPX2, suggesting that the ability of Aurora A to transform cells could be regulated by p53, TPX2, or other binding proteins.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.	jim.maller@uchsc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28353-21] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bishop JD, 2002, J BIOL CHEM, V277, P27577, DOI 10.1074/jbc.C200307200; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; CHAN CSM, 1993, GENETICS, V135, P677; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Garrett S, 2002, CURR BIOL, V12, P2055, DOI 10.1016/S0960-9822(02)01277-0; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 2000, EXP CELL RES, V258, P145, DOI 10.1006/excr.2000.4903; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Giet R, 2001, J CELL SCI, V114, P2095; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hamada M, 2003, BRIT J HAEMATOL, V121, P439, DOI 10.1046/j.1365-2141.2003.04311.x; Haydon CE, 2003, MOL CELL PROTEOMICS, V2, P1055, DOI 10.1074/mcp.M300054-MCP200; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Li DH, 2003, CLIN CANCER RES, V9, P991; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Roghi C, 1998, J CELL SCI, V111, P557; Schatz CA, 2003, EMBO J, V22, P2060, DOI 10.1093/emboj/cdg195; Terada Y, 2003, J CELL BIOL, V162, P757, DOI 10.1083/jcb.200305048; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673; Wittmann T, 2000, J CELL BIOL, V149, P1405, DOI 10.1083/jcb.149.7.1405; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	38	108	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9008	9015		10.1074/jbc.M312424200	http://dx.doi.org/10.1074/jbc.M312424200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14701852	hybrid			2022-12-25	WOS:000189265900060
J	Cannon, ML; Cesarman, E				Cannon, ML; Cesarman, E			The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells	ONCOGENE			English	Article						Kaposi's sarcoma-associated virus (KSHV); G protein-coupled receptor (GPCR); primary effusion lymphoma (PEL); signaling	SARCOMA-ASSOCIATED HERPESVIRUS; NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; SRC TYROSINE KINASE; KAPOSIS-SARCOMA; PHOSPHOLIPASE-C; DNA-SEQUENCES; HUMAN-HERPESVIRUS-8 ENCODES; VASCULAR-PERMEABILITY; CONSTITUTIVE ACTIVITY	Kaposi#39;s sarcoma-associated virus (KSHV) is the causative agent of Kaposi#39;s sarcoma (KS) and primary effusion lymphoma (PEL). The KSHV G protein-couple receptor (vGPCR) is a homologue of the human IL-8 receptor that signals constitutively, activates mitogen- and stress-activated kinases, and induces transcription via multiple transcription factors including AP-1 and NF#954;B. Furthermore, vGPCR causes cellular transformation in vitro and leads to KS-like tumors in transgenic mouse models. vGPCR has therefore become an exciting potential therapeutic target for KSHV-mediated disease, but its signaling properties need to be better understood in the context of KSHV-infected hematopoietic cells. We recently described a PEL cell line that expresses vGPCR via an inducible promoter and have shown that vGPCR has broad capabilities of affecting cellular and viral transcription patterns in this highly relevant cell type. To elucidate the predominant signaling pathways used by vGPCR in PEL cells, we have used reporter gene assays to measure vGPCR activity in the presence of various pharmacologic enzyme inhibitors and plasmid constructs. We show that vGPCR-induced activation of AP-1 and CREB is mediated cooperatively by a Gq-ERK-1#47;2 and a Gi#8211;PI3K-Src axis. Furthermore, unlike in other cell types, NF#954;B activation by vGPCR seems not to be substantially mediated by Gi or PI3K#47;Akt in PEL cells.Oncogene (2004) 23, 514#8211;523. doi:10.1038/sj.onc.1207021	Cornell Univ, Weill Med Coll, Dept Med, Div Int Med & Infect Dis, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA	Cornell University; Cornell University	Cannon, ML (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Int Med & Infect Dis, 1300 York Ave,Room A-421, New York, NY 10021 USA.	mlcannon@med.cornell.edu			NATIONAL CANCER INSTITUTE [R01CA073531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI053971] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA73531] Funding Source: Medline; NIAID NIH HHS [K08-AI53971-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Aoki Y, 1999, BLOOD, V94, P4247, DOI 10.1182/blood.V94.12.4247; Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Arvanitakis L, 1998, TRENDS ENDOCRIN MET, V9, P27, DOI 10.1016/S1043-2760(98)00007-1; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Burger M, 1999, J IMMUNOL, V163, P2017; Cannon M, 2003, J VIROL, V77, P57, DOI 10.1128/JVI.77.1.57-67.2003; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; CIVATI G, 1988, TRANSPLANT P, V20, P924; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Deng HY, 2002, J VIROL, V76, P8252, DOI 10.1128/JVI.76.16.8252-8264.2002; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dupin N, 2000, BLOOD, V95, P1406, DOI 10.1182/blood.V95.4.1406.004k26_1406_1412; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Franceschi S, 1995, TUMORI, V81, P308, DOI 10.1177/030089169508100502; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, J EXP MED, V187, P801, DOI 10.1084/jem.187.5.801; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; Ho HH, 2001, J BIOL CHEM, V276, P1376, DOI 10.1074/jbc.M007885200; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Jones KD, 1999, BLOOD, V94, P2871; Keller SA, 2000, BLOOD, V96, P2537; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marshall AJ, 2000, IMMUNOL REV, V176, P30; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2001, CANCER RES, V61, P2641; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Neipel F, 1997, J VIROL, V71, P839, DOI 10.1128/JVI.71.1.839-842.1997; Nicholas J, 1998, J Natl Cancer Inst Monogr, P79; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; Pati S, 2003, J VIROL, V77, P5759, DOI 10.1128/JVI.77.10.5759-5773.2003; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Polson AG, 2002, CANCER RES, V62, P4525; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Samaniego F, 1998, AM J PATHOL, V152, P1433; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; SHEPARD LW, 2001, J BIOL CHEM, V4, P4; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Sodhi A, 2000, CANCER RES, V60, P4873; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106; Wakeling MN, 2001, J GEN VIROL, V82, P1187, DOI 10.1099/0022-1317-82-5-1187; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; Wong WW, 1998, AGENT ACTION SUPPL, V49, P5; WU DQ, 1992, J BIOL CHEM, V267, P1811; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Ziegler JL, 1996, INT J CANCER, V65, P200, DOI 10.1002/(SICI)1097-0215(19960117)65:2&lt;200::AID-IJC12&gt;3.0.CO;2-H; Zoeteweij JP, 2001, BLOOD, V97, P2374, DOI 10.1182/blood.V97.8.2374	77	61	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					514	523		10.1038/sj.onc.1207021	http://dx.doi.org/10.1038/sj.onc.1207021			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724579				2022-12-25	WOS:000188098300022
J	Choi, JA; Park, MT; Kang, CM; Um, HD; Bae, S; Lee, KH; Kim, TH; Kim, JH; Cho, CK; Lee, YS; Chung, HY; Lee, SJ				Choi, JA; Park, MT; Kang, CM; Um, HD; Bae, S; Lee, KH; Kim, TH; Kim, JH; Cho, CK; Lee, YS; Chung, HY; Lee, SJ			Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways	ONCOGENE			English	Article						12V-Ki-Ras; 12V-Ha-Ras; radiation-induced apoptosis; PI3K/Akt; Rac/p38 MAPK; Bax translocation	CYTOCHROME-C RELEASE; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-SURVIVAL; NIH-3T3 CELLS; CANCER CELLS; N-RAS; RESISTANCE; BAX; ONCOGENE; P38	It has been well known that Ras signaling is involved in various cellular processes, including proliferation, differentiation, and apoptosis. However, distinct cellular functions of Ras isozymes are not fully understood. Here we show the opposing roles of Ha-Ras and Ki-Ras genes in the modulation of cell sensitivity to ionizing radiation. Overexpression of active isoform of Ha-Ras (12V-Ha-Ras) in Rat2 cells increases resistance to the ionizing radiation. Constitutive activation of phosphoinositide-3-kinase (PI3K) and Akt is detected specifically in 12V-Ha-Ras-overexpressing cells. The specific PI3K inhibitor LY294002 inhibits PI3K/Akt signaling and potentiates the radiation-induced apoptosis, suggesting that activation of the PI3K/47;Akt signaling pathway is involved in the increased radio-resistance in cells overexpressing 12V-Ha-Ras. Overexpression of activated Ki-Ras (12V-Ki-Ras), on the other hand, markedly increases radiation sensitivity. The p38 mitogen-activated protein kinase (MAPK) activity is selectively enhanced by ionizing radiation in cells overexpressing 12V-Ki-Ras. The specific p38 MAPK inhibitor, PD169316, or dominant-negative p38 MAPK decreases radiation-induced cell death. We further show that the mechanism that underlies potentiation of cell death in cells overexpressing 12V-Ki-Ras involves Bax translocation to the mitochondrial membrane. Elevated Bax translocation following ionizing irradiation in 12V-Ki-Ras-overexpressing cells is completely inhibited by PD169316 or dominant-negative p38 MAPK. In addition, introduction of cells with RacN17, a dominant-negative mutant of Rac, resulted in a marked inhibition of radiation-induced Bax translocation and apoptotic cell death as well as p38 MAPK activation. Taken together, these findings explain the opposite effects of Ha-Ras and Ki-Ras on modulation of radiosensitivity, and suggest that differential activation of PI3K/Akt and Rac/p38 MAPK signaling by Ha-Ras and Ki-Ras may account for the opposing response to the ionizing radiation. These data provide an explanation for the diverse biological functions of Ras isozymes, and partly accounts for the differential response of transformed cells to anticancer treatments.	Korea Inst Radiol & Med Sci, Lab Radiat Effect, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Expt Pathol, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Oncol Mol Lab, Seoul 139706, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea University; Hanyang University	Lee, SJ (corresponding author), Korea Inst Radiol & Med Sci, Lab Radiat Effect, Seoul 139706, South Korea.	sjlee@kcchsun.kcch.re.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208; Chung, Hee Yong/0000-0001-7580-0537				Ayllon V, 2000, MOL MEMBR BIOL, V17, P65; Bache M, 2001, INT J CANCER, V96, P110, DOI 10.1002/ijc.1002; Belka C, 2000, ANTICANCER RES, V20, P3243; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 2000, CANCER RES, V60, P6597; BOS JL, 1989, CANCER RES, V49, P4682; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Brooks DG, 2001, ONCOGENE, V20, P2144, DOI 10.1038/sj.onc.1204309; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Cheng GJ, 2001, ONCOGENE, V20, P7334, DOI 10.1038/sj.onc.1204928; Choi JA, 2001, INT J ONCOL, V19, P837; Chuang SM, 2000, CARCINOGENESIS, V21, P1423, DOI 10.1093/carcin/21.7.1423; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Cuda G, 2002, CIRCULATION, V105, P968, DOI 10.1161/hc0802.104324; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eom YW, 2001, BIOCHEM BIOPH RES CO, V285, P825, DOI 10.1006/bbrc.2001.5233; Fedorov YV, 2001, J CELL BIOL, V152, P1301, DOI 10.1083/jcb.152.6.1301; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FITZGERALD TJ, 1985, AM J CLIN ONCOL-CANC, V8, P517, DOI 10.1097/00000421-198512000-00012; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Grana TM, 2002, CANCER RES, V62, P4142; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2000, RADIAT RES, V154, P64, DOI 10.1667/0033-7587(2000)154[0064:RMRRIN]2.0.CO;2; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HARRIS JF, 1990, SOMAT CELL MOLEC GEN, V16, P39, DOI 10.1007/BF01650478; HERMENS AF, 1992, CANCER RES, V52, P3073; Hosoi Y, 1998, INT J CANCER, V78, P642, DOI 10.1002/(SICI)1097-0215(19981123)78:5<642::AID-IJC19>3.0.CO;2-3; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kunz M, 2001, CELL GROWTH DIFFER, V12, P137; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; MCKENNA WG, 1990, CANCER RES, V50, P97; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Nagase M, 2001, BIOSCI BIOTECH BIOCH, V65, P1741, DOI 10.1271/bbb.65.1741; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pan JX, 2001, J CLIN ENDOCR METAB, V86, P4731, DOI 10.1210/jc.86.10.4731; Pennisi E, 1997, SCIENCE, V275, P1567, DOI 10.1126/science.275.5306.1567; Pervaiz S, 2001, ONCOGENE, V20, P6263, DOI 10.1038/sj.onc.1204840; PIROLLO KF, 1993, RADIAT RES, V135, P234, DOI 10.2307/3578300; Prior IA, 2001, J CELL SCI, V114, P1603; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; Santillo M, 2001, CURR BIOL, V11, P614, DOI 10.1016/S0960-9822(01)00159-2; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; Stadheim TA, 2000, BIOCHEM PHARMACOL, V59, P407, DOI 10.1016/S0006-2952(99)00330-5; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoshino T, 2001, EUR J IMMUNOL, V31, P2702, DOI 10.1002/1521-4141(200109)31:9<2702::AID-IMMU2702>3.0.CO;2-8	62	50	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					9	20		10.1038/sj.onc.1206982	http://dx.doi.org/10.1038/sj.onc.1206982			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712206				2022-12-25	WOS:000187895300002
J	Weissman, JT; Ma, JN; Essex, A; Gao, Y; Burstein, ES				Weissman, JT; Ma, JN; Essex, A; Gao, Y; Burstein, ES			G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel G alpha i regulated pathway	ONCOGENE			English	Article						Rap; Ras; G-protein; receptor; proliferation; transformation	NUCLEOTIDE-EXCHANGE FACTOR; GROWTH-FACTOR RECEPTOR; SRC-DEPENDENT PHOSPHORYLATION; BETA-GAMMA-SUBUNITS; CYCLIC-AMP; MAP KINASE; B-RAF; BETA(2)-ADRENERGIC RECEPTOR; BINDING PROTEINS; HUMAN PLATELETS	Ras proteins mediate the proliferative effects of G-protein-coupled receptors (GPCRs), but the role of Rap proteins in GPCR signaling is unclear. We have developed a novel cellular proliferation assay for examining signal transduction to Rap utilizing Ras/rap chimeras that respond selectively to Rap-specific exchange factors, but which stimulate cellular proliferation through Ras effectors. Both the D1 dopamine receptor (Gs-coupled) and the 5HT1E serotonin receptor (Gi-coupled) mediated cellular proliferation in a Ras/rap chimera-dependent manner. Responses to both receptors were PKA-independent. Both receptors activated Ras/rap and full-length Rap as measured by activation-specific probes. Pertussis toxin blocked Ras/rap-dependent responses to 5HT1E but not D1. Ras/rap-dependent responses to both receptors were insensitive to beta-gamma scavengers. Responses to 5HT1E, but not D1, were sensitive to inhibition by a dominant-negative C3G fragment, by the Src-like kinase inhibitors PP1 and PP2, and by a dominant-negative mutant of Src. Very similar data were obtained for two other Gi-coupled receptors, the D2 dopamine receptor and the alpha2C adrenergic receptor. A constitutively active mutant of Galphai2 also mediated Ras/rap-dependent responses. These data indicate that GPCRs coupled to pertussis-toxin-sensitive G-proteins activate Rap through a Galpha subunit, C3G, and Src-dependent pathway.	ACADIA Pharmaceut Inc, San Diego, CA 92121 USA		Burstein, ES (corresponding author), ACADIA Pharmaceut Inc, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.	eburstein@acadia-pharm.com						ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Burstein ES, 1997, J NEUROCHEM, V68, P525; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gao YL, 2001, J PHARMACOL EXP THER, V296, P426; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1991, J BIOL CHEM, V266, P6571; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Lova P, 2003, J BIOL CHEM, V278, P131, DOI 10.1074/jbc.M204821200; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Smit MJ, 2002, METHOD ENZYMOL, V343, P430; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tsygankova OM, 2000, ONCOGENE, V19, P3609, DOI 10.1038/sj.onc.1203680; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; van den Berghe N, 1999, J BIOL CHEM, V274, P11078, DOI 10.1074/jbc.274.16.11078; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	51	30	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					241	249		10.1038/sj.onc.1207014	http://dx.doi.org/10.1038/sj.onc.1207014			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712229				2022-12-25	WOS:000187895300025
J	Lee, YI; Hwang, JM; Im, JH; Lee, YI; Kim, NS; Kim, DG; Yu, DY; Moon, HB; Park, SK				Lee, YI; Hwang, JM; Im, JH; Lee, YI; Kim, NS; Kim, DG; Yu, DY; Moon, HB; Park, SK			Human hepatitis B virus-X protein alters mitochondrial function and physiology in human liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HBX PROTEIN; NUCLEAR-FACTOR; CYTOCHROME-C; T-CELLS; KAPPA-B; TRANSITION; GENERATION; EXPRESSION; REDUCTION; APOPTOSIS	The hepatitis B virus-X protein (HBx) regulates fundamental aspects of mitochondrial physiology. We show that HBx down-regulates mitochondrial enzymes involved in electron transport in oxidative phosphorylation ( complexes I, III, IV, and V) and sensitizes the mitochondrial membrane potential in a hepatoma cell line. HBx also increases the level of mitochondrial reactive oxygen species and lipid peroxide production. HBx does not activate apoptotic signaling, although it sensitizes hepatoma cells to apoptotic signaling, which is dependent on reactive oxygen species. Increased intrahepatic lipid peroxidation in HBx transgenic mice demonstrated that oxidative injury occurs as a direct result of HBx expression. Therefore, we conclude that mitochondrial dysfunction is a crucial pathophysiological factor in HBx-expressing hepatoma cells and provides an experimental rationale in the investigation of mitochondrial function in rapidly renewed tissues, as in hepatocellular carcinomas.	Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Lab, Taejon 305600, South Korea; Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Dev & Differentiat Lab, Taejon 305600, South Korea; Wonkwang Univ, Wonkwang Med Sch, Dept Pathol, Iksan 570749, Chonbook, South Korea; Conbook Natl Univ, Div Gastroenterol & Hepatol, Chonju 561756, Chonbook, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Wonkwang University; Jeonbuk National University	Lee, YI (corresponding author), Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Lab, POB 115, Taejon 305600, South Korea.	yilee@mail.kribb.re.kr			NIGMS NIH HHS [0GM0100311] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey SM, 1999, FREE RADICAL BIO MED, V27, P891, DOI 10.1016/S0891-5849(99)00138-0; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; BHAT NK, 1982, BIOCHEMISTRY-US, V21, P2452, DOI 10.1021/bi00539a026; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Das AM, 2003, MOL GENET METAB, V79, P71, DOI 10.1016/S1096-7192(03)00069-6; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Heerdt BG, 1997, CELL GROWTH DIFFER, V8, P523; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Kageyama F, 2000, AM J GASTROENTEROL, V95, P1041, DOI 10.1111/j.1572-0241.2000.01979.x; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM YH, 1993, BIOCHEM BIOPH RES CO, V197, P894, DOI 10.1006/bbrc.1993.2563; KIM YS, 1984, KOREAN BIOCH J, V17, P70; KITA K, 1989, J BIOL CHEM, V264, P2672; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Lee Y, 1998, GENE, V207, P111, DOI 10.1016/S0378-1119(97)00603-3; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; Montine TJ, 1996, AM J PATHOL, V148, P89; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; Munger J, 2001, P NATL ACAD SCI USA, V98, P10410, DOI 10.1073/pnas.181344498; Oh SW, 1998, MOL CELLS, V8, P212; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Park US, 2000, ONCOGENE, V19, P3384, DOI 10.1038/sj.onc.1203674; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; RICHTER C, 1993, TOXICOL LETT, V67, P119, DOI 10.1016/0378-4274(93)90050-8; Salvi M, 2002, BBA-BIOENERGETICS, V1556, P187, DOI 10.1016/S0005-2728(02)00361-4; SHEFFLER IE, 1999, MITOCHONDRIA; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shirakata Y, 2003, J BIOL CHEM, V278, P22071, DOI 10.1074/jbc.M301606200; Staniek K, 2002, FREE RADICAL RES, V36, P381, DOI 10.1080/10715760290021225; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; Vander Heiden MG, 1999, MOL CELL, V3, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VIZI V, 2003, J NEUROCHEM, V85, P3; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	48	129	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15460	15471		10.1074/jbc.M309280200	http://dx.doi.org/10.1074/jbc.M309280200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14724286	hybrid			2022-12-25	WOS:000220594700117
J	Sinha, SC; Chaudhuri, BN; Burgner, JW; Yakovleva, G; Davisson, VJ; Smith, JL				Sinha, SC; Chaudhuri, BN; Burgner, JW; Yakovleva, G; Davisson, VJ; Smith, JL			Crystal structure of imidazole glycerol-phosphate dehydratase - Duplication of an unusual fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIZE-DISTRIBUTION ANALYSIS; GHMP KINASE SUPERFAMILY; IMIDAZOLEGLYCEROLPHOSPHATE DEHYDRATASE; SALMONELLA-TYPHIMURIUM; ANALYTICAL ULTRACENTRIFUGATION; SACCHAROMYCES-CEREVISIAE; BIFUNCTIONAL ENZYME; PROTEIN STRUCTURES; ESCHERICHIA-COLI; HISB GENE	Imidazole glycerol-phosphate dehydratase (IGPD) catalyzes the sixth step of histidine biosynthesis. The enzyme is of fundamental biochemical interest, because it catalyzes removal of a non-acidic hydrogen atom in the dehydration reaction. It is also a potential target for development of herbicides. IGPD is a metalloenzyme in which transition metals induce aggregation and are required for catalysis. Addition of 1 equivalent of Mn2+/ subunit is shown by analytical ultracentrifugation to induce the formation of 24-mers from trimeric IGPD. Two histidine-rich motifs may participate in metal binding and aggregation. The 2.3-Angstrom crystal structure of metal-free trimeric IGPD from the fungus Filobasidiella neoformans reveals a novel fold containing an internal repeat, apparently the result of gene duplication. The 95-residue alpha/beta half-domain occurs in a few other proteins, including the GHMP kinase superfamily (galactohomoserine-mevalonate-phosphomevalonate), but duplication to form a compact domain has not been seen elsewhere. Conserved residues cluster at two types of sites in the trimer, each site containing a conserved histidine-rich motif. A model is proposed for the intact, active 24-mer in which all highly conserved residues, including the histidine-rich motifs in both the N- and C-terminal halves of the polypeptide, cluster at a common site between trimers. This site is a candidate for the active site and also for metal binding leading to aggregation of trimers. The structure provides a basis for further studies of enzyme function and mechanism and for development of more potent and specific herbicides.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Med Chem & Pharmacol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Smith, JL (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	smithj@purdue.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042303, R37DK042303] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK042303, DK-42303] Funding Source: Medline; NIGMS NIH HHS [GM-45756] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; AMES BN, 1957, J BIOL CHEM, V228, P131; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bonanno JB, 2001, P NATL ACAD SCI USA, V98, P12896, DOI 10.1073/pnas.181466998; BRADY DR, 1973, J BIOL CHEM, V248, P2588; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHIARIOTTI L, 1986, MOL GEN GENET, V202, P42, DOI 10.1007/BF00330514; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Fu ZJ, 2002, J BIOL CHEM, V277, P18134, DOI 10.1074/jbc.M200912200; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; GLASER RD, 1974, BIOCHEMISTRY-US, V13, P5145, DOI 10.1021/bi00722a015; HAWKES TR, 1995, BIOCHEM J, V306, P385, DOI 10.1042/bj3060385; HAWKES TR, 1993, PROC BRIGHTON CROP, P739; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOUSTON LL, 1973, J BIOL CHEM, V248, P4144; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, J MOL BIOL, V285, P1887, DOI 10.1006/jmbi.1998.2393; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; LOPER JC, 1961, P NATL ACAD SCI USA, V47, P1440, DOI 10.1073/pnas.47.9.1440; MANO J, 1993, PLANT PHYSIOL, V103, P733, DOI 10.1104/pp.103.3.733; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORI I, 1995, J AM CHEM SOC, V117, P4411, DOI 10.1021/ja00120a029; MORI I, 1995, PLANT PHYSIOL, V107, P719, DOI 10.1104/pp.107.3.719; MURZIN AG, 1995, NAT STRUCT BIOL, V2, P25, DOI 10.1038/nsb0195-25; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARKER A, 1995, MED CHEM MOL PHARMAC, P218; PARKER AR, 1994, GENE, V145, P135, DOI 10.1016/0378-1119(94)90336-0; Petersen J, 2000, J INORG BIOCHEM, V80, P161, DOI 10.1016/S0162-0134(00)00025-8; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Romanowski MJ, 2002, PROTEINS, V47, P568, DOI 10.1002/prot.10118; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Stams T, 1998, SCIENCE, V280, P752, DOI 10.1126/science.280.5364.752; STAPLES MA, 1979, J BIOL CHEM, V254, P1395; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; TADA S, 1995, PLANT PHYSIOL, V109, P153, DOI 10.1104/pp.109.1.153; TADA S, 1994, PLANT PHYSIOL, V105, P579, DOI 10.1104/pp.105.2.579; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VASINGTON FD, 1967, BIOCHEM BIOPH RES CO, V26, P153, DOI 10.1016/0006-291X(67)90227-6; Wallace AC, 1997, PROTEIN SCI, V6, P2308; WILKINSON KW, 1995, ACTA CRYSTALLOGR D, V51, P845, DOI 10.1107/S0907444995001569; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5	47	23	24	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15491	15498		10.1074/jbc.M312733200	http://dx.doi.org/10.1074/jbc.M312733200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14724278	hybrid			2022-12-25	WOS:000220594700120
J	Takada, Y; Singh, S; Aggarwal, BB				Takada, Y; Singh, S; Aggarwal, BB			Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappa B-mediated gene expression and up-regulation of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NUCLEAR-LOCALIZATION SEQUENCE; CASEIN KINASE-II; FACTOR-ALPHA; TRANSCRIPTIONAL ACTIVITY; TRANSACTIVATION DOMAIN; PROTEIN TRANSDUCTION; SIGNAL-TRANSDUCTION; PERMEABLE PEPTIDES; CYCLIN D1	Because of the critical role of the nuclear transcription factor NF-kappaB in inflammation, viral replication, carcinogenesis, antiapoptosis, invasion, and metastasis, specific inhibitors of this nuclear factor are being sought and tested as treatments. NF-kappaB activation is known to require p65 phosphorylation at serine residues 276, 529, and 536 before it undergoes nuclear translocation. Small protein domains, termed protein transduction domains (PTDs), which are able to penetrate cell membranes can be used to transport other proteins across the cell membrane. We have identified two peptides from the p65 subunit of NF-kappaB (P1 and P6 were from amino acid residues 271 - 282 and 525 - 537, respectively) that, when linked with a PTD derived from the third helix sequence of antenna-pedia, inhibited tumor necrosis factor (TNF)-induced NF-kappaB activation in vivo. Linkage to the PTD was not, however, required to suppress the binding of the p50-p65-heterodimer to the DNA in vitro. PTD-p65-P1 had no effect on TNF-induced AP-1 activation. PTD-p65-P1 suppressed NF-kappaB activation induced by lipopolysaccharide, interleukin-1, okadaic acid, phorbol 12-myristate 13-acetate, H2O2, and cigarette smoke condensate as well as that induced by TNF. PTD-p65-P1 had no effect on TNF-induced inhibitory subunit of NF-kappaB (IkappaBalpha) phosphorylation, IkappaBalpha degradation, or IkappaBalpha kinase activation, but it blocked TNF-induced p65 phosphorylation and nuclear translocation. NF-kappaB-regulated reporter gene expression induced by TNF, TNF receptor 1, TNF receptor-associated death domain, TNF receptor-associated factor-2, NF-kappaB-inducing kinase, IkappaBalpha kinase, and p65 was also suppressed by these peptides. Suppression of NF-kappaB by PTD-p65-P1 enhanced the apoptosis induced by TNF and chemotherapeutic agents. Overall, our results demonstrate the identification of a p65 peptide that can selectively inhibit NF-kappaB activation induced by various inflammatory stimuli, down-regulate NF-kappaB-mediated gene expression, and up-regulate apoptosis.	Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Bioimmunotherapy,Unit 143, Houston, TX 77030 USA; Imgenex, San Diego, CA 92121 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Bioimmunotherapy,Unit 143, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		DIVISION OF BASIC SCIENCES - NCI [Z01BC010610] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [CA 91844, BC 010610] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Cao GD, 2002, J NEUROSCI, V22, P5423; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Fujihara SM, 2000, J IMMUNOL, V165, P1004, DOI 10.4049/jimmunol.165.2.1004; Futaki S, 2003, CURR PROTEIN PEPT SC, V4, P87, DOI 10.2174/1389203033487261; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Kabouridis PS, 2002, J IMMUNOL, V169, P2587, DOI 10.4049/jimmunol.169.5.2587; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Liu XY, 2000, J BIOL CHEM, V275, P16774; Mai JC, 2001, CANCER RES, V61, P7709; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Roshak AK, 2002, CURR OPIN PHARMACOL, V2, P316, DOI 10.1016/S1471-4892(02)00165-0; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Valen G, 2001, J AM COLL CARDIOL, V38, P307, DOI 10.1016/S0735-1097(01)01377-8; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; Yamamoto Yumi, 2001, Current Molecular Medicine (Hilversum), V1, P287; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zingarelli B, 2003, CRIT CARE MED, V31, pS105, DOI 10.1097/00003246-200301001-00015	60	158	166	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15096	15104		10.1074/jbc.M311192200	http://dx.doi.org/10.1074/jbc.M311192200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14711835	hybrid			2022-12-25	WOS:000220594700075
J	Wimalasena, DS; Wimalasena, K				Wimalasena, DS; Wimalasena, K			Kinetic evidence for channeling of dopamine between monoamine transporter and membranous dopamine-beta-monooxygenase in chromaffin granule ghosts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL-MEDULLA; REDUCING EQUIVALENTS; PH-GRADIENT; HYDROXYLASE; ASCORBATE; CATECHOLAMINES; QUANTITATION; DEPENDENCE; MECHANISMS; PROTEINS	The nature of coupling between the uptake and dopamine-beta-monooxygenase (DbetaM) catalyzed hydroxylation of dopamine (DA) was studied in bovine chromaffin granule ghosts. Initial rate and transient kinetics of DA uptake and conversion were determined under a variety of conditions. The uptake kinetics of DA, norepinephrine (NE), and epinephrine demonstrate that DA is a better substrate than NE and epinephrine under optimal uptake conditions. The transient kinetics of DA accumulation and NE production under both optimal uptake and uptake and conversion conditions were zero-order with no detectable lag or burst periods. The mathematical analyses of the data show that a normal sequential uptake followed by the conversion process could not explain the observed kinetics, under any condition. On the other hand, all experimental data are in agreement with a mechanism in which DA is efficiently channeled from the vesicular monoamine transporter to membranous DbetaM for hydroxylation, prior to the release into the bulk medium of the ghost interior. The slow accumulation of DA under optimal conversion conditions appears to be caused by the slow leakage of DA from the channeling pathway to the ghost interior. Because DbetaM activity in intact granules is equally distributed between soluble and membranous forms of DbetaM, if an efficient channeling mechanism is operative in vivo, soluble DbetaM may not have access to the substrate, making the catalytic activity of soluble DbetaM physiologically insignificant, which is consistent with the increasing experimental evidence that membranous DbetaM may be the physiologically functional form.	Wichita State Univ, Dept Chem, Wichita, KS 67260 USA	Wichita State University	Wimalasena, K (corresponding author), Wichita State Univ, Dept Chem, Wichita, KS 67260 USA.	kandatege.wimalasena@wichita.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039423] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 39423] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHN NG, 1989, J BIOL CHEM, V264, P12259; Anderson KS, 1999, METHOD ENZYMOL, V308, P111; APPS DK, 1980, FEBS LETT, V111, P386, DOI 10.1016/0014-5793(80)80833-7; BEERS MF, 1986, J BIOL CHEM, V261, P2529; BELPAIRE F, 1968, BIOCHEM PHARMACOL, V17, P411, DOI 10.1016/0006-2952(68)90251-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; HENRY JP, 1994, J EXP BIOL, V196, P251; Henry JP, 1998, NEUROCHEM INT, V32, P227, DOI 10.1016/S0197-0186(97)00092-2; HERMAN HH, 1988, J BIOL CHEM, V263, P666; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; HUYGHE BG, 1991, J BIOL CHEM, V266, P11544; ISAMBERT MF, 1985, BIOCHEMISTRY-US, V24, P3660, DOI 10.1021/bi00335a039; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; KELLEY PM, 1988, J BIOL CHEM, V263, P3799; KIRSHNER N, 1962, J BIOL CHEM, V237, P2311; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KNOTH J, 1981, J BIOL CHEM, V256, P6541; KNOTH J, 1980, BIOCHEMISTRY-US, V19, P2938, DOI 10.1021/bi00554a019; LJONES T, 1984, COPPER PROTEINS COPP, V2, P131; MCCLURE WR, 1969, BIOCHEMISTRY-US, V8, P2782, DOI 10.1021/bi00835a014; MENNITI FS, 1987, J BIOL CHEM, V262, P7651; NJUS D, 1983, J BIOL CHEM, V258, P27; NJUS D, 1979, BIOCHEM J, V180, P579, DOI 10.1042/bj1800579; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; PHILLIPS JH, 1974, BIOCHEM J, V144, P319, DOI 10.1042/bj1440319; Rosenberg R C, 1980, Essays Neurochem Neuropharmacol, V4, P163; Rudnick G, 1998, J BIOENERG BIOMEMBR, V30, P173, DOI 10.1023/A:1020573325823; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SALAMA G, 1980, J GEN PHYSIOL, V75, P109, DOI 10.1085/jgp.75.2.109; SCHERMAN D, 1980, BIOCHEM PHARMACOL, V29, P1883, DOI 10.1016/0006-2952(80)90098-2; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; Terland O, 2000, ADV EXP MED BIOL, V482, P55; VILLAFRANCA JJ, 1981, COPPER PROTEINS, P263; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9739; WIMALASENA K, 1989, J BIOL CHEM, V264, P124; WIMALASENA K, 1995, J BIOL CHEM, V270, P27516, DOI 10.1074/jbc.270.46.27516; WINKLER H, 1970, BIOCHEM J, V118, P303, DOI 10.1042/bj1180303; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7	42	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15298	15304		10.1074/jbc.M313325200	http://dx.doi.org/10.1074/jbc.M313325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14732710	hybrid			2022-12-25	WOS:000220594700098
J	Satagopan, S; Spreitzer, RJ				Satagopan, S; Spreitzer, RJ			Substitutions at the Asp-473 latch residue of chlamydomonas ribulosebisphosphate carboxylase/oxygenase cause decreases in carboxylation efficiency and CO2/O-2 specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; CHLOROPLAST RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; X-RAY-STRUCTURE; LARGE SUBUNIT; CRYSTAL-STRUCTURE; ACTIVE-SITE; DIRECTED MUTAGENESIS; THERMAL-STABILITY; SUPPRESSOR MUTATIONS; MUTANT FORMS	The loop between alpha-helix 6 and beta-strand 6 in the alpha/beta-barrel active site of ribulose-1,5-bisphosphate carboxylase/ oxygenase (Rubisco, EC 4.1.1.39) plays a key role in discriminating between gaseous substrates CO2 and O-2. Based on numerous x-ray crystal structures, loop 6 is either closed or open depending on the presence or absence, respectively, of substrate ligands. The carboxyl terminus folds over loop 6 in the closed conformation, prompting speculation that it may trigger or latch loop 6 closure. Because an x-ray crystal structure of tobacco Rubisco revealed that phosphate is located at a site in the open form that is occupied by the carboxyl group of Asp-473 in the closed form, it was proposed that Asp-473 may serve as the latch that holds the carboxyl terminus over loop 6. To assess the essentiality of Asp-473 in catalysis, we used directed mutagenesis and chloroplast transformation of the green alga Chlamydomonas reinhardtii to create D473A and D473E mutant enzymes. The D473A and D473E mutant strains can grow photoautotrophically, indicating that Asp-473 is not essential for catalysis. However, both substitutions caused 87% decreases in carboxylation catalytic efficiency (V-max/K-m) and similar to16% decreases in CO2/O-2 specificity. If the carboxyl terminus is required for stabilizing loop 6 in the closed conformation, there must be additional residues at the carboxyl terminus/loop 6 interface that contribute to this mechanism. Considering that substitutions at residue 473 can influence CO2/O-2 specificity, further study of interactions between loop 6 and the carboxyl terminus may provide clues for engineering an improved Rubisco.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Spreitzer, RJ (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rspreitzer1@unl.edu	Satagopan, Sriram/B-3198-2011	Satagopan, Sriram/0000-0002-4867-531X				Andersson I, 2003, ARCH BIOCHEM BIOPHYS, V414, P130, DOI 10.1016/S0003-9861(03)00164-4; Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Andrews TJ, 1996, NAT STRUCT BIOL, V3, P3, DOI 10.1038/nsb0196-3; Bainbridge G, 1998, BIOCHEM J, V336, P387, DOI 10.1042/bj3360387; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN Z, 1988, P NATL ACAD SCI USA, V85, P4696, DOI 10.1073/pnas.85.13.4696; CHEN ZX, 1992, PHOTOSYNTH RES, V31, P157, DOI 10.1007/BF00028792; CHEN ZX, 1991, PLANTA, V183, P597, DOI 10.1007/BF00194282; CHEN ZX, 1993, PLANT PHYSIOL, V101, P1189, DOI 10.1104/pp.101.4.1189; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; Cheng ZQ, 1998, PROTEIN ENG, V11, P457, DOI 10.1093/protein/11.6.457; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; Du YC, 2003, J BIOL CHEM, V278, P49401, DOI 10.1074/jbc.M309993200; Du YC, 2000, P NATL ACAD SCI USA, V97, P14206, DOI 10.1073/pnas.260503997; Du YC, 2000, J BIOL CHEM, V275, P19844, DOI 10.1074/jbc.M002321200; Duff AP, 2000, J MOL BIOL, V298, P903, DOI 10.1006/jmbi.2000.3724; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; GUTTERIDGE S, 1993, J BIOL CHEM, V268, P7818; Hansen S, 1999, J MOL BIOL, V288, P609, DOI 10.1006/jmbi.1999.2701; HOLLINGSHEAD S, 1985, PLASMID, V13, P17, DOI 10.1016/0147-619X(85)90052-6; JORDAN DB, 1981, NATURE, V291, P513, DOI 10.1038/291513a0; JORDAN DB, 1981, PLANT PHYSIOL, V67, P237, DOI 10.1104/pp.67.2.237; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LARSON EM, 1995, BIOCHEMISTRY-US, V34, P4531, DOI 10.1021/bi00014a005; Larson EM, 1997, J BIOL CHEM, V272, P17033, DOI 10.1074/jbc.272.27.17033; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; Okano Y, 2002, FEBS LETT, V527, P33, DOI 10.1016/S0014-5793(02)03148-4; Ott CM, 2000, J BIOL CHEM, V275, P26241, DOI 10.1074/jbc.M004580200; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; Parry MAJ, 2003, J EXP BOT, V54, P1321, DOI 10.1093/jxb/erg141; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; Portis AR, 2003, PHOTOSYNTH RES, V75, P11, DOI 10.1023/A:1022458108678; PORTIS AR, 1990, ARCH BIOCHEM BIOPHYS, V283, P397, DOI 10.1016/0003-9861(90)90660-Q; RANTY B, 1990, EMBO J, V9, P1365, DOI 10.1002/j.1460-2075.1990.tb08251.x; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; Smith SA, 2003, J MOL BIOL, V331, P557, DOI 10.1016/S0022-2836(03)00786-1; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Spreitzer RJ, 2001, BIOCHEMISTRY-US, V40, P5615, DOI 10.1021/bi002943e; SPREITZER RJ, 1982, FEBS LETT, V148, P117, DOI 10.1016/0014-5793(82)81255-6; SPREITZER RJ, 1985, P NATL ACAD SCI USA, V82, P5460, DOI 10.1073/pnas.82.16.5460; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1998, MOL BIOL CHLOROPLAST, P515; Sugawara H, 1999, J BIOL CHEM, V274, P15655, DOI 10.1074/jbc.274.22.15655; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; Taylor TC, 1996, NAT STRUCT BIOL, V3, P95, DOI 10.1038/nsb0196-95; Taylor TC, 1997, J MOL BIOL, V265, P432, DOI 10.1006/jmbi.1996.0738; Taylor TC, 2001, J BIOL CHEM, V276, P48159, DOI 10.1074/jbc.M107765200; THOW G, 1994, BIOCHEMISTRY-US, V33, P5109, DOI 10.1021/bi00183a014; Wierenga RK, 2001, FEBS LETT, V492, P193, DOI 10.1016/S0014-5793(01)02236-0; Zhu GH, 1998, PHOTOSYNTH RES, V57, P71, DOI 10.1023/A:1006020424581; ZHU GH, 1990, PLANT PHYSIOL, V93, P244, DOI 10.1104/pp.93.1.244; Zhu GH, 1996, J BIOL CHEM, V271, P18494, DOI 10.1074/jbc.271.31.18494; ZHU GH, 1994, J BIOL CHEM, V269, P3952	59	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14240	14244		10.1074/jbc.M313215200	http://dx.doi.org/10.1074/jbc.M313215200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734540	hybrid			2022-12-25	WOS:000220478500117
J	Wang, S; Ge, K; Roeder, RG; Hankinson, O				Wang, S; Ge, K; Roeder, RG; Hankinson, O			Role of mediator in transcriptional activation by the aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-P1-450 GENE-TRANSCRIPTION; NUCLEAR TRANSLOCATOR PROTEIN; SIGNAL-TRANSDUCTION PATHWAYS; ESTROGEN-RECEPTOR; WILD-TYPE; IN-VIVO; COACTIVATOR COMPLEX; TRAP220 COMPONENT; AH RECEPTOR; TRANSACTIVATION	The aryl hydrocarbon receptor (AHR) binds many aromatic hydrocarbon compounds and mediates their carcinogenesis. We demonstrate that the endogenous AHR physically associates with the endogenous TRAP/DRIP/ ARC/Mediator complex in a ligand-dependent manner. The Med220 subunit, which is known to interact with several nuclear hormone receptors through its LXXLL motifs, potentiates AHR-dependent reporter gene activity in an LXXLL-independent manner. Depletion of Med220 substantially reduces endogenous AHR-mediated transcription from the mouse cytochrome P4501A1 gene (CYP1A1). Both Med220 and CDK8 ( another subunit of TRAP/DRIP/ ARC/Mediator) are recruited to the CYP1A1 enhancer in a TCDD ( 2,3,7,8-tetrachlorodibenzop- dioxin)-dependent fashion in vivo, and Med220 LXXLL motifs are not required. Med220 rapidly and persistently associates with the enhancer but not the promoter of the CYP1A1 gene after TCDD treatment with similar kinetics as AHR and the coactivators p300 and p/CIP. Our findings demonstrate a novel role for Med220 in AHR-regulated transcription that differs mechanistically from its role in transcriptional regulation by other previously studied transcription factors.	Univ Calif Los Angeles, Inst Mol Biol, Jonsson Comprehens Canc Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Rockefeller University	Hankinson, O (corresponding author), Univ Calif Los Angeles, Med Ctr, Dept Pathol & Lab Med, Ctr Hlth Sci, Box 951732, Los Angeles, CA 90095 USA.	ohank@mednet.ucla.edu	Ge, Kai/H-2810-2019	Ge, Kai/0000-0002-7442-5138	NCI NIH HHS [R01 CA28868, R01 CA028868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK075003] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander DL, 1998, J CELL SCI, V111, P3311; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Devito Michael J., 1994, P139; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; GIERTHY JF, 1994, J CELL BIOCHEM, V54, P231, DOI 10.1002/jcb.240540211; GIERTHY JF, 1993, CANCER RES, V53, P3149; Gradin K, 1999, J BIOL CHEM, V274, P13511, DOI 10.1074/jbc.274.19.13511; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Jana NR, 1999, BIOCHEM BIOPH RES CO, V256, P462, DOI 10.1006/bbrc.1999.0367; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kuil CW, 1998, J BIOL CHEM, V273, P8829, DOI 10.1074/jbc.273.15.8829; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PROBST MR, 1993, MOL PHARMACOL, V44, P511; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Rowlands JC, 1996, MOL PHARMACOL, V50, P538; Safe S, 1998, TOXICOL LETT, V103, P343; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; SPINK DC, 1990, P NATL ACAD SCI USA, V87, P6917, DOI 10.1073/pnas.87.17.6917; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; Sun WM, 1997, J BIOL CHEM, V272, P31845, DOI 10.1074/jbc.272.50.31845; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; ZACHAREWSKI T, 1991, BIOCHEM PHARMACOL, V41, P1931, DOI 10.1016/0006-2952(91)90133-P	55	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13593	13600		10.1074/jbc.M312274200	http://dx.doi.org/10.1074/jbc.M312274200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729673	hybrid			2022-12-25	WOS:000220478500039
J	Fairfax, BP; Pitcher, JA; Scott, MGH; Calver, AR; Pangalos, MN; Moss, SJ; Couve, A'S				Fairfax, BP; Pitcher, JA; Scott, MGH; Calver, AR; Pangalos, MN; Moss, SJ; Couve, A'S			Phosphorylation and chronic agonist treatment atypically modulate GABA(B) receptor cell surface stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DOWN-REGULATION; POSTSYNAPTIC GABA(B); INTRATHECAL BACLOFEN; HIPPOCAMPAL-NEURONS; SUBUNIT EXPRESSION; ENDOCYTOSIS; DESENSITIZATION; LOCALIZATION; ASSOCIATION	GABA(B) receptors are heterodimeric G protein-coupled receptors that mediate slow synaptic inhibition in the central nervous system. The dynamic control of the cell surface stability of GABA(B) receptors is likely to be of fundamental importance in the modulation of receptor signaling. Presently, however, this process is poorly understood. Here we demonstrate that GABA(B) receptors are remarkably stable at the plasma membrane showing little basal endocytosis in cultured cortical and hippocampal neurons. In addition, we show that exposure to baclofen, a well characterized GABA(B) receptor agonist, fails to enhance GABA(B) receptor endocytosis. Lack of receptor internalization in neurons correlates with an absence of agonist-induced phosphorylation and lack of arrestin recruitment in heterologous systems. We also demonstrate that chronic exposure to baclofen selectively promotes endocytosis-independent GABA(B) receptor degradation. The effect of baclofen can be attenuated by activation of cAMP-dependent protein kinase or co-stimulation of beta-adrenergic receptors. Furthermore, we show that increased degradation rates are correlated with reduced receptor phosphorylation at serine 892 in GABA(B)R2. Our results support a model in which GABA(B)R2 phosphorylation specifically stabilizes surface GABA(B) receptors in neurons. We propose that signaling pathways that regulate cAMP levels in neurons may have profound effects on the tonic synaptic inhibition by modulating the availability of GABA(B) receptors.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; GlaxoSmithKline Inc, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England	University of Pennsylvania; University of London; University College London; University of London; University College London; GlaxoSmithKline	Moss, SJ (corresponding author), Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA.	sjmoss@mail.med.upenn.edu	Pitcher, Julie/ABH-2078-2020; couve, andres/I-2249-2013; Scott, Mark/R-3521-2019	couve, andres/0000-0003-4216-8672; Fairfax, Benjamin/0000-0001-7413-5002; Scott, Mark G.H./0000-0002-1557-1856				Armstrong RW, 1997, J NEUROSURG, V87, P409, DOI 10.3171/jns.1997.87.3.0409; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Calver AR, 2000, NEUROSCIENCE, V100, P155, DOI 10.1016/S0306-4522(00)00262-1; Calver AR, 2001, J NEUROSCI, V21, P1203; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Couve A, 2000, MOL CELL NEUROSCI, V16, P296, DOI 10.1006/mcne.2000.0908; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Couve A, 2002, NAT NEUROSCI, V5, P415, DOI 10.1038/nn833; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Craig AM, 2001, NAT NEUROSCI, V4, P569, DOI 10.1038/88388; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; El Far O, 2002, BIOCHEM J, V365, P329, DOI 10.1042/BJ20020481; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Filippov AK, 2000, J NEUROSCI, V20, P2867; Fritschy JM, 1999, EUR J NEUROSCI, V11, P761, DOI 10.1046/j.1460-9568.1999.00481.x; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kelly MJ, 1999, TRENDS ENDOCRIN MET, V10, P369, DOI 10.1016/S1043-2760(99)00190-3; Kittler JT, 2000, J NEUROSCI, V20, P7972; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; Kulik A, 2002, EUR J NEUROSCI, V15, P291, DOI 10.1046/j.0953-816x.2001.01855.x; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LAW PY, 1984, J BIOL CHEM, V259, P4096; Lehmann A, 2003, NEUROCHEM RES, V28, P387, DOI 10.1023/A:1022353923578; Luttrell LM, 2002, J CELL SCI, V115, P455; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P155, DOI 10.1053/apmr.2001.19246; Meythaler JM, 1999, SPINAL DRUG DELIVERY, P513; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; MOTT DD, 1994, INT REV NEUROBIOL, V36, P97, DOI 10.1016/S0074-7742(08)60304-9; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prosser HM, 2001, MOL CELL NEUROSCI, V17, P1059, DOI 10.1006/mcne.2001.0995; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Roberts DCS, 1997, PSYCHOPHARMACOLOGY, V131, P271, DOI 10.1007/s002130050293; Sallese M, 2000, FASEB J, V14, P2569, DOI 10.1096/fj.00-0072com; Sands SA, 2003, J PHARMACOL EXP THER, V305, P191, DOI 10.1124/jpet.102.046342; Scanziani M, 2000, NEURON, V25, P673, DOI 10.1016/S0896-6273(00)81069-7; Schuler V, 2001, NEURON, V31, P47, DOI 10.1016/S0896-6273(01)00345-2; Scott MGH, 2002, J BIOL CHEM, V277, P3552, DOI 10.1074/jbc.M106586200; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Vernon E, 2001, MOL CELL NEUROSCI, V17, P637, DOI 10.1006/mcne.2000.0960; Wetherington JP, 2002, J PHYSIOL-LONDON, V544, P459, DOI 10.1113/jphysiol.2002.023093; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; Xi ZX, 2003, J NEUROSCI, V23, P3498	50	85	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12565	12573		10.1074/jbc.M311389200	http://dx.doi.org/10.1074/jbc.M311389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707142	hybrid			2022-12-25	WOS:000220334900069
J	Fujimura, T; Esteban, R				Fujimura, T; Esteban, R			Bipartite 3 '-cis-acting signal for replication in yeast 23 S RNA virus and its repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CCA-ADDING ENZYME; 23 S RNA; SACCHAROMYCES-CEREVISIAE; 20S RNA; 20-S RNA; POLYMERASE; FORM; IDENTIFICATION; POLYMERIZATION	23 S RNA narnavirus is a persistent positive strand RNA virus found in Saccharomyces cerevisiae. The viral genome is small (2.9 kb) and only encodes its RNA-dependent RNA polymerase. Recently, we have succeeded in generating 23 S RNA virus from an expression vector containing the entire viral cDNA sequence. Using this in vivo launching system, we analyzed the 3'-cis-acting signals for replication. The 3'-non-coding region of 23 S RNA contains two cis-elements. One is a stretch of 4 Cs at the 3' end, and the other is a mismatched pair in a stem-loop structure that partially overlaps the terminal 4 Cs. In the latter element, the loop or stem sequence is not important but the stem structure with the mismatch pair is essential. The mismatched bases should be purines. Any combination of purines at the mismatch pair bestowed capability of replication on the RNA, whereas converting it to a single bulge at either side of the stem abolished the activity. The terminal and penultimate Cs at the 3' end could be eliminated or modified to other nucleotides in the launching plasmid without affecting virus generation. However, the viruses generated regained or restored these Cs at the 3' terminus. Considering the importance of the viral 3' ends in RNA replication, these results suggest that this 3' end repair may contribute to the persistence of 23 S RNA virus in yeast by maintaining the genomic RNA termini intact. We discuss possible mechanisms for this 3' end repair in vivo.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Fujimura, T (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain.	tfujimura@usal.es	Esteban, Rosa/K-4356-2014; Fujimura, Tsutomu/K-5807-2014	Esteban, Rosa/0000-0001-6804-7209; Fujimura, Tsutomu/0000-0002-9457-6769				Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Chapman MR, 1999, J MOL BIOL, V286, P709, DOI 10.1006/jmbi.1998.2503; ESTEBAN LM, 1992, J BIOL CHEM, V267, P10874; ESTEBAN LM, 1994, J BIOL CHEM, V269, P29771; ESTEBAN LM, 1993, THESIS U SALAMANCA S; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; Esteban R, 2003, P NATL ACAD SCI USA, V100, P2568, DOI 10.1073/pnas.0530167100; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; GARCIACUELLAR MP, 1995, J BIOL CHEM, V270, P20084, DOI 10.1074/jbc.270.34.20084; Guan HC, 2000, P NATL ACAD SCI USA, V97, P12451, DOI 10.1073/pnas.97.23.12451; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; Li F, 2002, CELL, V111, P815, DOI 10.1016/S0092-8674(02)01115-7; Maniatis T., 1982, MOL CLONING LAB MANU; MANS RMW, 1991, EUR J BIOCHEM, V201, P303, DOI 10.1111/j.1432-1033.1991.tb16288.x; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; Nagy PD, 1997, P NATL ACAD SCI USA, V94, P1113, DOI 10.1073/pnas.94.4.1113; NEUFELD KL, 1994, J VIROL, V68, P5811, DOI 10.1128/JVI.68.9.5811-5818.1994; RAO ALN, 1989, P NATL ACAD SCI USA, V86, P5335, DOI 10.1073/pnas.86.14.5335; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P20363, DOI 10.1074/jbc.273.32.20363; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; Schwartz M, 2002, MOL CELL, V9, P505, DOI 10.1016/S1097-2765(02)00474-4; SHI JP, 1992, BIOCHEMISTRY-US, V31, P4931, DOI 10.1021/bi00136a002; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Shi PY, 1998, RNA, V4, P276; Siegel RW, 1999, J VIROL, V73, P6424, DOI 10.1128/JVI.73.8.6424-6429.1999; Solorzano A, 2000, J BIOL CHEM, V275, P26428, DOI 10.1074/jbc.M002281200; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; WICKNER RB, 1980, CELL, V21, P217, DOI 10.1016/0092-8674(80)90129-4; WICKNER RB, 2000, VIRUS TAXONOMY, P651; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905	39	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13215	13223		10.1074/jbc.M313797200	http://dx.doi.org/10.1074/jbc.M313797200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722081	hybrid			2022-12-25	WOS:000220334900143
J	Huang, CC; You, JL; Wu, MY; Hsu, KS				Huang, CC; You, JL; Wu, MY; Hsu, KS			Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI center dot Rab5 complex - Potential role in (S)-3,5-dihydroxyphenylglycine-induced long term depression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DHPG-INDUCED LTD; METABOTROPIC GLUTAMATE RECEPTORS; HIPPOCAMPAL CA1 REGION; G-BETA-GAMMA; MAP KINASE; SYNAPTIC PLASTICITY; COUPLED RECEPTORS; FREQUENCY STIMULATION; RAT HIPPOCAMPUS; AREA CA1	Recent evidence has emphasized the importance of p38 mitogen-activated protein kinase (MAPK) in the induction of metabotropic glutamate receptor (mGluR)-dependent long term depression (LTD) at hippocampal CA3-CA1 synapses. However, the cascade responsible of mGluR to activate p38 MAPK and the signaling pathway immediately downstream from it to induce synaptic depression is poorly understood. Here, we show that transient activation of group I mGluR with the selective agonist (S)-3,5-dihydroxyphenylglycine (DHPG) activates p38 MAPK through G protein betagamma-subunit, small GTPase Rap1, and MAPK kinase 3/6 (MKK3/6), thus resulting in mGluR5-dependent LTD. Furthermore, our data clearly show that an accelerating AMPA receptor endocytosis by stimulating the formation of guanyl nucleotide dissociation inhibitor-Rab5 complex is a potential downstream processing of p38 MAPK activation to mediate DHPG-LTD. These results suggest an important role for Rap1-MKK3/6-p38 MAPK pathway in the induction of mGluR-dependent LTD by directly coupling to receptor trafficking machineries to facilitate the loss of synaptic AMPA receptors.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan	National Cheng Kung University	Hsu, KS (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, No 1 Univ Rd, Tainan 701, Taiwan.	richard@mail.ncku.edu.tw	Hsu, Kuei-Sen/AAV-8386-2021	Yu, Chia-Ling/0000-0003-4471-8711				Bashir ZI, 2003, NEUROSCI RES, V45, P363, DOI 10.1016/S0168-0102(03)00002-6; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bolshakov VY, 2000, NAT NEUROSCI, V3, P1107, DOI 10.1038/80624; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Cavalli V, 2001, MOL CELL, V7, P421, DOI 10.1016/S1097-2765(01)00189-7; Clark BP, 1997, BIOORG MED CHEM LETT, V7, P2777, DOI 10.1016/S0960-894X(97)10071-3; Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Faas GC, 2002, J NEUROSCI, V22, P6885; Fitzjohn SM, 1999, NEUROPHARMACOLOGY, V38, P1577, DOI 10.1016/S0028-3908(99)00123-9; Fitzjohn SM, 2001, J PHYSIOL-LONDON, V537, P421, DOI 10.1111/j.1469-7793.2001.00421.x; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Huang CC, 1999, J NEUROSCI, V19, P9728; Huber KM, 2001, J NEUROPHYSIOL, V86, P321, DOI 10.1152/jn.2001.86.1.321; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kemp N, 1999, NEUROPHARMACOLOGY, V38, P495, DOI 10.1016/S0028-3908(98)00222-6; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Kleppisch T, 2001, J NEUROSCI, V21, P4943, DOI 10.1523/JNEUROSCI.21-14-04943.2001; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; Morozov A, 2003, NEURON, V39, P309, DOI 10.1016/S0896-6273(03)00404-5; Moult PR, 2002, NEUROPHARMACOLOGY, V43, P175, DOI 10.1016/S0028-3908(02)00110-7; Palmer MJ, 1997, NEUROPHARMACOLOGY, V36, P1517, DOI 10.1016/S0028-3908(97)00181-0; Rammes G, 2003, J PHYSIOL-LONDON, V546, P455, DOI 10.1113/jphysiol.2002.033514; Rush AM, 2002, J NEUROSCI, V22, P6121; Sawada Y, 2001, J CELL SCI, V114, P1221; Schnabel R, 1999, NEUROPHARMACOLOGY, V38, P1585, DOI 10.1016/S0028-3908(99)00062-3; Schnabel R, 1999, NEUROPHARMACOLOGY, V38, P605, DOI 10.1016/S0028-3908(98)00229-9; Schnabel R, 2001, BRIT J PHARMACOL, V132, P1095, DOI 10.1038/sj.bjp.0703905; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Sellers LA, 2000, MOL CELL BIOL, V20, P5974, DOI 10.1128/MCB.20.16.5974-5985.2000; Seo M, 2002, J BIOL CHEM, V277, P24197, DOI 10.1074/jbc.M201717200; Siegelbaum S A, 1991, Curr Opin Neurobiol, V1, P113, DOI 10.1016/0959-4388(91)90018-3; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Steward O, 2003, NEURON, V40, P347, DOI 10.1016/S0896-6273(03)00635-4; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Watabe AM, 2002, J NEUROPHYSIOL, V87, P1395, DOI 10.1152/jn.00723.2001; Xiao MY, 2001, NEUROPHARMACOLOGY, V41, P664, DOI 10.1016/S0028-3908(01)00134-4; Yamauchi J, 2001, J BIOL CHEM, V276, P23362, DOI 10.1074/jbc.M011752200; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Zho WM, 2002, J NEUROSCI, V22, P8838; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	50	148	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12286	12292		10.1074/jbc.M312868200	http://dx.doi.org/10.1074/jbc.M312868200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709549	hybrid			2022-12-25	WOS:000220334900035
J	Ogushi, K; Wada, A; Niidome, T; Okuda, T; Llanes, R; Nakayama, M; Nishi, Y; Kurazono, H; Smith, KD; Aderem, A; Moss, J; Hirayama, T				Ogushi, K; Wada, A; Niidome, T; Okuda, T; Llanes, R; Nakayama, M; Nishi, Y; Kurazono, H; Smith, KD; Aderem, A; Moss, J; Hirayama, T			Gangliosides act as co-receptors for Salmonella enteritidis FliC and promote FliC induction of human beta-defensin-2 expression in Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAYS; TOLL-LIKE RECEPTORS; EPITHELIAL-CELLS; BETA-DEFENSINS; HELICOBACTER-PYLORI; BACTERIAL FLAGELLIN; DENDRITIC CELLS; INNATE IMMUNITY; INFLUENZA-VIRUS; LINKING INNATE	Antimicrobial peptides such as defensins are crucial for host defense at mucosal surfaces. We reported previously that Salmonella enteritidis flagellin (FliC) induced human beta-defensin-2 (hBD-2) mRNA expression in Caco-2 cells via NF-kappaB activation (Ogushi, K., Wada, A., Niidome, T., Mori, N., Oishi, K., Nagatake, T., Takahashi, A., Asakura, H., Makino, S., Hojo, H., Nakahara, Y., Ohsaki, M., Hatakeyama, T., Aoyagi, H., Kurazono, H., Moss, J., and Hirayama, T. (2001) J. Biol. Chem. 276, 30521-30526). In this study, we examined the role of ganglioside as co-receptors with Toll-like receptor 5 (TLR5) on FliC induction of hBD-2 expression in Caco-2 cells. Exogenous gangliosides suppressed FliC induction of hBD-2 promoter activity and binding of FliC to Caco-2 cells. Incorporation of exogenous ganglioside GD1a into Caco-2 cell membranes increased the effect of FliC on hBD-2 promoter activity. In support of a role for endogenous gangliosides, incubation of Caco-2 cells with DL-threo-2-hexadecanoylamino-3-morpholino-1-phenylpropanol, a glucosylceramide synthase inhibitor, reduced FliC induction of hBD-2 promoter activity. GD1a-loaded CHO-K1-expressing TLR5 cells had a higher potential for hBD-2 induction following FliC stimulation than GD1a-loaded CHO-K1 cells not expressing TLR5. FliC increased phosphorylation of mitogen-activated protein kinase, p38, and ERK1/2. Exogenous gangliosides GD1a, GD1b, and GT1b each suppressed FliC induction of p38 and ERK1/2 phosphorylation. Furthermore, FliC did not enhance luciferase activity in Caco-2 cells transfected with a plasmid containing a mutated activator protein 1-binding site. These results suggest that gangliosides act as co-receptors with TLR5 for FliC and promote hBD-2 expression via mitogen-activated protein kinase.	Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan; Nagasaki Univ, Fac Engn, Dept Appl Chem, Nagasaki 8528521, Japan; Okayama Univ, Sch Med, Fac Hlth Sci, Okayama 7008558, Japan; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Inst Syst Biol, Seattle, WA 98103 USA; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Nagasaki University; Nagasaki University; Okayama University; University of Washington; University of Washington Seattle; Institute for Systems Biology (ISB); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hirayama, T (corresponding author), Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan.	hirayama@net.nagasaki-u.ac.jp	Niidome, Takuro/F-1508-2010	Niidome, Takuro/0000-0002-8070-8708	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; BENSCH KW, 1995, FEBS LETT, V368, P311; BERGELSON LD, 1982, EUR J BIOCHEM, V128, P467; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Biragyn A, 2001, J IMMUNOL, V167, P6644, DOI 10.4049/jimmunol.167.11.6644; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; FISHMAN PH, 1982, J MEMBRANE BIOL, V69, P85, DOI 10.1007/BF01872268; Frendeus B, 2001, MOL MICROBIOL, V40, P37, DOI 10.1046/j.1365-2958.2001.02361.x; Fritz VMR, 1997, BBA-GENE STRUCT EXPR, V1354, P153, DOI 10.1016/S0167-4781(97)00117-6; Garcia JRC, 2001, FASEB J, V15, P1819, DOI 10.1096/fj.00-0865fje; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; GOUY H, 1994, J IMMUNOL, V152, P3271; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hazeki K, 2003, EUR J IMMUNOL, V33, P740, DOI 10.1002/eji.200323375; Hobbie S, 1997, J IMMUNOL, V159, P5550; Hug P, 2000, J VIROL, V74, P6377, DOI 10.1128/JVI.74.14.6377-6385.2000; Jia HP, 2001, GENE, V263, P211; JONES DE, 1992, J BIOL CHEM, V267, P23216; JONES DE, 1993, FEBS LETT, V315, P182; Krisanaprakornkit S, 2002, J IMMUNOL, V168, P316, DOI 10.4049/jimmunol.168.1.316; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Li RX, 2001, J BIOL CHEM, V276, P42782, DOI 10.1074/jbc.M101481200; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; McNamara N, 2001, P NATL ACAD SCI USA, V98, P9086, DOI 10.1073/pnas.161290898; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Moon SK, 2002, BBA-MOL CELL RES, V1590, P41, DOI 10.1016/S0167-4889(02)00196-9; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Ogushi K, 2001, J BIOL CHEM, V276, P30521, DOI 10.1074/jbc.M011618200; Ohsaki M, 2002, BIOCONJUGATE CHEM, V13, P510, DOI 10.1021/bc015525a; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; Rusnati M, 1999, MOL BIOL CELL, V10, P313, DOI 10.1091/mbc.10.2.313; Rusnati M, 2002, P NATL ACAD SCI USA, V99, P4367, DOI 10.1073/pnas.072651899; SUZUKI Y, 1985, J BIOL CHEM, V260, P1362; Svanborg C, 2001, J INFECT DIS, V183, pS61, DOI 10.1086/318858; Svinarich DM, 1997, AM J OBSTET GYNECOL, V176, P470, DOI 10.1016/S0002-9378(97)70517-9; Takahashi A, 2001, FEBS LETT, V508, P484, DOI 10.1016/S0014-5793(01)03088-5; Wada A, 1999, BIOCHEM BIOPH RES CO, V263, P770, DOI 10.1006/bbrc.1999.1452; Yahiro K, 2003, J BIOL CHEM, V278, P19183, DOI 10.1074/jbc.M300117200; YAMADA KM, 1983, EXP CELL RES, V143, P295, DOI 10.1016/0014-4827(83)90054-X; Yamaguchi Y, 2002, J IMMUNOL, V169, P2516, DOI 10.4049/jimmunol.169.5.2516; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yowler BC, 2002, J BIOL CHEM, V277, P32815, DOI 10.1074/jbc.M205258200; Yu YM, 2003, AM J PHYSIOL-GASTR L, V285, pG282, DOI 10.1152/ajpgi.00503.2002; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	51	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12213	12219		10.1074/jbc.M307944200	http://dx.doi.org/10.1074/jbc.M307944200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707135	hybrid			2022-12-25	WOS:000220334900027
J	Weiss, S; Doan, T; Bernstein, KE; Dascal, N				Weiss, S; Doan, T; Bernstein, KE; Dascal, N			Modulation of cardiac Ca2+ channel by G(q)-activating neurotransmitters reconstituted in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VASCULAR SMOOTH-MUSCLE; SENSITIVE CALCIUM-CHANNEL; PHORBOL ESTER INCREASES; ANGIOTENSIN-II; ALPHA(1C) SUBUNIT; RENAL VASOCONSTRICTION; FUNCTIONAL EXPRESSION; TYROSINE KINASE; N-TERMINUS	L-type dihydropyridine-sensitive voltage dependent Ca2+ channels (L-VDCCs; alpha(1C)) are crucial in cardiovascular physiology. Currents via L-VDCCs are enhanced by hormones and transmitters operating via G(q), such as angiotensin II (AngII) and acetylcholine (ACh). It has been proposed that these modulations are mediated by protein kinase C (PKC). However, reports on effects of PKC activators on L-type channels are contradictory; inhibitory and/or enhancing effects have been observed. Attempts to reproduce the enhancing effect of AngII in heterologous expression systems failed. We previously found that PKC modulation of the channel depends on alpha(1C) isoform used; only a long N-terminal (NT) isoform was up-regulated. Here we report the reconstitution of the AngII- and ACh-induced enhancement of the long-NT isoform of L-VDCC expressed in Xenopus oocytes. The current initially increased over several minutes but later declined to below baseline levels. Using different NT deletion mutants and human short- and long-NT isoforms of the channel, we found the initial segment of the NT to be crucial for the enhancing, but not for the inhibitory, effect. Using blockers of PKC and of phospholipase C ( PLC) and a mutated AngII receptor lacking Gq coupling, we demonstrate that the signaling pathway of the enhancing effect includes the activation of Gq, PLC, and PKC. The inhibitory modulation, present in both alpha(1C) isoforms, was G(q)- and PLC-independent and Ca2+-dependent, but not Ca2+-mediated, as only basal levels of Ca2+ were essential. Reconstitution of AngII and ACh effects in Xenopus oocytes will advance the study of molecular mechanisms of these physiologically important modulations.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Tel Aviv University; Sackler Faculty of Medicine; Emory University	Weiss, S (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.		Dascal, Nathan/O-3915-2015	Dascal, Nathan/0000-0002-5397-4146; Bernstein, Kenneth/0000-0001-8097-3272; Weiss, Sharon/0000-0002-0981-6917	NIDDK NIH HHS [DK 39777, DK 44280] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044280, R37DK039777, R01DK039777] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bauer J, 1999, AM J PHYSIOL-HEART C, V277, pH1, DOI 10.1152/ajpheart.1999.277.1.H1; Beech DJ, 1997, PHARMACOL THERAPEUT, V73, P91, DOI 10.1016/S0163-7258(97)87271-3; BENHAM CD, 1985, NATURE, V316, P345, DOI 10.1038/316345a0; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Blumenstein Y, 2002, J BIOL CHEM, V277, P3419, DOI 10.1074/jbc.C100642200; Boixel C, 2000, AM J PHYSIOL-HEART C, V278, pH670, DOI 10.1152/ajpheart.2000.278.2.H670; Bouron A, 1995, FEBS LETT, V377, P159, DOI 10.1016/0014-5793(95)01327-X; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; Dai BS, 2002, BIOCHEM BIOPH RES CO, V296, P429, DOI 10.1016/S0006-291X(02)00894-X; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; Doan TN, 2001, J BIOL CHEM, V276, P20954, DOI 10.1074/jbc.C100199200; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; EGLEN RM, 1994, TRENDS PHARMACOL SCI, V15, P114, DOI 10.1016/0165-6147(94)90047-7; Fan QI, 2002, BBA-GENE STRUCT EXPR, V1577, P401, DOI 10.1016/S0167-4781(02)00441-4; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hughes AD, 1995, J VASC RES, V32, P353, DOI 10.1159/000159111; JACKSON EK, 1996, GOODMAN GILMANS PHAR, P733; Kanki H, 2001, MOL PHARMACOL, V60, P989, DOI 10.1124/mol.60.5.989; KATO H, 1992, BIOCHEM BIOPH RES CO, V188, P934, DOI 10.1016/0006-291X(92)91145-G; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; LAMBERT C, 1995, BRIT J PHARMACOL, V115, P795, DOI 10.1111/j.1476-5381.1995.tb15003.x; LIU QY, 1993, BIOCHEM BIOPH RES CO, V191, P796, DOI 10.1006/bbrc.1993.1287; Liu XR, 2001, GASTROENTEROLOGY, V120, P480, DOI 10.1053/gast.2001.21167; Love JA, 1998, AM J PHYSIOL-GASTR L, V274, pG397, DOI 10.1152/ajpgi.1998.274.2.G397; MacrezLepretre N, 1996, J PHARMACOL EXP THER, V278, P468; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McHugh D, 2000, P NATL ACAD SCI USA, V97, P12334, DOI 10.1073/pnas.210384297; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Nagahama T, 2000, KIDNEY INT, V57, P215, DOI 10.1046/j.1523-1755.2000.00822.x; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Oz M, 1998, MOL PHARMACOL, V54, P1106, DOI 10.1124/mol.54.6.1106; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; PURDY RE, 1988, CIRC RES, V63, P748, DOI 10.1161/01.RES.63.4.748; Quignard JF, 2001, J BIOL CHEM, V276, P32545, DOI 10.1074/jbc.M102582200; REEVE HL, 1995, PFLUG ARCH EUR J PHY, V429, P729, DOI 10.1007/BF00373996; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; Savignac M, 2001, FASEB J, V15, P1577, DOI 10.1096/fj.00-0733fje; SCHOLZ H, 1990, AM J PHYSIOL, V259, pC421, DOI 10.1152/ajpcell.1990.259.3.C421; SCHUHMANN K, 1994, FEBS LETT, V341, P208, DOI 10.1016/0014-5793(94)80458-3; Seki T, 1999, PFLUG ARCH EUR J PHY, V437, P317, DOI 10.1007/s004240050785; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; SHI SZ, 2000, AM J PHYSIOL-GASTR L, V278, pG234; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SINGERLAHAT D, 1992, FEBS LETT, V306, P113, DOI 10.1016/0014-5793(92)80980-U; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; TAKENAKA T, 1993, CIRC RES, V73, P743, DOI 10.1161/01.RES.73.4.743; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; TSENG GN, 1991, AM J PHYSIOL, V261, pH364, DOI 10.1152/ajpheart.1991.261.2.H364; Watts SW, 1998, J PHARMACOL EXP THER, V286, P1431; XIONG ZL, 1995, J MOL CELL CARDIOL, V27, P75, DOI 10.1016/S0022-2828(08)80009-0; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	63	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12503	12510		10.1074/jbc.M310196200	http://dx.doi.org/10.1074/jbc.M310196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722109	hybrid			2022-12-25	WOS:000220334900061
J	Kimbell, LM; Ohno, K; Engel, AG; Rotundo, RL				Kimbell, LM; Ohno, K; Engel, AG; Rotundo, RL			C-terminal and heparin-binding domains of collagenic tail subunit are both essential for anchoring acetylcholinesterase at the synapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MYASTHENIC SYNDROME; EXONIC SPLICING ENHANCERS; NEUROMUSCULAR-JUNCTION; EXTRACELLULAR-MATRIX; SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE; ASYMMETRIC FORMS; SKELETAL-MUSCLE; BASAL LAMINA; DEFICIENCY	The collagen-tailed form of acetylcholinesterase (A(12)-AChE) appears to be localized at the neuromuscular junction in association with the transmembrane dystroglycan complex through binding of its collagenic tail (ColQ) to the proteoglycan perlecan. The heparan sulfate binding domains (HSBD) of ColQ are thought to be involved in anchoring ColQ to the synaptic basal lamina. The C-terminal domain (CTD) of ColQ is also likely involved, but there has been no direct evidence. Mutations in COLQ cause endplate AChE deficiency in humans. Nine previously reported and three novel mutations are in CTD of ColQ, and most CTD mutations do not abrogate formation of A(12)-AChE in transfected COS cells. Patient endplates, however, are devoid of AChE, suggesting that CTD mutations affect anchoring of ColQ to the synaptic basal lamina. Based on our observations that purified AChE can be transplanted to the heterologous frog neuromuscular junction, we tested insertion competence of nine naturally occurring CTD mutants and two artificial HSBD mutants. Wild-type human A(12)-AChE inserted into the frog neuromuscular junction, whereas six CTD mutants and two HSBD mutants did not. Our studies establish that the CTD mutations indeed compromise anchoring of ColQ and that both HSBD and CTD are essential for anchoring ColQ to the synaptic basal lamina.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA; Univ Miami, Sch Med, Neurosci Program, Miami, FL 33136 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Neuromuscular Res Lab, Rochester, MN 55905 USA	University of Miami; University of Miami; Mayo Clinic; Mayo Clinic	Rotundo, RL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat R124, 1600 NW 10th Ave, Miami, FL 33136 USA.	rrotundo@med.miami.edu	Ohno, Kinji/H-4020-2012; Ohno, Kinji/ABD-5787-2020	Ohno, Kinji/0000-0002-1529-2750; Ohno, Kinji/0000-0002-1529-2750	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS006277] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG005917, AG05917] Funding Source: Medline; NINDS NIH HHS [NS6277] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON MJ, 1983, J CELL BIOL, V97, P1396, DOI 10.1083/jcb.97.5.1396; Anglister L, 1998, J NEUROSCI METH, V81, P63, DOI 10.1016/S0165-0270(98)00015-6; Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; Bon S, 2003, NEUROCHEM RES, V28, P523, DOI 10.1023/A:1022821306722; BON S, 1978, EUR J BIOCHEM, V85, P1, DOI 10.1111/j.1432-1033.1978.tb12207.x; BRANDAN E, 1985, J CELL BIOL, V101, P985, DOI 10.1083/jcb.101.3.985; BRANDAN E, 1984, BIOCHEM J, V221, P415, DOI 10.1042/bj2210415; CAMP S, 1995, J CLIN INVEST, V95, P333, DOI 10.1172/JCI117661; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Deprez P, 2003, J BIOL CHEM, V278, P23233, DOI 10.1074/jbc.M301384200; DEPREZ PN, 1995, J BIOL CHEM, V270, P11043, DOI 10.1074/jbc.270.19.11043; Donger C, 1998, AM J HUM GENET, V63, P967, DOI 10.1086/302059; DUVAL N, 1992, EMBO J, V11, P3255, DOI 10.1002/j.1460-2075.1992.tb05403.x; FAMBROUGH DM, 1982, P NATL ACAD SCI-BIOL, V79, P1078, DOI 10.1073/pnas.79.4.1078; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; Gorlov IP, 2003, AM J HUM GENET, V73, P1157, DOI 10.1086/378819; HALL ZW, 1973, J NEUROBIOL, V4, P343, DOI 10.1002/neu.480040404; HUTCHINSON DO, 1993, BRAIN, V116, P633, DOI 10.1093/brain/116.3.633; INESTROSA NC, 1989, TRENDS PHARMACOL SCI, V10, P325, DOI 10.1016/0165-6147(89)90067-9; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; Legay C, 2000, MICROSC RES TECHNIQ, V49, P56, DOI 10.1002/(SICI)1097-0029(20000401)49:1<56::AID-JEMT7>3.0.CO;2-R; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; Ohno K, 1999, AM J HUM GENET, V65, P635, DOI 10.1086/302551; OHNO K, 1995, P NATL ACAD SCI USA, V92, P758, DOI 10.1073/pnas.92.3.758; Ohno K, 2000, ANN NEUROL, V47, P162, DOI 10.1002/1531-8249(200002)47:2<162::AID-ANA5>3.0.CO;2-Q; Ohno K, 1998, P NATL ACAD SCI USA, V95, P9654, DOI 10.1073/pnas.95.16.9654; Peng HB, 1998, CELL ADHES COMMUN, V5, P475, DOI 10.3109/15419069809005605; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; Rossi SG, 1996, J BIOL CHEM, V271, P1979, DOI 10.1074/jbc.271.4.1979; ROSSI SG, 1993, J BIOL CHEM, V268, P19152; Rotundo RL, 1997, J CELL BIOL, V136, P367, DOI 10.1083/jcb.136.2.367; Rotundo RL, 1994, MYOLOGY, P607; SALPETER MM, 1987, VERTEBRATE NEUROMUSC, P247; SANES JR, 1986, J CELL BIOL, V102, P420, DOI 10.1083/jcb.102.2.420; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; VIGNY M, 1983, J BIOL CHEM, V258, P8794	41	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10997	11005		10.1074/jbc.M305462200	http://dx.doi.org/10.1074/jbc.M305462200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702351	hybrid			2022-12-25	WOS:000220157600022
J	Rishi, V; Gal, J; Krylov, D; Fridriksson, J; Boysen, MS; Mandrup, S; Vinson, C				Rishi, V; Gal, J; Krylov, D; Fridriksson, J; Boysen, MS; Mandrup, S; Vinson, C			SREBP-1 dimerization specificity maps to both the helix-loop-helix and leucine zipper domains - Use of a dominant negative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL SYSTEM; DNA-BINDING; GENE-EXPRESSION; AMINO-ACID; TRANSCRIPTION FACTOR; B/HLH/Z DOMAIN; PROTEINS; CHOLESTEROL; STABILITY; RECOGNITION	The mammalian SREBP family contains two genes that code for B-HLH-ZIP proteins that bind sequence-specific DNA to regulate the expression of genes involved in lipid metabolism. We have designed a dominant negative (DN), termed A-SREBP-1, that inhibits the DNA binding of either SREBP protein. A-SREBP-1 consists of the dimerization domain of B-SREBP-1 and a polyglutamic acid sequence that replaces the basic region. A-SREBP-1 heterodimerizes with either B-SREBP-1 or B-SREBP-2, and both heterodimers are more stable than B-SREBP-1 bound to DNA. Circular dichroism thermal denaturation studies show that the B-SREBP-1 . A-SREBP-1 heterodimer is - 9.8 kcal mol(-1) dimer(-1) more stable than the B-SREBP-1 homodimer. EMSA assays demonstrate that A-SREBP-1 can inhibit the DNA binding of either B-SREBP-1 or B-SREBP-2 in an equimolar competition but does not inhibit the DNA binding of the three B-HLH-ZIP proteins MAX, USF, or MITF, even at 100 molar eq. Chimeric proteins containing the HLH domain of SREBP-1 and the leucine zipper from either MAX, USF, or MITF indicate that both the HLH and leucine zipper regions of SREBP-1 contribute to its dimerization specificity. Transient co-transfection studies demonstrate that A-SREBP-1 can inhibit the transactivation of SREBP-1 and SREBP-2 but not USF. A-SREBP-1 may be useful in metabolic diseases where SREBP family members are overexpressed.	NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; Gene Log Inc, Gaithersburg, MD 20878 USA; Univ So Denmark, Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern Denmark	Vinson, C (corresponding author), NCI, Lab Metab, NIH, Bldg 37,Rm 3128C, Bethesda, MD 20892 USA.	Vinsonc@dc37a.nci.nih.gov	Mandrup, Susanne/B-6693-2008	Gal, Jozsef/0000-0002-5865-6534; Mandrup, Susanne/0000-0002-0961-5787	NATIONAL CANCER INSTITUTE [ZIABC005271, Z01BC005271] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya A, 2002, BIOCHEMISTRY-US, V41, P14122, DOI 10.1021/bi020486r; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Dragan AI, 2002, J MOL BIOL, V321, P891, DOI 10.1016/S0022-2836(02)00699-X; Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; Krylov D, 1998, J MOL BIOL, V279, P959, DOI 10.1006/jmbi.1998.1762; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; LEDENT V, 2002, GENOME BIOL; Litowski JR, 2002, J BIOL CHEM, V277, P37272, DOI 10.1074/jbc.M204257200; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Moll JR, 2000, J BIOL CHEM, V275, P34826, DOI 10.1074/jbc.M004545200; Moll JR, 2002, NUCLEIC ACIDS RES, V30, P1240, DOI 10.1093/nar/30.5.1240; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Parraga A, 1998, STRUCT FOLD DES, V6, P661, DOI 10.1016/S0969-2126(98)00067-7; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; VINSON CR, 1992, NEW BIOL, V4, P396; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; Zeng X, 1997, P NATL ACAD SCI USA, V94, P3673, DOI 10.1073/pnas.94.8.3673; Zitzewitz JA, 2000, J MOL BIOL, V296, P1105, DOI 10.1006/jmbi.2000.3507	35	29	29	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11863	11874		10.1074/jbc.M308000200	http://dx.doi.org/10.1074/jbc.M308000200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702347	hybrid			2022-12-25	WOS:000220157600123
J	Tanabe, H; Qu, XQ; Weeks, CS; Cummings, JE; Kolusheva, S; Walsh, KB; Jelinek, R; Vanderlick, TK; Selsted, ME; Ouellette, AJ				Tanabe, H; Qu, XQ; Weeks, CS; Cummings, JE; Kolusheva, S; Walsh, KB; Jelinek, R; Vanderlick, TK; Selsted, ME; Ouellette, AJ			Structure-activity determinants in Paneth cell alpha-defensins - Loss-of-function in mouse cryptdin-4 by charge-reversal at arginine residue positions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT NEUTROPHIL DEFENSINS; INTESTINAL HOST-DEFENSE; ANTIMICROBIAL PEPTIDES; MEMBRANE PERMEABILIZATION; MICROBICIDAL PROTEINS; ESCHERICHIA-COLI; INNATE IMMUNITY; HUMAN HNP-1; GERM-FREE; MECHANISM	Paneth cells secrete microbicidal enteric alpha-defensins into the small intestinal lumen, and cryptdin-4 (Crp4) is the most bactericidal of the mouse alpha-defensin peptides in vitro. Here, site-directed Arg to Asp mutations in Crp4 have been shown to attenuate or eliminate microbicidal activity against all of the bacterial species tested regardless of the Arg residue position. R31D/R32D charge-reversal mutagenesis at the C terminus and mutations at R16D/R18D, R16D/R24D, and R18D/R24D in the Crp4 polypeptide chain eliminated in vitro bactericidal activity, blocked peptide-membrane interactions, as well as Crp4-mediated membrane vesicle disruption. Lys for Arg charge-neutral substitutions in (R16K/R18K)-Crp4 did not alter the bactericidal activity relative to Crp4, showing that bactericidal activity appears not to require the guanidinium side chain of Arg at those two positions. Partial restoration of (R31D/R32D)-Crp4 bactericidal activity occurred when an electropositive Arg for Gly substitution was introduced at the peptide N terminus and the (G1R/R31D/R32D)-Crp4 peptide exhibited intermediate membrane binding capability. Also, the loss of peptide bactericidal activity in (G1D/R31D/ R32D)-Crp4 and (R16D/R24D)-Crp4 mutants corresponded with diminished phospholipid vesicle disruptive activity. Fluorophore leakage from anionic phospholipid vesicles induced by the charge-reversal variants was negligible relative to Crp4 and lower than that induced by pro-Crp4, the inactive Crp4 precursor. Thus, Arg residues function as determinants of Crp4 bactericidal activity by facilitating or enabling target cell membrane disruption. The role of the Arg residues, however, was surprisingly independent of their position in the polypeptide chain.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA; Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Princeton University; Ben Gurion University	Ouellette, AJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Med Sci I D-440, Irvine, CA 92697 USA.	aouellet@uci.edu	Van Damme, Els J/B-4410-2015; JELINEK, RAZ/F-2023-2012	Kolusheva, Sofiya/0000-0002-4406-2241; jelinek, raz/0000-0002-0336-1384	NIAID NIH HHS [AI22931] Funding Source: Medline; NIDDK NIH HHS [DK44632] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022931, R01AI022931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044632, R01DK044632] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Bevins CL, 1999, GUT, V45, P911, DOI 10.1136/gut.45.6.911; CROSS M, 1990, EMBO J, V9, P1283, DOI 10.1002/j.1460-2075.1990.tb08237.x; Cummings JE, 2003, AUST J CHEM, V56, P1031, DOI 10.1071/CH03110; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GEYER G, 1973, ACTA HISTOCHEM, V45, P126; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Hristova K, 1996, BIOCHEMISTRY-US, V35, P11888, DOI 10.1021/bi961100d; Hristova K, 1997, J BIOL CHEM, V272, P24224, DOI 10.1074/jbc.272.39.24224; HUANG HW, 1999, NOVARTIS FD S, V225, P186; Kolusheva S, 2000, NAT BIOTECHNOL, V18, P225, DOI 10.1038/72697; Kolusheva S, 2000, BIOCHEMISTRY-US, V39, P15851, DOI 10.1021/bi000570b; Kolusheva S, 2001, J AM CHEM SOC, V123, P417, DOI 10.1021/ja0034139; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P15144, DOI 10.1021/bi9811617; MICHAELSON D, 1992, J LEUKOCYTE BIOL, V51, P634, DOI 10.1002/jlb.51.6.634; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; MITCHELL JBO, 1992, J MOL BIOL, V226, P251, DOI 10.1016/0022-2836(92)90137-9; Nyman KM, 2000, J HISTOCHEM CYTOCHEM, V48, P1469, DOI 10.1177/002215540004801104; Ouellette AJ, 2000, J BIOL CHEM, V275, P33969, DOI 10.1074/jbc.M004062200; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; Ouellette AJ, 2001, INFLAMM BOWEL DIS, V7, P43, DOI 10.1097/00054725-200102000-00007; PARDI A, 1988, J MOL BIOL, V201, P625, DOI 10.1016/0022-2836(88)90643-2; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; Porter EM, 2002, CELL MOL LIFE SCI, V59, P156, DOI 10.1007/s00018-002-8412-z; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Satchell DP, 2003, PEPTIDES, V24, P1795, DOI 10.1016/j.peptides.2003.08.020; Satchell DP, 2003, J BIOL CHEM, V278, P13838, DOI 10.1074/jbc.M212115200; SATOH Y, 1986, DIGESTION, V34, P115, DOI 10.1159/000199319; SATOH Y, 1988, CELL TISSUE RES, V251, P87, DOI 10.1007/BF00215451; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shirafuji Y, 2003, J BIOL CHEM, V278, P7910, DOI 10.1074/jbc.M210600200; SMOLARSKY M, 1977, J IMMUNOL METHODS, V15, P255, DOI 10.1016/0022-1759(77)90063-1; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Zanetti M, 1997, ANN NY ACAD SCI, V832, P147, DOI 10.1111/j.1749-6632.1997.tb46244.x; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; ZHANG XL, 1992, BIOCHEMISTRY-US, V31, P11348, DOI 10.1021/bi00161a012	50	63	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11976	11983		10.1074/jbc.M310251200	http://dx.doi.org/10.1074/jbc.M310251200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702345	hybrid			2022-12-25	WOS:000220157600135
J	Tang, W; Hemler, ME				Tang, W; Hemler, ME			Caveolin-1 regulates matrix metalloproteinases-1 induction and CD147/EMMPRIN cell surface clustering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGENASE-STIMULATORY FACTOR; IMMUNOGLOBULIN SUPERFAMILY; EXPRESSION; INTEGRIN; CD147; TUMOR; BASIGIN; INDUCER; EMMPRIN; MEMBER	CD147, a regulator of matrix metalloproteinase (MMP) production, showed highly specific association with caveolin-1 on the surface of multiple cell types. CD147-caveolin-1 complex formation was temperature and cholesterol dependent, reminiscent of associations seen within caveolae/lipid rafts. However, the subset of caveolin-1 associated with CD147 appeared exclusively within intermediate density sucrose gradient fractions, rather than in the low density fractions containing the bulk of caveolin-1. Mutagenesis experiments revealed that CD147 Ig domain 2 was required for caveolin-1 association. In contrast to CD147-caveolin-1 complexes, CD147-alpha(3) integrin association was not disrupted upon cholesterol depletion, occurred in high density sucrose fractions, and did not involve CD147 Ig domain 2. Overexpression of caveolin-1 caused a specific decrease in clustering of cell surface CD147, as detected by "cluster specific" mAb M6/13. Conversely, a mutant CD147 deficient in caveolin-1 association showed enhanced spontaneous cell surface clustering ( detected by mAb M6/13), and did not show decreased clustering in response to caveolin-1 overexpression. Furthermore, the same CD147 mutant yielded an elevated induction of MMP-1. In conclusion, caveolin-1 associates with CD147, in a complex distinct from CD147-alpha(3) integrin complexes, thereby diminishing both CD147 clustering and CD147-dependent MMP-1-inducing activity.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Hemler, ME (corresponding author), Dana Farber Canc Inst, Rm D-1430,44 Binney St, Boston, MA 02115 USA.	Martin_Hemler@dfci.harvard.edu			NCI NIH HHS [CA86712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BISWAS C, 1995, CANCER RES, V55, P434; Bordador LC, 2000, INT J CANCER, V85, P347, DOI 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.3.CO;2-R; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Coste I, 2001, BLOOD, V97, P3984, DOI 10.1182/blood.V97.12.3984; Deeg HJ, 2001, BLOOD, V98, P2052, DOI 10.1182/blood.V98.7.2052; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elliott MH, 2003, BIOCHEMISTRY-US, V42, P7892, DOI 10.1021/bi027162n; ELLIS SM, 1989, CANCER RES, V49, P3385; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Guo HM, 1997, J BIOL CHEM, V272, P24; Hori K, 2000, INVEST OPHTH VIS SCI, V41, P3128; Igakura T, 1996, BIOCHEM BIOPH RES CO, V224, P33, DOI 10.1006/bbrc.1996.0980; Igakura T, 1998, DEV BIOL, V194, P152, DOI 10.1006/dbio.1997.8819; Jiang JL, 2001, J BIOL CHEM, V276, P46870, DOI 10.1074/jbc.M108291200; Kanekura T, 2002, INT J CANCER, V99, P520, DOI 10.1002/ijc.10390; KASINRERK W, 1992, J IMMUNOL, V149, P847; KATAOKA H, 1993, CANCER RES, V53, P3154; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Koch C, 1999, INT IMMUNOL, V11, P777, DOI 10.1093/intimm/11.5.777; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; Kuno N, 1998, FEBS LETT, V425, P191, DOI 10.1016/S0014-5793(98)00213-0; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; MURAOKA K, 1993, INT J CANCER, V55, P19, DOI 10.1002/ijc.2910550105; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Philp NJ, 2003, INVEST OPHTH VIS SCI, V44, P1305, DOI 10.1167/iovs.02-0552; Polette M, 1997, J HISTOCHEM CYTOCHEM, V45, P703, DOI 10.1177/002215549704500508; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Renno T, 2002, J IMMUNOL, V168, P4946, DOI 10.4049/jimmunol.168.10.4946; Sameshima T, 2000, INT J CANCER, V88, P21, DOI 10.1002/1097-0215(20001001)88:1<21::AID-IJC4>3.0.CO;2-S; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Sun JX, 2001, CANCER RES, V61, P2276; Taylor PM, 2002, ONCOGENE, V21, P5765, DOI 10.1038/sj.onc.1205702; Tomita T, 2002, ARTHRITIS RHEUM, V46, P373, DOI 10.1002/art.10050; vandenOord JJ, 1997, AM J PATHOL, V151, P665; Walmsley AR, 2003, J BIOL CHEM, V278, P37241, DOI 10.1074/jbc.M302036200; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Yang HL, 2001, J BIOL CHEM, V276, P18775, DOI 10.1074/jbc.M009852200; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	51	129	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11112	11118		10.1074/jbc.M312947200	http://dx.doi.org/10.1074/jbc.M312947200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707126	hybrid			2022-12-25	WOS:000220157600035
J	Cho, WK; Siegrist, VJ; Zinzow, W				Cho, WK; Siegrist, VJ; Zinzow, W			Impaired regulatory volume decrease in freshly isolated cholangiocytes from cystic fibrosis mice - Implications for cystic fibrosis transmembrane conductance regulator effect on potassium conductance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	52nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases/International-Liver-Transplantation-Society	NOV 09-13, 2001	DALLAS, TX	Amer Assoc Study Liver Dis, Int Liver Transplant Soc			INTRACELLULAR PH REGULATION; BILE-DUCT UNITS; CELL-VOLUME; ATP RELEASE; PRIMARY CULTURES; HYPOTONIC SHOCK; ANION CHANNELS; CL-CHANNELS; K+ CHANNELS; RAT	Various K+ and Cl- channels are important in cell volume regulation and biliary secretion, but the specific role of cystic fibrosis transmembrane conductance regulator in cholangiocyte cell volume regulation is not known. The goal of this research was to study regulatory volume decrease (RVD) in bile duct cell clusters (BD-CCs) from normal and cystic fibrosis (CF) mouse livers. Mouse BDCCs without an enclosed lumen were prepared as described (Cho, W. K. (2002) Am. J. Physiol. 283, G1320 - G1327). The isotonic solution consisted of HEPES buffer with 40% of the NaCl replaced with isomolar amounts of sucrose, whereas hypotonic solution was the same as isotonic solution without sucrose. The cell volume changes were indirectly assessed by measuring cross-sectional area (CSA) changes of the BDCCs using quantitative videomicroscopy. Exposure to hypotonic solutions increased relative CSAs of normal BDCCs to 1.20 +/- 0.01 (mean +/- S. E., n = 50) in 10 min, followed by RVD to 1.07 +/- 0.01 by 40 min. Hypotonic challenge in CF mouse BDCCs also increased relative CSA to 1.20 +/- 0.01 ( n = 53) in 10 min but without significant recovery. Coadministration of the K+-selective ionophore valinomycin restored RVD in CF mouse BDCCs, suggesting that the impaired RVD was likely from a defect in K+ conductance. Moreover, this valinomycin-induced RVD in CF mice was inhibited by 5-nitro-2'-(3-phenylpropylamino)benzoate, indicating that it is not from nonspecific effects. Neither cAMP nor calcium agonists could reverse the impaired RVD seen in CF cholangiocytes. Our conclusion is that CF mouse cholangiocytes have defective RVD from an impaired K+ efflux pathway, which could not be reversed by cAMP nor calcium agonists.	Indiana Univ, Sch Med, Dept Med, Div Gastroenterol Hepatol, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; University of North Carolina; University of North Carolina Chapel Hill	Cho, WK (corresponding author), Indiana Univ, Sch Med, Roudebush VA Med Ctr, Div GI Hepatol 111G, 1481 W 10th St, Indianapolis, IN 46202 USA.	wkcho@iupui.edu		Zinzow-Kramer, Wendy/0000-0003-1469-5803	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002613, R03DK061409] Funding Source: NIH RePORTER; NIDDK NIH HHS [R03 DK61409, K08 DK02613] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVARO D, 1993, J CLIN INVEST, V92, P1314, DOI 10.1172/JCI116705; Ando-Akatsuka Y, 2002, PFLUG ARCH EUR J PHY, V445, P177, DOI 10.1007/s00424-002-0920-z; Arreola J, 2003, J PHYSIOL-LONDON, V547, P197, DOI 10.1113/jphysiol.2002.028373; BANDERALI U, 1992, J MEMBRANE BIOL, V126, P219; Barriere H, 2003, AM J PHYSIOL-RENAL, V284, pF796, DOI 10.1152/ajprenal.00237.2002; Belfodil R, 2003, AM J PHYSIOL-RENAL, V284, pF812, DOI 10.1152/ajprenal.00238.2002; BENEDETTI A, 1993, HEPATOLOGY, V18, P422, DOI 10.1016/0270-9139(93)90028-L; BRUCK R, 1992, AM J PHYSIOL, V262, pG806, DOI 10.1152/ajpgi.1992.262.5.G806; Cho WK, 2002, AM J PHYSIOL-GASTR L, V283, pG1320, DOI 10.1152/ajpgi.00256.2002; Cho WK, 1998, HEPATOLOGY, V28, p534A; Cho WK, 2001, AM J PHYSIOL-GASTR L, V280, pG241, DOI 10.1152/ajpgi.2001.280.2.G241; CHO WK, 2000, GASTR HEPAT, V7, P99; CIVAN MM, 1992, EXP EYE RES, V54, P181, DOI 10.1016/S0014-4835(05)80207-6; CIVAN MM, 1994, INVEST OPHTH VIS SCI, V35, P2876; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; COHN JA, 1993, GASTROENTEROLOGY, V105, P1857, DOI 10.1016/0016-5085(93)91085-V; Feranchak AP, 2002, SEMIN LIVER DIS, V22, P251, DOI 10.1055/s-2002-34503; Fischbarg J, 1997, BRIT J OPHTHALMOL, V81, P85, DOI 10.1136/bjo.81.1.85; FITZ JG, 1993, J CLIN INVEST, V91, P319, DOI 10.1172/JCI116188; FOSKETT JK, 1994, J EXP ZOOL, V268, P104, DOI 10.1002/jez.1402680206; Graf J, 1996, J HEPATOL, V24, P53; GRINSTEIN S, 1990, J GEN PHYSIOL, V95, P97, DOI 10.1085/jgp.95.1.97; HALL SK, 1995, J PHYSIOL-LONDON, V488, P359, DOI 10.1113/jphysiol.1995.sp020972; Haussinger D, 1996, Prog Liver Dis, V14, P29; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; Hazama A, 2000, J PHYSIOL-LONDON, V523, P1, DOI 10.1111/j.1469-7793.2000.t01-6-00001.x; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; Konstas AA, 2002, J BIOL CHEM, V277, P25377, DOI 10.1074/jbc.M201925200; LIRA M, 1992, GASTROENTEROLOGY, V102, P563, DOI 10.1016/0016-5085(92)90104-7; LOHR JW, 1994, BRAIN RES, V667, P263, DOI 10.1016/0006-8993(94)91504-0; MCCARTY NA, 1991, J MEMBRANE BIOL, V123, P149, DOI 10.1007/BF01998085; MCGILL JM, 1992, AM J PHYSIOL, V262, pG703, DOI 10.1152/ajpgi.1992.262.4.G703; McNicholas CM, 1997, AM J PHYSIOL-RENAL, V273, pF843, DOI 10.1152/ajprenal.1997.273.5.F843; MENNONE A, 1995, P NATL ACAD SCI USA, V92, P6527, DOI 10.1073/pnas.92.14.6527; Mignen O, 1999, J PHYSIOL-LONDON, V515, P501, DOI 10.1111/j.1469-7793.1999.501ac.x; MONTROSERAFIZADEH C, 1991, AM J PHYSIOL, V260, pF402, DOI 10.1152/ajprenal.1991.260.3.F402; Morales-Mulia S, 1998, J NEUROCHEM, V71, P2330; Moran J, 1997, J NEUROSCI RES, V47, P144, DOI 10.1002/(SICI)1097-4547(19970115)47:2<144::AID-JNR3>3.0.CO;2-F; ROBERTS SK, 1994, P NATL ACAD SCI USA, V91, P13009, DOI 10.1073/pnas.91.26.13009; Roman R, 2002, AM J PHYSIOL-GASTR L, V282, pG116, DOI 10.1152/ajpgi.2002.282.1.G116; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; Roman RM, 1996, AM J PHYSIOL-GASTR L, V271, pG239, DOI 10.1152/ajpgi.1996.271.2.G239; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SIRICA AE, 1985, AM J PATHOL, V120, P67; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STRAZZABOSCO M, 1991, J CLIN INVEST, V87, P1503, DOI 10.1172/JCI115160; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; THOMASYOUNG RJ, 1993, BIOCHIM BIOPHYS ACTA, V1146, P81, DOI 10.1016/0005-2736(93)90341-V; Tinel H, 2000, CELL PHYSIOL BIOCHEM, V10, P297, DOI 10.1159/000016375; VALVERDE MA, 1995, P NATL ACAD SCI USA, V92, P9038, DOI 10.1073/pnas.92.20.9038; Vennekens R, 1999, J PHYSIOL-LONDON, V515, P75, DOI 10.1111/j.1469-7793.1999.075ad.x; Walker VE, 1999, AM J PHYSIOL-CELL PH, V276, pC1432, DOI 10.1152/ajpcell.1999.276.6.C1432; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Wang ZR, 1997, J GEN PHYSIOL, V110, P73, DOI 10.1085/jgp.110.1.73; Weskamp M, 2000, J MEMBRANE BIOL, V178, P11, DOI 10.1007/s002320010010	55	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14610	14618		10.1074/jbc.M310855200	http://dx.doi.org/10.1074/jbc.M310855200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	808UT	14722124	hybrid			2022-12-25	WOS:000220594700019
J	Brame, CJ; Boutaud, O; Davies, SS; Yang, T; Oates, JA; Roden, D; Roberts, LJ				Brame, CJ; Boutaud, O; Davies, SS; Yang, T; Oates, JA; Roden, D; Roberts, LJ			Modification of proteins by isoketal-containing oxidized phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; VENTRICULAR MYOCYTES; ALDEHYDIC PRODUCT; FREE-RADICALS; PROSTANOIDS F2-ISOPROSTANES; 4-HYDROXYNONENAL TRIGGERS; CA2+ INFLUX; PATHWAY; INHIBITION; CURRENTS	Oxidative stress frequently leads to altered function of membrane proteins. Isoketals are highly reactive products of the isoprostane pathway of free radical-induced lipid peroxidation that rapidly form covalent protein adducts and exhibit a remarkable proclivity to form protein cross links in vitro. Examination of isoketal adducts from an animal model of oxidative injury revealed that initial adducts were formed by isoketals esterified in phospholipids, representing a novel oxidative injury-associated modification of proteins by phospholipids. Maturation of adducts involved cleavage from phospholipids and conversion of adducts to a more stable chemical form that can be detected for extended periods. Because initial adducts were formed by phospholipid-esterified isoketals, the functional consequence of isoketal adduction was examined using a model membrane protein ( a cardiac K+ channel). These studies revealed that isoketal adduction profoundly altered protein function, inhibiting potassium current in a dose-dependent manner. These findings indicate that phospholipid-esterified isoketals rapidly adduct membrane proteins and that such modification can alter protein function, suggesting a generalized cellular mechanism for alteration of membrane function as a consequence of oxidative stress.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA; Vanderbilt Univ, Dept Med, Nashville, TN USA	Vanderbilt University; Vanderbilt University	Roberts, LJ (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA.	jack.roberts@vanderbilt.edu	Roden, Dan/ABD-5412-2021	Davies, Sean/0000-0001-9879-8062	NHLBI NIH HHS [HL46881] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM42056, GM15431] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042056, P50GM015431, R01GM042056, P01GM015431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antoine S, 1998, J MOL CELL CARDIOL, V30, P2623, DOI 10.1006/jmcc.1998.0818; Bernoud-Hubac N, 2001, J BIOL CHEM, V276, P30964, DOI 10.1074/jbc.M103768200; BHATNAGAR A, 1995, CIRC RES, V76, P293, DOI 10.1161/01.RES.76.2.293; Blanc EM, 1997, J NEUROCHEM, V69, P570; Boutaud O, 1999, BIOCHEMISTRY-US, V38, P9389, DOI 10.1021/bi990470+; Brame CJ, 1999, J BIOL CHEM, V274, P13139, DOI 10.1074/jbc.274.19.13139; Butterfield DA, 1997, CHEM RES TOXICOL, V10, P495, DOI 10.1021/tx960130e; Carini R, 1996, BIOCHEM BIOPH RES CO, V218, P772, DOI 10.1006/bbrc.1996.0137; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; DIX TA, 1993, CHEM RES TOXICOL, V6, P2, DOI 10.1021/tx00031a001; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GILL JS, 1995, EUR J PHARM-ENVIRON, V292, P337, DOI 10.1016/0926-6917(95)90042-X; GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Kagan V. E, 1988, LIPID PEROXIDATION B; Kawakami M, 1998, MOL PHARMACOL, V53, P497, DOI 10.1124/mol.53.3.497; Liu W, 1999, J CELL SCI, V112, P2409; Mark RJ, 1997, J NEUROCHEM, V68, P255; MILLER DB, 1990, J ORG CHEM, V55, P3164, DOI 10.1021/jo00297a036; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; SATOH N, 1995, EUR J PHARM-ENVIRON, V292, P233, DOI 10.1016/0926-6917(95)90027-6; SHATTOCK MJ, 1993, CIRC RES, V72, P91, DOI 10.1161/01.RES.72.1.91; Tokube K, 1996, AM J PHYSIOL-HEART C, V271, pH478, DOI 10.1152/ajpheart.1996.271.2.H478; Ueda K, 1997, J NEUROCHEM, V68, P265; YANG T, 1994, CIRC RES, V75, P870, DOI 10.1161/01.RES.75.5.870	27	70	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13447	13451		10.1074/jbc.M313349200	http://dx.doi.org/10.1074/jbc.M313349200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14715668	hybrid			2022-12-25	WOS:000220478500022
J	Cottrell, GS; Amadesi, S; Grady, EF; Bunnett, NW				Cottrell, GS; Amadesi, S; Grady, EF; Bunnett, NW			Trypsin IV, a novel agonist of protease-activated receptors 2 and 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL TRYPTASE; MOLECULAR-CLONING; THROMBIN RECEPTOR; INHIBITOR RESISTANCE; MYENTERIC NEURONS; EPITHELIAL-CELLS; SERINE PROTEASES; EXPRESSION; IDENTIFICATION; TISSUE	Certain serine proteases signal to cells by cleaving protease-activated receptors (PARs) and thereby regulate hemostasis, inflammation, pain and healing. However, in many tissues the proteases that activate PARs are unknown. Although pancreatic trypsin may be a physiological agonist of PAR(2) and PAR(4) in the small intestine and pancreas, these receptors are expressed by cells not normally exposed pancreatic trypsin. We investigated whether extrapancreatic forms of trypsin are PAR agonists. Epithelial cells lines from prostate, colon, and airway and human colonic mucosa expressed mRNA encoding PAR(2), trypsinogen IV, and enteropeptidase, which activates the zymogen. Immunoreactive trypsinogen IV was detected in vesicles in these cells. Trypsinogen IV was cloned from PC-3 cells and expressed in CHO cells, where it was also localized to cytoplasmic vesicles. We expressed trypsinogen IV with an N-terminal Igkappa signal peptide to direct constitutive secretion and allow enzymatic characterization. Treatment of conditioned medium with enteropeptidase reduced the apparent molecular mass of trypsinogen IV from 36 to 30 kDa and generated enzymatic activity, consistent with formation of trypsin IV. In contrast to pancreatic trypsin, trypsin IV was completely resistant to inhibition by polypeptide inhibitors. Exposure of cell lines expressing PAR(2) and PAR(4) to trypsin IV increased [Ca2+](i) and strongly desensitized cells to PAR agonists, whereas there were no responses in cells lacking these receptors. Thus, trypsin IV is a potential agonist of PAR(2) and PAR(4) in epithelial tissues where its resistance to endogenous trypsin inhibitors may permit prolonged signaling.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.	nigelb@itsa.ucsf.edu		Bunnett, Nigel W./0000-0003-3367-0644; Cottrell, Graeme/0000-0001-9098-7627	NIDDK NIH HHS [DK52388, DK43207, DK57840] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057840, R01DK043207, R56DK043207, R01DK052388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alm AK, 2000, BIOCHEM BIOPH RES CO, V275, P77, DOI 10.1006/bbrc.2000.3267; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002-9440(10)64466-5; Compton SJ, 2002, BIOCHEM J, V368, P495, DOI 10.1042/BJ20020706; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Corvera CU, 1999, J PHYSIOL-LONDON, V517, P741, DOI 10.1111/j.1469-7793.1999.0741s.x; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Ducroc R, 2002, LIFE SCI, V70, P1359, DOI 10.1016/S0024-3205(01)01519-3; EMI M, 1986, GENE, V41, P305; Ferris HA, 1997, PEPTIDES, V18, P663, DOI 10.1016/S0196-9781(97)00127-7; Gao CY, 2002, GASTROENTEROLOGY, V123, P1554, DOI 10.1053/gast.2002.36581; Hoogerwerf WA, 2002, BMC MOL BIOL, V3, DOI 10.1186/1471-2199-3-2; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Katona G, 2002, J MOL BIOL, V315, P1209, DOI 10.1006/jmbi.2001.5305; KOIVUNEN E, 1989, J BIOL CHEM, V264, P14095; KOIVUNEN E, 1991, INT J CANCER, V47, P592, DOI 10.1002/ijc.2910470419; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; KOSHIKAWA N, 1994, BIOCHEM J, V303, P187, DOI 10.1042/bj3030187; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; Koshikawa N, 1998, AM J PATHOL, V153, P937, DOI 10.1016/S0002-9440(10)65635-0; Kunitz M, 1939, J GEN PHYSIOL, V22, P429, DOI 10.1085/jgp.22.4.429; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Minn A, 1998, GLIA, V22, P338, DOI 10.1002/(SICI)1098-1136(199804)22:4<338::AID-GLIA3>3.0.CO;2-#; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Nyaruhucha CNM, 1997, J BIOL CHEM, V272, P10573; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; OSSOVSKAYA VS, 2004, IN PRESS PHYSL REV; Reed DE, 2003, J PHYSIOL-LONDON, V547, P531, DOI 10.1113/jphysiol.2002.032011; RINDERKNECHT H, 1984, GASTROENTEROLOGY, V86, P681; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SmithSwintosky VL, 1997, J NEUROCHEM, V69, P1890; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Szmola R, 2003, J BIOL CHEM, V278, P48580, DOI 10.1074/jbc.M310301200; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; YAMASHINA I, 1956, ACTA CHEM SCAND, V10, P739, DOI 10.3891/acta.chem.scand.10-0739	49	138	144	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13532	13539		10.1074/jbc.M312090200	http://dx.doi.org/10.1074/jbc.M312090200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726524	hybrid			2022-12-25	WOS:000220478500032
J	O'Callaghan, DW; Burgoyne, RD				O'Callaghan, DW; Burgoyne, RD			Identification of residues that determine the absence of a Ca2+/myristoyl switch in neuronal calcium sensor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING PROTEIN-1; BINDING PROTEIN; MEMBRANE ASSOCIATION; POTASSIUM CHANNELS; NEUROCALCIN-DELTA; CRYSTAL-STRUCTURE; MYRISTOYL GROUP; FREQUENIN; CHROMAFFIN; FAMILY	The neuronal calcium sensor (NCS) family of Ca2+-binding proteins regulates a number of different processes in neurons and photoreceptor cells. The first of these proteins to be characterized, recoverin, was shown to exhibit a Ca2+/myristoyl switch whereby its N-terminal myristoyl group is sequestered in the Ca2+-free form and is exposed on Ca2+ binding to allow the protein to become membrane-associated. It has subsequently been shown that certain other family members also exhibit this mechanism in living cells. In contrast, NCS-1 does not show the Ca2+/myristoyl switch and is membrane-associated even at low Ca2+ concentrations. We have used sequence comparison combined with information from structural analyses to attempt to identify candidate residues within the NCS proteins that determine whether or not the Ca2+/myristoyl switch operates in cells and have tested their functional significance by mutagenesis. The results show that NCS-1 possesses residues within its N terminus that lock the myristoyl group in an exposed conformation. In addition, other structural aspects within the C-terminal domains are required to allow the switch to operate. We have determined a key role for residues within the motif EELTRK in NCS-1 in keeping the myristoyl group exposed and allowing the protein to be constitutively membrane-associated.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liv.ac.uk	Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387				Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Burgoyne RD, 2001, BIOCHEM J, V353, P1; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; Cheng HYM, 2002, CELL, V108, P31, DOI 10.1016/S0092-8674(01)00629-8; COX JA, 1994, J BIOL CHEM, V269, P32807; Gomez M, 2001, NEURON, V30, P241, DOI 10.1016/S0896-6273(01)00276-8; Guo WN, 2002, J BIOL CHEM, V277, P26436, DOI 10.1074/jbc.M201431200; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Heo WD, 2003, CELL, V113, P315; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; Hwang JY, 2002, BBA-PROTEINS PROTEOM, V1600, P111, DOI 10.1016/S1570-9639(02)00451-X; Hwang JY, 2002, BIOCHEMISTRY-US, V41, P13021, DOI 10.1021/bi026618y; Ivings L, 2002, BIOCHEM J, V363, P599, DOI 10.1042/0264-6021:3630599; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; Koizumi S, 2002, J BIOL CHEM, V277, P30315, DOI 10.1074/jbc.M201132200; LADANT D, 1995, J BIOL CHEM, V270, P3179; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Martone ME, 1999, CELL TISSUE RES, V295, P395, DOI 10.1007/s004410051246; Matsuda S, 1999, BIOCHEMISTRY-US, V38, P1310, DOI 10.1021/bi982117u; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; O'Callaghan DW, 2003, J CELL SCI, V116, P4833, DOI 10.1242/jcs.00803; O'Callaghan DW, 2002, J BIOL CHEM, V277, P14227, DOI 10.1074/jbc.M111750200; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Spilker C, 2000, NEUROSCIENCE, V96, P121, DOI 10.1016/S0306-4522(99)00536-9; Spilker C, 2002, J NEUROSCI, V22, P7331; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Tsujimoto T, 2002, SCIENCE, V295, P2276, DOI 10.1126/science.1068278; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Weiss JL, 2002, TRENDS NEUROSCI, V25, P489, DOI 10.1016/S0166-2236(02)02247-6; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	42	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14347	14354		10.1074/jbc.M310152200	http://dx.doi.org/10.1074/jbc.M310152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726528	hybrid			2022-12-25	WOS:000220478500130
J	Planque, S; Bangale, Y; Song, XT; Karle, S; Taguchi, H; Poindexter, B; Bick, R; Edmundson, A; Nishiyama, Y; Paul, S				Planque, S; Bangale, Y; Song, XT; Karle, S; Taguchi, H; Poindexter, B; Bick, R; Edmundson, A; Nishiyama, Y; Paul, S			Ontogeny of proteolytic immunity - IgM serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ANTIBODIES; MONOCLONAL-ANTIBODIES; MURINE IGM; B-CELLS; BINDING; INHIBITORS; PEPTIDE; HYDROLYSIS; EXPRESSION; REACTIVITY	We report the chemical activity of immunoglobulin mu and kappa/lambda subunits expressed on the surface of B cells and in secreted IgM antibodies (Abs) found in the preimmune repertoire. Most of the nucleophilic reactivity of B cells measured by formation of covalent adducts of a hapten amidino phosphonate diester was attributed to mu and kappa/lambda subunits of the B cell receptor. Secreted IgM Abs displayed superior nucleophilic reactivity than IgG Abs. IgM Abs catalyzed the cleavage of model peptide substrates at rates up to 344-fold greater than IgG Abs. Catalytic activities were observed in polyclonal IgM Abs from immunologically naive mice and humans without immunological disease, as well as monoclonal IgM Abs to unrelated antigens. Comparison of several IgM Abs indicated divergent activity levels and substrate preferences, with the common requirement of a basic residue flanking the cleavage site. Fab fragments of a monoclonal IgM Ab expressed catalytic activity, confirming the V domain location of the catalytic site. The catalytic reaction was inhibited by the covalently reactive hapten probe and diisopropylfluorophosphate, suggesting a serine protease-like mechanism. These observations indicate the existence of serine protease-like BCRs and secreted IgM Abs as innate immunity components with potential roles in B cell development and Ab effector functions.	Univ Texas, Sch Med, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA; Oklahoma Med Res Fdn, Crystallog Program, Oklahoma City, OK 73104 USA	University of Texas System; Oklahoma Medical Research Foundation	Paul, S (corresponding author), Univ Texas, Sch Med, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, 6431 Fannin, Houston, TX 77030 USA.	Sudhir.Paul@uth.tmc.edu			NCI NIH HHS [CA80312] Funding Source: Medline; NIAID NIH HHS [AI31268] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI031268, R01AI031268] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLARD DW, 1983, P NATL ACAD SCI-BIOL, V80, P5071, DOI 10.1073/pnas.80.16.5071; Bangale Y, 2003, FASEB J, V17, P628, DOI 10.1096/fj.02-0475com; BERBERIAN L, 1993, SCIENCE, V261, P1588, DOI 10.1126/science.7690497; Berisha HI, 2002, PULM PHARMACOL THER, V15, P121, DOI 10.1006/pupt.2001.0337; BIRO A, 1992, EUR J IMMUNOL, V22, P2547, DOI 10.1002/eji.1830221013; CHAVIN SI, 1969, J BIOL CHEM, V244, P1345; CHEN TY, 1993, AM J HEMATOL, V44, P276, DOI 10.1002/ajh.2830440411; CORNISHBOWDEN AJ, 1969, BIOCHEM J, V113, P353, DOI 10.1042/bj1130353; Crabb JW, 2002, PROTEIN SCI, V11, P831, DOI 10.1110/ps.4400102; Dunn-Walters DK, 2000, J IMMUNOL, V164, P1595, DOI 10.4049/jimmunol.164.3.1595; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Hatiuchi K, 2003, IMMUNOL LETT, V86, P249, DOI 10.1016/S0165-2478(03)00030-0; Hifumi E, 1999, J BIOSCI BIOENG, V88, P323, DOI 10.1016/S1389-1723(00)80018-3; Jeannin P, 1998, EUR J IMMUNOL, V28, P1815, DOI 10.1002/(SICI)1521-4141(199806)28:06<1815::AID-IMMU1815>3.0.CO;2-5; KALAGA R, 1995, J IMMUNOL, V155, P2695; KOHEN F, 1980, FEBS LETT, V111, P427, DOI 10.1016/0014-5793(80)80842-8; Kolesnikov AV, 2000, P NATL ACAD SCI USA, V97, P13526, DOI 10.1073/pnas.200360497; KU GSB, 1983, J IMMUNOL, V131, P2494; KU GSB, 1981, J IMMUNOL, V126, P2209; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; Li L, 1996, MOL IMMUNOL, V33, P593, DOI 10.1016/0161-5890(96)00021-1; LI L, 1995, J IMMUNOL, V154, P3328; MACKENZIE MR, 1978, SCAND J IMMUNOL, V7, P367, DOI 10.1111/j.1365-3083.1978.tb00466.x; Malynn BA, 2002, MOL IMMUNOL, V38, P547, DOI 10.1016/S0161-5890(01)00085-2; Marangoni AG, 2002, ENZYME KINETICS, P70; MARKS R, 1985, J EXP MED, V162, P1862, DOI 10.1084/jem.162.6.1862; Matsuura K, 1998, IMMUNOLOGY, V95, P26; Melchers F, 2000, IMMUNOL REV, V175, P33, DOI 10.1111/j.1600-065X.2000.imr017510.x; MIZUGUCHI J, 1989, BIOCHEM J, V263, P641, DOI 10.1042/bj2630641; MORELOCK MM, 1994, J BIOL CHEM, V269, P13048; Nishiyama Y, 2002, ARCH BIOCHEM BIOPHYS, V402, P281, DOI 10.1016/S0003-9861(02)00087-5; OLEKSYSZYN J, 1994, METHOD ENZYMOL, V244, P423; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; Papavasiliou F, 1997, SCIENCE, V278, P298, DOI 10.1126/science.278.5336.298; PAUL S, 1995, J BIOL CHEM, V270, P15257, DOI 10.1074/jbc.270.25.15257; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1992, J BIOL CHEM, V267, P13142; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; Planque S, 2003, J BIOL CHEM, V278, P20436, DOI 10.1074/jbc.M301468200; Poindexter BJ, 2002, MICROSC ANAL, V89, P21; PRAK EL, 1995, J EXP MED, V182, P541, DOI 10.1084/jem.182.2.541; RASO V, 1975, BIOCHEMISTRY-US, V14, P591, DOI 10.1021/bi00674a020; ROHEN PW, 1995, J IMMUNOL, V154, P6437; Roux KH, 1998, J IMMUNOL, V161, P4083; SAMPSON NS, 1991, BIOCHEMISTRY-US, V30, P2255, DOI 10.1021/bi00222a031; Sato S, 1996, J IMMUNOL, V157, P4371; Saveliev AN, 2003, IMMUNOL LETT, V86, P291, DOI 10.1016/S0165-2478(03)00042-7; Shaw DC, 2002, J MOL RECOGNIT, V15, P341, DOI 10.1002/jmr.596; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; TAWFIK DS, 1995, P NATL ACAD SCI USA, V92, P2145, DOI 10.1073/pnas.92.6.2145; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; Tramontano A, 2000, CHEM IMMUNOL, V77, P1, DOI 10.1159/000058794; VANERP R, 1991, J IMMUNOL METHODS, V140, P235, DOI 10.1016/0022-1759(91)90376-Q; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6	54	57	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14024	14032		10.1074/jbc.M312152200	http://dx.doi.org/10.1074/jbc.M312152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726510	hybrid			2022-12-25	WOS:000220478500091
J	Denti, S; Sirri, A; Cheli, A; Rogge, L; Innamorati, G; Putignano, S; Fabbri, M; Pardi, R; Bianchi, E				Denti, S; Sirri, A; Cheli, A; Rogge, L; Innamorati, G; Putignano, S; Fabbri, M; Pardi, R; Bianchi, E			RanBPM is a phosphoprotein that associates with the plasma membrane and interacts with the integrin LFA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; MAP KINASE; SIGNAL-TRANSDUCTION; NUCLEAR-PROTEIN; BINDING-PROTEIN; CELL-MIGRATION; ACTIVATION; PHOSPHORYLATION; ADHESION; IDENTIFICATION	Integrin adhesion receptors can act as signaling receptors that transmit information from the extracellular environment to the interior of the cell, affecting many fundamental cellular processes, such as cell motility, proliferation, differentiation, and survival. Integrin signaling depends on the formation of organized sub- membrane complexes that comprise cytoskeletal, adapter, and signaling molecules. The identification of molecules that interact with the cytoplasmic domain of integrins has been the focus of research aimed to elucidating the mechanistic basis of integrin signal transduction. We have identified RanBPM as a novel interactor of the beta(2) integrin LFA- 1 in a yeast- two- hybrid screen. In the same assay, RanBPM also interacted with the beta(1) integrin cytoplasmic domain. We demonstrate that RanBPM is a peripheral membrane protein and that integrins and RanBPM interact in vitro and in vivo and co- localize at the cell membrane. We find that RanBPM is phosphorylated on serine residues; phosphorylation of RanBPM is increased by stress stimuli and decreased by treatment with the p38 kinase inhibitor SB203580. Transfection of RanBPM synergizes with LFA- 1- mediated adhesion in the transcriptional activation of an AP- 1- dependent promoter, indicating that the two proteins interact functionally as well. We suggest that RanBPM may constitute a molecular scaffold that contributes to coupling LFA- 1 and other integrins with intracellular signaling pathways.	Inst Pasteur, Dept Immunol, Immunoregulat Lab, F-75724 Paris, France; DIBIT, Lab Leukocyte Biol, I-20132 Milan, Italy; Univ Vita San Raffaele, I-20132 Milan, Italy	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bianchi, E (corresponding author), Inst Pasteur, Dept Immunol, Immunoregulat Lab, 25 Rue Dr Roux, F-75724 Paris, France.	ebianchi@pasteur.fr	Rogge, Lars/GYJ-6142-2022; Innamorati, Giulio/AAR-6314-2020; Innamorati, Giulio/GVU-1941-2022	Innamorati, Giulio/0000-0003-0123-8777; Rogge, Lars/0000-0003-1262-9204	Telethon [E.1300] Funding Source: Medline	Telethon(Fondazione Telethon)		Adams JC, 1998, EMBO J, V17, P4964, DOI 10.1093/emboj/17.17.4964; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bai D, 2003, BIOCHEM BIOPH RES CO, V309, P552, DOI 10.1016/j.bbrc.2003.08.033; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Bokel C, 2002, DEV CELL, V3, P311, DOI 10.1016/S1534-5807(02)00265-4; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHEN QM, 1994, J BIOL CHEM, V269, P26602; COPPOLINO M, 1995, BIOCHEM J, V306, P129, DOI 10.1042/bj3060129; de Fougerolles AR, 2000, IMMUNITY, V13, P749, DOI 10.1016/S1074-7613(00)00073-X; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Geginat J, 1999, J IMMUNOL, V162, P5085; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hogg N, 2001, J LEUKOCYTE BIOL, V69, P893; Hogg N, 2000, MATRIX BIOL, V19, P211, DOI 10.1016/S0945-053X(00)00066-4; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Juliano RL, 2001, METHOD ENZYMOL, V333, P151; Liu SC, 2000, J CELL SCI, V113, P3563; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nebe B, 1998, EXP CELL RES, V243, P263, DOI 10.1006/excr.1998.4143; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Rao MA, 2002, J BIOL CHEM, V277, P48020, DOI 10.1074/jbc.M209741200; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Smith J.A., 2000, CURRENT PROTOCOLS MO; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TOMASELLI KJ, 1988, J CELL BIOL, V107, P1241, DOI 10.1083/jcb.107.3.1241; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Umeda M, 2003, GENE, V303, P47, DOI 10.1016/S0378-1119(02)01153-8; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Xie B, 2001, J BIOL CHEM, V276, P19512, DOI 10.1074/jbc.M009063200; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273; Zou YL, 2003, J BIOL CHEM, V278, P49573, DOI 10.1074/jbc.M307556200	47	83	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13027	13034		10.1074/jbc.M313515200	http://dx.doi.org/10.1074/jbc.M313515200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722085	hybrid			2022-12-25	WOS:000220334900123
J	Jones, CE; Mueser, TC; Nossal, NG				Jones, CE; Mueser, TC; Nossal, NG			Bacteriophage T4 32 protein is required for helicase-dependent leading strand synthesis when the helicase is loaded by the T4 59 helicase-loading protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE 32 PROTEIN; DNA-BINDING-PROTEIN; POLAR BRANCH MIGRATION; REPLICATION FORK; ASSEMBLY PROTEIN; NUCLEIC-ACIDS; MACROMOLECULAR MACHINES; MINICIRCLE SUBSTRATE; CRYSTAL-STRUCTURE; POLYMERASE GP43	In the bacteriophage T4 DNA replication system, T4 gene 59 protein binds preferentially to fork DNA and accelerates the loading of the T4 41 helicase. 59 protein also binds the T4 32 single-stranded DNA-binding protein that coats the lagging strand template. Here we explore the function of the strong affinity between the 32 and 59 proteins at the replication fork. We show that, in contrast to the 59 helicase loader, 32 protein does not bind forked DNA more tightly than linear DNA. 32 protein displays a strong binding polarity on fork DNA, binding with much higher affinity to the 5' single-stranded lagging strand template arm of a model fork, than to the 3' single-stranded leading strand arm. 59 protein promotes the binding of 32 protein on forks too short for cooperative binding by 32 protein. We show that 32 protein is required for helicase-dependent leading strand DNA synthesis when the helicase is loaded by 59 protein. However, 32 protein is not required for leading strand synthesis when helicase is loaded, less efficiently, without 59 protein. Leading strand synthesis by wild type T4 polymerase is strongly inhibited when 59 protein is present without 32 protein. Because 59 protein can load the helicase on forks without 32 protein, our results are best explained by a model in which 59 helicase loader at the fork prevents the coupling of the leading strand polymerase and the helicase, unless the position of 59 protein is shifted by its association with 32 protein.	NIDDK, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Toledo, Dept Chem, Toledo, OH 43606 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University System of Ohio; University of Toledo	Nossal, NG (corresponding author), NIDDK, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm 2A19, Bethesda, MD 20892 USA.	ngn@helix.nih.gov	Jones, Charles/GVS-9497-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057801] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADHYA S, 1982, CELL, V29, P939, DOI 10.1016/0092-8674(82)90456-1; BARRY J, 1994, J BIOL CHEM, V269, P33049; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Bhagwat M, 2001, J BIOL CHEM, V276, P28516, DOI 10.1074/jbc.M103914200; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CHA TA, 1989, J BIOL CHEM, V264, P12220; Chastain PD, 2000, MOL CELL, V6, P803, DOI 10.1016/S1097-2765(05)00093-6; Chastain PD, 2003, J BIOL CHEM, V278, P21276, DOI 10.1074/jbc.M301573200; Delagoutte E, 2003, Q REV BIOPHYS, V36, P1, DOI 10.1017/S0033583502003864; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; Dong F, 1996, P NATL ACAD SCI USA, V93, P14456, DOI 10.1073/pnas.93.25.14456; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; HOSODA J, 1978, J BIOL CHEM, V253, P7547; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; JIANG H, 1993, J BIOL CHEM, V268, P7904; Jones CE, 2001, P NATL ACAD SCI USA, V98, P8312, DOI 10.1073/pnas.121009398; Jones CE, 2000, J BIOL CHEM, V275, P27145; Kadyrov FA, 2001, J BIOL CHEM, V276, P29559, DOI 10.1074/jbc.M101310200; Klein HL, 2002, MOL CELL, V9, P471, DOI 10.1016/S1097-2765(02)00493-8; Kong DC, 1997, J BIOL CHEM, V272, P8380; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; Nossal NG, 2001, MOL CELL, V7, P31, DOI 10.1016/S1097-2765(01)00152-6; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; SPICER EK, 1979, J BIOL CHEM, V254, P6433; TARUMI K, 1995, J BIOL CHEM, V270, P2614, DOI 10.1074/jbc.270.6.2614; Valentine AM, 2001, BIOCHEMISTRY-US, V40, P15074, DOI 10.1021/bi0108554; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; VONHIPPEL PH, 1982, J MOL BIOL, V162, P795, DOI 10.1016/0022-2836(82)90548-4; Waidner LA, 2001, J BIOL CHEM, V276, P2509, DOI 10.1074/jbc.M007778200; WILLIAMS KR, 1994, MOL BIOL BACTERIOP T, V4, P301; WU R, 1975, J VIROL, V16, P5, DOI 10.1128/JVI.16.1.5-16.1975; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; Yang JS, 2003, J BIOL CHEM, V278, P49828, DOI 10.1074/jbc.M307406200; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	54	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12067	12075		10.1074/jbc.M313840200	http://dx.doi.org/10.1074/jbc.M313840200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14729909	hybrid			2022-12-25	WOS:000220334900010
J	Nakai, Y; Umeda, N; Suzuki, T; Nakai, M; Hayashi, H; Watanabe, K; Kagamiyama, H				Nakai, Y; Umeda, N; Suzuki, T; Nakai, M; Hayashi, H; Watanabe, K; Kagamiyama, H			Yeast Nfs1p is involved in thio-modification of both mitochondrial and cytoplasmic tRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; ENTERICA SEROVAR TYPHIMURIUM; ANTICODON WOBBLE NUCLEOTIDE; IN-VITRO BIOSYNTHESIS; COLI TRANSFER-RNA; FE-S CLUSTER; ESCHERICHIA-COLI; CYSTEINE DESULFURASE; SACCHAROMYCES-CEREVISIAE; AZOTOBACTER-VINELANDII	The IscS protein is a pyridoxal phosphate-containing cysteine desulfurase involved in iron-sulfur cluster biogenesis. In prokaryotes, IscS is also involved in various metabolic functions, including thio-modification of tRNA. By contrast, the eukaryotic ortholog of IscS (Nfs1) has thus far been shown to be functional only in mitochondrial iron-sulfur cluster biogenesis. We demonstrate here that yeast Nfs1p is also required for the post-transcriptional thio-modification of both mitochondrial (mt) and cytoplasmic (cy) tRNAs in vivo. Depletion of Nfs1p resulted in an immediate impairment of the 2-thio-modification of 5-carboxymethylaminomethyl-2-thiouridine at the wobble positions of mt-tRNA(UUU)(Lys) and mt-tRNA(UUG)(Gln). In addition, we observed a severe reduction in the 2-thiomodification of 5-methoxycarbonylmethyl-2-thiouridine (mcm(5)s(2)U) of cy-tRNA(UUU)(Lys2) and cy-tRNA(UUC)(Glu3), although the effect was somewhat delayed compared with that seen in mt-tRNAs. Mass spectrometry analysis revealed an increase in 5-methoxycarbonylmethyluridine concomitant with a decrease in mcm(5)s(2)U in cy-tRNAs that were prepared from Nfs1p-depleted cells. These results suggest that Nfs1p is involved in the 2-thio-modification of both 5-carboxymethylaminomethyl-2-thiouridine in mt-tRNAs and mcm(5)s(2)U in cy-tRNAs.	Osaka Med Coll, Dept Biochem, Osaka 5698686, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Chiba 2778562, Japan; Osaka Univ, Inst Prot Res, Div Enzymol, Suita, Osaka 5650871, Japan	Osaka Medical College; University of Tokyo; Osaka University	Nakai, Y (corresponding author), Osaka Med Coll, Dept Biochem, 2-7 Daigaku Machi, Osaka 5698686, Japan.	med004@art.osaka-med.ac.jp	Suzuki, Tsutomu/J-1776-2015	Suzuki, Tsutomu/0000-0002-9731-1731				Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529; Bjork GR, 1995, TRNA STRUCTURE BIOSY; Chheda GB, 1999, NUCLEOS NUCLEOT, V18, P2155, DOI 10.1080/07328319908044873; Cupp-Vickery JR, 2003, J MOL BIOL, V330, P1049, DOI 10.1016/S0022-2836(03)00690-9; Flint DH, 1996, J BIOL CHEM, V271, P16068; Frazzon J, 2002, BIOCHEM SOC T, V30, P680, DOI 10.1042/BST0300680; GROSSENBACHER AM, 1986, J BIOL CHEM, V261, P6351; Hagervall TG, 1998, J MOL BIOL, V284, P33, DOI 10.1006/jmbi.1998.2162; Hani J, 1998, NUCLEIC ACIDS RES, V26, P689, DOI 10.1093/nar/26.3.689; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; ISEL C, 1993, J BIOL CHEM, V268, P25269; Jaschkowitz K, 2000, BIOCHEMISTRY-US, V39, P3416, DOI 10.1021/bi992147c; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; LATEN HM, 1983, BIOCHIM BIOPHYS ACTA, V741, P1, DOI 10.1016/0167-4781(83)90002-7; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Mihara H, 2002, P NATL ACAD SCI USA, V99, P6679, DOI 10.1073/pnas.102176099; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Nakai Y, 1998, FEBS LETT, V433, P143, DOI 10.1016/S0014-5793(98)00897-7; Nakai Y, 2001, J BIOL CHEM, V276, P8314, DOI 10.1074/jbc.M007878200; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; PATWARDHAN S, 1985, J BACTERIOL, V62, P55; Pierrel F, 2002, J BIOL CHEM, V277, P13367, DOI 10.1074/jbc.C100609200; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Shigi N, 2002, J BIOL CHEM, V277, P39128, DOI 10.1074/jbc.M207323200; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Skovran E, 2000, J BACTERIOL, V182, P3896, DOI 10.1128/JB.182.14.3896-3903.2000; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251; Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	47	98	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12363	12368		10.1074/jbc.M312448200	http://dx.doi.org/10.1074/jbc.M312448200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722066	hybrid			2022-12-25	WOS:000220334900044
J	van Slegtenhorst, M; Carr, E; Stoyanova, R; Kruger, WD; Henske, EP				van Slegtenhorst, M; Carr, E; Stoyanova, R; Kruger, WD; Henske, EP			Tsc1(+) and tsc2(+) regulate arginine uptake and metabolism in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEINS; TUBEROUS SCLEROSIS GENE; CELL-GROWTH; FISSION YEAST; CANAVANINE RESISTANCE; POLYAMINE METABOLISM; 3-KINASE/AKT PATHWAY; DIRECT TARGET; RHEB GTPASE; COMPLEX	Mutations in either TSC1 or TSC2 cause tuberous sclerosis complex, an autosomal dominant disorder characterized by seizures, mental retardation, and benign tumors of the skin, brain, heart, and kidneys. Homologs for the TSC1 and TSC2 genes have been identified in mouse, rat, Fugu, Drosophila, and in the yeast Schizosaccharomyces pombe. Here we show that S. pombe lacking tsc1(+) or tsc2(+) have similar phenotypes including decreased arginine uptake, decreased expression of three amino acid permeases, and low intracellular levels of four members of the arginine biosynthesis pathway. Recently, the small GTPase Rheb was identified as a target of the GTPase-activating domain of tuberin in mammalian cells and in Drosophila. We show that the defect in arginine uptake in cells lacking tsc2(+) is rescued by the expression of a dominant negative form of rhb1(+), the Rheb homolog in S. pombe, but not by expressing wildtype rhb1(+). Expression of the tsc2(+) gene with a patient-derived mutation within the GAP domain did not rescue the arginine uptake defect in tsc2(+) mutant yeast. Taken together, these findings support a model in which arginine uptake is regulated through tsc1(+), tsc2(+), and rhb1(+) in S. pombe and also suggest a role for the Tsc1 and Tsc2 proteins in amino acid biosynthesis and sensing.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	van Slegtenhorst, M (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Marjon.van.Slegtenhorst@fccc.edu; Elizabeth.Henske@fccc.edu	kruger, warren/A-6407-2008; Kruger, Warren/Y-2541-2018	kruger, warren/0000-0002-4990-3695; 				ASTRINIDIS A, 2003, J BIOL CHEM; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bansal V, 2003, CURR OPIN CLIN NUTR, V6, P223, DOI 10.1097/00075197-200303000-00012; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chattopadhyay MK, 2002, P NATL ACAD SCI USA, V99, P10330, DOI 10.1073/pnas.162362899; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; GRIMM C, 1988, MOL GEN GENET, V215, P87, DOI 10.1007/BF00331308; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Mach KE, 2000, GENETICS, V155, P611; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Matsumoto S, 2002, GENETICS, V161, P1053; NELLIST M, 1993, CELL, V75, P1305; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Wong M, 2003, ANN NEUROL, V54, P251, DOI 10.1002/ana.10648; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Yang WL, 2001, MOL MICROBIOL, V41, P1339, DOI 10.1046/j.1365-2958.2001.02599.x; Yang WL, 2000, J BIOL CHEM, V275, P429, DOI 10.1074/jbc.275.1.429; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	40	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12706	12713		10.1074/jbc.M313874200	http://dx.doi.org/10.1074/jbc.M313874200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718525	hybrid			2022-12-25	WOS:000220334900084
J	Yamamoto, T; Shimano, H; Nakagawa, Y; Ide, T; Yahagi, N; Matsuzaka, T; Nakakuki, M; Takahashi, A; Suzuki, H; Sone, H; Toyoshima, H; Sato, R; Yamada, N				Yamamoto, T; Shimano, H; Nakagawa, Y; Ide, T; Yahagi, N; Matsuzaka, T; Nakakuki, M; Takahashi, A; Suzuki, H; Sone, H; Toyoshima, H; Sato, R; Yamada, N			SREBP-1 interacts with hepatocyte nuclear factor-4 alpha and interferes with PGC-1 recruitment to suppress hepatic gluconeogenic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1; TRANSCRIPTION FACTOR; MISSENSE MUTATION; PROMOTER ACTIVITY; TRANSGENIC MICE; FACTOR 4-ALPHA; X-RECEPTOR; CHOLESTEROL; EXPRESSION; INSULIN	The hepatocyte nuclear factor-4alpha (HNF-4alpha)/PGC-1 pathway plays a crucial role in the transcriptional regulation of hepatic gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase (PEPCK) and Glc-6-Pase, genes that are activated at fasting and suppressed in a fed state. SREBP-1c dominates the nutritional regulation of lipogenic genes inverse to gluconeogenesis. Here we show the mechanism by which SREBP-1 suppresses expression of gluconeogenic genes. A series of luciferase reporter assays demonstrated that SREBP-1a and - 1c effectively inhibited the PEPCK promoter activity that was induced by HNF-4alpha. The HNF-4alpha-binding site in the glucocorticoid-response unit was responsible for the SREBP-1 inhibition, although SREBP-1 did not bind to the PEPCK promoter as demonstrated by electrophoretic mobility shift assays. The inhibitory effect was more potent in the isoform of SREBP-1a than SREBP-1c and was eliminated by deletion of the amino-terminal transactivation domain of SREBP-1. Coimmunoprecipitation experiments demonstrated that these two transcription factors directly interact through the transactivation domain of SREBP-1 and the ligand binding/ AF2 domains of HNF-4alpha. Estimation of coactivator recruitment using HNF-4alpha-Gal4DBD fusion assay showed that SREBP-1 competitively inhibited PGC-1 recruitment, a requirement for HNF-4alpha activation. Consistent with these results, hepatic PEPCK and Glc-6-Pase mRNA levels are suppressed by overexpression of SREBP-1a and - 1c in the transgenic mice. Our data indicate that SREBP-1 has a novel role as negative regulator of gluconeogenic genes through a cross-talk with HNF-4alpha interference with PGC-1 recruitment.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan	University of Tsukuba; University of Tokyo; University of Tokyo	Shimano, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Sone, Hirohito/ABC-9346-2021; Shimano, Hitoshi/AAI-5648-2020; Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/V-1761-2019	Sone, Hirohito/0000-0003-1263-2817; Yahagi, Naoya/0000-0002-1823-1865; Shimano, Hitoshi/0000-0002-5562-5572				Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Chakravarty K, 2001, J BIOL CHEM, V276, P34816, DOI 10.1074/jbc.M103310200; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Drewes T, 1996, MOL CELL BIOL, V16, P925; Furuta H, 1997, DIABETES, V46, P1652, DOI 10.2337/diabetes.46.10.1652; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hani E, 1998, J CLIN INVEST, V101, P521, DOI 10.1172/JCI1403; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Ide T, 2003, MOL ENDOCRINOL, V17, P1255, DOI 10.1210/me.2002-0191; Misawa K, 2003, J BIOL CHEM, V278, P36176, DOI 10.1074/jbc.M302387200; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 2002, VITAM HORM, V65, P167, DOI 10.1016/S0083-6729(02)65064-2; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 2000, TRENDS CARDIOVAS MED, V10, P275, DOI 10.1016/S1050-1738(00)00079-7; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yoshikawa T, 2003, MOL ENDOCRINOL, V17, P1240, DOI 10.1210/me.2002-0190; Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	33	121	126	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12027	12035		10.1074/jbc.M310333200	http://dx.doi.org/10.1074/jbc.M310333200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722127	hybrid			2022-12-25	WOS:000220334900005
J	Weber, J; Wilke-Mounts, S; Nadanaciva, S; Senior, AE				Weber, J; Wilke-Mounts, S; Nadanaciva, S; Senior, AE			Quantitative determination of direct binding of b subunit to F-1 in Escherichia coli F1F0-ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; DELTA-SUBUNIT; ELECTRON-MICROSCOPY; CATALYTIC SITES; CROSS-LINKING; ALPHA-SUBUNIT; 2ND STALK; F-1-ATPASE; F1-ATPASE; STATOR	The stator in F1F0-ATP synthase resists strain generated by rotor torque. In Escherichia coli, the b(2)delta subunit complex comprises the stator, bound to subunit a in F-0 and to the alpha(3)beta(3) hexagon of F-1. To quantitatively characterize binding of b subunit to the F-1 alpha(3)beta(3) hexagon, we developed fluorimetric assays in which wild-type F-1, or F-1 enzymes containing introduced Trp residues, were titrated with a soluble portion of the b subunit (b(ST34-156)). With five different F-1 enzymes, K-d(b(ST34-156)) ranged from 91 to 157 nM. Binding was strongly Mg2+-dependent; in EDTA buffer, K-d(b(ST34-156)) was increased to 1.25 muM. The addition of the cytoplasmic portion of the b subunit increases the affinity of binding of delta subunit to delta-depleted F-1. The apparent K-d(b(ST34-156)) for this effect was increased from 150 nM in Mg2+ buffer to 1.36 muM in EDTA buffer. This work demonstrates quantitatively how binding of the cytoplasmic portion of the b subunit directly to F-1 contributes to stator resistance and emphasizes the importance of Mg2+ in stator interactions.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu			NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Capaldi RA, 2000, J EXP BIOL, V203, P29; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1980, J BIOL CHEM, V255, P6891; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; Grabar TB, 2003, J BIOL CHEM, V278, P34751, DOI 10.1074/jbc.M303361200; Hasler K, 1999, BIOCHEMISTRY-US, V38, P13759, DOI 10.1021/bi991236m; HAZARD AL, 1994, J BIOL CHEM, V269, P418; Junge W, 2001, FEBS LETT, V504, P152, DOI 10.1016/S0014-5793(01)02745-4; Kersten MV, 2000, BIOCHEMISTRY-US, V39, P3856, DOI 10.1021/bi992699v; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; McLachlin DT, 2000, BIOCHEMISTRY-US, V39, P3486, DOI 10.1021/bi992586b; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Panke O, 2001, BIOPHYS J, V81, P1220, DOI 10.1016/S0006-3495(01)75780-3; RAO R, 1988, J BIOL CHEM, V263, P5569; Revington M, 2002, PROTEIN SCI, V11, P1227, DOI 10.1110/ps.3200102; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Rubinstein JL, 2002, J MOL BIOL, V321, P613, DOI 10.1016/S0022-2836(02)00671-X; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WEBER J, 1994, J BIOL CHEM, V269, P20462; Weber J, 2003, J BIOL CHEM, V278, P13409, DOI 10.1074/jbc.M212037200; Weber J, 2002, J BIOL CHEM, V277, P18390, DOI 10.1074/jbc.M201047200; Weber J, 2000, BIOCHEMISTRY-US, V39, P5287, DOI 10.1021/bi992730t; Weber J, 2003, J BIOL CHEM, V278, P13623, DOI 10.1074/jbc.C300061200; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; Weber J, 1998, BIOCHEMISTRY-US, V37, P12042, DOI 10.1021/bi981089c; WILKEMOUNTS S, 1994, ARCH BIOCHEM BIOPHYS, V309, P363, DOI 10.1006/abbi.1994.1125; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	44	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11253	11258		10.1074/jbc.M312576200	http://dx.doi.org/10.1074/jbc.M312576200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722065	hybrid			2022-12-25	WOS:000220157600052
J	Luo, Q; Li, J; Cenkci, B; Kretzner, L				Luo, Q; Li, J; Cenkci, B; Kretzner, L			Autorepression of c-myc requires both initiator and E2F-binding site elements and cooperation with the p107 gene product	ONCOGENE			English	Article						transcriptional repression; c-Myc; Mxi1; p107; initiator; E2F binding sites	TRANSCRIPTIONAL REPRESSION; NEGATIVE AUTOREGULATION; RETINOBLASTOMA PROTEIN; GROWTH SUPPRESSION; CELL-PROLIFERATION; TRANS-ACTIVATION; IN-VIVO; PROMOTER; MAX; E2F	Myc proteins are transcriptional activators, but also repress transcription through initiator (Inr) elements. Repression requires the conserved Myc Box II, but the cis-acting element(s) required for c-myc autorepression have eluded definition. Since the gene has a candidate Inr at the P2 promoter, we tested whether Myc autorepression operates through the Inr/BoxII mechanism. Overexpression of c-Myc but not a Box II deletion mutation represses both c-myc P2 reporter genes and endogenous c-myc, as does Mxi1 expression. Only 45 nucleotides surrounding the P2 start suffice to mediate autorepression, but Myc and Mxi1 also downregulate P2 Inr mutations, suggesting other core promoter sequence requirements for autorepression. We tested the importance of conserved E2F sites, based on known Myc interaction with the pRb-related p107 and on the transrepressive effects of Rb family proteins. Myc, Mxi1, and p107 repress c-myc somewhat less well in the absence of E2F binding sites, while an E2F + Inr double mutation is not repressed at all by these gene products. Further, Myc repression at the c-myc P2 core promoter is augmented by p107, but not by pRb or p130, nor by p107 lacking the conserved pocket domain. Our data suggest that Myc autorepression requires both the c-myc Inr and E2F sites in cis, as well as p107 in trans. Consistent with this, we found that retrovirally transduced c-Myc cannot downregulate endogenous c-myc in p107-null fibroblasts, and show evidence that both Myc and p107 are present in a complex assembled at the c-myc P2 core promoter.	Univ S Dakota, Sch Med, Dept Cellular & Mol Biol, Div Basic Biomed Sci, Vermillion, SD 57069 USA	University of South Dakota	Kretzner, L (corresponding author), City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.	lkretzner@coh.org						AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIPP M, 1989, ONCOGENE, V4, P535; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; MANGO SE, 1989, MOL CELL BIOL, V9, P3482, DOI 10.1128/MCB.9.8.3482; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; Peters MA, 1998, CRIT REV EUKAR GENE, V8, P277, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.30; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; Smale ST, 1998, COLD SPRING HARB SYM, V63, P21, DOI 10.1101/sqb.1998.63.21; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Starostik P, 1996, MOL CELL BIOL, V16, P3606; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	46	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1088	1097		10.1038/sj.onc.1207225	http://dx.doi.org/10.1038/sj.onc.1207225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14716294				2022-12-25	WOS:000188749900007
J	Guo, GZ; Wang, TL; Gao, Q; Tamae, D; Wong, P; Chen, T; Chen, WC; Shively, JE; Wong, JYC; Li, JJ				Guo, GZ; Wang, TL; Gao, Q; Tamae, D; Wong, P; Chen, T; Chen, WC; Shively, JE; Wong, JYC; Li, JJ			Expression of ErbB2 enhances radiation-induced NF-kappa B activation	ONCOGENE			English	Article						NF-kappa B; ErbB2; breast cancer; radioresistance	HUMAN-BREAST-CANCER; GROWTH-FACTOR RECEPTOR; IONIZING-RADIATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MONOCLONAL-ANTIBODY; TNF-ALPHA; CYCLIN B1; TRAIL/APO2L-INDUCED APOPTOSIS; SIGNALING PATHWAY	Her-2/neu (ErbB2) oncogene, the second member of the epidermal growth factor receptor (EGFR) family, encodes a transmembrane tyrosine kinase receptor in Her-2-positive tumors. Accumulating evidences demonstrate that signaling networks activated by EGFR and transcription factor NF-kappaB are associated with cell response to ionizing radiation (IR). The present study shows that overexpression of ErbB2 enhanced NF-kappaB activation induced by IR in human breast carcinoma MCF-7 cells transfected with ErbB2 genes (MCF-7/ErbB2). Stable transfection of dominant-negative mutant IkappaB (MCF-7/ErbB2/mIkappaB) or treatment with anti-ErbB2 antibody, Herceptin, inhibited NF-kappaB activation and radiosensitized MCF-7/ErbB2 cells. Consistent with NF-kappaB regulation, basal and IR-induced Akt, a kinase downstream of ErbB2, was activated in MCF-7/ErbB2 cells and inhibited by Herceptin. To identify specific genes affected by ErbB2-mediated NF-kappaB activation, a group of IR-responsive elements Cyclin B1, Cyclin D1, Bcl-2, Bcl/XL, BAD and BAX were evaluated. Basal levels of prosurvival elements Cyclin B1, Cyclin D1, Bcl-2 and Bcl/XL but not apoptotic BAD and BAX were upregulated in MCF-7/ErbB2 cells with striking enhancements in Bcl-2 and Bcl/XL. IR further induced Cyclin B1 and Cyclin D1 expression that was reduced by Herceptin. Bcl-2 kept a high steady level after Herceptin+IR treatment and, in contrast to control MCF-7/Vector cells, Bcl/XL was inhibited in MCF-7/ErbB2 cells by Herceptin+IR treatment. However, all four prosurvival proteins were downregulated by inhibition of NF-kappaB in MCF-7/ErbB/mIkappaB cells. These results thus provide evidence suggesting that overexpression of ErbB2 is able to enhance NF-kappaB response to IR, and that a specific prosurvival network downstream of NF-kappaB is triggered by treatments using anti-ErbB2 antibody combined with radiation.	City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, Duarte, CA 91010 USA; Biorad Labs, Life Sci Grp, Hercules, CA 94547 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Li, JJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	jjli@coh.org		Li, Jian Jian/0000-0003-3694-9675				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Beetz A, 2000, INT J RADIAT BIOL, V76, P1443, DOI 10.1080/09553000050176207; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Bradbury CM, 2001, CANCER RES, V61, P7689; Chen XF, 2002, CANCER RES, V62, P1213; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Daosukho C, 2002, ONCOGENE, V21, P3603, DOI 10.1038/sj.onc.1205448; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Fornace AJ, 1999, GENE EXPRESSION, V7, P387; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gius D, 1999, TOXICOL LETT, V106, P93, DOI 10.1016/S0378-4274(99)00024-7; Granville DJ, 2000, BLOOD, V95, P256; Grdina DJ, 2002, SEMIN RADIAT ONCOL, V12, P103, DOI 10.1053/srao.2002.31383; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Gupta AK, 2001, CANCER RES, V61, P4278; Hallahan DE, 1998, CANCER RES, V58, P5484; Hassan KA, 2002, CANCER RES, V62, P6414; Hassan KA, 2001, CLIN CANCER RES, V7, P2458; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Herscher LL, 1999, ONCOLOGY-NY, V13, P11; Kato T, 2000, HEAD NECK-J SCI SPEC, V22, P748, DOI 10.1002/1097-0347(200012)22:8<748::AID-HED2>3.3.CO;2-Y; Kurland JF, 2001, INT J CANCER, V96, P327, DOI 10.1002/ijc.1040; Kurokawa H, 2001, CLIN CANCER RES, V7, p4436s; Kurokawa L, 2001, CLIN CANCER RES, V7, p4436S; LABUDDA K, 1995, VIROLOGY, V206, P269, DOI 10.1016/S0042-6822(95)80042-5; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, CLIN CANCER RES, V7, P682; Lee S, 2002, CANCER RES, V62, P5703; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li ZK, 2001, RADIAT RES, V155, P543, DOI 10.1667/0033-7587(2001)155[0543:EGAIMH]2.0.CO;2; Liang K, 2003, MOL CANCER THER, V2, P353; Locke JE, 2002, INT J RADIAT BIOL, V78, P493, DOI [10.1080/095530002317577312, 10.1080/09553000110120355]; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; McBride William H, 2002, Mil Med, V167, P66; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; Miyakoshi J, 2000, BRIT J CANCER, V82, P28; Pegram M, 2000, SEMIN ONCOL, V27, P13; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Pietras RJ, 1999, CANCER RES, V59, P1347; Ravi R, 2002, CANCER RES, V62, P1583; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Schmidt M, 2001, GYNECOL ONCOL, V80, P145, DOI 10.1006/gyno.2000.6040; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Sherman L, 1999, ONCOGENE, V18, P6692, DOI 10.1038/sj.onc.1203055; Slamon D J, 1990, Cancer Invest, V8, P253, DOI 10.3109/07357909009017573; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soria JC, 2000, CANCER RES, V60, P4000; Stoica GE, 2003, ONCOGENE, V22, P2073, DOI 10.1038/sj.onc.1206311; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464; Zhou DH, 2001, INT J RADIAT BIOL, V77, P763, DOI 10.1080/09553000110050047	70	78	82	3	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					535	545		10.1038/sj.onc.1207149	http://dx.doi.org/10.1038/sj.onc.1207149			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724581				2022-12-25	WOS:000188098300024
J	Krams, M; Parwaresch, R; Sipos, B; Heidorn, K; Harms, D; Rudolph, P				Krams, M; Parwaresch, R; Sipos, B; Heidorn, K; Harms, D; Rudolph, P			Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis	ONCOGENE			English	Article						c-kit; transcription; neuroblastoma; differentiation; prognosis	STEM-CELL FACTOR; TRANSCRIPTASE MESSENGER-RNA; TYROSINE KINASE; TELOMERASE ACTIVITY; INTERSTITIAL-CELLS; SIGNALING PATHWAYS; PROGENITOR CELLS; LUNG-CARCINOMA; HUMAN TISSUES; SURVIVAL	Expression of the c-kit proto-oncogene product in neuroblastomas has been reported, but its clinical relevance is unclear. We determined the expression of c-kit by immunohistochemistry in a series of 155 neuroblastomas with long-term follow-up. The specificity of the reaction was verified by Western blot analysis and quantitative RT-PCR, and exon 11 of the kit gene was screened for mutations by PCR and capillary electrophoresis. No mutations were detected, and transcription of the kit gene correlated with protein expression. c-kit expression was associated with lower tumor stages and a low rate of MYCN amplification. More importantly, it coincided with tumor differentiation (P < 0.0001), and portended a favorable outcome with a relative risk of 0.18 (P < 0.0001). In a multivariate analysis of event-free survival, loss of c-kit (relative risk 4.25, P < 0.0001) was an independent prognostic factor next to INSS stage 4 and before MYCN amplification. It is concluded that c-kit is transcriptionally regulated in neuroblastomas. Its expression likely identifies a subset of neuroblastomas with conserved capacity for differentiation, which may represent the embryonal variety of the disease. Assessment of c-kit may improve prognostic models for neuroblastoma and provide a basis for new therapy concepts.	Univ Kiel, Dept Pediat Pathol, D-24098 Kiel, Germany; Univ Kiel, Dept Hematopathol, D-24098 Kiel, Germany; Univ Kiel, Dept Gen Pathol, D-24098 Kiel, Germany	University of Kiel; University of Kiel; University of Kiel	Rudolph, P (corresponding author), Univ Kiel, Dept Pathol, Michaelisstr 11, D-24105 Kiel, Germany.	prudolph@path.uni-kiel.de						Arber DA, 1998, HUM PATHOL, V29, P498, DOI 10.1016/S0046-8177(98)90066-1; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; BECK D, 1995, BLOOD, V86, P3132, DOI 10.1182/blood.V86.8.3132.bloodjournal8683132; Berthold F, 1997, EUR J CANCER, V33, P2092, DOI 10.1016/S0959-8049(97)00237-2; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; COHEN PS, 1994, BLOOD, V84, P3465; De Sepulveda P, 1999, EMBO J, V18, P904; DiPaola RS, 1997, CANCER GENE THER, V4, P176; Hayashi S, 1995, DNA Res, V2, P211, DOI 10.1093/dnares/2.5.211; HIRATA T, 1993, DEVELOPMENT, V119, P49; Hirota Seiichi, 2001, International Journal of Clinical Oncology, V6, P1, DOI 10.1007/PL00012072; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Hornick JL, 2002, AM J CLIN PATHOL, V117, P188; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IDA JA, 1993, J NEUROSCI RES, V36, P596, DOI 10.1002/jnr.490360512; Jahn T, 2002, ONCOGENE, V21, P4508, DOI 10.1038/sj.onc.1205559; JOSHI VV, 1992, CANCER-AM CANCER SOC, V69, P2197, DOI 10.1002/1097-0142(19920415)69:8<2197::AID-CNCR2820690829>3.0.CO;2-X; Kapur R, 2001, BLOOD, V97, P1975, DOI 10.1182/blood.V97.7.1975; KELLER JR, 1995, BLOOD, V86, P1757, DOI 10.1182/blood.V86.5.1757.bloodjournal8651757; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Krams M, 2002, CANCER, V94, P854, DOI 10.1002/cncr.10256.abs; Krams M, 2003, AM J PATHOL, V162, P1019, DOI 10.1016/S0002-9440(10)63896-5; Krams M, 2001, AM J PATHOL, V159, P1925, DOI 10.1016/S0002-9440(10)63039-8; LAMMIE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1417, DOI 10.1177/42.11.7523489; LEV S, 1994, CRIT REV ONCOGENESIS, V5, P141, DOI 10.1615/CritRevOncog.v5.i2-3.30; MAEDA H, 1992, DEVELOPMENT, V116, P369; Makhlouf HR, 2002, AM J SURG PATHOL, V26, P493, DOI 10.1097/00000478-200204000-00012; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; Montone KT, 1997, MODERN PATHOL, V10, P939; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NATALI PG, 1992, CANCER RES, V52, P6139; Robinson LLL, 2001, MOL HUM REPROD, V7, P845, DOI 10.1093/molehr/7.9.845; Rudolph P, 2002, VIRCHOWS ARCH, V441, P238, DOI 10.1007/s00428-002-0673-2; Schwartz S, 1999, LEUKEMIA LYMPHOMA, V34, P85, DOI 10.3109/10428199909083383; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Sipos B, 2002, INT J CANCER, V102, P592, DOI 10.1002/ijc.10753; Smithey BE, 2002, AM J SURG PATHOL, V26, P486, DOI 10.1097/00000478-200204000-00011; Timeus F, 1997, EXP HEMATOL, V25, P1253; Torihashi S, 1999, GASTROENTEROLOGY, V117, P140, DOI 10.1016/S0016-5085(99)70560-3; TSUURA Y, 1994, VIRCHOWS ARCH, V424, P135; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	42	40	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					588	595		10.1038/sj.onc.1207145	http://dx.doi.org/10.1038/sj.onc.1207145			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724587				2022-12-25	WOS:000188098300030
J	Huang, MC; Lee, HY; Yeh, CC; Kong, Y; Zaloudek, CJ; Goetzl, EJ				Huang, MC; Lee, HY; Yeh, CC; Kong, Y; Zaloudek, CJ; Goetzl, EJ			Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA(2))	ONCOGENE			English	Article						vascular endothelial growth factor; urokinase-type plasminogen activator; lysophospholipids; lipid mediators; ovarian cancer	VASCULAR-PERMEABILITY FACTOR; PROSTATE-CANCER CELLS; SIGNAL-TRANSDUCTION; FACTOR VEGF; LYSOPHOSPHOLIPASE-D; ASCITES-FORMATION; SPLICE VARIANTS; EXPRESSION; TUMORS; GENE	The lipid growth factor lysophosphatidic acid (LPA) is produced by ovarian cancer cells in quantities sufficient to attain concentrations of up to 10 muM. An autocrine circuit was demonstrated when ovarian cancer cells, but not normal ovarian surface epithelial cells, were proven to express LPA(2) (Edg-4) and LPA(3) (Edg-7) G protein-coupled receptors for LPA. Human LPA(2) now has been expressed transgenically in C57BL/6 mouse ovaries under direction of the alpha-inhibin large promoter. Human LPA(2) mRNA and protein were detected in all transgenic (TG) mouse ovaries at levels far higher than in other tissues and at least fivefold higher than in cultured lines of human ovarian cancer cells, with the expected sex cord-stromal distribution. Most LPA(2) TG ovaries produced significantly higher levels than non-TG ovaries of type A, but not type B, vascular endothelial growth factor (VEGF), isomers of VEGF-A, and urokinase-type plasminogen activator (uPA). Many LPA(2) TG ovaries had elevated expression of VEGF receptors 1 and 2, and a depressed level of type 2 PA inhibitor. Thus, the LPA-LPA(2) circuit regulates ovarian cells both directly and through increases in protein growth factor systems.	Univ Calif San Francisco, Med Ctr, Dept Med Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med Microbiol & Immunol, UB8B,Box 0711,533 Parnassus Ave, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu		Lee, Hsinyu/0000-0002-1477-0183				Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Dolezalova H, 2003, J CELL BIOCHEM, V88, P732, DOI 10.1002/jcb.10394; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fujimoto J, 1998, CANCER-AM CANCER SOC, V83, P2528, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2528::AID-CNCR18>3.0.CO;2-N; Fujita T, 2003, CANCER LETT, V192, P161, DOI 10.1016/S0304-3835(02)00713-9; Gerber HP, 2000, CANCER RES, V60, P6253; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Goetzl EJ, 1999, CANCER RES, V59, P5370; Hazelton D, 1999, CLIN CANCER RES, V5, P823; Hsu SY, 1996, ENDOCRINOLOGY, V137, P4837, DOI 10.1210/en.137.11.4837; Hu LM, 2002, AM J PATHOL, V161, P1917, DOI 10.1016/S0002-9440(10)64467-7; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Huang MC, 2002, BBA-MOL CELL BIOL L, V1582, P161, DOI 10.1016/S1388-1981(02)00151-8; KANANEN K, 1995, MOL ENDOCRINOL, V9, P616, DOI 10.1210/me.9.5.616; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Luo JC, 1998, CANCER RES, V58, P2652; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; MILLS GB, 1990, J CLIN INVEST, V86, P851, DOI 10.1172/JCI114784; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; Moolenaar WH, 2002, J CELL BIOL, V158, P197, DOI 10.1083/jcb.200206094; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Orre M, 1999, INT J CANCER, V84, P101, DOI 10.1002/(SICI)1097-0215(19990420)84:2<101::AID-IJC2>3.0.CO;2-5; Qi C, 1998, J CELL PHYSIOL, V174, P261, DOI 10.1002/(SICI)1097-4652(199802)174:2<261::AID-JCP13>3.0.CO;2-F; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Stimpfl M, 2002, CLIN CANCER RES, V8, P2253; TIGYI G, 2002, MOL CELLULAR BIOL LI, V1582, P1; Tober KL, 1998, BIOCHEM BIOPH RES CO, V247, P644, DOI 10.1006/bbrc.1998.8787; Tokumura A, 2002, BBA-MOL CELL BIOL L, V1582, P18, DOI 10.1016/S1388-1981(02)00133-6; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Xu Y, 2002, BBA-MOL CELL BIOL L, V1582, P81, DOI 10.1016/S1388-1981(02)00140-3; Xu Yan, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P23, DOI 10.2174/1568008033340414; Yukita A, 2000, ANTICANCER RES, V20, P155; Zebrowski BK, 1999, ANN SURG ONCOL, V6, P373, DOI 10.1007/s10434-999-0373-0; Zhang L, 2002, BIOCHEM BIOPH RES CO, V292, P860, DOI 10.1006/bbrc.2002.6710; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	42	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					122	129		10.1038/sj.onc.1206986	http://dx.doi.org/10.1038/sj.onc.1206986			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712217				2022-12-25	WOS:000187895300013
J	Tortorella, MD; Arner, EC; Hills, R; Easton, A; Korte-Sarfaty, J; Fok, K; Wittwer, AJ; Liu, RQ; Malfait, AM				Tortorella, MD; Arner, EC; Hills, R; Easton, A; Korte-Sarfaty, J; Fok, K; Wittwer, AJ; Liu, RQ; Malfait, AM			alpha(2)-Macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATED GLYCOSAMINOGLYCANS; ALPHA-MACROGLOBULIN; AGGRECANASE SITE; SYNOVIAL-FLUID; CLEAVAGE SITES; BAIT REGION; CARTILAGE; ALPHA-2-MACROGLOBULIN; METALLOPROTEINASES; DEGRADATION	Osteoarthritis is characterized by the loss of aggrecan and collagen from the cartilage extracellular matrix. The proteinases responsible for the breakdown of cartilage aggrecan include ADAMTS-4 (aggrecanase 1) and ADAMTS-5 (aggrecanase 2). Post-translational inhibition of ADAMTS-4/-5 activity may be important for maintaining normal homeostasis of aggrecan metabolism, and thus, any disruption to this inhibition could lead to accelerated aggrecan breakdown. To date TIMP-3 (tissue inhibitor of matrix metalloproteinases-3) is the only endogenous inhibitor of ADAMTS-4/-5 that has been identified. In the present studies we identify alpha(2)-macroglobulin (alpha(2)M) as an additional endogenous inhibitor of ADAMTS-4 and ADAMTS-5. alpha(2)M inhibited the activity of both ADAMTS-4 and ADAMTS-5 in a concentration-dependent manner, demonstrating 1:1 stoichiometry with second-order rate constants on the order of 10(6) and 10(5) M-1 s(-1), respectively. Inhibition of the aggrecanases was mediated by proteolysis of the bait region within alpha(2)M, resulting in physical entrapment of these proteinases. Both ADAMTS-4 and ADAMTS-5 cleaved alpha(2)M at Met(690)/Gly(691), representing a novel proteinase cleavage site within alpha(2)M and a novel site of cleavage for ADAMTS-4 and ADAMTS-5. Finally, the use of the anti-neoepitope antibodies to detect aggrecanase-generated alpha(2)M-fragments in synovial fluid was investigated and found to be uninformative.	Pfizer Global Res & Dev, Chesterfield, MO 63017 USA; Bristol Myers Squibb Co, Wilmington, DE 19880 USA	Pfizer; Bristol-Myers Squibb	Tortorella, MD (corresponding author), Pfizer Global Res & Dev, 700 Chesterfield Pkwy, Chesterfield, MO 63017 USA.	micky.d.tortorella@pfizer.com		Malfait, Anne-Marie/0000-0003-1428-0384				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Andersen OM, 2000, BIOCHEMISTRY-US, V39, P10627, DOI 10.1021/bi000498h; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; CHU CT, 1994, ANN NY ACAD SCI, V737, P291, DOI 10.1111/j.1749-6632.1994.tb44319.x; Curtis CL, 2002, ARTHRITIS RHEUM, V46, P1544, DOI 10.1002/art.10305; DeGroot J, 2002, CURR OPIN RHEUMATOL, V14, P585, DOI 10.1097/00002281-200209000-00019; DOWNING MR, 1978, BIOCHEMISTRY-US, V17, P2649, DOI 10.1021/bi00606a030; ELLIS V, 1982, BIOCHIM BIOPHYS ACTA, V701, P24; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; GEORGIADIS KE, 2002, 48 ANN M ORTH RES SO; HADLER NM, 1981, ANN RHEUM DIS, V40, P55, DOI 10.1136/ard.40.1.55; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; Hashimoto G, 2001, FEBS LETT, V494, P192, DOI 10.1016/S0014-5793(01)02323-7; Horber C, 2000, MATRIX BIOL, V19, P533, DOI 10.1016/S0945-053X(00)00113-X; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Malfait AM, 2002, J BIOL CHEM, V277, P22201, DOI 10.1074/jbc.M200431200; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; MORT JS, 2003, 49 ANN M ORTH RES SO; MORTENSEN SB, 1981, FEBS LETT, V135, P295, DOI 10.1016/0014-5793(81)80804-6; Patwari P, 2000, ARCH BIOCHEM BIOPHYS, V374, P79, DOI 10.1006/abbi.1999.1538; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Pratta MA, 2003, ARTHRITIS RHEUM, V48, P119, DOI 10.1002/art.10726; SALVESEN GS, 1981, BIOCHEM J, V195, P453, DOI 10.1042/bj1950453; Sandy JD, 2001, BIOCHEM J, V358, P615, DOI 10.1042/0264-6021:3580615; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P127, DOI 10.1016/0014-5793(81)81097-6; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; Su S, 1999, RHEUMATOL INT, V18, P183, DOI 10.1007/s002960050083; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945-053X(02)00069-0; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; VANLEUVEN F, 1982, BIOCHEM J, V201, P119, DOI 10.1042/bj2010119; Westling J, 2002, J BIOL CHEM, V277, P16059, DOI 10.1074/jbc.M108607200; Yamanishi Y, 2002, J IMMUNOL, V168, P1405, DOI 10.4049/jimmunol.168.3.1405; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	50	97	109	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17554	17561		10.1074/jbc.M313041200	http://dx.doi.org/10.1074/jbc.M313041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14715656	hybrid			2022-12-25	WOS:000220870400083
J	Bergman, A; Hansson, EM; Pursglove, SE; Farmery, MR; Lannfelt, L; Lendahl, U; Lundkvist, J; Naslund, J				Bergman, A; Hansson, EM; Pursglove, SE; Farmery, MR; Lannfelt, L; Lendahl, U; Lundkvist, J; Naslund, J			Pen-2 is sequestered in the endoplasmic reticulum and subjected to ubiquitylation and proteasome-mediated degradation in the absence of presenilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE CLEAVAGE; AMYLOID PRECURSOR PROTEIN; BETA-PEPTIDE PRODUCTION; INTRACELLULAR DOMAIN; INTRAMEMBRANE PROTEOLYSIS; SIGNAL-TRANSDUCTION; NOTCH; NICASTRIN; APH-1; PATHWAY	The gamma-secretase complex catalyzes intramembrane proteolysis of a number of transmembrane proteins, including amyloid precursor protein, Notch, ErbB4, and E-cadherin. gamma-Secretase is known to contain four major protein constituents: presenilin (PS), nicastrin, Aph-1, and Pen-2, all of which are integral membrane proteins. There is increasing evidence that the formation of the complex and the stability of the individual components are tightly controlled in the cell, assuring correct composition of functional complexes. In this report, we investigate the topology, localization, and mechanism for destabilization of Pen-2 in relation to PS function. We show that PS1 regulates the subcellular localization of Pen-2: in the absence of PS, Pen-2 is sequestered in the endoplasmic reticulum ( ER) and not transported to post-ER compartments, where the mature gamma-secretase complexes reside. PS deficiency also leads to destabilization of Pen-2, which is alleviated by proteasome inhibitors. In keeping with this, we show that Pen-2, which adopts a hairpin structure with the N and C termini facing the luminal space, is ubiquitylated prior to degradation and presumably retrotranslocated from the ER to the cytoplasm. Collectively, our data suggest that failure to become incorporated into the gamma-secretase complex leads to degradation of Pen-2 through the ER-associated degradation-proteasome pathway.	Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurotec, Sect Expt Geriatr, Novum, SE-14186 Huddinge, Sweden; Univ Uppsala Hosp, Dept Geriatr Med, SE-75125 Uppsala, Sweden	Karolinska Institutet; Karolinska Institutet; Uppsala University; Uppsala University Hospital	Lundkvist, J (corresponding author), Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden.	johan.lundkvist@cmb.ki.se		Lendahl, Urban/0000-0001-9543-8141				Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li JH, 2002, J NEUROCHEM, V82, P1540, DOI 10.1046/j.1471-4159.2002.01105.x; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Mathews PM, 2002, J BIOL CHEM, V277, P36415, DOI 10.1074/jbc.M205208200; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	32	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16744	16753		10.1074/jbc.M313999200	http://dx.doi.org/10.1074/jbc.M313999200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14724271	hybrid			2022-12-25	WOS:000220747900127
J	Zhou, JL; Hoggatt, AM; Herring, BP				Zhou, JL; Hoggatt, AM; Herring, BP			Activation of the smooth muscle-specific telokin gene by thyrotroph embryonic factor (TEF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; LEUCINE-ZIPPER PROTEINS; DNA-BINDING SPECIFICITY; LIGHT-CHAIN KINASE; TRANSCRIPTION FACTOR; EXPRESSION; PROMOTER; MYOSIN; PAR; DOMAIN	Transcription of the telokin gene is restricted to smooth muscle cells throughout development, making this gene an excellent model for unraveling the mechanisms that regulate gene expression in smooth muscle tissues. To identify proteins that bind to the telokin promoter, the AT-rich/CArG core of the promoter was used as a probe to perform a Southwestern screen of a mouse bladder cDNA library. Four clones corresponding to two distinct isoforms of mouse thyrotroph embryonic factor (TEFalpha and TEFbeta) were identified from this screen. The two TEF isoforms differ from each other at their amino termini and result from alternative promoter usage. An RNase protection assay showed that both TEF isoforms are expressed at high levels in mouse lung, bladder, kidney, gut, and brain. Gel mobility shift assays demonstrated that purified TEF protein can specifically bind to an AT-rich region within the core of the telokin promoter. Furthermore, when overexpressed in 10T1/2 cells, TEF significantly increased the activity of a telokin promoter-reporter gene; this activation was further augmented by elevated intracellular calcium levels. In contrast, overexpression of TEF had no effect on reporter genes driven by SM22alpha, smooth muscle alpha-actin, or smooth muscle myosin heavy chain promoters. Consistent with these results, overexpression of TEFalpha and TEFbeta in A10 cells, using adenoviral vectors, increased expression of endogenous telokin without altering expression of myosin light chain 20, SM22alpha, smooth muscle alpha-actin, or calponin. These findings suggest that TEF factors contribute to the activation of the telokin promoter in smooth muscle cells in a calcium-dependent manner. These data also suggest that distinct transcription factors are required to control the expression of different smooth muscle genes in a single tissue.	Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Herring, BP (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	pherring@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061130] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL058571] Funding Source: Medline; NIDDK NIH HHS [DK61130] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BURCH JBE, 1994, NUCLEIC ACIDS RES, V22, P4733, DOI 10.1093/nar/22.22.4733; Crable SC, 2003, BLOOD, V101, P4757, DOI 10.1182/blood-2002-09-2702; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; Falvey E, 1996, BIOL CHEM, V377, P797; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; HAAS NB, 1995, MOL CELL BIOL, V15, P1923; Herring BP, 2001, AM J PHYSIOL-CELL PH, V280, pC12, DOI 10.1152/ajpcell.2001.280.1.C12; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; Hoggatt AM, 2002, CIRC RES, V91, P1151, DOI 10.1161/01.RES.0000047508.30800.4F; Hoggatt AM, 2000, J BIOL CHEM, V275, P31162, DOI 10.1074/jbc.M005595200; Hunger SP, 1996, BLOOD, V87, P4607, DOI 10.1182/blood.V87.11.4607.bloodjournal87114607; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; KATAYAMA E, 1995, J BIOL CHEM, V270, P3919, DOI 10.1074/jbc.270.8.3919; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Krueger DA, 2000, J BIOL CHEM, V275, P14524, DOI 10.1074/jbc.275.19.14524; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; Ossipow V, 1999, MOL CELL BIOL, V19, P1242; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; Smith AF, 1998, AM J PHYSIOL-CELL PH, V274, pC1188, DOI 10.1152/ajpcell.1998.274.5.C1188; Watanabe M, 2002, CIRC RES, V91, P382, DOI 10.1161/01.RES.0000033593.05545.7B; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362; WUARIN J, 1992, J CELL SCI, P123; Zeidan A, 2003, AM J PHYSIOL-CELL PH, V284, pC1387, DOI 10.1152/ajpcell.00508.2002	33	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15929	15937		10.1074/jbc.M313822200	http://dx.doi.org/10.1074/jbc.M313822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14702338	hybrid			2022-12-25	WOS:000220747900029
J	Ling, X; Bernacki, RJ; Brattain, MG; Li, FZ				Ling, X; Bernacki, RJ; Brattain, MG; Li, FZ			Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G(2)/M arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OVARIAN-CANCER; INDUCED APOPTOSIS; PROTEIN SURVIVIN; CELL-CYCLE; CASPASE ACTIVITY; BREAST-CANCER; GENE; PATHWAY; TUBULIN; PHOSPHORYLATION	Survivin is a novel anti-apoptotic protein that is highly expressed in cancer but is undetectable in most normal adult tissues. It was reported that taxol-mediated mitotic arrest of cancer cells is associated with survivin induction, which preserves a survival pathway and results in resistance to taxol. In this study, we provide new evidence that induction of survivin by taxol is an early event and is independent of taxol-mediated G(2)/M arrest. Taxol treatment of MCF-7 cells rapidly up-regulated survivin expression (3.5-15-fold) within 4 h without G(2)/M arrest. Lengthening the treatment of cells (48 h) with taxol resulted in decreased survivin expression in comparison with early times following taxol treatment, although G(2)/M cells were significantly increased at later times. Interestingly, 3 nM taxol induces survivin as effectively as 300 nM and more effectively than 3000 nM. As a result, 3 nM taxol is ineffective at inducing cell death. However, inhibition of taxol-mediated survivin induction by small interfering RNA significantly increased taxol-mediated cell death. Taxol rapidly activated the phosphatidylinositol 3-kinase/Akt and MAPK pathways. Inhibition of these pathways diminished survivin induction and sensitized cells to taxol-mediated cell death. A cis-acting DNA element upstream of -1430 in the survivin pLuc-2840 construct is at least partially responsible for taxol-mediated survivin induction. Together, these data show, for the first time, that taxol-mediated induction of survivin is an early event and independent of taxol-mediated G(2)/M arrest. This appears to be a new mechanism for cancer cells to evade taxol-induced apoptosis. Targeting this survival pathway may result in novel approaches for cancer therapeutics.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Li, FZ (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	fengzhi.li@roswellpark.org	Li, Fengzhi/GXF-0115-2022		NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA109481, CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; BHALLA K, 1994, LEUKEMIA, V8, P465; Blagosklonny MV, 2002, CANCER BIOL THER, V1, P113, DOI 10.4161/cbt.53; Casazza A M, 1996, Cancer Treat Res, V87, P149; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Eisenhauer EA, 1998, DRUGS, V55, P5, DOI 10.2165/00003495-199855010-00002; Fan WM, 1999, BIOCHEM PHARMACOL, V57, P1215; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Grossman D, 1999, LAB INVEST, V79, P1121; IRELAND CM, 1995, BIOCHEM PHARMACOL, V49, P1491, DOI 10.1016/0006-2952(95)00030-4; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; KUMAR N, 1981, J BIOL CHEM, V256, P435; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; LIEBMANN JE, 1993, BRIT J CANCER, V68, P1104, DOI 10.1038/bjc.1993.488; LING X, 2004, IN PRESS BIOTECHNIQU; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Olie RA, 2000, CANCER RES, V60, P2805; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SCHIBLER MJ, 1986, J CELL BIOL, V102, P1522, DOI 10.1083/jcb.102.4.1522; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Stadheim TA, 2001, CANCER RES, V61, P1533; Tamm I, 1998, CANCER RES, V58, P5315; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Wall NR, 2003, CANCER RES, V63, P230; Wiseman LR, 1998, DRUG AGING, V12, P305, DOI 10.2165/00002512-199812040-00005; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; Zaffaroni N, 2002, CELL MOL LIFE SCI, V59, P1406, DOI 10.1007/s00018-002-8518-3	45	157	169	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15196	15203		10.1074/jbc.M310947200	http://dx.doi.org/10.1074/jbc.M310947200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722122	hybrid			2022-12-25	WOS:000220594700086
J	Singer, AL; Bunnell, SC; Obstfeld, AE; Jordan, MS; Wu, JN; Myung, PS; Samelson, LE; Koretzky, GA				Singer, AL; Bunnell, SC; Obstfeld, AE; Jordan, MS; Wu, JN; Myung, PS; Samelson, LE; Koretzky, GA			Roles of the proline-rich domain in SLP-76 subcellular localization and T cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN SLP-76; ANTIGEN RECEPTOR; DIFFERENTIAL REQUIREMENT; TYROSINE PHOSPHORYLATION; INTERLEUKIN-2 PRODUCTION; MEDIATED ACTIVATION; MOLECULAR-CLONING; LINKER PROTEIN; LIVING CELLS; LAT	The adaptor protein Src homology (SH) 2 domain-containing and leukocyte-specific phosphoprotein of 76 kDa (SLP-76) is critical for signal transduction in multiple hematopoietic lineages. It links proximal and distal T cell receptor signaling events through its function as a molecular scaffold in the assembly of multimolecular signaling complexes. Here we studied the functional roles of sub-domains within the SLP-76 proline-rich region, specifically the Gads binding domain and the recently defined P1 domain. To gain a further understanding of the functions mediated by this region, we used three complementary approaches as follows: reconstitution of SLP-76-deficient cells with functional domain deletion mutants, blocking molecular associations through the expression of a dominant negative protein fragment, and directed localization of SLP-76 to assess the role of the domains in SLP-76 recruitment. We find the Gads binding domain and the P1 domain are both necessary for optimal SLP-76 function, and in the absence of these two regions, SLP-76 is functionally inert. Furthermore, we provide direct evidence that SLP-76 localization and, in turn, function are dependent upon association with Gads.	Univ Penn, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Signal Transduct Program, Philadelphia, PA 19104 USA; NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; Pennsylvania Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Koretzky, GA (corresponding author), 421 Curie Blvd,415 BRB 2-3, Philadelphia, PA 19104 USA.	koretzky@mail.med.upenn.edu	Koretzky, Gary/AAU-5381-2021	Bunnell, Stephen/0000-0001-6887-0828	NCI NIH HHS [P01-CA93615] Funding Source: Medline; NIAMS NIH HHS [T32-AR07442] Funding Source: Medline; NIDDK NIH HHS [F32-DK09969] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA093615, Z01BC010304, ZIABC010304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009969] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abtahian F, 2003, SCIENCE, V299, P247, DOI 10.1126/science.1079477; Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Berry DM, 2002, CURR BIOL, V12, P1336, DOI 10.1016/S0960-9822(02)01038-2; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; BUDAY L, 1994, J BIOL CHEM, V269, P9019; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; BUNNELL SC, 2003, SCIENCES; Clements JL, 1998, J IMMUNOL, V161, P3880; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Ellis JH, 2000, J IMMUNOL, V164, P5805, DOI 10.4049/jimmunol.164.11.5805; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Judd BA, 2002, J EXP MED, V195, P705, DOI 10.1084/jem.20011583; Kumar L, 2002, P NATL ACAD SCI USA, V99, P884, DOI 10.1073/pnas.022619199; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Myung PS, 2001, IMMUNITY, V15, P1011, DOI 10.1016/S1074-7613(01)00253-9; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Peterson EJ, 1999, EUR J IMMUNOL, V29, P2223, DOI 10.1002/(SICI)1521-4141(199907)29:07<2223::AID-IMMU2223>3.0.CO;2-6; Peterson EJ, 2001, SCIENCE, V293, P2263, DOI 10.1126/science.1063486; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Stephens DJ, 2003, SCIENCE, V300, P82, DOI 10.1126/science.1082160; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Weijer CJ, 2003, SCIENCE, V300, P96, DOI 10.1126/science.1082830; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yamasaki S, 2003, MOL CELL BIOL, V23, P2515, DOI 10.1128/MCB.23.7.2515-2529.2003; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	52	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15481	15490		10.1074/jbc.M313339200	http://dx.doi.org/10.1074/jbc.M313339200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722089	hybrid			2022-12-25	WOS:000220594700119
J	Walker, AK; Shi, Y; Blackwell, TK				Walker, AK; Shi, Y; Blackwell, TK			An extensive requirement for transcription factor IID-specific TAF-1 in Caenorhabditis elegans embryonic transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TBP-LIKE FACTOR; CELL-CYCLE PROGRESSION; C-TERMINAL DOMAIN; IN-VIVO; GENE-EXPRESSION; P-TEFB; SINGLE BLASTOMERE; SAGA COMPLEXES; YEAST	The general transcription factor TFIID sets the mRNA start site and consists of TATA-binding protein and associated factors (TAF(II)s), some of which are also present in SPT-ADA-GCN5 (SAGA)-related complexes. In yeast, results of multiple studies indicate that TFIID-specific TAFIIs are not required for the transcription of most genes, implying that intact TFIID may have a surprisingly specialized role in transcription. Relatively little is known about how TAFIIs contribute to metazoan transcription in vivo, especially at developmental and tissue-specific genes. Previously, we investigated functions of four shared TFIID/SAGA TAF(II)s in Caenorhabditis elegans. Whereas TAF-4 was required for essentially all embryonic transcription, TAF-5, TAF-9, and TAF-10 were dispensable at multiple developmental and other metazoan-specific promoters. Here we show evidence that in C. elegans embryos transcription of most genes requires TFIID-specific TAF-1. TAF-1 is not as universally required as TAF-4, but it is essential for a greater proportion of transcription than TAF-5, -9, or -10 and is important for transcription of many developmental and other metazoan-specific genes. TAF-2, which binds core promoters with TAF-1, appears to be required for a similarly substantial proportion of transcription. C. elegans TAF-1 overlaps functionally with the coactivator p300/CBP (CBP-1), and at some genes it is required along with the TBP-like protein TLF(TRF2). We conclude that during C. elegans embryogenesis TAF-1 and TFIID have broad roles in transcription and development and that TFIID and TLF may act together at certain promoters. Our findings imply that in metazoans TFIID may be of widespread importance for transcription and for expression of tissue-specific genes.	Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Blackwell, TK (corresponding author), Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, 1 Joslin Pl, Boston, MA 02115 USA.	keith.blackwell@joslin.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062891] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Andel F, 1999, SCIENCE, V286, P2153, DOI 10.1126/science.286.5447.2153; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Batchelder C, 1999, GENE DEV, V13, P202, DOI 10.1101/gad.13.2.202; Baugh LR, 2003, DEVELOPMENT, V130, P889, DOI 10.1242/dev.00302; Bowerman B, 1997, DEVELOPMENT, V124, P3815; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Calvo D, 2001, EMBO J, V20, P7197, DOI 10.1093/emboj/20.24.7197; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; Durso RJ, 2001, MOL CELL BIOL, V21, P7331, DOI 10.1128/MCB.21.21.7331-7344.2001; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Hardy S, 2002, J BIOL CHEM, V277, P32875, DOI 10.1074/jbc.M205860200; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Hochheimer A, 2002, NATURE, V420, P439, DOI 10.1038/nature01167; Hochheimer A, 2003, GENE DEV, V17, P1309, DOI 10.1101/gad.1099903; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Horner MA, 1998, GENE DEV, V12, P1947, DOI 10.1101/gad.12.13.1947; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Kalb JM, 1998, DEVELOPMENT, V125, P2171; Kaltenbach L, 2000, MOL CELL, V6, P705, DOI 10.1016/S1097-2765(00)00068-X; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Li XY, 2002, CURR BIOL, V12, P1240, DOI 10.1016/S0960-9822(02)00932-6; Maduro MF, 2001, MOL CELL, V7, P475, DOI 10.1016/S1097-2765(01)00195-2; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Martianov I, 2001, MOL CELL, V7, P509, DOI 10.1016/S1097-2765(01)00198-8; Martianov I, 2002, DEVELOPMENT, V129, P945; Matangkasombut O, 2000, GENE DEV, V14, P951; Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Muller F, 2001, CURR BIOL, V11, P282, DOI 10.1016/S0960-9822(01)00076-8; Newman-Smith ED, 1998, CURR OPIN GENET DEV, V8, P472, DOI 10.1016/S0959-437X(98)80120-2; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Reese JC, 2000, J BIOL CHEM, V275, P17391, DOI 10.1074/jbc.M001635200; Reese KJ, 2000, MOL CELL, V6, P445, DOI 10.1016/S1097-2765(00)00043-5; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Seydoux G, 1997, DEVELOPMENT, V124, P2191; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; Shen WC, 2003, EMBO J, V22, P3395, DOI 10.1093/emboj/cdg336; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Shim EY, 2002, J BIOL CHEM, V277, P30413, DOI 10.1074/jbc.C200305200; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Takagi T, 2003, J BIOL CHEM, V278, P14174, DOI 10.1074/jbc.M212101200; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Veenstra GJC, 2000, SCIENCE, V290, P2312, DOI 10.1126/science.290.5500.2312; Victor M, 2002, EMBO REP, V3, P50, DOI 10.1093/embo-reports/kvf006; Walker AK, 2003, J BIOL CHEM, V278, P6181, DOI 10.1074/jbc.M211056200; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; Wallenfang MR, 2002, P NATL ACAD SCI USA, V99, P5527, DOI 10.1073/pnas.082618399; Wassarman DA, 2000, P NATL ACAD SCI USA, V97, P1154, DOI 10.1073/pnas.97.3.1154; Wassarman DA, 2001, J CELL SCI, V114, P2895; Zhang F, 2003, GENE DEV, V17, P748, DOI 10.1101/gad.1068203	71	14	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15339	15347		10.1074/jbc.M310731200	http://dx.doi.org/10.1074/jbc.M310731200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14726532	hybrid			2022-12-25	WOS:000220594700103
J	Hyun, TS; Rao, DS; Saint-Dic, D; Michael, LE; Kumar, PD; Bradley, SV; Mizukami, IF; Oravecz-Wilson, KI; Ross, TS				Hyun, TS; Rao, DS; Saint-Dic, D; Michael, LE; Kumar, PD; Bradley, SV; Mizukami, IF; Oravecz-Wilson, KI; Ross, TS			HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTIN-INTERACTING PROTEIN; GROWTH-FACTOR RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; ENTH-DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; EARLY ENDOSOMES; COLON-CANCER; COATED PITS; CELLS; ACTIN	Huntingtin-interacting protein 1-related (HIP1r) is the only known mammalian relative of huntingtin-interacting protein 1 (HIP1), a protein that transforms fibroblasts via undefined mechanisms. Here we demonstrate that both HIP1r and HIP1 bind inositol lipids via their epsin N-terminal homology (ENTH) domains. In contrast to other ENTH domain-containing proteins, lipid binding is preferential to the 3-phosphate-containing inositol lipids, phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,5-bisphosphate. Furthermore, the HIP1r ENTH domain, like that of HIP1, is necessary for lipid binding, and expression of an ENTH domain-deletion mutant, HIP1r/DeltaE, induces apoptosis. Consistent with the ability of HIP1r and HIP1 to affect cell survival, full-length HIP1 and HIP1r stabilize pools of growth factor receptors by prolonging their half-life following ligand-induced endocytosis. Although HIP1r and HIP1 display only a partially overlapping pattern of protein interactions, these data suggest that both proteins share a functional homology by binding 3-phosphorylated inositol lipids and stabilizing receptor tyrosine kinases in a fashion that may contribute to their ability to alter cell growth and survival.	Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Grad Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ross, TS (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.	tsross@umich.edu	Rao, Dinesh/AAE-9625-2019	Ross, Theodora/0000-0002-9166-1802; Hyun, Teresa/0000-0002-9350-2733; Bradley, Sarah/0000-0001-8491-7809; Rao, Dinesh/0000-0002-0794-9337	NATIONAL CANCER INSTITUTE [R01CA082363, R01CA098730] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82363-01A1, R01 CA 098730-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen XM, 2001, EMBO REP, V2, P842, DOI 10.1093/embo-reports/kve179; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Corvera S, 2001, TRAFFIC, V2, P859, DOI 10.1034/j.1600-0854.2001.21201.x; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Friant S, 2003, DEV CELL, V5, P499, DOI 10.1016/S1534-5807(03)00238-7; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hackam AS, 2000, J BIOL CHEM, V275, P41299, DOI 10.1074/jbc.M008408200; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Hussain NK, 2003, J BIOL CHEM, V278, P28823, DOI 10.1074/jbc.M300995200; Itoh T, 2002, CELL SIGNAL, V14, P733, DOI 10.1016/S0898-6568(02)00028-1; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kalthoff C, 2002, MOL BIOL CELL, V13, P4060, DOI 10.1091/mbc.E02-03-0171; Kari C, 2003, CANCER RES, V63, P1; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Legendre-Guillemin V, 2002, J BIOL CHEM, V277, P19897, DOI 10.1074/jbc.M112310200; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Metzler M, 2003, EMBO J, V22, P3254, DOI 10.1093/emboj/cdg334; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Rao DS, 2003, CANCER CELL, V3, P471, DOI 10.1016/S1535-6108(03)00107-7; Rao DS, 2002, J CLIN INVEST, V110, P351, DOI 10.1172/JCI200215529; Rao DS, 2001, MOL CELL BIOL, V21, P7796, DOI 10.1128/MCB.21.22.7796-7806.2001; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Ross TS, 1999, J BIOL CHEM, V274, P22328, DOI 10.1074/jbc.274.32.22328; Ross TS, 1998, BLOOD, V91, P4419, DOI 10.1182/blood.V91.12.4419.412k43_4419_4426; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Scanlan MJ, 2002, CANCER RES, V62, P4041; Seki N, 1998, J HUM GENET, V43, P268, DOI 10.1007/s100380050087; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Waelter S, 2001, HUM MOL GENET, V10, P1807, DOI 10.1093/hmg/10.17.1807; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078	44	53	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14294	14306		10.1074/jbc.M312645200	http://dx.doi.org/10.1074/jbc.M312645200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732715	hybrid			2022-12-25	WOS:000220478500124
J	Luo, SH; Rohloff, P; Cox, J; Uyemura, SA; Docampo, R				Luo, SH; Rohloff, P; Cox, J; Uyemura, SA; Docampo, R			Trypanosoma brucei plasma membrane-type Ca2+-ATPase 1 (TbPMC1) and 2 (TbPMC2) genes encode functional Ca2+-ATPases localized to the acidocalcisomes and plasma membrane, and essential for Ca2+ homeostasis and growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; P-TYPE ATPASE; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; H+-PYROPHOSPHATASE; CALCIUM-PUMP; EXPRESSION; FORMS; INTERFERENCE; INHIBITION	Trypanosoma brucei adaptation and survival in its host involve integrated regulation of Ca2+ pumps (Ca2+-ATPases), which are essential in calcium ion homeostasis. Here we report the cloning and sequencing of two genes (TbPMC1 and TbPMC2) encoding plasma membrane-type Ca2+-ATPases (PMCAs) of T. brucei, an agent of African trypanosomiasis. Indirect immunofluorescence analysis using antibodies against the proteins and against epitope tags introduced into each protein showed that TbPMC1 co-localized with the vacuolar H+-pyrophosphatase to the acidocalcisomes while TbPMC2 localized to the plasma membrane. Northern and Western blot analyses revealed that TbPMC1 and TbPMC2 are up-regulated during blood stages. TbPMC1 and TbPMC2 suppressed the Ca2+ hypersensitivity of a mutant of S. cerevisiae that has a defect in vacuolar Ca2+ accumulation. T. brucei Ca2+-ATPase genes were functionally characterized by using double-stranded RNA interference (RNAi) methodology to produce inducible Ca2+-ATPase-deficient procyclic forms. Similar results were obtained with bloodstream form trypomastigotes, except that the RNAi system was leaky and mRNA and protein levels recovered with time. The induction of dsRNA ( RNAi) caused gross morphological alterations, and growth inhibition of procyclic forms. Induction of RNAi against TbPMC1 but not against TbPMC2 caused elevated levels of cytosolic Ca2+ and decreased mobilization of Ca2+ from intracellular stores following ionophore addition. These results establish that T. brucei PMCA-Ca2+-ATPases are essential for parasite viability and validate them as targets for drug development.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Coll Vet Med, Ctr Zoonoses Res, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Uyemura, Sergio/B-4656-2011; Rohloff, Peter/P-8722-2017	Uyemura, Sergio/0000-0001-5505-9817; Rohloff, Peter/0000-0001-7274-8315				ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BABABUNMI E, 1982, ANN NY ACAD SCI, V402, P349; BABABUNMI E A, 1987, Microbios Letters, V36, P71; BASSILIAN R, 1981, ANNU REV BIOCHEM, V50, P349; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; BENAIM G, 1993, BIOCHEM J, V296, P759, DOI 10.1042/bj2960759; BRUN R, 1979, ACTA TROP, V36, P289; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Docampo R, 2003, PARASITOL RES, V90, pS10, DOI 10.1007/s00436-002-0752-y; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Ghosh SK, 2000, MOL BIOCHEM PARASIT, V108, P125, DOI 10.1016/S0166-6851(00)00196-1; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemercier G, 2002, J BIOL CHEM, V277, P37369, DOI 10.1074/jbc.M204744200; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55; Marchesini N, 2002, J BIOL CHEM, V277, P8146, DOI 10.1074/jbc.M111130200; MATTSSON JP, 1991, BIOCHIM BIOPHYS ACTA, V1065, P261, DOI 10.1016/0005-2736(91)90238-4; MCLAUGHLIN J, 1985, MOL BIOCHEM PARASIT, V15, P189, DOI 10.1016/0166-6851(85)90119-7; MONIAKIS J, 1995, J BIOL CHEM, V270, P28276; Morris JC, 2001, MOL BIOCHEM PARASIT, V117, P111, DOI 10.1016/S0166-6851(01)00334-6; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; NOLAN DP, 1994, J BIOL CHEM, V269, P26045; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZMANN HJ, 1953, HELV PHYSIOL PHARM A, V11, P346; SCOTT DA, 1995, BIOCHEM J, V310, P789, DOI 10.1042/bj3100789; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; SVERDLOV ED, 1987, FEBS LETT, V221, P129, DOI 10.1016/0014-5793(87)80366-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; Wang CC, 1997, PARASITOLOGY, V114, pS31; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835	49	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14427	14439		10.1074/jbc.M309978200	http://dx.doi.org/10.1074/jbc.M309978200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724285	hybrid			2022-12-25	WOS:000220478500139
J	Sanna, MG; Liao, JY; Jo, EJ; Alfonso, C; Ahn, MY; Peterson, MS; Webb, B; Lefebvre, S; Chun, J; Gray, N; Rosen, H				Sanna, MG; Liao, JY; Jo, EJ; Alfonso, C; Ahn, MY; Peterson, MS; Webb, B; Lefebvre, S; Chun, J; Gray, N; Rosen, H			Sphingosine 1-phosphate (S1P) receptor subtypes S1P(1) and S1P(3), respectively, regulate lymphocyte recirculation and heart rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SPHINGOSINE-1-PHOSPHATE; FTY720; ACTIVATION; EDG-1; LYSOPHOSPHOLIPIDS; TRANSPLANTATION; TRAFFICKING; CELLS	Sphingosine 1-phosphate (S1P) influences heart rate, coronary artery caliber, endothelial integrity, and lymphocyte recirculation through five related high affinity G-protein-coupled receptors. Inhibition of lymphocyte recirculation by non-selective S1P receptor agonists produces clinical immunosuppression preventing transplant rejection but is associated with transient bradycardia. Understanding the contribution of individual receptors has been limited by the embryonic lethality of the S1P(1) knock-out and the unavailability of selective agonists or antagonists. A potent, S1P(1)-receptor selective agonist structurally unrelated to S1P was found to activate multiple signals triggered by S1P, including guanosine 5'-3-O-( thio) triphosphate binding, calcium flux, Akt and ERK1/2 phosphorylation, and stimulation of migration of S1P(1)- but not S1P(3)-expressing cells in vitro. The agonist also alters lymphocyte trafficking in vivo. Use of selective agonism together with deletant mice lacking S1P(3) receptor reveals that agonism of S1P(1) receptor alone is sufficient to control lymphocyte recirculation. Moreover, S1P(1) receptor agonist plasma levels are causally associated with induction and maintenance of lymphopenia. S1P(3), and not S1P(1), is directly implicated in sinus bradycardia. The sustained bradycardia induced by S1P receptor nonselective immunosuppressive agonists in wild-type mice is abolished in S1P(3)(-/-) mice, whereas S1P(1)-selective agonist does not produce bradycardia. Separation of receptor subtype usage for control of lymphocyte recirculation and heart rate may allow the identification of selective immunosuppressive S1P(1) receptor agonists with an enhanced therapeutic window. S1P(1)- selective agonists will be of broad utility in understanding cell functions in vitro, and vascular physiology in vivo, and the success of the chemical approach for S1P(1) suggests that selective tools for the resolution of function across this broad lipid receptor family are now possible.	Scripps Res Inst, Ctr Mass Spectrometry, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Novartis	Rosen, H (corresponding author), Scripps Res Inst, Ctr Mass Spectrometry, Dept Immunol, 10550 N torrey Pines Rd,ICND 118, La Jolla, CA 92037 USA.	hrosen@scripps.edu	Chun, Jerold/Y-4670-2019	Jo, Euijung/0000-0003-1131-2723				Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2002, CURR OPIN IMMUNOL, V14, P569, DOI 10.1016/S0952-7915(02)00374-6; Brinkmann V, 2000, TRENDS PHARMACOL SCI, V21, P49, DOI 10.1016/S0165-6147(99)01419-4; Brinkmann V, 2001, TRANSPLANT P, V33, P530, DOI 10.1016/S0041-1345(00)02126-6; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Budde K, 2003, AM J TRANSPLANT, V3, P846, DOI 10.1034/j.1600-6143.2003.00130.x; Dantas APV, 2003, AM J PHYSIOL-HEART C, V284, pH2045, DOI 10.1152/ajpheart.01089.2002; DOHERTY G, 2003, Patent No. 03061567; English D, 2002, BBA-MOL CELL BIOL L, V1582, P228, DOI 10.1016/S1388-1981(02)00176-2; FORREST M, 2004, IN PRESS J PHARM EXP; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Gowans J L, 1980, Ciba Found Symp, V71, P113, DOI 10.1002/9780470720547.ch7; GOWANS JL, 1971, INT ARCH ALLER A IMM, V41, P1; GOWANS JL, 1975, J RETICULOENDOTH SOC, V17, P97; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; GRAELER M, 2002, BIOCHIM BIOPHYS ACTA, V1582, P168; Himmel HM, 2000, MOL PHARMACOL, V58, P449, DOI 10.1124/mol.58.2.449; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Igarashi J, 2001, J BIOL CHEM, V276, P36281, DOI 10.1074/jbc.M105628200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Karliner JS, 2002, BBA-MOL CELL BIOL L, V1582, P216, DOI 10.1016/S1388-1981(02)00174-9; KLUCK MJ, 2002, BIOCHIM BIOPHYS ACTA, V1582, P72; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Mazurais D, 2002, J HISTOCHEM CYTOCHEM, V50, P661, DOI 10.1177/002215540205000507; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; Ohmori T, 2003, CARDIOVASC RES, V58, P170, DOI 10.1016/S0008-6363(03)00260-8; Parrill AL, 2000, J BIOL CHEM, V275, P39379, DOI 10.1074/jbc.M007680200; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Rosen H, 2003, IMMUNOL REV, V195, P160, DOI 10.1034/j.1600-065X.2003.00068.x; Rosen H, 2003, CURR OPIN CHEM BIOL, V7, P461, DOI 10.1016/S1367-5931(03)00085-1; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Sugiyama A, 2000, CARDIOVASC RES, V46, P119, DOI 10.1016/S0008-6363(00)00013-4; Xie JH, 2003, J IMMUNOL, V170, P3662, DOI 10.4049/jimmunol.170.7.3662; Yagi H, 2000, EUR J IMMUNOL, V30, P1435, DOI 10.1002/(SICI)1521-4141(200005)30:5<1435::AID-IMMU1435>3.0.CO;2-O	43	516	592	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13839	13848		10.1074/jbc.M311743200	http://dx.doi.org/10.1074/jbc.M311743200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732717	hybrid			2022-12-25	WOS:000220478500070
J	Cahoon, EB; Kinney, AJ				Cahoon, EB; Kinney, AJ			Dimorphecolic acid is synthesized by the coordinate activities of two divergent Delta(12)-oleic acid desaturases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID; OLEATE 12-HYDROXYLASE; CALENDULA-OFFICINALIS; BIOSYNTHETIC ORIGIN; SOYBEAN EMBRYOS; IDENTIFICATION; BONDS; OILS; EXPRESSION; COMPONENTS	Dimorphecolic acid (9-OH-18:2Delta(10trans,12trans)) is the major fatty acid of seeds of Dimorphotheca species. This fatty acid contains structural features that are not typically found in plant fatty acids, including a C-9 hydroxyl group, Delta(10),Delta(12)-conjugated double bonds, and trans-Delta(12) unsaturation. Expressed sequence tag analysis was conducted to determine the biosynthetic origin of dimorphecolic acid. cDNAs for two divergent forms of Delta(12)-oleic acid desaturase, designated DsFAD2-1 and Ds-FAD2-2, were identified among expressed sequence tags generated from developing Dimorphotheca sinuata seeds. Expression of DsFAD2-1 in Saccharomyces cerevisiae and soybean somatic embryos resulted in the accumulation of the trans-Delta(12) isomer of linoleic acid (18: 2Delta(9cis,12trans)) rather than the more typical cis-Delta(12) isomer. When co-expressed with DsFAD2-1 in soybean embryos or yeast, DsFAD2-2 converted 18:2Delta(9cis,12trans) into dimorphecolic acid. When DsFAD2-2 was expressed alone in soybean embryos or together with a typical cis-Delta(12)-oleic acid desaturase in yeast, trace amounts of the cis-Delta(12) isomer of dimorphecolic acid (9-OH-18:2Delta(9cis,12cis)) were formed from DsFAD2-2 activity with cis-Delta(12)-linoleic acid. These results indicate that DsFAD2-2 catalyzes the conversion of the Delta(9) double bond of linoleic acid into a C-9 hydroxyl group and Delta(10trans) double bond and displays a substrate preference for the trans-Delta(12), rather than the cis-Delta(12), isomer of linoleic acid. Overall these data are consistent with a biosynthetic pathway of dimorphecolic acid involving the concerted activities of DsFAD2-1 and DsFAD2-2. The evolution of two divergent Delta(12)-oleic acid desaturases for the biosynthesis of an unusual fatty acid is unprecedented in plants.	ARS, USDA, Plant Genet Res Unit, Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; DuPont Co Inc, Expt Stn, Pioneer Hi Bred Int Inc, Crop Genet Res, Wilmington, DE 19880 USA	Donald Danforth Plant Science Center; United States Department of Agriculture (USDA); DuPont	Cahoon, EB (corresponding author), ARS, USDA, Plant Genet Res Unit, Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	ecahoon@danforthcenter.org						*AG TECHN, 2002, CHROM SUPPL REF GUID, P391; Bao XM, 2002, P NATL ACAD SCI USA, V99, P7172, DOI 10.1073/pnas.092152999; Behrouzian B, 2002, CURR OPIN CHEM BIOL, V6, P577, DOI 10.1016/S1367-5931(02)00365-4; Broadwater JA, 2002, J BIOL CHEM, V277, P15613, DOI 10.1074/jbc.M200231200; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; Cahoon EB, 2000, PLANT PHYSIOL, V124, P243, DOI 10.1104/pp.124.1.243; Cahoon EB, 1999, P NATL ACAD SCI USA, V96, P12935, DOI 10.1073/pnas.96.22.12935; Cahoon EB, 2002, PLANT PHYSIOL, V128, P615, DOI 10.1104/pp.010768; Cahoon EB, 2001, J BIOL CHEM, V276, P2637, DOI 10.1074/jbc.M009188200; Covello PS, 1996, PLANT PHYSIOL, V111, P223, DOI 10.1104/pp.111.1.223; Dyer JM, 2002, PLANT PHYSIOL, V130, P2027, DOI 10.1104/pp.102.010835; Finer JJ., 1991, IN VITRO CELL DEV-PL, V27, P175, DOI [10.1007/bf02632213, DOI 10.1007/BF02632213, 10.2307/4292952]; GEITZ RD, 1994, MOL GENETICS YEAST P, P121; Hitz WD, 1998, U.S. Patent, Patent No. [5,846,784, 5846784]; Hof L., 1996, Progress in new crops: Proceedings of the Third National Symposium Indianapolis, Indiana, 22-25 October, 1996., P372; Hornung E, 2002, EUR J BIOCHEM, V269, P4852, DOI 10.1046/j.1432-1033.2002.03184.x; JONES A, 1995, PLANT CELL, V7, P359, DOI 10.1105/tpc.7.3.359; Kinney AJ, 1996, J FOOD LIPIDS, V3, P273, DOI 10.1111/j.1745-4522.1996.tb00074.x; Lee M, 1998, SCIENCE, V280, P915, DOI 10.1126/science.280.5365.915; MCCLEAN J, 1956, J CHEM SOC, P777; MORRIS F M, 1960, Am J Optom Arch Am Acad Optom, V37, P327; MORRIS LJ, 1966, CHEM IND-LONDON, P1493; Muuse B. G., 1992, Industrial Crops and Products, V1, P57, DOI 10.1016/0926-6690(92)90046-X; NILSSON R, 1991, PHYTOCHEM ANALYSIS, V2, P253, DOI 10.1002/pca.2800020604; Qiu X, 2001, PLANT PHYSIOL, V125, P847, DOI 10.1104/pp.125.2.847; Reed DW, 2002, EUR J BIOCHEM, V269, P5024, DOI 10.1046/j.1432-1033.2002.03209.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; SMITH CR, 1960, J AM CHEM SOC, V82, P1417, DOI 10.1021/ja01491a034; Sperling P, 1998, J BIOL CHEM, V273, P28590, DOI 10.1074/jbc.273.44.28590; Sperling P., 2002, PROSTAGLANDINS LEUKO, V68, P73; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743	32	42	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12495	12502		10.1074/jbc.M314329200	http://dx.doi.org/10.1074/jbc.M314329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718523	hybrid			2022-12-25	WOS:000220334900060
J	Chiba, H; Michibata, H; Wakimoto, K; Seishima, M; Kawasaki, S; Okubo, K; Mitsui, H; Torii, H; Imai, Y				Chiba, H; Michibata, H; Wakimoto, K; Seishima, M; Kawasaki, S; Okubo, K; Mitsui, H; Torii, H; Imai, Y			Cloning of a gene for a novel epithelium-specific cytosolic phospholipase A(2), cPLA(2)delta, induced in psoriatic skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; MOLECULAR-CLONING; MESSENGER-RNA; EXPRESSION; A(2); PROTEIN; HOMOLOGY; CONTAINS; MOUSE; GAP	Psoriasis is a common skin disease characterized by hyperplastic regenerative epidermal growth and infiltration of immunocytes. The etiology of psoriasis is unknown, although several genetic and cellular factors have been elucidated. To find new psoriasis- related genes, we have cloned cDNAs that are differentially expressed between normal and psoriatic skins. Among these clones, we have identified a new gene that codes for a new member of the type IV cytosolic phospholipase A(2) ( cPLA(2)) family. We refer to this gene as cPLA(2)delta. It encodes a polypeptide of 818 amino acids that has significant homology with known cPLA(2) proteins in the C2 and catalytic domains. The cPLA(2)delta gene was mapped to the 15q13 - 14 chromosomal locus, near to the locus of the cPLA(2)beta gene, from which it is separated by a physical distance of about 220 kb. To identify the phospholipase A(2) activity of cPLA(2)delta, we transfected COS- 7 cells with His- tagged cPLA(2)delta. The cell lysate from these cells had calcium- dependent phospholipase A(2) activity. Northern blot analysis revealed that a cPLA(2)delta transcript of about 4 kb is expressed in stratified squamous epithelia, such as those in skin and cervix, but not in other tissues. In situ hybridization and immunohistochemistry revealed that cPLA(2)delta is expressed strongly in the upper spinous layer of the psoriatic epidermis, expressed weakly and discontinuously in atopic dermatitis and mycosis fungoides, and not detected in the epidermis of normal skin; cPLA(2)alpha is not detected in either normal or psoriatic skin. These results suggest that cPLA(2)delta exhibits a unique distribution pattern compared with that of known cPLA(2) subtypes, and it may play a critical role in inflammation in psoriatic lesions.	Tanabe Seiyaku Co Ltd, Discovery & Pharmacol Res Labs, Toda, Saitama 3358305, Japan; Tanabe Seiyaku Co Ltd, Discovery & Pharmacol Res Labs, Yodogawa Ku, Osaka 5328505, Japan; Ogaki Municipal Hosp, Dept Dermatol, Ogaki 5038502, Japan; Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kyoto 6028566, Japan; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, Tokyo 1138655, Japan; Social Hlth Insurance Med Ctr, Dept Dermatol, Shinjyuku Ku, Tokyo 1690073, Japan	Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Ogaki Municipal Hospital; Kyoto Prefectural University of Medicine; Kyushu University; University of Tokyo	Imai, Y (corresponding author), Tanabe Seiyaku Co Ltd, Discovery & Pharmacol Res Labs, 2-50 Kawagishi 2 Chome, Toda, Saitama 3358305, Japan.	y-imai@tanabe.co.jp		Torii, Hideshi/0000-0003-2123-3033				ANDERSEN S, 1994, INFLAMMATION, V18, P1, DOI 10.1007/BF01534593; BAER AN, 1990, J LIPID RES, V31, P125; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DOHERTY NS, 1988, J INVEST DERMATOL, V91, P298, DOI 10.1111/1523-1747.ep12475630; FARBER EM, 1974, DERMATOLOGICA, V148, P1, DOI 10.1159/000251595; FOGH K, 1989, J INVEST DERMATOL, V92, P837, DOI 10.1111/1523-1747.ep12696858; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; IMAI Y, 1994, MOL BRAIN RES, V24, P313, DOI 10.1016/0169-328X(94)90144-9; JUHLIN L, 1992, ACTA DERM-VENEREOL, V72, P407; Kawamoto S, 1999, GENOME RES, V9, P1305, DOI 10.1101/gr.9.12.1305; KOMMINOTH P, 1992, HISTOCHEMISTRY, V98, P217, DOI 10.1007/BF00271035; LEIGH IM, 1995, BRIT J DERMATOL, V133, P501, DOI 10.1111/j.1365-2133.1995.tb02696.x; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MADSEN P, 1991, J INVEST DERMATOL, V97, P701, DOI 10.1111/1523-1747.ep12484041; Nickoloff BJ, 1999, J CLIN INVEST, V104, P1161, DOI 10.1172/JCI8633; Nyman KM, 2000, J HISTOCHEM CYTOCHEM, V48, P1469, DOI 10.1177/002215540004801104; Okubo K, 1991, DNA Seq, V2, P137, DOI 10.3109/10425179109039684; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; SCHALKWIJK J, 1991, BIOCHIM BIOPHYS ACTA, V1096, P148, DOI 10.1016/0925-4439(91)90053-C; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; ZHANG YY, 1991, METHOD ENZYMOL, V197, P456	26	59	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12890	12897		10.1074/jbc.M305801200	http://dx.doi.org/10.1074/jbc.M305801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709560	hybrid			2022-12-25	WOS:000220334900106
J	Kang, MR; Muller, MT; Chung, IK				Kang, MR; Muller, MT; Chung, IK			Telomeric DNA damage by topoisomerase I - A possible mechanism for cell killing by camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TOPOISOMERASE; CLEAVAGE; SEQUENCE; COMPLEXES; BREAKAGE; SITES; VITRO	Topoisomerase I adjusts torsional stress in the genome by breaking and resealing one strand of the helix through a transient covalent coupling between enzyme and DNA. Camptothecin, a specific topoisomerase I poison, traps this covalent intermediate, thereby damaging the genome. Here we examined the activity of topoisomerase I at telomeric repeats to determine whether telomere structures are targets for DNA damage. We show that topoisomerase I is catalytically active in cleaving the G-rich telomeric strand in vitro in the presence of camptothecin but not in cleaving the C-rich strand. The topoisomerase I cleavage site is 5'-TT down arrow AGGG-3' ( cleavage site marked by the 2). We also show that endogenous topoisomerase I can access telomeric DNA in vivo and form camptothecin-dependent covalent complexes. Therefore, each telomeric repeat represents a potential topoisomerase I cleavage site in vivo. Because telomere structures are comprised of a large number of repeats, telomeres in fact represent a high concentration of nested topoisomerase I sites. Therefore, more telomeric DNA damage by camptothecin could occur in cells with longer telomeres when cells possess equivalent levels of topoisomerase I. The evidence presented here suggests that DNA damage at telomeric repeats by topoisomerase I is a prominent feature of cell killing by camptothecin and triggers camptothecin-induced apoptosis.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Mol Aging Res Ctr, Seoul 120749, South Korea; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	Yonsei University; Yonsei University; Ohio State University	Chung, IK (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, 134 Shinchon Dong, Seoul 120749, South Korea.	topoviro@yonsei.ac.kr						BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Capranico G, 1998, BBA-GENE STRUCT EXPR, V1400, P185, DOI 10.1016/S0167-4781(98)00135-3; CASERTA M, 1989, NUCLEIC ACIDS RES, V17, P8463, DOI 10.1093/nar/17.21.8463; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Harrington L, 2002, ONCOGENE, V21, P592, DOI 10.1038/sj.onc.1205084; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; HORWITZ SB, 1973, CANCER RES, V33, P2834; JAXEL C, 1991, J BIOL CHEM, V266, P20418; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Mao YH, 2000, CANCER RES, V60, P4538; MULLER MT, 1988, MOL CELL BIOL, V8, P3661, DOI 10.1128/MCB.8.9.3661; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Ramirez R, 2003, J BIOL CHEM, V278, P836, DOI 10.1074/jbc.M206818200; Subramanian D, 2000, METH MOL B, V95, P137; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; Subramanian D, 1998, CANCER RES, V58, P976; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; TRASK DK, 1984, EMBO J, V3, P671, DOI 10.1002/j.1460-2075.1984.tb01865.x; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yoon HJ, 1998, BBA-GENE STRUCT EXPR, V1395, P110, DOI 10.1016/S0167-4781(97)00139-5	35	23	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12535	12541		10.1074/jbc.M309779200	http://dx.doi.org/10.1074/jbc.M309779200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14729676	hybrid			2022-12-25	WOS:000220334900065
J	Gao, G; Plaas, A; Thompson, VP; Jin, S; Zuo, FR; Sandy, JD				Gao, G; Plaas, A; Thompson, VP; Jin, S; Zuo, FR; Sandy, JD			ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE PROTEOGLYCAN DEGRADATION; HUMAN SYNOVIAL-FLUID; MATRIX-METALLOPROTEINASE; INTERGLOBULAR DOMAIN; ARTICULAR-CARTILAGE; STRUCTURAL CHARACTERIZATION; MEDIATED CATABOLISM; PHYSICAL-PROPERTIES; EPITHELIAL-CELLS; EXPLANT CULTURES	C-terminal truncation of ADAMTS-4 from the p68 form to the p53 form is required for activation of its capacity to cleave the Glu(373)-Ala(374) interglobular domain bond of aggrecan. In transfected human chondrosarcoma cells, this process is not autoproteolytic because the same products form with an inactive mutant of ADAMTS4 (a disintegrin and metalloproteinase with thrombospondin-like motif 4) and truncation is completely blocked by tissue inhibitor of metalloproteinase-1. Instead, activation can be mediated by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase (MT4-MMP, MMP-17) because co-transfection with the active form of MT4-MMP markedly enhanced activation, whereas an inactive mutant of MT4-MMP was ineffective. Treatment of co-transfected cells with phosphatidylinositol-specific phospholipase C liberated the complex of MT4-MMP and p68 ADAMTS4 from the cell membrane, but the p53 ADAMTS4 remained associated. Specific glycosaminoglycan lyase digestions, followed by product analyses using fluorescence-assisted carbohydrate electrophoresis and immunoprecipitation experiments, showed that the p53 form is associated with syndecan-1 through both chondroitin sulfate and heparan sulfate. We conclude that ADAMTS-4 activation in this cell system involves the coordinated activity of both glycosylphosphatidyl inositol-anchored MT4-MMP and the proteoglycan form of syndecan-1 on the cell surface.	Shriners Hosp Children, Ctr Res Skeletal Dev & Paediat Orthopaed, Tampa, FL 33612 USA; Univ S Florida, Dept Internal Med, Tampa, FL 33620 USA; Univ S Florida, Dept Pharmacol & Therapeut, Tampa, FL 33620 USA; Roche Biosci, Arthrit Dept, Palo Alto, CA 94304 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Roche Holding	Sandy, JD (corresponding author), Shriners Hosp Children, Ctr Res Skeletal Dev & Paediat Orthopaed, 12502 N Pine Dr, Tampa, FL 33612 USA.	jsandy@shctampa.usf.edu						Arner EC, 1999, ANN NY ACAD SCI, V878, P92, DOI 10.1111/j.1749-6632.1999.tb07676.x; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Bonassar LJ, 1997, ARCH BIOCHEM BIOPHYS, V344, P404, DOI 10.1006/abbi.1997.0205; Bryson H, 1998, ARCH BIOCHEM BIOPHYS, V355, P15, DOI 10.1006/abbi.1998.0696; BUTTLE DJ, 1992, BIOCHEM J, V281, P175, DOI 10.1042/bj2810175; Buttner FH, 1998, BIOCHEM J, V333, P159, DOI 10.1042/bj3330159; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; Chevrier A, 2001, ARCH BIOCHEM BIOPHYS, V396, P178, DOI 10.1006/abbi.2001.2608; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; English WR, 2001, FEBS LETT, V491, P137, DOI 10.1016/S0014-5793(01)02150-0; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; FLANNERY CR, 2003, ORTHOP RES SOC, V28, P157; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Grant GM, 1999, MATRIX BIOL, V18, P145, DOI 10.1016/S0945-053X(99)00003-7; Hahn-Dantona E, 1999, ANN NY ACAD SCI, V878, P372, DOI 10.1111/j.1749-6632.1999.tb07696.x; Ilic MZ, 2003, OSTEOARTHR CARTILAGE, V11, P613, DOI 10.1016/S1063-4584(03)00092-X; KASHIWAGI M, 2003, J BIOL CHEM; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Malfait AM, 2002, J BIOL CHEM, V277, P22201, DOI 10.1074/jbc.M200431200; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; Munteanu SE, 2002, MATRIX BIOL, V21, P429, DOI 10.1016/S0945-053X(02)00034-3; Patwari P, 2000, ARCH BIOCHEM BIOPHYS, V374, P79, DOI 10.1006/abbi.1999.1538; Plaas AHK, 2001, GLYCOBIOLOGY, V11, P779, DOI 10.1093/glycob/11.10.779; PLAAS AHK, 1993, MATRIX, V13, P135, DOI 10.1016/S0934-8832(11)80072-7; Plaimauer B, 2002, BLOOD, V100, P3626, DOI 10.1182/blood-2002-05-1397; Pratta MA, 2003, ARTHRITIS RHEUM, V48, P119, DOI 10.1002/art.10726; Puente XS, 1996, CANCER RES, V56, P944; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; Sandy JD, 1999, ARCH BIOCHEM BIOPHYS, V367, P258, DOI 10.1006/abbi.1999.1234; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Sandy JD, 2001, BIOCHEM J, V358, P615, DOI 10.1042/0264-6021:3580615; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Schwartz AJ, 2002, AM J VET RES, V63, P1564, DOI 10.2460/ajvr.2002.63.1564; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Stanton H, 2002, BIOCHEM J, V364, P181, DOI 10.1042/bj3640181; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sztrolovics R, 2002, BIOCHEM J, V362, P465, DOI 10.1042/0264-6021:3620465; Tolboom TCA, 2002, ANN RHEUM DIS, V61, P975, DOI 10.1136/ard.61.11.975; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1998, J BIOL CHEM, V273, P5846, DOI 10.1074/jbc.273.10.5846; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x; Westling J, 2004, BIOCHEM J, V377, P787, DOI 10.1042/bj20030896; Westling J, 2002, J BIOL CHEM, V277, P16059, DOI 10.1074/jbc.M108607200; Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573; YAMADA H, 1995, BIOCHEM BIOPH RES CO, V216, P957, DOI 10.1006/bbrc.1995.2713; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690; Yamanishi Y, 2002, J IMMUNOL, V168, P1405, DOI 10.4049/jimmunol.168.3.1405; Yuan W, 2002, NEUROSCIENCE, V114, P1091, DOI 10.1016/S0306-4522(02)00347-0	64	155	163	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10042	10051		10.1074/jbc.M312100200	http://dx.doi.org/10.1074/jbc.M312100200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701864	hybrid			2022-12-25	WOS:000220050400048
J	Koivunen, P; Hirsila, M; Gunzler, V; Kivirikko, KI; Myllyharju, J				Koivunen, P; Hirsila, M; Gunzler, V; Kivirikko, KI; Myllyharju, J			Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; DISULFIDE-ISOMERASE SUBUNIT; VON-HIPPEL-LINDAU; HIF-ALPHA; COLLAGEN; PROTEIN; FAMILY; BIOSYNTHESIS; HIF-1-ALPHA; DESTRUCTION	The activity of hypoxia-inducible transcription factor HIF, an alphabeta heterodimer that has an essential role in adaptation to low oxygen availability, is regulated by two oxygen-dependent hydroxylation events. Hydroxylation of specific proline residues by HIF prolyl 4-hydroxylases targets the HIF-alpha subunit for proteasomal destruction, whereas hydroxylation of an asparagine in the C-terminal transactivation domain prevents its interaction with the transcriptional coactivator p300. The HIF asparaginyl hydroxylase is identical to a previously known factor inhibiting HIF (FIH). We report here that recombinant FIH has unique catalytic and inhibitory properties when compared with those of the HIF prolyl 4-hydroxylases. FIH was found to require particularly long peptide substrates so that omission of only a few residues from the N or C terminus of a 35-residue HIF-1alpha sequence markedly reduced its substrate activity. Hydroxylation of two HIF-2alpha peptides was far less efficient than that of the corresponding HIF-1alpha peptides. The K-m of FIH for O-2 was about 40% of its atmospheric concentration, being about one-third of those of the HIF prolyl 4-hydroxylases but 2.5 times that of the type I collagen prolyl 4-hydroxylase. Several 2-oxoglutarate analogs were found to inhibit FIH but with distinctly different potencies from the HIF prolyl 4-hydroxylases. For example, the two most potent HIF prolyl 4-hydroxylase inhibitors among the compounds studied were the least effective ones for FIH. It should therefore be possible to develop specific small molecule inhibitors for the two enzyme classes involved in the hypoxia response.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; FibroGen Inc, San Francisco, CA 94080 USA	University of Oulu; University of Oulu; FibroGen	Myllyharju, J (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						ACKER H, 2003, OXYGEN SENSING RESPO, P507; BAADER E, 1994, BIOCHEM J, V300, P525, DOI 10.1042/bj3000525; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; Dann CE, 2002, P NATL ACAD SCI USA, V99, P15351, DOI 10.1073/pnas.202614999; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hieta R, 2003, J BIOL CHEM, V278, P34966, DOI 10.1074/jbc.M303624200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee C, 2003, J BIOL CHEM, V278, P7558, DOI 10.1074/jbc.M210385200; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rautavuoma K, 2002, J BIOL CHEM, V277, P23084, DOI 10.1074/jbc.M112077200; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	31	317	327	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9899	9904		10.1074/jbc.M312254200	http://dx.doi.org/10.1074/jbc.M312254200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701857	hybrid			2022-12-25	WOS:000220050400030
J	Wang, XH; Ling, MT; Guan, XY; Tsao, SW; Cheung, HW; Lee, DT; Wong, YC				Wang, XH; Ling, MT; Guan, XY; Tsao, SW; Cheung, HW; Lee, DT; Wong, YC			Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells	ONCOGENE			English	Article						TWIST; taxol; cancer; resistance	SAETHRE-CHOTZEN-SYNDROME; HELIX TRANSCRIPTION FACTOR; CARCINOMA-CELLS; PROSTATE-CANCER; BCL-2 PHOSPHORYLATION; ALTERED EXPRESSION; SIGNALING PATHWAY; HUMAN OVARIAN; TUMOR-CELLS; PACLITAXEL	Taxol is one of the widely used chemotherapeutic drugs against many types of human cancer. While it is considered as one of the most effective anticancer drugs, treatment failure often occurs due to development of acquired resistance. Therefore, it is important to understand the molecular mechanisms responsible for the development of drug resistance. Although it is generally believed that taxol induces cell death through interfering with microtubules leading to mitotic arrest, recent evidence has suggested that taxol-induced cell death also occurs through pathways independent of either microtubule or mitotic arrest. In this study, we report the identification of a novel role for TWIST, a basic helix-loop-helix protein, which plays a central role in cell type determination and differentiation, during generation of acquired resistance to taxol in a nasopharyngeal carcinoma cell line, HNE1-T3, using comparative genome hybridization (CGH) and subsequent RT-PCR and Western blotting. We found that upregulation of TWIST was associated with cellular resistance to taxol but not other drugs with different mechanisms of action. The fact that increased TWIST protein levels were also associated with another microtubule-targeting anticancer drug, vincristine, in four types of human cancer including nasopharyngeal, bladder, ovarian and prostate, indicates that it may play a central role in the resistance to microtubule-disrupting agents. In addition, ectopic expression of TWIST into human cancer cells also led to increased resistance to both taxol and vincristine. Our results indicate a novel mechanism that leads to resistance to microtubule-disrupting anticancer drugs through upregulation of TWIST. Our evidence provides a therapeutic strategy to overcome acquired resistance through inactivation of TWIST expression in human cancer.	Univ Hong Kong, Fac Med, Dept Anat, Canc Biol Grp, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Med, Dept Clin Oncol, Canc Biol Grp, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Wang, XH (corresponding author), Univ Hong Kong, Fac Med, Dept Anat, Canc Biol Grp, 1-F,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xhwang@hkucc.hku.hk	Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805				Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Dupont J, 2001, J BIOL CHEM, V276, P26699, DOI 10.1074/jbc.M102664200; ElGhouzzi V, 1997, NAT GENET, V15, P42; Funato N, 2001, MOL CELL BIOL, V21, P7416, DOI 10.1128/MCB.21.21.7416-7428.2001; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Gu SU, 1983, CHINESE J CANCER, V2, P70; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; Haldar S, 1996, CANCER RES, V56, P1253; Hjiantoniou E, 2003, BIOCHEM BIOPH RES CO, V300, P178, DOI 10.1016/S0006-291X(02)02804-8; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Huang Y, 2000, CANCER RES, V60, P4426; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; LIN CT, 1990, LAB INVEST, V62, P713; Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007; Ling MT, 2001, J ENDOCRINOL, V170, P287, DOI 10.1677/joe.0.1700287; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; McDaid HM, 2001, MOL PHARMACOL, V60, P290, DOI 10.1124/mol.60.2.290; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pajer P, 2003, ONCOGENE, V22, P665, DOI 10.1038/sj.onc.1206105; Ranganathan S, 1998, BRIT J CANCER, V77, P562, DOI 10.1038/bjc.1998.91; Rauh-Adelmann C, 2000, MOL CARCINOGEN, V28, P236, DOI 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; Urakami S, 2002, J UROLOGY, V168, P2444, DOI 10.1016/S0022-5347(05)64164-X; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2003, ONCOGENE, V22, P109, DOI 10.1038/sj.onc.1206069; Yousfi M, 2002, HUM MOL GENET, V11, P359, DOI 10.1093/hmg/11.4.359	36	189	206	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	2004	23	2					474	482		10.1038/sj.onc.1207128	http://dx.doi.org/10.1038/sj.onc.1207128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724576				2022-12-25	WOS:000188098300018
J	Bartholome, B; Spies, CM; Gaber, T; Schuchmann, S; Berki, T; Kunkel, D; Bienert, M; Radbruch, A; Burmester, GR; Lauster, R; Scheffold, A; Buttgereit, F				Bartholome, B; Spies, CM; Gaber, T; Schuchmann, S; Berki, T; Kunkel, D; Bienert, M; Radbruch, A; Burmester, GR; Lauster, R; Scheffold, A; Buttgereit, F			Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis	FASEB JOURNAL			English	Article						nongenomic glucocorticoid effects; high-sensitivity immunofluorescent staining; mGCR-positive monocytes; human glucocorticoid receptor alpha	NONGENOMIC ACTIONS; SURFACE; ACTIVATION; LYMPHOMA; CLASSIFICATION; TESTOSTERONE; ASSOCIATION; MECHANISM; NUCLEAR; ALPHA	Glucocorticoids mediate their therapeutic actions mostly by genomic effects via cytosolic receptors, but some effects are too rapid to be mediated by changes at the genomic level. The detailed mechanisms of these nongenomic actions are still unclear. Membrane-bound glucocorticoid receptors (mGCR) have been suggested to be involved, although their physiological existence in humans so far is hypothetical. For the first time we demonstrate the existence of mGCR on monocytes and B cells obtained from healthy blood donors using high-sensitivity immunofluorescent staining. Immunostimulation with lipopolysaccharide increases the percentage of mGCR-positive monocytes, which can be prevented by inhibiting the secretory pathway. Overexpression of the human glucocorticoid receptor alpha alone is not sufficient to enhance mGCR expression. These in vitro findings are consistent with our clinical observation that in patients with rheumatoid arthritis the frequency of mGCR positive monocytes is increased and positively correlated with disease activity. We conclude that mGCR are 1) indeed physiologically present in healthy blood donors, but remained unidentified by conventional techniques due to their small number per cell and 2) actively up-regulated and transported through the cell after immunostimulation. These receptors may reflect a feedback mechanism of the organism upon immunostimulation and/or play a role in pathogenesis.	Humboldt Univ, Dept Rheumatol & Clin Immunol, Charite Univ Hosp, D-10117 Berlin, Germany; Deutsch Rheuma Forschungszentrum Berlin, D-10117 Berlin, Germany; Univ Pecs, Fac Med, Dept Immunol & Biotechnol, H-7643 Pecs, Hungary	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Deutsches Rheuma-Forschungszentrum (DRFZ); University of Pecs	Buttgereit, F (corresponding author), Humboldt Univ, Dept Rheumatol & Clin Immunol, Charite Univ Hosp, Schumannstr 20-21, D-10117 Berlin, Germany.	frank.buttgereit@charite.de	Scheffold, Alexander/S-2090-2016; Burmester, Gerd R./AAY-7514-2020	Scheffold, Alexander/0000-0002-0626-343X; Buttgereit, Frank/0000-0003-2534-550X; Radbruch, Andreas/0000-0001-5753-0000; Berki, Timea/0000-0002-0134-8127				Almawi WY, 2002, J MOL ENDOCRINOL, V28, P69, DOI 10.1677/jme.0.0280069; Alzamora R, 2003, ENDOCRINOLOGY, V144, P1266, DOI 10.1210/en.2002-220950; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Benten WPM, 2002, STEROIDS, V67, P647, DOI 10.1016/S0039-128X(02)00013-2; Benten WPM, 2001, ENDOCRINOLOGY, V142, P1669, DOI 10.1210/en.142.4.1669; Berki T, 1998, J IMMUNOL METHODS, V214, P19, DOI 10.1016/S0022-1759(98)00037-4; Borski RJ, 2000, TRENDS ENDOCRIN MET, V11, P427, DOI 10.1016/S1043-2760(00)00325-8; Broutman G, 2001, J NEUROSCI, V21, P27, DOI 10.1523/JNEUROSCI.21-01-00027.2001; Bruno L, 1999, CURR BIOL, V9, P559, DOI 10.1016/S0960-9822(99)80259-0; Buttgereit F, 2000, IMMUNOL TODAY, V21, P192; Buttgereit F, 2002, STEROIDS, V67, P529, DOI 10.1016/S0039-128X(01)00171-4; Buttgereit F, 1998, ARTHRITIS RHEUM, V41, P761, DOI 10.1002/1529-0131(199805)41:5<761::AID-ART2>3.0.CO;2-M; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; Chen FH, 1999, J CELL BIOCHEM, V74, P430, DOI 10.1002/(SICI)1097-4644(19990901)74:3<430::AID-JCB11>3.0.CO;2-5; Chen HC, 1999, CURR BIOL, V9, pR478, DOI 10.1016/S0960-9822(99)80300-5; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Davis PJ, 2002, THYROID, V12, P459, DOI 10.1089/105072502760143827; Diba F, 2001, J CELL BIOCHEM, V81, P149, DOI 10.1002/1097-4644(20010401)81:1<149::AID-JCB1031>3.3.CO;2-N; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Falkenstein E, 2000, J CLIN ENDOCR METAB, V85, P2072, DOI 10.1210/jc.85.5.2072; Gametchu B, 1999, STEROIDS, V64, P107, DOI 10.1016/S0039-128X(98)00097-X; GAMETCHU B, 1993, FASEB J, V7, P1283, DOI 10.1096/fasebj.7.13.8405814; Guo ZY, 2002, J BIOL CHEM, V277, P29600, DOI 10.1074/jbc.M202997200; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Nadal A, 2001, TRENDS PHARMACOL SCI, V22, P597, DOI 10.1016/S0165-6147(00)01846-0; ORCHINIK M, 1991, SCIENCE, V252, P1848, DOI 10.1126/science.2063198; Powell CE, 1999, ENDOCRINE, V10, P271, DOI 10.1007/BF02738626; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Sackey FNA, 1997, AM J PHYSIOL-ENDOC M, V273, pE571, DOI 10.1152/ajpendo.1997.273.3.E571; SALKOWSKI CA, 1992, J IMMUNOL, V149, P4041; Scheffold A, 2000, NAT MED, V6, P107, DOI 10.1038/71441; Solito E, 2003, ENDOCRINOLOGY, V144, P1164, DOI 10.1210/en.2002-220592; Verheggen MM, 1996, EUR RESPIR J, V9, P2036, DOI 10.1183/09031936.96.09102036; Villaverde V, 2000, J RHEUMATOL, V27, P2576; Wang ZY, 2001, NATURE, V410, P380, DOI 10.1038/35066597; Zola H, 1994, IMMUNOLOGIST, V2, P47	44	157	165	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					70	80		10.1096/fj.03-0328com	http://dx.doi.org/10.1096/fj.03-0328com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718388				2022-12-25	WOS:000188829300041
J	DeLong, LJ; Bonamy, GMC; Fink, EN; Allison, LA				DeLong, LJ; Bonamy, GMC; Fink, EN; Allison, LA			Nuclear export of the oncoprotein v-ErbA is mediated by acquisition of a viral nuclear export sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; DOMINANT-NEGATIVE ACTIVITY; C-ERBA; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; ONCOGENE PROTEIN; XENOPUS OOCYTES; RETINOIC ACID; A PROTEIN; IN-VIVO	v-ErbA, an oncogenic derivative of the thyroid hormone receptor alpha(TRalpha) carried by the avian erythroblastosis virus, contains several alterations including fusion of a portion of avian erythroblastosis virus Gag to its N terminus, N- and C-terminal deletions, and 13 amino acid substitutions. Nuclear export of v-ErbA occurs through a CRM1-mediated pathway. In contrast, nuclear export of TRalpha and another isoform, TRbeta, is CRM1-independent. To determine which amino acid changes in v-ErbA confer CRM1-dependent nuclear export, we expressed a panel of green and yellow fluorescent protein-tagged mutant and chimeric proteins in mammalian cells. The sensitivity of subcellular trafficking of these mutants to leptomycin B (LMB), a specific inhibitor of CRM1, was assessed by fluorescence microscopy. Our data showed that a nuclear export sequence resides within a 70-amino acid domain in the C-terminal portion of the p10 region of Gag, and in vitro binding assays demonstrated that Gag interacts directly with CRM1. However, a panel of ligand-binding domain mutants of v-ErbA lacking the Gag sequence exhibited greater nuclear localization in the presence of LMB, suggesting that the various amino acid substitutions/deletions may cause a conformation shift, unmasking an additional CRM1-dependent nuclear export sequence. In contrast, the altered DNA-binding domain of the oncoprotein did not contribute to CRM1-dependent nuclear export. Heterokaryon experiments revealed that v-ErbA did not undergo nucleocytoplasmic shuttling when the CRM1 export pathway was blocked by LMB treatment, suggesting that the ability to follow the export pathway used by TRalpha has been lost by the oncoprotein during its evolution. Our findings thus point to the intriguing possibility that acquisition of altered nuclear export capabilities contributes to the oncogenic properties of v-ErbA.	Coll William & Mary, Dept Biol, Williamsburg, VA 23187 USA; Univ Paris 07, F-75251 Paris, France	William & Mary; UDICE-French Research Universities; Universite Paris Cite	Allison, LA (corresponding author), Coll William & Mary, Dept Biol, POB 8795,Millington Hall 116, Williamsburg, VA 23187 USA.	laalli@wm.edu		Bonamy, Ghislain/0000-0002-2826-5225	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R15DK058028] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK058028-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson ML, 2000, ONCOGENE, V19, P3563, DOI 10.1038/sj.onc.1203692; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; Black BE, 2001, CURR BIOL, V11, P1749, DOI 10.1016/S0960-9822(01)00537-1; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOUCHER P, 1990, ONCOGENE, V5, P1303; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; Braliou GG, 2001, ONCOGENE, V20, P775, DOI 10.1038/sj.onc.1204159; Bunn CF, 2001, MOL ENDOCRINOL, V15, P512, DOI 10.1210/mend.15.4.0619; Busch K, 1997, MOL ENDOCRINOL, V11, P379, DOI 10.1210/me.11.3.379; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Forgues M, 2001, J BIOL CHEM, V276, P22797, DOI 10.1074/jbc.M101259200; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FORREST D, 1990, ONCOGENE, V5, P309; Gama-Carvalho M, 2001, FEBS LETT, V498, P157, DOI 10.1016/S0014-5793(01)02487-5; GANDRILLON O, 1994, ONCOGENE, V9, P749; Harbers M, 2001, J BIOL CHEM, V276, P48596, DOI 10.1074/jbc.M108077200; HERMANN T, 1993, ONCOGENE, V8, P55; Holaska JM, 2002, MOL CELL BIOL, V22, P6286, DOI 10.1128/MCB.22.17.6286-6297.2002; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Li YZ, 1998, P NATL ACAD SCI USA, V95, P4864, DOI 10.1073/pnas.95.9.4864; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; Mey A, 2002, ONCOGENE, V21, P2864, DOI 10.1038/sj.onc.1205411; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NAGL SB, 1995, MOL ENDOCRINOL, V9, P1522, DOI 10.1210/me.9.11.1522; Nagl SB, 1997, J CELL BIOCHEM, V67, P184, DOI 10.1002/(SICI)1097-4644(19971101)67:2<184::AID-JCB4>3.3.CO;2-F; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Scheifele LZ, 2002, P NATL ACAD SCI USA, V99, P3944, DOI 10.1073/pnas.062652199; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARIF M, 1992, ONCOGENE, V7, P953; Shen Q, 2000, J BIOL CHEM, V275, P41018, DOI 10.1074/jbc.M006111200; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; STUNNENBERG HG, 1998, BIOCHIM BIOPHYS ACTA, V1423, pF15; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; Subauste JS, 1998, MOL ENDOCRINOL, V12, P1380, DOI 10.1210/me.12.9.1380; THORAVAL P, 1987, NUCLEIC ACIDS RES, V15, P9612, DOI 10.1093/nar/15.22.9612; Trapasso F, 1996, ONCOGENE, V12, P1879; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; WONG CW, 1995, MOL ENDOCRINOL, V9, P551, DOI 10.1210/me.9.5.551; YEN PM, 1994, MOL ENDOCRINOL, V8, P1450, DOI 10.1210/me.8.11.1450; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	59	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15356	15367		10.1074/jbc.M308214200	http://dx.doi.org/10.1074/jbc.M308214200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14729678	hybrid, Green Published			2022-12-25	WOS:000220594700105
J	Gao, ZQ; Joseph, E; Ruden, DM; Lu, XY				Gao, ZQ; Joseph, E; Ruden, DM; Lu, XY			Drosophila Pkd2 is haploid-insufficient for mediating optimal smooth muscle contractility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; RYANODINE-RECEPTOR; CATION CHANNEL; VASCULAR EXPRESSION; SKELETAL-MUSCLE; MALE-FERTILITY; 2-HIT MODEL; PKD2; CELLS; GENE	Humans heterozygous for PKD1 or PKD2 develop autosomal dominant polycystic kidney disease, a common genetic disorder characterized by renal cyst formation and extrarenal complications such as hypertension and vascular aneurysms. Cyst formation requires the somatic inactivation of the wild type allele. However, it is unknown whether this recessive mechanism applies to life-threatening vascular aneurysms, which could involve weakening of the endothelial lining or surrounding vascular smooth muscle cells (SMCs). Drosophila Pkd2 at 33E3 (Pkd2) encodes a PKD2 family of Ca2+-activated Ca2+-permeable cation channels. We show here that loss-of-function Pkd2 mutations severely reduced the contractility of the visceral SMCs, which was restored by expressing wild type Pkd2 cDNA via a muscle-specific Gal4 driver. The effect of Pkd2 mutations alone on the skeletal muscle was minimal but was exacerbated by ryanodine-induced perturbation of intracellular Ca2+ stores. Consistent with this, Pkd2 interacted strongly with a ryanodine receptor mutation, causing a synergistic reduction of larval body wall contraction rate that is normally regulated through Ca2+ oscillation during excitation-contraction coupling in the skeletal muscle. These results suggest that PKD2 cooperates with the ryanodine receptor to promote optimal muscle contractility through intracellular Ca2+ homeostasis. Further genetic analysis indicated that Pkd2 is strongly haploinsufficient for normal SMC contractility. Since Ca2+ homeostasis is a conserved mechanism for optimal muscle performance, our results raise the possibility that inactivation of just one PKD2 copy is sufficient to compromise vascular SMC contractility and function in PKD2 heterozygous patients, thus explaining their increased susceptibility to hypertension and vascular aneurysms.	Univ Alabama, Dept Environm Hlth Sci, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Lu, XY (corresponding author), Univ Alabama, Dept Environm Hlth Sci, RPHB 623A,1530 3rd Ave S, Birmingham, AL 35294 USA.	xlu@uab.edu	Ruden, Douglas/ABE-1418-2021; Ruden, Douglas/A-5008-2016	Ruden, Douglas/0000-0002-0070-437X	NCI NIH HHS [R01 CA105349] Funding Source: Medline; NIAAA NIH HHS [R01 AA012276] Funding Source: Medline; NIDDK NIH HHS [P50-DK57301, R21-DK60821] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK060821, P50DK057301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnaout MA, 2000, KIDNEY INT, V58, P2599, DOI 10.1046/j.1523-1755.2000.00446.x; BATE M, 1993, DEV DROSOPHILA METAN, V2, P1013; Boulter C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/pnas.211191098; BRAND AH, 1993, DEVELOPMENT, V118, P401; Calvet JP, 2001, SEMIN NEPHROL, V21, P107, DOI 10.1053/snep.2001.20929; Chen XZ, 2001, BIOCHEM BIOPH RES CO, V282, P1251, DOI 10.1006/bbrc.2001.4720; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gao ZQ, 2003, CURR BIOL, V13, P2175, DOI 10.1016/j.cub.2003.11.053; Gonzalez-Perrett S, 2002, J BIOL CHEM, V277, P24959, DOI 10.1074/jbc.M105084200; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Griffin MD, 1997, J AM SOC NEPHROL, V8, P616; Haycraft CJ, 2001, DEVELOPMENT, V128, P1493; Hoskins RA, 2001, GENOME RES, V11, P1100, DOI 10.1101/gr.GR-1780R; Kim K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/pnas.040550097; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Maryon EB, 1998, J CELL SCI, V111, P2885; McGrath J, 2003, CELL, V114, P61, DOI 10.1016/S0092-8674(03)00511-7; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Pei Y, 1999, J AM SOC NEPHROL, V10, P1524; Perrone RD, 1997, KIDNEY INT, V51, P2022, DOI 10.1038/ki.1997.276; Perrone RD, 2001, AM J KIDNEY DIS, V38, P777, DOI 10.1053/ajkd.2001.27720; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian Q, 2003, J AM SOC NEPHROL, V14, P2280, DOI 10.1097/01.ASN.0000080185.38113.A3; Qian Q, 2003, HUM MOL GENET, V12, P1875, DOI 10.1093/hmg/ddg190; Rong YKS, 2002, GENE DEV, V16, P1568, DOI 10.1101/gad.986602; Scheffers MS, 2002, HUM MOL GENET, V11, P59, DOI 10.1093/hmg/11.1.59; Sharma Y, 2002, GENESIS, V34, P115, DOI 10.1002/gene.10127; Sullivan KMC, 2000, P NATL ACAD SCI USA, V97, P5942, DOI 10.1073/pnas.110145997; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Torres VE, 2001, J AM SOC NEPHROL, V12, P1, DOI 10.1681/ASN.V1211; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Watnick TJ, 2003, CURR BIOL, V13, P2179, DOI 10.1016/S0960-9822(03)00913-8; Watnick TJ, 1998, MOL CELL, V2, P247, DOI 10.1016/S1097-2765(00)80135-5; Wernig F, 2002, PROG BIOPHYS MOL BIO, V78, P105, DOI 10.1016/S0079-6107(02)00008-1; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161	38	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14225	14231		10.1074/jbc.M312223200	http://dx.doi.org/10.1074/jbc.M312223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732716	hybrid			2022-12-25	WOS:000220478500115
J	Gazo, BM; Murphy, P; Gatchel, JR; Browning, KS				Gazo, BM; Murphy, P; Gatchel, JR; Browning, KS			A novel interaction of cap-binding protein complexes eukaryotic initiation factor (eIF) 4F and eIF(iso)4F with a region in the 3 '-untranslated region of satellite tobacco necrosis virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL ENHANCER DOMAIN; RIBOSOME ENTRY SITE; MESSENGER-RNA; WHEAT-GERM; ARABIDOPSIS-THALIANA; ISOZYME FORM; NUCLEOTIDE-SEQUENCE; INDEPENDENT TRANSLATION; STIMULATES TRANSLATION; UNTRANSLATED REGIONS	Satellite tobacco necrosis virus (STNV) RNA is naturally uncapped at its 5' end and lacks polyadenylation at its 3' end. Despite lacking these two hallmarks of eukaryotic mRNAs, STNV-1 RNA is translated very efficiently. A similar to 130-nucleotide translational enhancer (TED), located 3' to the termination codon, is necessary for efficient cap-independent translation of STNV-1 RNA. The STNV-1 TED RNA fragment binds to the eukaryotic cap-binding complexes, initiation factor (eIF) 4F and eIF(iso) 4F, as measured by nitrocellulose binding and fluorescence titration. STNV-1 TED is a potent inhibitor of in vitro translation when added in trans. This inhibition is reversed by the addition of eIF4F or eIF( iso) 4F, and the subunits of eIF4F and eIF( iso) 4F cross-link to STNV-1 TED, providing additional evidence that these factors interact directly with STNV-1 TED. Deletion mutagenesis of the STNV-1 TED indicates that a minimal region of similar to100 nucleotides is necessary to promote cap-independent translation primarily through interaction with the cap binding subunits (eIF4E or eIF(iso) 4E) of eIF4F or eIF(iso) 4F.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Browning, KS (corresponding author), Univ Texas, Dept Chem & Biochem, 1 Univ Stn A5300, Austin, TX 78712 USA.	kbrowning@mail.utexas.edu		Gatchel, Jennifer/0000-0002-3892-9742				ALLEN ML, 1992, J BIOL CHEM, V267, P23232; Bernstein DS, 2002, METHODS, V26, P123, DOI 10.1016/S1046-2023(02)00015-4; BOKROS CL, 1995, P NATL ACAD SCI USA, V92, P7120, DOI 10.1073/pnas.92.15.7120; Bringloe DH, 1998, J GEN VIROL, V79, P1539, DOI 10.1099/0022-1317-79-6-1539; BROWNING KS, 1980, BIOCHEMISTRY-US, V19, P2276, DOI 10.1021/bi00551a044; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1988, J BIOL CHEM, V263, P8380; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; Browning KS, 1996, PLANT MOL BIOL, V32, P107, DOI 10.1007/BF00039380; Bushell M, 2002, J CELL BIOL, V158, P395, DOI 10.1083/jcb.200205044; DANTHINNE X, 1991, VIROLOGY, V185, P605, DOI 10.1016/0042-6822(91)90531-F; DANTHINNE X, 1993, MOL CELL BIOL, V13, P3340, DOI 10.1128/MCB.13.6.3340; De Quinto SL, 2001, RNA, V7, P1213, DOI 10.1017/S1355838201010433; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; FLETCHER L, 1990, J BIOL CHEM, V265, P19582; Gale M, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239-280.2000; Gallie DR, 2002, PLANT MOL BIOL, V50, P949, DOI 10.1023/A:1021220910664; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Groft CM, 2002, MOL CELL, V9, P1273, DOI 10.1016/S1097-2765(02)00555-5; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; Guo L, 2001, MOL CELL, V7, P1103, DOI 10.1016/S1097-2765(01)00252-0; Guo L, 2000, RNA, V6, P1808, DOI 10.1017/S1355838200001539; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HORST J, 1971, BIOCHEMISTRY-US, V10, P4748, DOI 10.1021/bi00801a022; Jan E, 2002, J MOL BIOL, V324, P889, DOI 10.1016/S0022-2836(02)01099-9; KAEMPFER R, 1981, P NATL ACAD SCI-BIOL, V78, P1542, DOI 10.1073/pnas.78.3.1542; KASSANIS B, 1961, J GEN MICROBIOL, V25, P459, DOI 10.1099/00221287-25-3-459; KASSANIS B, 1970, J GEN VIROL, V9, P119, DOI 10.1099/0022-1317-9-2-119; KASSANIS B, 1962, J GEN MICROBIOL, V27, P477, DOI 10.1099/00221287-27-3-477; Kraemer B, 2000, METHOD ENZYMOL, V328, P297, DOI 10.1016/S0076-6879(00)28404-8; LAX SR, 1986, METHOD ENZYMOL, V118, P109; Lellis AD, 2002, CURR BIOL, V12, P1046, DOI 10.1016/S0960-9822(02)00898-9; Leonard S, 2000, J VIROL, V74, P7730, DOI 10.1128/JVI.74.17.7730-7737.2000; Leonard S, 2002, J GEN VIROL, V83, P2085, DOI 10.1099/0022-1317-83-8-2085; LEUNG DW, 1979, BIOCHEMISTRY-US, V18, P1361, DOI 10.1021/bi00574a036; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; Marcotrigiano J, 2003, ADV PROTEIN CHEM, V61, P269; Martinez-Salas E, 2001, J GEN VIROL, V82, P973, DOI 10.1099/0022-1317-82-5-973; Mathews MB, 2002, TRENDS BIOCHEM SCI, V27, P267, DOI 10.1016/S0968-0004(02)02087-X; Metz AM, 1996, J BIOL CHEM, V271, P31033, DOI 10.1074/jbc.271.49.31033; Metz AM, 1999, BIOCHEM BIOPH RES CO, V266, P314, DOI 10.1006/bbrc.1999.1814; METZ AM, 1992, NUCLEIC ACIDS RES, V20, P4096, DOI 10.1093/nar/20.15.4096; Meulewaeter F, 1998, RNA, V4, P1347, DOI 10.1017/S135583829898092X; Meulewaeter F, 1998, PLANT J, V14, P169, DOI 10.1046/j.1365-313X.1998.00104.x; Nicaise V, 2003, PLANT PHYSIOL, V132, P1272, DOI 10.1104/pp.102.017855; Pestova TV, 2002, GENE DEV, V16, P2906, DOI 10.1101/gad.1020902; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; Rodriguez CM, 1998, PLANT J, V13, P465, DOI 10.1046/j.1365-313X.1998.00047.x; Ruffel S, 2002, PLANT J, V32, P1067, DOI 10.1046/j.1365-313X.2002.01499.x; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; Sarnow P, 2003, J VIROL, V77, P2801, DOI 10.1128/JVI.77.5.2801-2806.2003; Schaad MC, 2000, VIROLOGY, V273, P300, DOI 10.1006/viro.2000.0416; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SMITH RE, 1979, BIOCHEMISTRY-US, V18, P1366, DOI 10.1021/bi00574a037; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; Urcuqui-Inchima S, 2001, VIRUS RES, V74, P157, DOI 10.1016/S0168-1702(01)00220-9; Van Lipzig R, 2002, RNA, V8, P229, DOI 10.1017/S1355838202018071; van Lipzig R, 2001, NUCLEIC ACIDS RES, V29, P1080, DOI 10.1093/nar/29.5.1080; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; Varani G, 2002, NAT STRUCT BIOL, V9, P158, DOI 10.1038/nsb0302-158; WANG SP, 1995, J BIOL CHEM, V270, P13446, DOI 10.1074/jbc.270.22.13446; Wang SP, 1999, RNA, V5, P728, DOI 10.1017/S1355838299981979; Wang SP, 1997, EMBO J, V16, P4107, DOI 10.1093/emboj/16.13.4107; Wittmann S, 1997, VIROLOGY, V234, P84, DOI 10.1006/viro.1997.8634; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; YSEBAERT M, 1980, J MOL BIOL, V143, P273, DOI 10.1016/0022-2836(80)90190-4	70	72	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13584	13592		10.1074/jbc.M311361200	http://dx.doi.org/10.1074/jbc.M311361200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729906	hybrid			2022-12-25	WOS:000220478500038
J	Eichler, R; Lenz, O; Strecker, T; Eickmann, M; Klenk, HD; Garten, W				Eichler, R; Lenz, O; Strecker, T; Eickmann, M; Klenk, HD; Garten, W			Lassa virus glycoprotein signal peptide displays a novel topology with an extended endoplasmic reticulum luminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; POSITIVELY CHARGED RESIDUES; SUBTILASE SKI-1/S1P; ANCHOR PROTEINS; ER MEMBRANE; GP-C; ORIENTATION; IDENTIFICATION; SEQUENCE; DOMAIN	Lassa virus glycoprotein C (GP-C) is translated as a precursor (preGP-C) into the lumen of the endoplasmic reticulum (ER) and cotranslationally cleaved into the signal peptide and immature GP-C before GP-C is proteolytically processed into its subunits, GP-1 and GP-2, which form the mature virion spikes. The signal peptide of preGP-C comprises 58 amino acids and contains two distinct hydrophobic domains. Here, we show that each hydrophobic domain alone can insert preGP-C into the ER membrane. Furthermore, we demonstrate that the native signal peptide only uses the N-terminal hydrophobic domain for membrane insertion, exhibiting a novel type of a topology for signal peptides with an extended ER luminal part, which is essential for proteolytic processing of GP-C into GP-1 and GP-2.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Philipps University Marburg	Garten, W (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.	garten@mailer.uni-marburg.de	Strecker, Thomas/AAR-8442-2020	Strecker, Thomas/0000-0002-7857-937X				ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; Beyer WR, 2003, J VIROL, V77, P2866, DOI 10.1128/JVI.77.5.2866-2872.2003; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079; Cocquerel L, 2002, EMBO J, V21, P2893, DOI 10.1093/emboj/cdf295; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; Eichler R, 2003, EMBO REP, V4, P1084, DOI 10.1038/sj.embor.7400002; Eichler R, 2003, FEBS LETT, V538, P203, DOI 10.1016/S0014-5793(03)00160-1; Froeschke M, 2003, J BIOL CHEM, V278, P41914, DOI 10.1074/jbc.M302343200; Goder V, 2003, EMBO J, V22, P3645, DOI 10.1093/emboj/cdg361; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Laemmli U. K., 1970, NATURE, V227, P860; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lenz O, 2001, P NATL ACAD SCI USA, V98, P12701, DOI 10.1073/pnas.221447598; Lenz O, 2000, J VIROL, V74, P11418, DOI 10.1128/JVI.74.23.11418-11421.2000; Lindemann D, 2001, J VIROL, V75, P5762, DOI 10.1128/JVI.75.13.5762-5771.2001; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; MCCORMICK JB, 1987, J INFECT DIS, V155, P445, DOI 10.1093/infdis/155.3.445; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Sanz MA, 2003, J BIOL CHEM, V278, P2051, DOI 10.1074/jbc.M206611200; Sato M, 1998, J BIOL CHEM, V273, P25203, DOI 10.1074/jbc.273.39.25203; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; von Heijne G, 1994, Subcell Biochem, V22, P1; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555	34	31	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12293	12299		10.1074/jbc.M312975200	http://dx.doi.org/10.1074/jbc.M312975200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709548	hybrid			2022-12-25	WOS:000220334900036
J	Yasui, Y; Urano, T; Kawajiri, A; Nagata, K; Tatsuka, M; Saya, H; Furukawa, K; Takahashi, T; Izawa, I; Inagaki, M				Yasui, Y; Urano, T; Kawajiri, A; Nagata, K; Tatsuka, M; Saya, H; Furukawa, K; Takahashi, T; Izawa, I; Inagaki, M			Autophosphorylation of a newly identified site of Aurora-B is indispensable for cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3 PHOSPHORYLATION; CHROMOSOME SEGREGATION; CLEAVAGE FURROW; CENTRAL SPINDLE; KINASE; FILAMENTS; INCENP; CONDENSATION; PHOSPHATASE; REGULATORS	Mitotic kinases regulate cell division and its checkpoints, errors of which can lead to aneuploidy or genetic instability. One of these is Aurora- B, a key kinase that is required for chromosome alignment at the metaphase plate and for cytokinesis in mammalian cells. We report here that human Aurora- B is phosphorylated at Thr- 232 through interaction with the inner centromere protein ( INCENP) in vivo. The phosphorylation of Thr- 232 occurs by means of an autophosphorylation mechanism, which is indispensable for the Aurora- B kinase activity. The activation of Aurora- B spatio- temporally correlated with the site- specific phosphorylation of its physiological substrates, histone H3 and vimentin. Overexpression of the TA mutant of Aurora- B, in which Thr- 232 was changed into alanine, frequently induced multinuclearity in cells. These results indicate that the phosphorylation of Thr- 232 is an essential regulatory mechanism for Aurora- B activation.	Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Immunol, Chikusa Ku, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, Hiroshima 7348553, Japan; Kumamoto Univ, Dept Tumor Genet & Biol, Sch Med, Kumamoto 8600811, Japan	Aichi Cancer Center; Aichi Cancer Center; Nagoya University; Hiroshima University; Kumamoto University	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Aichi 4648681, Japan.	minagaki@aichi-cc.jp	Saya, Hideyuki/J-4325-2013; Inagaki, Masaki/B-9920-2016	Urano, Takeshi/0000-0003-3383-3554				Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bishop JD, 2002, J BIOL CHEM, V277, P27577, DOI 10.1074/jbc.C200307200; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kang JS, 2001, J CELL BIOL, V155, P763, DOI 10.1083/jcb.200105029; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Morrison C, 2002, NUCLEIC ACIDS RES, V30, P5318, DOI 10.1093/nar/gkf665; Murata-Hori M, 2000, J BIOCHEM-TOKYO, V128, P903, DOI 10.1093/oxfordjournals.jbchem.a022840; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Tatsuka M, 1998, CANCER RES, V58, P4811; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; YASNI Y, 1998, J CELL BIOL, V143, P1249; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; Yasui Y, 2001, ONCOGENE, V20, P2868, DOI 10.1038/sj.onc.1204407; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125	26	182	186	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12997	13003		10.1074/jbc.M311128200	http://dx.doi.org/10.1074/jbc.M311128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722118	hybrid			2022-12-25	WOS:000220334900119
J	Condliffe, SB; Zhang, H; Frizzell, RA				Condliffe, SB; Zhang, H; Frizzell, RA			Syntaxin 1A regulates ENaC channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; CFTR CHLORIDE CHANNELS; NA+ CHANNEL; TRAFFICKING; SPECIFICITY; INSERTION; SNARES; KV2.1; CAMP	Na+ entry across the apical membranes of many absorptive epithelia is determined by the number (N) and open probability (P-o) of epithelial sodium channels (ENaC). Previous results showed that the H3 domain of syntaxin-1A (S1A) binds to ENaC to reduce N, supporting a role for S1A in the regulation of ENaC trafficking. The aim of this study was to determine whether S1A-induced reductions in ENaC current also result from interactions between cell surface ENaC and S1A that alter ENaC P-o. Injection of a glutathione S-transferase (GST)-H3 S1A fusion protein into ENaC-expressing Xenopus oocytes inhibited whole cell Na+ current (I-Na) by 33% within 5 min. This effect was dose-dependent, with a K-i of 7 ng/mul (similar to200 nM). In contrast, injection of GST alone or a H3 domain-deleted GST-S1A fusion protein had no effect on I-Na. In cell-attached patch clamp experiments, GST-H3 acutely decreased ENaC P-o by 30%, whereas GST-S1ADeltaH3 was without effect. Further analysis revealed that ENaC mean closed time was significantly prolonged by S1A. Interestingly, GST-H3 had no effect on channel activity of an ENaC pore mutant that constitutively gates open (P-o congruent to 1.0), supporting the idea that S1A alters the closed state of ENaC and indicating that the actions of S1A on ENaC trafficking and gating can be separated experimentally. This study indicates that, in addition to a primary effect on ENaC trafficking, S1A interacts with cell surface ENaC to rapidly decrease channel gating. This rapid effect of S1A may modulate Na+ entry rate during rapid increases in ENaC N.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S362 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.	frizzell@pitt.edu			NIDDK NIH HHS [DK54814] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054814] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Bezprozvanny I, 2000, P NATL ACAD SCI USA, V97, P13943, DOI 10.1073/pnas.220389697; Butterworth MB, 2003, FASEB J, V17, pA914; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Condliffe SB, 2003, J BIOL CHEM, V278, P12796, DOI 10.1074/jbc.M210772200; Cormet-Boyaka E, 2002, P NATL ACAD SCI USA, V99, P12477, DOI 10.1073/pnas.192203899; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Ganeshan R, 2003, J BIOL CHEM, V278, P2876, DOI 10.1074/jbc.M211790200; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Gouraud S, 2002, J CELL SCI, V115, P3667, DOI 10.1242/jcs.00053; Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; Li GM, 2003, J BIOL CHEM, V278, P19791, DOI 10.1074/jbc.M212250200; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; Michaelevski I, 2003, J BIOL CHEM, V278, P34320, DOI 10.1074/jbc.M304943200; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Sterling H, 2003, AM J PHYSIOL-RENAL, V284, pF510, DOI 10.1152/ajprenal.00309.2002; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659	31	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10085	10092		10.1074/jbc.M313592200	http://dx.doi.org/10.1074/jbc.M313592200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14703519	hybrid			2022-12-25	WOS:000220050400053
J	Richardson, C; Stark, JM; Ommundsen, M; Jasin, M				Richardson, C; Stark, JM; Ommundsen, M; Jasin, M			Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability	ONCOGENE			English	Article						translocation; DNA double-strand break; homologous recombination; crossover; genome instability; aneuploidy; Rad51	INDUCED DNA-REPLICATION; ACUTE MYELOID-LEUKEMIA; MAMMALIAN-CELLS; HOMOLOGOUS RECOMBINATION; GENE CONVERSION; CHROMOSOMAL TRANSLOCATIONS; ATP HYDROLYSIS; ES CELLS; C-MYC; PROTEIN	Genomic instability is characteristic of tumor cells, and a strong correlation exists between abnormal karyotype and tumorigenicity. Increased expression of the homologous recombination and DNA repair protein Rad51 has been reported in immortalized and tumor cells, which could alter recombination pathways to contribute to the chromosomal rearrangements found in these cells. We used a genetic system to examine the potential for multiple double-strand breaks to lead to genome rearrangements in the presence of increased Rad51 expression. Analysis of repair revealed a novel class of products consistent with crossing over, involving gene conversion associated with an exchange of flanking markers leading to chromosomal translocations. Increased Rad51 also promoted aneuploidy and multiple chromosomal rearrangements. These data provide a link between elevated Rad51 protein levels, genome instability, and tumor progression.	Columbia Univ Coll Phys & Surg, Inst Canc Genet, Dept Pathol, New York, NY 10032 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Columbia University; Cornell University; Memorial Sloan Kettering Cancer Center	Richardson, C (corresponding author), Columbia Univ Coll Phys & Surg, Inst Canc Genet, Dept Pathol, 1150 St Nicholas Ave, New York, NY 10032 USA.	car10@columbia.edu			NCI NIH HHS [P30 CA13696] Funding Source: Medline; NCRR NIH HHS [S10 RR10506, S10 RR13701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013701, S10RR010506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGUILERA A, 1989, GENETICS, V123, P683; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; ANTONARAKIS SE, 2002, GENETIC BASIS HUMAN, P7; Arnaudeau C, 1999, J MOL BIOL, V289, P1231, DOI 10.1006/jmbi.1999.2856; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bosco G, 1998, GENETICS, V150, P1037; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Cory S, 1999, CANCER RES, V59, p1685S; Flygare J, 2001, EXP CELL RES, V268, P61, DOI 10.1006/excr.2001.5265; Gibson L, 1996, ONCOGENE, V13, P665; Gloor GB, 1998, TRENDS GENET, V14, P43, DOI 10.1016/S0168-9525(97)01365-6; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; JASIN M, 1988, GENE DEV, V2, P1353, DOI 10.1101/gad.2.11.1353; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Karlsson A, 2003, BLOOD, V101, P2797, DOI 10.1182/blood-2002-10-3091; Kim PM, 2001, NUCLEIC ACIDS RES, V29, P4352, DOI 10.1093/nar/29.21.4352; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Morrison C, 1999, MOL CELL BIOL, V19, P6891; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PEDERSENBJERGAARD J, 1994, BLOOD, V83, P2780, DOI 10.1182/blood.V83.10.2780.2780; Raderschall E, 2002, J CELL SCI, V115, P153; Raderschall E, 2002, CANCER RES, V62, P219; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Stark JM, 2003, MOL CELL BIOL, V23, P733, DOI 10.1128/MCB.23.2.733-743.2003; Stark JM, 2002, J BIOL CHEM, V277, P20185, DOI 10.1074/jbc.M112132200; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUPER HJG, 1993, BLOOD, V82, P3705; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tremblay A, 2000, MOL CELL BIOL, V20, P54, DOI 10.1128/MCB.20.1.54-60.2000; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Yanez RJ, 1999, GENE THER, V6, P1282, DOI 10.1038/sj.gt.3300945	63	184	193	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					546	553		10.1038/sj.onc.1207098	http://dx.doi.org/10.1038/sj.onc.1207098			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724582				2022-12-25	WOS:000188098300025
J	Al-Mohanna, MA; Manogaran, PS; Al-Mukhalafi, Z; Al-Hussein, KA; Aboussekhra, A				Al-Mohanna, MA; Manogaran, PS; Al-Mukhalafi, Z; Al-Hussein, KA; Aboussekhra, A			The tumor suppressor p16(INK4a) gene is a regulator of apoptosis induced by ultraviolet light and cisplatin	ONCOGENE			English	Article						apoptosis; Bax; cisplatin; p16(INK4a); UV damage	CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; BAX EXPRESSION; RNA-POLYMERASE; GROWTH ARREST; DNA-REPAIR; P53; BCL-2; SKIN; P16(CDKN2A)	p16(INK4a) (hereafter referred to as p16), a major cyclin-dependent kinase (CDK) inhibitor, is the product of a tumor-suppressor gene that has been found inactivated in different cancer types. In the present study, we sought to investigate the role of p16 in apoptosis induced by ultraviolet light (the most important etiological cause of skin cancer) and cisplatin (an anticancer DNA damaging agent). It is clearly shown that p16-compromised osteosarcoma U2OS cell line and p16-/- mouse embryo fibroblasts are sensitive to UV-induced apoptosis, as compared to their respective isogenic p16-expressing cells (EH1, EH2) and p16 +/+, indicating that p16 protects cells from undergoing apoptosis in response to UV light. Importantly, this reduction in UV-mediated apoptosis was associated with downregulation of the proapoptotic Bax protein, with no effect on Bcl-2 expression, suggesting that this antiapoptotic role of p16 is mediated via the intrinsic-mitochondrial pathway. On the other hand, p16 sensitized cells to cisplatin-mediated apoptosis through Bcl-2 decline. Interestingly, only proliferating but not G1-arrested EH1 cells underwent apoptosis in response to the anticancer drug. These novel findings provide further insight into the role of p16 in carcinogenesis, and has potential implications for future therapy strategies.	King Faisal Specialist Hosp & Res Ctr, BMR, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center	Aboussekhra, A (corresponding author), King Faisal Specialist Hosp & Res Ctr, BMR, MBC 03,POB 3354, Riyadh 11211, Saudi Arabia.	aboussekhra@kfshrc.edu.sa						Abrahams PJ, 1998, MUTAT RES-DNA REPAIR, V407, P189, DOI 10.1016/S0921-8777(98)00009-3; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Al-Mohanna MA, 2001, CARCINOGENESIS, V22, P573, DOI 10.1093/carcin/22.4.573; Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Amundson SA, 2000, CANCER RES, V60, P6101; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; Canman CE, 1998, ONCOGENE, V16, P957, DOI 10.1038/sj.onc.1201612; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; EVANS DL, 1994, CANCER RES, V54, P1596; Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Grim J, 1997, CLIN CANCER RES, V3, P2415; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Ljungman M, 1996, ONCOGENE, V13, P823; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Moriwaki SI, 1997, CANCER RES, V57, P4637; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Pavey S, 1999, CANCER RES, V59, P4185; Pavey S, 2002, CANCER RES, V62, P875; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SORENSON CM, 1988, CANCER RES, V48, P4484; SORENSON CM, 1988, CANCER RES, V48, P6703; Stone S, 1996, CANCER RES, V56, P3199; Tamm I, 2002, CANCER GENE THER, V9, P641, DOI 10.1038/sj.cgt.7700480; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zornig M., 2001, BIOCHIM BIOPHYS ACTA, V1551, P1	49	49	54	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					201	212		10.1038/sj.onc.1206927	http://dx.doi.org/10.1038/sj.onc.1206927			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712225				2022-12-25	WOS:000187895300021
J	Peterson, S; Bogenmann, E				Peterson, S; Bogenmann, E			The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation	ONCOGENE			English	Article						neuroblastoma; neurotrophic factors; differentiation; TRKA; RET	NERVE GROWTH-FACTOR; NEUROTROPHIN RECEPTOR P75(NTR); MICE LACKING GDNF; SYMPATHETIC NEURONS; PROTEIN-SYNTHESIS; RETINOIC ACID; NEURAL CREST; C-RET; EXPRESSION; CELLS	Neuroblastoma (NB) is a childhood cancer that arises in the adrenal gland and often shows differentiated neuronal and glial elements. The RET receptor signal pathway is functional in most NB, while loss of nerve growth factor (NGF) receptor (trkA) gene expression correlates with an aggressive phenotype. Thus, we hypothesized that the RET and TRKA signal pathways collaborate to instruct NB differentiation, reminiscent of normal neuronal maturation. Here, we demonstrate that activation of the RET receptor by glial cell line-derived neurotrophic factor (GDNF) increases expression of the RET receptor complex in a panel of malignant human NB cell lines, indicative of a positive feedback mechanism. GDNF also induces growth cessation concomitant with an arrest of cells in the G(0)/G(1) phase of the cell cycle. Furthermore, GDNF synergizes with ciliary neurotrophic factor (CNTF) to enhance TRKA receptor expression, thereby strengthening the NGF-mediated differentiation signal. Differentiated NB cells downregulate expression of the amplified N-myc gene, concurrent with the arrest of cell proliferation, while expressing neuron-specific markers (i.e., SCG10). Interestingly, maintenance of differentiated NB cells in culture is independent of the trophic activity of GDNF, but depends on TRKA signaling, thereby re-enacting the differentiation of normal sympathoadrenal (SA) progenitor cells.	Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles	Bogenmann, E (corresponding author), Childrens Hosp Los Angeles, Div Hematol Oncol, Smith Res Tower,Mail Stop 57,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	ebogenmann@chla.usc.edu			NINDS NIH HHS [R01 NS36978] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036978] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Anderson DJ, 1997, COLD SPRING HARB SYM, V62, P493; Baldassarre G, 2002, ONCOGENE, V21, P1739, DOI 10.1038/sj.onc.1205226; Barnett MW, 2002, J CELL SCI, V115, P4495, DOI 10.1242/jcs.00114; Barone MV, 2001, ONCOGENE, V20, P6973, DOI 10.1038/sj.onc.1204886; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; BIEDLER JL, 1976, SCIENCE, V191, P185, DOI 10.1126/science.942798; Bogenmann E, 1998, ONCOGENE, V17, P2367, DOI 10.1038/sj.onc.1202160; Bogenmann E, 1996, INT J CANCER, V67, P379, DOI 10.1002/(SICI)1097-0215(19960729)67:3<379::AID-IJC12>3.0.CO;2-3; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Hishiki T, 1998, CANCER RES, V58, P2158; Hofstra RMW, 1996, HUM GENET, V97, P362, DOI 10.1007/BF02185773; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; Krieglstein K, 1998, J NEUROSCI, V18, P9822; KUMAR S, 1970, J PEDIATR SURG, V5, P18, DOI 10.1016/0022-3468(70)90515-4; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; MATSUSHIMA H, 1992, INT J CANCER, V51, P250, DOI 10.1002/ijc.2910510214; MATSUSHIMA H, 1992, INT J CANCER, V51, P727, DOI 10.1002/ijc.2910510511; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATSUSHIMA H, 1993, ADV NEUROBLASTOMA RE, V4; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Miyake M, 1994, Prog Clin Biol Res, V385, P163; Molliver DC, 1997, J COMP NEUROL, V381, P428, DOI 10.1002/(SICI)1096-9861(19970519)381:4<428::AID-CNE3>3.0.CO;2-4; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; Natarajan D, 2002, DEVELOPMENT, V129, P5151; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; SANTORO M, 1990, ONCOGENE, V5, P1595; Seeger Robert C., 1993, P2172; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; Sleeman M W, 2000, Pharm Acta Helv, V74, P265, DOI 10.1016/S0031-6865(99)00050-3; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Torres M, 1996, ONCOGENE, V12, P77; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Tsui-Pierchala B, 2002, NEURON, V33, P261, DOI 10.1016/S0896-6273(01)00585-2; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4	56	42	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					213	225		10.1038/sj.onc.1206980	http://dx.doi.org/10.1038/sj.onc.1206980			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712226				2022-12-25	WOS:000187895300022
J	Wagner, CT; Lu, IY; Hoffman, MH; Sun, WQ; Trent, JD; Connor, J				Wagner, CT; Lu, IY; Hoffman, MH; Sun, WQ; Trent, JD; Connor, J			T-complex polypeptide-1 interacts with the erythrocyte cytoskeleton in response to elevated temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; GROUP-II CHAPERONIN; EUKARYOTIC CHAPERONIN; MOLECULAR CHAPERONE; MEMBRANE SKELETON; YEAST TCP1; IN-VIVO; THERMOTOLERANCE; CELL; LOCALIZATION	Chaperonins are double ring complexes composed of highly conserved 60-kDa protein subunits that are divided into two subgroups. Group II chaperonins are found in archaea and the cytoplasm of eukarya and are believed to function like other chaperonins as part of a protein folding system. We report here that human erythrocytes contain the group II chaperonin T-complex polypeptide 1 (TCP-1) and that this complex translocates from the cytoplasm to the cytoskeleton in response to heat treatment in the absence of overt cell damage. Identification as TCP-1 was determined by immunodetection for TCP-1alpha and corroborated by mass spectroscopy peptide sequencing. Direct visualization by immunofluorescence confirmed peripherally localized TCP-1 in response to heat treatment. Temperatures ranging from 37-50degreesC were demonstrated to have distinct kinetic profiles of induced translocation. Heat-induced binding was shown by Triton shell analysis to be specifically associated with the cytoskeletal proteins. Furthermore, the binding was reversible following removal of the stimulatory condition. A stabilizing process is hypothesized based on the known interactions of chaperonins.	LifeCell Corp, Branchburg, NJ 08876 USA; NASA, Astrobiol & Technol Branch, Ames Res Ctr, Moffett Field, CA 94035 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Wagner, CT (corresponding author), LifeCell Corp, 1 Millennium Way, Branchburg, NJ 08876 USA.	cwagner@lifecell.com						BRECHER ME, 2002, TECHNICAL MANUAL, P733; Chow KC, 1998, BIOCHEM BIOPH RES CO, V253, P502, DOI 10.1006/bbrc.1998.9766; CREUTZ CE, 1983, J BIOL CHEM, V258, P4664; Ellis RJ, 1999, CURR BIOL, V9, pR137; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; FISHER B, 1992, CANCER RES, V52, P2854; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Garduno RA, 1998, J BACTERIOL, V180, P505; GERSHFELD NL, 1988, J MEMBRANE BIOL, V101, P67, DOI 10.1007/BF01872821; Greenwalt TJ, 1997, TRANSFUSION, V37, P269, DOI 10.1046/j.1537-2995.1997.37397240208.x; GROMOV PS, 1991, EXP CELL RES, V195, P556, DOI 10.1016/0014-4827(91)90412-N; Gross C, 1996, BIOCHEM BIOPH RES CO, V220, P766, DOI 10.1006/bbrc.1996.0478; GUDI SRP, 1990, BIOCHIM BIOPHYS ACTA, V1023, P63, DOI 10.1016/0005-2736(90)90010-L; GUDI T, 1993, J BIOL CHEM, V268, P21344; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HO KC, 1991, RADIAT RES, V125, P20, DOI 10.2307/3577977; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; JOHNSTON RN, 1988, SCIENCE, V242, P1551, DOI 10.1126/science.3201244; Kagawa HK, 2003, MOL MICROBIOL, V48, P143, DOI 10.1046/j.1365-2958.2003.03418.x; KIFOR G, 1993, J MEMBRANE BIOL, V134, P169; KOTER M, 1989, INT J RADIAT BIOL, V56, P59, DOI 10.1080/09553008914551181; KOTER M, 1993, CELL BIOL INT, V17, P665, DOI 10.1006/cbir.1993.1116; KOZWIAK Z, 1991, INT J RADIAT BIOL, V59, P479; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; KUBOTA H, 1997, GUIDEBOOK MOL CHAPER, P207; KUMAR A, 1990, BIOCHIM BIOPHYS ACTA, V1030, P269, DOI 10.1016/0005-2736(90)90303-6; LASZLO A, 1988, EXP CELL RES, V178, P401, DOI 10.1016/0014-4827(88)90409-0; LEE YJ, 1987, J CELL PHYSIOL, V132, P41, DOI 10.1002/jcp.1041320106; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Mohandas N., 1978, RED CELL, P453; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Norcum MT, 1996, PROTEIN SCI, V5, P1366, DOI 10.1002/pro.5560050715; PARKES JL, 1989, ARCH BIOCHEM BIOPHYS, V275, P459, DOI 10.1016/0003-9861(89)90392-5; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; Ruggero D, 1998, EMBO J, V17, P3471, DOI 10.1093/emboj/17.12.3471; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANDERS BM, 1993, CRIT REV TOXICOL, V23, P49, DOI 10.3109/10408449309104074; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schluter A, 2000, BBA-GENE STRUCT EXPR, V1491, P65, DOI 10.1016/S0167-4781(00)00028-2; Schoehn G, 2000, J MOL BIOL, V301, P323, DOI 10.1006/jmbi.2000.3952; Soltys BJ, 1996, EXP CELL RES, V222, P16, DOI 10.1006/excr.1996.0003; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; Stoldt V, 1996, YEAST, V12, P523, DOI 10.1002/(SICI)1097-0061(199605)12:6<523::AID-YEA962>3.3.CO;2-3; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; Torok Z, 1997, P NATL ACAD SCI USA, V94, P2192, DOI 10.1073/pnas.94.6.2192; Trent JD, 1997, P NATL ACAD SCI USA, V94, P5383, DOI 10.1073/pnas.94.10.5383; Trent JD, 2003, P NATL ACAD SCI USA, V100, P15589, DOI 10.1073/pnas.2136795100; Trent JD, 1998, ANN NY ACAD SCI, V851, P36, DOI 10.1111/j.1749-6632.1998.tb08974.x; URSIC D, 1994, MOL BIOL CELL, V5, P1065, DOI 10.1091/mbc.5.10.1065; URSIC D, 1992, NATURE, V356, P392; VANBOGELEN RA, 1987, GENE DEV, V1, P525, DOI 10.1101/gad.1.6.525; VANDERWALT JH, 1978, BRIT J ANAESTH, V50, P815, DOI 10.1093/bja/50.8.815; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; Wagner CT, 2003, TRANSFUSION, V43, p66A; Wagner CT, 2002, CRYOBIOLOGY, V45, P153, DOI 10.1016/S0011-2240(02)00124-4; Wagner CT, 2000, CRYOBIOLOGY, V41, P178, DOI 10.1006/cryo.2000.2279; WATSON K, 1990, ADV MICROB PHYSIOL, V31, P183; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; Zaric J, 1998, MOL CELL BIOCHEM, V178, P119, DOI 10.1023/A:1006877026611	62	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16223	16228		10.1074/jbc.M310730200	http://dx.doi.org/10.1074/jbc.M310730200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14729905	hybrid			2022-12-25	WOS:000220747900065
J	Li, L; Wang, CC				Li, L; Wang, CC			Capped mRNA with a single nucleotide leader is optimally translated in a primitive eukaryote, Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA; SECONDARY STRUCTURE; FIREFLY LUCIFERASE; INITIATOR CODONS; SEQUENCE; GENE; IDENTIFICATION; RECOGNITION; TRANSCRIPT; ELEMENTS	The 5'-untranslated region (5'-UTR) of an mRNA plays an important role in translation initiation in eukaryotes. A minimal length of about 20 nucleotides is required to prevent leaky ribosome scanning. In one of the most primitive eukaryotes, Giardia lamblia, however, the mRNAs have 5'-UTRs mostly in the range of 0 to 14 nucleotides without a conserved sequence, which raises the question on how the ribosome could effectively scan such short 5'-UTRs for an accurate initiation of translation. In the present study, we expressed capped transcripts of luciferase gene in Giardia trophozoites via transfection and observed that when the 5'-UTR of the transcript was lengthened from 9 to 21 nucleotides, there was a corresponding decrease of translation efficiency. Conversely, shortening of the 5'-UTR from nine nucleotides down to a single nucleotide did not result in any reduced translation or leaky scanning. Translation appeared to initiate exclusively from the first initiation codon located downstream from the cap. Experimental evidence indicated also that a stem-loop structure immediately downstream from the initiation codon exerted significant inhibition on translation initiation when the 5'-UTR consisted of less than seven nucleotides. This inhibitory effect was abolished by increasing the distance between the stem-loop and the cap-G structure either upstream or downstream from the start codon, thus suggesting a spatial requirement for effective ribosome recruitment. Overall, our results suggest an absence of ribosome scanning for AUG in initiating translation in Giardia. A capped mRNA with a single nucleotide leader is apparently sufficient for recruiting ribosome and initiating translation.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu			NIAID NIH HHS [AI-30475] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030475] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adam RD, 2000, INT J PARASITOL, V30, P475, DOI 10.1016/S0020-7519(99)00191-5; Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; BRUCHHAUS I, 1993, DNA CELL BIOL, V12, P925, DOI 10.1089/dna.1993.12.925; CIGAN AM, 1987, GENE, V59, P1; Davis-Hayman SR, 2000, PARASITOL RES, V86, P608, DOI 10.1007/PL00008538; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Elmendorf HG, 2001, MOL BIOCHEM PARASIT, V113, P157, DOI 10.1016/S0166-6851(01)00211-0; Elmendorf HG, 2001, NUCLEIC ACIDS RES, V29, P4674, DOI 10.1093/nar/29.22.4674; Garlapati S, 2002, RNA, V8, P601, DOI 10.1017/S135583820202071X; Garlapati S, 2001, J MOL BIOL, V308, P623, DOI 10.1006/jmbi.2001.4568; Inagaki Y, 2000, MOL BIOL EVOL, V17, P882, DOI 10.1093/oxfordjournals.molbev.a026368; Keeling PJ, 1998, J MOL EVOL, V47, P649, DOI 10.1007/PL00006422; KIRKMASON KE, 1989, MOL BIOCHEM PARASIT, V36, P87, DOI 10.1016/0166-6851(89)90204-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Kozak M, 2002, MAMM GENOME, V13, P401, DOI 10.1007/s00335-002-4002-5; KOZAK M, 1991, GENE EXPRESSION, V1, P117; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1991, GENE EXPRESSION, V1, P111; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Li L, 2001, J VIROL, V75, P10612, DOI 10.1128/JVI.75.22.10612-10622.2001; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Moll I, 2002, MOL MICROBIOL, V43, P239, DOI 10.1046/j.1365-2958.2002.02739.x; Nixon JEJ, 2002, P NATL ACAD SCI USA, V99, P3701, DOI 10.1073/pnas.042700299; NOHRIA A, 1992, MOL BIOCHEM PARASIT, V56, P27, DOI 10.1016/0166-6851(92)90151-9; Pestova TV, 2002, GENE DEV, V16, P2906, DOI 10.1101/gad.1020902; Prevot D, 2003, EMBO J, V22, P1909, DOI 10.1093/emboj/cdg175; Roger AJ, 1998, P NATL ACAD SCI USA, V95, P229, DOI 10.1073/pnas.95.1.229; Sachs MS, 2002, METHODS, V26, P105, DOI 10.1016/S1046-2023(02)00013-0; SHINE J, 1975, EUR J BIOCHEM, V57, P221, DOI 10.1111/j.1432-1033.1975.tb02294.x; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; WANG AL, 1986, MOL BIOCHEM PARASIT, V21, P269, DOI 10.1016/0166-6851(86)90132-5; Wang XC, 2002, INT J BIOCHEM CELL B, V34, P983, DOI 10.1016/S1357-2725(02)00019-5; Yu DC, 1998, MOL BIOCHEM PARASIT, V96, P151, DOI 10.1016/S0166-6851(98)00126-1; YU DC, 1995, MOL CELL BIOL, V15, P4867	39	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14656	14664		10.1074/jbc.M309879200	http://dx.doi.org/10.1074/jbc.M309879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722094	hybrid			2022-12-25	WOS:000220594700024
J	Papadakis, M; Hawkins, LM; Stephenson, FA				Papadakis, M; Hawkins, LM; Stephenson, FA			Appropriate NR1-NR1 disulfide-linked homodimer formation is requisite for efficient expression of functional, cell surface N-methyl-D-aspartate NR1/NR2 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-BINDING-SITE; NMDA-RECEPTOR; GLUTAMATE-RECEPTOR; CYSTEINE RESIDUES; MOLECULAR DETERMINANTS; BIOCHEMICAL-EVIDENCE; CRYSTAL-STRUCTURES; SUBUNITS; PROTEIN; NR1	A c-Myc epitope-tagged N-methyl-D-aspartate receptor NR1-2a subunit was generated, NR1-2a(c-Myc), where the tag was inserted after amino acid 81. NR1-2a(c-Myc)/NR2A receptors when expressed in mammalian cells are not trafficked to the cell surface nor do they yield cell cytotoxicity post-transfection. NR1-2a(c-Myc) was, however, shown to assemble with NR2A subunits by immunoprecipitation and [H-3] MK801 radioligand binding assays. Immunoblots of cells co-transfected with wild-type NR1-2a/ NR2A subunits yielded two NR1-2a immunoreactive species with molecular masses of 115 and 226 kDa. Two-dimensional electrophoresis under non-reducing and reducing conditions revealed that the 226-kDa band contained disulfide-linked NR1-2a subunits. Only the 115-kDa NR1-2a species was detected for NR1-2a(c-Myc)/NR2A. The c-Myc epitope is inserted adjacent to cysteine 79 of the NR1-2a subunit; therefore, it is possible that the tag may prevent the formation of NR1 disulfide bridges. A series of cysteine --> alanine NR1-2a mutants was generated, and the NR1-2a mutants were co-expressed with NR2A or NR2B subunits in mammalian cells and characterized with respect to cell surface expression, cell cytotoxicity post-transfection, co-association by immunoprecipitation, and immunoblotting following SDS-PAGE under both reducing and non-reducing conditions. When co-expressed with NR2A in mammalian cells, NR1-2a(C79A)/NR2A displayed similar properties to NR1-2a(c-Myc)/NR2A in that the 226-kDa NR1 immunoreactive species was not detectable, and trafficking to the cell surface was impaired compared with wild-type NR1/NR2 receptors. These results provide the first biochemical evidence for the formation of NR1-NR1 intersubunit disulfide-linked homodimers involving cysteine 79. They suggest that disulfide bridging and structural integrity within the NR1 N-terminal domain is requisite for cell surface N-methyl-D-aspartate receptor expression.	Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England	University of London; University College London; University of London School of Pharmacy	Stephenson, FA (corresponding author), Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, 29-39 Brunswick Sq, London WC1N 1AX, England.	anne.stephenson@ulsop.ac.uk						Anson LC, 1998, J NEUROSCI, V18, P581; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; Chatterton JE, 2002, NATURE, V415, P793, DOI 10.1038/nature715; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; Chazot PL, 1997, J NEUROCHEM, V68, P507; Chazot PL, 1995, MOL MEMBR BIOL, V12, P331, DOI 10.3109/09687689509072435; Cho HC, 2000, BIOCHEMISTRY-US, V39, P4649, DOI 10.1021/bi992469g; Choi YB, 2001, J NEUROSCI, V21, P392, DOI 10.1523/JNEUROSCI.21-02-00392.2001; CHOPRA B, 2000, BRIT J PHARMACOL, V30, P65; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; Dingledine R, 1999, PHARMACOL REV, V51, P7; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; Hughes PD, 2001, DEV BRAIN RES, V129, P135, DOI 10.1016/S0165-3806(01)00192-4; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; Lipton SA, 2002, TRENDS NEUROSCI, V25, P474, DOI 10.1016/S0166-2236(02)02245-2; LYNCH DR, 1994, MOL PHARMACOL, V45, P540; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Prybylowski K, 2002, J NEUROSCI, V22, P8902; Rutter AR, 2000, J NEUROCHEM, V75, P2501, DOI 10.1046/j.1471-4159.2000.0752501.x; Rutter AR, 2002, J NEUROCHEM, V81, P1298, DOI 10.1046/j.1471-4159.2002.00923.x; Sandhu S, 1999, J NEUROCHEM, V72, P1694, DOI 10.1046/j.1471-4159.1999.721694.x; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; SHENG M, 1996, NEURON, V17, P576; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Wu TY, 1996, BIOCHEM J, V319, P731, DOI 10.1042/bj3190731	39	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14703	14712		10.1074/jbc.M313446200	http://dx.doi.org/10.1074/jbc.M313446200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14732708	hybrid			2022-12-25	WOS:000220594700030
J	Wilson, HL; Rajagopalan, KV				Wilson, HL; Rajagopalan, KV			The role of tyrosine 343 in substrate binding and catalysis by human sulfite oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ELECTRON-TRANSFER; RAY-ABSORPTION-SPECTROSCOPY; MOLECULAR-CLONING; ESCHERICHIA-COLI; CYSTEINE 207; ACTIVE-SITE; MOLYBDENUM; IDENTIFICATION; EXPRESSION; MOLYBDOPTERIN	In the crystal structure of chicken sulfite oxidase, the residue Tyr(322) (Tyr(343) in human sulfite oxidase) was found to directly interact with a bound sulfate molecule and was proposed to have an important role in mediating the substrate specificity and catalytic activity of this molybdoprotein. In order to understand the role of this residue in the catalytic mechanism of sulfite oxidase, steady-state and stopped-flow analyses were performed on wild-type and Y343F human sulfite oxidase over the pH range 6 - 10. In steady-state assays of Y343F sulfite oxidase using cytochrome c as the electron acceptor, k(cat) was somewhat impaired ( similar to 34% wild-type activity at pH 8.5), whereas the K-m(sulfite) showed a 5-fold increase over wild type. In rapid kinetic assays of the reductive half-reaction of wild-type human sulfite oxidase, k(red)(heme) changed very little over the entire pH range, with a significant increase in K-d(sulfite) at high pH. The k(red)(heme) of the Y343F variant was significantly impaired across the entire pH range, and unlike the wildtype protein, both k(red)(heme) and K-d(sulfite) were dependent on pH, with a significant increase in both kinetic parameters at high pH. Additionally, reduction of the molybdenum center by sulfite was directly measured for the first time in rapid reaction assays using sulfite oxidase lacking the N-terminal heme-containing domain. Reduction of the molybdenum center was quite fast (k(red)(Mo) = 972 s(-1) at pH 8.65 for wild-type protein), indicating that this is not the rate-limiting step in the catalytic cycle. Reduction of the molybdenum center of the Y343F variant by sulfite was more significantly impaired at high pH than at low pH. These results demonstrate that the Tyr(343) residue is important for both substrate binding and oxidation of sulfite by sulfite oxidase.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raj@biochem.duke.edu			NIGMS NIH HHS [GM 44283] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astashkin AV, 2002, J AM CHEM SOC, V124, P6109, DOI 10.1021/ja0115417; Brody MS, 1999, BIOCHEMISTRY-US, V38, P6668, DOI 10.1021/bi9902539; BRODY MS, 1995, BBA-PROTEIN STRUCT M, V1253, P133, DOI 10.1016/0167-4838(95)00194-4; Codd R, 2002, J BIOL INORG CHEM, V7, P338, DOI 10.1007/s00775-001-0303-5; COHEN HJ, 1971, J BIOL CHEM, V246, P374; Davis J.R.E., 2002, WILEY ENCY MOL MED, DOI [10.1002/0471203076.emm1201, DOI 10.1002/0471203076.EMM1201]; Enemark JH, 2002, MET IONS BIOL SYST, V39, P621; Feng CJ, 2003, BIOCHEMISTRY-US, V42, P12235, DOI 10.1021/bi0350194; Feng CJ, 2003, J BIOL CHEM, V278, P2913, DOI 10.1074/jbc.M210374200; Feng CJ, 2002, BIOCHEMISTRY-US, V41, P5816, DOI 10.1021/bi016059f; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GARRETT RM, 1995, BBA-GENE STRUCT EXPR, V1262, P147, DOI 10.1016/0167-4781(95)00068-R; Garrett RM, 1998, P NATL ACAD SCI USA, V95, P6394, DOI 10.1073/pnas.95.11.6394; Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; Garton SD, 1997, J AM CHEM SOC, V119, P2590, DOI 10.1021/ja963931c; George GN, 1996, J AM CHEM SOC, V118, P8588, DOI 10.1021/ja961218h; GEORGE GN, 1989, BIOCHEMISTRY-US, V28, P5075, DOI 10.1021/bi00438a026; Johnson Jean L, 2002, Hum Mutat, V20, P74, DOI 10.1002/humu.9038; JOHNSON JL, 1993, ADV EXP MED BIOL, V338, P373; JOHNSON JL, 1988, METHOD ENZYMOL, V158, P371, DOI 10.1016/0076-6879(88)58069-2; JOHNSON JL, 1977, J BIOL CHEM, V252, P2017; JOHNSON JL, 1988, BIOCHEM MED METAB B, V40, P86, DOI 10.1016/0885-4505(88)90108-9; KESSLER DL, 1974, BIOCHIM BIOPHYS ACTA, V370, P389, DOI 10.1016/0005-2744(74)90100-4; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Pacheco A, 1999, J BIOL INORG CHEM, V4, P390, DOI 10.1007/s007750050325; RAJAGOPALAN KV, 1958, MOLYBDENUM MOLYBDENU, P241; Schindelin H, 2001, ADV PROTEIN CHEM, V58, P47; Schrader N, 2003, STRUCTURE, V11, P1251, DOI 10.1016/j.str.2003.09.001; STIEFEL EI, 1973, P NATL ACAD SCI USA, V70, P988, DOI 10.1073/pnas.70.4.988; SULLIVAN EP, 1992, J AM CHEM SOC, V114, P9662, DOI 10.1021/ja00050a058; SULLIVAN EP, 1993, BIOCHEMISTRY-US, V32, P12465, DOI 10.1021/bi00097a026; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Wuebbens MM, 2003, J BIOL CHEM, V278, P14523, DOI 10.1074/jbc.M300453200	33	58	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15105	15113		10.1074/jbc.M314288200	http://dx.doi.org/10.1074/jbc.M314288200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14729666	hybrid			2022-12-25	WOS:000220594700076
J	Tropak, MB; Reid, SP; Guiral, M; Withers, SG; Mahuran, D				Tropak, MB; Reid, SP; Guiral, M; Withers, SG; Mahuran, D			Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL STORAGE DISORDERS; N-BUTYLDEOXYNOJIRIMYCIN; MOLECULAR-BASIS; HEXA-GENE; DISEASE; SUBUNIT; ENZYME; BIOSYNTHESIS; INHIBITOR; MUTATIONS	Tay-Sachs and Sandhoff diseases are lysosomal storage disorders that result from an inherited deficiency of beta-hexosaminidase A (alphabeta). Whereas the acute forms are associated with a total absence of hexosaminidase A and early death, the chronic adult forms exist with activity and protein levels of similar to5%, and unaffected individuals have been found with only 10% of normal levels. Surprisingly, almost all disease-associated missense mutations do not affect the active site of the enzyme but, rather, inhibit its ability to obtain and/or retain its native fold in the endoplasmic reticulum, resulting in its retention and accelerated degradation. By growing adult TaySachs fibroblasts in culture medium containing known inhibitors of hexosaminidase we have raised the residual protein and activity levels of intralysosomal hexosaminidase A well above the critical 10% of normal levels. A similar effect was observed in fibroblasts from an adult Sandhoff patient. We propose that these hexosaminidase inhibitors function as pharmacological chaperones, enhancing the stability of the native conformation of the enzyme, increasing the amount of hexosaminidase A capable of exiting the endoplasmic reticulum for transport to the lysosome. Therefore, pharmacological chaperones could provide a novel approach to the treatment of adult Tay-Sachs and possibly Sandhoff diseases.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1Z1, Canada; Univ Toronto, Banting Inst, Dept Lab Med & Pathol, Toronto, ON M5G 1L5, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of British Columbia; University of Toronto	Mahuran, D (corresponding author), Hosp Sick Children, Res Inst, Rm 9146A,Elm Wing,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hex@sickkids.ca			Canadian Institutes of Health Research [82944] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		AKLI S, 1993, HUM MOL GENET, V2, P61, DOI 10.1093/hmg/2.1.61; Andersson U, 2000, BIOCHEM PHARMACOL, V59, P821, DOI 10.1016/S0006-2952(99)00384-6; BIKKER H, 1988, NUCLEIC ACIDS RES, V16, P8198, DOI 10.1093/nar/16.16.8198; BOLHUIS PA, 1993, BIOCHIM BIOPHYS ACTA, V1182, P142, DOI 10.1016/0925-4439(93)90134-M; BROWN CA, 1993, AM J HUM GENET, V53, P497; Cao ZM, 1997, J BIOL CHEM, V272, P14975, DOI 10.1074/jbc.272.23.14975; CONZELMANN E, 1984, DEV NEUROSCI-BASEL, V6, P58, DOI 10.1159/000112332; DeGasperi R, 1996, NEUROLOGY, V47, P547, DOI 10.1212/WNL.47.2.547; Diettrich O, 1998, FEBS LETT, V441, P369, DOI 10.1016/S0014-5793(98)01578-6; DLOTT B, 1990, J BIOL CHEM, V265, P17921; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Fan JQ, 2003, TRENDS PHARMACOL SCI, V24, P355, DOI 10.1016/S0165-6147(03)00158-5; Fernandes MJG, 1997, EUR J HUM GENET, V5, P129, DOI 10.1159/000484748; Frustaci A, 2001, NEW ENGL J MED, V345, P25, DOI 10.1056/NEJM200107053450104; Glombitza GJ, 1997, J BIOL CHEM, V272, P5199, DOI 10.1074/jbc.272.8.5199; Gravel R. A., 1995, METABOLIC MOL BASIS, P2839; HOEKSEMA HL, 1977, AM J HUM GENET, V29, P14; Hou YM, 1998, J BIOL CHEM, V273, P21386, DOI 10.1074/jbc.273.33.21386; Hou YM, 1996, BIOCHEMISTRY-US, V35, P3963, DOI 10.1021/bi9524575; JONAS AJ, 1989, J BIOL CHEM, V264, P4953; KAPPES E, 1989, J CARBOHYD CHEM, V8, P371, DOI 10.1080/07328308908048567; KAPUR DK, 1986, BIOCHEM J, V236, P103, DOI 10.1042/bj2360103; Knapp S, 1996, J AM CHEM SOC, V118, P6804, DOI 10.1021/ja960826u; Kolter T, 2002, J BIOL CHEM, V277, P25859, DOI 10.1074/jbc.R200001200; LIU PS, 1991, TETRAHEDRON LETT, V32, P719, DOI 10.1016/S0040-4039(00)74866-0; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; MAHURAN DJ, 1991, BIOCHIM BIOPHYS ACTA, V1096, P87, DOI 10.1016/0925-4439(91)90044-A; Mark BL, 2003, J MOL BIOL, V327, P1093, DOI 10.1016/S0022-2836(03)00216-X; NAVON R, 1995, NEUROLOGY, V45, P539, DOI 10.1212/WNL.45.3.539; NEOTE K, 1990, J BIOL CHEM, V265, P20799; ODOWD B, 1986, ENZYMES LIPID METABO, V2, P779; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PROIA RL, 1984, J BIOL CHEM, V259, P3350; RUBIN M, 1988, J NEUROL SCI, V87, P103, DOI 10.1016/0022-510X(88)90058-5; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Tominaga L, 2001, BRAIN DEV-JPN, V23, P284, DOI 10.1016/S0387-7604(01)00216-9; Zhao KW, 2000, PROTEIN EXPRES PURIF, V19, P202, DOI 10.1006/prep.2000.1230	40	164	180	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13478	13487		10.1074/jbc.M308523200	http://dx.doi.org/10.1074/jbc.M308523200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724290	hybrid, Green Accepted			2022-12-25	WOS:000220478500026
J	Green, JD; Goldsbury, C; Kistler, J; Cooper, GJS; Aebi, U				Green, JD; Goldsbury, C; Kistler, J; Cooper, GJS; Aebi, U			Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; ATOMIC-FORCE MICROSCOPY; BETA-PROTEIN; CONGO-RED; TRANSGENIC MICE; PARKINSONS-DISEASE; DIABETES-MELLITUS; PLAQUE-FORMATION; ALPHA-SYNUCLEIN; IN-VITRO	Human amylin (hA), a 37-amino-acid polypeptide, is one of a number of peptides with the ability to form amyloid fibrils and cause disease. It is the main constituent of the pancreatic amyloid deposits associated with type 2 diabetes. Increasing interest in early assembly intermediates rather than the mature fibrils as the cytotoxic agent has led to this study in which the smallest hA oligomers have been captured by atomic force microscopy. These are 2.3 +/- 1.9 nm in height, 23 +/- 14 nm in length, and consist of an estimated 16 hA molecules. Oligomers first grow to a height of about 6 nm before they begin to significantly elongate into fibrils. Congo red inhibits elongation but not the growth in height of hA oligomers. Two distinct phases have thus been identified in hA fibrillogenesis: lateral growth of oligomers followed by longitudinal growth into mature fibrils. These observations suggest that mature fibrils are assembled directly via longitudinal growth of full-width oligomers, making assembly by lateral association of protofibrils appear less likely.	Univ Basel, Biozentrum, ME Muller Inst Struct Biol, CH-4056 Basel, Switzerland; Univ Auckland, Fac Sci, Sch Biol Sci, Auckland 1, New Zealand; Univ Auckland, Sch Med, Dept Med, Auckland, New Zealand	University of Basel; University of Auckland; University of Auckland	Aebi, U (corresponding author), Univ Basel, Biozentrum, ME Muller Inst Struct Biol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Ueli.Aebi@unibas.ch	Cooper, Garth JS/I-3201-2015	Cooper, Garth JS/0000-0001-5241-3163; Goldsbury, Claire/0000-0003-0647-1789				Aitken JF, 2003, BIOCHEM J, V374, P779, DOI 10.1042/BJ20030422; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; BURGEVIN MC, 1994, NEUROREPORT, V5, P2429, DOI 10.1097/00001756-199412000-00006; Butler AE, 2003, DIABETES, V52, P2304, DOI 10.2337/diabetes.52.9.2304; Castle AL, 1998, AM J PHYSIOL-ENDOC M, V275, pE531, DOI 10.1152/ajpendo.1998.275.3.E531; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; CLARK A, 1987, LANCET, V2, P231; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; COOPER GJS, 1994, ENDOCR REV, V15, P163, DOI 10.1210/er.15.2.163; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; Cornish J, 1998, AM J PHYSIOL-ENDOC M, V275, pE694, DOI 10.1152/ajpendo.1998.275.4.E694; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Goldsbury C, 2000, J STRUCT BIOL, V130, P352, DOI 10.1006/jsbi.2000.4268; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; Goldsbury CS, 1997, J STRUCT BIOL, V119, P17, DOI 10.1006/jsbi.1997.3858; Harroun TA, 2001, FEBS LETT, V507, P200, DOI 10.1016/S0014-5793(01)02972-6; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hettiarachchi M, 1997, AM J PHYSIOL-ENDOC M, V273, pE859, DOI 10.1152/ajpendo.1997.273.5.E859; Janson J, 1996, P NATL ACAD SCI USA, V93, P7283, DOI 10.1073/pnas.93.14.7283; Janson J, 1999, DIABETES, V48, P491, DOI 10.2337/diabetes.48.3.491; Kayed R, 1999, J MOL BIOL, V287, P781, DOI 10.1006/jmbi.1999.2646; Kim YS, 2003, J BIOL CHEM, V278, P10842, DOI 10.1074/jbc.M212540200; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Modler AJ, 2003, J MOL BIOL, V325, P135, DOI 10.1016/S0022-2836(02)01175-0; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Padrick SB, 2002, BIOCHEMISTRY-US, V41, P4694, DOI 10.1021/bi0160462; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; Rhoades E, 2000, BBA-PROTEIN STRUCT M, V1476, P230, DOI 10.1016/S0167-4838(99)00248-4; Schneider SW, 1998, PFLUG ARCH EUR J PHY, V435, P362, DOI 10.1007/s004240050524; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Yong W, 2002, P NATL ACAD SCI USA, V99, P150, DOI 10.1073/pnas.012584899; YOUNG AA, 1993, AM J PHYSIOL, V264, P943; Zhu M, 2002, J BIOL CHEM, V277, P50914, DOI 10.1074/jbc.M207225200	40	134	137	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12206	12212		10.1074/jbc.M312452200	http://dx.doi.org/10.1074/jbc.M312452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14704152	hybrid			2022-12-25	WOS:000220334900026
J	Hamasaki-Katagiri, N; Molchanova, T; Takeda, K; Ames, JB				Hamasaki-Katagiri, N; Molchanova, T; Takeda, K; Ames, JB			Fission yeast homolog of neuronal calcium sensor-1 (Ncs1p) regulates sporulation and confers calcium tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; EF-HAND PROTEINS; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; RHODOPSIN PHOSPHORYLATION; MYRISTOYLATED RECOVERIN; RECOMBINANT RECOVERIN; CA2+-BINDING PROTEINS; CRYSTAL-STRUCTURE; BINDING PROTEIN	The neuronal calcium sensor (NCS) proteins (e.g. recoverin, neurocalcins, and frequenin) are expressed at highest levels in excitable cells, and some of them regulate desensitization of G protein-coupled receptors. Here we present NMR analysis and genetic functional studies of an NCS homolog in fission yeast (Ncs1p). Ncs1p binds three Ca2+ ions at saturation with an apparent affinity of 2 muM and Hill coefficient of 1.9. Analysis of NMR and fluorescence spectra of Ncs1p revealed significant Ca2+-induced protein conformational changes indicative of a Ca2+-myristoyl switch. The amino-terminal myristoyl group is sequestered inside a hydrophobic cavity of the Ca2+-free protein and becomes solvent-exposed in the Ca2+-bound protein. Subcellular fractionation experiments showed that myristoylation and Ca2+ binding by Ncs1p are essential for its translocation from cytoplasm to membranes. The ncs1 deletion mutant (ncs1Delta) showed two distinct phenotypes: nutrition-insensitive sexual development and a growth defect at high levels of extracellular Ca2+ (0.1 M CaCl2). Analysis of Ncs1p mutants lacking myristoylation (Ncs1p(G2A)) or deficient in Ca2+ binding (Ncs1p(E84Q/E120Q/E168Q)) revealed that Ca2+ binding was essential for both phenotypes, while myristoylation was less critical. Exogenous cAMP, a key regulator for sexual development, suppressed conjugation and sporulation of ncs1Delta, suggesting involvement of Ncs1p in the adenylate cyclase pathway turned on by the glucose-sensing G protein-coupled receptor Git3p. Starvation-independent sexual development of ncs1Delta was also complemented by retinal recoverin, which controls Ca2+-regulated desensitization of rhodopsin. In contrast, the Ca2+ intolerance of ncs1Delta was not affected by cAMP or recoverin, suggesting that the two ncs1Delta phenotypes are mechanistically independent. We propose that Schizosaccharomyces pombe Ncs1p negatively regulates sporulation perhaps by controlling Ca2+-dependent desensitization of Git3p.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; NHLBI, Pathol Core, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Ames, JB (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	james@carb.nist.gov			NATIONAL EYE INSTITUTE [R01EY012347] Funding Source: NIH RePORTER; NEI NIH HHS [EY 12347] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALFA C, 1993, EXPT FISSION YEAST, P77; AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Andoh T, 1998, MOL GEN GENET, V258, P139, DOI 10.1007/s004380050716; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Carnero E, 2000, MOL GEN GENET, V264, P173, DOI 10.1007/s004380000318; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Catty P, 1996, BIOSCIENCE REP, V16, P75, DOI 10.1007/BF01206198; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; D'souza VM, 2001, CELL STRUCT FUNCT, V26, P555, DOI 10.1247/csf.26.555; DAVIS TN, 1995, ADV SEC MESS PHOSPH, V30, P339; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; Erickson MA, 1998, P NATL ACAD SCI USA, V95, P6474, DOI 10.1073/pnas.95.11.6474; Facanha ALO, 2002, J CELL BIOL, V157, P1029, DOI 10.1083/jcb.200111012; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; Fisher JR, 2000, PROTEIN EXPRES PURIF, V20, P66, DOI 10.1006/prep.2000.1298; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GHISLAIN M, 1990, J BIOL CHEM, V265, P18400; HALACHMI D, 1992, EUR J BIOCHEM, V207, P1003, DOI 10.1111/j.1432-1033.1992.tb17136.x; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; HIDAKA H, 1993, NEUROSCI RES, V16, P73, DOI 10.1016/0168-0102(93)90074-Z; Hirayama S, 2003, J BIOL CHEM, V278, P18078, DOI 10.1074/jbc.M212900200; Huttner IG, 2003, J BIOL CHEM, V278, P4862, DOI 10.1074/jbc.M207920200; IIDA H, 1990, J BIOL CHEM, V265, P13391; IIDA H, 1994, MOL CELL BIOL, V14, P8259, DOI 10.1128/MCB.14.12.8259; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KAWAMUKAI M, 1991, CELL REGUL, V2, P155, DOI 10.1091/mbc.2.2.155; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; Kitamura K, 1998, GENE, V214, P131, DOI 10.1016/S0378-1119(98)00203-0; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; MOCHIZUKI N, 1992, MOL GEN GENET, V233, P17, DOI 10.1007/BF00587556; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Moser MJ, 1997, J CELL SCI, V110, P1805; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Okorokov LA, 2001, FEBS LETT, V505, P321, DOI 10.1016/S0014-5793(01)02852-6; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Panaretou B, 1996, Methods Mol Biol, V53, P117; PAULUS H, 1969, ANAL BIOCHEM, V32, P91, DOI 10.1016/0003-2697(69)90107-9; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; Saitoh K, 2003, BIOSCI BIOTECH BIOCH, V67, P651, DOI 10.1271/bbb.67.651; Sallese M, 2000, BBA-MOL CELL RES, V1498, P112, DOI 10.1016/S0167-4889(00)00088-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Slupsky CM, 2001, J BIOL CHEM, V276, P5943, DOI 10.1074/jbc.M008716200; Tanaka T, 1998, J BIOMOL NMR, V11, P135, DOI 10.1023/A:1008212316986; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Tasaka Y, 2000, BIOCHEM BIOPH RES CO, V269, P265, DOI 10.1006/bbrc.2000.2278; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Welton RM, 2000, GENETICS, V156, P513; Wu JQ, 2001, MOL BIOL CELL, V12, P1061, DOI 10.1091/mbc.12.4.1061; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	71	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12744	12754		10.1074/jbc.M311895200	http://dx.doi.org/10.1074/jbc.M311895200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722091	hybrid			2022-12-25	WOS:000220334900088
J	Ochi, S; Oda, M; Matsuda, H; Ikari, S; Sakurai, J				Ochi, S; Oda, M; Matsuda, H; Ikari, S; Sakurai, J			Clostridium perfringens alpha-toxin activates the sphingomyelin metabolism system in sheep erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; SITE-DIRECTED MUTAGENESIS; RAT ISOLATED AORTA; PROTEIN-KINASE; PHOSPHOLIPASE-C; QUANTITATIVE MEASUREMENT; RABBIT ERYTHROCYTES; HL-60 CELLS; CERAMIDE	Clostridium perfringens alpha-toxin induces hemolysis of rabbit erythrocytes through the activation of glycerophospholipid metabolism. Sheep erythrocytes contain large amounts of sphingomyelin (SM) but not phosphatidylcholine. We investigated the relationship between the toxin-induced hemolysis and SM metabolic system in sheep erythrocytes. alpha-Toxin simultaneously induced hemolysis and a reduction in the levels of SM and formation of ceramide and sphingosine 1-phosphate (S1P). N-Oleoylethanolamine, a ceramidase inhibitor, inhibited the toxin-induced hemolysis and caused ceramide to accumulate in the toxin-treated cells. Furthermore, DL-threo-dihydrosphingosine and B-5354c, isolated from a novel marine bacterium, both sphingosine kinase inhibitors, blocked the toxin-induced hemolysis and production of S1P and caused sphingosine to accumulate. These observations suggest that the toxin-induced activation of the SM metabolic system is closely related to hemolysis. S1P potentiated the toxin-induced hemolysis of saponin-permeabilized erythrocytes but had no effect on that of intact cells. Preincubation of lysated sheep erythrocytes with pertussis toxin blocked the alpha-toxin-induced formation of ceramide from SM. In addition, incubation of C. botulinum C3 exoenzyme-treated lysates of sheep erythrocytes with alpha-toxin caused an accumulation of sphingosine and inhibition of the formation of S1P. These observations suggest that the alpha-toxin-induced hemolysis of sheep erythrocytes is dependent on the activation of the SM metabolic system through GTP-binding proteins, especially the formation of S1P.	Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Microbiol, Tokushima 7708514, Japan; Fujita Hlth Univ, Sch Med, Dept Microbiol, Aichi 4701192, Japan	Tokushima Bunri University; Fujita Health University	Sakurai, J (corresponding author), Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Microbiol, Yamashiro Cho, Tokushima 7708514, Japan.	sakurai@ph.bunri-u.ac.jp	Oda, Masataka/ABG-6047-2020					Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Choi OH, 1996, NATURE, V380, P634; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; DITTMER JC, 1964, J LIPID RES, V5, P126; FUJII Y, 1989, BRIT J PHARMACOL, V97, P119, DOI 10.1111/j.1476-5381.1989.tb11931.x; FUJII Y, 1986, BRIT J PHARMACOL, V88, P531, DOI 10.1111/j.1476-5381.1986.tb10233.x; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Guillouard I, 1996, INFECT IMMUN, V64, P2440, DOI 10.1128/IAI.64.7.2440-2444.1996; Guo C, 1998, EUR J BIOCHEM, V257, P403, DOI 10.1046/j.1432-1327.1998.2570403.x; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; IKEZAWA H, 1982, J TOXICOL-TOXIN REV, V1, P223; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Kono K, 2000, J ANTIBIOT, V53, P759, DOI 10.7164/antibiotics.53.759; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; MACFARLANE MG, 1950, BIOCHEM J, V47, P270, DOI 10.1042/bj0470270; McDonel J. L., 1986, Pharmacology of bacterial toxins, P477; NAGAHAMA M, 1995, J BACTERIOL, V177, P1179, DOI 10.1128/jb.177.5.1179-1185.1995; Nagahama M, 2002, MICROBIOL IMMUNOL, V46, P647, DOI 10.1111/j.1348-0421.2002.tb02748.x; Nagahama M, 1996, BBA-BIOMEMBRANES, V1280, P120, DOI 10.1016/0005-2736(95)00288-X; NAKASHIMA S, 1989, BIOCHEM J, V259, P139, DOI 10.1042/bj2590139; NELSON GJ, 1967, BIOCHIM BIOPHYS ACTA, V144, P221, DOI 10.1016/0005-2760(67)90152-X; Niedernberg A, 2003, BRIT J PHARMACOL, V138, P481, DOI 10.1038/sj.bjp.0705055; Ochi S, 2002, MICROBIOL-SGM, V148, P237, DOI 10.1099/00221287-148-1-237; Ochi S, 1996, INFECT IMMUN, V64, P3930, DOI 10.1128/IAI.64.9.3930-3933.1996; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; PREISS J, 1986, J BIOL CHEM, V261, P8597; Pyne S, 1996, BIOCHEM J, V315, P917, DOI 10.1042/bj3150917; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Rani CSS, 1997, J BIOL CHEM, V272, P10777; SAKURAI J, 1990, TOXICON, V28, P411, DOI 10.1016/0041-0101(90)90079-M; Sakurai J., 1995, Reviews in Medical Microbiology, V6, P175; SAKURAI J, 1993, INFECT IMMUN, V61, P3711, DOI 10.1128/IAI.61.9.3711-3718.1993; SAKURAI J, 1994, INFECT IMMUN, V62, P717, DOI 10.1128/IAI.62.2.717-721.1994; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spinedi A, 1999, BIOCHEM BIOPH RES CO, V255, P456, DOI 10.1006/bbrc.1999.0230; Stevens DL, 2000, INT J MED MICROBIOL, V290, P497; TITBALL RW, 1991, INFECT IMMUN, V59, P1872, DOI 10.1128/IAI.59.5.1872-1874.1991; TITBALL RW, 1993, MICROBIOL REV, V57, P347, DOI 10.1128/MMBR.57.2.347-366.1993; Titball RW, 1997, CLOSTRIDIA MOL BIOL, P223; UI M, 1990, ADP RIBOSYLATING TOX, P45; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; YATOMI Y, 1995, ANAL BIOCHEM, V230, P315, DOI 10.1006/abio.1995.1480; Young KW, 2001, SEMIN CELL DEV BIOL, V12, P19, DOI 10.1006/scdb.2000.0213; Zhang P, 1997, J BIOL CHEM, V272, P9609	57	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12181	12189		10.1074/jbc.M307046200	http://dx.doi.org/10.1074/jbc.M307046200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14702348	hybrid			2022-12-25	WOS:000220334900024
J	Shang, J; Lehrman, MA				Shang, J; Lehrman, MA			Activation of glycogen phosphorylase with 5-aminoimidazole-4-carboxamide riboside (AICAR) - Assessment of glycogen as a precursor of mannosyl residues in glycoconjugates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; 5-AMINO-4-IMIDAZOLECARBOXAMIDE RIBOSIDE; SKELETAL-MUSCLE; GLYCOSYLATION; METABOLISM; SUBSTRATE; STRESS	The experimental evaluation of the contribution of glycogen phosphorylase ( GP) to biochemical pathways is limited to methods that raise cAMP, activating the cAMP-dependent protein kinase/phosphorylase kinase/ GP cascade. Such methods convert the unphosphorylated form, "GPb," which catalyzes glycogenolysis only in the presence of appropriate allosteric activators such as AMP, to the phosphorylated, constitutively activated form, "GPa." However, activation of GP in this way is indirect, requires a functional cAMP kinase cascade, and is complicated by other actions of cAMP. Here, we demonstrate a strategy for the experimental manipulation of GP in intact dermal fibroblasts, involving activation by the membrane-permeable adenosine analog 5-aminoimidazole-4-carboxamide riboside ( AICAR) and inhibition by caffeine and Pfizer compound CP-91149, which bind to GP at distinct sites. Potential complications because of activation of AMP-activated protein kinase by AICAR were assessed with metformin, which activates this kinase but does not activate GP. Using this strategy, we show that glycogen can be a significant and regulatable precursor of mannosyl units in lipid-linked oligosaccharides and glycoproteins.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lehrman, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	mark.lehrman@utsouthwestern.edu			NIGMS NIH HHS [R01 GM038545, GM 38545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038545, R01GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand M, 2001, MOL BIOL CELL, V12, P487, DOI 10.1091/mbc.12.2.487; Beyer A, 2000, BIOL CHEM, V381, P457, DOI 10.1515/BC.2000.060; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Doerrler WT, 1999, P NATL ACAD SCI USA, V96, P13050, DOI 10.1073/pnas.96.23.13050; Gill A, 2002, J BIOL CHEM, V277, P44747, DOI 10.1074/jbc.M205001200; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Henin N, 1996, BBA-GEN SUBJECTS, V1290, P197, DOI 10.1016/0304-4165(96)00021-9; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Longnus SL, 2003, AM J PHYSIOL-REG I, V284, pR936, DOI 10.1152/ajpregu.00319.2002; Martin WH, 1998, P NATL ACAD SCI USA, V95, P1776, DOI 10.1073/pnas.95.4.1776; McMahon RJ, 1996, AM J PHYSIOL-ENDOC M, V270, pE640, DOI 10.1152/ajpendo.1996.270.4.E640; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Rath VL, 2000, CHEM BIOL, V7, P677, DOI 10.1016/S1074-5521(00)00004-1; SABINA RL, 1982, J BIOL CHEM, V257, P178; SABINA RL, 1985, J BIOL CHEM, V260, P6107; Shang J, 2004, J BIOL CHEM, V279, P12076, DOI 10.1074/jbc.M400431200; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Young ME, 1996, FEBS LETT, V382, P43, DOI 10.1016/0014-5793(96)00129-9; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	25	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12076	12080		10.1074/jbc.M400431200	http://dx.doi.org/10.1074/jbc.M400431200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14729664	hybrid			2022-12-25	WOS:000220334900011
J	Noguchi, S; Keira, Y; Murayama, K; Ogawa, M; Fujita, M; Kawahara, G; Oya, Y; Imazawa, M; Goto, Y; Hayashi, YK; Nonaka, I; Nishino, I				Noguchi, S; Keira, Y; Murayama, K; Ogawa, M; Fujita, M; Kawahara, G; Oya, Y; Imazawa, M; Goto, Y; Hayashi, YK; Nonaka, I; Nishino, I			Reduction of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION-BODY MYOPATHY; SIALIC-ACID; BIFUNCTIONAL ENZYME; MUSCULAR-DYSTROPHY; BIOSYNTHESIS; AGGLUTININ; LECTINS; GLCNAC; LOCUS; GENE	Distal myopathy with rimmed vacuoles is an autosomal recessive muscle disease with preferential involvement of the tibialis anterior that spares the quadriceps muscles in young adulthood. In a Japanese patient with distal myopathy with rimmed vacuoles, we identified pathogenic mutations in the gene encoding the bifunctional enzyme UDP-GlcNAc 2-epimerase/ManNAc kinase, which catalyzes the initial two steps in the biosynthesis of sialic acid. In this study, we demonstrated the relationship between the genetic mutations and enzymatic activities using an in vitro expression assay system. Furthermore, we also showed that the levels of sialic acid in muscle and primary cultured cells from DMRV patients were reduced to 60-75% of control. The reactivities to lectins were also variable in some myofibers, suggesting that hyposialylation and abnormal glycosylation in muscles may contribute to the focal accumulations of autophagic vacuoles, amyloid deposits, or both in patient muscle tissue. The addition of ManNAc and NeuAc to primary cultured cells normalized sialylation levels, thus demonstrating the therapeutic potential of these compounds for this disease.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo 1878502, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Radiat Protect, Tokyo 1878502, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo 1878502, Japan; Natl Ctr Neurol & Psychiat, Natl Ctr Hosp Mental Nervous & Muscular Disorders, Tokyo 1878502, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Japan Science & Technology Agency (JST)	Noguchi, S (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.	noguchi@ncnp.go.jp	Nishino, Ichizo/G-2676-2010	Nishino, Ichizo/0000-0001-9452-112X				BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Effertz K, 1999, J BIOL CHEM, V274, P28771, DOI 10.1074/jbc.274.40.28771; Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718; Eisenberg I, 1999, GENOMICS, V55, P43, DOI 10.1006/geno.1998.5630; Eisenberg Iris, 2003, Hum Mutat, V21, P99, DOI 10.1002/humu.9100; GRIGGS RC, 1995, ANN NEUROL, V38, P705, DOI 10.1002/ana.410380504; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Ikeuchi T, 1997, ANN NEUROL, V41, P432, DOI 10.1002/ana.410410405; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Lucka L, 1999, FEBS LETT, V454, P341, DOI 10.1016/S0014-5793(99)00837-6; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Nishino I, 2002, NEUROLOGY, V59, P1689, DOI 10.1212/01.WNL.0000041631.28557.C6; Noguchi S, 2000, EUR J BIOCHEM, V267, P640, DOI 10.1046/j.1432-1327.2000.00998.x; Nonaka I, 1998, NEUROMUSCULAR DISORD, V8, P333, DOI 10.1016/S0960-8966(98)00027-3; NONAKA I, 1981, J NEUROL SCI, V51, P141, DOI 10.1016/0022-510X(81)90067-8; NONAKA I, 1985, ANN NEUROL, V17, P51, DOI 10.1002/ana.410170113; Oetke C, 2001, EUR J BIOCHEM, V268, P4553, DOI 10.1046/j.1432-1327.2001.02379.x; PALJARVI L, 1984, ARCH NEUROL-CHICAGO, V41, P39, DOI 10.1001/archneur.1984.04050130045020; PEREIRA MEA, 1974, CARBOHYD RES, V37, P89, DOI 10.1016/S0008-6215(00)87066-4; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; SHIBUYA N, 1989, J BIOCHEM-TOKYO, V106, P1098, DOI 10.1093/oxfordjournals.jbchem.a122972; Yamamoto K, 1997, J BIOCHEM-TOKYO, V121, P756	24	116	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11402	11407		10.1074/jbc.M313171200	http://dx.doi.org/10.1074/jbc.M313171200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707127	hybrid			2022-12-25	WOS:000220157600070
J	Runko, AP; Sagerstrom, CG				Runko, AP; Sagerstrom, CG			Isolation of nlz2 and characterization of essential domains in Nlz family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; ZINC-FINGER PROTEINS; DROSOPHILA GENE PAIR; AUG INITIATOR CODON; DNA-BINDING; ACTIVATION DOMAINS; ZEBRAFISH; RECOGNITION; EXPRESSION; NUCLEOTIDES	In this study, we first cloned nlz2, a second zebrafish member of the nlz-related zinc-finger gene family. nlz2 was expressed together with nlz1 in a broad posterior domain during gastrula stages as well as at the mid-brain-hindbrain boundary and in the hindbrain caudal to rhombomere 4 during segmentation. nlz2 was also expressed in regions distinct from nlz1, notably in the forebrain, midbrain, and trunk. Misexpression of nlz2 in zebrafish embryos disrupted gene expression in the rostral hindbrain, similar to the effect of misexpressing nlz1. We next compared the nlz1 and nlz2 sequences to identify and characterize domains conserved within this family. We found a C-terminal domain required for nuclear localization and two conserved domains ( the Sp motif and a putative C2H2 zinc finger) required for nlz1 function. We also demonstrate that Nlz1 self-associated via its C terminus, interacted with Nlz2, and bound to histone deacetylases. Last, we found two forms of Nlz1 generated from alternative translation initiation sites in vivo. These forms have distinct activities, apparently depending on the function of the N-terminal Sp motif. Our data demonstrate that nlz2 functions similarly to nlz1 and define conserved domains essential for nuclear localization, self-association, and corepressor binding in this novel family of zinc-finger genes.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Sagerstrom, CG (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, LRB 822,364 Plantat St, Worcester, MA 01605 USA.	charles.sagerstrom@umassmed.edu			NICHD NIH HHS [HD39156] Funding Source: Medline; NINDS NIH HHS [NS38183] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038183, R56NS038183] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andreazzoli M, 2001, MECH DEVELOP, V104, P117, DOI 10.1016/S0925-4773(01)00359-8; Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; BERG JM, 1990, J BIOL CHEM, V265, P6513; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; CHEAH PY, 1994, MOL CELL BIOL, V14, P1487, DOI 10.1128/MCB.14.2.1487; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Courey AJ, 2001, GENE DEV, V15, P2786; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Dorfman R, 2002, DEVELOPMENT, V129, P3585; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; Gollner H, 2001, MECH DEVELOP, V106, P77, DOI 10.1016/S0925-4773(01)00420-8; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Harrison SM, 2000, DEV BIOL, V227, P358, DOI 10.1006/dbio.2000.9878; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; Iuchi S, 2001, CELL MOL LIFE SCI, V58, P625, DOI 10.1007/PL00000885; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KLUG A, 1987, COLD SPRING HARB SYM, V52, P473, DOI 10.1101/SQB.1987.052.01.054; Kobayashi M, 2001, DEV BIOL, V232, P315, DOI 10.1006/dbio.2001.0185; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Omichinski JG, 1997, NAT STRUCT BIOL, V4, P122, DOI 10.1038/nsb0297-122; Ossipova O, 2002, MECH DEVELOP, V115, P117, DOI 10.1016/S0925-4773(02)00086-2; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Runko AP, 2003, DEV BIOL, V262, P254, DOI 10.1016/S0012-1606(03)00388-9; Sagerstrom CG, 1996, DEVELOPMENT, V122, P1873; Sagerstrom GC, 2001, DEV DYNAM, V220, P402, DOI 10.1002/dvdy.1119; Schock F, 1999, MECH DEVELOP, V89, P125, DOI 10.1016/S0925-4773(99)00215-4; SEDMAN SA, 1990, J VIROL, V64, P453, DOI 10.1128/JVI.64.1.453-457.1990; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Tallafuss A, 2001, DEVELOPMENT, V128, P4021; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; WIMMER EA, 1993, NATURE, V366, P690, DOI 10.1038/366690a0; Wimmer EA, 1996, MECH DEVELOP, V59, P53, DOI 10.1016/0925-4773(96)00575-8; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wulbeck C, 1997, DEV GENES EVOL, V207, P156, DOI 10.1007/s004270050103; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; Zhao XJ, 2002, DEVELOPMENT, V129, P1497	50	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11917	11925		10.1074/jbc.M310076200	http://dx.doi.org/10.1074/jbc.M310076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14709556	hybrid			2022-12-25	WOS:000220157600129
J	Dermott, JM; Ha, JH; Lee, CH; Dhanasekaran, N				Dermott, JM; Ha, JH; Lee, CH; Dhanasekaran, N			Differential regulation of Jun N-terminal kinase and p38MAP kinase by G alpha(12)	ONCOGENE			English	Article						G protein; JNK; p38MAPK; MKK; cell proliferation	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; NH2-TERMINAL KINASE; SYNERGISTIC ACTIVATION; IN-VITRO; MKK4; TRANSFORMATION; SPECIFICITY; FIBROBLASTS; INHIBITION	Based on the findings that the overexpression of the wild-type Galpha(12) (Galpha(12)WT) result in the oncogenic transformation of NIH3T3 cells in a serum-dependent manner, a model system has been established in which the mitogenic and subsequent cell transformation pathways activated by Galpha(12) can be turned on or off by the addition or removal of serum. Using this model system, our previous studies have shown that the stimulation of Galpha(12)WT or the expression of an activated mutant of Galpha(12) (Galpha(12)QL) leads to increased cell proliferation and subsequent oncogenic transformation of NIH3T3 cells, as well as persistent activation of Jun N-terminal kinases (JNKs). In the present studies, we show that the stimulation of Galpha(12)WT or the expression of Galpha(12)QL results in a potent inhibition of p38MAPK, and that the mechanism by which Galpha(12) inhibits p38MAPK activity involves the dual specificity kinases upstream of p38MAPK. The results indicate that Galpha(12) attenuates the activation of MKK3 and MKK4, which are known to stimulate only p38MAPK or p38MAPK and JNK, respectively. The results also suggest that Galpha(12) activates JNKs specifically through the stimulation of the JNK-specific upstream kinase MKK7. These findings demonstrate for the first time that Galpha(12) differentially regulates JNK and p38MAPK by specifically activating MKK7, while inhibiting MKK3 and MKK4 in NIH3T3 cells. Since the stimulation of p38MAPK is often associated with apoptotic responses, our findings suggest that Galpha(12) stimulates cell proliferation and neoplastic transformation of NIH3T3 cells by attenuating p38MAPK-associated apoptotic responses, while activating the mitogenic responses through the stimulation of ERK- and JNK-mediated signaling pathways.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Hanyang Univ, Coll Med, Dept Pharmacol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Inst Biomed Sci, Seoul 133791, South Korea	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Hanyang University; Hanyang University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.	danny001@temple.edu		HA, Ji Hee/0000-0002-6281-1904	NIGMS NIH HHS [GM49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dermott JM, 2002, METHOD ENZYMOL, V344, P298; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; JIANG H, 1993, FEBS LETT, V3, P319; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; VARAPRASAD MVV, 1995, J BIOL CHEM, V270, P18655; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Weston CR, 2002, SCIENCE, V296, P2345, DOI 10.1126/science.1073344; XU N, 1993, P NATL ACAD SCI USA, V90, P11354; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	26	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					226	232		10.1038/sj.onc.1207009	http://dx.doi.org/10.1038/sj.onc.1207009			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712227				2022-12-25	WOS:000187895300023
J	Fernandis, AZ; Prasad, A; Band, H; Klosel, R; Ganju, RK				Fernandis, AZ; Prasad, A; Band, H; Klosel, R; Ganju, RK			Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells	ONCOGENE			English	Article						CXCR4; chemotaxis; chemoinvasion; focal adhesion; metastasis; signaling	FOCAL ADHESION PROTEINS; RECEPTOR CCR5 SIGNALS; TYROSINE PHOSPHORYLATION; CHEMOKINE RECEPTORS; FACTOR-I; MATRIX METALLOPROTEINASES; ALPHA-CHEMOKINE; TUMOR-GROWTH; KINASE; CBL	The chemokine-CXCL12 and its receptor, CXCR4, have recently been shown to play an important role in regulating the directional migration of breast cancer cells to sites of metastasis. In the present study, we showed that CXCL12 enhanced the chemotaxis, chemoinvasion and adhesive properties of breast cancer cells; parameters that are critical for development of metastasis. We have also evaluated the signaling mechanisms that regulate CXCL12-induced and CXCR4-mediated breast cancer cell motility and invasion. These studies revealed that CXCL12 induces the tyrosine phosphorylation of focal adhesion kinase (FAK) at residues 397 and 577, and of RAFTK/Pyk2 at residues 402 and 579/580. The cytoskeletal proteins paxillin and Crk, as well as tyrosine phosphatase SHP2 and adaptor protein Cbl, were also phosphorylated. CXCL12 induced the activation of PI 3-kinase, and increased its association with Cbl and SHP2. PI 3-kinase, RAFTK/Pyk2 and tyrosine phosphatase inhibitors significantly blocked CXCL12-induced chemotaxis and chemoinvasion. The role of SHP2 and Cbl in CXCL12-induced chemotaxis and chemoinvasion in breast cancer cells was further defined by transiently overexpressing wild-type SHP2, wild-type Cbl, dominant-negative SHP2, Cbl mutants 70Z/3 and G306E or double transfectants of the Cbl and SHP2 constructs. We found a novel role of Cbl in CXCL12-induced chemotaxis, which may be mediated through the activation and formation of a multimeric complex comprised of Cbl, SHP2 and PI 3-kinase. We also observed the activation of matrix metalloproteinases 2 and 9 upon CXCL12 stimulation. These studies provide new information regarding signaling pathways that may regulate CXCL12-induced metastasis in breast cancer cells.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Inst Med,Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Biontex Labs GmbH, D-80807 Munich, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ganju, RK (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Inst Med,Div Expt Med, 4 Blackfan Circle,Room 343, Boston, MA 02115 USA.	rganju@bidmc.harvard.edu	Fernandis, Aaron/C-3718-2012					ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Arboleda MJ, 2003, CANCER RES, V63, P196; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Camacho SA, 2001, NAT IMMUNOL, V2, P523, DOI 10.1038/88720; Cass I, 2001, GYNECOL ONCOL, V80, P56, DOI 10.1006/gyno.2000.6027; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Fernandis AZ, 2003, J BIOL CHEM, V278, P9536, DOI 10.1074/jbc.M211803200; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Fournier TM, 2000, MOL BIOL CELL, V11, P3397, DOI 10.1091/mbc.11.10.3397; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Ganju RK, 2000, J BIOL CHEM, V275, P17263, DOI 10.1074/jbc.M000689200; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Gonzalo JA, 2000, J IMMUNOL, V165, P499, DOI 10.4049/jimmunol.165.1.499; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Hyder SM, 2001, INT J CANCER, V92, P469, DOI 10.1002/ijc.1236; Inoue K, 2000, CANCER RES, V60, P2290; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; Janowska-Wieczorek A, 2000, EXP HEMATOL, V28, P1274, DOI 10.1016/S0301-472X(00)00532-4; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Luca M, 1997, AM J PATHOL, V151, P1105; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Manes S, 1999, MOL CELL BIOL, V19, P3125; Mashino K, 2002, CANCER RES, V62, P2937; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Mohle R, 2000, BRIT J HAEMATOL, V110, P563, DOI 10.1046/j.1365-2141.2000.02157.x; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Payne AS, 2002, J INVEST DERMATOL, V118, P915, DOI 10.1046/j.1523-1747.2002.01725.x; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Price John T, 2002, Expert Opin Ther Targets, V6, P217; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Saphner T, 1996, J CLIN ONCOL, V14, P2738, DOI 10.1200/JCO.1996.14.10.2738; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Scaife RM, 2000, J CELL SCI, V113, P215; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Scotton CJ, 2001, CANCER RES, V61, P4961; Scotton CJ, 2002, CANCER RES, V62, P5930; Taichman RS, 2002, CANCER RES, V62, P1832; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; Yoshie O, 2000, INT J HEMATOL, V72, P399; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342	64	230	242	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					157	167		10.1038/sj.onc.1206910	http://dx.doi.org/10.1038/sj.onc.1206910			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712221	Bronze			2022-12-25	WOS:000187895300017
J	Liu, T; Brouha, B; Grossman, D				Liu, T; Brouha, B; Grossman, D			Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells	ONCOGENE			English	Article						apoptosis; survivin; caspase; AIF; melanoma; mitochondria	CRYSTAL-STRUCTURE; PROTEIN SURVIVIN; DIRECT INHIBITOR; CYTOCHROME-C; CANCER; DEATH; EXPRESSION; GENE; IAP; AIF	The inhibitor of apoptosis (IAP) protein Survivin is expressed in most cancers and is a key factor in maintaining apoptosis resistance. Although several IAPs have been shown to act as direct inhibitors of caspases, the precise antiapoptotic function of Survivin remains controversial. To clarify the mechanism by which Survivin protects cells, we investigated the kinetics of apoptosis and apoptotic events following Survivin inhibition utilizing a melanoma cell line harboring a tetracycline-regulated Survivin dominant-negative mutant (Survivin-T34A). Blocking Survivin resulted in both caspase activation and apoptosis; however, the level of apoptosis was only partially reduced by caspase inhibition. Survivin blockade also resulted in mitochondrial events that preceded caspase activation, including depolarization and release of cytochrome c and Smac/DIABLO. Levels of other IAPs were not altered in Survivin-targeted cells, although modest cleavage of XIAP and Livin was observed. The earliest proapoptotic event observed in Survivin-targeted cells was nuclear translocation of mitochondrial apoptosis-inducing factor (AIF), known to trigger both apoptotic mitochondrial events and caspase-independent DNA fragmentation. These findings suggest that a key antiapoptotic function of Survivin relates to inhibition of mitochondrial and AIF-dependent apoptotic pathways, and its expression in melanoma and other cancers likely protects against both caspase-independent and -dependent apoptosis.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Dermatol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Grossman, D (corresponding author), Univ Utah, Huntsman Canc Inst, Suite 5243,2000 Circle Hope, Salt Lake City, UT 84112 USA.	doug.grossman@hci.utah.edu			NIAMS NIH HHS [KO8AR48618, R01 AR050102-01A1, R01 AR050102, K08 AR048618, K08 AR048618-04] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050102, K08AR048618] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adida C, 1998, AM J PATHOL, V152, P43; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; Chantalat L, 2000, MOL CELL, V6, P183, DOI 10.1016/S1097-2765(00)00019-8; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fortugno P, 2002, J CELL SCI, V115, P575; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 1999, LAB INVEST, V79, P1121; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Mahotka C, 1999, CANCER RES, V59, P6097; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Olie RA, 2000, CANCER RES, V60, P2805; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 2001, J CLIN INVEST, V108, P965, DOI 10.1172/JCI14123; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Reutelingsperger CPM, 1997, CELL MOL LIFE SCI, V53, P527, DOI 10.1007/s000180050067; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tamm I, 1998, CANCER RES, V58, P5315; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030	62	154	170	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					39	48		10.1038/sj.onc.1206978	http://dx.doi.org/10.1038/sj.onc.1206978			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712209	Green Accepted			2022-12-25	WOS:000187895300005
J	Kumar, A; Khandelwal, N; Malya, R; Reid, MB; Boriek, AM				Kumar, A; Khandelwal, N; Malya, R; Reid, MB; Boriek, AM			Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers	FASEB JOURNAL			English	Article						dystrophin; skeletal muscle; MAP kinases; AP-1; mechanotransduction	DUCHENNE MUSCULAR-DYSTROPHY; SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASES; GLYCOPROTEIN COMPLEX; ACTIVATOR PROTEIN-1; MAPK ACTIVATION; MDX-MYOTUBES; IN-VIVO; CELLS; STRETCH	Dystrophin is a cytoskeletal protein found at the inner surface of skeletal and cardiac muscle fibers. We hypothesize that deficiency of dystrophin increases muscle compliance and causes an aberrant mechanotransduction in muscle fibers. To test this hypothesis, we measured the length-tension relationships and determined intracellular signaling leading to the activation of mitogen-activated protein (MAP) kinases in diaphragm muscle fibers from dystrophin-deficient mdx mice. Compared with controls, length-tension curves of the mdx mice were shifted to the right. A higher level of activation of extracellular signal-reffulated kinase 1/2 (ERK1/2) but not c-Jun N-terminal kinase-1 or p38 MAP kinase was observed in the mdx muscle compared with the normal muscle in response to mechanical stretch. Removal of Ca2+ from the medium inhibited stretch-induced ERK1/2 activation only in mdx muscle fibers but not in the normal fibers. Conversely, pretreatment with TMB-8 (an antagonist of intracellular Ca2+) blocked the mechanical stretch-induced ERK1/2 activation in normal but not in mdx muscle fibers. pretreatment of muscle with nifedipine (L-type calcium channel antagonist) marginally decreased the activation of ERK1/2 in normal or mdx muscle whereas pretreatment with gadolinium (III) chloride (an inhibitor of stretch-activated channels) only blocked the activation of ERK1/2 in mdx muscle, with no significant effect on normal muscle. A higher basal level of activation of activator protein-1 (AP-1) transcription factor was observed in dystrophin-deficient diaphragm, which was further augmented by mechanical stretch. Mechanical stretch-induced activation of AP-1 was decreased by pretreatment of muscle fibers with PD98059 (ERK1/2 inhibitor) and removal of Ca2+ ions from incubation medium. Our results show that dystrophin is a load-bearing element and its deficiency leads to loss of muscle stiffness and aberrant mechanotransduction in skeletal muscle fibers.	Baylor Coll Med, Dept Med, Pulm Sect, Houston, TX 77030 USA	Baylor College of Medicine	Boriek, AM (corresponding author), Baylor Coll Med, Dept Med, Pulm Sect, 1 Baylor Plaza,Suite 520B, Houston, TX 77030 USA.	boriek@bcm.tmc.edu		Kumar, Ashok/0000-0001-8571-2848; Kumar, Ashok/0000-0002-2444-9529	PHS HHS [R01-46230, R01-63134] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Alderton JM, 2000, J BIOL CHEM, V275, P9452, DOI 10.1074/jbc.275.13.9452; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Boriek AM, 2001, AM J PHYSIOL-CELL PH, V280, pC46, DOI 10.1152/ajpcell.2001.280.1.C46; BORIEK AM, 1994, AM J RESP CRIT CARE, V149, pA226; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Danialou G, 2001, FASEB J, V15, P1655, DOI 10.1096/fj.01-0030fje; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Ehmsen J, 2002, J CELL SCI, V115, P2801; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; FRANCO A, 1991, BIOPHYS J, V59, P1164, DOI 10.1016/S0006-3495(91)82332-3; Franco-Obregon A, 2002, J PHYSIOL-LONDON, V539, P391, DOI 10.1113/jphysiol.2001.013043; Gailly P, 2002, BBA-PROTEINS PROTEOM, V1600, P38, DOI 10.1016/S1570-9639(02)00442-9; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, SCIENCE, V238, P347, DOI 10.1126/science.3659917; Ingber DE, 1998, BIOL BULL-US, V194, P323, DOI 10.2307/1543102; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Kamogawa Y, 2001, CARDIOVASC RES, V50, P509, DOI 10.1016/S0008-6363(01)00205-X; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kato T, 1998, BIOCHEM BIOPH RES CO, V244, P615, DOI 10.1006/bbrc.1998.8335; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Kumar A, 1999, METHOD ENZYMOL, V300, P339; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2003, J BIOL CHEM, V278, P18868, DOI 10.1074/jbc.M212777200; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Kumar A, 1998, J IMMUNOL, V161, P776; LAW DJ, 1994, J CELL SCI, V107, P1477; Li W, 2001, AM J PHYSIOL-GASTR L, V280, pG75, DOI 10.1152/ajpgi.2001.280.1.G75; Liu MY, 1999, AM J PHYSIOL-LUNG C, V277, pL667, DOI 10.1152/ajplung.1999.277.4.L667; Martineau LC, 2001, J APPL PHYSIOL, V91, P693, DOI 10.1152/jappl.2001.91.2.693; MASSA R, 1994, ACTA NEUROPATHOL, V87, P377; O'Brien KF, 2001, MOL GENET METAB, V74, P75, DOI 10.1006/mgme.2001.3220; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rando TA, 2001, MUSCLE NERVE, V24, P1575, DOI 10.1002/mus.1192; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Spencer MJ, 1997, J CLIN INVEST, V99, P2745, DOI 10.1172/JCI119464; SPENCER MJ, 1995, J BIOL CHEM, V270, P10909, DOI 10.1074/jbc.270.18.10909; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; TIDBALL JG, 1995, J CELL SCI, V108, P2197; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Winder SJ, 1997, J MUSCLE RES CELL M, V18, P617, DOI 10.1023/A:1018627705273; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685	59	121	126	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					102	113		10.1096/fj.03-0453com	http://dx.doi.org/10.1096/fj.03-0453com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718391				2022-12-25	WOS:000188829300044
J	Mellott, TJ; Williams, CL; Meck, WH; Blusztajn, JK				Mellott, TJ; Williams, CL; Meck, WH; Blusztajn, JK			Prenatal choline supplementation advances hippocampal development and enhances MAPK and CREB activation	FASEB JOURNAL			English	Article						behavior; nutrition; pregnancy; learning; memory	ELEMENT-BINDING PROTEIN; LONG-TERM-MEMORY; CAMP-RESPONSIVE ELEMENT; SPATIAL MEMORY; ADULT RATS; DIETARY SUPPLEMENTATION; REARING ENVIRONMENT; KINASE CASCADE; PROXIMAL-CUE; DISTAL-CUE	Choline is an essential nutrient for animals and humans. Previous studies showed that supplementing the maternal diet with choline during the second half of gestation in rats permanently enhances memory performance of the adult offspring. Here we show that prenatal choline supplementation causes a 3-day advancement in the ability of juvenile rats to use relational cues in a water maze task, indicating that the treatment accelerates hippocampal maturation. Moreover, phosphorylation and therefore activation of hippocampal mitogen-ctivated protein kinase (MAPK) and cAMP-response element binding protein (CREB) in response to stimulation by glutamate, N-methyl-D-aspartate, or depolarizing concentrations of K+ were increased by prenatal choline supplementation and reduced by prenatal choline deficiency. These data provide the first evidence that developmental plasticity of the hippocampal MAPK and CREB signaling pathways is controlled by the supply of a single essential nutrient, choline, during fetal development and point to these pathways as candidate mechanisms for the developmental and long-term cognitive enhancement induced by prenatal choline supplementation.	Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Duke Univ, Dept Psychol & Brain Sci, Durham, NC 27708 USA	Boston University; Duke University	Blusztajn, JK (corresponding author), Boston Univ, Sch Med, Dept Pathol & Lab Med, 715 Albany St,L804, Boston, MA 02118 USA.	jbluszta@bu.edu		/0000-0001-8438-3122; Meck, Warren/0000-0002-6120-4790; Mellott, Tiffany/0000-0003-3287-9374				Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; Berman DE, 1998, J NEUROSCI, V18, P10037; Bernabeu R, 1997, P NATL ACAD SCI USA, V94, P7041, DOI 10.1073/pnas.94.13.7041; Blum S, 1999, J NEUROSCI, V19, P3535; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brandner C, 2002, BRAIN RES, V928, P85, DOI 10.1016/S0006-8993(01)03363-7; Cammarota M, 2000, MOL BRAIN RES, V76, P36, DOI 10.1016/S0169-328X(99)00329-0; CASTRO CA, 1987, DEV PSYCHOBIOL, V20, P521, DOI 10.1002/dev.420200506; Cermak JM, 1998, FASEB J, V12, P349, DOI 10.1096/fasebj.12.3.349; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; *FOOD NUTR BOARD I, 1998, DIET REF INT THIAM R; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; Holmes GL, 2002, EPILEPSY RES, V48, P3, DOI 10.1016/S0920-1211(01)00321-7; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799; Jones JP, 1999, DEV BRAIN RES, V118, P159, DOI 10.1016/S0165-3806(99)00103-0; Josselyn SA, 2001, J NEUROSCI, V21, P2404, DOI 10.1523/JNEUROSCI.21-07-02404.2001; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kogan JH, 1997, CURR BIOL, V7, P1, DOI 10.1016/S0960-9822(06)00022-4; Lamprecht R, 1997, J NEUROSCI, V17, P8443; Lucas A, 1998, J NUTR, V128, p401S, DOI 10.1093/jn/128.2.401S; Martinez JL, 1996, ANNU REV PSYCHOL, V47, P173, DOI 10.1146/annurev.psych.47.1.173; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; Meck WH, 2003, NEUROSCI BIOBEHAV R, V27, P385, DOI 10.1016/S0149-7634(03)00069-1; Montoya D, 2000, NEUROSCI LETT, V296, P85, DOI 10.1016/S0304-3940(00)01660-8; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; Ricceri L, 1998, BEHAV NEUROSCI, V112, P1387, DOI 10.1037/0735-7044.112.6.1387; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; Schenk F, 1995, PSYCHOBIOLOGY, V23, P302; Selcher JC, 1999, LEARN MEMORY, V6, P478, DOI 10.1101/lm.6.5.478; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Taubenfeld SM, 1999, NAT NEUROSCI, V2, P309, DOI 10.1038/7217; Tees RC, 1999, DEV PSYCHOBIOL, V35, P328, DOI 10.1002/(SICI)1098-2302(199912)35:4&lt;328::AID-DEV7&gt;3.0.CO;2-4; Tees RC, 1999, DEV PSYCHOBIOL, V35, P226, DOI 10.1002/(SICI)1098-2302(199911)35:3&lt;226::AID-DEV7&gt;3.0.CO;2-H; Tees RC, 1999, BEHAV BRAIN RES, V105, P173, DOI 10.1016/S0166-4328(99)00074-1; Viola HE, 2000, J NEUROSCI, V20; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang YL, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0006.2000; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	55	90	92	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					545	+		10.1096/fj.03-0877fje	http://dx.doi.org/10.1096/fj.03-0877fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715695				2022-12-25	WOS:000188829300022
J	Nyborg, AC; Kornilova, AY; Jansen, K; Ladd, TB; Wolfe, MS; Golde, TE				Nyborg, AC; Kornilova, AY; Jansen, K; Ladd, TB; Wolfe, MS; Golde, TE			Signal peptide peptidase forms a homodimer that is labeled by an active site-directed gamma-secretase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMEMBRANE-CLEAVING PROTEASES; FAMILIAL ALZHEIMERS-DISEASE; ASPARTYL PROTEASE; BETA-APP; IN-VIVO; PRESENILIN; COMPLEX; NICASTRIN; TARGETS; ENDOPROTEOLYSIS	Presenilin (PS) is the presumptive catalytic component of the intramembrane aspartyl protease gamma-secretase complex. Recently a family of presenilin homologs was identified. One member of this family, signal peptide peptidase (SPP), has been shown to be a protease, which supports the hypothesis that PS and presenilin homologs are related intramembrane-cleaving aspartyl proteases. SPP has been reported as a glycoprotein of similar to 45 kDa. Our initial characterization of SPP isolated from human brain and cell lines demonstrated that SPP is primarily present as an SDS-stable similar to 95-kDa protein on Western blots. Upon heating or treatment of this similar to95-kDa SPP band with acid, a similar to45-kDa band could be resolved. Co-purification of two different epitope-tagged forms of SPP from a stably transfected cell line expressing both tagged versions demonstrated that the similar to 95-kDa band is a homodimer of SPP. Pulse-chase metabolic labeling studies demonstrated that the SPP homodimer assembles rapidly and is metabolically stable. In a glycerol velocity gradient, SPP sedimented from similar to 100 - 200 kDa. Significantly the SPP homodimer was specifically labeled by an active site-directed photoaffinity probe (III-63) for PS, indicating that the active sites of SPP and PS/gamma-secretase are similar and providing strong evidence that the homodimer is functionally active. Collectively these data suggest that SPP exists in vivo as a functional dimer.	Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL 32224 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Mayo Clinic; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Golde, TE (corresponding author), Mayo Clin Jacksonville, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	tgolde@mayo.edu			NINDS NIH HHS [NS44734, NS41355, NS39072] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039072, R01NS041355, F32NS044734] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cervantes S, 2001, FEBS LETT, V505, P81, DOI 10.1016/S0014-5793(01)02785-5; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, NAT CELL BIOL, V4, pE110, DOI 10.1038/ncb0502-e110b; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Golde TE, 2001, TRENDS MOL MED, V7, P264, DOI 10.1016/S1471-4914(01)02064-0; GOLDE TE, 2003, SCI STKE; Grigorenko AP, 2002, BIOCHEMISTRY-MOSCOW+, V67, P826, DOI 10.1023/A:1016365227942; Hebert SS, 2003, BIOCHEM BIOPH RES CO, V301, P119, DOI 10.1016/S0006-291X(02)02984-4; KARRE K, 1991, IMMUNOL TODAY, V12, P343, DOI 10.1016/0167-5699(91)90062-X; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Urny J, 2003, GENE EXPR PATTERNS, V3, P685, DOI 10.1016/S1567-133X(03)00094-2; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	36	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15153	15160		10.1074/jbc.M309305200	http://dx.doi.org/10.1074/jbc.M309305200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14704149	hybrid			2022-12-25	WOS:000220594700081
J	Bharadwaj, S; Hitchcock-DeGregori, S; Thorburn, A; Prasad, GL				Bharadwaj, S; Hitchcock-DeGregori, S; Thorburn, A; Prasad, GL			N terminus is essential for tropomyosin functions - N-terminal modification disrupts stress fiber organization and abolishes anti-oncogenic effects of tropomyosin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-TRANSFORMED FIBROBLASTS; ALTERNATIVELY SPLICED EXONS; SIGNAL-REGULATED KINASE; II TUMOR-SUPPRESSOR; ACTIN CYTOSKELETON; FORCED EXPRESSION; DOWN-REGULATION; LIM-KINASE; NONMUSCLE CALDESMON; MUSCLE TROPOMYOSIN	Down-regulation of several key actin-binding proteins, such as alpha-actinin, vinculin, gelsolin, and tropomyosins (TMs), is considered to contribute to the disorganized cytoskeleton present in many neoplastic cells. TMs stabilize actin filaments against the gel severing actions of proteins such as cofilin. Among multiple TMs expressed in non-muscle cells, tropomyosin-1 (TM1) isoform induces stress fibers and functions as a suppressor of malignant transformation. However, the molecular mechanisms of TM1-mediated cytoskeletal effects and tumor suppression remain poorly understood. We have hypothesized that the ability of TM1 to stabilize microfilaments is crucial for tumor suppression. In this study, by employing a variant TM1, which contains an N-terminal hemagglutinin epitope tag, we demonstrate that the N terminus is a key determinant of tropomyosin-1 function. Unlike the wild type TM1, the modified protein fails to restore stress fibers and inhibit anchorage-independent growth in transformed cells. Furthermore, the N-terminal modification of TM1 disorganizes the cytoskeleton and delays cytokinesis in normal cells, abolishes binding to F-actin, and disrupts the dimeric associations in vivo. The functionally defective TM1 allows the association of cofilin to stress fibers and disorganizes the microfilaments, whereas wild type TM1 appears to restrict the binding of cofilin to stress fibers. TM1-induced cytoskeletal reorganization appears to be mediated through preventing cofilin interaction with microfilaments. Our studies provide in vivo functional evidence that the N terminus is a critical determinant of TM1 functions, which in turn determines the organization of stress fibers.	Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Prasad, GL (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	gprasad@wfubmc.edu			NIGMS NIH HHS [GM 63257] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063257] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; Blanchoin L, 2001, CURR BIOL, V11, P1300, DOI 10.1016/S0960-9822(01)00395-5; Braverman RH, 1996, ONCOGENE, V13, P537; Bryce NS, 2003, MOL BIOL CELL, V14, P1002, DOI 10.1091/mbc.E02-04-0244; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; CHO YJ, 1990, J BIOL CHEM, V265, P538; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; Cooper JA, 2002, CURR BIOL, V12, pR523, DOI 10.1016/S0960-9822(02)01028-X; DesMarais V, 2002, J CELL SCI, V115, P4649, DOI 10.1242/jcs.00147; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; Glantz SA., 1997, PRIMER BIOSTATISTICS; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Houle FO, 2003, MOL BIOL CELL, V14, P1418, DOI 10.1091/mbc.E02-04-0235; Hughes JAI, 2003, GLIA, V42, P25, DOI 10.1002/glia.10174; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; Jagatheesan G, 2003, J BIOL CHEM, V278, P23204, DOI 10.1074/jbc.M303073200; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; LEHRER SS, 1987, ARCH BIOCHEM BIOPHYS, V256, P1, DOI 10.1016/0003-9861(87)90419-X; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mahadev K, 2002, EXP CELL RES, V279, P40, DOI 10.1006/excr.2002.5583; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Maytum R, 2000, BIOCHEMISTRY-US, V39, P11913, DOI 10.1021/bi000977g; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; Michele DE, 1999, J CELL BIOL, V145, P1483, DOI 10.1083/jcb.145.7.1483; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Moraczewska J, 1999, BIOCHEMISTRY-US, V38, P15885, DOI 10.1021/bi991816j; NicholsonFlynn K, 1996, J NEUROSCI, V16, P6853; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V25, P267, DOI 10.1002/cm.970250307; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; Ono S, 2002, J CELL BIOL, V156, P1065, DOI 10.1083/jcb.200110013; Pawlak G, 2002, J BIOL CHEM, V277, P26927, DOI 10.1074/jbc.M202261200; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Perry SV, 2001, J MUSCLE RES CELL M, V22, P5, DOI 10.1023/A:1010303732441; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; Polevoda B, 2003, J BIOL CHEM, V278, P30686, DOI 10.1074/jbc.M304690200; PRASAD GL, 1994, EUR J BIOCHEM, V224, P1, DOI 10.1111/j.1432-1033.1994.tb19988.x; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RANUCCI D, 1993, CELL MOTIL CYTOSKEL, V24, P119, DOI 10.1002/cm.970240205; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Singer JM, 2003, P NATL ACAD SCI USA, V100, P7644, DOI 10.1073/pnas.1232343100; SOBUE K, 1991, J BIOL CHEM, V266, P12115; Strand J, 2001, J BIOL CHEM, V276, P34832, DOI 10.1074/jbc.M104750200; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; TARDIF M, 1995, J BIOL CHEM, V270, P28075; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; WARREN KS, 1995, J CELL BIOL, V129, P697, DOI 10.1083/jcb.129.3.697; Wen KK, 2000, J BIOL CHEM, V275, P40594, DOI 10.1074/jbc.M007201200; Wong K, 2000, CELL MOTIL CYTOSKEL, V45, P121, DOI 10.1002/(SICI)1097-0169(200002)45:2<121::AID-CM4>3.3.CO;2-R; Yager ML, 2003, BRIT J CANCER, V89, P860, DOI 10.1038/sj.bjc.6601201; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119	66	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14039	14048		10.1074/jbc.M310934200	http://dx.doi.org/10.1074/jbc.M310934200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722123	hybrid			2022-12-25	WOS:000220478500093
J	Simons, PC; Biggs, SM; Waller, A; Foutz, T; Cimino, DF; Guo, Q; Neubig, RR; Tang, WJ; Prossnitz, ER; Sklar, LA				Simons, PC; Biggs, SM; Waller, A; Foutz, T; Cimino, DF; Guo, Q; Neubig, RR; Tang, WJ; Prossnitz, ER; Sklar, LA			Real-time analysis of ternary complex on particles - Direct evidence for partial agonism at the agonist-receptor-G protein complex assembly step of signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; LIGAND-BINDING; AFFINITY; PHOSPHORYLATION; RECONSTITUTION; DOMAIN; FULL	We developed a novel and generalized approach to investigate G protein-coupled receptor molecular assemblies. We solubilized a fusion protein consisting of the beta(2)-adrenergic receptor and green fluorescent protein (GFP) for bead-based flow cytometric analysis. beta(2)-Adrenergic receptor GFP bound to dihydroalprenolol-conjugated beads, providing a K-d for the fusion protein and, in competition with beta(2)-adrenergic receptor ligands, K-d values for agonists and antagonists. Beads displaying chelated nickel bound purified hexahistidine-tagged G protein heterotrimers and, subsequently, the binary complex of agonist with beta(2)-adrenergic receptor GFP. The dose-response curves of ternary complex formation revealed maximal assembly for ligands previously classified as full agonists and reduced assembly for ligands previously classified as partial agonists. Guanosine 5'-3-O-( thio) triphosphate-induced dissociation rates of the ternary complex were the same for full and partial agonists. Soluble G protein, competing with ternary complexes on beads provided an affinity estimate of agonist-receptor complexes to G protein. When performed simultaneously, the two assemblies discriminated between agonist, antagonist or inactive molecule in a manner appropriate for high throughput, small volume drug discovery. The assemblies can be further generalized to other G protein coupled receptor protein-protein interactions.	Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Ctr Canc, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Univ Chicago, Ben May Canc Res Inst, Chicago, IL 60637 USA; Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of Chicago; University of Michigan System; University of Michigan	Sklar, LA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Ctr Canc, Albuquerque, NM 87131 USA.	lsklar@salud.unm.edu	Prossnitz, Eric R./B-4543-2008	Tang, Wei-Jen/0000-0002-8267-8995; Waller, Anna/0000-0003-3676-2501; Neubig, Richard/0000-0003-0501-0008	NHLBI NIH HHS [HL-476417] Funding Source: Medline; NIBIB NIH HHS [EB00264] Funding Source: Medline; NIGMS NIH HHS [GM60799, GM53459] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R24EB000264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053459, R24GM060799] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRETT TE, 1995, AM J RESP CRIT CARE, V151, P574, DOI 10.1164/ajrccm.151.2.7842223; Bennett TA, 2001, J BIOL CHEM, V276, P49195, DOI 10.1074/jbc.M106414200; Bennett TA, 2001, J BIOL CHEM, V276, P22453, DOI 10.1074/jbc.M009679200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bremner P, 1996, CHEST, V109, P957, DOI 10.1378/chest.109.4.957; BYLUND DB, 1978, BRAIN RES, V152, P391, DOI 10.1016/0006-8993(78)90270-6; CARON MG, 1979, J BIOL CHEM, V254, P2923; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Clark RB, 1999, TRENDS PHARMACOL SCI, V20, P279, DOI 10.1016/S0165-6147(99)01351-6; Cussac D, 2002, MOL PHARMACOL, V62, P578, DOI 10.1124/mol.62.3.578; DELEAN A, 1980, J BIOL CHEM, V255, P7108; GETHER U, 1995, J BIOL CHEM, V270, P28268; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; GREEN SA, 1993, J BIOL CHEM, V268, P23116; January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; KENT RS, 1980, MOL PHARMACOL, V17, P14; Key TA, 2001, J BIOL CHEM, V276, P49204, DOI 10.1074/jbc.M109475200; Krumins AM, 1997, MOL PHARMACOL, V52, P144, DOI 10.1124/mol.52.1.144; LEYSEN JE, 1988, J PHARMACOL EXP THER, V247, P661; MUKHERJEE C, 1976, MOL PHARMACOL, V12, P16; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nolan John P., 1998, P19; Nolan JP, 1998, NAT BIOTECHNOL, V16, P633, DOI 10.1038/nbt0798-633; Robillard L, 2000, CELL SIGNAL, V12, P673, DOI 10.1016/S0898-6568(00)00118-2; Simons PC, 2003, MOL PHARMACOL, V64, P1227, DOI 10.1124/mol.64.5.1227; STAEHELIN M, 1983, J BIOL CHEM, V258, P3496; TOTA MR, 1990, MOL PHARMACOL, V37, P996; UPRICHARD DC, 1978, J BIOL CHEM, V253, P5090; Waller A, 2003, COMB CHEM HIGH T SCR, V6, P389; Wise A, 2002, DRUG DISCOV TODAY, V7, P235, DOI 10.1016/S1359-6446(01)02131-6	31	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13514	13521		10.1074/jbc.M310306200	http://dx.doi.org/10.1074/jbc.M310306200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726530	hybrid			2022-12-25	WOS:000220478500030
J	Akari, H; Fujita, M; Kao, S; Khan, MA; Shehu-Xhilaga, M; Adachi, A; Strebel, K				Akari, H; Fujita, M; Kao, S; Khan, MA; Shehu-Xhilaga, M; Adachi, A; Strebel, K			High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the gag precursor at the p2/nucleocapsid processing site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 VIF; ANTIVIRAL ACTIVITY; CO-ENCAPSIDATION; ENZYME APOBEC3G; PROTEIN BINDS; CELL-LINE; DNA; DEGRADATION; VIRIONS; STABILITY	The human immunodeficiency virus type-1 Vif protein has a crucial role in regulating viral infectivity. However, we found that newly synthesized Vif is rapidly degraded by cellular proteases. We tested the dose dependence of Vif in non-permissive H9 cells and found that Vif, when expressed at low levels, increased virus infectivity in a dose-dependent manner. Surprisingly, however, the range of Vif required for optimal virus infectivity was narrow, and further increases in Vif severely reduced viral infectivity. Inhibition of viral infectivity at higher levels of Vif was cell type-independent and was associated with an accumulation of Gag-processing intermediates. Vif did not act as a general protease inhibitor but selectively inhibited Gag processing at the capsid and nucleocapsid (NC) boundary. Identification of Vif variants that were efficiently packaged but were unable to modulate Gag processing suggests that Vif packaging was necessary but insufficient for the production of 33- and 34-kDa processing intermediates. Interestingly, these processing intermediates, like Vif, associated with viral nucleoprotein complexes more rigidly than mature capsid and NC. We conclude that virus-associated Vif inhibits processing of a subset of Gag precursor molecules at the p2/NC primary cleavage site. Modulation of processing of a small subset of Gag molecules by physiological levels of Vif may be important for virus maturation. However, the accumulation of such processing intermediates at high levels of Vif is inhibitory. Thus, rapid intracellular degradation of Vif may have evolved as a mechanism to prevent such inhibitory effects of Vif.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Natl Inst Infect Dis, Tsukuba Primate Ctr Med Sci, Ibaraki 3050843, Japan; Univ Tokushima, Grad Sch Med, Dept Virol, Tokushima 7708502, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institute of Infectious Diseases (NIID); Tokushima University	Strebel, K (corresponding author), NIAID, Mol Microbiol Lab, NIH, 4-312,4 Ctr Dr,MSC 0460, Bethesda, MD 20892 USA.	kstrebel@nih.gov	botla, Gomathi/A-5724-2008; AKARI, Hirofumi/AGR-4616-2022	Akari, Hirofumi/0000-0003-2166-6015; Fujita, Mikako/0000-0001-6705-4052; Adachi, Akio/0000-0003-1674-332X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000669, ZIAAI000669] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Aiken C, 1997, J VIROL, V71, P5871, DOI 10.1128/JVI.71.8.5871-5877.1997; Akari H, 1999, J GEN VIROL, V80, P2945, DOI 10.1099/0022-1317-80-11-2945; Bardy M, 2001, J GEN VIROL, V82, P2719, DOI 10.1099/0022-1317-82-11-2719; Bour S, 1996, J VIROL, V70, P8285, DOI 10.1128/JVI.70.12.8285-8300.1996; Bour S, 2000, Adv Pharmacol, V48, P75; Bouyac M, 1997, J VIROL, V71, P9358, DOI 10.1128/JVI.71.12.9358-9365.1997; Chowdhury IH, 1996, J VIROL, V70, P5336, DOI 10.1128/JVI.70.8.5336-5345.1996; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; COURCOUL M, 1995, J VIROL, V69, P2068, DOI 10.1128/JVI.69.4.2068-2074.1995; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; ERICKSONVIITANEN S, 1989, AIDS RES HUM RETROV, V5, P577, DOI 10.1089/aid.1989.5.577; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; GORNY MK, 1989, P NATL ACAD SCI USA, V86, P1624, DOI 10.1073/pnas.86.5.1624; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; HENDERSON LE, 1990, J MED PRIMATOL, V19, P411; HOGLUND S, 1994, VIROLOGY, V201, P349, DOI 10.1006/viro.1994.1300; Huvent I, 1998, J GEN VIROL, V79, P1069, DOI 10.1099/0022-1317-79-5-1069; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Kao S, 2003, J VIROL, V77, P1131, DOI 10.1128/JVI.77.2.1131-1140.2003; Karczewski MK, 1996, J VIROL, V70, P494, DOI 10.1128/JVI.70.1.494-507.1996; Khan MA, 2002, J VIROL, V76, P9112, DOI 10.1128/JVI.76.18.9112-9123.2002; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Ohagen A, 2000, J VIROL, V74, P11055, DOI 10.1128/JVI.74.23.11055-11066.2000; PETTIT SC, 1994, J VIROL, V68, P8017, DOI 10.1128/JVI.68.12.8017-8027.1994; REDDY TR, 1995, J VIROL, V69, P3549, DOI 10.1128/JVI.69.6.3549-3553.1995; Roos JW, 2000, VIROLOGY, V273, P307, DOI 10.1006/viro.2000.0431; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; Varthakavi V, 1999, J VIROL, V73, P10329, DOI 10.1128/JVI.73.12.10329-10338.1999; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Wiegers K, 1998, J VIROL, V72, P2846, DOI 10.1128/JVI.72.4.2846-2854.1998; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	46	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12355	12362		10.1074/jbc.M312426200	http://dx.doi.org/10.1074/jbc.M312426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722068	hybrid			2022-12-25	WOS:000220334900043
J	Browne, GJ; Finn, SG; Proud, CG				Browne, GJ; Finn, SG; Proud, CG			Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, Serine 398	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MR 100,000 SUBSTRATE; FACTOR-II KINASE; FACTOR-2 KINASE; MAMMALIAN-CELLS; EEF2 KINASE; TRANSLATION; IDENTIFICATION; PURIFICATION; INSULIN; SYSTEM	Protein synthesis consumes a high proportion of the metabolic energy of mammalian cells, and most of this is used by peptide chain elongation. An important regulator of energy supply and demand in eukaryotic cells is the AMP-activated protein kinase (AMPK). The rate of peptide chain elongation can be modulated through the phosphorylation of eukaryotic elongation factor (eEF) 2, which inhibits its activity and is catalyzed by a specific calcium/calmodulin-dependent protein kinase termed eEF2 kinase. Here we show that AMPK directly phosphorylates eEF2 kinase, and we identify the major site of phosphorylation as Ser-398 in a regulatory domain of eEF2 kinase. AMPK also phosphorylates two other sites (Ser-78 and Ser-366) in eEF2 kinase in vitro. We develop appropriate phosphospecific antisera and show that phosphorylation of Ser-398 in eEF2 kinase is enhanced in intact cells under a range of conditions that activate AMPK and increase the phosphorylation of eEF2. Ser-78 and Ser-366 do not appear to be phosphorylated by AMPK within cells. Although cardiomyocytes appear to contain a distinct isoform of eEF2 kinase, it also contains a site corresponding to Ser-398 that is phosphorylated by AMPK in vitro. Stimuli that activate AMPK and increase eEF2 phosphorylation within cells increase the activity of eEF2 kinase. Thus, AMPK and eEF2 kinase may provide a key link between cellular energy status and the inhibition of protein synthesis, a major consumer of metabolic energy.	Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland	University of Dundee	Proud, CG (corresponding author), Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland.	c.g.proud@dundee.ac.uk		Proud, Christopher/0000-0003-0704-6442				Arthur PG, 2000, BBA-GEN SUBJECTS, V1475, P83, DOI 10.1016/S0304-4165(00)00046-5; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x; BROWNE GJ, 2004, IN PRESS MOL CELL BI, V24; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Diggle TA, 1999, FEBS LETT, V457, P189, DOI 10.1016/S0014-5793(99)01034-0; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HENIN N, 2003, BIOCHIM BIOPHYS ACTA, V1290, P197; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Horman S, 2003, J BIOL CHEM, V278, P41970, DOI 10.1074/jbc.M302403200; Kimball SR, 2002, CURR OPIN CLIN NUTR, V5, P63, DOI 10.1097/00075197-200201000-00012; Knebel A, 2002, BIOCHEM J, V367, P525, DOI 10.1042/BJ20020916; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; McLeod LE, 2001, FEBS LETT, V489, P225, DOI 10.1016/S0014-5793(01)02100-7; MERRICK WC, 2000, TRANSLATIONAL CONTRO, P59; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; Pavur KS, 2000, BIOCHEMISTRY-US, V39, P12216, DOI 10.1021/bi0007270; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; REDPATH NT, 1993, BIOCHEM J, V293, P31, DOI 10.1042/bj2930031; REDPATH NT, 1993, EUR J BIOCHEM, V212, P511, DOI 10.1111/j.1432-1033.1993.tb17688.x; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; RYAZANOV AG, 1988, BIOCHIMIE, V70, P619, DOI 10.1016/0300-9084(88)90245-3; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Wang LJ, 2000, AM J PHYSIOL-HEART C, V278, pH1056, DOI 10.1152/ajpheart.2000.278.4.H1056; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Yan LM, 2003, J BIOL CHEM, V278, P18177, DOI 10.1074/jbc.M301116200	35	250	266	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12220	12231		10.1074/jbc.M309773200	http://dx.doi.org/10.1074/jbc.M309773200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709557	hybrid			2022-12-25	WOS:000220334900028
J	Gautam, R; Chintala, S; Li, W; Zhang, Q; Tan, J; Novak, EK; Di Pietro, SM; Dell'Angelica, EC; Swank, RT				Gautam, R; Chintala, S; Li, W; Zhang, Q; Tan, J; Novak, EK; Di Pietro, SM; Dell'Angelica, EC; Swank, RT			The Hermansky-Pudlak syndrome 3 (cocoa) protein is a component of the biogenesis of lysosome-related organelles complex-2 (BLOC-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERMANSKY-PUDLAK-SYNDROME; STORAGE-POOL DEFICIENCY; PLATELET-DENSE GRANULES; MOUSE MODELS; RUBY-EYE; GENE; MUTATION; HPS1; MELANOSOMES; PALLIDIN	Hermansky- Pudlak syndrome ( HPS) is a genetically heterogeneous inherited disease affecting vesicle trafficking among lysosome- related organelles. The Hps3, Hps5, and Hps6 genes are mutated in the cocoa, rubyeye-2, and ruby- eye mouse pigment mutants, respectively, and their human orthologs are mutated in HPS3, HPS5, and HPS6 patients. These three genes encode novel proteins of unknown function. The phenotypes of Hps5/ Hps5, Hps6/ Hps6 and Hps3/ Hps3, Hps6/ Hps6 double mutant mice mimic, in coat and eye colors, in melanosome ultrastructure, and in levels of platelet dense granule serotonin, the corresponding phenotypes of single mutants. These facts suggest that the proteins encoded by these genes act within the same pathway or protein complex in vivo to regulate vesicle trafficking. Further, the Hps5 protein is destabilized within tissues of Hps3 and Hps6 mutants, as is the Hps6 protein within tissues of Hps3 and Hps5 mutants. Also, proteins encoded by these genes co- immunoprecipitate and occur in a complex of 350 kDa as determined by sucrose gradient and gel filtration analyses. Together, these results indicate that the Hps3, Hps5, and Hps6 proteins regulate vesicle trafficking to lysosome- related organelles at the physiological level as components of the BLOC- 2 ( biogenesis of lysosome- related organelles complex- 2) protein complex and suggest that the pathogenesis and future therapies of HPS3, HPS5, and HPS6 patients are likely to be similar. Interaction of the Hps5 and Hps6 proteins within BLOC- 2 is abolished by the three- amino acid deletion in the Hps6(ru) mutant allele, indicating that these three amino acids are important for normal BLOC- 2 complex formation.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA	Roswell Park Cancer Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Swank, RT (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	Richard.Swank@roswellpark.org	di pietro, santiago/AAR-6899-2020		NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051480, R01HL031698, R01HL068117] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056] Funding Source: Medline; NEI NIH HHS [EY 12104] Funding Source: Medline; NHLBI NIH HHS [HL 31698, HL 51480, HL 68117] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Chiang PW, 2003, J BIOL CHEM, V278, P20332, DOI 10.1074/jbc.M300090200; Ciciotte SL, 2003, BLOOD, V101, P4402, DOI 10.1182/blood-2003-01-0020; Falcon-Perez JM, 2002, J BIOL CHEM, V277, P28191, DOI 10.1074/jbc.M204011200; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Feng LJ, 2002, BLOOD, V99, P1651, DOI 10.1182/blood.V99.5.1651.h8001651_1651_1658; Gwynn B, 2000, BLOOD, V96, P4227; Huizing M, 2002, Curr Mol Med, V2, P451, DOI 10.2174/1566524023362357; Huizing M, 2001, AM J HUM GENET, V69, P1022, DOI 10.1086/324168; Kantheti P, 2003, MAMM GENOME, V14, P157, DOI 10.1007/s00335-002-2238-8; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Li W, 2003, NAT GENET, V35, P84, DOI 10.1038/ng1229; Luzio JP, 2003, MOL MEMBR BIOL, V20, P141, DOI 10.1080/0968768031000089546; Martina JA, 2003, J BIOL CHEM, V278, P29376, DOI 10.1074/jbc.M301294200; MEISLER MH, 1984, J HERED, V75, P103, DOI 10.1093/oxfordjournals.jhered.a109881; Moriyama K, 2002, TRAFFIC, V3, P666, DOI 10.1034/j.1600-0854.2002.30908.x; Nazarian R, 2003, P NATL ACAD SCI USA, V100, P8770, DOI 10.1073/pnas.1532040100; Nguyen T, 2002, J INVEST DERMATOL, V119, P1156, DOI 10.1046/j.1523-1747.2002.19535.x; NOVAK EK, 1988, BRIT J HAEMATOL, V69, P371, DOI 10.1111/j.1365-2141.1988.tb02376.x; NOVAK EK, 1984, BLOOD, V63, P536; NOVAK EK, 1980, BIOCHEM GENET, V18, P549, DOI 10.1007/BF00484401; Oberhauser AF, 1996, P NATL ACAD SCI USA, V93, P14349, DOI 10.1073/pnas.93.25.14349; Peterson MR, 2001, TRAFFIC, V2, P476, DOI 10.1034/j.1600-0854.2001.20705.x; REDDINGTON M, 1987, BLOOD, V69, P1300; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; SILVERS WK, 1979, COAT COLORS MICE MOD, P103; Spritz RA, 1999, TRENDS GENET, V15, P337, DOI 10.1016/S0168-9525(99)01785-0; Suzuki T, 2003, P NATL ACAD SCI USA, V100, P1146, DOI 10.1073/pnas.0237292100; Suzuki T, 2001, GENOMICS, V78, P30, DOI 10.1006/geno.2001.6644; Sviderskaya EV, 1998, GENETICS, V148, P381; SWANK RT, 1991, BLOOD, V78, P2036, DOI 10.1182/blood.V78.8.2036.bloodjournal7882036; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Swank RT, 2000, PIGM CELL RES, V13, P59, DOI 10.1034/j.1600-0749.13.s8.12.x; SWEET HO, 1985, MOUSE NEWS LETT, V73, P18; Yang W, 2000, J CELL SCI, V113, P4077; Zhang Q, 2003, NAT GENET, V33, P145, DOI 10.1038/ng1087	38	61	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12935	12942		10.1074/jbc.M311311200	http://dx.doi.org/10.1074/jbc.M311311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718540	hybrid			2022-12-25	WOS:000220334900111
J	van den Heuvel, RHH; Westphal, AH; Heck, AJR; Walsh, MA; Rovida, S; van Berkel, WJH; Mattevi, A				van den Heuvel, RHH; Westphal, AH; Heck, AJR; Walsh, MA; Rovida, S; van Berkel, WJH; Mattevi, A			Structural studies on flavin reductase PheA2 reveal binding of NAD in an unusual folded conformation and support novel mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-THERMOGLUCOSIDASIUS A7; CRYSTAL-STRUCTURE; NAD(P)H-FLAVIN OXIDOREDUCTASE; BIOLUMINESCENT BACTERIUM; ELECTROSPRAY-IONIZATION; PHENOL HYDROXYLASE; ESCHERICHIA-COLI; FERRIC REDUCTASE; VIBRIO-FISCHERI; DNA PHOTOLYASE	The catabolism of toxic phenols in the thermophilic organism Bacillus thermoglucosidasius A7 is initiated by a two-component enzyme system. The smaller flavin reductase PheA2 component catalyzes the NADH-dependent reduction of free FAD according to a ping-pong bisubstrate-biproduct mechanism. The reduced FAD is then used by the larger oxygenase component PheA1 to hydroxylate phenols to the corresponding catechols. We have determined the x-ray structure of PheA2 containing a bound FAD cofactor (2.2 Angstrom), which is the first structure of a member of this flavin reductase family. We have also determined the x-ray structure of reduced holo-PheA2 in complex with oxidized NAD (2.1 Angstrom). PheA2 is a single domain homodimeric protein with each FAD-containing subunit being organized around a six-stranded beta-sheet and a capping alpha-helix. The tightly bound FAD prosthetic group (K-d=10 nM) binds near the dimer interface, and the re face of the FAD isoalloxazine ring is fully exposed to solvent. The addition of NADH to crystalline PheA2 reduced the flavin cofactor, and the NAD product was bound in a wide solvent-accessible groove adopting an unusual folded conformation with ring stacking. This is the first observation of an enzyme that is very likely to react with a folded compact pyridine nucleotide. The PheA2 crystallographic models strongly suggest that reactive exogenous FAD substrate binds in the NADH cleft after release of NAD product. Nanoflow electrospray mass spectrometry data indeed showed that PheA2 is able to bind one FAD cofactor and one FAD substrate. In conclusion, the structural data provide evidence that PheA2 contains a dual binding cleft for NADH and FAD substrate, which alternate during catalysis.	Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Wageningen & Res Ctr, Biochem Lab, NL-6703 HA Wageningen, Netherlands; European Synchrotron Radiat Facil, MRC France, F-38043 Grenoble, France	University of Pavia; Utrecht University; Utrecht University; Wageningen University & Research; European Synchrotron Radiation Facility (ESRF)	van den Heuvel, RHH (corresponding author), Univ Pavia, Dept Genet & Microbiol, Via Abbiategrasso 207, I-27100 Pavia, Italy.	r.h.h.vandenheuvel@chem.uu.nl; mattevi@ipvgen.unipv.it	Mattevi, Andrea/R-4469-2019; mattevi, andrea/K-5464-2012; van Berkel, Willem J.H./O-2431-2014; Heck, Albert/D-7098-2011; Westphal, Adrie Herman/L-3517-2019; Walsh, Martin A/I-1566-2013	Mattevi, Andrea/0000-0002-9523-7128; mattevi, andrea/0000-0002-9523-7128; van Berkel, Willem J.H./0000-0002-6551-2782; Heck, Albert/0000-0002-2405-4404; Westphal, Adrie Herman/0000-0003-4264-6267; Walsh, Martin A/0000-0001-5683-1151				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bell CE, 1997, PROTEIN SCI, V6, P2084; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHIEN Y, 1973, BIOCHEM BIOPH RES CO, V50, P538, DOI 10.1016/0006-291X(73)90873-5; Chiu HJ, 2001, STRUCTURE, V9, P311, DOI 10.1016/S0969-2126(01)00589-5; Christendat D, 2000, NAT STRUCT BIOL, V7, P903; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Duffner FM, 2000, GENE, V256, P215, DOI 10.1016/S0378-1119(00)00352-8; Duffner FM, 1998, FEMS MICROBIOL LETT, V161, P37, DOI 10.1016/S0378-1097(98)00047-0; Engel MFM, 2002, J BIOL CHEM, V277, P10922, DOI 10.1074/jbc.M106005200; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Filisetti L, 2003, J BIOL CHEM, V278, P296, DOI 10.1074/jbc.M209689200; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; Gray KA, 1996, NAT BIOTECHNOL, V14, P1705, DOI 10.1038/nbt1296-1705; HECK AJR, 2004, IN PRESS MASS SPECTR; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ingelman M, 1999, BIOCHEMISTRY-US, V38, P7040, DOI 10.1021/bi982849m; Jeffers CE, 2001, BIOCHEMISTRY-US, V40, P1749, DOI 10.1021/bi0024310; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; Kirchner U, 2003, J BIOL CHEM, V278, P47545, DOI 10.1074/jbc.M307397200; Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P975, DOI 10.1038/nsb1297-975; Loo JA, 1997, MASS SPECTROM REV, V16, P1; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Murzin AG, 1998, NAT STRUCT BIOL, V5, P101, DOI 10.1038/nsb0298-101; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Parry RJ, 1997, J BIOL CHEM, V272, P23303, DOI 10.1074/jbc.272.37.23303; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schroder I, 2003, FEMS MICROBIOL REV, V27, P427, DOI 10.1016/S0168-6445(03)00043-3; Singh SK, 2002, J BIOL CHEM, V277, P33291, DOI 10.1074/jbc.M204368200; Smith PE, 2000, J MOL RECOGNIT, V13, P27, DOI 10.1002/(SICI)1099-1352(200001/02)13:1<27::AID-JMR483>3.3.CO;2-#; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tahallah N, 2002, J BIOL CHEM, V277, P36425, DOI 10.1074/jbc.M205841200; TAKIZAWA N, 1995, J FERMENT BIOENG, V80, P318, DOI 10.1016/0922-338X(95)94198-Z; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; Tanner JJ, 1999, PROTEIN SCI, V8, P1725, DOI 10.1110/ps.8.9.1725; THIBAUT D, 1995, J BACTERIOL, V177, P5199, DOI 10.1128/jb.177.18.5199-5205.1995; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; UETZ T, 1992, J BACTERIOL, V174, P1179, DOI 10.1128/jb.174.4.1179-1188.1992; Vadas A, 1999, J BIOL CHEM, V274, P36715, DOI 10.1074/jbc.274.51.36715; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Witschel M, 1997, J BACTERIOL, V179, P6937, DOI 10.1128/jb.179.22.6937-6943.1997; ZENNO S, 1994, J BACTERIOL, V176, P3536, DOI 10.1128/JB.176.12.3536-3543.1994	56	66	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12860	12867		10.1074/jbc.M313765200	http://dx.doi.org/10.1074/jbc.M313765200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14703520	hybrid			2022-12-25	WOS:000220334900102
J	Yang, Y; Rijnbrand, R; Watowich, S; Lemon, SM				Yang, Y; Rijnbrand, R; Watowich, S; Lemon, SM			Genetic evidence for an interaction between a picornaviral cis-acting RNA replication element and 3CD protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; POLIOVIRUS RNA; VPG URIDYLYLATION; POSITIVE-STRAND; CODING SEQUENCE; VIRAL-RNA; IDENTIFICATION; BINDING; GENOME; CRE	Internally located, cis-acting RNA replication elements, termed cres, are essential for replication of the genomes of picornaviruses such as human rhinovirus 14 (HRV-14) and poliovirus because they template uridylylation of the protein primer, VPg, by the polymerase 3D(pol). These cres form stem-loop structures sharing a common loop motif, and the HRV-14 cre can substitute functionally for the poliovirus cre in both uridylylation in vitro and RNA replication in vivo. We show, however, that the poliovirus cre is unable to support HRV-14 RNA replication. This lack of complementation maps to the stem of the poliovirus cre and was reversed by single nucleotide substitutions in the stem as well as the base of the loop. Replication-competent, revertant viruses rescued from dicistronic HRV-14 RNAs containing the poliovirus cre, or a chimeric cre containing the poliovirus stem, contained adaptive amino acid substitutions. These mapped to the surface of both the polymerase 3D(pol), at the tip of the "thumb" domain, and the protease 3C(pro), on the side opposing the active site and near the end of an extended strand segment implicated previously in RNA binding. These mutations substantially enhanced replication competence when introduced into HRV-14 RNAs containing the poliovirus cre, and they were additive in their effects. The data support a model in which 3CD or its derivatives 3C(pro) and 3D(pol) interact directly with the stem of the cre during uridylylation of VPg.	Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Lemon, SM (corresponding author), Univ Texas, Med Branch, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA.	smlemon@utmb.ed			NIAID NIH HHS [R01 AI 140282] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, J VIROL, V64, P607, DOI 10.1128/JVI.64.2.607-612.1990; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P961, DOI 10.1073/pnas.74.3.961; Gamarnik AV, 2000, J VIROL, V74, P2219, DOI 10.1128/JVI.74.5.2219-2226.2000; Gerber K, 2001, J VIROL, V75, P10979, DOI 10.1128/JVI.75.22.10979-10990.2001; Goodfellow I, 2000, J VIROL, V74, P4590, DOI 10.1128/JVI.74.10.4590-4600.2000; Goodfellow IG, 2003, RNA, V9, P124, DOI 10.1261/rna.2950603; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HARRIS KS, 1992, J VIROL, V66, P7481, DOI 10.1128/JVI.66.12.7481-7489.1992; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2; LEE YF, 1977, P NATL ACAD SCI USA, V74, P59, DOI 10.1073/pnas.74.1.59; LEONG LEC, 1993, J BIOL CHEM, V268, P25735; Lobert PE, 1999, P NATL ACAD SCI USA, V96, P11560, DOI 10.1073/pnas.96.20.11560; Mason PW, 2002, J VIROL, V76, P9686, DOI 10.1128/JVI.76.19.9686-9694.2002; Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; McKnight KL, 1998, RNA, V4, P1569, DOI 10.1017/S1355838298981006; McKnight KL, 1996, J VIROL, V70, P1941, DOI 10.1128/JVI.70.3.1941-1952.1996; Melchers WJG, 1997, J VIROL, V71, P686, DOI 10.1128/JVI.71.1.686-696.1997; Mellits KH, 1998, J GEN VIROL, V79, P1715, DOI 10.1099/0022-1317-79-7-1715; Meredith JM, 1999, J VIROL, V73, P9952, DOI 10.1128/JVI.73.12.9952-9958.1999; Mirmomeni MH, 1997, J VIROL, V71, P2363, DOI 10.1128/JVI.71.3.2363-2370.1997; Morasco BJ, 2003, J VIROL, V77, P5136, DOI 10.1128/JVI.77.9.5136-5144.2003; Mosimann SC, 1997, J MOL BIOL, V273, P1032, DOI 10.1006/jmbi.1997.1306; Murray KE, 2003, J VIROL, V77, P4739, DOI 10.1128/JVI.77.8.4739-4750.2003; Pathak HB, 2002, J BIOL CHEM, V277, P31551, DOI 10.1074/jbc.M204408200; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Pilipenko EV, 1996, EMBO J, V15, P5428, DOI 10.1002/j.1460-2075.1996.tb00926.x; Racaniello V.R., 2001, FIELDS VIROLOGY, P455; REGENMORTEL MHV, 2000, VIRUS TAXONOMY CLASS, P657; ROHLL JB, 1995, J VIROL, V69, P7835, DOI 10.1128/JVI.69.12.7835-7844.1995; Seipelt J, 1999, VIRUS RES, V62, P159, DOI 10.1016/S0168-1702(99)00043-X; Todd S, 1997, J VIROL, V71, P8868, DOI 10.1128/JVI.71.11.8868-8874.1997; TODD S, 1995, J VIROL, V69, P3605, DOI 10.1128/JVI.69.6.3605-3614.1995; XIANG WK, 1995, J VIROL, V69, P3658, DOI 10.1128/JVI.69.6.3658-3667.1995; Yang Y, 2002, J VIROL, V76, P7485, DOI 10.1128/JVI.76.15.7485-7494.2002; Yin J, 2003, J VIROL, V77, P5152, DOI 10.1128/JVI.77.9.5152-5166.2003	41	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12659	12667		10.1074/jbc.M312992200	http://dx.doi.org/10.1074/jbc.M312992200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711816	hybrid			2022-12-25	WOS:000220334900079
J	Zhong, L; Qing, KY; Si, Y; Chen, LY; Tan, MQ; Srivastava, A				Zhong, L; Qing, KY; Si, Y; Chen, LY; Tan, MQ; Srivastava, A			Heat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vectors is independent of the cellular heat-shock protein 90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-MEDIATED GENE-TRANSFER; GROWTH-FACTOR RECEPTOR; CASEIN KINASE-II; IMPAIRED INTRACELLULAR TRAFFICKING; HEMATOPOIETIC PROGENITOR CELLS; PROTEIN-TYROSINE-PHOSPHATASE; INVERTED TERMINAL REPEATS; MILD LUNG-DISEASE; BETA-GLOBIN GENE; TRANSGENE EXPRESSION	Recombinant adeno-associated virus 2 (AAV) vectors transduction efficiency varies greatly in different cell types. We have described that a cellular protein, FKBP52, in its phosphorylated form interacts with the D-sequence in the viral inverted terminal repeat, inhibits viral second strand DNA synthesis, and limits transgene expression. Here we investigated the role of cellular heat-shock protein 90 (HSP90) in AAV transduction because FKBP52 forms a complex with HSP90, and because heat-shock treatment augments AAV transduction efficiency. Heat-shock treatment of HeLa cells resulted in tyrosine dephosphorylation of FKBP52, led to stabilization of the FKBP52-HSP90 complex, and resulted in similar to6-fold increase in AAV transduction. However, when HeLa cells were pre-treated with tyrphostin 23, a specific inhibitor of cellular epidermal growth factor receptor tyrosine kinase, which phosphorylates FKBP52 at tyrosine residues, heat-shock treatment resulted in a further 18-fold increase in AAV transduction. HSP90 was shown to be a part of the FKBP52-AAV D-sequence complex, but HSP90 by itself did not bind to the D-sequence. Geldanamycin treatment, which disrupts the HSP90-FKBP52 complex, resulted in >22-fold increase in AAV transduction in heat-shock-treated cells compared with heat shock alone. Deliberate overexpression of the human HSP90 gene resulted in a significant decrease in AAV-mediated transduction in tyrphostin 23-treated cells, whereas down-modulation of HSP90 levels led to a decrease in HSP90-FKBP52-AAV D-sequence complex formation, resulting in a significant increase in AAV transduction following pre-treatment with tyrphostin 23. These studies suggest that the observed increase in AAV transduction efficiency following heat-shock treatment is unlikely to be mediated by HSP90 alone and that increased levels of HSP90, in the absence of heat shock, facilitate binding of FKBP52 to the AAV D-sequence, thereby leading to inhibition of AAV-mediated transgene expression. These studies have implications in the optimal use of recombinant AAV vectors in human gene therapy.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Walther Oncol Ctr,Walther Canc Inst, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202 USA; Eli Lilly & Co, Indianapolis, IN 46229 USA; Cent S Univ, Xiang Ya Sch Med, Changsha 410078, Hunan, Peoples R China	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly; Central South University	Srivastava, A (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, Walther Oncol Ctr,Walther Canc Inst, Med Sci Bldg,Rm 415-A,635 Barnhill Dr, Indianapolis, IN 46202 USA.	asrivast@iupui.edu	Si, Yue/A-1171-2010		NHLBI NIH HHS [HL 65570, R01 HL058881, R01 HL058881-06, R01 HL065570] Funding Source: Medline; NIBIB NIH HHS [R01 EB002073, R01 EB 002073] Funding Source: Medline; NIDDK NIH HHS [P01 DK058327, P50 DK049218-050003, P01 DK058327-060004, P50 DK049218] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065570, R01HL058881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049218, P01DK058327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aitken ML, 2001, HUM GENE THER, V12, P1907, DOI 10.1089/104303401753153956; Ashok A, 2003, J VIROL, V77, P1347, DOI 10.1128/JVI.77.2.1347-1356.2003; Bartlett JS, 2000, J VIROL, V74, P2777, DOI 10.1128/JVI.74.6.2777-2785.2000; Berns KI, 1996, CURR TOP MICROBIOL, V218, P1; Carter BJ, 1996, CURR TOP MICROBIOL, V218, P119; Chatterjee S, 1995, ANN NY ACAD SCI, V770, P79, DOI 10.1111/j.1749-6632.1995.tb31045.x; CYBULSKY AV, 1994, AM J PHYSIOL, V267, pF428, DOI 10.1152/ajprenal.1994.267.3.F428; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; Duan DS, 2000, J CLIN INVEST, V105, P1573, DOI 10.1172/JCI8317; Duan DS, 1999, J VIROL, V73, P10371, DOI 10.1128/JVI.73.12.10371-10376.1999; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; Flotte T, 1996, HUM GENE THER, V7, P1145, DOI 10.1089/hum.1996.7.9-1145; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hansen J, 2001, MOL THER, V4, P289, DOI 10.1006/mthe.2001.0457; Hansen J, 2000, J VIROL, V74, P992, DOI 10.1128/JVI.74.2.992-996.2000; Hansen J, 2001, J VIROL, V75, P4080, DOI 10.1128/JVI.75.9.4080-4090.2001; Hung JJ, 2002, J VIROL, V76, P1379, DOI 10.1128/JVI.76.3.1379-1390.2002; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; Kaplitt MG, 1996, ANN THORAC SURG, V62, P1669, DOI 10.1016/S0003-4975(96)00946-0; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Knossl M, 1999, J VIROL, V73, P1254; Koeberl DD, 1997, P NATL ACAD SCI USA, V94, P1426, DOI 10.1073/pnas.94.4.1426; KOTIN RM, 1991, GENOMICS, V10, P831, DOI 10.1016/0888-7543(91)90470-Y; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; Kube DM, 1997, J VIROL, V71, P7361, DOI 10.1128/JVI.71.10.7361-7371.1997; Lam MHC, 2001, J BIOL CHEM, V276, P37700, DOI 10.1074/jbc.M105128200; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Mah C, 1998, J VIROL, V72, P9835, DOI 10.1128/JVI.72.12.9835-9843.1998; MAH C, 1999, GENE THER MOL BIOL, V3, P57; Manno CS, 2003, BLOOD, V101, P2963, DOI 10.1182/blood-2002-10-3296; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Miyata Y, 1997, P NATL ACAD SCI USA, V94, P14500, DOI 10.1073/pnas.94.26.14500; MULLER MT, 1987, J VIROL, V61, P858, DOI 10.1128/JVI.61.3.858-865.1987; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; Nathwani AC, 2000, GENE THER, V7, P183, DOI 10.1038/sj.gt.3301068; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pennisi E, 1998, SCIENCE, V282, P1796; Petit C, 2003, J CELL SCI, V116, P3433, DOI 10.1242/jcs.00613; Ping P., 1996, Microcirculation (Philadelphia), V3, P225, DOI 10.3109/10739689609148292; Ponnazhagan S, 1997, GENE, V190, P203, DOI 10.1016/S0378-1119(96)00576-8; Ponnazhagan S, 1997, J VIROL, V71, P3098, DOI 10.1128/JVI.71.4.3098-3104.1997; Ponnazhagan S, 1997, J VIROL, V71, P8262, DOI 10.1128/JVI.71.11.8262-8267.1997; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; Qing KY, 2001, J VIROL, V75, P8968, DOI 10.1128/JVI.75.19.8968-8976.2001; Qing KY, 2003, J VIROL, V77, P2741, DOI 10.1128/JVI.77.4.2741-2746.2003; Qing KY, 1997, P NATL ACAD SCI USA, V94, P10879, DOI 10.1073/pnas.94.20.10879; Qing KY, 1998, J VIROL, V72, P1593, DOI 10.1128/JVI.72.2.1593-1599.1998; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; Sanlioglu S, 2000, J VIROL, V74, P9184, DOI 10.1128/JVI.74.19.9184-9196.2000; Schlatter H, 2002, BIOCHEM J, V362, P675, DOI 10.1042/0264-6021:3620675; Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Srivastava A, 1996, CURR TOP MICROBIOL, V218, P93; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Suomalainen M, 1999, J CELL BIOL, V144, P657, DOI 10.1083/jcb.144.4.657; Tan MQ, 2001, MOL THER, V3, P940, DOI 10.1006/mthe.2001.0346; Wagner JA, 2002, HUM GENE THER, V13, P1349, DOI 10.1089/104303402760128577; WALSH CE, 1993, P SOC EXP BIOL MED, V204, P289, DOI 10.3181/00379727-204-43665; Wang XS, 1997, J VIROL, V71, P3077, DOI 10.1128/JVI.71.4.3077-3082.1997; Wang XS, 1996, J VIROL, V70, P1668, DOI 10.1128/JVI.70.3.1668-1677.1996; WEBER W, 1984, J BIOL CHEM, V259, P4631; Xiao W, 2002, J VIROL, V76, P11505, DOI 10.1128/JVI.76.22.11505-11517.2002; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; YAKINOGLU AO, 1988, CANCER RES, V48, P3123; Yang ZC, 2003, MOL THER, V7, pS14; Zhao YG, 2001, J BIOL CHEM, V276, P32822, DOI 10.1074/jbc.M105562200; Zhong L, 2002, ANESTHESIOLOGY, V96, P148, DOI 10.1097/00000542-200201000-00028; Zhou SZ, 1996, GENE THER, V3, P223	86	33	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12714	12723		10.1074/jbc.M310548200	http://dx.doi.org/10.1074/jbc.M310548200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711833	hybrid, Green Accepted			2022-12-25	WOS:000220334900085
J	de Jong, RM; Brugman, W; Poelarends, GJ; Whitman, CP; Dijkstra, BW				de Jong, RM; Brugman, W; Poelarends, GJ; Whitman, CP; Dijkstra, BW			The X-ray structure of trans-3-chloroacrylic acid dehalogenase reveals a novel hydration mechanism in the tautomerase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1.8 ANGSTROM RESOLUTION; AMINO-TERMINAL PROLINE; SITE ARGININE RESIDUES; 4-OXALOCROTONATE TAUTOMERASE; CRYSTAL-STRUCTURE; PH-DEPENDENCE; PK(A) VALUES; MUTATIONS; PROGRAM; ENZYME	Isomer-specific 3-chloroacrylic acid dehalogenases function in the bacterial degradation of 1,3-dichloropropene, a compound used in agriculture to kill plant-parasitic nematodes. The crystal structure of the heterohexameric trans-3-chloroacrylic acid dehalogenase (CaaD) from Pseudomonas pavonaceae 170 inactivated by 3-bromopropiolate shows that Glu-52 in the alpha-subunit is positioned to function as the water-activating base for the addition of a hydroxyl group to C-3 of 3-chloroacrylate and 3-bromopropiolate, whereas the nearby Pro-1 in the beta-subunit is positioned to provide a proton to C-2. Two arginine residues, alphaArg-8 and alphaArg-11, interact with the C-1 carboxylate groups, thereby polarizing the alpha,beta-unsaturated acids. The reaction with 3-chloroacrylate results in the production of an unstable halohydrin, 3-chloro-3-hydroxypropanoate, which decomposes into the products malonate semialdehyde and HCl. In the inactivation mechanism, however, malonyl bromide is produced, which irreversibly alkylates the betaPro-1. CaaD is related to 4-oxalocrotonate tautomerase, with which it shares an N-terminal proline. However, in 4-oxalocrotonate tautomerase, Pro-1 functions as a base participating in proton transfer within a hydrophobic active site, whereas in CaaD, the acidic proline is stabilized in a hydrophilic active site. The altered active site environment of CaaD thus facilitates a previously unknown reaction in the tautomerase superfamily, the hydration of the alpha,beta-unsaturated bonds of trans-3-chloroacrylate and 3-bromopropiolate. The mechanism for these hydration reactions represents a novel catalytic strategy that results in carbon-halogen bond cleavage.	Univ Groningen, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA	University of Groningen; University of Texas System; University of Texas Austin	Dijkstra, BW (corresponding author), Univ Groningen, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	B.W.Dijkstra@chem.rug.nl	Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586; Poelarends, Gerrit/0000-0002-6917-6368	NIGMS NIH HHS [GM-65324] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065324] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2002, BIOCHEMISTRY-US, V41, P12010, DOI 10.1021/bi020271h; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; BRUICE PY, 2003, ORGANIC CHEM, P670; CHEN LH, 1992, J BIOL CHEM, V267, P17716; Czerwinski RM, 2001, BIOCHEMISTRY-US, V40, P1984, DOI 10.1021/bi0024714; Czerwinski RM, 1999, BIOCHEMISTRY-US, V38, P12358, DOI 10.1021/bi9911177; Czerwinski RM, 1997, BIOCHEMISTRY-US, V36, P14551, DOI 10.1021/bi971545h; de Jong RM, 2003, EMBO J, V22, P4933, DOI 10.1093/emboj/cdg479; Harris TK, 1999, BIOCHEMISTRY-US, V38, P12343, DOI 10.1021/bi991116e; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ikeda M, 2003, APPL MICROBIOL BIOT, V62, P99, DOI 10.1007/s00253-003-1328-1; Janssen DB, 2003, DEHALOGENATION: MICROBIAL PROCESSES AND ENVIRONMENTAL APPLICATIONS, P207; Janssen DB, 2001, CURR OPIN BIOTECH, V12, P254, DOI 10.1016/S0958-1669(00)00208-1; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P116; Kiefer PM, 2002, BIOCHEMISTRY-US, V41, P1315, DOI 10.1021/bi0117504; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARLETTA MA, 1982, BIOCHEMISTRY-US, V21, P2637, DOI 10.1021/bi00540a010; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Neumann A, 2002, ARCH MICROBIOL, V177, P420, DOI 10.1007/s00203-002-0409-3; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poelarends GJ, 2003, J BIOL CHEM, V278, P48674, DOI 10.1074/jbc.M306706200; Poelarends GJ, 1998, APPL ENVIRON MICROB, V64, P2931; Poelarends GJ, 2001, J BACTERIOL, V183, P4269, DOI 10.1128/JB.183.14.4269-4277.2001; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Ridder IS, 1997, J BIOL CHEM, V272, P33015, DOI 10.1074/jbc.272.52.33015; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P814, DOI 10.1021/bi9510789; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P803, DOI 10.1021/bi951077g; Straus F, 1930, BER DTSCH CHEM GES, V63, P1868, DOI 10.1002/cber.19300630739; Subramanya HS, 1996, BIOCHEMISTRY-US, V35, P792, DOI 10.1021/bi951732k; Taylor AB, 1999, BIOCHEMISTRY-US, V38, P7444, DOI 10.1021/bi9904048; Taylor AB, 1998, BIOCHEMISTRY-US, V37, P14692, DOI 10.1021/bi981607j; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; van Hylckama Vlieg J E, 1991, Biodegradation, V2, P139; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; Wang SC, 2003, J AM CHEM SOC, V125, P14282, DOI 10.1021/ja0370948; Wang SC, 2003, BIOCHEMISTRY-US, V42, P8762, DOI 10.1021/bi034598+; Whitman CP, 2002, ARCH BIOCHEM BIOPHYS, V402, P1, DOI 10.1016/S0003-9861(02)00052-8	45	42	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11546	11552		10.1074/jbc.M311966200	http://dx.doi.org/10.1074/jbc.M311966200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701869	Green Published, hybrid			2022-12-25	WOS:000220157600087
J	Nakano, N; Higashiyama, S; Ohmoto, H; Ishiguro, H; Taniguchi, N; Wada, Y				Nakano, N; Higashiyama, S; Ohmoto, H; Ishiguro, H; Taniguchi, N; Wada, Y			The N-terminal region of NTAK/neuregulin-2 isoforms has an inhibitory activity on angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASES; TUMOR-GROWTH; CELL-GROWTH; RECEPTOR; GENE; ACTIVATION; FAMILY; NEUREGULINS; EXPRESSION	NTAK (neural- and thymus-derived activator for ErbB kinases), also known as neuregulin-2, is a member of the epidermal growth factor (EGF) family, which binds directly to ErbB3 and ErbB4 and transactivates ErbB2. Because ErbB signaling has been implicated in various angiogenic mechanisms, the effect of NTAK (which has at least nine isoforms due to alternative splicing) in angiogenesis is explored. One isoform, NTAKgamma, inhibited cell growth in terms of DNA synthesis and cell numbers in vascular endothelial cells specifically, whereas NTAKalpha and beta had no activity. On the other hand, NTAKgamma secreted by transfected MDA-MB-231 cells inhibited endothelial cell growth, and NTAKgamma expressed in endothelial cells by adenovirus infection suppressed cell growth in a dose-dependent manner. The EGF-like domain of NTAKgamma did not have this activity. The NTAKdelta isoform, which had the Ig-like domain but not the EGF-like domain, inhibited proliferation of endothelial cells. NTAKdelta prevented hyper-phosphorylation of the retinoblastoma tumor suppressor protein and caused G(1) arrest in endothelial cells. Both NTAKgamma and delta isoforms displayed anti-angiogenic activity in the chick embryo chorioallantoic membrane in vivo. These results suggest that the active site of NTAK is localized outside of the EGF-like domain but within the N-terminal region, including the Ig-like domain, of NTAK.	Osaka Med Ctr & Res Inst Maternal & Child Hlth, Dept Mol Med, Osaka 5941101, Japan; Ehime Univ, Sch Med, Dept Med Biochem, Shigenobu, Ehime 7910295, Japan; Carna Biosci Inc, Chuo Ku, Kobe, Hyogo 6508543, Japan; Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Ehime University; Osaka University	Nakano, N (corresponding author), Osaka Med Ctr & Res Inst Maternal & Child Hlth, Dept Mol Med, 840 Murodo Cho, Osaka 5941101, Japan.	nakanon@lab.mch.pref.osaka.jp	Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Busfield SJ, 1997, MOL CELL BIOL, V17, P4007, DOI 10.1128/MCB.17.7.4007; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; ELYAZIDI I, 1995, ANTICANCER RES, V15, P783; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; Hyder SM, 1998, CANCER RES, V58, P392; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Kuba K, 2000, CANCER RES, V60, P6737; Li QF, 2001, J BIOL CHEM, V276, P38068; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; Nakano N, 2000, J BIOCHEM-TOKYO, V127, P925, DOI 10.1093/oxfordjournals.jbchem.a022688; Nakano N, 1999, J BIOCHEM, V125, P368; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Petit AMV, 1997, AM J PATHOL, V151, P1523; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; TANAKA NG, 1986, EXP PATHOL-JENA, V30, P143, DOI 10.1016/S0232-1513(86)80087-1; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamada K, 2000, GENE, V255, P15, DOI 10.1016/S0378-1119(00)00309-7; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	29	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11465	11470		10.1074/jbc.M311045200	http://dx.doi.org/10.1074/jbc.M311045200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722120	hybrid			2022-12-25	WOS:000220157600077
J	Sinha, D; Bannergee, S; Schwartz, JH; Lieberthal, W; Levine, JS				Sinha, D; Bannergee, S; Schwartz, JH; Lieberthal, W; Levine, JS			Inhibition of ligand-independent ERK1/2 activity in kidney proximal tubular cells deprived of soluble survival factors up-regulates Akt and prevents apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL S6 KINASE; 2 DISTINCT PHASES; LYSOPHOSPHATIDIC ACID; PROTEIN; GROWTH; ACTIVATION; PHOSPHORYLATION; TRANSLOCATION; 3-KINASE; PKB/AKT	Mouse kidney proximal tubular epithelial (MK-PT) cells die by apoptosis over 7-10 days when deprived of all survival factors. We show here that withdrawal of all survival factors from MK-PT cells is associated with a progressive increase in the activity of extracellular signal-regulated kinase-1 and -2 (ERK1/2) and a progressive decrease in phosphorylated Akt, a kinase critical to cell survival. Pharmacological inhibition of MEK1/2, the immediate upstream kinase for ERK1/2, not only prevented the decrease in phosphorylated Akt, but also prolonged MK-PT cell survival. Inhibition of ERK1/2, by itself, in the absence of any other known survival factors, was as potent as epidermal growth factor in maintaining MK-PT cell viability. ERK1/2 co-immunoprecipitated with Akt in a multimolecular assembly of signaling molecules, containing at a minimum ERK1/2, Akt, Rsk, and 3-phosphoinositide dependent kinase 1 (PDK1). We hypothesize that the kinase Rsk, whose activation requires phosphorylation by both ERK1/2 and PDK1, acts as a bridge bringing ERK1/2 into proximity with PDK1-associated Akt. Although a number of interactions between the Raf-MEK-ERK and PI3K-Akt signaling pathways have been described, our results are the first to show modulation of Akt activity by signaling events originating with ERK1/2. Spontaneous activation of ERK1/2 occurs via MEK1/2 and appears to depend on oxidant stress, accompanying induction of the default pathway of apoptosis. Together, these data suggest that the spontaneous activation of ERK1/2, in the absence of known extracellular stimuli, represents a previously unrecognized major regulatory pathway determining the fate of cells destined to die by the default pathway of apoptosis.	Univ Chicago, Nephrol Sect, Chicago, IL 60637 USA; Boston Univ, Sch Med, Boston Med Ctr, Renal Sect, Boston, MA 02118 USA	University of Chicago; Boston Medical Center; Boston University	Levine, JS (corresponding author), Univ Chicago, Nephrol Sect, MC-5100,S-506,5841 S Maryland Ave, Chicago, IL 60637 USA.	jlevine@medicine.bsd.uchicago.edu	Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681	NHLBI NIH HHS [HL69722] Funding Source: Medline; NIDDK NIH HHS [DK52898, DK59793] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL069722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052898, R01DK059793] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Balciunaite E, 2000, CURR BIOL, V10, P261, DOI 10.1016/S0960-9822(00)00358-4; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Bergin E, 2000, AM J PHYSIOL-RENAL, V278, pF758, DOI 10.1152/ajprenal.2000.278.5.F758; Blagosklonny MV, 1999, BIOESSAYS, V21, P704, DOI 10.1002/(SICI)1521-1878(199908)21:8<704::AID-BIES10>3.0.CO;2-5; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DINHA D, 2002, AM J PHYSIOL, V284, pF488; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Igleslas J, 1999, AM J PHYSIOL-RENAL, V277, pF711, DOI 10.1152/ajprenal.1999.277.5.F711; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; Levine JS, 1997, AM J PHYSIOL-RENAL, V273, pF575, DOI 10.1152/ajprenal.1997.273.4.F575; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V275, pF691, DOI 10.1152/ajprenal.1998.275.5.F691; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Price VR, 2002, J AM SOC NEPHROL, V13, P1152, DOI 10.1097/01.ASN.0000012609.22035.44; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sinha D, 2003, AM J PHYSIOL-RENAL, V284, pF488, DOI 10.1152/ajprenal.00172.2002; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Torres M, 2003, FRONT BIOSCI, V8, pD369, DOI 10.2741/999; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WILSON NJ, 1988, BIOCHEM BIOPH RES CO, V244, P475; Wright BE, 1999, P NATL ACAD SCI USA, V96, P5089, DOI 10.1073/pnas.96.9.5089; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	45	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10962	10972		10.1074/jbc.M312048200	http://dx.doi.org/10.1074/jbc.M312048200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701865	hybrid			2022-12-25	WOS:000220157600018
J	Tsai, PL; Chen, CH; Huang, CJ; Chou, CM; Chang, GD				Tsai, PL; Chen, CH; Huang, CJ; Chou, CM; Chang, GD			Purification and cloning of an endogenous protein inhibitor of carp nephrosin, an astacin metalloproteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAKE-VENOM METALLOPROTEINASE; RAY CRYSTAL-STRUCTURE; 2 CONSTITUENT PROTEASES; GEL-ELECTROPHORESIS; ZINC-ENDOPEPTIDASE; MATRIX METALLOPROTEINASES; MOLECULAR-STRUCTURE; POLYACRYLAMIDE-GEL; CATALYTIC DOMAIN; HATCHING ENZYME	Nephrosin is a newly discovered member of the astacin family. It is a secreted proteinase and is present in carp head kidney, kidney, and spleen, all of which are responsible for immune and hematopoietic functions in fish. A complex formed by nephrosin and its inhibitor was purified from carp kidney extract by heparin affinity column chromatography. The presence of the nephrosin-inhibitor complex in different tissues was examined by immunoblotting with polyclonal antisera against the purified nephrosin inhibitor and nephrosin. Both nephrosin and the nephrosin inhibitor were present mainly in gill, head kidney, kidney, and spleen. In addition, we have cloned the cDNA encoding the nephrosin inhibitor. There are two different cDNA clones possibly resulting from two different genes, and the long form contains unique tandem repeat sequences in the 3'-end. The deduced primary structure of nephrosin inhibitor is similar to that of fetuin-A, a mammalian protein present in blood, liver, cerebrospinal fluid, and cerebral cortex during fetal development. Treatment with both N-glycosidase F and O-glycosidase removed the carbohydrate moiety of the nephrosin inhibitor and decreased the apparent molecular mass from 40 to 30 kDa. The nephrosin inhibitor seems to be synthesized in liver and then secreted to the blood as a precursor. When it was distributed into hematopoietic tissues, it was processed from 67 to 40 kDa and acquired inhibitory activity. This processing phenomenon of fetuin has not been reported elsewhere. Importantly, the presence of an endogenous inhibitor of nephrosin is the first report of this kind for astacin enzymes. It is very likely that endogenous tissue inhibitors may also be present for the regulation of other astacin enzymes.	Natl Taiwan Univ, Grad Inst Biochem Sci, Taipei 106, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Taipei Med Univ, Dept Biochem, Taipei 117, Taiwan	National Taiwan University; Academia Sinica - Taiwan; Taipei Medical University	Chang, GD (corresponding author), Natl Taiwan Univ, Grad Inst Biochem Sci, POB 23-106, Taipei 106, Taiwan.	gdchang@ccms.ntu.edu.tw						Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; Binkert C, 1999, J BIOL CHEM, V274, P28514, DOI 10.1074/jbc.274.40.28514; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORKAKOTI N, 1994, NAT STRUCT BIOL, V1, P106, DOI 10.1038/nsb0294-106; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brown WM, 1997, PROTEIN SCI, V6, P5; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; CAYATTE AJ, 1990, J BIOL CHEM, V265, P5883; Chen HW, 2001, ELECTROPHORESIS, V22, P1894, DOI 10.1002/1522-2683(200106)22:10<1894::AID-ELPS1894>3.0.CO;2-5; Doherty NS, 1998, ELECTROPHORESIS, V19, P355, DOI 10.1002/elps.1150190234; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; GOMISRUTH FX, 1994, J MOL BIOL, V239, P513, DOI 10.1006/jmbi.1994.1392; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hung CH, 1997, J BIOL CHEM, V272, P13772, DOI 10.1074/jbc.272.21.13772; Hutton M, 1998, BIOCHEMISTRY-US, V37, P10094, DOI 10.1021/bi980616p; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Johnson GD, 1997, J BIOL CHEM, V272, P28126, DOI 10.1074/jbc.272.44.28126; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; LEBRETON JP, 1979, J CLIN INVEST, V64, P1118, DOI 10.1172/JCI109551; LEE KS, 1994, FEBS LETT, V339, P281, DOI 10.1016/0014-5793(94)80431-1; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Perez JC, 1999, TOXICON, V37, P703, DOI 10.1016/S0041-0101(98)00205-0; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Price PA, 2002, J BIOL CHEM, V277, P3926, DOI 10.1074/jbc.M106366200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; STOCKER W, 1995, PROTEIN SCI, V4, P823; Szweras M, 2002, J BIOL CHEM, V277, P19991, DOI 10.1074/jbc.M112234200; Taylor KB, 1996, J BIOL CHEM, V271, P23938, DOI 10.1074/jbc.271.39.23938; Traut R., 1989, PROTEIN FUNCTION PRA, P101; Valente RH, 2001, EUR J BIOCHEM, V268, P3042, DOI 10.1046/j.1432-1327.2001.02199.x; VOGT G, 1989, HISTOCHEMISTRY, V91, P373, DOI 10.1007/BF00493824; Wang HC, 1998, P NATL ACAD SCI USA, V95, P14429, DOI 10.1073/pnas.95.24.14429; YAMAGUCHI T, 1993, BIOCHEMISTRY-US, V113, P299; YAMAKAWA Y, 1992, J BIOCHEM-TOKYO, V112, P583, DOI 10.1093/oxfordjournals.jbchem.a123944; YAN L, 1995, DEVELOPMENT, V121, P1591; YASUMASU S, 1992, DEV BIOL, V149, P349, DOI 10.1016/0012-1606(92)90290-W; YASUMASU S, 1992, DEV BIOL, V153, P250, DOI 10.1016/0012-1606(92)90110-3	52	19	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11146	11155		10.1074/jbc.M310423200	http://dx.doi.org/10.1074/jbc.M310423200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14709555	Green Published, hybrid			2022-12-25	WOS:000220157600039
J	Zwartjes, CGM; Jayne, S; van den Berg, DLC; Timmers, HTM				Zwartjes, CGM; Jayne, S; van den Berg, DLC; Timmers, HTM			Repression of promoter activity by CNOT2, a subunit of the transcription regulatory Ccr4-not complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEADENYLASE; GENE-EXPRESSION; RETINOIC ACID; CAF1 PROTEINS; YEAST; HISTONE; TBP; COMPONENTS; MEDIATOR; NOT2	The evolutionary conserved Ccr4-Not complex controls mRNA metabolism at multiple levels in eukaryotic cells. Genetic analysis of not mutants in yeast identifies a negative role in transcription, which is dependent on core promoter structure. To obtain direct support for this we targeted individual core subunits of the human Ccr4-Not complex to promoters in transient transfections of human cells. In this experimental setup we found that the CNOT2 and CNOT9(hRcd1/hCaf40) subunits act as repressors of reporter gene activity. Interestingly, recruitment of other Ccr4-Not subunits did not affect the reporter gene. The major repression function of CNOT2 is localized in a specialized protein motif, the Not-Box. This conserved motif is present in all CNOT2 orthologs and surprisingly also in CNOT3 orthologs. Repression by the Not-Box was sensitive to treatment with the histone deacetylase inhibitor trichostatin A. In addition, mutation of a canonical TATA-box enhanced repression. Our experiments show for the first time direct regulation of promoter activity by components of the Ccr4-Not complex.	Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Timmers, HTM (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Stratenum STR 3-229,Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	h.t.m.timmers@med.uu.nl./		van den Berg, Debbie L.C./0000-0001-6026-8808				Albert TK, 2002, EMBO J, V21, P355, DOI 10.1093/emboj/21.3.355; Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Aoki T, 2002, BIOCHEM BIOPH RES CO, V296, P1097, DOI 10.1016/S0006-291X(02)02031-4; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Badarinarayana V, 2000, GENETICS, V155, P1045; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; Bai YL, 1999, MOL CELL BIOL, V19, P6642; Benson JD, 1998, EMBO J, V17, P6714, DOI 10.1093/emboj/17.22.6714; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Collart MA, 2003, GENE, V313, P1, DOI 10.1016/S0378-1119(03)00672-3; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; Deluen C, 2002, MOL CELL BIOL, V22, P6735, DOI 10.1128/MCB.22.19.6735-6749.2002; Denis CL, 2003, PROG NUCLEIC ACID RE, V73, P221, DOI 10.1016/S0079-6603(03)01007-9; DERUWE MJ, 2000, THESIS UTRECHT U UTR, P55; Dupressoir A, 2001, BMC Genomics, V2, P9, DOI 10.1186/1471-2164-2-9; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; Hiroi N, 2002, EMBO J, V21, P5235, DOI 10.1093/emboj/cdf521; Johnson KM, 2002, GENE DEV, V16, P1852, DOI 10.1101/gad.995702; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KEAVENEY M, 1993, NATURE, V365, P562, DOI 10.1038/365562a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Maillet L, 2000, J MOL BIOL, V303, P131, DOI 10.1006/jmbi.2000.4131; Makino Y, 1999, MOL CELL BIOL, V19, P7951; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Malik S, 2002, MOL CELL BIOL, V22, P5626, DOI 10.1128/MCB.22.15.5626-5637.2002; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Morel AP, 2003, J CELL SCI, V116, P2929, DOI 10.1242/jcs.00480; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Ricci AR, 2002, MOL CELL BIOL, V22, P4033, DOI 10.1128/MCB.22.12.4033-4042.2002; Russell P, 2002, J MOL BIOL, V322, P27, DOI 10.1016/S0022-2836(02)00707-6; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Swanson MJ, 2003, MOL CELL BIOL, V23, P2800, DOI 10.1128/MCB.23.8.2800-2820.2003; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; van der Eb A J, 1980, Methods Enzymol, V65, P826; Yogosawa S, 1996, BIOCHEM BIOPH RES CO, V229, P612, DOI 10.1006/bbrc.1996.1852; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300	52	45	48	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10848	10854		10.1074/jbc.M311747200	http://dx.doi.org/10.1074/jbc.M311747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707134	hybrid			2022-12-25	WOS:000220157600005
J	Holstein, DM; Berg, KA; Leeb-Lundberg, LMF; Olson, MS; Saunders, C				Holstein, DM; Berg, KA; Leeb-Lundberg, LMF; Olson, MS; Saunders, C			Calcium-sensing receptor-mediated ERK1/2 activation requires G alpha(i2) coupling and dynamin-independent receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CALCIUM; PROTEIN-KINASE; CA2+-SENSING RECEPTOR; PROLIFERATION; EXPRESSION; CELLS; CA2+; PHOSPHORYLATION; STIMULATION; ENDOCYTOSIS	The calcium-sensing receptor (CaR) recently has been shown to activate MAP kinase (ERK1/2) in various cell types as well as in heterologous expression systems. In this study we show that the CaR agonist NPS R-467 (1 muM), which does not activate the CaR by itself, robustly activates ERK1/2 in the presence of a low concentration of Ca2+ (0.5 mM CaCl2) in human embryonic kidney (HEK) cells permanently expressing the human CaR (HEK-hCaR). Ca2+ (4 mM) also activates ERK1/2 but with differing kinetics. CaR-dependent ERK1/2 activation begins to desensitize to 4 mM Ca2+ after 10 min, whereas there is no desensitization to NPS R-467/CaCl2 as late as 4 h. Moreover, recovery from desensitization occurs as rapidly as 30 min with 4 mM CaCl2. Pretreatment of HEK-hCaR cells with concanavalin A (250 mug/ml) to block CaR internalization completely eliminated the NPS R-467/CaCl2-mediated ERK1/2 activation but did not block the 2-min time point of 4 mM Ca2+-mediated ERK1/2 activation. Neither dominant-negative dynamin (K44A) nor dominant-negative beta-arrestin inhibited ERK1/2 activation by either CaR agonist treatment, suggesting that CaR- elicited ERK1/2 signaling occurs via a dynamin-independent pathway. Pertussis toxin pretreatment partially attenuated the 4 mM Ca2+-ERK1/2 activation; this attenuated activity was completely restored by co-expression of the Galpha(i2)(C351I) but not Galpha(i1)(C351I) or Galpha(i3)(C351I) G proteins, PTX-insensitive G protein mutants. Taken together, these data suggest that both 4 mM Ca2+ and NPS R-467/CaCl2 activate ERK1/2 via distinguishable pathways in HEK-hCaR cells and may represent a nexus to differentially regulate differentiation versus proliferation via CaR activation.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA	Vanderbilt University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Saunders, C (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 417B Preston Res Bldg, Nashville, TN 37232 USA.	christine.saunders@vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879, K01DK002852] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-02852, DK-43879] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Bennett VJ, 2002, J PHARMACOL EXP THER, V303, P1155, DOI 10.1124/jpet.102.040378; Bilderback TR, 2002, AM J PHYSIOL-CELL PH, V283, pC282, DOI 10.1152/ajpcell.00437.2001; Blaukat A, 1999, FEBS LETT, V451, P337, DOI 10.1016/S0014-5793(99)00613-4; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1998, RECENT PROG HORM RES, V53, P257; Brown EM, 1997, HORM RES, V48, P199, DOI 10.1159/000185516; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15; Bruce JIE, 1999, J BIOL CHEM, V274, P20561, DOI 10.1074/jbc.274.29.20561; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Chattopadhyay N, 1997, BIOCHEM BIOPH RES CO, V233, P801, DOI 10.1006/bbrc.1997.6553; Chattopadhyay N, 1997, BIOL CHEM, V378, P759; Chattopadhyay N, 1999, BRAIN RES, V851, P116, DOI 10.1016/S0006-8993(99)02132-0; Chattopadhyay N, 1996, AM J PHYSIOL-RENAL, V271, pF736, DOI 10.1152/ajprenal.1996.271.3.F736; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Delmas P, 1999, J PHYSIOL-LONDON, V518, P23, DOI 10.1111/j.1469-7793.1999.0023r.x; Diaz R, 1997, AM J PHYSIOL-REG I, V273, pR1008, DOI 10.1152/ajpregu.1997.273.3.R1008; Dutour A, 1996, EUR J ENDOCRINOL, V134, P542, DOI 10.1530/eje.0.1340542; Hammerland LG, 1998, MOL PHARMACOL, V53, P1083; Handlogten ME, 2001, J BIOL CHEM, V276, P13941, DOI 10.1074/jbc.M007306200; Handlogten ME, 2000, AM J PHYSIOL-RENAL, V279, pF1083, DOI 10.1152/ajprenal.2000.279.6.F1083; Hinson TK, 1997, GENOMICS, V45, P279, DOI 10.1006/geno.1997.4943; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Hobson SA, 2000, EXP CELL RES, V258, P1, DOI 10.1006/excr.2000.4910; Hoff Ana O., 1999, Neoplasia (New York), V1, P485; Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Kallay E, 1997, BIOCHEM BIOPH RES CO, V232, P80, DOI 10.1006/bbrc.1997.6225; Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448; Kifor O, 2001, AM J PHYSIOL-RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MacLeod RJ, 2003, AM J PHYSIOL-ENDOC M, V284, pE435, DOI 10.1152/ajpendo.00143.2002; McNeil L, 1998, AM J OBSTET GYNECOL, V178, P305, DOI 10.1016/S0002-9378(98)80017-3; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Oda Y, 1998, J BIOL CHEM, V273, P23344, DOI 10.1074/jbc.273.36.23344; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; ROGERS KV, 1995, J BONE MINER RES, V10, pS483; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Tang H, 2000, J BIOL CHEM, V275, P13420, DOI 10.1074/jbc.275.18.13420; TOEWS ML, 1984, J BIOL CHEM, V259, P1844; Vargas-Poussou R, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000025781.16723.68; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Ward DT, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015623.73739.B8; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Yamaguchi T, 1998, J BONE MINER RES, V13, P1530, DOI 10.1359/jbmr.1998.13.10.1530; Yamaguchi T, 2000, BIOCHEM BIOPH RES CO, V279, P363, DOI 10.1006/bbrc.2000.3955; Ye CP, 1996, BIOCHEM BIOPH RES CO, V226, P572, DOI 10.1006/bbrc.1996.1396	53	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10060	10069		10.1074/jbc.M312039200	http://dx.doi.org/10.1074/jbc.M312039200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701866	hybrid			2022-12-25	WOS:000220050400050
J	Sato, N; Fukushima, N; Matsubayashi, H; Goggins, M				Sato, N; Fukushima, N; Matsubayashi, H; Goggins, M			Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling	ONCOGENE			English	Article						hypomethylation; maspin; SERPINB5; S100P; microarray	TUMOR-SUPPRESSOR GENE; HUMAN BREAST-CANCER; DNA METHYLATION; ABERRANT METHYLATION; CPG-ISLANDS; EPITHELIAL-CELLS; MULTIPLE GENES; DUCTAL ADENOCARCINOMA; PLASMINOGEN-ACTIVATOR; OVARIAN-CARCINOMA	DNA hypomethylation is one of the major epigenetic alterations in human cancers. We have previously shown that genes identified as hypomethylated in pancreatic cancer are expressed in pancreatic cancer cell lines, but not in normal pancreatic ductal epithelium and can be reexpressed in nonexpressing cells using 'epigenetic modifying agents' such as DNA methyltransferase inhibitors. To identify additional targets for aberrant hypomethylation in pancreatic cancer, we used oligonucleotide microarrays to screen for genes that displayed expression patterns associated with hypomethylation. This analysis identified a substantial number of candidates including previously reported hypomethylated genes. A subset of eight genes were selected for further methylation analysis, and two cancer-related genes, maspin and S100P, were found to be aberrantly hypomethylated in a large fraction of pancreatic cancer cell lines and primary pancreatic carcinomas. Combined treatment with 5-aza-2'-deoxycytidie and trichostatin A resulted in synergistic induction of maspin and S100P mRNA in MiaPaCa2 cells where both genes were methylated. Furthermore, there was an inverse correlation between methylation and mRNA expression level for maspin and S100P in a large panel of pancreatic cancer cell lines. We also found a significant difference in the methylation patterns of maspin and two previously identified hypomethylated genes (trefoil factor 2 and lipocalin 2) between pancreatic and breast cancer cell lines, suggesting cancer-type specificity for some hypomethylation patterns. Thus, our present results confirm that DNA hypomethylation is a frequent epigenetic event in pancreatic cancer, and suggest that gene expression pro. ling may help to identify potential targets affected by this epigenetic alteration.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA090709, P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924, CA90709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Da Silva IDCG, 2000, INT J ONCOL, V16, P231; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Diaz VM, 2002, GASTROENTEROLOGY, V122, P806, DOI 10.1053/gast.2002.31885; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2001, CANCER RES, V61, P3225; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Goggins M, 1999, ANN ONCOL, V10, P4, DOI 10.1023/A:1008307913019; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Gupta A, 2003, CANCER RES, V63, P664; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Koltzscher M, 2003, MOL BIOL CELL, V14, P2372, DOI 10.1091/mbc.E02-09-0553; Liang G, 2002, CANCER RES, V62, P961; Logsdon CD, 2003, CANCER RES, V63, P2649; Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8; Maass N, 2001, CLIN CANCER RES, V7, P812; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Matsubayashi H, 2003, CLIN CANCER RES, V9, P1446; Mousses S, 2002, CANCER RES, V62, P1256; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Ryu B, 2002, CANCER RES, V62, P819; Sato N, 2003, CANCER RES, V63, P4158; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Sato N, 2003, CANCER RES, V63, P3735; Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sood AK, 2002, CLIN CANCER RES, V8, P2924; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	52	124	141	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1531	1538		10.1038/sj.onc.1207269	http://dx.doi.org/10.1038/sj.onc.1207269			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716296				2022-12-25	WOS:000189219500006
J	Machwe, A; Xiao, LR; Orren, DK				Machwe, A; Xiao, LR; Orren, DK			TRF2 recruits the Werner syndrome (WRN) exonuclease for processing of telomeric DNA	ONCOGENE			English	Article						telomeres; Werner syndrome; RecQ helicases; cellular senescence; aging; cancer	SYNDROME PROTEIN; MAMMALIAN TELOMERES; SYNDROME CELLS; IN-VITRO; REPLICATION; BINDING; LENGTH; CANCER; MAINTENANCE; HELICASES	The cancer-prone and premature aging disease Werner syndrome is due to loss of WRN gene function. Cells lacking WRN demonstrate genomic instability, including telomeric abnormalities and undergo premature senescence, suggesting defects in telomere metabolism. This notion is strongly supported by our finding of physical and functional interactions between WRN and TRF2, a telomeric repeat binding factor essential for proper telomeric structure. TRF2 binds to DNA substrates containing telomeric repeats and facilitates their degradation specifically by WRN exonuclease activity. WRN and TRF2 also interact directly in the absence of DNA. These results suggest that TRF2 recruits WRN for accurate processing of telomeric structures in vivo. Thus, our findings link problems in telomere maintenance to both carcinogenesis and specific features of aging.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Kentucky	Orren, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 326 HSRB,800 Rose St, Lexington, KY 40536 USA.	dkorre2@pop.uky.edu						Ancelin K, 2002, MOL CELL BIOL, V22, P3474, DOI 10.1128/MCB.22.10.3474-3487.2002; Bianchi A, 1999, EMBO J, V18, P5735, DOI 10.1093/emboj/18.20.5735; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lundblad V, 2002, ONCOGENE, V21, P522, DOI 10.1038/sj.onc.1205079; Machwe A, 2002, J BIOL CHEM, V277, P4492, DOI 10.1074/jbc.M108880200; MARTIN GM, 1970, LAB INVEST, V23, P86; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Orren DK, 2002, BIOCHEMISTRY-US, V41, P13483, DOI 10.1021/bi0266986; Oshima J, 2000, BIOESSAYS, V22, P894, DOI 10.1002/1521-1878(200010)22:10<894::AID-BIES4>3.0.CO;2-B; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Schulz VP, 1996, HUM GENET, V97, P750; Shay JW, 2001, RADIAT RES, V155, P188, DOI 10.1667/0033-7587(2001)155[0188:TATIFC]2.0.CO;2; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Stansel RM, 2001, EMBO J, V20, P5532; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630	32	97	99	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					149	156		10.1038/sj.onc.1206906	http://dx.doi.org/10.1038/sj.onc.1206906			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712220				2022-12-25	WOS:000187895300016
J	Gao, YT; Smith, SME; Weinberg, JB; Montgomery, HJ; Newman, E; Guillemette, JG; Ghosh, DK; Roman, LJ; Martasek, P; Salerno, JC				Gao, YT; Smith, SME; Weinberg, JB; Montgomery, HJ; Newman, E; Guillemette, JG; Ghosh, DK; Roman, LJ; Martasek, P; Salerno, JC			Thermodynamics of oxidation-reduction reactions in mammalian nitric-oxide synthase Isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDOX PROPERTIES; MOLECULAR-CLONING; FLAVIN; EXPRESSION; BRAIN; INDUCTION; SUBSTRATE; RELEASE; P-450; HEME	The three mammalian nitric-oxide synthases produce NO from arginine in a reaction requiring 3 electrons per NO, which are supplied to the catalytic center from NADPH through reductase domains incorporating FAD and FMN cofactors. The isoforms share a common reaction mechanism and requirements for reducing equivalents but differ in regulation; the endothelial and neuronal isoforms are controlled by calcium/calmodulin modulation of the electron transfer system, while the inducible isoform binds calmodulin at all physiological Ca2+ concentrations and is always on. The thermodynamics of electron transfer through the flavin domains in all three isoforms are basically similar. The major flavin states are FMN, FMNH., FMNH2, FAD, FADH(.), and FADH(2). The FMN/FMNH. couple is high potential ( similar to 100 mV) in all three isoforms and is unlikely to be catalytically competent; the other three flavin couples form a nearly isopotential group clustered around - 250 mV. Reduction of the flavins by the pyridine nucleotide couple at - 325 mV is thus moderately thermodynamically favorable. The ferri/ferroheme couple in all three isoforms is similar to - 270 mV in the presence of saturating arginine. Ca2+/calmodulin has no effect on the potentials of any of the couples in endothelial nitric-oxide synthase ( eNOS) or neuronal nitric-oxide synthase ( nNOS). The pH dependence of the flavin couples suggests the presence of ionizable groups coupled to the flavin redox/ protonation states.	Rensselaer Polytech Inst, Dept Biol, Troy, NY 12180 USA; Duke Univ, Dept Med, Durham, NC 27705 USA; Vet Affairs Med Ctr, Durham, NC 27705 USA; Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada; Univ Texas, SW Hlth Ctr, Dept Biochem, San Antonio, TX 78284 USA	Rensselaer Polytechnic Institute; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Waterloo; University of Texas System	Salerno, JC (corresponding author), Rensselaer Polytech Inst, Dept Biol, 110 8th St, Troy, NY 12180 USA.	salerj@rpi.edu	Martásek, Pavel/G-6622-2017; salerno, john c/A-2595-2014	Martásek, Pavel/0000-0001-6165-4444; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52419] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; Du M, 2003, J BIOL CHEM, V278, P6002, DOI 10.1074/jbc.M209606200; Dutton P L, 1978, Methods Enzymol, V54, P411; FURCHGOTT R F, 1988, P401; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Ghosh DK, 2001, P NATL ACAD SCI USA, V98, P10392, DOI 10.1073/pnas.181251298; GUNSALUS IC, 1976, BIOCHIMIE, V58, P143, DOI 10.1016/S0300-9084(76)80364-1; HAUSCHILDT S, 1990, BIOCHEM J, V270, P351, DOI 10.1042/bj2700351; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCCALL TB, 1989, BIOCHEM J, V261, P293, DOI 10.1042/bj2610293; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno J. C., 2002, Nitric Oxide, V6, P458; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SLIGAR SG, 1979, BIOCHEM BIOPH RES CO, V90, P925, DOI 10.1016/0006-291X(79)91916-8; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; Stuehr D J, 1995, Adv Pharmacol, V34, P207; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	36	51	52	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18759	18766		10.1074/jbc.M308936200	http://dx.doi.org/10.1074/jbc.M308936200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14715665	hybrid			2022-12-25	WOS:000221041500083
J	Dubrovay, Z; Gaspari, Z; Hunyadi-Gulyes, E; Medzihradszky, KF; Perczel, A; Vertessy, BG				Dubrovay, Z; Gaspari, Z; Hunyadi-Gulyes, E; Medzihradszky, KF; Perczel, A; Vertessy, BG			Multidimensional NMR identifies the conformational shift essential for catalytic competence in the 60-kDa Drosophila melanogaster dUTPase trimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS-ANEMIA VIRUS; ESCHERICHIA-COLI; C-TERMINUS; KINETIC CHARACTERIZATION; SUBSTRATE-ANALOG; LIGAND-BINDING; ACTIVE-SITE; PYROPHOSPHATASE; TRIPHOSPHATE; PHOSPHORYLASE	The catalytic mechanism of dUTP pyrophosphatase (dUTPase), responsible for the prevention of uracil incorporation into DNA, involves ordering of the flexible C terminus of the enzyme. This conformational shift is investigated by multidimensional NMR on the Drosophila enzyme. Flexible segments of the homotrimer give rise to sharp resonances in the (1)H-(15)N heteronuclear single-quantum coherence (HSQC) spectra, which are clearly distinguishable from the background resonances of the well folded protein globule. Binding of the product dUMP or the analogues dUDP and alpha,beta-imino-dUTP to the enzyme induces a conformational change reflected in the disappearance of eight sharp resonances. This phenomenon is interpreted as nucleotide binding-induced ordering of some residues upon the folded protein globule. Three-dimensional (15)N-edited (1)H-(15)N HSQC total correlation spectroscopy (TOCSY) and (1)H-(15)N HSQC nuclear Overhauser effect spectroscopy measurements allowed clear assignment of these eight specific resonance peaks. The residues identified correspond to the conserved C-terminal sequence motif, indicating that (i) this conformational shift is amenable to NMR studies in solution even in the large trimeric molecule and (ii) formation of the closed enzyme conformer in the case of the Drosophila enzyme does not require the complete triphosphate chain of the substrate. NMR titration of the enzyme with the nucleotide ligands as well as kinetic data indicated significant deviation from the model of independent active sites within the homotrimer. The results suggest allosterism in the eukaryotic dUTPase.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary; Eotvos Lorand Univ, Dept Organ Chem, H-1518 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Mass Spectrometry Facil, H-6701 Szeged, Hungary; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; University of California System; University of California San Francisco	Vertessy, BG (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	vertessy@enzim.hu	Gáspári, Zoltán/D-9594-2011; Vertessy, Beata G/H-6202-2012	Gáspári, Zoltán/0000-0002-8692-740X; Hunyadi-Gulyas, Eva/0000-0003-2089-1499; Vertessy, Beata G./0000-0002-1288-2982				Fiser A, 2000, BIOCHEM BIOPH RES CO, V279, P534, DOI 10.1006/bbrc.2000.3994; Hill A.V, 1910, J PHYSL, V40, piv, DOI DOI 10.1113/JPHYSIOL.1910.SP001386; HUDSON JW, 1993, J MOL BIOL, V234, P700, DOI 10.1006/jmbi.1993.1621; Kovari J, 2004, J BIOL CHEM, V279, P17932, DOI 10.1074/jbc.M313643200; LARSEN M, 1969, SCIENCE, V166, P1510, DOI 10.1126/science.166.3912.1510; Larsson G, 1996, J BIOL CHEM, V271, P24010, DOI 10.1074/jbc.271.39.24010; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; Nord J, 2001, FEBS LETT, V492, P228, DOI 10.1016/S0014-5793(01)02257-8; Nord J, 2000, FEBS LETT, V472, P312, DOI 10.1016/S0014-5793(00)01453-8; Nyman PO, 2001, CURR PROTEIN PEPT SC, V2, P277, DOI 10.2174/1389203013381071; Persson T, 1996, BIOORGAN MED CHEM, V4, P553, DOI 10.1016/0968-0896(96)00044-2; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; Prasad GS, 2001, CURR PROTEIN PEPT SC, V2, P301, DOI 10.2174/1389203013381017; Rath VL, 1996, STRUCTURE, V4, P463, DOI 10.1016/S0969-2126(96)00051-2; Shao H, 1997, BBA-PROTEIN STRUCT M, V1339, P181, DOI 10.1016/S0167-4838(96)00229-4; TRIPOS I, 1998, SYBYL VERSION 6 5; Venters RA, 2002, J MOL STRUCT, V602, P275, DOI 10.1016/S0022-2860(01)00690-1; Vertessy BG, 1996, BIOCHEM BIOPH RES CO, V219, P294, DOI 10.1006/bbrc.1996.0226; Vertessy BG, 1997, PROTEINS, V28, P568, DOI 10.1002/(SICI)1097-0134(199708)28:4<568::AID-PROT10>3.0.CO;2-E; Vertessy BG, 1998, FEBS LETT, V421, P83, DOI 10.1016/S0014-5793(97)01545-7; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2490, DOI 10.1021/bi00789a010	22	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17945	17950		10.1074/jbc.M313644200	http://dx.doi.org/10.1074/jbc.M313644200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14724273	hybrid			2022-12-25	WOS:000220870400128
J	Sau, AK; Li, ZL; Anderson, KS				Sau, AK; Li, ZL; Anderson, KS			Probing the role of metal ions in the catalysis of Helicobacter pylori 3-deoxy-D-manno-octulosonate-8-phosphate synthase using a transient kinetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7-PHOSPHATE DAHP SYNTHETASE; 8-PHOSPHATE SYNTHASE; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE BIOSYNTHESIS; KDO8P SYNTHASE; MECHANISM; AEOLICUS; ACID; PHOSPHOENOLPYRUVATE; STEREOCHEMISTRY	3-Deoxy-D-manno-2-octulosonate-8-phosphate (KDO8P) synthase catalyzes the net condensation of phosphoenolpyruvate and D-arabinose 5-phosphate to form KDO8P and inorganic phosphate (Pi). Two classes of KDO8P synthases have been identified. The Class I KDO8P synthases (e. g. Escherchia coli KDO8P synthase) catalyze the condensation reaction in a metal-independent fashion, whereas the Class II enzymes (e. g. Aquifex aeolicus) require metal ions for catalysis. Helicobacter pylori (H. pylori) KDO8P synthase, a Zn2+- dependent metalloenzyme, has recently been found to be a Class II enzyme and has a high degree of clinical significance since it is an attractive molecular target for the design of novel antibiotic therapy. Although the presence of a divalent metal ion in Class II KDO8P synthases is essential for catalysis, there is a paucity of mechanistic information on the role of the metal ions and functional differences as compared with Class I enzymes. Using H. pylori KDO8P synthase as a prototypical Class II enzyme, a steady-state and transient kinetic approach was undertaken to understand the role of the metal ion in catalysis and define the kinetic reaction pathway. Metal reconstitution experiments examining the reaction kinetics using Zn2+, Cd2+, Cu2+, Co2+, Mn2+, and Ni2+ yielded surprising results in that the Cd2+ enzyme has the greatest activity. Unlike Class-I KDO8P synthases, the Class II metallo-KDO8P synthases containing Zn2+, Cd2+, Cu2+, and Co2+ show cooperativity. This study presents the first detailed kinetic characterization of a metal-dependent Class II KDO8P synthase and offers mechanistic insight for how the divalent metal ions modulate catalysis through effects on chemistry as well as quaternary protein structure.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	karen.anderson@yale.edu			NIGMS NIH HHS [GM61413] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON L, 1983, ACS S SERIES, V231; Baasov T, 2000, DRUG DEVELOP RES, V50, P416; Birck MR, 2001, J MOL EVOL, V52, P205, DOI 10.1007/s002390010149; Blaser MJ, 1998, BRIT MED J, V316, P1507, DOI 10.1136/bmj.316.7143.1507; BLASER MJ, 1992, CLIN INFECT DIS, V15, P386, DOI 10.1093/clind/15.3.386; Brabetz W, 2000, PLANTA, V212, P136, DOI 10.1007/s004250000459; COVER TL, 1992, ANNU REV MED, V43, P135, DOI 10.1146/annurev.me.43.020192.001031; DELEO AB, 1968, BIOCHEM BIOPH RES CO, V32, P873, DOI 10.1016/0006-291X(68)90322-7; DELEO AB, 1973, J BIOL CHEM, V248, P2344; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; Duewel HS, 2001, J BIOL CHEM, V276, P8393, DOI 10.1074/jbc.M007884200; Duewel HS, 2000, J BIOL CHEM, V275, P22824, DOI 10.1074/jbc.M000133200; EIDT S, 1995, EUR J GASTROEN HEPAT, V7, P318; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; Hunt RH, 1996, SCAND J GASTROENTERO, V31, P3, DOI 10.3109/00365529609094743; INOUYE M, 1979, BACTERIAL OUTER MEMB; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; KOHEN A, 1993, BIOORG MED CHEM LETT, V3, P1577, DOI 10.1016/S0960-894X(00)80021-9; KOHEN A, 1992, EUR J BIOCHEM, V208, P443, DOI 10.1111/j.1432-1033.1992.tb17206.x; Krosky DJ, 2002, BBA-PROTEIN STRUCT M, V1594, P297, DOI 10.1016/S0167-4838(01)00319-3; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; Li ZL, 2003, J AM CHEM SOC, V125, P9938, DOI 10.1021/ja0354768; Liang PH, 1997, BIOORG MED CHEM LETT, V7, P2463; Liang PH, 1998, BIOCHEMISTRY-US, V37, P16390, DOI 10.1021/bi981374w; ONDERKA DK, 1969, BIOCHEM BIOPH RES CO, V35, P801, DOI 10.1016/0006-291X(69)90694-9; ONDERKA DK, 1969, J AM CHEM SOC, V91, P5894, DOI 10.1021/ja01049a046; Perez-Canadillas JM, 1998, BIOCHEMISTRY-US, V37, P15865, DOI 10.1021/bi981672t; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAY PH, 1980, J BACTERIOL, V141, P635, DOI 10.1128/JB.141.2.635-644.1980; SHULAMI S, 2003, IN PRESS EXTREMOPHIL; Shumilin IA, 1999, STRUCTURE, V7, P865, DOI 10.1016/S0969-2126(99)80109-9; Stolte, 1998, Oncologist, V3, P124; Subramaniam PS, 1998, J BACTERIOL, V180, P119, DOI 10.1128/JB.180.1.119-127.1998; Walsh AG, 1999, FEMS MICROBIOL LETT, V173, P27, DOI 10.1111/j.1574-6968.1999.tb13480.x; Walsh CT, 1996, CHEM BIOL, V3, P83, DOI 10.1016/S1074-5521(96)90282-3	36	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15787	15794		10.1074/jbc.M308989200	http://dx.doi.org/10.1074/jbc.M308989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14701842	hybrid			2022-12-25	WOS:000220747900013
J	Lee, JL; Lin, CT; Chueh, LL; Chang, CJ				Lee, JL; Lin, CT; Chueh, LL; Chang, CJ			Autocrine/paracrine secreted Frizzled-related protein 2 induces cellular resistance to apoptosis - A possible mechanism of mammary tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL EXPRESSION; EXTRACELLULAR-MATRIX; INHIBIT MOTILITY; FIBRONECTIN; CANCER; CELLS; RECEPTOR; INTEGRIN; OVARIAN; GROWTH	Abnormal regulation of apoptosis and cell proliferation is thought to be involved in tumor formation. The secreted Frizzled-related protein 2 (SFRP2) was detected in primary culture of canine mammary gland tumors but not in normal mammary tissues. Thus, to elucidate the role of SFRP2 in mammary tumorigenesis, we overexpressed SFRP2 in mammary gland tumor and MCF7 cells. The results indicated that SFRP2 is secreted and incorporated into the extracellular matrix (ECM) of the tumor and normal cells. In an attempt to understand the molecular basis underlying the interaction between SFRP2 and ECM, co-immunoprecipitation and cell adhesion assays were carried out. SFRP2 was found to be associated with the fibronectin-integrin protein complex and could promote cell adhesion. DNA fragmentation and caspase 3 activity analyses showed that the susceptibility of the cells to UV-induced apoptosis decreased in the context of SFRP2 overexpression. Upon disruption of the fibronectin-integrin connection, the antiapoptosis activity of SFRP2 was decreased. Moreover, SFRP2 was found to induce tumorous transformation in normal mammary epithelial cells and to inhibit apoptosis in a modified paracrine model. Collectively, our results emphasize the relevance of SFRP2 and ECM in mammary tumorigenesis and provide further insight into the mechanism of SFRP2 action.	Acad Sinica, Inst Biol Chem, Taipei 106, Taiwan; Natl Taiwan Univ, Coll Bioresources & Agr, Dept & Grad Inst Vet Med, Taipei 10764, Taiwan	Academia Sinica - Taiwan; National Taiwan University	Chang, CJ (corresponding author), Acad Sinica, Inst Biol Chem, 1,Sect 4,Roosevelt Rd, Taipei 106, Taiwan.	chingjin@gate.sinica.edu.tw	Chang, Ching-Jin/G-4511-2019	Lee, Jia-Lin/0000-0002-6984-1313; Chang, Ching-Jin/0000-0001-7129-8092				Abu-Jawdeh G, 1999, LAB INVEST, V79, P439; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Cosgrove RH, 2002, SEMIN THROMB HEMOST, V28, P79, DOI 10.1055/s-2002-20566; Dale TC, 1996, CANCER RES, V56, P4320; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Das SK, 2000, J BIOL CHEM, V275, P28834, DOI 10.1074/jbc.M003827200; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; HUGUET EL, 1994, CANCER RES, V54, P2615; Jones SE, 2000, INVEST OPHTH VIS SCI, V41, P1297; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Kakkar AK, 1999, BMJ-BRIT MED J, V318, P1571, DOI 10.1136/bmj.318.7198.1571; Kim AS, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-05-j0002.2001; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Lee JL, 2003, IN VITRO CELL DEV-AN, V39, P221; LEE JL, 2004, IN PRESS BREAST CANC; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin CT, 1997, NUCLEIC ACIDS RES, V25, P4427, DOI 10.1093/nar/25.21.4427; Lin CT, 2001, BIOCHEM BIOPH RES CO, V282, P394, DOI 10.1006/bbrc.2001.4587; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PRICE JE, 1990, CANCER RES, V50, P717; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Ruest LB, 2002, J BIOL CHEM, V277, P5418, DOI 10.1074/jbc.M110685200; RUOSLAHTI E, 1981, J BIOL CHEM, V256, P7277; Schleger C, 1997, EXP CELL RES, V236, P418, DOI 10.1006/excr.1997.3744; Smorenburg SM, 2001, PHARMACOL REV, V53, P93; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Woodward TL, 2001, ENDOCRINOLOGY, V142, P3214, DOI 10.1210/en.142.7.3214; Woodward TL, 2000, ENDOCRINOLOGY, V141, P3578, DOI 10.1210/en.141.10.3578; Xu Y, 2001, J BIOL CHEM, V276, P34990, DOI 10.1074/jbc.M103661200	51	74	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14602	14609		10.1074/jbc.M309008200	http://dx.doi.org/10.1074/jbc.M309008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14709558	Green Submitted, hybrid, Green Published			2022-12-25	WOS:000220594700018
J	Eckhardt, ERM; Cai, L; Sun, B; Webb, NR; van der Westhuyzen, DR				Eckhardt, ERM; Cai, L; Sun, B; Webb, NR; van der Westhuyzen, DR			High density lipoprotein uptake by scavenger receptor SR-BII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B TYPE-I; MICROVILLAR CHANNEL FORMATION; CHOLESTERYL ESTER UPTAKE; SELECTIVE LIPID UPTAKE; HDL PARTICLE UPTAKE; APOPROTEIN-A-I; CELL-SURFACE; APOLIPOPROTEIN-E; ADRENAL-CELLS; METABOLISM	Scavenger receptor class B, type I (SR-BI) mediates selective uptake of high density lipoprotein (HDL) lipids. It is unclear whether this process occurs at the cell membrane or via endocytosis. Our group previously identified an alternative mRNA splicing variant of SR-BI, named SR-BII, with an entirely different, yet highly conserved cytoplasmic C terminus. In this study we aimed to compare HDL uptake by both isoforms. Whereas SR-BI was mainly (similar to70%) localized on the surface of transfected Chinese hamster ovary cells, as determined by biotinylation, HDL binding at 4 degreesC, and studies of enhanced green fluorescent protein-tagged SR-BI/II fusion proteins, the majority of SR-BII ( similar to 80-90%) was expressed intracellularly. The cellular distribution of SR-BI was not affected by deletion of the C terminus, which suggests that the distinct C terminus of SR-BII is responsible for its intracellular expression. Pulse-chase experiments showed that SR-BII rapidly internalized HDL protein, whereas in the case of SR-BI most HDL protein remained surface bound. Like its ligand, SR-BII was more rapidly endocytosed compared with SR-BI. Despite more rapid HDL uptake by SR-BII than SR-BI, selective cholesteryl ether uptake was significantly lower. Relative to their levels of expression at the cell surface, however, both isoforms mediated selective uptake with similar efficiency. HDL protein that was internalized by SR-BII largely co-localized with transferrin in the endosomal recycling compartment. Within the endosomal recycling compartment of SR-BII cells, there was extensive co-localization of internalized HDL lipid and protein. These results do not support a model that selective lipid uptake by SR-BI requires receptor/ligand recycling within the cell. We conclude that SR-BII may influence cellular cholesterol trafficking and homeostasis in a manner that is distinct from SR-BI.	Univ Kentucky, Med Ctr, Dept Internal Med, MN 520, Lexington, KY 40536 USA; Dept Vet Affairs Med Ctr, Lexington, KY 40536 USA	University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	van der Westhuyzen, DR (corresponding author), Univ Kentucky, Med Ctr, Dept Internal Med, MN 520, 800 Rose St, Lexington, KY 40536 USA.	dvwest1@uky.edu	Webb, Nancy/AAL-7030-2021; Sun, Bing/D-3758-2009; Eckhardt, Erik/G-1567-2010	Eckhardt, Erik/0000-0002-3015-5180	NHLBI NIH HHS [HL63763] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063763] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ALAM R, 1989, BIOCHIM BIOPHYS ACTA, V1004, P292, DOI 10.1016/0005-2760(89)90076-3; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; Connelly MA, 2001, BIOCHEMISTRY-US, V40, P5249, DOI 10.1021/bi002825r; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756; Farkas MH, 2003, J BIOL CHEM, V278, P9412, DOI 10.1074/jbc.M208026200; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; Graf GA, 2001, J LIPID RES, V42, P1444; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; Heeren J, 2003, J BIOL CHEM, V278, P14370, DOI 10.1074/jbc.M209006200; Heeren J, 2001, J BIOL CHEM, V276, P42333, DOI 10.1074/jbc.M107461200; HEROLD G, 1994, LIPIDS, V29, P735, DOI 10.1007/BF02536694; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Liu B, 2002, J BIOL CHEM, V277, P34125, DOI 10.1074/jbc.M204265200; Mardones P, 2001, J LIPID RES, V42, P170; McGwire GB, 1999, J BIOL CHEM, V274, P31632, DOI 10.1074/jbc.274.44.31632; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Reaven E, 2001, P NATL ACAD SCI USA, V98, P1613, DOI 10.1073/pnas.98.4.1613; Reaven E, 2000, J LIPID RES, V41, P343; Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037; RINNINGER F, 1994, ATHEROSCLEROSIS, V105, P145, DOI 10.1016/0021-9150(94)90044-2; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; ROGLER G, 1992, GASTROENTEROLOGY, V103, P469, DOI 10.1016/0016-5085(92)90836-N; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 2002, J BIOL CHEM, V277, P34042, DOI 10.1074/jbc.M206584200; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Trigatti BL, 2003, ARTERIOSCL THROM VAS, V23, P1732, DOI 10.1161/01.ATV.0000091363.28501.84; Vishnyakova TG, 2003, J BIOL CHEM, V278, P22771, DOI 10.1074/jbc.M211032200; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Webb NR, 1997, J LIPID RES, V38, P1490; Williams DL, 2002, J LIPID RES, V43, P544	44	85	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14372	14381		10.1074/jbc.M313793200	http://dx.doi.org/10.1074/jbc.M313793200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726519	hybrid			2022-12-25	WOS:000220478500133
J	Fu, Y; Hoang, A; Escher, G; Parton, RG; Krozowski, Z; Sviridov, D				Fu, Y; Hoang, A; Escher, G; Parton, RG; Krozowski, Z; Sviridov, D			Expression of caveolin-1 enhances cholesterol efflux in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; RECEPTOR CLASS-B; CELLULAR CHOLESTEROL; PLASMA-MEMBRANE; SR-BI; INTRACELLULAR CHOLESTEROL; ENDOPLASMIC-RETICULUM; SELECTIVE UPTAKE; MEDIATED EXPRESSION	HepG2 cells were stably transfected with human caveolin-1 (HepG2/cav cells). Transfection resulted in expression of caveolin-1 mRNA, a high abundance of caveolin-1 protein, and the formation of caveolae on the plasma membrane. Cholesterol efflux from HepG2/cav cells was 280 and 45% higher than that from parent HepG2 cells when human plasma and human apoA-I, respectively, were used as acceptors. The difference in efflux was eliminated by treatment of cells with progesterone. There was no difference in cholesterol efflux to cyclodextrin. Cholesterol efflux from plasma membrane vesicles was similar for the two cell types. Transfection led to a 40% increase in the amount of plasma membrane cholesterol in cholesterol-rich domains ( caveolae and/or rafts) and a 67% increase in the rate of cholesterol trafficking from intracellular compartments to these domains. Cholesterol biosynthesis in HepG2/cav cells was increased by 2-fold, and cholesterol esterification was reduced by 50% compared with parent HepG2 cells. The proliferation rate of transfected cells was significantly lower than that of non-transfected cells. Transfection did not affect expression of ABCA1 or the abundance of ABCA1 protein, but decreased secretion of apoA-I. We conclude that overexpression of caveolin-1 in hepatic cells stimulates cholesterol efflux by enhancing transfer of cholesterol to cholesterol-rich domains in the plasma membrane.	Baker Heart Res Inst, Melbourne, Vic 8008, Australia; Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	Baker Heart and Diabetes Institute; University of Queensland; University of Queensland	Sviridov, D (corresponding author), Baker Heart Res Inst, Wynn Domain,St Kilda Rd Cent,POB 6492, Melbourne, Vic 8008, Australia.	Dmitri.Sviridov@Baker.edu.au	Sviridov, Dmitri/E-7943-2010; Parton, Robert G/C-5673-2009	Parton, Robert G/0000-0002-7494-5248; fu, ying/0000-0002-1261-3336; Escher, Genevieve/0000-0002-5125-2262				Arakawa R, 2000, J LIPID RES, V41, P1952; Barter P, 2003, ATHEROSCLEROSIS, V168, P195, DOI 10.1016/S0021-9150(03)00006-6; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; BELLINI F, 1984, BIOCHIM BIOPHYS ACTA, V777, P209, DOI 10.1016/0005-2736(84)90422-X; Briand O, 2003, BBA-MOL CELL BIOL L, V1631, P42, DOI 10.1016/S1388-1981(02)00354-2; Chao WT, 2003, J LIPID RES, V44, P1094, DOI 10.1194/jlr.M300033-JLR200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Escher G, 2003, J BIOL CHEM, V278, P11015, DOI 10.1074/jbc.M212780200; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; Fielding CJ, 2003, BBA-BIOMEMBRANES, V1610, P219, DOI 10.1016/S0005-2736(03)00020-8; Fielding PE, 1996, BIOCHEMISTRY-US, V35, P14932, DOI 10.1021/bi9613382; Fielding PE, 2002, BIOCHEMISTRY-US, V41, P4929, DOI 10.1021/bi012091y; Frank PG, 2002, BIOCHEMISTRY-US, V41, P11931, DOI 10.1021/bi0257078; Frank PG, 2001, AM J PHYSIOL-CELL PH, V280, pC1204, DOI 10.1152/ajpcell.2001.280.5.C1204; Frank PG, 2001, BIOCHEMISTRY-US, V40, P10892, DOI 10.1021/bi0106437; Fujimoto T, 2000, J CELL SCI, V113, P3509; Gargalovic P, 2003, J LIPID RES, V44, P11, DOI 10.1194/jlr.R200005-JLR200; Gaus K, 2001, BIOCHEMISTRY-US, V40, P13002, DOI 10.1021/bi010833h; Hailstones D, 1998, J LIPID RES, V39, P369; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; Ishiguro H, 2001, J BIOL CHEM, V276, P36742, DOI 10.1074/jbc.M106027200; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Joyce C, 2003, ARTERIOSCL THROM VAS, V23, P965, DOI 10.1161/01.ATV.0000055194.85073.FF; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; Major AS, 2001, ARTERIOSCL THROM VAS, V21, P1790, DOI 10.1161/hq1101.097798; Matveev S, 2001, EUR J BIOCHEM, V268, P5609, DOI 10.1046/j.1432-1033.2001.02496.x; MORRISON JR, 1990, ANAL BIOCHEM, V186, P145, DOI 10.1016/0003-2697(90)90588-Z; Okazaki H, 2002, J BIOL CHEM, V277, P31893, DOI 10.1074/jbc.M204016200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Peterson TE, 2003, ARTERIOSCL THROM VAS, V23, P1521, DOI 10.1161/01.ATV.0000081743.35125.05; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Su YR, 2002, J LIPID RES, V43, P2180, DOI 10.1194/jlr.D200020-JLR200; SVIRIDOV D, 1995, BBA-LIPID LIPID MET, V1256, P210, DOI 10.1016/0005-2760(95)00028-B; Sviridov D, 1999, PROTEIN EXPRES PURIF, V17, P231, DOI 10.1006/prep.1999.1114; SVIRIDOV D, 1995, J LIPID RES, V36, P1887; Sviridov D, 2002, ATHEROSCLEROSIS, V161, P245, DOI 10.1016/S0021-9150(01)00677-3; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; Sviridov D, 2001, BIOCHEM J, V358, P79, DOI 10.1042/0264-6021:3580079; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; URBANI L, 1990, J BIOL CHEM, V265, P1919; Wang LB, 2003, J LIPID RES, V44, P807, DOI 10.1194/jlr.M200449-JLR200; Williams DL, 2002, J LIPID RES, V43, P544; Zhang ZY, 2001, ATHEROSCLEROSIS, V159, P67, DOI 10.1016/S0021-9150(01)00490-7	48	92	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14140	14146		10.1074/jbc.M311061200	http://dx.doi.org/10.1074/jbc.M311061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729661	hybrid			2022-12-25	WOS:000220478500104
J	Havaux, M; Dall'Osto, L; Cuine, S; Giuliano, G; Bassi, R				Havaux, M; Dall'Osto, L; Cuine, S; Giuliano, G; Bassi, R			The effect of zeaxanthin as the only xanthophyll on the structure and function of the photosynthetic apparatus in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; CHLOROPHYLL A/B PROTEIN; ACID-DEFICIENT MUTANTS; PHOTOSYSTEM-II; ANTENNA COMPLEX; VIOLAXANTHIN CYCLE; BINDING-SITES; BETA-CAROTENE; LHC PROTEINS; IN-VITRO	In green plants, the xanthophyll carotenoid zeaxanthin is synthesized transiently under conditions of excess light energy and participates in photoprotection. In the Arabidopsis lut2 npq2 double mutant, all xanthophylls were replaced constitutively by zeaxanthin, the only xanthophyll whose synthesis was not impaired. The relative proportions of the different chlorophyll antenna proteins were strongly affected with respect to the wild-type strain. The major antenna, LHCII, did not form trimers, and its abundance was strongly reduced as was CP26, albeit to a lesser extent. In contrast, CP29, CP24, LHCI proteins, and the PSI and PSII core complexes did not undergo major changes. PSII-LHCII supercomplexes were not detectable while the PSI-LHCI supercomplex remained unaffected. The effect of zeaxanthin accumulation on the stability of the different Lhc proteins was uneven: the LHCII proteins from lut2 npq2 had a lower melting temperature as compared with the wild-type complex while LHCI showed increased resistance to heat denaturation. Consistent with the loss of LHCII, light-state 1 to state 2 transitions were suppressed, the photochemical efficiency in limiting light was reduced and photosynthesis was saturated at higher light intensities in lut2 npq2 leaves, resulting in a photosynthetic phenotype resembling that of high light-acclimated leaves. Zeaxanthin functioned in vivo as a light-harvesting accessory pigment in lut2 npq2 chlorophyll antennae. As a whole, the in vivo data are consistent with the results obtained by using recombinant Lhc proteins reconstituted in vitro with purified zeaxanthin. While PSII photoinhibition was similar in wild type and lut2 npq2 exposed to high light at low temperature, the double mutant was much more resistant to photooxidative stress and lipid peroxidation than the wild type. The latter observation is consistent with an antioxidant and lipid protective role of zeaxanthin in vivo.	Univ Mediterranee, CEA 1000,CNRS,UMR 163, Lab Ecophysiol Photosynth, CEA Cadarache,DSV,DEVM, F-13108 St Paul Les Durance, France; Univ Verona, Dipartimento Sci Tecnol, I-37134 Verona, Italy; ENEA, Casaccia Res Ctr, I-00100 Rome AD, Italy; Univ Meditarranee, CNRS,UMR 163, CEA Cadarache, DSV,DEVM,Lab Genet & Biophys Plantes, F-13288 Marseille 09, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Verona; Italian National Agency New Technical Energy & Sustainable Economics Development; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Havaux, M (corresponding author), Univ Mediterranee, CEA 1000,CNRS,UMR 163, Lab Ecophysiol Photosynth, CEA Cadarache,DSV,DEVM, F-13108 St Paul Les Durance, France.	michel.havaux@cea.fr	Giuliano, Giovanni/A-2701-2012; Dall'Osto, Luca/A-9384-2010	Giuliano, Giovanni/0000-0002-2486-0510; bassi, roberto/0000-0002-4140-8446; Dall'Osto, Luca/0000-0001-9497-5156				ADAMS WW, 1995, AUST J PLANT PHYSIOL, V22, P75, DOI 10.1071/PP9950075; Bailey S, 2001, PLANTA, V213, P794, DOI 10.1007/s004250100556; Baroli I, 2003, PLANT CELL, V15, P992, DOI 10.1105/tpc.010405; Baroli I, 1998, PLANTA, V205, P288, DOI 10.1007/s004250050323; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V935, P152, DOI 10.1016/0005-2728(88)90212-5; Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; BAZDA V, 1996, BIOCHEMISTRY-US, V35, P8981; Caffarri S, 2001, J BIOL CHEM, V276, P35924, DOI 10.1074/jbc.M105199200; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Davison PA, 2002, NATURE, V418, P203, DOI 10.1038/nature00861; Demmig-Adams B, 2000, NATURE, V403, P371, DOI 10.1038/35000315; DUCKHAM SC, 1991, PLANT CELL ENVIRON, V14, P601, DOI 10.1111/j.1365-3040.1991.tb01531.x; Eskling M, 1997, PHYSIOL PLANTARUM, V100, P806, DOI 10.1034/j.1399-3054.1997.1000407.x; Espineda CE, 1999, P NATL ACAD SCI USA, V96, P10507, DOI 10.1073/pnas.96.18.10507; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; Frank HA, 2001, BIOCHEMISTRY-US, V40, P1220, DOI 10.1021/bi001160q; Garab G, 2002, BIOCHEMISTRY-US, V41, P15121, DOI 10.1021/bi026157g; Gastaldelli M, 2003, J BIOL CHEM, V278, P19190, DOI 10.1074/jbc.M212125200; Gotz T, 2002, PLANT MOL BIOL, V50, P129, DOI 10.1023/A:1016072218801; Gussakovsky EE, 1997, PHOTOSYNTH RES, V51, P119, DOI 10.1023/A:1005775720376; HAGER A, 1994, PLANTA, V192, P581, DOI 10.1007/BF00203597; Harrer R, 1998, EUR J BIOCHEM, V255, P196, DOI 10.1046/j.1432-1327.1998.2550196.x; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Havaux M, 2003, TRENDS PLANT SCI, V8, P409, DOI 10.1016/S1360-1385(03)00185-7; Havaux M, 2003, PLANT PHYSIOL, V132, P300, DOI 10.1104/pp.102.017178; Havaux M, 1997, PLANT PHYSIOL, V113, P913, DOI 10.1104/pp.113.3.913; Havaux M, 2001, PLANTA, V213, P953, DOI 10.1007/s004250100572; Havaux M, 2000, PLANT PHYSIOL, V124, P273, DOI 10.1104/pp.124.1.273; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Hurry V, 1997, PLANT PHYSIOL, V113, P639, DOI 10.1104/pp.113.2.639; Kulheim C, 2002, SCIENCE, V297, P91, DOI 10.1126/science.1072359; Lee JW, 2002, APPL BIOCHEM BIOTECH, V98, P37, DOI 10.1385/ABAB:98-100:1-9:37; LIM BP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P178; Lokstein H, 2002, BBA-BIOENERGETICS, V1553, P309, DOI 10.1016/S0005-2728(02)00184-6; MALKIN S, 1981, PLANT PHYSIOL, V67, P570, DOI 10.1104/pp.67.3.570; MALKIN S, 1994, ANNU REV PLANT PHYS, V45, P493, DOI 10.1146/annurev.pp.45.060194.002425; Meurer J, 1996, PLANTA, V198, P385, DOI 10.1007/BF00620055; Morosinotto T, 2003, PHYSIOL PLANTARUM, V119, P347, DOI 10.1034/j.1399-3054.2003.00213.x; Morosinotto T, 2002, J BIOL CHEM, V277, P36253, DOI 10.1074/jbc.M205062200; Morosinotto T, 2002, J BIOL CHEM, V277, P36913, DOI 10.1074/jbc.M205339200; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; MULLERMOULE P, 2003, PLANT PHYSIOL, DOI DOI 10.1104/PP103.025320; MURRAY DL, 1991, PLANT MOL BIOL, V16, P71, DOI 10.1007/BF00017918; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; PALOZZA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P184, DOI 10.1016/0003-9861(92)90658-J; Pesaresi P, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL IV, P95; PETER GF, 1991, J BIOL CHEM, V266, P16745; Pogson B, 1996, PLANT CELL, V8, P1627, DOI 10.1105/tpc.8.9.1627; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; Polivka T, 2002, BIOCHEMISTRY-US, V41, P439, DOI 10.1021/bi011589x; Polle JEW, 2001, PLANT CELL PHYSIOL, V42, P482, DOI 10.1093/pcp/pce058; ROBINSON HH, 1980, BIOCHIM BIOPHYS ACTA, V590, P97, DOI 10.1016/0005-2728(80)90149-8; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; Ruban AV, 2003, NATURE, V421, P648, DOI 10.1038/nature01344; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Tardy F, 1996, J PHOTOCH PHOTOBIO B, V34, P87, DOI 10.1016/1011-1344(95)07272-1; TYYSTJARVI E, 1994, BBA-BIOENERGETICS, V1186, P177, DOI 10.1016/0005-2728(94)90177-5; TYYSTJARVI E, 1991, PLANT PHYSIOL, V97, P477, DOI 10.1104/pp.97.2.477; Vavilin DV, 1998, PHOTOCHEM PHOTOBIOL, V68, P191, DOI 10.1111/j.1751-1097.1998.tb02488.x; WALTERS RG, 1994, PLANTA, V195, P248, DOI 10.1007/BF00199685; WISE RR, 1995, PHOTOSYNTH RES, V45, P79, DOI 10.1007/BF00032579; Yakushevska AE, 2003, BIOCHEMISTRY-US, V42, P608, DOI 10.1021/bi027109z; YAMAMOTO HY, 1979, PURE APPL CHEM, V51, P639, DOI 10.1351/pac197951030639; Yang DH, 2000, FEBS LETT, V466, P385, DOI 10.1016/S0014-5793(00)01107-8; Yang DH, 1998, PLANT PHYSIOL, V118, P827, DOI 10.1104/pp.118.3.827	66	133	140	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13878	13888		10.1074/jbc.M311154200	http://dx.doi.org/10.1074/jbc.M311154200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722117	hybrid			2022-12-25	WOS:000220478500074
J	Kallen, J; Schlaeppi, JM; Bitsch, F; Delhon, I; Fournier, B				Kallen, J; Schlaeppi, JM; Bitsch, F; Delhon, I; Fournier, B			Crystal structure of the human ROR alpha ligand binding domain in complex with cholesterol sulfate at 2.2 angstrom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID; NUCLEAR; DISRUPTION; METABOLISM	The retinoic acid-related orphan receptor alpha (RORalpha) is an orphan member of the subfamily 1 of nuclear hormone receptors. Our recent structural and functional studies have led to the hypothesis that cholesterol or a cholesterol derivative is the natural ligand of RORalpha. We have now solved the x-ray crystal structure of the ligand binding domain of RORalpha in complex with cholesterol-3-O-sulfate following a ligand exchange experiment. In contrast to the 3-hydroxyl of cholesterol, the 3-O-sulfate group makes additional direct hydrogen bonds with three residues of the RORalpha ligand binding domain, namely NH-Gln(289), NH-Tyr(290), and NH1-Arg(370). When compared with the complex with cholesterol, seven well ordered water molecules have been displaced, and the ligand is slightly shifted toward the hydrophilic part of the ligand binding pocket, which is ideally suited for interactions with a sulfate group. These additional ligand-protein interactions result in an increased affinity of cholesterol sulfate when compared with cholesterol, as shown by mass spectrometry analysis done under native conditions and differential scanning calorimetry. Moreover, mutational studies show that the higher binding affinity of cholesterol sulfate translates into an increased transcriptional activity of RORalpha. Our findings suggest that cholesterol sulfate could play a crucial role in the regulation of RORalpha in vivo.	Novartis Pharma AG, Prot Struct Unit, Discovery Technol, CH-4002 Basel, Switzerland; Novartis Pharma AG, Biomol Prod Unit, Discovery Technol, CH-4002 Basel, Switzerland; Novartis Pharma AG, Bone Metab Unit, Arthrit & Bone Metab, CH-4002 Basel, Switzerland	Novartis; Novartis; Novartis	Kallen, J (corresponding author), Novartis Pharma AG, Prot Struct Unit, Discovery Technol, CH-4002 Basel, Switzerland.	joerg.kallen@pharma.novartis.com; brigitte.fournier@pharma.novartis.com						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bitsch F, 2003, ANAL BIOCHEM, V323, P139, DOI 10.1016/j.ab.2003.08.029; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; EPSTEIN EH, 1981, SCIENCE, V214, P659, DOI 10.1126/science.6945674; Falany JL, 2002, BREAST CANCER RES TR, V74, P167, DOI 10.1023/A:1016147004188; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Hanley K, 2001, J LIPID RES, V42, P390; Jarvis CI, 2002, MOL CELL ENDOCRINOL, V186, P1, DOI 10.1016/S0303-7207(01)00668-2; JETTEN AM, 1989, J INVEST DERMATOL, V92, P203, DOI 10.1111/1523-1747.ep12276731; Jetten AM, 2001, PROG NUCLEIC ACID RE, V69, P205, DOI 10.1016/S0079-6603(01)69048-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kashiwagi M, 2002, J BIOCHEM, V132, P853, DOI 10.1093/oxfordjournals.jbchem.a003297; Kawabe S, 1998, J INVEST DERMATOL, V111, P1098, DOI 10.1046/j.1523-1747.1998.00441.x; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN YN, 1980, STEROIDS, V36, P697, DOI 10.1016/0039-128X(80)90052-5; MASON JI, 1982, ENDOCRINOLOGY, V111, P208, DOI 10.1210/endo-111-1-208; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKAGAWA M, 1976, J BIOCHEM-TOKYO, V80, P729, DOI 10.1093/oxfordjournals.jbchem.a131333; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qian YM, 2001, ENDOCRINOLOGY, V142, P5342, DOI 10.1210/en.142.12.5342; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Stehlin-Gaon C, 2003, NAT STRUCT BIOL, V10, P820, DOI 10.1038/nsb979; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; Strott CA, 2003, J LIPID RES, V44, P1268, DOI 10.1194/jlr.R300005-JLR200; Strott CA, 2002, ENDOCR REV, V23, P703, DOI 10.1210/er.2001-0040; Tsutsui K, 2003, J STEROID BIOCHEM, V85, P311, DOI 10.1016/S0960-0760(03)00229-2; WILLIAMS ML, 1981, J CLIN INVEST, V68, P1404, DOI 10.1172/JCI110391; WILLIAMS ML, 1985, BIOCHIM BIOPHYS ACTA, V845, P349, DOI 10.1016/0167-4889(85)90198-3	31	178	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14033	14038		10.1074/jbc.M400302200	http://dx.doi.org/10.1074/jbc.M400302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722075	hybrid, Green Published			2022-12-25	WOS:000220478500092
J	Rameau, GA; Chiu, LY; Ziff, EB				Rameau, GA; Chiu, LY; Ziff, EB			Bidirectional regulation of neuronal nitric-oxide synthase phosphorylation at serine 847 by the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; AUTOINHIBITORY CONTROL ELEMENT; ISCHEMIC-STROKE; TERNARY COMPLEX; ACID RECEPTOR; NMDA; GLUTAMATE; CALCINEURIN; INDUCTION	At glutamatergic synapses, the scaffolding protein PSD95 links the neuronal isoform of nitric-oxide synthase (nNOS) to the N-methyl-D-aspartate (NMDA) receptor. Phosphorylation of nNOS at serine 847 (Ser(847)) by the calcium-calmodulin protein kinase II (CaMKII) inhibits nNOS activity, possibly by blocking the binding of Ca2+-CaM. Here we show that the NMDA mediates a novel bidirectional regulation of Ser(847) phosphorylation. nNOS phosphorylated at Ser(847) colocalizes with the NMDA receptor at spines of cultured hippocampal neurons. Treatment of neurons with 5 muM glutamate stimulated CaMKII phosphorylation of nNOS at Ser(847), whereas excitotoxic concentrations of glutamate, 100 and 500 muM, induced Ser(847)-PO4 dephosphorylation by protein phosphatase 1. Strong NMDA receptor stimulation was likely to activate nNOS under these conditions because protein nitration to form nitrotyrosine, a marker of nNOS activity, correlated in individual neurons with Ser(847)-PO4 dephosphorylation. Of particular note, stimulation with low glutamate that increased phosphorylation of nNOS at Ser(847) could be reversed by subsequent high glutamate treatment which induced dephosphorylation. The reversibility of NMDA receptor-induced phosphorylation at Ser(847) by different doses of glutamate suggests two mechanisms with opposite effects: 1) a time-dependent negative feedback induced by physiological concentrations of glutamate that limits nNOS activation and precludes the overproduction of NO; and 2) a pathological stimulation by high concentrations of glutamate that leads to unregulated nNOS activation and production of toxic levels of NO. These mechanisms may share pathways, respectively, with NMDA receptor-induced forms of synaptic plasticity and excitotoxicity.	NYU, Sch Med, Howard Hughes Med Inst, Dept Biochem, New York, NY 10016 USA	Howard Hughes Medical Institute; New York University	Ziff, EB (corresponding author), NYU, Sch Med, Howard Hughes Med Inst, Dept Biochem, 550 1st Ave, New York, NY 10016 USA.	edward.ziff@med.nyu.edu		Ziff, Edward/0000-0001-7389-8649	NIA NIH HHS [R01 AG13620] Funding Source: Medline; NIEHS NIH HHS [ES00260] Funding Source: Medline; NINDS NIH HHS [NS 07457-04] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013620] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; Aronowski J, 2000, J CEREBR BLOOD F MET, V20, P343, DOI 10.1097/00004647-200002000-00016; Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; Ayata C, 1997, J NEUROSCI, V17, P6908; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1997, DEV NEUROSCI-BASEL, V19, P224, DOI 10.1159/000111211; Brown GP, 2000, J NEUROSCI, V20, P7880; Burette A, 2002, J NEUROSCI, V22, P8961; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1994, PROG BRAIN RES, V100, P47; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; Cohen PTW, 2002, J CELL SCI, V115, P241; CONNOR JA, 1988, SCIENCE, V240, P649, DOI 10.1126/science.2452481; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; Dawson T M, 1993, NIDA Res Monogr, V136, P258; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Dawson VL, 1996, J NEUROSCI, V16, P2479; Diamond JS, 1997, J NEUROSCI, V17, P4672; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Eliasson MJL, 1999, J NEUROSCI, V19, P5910, DOI 10.1523/JNEUROSCI.19-14-05910.1999; Eliasson MJL, 1997, P NATL ACAD SCI USA, V94, P3396, DOI 10.1073/pnas.94.7.3396; Esplugues JV, 2002, BRIT J PHARMACOL, V135, P1079, DOI 10.1038/sj.bjp.0704569; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Franks KM, 2002, BIOESSAYS, V24, P1130, DOI 10.1002/bies.10193; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Hansel C, 1996, J PHYSIOLOGY-PARIS, V90, P317, DOI 10.1016/S0928-4257(97)87906-5; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hasegawa Y, 2003, J CEREBR BLOOD F MET, V23, P1040, DOI 10.1097/01.WCB.0000085160.71791.3F; Hayashi Y, 1999, J BIOL CHEM, V274, P20597, DOI 10.1074/jbc.274.29.20597; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Jaffrey SR, 2002, P NATL ACAD SCI USA, V99, P3199, DOI 10.1073/pnas.261705799; Kang-Park MH, 2003, J NEUROPHYSIOL, V89, P684, DOI 10.1152/jn.01041.2001; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; Komeima K, 2000, J BIOL CHEM, V275, P28139; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lane P, 2000, ACTA PHYSIOL SCAND, V168, P53; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; Nishi A, 2002, J NEUROCHEM, V81, P832, DOI 10.1046/j.1471-4159.2002.00876.x; Rameau GA, 2003, NEUROBIOL AGING, V24, P1123, DOI 10.1016/j.neurobiolaging.2003.07.002; Rameau GA, 2000, NEUROPHARMACOLOGY, V39, P2255, DOI 10.1016/S0028-3908(00)00066-6; Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Sattler R, 2000, J MOL MED, V78, P3, DOI 10.1007/s001090000077; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; Springer JE, 2000, J NEUROSCI, V20, P7246; Zanelli SA, 2002, NEUROSCIENCE, V112, P869, DOI 10.1016/S0306-4522(02)00141-0; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	71	98	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14307	14314		10.1074/jbc.M311103200	http://dx.doi.org/10.1074/jbc.M311103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722119	hybrid			2022-12-25	WOS:000220478500125
J	Rosini, P; De Chiara, G; Bonini, P; Lucibello, M; Marcocci, ME; Garaci, E; Cozzolino, F; Torcia, M				Rosini, P; De Chiara, G; Bonini, P; Lucibello, M; Marcocci, ME; Garaci, E; Cozzolino, F; Torcia, M			Nerve growth factor-dependent survival of CESS B cell line is mediated by increased expression and decreased degradation of MAPK phosphatase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BCL-2 PHOSPHORYLATION; P38 MAPK; TYROSINE-PHOSPHATASE; INDUCED APOPTOSIS; CONDITIONAL EXPRESSION; SYMPATHETIC NEURONS; MKP-1; INHIBITION; STRESS	The sIgG(+) lymphoblastoid B cell line CESS spontaneously produces a high amount of nerve growth factor (NGF) and expresses both high affinity (p140(Trk-A)) and low affinity (p75(NTR)) NGF receptors. Autocrine production of NGF maintains the survival of CESS cells through the continuous deactivation of p38 MAPK, an enzyme able to induce Bcl-2 phosphorylation and subsequent cytochrome c release and caspase activation. In this paper, we show that NGF induces transcriptional activation and synthesis of MAPK phosphatase 1 (MKP-1), a dual specificity phosphatase that dephosphorylates p38 MAPK, thus preventing Bcl-2 phosphorylation. Furthermore, NGF increases MKP-1 protein stability by preventing its degradation through the proteasome pathway. Following NGF stimulation, MKP-1 protein mainly localizes on mitochondria, suggesting an interaction with p38 MAPK in this compartment. Incubation of CESS cells with MKP-1-specific antisense oligonucleotides induces cell death, which was not prevented by exogenous NGF. By contrast, overexpression of native MKP-1, but not of its catalytically impaired form, inhibits apoptosis induced by NGF neutralization in CESS cells. Thus, the molecular mechanisms underlying the survival function of NGF in CESS B cell line predominantly consist in maintaining elevated levels of MKP-1 protein, which controls p38 MAPK activation.	Univ Florence, Dept Clin Physiopathol, I-50139 Florence, Italy; Univ Roma Tor Vergata, Dept Expt Med, I-00133 Rome, Italy; CNR, Inst Neurobiol & Mol Med, I-00133 Rome, Italy	University of Florence; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR)	Torcia, M (corresponding author), Univ Florence, Dept Clin Physiopathol, Viale Pieraccini 6, I-50139 Florence, Italy.	g.torcia@dfc.unifi.it	Elena, Marcocci Maria/I-9550-2014; Torcia, Maria Gabriella G/K-1840-2018; De Chiara, Giovanna/AAJ-7843-2021; lucibello, maria/AAI-1417-2020; GARACI, ENRICO/AAB-3349-2021	Elena, Marcocci Maria/0000-0003-4751-4263; Torcia, Maria Gabriella G/0000-0003-4740-4646; De Chiara, Giovanna/0000-0002-2219-6097; Cozzolino, Federico/0000-0002-2800-640X				ALESSI DR, 1993, ONCOGENE, V8, P2015; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 1997, CANCER RES, V57, P130; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen PL, 2002, J IMMUNOL, V169, P6408, DOI 10.4049/jimmunol.169.11.6408; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; FRANKLIN RA, 1995, J IMMUNOL, V154, P4965; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Guo YL, 1998, J BIOL CHEM, V273, P10362, DOI 10.1074/jbc.273.17.10362; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jacob A, 2002, AM J PHYSIOL-CELL PH, V283, pC704, DOI 10.1152/ajpcell.00110.2002; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Katoh S, 1996, BIOCHEM BIOPH RES CO, V229, P653, DOI 10.1006/bbrc.1996.1859; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Muda M, 1996, J BIOL CHEM, V271, P4319; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Pathan N, 2001, NEOPLASIA, V3, P70, DOI 10.1038/sj.neo.7900131; Peinado-Ramon P, 1998, MOL BRAIN RES, V56, P256, DOI 10.1016/S0169-328X(98)00047-3; Pincelli C, 2000, J DERMATOL SCI, V22, P71, DOI 10.1016/S0923-1811(99)00065-1; Ridderstad A, 1998, J IMMUNOL, V160, P4688; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; Ryser S, 2001, J BIOL CHEM, V276, P33319, DOI 10.1074/jbc.M102326200; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; WHITMARSH AJ, 1999, SCI STKE; Wiltshire C, 2002, BIOCHEM J, V367, P577, DOI 10.1042/BJ20020553; Xu QH, 2002, J BIOL CHEM, V277, P41693, DOI 10.1074/jbc.M207095200; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	55	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14016	14023		10.1074/jbc.M305356200	http://dx.doi.org/10.1074/jbc.M305356200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724291	hybrid, Green Published			2022-12-25	WOS:000220478500090
J	Dale, LB; Seachrist, JL; Babwah, AV; Ferguson, SSG				Dale, LB; Seachrist, JL; Babwah, AV; Ferguson, SSG			Regulation of angiotensin II type 1A receptor intracellular retention, degradation, and recycling by Rab5, Rab7, and Rab11 GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; DOWN-REGULATION; MEDIATED ENDOCYTOSIS; GTP-BINDING; SUBSTANCE-P; TRAFFICKING; INTERNALIZATION; MECHANISMS	Previous studies have demonstrated that the interaction of the angiotensin II type 1A receptor (AT(1A)R) carboxylterminal tail with Rab5a may modulate Rab5a activity, leading to the homotypic fusion of endocytic vesicles. Therefore, we have investigated whether AT(1A)R/Rab5a interactions mediate the retention of AT(1A)R.beta-arrestin complexes in early endosomes and whether the overexpression of Rab7 and Rab11 GTPases influences AT(1A)R lysosomal degradation and plasma membrane recycling. We found that internalized AT(1A)R was retained in Rab5a-positive early endosomes and was neither targeted to lysosomes nor recycled back to the cell surface, whereas a mutant defective in Rab5a binding, AT(1A)R-(1 - 349), was targeted to lysosomes for degradation. However, the loss of Rab5a binding to the AT(1A)R carboxyl-terminal tail did not promote AT(1A)R recycling. Rather, it was the stable binding of beta-arrestin to the AT(1A)R that prevented, at least in part, AT1AR recycling. The overexpression of wild-type Rab7 and Rab7-Q67L resulted in both increased AT(1A)R degradation and AT(1A)R targeting to lysosomes. The Rab7 expression-dependent transition of "putative" AT(1A)R.beta-arrestin complexes to late endosomes was blocked by the expression of dominant-negative Rab5a-S34N. Rab11 overexpression established AT(1A)R recycling and promoted the redistribution of AT(1A)R.beta-arrestin complexes from early to recycling endosomes. Taken together, our data suggest that Rab5, Rab7, and Rab11 work in concert with one another to regulate the intracellular trafficking patterns of the AT(1A)R.	John P Robarts Res Inst, Cell Biol Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Ferguson, SSG (corresponding author), John P Robarts Res Inst, Cell Biol Res Grp, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.	ferguson@robarts.ca						Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Fan GH, 2003, BLOOD, V101, P2115, DOI 10.1182/blood-2002-07-1965; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Kreuzer OJ, 2001, J NEUROENDOCRINOL, V13, P279, DOI 10.1046/j.1365-2826.2001.00630.x; Li JG, 2000, MOL PHARMACOL, V58, P795, DOI 10.1124/mol.58.4.795; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; Moore RH, 1999, J CELL SCI, V112, P329; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Paasche JD, 2001, J BIOL CHEM, V276, P34041, DOI 10.1074/jbc.M103243200; Rodman JS, 2000, J CELL SCI, V113, P183; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Schmidlin F, 2001, J BIOL CHEM, V276, P25427, DOI 10.1074/jbc.M101688200; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Seachrist JL, 2002, J BIOL CHEM, V277, P679, DOI 10.1074/jbc.M109022200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Touyz RM, 2000, PHARMACOL REV, V52, P639; Trischler M, 1999, J CELL SCI, V112, P4773; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Volpicelli LA, 2002, J NEUROSCI, V22, P9776, DOI 10.1523/jneurosci.22-22-09776.2002; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	40	98	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13110	13118		10.1074/jbc.M313333200	http://dx.doi.org/10.1074/jbc.M313333200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711821	hybrid			2022-12-25	WOS:000220334900132
J	Abad, MFC; Di Benedetto, G; Magalhaes, PJ; Filippin, L; Pozzan, T				Abad, MFC; Di Benedetto, G; Magalhaes, PJ; Filippin, L; Pozzan, T			Mitochondrial pH monitored by a new engineered green fluorescent protein mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVING CELLS; INTACT-CELLS; CA2+; CALCIUM; VARIANTS; HOMEOSTASIS; APOPTOSIS; SECRETION; TRANSPORT; INDICATOR	We here describe a new molecularly engineered green fluorescent protein chimera that shows a high sensitivity to pH in the alkaline range. This probe was named mtAlpHi, for mitochondrial alkaline pH indicator, and possesses several key properties that render it optimal for studying the dynamics of mitochondrial matrix pH, e. g. it has an apparent pK(a) (pK(a)') around 8.5, it shows reversible and large changes in fluorescence in response to changes in pH (both in vitro and in intact cells), and it is selectively targeted to the mitochondrial matrix. Using mtAlpHi we could monitor pH changes that occur in the mitochondrial matrix in a variety of situations, e. g. treatment with uncouplers or Ca2+ ionophores, addition of drugs that interfere with ATP synthesis or electron flow in the respiratory chain, weak bases or acids, and receptor activation. We observed heterogeneous pH increases in the mitochondrial matrix during Ca2+ accumulation by this organelle. Finally, we demonstrate that Ca2+ mobilization from internal stores induced by ionomycin and A23187 cause a dramatic acidification of the mitochondrial matrix.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; CNR, Inst Neurosci, I-35121 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); Veneto Institute Molecular Medicine	Pozzan, T (corresponding author), Univ Padua, Dept Biomed Sci, Viale G Colombo 3, I-35121 Padua, Italy.	tullio.pozzan@unipd.it	Di Benedetto, Giulietta/L-9842-2019	Di Benedetto, Giulietta/0000-0002-1489-3896; Cano-Abad, Maria F./0000-0002-2602-6626; Filippin, Luisa/0000-0001-7690-9147	Telethon [1226] Funding Source: Medline	Telethon(Fondazione Telethon)		ARSLAN P, 1985, J BIOL CHEM, V260, P2719; Awaji T, 2001, BIOCHEM BIOPH RES CO, V289, P457, DOI 10.1006/bbrc.2001.6004; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Burgo A, 2003, J PHYSIOL-LONDON, V549, P537, DOI 10.1113/jphysiol.2003.041871; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Hanson GT, 2002, BIOCHEMISTRY-US, V41, P15477, DOI 10.1021/bi026609p; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; McAnaney TB, 2002, BIOCHEMISTRY-US, V41, P15489, DOI 10.1021/bi026610o; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; PASTI L, 1995, J BIOL CHEM, V270, P15203, DOI 10.1074/jbc.270.25.15203; Pozzan T, 2003, EUR J BIOCHEM, V270, P2343, DOI 10.1046/j.1432-1033.2003.03615.x; Pozzan T, 2000, CELL CALCIUM, V28, P279, DOI 10.1054/ceca.2000.0166; Pozzan T, 2000, EUR J BIOCHEM, V267, P5269, DOI 10.1046/j.1432-1327.2000.01567.x; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rudolf R, 2003, NAT REV MOL CELL BIO, V4, P579, DOI 10.1038/nrm1153; Sankaranarayanan S, 2000, BIOPHYS J, V79, P2199, DOI 10.1016/S0006-3495(00)76468-X; Takahashi A, 2001, BIOTECHNIQUES, V30, P804, DOI 10.2144/01304rv01; THOMAS PJ, 1991, ARCH BIOCHEM BIOPHYS, V288, P250, DOI 10.1016/0003-9861(91)90192-L; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0; Weinlich M, 1998, J EXP BIOL, V201, P57; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345	32	196	200	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11521	11529		10.1074/jbc.M306766200	http://dx.doi.org/10.1074/jbc.M306766200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701849	hybrid			2022-12-25	WOS:000220157600084
J	Jana, NR; Dikshit, P; Goswami, A; Nukina, N				Jana, NR; Dikshit, P; Goswami, A; Nukina, N			Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-MYELOMA CELLS; CYTOCHROME-C RELEASE; AK-5 TUMOR-CELLS; FACTOR-KAPPA-B; COLON CARCINOGENESIS; MEDIATED APOPTOSIS; CASPASE ACTIVATION; SIGNALING PATHWAY; OXIDATIVE STRESS; DOWN-REGULATION	Curcumin is a natural polyphenolic compound having an antiproliferative property, which recent evidence suggests is due to its ability to induce apoptosis. However, the molecular mechanisms through which curcumin induces apoptosis are not fully understood. Here, we report that the curcumin-induced apoptosis is mediated through the impairment of the ubiquitin-proteasome system. Exposure of curcumin to the mouse neuro 2a cells causes a dose-dependent decrease in proteasome activity and an increase in ubiquitinated proteins. Curcumin exposure also decreases the turnover of the destabilized enhanced green fluorescence protein, a model substrate for proteasome and cellular p53 protein. Like other proteasome inhibitors, curcumin targets proliferative cells more efficiently than differentiated cells and induces apoptosis via mitochondrial pathways. Addition of curcumin to neuro 2a cells induces a rapid decrease in mitochondrial membrane potential and the release of cytochrome c into cytosol, followed by activation of caspase-9 and caspase-3.	Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Manesar 122050, Gurgaon, India; RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Wako, Saitama 3510198, Japan	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC); RIKEN	Jana, NR (corresponding author), Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Manesar 122050, Gurgaon, India.	nihar@nbrc.ac.in	Nukina, Nobuyuki/GPP-6265-2022	Jana, Nihar/0000-0002-6549-4211				Aggarwal BB, 2003, ANTICANCER RES, V23, P363; AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Bhaumik S, 1999, FEBS LETT, V456, P311, DOI 10.1016/S0014-5793(99)00969-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bush JA, 2001, EXP CELL RES, V271, P305, DOI 10.1006/excr.2001.5381; Chaudhury LR, 2003, J CELL BIOCHEM, V89, P1, DOI 10.1002/jcb.10495; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Chuang SE, 2000, CARCINOGENESIS, V21, P331, DOI 10.1093/carcin/21.2.331; DIDIER M, 2001, FEBS LETT, V495, P131; Ding QX, 2001, J NEUROCHEM, V77, P1010, DOI 10.1046/j.1471-4159.2001.00302.x; Drexler HCA, 2000, FASEB J, V14, P65, DOI 10.1096/fasebj.14.1.65; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Huang MT, 1997, CARCINOGENESIS, V18, P83, DOI 10.1093/carcin/18.1.83; HUANG MT, 1994, CANCER RES, V54, P5841; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Jee SH, 1998, J INVEST DERMATOL, V111, P656, DOI 10.1046/j.1523-1747.1998.00352.x; Kato K, 1998, CELL STRESS CHAPERON, V3, P152, DOI 10.1379/1466-1268(1998)003<0152:SOTSIE>2.3.CO;2; Khar A, 1999, FEBS LETT, V445, P165, DOI 10.1016/S0014-5793(99)00114-3; KIEFER J, 1995, J IMMUNOL, V145, P1227; Kim JM, 1998, CARCINOGENESIS, V19, P81, DOI 10.1093/carcin/19.1.81; Li N, 2002, CARCINOGENESIS, V23, P1307, DOI 10.1093/carcin/23.8.1307; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Martin MC, 2001, J BIOL CHEM, V276, P45041, DOI 10.1074/jbc.M105197200; Mehta K, 1997, ANTI-CANCER DRUG, V8, P470, DOI 10.1097/00001813-199706000-00010; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Mullally JE, 2002, MOL PHARMACOL, V62, P351, DOI 10.1124/mol.62.2.351; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; Pal S, 2001, BIOCHEM BIOPH RES CO, V288, P658, DOI 10.1006/bbrc.2001.5823; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; REDDY ACP, 1994, MOL CELL BIOCHEM, V137, P1, DOI 10.1007/BF00926033; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Wang GH, 1999, NEUROREPORT, V10, P2435, DOI 10.1097/00001756-199908200-00001; Woo JH, 2003, CARCINOGENESIS, V24, P1199, DOI 10.1093/carcin/bgg082	43	191	195	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11680	11685		10.1074/jbc.M310369200	http://dx.doi.org/10.1074/jbc.M310369200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701837	hybrid			2022-12-25	WOS:000220157600103
J	Tohyama, O; Imura, A; Iwano, A; Freund, JN; Henrissat, B; Fujimori, T; Nabeshima, Y				Tohyama, O; Imura, A; Iwano, A; Freund, JN; Henrissat, B; Fujimori, T; Nabeshima, Y			Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BASED CLASSIFICATION; GLYCOSYL HYDROLASES; HUMAN LIVER; LACTOSE-INTOLERANCE; GLUCOSIDASE; GENE; EXPRESSION; MECHANISMS; PROTEIN; SIMILARITIES	klotho mutant mice provide a unique model to analyze mechanisms of aging because their phenotypes resemble those of human aging-associated disorders. The klotho gene encodes Klotho, a type I membrane protein that shares sequence similarity with members of the glycosidase family 1. Because Klotho lacks the glutamic acid residues that have been shown to be involved in the catalytic activity of this family of enzymes, the function of this protein was unknown. Here, we have studied the biochemical characteristics of recombinant Klotho. The purified chimeric Klotho-human IgG1 Fc protein (KLFc) was assayed with a series of 4-methylumbelliferyl (4Mu) beta-glycosides as potential substrates. An enzymatic activity of Klotho was observed only with 4-methylumbelliferyl beta-D-glucuronide in contrast to bovine liver beta-glucuronidase, which exhibits a rather wide substrate specificity. Furthermore, the enzymatic activity of KLFc was reduced by the addition of specific inhibitors of beta-glucuronidase. A number of natural beta-glucuronides were screened by competitive inhibition for KLFc beta-glucuronidase. We found that steroid beta-glucuronides such as beta-estradiol 3-beta-D-glucuronide, estrone 3-beta-D-glucuronide, and estriol 3beta-D-glucuronide were hydrolyzed by KLFc. The artificial fluorescent substrate and the steroid conjugates share a common phenolic structure. Collectively, these data suggest that Klotho functions as a novel beta-glucuronidase and that steroid beta-glucuronides are potential candidates for the natural substrate(s) of Klotho.	Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Horizontal Med Res Org, Sakyo Ku, Kyoto 6068501, Japan; Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan; INSERM, U381, F-67200 Strasbourg, France; CNRS, UMR 6098, F-13402 Marseille, France; Univ Aix Marseille 1, F-13402 Marseille, France; Univ Aix Marseille 2, F-13402 Marseille, France	Kyoto University; Kyoto University; Japan Science & Technology Agency (JST); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Nabeshima, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan.	nabemr@lmls.med.kyoto-u.ac.jp	Fujimori, Toshihiko/L-7711-2016; Henrissat, Bernard/J-2475-2012; Freund, Jean-Noel/R-4383-2016	Fujimori, Toshihiko/0000-0001-5200-4634; Henrissat, Bernard/0000-0002-3434-8588; Freund, Jean-Noel/0000-0002-0971-3774				BRZOBOHATY B, 1993, SCIENCE, V262, P1051, DOI 10.1126/science.8235622; BULLER HA, 1990, ANNU REV MED, V41, P141; Burmeister WP, 2000, J BIOL CHEM, V275, P39385, DOI 10.1074/jbc.M006796200; CHESTER MA, 1976, BIOCHIM BIOPHYS ACTA, V429, P517, DOI 10.1016/0005-2744(76)90299-0; CONTRACTOR SF, 1972, BIOCHEM J, V128, P11, DOI 10.1042/bj1280011; Coutinho PM, 2003, TRENDS PLANT SCI, V8, P563, DOI 10.1016/j.tplants.2003.10.002; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; GOPALAN V, 1992, J BIOL CHEM, V267, P14027; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Higashi T, 1999, STEROIDS, V64, P715, DOI 10.1016/S0039-128X(99)00057-4; Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1; Ito S, 2002, BBA-GENE STRUCT EXPR, V1576, P341, DOI 10.1016/S0167-4781(02)00281-6; Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; LAMARCO KL, 1986, BIOCHEM J, V237, P469, DOI 10.1042/bj2370469; Lotsch J, 2001, CLIN PHARMACOKINET, V40, P485; Matern H, 1997, J BIOL CHEM, V272, P11261; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; Nabeshima Y, 2002, AGEING RES REV, V1, P627, DOI 10.1016/S1568-1637(02)00027-2; Naim HY, 2001, HISTOL HISTOPATHOL, V16, P553, DOI 10.14670/HH-16.553; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; O'Leary KA, 2001, FEBS LETT, V503, P103, DOI 10.1016/S0014-5793(01)02684-9; Rask L, 2000, PLANT MOL BIOL, V42, P93, DOI 10.1023/A:1006380021658; Raychaudhuri A, 2003, BIOCHEMISTRY-US, V42, P6848, DOI 10.1021/bi034137o; Ritter JK, 2000, CHEM-BIOL INTERACT, V129, P171, DOI 10.1016/S0009-2797(00)00198-8; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; Semenza G, 1989, METABOLIC BASIS INHE, V6th, P2975; SINNOTT M, 1990, CHEM REV, V90, P149; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsujikawa H, 2003, MOL ENDOCRINOL, V17, P2393, DOI 10.1210/me.2003-0048; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Vishwanath BS, 1996, BIOCHEM J, V320, P93, DOI 10.1042/bj3200093; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Wittstock U, 2002, TRENDS PLANT SCI, V7, P263, DOI 10.1016/S1360-1385(02)02273-2; Yoshida T, 2002, ENDOCRINOLOGY, V143, P683, DOI 10.1210/en.143.2.683; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	42	174	192	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9777	9784		10.1074/jbc.M312392200	http://dx.doi.org/10.1074/jbc.M312392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701853	hybrid, Green Published			2022-12-25	WOS:000220050400016
J	Xing, HY; Mayhew, CN; Cullen, KE; Park-Sarge, OK; Sarge, KD				Xing, HY; Mayhew, CN; Cullen, KE; Park-Sarge, OK; Sarge, KD			HSF1 modulation of hsp70 mRNA polyadenylation via interaction with symplekin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; HEAT-SHOCK PROTEINS; POLYMERASE-II; TERMINAL DOMAIN; TRANSCRIPTION; STRESS; ACTIVATION; GRANULES	Induction of heat shock protein (HSP) gene expression by stress is initiated by binding of HSF1 to HSP gene promoters to increase their transcription. The cytoprotective functions of these HSPs are essential for cell survival, and thus it is critical that inducible HSP gene expression be executed rapidly and efficiently. Here we report an interaction between heat shock factor 1 ( HSF1) and symplekin, a protein known to form a complex with the polyadenylation factors CstF and CPSF. HSF1-symplekin complexes are detected only after stress treatment, and these two proteins co-localize in punctate nuclear structures in stressed cells. HSF1 also complexes in a stress-induced manner with the 3' processing factor CstF-64. Interfering with HSF1-symplekin interaction by overexpressing a non-DNA-binding mutant HSF1 protein significantly decreases Hsp70 mRNA polyadenylation in stressed cells, supporting the functional role for HSF1 in promoting 3' processing of this transcript. Importantly, this was also found to result in a significant loss of Hsp70 protein induction and increased cell death in response to stress exposure. These results indicate that the HSF1-symplekin interaction functions as a mechanism for recruiting polyadenylation factors to HSP genes to enhance the efficiency/ kinetics of production of mature Hsp mRNA transcripts to achieve the critical cellular need for rapid HSP expression after stress. Thus, HSF1 regulates HSP gene expression at not one but two different steps of the expression pathway, functioning both as a transcription factor and a polyadenylation stimulatory factor.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Albert B Chandler Med Ctr, Dept Physiol, Lexington, KY 40536 USA; Univ Cincinnati, Dept Anat Cell Biol & Neurobiol, Cincinnati, OH 45267 USA	University of Kentucky; University of Kentucky; University System of Ohio; University of Cincinnati	Sarge, KD (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.	kdsarge@uky.edu	Mayhew, Christopher N/AGB-4929-2022					Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Christians ES, 2002, CRIT CARE MED, V30, pS43, DOI 10.1097/00003246-200201001-00006; Cotto JJ, 1997, J CELL SCI, V110, P2925; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; Fong N, 2001, GENE DEV, V15, P1783, DOI 10.1101/gad.889101; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 2000, GENE DEV, V14, P1415; Hofmann I, 2002, MOL BIOL CELL, V13, P1665, DOI 10.1091/mbc.01-12-0567; Holmberg CI, 2000, CELL STRESS CHAPERON, V5, P219, DOI 10.1379/1466-1268(2000)005<0219:FONHGV>2.0.CO;2; Hong YL, 1999, J BIOL CHEM, V274, P12967, DOI 10.1074/jbc.274.19.12967; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Kaufman Randal J., 1999, Biochimica et Biophysica Acta, V1423, pR13, DOI 10.1016/S0304-419X(98)00029-8; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Minvielle-Sebastia L, 1999, CURR OPIN CELL BIOL, V11, P352, DOI 10.1016/S0955-0674(99)80049-0; Morano KA, 1999, GENE EXPRESSION, V7, P271; Naylor DJ, 2001, BIOCHEM SOC SYMP, V68, P45, DOI 10.1042/bss0680045; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Ryan K, 2002, MOL CELL BIOL, V22, P1684, DOI 10.1128/MCB.22.6.1684-1692.2002; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000	27	49	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10551	10555		10.1074/jbc.M311719200	http://dx.doi.org/10.1074/jbc.M311719200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14707147	hybrid			2022-12-25	WOS:000220050400108
J	Huang, AM; Montagna, C; Sharan, S; Ni, YJ; Ried, T; Sterneck, E				Huang, AM; Montagna, C; Sharan, S; Ni, YJ; Ried, T; Sterneck, E			Loss of CCAAT/enhancer binding protein delta promotes chromosomal instability	ONCOGENE			English	Article						C/EBP; tumor suppressor; mouse embryo fibroblast; chromosomal rearrangements; genomic instability	GROWTH-FACTOR-BETA; I GENE-TRANSCRIPTION; ARREST-SPECIFIC GENE; ALPHA C/EBP-ALPHA; MICE LACKING; ADIPOCYTE DIFFERENTIATION; CENTROSOME AMPLIFICATION; CELL-PROLIFERATION; MESSENGER-RNA; EXPRESSION	The transcription factor CCAAT/enhancer binding protein delta (Cebpd, also known as C/EBPdelta, CRP3, CELF, NF-IL6beta) is implicated in diverse cellular functions such as the acute phase response, adipocyte differentiation, learning and memory, and mammary epithelial cell growth control. Here, we report that lack of Cebpd causes genomic instability and centrosome amplifications in primary embryonic fibroblasts derived from 129S1 mice. Upon spontaneous immortalization, Cebpd-deficient fibroblasts acquire transformed features such as impaired contact inhibition and reduced serum dependence. These data identify a novel role for Cebpd in the maintenance of chromosomal stability and suggest a potential tumor suppressor function in vivo.	Regulat Cell Growth Lab, Frederick, MD 21702 USA; NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sterneck, E (corresponding author), Regulat Cell Growth Lab, POB B, Frederick, MD 21702 USA.	sterneck@ncifcrf.gov		Huang, A-Mei/0000-0003-3723-0443; Sterneck, Esta/0000-0001-7716-8766	NATIONAL CANCER INSTITUTE [Z01BC010307, ZIABC010307] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Billiard J, 2001, J BIOL CHEM, V276, P31238, DOI 10.1074/jbc.M103634200; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Choy L, 2003, J BIOL CHEM, V278, P9609, DOI 10.1074/jbc.M212259200; DAVISSON MT, 1994, GENE, V147, P157, DOI 10.1016/0378-1119(94)90060-4; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Evdokiou A, 1998, INT J CANCER, V75, P568, DOI 10.1002/(SICI)1097-0215(19980209)75:4<568::AID-IJC13>3.0.CO;2-5; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; Gigliotti AP, 1999, BREAST CANCER RES TR, V58, P57, DOI 10.1023/A:1006381906288; Glick A, 1999, P NATL ACAD SCI USA, V96, P14949, DOI 10.1073/pnas.96.26.14949; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Janssen RAJ, 1997, MOL BIOL CELL, V8, P897, DOI 10.1091/mbc.8.5.897; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kreidberg JA, 2000, CANC DRUG DISC DEV, P3; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Reitmair AH, 1997, CANCER RES, V57, P3765; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Sterneck E, 1998, P NATL ACAD SCI USA, V95, P10908, DOI 10.1073/pnas.95.18.10908; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sugahara K, 1999, CELL TISSUE RES, V297, P261, DOI 10.1007/s004410051354; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tessarollo L, 2000, METH MOL B, V158, P47; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Welm AL, 2002, J BIOL CHEM, V277, P33848, DOI 10.1074/jbc.M204096200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zahnow CA, 2001, CANCER RES, V61, P261; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	62	64	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1549	1557		10.1038/sj.onc.1207285	http://dx.doi.org/10.1038/sj.onc.1207285			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716301				2022-12-25	WOS:000189219500008
J	Fowler, AM; Solodin, N; Preisler-Mashey, MT; Zhang, P; Lee, AV; Alarid, ET				Fowler, AM; Solodin, N; Preisler-Mashey, MT; Zhang, P; Lee, AV; Alarid, ET			Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen	FASEB JOURNAL			English	Article						nuclear receptor; steroid hormone; transcription; proliferation; ligand-independent	ACTIVATED PROTEIN-KINASE; PROTEASOME-MEDIATED PROTEOLYSIS; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; C-FOS; BINDING; GENE; PATHWAY; COACTIVATOR	A common phenotype in breast cancer is the expansion of the estrogen receptor-alpha (ER+) cell population and an inappropriate elevation of ERalpha protein, the latter predisposing patients for a poorer prognosis than those with lower levels of the receptor. A tetracycline-inducible ERalpha overexpression model was developed in the MCF-7 cell line to assess induction of endogenous gene activation and growth in response to elevations in ERalpha protein. Heightened levels of ERalpha resulted in aberrant promoter occupancy and gene activation in the absence of hormone, which was independent of ligand and AF-2 function. This increased receptor activity required the amino-terminal A/B domain and was not inhibited by tamoxifen, which supports an enhancement of AF-1 function, yet was independent of serine-104, 106, and 118 phosphorylation. Ligand-independent transcription was accompanied by an increase in growth in the absence of hormonal stimulation. The results suggest that elevated levels of ERalpha in breast cancer cells can result in activation of receptor transcriptional function in a manner distinct from classical mechanisms that involve ligand binding or growth factor-induced phosphorylation. Further, they describe a potential mechanism whereby increases in ERalpha concentration may provide a proliferative advantage by augmenting ERalpha function regardless of ligand status.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA	University of Wisconsin System; University of Wisconsin Madison; Baylor College of Medicine; Baylor College of Medicine	Alarid, ET (corresponding author), Univ Wisconsin, Dept Physiol, 120 Serv Mem Inst,1300 Univ Ave, Madison, WI 53706 USA.	alarid@physiology.wisc.edu			NATIONAL CANCER INSTITUTE [K01CA079090] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA-79090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLACK R, 1983, CLIN ONCOL, V9, P311; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Chan CMW, 2002, J STEROID BIOCHEM, V81, P333, DOI 10.1016/S0960-0760(02)00074-2; Chun TY, 1998, P NATL ACAD SCI USA, V95, P2325, DOI 10.1073/pnas.95.5.2325; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; Coleman KM, 2001, FRONT BIOSCI, V6, pD1379, DOI 10.2741/Coleman; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DUBIK D, 1988, J BIOL CHEM, V263, P12705; Dutertre M, 2003, MOL ENDOCRINOL, V17, P1296, DOI 10.1210/me.2001-0316; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FABRIS G, 1987, J STEROID BIOCHEM, V27, P171, DOI 10.1016/0022-4731(87)90307-4; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hupperets PS, 1997, AM J CLIN ONCOL-CANC, V20, P546, DOI 10.1097/00000421-199712000-00002; JOU WM, 1980, CELL, V19, P683, DOI 10.1016/S0092-8674(80)80045-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Maniatis T., 1982, MOL CLONING LAB MANU; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; MASAMURA S, 1995, J CLIN ENDOCR METAB, V80, P2918, DOI 10.1210/jc.80.10.2918; MASTERS JRW, 1978, EUR J CANCER, V14, P303, DOI 10.1016/0014-2964(78)90194-9; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Monje P, 2001, MOL CELL ENDOCRINOL, V181, P117, DOI 10.1016/S0303-7207(01)00526-3; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Preisler-Mashek MT, 2002, AM J PHYSIOL-ENDOC M, V282, pE891, DOI 10.1152/ajpendo.00353.2001; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; REDDEL RR, 1984, CANCER RES, V44, P2398; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; ROMAIN S, 1994, INT J CANCER, V59, P17, DOI 10.1002/ijc.2910590105; SANCHOGARNIER H, 1995, EUR J CANCER, V31A, P1851, DOI 10.1016/0959-8049(95)00387-X; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; THORPE SM, 1993, EUR J CANCER, V29A, P971, DOI 10.1016/S0959-8049(05)80204-7; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Watters JJ, 2000, MOL ENDOCRINOL, V14, P1872, DOI 10.1210/me.14.11.1872; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; WEBB P, 1992, MOL ENDOCRINOL, V6, P157, DOI 10.1210/me.6.2.157; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WELSHONS WV, 1987, EUR J CANCER CLIN ON, V23, P1935, DOI 10.1016/0277-5379(87)90062-9; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wu XY, 2001, J BIOL CHEM, V276, P23962, DOI 10.1074/jbc.M101041200; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; ZAJCHOWSKI DA, 1993, CANCER RES, V53, P5004; ZHANG HJ, 1984, BREAST CANCER RES TR, V4, P221, DOI 10.1007/BF01806488	67	63	64	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					81	93		10.1096/fj.03-0038com	http://dx.doi.org/10.1096/fj.03-0038com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718389				2022-12-25	WOS:000188829300042
J	Li, MH; Kwok, F; Chang, WR; Liu, SQ; Lo, SCL; Zhang, JP; Jiang, T; Liang, DC				Li, MH; Kwok, F; Chang, WR; Liu, SQ; Lo, SCL; Zhang, JP; Jiang, T; Liang, DC			Conformational changes in the reaction of pyridoxal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1.5 ANGSTROM RESOLUTION; ESCHERICHIA-COLI K-12; CRYSTAL-STRUCTURE; MOLECULAR REPLACEMENT; ADENOSINE KINASE; BRAIN; RIBOKINASE; PROGRAM; IDENTIFICATION; ENCODES	To understand the processes involved in the catalytic mechanism of pyridoxal kinase (PLK),(1) we determined the crystal structures of PLK.AMP-PCP-pyridoxamine, PLK.ADP.PLP, and PLK.ADP complexes. Comparisons of these structures have revealed that PLK exhibits different conformations during its catalytic process. After the binding of AMP-PCP (an analogue that replaced ATP) and pyridoxamine to PLK, this enzyme retains a conformation similar to that of the PLK.ATP complex. The distance between the reacting groups of the two substrates is 5.8 Angstrom apart, indicating that the position of ATP is not favorable to spontaneous transfer of its phosphate group. However, the structure of PLK.ADP.PLP complex exhibited significant changes in both the conformation of the enzyme and the location of the ligands at the active site. Therefore, it appears that after binding of both substrates, the enzyme-substrate complex requires changes in the protein structure to enable the transfer of the phosphate group from ATP to vitamin B-6. Furthermore, a conformation of the enzyme-substrate complex before the transition state of the enzymatic reaction was also hypothesized.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Dept Appl Biol Chem Technol, Hong Kong, Hong Kong, Peoples R China; Polytech Univ, Hong Kong, Hong Kong, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Jiang, T (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	x-ray@sun5.ibp.ac.cn		Lo, Samuel Chun-lap/0000-0003-1134-7299				BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campobasso N, 2000, BIOCHEMISTRY-US, V39, P7868, DOI 10.1021/bi0000061; Cheng G, 2002, STRUCTURE, V10, P225, DOI 10.1016/S0969-2126(02)00708-6; Hanna MC, 1997, J BIOL CHEM, V272, P10756; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERRY JA, 1986, EUR J BIOCHEM, V158, P581, DOI 10.1111/j.1432-1033.1986.tb09794.x; KIM YT, 1988, J BIOL CHEM, V263, P13712; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWOK F, 1980, J BIOL CHEM, V255, P882; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li MH, 2002, ACTA CRYSTALLOGR D, V58, P1479, DOI 10.1107/S0907444902011034; Li MH, 2002, J BIOL CHEM, V277, P46385, DOI 10.1074/jbc.M208600200; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; MCCORMICK D, 1961, J BIOL CHEM, V236, P2085; MCCORMICK DB, 1959, P NATL ACAD SCI USA, V45, P1371, DOI 10.1073/pnas.45.9.1371; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Schumacher MA, 2000, J MOL BIOL, V298, P875, DOI 10.1006/jmbi.2000.3753; Sigrell JA, 1998, STRUCTURE, V6, P183, DOI 10.1016/S0969-2126(98)00020-3; Sigrell JA, 1999, J MOL BIOL, V290, P1009, DOI 10.1006/jmbi.1999.2938; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Yang Y, 1996, FEMS MICROBIOL LETT, V141, P89, DOI 10.1016/0378-1097(96)00203-0; Yang Y, 1998, J BACTERIOL, V180, P1814, DOI 10.1128/JB.180.7.1814-1821.1998; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	27	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17459	17465		10.1074/jbc.M312380200	http://dx.doi.org/10.1074/jbc.M312380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14722069	hybrid			2022-12-25	WOS:000220870400072
J	Allende, ML; Dreier, JL; Mandala, S; Proia, RL				Allende, ML; Dreier, JL; Mandala, S; Proia, RL			Expression of the sphingosine 1-phosphate receptor, S1P(1), on T-cells controls thymic emigration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; THYMOCYTE EMIGRATION; VASCULAR MATURATION; ENDOTHELIAL-CELLS; SPHINGOSINE-1-PHOSPHATE; FTY720; LYSOPHOSPHOLIPIDS; EDG-1; IMMUNOSUPPRESSANT; PHOSPHORYLATION	S1P1 is a widely distributed G protein-coupled receptor whose ligand, sphingosine 1-phosphate, is present in high concentrations in the blood. The sphingosine 1-phosphate receptor-signaling pathway is believed to have potent effects on cell trafficking in the immune system. To determine the precise role of the S1P1 receptor on T-cells, we established a T-cell-specific S1P1 knock-out mouse. The mutant mice showed a block in the egress of mature T-cells into the periphery. The expression of the S1P1 receptor was up-regulated in mature thymocytes, and its deletion altered the chemotactic responses of thymocytes to sphingosine 1-phosphate. The results indicated that the expression of the S1P1 receptor on T-cells controls their exit from the thymus and entry into the blood and, thus, has a central role in regulating the numbers of peripheral T-cells.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; Merck Res Labs, Dept Immunol & Rheumatol, Rahway, NJ 07065 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Merck & Company	Proia, RL (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, Bldg 10,Rm 9N-314,10 Ctr Dr, Bethesda, MD 20892 USA.	proia@nih.gov	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0; An SZ, 1998, J CELL BIOCHEM, P147; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2000, TRENDS PHARMACOL SCI, V21, P49, DOI 10.1016/S0165-6147(99)01419-4; CHAFFIN KE, 1991, EUR J IMMUNOL, V21, P2565, DOI 10.1002/eji.1830211038; Chiba K, 1998, J IMMUNOL, V160, P5037; Dorsam G, 2003, J IMMUNOL, V171, P3500, DOI 10.4049/jimmunol.171.7.3500; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Gabor MJ, 1997, EUR J IMMUNOL, V27, P2010, DOI 10.1002/eji.1830270827; Goetzl EJ, 2001, PROSTAG OTH LIPID M, V64, P11, DOI 10.1016/S0090-6980(01)00104-6; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Hakomori S, 2003, CURR OPIN HEMATOL, V10, P16, DOI 10.1097/00062752-200301000-00004; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HLA T, 1990, J BIOL CHEM, V265, P9308; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Lee CK, 2001, BLOOD, V97, P1360, DOI 10.1182/blood.V97.5.1360; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; Shayman JA, 2000, KIDNEY INT, V58, P11, DOI 10.1046/j.1523-1755.2000.00136.x; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Yagi H, 2000, EUR J IMMUNOL, V30, P1435, DOI 10.1002/(SICI)1521-4141(200005)30:5<1435::AID-IMMU1435>3.0.CO;2-O; Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090-6980(01)00103-4; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7	37	362	380	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15396	15401		10.1074/jbc.M314291200	http://dx.doi.org/10.1074/jbc.M314291200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14732704	hybrid			2022-12-25	WOS:000220594700109
J	Abe, H; Matsubara, T; Iehara, N; Nagai, K; Takahashi, T; Arai, H; Kita, T; Doi, T				Abe, H; Matsubara, T; Iehara, N; Nagai, K; Takahashi, T; Arai, H; Kita, T; Doi, T			Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-LIKE KINASE-1; MESANGIAL CELLS; GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; EXPRESSION; MICE; GENE; COMPLICATIONS; ACTIVIN	Prolonged exposure to hyperglycemia is now recognized as the most significant causal factor of diabetic complications. Excessive advanced glycation end products (AGEs) as a result of hyperglycemia in tissues or in the circulation may critically affect the progression of diabetic nephropathy. In diabetic nephropathy, glomerulosclerosis is a typical pathologic feature characterized by the increase of the extracellular matrix (ECM). We have reported previously that alpha1 type IV collagen (Col4) is one of the major components of ECM, which is up-regulated by AGEs, and that the overexpression of Col4 is transcriptionally regulated by an unknown transcription factor binding to the promoter. Here we identified this protein as Smad1 by yeast one-hybrid screening. Using chromatin immunoprecipitation and reporter assay, we observed that Smad1 directly regulated transcription for Col4 through the binding of Smad1 to the promoter of Col4. Smad1 was significantly induced along with Col4 in AGE-treated mesangial cells. Moreover, suppression of Smad1 by antisense morpholino resulted in a decrease of AGE-induced Col4 overproduction. To elucidate the interaction between transforming growth factor-beta and Smad1, we investigated whether activin receptor-liked kinase1 (ALK1) was involved in this regulation. AGE stimulation significantly increased the expression of the ALK1 mRNA in mesangial cells. We also demonstrated that Smad1 and ALK1 were highly expressed in human diabetic nephropathy. These results suggest that the modulation of Smad1 expression is responsible for the initiation and progression of diabetic nephropathy and that blocking Smad1 signaling may be beneficial in preventing diabetic nephropathy and other various diabetic complications.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Artificial Kidney, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University	Doi, T (corresponding author), Univ Tokushima, Dept Clin Biol & Med, Course Biol Med, Tokushima 7708503, Japan.	doi@clin.med.tokushima-u.ac.jp	Arai, Hidenori/P-9816-2017	Arai, Hidenori/0000-0002-9000-6849				Abe H, 1999, J BIOL CHEM, V274, P20874, DOI 10.1074/jbc.274.30.20874; Ahn DG, 2002, NATURE, V417, P754, DOI 10.1038/nature00814; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BRUGGEMAN LA, 1992, ONCOGENE, V7, P1497; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; Chappey O, 1997, EUR J CLIN INVEST, V27, P97, DOI 10.1046/j.1365-2362.1997.710624.x; Chen S, 2003, BIOCHEM BIOPH RES CO, V300, P16, DOI 10.1016/S0006-291X(02)02708-0; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; DAVIES M, 1994, KIDNEY INT, V45, P320, DOI 10.1038/ki.1994.41; Dick A, 1998, DEV DYNAM, V211, P293, DOI 10.1002/(SICI)1097-0177(199804)211:4<293::AID-AJA1>3.0.CO;2-C; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; FLOEGE J, 1991, KIDNEY INT, V40, P477, DOI 10.1038/ki.1991.235; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huang SX, 2000, GENE, V258, P43, DOI 10.1016/S0378-1119(00)00396-6; HUIJBERTS MSP, 1993, J CLIN INVEST, V92, P1407, DOI 10.1172/JCI116716; Iehara N, 1996, KIDNEY INT, V50, P1166, DOI 10.1038/ki.1996.424; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.0.CO;2-L; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; THROCKMORTON DC, 1995, KIDNEY INT, V48, P111, DOI 10.1038/ki.1995.274; Tremblay KD, 2001, DEVELOPMENT, V128, P3609; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Urness LD, 2000, NAT GENET, V26, P328, DOI 10.1038/81634; VLASSARA H, 1994, P NATL ACAD SCI USA, V91, P11704, DOI 10.1073/pnas.91.24.11704; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; YANG CW, 1994, P NATL ACAD SCI USA, V91, P9436, DOI 10.1073/pnas.91.20.9436; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	40	72	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14201	14206		10.1074/jbc.M310427200	http://dx.doi.org/10.1074/jbc.M310427200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732718	hybrid			2022-12-25	WOS:000220478500112
J	Hirotani, H; Tuohy, NA; Woo, JT; Stern, PH; Clipstone, NA				Hirotani, H; Tuohy, NA; Woo, JT; Stern, PH; Clipstone, NA			The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE-3; NECROSIS-FACTOR-ALPHA; CYCLOSPORINE-A; BONE-RESORPTION; TRANSCRIPTION FACTOR; OSTEOPROTEGERIN LIGAND; GENE-EXPRESSION; NUCLEAR FACTOR; KEY REGULATOR	Although best known for its role in T lymphocyte activation, the calcineurin/nuclear factor of activated T cells ( NFAT) signaling pathway is also known to be involved in a wide range of other biological responses in a variety of different cell types. Here we have investigated the role of the calcineurin/NFAT signaling pathway in the regulation of osteoclast differentiation. Osteoclasts are bone-resorbing multinucleated cells that are derived from the monocyte/macrophage cell lineage after stimulation with a member of the tumor necrosis factor family of ligands known as receptor activator of nuclear factor-kappaB ligand (RANKL). We now report that inhibition of calcineurin with either the immunosuppressant drugs cyclosporin A and FK506, or the retrovirally mediated ectopic expression of a specific calcineurin inhibitory peptide, all potently inhibit the RANKL-induced differentiation of the RAW264.7 monocyte/macrophage cell line into mature multinucleated osteoclasts. In addition, we find that NFAT family members are expressed in RAW264.7 cells and that their expression is up-regulated in response to RANKL stimulation. Most importantly, we find that ectopic expression of a constitutively active, calcineurin-independent NFATc1 mutant in RAW264.7 cells is sufficient to induce these cells to express an osteoclast-specific pattern of gene expression and differentiate into morphologically distinct, multinucleated osteoclasts capable of inducing the resorption of a physiological mineralized matrix substrate. Taken together, these data define calcineurin as an essential downstream effector of the RANKL-induced signal transduction pathway leading toward the induction of osteoclast differentiation and furthermore, indicate that the activation of the NFATc1 transcription factor is sufficient to initiate a genetic program that results in the specification of the mature functional osteoclast cell phenotype.	Northwestern Univ, Feinberg Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Clipstone, NA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Biol Chem & Mol Pharmacol, 303 E Chicago Ave, Chicago, IL 60611 USA.	n-clipstone@northwestern.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR030692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055292] Funding Source: NIH RePORTER; NIAMS NIH HHS [P60 AR30692] Funding Source: Medline; NIGMS NIH HHS [R29 GM55292] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Anusaksathien O, 2001, J BIOL CHEM, V276, P22663, DOI 10.1074/jbc.M007104200; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0; Awumey EM, 1999, BIOCHEM BIOPH RES CO, V254, P248, DOI 10.1006/bbrc.1998.9785; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; BALDARI CT, 1993, FEBS LETT, V323, P233, DOI 10.1016/0014-5793(93)81346-2; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHOWDHURY MH, 1991, CALCIFIED TISSUE INT, V49, P275, DOI 10.1007/BF02556217; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Igarashi K, 2002, BIOCHEM PHARMACOL, V63, P523, DOI 10.1016/S0006-2952(01)00861-9; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200; Kitazawa R, 1999, BBA-GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167-4781(99)00032-9; KLAUSHOFER K, 1987, J PHARMACOL EXP THER, V243, P584; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; LEE SK, 1995, ENDOCRINOLOGY, V136, P4572, DOI 10.1210/en.136.10.4572; Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105; Liu BY, 1998, ENDOCRINOLOGY, V139, P1952, DOI 10.1210/en.139.4.1952; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Neal JW, 2002, J BIOL CHEM, V277, P49776, DOI 10.1074/jbc.M207913200; ORCEL P, 1991, ENDOCRINOLOGY, V128, P1638, DOI 10.1210/endo-128-3-1638; Owens JM, 1999, J CELL PHYSIOL, V179, P170, DOI 10.1002/(SICI)1097-4652(199905)179:2<170::AID-JCP7>3.0.CO;2-K; Porter CM, 2002, J IMMUNOL, V168, P4936, DOI 10.4049/jimmunol.168.10.4936; Quinn JMW, 1999, BONE, V25, P1, DOI 10.1016/S8756-3282(99)00094-0; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SKJODT H, 1985, BRIT J RHEUMATOL, V24, P165; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; STEWART PJ, 1986, J BONE MINER RES, V1, P285; SUDA T, 1995, BONE S2, V17, P87; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; TONG HS, 1994, J BONE MINER RES, V9, P577; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Woo JT, 2000, J BONE MINER RES, V15, P650, DOI 10.1359/jbmr.2000.15.4.650; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	69	209	216	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13984	13992		10.1074/jbc.M213067200	http://dx.doi.org/10.1074/jbc.M213067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722106	hybrid			2022-12-25	WOS:000220478500086
J	Lengqvist, J; Svensson, R; Evergren, E; Morgenstern, R; Griffiths, WJ				Lengqvist, J; Svensson, R; Evergren, E; Morgenstern, R; Griffiths, WJ			Observation of an intact noncovalent homotrimer of detergent-solubilized rat microsomal glutathione transferase-1 by electrospray mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6 ANGSTROM RESOLUTION; S-TRANSFERASE; PROTEIN COMPLEXES; MEMBRANE-PROTEIN; HYDROGEN/DEUTERIUM EXCHANGE; TRANSMEMBRANE PEPTIDES; PROJECTION STRUCTURE; LIPID-BILAYERS; IONIZATION; CRYSTALS	Microsomal glutathione transferase-1 (MGST1) is a membrane-bound enzyme involved in the detoxification of xenobiotics and the protection of cells against oxidative stress. The proposed active form of the enzyme is a noncovalently associated homotrimer that binds one substrate glutathione molecule/trimer. In this study, this complex has been directly observed by electrospray mass spectrometry analysis of active rat liver MGST1 reconstituted in a minimum amount of detergent. The measured mass of the homotrimer is 53 kDa, allowing for the mass of three MGST molecules in complex with one glutathione molecule. Collision-induced dissociation of the trimer complex resulted in the formation of monomer and homodimer ion species. Two distinct species of homodimer were observed, one unliganded and one identified as a homodimer . glutathione complex. Activation of the enzyme by N-ethylmaleimide through modification of Cys(49) (Svensson, R., Rinaldi, R., Swedmark, S., and Morgenstern, R. (2000) Biochemistry 39, 15144 - 15149) was monitored by the observation of an appropriate increase in mass in both the denatured monomeric and native trimeric forms of MGST1. Together, the data correspond well with the proposed functional organization of MGST1. These results also represent the first example of direct electrospray mass spectrometry analysis of a detergent-solubilized multimeric membrane protein complex in its native state.	Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Karolinska Inst, Ludwig Inst Canc Res, SE-17177 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Div Biochem Toxicol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurosci, Ctr Excellence Dev Biol, SE-17177 Stockholm, Sweden; Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research; Karolinska Institutet; Karolinska Institutet; University of London; University College London; University of London School of Pharmacy	Griffiths, WJ (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.	william.griffiths@ulsop.ac.uk	Morgenstern, Ralf/GZH-0158-2022; Griffiths, William/N-4641-2016; Evergren, Emma/X-3677-2019	Griffiths, William/0000-0002-4129-6616; Evergren, Emma/0000-0002-0775-2921				ANDERSSON C, 1994, BBA-PROTEIN STRUCT M, V1204, P298, DOI 10.1016/0167-4838(94)90021-3; Barnidge DR, 1999, ANAL BIOCHEM, V269, P1, DOI 10.1006/abio.1999.4012; BOYER TD, 1986, J BIOL CHEM, V261, P6963; Chung EW, 1997, PROTEIN SCI, V6, P1316, DOI 10.1002/pro.5560060620; Codreanu SG, 2002, BIOCHEMISTRY-US, V41, P15161, DOI 10.1021/bi026776p; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; Demmers JAA, 2000, P NATL ACAD SCI USA, V97, P3189, DOI 10.1073/pnas.050444797; Demmers JAA, 2002, J AM CHEM SOC, V124, P11191, DOI 10.1021/ja0125927; Demmers JAA, 2003, FEBS LETT, V541, P28, DOI 10.1016/S0014-5793(03)00282-5; Demmers JAA, 2001, J BIOL CHEM, V276, P34501, DOI 10.1074/jbc.M101401200; Fandrich M, 2000, P NATL ACAD SCI USA, V97, P14151, DOI 10.1073/pnas.240326597; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; Green BN, 2001, J MOL BIOL, V309, P553, DOI 10.1006/jmbi.2001.4704; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hanson CL, 2003, J BIOL CHEM, V278, P1259, DOI 10.1074/jbc.M208966200; Hebert H, 1997, J MOL BIOL, V271, P751, DOI 10.1006/jmbi.1997.1216; Holm PJ, 2002, BBA-PROTEIN STRUCT M, V1594, P276, DOI 10.1016/S0167-4838(01)00311-9; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; KATTA V, 1991, RAPID COMMUN MASS SP, V5, P214, DOI 10.1002/rcm.1290050415; Kelner MJ, 2000, J BIOL CHEM, V275, P13000, DOI 10.1074/jbc.275.17.13000; Loo JA, 1997, MASS SPECTROM REV, V16, P1; LUNDQVIST G, 1992, BIOCHIM BIOPHYS ACTA, V1159, P103, DOI 10.1016/0167-4838(92)90081-N; Miranker AD, 2000, CURR OPIN STRUC BIOL, V10, P601, DOI 10.1016/S0959-440X(00)00137-8; Moniatte M, 1996, FEBS LETT, V384, P269, DOI 10.1016/0014-5793(96)00328-6; Moniatte M, 1997, INT J MASS SPECTROM, V169, P179, DOI 10.1016/S0168-1176(97)00213-9; Morgenstern R, 2001, BIOCHEMISTRY-US, V40, P3378, DOI 10.1021/bi0023394; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; MORGENSTERN R, 1983, EUR J BIOCHEM, V134, P591, DOI 10.1111/j.1432-1033.1983.tb07607.x; Rostom AA, 1999, J AM CHEM SOC, V121, P4718, DOI 10.1021/ja990238r; Rundlett KL, 1996, ANAL CHEM, V68, P3493, DOI 10.1021/ac960472p; Schmidt-Krey I, 2000, EMBO J, V19, P6311, DOI 10.1093/emboj/19.23.6311; Schmidt-Krey I, 1999, J MOL BIOL, V288, P243, DOI 10.1006/jmbi.1999.2683; SHORE LJ, 1995, BIOCHEM PHARMACOL, V49, P181, DOI 10.1016/S0006-2952(94)00488-9; Sobott F, 2002, CURR OPIN STRUC BIOL, V12, P729, DOI 10.1016/S0959-440X(02)00400-1; Sun TH, 1997, BIOCHEM J, V326, P193, DOI 10.1042/bj3260193; Svensson R, 2000, BIOCHEMISTRY-US, V39, P15144, DOI 10.1021/bi001764u; Torres J, 2003, TRENDS BIOCHEM SCI, V28, P137, DOI 10.1016/S0968-0004(03)00026-4; Werten PJL, 2002, FEBS LETT, V529, P65, DOI 10.1016/S0014-5793(02)03290-8; Whitelegge JP, 1999, P NATL ACAD SCI USA, V96, P10695, DOI 10.1073/pnas.96.19.10695; Whitelegge JP, 2002, MOL CELL PROTEOMICS, V1, P816, DOI 10.1074/mcp.M200045-MCP200; Whitelegge JP, 1998, PROTEIN SCI, V7, P1423, DOI 10.1002/pro.5560070619	42	40	41	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13311	13316		10.1074/jbc.M310958200	http://dx.doi.org/10.1074/jbc.M310958200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726533	hybrid			2022-12-25	WOS:000220478500007
J	Yoo, B; Iyengar, R; Chen, YB				Yoo, B; Iyengar, R; Chen, YB			Functional analysis of the interface regions involved in interactions between the central cytoplasmic loop and the C-terminal tail of adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; INHIBITION; MUTANTS; DOMAINS; GAMMA; SITE	The mammalian adenylyl cyclase is a membrane-bound enzyme that is predicted to have 12 trans-membrane spans. Between membrane spans 6 and 7 there is a large cytoplasmic loop, which, along with the C-terminal tail, makes up the catalytic site of the enzyme. Crystal structures of these soluble cytoplasmic domains have identified the regions that are involved in interactions with each other. The functional consequences of these interactions in the full-length membrane-embedded enzymes have not been established. In this study, we analyzed the role of various interaction regions within the central cytoplasmic loop (C1) and the C-terminal tail (C2) on basal, Galphas-, forskolin-, and Mn2+-stimulated activities of adenylyl cyclases 2 and 6 (AC2 and AC6). We tested synthetic peptides encoding the different interface surfaces of both the C1 and C2 domain on different activities of membrane-bound AC2 and AC6 expressed in insect cells. We found the C1-alpha2-beta2-beta3 and C2-beta2'-beta3' regions to be involved in stimulation by Galphas and forskolin but not in the basal or Mn2+-stimulated activities. Both the C1-beta4-beta5-alpha4 region and the C2-alpha3'-beta4' region play a role in the Galphas- and forskolin-stimulated activities as well as in basal activity, because the peptides encoding these regions inhibit basal activity by 30%. In contrast, the C2-alpha2' region peptide inhibits both basal and Mn2+-stimulated activity by > 50%. These results suggest that the different stimulated activities may involve distinct interface interactions in the intact enzyme and, consequently, the distinct mechanisms by which Mn2+ activates the enzyme as compared with Galphas and forskolin, leading to the possibility that the full-length adenylyl cyclase may have multiple catalytically competent configurations.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Iyengar, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1215,1 Gustave Levy Pl, New York, NY 10029 USA.	ravi.iyengar@mssm.edu			NIDDK NIH HHS [DK-38761] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen YB, 2001, J BIOL CHEM, V276, P45751, DOI 10.1074/jbc.M107191200; Dessauer CW, 2002, J BIOL CHEM, V277, P28823, DOI 10.1074/jbc.M203962200; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; DESSAUER CW, 1997, J BIOL CHEM, V272, P27772; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Harry A, 1997, J BIOL CHEM, V272, P19017, DOI 10.1074/jbc.272.30.19017; Hatley ME, 2000, J BIOL CHEM, V275, P38626, DOI 10.1074/jbc.M007148200; HILDEBRANDT JD, 1983, J BIOL CHEM, V258, P3141; Parent CA, 2002, J BIOL CHEM, V277, P1354, DOI 10.1074/jbc.M106430200; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; Skiba NP, 1998, NAT STRUCT BIOL, V5, P88, DOI 10.1038/nsb0298-88; Smit Martine J., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P1; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; Wittpoth C, 1999, P NATL ACAD SCI USA, V96, P9551, DOI 10.1073/pnas.96.17.9551; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849	20	2	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13925	13933		10.1074/jbc.M314334200	http://dx.doi.org/10.1074/jbc.M314334200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722077	hybrid			2022-12-25	WOS:000220478500079
J	De Cristofaro, R; Akhavan, S; Altomare, C; Carotti, A; Peyvandi, F; Mannucci, PM				De Cristofaro, R; Akhavan, S; Altomare, C; Carotti, A; Peyvandi, F; Mannucci, PM			A natural prothrombin mutant reveals an unexpected influence of A-chain structure on the activity of human alpha-thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; ACTIVATION; MECHANISM; ANTITHROMBIN; DEFICIENCY; FIBRINOGEN; INHIBITORS; MUTATIONS; LETHALITY; GEOMETRY	We have recently identified in two unrelated patients with bleeding tendency a homozygous mutation causing a deletion of one of the two contiguous Lys(9)/Lys(10) residues in the A- chain of alpha-thrombin ( DeltaK9). We used in vitro expression analysis to clarify the role of the deletion of Lys(9) or Lys(10) in the thrombin function. The k(cat)/ K-m value of the hydrolysis by DeltaK9 of the synthetic substrate Phe-Pip- Arg- p- nitroanilide ( where Pip represents L- pipecolyl) and fibrinopeptide A was 18- and 60- fold lower, respectively, compared with wild type ( WT). Interaction with antithrombin was also reduced in the mutant, the association rate being about 20- fold lower than in the WT thrombin. The sensitivity to sodium ion of DeltaK9 was found significantly attenuated compared with the WT form. DeltaK9 has a very weak platelet- activating capacity, attributed to a severely defective PAR1 interaction, whereas the binding to the platelet glycoprotein Ibalpha was unaffected. Likewise, the interaction with protein C was severely impaired, whereas interaction with thrombomodulin had a normal K-d value. At variance with these findings, both low affinity ( basic pancreatic trypsin inhibitor) and high affinity ( N-alpha-[2-naphthylsulfonyl- glycyl]4- amidinophenylalanine- piperidide) thrombin inhibitors displayed a better binding to DeltaK9 than to the WT form, indicating a better accommodation of these inhibitors into the catalytic pocket of DeltaK9. A molecular dynamics simulation of the DeltaK9 thrombin in full explicit water solvent provided support to the role of the A-chain in affecting conformation and catalytic properties of the B- chain, especially in some insertion loops of the enzyme, such as the 60- loop, as well as in the geometry of the catalytic triad residues.	Catholic Univ, Sch Med, Inst Internal Med & Geriatr, Hemostasis Res Ctr, I-00168 Rome, Italy; Univ Milan, IRCCS Maggiore Hosp, Angelo Bianchi Hemophilia & Thrombosis Ctr, I-20121 Milan, Italy; Univ Milan, IRCCS Maggiore Hosp, Fdn Luigi Villa, I-20121 Milan, Italy; Univ Bari, Dept Pharmaceut Chem, I-70125 Bari, Italy; Univ Paris 07, Fac Xavier Bichat, INSERM, E0348, F-75870 Paris, France	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Universita degli Studi di Bari Aldo Moro; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	De Cristofaro, R (corresponding author), Catholic Univ, Sch Med, Inst Internal Med, Hemostasis Res Ctr, Largo F Vito 1, I-00168 Rome, Italy.	rdecristofaro@rm.unicatt.it	De Cristofaro, Raimondo/K-3942-2018; Peyvandi, Flora/AAK-7437-2020; Carotti, Andrea/B-4825-2015	De Cristofaro, Raimondo/0000-0002-8066-8849; Peyvandi, Flora/0000-0001-7423-9864; Carotti, Andrea/0000-0001-6097-3996				Akhavan S, 2000, THROMB HAEMOSTASIS, V84, P989; Akhavan S, 2003, BRIT J HAEMATOL, V120, P142, DOI 10.1046/j.1365-2141.2003.03986.x; Akhavan S, 2002, BLOOD, V100, P1347, DOI 10.1182/blood-2002-01-0243; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berendsen HJC, 1981, INTERMOLECULAR FORCE, P331, DOI [DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658-1_21]; BODE W, 1992, PROTEIN SCI, V1, P426; BURGI HB, 1973, J AM CHEM SOC, V95, P5065, DOI 10.1021/ja00796a058; De Cristofaro R, 2000, J BIOL CHEM, V275, P3887, DOI 10.1074/jbc.275.6.3887; De Cristofaro R, 1999, EUR J BIOCHEM, V260, P97, DOI 10.1046/j.1432-1327.1999.00118.x; De Filippis V, 2002, BIOCHEMISTRY-US, V41, P13556, DOI 10.1021/bi0203482; DECRISTOFARO R, 1993, BIOCHEM J, V289, P475, DOI 10.1042/bj2890475; DECRISTOFARO R, 1994, J MOL BIOL, V239, P569, DOI 10.1006/jmbi.1994.1396; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P6165, DOI 10.1021/bi00393a033; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; FERSHT A, 1985, ENZYME STRUCTURE MEC, P405; Fischer BE, 1996, PROTEIN ENG, V9, P921, DOI 10.1093/protein/9.10.921; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; GEPPERT AG, 1992, ARCH BIOCHEM BIOPHYS, V297, P205, DOI 10.1016/0003-9861(92)90663-H; HAGEMAN TC, 1975, ARCH BIOCHEM BIOPHYS, V171, P327, DOI 10.1016/0003-9861(75)90039-9; HARTLEY BS, 1970, PHILOS T ROY SOC B, V257, P77, DOI 10.1098/rstb.1970.0010; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; HILL TL, 1975, P NATL ACAD SCI USA, V72, P4918, DOI 10.1073/pnas.72.12.4918; Huntington JA, 2003, STRUCTURE, V11, P469, DOI 10.1016/S0969-2126(03)00049-2; Lefkowitz JB, 2000, BRIT J HAEMATOL, V108, P182, DOI 10.1046/j.1365-2141.2000.01810.x; MARQUART M, 1983, ACTA CRYSTALLOGR B, V39, P480, DOI 10.1107/S010876818300275X; ORTIZ I, 2002, HAEMOPHILIA, V8, P836; Petrovan RJ, 1998, BIOCHEMISTRY-US, V37, P1185, DOI 10.1021/bi971948h; PICOZZI M, 1994, EUR J BIOCHEM, V219, P1013, DOI 10.1111/j.1432-1033.1994.tb18584.x; SEREISKAYA A A, 1989, Biokhimiya, V54, P542; SPEIJER H, 1986, J BIOL CHEM, V261, P3258; STONE SR, 1991, BIOCHEMISTRY-US, V30, P9841, DOI 10.1021/bi00105a005; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; Sun WY, 1998, P NATL ACAD SCI USA, V95, P7597, DOI 10.1073/pnas.95.13.7597; Sun WY, 2001, THROMB HAEMOSTASIS, V85, P651, DOI 10.1055/s-0037-1615648; van Gunsteren W. F., 1998, ENCY COMPUTATIONAL C, V2, P1211, DOI DOI 10.1002/0470845015.CGA011; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Xue JC, 1998, P NATL ACAD SCI USA, V95, P7603, DOI 10.1073/pnas.95.13.7603	39	21	23	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13035	13043		10.1074/jbc.M312430200	http://dx.doi.org/10.1074/jbc.M312430200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722067	hybrid			2022-12-25	WOS:000220334900124
J	Herr, DR; Fyrst, H; Creason, MB; Phan, VH; Saba, JD; Harris, GL				Herr, DR; Fyrst, H; Creason, MB; Phan, VH; Saba, JD; Harris, GL			Characterization of the Drosophila sphingosine kinases and requirement for Sk2 in normal reproductive function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; DIACYLGLYCEROL KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; PROTEIN; GENE; LOCALIZATION; TRANSLOCATION	Sphingosine kinase is a highly conserved enzyme that catalyzes the synthesis of sphingosine 1-phosphate and reduces cellular levels of sphingosine and ceramide. Although ceramide is pro-apoptotic and sphingosine is generally growth-inhibitory, sphingosine 1-phosphate signaling promotes cell proliferation, survival, and migration. Sphingosine kinase is thus in a strategic position to regulate important cell fate decisions which may contribute to normal animal development. To facilitate studies examining the potential role of sphingosine kinase and long chain base metabolism in Drosophila development, we characterized two putative Drosophila sphingosine kinase genes, Sk1 and Sk2. Both genes functionally and biochemically complement a yeast sphingosine kinase mutant, express predominantly cytosolic activities, and are capable of phosphorylating a range of endogenous and non-endogenous sphingoid base substrates. The two genes demonstrate overlapping but distinct temporal and spatial expression patterns in the Drosophila embryo, and timing of expression is consistent with observed changes in long chain base levels throughout development. A null Sk2 transposon insertion mutant demonstrated elevated long chain base levels, impaired flight performance, and diminished ovulation. This is the first reported mutation of a sphingosine kinase in an animal model; the associated phenotypes indicate that Sk1 and Sk2 are not redundant in biological function and that sphingosine kinase is essential for diverse physiological functions in this organism.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; California State University System; San Diego State University; California State University System; San Diego State University	Saba, JD (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	jsaba@chori.org; gharris@sunstroke.sdsu.edu	Herr, Deron/AAB-7380-2020	Herr, Deron/0000-0001-5755-0896	NATIONAL CANCER INSTITUTE [R01CA077528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066954] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA 77528] Funding Source: Medline; NIGMS NIH HHS [1R01 GM 066954] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549; Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P7276; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Bolz SS, 2003, CIRCULATION, V108, P342, DOI 10.1161/01.CIR.0000080324.12530.0D; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; Corvera S, 2001, TRAFFIC, V2, P859, DOI 10.1034/j.1600-0854.2001.21201.x; Coursol S, 2003, NATURE, V423, P651, DOI 10.1038/nature01643; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Fukuda Y, 2003, BIOCHEM BIOPH RES CO, V309, P155, DOI 10.1016/S0006-291X(03)01551-1; Fyrst H, 2004, J LIPID RES, V45, P54, DOI 10.1194/jlr.M300005-JLR200; Herr DR, 2003, DEVELOPMENT, V130, P2443, DOI 10.1242/dev.00456; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; Kim S, 2000, GENETICS, V156, P1519; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lanterman MM, 1998, BIOCHEM J, V332, P525, DOI 10.1042/bj3320525; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Martelli AM, 2002, CELL MOL LIFE SCI, V59, P1129, DOI 10.1007/s00018-002-8492-9; Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5; Mendel J, 2003, J BIOL CHEM, V278, P22341, DOI 10.1074/jbc.M302857200; MISRA S, 2002, GENOME BIOL, V3, P14; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Murate T, 2001, J HISTOCHEM CYTOCHEM, V49, P845, DOI 10.1177/002215540104900705; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Nishiura H, 2000, BIOCHEM SOC T, V28, P747, DOI 10.1042/BST0280747; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Qazi MCB, 2003, DEV BIOL, V256, P195, DOI 10.1016/S0012-1606(02)00125-2; Renault Andrew D., 2002, Gene Expression Patterns, V2, P337, DOI 10.1016/S0925-4773(02)00389-1; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; ROSEMAN RR, 1995, GENETICS, V141, P1061; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Stapleton M, 2002, GENOME RES, V12, P1294, DOI 10.1101/gr.269102; Sukocheva OA, 2003, MOL ENDOCRINOL, V17, P2002, DOI 10.1210/me.2003-0119; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Vann LR, 2002, J BIOL CHEM, V277, P12649, DOI 10.1074/jbc.M109111200; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Young KW, 2003, CELL CALCIUM, V33, P119, DOI 10.1016/S0143-4160(02)00205-1	56	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12685	12694		10.1074/jbc.M310647200	http://dx.doi.org/10.1074/jbc.M310647200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722126	hybrid			2022-12-25	WOS:000220334900082
J	Masuyama, H; Hiramatsu, Y				Masuyama, H; Hiramatsu, Y			Involvement of suppressor for Gal 1 in the ubiquitin/proteasome-mediated degradation of estrogen receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME-DEPENDENT DEGRADATION; ENDOCRINE-DISRUPTING CHEMICALS; PREGNANE-X RECEPTOR; HORMONE RECEPTOR; 26S PROTEASOME; AF-2 DOMAIN; TRANSCRIPTION; COACTIVATOR; SUPERFAMILY; ACTIVATION	The proteasome-mediated pathway involves the degradation of several nuclear receptors. Previously we demonstrated that the interaction between the suppressor for Gal 1 (SUG1) and nuclear receptors, the vitamin D receptor, or the pregnane X receptor was involved in proteasome-mediated degradation. In our recent experiments, we examined the potential role of SUG1 in the proteasome-mediated degradation of estrogen receptors (ER)alpha and - beta. Both ERs interacted with SUG1 in a ligand-dependent manner. Functionally, the overexpression of SUG1 inhibited both ERalpha- and ERbeta-mediated transcription in the presence of ligands. Transient expression studies demonstrated that the overexpression of wildtype SUG1 generated proteolytic fragments of both ERs and that these products were blocked by a proteasome inhibitor. The overexpression of SUG1 also enhanced the formation of ubiquitinated proteins of both ERs in the presence of ligand. On the other hand, bisphenol A (BSA), which activated ER-mediated transcription, did not enhance the interaction between ERbeta and SUG1. Furthermore, the degradation of ERbeta was much slower in the presence of BSA than in the presence of estradiol or phthalate, which is another endocrine-disrupting chemical. Also, BSA had no effect on the formation of proteolytic fragments of ERbeta, and neither did it have any effect on the ubiquitination of ERbeta. These findings indicate that the ubiquitin/proteasome-mediated degradation of both ER proteins may involve the interaction of SUG1 with both ERs. Moreover, BSA strongly blocked the ubiquitination and degradation of ERbeta compared with estradiol, suggesting that BSA may affect the ERbeta-mediated transcription of target genes by inhibiting ERbeta degradation.	Okayama Univ, Sch Med, Dept Obstet & Gynecol, Okayama 7008558, Japan	Okayama University	Masuyama, H (corresponding author), Okayama Univ, Sch Med, Dept Obstet & Gynecol, 2-5-1 Shikata, Okayama 7008558, Japan.	masuyama@cc.okayama-u.ac.jp						Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cooper RL, 1997, J ENDOCRINOL, V152, P159, DOI 10.1677/joe.0.1520159; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ECKERT RL, 1984, ENDOCRINOLOGY, V114, P629, DOI 10.1210/endo-114-2-629; Gorbea C, 1999, MOL BIOL REP, V26, P15, DOI 10.1023/A:1006957802028; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Inoshita H, 2003, J MOL ENDOCRINOL, V31, P551, DOI 10.1677/jme.0.0310551; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.1289/ehp.96104s4715; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Masuyama H, 2000, MOL ENDOCRINOL, V14, P421, DOI 10.1210/me.14.3.421; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; Masuyama H, 2002, ENDOCRINOLOGY, V143, P55, DOI 10.1210/en.143.1.55; Masuyama H, 1998, J CELL BIOCHEM, V71, P429, DOI 10.1002/(SICI)1097-4644(19981201)71:3<429::AID-JCB11>3.0.CO;2-P; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; ONATE SA, 1995, SCIENCE, V270, P1354; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Su KH, 2000, BIOCHEM J, V348, P281, DOI 10.1042/0264-6021:3480281; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; Syvala H, 1998, LIFE SCI, V63, P1505, DOI 10.1016/S0024-3205(98)00417-2; Tanahashi N, 1999, MOL BIOL REP, V26, P3, DOI 10.1023/A:1006909522731; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VOM BE, 1996, EMBO J, V15, P110	28	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12020	12026		10.1074/jbc.M312762200	http://dx.doi.org/10.1074/jbc.M312762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14702340	hybrid			2022-12-25	WOS:000220334900004
J	Yamamura, H; Ugawa, S; Ueda, T; Nagao, M; Shimada, S				Yamamura, H; Ugawa, S; Ueda, T; Nagao, M; Shimada, S			Protons activate the delta-subunit of the epithelial Na+ channel in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; ION CHANNELS; MOLECULAR-CLONING; PH SENSITIVITY; EXPRESSION; NEURODEGENERATION; NEURONS; FAMILY	The amiloride-sensitive epithelial Na+ channel (ENaC) controls Na+ transport into cells and across epithelia. So far, four homologous subunits of mammalian ENaC have been isolated and are denoted as alpha, beta, gamma, and delta. ENaCdelta can associate with beta and gamma subunits and generate a constitutive current that is 2 orders of magnitude larger than that of homomeric ENaCdelta. However, the distribution pattern of ENaCdelta is not consistent with that of the beta and gamma subunits. ENaCdelta is expressed mainly in the brain in contrast to beta and gamma subunits, which are expressed in non-neuronal tissues. To explain this discrepancy, we searched for novel functional properties of homomeric ENaCdelta and investigated the detailed tissue distribution in humans. When human ENaCdelta was expressed in Xenopus oocytes and Chinese hamster ovary cells, a reduction of extracellular pH activated this channel (half-maximal pH for an activation of 5.0), and the acid-induced current was abolished by amiloride. The most striking finding was that the desensitization of the acid-evoked current was much slower ( by similar to 10% 120 s later), dissociating from the kinetics of acid-sensing ion channels in the degenerin/epithelial Na+ channel family, which were rapidly desensitized during acidification. RNA dot-blot analyses showed that ENaCdelta mRNA was widely distributed throughout the brain and was also expressed in the heart, kidney, and pancreas in humans. Northern blotting confirmed that ENaCdelta was expressed in the cerebellum and the hippocampus. In conclusion, human ENaCdelta activity is regulated by protons, indicating that it may contribute to the pH sensation and/or pH regulation in the human brain.	Nagoya City Univ, Grad Sch Med Sci, Dept Mol Morphol, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Forens Med Sci, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University	Yamamura, H (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Mol Morphol, Mizuho Ku, 1 Kawasumi Mizuhocho, Nagoya, Aichi 4678601, Japan.	yamamura@med.nagoya-cu.ac.jp						Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chalfant ML, 1999, AM J PHYSIOL-CELL PH, V276, pC477, DOI 10.1152/ajpcell.1999.276.2.C477; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Konstas AA, 2000, PFLUG ARCH EUR J PHY, V441, P341, DOI 10.1007/s004240000430; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Ugawa S, 1998, NATURE, V395, P555, DOI 10.1038/26882; Ugawa S, 2001, NEUROREPORT, V12, P2141, DOI 10.1097/00001756-200107200-00020; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1996, GENOMICS, V34, P262, DOI 10.1006/geno.1996.0282; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Zhang P, 1999, BIOPHYS J, V77, P3043, DOI 10.1016/S0006-3495(99)77135-3	22	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12529	12534		10.1074/jbc.M400274200	http://dx.doi.org/10.1074/jbc.M400274200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14726523	hybrid			2022-12-25	WOS:000220334900064
J	Zitt, C; Strauss, B; Schwarz, EC; Spaeth, N; Rast, G; Hatzelmann, A; Hoth, M				Zitt, C; Strauss, B; Schwarz, EC; Spaeth, N; Rast, G; Hatzelmann, A; Hoth, M			Potent inhibition of Ca2+ release-activated Ca2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-AMINOETHOXYDIPHENYL BORATE; MAST-CELLS; STORE DEPLETION; CALCIUM-RELEASE; IL-2 PRODUCTION; CRAC CHANNELS; MIC CHANNELS; INFLUX; ENTRY; 3,5-BIS(TRIFLUOROMETHYL)PYRAZOLES	Ca2+ entry through store-operated Ca2+ release-activated Ca2+ (CRAC) channels is essential for T-cell activation and proliferation. Recently, it has been shown that 3,5-bistrifluoromethyl pyrazole (BTP) derivatives are specific inhibitors of Ca2+-dependent transcriptional activity in T-cells (Trevillyan, J.M., Chiou, X. G., Chen, Y.W., Ballaron, S.J., Sheets, M. P., Smith, M. L., Wiedeman, P. E., Warrior, U., Wilkins, J., Gubbins, E. J., Gagne, G. D., Fagerland, J., Carter, G. W., Luly, J. R., Mollison, K. W., and Djuric, S. W. (2001) J. Biol. Chem. 276, 48118-48126). Whereas inhibition of Ca2+ signals was reported for BTP2 (Ishikawa, J., Ohga, K., Yoshino, T., Takezawa, R., Ichikawa, A., Kubota, H., and Yamada, T. (2003) J. Immunol. 170, 4441-4449), it was not found for BTP3 (Chen, Y., Smith, M. L., Chiou, G. X., Ballaron, S., Sheets, M. P., Gubbins, E., Warrior, U., Wilkins, J., Surowy, C., Nakane, M., Carter, G. W., Trevillyan, J. M., Mollison, K., and Djuric, S. W. ( 2002) Cell. Immunol. 220, 134-142). We show that BTP2 specifically inhibits CRAC channels in T-cells with an IC50 of similar to10 nM. It does not interfere with other mechanisms important for Ca2+ signals in T-cells, including Ca2+ pumps, mitochondrial Ca2+ signaling, endoplasmic reticulum Ca2+ release, and K+ channels. BTP2 inhibits Ca2+ signals in peripheral blood T-lymphocytes (in particular in CD4(+) T-cells) and in human Jurkat T-cells. Inhibition of Ca2+ signals is independent of the stimulation method as Ca2+ entry was blocked following stimulation with anti-CD3, which activates the T-cell receptor, and also following stimulation with thapsigargin or inositol 1,4,5-trisphosphate. BTP2 also inhibited Ca2+-dependent gene expression (interleukins 2 and 5 and interferon gamma) and proliferation of T-lymphocytes with similar IC50 values. BTP2 is the first potent and specific inhibitor of CRAC channels in primary T-lymphocytes. The inhibition of CRAC channels as well as Ca2+-dependent signal transduction with similar IC50 values in T-lymphocytes emphasizes the importance of CRAC channel activity during T-cell activation. Furthermore, BTP2 could prove to be a tool to finally unmask the molecular identity of CRAC channels.	Univ Saarland, Dept Physiol, D-66421 Homburg, Germany; ALTANA Pharma AG, Dept Biochem, RDR B2, D-78467 Constance, Germany	Saarland University; Altana	Hoth, M (corresponding author), Univ Saarland, Dept Physiol, D-66421 Homburg, Germany.	markus.hoth@uniklinik-saarland.de		Hoth, Markus/0000-0001-7080-4643; Schwarz, Eva C./0000-0002-6503-4864				Bautista DM, 2002, J PHYSIOL-LONDON, V541, P877, DOI 10.1113/jphysiol.2001.016154; Braun FJ, 2003, MOL PHARMACOL, V63, P1304, DOI 10.1124/mol.63.6.1304; Chen YW, 2002, CELL IMMUNOL, V220, P134, DOI 10.1016/S0008-8749(03)00005-4; CHUNG SC, 1994, BRIT J PHARMACOL, V113, P861, DOI 10.1111/j.1476-5381.1994.tb17072.x; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Djuric SW, 2000, J MED CHEM, V43, P2975, DOI 10.1021/jm990615a; DONNADIEU E, 1993, PFLUG ARCH EUR J PHY, V424, P448, DOI 10.1007/BF00374907; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; FRANZIUS D, 1994, PFLUG ARCH EUR J PHY, V428, P433, DOI 10.1007/BF00374562; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Ishikawa J, 2003, J IMMUNOL, V170, P4441, DOI 10.4049/jimmunol.170.9.4441; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Trevillyan JM, 2001, J BIOL CHEM, V276, P48118, DOI 10.1074/jbc.M107919200; Wu J, 2000, MOL PHARMACOL, V58, P1368, DOI 10.1124/mol.58.6.1368; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	32	226	242	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12427	12437		10.1074/jbc.M309297200	http://dx.doi.org/10.1074/jbc.M309297200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718545	hybrid			2022-12-25	WOS:000220334900052
J	Cha, MK; Hong, SK; Lee, DS; Kim, IH				Cha, MK; Hong, SK; Lee, DS; Kim, IH			Vibrio cholerae thiol peroxidase-glutaredoxin fusion is a 2-Cys TSA/AhpC subfamily acting as a lipid hydroperoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ANTIOXIDANT PROTEIN; PEROXIREDOXIN; THIOREDOXIN; FAMILY; PURIFICATION; OXIDATION; POPLAR; ENZYME	Recently, novel hybrid thiol peroxidase (TPx) proteins fused with a glutaredoxin (Grx) were found from some pathogenic bacteria, cyanobacteria, and anaerobic sulfur-oxidizing phototroph. The phylogenic tree analysis that was constructed from the aligned sequences showed two major branches. Haemophilus influenzae TPx.Grx was grouped in one branch as a 1-Cys subfamily of the thiol-specific antioxident protein/AhpC family. Most TPx.Grx proteins, including Vibrio cholerae TPx.Grx, were grouped in the 2-Cys subfamily. To explain the existence of two subgroups in novel hybrid TPx proteins, we have compared the kinetics given by V. cholerae TPx.Grx, H. influenzae TPx.Grx, their separated TPx domains, and a set of mutants devoid of the redox-active cysteines. The kinetic study described here demonstrates clearly that V. cholerae TPx.Grx is a 2-Cys TPx subfamily. For the first time, we also demonstrate the lipid peroxidase activity of V. cholerae TPx.Grx fusion and suggest the in vivo function of 2-Cys TPx.Grx fusion serving as a lipid peroxidase.	Paichai Univ, Dept Biochem, Taejon 302735, South Korea	Pai Chai University	Kim, IH (corresponding author), Paichai Univ, Dept Biochem, 439-6 Doma 2 Dong, Taejon 302735, South Korea.	ihkim@mail.paichai.ac.kr	Kim, Il-Han/W-1401-2019					BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Cha MK, 2003, J BIOL CHEM, V278, P24636, DOI 10.1074/jbc.M302628200; Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; FERRI A, 1995, BIOCHEM MOL BIOL INT, V35, P691; Halliwell B, 1999, FREE RADICAL BIO MED, P105, DOI DOI 10.1093/ACPR0F:0S0/9780198717478.003.0005; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; JIANG ZY, 1991, LIPIDS, V26, P853, DOI 10.1007/BF02536169; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kim SJ, 2003, J BIOL CHEM, V278, P10790, DOI 10.1074/jbc.M209553200; Link AJ, 1997, ELECTROPHORESIS, V18, P1259, DOI 10.1002/elps.1150180807; LYNCH AS, 1996, E COLI SALMONELLA CE, V6, P1526; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Pauwels F, 2003, J BIOL CHEM, V278, P16658, DOI 10.1074/jbc.M300157200; Poole LB, 2000, EUR J BIOCHEM, V267, P6126, DOI 10.1046/j.1432-1327.2000.01704.x; POOLE LB, 2003, SIGNAL TRANSDUCTION, P80; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Rouhier N, 2002, J BIOL CHEM, V277, P13609, DOI 10.1074/jbc.M111489200; Rouhier N, 2001, PLANT PHYSIOL, V127, P1299, DOI 10.1104/pp.010586; Sambrook J, 2001, MOL CLONING LAB MANU; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; SIKORSKI RS, 1989, GENETICS, V122, P19; TENHAKEN R, 1995, P NATL ACAD SCI USA, V92, P4158, DOI 10.1073/pnas.92.10.4158; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vergauwen B, 2001, J BIOL CHEM, V276, P20890, DOI 10.1074/jbc.M102026200; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8	35	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11035	11041		10.1074/jbc.M312657200	http://dx.doi.org/10.1074/jbc.M312657200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702341	hybrid			2022-12-25	WOS:000220157600026
J	Kozlov, G; Cheng, J; Ziomek, E; Banville, D; Gehring, K; Ekiel, I				Kozlov, G; Cheng, J; Ziomek, E; Banville, D; Gehring, K; Ekiel, I			Structural insights into molecular function of the metastasis-associated phosphatase PRL-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; TUMOR-SUPPRESSOR; REDOX REGULATION; NMR; SPECIFICITY; 1B; INACTIVATION; PRENYLATION	Phosphatases and kinases are the cellular signal transduction enzymes that control protein phosphorylation. PRL phosphatases constitute a novel class of small (20 kDa), prenylated phosphatases with oncogenic activity. In particular, PRL-3 is consistently overexpressed in liver metastasis in colorectal cancer cells and represents a new therapeutic target. Here, we present the solution structure of PRL-3, the first structure of a PRL phosphatase. The structure places PRL phosphatases in the class of dual specificity phosphatases with closest structural homology to the VHR phosphatase. The structure, coupled with kinetic studies of site-directed mutants, identifies functionally important residues and reveals unique features, differentiating PRLs from other phosphatases. These differences include an unusually hydrophobic active site without the catalytically important serine/threonine found in most other phosphatases. The position of the general acid loop indicates the presence of conformational change upon catalysis. The studies also identify a potential regulatory role of Cys(49) that forms an intramolecular disulfide bond with the catalytic Cys(104) even under mildly reducing conditions. Molecular modeling of the highly homologous PRL-1 and PRL-2 phosphatases revealed unique surface elements that are potentially important for specificity.	Natl Res Council Canada, Biotechnol Res Inst, Hlth Sector, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H3G 1M8, Canada	National Research Council Canada; McGill University; Concordia University - Canada	Ekiel, I (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Hlth Sector, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	irena.ekiel@nrc.ca	Gehring, Kalle/N-2945-2019; Gehring, Kalle/I-4403-2013	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184				Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Bardelli A, 2003, CLIN CANCER RES, V9, P5607; Billeter M, 1995, J BIOMOL NMR, V5, P1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Diamond RH, 1996, AM J PHYSIOL-GASTR L, V271, pG121, DOI 10.1152/ajpgi.1996.271.1.G121; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kozlov G, 2002, J BIOMOL NMR, V24, P169, DOI 10.1023/A:1020937316065; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Matter WF, 2001, BIOCHEM BIOPH RES CO, V283, P1061, DOI 10.1006/bbrc.2001.4881; McCain DF, 2002, J BIOL CHEM, V277, P11190, DOI 10.1074/jbc.M109636200; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Wang J, 2002, J BIOL CHEM, V277, P46659, DOI 10.1074/jbc.M206407200; Werner SR, 2003, CANCER LETT, V202, P201, DOI 10.1016/S0304-3835(03)00517-2; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zama T, 2002, J BIOL CHEM, V277, P23909, DOI 10.1074/jbc.M200837200; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 2003, CANCER RES, V63, P2716; Zeng Q, 1998, BIOCHEM BIOPH RES CO, V244, P421, DOI 10.1006/bbrc.1998.8291; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16389, DOI 10.1021/bi00050a020; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616	43	87	96	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11882	11889		10.1074/jbc.M312905200	http://dx.doi.org/10.1074/jbc.M312905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14704153	hybrid			2022-12-25	WOS:000220157600125
J	Stromer, T; Fischer, E; Richter, K; Haslbeck, M; Buchner, J				Stromer, T; Fischer, E; Richter, K; Haslbeck, M; Buchner, J			Analysis of the regulation of the molecular chaperone Hsp26 by temperature-induced dissociation - The N-terminal domain is important for oligomer assembly and the binding of unfolding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ALPHA-CRYSTALLIN; QUATERNARY STRUCTURE; ESCHERICHIA-COLI; SUBUNIT EXCHANGE; CITRATE SYNTHASE; EXPRESSION; EVOLUTION; FAMILY	Small heat shock proteins (sHsps) are molecular chaperones that efficiently bind non-native proteins. All members of this family investigated so far are oligomeric complexes. For Hsp26, an sHsp from the cytosol of Saccharomyces cerevisiae, it has been shown that at elevated temperatures the 24-subunit complex dissociates into dimers. This dissociation seems to be required for the efficient interaction with unfolding proteins that results in the formation of large, regular complexes comprising Hsp26 and the non-native proteins. To gain insight into the molecular mechanism of this chaperone, we analyzed the dynamics and stability of the two oligomeric forms of Hsp 26 (i.e. the 24-mer and the dimer) in comparison to a construct lacking the N-terminal domain (Hsp26DeltaN). Furthermore, we determined the stabilities of complexes between Hsp26 and non-native proteins. We show that the temperature-induced dissociation of Hsp26 into dimers is a completely reversible process that involves only a small change in energy. The unfolding of the dissociated Hsp26 dimer or Hsp26DeltaN, which is a dimer, requires a much higher energy. Because Hsp26DeltaN was inactive as a chaperone, these results imply that the N-terminal domain is of critical importance for both the association of Hsp26 with non-native proteins and the formation of large oligomeric complexes. Interestingly, complexes of Hsp26 with non-native proteins are significantly stabilized against dissociation compared with Hsp26 complexes. Taken together, our findings suggest that the quaternary structure of Hsp26 is determined by two elements, (i) weak, regulatory interactions required to form the shell of 24 subunits and (ii) a strong and stable dimerization of the C-terminal domain.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Buchner, Johannes/A-2651-2010; Richter, Klaus/A-2673-2010; Haslbeck, Martin/A-4413-2013	Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				Arrigo AP, 2000, PATHOL BIOL, V48, P280; BENTLEY NJ, 1992, YEAST, V8, P95, DOI 10.1002/yea.320080204; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; DUDICH IV, 1995, BBA-PROTEIN STRUCT M, V1253, P163, DOI 10.1016/0167-4838(95)00135-X; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Feil IK, 2001, J BIOL CHEM, V276, P12024, DOI 10.1074/jbc.M010856200; Halevi I, 1998, J PALESTINE STUD, V27, P35, DOI 10.1525/jps.1998.27.3.00p0186t; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492; Haslbeck M, 2003, J CHROMATOGR B, V786, P127, DOI 10.1016/S1570-0232(02)00716-X; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; JAENICKE R, 1993, CURR BIOL, V3, P234, DOI 10.1016/0960-9822(93)90342-L; Kappe Guido, 2002, Prog Mol Subcell Biol, V28, P1; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kokke BPA, 1998, FEBS LETT, V433, P228, DOI 10.1016/S0014-5793(98)00917-X; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Sobott F, 2002, J BIOL CHEM, V277, P38921, DOI 10.1074/jbc.M206060200; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; Studer S, 2000, J BIOL CHEM, V275, P37212, DOI 10.1074/jbc.M004701200; van de Klundert FAJM, 1998, EUR J BIOCHEM, V258, P1014, DOI 10.1046/j.1432-1327.1998.2581014.x; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VIERLING E, 1989, MOL CELL BIOL, V9, P461, DOI 10.1128/MCB.9.2.461; Walter S, 2002, ANGEW CHEM INT EDIT, V41, P1098, DOI 10.1002/1521-3773(20020402)41:7<1098::AID-ANIE1098>3.0.CO;2-9; Waters ER, 1999, P NATL ACAD SCI USA, V96, P14394, DOI 10.1073/pnas.96.25.14394	33	112	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11222	11228		10.1074/jbc.M310149200	http://dx.doi.org/10.1074/jbc.M310149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722093	hybrid			2022-12-25	WOS:000220157600048
J	Bossi, G; Mazzaro, G; Porrello, A; Crescenzi, M; Soddu, S; Sacchi, A				Bossi, G; Mazzaro, G; Porrello, A; Crescenzi, M; Soddu, S; Sacchi, A			Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy	ONCOGENE			English	Article						p53; gene therapy; tumor targeting; normal cells; retrovirus vector	HEMATOPOIETIC STEM-CELLS; SUPPRESSOR GENE; RETROVIRAL VECTORS; EXOGENOUS WT-P53; 32D CELLS; CANCER; DIFFERENTIATION; TRANSPLANTATION; EXPRESSION; ONCOGENES	The p53 oncosuppressor is strictly maintained in an inactive form under normal conditions, while it is post-translationally activated by a variety of stresses, enacting different protective biological functions. Since one critical issue in cancer gene therapy is tumor specificity, we asked whether the tight p53 regulation applies also to exogenously transferred p53. In principle, this type of regulation could allow p53 gene transfer in both normal and tumor cells to produce detrimental effects only in the latter ones. Here, we report that primary bone marrow cells infected with a p53 recombinant retrovirus and transplanted into irradiated mice reconstitute the hematopoietic system, with no detectable alterations in any of its compartments. Furthermore, simultaneous infection of leukemia and bone marrow cells depleted the neoplastic contamination, allowing lifelong, disease-free survival of 65% of the transplanted animals. These results show that exogenous p53 is controlled as tightly as the endogenous one, and opens the way to p53 gene therapy, without requiring tumor targeting.	Regina Elena Inst Canc Res, Dept Expt Oncol, Mol Oncogenesis Lab, I-00158 Rome, Italy; Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS)	Soddu, S (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Mol Oncogenesis Lab, Via Messi Oro 156, I-00158 Rome, Italy.	soddu@ifo.it; sacchi@ifo.it	Bossi, Gianluca/G-8375-2016; Bossi, Gianluca/ABH-6846-2020; Soddu, Silvia/K-2467-2018; Soddu, Silvia/ABH-6774-2020; Crescenzi, Marco/J-3603-2018; Bossi, Gianluca/B-9394-2017	Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; Crescenzi, Marco/0000-0003-0156-1494; Bossi, Gianluca/0000-0002-2947-1063	Telethon [GP0234Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Appella E, 2000, PATHOL BIOL, V48, P227; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BLANDINO G, 1995, ONCOGENE, V10, P731; BODINE DM, 1991, EXP HEMATOL, V19, P206; Bossi G, 2000, CANCER GENE THER, V7, P135, DOI 10.1038/sj.cgt.7700101; CLAYMAN GL, 1995, CANCER RES, V55, P1; D'Orazi G, 2000, J GENE MED, V2, P11; Domen J, 1999, MOL MED TODAY, V5, P201, DOI 10.1016/S1357-4310(99)01464-1; Favrot M, 1998, GENE THER, V5, P728, DOI 10.1038/sj.gt.3300661; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Gorin NC, 2002, CURR OPIN ONCOL, V14, P152, DOI 10.1097/00001622-200203000-00003; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Heslop HE, 1995, BLOOD REV, V9, P220, DOI 10.1016/S0268-960X(95)90013-6; Karlsson S, 1997, J INTERN MED, V242, P95, DOI 10.1111/joim.1997.242.s740.95; KASTAN MB, 1991, CANCER RES, V51, P4279; LaCasse EC, 1999, BLOOD, V94, P2901; Martinelli R, 1997, ONCOGENE, V15, P607, DOI 10.1038/sj.onc.1201218; Mazzaro G, 1999, ONCOGENE, V18, P5831, DOI 10.1038/sj.onc.1202962; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nielsen LL, 1998, CANCER GENE THER, V5, P52; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Scardigli R, 1997, GENE THER, V4, P1371, DOI 10.1038/sj.gt.3300530; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; Soddu S, 1996, MOL CELL BIOL, V16, P487; Soddu S, 1998, CYTOKINES CELL MOL T, V4, P177; TAKAHASHI T, 1992, CANCER RES, V52, P2340; Williams David A., 2000, Hematology Am Soc Hematol Educ Program, P376; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155	34	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					418	425		10.1038/sj.onc.1207042	http://dx.doi.org/10.1038/sj.onc.1207042			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724570				2022-12-25	WOS:000188098300012
J	Petrovics, G; Zhang, W; Makarem, M; Street, JP; Connelly, R; Sun, L; Sesterhenn, IA; Srikantan, V; Moul, JW; Srivastava, S				Petrovics, G; Zhang, W; Makarem, M; Street, JP; Connelly, R; Sun, L; Sesterhenn, IA; Srikantan, V; Moul, JW; Srivastava, S			Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients	ONCOGENE			English	Article						PCGEM1; prostate-specific gene; prostate cancer; high-risk patients; cell proliferation	VIRUS-INDUCED LYMPHOMAS; AFRICAN-AMERICAN; RETINOBLASTOMA PROTEIN; PHOSPHORYLATION; OVEREXPRESSION; INSERTIONS; RACEMASE; MARKERS; RNA	PCGEM1 is a novel, highly prostate tissue-specific, androgen-regulated gene. Here, we demonstrate that PCGEM1 expression is significantly higher in prostate cancer (CaP) cells of African-American men than in Caucasian-American men (P=0.0002). Further, increased PCGEM1 expression associates with normal prostate epithelial cells of CaP patients with a family history of CaP (P=0.0400). PCGEM1 overexpression in LNCaP and in NIH3T3 cells promotes cell proliferation and a dramatic increase in colony formation, suggesting a biological role of PCGEM1 in cell growth regulation. Taken together, the cell proliferation/colony formation-promoting functions of PCGEM1 and the association of its increased expression with high-risk CaP patients suggest the potential roles of PCGEM1 in CaP onset/progression, especially in these high-risk groups.	Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, US Mil Canc Inst, Bethesda, MD 20814 USA; Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20306 USA; Walter Reed Army Med Ctr, Serv Urol, Washington, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Petrovics, G (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, 1530 E Jefferson St, Rockville, MD 20852 USA.	gpetrovics@cpdr.org		Petrovics, Gyorgy/0000-0003-3732-284X	NCI NIH HHS [1R01CA85596-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1994, MOL CELL BIOL, V14, P1743, DOI 10.1128/MCB.14.3.1743; Brantey MA, 2000, CANCER RES, V60, P4320; Brawley O W, 1998, Semin Urol Oncol, V16, P193; Bussemakers MJG, 1999, CANCER RES, V59, P5975; Cussenot O, 2001, Eur J Intern Med, V12, P11, DOI 10.1016/S0953-6205(00)00136-9; de Kok JB, 2002, CANCER RES, V62, P2695; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Guo YP, 2000, PROSTATE, V42, P130, DOI 10.1002/(SICI)1097-0045(20000201)42:2<130::AID-PROS7>3.0.CO;2-3; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Isaacs W, 2002, CANCER CELL, V2, P113, DOI 10.1016/S1535-6108(02)00103-4; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Luo J, 2002, CANCER RES, V62, P2220; Magee JA, 2001, CANCER RES, V61, P5692; MOUL JW, 1995, JAMA-J AM MED ASSOC, V274, P1277, DOI 10.1001/jama.274.16.1277; Nelson WG, 2001, ANN NY ACAD SCI, V952, P135, DOI 10.1111/j.1749-6632.2001.tb02734.x; Paris PL, 1999, CANCER EPIDEM BIOMAR, V8, P901; Platz EA, 2000, JNCI-J NATL CANCER I, V92, P2009, DOI 10.1093/jnci/92.24.2009; Powell I J, 1998, Semin Urol Oncol, V16, P221; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Small Eric J., 1998, Current Opinion in Oncology, V10, P244, DOI 10.1097/00001622-199805000-00012; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Szymanski M, 2002, GENOME BIOL, V3; Tam W, 2002, J VIROL, V76, P4275, DOI 10.1128/JVI.76.9.4275-4286.2002; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; Taylor JA, 1996, CANCER RES, V56, P4108; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Welsh JB, 2001, CANCER RES, V61, P5974; Xu JF, 2002, NAT GENET, V32, P321, DOI 10.1038/ng994; Xu LL, 2000, J UROLOGY, V163, P972, DOI 10.1016/S0022-5347(05)67867-6; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Yang G, 2000, CLIN CANCER RES, V6, P3430	33	190	211	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					605	611		10.1038/sj.onc.1207069	http://dx.doi.org/10.1038/sj.onc.1207069			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724589				2022-12-25	WOS:000188098300032
J	Yoshida, K; Oyaizu, N; Dutta, A; Inoue, I				Yoshida, K; Oyaizu, N; Dutta, A; Inoue, I			The destruction box of human Geminin is critical for proliferation and tumor growth in human colon cancer cells	ONCOGENE			English	Article						Geminin; destruction box; DNA replication initiation; tumor growth	DNA-REPLICATION; CHECKPOINT; INHIBITION; COMPLEXES; ARREST; ORIP; CDT1; P53; PROTEINS; ANAPHASE	A domain-specific disruption was performed on the destruction box sequence of endogenous Geminin gene, an inhibitor of the DNA replication initiation complex, in a human cancer cell line HCT116 resulting in the formation of a protein that was stable in the G1 phase of the cell cycle. Although the total amount of Geminin in asynchronous cultures was not elevated, the G1-specific stabilization of Geminin, diminished chromatin loading of minichromosome maintenance complex, inhibited DNA replication, and resulted in the accumulation of cells in G1. The mutated Geminin suppressed in vivo tumorigenicity and in vitro cell growth. Cells carrying this mutation failed to support the replication of a plasmid bearing the oriP replicator of Epstein-Barr virus. The DNA damage checkpoint pathway was activated in the mutated cells with increased levels of p53 protein and its target, the p21 protein. All these deficits were rescued by overexpression of Cdt1, a replication initiator protein that binds to Geminin. Therefore, alteration of the cell cycle-dependent regulation of endogenous Geminin in human cells without increasing total protein level inhibits DNA replication and suppresses tumor growth.	Univ Tokyo, Inst Med Sci, Div Genet Diag, Minato Ku, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Dept Lab Med, Div Mol Pathol,Minato Ku, Tokyo, Japan; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Tokyo; University of Tokyo; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Yoshida, K (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet Diag, Minato Ku, 4-6-1 Shirokanedai, Tokyo, Japan.	yoshidak@ims.u-tokyo.ac.jp	Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; Chehab NH, 2000, GENE DEV, V14, P278; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Lei M, 2001, J CELL SCI, V114, P1447; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Shieh SY, 2000, GENE DEV, V14, P289; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; WALDMAN T, 1995, CANCER RES, V55, P5187; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yates JL, 2000, J VIROL, V74, P4512, DOI 10.1128/JVI.74.10.4512-4522.2000; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	36	33	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					58	70		10.1038/sj.onc.1206987	http://dx.doi.org/10.1038/sj.onc.1206987			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712211				2022-12-25	WOS:000187895300007
J	Benazzouz, A; Tai, CH; Meissner, W; Bioulac, B; Bezard, E; Gross, C				Benazzouz, A; Tai, CH; Meissner, W; Bioulac, B; Bezard, E; Gross, C			High-frequency stimulation of both zona incerta and subthalamic nucleus induces a normalization of basal ganglia metabolic activity in experimental parkinsonism	FASEB JOURNAL			English	Article						cytochrome oxidase; globus pallidus; deep brain stimulation; Parkinson's Disease; substantia nigra	NIGRA PARS RETICULATA; DECARBOXYLASE MESSENGER-RNA; CONVERGENT SYNAPTIC INPUTS; GLOBUS-PALLIDUS NEURONS; DEEP BRAIN-STIMULATION; MPTP-TREATED MONKEYS; NIGROSTRIATAL DENERVATION; FIRING PATTERN; ENTOPEDUNCULAR NUCLEUS; CYTOCHROME-OXIDASE	High-frequency stimulation (HFS) of the subthalamic nucleus (STN) alleviates dramatically motor symptoms in Parkinson's disease, and recently it has been suggested that zona incerta (ZI) stimulation might be as beneficial to patients. We used in situ cytochrome oxidase (Col) mRNA hybridization to investigate and compare the effects of HFS of the STN and the ZI on metabolic activity of the STN, globus pallidus (GP), and substantia nigra reticulata (SNr) in normal rats as well as in rats with 6-hydroxydopamine (6-OHDA) lesion, an animal model of Parkinson's disease. In normal rats, HFS of the STN, as well as of the ZI, induced a significant decrease in Col mRNA expression within the STN and SNr but an increase within the GP. In 6-OHDA rats, HFS of the STN reversed dopamine denervation-induced changes in the expression of Col mRNA in the STN, SNr, and GP. Similar results were obtained with HFS of the ZI except for the STN, which showed only a trend toward nomlization. These data suggest that the ZI, as well as the STN, are implicated in the functional mechanism of HFS supporting the involvement of GABA transmission for the reduction of neuronal activity in the basal ganglia output structures.	Univ Victor Segalen, CNRS, UMR 5543, Lab Physiol & Physiopathol Signalisat Cellulaire, F-33076 Bordeaux, France; Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Taipei, Taiwan; Humboldt Univ, Charite Campus Virchow, Dept Neurol, Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Benazzouz, A (corresponding author), Univ Victor Segalen, CNRS, UMR 5543, Lab Physiol & Physiopathol Signalisat Cellulaire, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	Abdelhamid.Benazzouz@umr5543.u-bordeaux2.fr	Benazzouz, Abdelhamid/E-5050-2016; Bezard, Erwan/ABD-5153-2021; Meissner, Wassilios/C-7817-2015; Bezard, Erwan/A-8173-2008	Meissner, Wassilios/0000-0003-2172-7527; Tai, Chun-Hwei/0000-0002-3493-8879; Bezard, Erwan/0000-0002-0410-4638				AZIZ TZ, 1992, BRIT J NEUROSURG, V6, P575, DOI 10.3109/02688699209002375; BENABID AL, 1994, STEREOT FUNCT NEUROS, V62, P76, DOI 10.1159/000098600; BENAZZOUZ A, 1995, NEUROSCI LETT, V189, P77, DOI 10.1016/0304-3940(95)11455-6; Benazzouz A, 2002, MOVEMENT DISORD, V17, pS145, DOI 10.1002/mds.10156; Benazzouz A, 1996, MOVEMENT DISORD, V11, P627, DOI 10.1002/mds.870110606; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; Benazzouz A, 2000, NEUROSCIENCE, V99, P289, DOI 10.1016/S0306-4522(00)00199-8; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Beurrier C, 2001, J NEUROPHYSIOL, V85, P1351, DOI 10.1152/jn.2001.85.4.1351; BEVAN MD, 1994, BRAIN RES, V659, P99, DOI 10.1016/0006-8993(94)90868-0; BEVAN MD, 1994, EUR J NEUROSCI, V6, P320, DOI 10.1111/j.1460-9568.1994.tb00275.x; Bezard E, 1999, EUR J NEUROSCI, V11, P2167, DOI 10.1046/j.1460-9568.1999.00627.x; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; BEZARD E, 2001, FASEB J, V10, P1096; BOLAM JP, 1992, J COMP NEUROL, V321, P456, DOI 10.1002/cne.903210312; Boraud T, 2001, BRAIN, V124, P546, DOI 10.1093/brain/124.3.546; Boraud T, 1998, BRAIN RES, V787, P157, DOI 10.1016/S0006-8993(97)01563-1; BURBAUD P, 1995, EXP BRAIN RES, V105, P48; DELFS JM, 1995, EXP NEUROL, V133, P175, DOI 10.1006/exnr.1995.1020; DELFS JM, 1995, J NEUROSCI, V15, P6562; DeLong M. R., 1987, BASAL GANGLIA, P415, DOI 10.1007/978-1-4684-5347-8_29; Dostrovsky JO, 2002, MOVEMENT DISORD, V17, pS63, DOI 10.1002/mds.10143; Gross CE, 2003, J NEUROCHEM, V84, P1246, DOI 10.1046/j.1471-4159.2003.01600.x; Gross CE, 1999, PROG NEUROBIOL, V59, P509, DOI 10.1016/S0301-0082(99)00015-5; Guridi J, 1996, BRAIN, V119, P1717, DOI 10.1093/brain/119.5.1717; Hashimoto T, 2003, J NEUROSCI, V23, P1916; Hassani OK, 1996, NEUROSCIENCE, V72, P105, DOI 10.1016/0306-4522(95)00535-8; HASSLER R, 1965, CONFIN NEUROL, V26, P282; HEVNER RF, 1992, NEUROSCI LETT, V138, P188, DOI 10.1016/0304-3940(92)90502-X; Hirsch EC, 2000, TRENDS NEUROSCI, V23, pS78, DOI 10.1016/S1471-1931(00)00021-5; HOLLERMAN JR, 1992, BRAIN RES, V590, P291, DOI 10.1016/0006-8993(92)91108-Q; Hutchison WD, 1998, ANN NEUROL, V44, P622, DOI 10.1002/ana.410440407; KINCAID AE, 1992, NEUROSCIENCE, V51, P705, DOI 10.1016/0306-4522(92)90309-P; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; MARGINOSASCONE C, 2002, NEUROSCIENCE, V115, P1109; Miller Rupert G., 1981, SIMULTANEOUS STAT IN, V2nd, DOI [DOI 10.1007/978-1-4613-8122-8, 10.1007/978-1-4613-8122-8_1]; MILNER KL, 1988, BRAIN RES, V452, P273, DOI 10.1016/0006-8993(88)90031-5; Murer MG, 1997, SYNAPSE, V27, P278, DOI 10.1002/(SICI)1098-2396(199712)27:4<278::AID-SYN2>3.3.CO;2-S; Ni ZG, 2001, BRAIN RES, V899, P142, DOI 10.1016/S0006-8993(01)02219-3; Ni ZG, 2001, SYNAPSE, V40, P145, DOI 10.1002/syn.1036.abs; Ni ZG, 2000, EUR J NEUROSCI, V12, P4338, DOI 10.1111/j.1460-9568.2000.01346.x; NI ZG, 2000, IN PRESS NEUROSCIENC; PAN HS, 1988, SYNAPSE, V2, P650, DOI 10.1002/syn.890020612; Paxinos G., 1996, RAT BRAIN STEREOTAXI; Perier C, 2000, NEUROREPORT, V11, P3275, DOI 10.1097/00001756-200009280-00045; Perier C, 2000, EXP NEUROL, V162, P215, DOI 10.1006/exnr.1999.7331; Perier C, 2002, J NEUROSCI, V22, P8711; Raz A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-03-j0006.2001; Saint-Cyr JA, 2002, J NEUROSURG, V97, P1152, DOI 10.3171/jns.2002.97.5.1152; Salin P, 2002, J NEUROSCI, V22, P5137, DOI 10.1523/JNEUROSCI.22-12-05137.2002; SOGHOMONIAN JJ, 1992, SYNAPSE, V11, P124, DOI 10.1002/syn.890110205; SUPKO DE, 1991, BRAIN RES, V564, P159, DOI 10.1016/0006-8993(91)91367-A; Tai CH, 2003, FASEB J, V17, P1820, DOI 10.1096/fj.03-0163com; Vila M, 2000, EUR J NEUROSCI, V12, P337, DOI 10.1046/j.1460-9568.2000.00901.x; Vila M, 1997, J NEUROSCI, V17, P765; Vila M, 1996, NEUROLOGY, V46, P802, DOI 10.1212/WNL.46.3.802; Voges J, 2002, J NEUROSURG, V96, P269, DOI 10.3171/jns.2002.96.2.0269; Wichmann T, 1999, EXP BRAIN RES, V125, P397, DOI 10.1007/s002210050696; WINDELS F, 2002, INVOLVEMENT GABA MEC; WONGRILEY MTT, 1989, TRENDS NEUROSCI, V12, P94, DOI 10.1016/0166-2236(89)90165-3	63	45	47	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					528	+		10.1096/fj.03-0576fje	http://dx.doi.org/10.1096/fj.03-0576fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715698				2022-12-25	WOS:000188829300020
J	Quintana, E; Hernandez, C; Alvarez-Barrientos, A; Esplugues, JV; Barrachina, MD				Quintana, E; Hernandez, C; Alvarez-Barrientos, A; Esplugues, JV; Barrachina, MD			Synthesis of nitric oxide in post-ganglionic myenteric neurons during endotoxemia: implications for gastric motor function	FASEB JOURNAL			English	Article						myenteric plexus; motility; confocal microscopy; DAF; neuronal NOS	VASOACTIVE INTESTINAL POLYPEPTIDE; NONADRENERGIC NONCHOLINERGIC RELAXATION; RAT HIPPOCAMPAL SLICES; SMOOTH-MUSCLE-CELLS; SYNTHASE EXPRESSION; CIRCULAR MUSCLE; NERVOUS-SYSTEM; FUNDUS; INVOLVEMENT; PATHWAY	We have investigated the mechanisms underlying acute changes in gastric motor function triggered by endotoxemia. In fundal strips from rats pre-treated with endotoxin (40 mug/kg, i.p. 30 min), mechanical activity was analyzed and the source of nitric oxide (NO) was visualized by confocal microscopy of tissue loaded with the fluorescent dye DAF-FM. NOS expression was determined by quantitative RT-PCR and Western blot, and enzyme activity by the citrulline assay. Strips from endotoxin-treated rats were hypo-contractile. This was prevented by preincubation with the neurotoxin tetrodotoxin, the gangliar blocker hexamethonium, or nonselective and neuronal-specific NOS inhibitors (L-NOARG and TRIM, respectively). The Ca2+ soluble guanylyl cyclase (sGC) inhibitor ODQ and the inhibitor of small conductance Ca2+-activated K+ channels apamin prevented relaxation induced by endotoxin, nicotine, exogenous NO (DETA-NONOate), and the NO-independent sGC activator BAY 41-2272. NO synthesis was observed in neuronal soma, axons, and nerve endings of the myenteric plexus in the fundus of endotoxin-treated rats and was prevented by L-NAME, tetrodotoxin, and hexamethonium. nNOS and iNOS mRNA and protein contents were unchanged. Our findings demonstrate synthesis of NO in post-ganglionic myenteric neurons during early endotoxemia that mediates Ca2+-gastric hypo-contractility. The effect of NO is mediated via sGC and small conductance Ca2+-activated K+ channels.	Univ Valencia, Fac Med, Dept Pharmacol, Valencia 46010, Spain; Univ Valencia, Fac Med, CNIC UVEG, Unidad Mixta, Valencia 46010, Spain; Fdn Ctr Nacl Invest Cardiovasc, Cytometry Unit, Madrid 28029, Spain	University of Valencia; University of Valencia; Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Esplugues, JV (corresponding author), Univ Valencia, Fac Med, Dept Pharmacol, Avd Blasco Ibanez 15, Valencia 46010, Spain.	Juan.V.Esplugues@uv.es	SAEZ, CARLOS HERNANDEZ/M-3029-2014; Alvarez-Barrientos, Alberto/L-9299-2014; Esplugues, Juan/ABC-1488-2021; Barrachina, Maria/ABB-9683-2021	SAEZ, CARLOS HERNANDEZ/0000-0001-8536-429X; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Esplugues Mota, Juan Vicente/0000-0001-8205-021X; Barrachina, Maria Dolores/0000-0002-4332-2929				BARRETT HC, 2001, MIND SOC, V3, P1; BERTHOUD HR, 1995, J COMP NEUROL, V358, P428, DOI 10.1002/cne.903580309; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Brown LA, 2000, NEUROSCI LETT, V294, P9, DOI 10.1016/S0304-3940(00)01521-4; Calatayud S, 2003, BRIT J PHARMACOL, V139, P263, DOI 10.1038/sj.bjp.0705239; Calatayud S, 2003, N-S ARCH PHARMACOL, V367, P51, DOI 10.1007/s00210-002-0646-7; Calatayud S, 2002, AM J PHYSIOL-GASTR L, V283, pG1360, DOI 10.1152/ajpgi.00168.2002; Calatayud S, 2001, N-S ARCH PHARMACOL, V363, P276, DOI 10.1007/s002100000359; Chang HY, 2003, AM J PHYSIOL-GASTR L, V284, pG357, DOI 10.1152/ajpgi.00478.2002; DAMATO M, 1992, J AUTONOM NERV SYST, V37, P175, DOI 10.1016/0165-1838(92)90039-J; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DESAI KM, 1991, P NATL ACAD SCI USA, V88, P11490, DOI 10.1073/pnas.88.24.11490; Dick JMC, 2000, EUR J PHARMACOL, V397, P389, DOI 10.1016/S0014-2999(00)00299-5; Elmquist JK, 1996, J COMP NEUROL, V371, P85, DOI 10.1002/(SICI)1096-9861(19960715)371:1<85::AID-CNE5>3.0.CO;2-H; Ergun Y, 2001, PHARMACOL RES, V44, P221, DOI 10.1006/phrs.2001.0844; Eskandari MK, 1999, AM J PHYSIOL-GASTR L, V277, pG478, DOI 10.1152/ajpgi.1999.277.2.G478; Esplugues JV, 2002, BRIT J PHARMACOL, V135, P1079, DOI 10.1038/sj.bjp.0704569; Fossier P, 1999, TRENDS NEUROSCI, V22, P161, DOI 10.1016/S0166-2236(98)01307-1; Furness JB, 2000, J AUTONOM NERV SYST, V81, P87, DOI 10.1016/S0165-1838(00)00127-2; GRIDER JR, 1990, J PHARMACOL EXP THER, V253, P738; Guilmard C, 1998, NITRIC OXIDE-BIOL CH, V2, P147, DOI 10.1006/niox.1998.0170; Haugland R.P., 2002, HDB FLUORESCENT PROB; Helmer KS, 2002, J SURG RES, V104, P46, DOI 10.1006/jsre.2002.6404; Helmer KS, 2002, GASTROENTEROLOGY, V123, P173, DOI 10.1053/gast.2002.34178; HOM GJ, 1995, J PHARMACOL EXP THER, V272, P452; Ishiguchi T, 2000, AM J PHYSIOL-GASTR L, V279, pG740, DOI 10.1152/ajpgi.2000.279.4.G740; Jenkinson KM, 2000, BRIT J PHARMACOL, V130, P1627, DOI 10.1038/sj.bjp.0703481; Kalsi JS, 2003, J UROLOGY, V169, P761, DOI 10.1016/S0022-5347(05)64009-8; KAMATA K, 1993, GEN PHARMACOL, V24, P1403, DOI 10.1016/0306-3623(93)90426-X; KITAMURA K, 1993, BRIT J PHARMACOL, V109, P415, DOI 10.1111/j.1476-5381.1993.tb13585.x; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; Kojima H, 2001, J NEUROCHEM, V76, P1404, DOI 10.1046/j.1471-4159.2001.00161.x; LEFEBVRE RA, 1995, BRIT J PHARMACOL, V116, P2017, DOI 10.1111/j.1476-5381.1995.tb16406.x; Lefebvre RA, 1998, BRIT J PHARMACOL, V124, P1439, DOI 10.1038/sj.bjp.0701992; LI CG, 1990, EUR J PHARMACOL, V191, P303; MartinezCuesta MA, 1996, BRIT J PHARMACOL, V118, P1335, DOI 10.1111/j.1476-5381.1996.tb15542.x; Mashimo H, 2000, GASTROENTEROLOGY, V119, P766, DOI 10.1053/gast.2000.16509; MATHARU MS, 1992, BRIT J PHARMACOL, V106, P395, DOI 10.1111/j.1476-5381.1992.tb14346.x; MCCALL TB, 1991, EUR J IMMUNOL, V21, P2523, DOI 10.1002/eji.1830211032; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nagano T, 2002, CHEM REV, V102, P1235, DOI 10.1021/cr010152s; Nakamura K, 1998, J CLIN INVEST, V101, P1479, DOI 10.1172/JCI627; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; Quintana E, 2001, BRIT J PHARMACOL, V134, P325, DOI 10.1038/sj.bjp.0704258; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; SANDERS KM, 1992, AM J PHYSIOL, V262, pG379, DOI 10.1152/ajpgi.1992.262.3.G379; Saur D, 2002, AM J PHYSIOL-GASTR L, V282, pG349, DOI 10.1152/ajpgi.00226.2001; Shuttleworth CWR, 1996, P SOC EXP BIOL MED, V211, P16, DOI 10.3181/00379727-211-43950C; Takakura K, 1997, ANESTHESIOLOGY, V87, P652, DOI 10.1097/00000542-199709000-00027; Teng BQ, 1998, AM J PHYSIOL-GASTR L, V275, pG342, DOI 10.1152/ajpgi.1998.275.2.G342; van Miert A S, 1970, Arch Int Pharmacodyn Ther, V184, P27; VOOGD TE, 1993, PHARMACOL REV, V45, P177; Wiklund NP, 1997, J NEUROSCI RES, V47, P224, DOI 10.1002/(SICI)1097-4547(19970115)47:2<224::AID-JNR11>3.0.CO;2-2; Willmott NJ, 2000, J NEUROSCI, V20, P1767	54	16	20	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					531	+		10.1096/fj.03-0596fje	http://dx.doi.org/10.1096/fj.03-0596fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715697				2022-12-25	WOS:000188829300029
J	El Hadri, K; Glorian, M; Monsempes, C; Dieudonne, MN; Pecquery, R; Giudicelli, Y; Andreani, M; Dugail, I; Feve, B				El Hadri, K; Glorian, M; Monsempes, C; Dieudonne, MN; Pecquery, R; Giudicelli, Y; Andreani, M; Dugail, I; Feve, B			In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV PROTEASE INHIBITORS; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS-INFECTION; ELEMENT-BINDING PROTEIN-1C; FATTY-ACID SYNTHETASE; INSULIN-RESISTANCE; HIV-1-INFECTED PATIENTS; ADIPOSE-TISSUE; GENE-EXPRESSION; DIABETES-MELLITUS	A serious metabolic syndrome combining insulin-resistance, dyslipidemia, central adiposity, and peripheral lipoatrophy has arisen in HIV-infected patients receiving highly active antiretroviral therapy. The aim of this work was to examine the effects of the nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz on adipocyte differentiation and metabolism. When induced to differentiate in the presence of efavirenz ( 5 - 50 muM), 3T3-F442A preadipocytes failed to accumulate cytoplasmic triacylglycerol droplets. This phenomenon was rapidly reversible and was also readily detectable in the 3T3-L1 preadipose cell line and in primary cultures of human preadipocytes. When applied to mature 3T3-F442A adipocytes, efavirenz induced a delayed and moderate reduction in cell triglyceride content. Measurement of [H-3] deoxyglucose uptake, basal and agonist-stimulated lipolysis, and cell viability indicated that these pathways are not involved in efavirenz effects on triacylglycerol accumulation. By contrast, we found that the NNRTI induced a dramatic dose- and time-dependent decrease in gene and protein expression of the lipogenic transcription factor sterol regulatory element-binding protein-1c (SREBP-1c). Adipose conversion was only altered at the highest efavirenz concentrations, as suggested by the mild reduction in peroxisome proliferator-activated receptor-gamma and CCAAT/enhancer-binding protein-alpha. CCAAT/enhancer-binding protein-beta remained unchanged. The inhibition of SREBP-1c expression was accompanied by a sharp reduction in the expression of SREBP-1c target genes and in the adipocyte lipogenic activity in efavirenz-treated cells. Finally, the inhibitory effect of efavirenz on cell triglyceride accumulation was prevented by directly providing free fatty acids to the cells and was reversed by overexpression of a dominant positive form of SREBP-1c, reinforcing the implication of this transcription factor in the antilipogenic effect of the drug. When considered together, these results demonstrate for the first time that the NNRTI efavirenz induces a strong inhibition of the SREBP-1c-dependent lipogenic pathway that might contribute to adipose tissue atrophy.	Univ Paris 06, CNRS, UMR 7079, F-75006 Paris, France; Ctr Rech Biomed Cordeliers, INSERM, U465, F-75006 Paris, France; Univ Versailles, Fac Med Paris Ile France Ouest, Ctr Hosp Poissy, Serv Biochim, F-78303 Poissy, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Hospital Chi of Poissy Saint Germain; UDICE-French Research Universities; Universite Paris Saclay	Feve, B (corresponding author), Univ Paris 06, CNRS, UMR 7079, 15 Rue Ecole Med, F-75006 Paris, France.	feve@bhdc.jussieu.fr	Dugail, Isabelle/L-1567-2017	Dugail, Isabelle/0000-0003-3631-2252; GLORIAN, Martine/0000-0002-4502-3543; EL HADRI, KHADIJA/0000-0002-1275-9861; Feve, Bruno/0000-0001-6577-9009				Barreiro P, 2000, AIDS, V14, P807, DOI 10.1097/00002030-200005050-00006; Bastard JP, 2002, LANCET, V359, P1026, DOI 10.1016/S0140-6736(02)08094-7; Beach JW, 1998, CLIN THER, V20, P2; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Boffito M, 2003, AIDS RES HUM RETROV, V19, P825, DOI 10.1089/088922203769232629; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Bonnet F, 2002, CLIN INFECT DIS, V35, P776, DOI 10.1086/342326; Caron M, 2003, AIDS, V17, P2437, DOI 10.1097/00002030-200311210-00005; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clumeck N, 2001, AIDS, V15, P1517, DOI 10.1097/00002030-200108170-00009; Dieleman JP, 1999, AIDS, V13, P1423, DOI 10.1097/00002030-199907300-00029; Dieudonne MN, 1998, AM J PHYSIOL-CELL PH, V274, pC1645, DOI 10.1152/ajpcell.1998.274.6.C1645; Diraison F, 2003, J LIPID RES, V44, P846, DOI 10.1194/jlr.M200461-JLR200; Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008; Doser N, 2001, J ACQ IMMUN DEF SYND, V26, P389, DOI 10.1097/00126334-200104010-00018; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; Dupin N, 2002, AIDS, V16, P2419, DOI 10.1097/00002030-200212060-00006; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; FOLCH J, 1957, J BIOL CHEM, V226, P497; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; Gagnon A, 1998, LANCET, V352, P1032, DOI 10.1016/S0140-6736(05)60074-8; Garg A, 2000, AM J MED, V108, P143, DOI 10.1016/S0002-9343(99)00414-3; GREEN A, 1994, ENDOCRINOLOGY, V134, P2581, DOI 10.1210/en.134.6.2581; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Grinspoon S, 2001, TRENDS ENDOCRIN MET, V12, P413, DOI 10.1016/S1043-2760(01)00472-6; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hirschel B, 2002, AIDS, V16, P381, DOI 10.1097/00002030-200202150-00009; Holmberg SD, 2002, LANCET, V360, P1747, DOI 10.1016/S0140-6736(02)11672-2; Hsieh SM, 2000, J ACQ IMMUN DEF SYND, V24, P287; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kotler DP, 1999, J ACQ IMMUN DEF SYND, V20, P228, DOI 10.1097/00042560-199903010-00003; KOZAK LP, 1974, J BIOL CHEM, V249, P7775; Langmann P, 2002, EUR J MED RES, V7, P309; Le Lay S, 2002, J BIOL CHEM, V277, P35625, DOI 10.1074/jbc.M203913200; Lenhard JM, 2000, ANTIVIR RES, V47, P121, DOI 10.1016/S0166-3542(00)00102-9; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Madge S, 1999, AIDS, V13, P735, DOI 10.1097/00002030-199904160-00020; Martinez E, 2003, NEW ENGL J MED, V349, P1036, DOI 10.1056/NEJMoa021589; Martinez E, 1999, AIDS, V13, P805, DOI 10.1097/00002030-199905070-00009; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Miserez AR, 2002, AIDS, V16, P1587, DOI 10.1097/00002030-200208160-00003; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Nerurkar PV, 2001, CLIN BIOCHEM, V34, P519, DOI 10.1016/S0009-9120(01)00239-9; Nguyen AT, 2000, AIDS, V14, P2467, DOI 10.1097/00002030-200011100-00007; Ogedegbe AEO, 2003, LANCET INFECT DIS, V3, P329, DOI 10.1016/S1473-3099(03)00654-6; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Rey D, 2001, J ACQ IMMUN DEF SYND, V27, P459, DOI 10.1097/00126334-200108150-00006; Riddle TM, 2001, J BIOL CHEM, V276, P37514, DOI 10.1074/jbc.M104557200; ROLLAND V, 1995, J BIOL CHEM, V270, P1102, DOI 10.1074/jbc.270.3.1102; Rosen ED, 2000, GENE DEV, V14, P1293; Rudich A, 2001, DIABETES, V50, P1425, DOI 10.2337/diabetes.50.6.1425; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Smith PF, 2001, CLIN PHARMACOKINET, V40, P893, DOI 10.2165/00003088-200140120-00002; Stocker DN, 1998, LANCET, V352, P320, DOI 10.1016/S0140-6736(05)60295-4; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Tashima KT, 1999, J INFECT DIS, V180, P862, DOI 10.1086/314945; van der Valk M, 2003, CURR OPIN INFECT DIS, V16, P19, DOI 10.1097/00001432-200302000-00004; Vernochet C, 2003, AIDS, V17, P2177, DOI 10.1097/00002030-200310170-00005; Vigouroux C, 1999, DIABETES METAB, V25, P225; Walli R, 1998, AIDS, V12, pF167, DOI 10.1097/00002030-199815000-00001; Wentworth JM, 2000, J ENDOCRINOL, V164, pR7, DOI 10.1677/joe.0.164R007; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zhang B, 1999, J CLIN ENDOCR METAB, V84, P4274, DOI 10.1210/jc.84.11.4274	76	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15130	15141		10.1074/jbc.M312875200	http://dx.doi.org/10.1074/jbc.M312875200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722061	hybrid			2022-12-25	WOS:000220594700079
J	Mao, HP; Wang, YH; Li, ZJ; Ruchalski, KL; Yu, XQ; Schwartz, JH; Borkan, SC				Mao, HP; Wang, YH; Li, ZJ; Ruchalski, KL; Yu, XQ; Schwartz, JH; Borkan, SC			Hsp72 interacts with paxillin and facilitates the reassembly of focal adhesions during recovery from ATP depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL EPITHELIAL-CELLS; HEAT-SHOCK PROTEINS; NA+-K+-ATPASE; MOLECULAR CHAPERONES; INHIBITS APOPTOSIS; SUBLETHAL INJURY; STRESS FIBER; ACTIN; CYTOSKELETON; REDISTRIBUTION	The cytoprotective effect of heat stress proteins on epithelial cell detachment, an important cause of acute, ischemic renal failure, was examined after ATP depletion by evaluating focal adhesion complex (FAC) integrity. The intracellular distribution of FAC proteins ( paxillin, talin, and vinculin) was assessed by immunohistochemistry before, during, and after exposure of renal epithelial cells to metabolic inhibitors. The resulting ATP depletion caused reversible re-distribution of all three proteins from focal adhesions to the cytosol. Paxillin, a key adaptor protein, was selected as a surrogate marker for FAC integrity in subsequent studies. Prior heat stress increased hsp72, a molecular chaperone, in both the Triton X-100-soluble and - insoluble protein fractions. Compared with ATP depleted control, heat stress significantly decreased paxillin and hsp72 shift from the Triton X-100 soluble to the insoluble protein fraction ( an established marker of denaturation and aggregation); increased paxillin-hsp72 interaction detected by co-immunoprecipitation; enhanced paxillin extractability from Triton X-100-insoluble precipitates, increased the reformation of focal adhesions, and improved cell attachment ( p < 0.05). To determine whether hsp72 mediates protection afforded by heat stress, cells were infected with adenovirus containing human hsp72 or empty vector. Hsp72 overexpression increased its interaction with paxillin and improved focal adhesion reformation during recovery, mimicking the protective effects of heat stress. These data suggest that hsp72 facilitates the reassembly of focal adhesions and improves cell attachment by reducing paxillin denaturation and increasing its re-solubilization after ATP depletion.	Zhongshan Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou 510080, Peoples R China; Boston Med Ctr, Renal Sect, Evans Biomed Res Ctr, Boston, MA 02118 USA	Sun Yat Sen University; Boston Medical Center	Borkan, SC (corresponding author), Boston Med Ctr, Renal Sect, Evans Biomed Res Ctr, Rm 546,650 Albany St, Boston, MA 02118 USA.	sborkan@bu.edu	Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681; Mao, Haiping/0000-0002-3608-3851; Borkan, Steven/0000-0003-3062-9486	NIDDK NIH HHS [DK-5298, DK-47994] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047994] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aufricht C, 1998, AM J PHYSIOL-RENAL, V274, pF268, DOI 10.1152/ajprenal.1998.274.2.F268; Aufricht C, 1998, AM J PHYSIOL-RENAL, V274, pF215, DOI 10.1152/ajprenal.1998.274.1.F215; Aufricht C, 2002, PEDIATR RES, V51, P722, DOI 10.1203/01.PDR.0000015128.65800.28; Beissinger M, 1998, BIOL CHEM, V379, P245; Bergin E, 2000, AM J PHYSIOL-RENAL, V278, pF758, DOI 10.1152/ajprenal.2000.278.5.F758; Bidmon B, 2000, KIDNEY INT, V58, P2400, DOI 10.1046/j.1523-1755.2000.00423.x; Bluhm WF, 1998, AM J PHYSIOL-HEART C, V275, pH2243, DOI 10.1152/ajpheart.1998.275.6.H2243; Borkan SC, 1997, AM J PHYSIOL-RENAL, V272, pF347, DOI 10.1152/ajprenal.1997.272.3.F347; BRADY HR, 2000, KIDNEY, V1, P1201; BRAGA VMM, 1995, CELL ADHES COMMUN, V3, P201, DOI 10.3109/15419069509081287; EMAMI A, 1991, AM J PHYSIOL, V260, pF479, DOI 10.1152/ajprenal.1991.260.4.F479; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; FISH EM, 1994, AM J PHYSIOL-RENAL, V267, pF566, DOI 10.1152/ajprenal.1994.267.4.F566; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Fujihara SM, 1999, EMBO J, V18, P411, DOI 10.1093/emboj/18.2.411; GABAI VL, 1992, TISSUE CELL, V24, P171, DOI 10.1016/0040-8166(92)90090-T; GABAI VL, 1993, FEBS LETT, V327, P247, DOI 10.1016/0014-5793(93)80997-9; GAILIT J, 1993, AM J PHYSIOL, V264, pF149, DOI 10.1152/ajprenal.1993.264.1.F149; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; GLASCOTT PA, 1987, CELL MOTIL CYTOSKEL, V8, P118, DOI 10.1002/cm.970080204; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; Herget-Rosenthal S, 2001, AM J PHYSIOL-CELL PH, V281, pC1858, DOI 10.1152/ajpcell.2001.281.6.C1858; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HINSHAW DB, 1988, AM J PATHOL, V132, P479; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KABAKOV AE, 1993, EXPERIENTIA, V49, P706, DOI 10.1007/BF01923956; KABAKOV AE, 2002, AM J PHYSIOL, V283, pL521; KROSHIAN VM, 1994, AM J PHYSIOL, V266, pF21, DOI 10.1152/ajprenal.1994.266.1.F21; Lieberthal W, 1998, SEMIN NEPHROL, V18, P505; Mao HP, 2003, J BIOL CHEM, V278, P18214, DOI 10.1074/jbc.M300126200; Martin JL, 1997, CIRCULATION, V96, P4343; Martin-Bermudo MD, 2000, J CELL SCI, V113, P3715; MIFFLIN LC, 1994, J BIOL CHEM, V269, P15710; MOLITORIS BA, 1991, AM J PHYSIOL, V260, pF769; MOLITORIS BA, 1992, AM J PHYSIOL, V263, pF488, DOI 10.1152/ajprenal.1992.263.3.F488; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; NGUYEN VT, 1989, J BIOL CHEM, V264, P10487; NOIRI E, 1994, KIDNEY INT, V46, P1050, DOI 10.1038/ki.1994.366; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; RACUSEN LC, 1991, LAB INVEST, V64, P546; Racusen LC, 1998, CLIN EXP PHARMACOL P, V25, P273, DOI 10.1111/j.1440-1681.1998.t01-3-.x; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schneider GB, 1998, J CELL PHYSIOL, V177, P575, DOI 10.1002/(SICI)1097-4652(199812)177:4<575::AID-JCP8>3.0.CO;2-1; Shelden EA, 2002, J AM SOC NEPHROL, V13, P2667, DOI 10.1097/01.ASN.0000033353.21502.31; Shelden EA, 2002, J AM SOC NEPHROL, V13, P332, DOI 10.1681/ASN.V132332; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; SIMON EE, 1994, AM J PHYSIOL-RENAL, V267, pF612, DOI 10.1152/ajprenal.1994.267.4.F612; Sogabe K, 1996, AM J PHYSIOL-RENAL, V271, pF292, DOI 10.1152/ajprenal.1996.271.2.F292; Tessier DJ, 2003, J SURG RES, V111, P152, DOI 10.1016/S0022-4804(03)00113-6; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; VANWHY SK, 1994, AM J PHYSIOL, V267, pF75, DOI 10.1152/ajprenal.1994.267.1.F75; Wang YH, 1999, KIDNEY INT, V55, P2224, DOI 10.1046/j.1523-1755.1999.00476.x; Wang YH, 1996, AM J PHYSIOL-RENAL, V270, pF1057, DOI 10.1152/ajprenal.1996.270.6.F1057; Wang YH, 2001, AM J PHYSIOL-CELL PH, V281, pC1667, DOI 10.1152/ajpcell.2001.281.5.C1667	59	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15472	15480		10.1074/jbc.M313484200	http://dx.doi.org/10.1074/jbc.M313484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14718530	hybrid			2022-12-25	WOS:000220594700118
J	Aamodt, RM; Falnes, PO; Johansen, RF; Seeberg, E; Bjoras, M				Aamodt, RM; Falnes, PO; Johansen, RF; Seeberg, E; Bjoras, M			The Bacillus subtilis counterpart of the mammalian 3-methyladenine DNA glycosylase has hypoxanthine and 1,N-6-ethenoadenine as preferred substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; OXIDATIVE DEMETHYLATION; ADAPTIVE RESPONSE; ALKYLATED DNA; BASE EXCISION; REPAIR; PURIFICATION; CDNA; GENE	The AAG family of 3-methyladenine DNA glycosylases was initially thought to be limited to mammalian cells, but genome sequencing efforts have revealed the presence of homologous proteins in certain prokaryotic species as well. Here, we report the first molecular characterization of a functional prokaryotic AAG homologue, i.e. YxlJ, termed bAag, from Bacillus subtilis. The B. subtilis aag gene was expressed in Escherichia coli, and the protein was purified to homogeneity. As expected, B. subtilis Aag was found to be a DNA glycosylase, which releases 3-alkylated purines and hypoxanthine, as well as the cyclic etheno adduct 1, N-6-ethenoadenine from DNA. However, kinetic analysis showed that bAag removed hypoxanthine much faster than human AAG with a 10-fold higher value for k(cat), whereas the rate of excision of 1, N-6-ethenoadenine was found to be similar. In contrast, it was found that bAag removes 3-methyladenine and 3-methylguanine similar to 10 - 20 times more slowly than human AAG, and there was hardly any detectable excision of 7-methylguanine. It thus appears that bAag has a minor role in the repair of DNA alkylation damage and an important role in preventing the mutagenic effects of deaminated purines and cyclic etheno adducts in Bacillus subtilis.	Univ Oslo, Natl Hosp, Inst Med Microbiol, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway; Univ Oslo, Natl Hosp, Inst Med Microbiol, Dept Mol Biol, N-0027 Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway	Bjoras, M (corresponding author), Univ Oslo, Natl Hosp, Inst Med Microbiol, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway.	magnar.bjoras@labmed.uio.no	Falnes, Pål Ø./AAA-4581-2020; Bjørås, Magnar/N-9286-2017	Falnes, Pal/0000-0001-8114-6025				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BERDAL KG, 1990, EMBO J, V9, P4563, DOI 10.1002/j.1460-2075.1990.tb07909.x; BESSHO T, 1993, P NATL ACAD SCI USA, V90, P8901, DOI 10.1073/pnas.90.19.8901; BJELLAND S, 1993, NUCLEIC ACIDS RES, V21, P2045, DOI 10.1093/nar/21.9.2045; BJELLAND S, 1987, NUCLEIC ACIDS RES, V15, P2787, DOI 10.1093/nar/15.7.2787; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; BJORAS M, 1995, BIOCHEMISTRY-US, V34, P4577, DOI 10.1021/bi00014a010; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; DOSANJH MK, 1994, BIOCHEMISTRY-US, V33, P1624, DOI 10.1021/bi00173a002; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; EVENSEN G, 1982, NATURE, V296, P773, DOI 10.1038/296773a0; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; Guo GM, 1998, J BACTERIOL, V180, P46, DOI 10.1128/JB.180.1.46-51.1998; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; KAMIYA H, 1995, CARCINOGENESIS, V16, P883, DOI 10.1093/carcin/16.4.883; KARRAN P, 1980, J MOL BIOL, V140, P101, DOI 10.1016/0022-2836(80)90358-7; KARRAN P, 1982, NATURE, V296, P770, DOI 10.1038/296770a0; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; NAIR J, 1995, CARCINOGENESIS, V16, P613, DOI 10.1093/carcin/16.3.613; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SAMSON L, 1977, NATURE, V267, P281, DOI 10.1038/267281a0; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SEDGWICK B, 1991, MUTAT RES, V250, P211, DOI 10.1016/0027-5107(91)90178-Q; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; Winterling KW, 1998, J BACTERIOL, V180, P2201, DOI 10.1128/JB.180.8.2201-2211.1998; Winterling KW, 1997, J BACTERIOL, V179, P1698, DOI 10.1128/jb.179.5.1698-1703.1997; YAO M, 1994, J BIOL CHEM, V269, P16260	37	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13601	13606		10.1074/jbc.M314277200	http://dx.doi.org/10.1074/jbc.M314277200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729667	hybrid			2022-12-25	WOS:000220478500040
J	Chumanevich, AA; Krupenko, SA; Davies, C				Chumanevich, AA; Krupenko, SA; Davies, C			The crystal structure of the hydrolase domain of 10-formyltetrahydrofolate dehydrogenase - Mechanism of hydrolysis and its interplay with the dehydrogenase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; ALDEHYDE DEHYDROGENASE; ESCHERICHIA-COLI; ACTIVE-SITE; TERMINAL DOMAIN; FORMYLTRANSFERASE; ENZYMES; LIVER; GENE; CYCLOHYDROLASE	10-Formyltetrahydrofolate dehydrogenase (FDH) converts 10-formyltetrahydrofolate, a precursor for nucleotide biosynthesis, to tetrahydrofolate. The protein comprises two functional domains: a hydrolase domain that removes a formyl group from 10-formyltetrahydrofolate and a NADP(+)-dependent dehydrogenase domain that reduces the formyl to carbon dioxide. As a first step toward deciphering the catalytic mechanism of the enzyme, we have determined the crystal structure of the hydrolase domain of FDH from rat, solved to 2.3-Angstrom resolution. The structure comprises two domains. As expected, domain 1 shares the same Rossmann fold as the related enzymes, methionyl-tRNA-formyltransferase and glycinamide ribonucleotide formyltransferase, but, unexpectedly, the structural similarity between the amino-terminal domain of 10-formyltetrahydrofolate dehydrogenase and methionyl-tRNA-formyltransferase extends to the C terminus of both proteins. The active site contains a molecule of beta-mercaptoethanol that is positioned between His-106 and Asp-142 and that appears to mimic the formate product. We propose a catalytic mechanism for the hydrolase reaction in which Asp-142 polarizes the catalytic water molecule and His-106 orients the carbonyl group of formyl. The structure also provides clues as to how, in the native enzyme, the hydrolase domain transfers its product to the dehydrogenase domain.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Krupenko, SA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	krupenko@musc.edu			NIDDK NIH HHS [DK54388] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; BENKOVIC SJ, 1984, TRENDS BIOCHEM SCI, V9, P320, DOI 10.1016/0968-0004(84)90302-5; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CHEN P, 1992, J MOL BIOL, V227, P283, DOI 10.1016/0022-2836(92)90698-J; Chu E., 1996, CANC CHEMOTHERAPY BI, P109; Chumanevich AA, 2002, ACTA CRYSTALLOGR D, V58, P1841, DOI 10.1107/S0907444902012155; COOK RJ, 1991, J BIOL CHEM, V266, P4965; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Greasley SE, 2001, NAT STRUCT BIOL, V8, P402, DOI 10.1038/87555; GREENBAU.AL, 1965, BIOCHEM J, V95, P161, DOI 10.1042/bj0950161; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kisliuk RL, 2000, PHARMACOL THERAPEUT, V85, P183, DOI 10.1016/S0163-7258(99)00056-X; KLEIN C, 1995, J MOL BIOL, V249, P153, DOI 10.1006/jmbi.1995.0286; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krupenko SA, 1997, J BIOL CHEM, V272, P10266; Krupenko SA, 1997, J BIOL CHEM, V272, P10273; Krupenko SA, 2002, CELL GROWTH DIFFER, V13, P227; Krupenko SA, 1998, PROTEIN EXPRES PURIF, V14, P146, DOI 10.1006/prep.1998.0937; Krupenko SA, 2001, J BIOL CHEM, V276, P24030, DOI 10.1074/jbc.M009257200; KRUPENKO SA, 1995, BIOCHEM J, V306, P651, DOI 10.1042/bj3060651; Krupenko SA, 1999, J BIOL CHEM, V274, P35777, DOI 10.1074/jbc.274.50.35777; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu XW, 2000, BIOCHEMISTRY-US, V39, P11523, DOI 10.1021/bi000665d; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NAGY PL, 1993, J BACTERIOL, V175, P7066, DOI 10.1128/jb.175.21.7066-7073.1993; NAGY PL, 1995, J BACTERIOL, V177, P1292, DOI 10.1128/jb.177.5.1292-1298.1995; Newton DT, 1999, BIOCHEM J, V339, P63, DOI 10.1042/0264-6021:3390063; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; Reuland SN, 2003, J BIOL CHEM, V278, P22894, DOI 10.1074/jbc.M302948200; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; Schmitt E, 1998, EMBO J, V17, P6819, DOI 10.1093/emboj/17.23.6819; Schmitt E, 1996, EMBO J, V15, P4749, DOI 10.1002/j.1460-2075.1996.tb00852.x; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; SMITH JM, 1987, J BIOL CHEM, V262, P10565; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Su Y, 1998, J MOL BIOL, V281, P485, DOI 10.1006/jmbi.1998.1931; TEPHLY TR, 1991, LIFE SCI, V48, P1031, DOI 10.1016/0024-3205(91)90504-5; Wagner C, 1995, FOLATE HLTH DIS, P23; Warren MS, 1996, BIOCHEMISTRY-US, V35, P8855, DOI 10.1021/bi9528715	52	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14355	14364		10.1074/jbc.M313934200	http://dx.doi.org/10.1074/jbc.M313934200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729668	hybrid			2022-12-25	WOS:000220478500131
J	Schneider, M; Brufatto, N; Neill, E; Nesheim, M				Schneider, M; Brufatto, N; Neill, E; Nesheim, M			Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCARBOXYPEPTIDASE-B; THERMAL-STABILITY; KINETICS; TAFI; ALPHA(2)-ANTIPLASMIN; ALPHA-2-ANTIPLASMIN; CARBOXYPEPTIDASE; VARIANTS; RESPECT; MODEL	Activated thrombin-activable fibrinolysis inhibitor (TAFIa) is a carboxypeptidase B-like plasma enzyme that can slow clot lysis by removing lysine residues exposed on fibrin as it is cleaved by plasmin. Previously, it was shown that fibrin treated with TAFIa is less able to promote plasminogen activation by tissue-type plasminogen activator. In this study, the effect of TAFIa modification of a fibrin surface on the rate of plasmin inhibition by antiplasmin was studied using high molecular weight fibrin degradation products (HMw-FDPs) as a soluble model for intact plasmin-modified fibrin. To quantify the inhibition, a novel end point assay was employed where plasmin, antiplasmin, and cofactors were mixed in the presence of a chromogenic substrate and the end point in the substrate hydrolysis reaction was used to measure the second order rate constant of inhibition. When HMw-FDPs were titrated in the presence of plasmin and antiplasmin, the rate constant for inhibition decreased by 16-fold at saturation (9.6 x 10(6) M-1 s(-1) to 0.59 x 10(6) M-1 s(-1)). When HMw-FDPs were pretreated with TAFIa, nearly two-thirds of the protective effect was lost. When 730 nM HMw-FDPs were treated for 20 min with TAFIa, the rate constant for plasmin inhibition was increased 3-fold from 1.9 x 10(6) M-1 s(-1) to 6.2 x 10(6) M-1 s(-1). Therefore, a novel mechanism was identified whereby TAFIa can modulate plasmin levels by increasing the susceptibility of plasmin to inhibition by antiplasmin.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Nesheim, M (corresponding author), Queens Univ, Dept Biochem, Rm A212,Botterell Hall, Kingston, ON K7L 3N6, Canada.	nesheimm@post.queensu.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANONICK PK, 1991, BIOCHEM J, V275, P53, DOI 10.1042/bj2750053; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Brufatto N, 2001, J BIOL CHEM, V276, P17663, DOI 10.1074/jbc.M011586200; Christensen U, 1996, FEBS LETT, V387, P58, DOI 10.1016/0014-5793(96)00429-2; EATON DL, 1991, J BIOL CHEM, V266, P21833; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; KOLEV K, 1994, J BIOL CHEM, V269, P17030; Lee AYY, 2001, THROMB HAEMOSTASIS, V85, P502, DOI 10.1055/s-0037-1615612; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; Mao SS, 1999, J BIOL CHEM, V274, P35046, DOI 10.1074/jbc.274.49.35046; Mutch NJ, 2003, J THROMB HAEMOST, V1, P2000, DOI 10.1046/j.1538-7836.2003.00383.x; Schneider M, 2002, J BIOL CHEM, V277, P1021, DOI 10.1074/jbc.M104444200; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; Walker JB, 2001, J BIOL CHEM, V276, P3138, DOI 10.1074/jbc.M005876200; Wang HY, 2003, EUR J BIOCHEM, V270, P2023, DOI 10.1046/j.1432-1033.2003.03578.x; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WANG W, 1994, J BIOL CHEM, V269, P15937; WIMAN B, 1978, EUR J BIOCHEM, V87, P143, DOI 10.1111/j.1432-1033.1978.tb12360.x; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x	25	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13340	13345		10.1074/jbc.M313211200	http://dx.doi.org/10.1074/jbc.M313211200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14715654	hybrid			2022-12-25	WOS:000220478500010
J	Chao, Y; Fu, D				Chao, Y; Fu, D			Kinetic study of the antiport mechanism of an Escherichia coli zinc transporter, ZitB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFUSION FACILITATOR FAMILY; CONFERS RESISTANCE; MAMMALIAN ZINC; UPTAKE SYSTEM; ZNTA GENE; MEMBER; ENCODES; CELLS; PH	ZitB is a member of the cation diffusion facilitator (CDF) family that mediates efflux of zinc across the plasma membrane of Escherichia coli. We describe the first kinetic study of the purified and reconstituted ZitB by stopped-flow measurements of transmembrane fluxes of metal ions using a metal-sensitive fluorescent indicator encapsulated in proteoliposomes. Metal ion filling experiments showed that the initial rate of Zn2+ influx was a linear function of the molar ratio of ZitB to lipid and was related to the concentration of Zn2+ or Cd2+ by a hyperbola with a Michaelis-Menten constant (K-m) of 104.9 +/- 5.4 muM and 90.1 +/- 3.7 muM, respectively. Depletion of proton stalled Cd2+ transport down its diffusion gradient, whereas tetraethylammonium ion substitution for K+ did not affect Cd2+ transport, indicating that Cd2+ transport is coupled to H+ rather than to K+. H+ transport was inferred by the H+ dependence of Cd2+ transport, showing a hyperbolic relationship with a K-m of 19.9 nM for H+. Applying H+ diffusion gradients across the membrane caused Cd2+ fluxes both into and out of proteoliposomes against the imposed H+ gradients. Likewise, applying outwardly oriented membrane electrical potential resulted in Cd2+ efflux, demonstrating the electrogenic effect of ZitB transport. Taken together, these results indicate that ZitB is an antiporter catalyzing the obligatory exchange of Zn2+ or Cd2+ for H+. The exchange stoichiometry of metal ion for proton is likely to be 1: 1.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Fu, D (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463, Upton, NY 11973 USA.	dax@bnl.gov		Fu, Dax/0000-0002-2663-1316	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065137] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 65137] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; Beard SJ, 1997, MOL MICROBIOL, V25, P883, DOI 10.1111/j.1365-2958.1997.mmi518.x; Beavis RC, 1996, METHOD ENZYMOL, V270, P519; Beyersmann D, 2001, BIOMETALS, V14, P331, DOI 10.1023/A:1012905406548; Blencowe DK, 2003, FEMS MICROBIOL REV, V27, P291, DOI 10.1016/S0168-6445(03)00041-X; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; DASILVA JJR, 2001, BIOL CHEM ELEMENTS I, P315; Dineley KE, 2002, MOL PHARMACOL, V62, P618, DOI 10.1124/mol.62.3.618; Eide DJ, 2003, J NUTR, V133, p1532S, DOI 10.1093/jn/133.5.1532S; Gee KR, 2002, CELL CALCIUM, V31, P245, DOI 10.1016/S0143-4160(02)00053-2; Grass G, 2002, J BACTERIOL, V184, P864, DOI 10.1128/JB.184.3.864-866.2002; Grass G, 2001, J BACTERIOL, V183, P4664, DOI 10.1128/JB.183.15.4664-4667.2001; Guffanti AA, 2002, MOL MICROBIOL, V45, P145, DOI 10.1046/j.1365-2958.2002.02998.x; Harris ED, 2002, NUTR REV, V60, P121, DOI 10.1301/00296640260085877; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; Kimura E, 2000, J BIOL INORG CHEM, V5, P139, DOI 10.1007/s007750050359; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Lee SM, 2002, FEMS MICROBIOL LETT, V215, P273, DOI 10.1016/S0378-1097(02)00961-8; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; NEGULESCU PA, 1990, METHOD ENZYMOL, V192, P38; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; PADAN E, 1987, J MEMBRANE BIOL, V95, P189, DOI 10.1007/BF01869481; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; PRESSMAN BC, 1967, P NATL ACAD SCI USA, V58, P1949, DOI 10.1073/pnas.58.5.1949; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; VENEMA K, 1993, BIOCHIM BIOPHYS ACTA, V1146, P87, DOI 10.1016/0005-2736(93)90342-W	33	112	121	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12043	12050		10.1074/jbc.M313510200	http://dx.doi.org/10.1074/jbc.M313510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715669	hybrid			2022-12-25	WOS:000220334900007
J	Hanson, GT; Aggeler, R; Oglesbee, D; Cannon, M; Capaldi, RA; Tsien, RY; Remington, SJ				Hanson, GT; Aggeler, R; Oglesbee, D; Cannon, M; Capaldi, RA; Tsien, RY; Remington, SJ			Investigating mitochondrial redox potential with redox-sensitive green fluorescent protein indicators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; STRUCTURAL BASIS; GLUTATHIONE; VARIANTS; PH; DEPENDENCE; ISOMERASE; PROGRAM; PATHWAY; BINDING	Current methods for determining ambient redox potential in cells are labor- intensive and generally require destruction of tissue. This precludes single cell or real time studies of changes in redox poise that result from metabolic processes or environmental influences. By substitution of surface- exposed residues on the Aequorea victoria green fluorescent protein ( GFP) with cysteines in appropriate positions to form disulfide bonds, reduction- oxidation- sensitive GFPs ( roGFPs) have been created. roGFPs have two fluorescence excitation maxima at about 400 and 490 nm and display rapid and reversible ratiometric changes in fluorescence in response to changes in ambient redox potential in vitro and in vivo. Crystal structure analyses of reduced and oxidized crystals of roGFP2 at 2.0- and 1.9-Angstrom resolution, respectively, reveal in the oxidized state a highly strained disulfide and localized main chain structural changes that presumably account for the state- dependent spectral changes. roGFP1 has been targeted to the mitochondria in HeLa cells. Fluorometric measurements on these cells using a fluorescence microscope or in cell suspension using a fluorometer reveal that the roGFP1 probe is in dynamic equilibrium with the mitochondrial redox status and responds to membrane- permeable reductants and oxidants. The roGFP1 probe reports that the matrix space in HeLa cell mitochondria is highly reducing, with a midpoint potential near - 360 mV ( assuming mitochondrial pH similar to8.0 at 37degreesC). In other work ( C. T. Dooley, T. M. Dore, G. Hanson, W. C. Jackson, S. J. Remington, and R. Y. Tsien, submitted for publication), it is shown that the cytosol of HeLa cells is also unusually reducing but somewhat less so than the mitochondrial matrix.	Univ Oregon, Inst Mol Biol, Dept Phys, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Dept Biol, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Dept Chem, Eugene, OR 97403 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of Oregon; University of Oregon; University of Oregon; University of California System; University of California San Diego; University of California System; University of California San Diego	Remington, SJ (corresponding author), Univ Oregon, Inst Mol Biol, Dept Phys, Eugene, OR 97403 USA.	jim@uoxray.uoregon.edu	Oglesbee, Devin/AAU-5420-2021	Oglesbee, Devin/0000-0002-7147-5527	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007759, R01GM042618] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 24526] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07759, GM 42618] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; CAPALDI RA, 2002, BIOCHIM BIOPHYS ACTA, V155, P192; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Chernyak BV, 1997, BIOSCIENCE REP, V17, P293, DOI 10.1023/A:1027384628678; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; Demple B, 2002, MOL CELL BIOCHEM, V234, P11, DOI 10.1023/A:1015933216079; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Gross E, 2002, NAT STRUCT BIOL, V9, P61, DOI 10.1038/nsb740; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Hanson GT, 2002, BIOCHEMISTRY-US, V41, P15477, DOI 10.1021/bi026609p; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jayaraman S, 2000, J BIOL CHEM, V275, P6047, DOI 10.1074/jbc.275.9.6047; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keese MA, 1999, FEBS LETT, V447, P135, DOI 10.1016/S0014-5793(99)00296-3; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEES WJ, 1993, J ORG CHEM, V58, P642, DOI 10.1021/jo00055a016; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P50; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Ostergaard H, 2001, EMBO J, V20, P5853, DOI 10.1093/emboj/20.21.5853; Palm GJ, 1997, NAT STRUCT BIOL, V4, P361, DOI 10.1038/nsb0597-361; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Remington SJ, 2000, METHOD ENZYMOL, V305, P196; Rhee S G, 2000, Sci STKE, V2000, ppe1; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Topell S, 1999, FEBS LETT, V457, P283, DOI 10.1016/S0014-5793(99)01044-3; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Wachter RM, 2000, J MOL BIOL, V301, P157, DOI 10.1006/jmbi.2000.3905; Wachter RM, 1999, CURR BIOL, V9, pR628, DOI 10.1016/S0960-9822(99)80408-4; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0; WHITAKER JE, 1991, ANAL BIOCHEM, V194, P330, DOI 10.1016/0003-2697(91)90237-N; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; ZHANG RM, 1989, J BIOL CHEM, V264, P18472; Zimmer M, 2002, CHEM REV, V102, P759, DOI 10.1021/cr010142r	63	700	724	5	139	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13044	13053		10.1074/jbc.M312846200	http://dx.doi.org/10.1074/jbc.M312846200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722062	hybrid			2022-12-25	WOS:000220334900125
J	Kounosu, A; Li, ZR; Cosper, NJ; Shokes, JE; Scott, RA; Imai, T; Urushiyama, A; Iwasaki, T				Kounosu, A; Li, ZR; Cosper, NJ; Shokes, JE; Scott, RA; Imai, T; Urushiyama, A; Iwasaki, T			Engineering a three-cysteine, one-histidine ligand environment into a new hyperthermophilic archaeal Rieske-type [2Fe-2S] ferredoxin from Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; RESONANCE RAMAN-SPECTRA; SP STRAIN 7; ABSORPTION SPECTROSCOPIC ANALYSIS; PYRROLIDONE CARBOXYL PEPTIDASE; NORMAL COORDINATE ANALYSIS; SITE-DIRECTED MUTAGENESIS; ECHO ENVELOPE MODULATION; WATER-SOLUBLE FRAGMENT; BLUE COPPER PROTEINS	We heterologously overproduced a hyperthermostable archaeal low potential (E-m = - 62 mV) Rieske-type ferredoxin (ARF) from Sulfolobus solfataricus strain P-1 and its variants in Escherichia coli to examine the influence of ligand substitutions on the properties of the [2Fe-2S] cluster. While two cysteine ligand residues (Cys(42) and Cys(61)) are essential for the cluster assembly and/or stability, the contributions of the two histidine ligands to the cluster assembly in the archaeal Rieske-type ferredoxin appear to be inequivalent as indicated by much higher stability of the His(64) --> Cys variant (H64C) than the His(44) --> Cys variant (H44C). The x-ray absorption and resonance Raman spectra of the H64C variant firmly established the formation of a novel, oxidized [2Fe-2S] cluster with one histidine and three cysteine ligands in the archaeal Rieske-type protein moiety. Comparative resonance Raman features of the wildtype, natural abundance and uniformly N-15-labeled ARF and its H64C variant showed significant mixing of the Fe-S and Fe-N stretching characters for an oxidized biological [2Fe-2S] cluster with partial histidine ligation.	Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan; Univ Georgia, Dept Chem, Athens, GA 30602 USA; Rikkyo St Pauls Univ, Dept Chem, Toshima Ku, Tokyo 1718501, Japan	Nippon Medical School; University System of Georgia; University of Georgia	Iwasaki, T (corresponding author), Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.	tiwasaki@nms.ac.jp	Li, Zhongrui/AAB-9111-2019; Li, Zhongrui/I-4872-2017	Li, Zhongrui/0000-0001-5371-7628; Iwasaki, Toshio/0000-0001-9562-4649; Scott, Robert/0000-0003-2236-1336	NIGMS NIH HHS [GM 42025] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042025] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Ankudinov AL, 1998, PHYS REV B, V58, P7565, DOI 10.1103/PhysRevB.58.7565; Beharry ZM, 2003, BIOCHEMISTRY-US, V42, P13625, DOI 10.1021/bi035385n; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Bonisch H, 2002, J MOL BIOL, V319, P791, DOI 10.1016/S0022-2836(02)00323-6; Brugna M, 1999, J BIOL CHEM, V274, P16766, DOI 10.1074/jbc.274.24.16766; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Cavagnero S, 1998, BIOCHEMISTRY-US, V37, P3369, DOI 10.1021/bi9721795; CLINE JF, 1985, J BIOL CHEM, V260, P3251; Colbert CL, 2000, STRUCTURE, V8, P1267, DOI 10.1016/S0969-2126(00)00536-0; COLPAS GJ, 1991, INORG CHEM, V30, P920, DOI 10.1021/ic00005a010; Cosper NJ, 2002, PROTEIN SCI, V11, P2969, DOI 10.1110/ps.0222402; Cosper NJ, 2001, J BIOCHEM, V130, P191, DOI 10.1093/oxfordjournals.jbchem.a002972; Couture MMJ, 2001, BIOCHEMISTRY-US, V40, P84, DOI 10.1021/bi001780r; Crouse BR, 1996, BIOCHEMISTRY-US, V35, P16222, DOI 10.1021/bi9620114; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; Degli Esposti M, 1987, Biochem J, V241, P285; Dikanov SA, 1996, J AM CHEM SOC, V118, P8408, DOI 10.1021/ja960781x; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; FEE JA, 1984, J BIOL CHEM, V259, P124; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; FU WG, 1992, J BIOL CHEM, V267, P15502; GASSNER GT, 1995, BIOCHEMISTRY-US, V34, P13460, DOI 10.1021/bi00041a025; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; GURBIEL RJ, 1991, BIOCHEMISTRY-US, V30, P11579, DOI 10.1021/bi00113a013; HAN J, 1991, BIOCHEMISTRY-US, V30, P10904, DOI 10.1021/bi00109a014; HAN S, 1989, J AM CHEM SOC, V111, P3496, DOI 10.1021/ja00192a002; HAN S, 1989, J AM CHEM SOC, V111, P3505, DOI 10.1021/ja00192a003; Holz RC, 1997, BIOCHEMISTRY-US, V36, P14690, DOI 10.1021/bi971831t; HUANG JJ, 1973, BIOCHEMISTRY-US, V12, P406, DOI 10.1021/bi00727a007; Hunsicker-Wang LM, 2003, BIOCHEMISTRY-US, V42, P7303, DOI 10.1021/bi0342719; Iwasaki T, 2000, J BIOL CHEM, V275, P25391, DOI 10.1074/jbc.M909243199; IWASAKI T, 1995, J BACTERIOL, V177, P2576, DOI 10.1128/jb.177.9.2576-2582.1995; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; Iwasaki T, 2002, EPR IN THE 21ST CENTURY: BASICS AND APPLICATIONS TO MATERIAL, LIFE AND EARTH SCIENCES, P488, DOI 10.1016/B978-044450973-4/50083-4; Iwasaki T, 2002, J BIOL CHEM, V277, P39642, DOI 10.1074/jbc.M207312200; Iwasaki T, 2001, METHOD ENZYMOL, V334, P3; Iwasaki T, 1996, J BIOL CHEM, V271, P27659, DOI 10.1074/jbc.271.44.27659; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Kauppi B, 1998, STRUCTURE, V6, P571, DOI 10.1016/S0969-2126(98)00059-8; Kaushik JK, 2002, J MOL BIOL, V316, P991, DOI 10.1006/jmbi.2001.5355; KUILA D, 1987, J AM CHEM SOC, V109, P1559, DOI 10.1021/ja00239a041; KUILA D, 1992, BIOCHIM BIOPHYS ACTA, V1140, P175, DOI 10.1016/0005-2728(92)90007-O; Li ZR, 2003, BIOCHEMISTRY-US, V42, P15003, DOI 10.1021/bi035078h; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; Link TA, 1999, ADV INORG CHEM, V47, P83, DOI 10.1016/S0898-8838(08)60077-X; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; Meyer J, 1997, BIOCHEMISTRY-US, V36, P13374, DOI 10.1021/bi971775w; MEYER J, 1994, BIOCHEMISTRY-US, V33, P13642, DOI 10.1021/bi00250a014; Ogasahara K, 1998, BIOCHEMISTRY-US, V37, P17537, DOI 10.1021/bi9814585; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; PALMER G, 1967, BIOCHEMISTRY-US, V6, P1658, DOI 10.1021/bi00858a012; RANDALL CR, 1995, INORG CHEM, V34, P1036, DOI 10.1021/ic00109a007; ROE AL, 1984, J AM CHEM SOC, V106, P1676, DOI 10.1021/ja00318a021; Rotsaert FAJ, 2003, J BIOL INORG CHEM, V8, P318, DOI 10.1007/s00775-002-0417-4; SAITO H, 1991, B CHEM SOC JPN, V64, P829, DOI 10.1246/bcsj.64.829; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Samoilova RI, 2002, J BIOL CHEM, V277, P4605, DOI 10.1074/jbc.C100664200; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Shergill JK, 1995, BIOCHEMISTRY-US, V34, P16533, DOI 10.1021/bi00051a001; Suzuki T, 2002, EXTREMOPHILES, V6, P39, DOI 10.1007/s007920100221; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; URUSHIYAMA A, 1990, B CHEM SOC JPN, V63, P1563, DOI 10.1246/bcsj.63.1563; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P8083, DOI 10.1021/bi00083a005; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; Xia B, 1999, BIOCHEMISTRY-US, V38, P727, DOI 10.1021/bi981851a; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	76	45	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12519	12528		10.1074/jbc.M305923200	http://dx.doi.org/10.1074/jbc.M305923200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14726526	hybrid			2022-12-25	WOS:000220334900063
J	Mani, K; Cheng, F; Havsmark, B; David, S; Fransson, LA				Mani, K; Cheng, F; Havsmark, B; David, S; Fransson, LA			Involvement of glycosylphosphatidylinositol-linked ceruloplasmin in the copper/zinc-nitric oxide-dependent degradation of glypican-1 heparan sulfate in rat C6 glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORED FORM; PROTEOGLYCANS; AUTOCLEAVAGE; MECHANISM; NEURONS	The core protein of glypican- 1, a glycosylphosphatidylinositol-linked heparan sulfate proteoglycan, can bind Cu( II) or Zn( II) ions and undergo S- nitrosylation in the presence of nitric oxide. Cu( II)- to- Cu( I)- reduction supports extensive and permanent nitrosothiol formation, whereas Zn( II) ions appear to support a more limited, possibly transient one. Ascorbate induces release of nitric oxide, which catalyzes deaminative degradation of the heparan sulfate chains on the same core protein. Although free Zn( II) ions support a more limited degradation, Cu( II) ions support a more extensive self- pruning process. Here, we have investigated processing of glypican- 1 in rat C6 glioma cells and the possible participation of the copper- containing glycosylphosphatidylinositol-linked splice variant of ceruloplasmin in nitrosothiol formation. Confocal microscopy demonstrated colocalization of glypican- 1 and ceruloplasmin in endosomal compartments. Ascorbate induced extensive, Zn( II)- supported heparan sulfate degradation, which could be demonstrated using a specific zinc probe. RNA interference silencing of ceruloplasmin expression reduced the extent of Zn( II)- supported degradation. In cell- free experiments, the presence of free Zn( II) ions prevented free Cu( II) ion from binding to glypican- 1 and precluded extensive heparan sulfate autodegradation. However, in the presence of Cu( II)- loaded ceruloplasmin, heparan sulfate in Zn( II)loaded glypican- 1 underwent extensive, ascorbate- induced degradation. We propose that the Cu( II)- to- Cu( I)- reduction that is required for S- nitrosylation of glypican- 1 can take place on ceruloplasmin and thereby ensure extensive glypican-1 processing in the presence of free Zn( II) ions.	Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, Biomed Ctr C13, SE-22184 Lund, Sweden; McGill Univ, Montreal Gen Hosp, Neurosci Res Ctr, Montreal, PQ H3G 1A4, Canada	Lund University; McGill University	Fransson, LA (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, Biomed Ctr C13, SE-22184 Lund, Sweden.	lars-ake.fransson@medkem.lu.se		Mani, Katrin/0000-0002-1821-0634				Bansal R, 1996, MOL CELL NEUROSCI, V7, P276, DOI 10.1006/mcne.1996.0021; Bansal R, 2002, DEV NEUROSCI-BASEL, V24, P35, DOI 10.1159/000064944; Belting M, 2003, J BIOL CHEM, V278, P47181, DOI 10.1074/jbc.M308325200; Berger UV, 2003, J NEUROCHEM, V86, P896, DOI 10.1046/j.1471-4159.2003.01891.x; Bielli P, 2002, CELL MOL LIFE SCI, V59, P1413, DOI 10.1007/s00018-002-8519-2; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Cheng F, 2002, J BIOL CHEM, V277, P44431, DOI 10.1074/jbc.M205241200; Ding K, 2002, J BIOL CHEM, V277, P33353, DOI 10.1074/jbc.M203383200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Fransson LA, 2003, INT J BIOCHEM CELL B, V35, P125, DOI 10.1016/S1357-2725(02)00095-X; Gitlin JD, 1998, PEDIATR RES, V44, P271, DOI 10.1203/00006450-199809000-00001; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Lee JY, 2003, J NEUROSCI RES, V73, P156, DOI 10.1002/jnr.10647; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Machonkin TE, 2000, J AM CHEM SOC, V122, P12547, DOI 10.1021/ja002339r; Mani K, 2003, J BIOL CHEM, V278, P38956, DOI 10.1074/jbc.M300394200; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; Nybakken K, 2002, BBA-GEN SUBJECTS, V1573, P280, DOI 10.1016/S0304-4165(02)00395-1; Ornitz DM, 2001, GENOME BIOL, V2; Patel BN, 2000, J BIOL CHEM, V275, P4305, DOI 10.1074/jbc.275.6.4305; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; Patel BN, 2002, J NEUROSCI, V22, P6578; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Qiao DH, 2003, J BIOL CHEM, V278, P16045, DOI 10.1074/jbc.M211259200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805	26	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12918	12923		10.1074/jbc.M313678200	http://dx.doi.org/10.1074/jbc.M313678200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707133	hybrid			2022-12-25	WOS:000220334900109
J	Mitsui, K; Ochi, F; Nakamura, N; Doi, Y; Inoue, H; Kanazawa, H				Mitsui, K; Ochi, F; Nakamura, N; Doi, Y; Inoue, H; Kanazawa, H			A novel membrane protein capable of binding the Na+/H+ antiporter (Nha1p) enhances the salinity-resistant cell growth of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCINEURIN HOMOLOGOUS PROTEIN; MOLECULAR-CLONING; ESCHERICHIA-COLI; INTRACELLULAR PH; SALT-TOLERANCE; EXCHANGER ISOFORM-1; BETA-SUBUNIT; YEAST; GENE; H+	The Na+/H+ antiporter Nha1p of Saccharomyces cerevisiae plays an important role in maintaining intracellular pH and Na+ homeostasis. Nha1p has a two-domain structure composed of integral membrane and hydrophilic tail regions. Overexpression of a peptide of similar to40 residues (C1 + C2 domains) that is localized in the juxtamembrane area of its cytoplasmic tail caused cell growth retardation in highly saline conditions, possibly by decreasing Na+/H+ antiporter activity. A multicopy suppressor gene of this growth retardation was identified from a yeast genome library. The clone encodes a novel membrane protein denoted as COS3 in the genome data base. Overexpression or deletion of COS3 increases or decreases salinity-resistant cell growth, respectively. However, in nha1Delta cells, overexpression of COS3 alone did not suppress the growth retardation. Cos3p and a hydrophilic portion of Cos3p interact with the C1 + C2 peptide in vitro, and Cos3p is co-precipitated with Nha1p from yeast cell extracts. Cos3p-GFP mainly resides at the vacuole, but overexpression of Nha1p caused a portion of the Cos3p-GFP proteins to shift to the cytoplasmic membrane. These observations suggest that Cos3p is a novel membrane protein that can enhance salinity-resistant cell growth by interacting with the C1 + C2 domain of Nha1p and thereby possibly activating the antiporter activity of this protein.	Osaka Univ, Grad Sch Sci, Dept Biol Sci, Toynaka, Osaka 5600043, Japan	Osaka University	Kanazawa, H (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol Sci, Machikaneyama Cho 1-16, Toynaka, Osaka 5600043, Japan.	kanazawa@bio.sci.osaka-u.ac.jp						ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; Banuelos MA, 1998, MICROBIOL-UK, V144, P2749, DOI 10.1099/00221287-144-10-2749; BANUELOS MA, 1995, EMBO J, V14, P3021, DOI 10.1002/j.1460-2075.1995.tb07304.x; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Blumwald E, 2000, CURR OPIN CELL BIOL, V12, P431, DOI 10.1016/S0955-0674(00)00112-5; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Ekuni A, 1998, FEBS LETT, V427, P64, DOI 10.1016/S0014-5793(98)00395-0; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; Goyal S, 2003, AM J PHYSIOL-RENAL, V284, pF467, DOI 10.1152/ajprenal.00352.2002; HOULE JG, 1983, DEV BIOL, V97, P302, DOI 10.1016/0012-1606(83)90088-X; Inoue H, 2003, BIOL PHARM BULL, V26, P148, DOI 10.1248/bpb.26.148; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; JOHNSON JD, 1976, NATURE, V262, P661, DOI 10.1038/262661a0; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kamauchi S, 2002, J BIOCHEM, V131, P821, DOI 10.1093/oxfordjournals.jbchem.a003171; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; Kinclova O, 2001, MOL MICROBIOL, V40, P656, DOI 10.1046/j.1365-2958.2001.02412.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mailander J, 2001, FEBS LETT, V507, P331, DOI 10.1016/S0014-5793(01)02986-6; MANIATAS T, 1982, MOL CLONING LAB MANU; Matsumoto M, 2001, J BIOCHEM, V130, P217, DOI 10.1093/oxfordjournals.jbchem.a002975; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MIKI J, 1992, ARCH BIOCHEM BIOPHYS, V294, P373, DOI 10.1016/0003-9861(92)90698-V; MIKI JJ, 1990, J BIOL CHEM, V265, P21567; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PADAN E, 1993, J BIOENERG BIOMEMBR, V25, P647; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; Padan E, 2001, BBA-BIOENERGETICS, V1505, P144, DOI 10.1016/S0005-2728(00)00284-X; Pang TX, 2002, J BIOL CHEM, V277, P43771, DOI 10.1074/jbc.M208313200; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; Quintero FJ, 2000, FEBS LETT, V471, P224, DOI 10.1016/S0014-5793(00)01412-5; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; RUBIN H, 1973, J CELL PHYSIOL, V82, P231, DOI 10.1002/jcp.1040820211; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Simon E, 2001, J BIOL CHEM, V276, P29740, DOI 10.1074/jbc.M101992200; Soong TW, 2000, MICROBIOL-UK, V146, P1035, DOI 10.1099/00221287-146-5-1035; Spode I, 2002, J MOL BIOL, V319, P407, DOI 10.1016/S0022-2836(02)00322-4; Sychrova H, 1999, FEMS MICROBIOL LETT, V171, P167, DOI 10.1111/j.1574-6968.1999.tb13428.x; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; WATANABE Y, 1995, YEAST, V11, P829, DOI 10.1002/yea.320110905; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Wiederkehr A, 2001, YEAST, V18, P759, DOI 10.1002/yea.726; WINKLER MM, 1978, NATURE, V273, P536, DOI 10.1038/273536a0	61	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12438	12447		10.1074/jbc.M310806200	http://dx.doi.org/10.1074/jbc.M310806200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718542	hybrid			2022-12-25	WOS:000220334900053
J	Whitehurst, AW; Robinson, FL; Moore, MS; Cobb, MH				Whitehurst, AW; Robinson, FL; Moore, MS; Cobb, MH			The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; EXPORT SIGNAL; GROWTH-FACTOR; BETA-CATENIN; CELL-CYCLE; TRANSLOCATION; PHOSPHORYLATION; LOCALIZATION; EXPRESSION; ACTIVATION	ERK2 nuclear-cytoplasmic distribution is regulated in response to hormones and cellular state without the requirement for karyopherin-mediated nuclear import. One proposed mechanism for the movement of ERK2 into the nucleus is through a direct interaction between ERK2 and nucleoporins present in the nuclear pore complex. Previous reports have attributed regulation of ERK2 localization to proteins that activate or deactivate ERK2, such as the mitogen-activated protein (MAP) kinase kinase MEK1 and MAP kinase phosphatases. Recently, a small non-catalytic protein, PEA-15, has also been demonstrated to promote a cytoplasmic ERK2 localization. We found that the MAP kinase insert in ERK2 is required for its interaction with PEA-15. Consistent with its recognition of the MAP kinase insert, PEA-15 blocked activation of ERK2 by MEK1, which also requires the MAP kinase insert to interact productively with ERK2. To determine how PEA-15 influences the localization of ERK2, we used a permeabilized cell system to examine the effect of PEA-15 on the localization of ERK2 and mutants that have lost the ability to bind PEA-15. Wild type ERK2 was unable to enter the nucleus in the presence of an excess of PEA-15; however, ERK2 lacking the MAP kinase insert largely retained the ability to enter the nucleus. Binding assays demonstrated that PEA-15 interfered with the ability of ERK2 to bind to nucleoporins. These results suggest that PEA-15 sequesters ERK2 in the cytoplasm at least in part by interfering with its ability to interact with nucleoporins, presenting a potential paradigm for regulation of ERK2 localization.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mcobb@mednet.swmed.edu		Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BRUNET A, 1996, SCIENCE, V272, P1653; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Hulleman E, 1999, J CELL PHYSIOL, V180, P325, DOI 10.1002/(SICI)1097-4652(199909)180:3<325::AID-JCP3>3.0.CO;2-R; Jacobs D, 1998, GENETICS, V149, P1809; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Menice CB, 1997, J BIOL CHEM, V272, P25157, DOI 10.1074/jbc.272.40.25157; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Robinson MJ, 2002, J BIOL CHEM, V277, P5094, DOI 10.1074/jbc.M110935200; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Tsukamoto T, 2000, CANCER LETT, V149, P105, DOI 10.1016/S0304-3835(99)00350-X; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710	51	62	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12840	12847		10.1074/jbc.M310031200	http://dx.doi.org/10.1074/jbc.M310031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707138	hybrid			2022-12-25	WOS:000220334900099
J	Ren, Y; Aguirre, J; Ntamack, AG; Chu, CH; Schulz, H				Ren, Y; Aguirre, J; Ntamack, AG; Chu, CH; Schulz, H			An alternative pathway of oleate beta-oxidation in Escherichia coli involving the hydrolysis of a dead end intermediate by a thioesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; RAT-HEART MITOCHONDRIA; DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE; MULTIENZYME COMPLEX; MOLECULAR-CLONING; DOUBLE-BONDS; COENZYME-A; OLEIC-ACID; METABOLISM; LIVER	The degradation of 2-trans,5-cis-tetradecadienoyl-CoA, a metabolite of oleic acid, by the purified complex of fatty acid oxidation from Escherichia coli was studied to determine how much of the metabolite is converted to 3,5-cis-tetradecadienoyl-CoA and thereby diverted from the classical, isomerase-dependent pathway of oleate beta-oxidation. Approximately 10% of the 2,5-intermediate was converted to the 3,5-isomer. When the latter compound was allowed to accumulate, it strongly inhibited the flux through the main pathway. Since Delta(3,5), Delta(2,4)-dienoyl-CoA isomerase was not detected in E. coli cells grown on oleate, the 3,5- intermediate cannot be metabolized via the reductase-dependent pathway. However, it was hydrolyzed by a thioesterase, which was most active with 3,5-cis-tetradecadienoyl-CoA as substrate and which was induced by growth of E. coli on oleate. An analysis of fatty acids present in the medium after growth of E. coli on oleate revealed the presence of 3,5-tetradecadienoate, which was not detected after cells were grown on palmitate or glucose. Altogether, these data prompt the conclusion that oleate is mostly degraded via the classical, isomerase-dependent pathway in E. coli but that a small amount of 2-trans, 5-cis-tetradecadienoyl-CoA is diverted from the pathway via conversion to 3,5- cis-tetradecadienoyl-CoA by Delta(3), Delta(2)-enoyl- CoA isomerase. The 3,5- intermediate, which would strongly inhibit beta-oxidation if allowed to accumulate, is hydrolyzed, and the resultant 3,5-tetradecadienoate is excreted into the growth medium. This study provides evidence for the novel function of a thioesterase in beta-oxidation.	CUNY City Coll, Dept Chem, New York, NY 10031 USA; CUNY, Grad Sch, New York, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System	Schulz, H (corresponding author), CUNY City Coll, Dept Chem, Convent Ave & 138th St, New York, NY 10031 USA.	hoschu@sci.ccny.cuny.edu			NCRR NIH HHS [RR03060] Funding Source: Medline; NHLBI NIH HHS [HL30847] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES EM, 1970, J BIOL CHEM, V245, P3122; BARNES EM, 1968, J BIOL CHEM, V243, P2955; BINSTOCK JF, 1977, P NATL ACAD SCI USA, V74, P492, DOI 10.1073/pnas.74.2.492; BONNER WM, 1972, J BIOL CHEM, V247, P3123; CHO HS, 1993, J BIOL CHEM, V268, P9238; CUEBAS D, 1982, J BIOL CHEM, V257, P4140; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fong J C, 1981, Methods Enzymol, V71 Pt C, P390; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; He XY, 1998, BBA-LIPID LIPID MET, V1392, P119, DOI 10.1016/S0005-2760(98)00031-9; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LINESTEAD RP, 1931, J CHEM SOC, P740; LUO MJ, 1994, J BIOL CHEM, V269, P2384; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; PAWAR S, 1981, J BIOL CHEM, V256, P3894; Ren Y, 2003, J BIOL CHEM, V278, P111, DOI 10.1074/jbc.M209261200; Schulz H, 1981, Methods Enzymol, V71 Pt C, P398; Shoukry K, 1998, J BIOL CHEM, V273, P6892, DOI 10.1074/jbc.273.12.6892; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; SPENCER AK, 1978, J BIOL CHEM, V253, P5922; STEINMAN H, 1965, METHOD ENZYMOL, V35, P136; THORPE C, 1986, ANAL BIOCHEM, V155, P391, DOI 10.1016/0003-2697(86)90452-5; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; Tserng KY, 1996, BIOCHEM J, V313, P581, DOI 10.1042/bj3130581; YANG SY, 1995, BIOCHEMISTRY-US, V34, P6441, DOI 10.1021/bi00019a025; YANG SY, 1988, J BACTERIOL, V170, P2543, DOI 10.1128/jb.170.6.2543-2548.1988; Zhang DY, 2002, J BIOL CHEM, V277, P9127, DOI 10.1074/jbc.M112228200; Zhang DY, 2001, J BIOL CHEM, V276, P13622, DOI 10.1074/jbc.M011315200	30	15	16	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11042	11050		10.1074/jbc.M310032200	http://dx.doi.org/10.1074/jbc.M310032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707139	hybrid			2022-12-25	WOS:000220157600027
J	Sharpless, NE; Ramsey, MR; Balasubramanian, P; Castrillon, DH; DePinho, RA				Sharpless, NE; Ramsey, MR; Balasubramanian, P; Castrillon, DH; DePinho, RA			The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis	ONCOGENE			English	Article						Rb; p14(ARF); p53; cdkn2a	MAMMARY EPITHELIAL-CELLS; HUMAN-DIPLOID FIBROBLASTS; TUMOR SUPPRESSION; INDUCED SENESCENCE; KERATINOCYTE SENESCENCE; GERMLINE MUTATION; FAMILIAL MELANOMA; INK4A LOCUS; IN-VIVO; INACTIVATION	Mounting genetic evidence suggests that each product of the Ink4/Arf locus, p16(INK4a) and p19(ARF), possesses tumor-suppressor activity (Kamijo et al., 1997; Krimpenfort et al., 2001; Sharpless et al., 2001a). We report the generation and characterization of a p19(ARF)-specific knockout allele (p19(ARF)-/-) and direct comparison with mice and derivative cells deficient for p16(INK4a), both p16(INK4a) and p19(ARF), and p53. Like Ink4/Arf-/- murine embryo fibroblasts (MEFs), p19(ARF)-/- MEFs were highly susceptible to oncogenic transformation, exhibited enhanced subcloning efficiency at low density, and resisted both RAS- and culture-induced growth arrest. In contrast, the biological profile of p16(INK4a)-/- MEFs in these assays more closely resembled that of wild-type cells. In vivo, however, both p19(ARF)-/- and p16(INK4a)-/- animals were significantly more tumor prone than wild-type animals, but each less so than p53-/- or Ink4/Arf-/- animals, and with differing tumor spectra. These data confirm the predominant role of p19(ARF) over p16(INK4a) in cell culture-based assays of MEFs, yet also underscore the importance of the analysis of tumor suppressors across many cell types within the organism. The cancer-prone conditions of mice singly deficient for either p16(INK4a) or p19(ARF) agree with data derived from human cancer genetics, and reinforce the view that both gene products play significant and nonredundant roles in suppressing malignant transformation in vivo.	Univ N Carolina, Sch Med, Lineberger Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Canc Ctr, Dept Genet, Chapel Hill, NC 27599 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sharpless, NE (corresponding author), Univ N Carolina, Sch Med, Lineberger Canc Ctr, Dept Med, CB 7295, Chapel Hill, NC 27599 USA.	NES@med.unc.edu		Ramsey, Matthew/0000-0003-2402-8502; Sharpless, Norman/0000-0001-7078-9455; DePinho, Ronald/0000-0002-5625-577X				Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Eischen CM, 2002, CANCER RES, V62, P2184; Festing M, 1998, MOUSE GENOME INFORMA; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Huschtscha LI, 1998, CANCER RES, V58, P3508; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P440; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MAO L, 1995, CANCER RES, V55, P2995; Munro J, 1999, CANCER RES, V59, P2516; OLSON DC, 1993, ONCOGENE, V8, P2353; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2002, CANCER RES, V62, P2761; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; SHARPLESS NE, 2003, IN PRESS ONCOGENE; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2001, CELL, V106, P531, DOI 10.1016/S0092-8674(01)00486-X; STONE S, 1995, CANCER RES, V55, P2988; Sviderskaya EV, 2003, J NATL CANCER I, V95, P723, DOI 10.1093/jnci/95.10.723; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	46	144	156	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	2004	23	2					379	385		10.1038/sj.onc.1207074	http://dx.doi.org/10.1038/sj.onc.1207074			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724566				2022-12-25	WOS:000188098300007
J	Kumaraswami, M; Howe, MM; Park, HW				Kumaraswami, M; Howe, MM; Park, HW			Crystal structure of the mor protein of bacteriophage Mu, a member of the Mor/C family of transcription activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; COLI RNA-POLYMERASE; TARGET SITE; DNA-BINDING; C-PROTEIN; P-M; REPRESSOR; PROMOTER; OPERATOR; ALIGNMENT	Transcription from the middle promoter, P-m, of bacteriophage Mu requires the phage-encoded activator protein Mor and bacterial RNA polymerase. Mor is a sequence-specific DNA-binding protein that mediates transcription activation through its interactions with the C-terminal domains of the alpha and sigma subunits of bacterial RNA polymerase. Here we present the first structure for a member of the Mor/C family of transcription activators, the crystal structure of Mor to 2.2-Angstrom resolution. Each monomer of the Mor dimer is composed of two domains, the N-terminal dimerization domain and C-terminal DNA-binding domain, which are connected by a linker containing a beta strand. The N-terminal dimerization domain has an unusual mode of dimerization; helices alpha1 and alpha2 of both monomers are intertwined to form a four-helix bundle, generating a hydrophobic core that is further stabilized by antiparallel interactions between the two beta strands. Mutational analysis of key leucine residues in helix alpha1 demonstrated a role for this hydrophobic core in protein solubility and function. The C-terminal domain has a classical helix-turn-helix DNA-binding motif that is located at opposite ends of the elongated dimer. Since the distance between the two helix-turn-helix motifs is too great to allow binding to two adjacent major grooves of the 16-bp Mor-binding site, we propose that conformational changes in the protein and DNA will be required for Mor to interact with the DNA. The highly conserved glycines flanking the beta strand may act as pivot points, facilitating the conformational changes of Mor, and the DNA may be bent.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Park, HW (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, 332 N Lauderdale St, Memphis, TN 38105 USA.	hee-won.park@stjude.org			NCI NIH HHS [CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Artsimovitch I, 1996, J BIOL CHEM, V271, P32343, DOI 10.1074/jbc.271.50.32343; Artsimovitch I, 1996, P NATL ACAD SCI USA, V93, P9408, DOI 10.1073/pnas.93.18.9408; Artsimovitch I, 1996, NUCLEIC ACIDS RES, V24, P450, DOI 10.1093/nar/24.3.450; ARTSIMOVITCH I, 1996, ACTIVATION MIDDLE TR; Bell CE, 2001, J MOL BIOL, V312, P921, DOI 10.1006/jmbi.2001.5024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Casjens S, 2003, MOL MICROBIOL, V49, P277, DOI 10.1046/j.1365-2958.2003.03580.x; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Duchaud E, 2003, NAT BIOTECHNOL, V21, P1307, DOI 10.1038/nbt886; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Heidelberg JF, 2002, NAT BIOTECHNOL, V20, P1118, DOI 10.1038/nbt749; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; Hochschild A, 1998, CELL, V92, P597, DOI 10.1016/S0092-8674(00)81126-5; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; HOWE MM, 1973, VIROLOGY, V54, P93, DOI 10.1016/0042-6822(73)90118-9; HOWE MM, 1997, MOL MICROBIOL, P65; JIANG Y, 1999, THESIS U TENNESSEE M; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KahmeyerGabbe M, 1996, J BACTERIOL, V178, P1585, DOI 10.1128/jb.178.6.1585-1592.1996; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu Y, 1997, MICROBIOL-UK, V143, P705, DOI 10.1099/00221287-143-3-705; Luscombe NM, 2000, GENOME BIOL, V1; MARGOLIN W, 1990, J BACTERIOL, V172, P1424, DOI 10.1128/jb.172.3.1424-1429.1990; MARGOLIN W, 1989, J BACTERIOL, V171, P2003, DOI 10.1128/jb.171.4.2003-2018.1989; Maris AE, 2002, NAT STRUCT BIOL, V9, P771, DOI 10.1038/nsb845; MARRS CF, 1990, VIROLOGY, V174, P192, DOI 10.1016/0042-6822(90)90068-3; MATHEE K, 1990, J BACTERIOL, V172, P6641, DOI 10.1128/jb.172.12.6641-6650.1990; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; McPherson A., 1989, PREPARATION ANAL PRO; Miller JH., 1972, EXPT MOL GENETICS; Morgan GJ, 2002, J MOL BIOL, V317, P337, DOI 10.1006/jmbi.2002.5437; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkhill J, 2001, NATURE, V413, P848, DOI 10.1038/35101607; Paul BD, 2003, PROTEINS, V52, P272, DOI 10.1002/prot.10413; POUDEROYEN VG, 1997, EMBO J, V16, P6044; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.genet.19.1.355; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sun WY, 1997, J MOL BIOL, V273, P765, DOI 10.1006/jmbi.1997.1349; Symonds N., 1987, PHAGE MU; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P501, DOI 10.1107/S0907444998012657; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VASCONCELOS ATR, 2003, P NATL ACAD SCI USA, V100, P11660, DOI 10.1073/pnas.1832124100; WILSON CM, 1983, METHOD ENZYMOL, V91, P236; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514; ZHANG H, 1994, J MOL BIOL, V238, P592, DOI 10.1006/jmbi.1994.1317; ZHAO Z, 1999, THESIS U TENNESSEE M	62	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16581	16590		10.1074/jbc.M313555200	http://dx.doi.org/10.1074/jbc.M313555200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14729670	hybrid			2022-12-25	WOS:000220747900108
J	Sik, A; Passer, BJ; Koonin, EV; Pellegrini, L				Sik, A; Passer, BJ; Koonin, EV; Pellegrini, L			Self-regulated cleavage of the mitochondrial intramembrane-cleaving protease PARL yields P beta, a nuclear-targeted peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED PROTEIN; ESTABLISHMENT; MECHANISM; APOPTOSIS; NEURONS; PATHWAY; COMPLEX; FAMILY; AXIS; OPA1	Regulated intramembrane proteolysis (RIP) is an emerging paradigm in signal transduction. RIP is mediated by intramembrane-cleaving proteases (I-CliPs), which liberate biologically active nuclear or secreted domains from their membrane-tethered precursor proteins. The yeast Pcp1p/Rbd1p protein is a Rhomboid-like I-CliP that regulates mitochondrial membrane remodeling and fusion through cleavage of Mgm1p, a regulator of these essential activities. Although this ancient function is conserved in PARL ((P) under bar resenilins-(a) under bar ssociated (R) double under bar homboid-(l) under bar ike protein), the mammalian ortholog of Pcp1p/Rbd1p, the two proteins show a strong divergence at their N termini. However, the N terminus of PARL is significantly conserved among vertebrates, particularly among mammals, suggesting that this domain evolved a distinct but still unknown function. Here, we show that the cytosolic N-terminal domain of PARL is cleaved at positions 52-53(alpha-site) and 77-78 (beta-site). Whereas alpha-cleavage is constitutive and removes the mitochondrial targeting sequence, beta-cleavage appears to be developmentally controlled and dependent on PARL I-CliP activity supplied in trans. The beta-cleavage of PARL liberates Pbeta, a nuclear targeted peptide whose sequence is conserved only in mammals. Thus, in addition to its evolutionarily conserved function in regulating mitochondrial dynamics, PARL might mediate a mammalian-specific, developmentally regulated mitochondria-to-nuclei signaling through regulated proteolysis of its N terminus and release of the Pbeta peptide.	Univ Laval, Ctr Rech Robert Giffard, Quebec City, PQ G1J 2G3, Canada; Univ Laval, Dept Psychiat, Quebec City, PQ G1J 2G3, Canada; Mol Engines Labs, F-75011 Paris, France; Natl Lib Med, NCBI, NIH, Bethesda, MD 20894 USA	Laval University; Laval University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Pellegrini, L (corresponding author), CRULRG, Mol Neurobiol Lab, 2601 Chemin Canardiere, Quebec City, PQ G1J 2G3, Canada.	Luca.Pellegrini@crulrg.ulaval.ca		Pellegrini, Luca/0000-0002-4235-7708	NATIONAL LIBRARY OF MEDICINE [Z01LM000061, ZIALM000061] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CLAROS MG, 1995, COMPUT APPL BIOSCI, V11, P441; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DeKoninck P, 1995, J NEUROSCI, V15, P7966; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Esser K, 2002, J MOL BIOL, V323, P835, DOI 10.1016/S0022-2836(02)01000-8; Gay F, 2003, GENE DEV, V17, P717, DOI 10.1101/gad.1042403; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200; Jeffery CJ, 2003, ANN MED, V35, P28, DOI 10.1080/07853890310004101; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; Koonin EV, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r19; Koonin EV, 2002, NATURE, V420, P218, DOI 10.1038/nature01256; McQuibban GA, 2003, NATURE, V423, P537, DOI 10.1038/nature01633; Moliaka YK, 2004, FEBS LETT, V557, P185, DOI 10.1016/S0014-5793(03)01489-3; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Pellegrini L, 2001, J ALZHEIMERS DIS, V3, P181; Piatigorsky J, 1998, ANN NY ACAD SCI, V842, P7, DOI 10.1111/j.1749-6632.1998.tb09626.x; Rakic P, 2002, PROG BRAIN RES, V138, P3, DOI 10.1016/S0079-6123(02)38067-1; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Re RN, 2002, REGUL PEPTIDES, V106, P1, DOI 10.1016/S0167-0115(02)00031-9; Rossi V, 1997, J BIOL CHEM, V272, P13758, DOI 10.1074/jbc.272.21.13758; RUOHOLABAKER H, 1993, CELL, V73, P953, DOI 10.1016/0092-8674(93)90273-S; Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Sik A, 1998, P NATL ACAD SCI USA, V95, P3245, DOI 10.1073/pnas.95.6.3245; Tandon A, 2002, GENOME BIOL, V3; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6	33	54	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15323	15329		10.1074/jbc.M313756200	http://dx.doi.org/10.1074/jbc.M313756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14732705	hybrid			2022-12-25	WOS:000220594700101
J	Teng, SC; Chen, YY; Su, YN; Chou, PC; Chiang, YC; Tseng, SF; Wu, KJ				Teng, SC; Chen, YY; Su, YN; Chou, PC; Chiang, YC; Tseng, SF; Wu, KJ			Direct activation of HSP90A transcription by c-Myc contributes to c-Myc-induced transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; INTERACTING PROTEIN; CELL-PROLIFERATION; DNA-BINDING; EXPRESSION; GENE; TARGET; COMPLEX; KINASE; IDENTIFICATION	The c-myc proto-oncogene encodes a ubiquitous transcription factor involved in the control of cell growth and differentiation and implicated in inducing tumorigenesis. Understanding the function of c-Myc and its role in cancer depends upon the identification of c-Myc target genes. Heat shock protein 90 (HSP90) is involved in the folding of proteins such as signal transduction molecules (Src, Raf1, cdk4) and steroid receptors and in enhancing the activity of telomerase and nitric-oxide synthase. Here we show that c-Myc directly activates HSP90A transcription. c-Myc-mediated induction of HSP90A transcription occurs in different tissues, is independent of cell proliferation, and is mediated by a c-Myc binding site in the proximal promoter region of HSP90A gene. Overexpression of HSP90A in Rat1a cells induces transformation. Short interference RNA of HSP90A/Hsp86alpha reduces transformation activity in HeLa and RatMyc cells. These results indicate that by induction of HSP90A c-Myc may control the activity of multiple signal pathways involved in cellular transformation.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 100, Taiwan; Natl Taiwan Univ, Dept Med Genet, Taipei 100, Taiwan	National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University	Wu, KJ (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.	kjwu2@ym.edu.tw	Wu, Kou-Juey/P-4654-2015; Chiang, Yun/GRJ-5251-2022	TENG, SHU-CHUN/0000-0002-6492-2560	PHS HHS [EX93-9329SI] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Akalin A, 2001, CANCER RES, V61, P4791; Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blagosklonny MV, 2001, LEUKEMIA, V15, P1537, DOI 10.1038/sj.leu.2402257; Bonvini P, 2002, CANCER RES, V62, P1559; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Cardillo MR, 2000, ANTICANCER RES, V20, P4579; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chiang YC, 2003, J BIOL CHEM, V278, P19286, DOI 10.1074/jbc.M212043200; Dang CV, 1999, MOL CELL BIOL, V19, P1; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; Donze O, 1999, MOL CELL BIOL, V19, P8422, DOI 10.1128/mcb.19.12.8422; Drissi R, 2001, J BIOL CHEM, V276, P29994, DOI 10.1074/jbc.M101899200; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Forsythe HL, 2001, J BIOL CHEM, V276, P15571, DOI 10.1074/jbc.C100055200; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Guo QM, 2000, CANCER RES, V60, P5922; Hermisson M, 2000, NEUROLOGY, V54, P1357, DOI 10.1212/WNL.54.6.1357; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hur E, 2002, MOL PHARMACOL, V62, P975, DOI 10.1124/mol.62.5.975; Imai J, 2000, MOL CELL BIOL, V20, P9262, DOI 10.1128/MCB.20.24.9262-9270.2000; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Ito T, 1998, J ORAL PATHOL MED, V27, P18; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; Nanbu K, 1996, CANCER, V77, P330, DOI 10.1002/(SICI)1097-0142(19960115)77:2<330::AID-CNCR16>3.0.CO;2-2; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ogata Masao, 2000, Journal of Nippon Medical School, V67, P177, DOI 10.1272/jnms.67.177; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SASSON S, 1991, PATHOL BIOL, V39, P59; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; Schnaider T, 1999, LIFE SCI, V65, P2417, DOI 10.1016/S0024-3205(99)00508-1; Schnaider T, 2000, LIFE SCI, V67, P1455, DOI 10.1016/S0024-3205(00)00735-9; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Wu KJ, 2002, ONCOGENE, V21, P7872, DOI 10.1038/sj.onc.1205986; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu WP, 2002, CELL STRESS CHAPERON, V7, P91, DOI 10.1379/1466-1268(2002)007<0091:HNGRTI>2.0.CO;2; Yano M, 1996, JPN J CANCER RES, V87, P908, DOI 10.1111/j.1349-7006.1996.tb02119.x; Yano M, 1999, CANCER LETT, V137, P45, DOI 10.1016/S0304-3835(98)00338-3; Zhang SL, 1999, FEBS LETT, V444, P130, DOI 10.1016/S0014-5793(99)00044-7; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	67	50	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14649	14655		10.1074/jbc.M308842200	http://dx.doi.org/10.1074/jbc.M308842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14724288	Green Published, hybrid			2022-12-25	WOS:000220594700023
J	Cao, J; Kozarekar, P; Pavlaki, M; Chiarelli, C; Bahou, WF; Zucker, S				Cao, J; Kozarekar, P; Pavlaki, M; Chiarelli, C; Bahou, WF; Zucker, S			Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; PRO-GELATINASE; PERICELLULAR PROTEOLYSIS; PROPEPTIDE DOMAIN; PROGELATINASE-A; TUMOR INVASION; RHO GTPASES; ACTIVATION	Substrate degradation and cell migration are key steps in cancer metastasis. Membrane-type 1-matrix metalloproteinase (MT1-MMP) has been linked with these processes. Using the fluorescein isothiocyanate (FITC)-labeled fibronectin degradation assay combined with the phagokinetic cell migration assay, structure-function relationships of MT1-MMP were studied. Our data indicate that MT1-MMP initiates substrate degradation and enhances cell migration; cell migration occurs as a concurrent but independent event. Using recombinant DNA approaches, we demonstrated that the hemopexin-like domain and a nonenzymatic component of the catalytic domain of MT1-MMP are essential for MT1-MMP-mediated cell migration. Because the cytoplasmic domain of MT1-MMP was not required for MT1-MMP-mediated fibronectin degradation and cell migration, it is proposed that cross-talk between the hemopexin domain of MT1-MMP and adjacent cell surface molecules is responsible for outside-in signaling. Employing cDNAs encoding dominant negative mutations, we demonstrated that Rac1 participates in the MT1-MMP signal transduction pathway. These data demonstrated that each domain of MT1-MMP plays a distinct role in substrate degradation and cell migration.	Vet Affairs Med Ctr, Dept Res, Northport, NY 11768 USA; SUNY Stony Brook, Sch Med, Dept Med, Stony Brook, NY 11794 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zucker, S (corresponding author), Vet Affairs Med Ctr, Dept Res, Mail Code 151, Northport, NY 11768 USA.	s_zucker@yahoo.com			NHLBI NIH HHS [HL49141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049141] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Chen Wen-Tien, 1994, Journal of Tissue Culture Methods, V16, P177, DOI 10.1007/BF01540646; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; English WR, 2001, J BIOL CHEM, V276, P42018, DOI 10.1074/jbc.M107783200; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2003, J BIOL CHEM, V278, P38765, DOI 10.1074/jbc.M306618200; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAREEL M, 1979, VIRCHOWS ARCH B, V30, P95; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Murphy G, 2000, FIBRINOLYSIS PROTEOL, V14, P165, DOI 10.1054/fipr.2000.0068; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Pavlaki M, 2003, CANCER METAST REV, V22, P177, DOI 10.1023/A:1023047431869; Pavlaki M, 2002, J BIOL CHEM, V277, P2740, DOI 10.1074/jbc.M108987200; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Silletti S, 1998, INT J CANCER, V76, P129, DOI 10.1002/(SICI)1097-0215(19980330)76:1<129::AID-IJC20>3.0.CO;2-6; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	51	74	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14129	14139		10.1074/jbc.M312120200	http://dx.doi.org/10.1074/jbc.M312120200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729674	hybrid			2022-12-25	WOS:000220478500103
J	Ramos, PC; Marques, AJ; London, MK; Dohmen, RJ				Ramos, PC; Marques, AJ; London, MK; Dohmen, RJ			Role of C-terminal extensions of Subunits beta 2 and beta 7 in assembly and activity of eukaryotic proteasomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN 20S PROTEASOME; SACCHAROMYCES-CEREVISIAE; SITE FORMATION; YEAST; MATURATION; RESOLUTION; PARTICLE; ACIDOPHILUM; PROPEPTIDES; COMPLETION	A close inspection of the crystal structure of the yeast 20 S proteasome revealed that a prominent connection between the two beta-rings is mediated by the subunit beta7/ Pre4. Its C-terminal extension intercalates between the beta1/Pre3 and beta2/Pup1 subunits on the opposite ring. We show that the interactions promoted by the beta7/Pre4 tail are important to facilitate the formation of 20 S particles from two half-proteasome precursor complexes and/or to stabilize mature 20 S proteasomes. The deletion of 19 residues from the beta7/Pre4 C terminus leads to an accumulation of half-proteasome precursor complexes containing the maturation factor Ump1. The C-terminal extension of beta7/Pre4, which forms several hydrogen bonds with beta1/Pre3, is in addition required for the post-acidic activity mediated by the latter subunit. Deletion of the C-terminal tail of beta7/Pre4 results in an inhibition of beta1/Pre3 propeptide processing and abrogation of post-acidic activity. Our data obtained with yeast strains that expressed the mature form of Pre3 lacking its propeptide suggest that interactions between the Pre4 C terminus and Pre3 stabilize a conformation of its active site, which is essential for post-acidic activity. Deletion of the C-terminal extension of beta2/Pup1, which wraps around beta3/Pup3 within the same beta-ring, is lethal, indicating that this extension serves an essential function in proteasome assembly or stability.	Univ Cologne, Inst Genet, D-50674 Cologne, Germany; Univ Algarve, Fac Ciencias & Tecnol, Dept Quim & Bioquim, P-8000117 Faro, Portugal	University of Cologne; Universidade do Algarve	Dohmen, RJ (corresponding author), Univ Cologne, Inst Genet, Zulpicher Str 47, D-50674 Cologne, Germany.	j.dohmen@uni-koeln.de	Dohmen, R. Jürgen/AAD-6649-2022	Dohmen, R. Jürgen/0000-0002-5756-6780				Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Arendt CS, 1999, EMBO J, V18, P3575, DOI 10.1093/emboj/18.13.3575; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Ditzel L, 1998, J MOL BIOL, V279, P1187, DOI 10.1006/jmbi.1998.1818; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HILT W, 1993, J BIOL CHEM, V268, P3479; Jager S, 1999, J MOL BIOL, V291, P997, DOI 10.1006/jmbi.1999.2995; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	25	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14323	14330		10.1074/jbc.M308757200	http://dx.doi.org/10.1074/jbc.M308757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722099	Green Published, hybrid			2022-12-25	WOS:000220478500127
J	Dohke, Y; Oh, YS; Ambudkar, IS; Turner, RJ				Dohke, Y; Oh, YS; Ambudkar, IS; Turner, RJ			Biogenesis and topology of the transient receptor potential Ca2+ channel TRPC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; TRANSMEMBRANE SEGMENTS; ANION-EXCHANGER; PREDICTION; INSERTION; IDENTIFICATION; TRANSLOCATION; INTEGRATION; MUTAGENESIS	The TRPC ion channels are candidates for the store-operated Ca2+ entry pathway activated in response to depletion of intracellular Ca2+ stores. Hydropathy analyses indicate that these proteins contain eight hydrophobic regions (HRs) that could potentially form alpha-helical membrane-spanning segments. Based on limited sequence similarities to other ion channels, it has been proposed that only six of the eight HRs actually span the membrane and that the last two membrane-spanning segments (HRs 6 and 8) border the ion-conducting pore of which HR 7 forms a part. Here we study the biogenesis and transmembrane topology of human TRPC1 to test this model. We have employed a truncation mutant approach combined with insertions of glycosylation sites into full-length TRPC1. In our truncation mutants, portions of the TRPC1 sequence containing one or more HRs were fused between the enhanced green fluorescent protein and a C-terminal glycosylation tag. These chimeras were transiently expressed in the human embryonic cell line HEK-293T. Glycosylation of the tag was used to monitor its location relative to the lumen of the endoplasmic reticulum and thereby HR orientation. Our data indicate that HRs 1, 4, and 6 cross the membrane from cytosol to the ER lumen, that HRs 2, 5, and 8 have the opposite orientation, and that HR 3 is left out of the membrane on the cytosolic side. Our results also show that the sequence downstream of HR 8 plays an important role in anchoring its C-terminal end on the cytosolic side of the membrane. This effect appears to prevent HR 7 from spanning the bilayer and to result in its forming a pore-like structure of the type previously envisioned for the TRPC channels. We speculate that a similar mechanism may be responsible for the formation of other ion channel pores.	Natl Inst Dent & Craniofacial Res, Membrane Biol Sect, NIH, DHHS, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Secretory Physiol Sec, Gene Therepy & Therapeut Branch, NIH,DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Turner, RJ (corresponding author), NIH, Bldg 10,Rm 1A01,10 Ctr Dr,MSC 1190, Bethesda, MD 20892 USA.	rjturner@nih.gov			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000415, Z01DE000438, Z01DE000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAMBERG K, 1994, J BIOL CHEM, V269, P16909; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; Chen CP, 2002, PROTEIN SCI, V11, P2774, DOI 10.1110/ps.0214502; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Dohke Y, 2002, J BIOL CHEM, V277, P15215, DOI 10.1074/jbc.C100646200; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; Guo DP, 1996, J BIOL CHEM, V271, P30829, DOI 10.1074/jbc.271.48.30829; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; Pasquier C, 1999, PROTEIN ENG, V12, P381, DOI 10.1093/protein/12.5.381; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sato Y, 2002, P NATL ACAD SCI USA, V99, P60, DOI 10.1073/pnas.012399799; SKACH WR, 1993, J BIOL CHEM, V268, P23552; Tatishchev S, 2003, BIOCHEMISTRY-US, V42, P755, DOI 10.1021/bi026826q; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Turner RJ, 2003, J MEMBRANE BIOL, V192, P149, DOI 10.1007/s00232-002-1071-z; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Vannier B, 1998, J BIOL CHEM, V273, P8675, DOI 10.1074/jbc.273.15.8675; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Zhu QS, 2003, J BIOL CHEM, V278, P3112, DOI 10.1074/jbc.M207797200; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	44	26	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12242	12248		10.1074/jbc.M312456200	http://dx.doi.org/10.1074/jbc.M312456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707123	hybrid			2022-12-25	WOS:000220334900030
J	Fritsch, RM; Saur, D; Kurjak, M; Oesterle, D; Schlossmann, J; Geiselhoringer, A; Hofmann, F; Allescher, HD				Fritsch, RM; Saur, D; Kurjak, M; Oesterle, D; Schlossmann, J; Geiselhoringer, A; Hofmann, F; Allescher, HD			InsP(3)R-associated cGMP kinase substrate (IRAG) is essential for nitric oxide-induced inhibition of calcium signaling in human colonic smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; SOLUBLE GUANYLATE-CYCLASE; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; PHOSPHORYLATION; COMPLEX; CELLS; TRANSDUCTION; VARIANTS	Nitric oxide (NO)-mediated relaxation of colonic smooth muscle is crucial for the maintenance of human gut function. The molecular mechanisms of NO-dependent smooth muscle relaxation involve cyclic GMP-mediated inhibition of store-dependent calcium signaling. Recently, IRAG (inositol 1,4,5-trisphophate receptor-associated cGMP kinase substrate) has been characterized as a novel target molecule of cGMP-dependent protein kinase (cGKI) mediating NO-/cGMP-dependent inhibition of inositol 1,4,5-trisphosphate (InsP(3))-dependent calcium release in transfected COS cells. The aim of the present study was to characterize IRAG expression and its functional role in NO-dependent signaling in human colonic smooth muscle. Reverse transcriptase-PCR revealed IRAG mRNA expression in human colon, rectum, and cultured colonic smooth muscle cells. In cultured human colonic smooth muscle cells, bradykinin (BK) elicited InsP(3)-dependent calcium transients that were repeatable and independent of extracellular calcium. The NO donor sodium nitroprusside and the specific cGK activator 8-(4-chlorophenylthio) guanosine-3', 5'-cyclicmonophosphate (8-pCPT-cGMP) significantly inhibited BK-induced increase in intracellular calcium. Cells transfected with antisense oligonucleotides raised against IRAG (IRAG-AS) showed strongly decreased IRAG protein expression. In these cells, sodium nitroprusside and 8-pCPT-cGMP both failed to modulate BK-induced calcium transients. Thus, endogenous IRAG appears to be essentially involved in the NO/cGK-dependent inhibition of InsP(3)-dependent Ca2+-signaling in colonic smooth muscle.	Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany; Tech Univ Munich, Inst Pharmakol & Toxikol, D-81675 Munich, Germany	Technical University of Munich; Technical University of Munich	Fritsch, RM (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin 2, Ismaninger Str 22, D-81675 Munich, Germany.	ralph.fritsch@lrz.tum.de	Saur, Dieter/G-4629-2011; Schlossmann, Jens/I-7743-2016; Saur, Dieter/O-8355-2015; Fritsch, Ralph/Q-8836-2019	Schlossmann, Jens/0000-0002-2550-6839; Saur, Dieter/0000-0001-5874-0210; Fritsch, Ralph/0000-0001-9639-3213				Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; Bielefeldt K, 1997, AM J PHYSIOL-GASTR L, V272, pG1439, DOI 10.1152/ajpgi.1997.272.6.G1439; BROOKES SJH, 1993, J GASTROEN HEPATOL, V8, P590, DOI 10.1111/j.1440-1746.1993.tb01658.x; Carvajal JA, 2000, J CELL PHYSIOL, V184, P409, DOI 10.1002/1097-4652(200009)184:3<409::AID-JCP16>3.3.CO;2-B; CLEMENTI E, 1995, MOL PHARMACOL, V47, P517; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; DANIEL EE, 1994, AM J PHYSIOL, V266, pG31, DOI 10.1152/ajpgi.1994.266.1.G31; Feil R, 2002, CIRC RES, V90, P1080, DOI 10.1161/01.RES.0000019586.95768.40; Fritsch RM, 2001, GASTROENTEROLOGY, V120, pA499; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; Hofmann F, 2000, J CELL SCI, V113, P1671; Huber A, 1998, AM J PHYSIOL-GASTR L, V275, pG1146, DOI 10.1152/ajpgi.1998.275.5.G1146; HYMAN PE, 1992, GASTROENTEROLOGY, V102, P1597, DOI 10.1016/0016-5085(92)91719-K; Kannan MS, 1997, AM J PHYSIOL-LUNG C, V272, pL1, DOI 10.1152/ajplung.1997.272.1.L1; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Lucas KA, 2000, PHARMACOL REV, V52, P375; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Murr MM, 1999, J SURG RES, V84, P8, DOI 10.1006/jsre.1999.5590; MURTHY KS, 1993, AM J PHYSIOL, V264, pG967, DOI 10.1152/ajpgi.1993.264.5.G967; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Porter AJ, 1997, GASTROENTEROLOGY, V113, P1916, DOI 10.1016/S0016-5085(97)70011-8; RAEYMAEKERS L, 1990, CELL CALCIUM, V11, P261, DOI 10.1016/0143-4160(90)90002-C; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; Saur D, 2002, AM J PHYSIOL-GASTR L, V282, pG349, DOI 10.1152/ajpgi.00226.2001; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; Saur D, 2002, J BIOL CHEM, V277, P25798, DOI 10.1074/jbc.M109802200; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Shuttleworth CWR, 1999, BRIT J PHARMACOL, V127, P1495, DOI 10.1038/sj.bjp.0702674; Shuttleworth CWR, 1996, P SOC EXP BIOL MED, V211, P16, DOI 10.3181/00379727-211-43950C; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STARK ME, 1992, GASTROENTEROLOGY, V103, P1928, DOI 10.1016/0016-5085(92)91454-C; Tao M, 1999, FEBS LETT, V454, P312, DOI 10.1016/S0014-5793(99)00814-5; Tertyshnikova X, 1998, J PHYSIOL-LONDON, V512, P89, DOI 10.1111/j.1469-7793.1998.089bf.x; Tomita R, 2001, J GASTROENTEROL, V36, P386, DOI 10.1007/s005350170082; Wassdal I, 1999, ACTA PHYSIOL SCAND, V165, P259; Zhao YD, 2000, BIOCHEMISTRY-US, V39, P10848, DOI 10.1021/bi9929296; Zholos AV, 2000, J PHYSIOL-LONDON, V528, P521, DOI 10.1111/j.1469-7793.2000.00521.x	42	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12551	12559		10.1074/jbc.M313365200	http://dx.doi.org/10.1074/jbc.M313365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14729908	hybrid			2022-12-25	WOS:000220334900067
J	Loayza, D; Parsons, H; Donigian, J; Hoke, K; de Lange, T				Loayza, D; Parsons, H; Donigian, J; Hoke, K; de Lange, T			DNA binding features of human POT1 - A nonamer 5 '-TAGGGTTAG-3 ' minimal binding site, sequence specificity, and internal binding to multimeric sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRANDED TELOMERIC DNA; PROTEIN; TRF1; CDC13; END; REPLICATION; RECOGNITION; LENGTH	The human telomeric protein POT1 is known to bind single-stranded telomeric DNA in vitro and to participate in the regulation of telomere maintenance by telomerase in vivo. We examined the in vitro DNA binding features of POT1. We report that deleting the oligosaccharide/ oligonucleotide-binding fold of POT1 abrogates its DNA binding activity. The minimal binding site (MBS) for POT1 was found to be the telomeric nonamer 5'-TAGGGTTAG-3', and the optimal substrate is [TTAGGG](n( n greater than or equal to 2)). POT1 displays exceptional sequence specificity when binding to MBS, tolerating changes only at position 7 (T7A). Whereas POT1 binding to MBS or [TTAGGG](2) was enhanced by the proximity of a 3' end, POT1 was able to bind to a [TTAGGG](5) array when positioned internally. These data indicate that POT1 has a strong sequence preference for the human telomeric repeat tract and predict that POT1 can bind both the 3' telomeric overhang and the displaced TTAGGG repeats at the base of the t-loop.	Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, 1230 York Ave, New York, NY 10021 USA.	delange@mail.rockefeller.edu	de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X	NCI NIH HHS [CA 076027, T32 CA 09673-26] Funding Source: Medline; NIGMS NIH HHS [GM 07739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076027, T32CA009673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson EM, 2003, BIOCHEMISTRY-US, V42, P3751, DOI 10.1021/bi027047c; Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bianchi A, 1999, EMBO J, V18, P5735, DOI 10.1093/emboj/18.20.5735; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Chandra A, 2001, GENE DEV, V15, P404, DOI 10.1101/gad.861001; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Hughes TR, 2000, P NATL ACAD SCI USA, V97, P6457, DOI 10.1073/pnas.97.12.6457; Lei M, 2002, BIOCHEMISTRY-US, V41, P14560, DOI 10.1021/bi026674z; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; MEYNE J, 1990, CHROMOSOMA, V99, P3, DOI 10.1007/BF01737283; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; SMOGORZEWSKA A, 2004, IN PRESS ANN REV BIO; SOUTHERN EM, 1970, NATURE, V227, P794, DOI 10.1038/227794a0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	19	125	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13241	13248		10.1074/jbc.M312309200	http://dx.doi.org/10.1074/jbc.M312309200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715659	hybrid			2022-12-25	WOS:000220334900146
J	Rickman, C; Archer, DA; Meunier, FA; Craxton, M; Fukuda, M; Burgoyne, RD; Davletov, B				Rickman, C; Archer, DA; Meunier, FA; Craxton, M; Fukuda, M; Burgoyne, RD; Davletov, B			Synaptotagmin interaction with the syntaxin/SNAP-25 dimer is mediated by an evolutionarily conserved motif and is sensitive to inositol hexakisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC-TRANSMISSION; PHOSPHOLIPID-BINDING; CRYSTAL-STRUCTURE; CA2+ SENSOR; I FUNCTIONS; TIME-COURSE; C2B DOMAIN; CALCIUM; EXOCYTOSIS; MEMBRANE	Synaptotagmins are membrane proteins that possess tandem C2 domains and play an important role in regulated membrane fusion in metazoan organisms. Here we show that both synaptotagmins I and II, the two major neuronal isoforms, can interact with the syntaxin/ synaptosomal-associated protein of 25 kDa (SNAP-25) dimer, the immediate precursor of the soluble NSF attachment protein receptor ( SNARE) fusion complex. A stretch of basic amino acids highly conserved throughout the animal kingdom is responsible for this calcium-independent interaction. Inositol hexakisphosphate modulates synaptotagmin coupling to the syntaxin/ SNAP-25 dimer, which is mirrored by changes in chromaffin cell exocytosis. Our results shed new light on the functional importance of the conserved polybasic synaptotagmin motif, suggesting that synaptotagmin interacts with the t-SNARE dimer to up-regulate the probability of SNARE-mediated membrane fusion.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England; RIKEN, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	MRC Laboratory Molecular Biology; University of Liverpool; RIKEN	Davletov, B (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	baz@mrc-lmb.cam.ac.uk	Burgoyne, Robert/C-6706-2008; Fukuda, MItsunori/I-1511-2015; Meunier, Frederic A/C-8161-2009; Davletov, Bazbek/ABA-8569-2021; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Fukuda, MItsunori/0000-0002-8620-5853; Meunier, Frederic A/0000-0001-6400-1107; Burgoyne, Robert D/0000-0002-9219-0387; Rickman, Colin/0000-0001-8938-524X; Davletov, Bazbek/0000-0003-4658-3275				ANGAUTPETIT D, 1995, BRAIN RES, V681, P213, DOI 10.1016/0006-8993(95)00294-Z; Archer DA, 2002, J BIOL CHEM, V277, P18249, DOI 10.1074/jbc.C200166200; Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; Bai JH, 2000, J BIOL CHEM, V275, P25427, DOI 10.1074/jbc.M906729199; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; Chow RH, 1996, NEURON, V16, P369, DOI 10.1016/S0896-6273(00)80054-9; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Fukuda M, 2000, P NATL ACAD SCI USA, V97, P14715, DOI 10.1073/pnas.260491197; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HAZUKA CD, 1999, FR MOLEC B, V23, P81; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; Juzans Pascal, 1996, Pfluegers Archiv European Journal of Physiology, V431, pR283, DOI 10.1007/BF02346379; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P496, DOI 10.1098/rspb.1965.0017; Koh TW, 2003, TRENDS NEUROSCI, V26, P413, DOI 10.1016/S0166-2236(03)00195-4; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Mackler JM, 2001, J COMP NEUROL, V436, P4, DOI 10.1002/cne.1049; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Meunier FA, 2002, EMBO J, V21, P6733, DOI 10.1093/emboj/cdf677; Osborne SL, 2001, NEURON, V32, P9, DOI 10.1016/S0896-6273(01)00455-X; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Rickman C, 2004, J BIOL CHEM, V279, P644, DOI 10.1074/jbc.M310879200; Rickman C, 2003, J BIOL CHEM, V278, P5501, DOI 10.1074/jbc.C200692200; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; SUDHOF TC, 2001, SYNAPSES; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Ubach J, 2001, BIOCHEMISTRY-US, V40, P5854, DOI 10.1021/bi010340c; Voets T, 2001, P NATL ACAD SCI USA, V98, P11680, DOI 10.1073/pnas.201398798; Wu Y, 2003, P NATL ACAD SCI USA, V100, P2082, DOI 10.1073/pnas.0435872100; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6	51	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12574	12579		10.1074/jbc.M310710200	http://dx.doi.org/10.1074/jbc.M310710200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709554	hybrid			2022-12-25	WOS:000220334900070
J	Gore, A; Moran, A; Hershfinkel, M; Sekler, I				Gore, A; Moran, A; Hershfinkel, M; Sekler, I			Inhibitory mechanism of store-operated Ca2+ channels by zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE ZINC; SYNAPTICALLY-RELEASED ZINC; CRAC CHANNELS; BINDING-SITE; PROTEIN-KINASE; CALCIUM-ENTRY; TRP CHANNEL; ZN2+; INFLUX; RECEPTORS	Capacitative calcium influx plays an important role in shaping the Ca2+ response of various tissues and cell types. Inhibition by heavy metals is a hallmark of store-operated calcium channel (SOCC) activity. Paradoxically, although zinc is the only potentially physiological relevant ion, it is the least investigated in terms of inhibitory mechanism. In the present study, we characterize the inhibitory mechanism of the SOCC by Zn2+ in the human salivary cell line, HSY, and rat salivary submandibular ducts and acini by monitoring SOCC activity using fluorescence imaging. Analysis of Zn2+ inhibition indicated that Zn2+ acts as a competitive inhibitor of Ca2+ influx but does not permeate through the SOCC, suggesting that Zn2+ interacts with an extracellular site of SOCC. Application of the reducing agents, dithiothreitol (DTT) and beta-mercaptoethanol, totally eliminated Zn2+ and Cd2+ inhibition of SOCC, suggesting that cysteines are part of the Zn2+ and Cd2+ binding site. Interestingly, reducing conditions failed to eliminate the inhibition of SOCC by La3+ and Gd3+, indicating that the Zn2+ and lanthanides binding sites are distinct. Finally, we show that changes in redox potential and Zn2+ are regulating, via SOCC activity, the agonist-induced Ca2+ response in salivary ducts. The presence of a specific Zn2+ site, responsive to physiological Zn2+ and redox potential, may not only be instrumental for future structural studies of various SOCC candidates but may also reveal novel physiological aspects of the interaction between zinc, redox potential, and cellular Ca2+ homeostasis.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Morphol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University; Ben Gurion University	Gore, A (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, POB 653, IL-84105 Beer Sheva, Israel.	arie@bgumail.bgu.ac.il; sekler@bgumail.bgu.ac.il	Hershfinkel, Michal/F-1548-2012; MORAN, ARIE/F-1210-2012	Hershfinkel, Michal/0000-0003-1652-1989; 				ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; Bakowski D, 2002, CELL CALCIUM, V32, P379, DOI 10.1016/S0143416002001914; Barroso AS, 2003, ARCH ORAL BIOL, V48, P133, DOI 10.1016/S0003-9969(02)00169-3; Canzoniero LMT, 1999, J NEUROSCI, V19; Canzoniero LMT, 1997, NEUROBIOL DIS, V4, P275, DOI 10.1006/nbdi.1997.0160; Carmel Z, 1999, ARCH ORAL BIOL, V44, pS63, DOI 10.1016/S0003-9969(99)00053-9; Chauthaiwale JV, 1998, J MEMBRANE BIOL, V162, P139, DOI 10.1007/s002329900351; Chetham PM, 1999, AM J PHYSIOL-LUNG C, V276, pL41, DOI 10.1152/ajplung.1999.276.1.L41; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Choi YB, 2001, J NEUROSCI, V21, P392, DOI 10.1523/JNEUROSCI.21-02-00392.2001; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; DEHAYE JP, 1995, J TRACE ELEM MED BIO, V9, P94, DOI 10.1016/S0946-672X(11)80017-9; Dehaye JP, 1999, ARCH ORAL BIOL, V44, pS39, DOI 10.1016/S0003-9969(99)00048-5; Ebisawa T, 2000, J ENDOCRINOL, V167, P473, DOI 10.1677/joe.0.1670473; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; Frederickson CJ, 2003, J NEUROCHEM, V85, P10, DOI 10.1046/j.1471-4159.85.s2.10_1.x; Gee KR, 2002, J AM CHEM SOC, V124, P776, DOI 10.1021/ja011774y; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; Hamada T, 1997, APOPTOSIS, V2, P359, DOI 10.1023/A:1026401506914; Hershfinkel M, 2001, P NATL ACAD SCI USA, V98, P11749, DOI 10.1073/pnas.201193398; Hosie AM, 2003, NAT NEUROSCI, V6, P362, DOI 10.1038/nn1030; HOTH M, 1995, PFLUG ARCH EUR J PHY, V430, P315, DOI 10.1007/BF00373905; Itagaki K, 2002, J IMMUNOL, V168, P4063, DOI 10.4049/jimmunol.168.8.4063; Kawamura M, 2003, J PHARMACOL SCI, V91, P23, DOI 10.1254/jphs.91.23; Kerchner GA, 2000, J PHYSIOL-LONDON, V528, P39, DOI 10.1111/j.1469-7793.2000.00039.x; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; KNUDSEN E, 1995, J NUTR, V125, P1274; Krishek BJ, 1998, J PHYSIOL-LONDON, V507, P639, DOI 10.1111/j.1469-7793.1998.639bs.x; Kunzelmann-Marche C, 2001, J BIOL CHEM, V276, P5134, DOI 10.1074/jbc.M007924200; Kurz LL, 1999, J BIOL CHEM, V274, P11687, DOI 10.1074/jbc.274.17.11687; Li CY, 1997, J PHYSIOL-LONDON, V505, P641, DOI 10.1111/j.1469-7793.1997.641ba.x; Liu XB, 1998, AM J PHYSIOL-CELL PH, V275, pC571, DOI 10.1152/ajpcell.1998.275.2.C571; Minke B, 2001, CELL MOL NEUROBIOL, V21, P629, DOI 10.1023/A:1015191702536; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Molnar P, 2001, BRAIN RES, V910, P205, DOI 10.1016/S0006-8993(01)02720-2; MORAN A, 1993, AM J PHYSIOL, V265, pC1405, DOI 10.1152/ajpcell.1993.265.5.C1405; Nagler RM, 1997, ARCH OTOLARYNGOL, V123, P989; NEVIN ST, 2003, J BIOL CHEM, V9, P9; Ng LC, 2001, CIRC RES, V89, P923, DOI 10.1161/hh2201.100315; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Norregaard L, 2000, BIOCHEMISTRY-US, V39, P15836, DOI 10.1021/bi0018335; Olivi L, 2000, CELL CALCIUM, V27, P187, DOI 10.1054/ceca.1999.0115; Paoletti P, 1997, J NEUROSCI, V17, P5711; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Prakriya M, 2003, CELL CALCIUM, V33, P311, DOI 10.1016/S0143-4160(03)00045-9; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; SCHMIDT HW, 1981, EUR J CELL BIOL, V24, P85; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 2002, NEUROBIOL DIS, V10, P100, DOI 10.1006/nbdi.2002.0493; Shan Q, 2002, J BIOL CHEM, V277, P44845, DOI 10.1074/jbc.M208647200; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Voets T, 2003, J MEMBRANE BIOL, V192, P1, DOI 10.1007/s00232-002-1059-8; Voets T, 2003, CELL CALCIUM, V33, P299, DOI 10.1016/S0143-4160(03)00044-7; Voss J, 1995, P NATL ACAD SCI USA, V92, P12295, DOI 10.1073/pnas.92.26.12295; Weiss JH, 2000, TRENDS NEUROSCI, V23, P365, DOI 10.1016/S0166-2236(00)01610-6; Wooltorton JRA, 1997, J PHYSIOL-LONDON, V505, P633, DOI 10.1111/j.1469-7793.1997.633ba.x; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	59	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11106	11111		10.1074/jbc.M400005200	http://dx.doi.org/10.1074/jbc.M400005200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14715648	hybrid			2022-12-25	WOS:000220157600034
J	Lin, TL; Shun, CT; Chang, KC; Wang, JT				Lin, TL; Shun, CT; Chang, KC; Wang, JT			Isolation and characterization of a HpyC1I restriction-modification system in Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGENS; GASTRIC-CARCINOMA; INFECTION; STRAINS; TRANSFORMATION; INFLAMMATION; RESISTANCE; SEQUENCE; PLASMID; ADHESIN	Using transposon shuttle mutagenesis, we identified six Helicobacter pylori mutants from the NTUH-C1 strain that exhibited decreased adherence and cell elongation. Inverse polymerase chain reaction and DNA sequencing revealed that the same locus was interrupted in these six mutants. Nucleotide and amino acid sequences showed no homologies with H. pylori 26695 and J99 strains. This novel open reading frame contained 1617 base pairs. The amino acid sequence shared 24% identity with a putative nicking enzyme in Bacillus halodurans and 23 and 20% identity with type IIS restriction endonucleases PleI and MlyI, respectively. The purified protein, HpyC1I, showed endonuclease activity with the recognition and cleavage site 5'-CCATC( 4/5)-3'. Two open reading frames were located upstream of the gene encoding HpyC1I. Together, HpyC1I and these two putative methyltransferases (M1.HpyC1I and M2.HpyC1I) function as a restriction-modification (R-M) system. The HpyC1I R-M genes were found in 9 of the 15 H. pylori strains tested. When compared with the full genome, significantly lower G + C content of HpyC1I R-M genes implied that these genes might have been acquired by horizontal gene transfer. Plasmid DNA transformation efficiencies and chromosomal DNA digestion assays demonstrated protection from HpyC1I digestion by the R-M system. In conclusion, we have identified a novel R-M system present in similar to60% of H. pylori strains. Disruption of this R-M system results in cell elongation and susceptibility to HpyC1I digestion.	Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10016, Taiwan; Natl Taiwan Univ Hosp, Dept Forens Med, Taipei 10016, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10016, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Wang, JT (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, 1,Sec 1,Jen Ai Rd, Taipei 10016, Taiwan.	wangjt@ccms.ntu.edu.tw	Shun, Chia-Tung/M-1400-2019	SHUN, CHIA-TUNG/0000-0002-0468-4468				Akopyants NS, 1998, P NATL ACAD SCI USA, V95, P13108, DOI 10.1073/pnas.95.22.13108; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Ando T, 2000, MOL MICROBIOL, V37, P1052, DOI 10.1046/j.1365-2958.2000.02049.x; Ang S, 2001, INFECT IMMUN, V69, P1679, DOI 10.1128/IAI.69.3.1679-1686.2001; Aras RA, 2002, NUCLEIC ACIDS RES, V30, P5391, DOI 10.1093/nar/gkf686; BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Chang KC, 2001, BIOCHEM BIOPH RES CO, V288, P961, DOI 10.1006/bbrc.2001.5877; Heuermann D, 1998, MOL GEN GENET, V257, P519, DOI 10.1007/s004380050677; Hsieh PF, 1998, J FORMOS MED ASSOC, V97, P445; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Jiang SY, 1996, ONCOLOGY-BASEL, V53, P334; Kovall RA, 1999, CURR OPIN CHEM BIOL, V3, P578, DOI 10.1016/S1367-5931(99)00012-5; LIN JT, 1993, SCAND J GASTROENTERO, V28, P1067, DOI 10.3109/00365529309098311; Lin LF, 2001, P NATL ACAD SCI USA, V98, P2740, DOI 10.1073/pnas.051612298; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; MARSHALL BJ, 1984, LANCET, V1, P1311; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P418, DOI 10.1093/nar/gkg069; Skowron PM, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng074; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Wang G, 1999, TRENDS MICROBIOL, V7, P488, DOI 10.1016/S0966-842X(99)01632-7; WANG Y, 1993, J GEN MICROBIOL, V139, P2485, DOI 10.1099/00221287-139-10-2485; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	26	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11156	11162		10.1074/jbc.M311639200	http://dx.doi.org/10.1074/jbc.M311639200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711809	hybrid			2022-12-25	WOS:000220157600040
J	Lopes, DHJ; Chapeaurouge, A; Manderson, GA; Johansson, JS; Ferreira, ST				Lopes, DHJ; Chapeaurouge, A; Manderson, GA; Johansson, JS; Ferreira, ST			Redesigning the folding energetics of a model three-helix bundle protein by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD DENATURATION; FREE-ENERGY; ACIDIC CONDITIONS; HYDROPHOBIC CORE; MOLTEN GLOBULE; HIGH-PRESSURE; EQUILIBRIUM; PATHWAY; INTERMEDIATE; MUTATIONS	Because of their limited size and complexity, de novo designed proteins are particularly useful for the detailed investigation of folding thermodynamics and mechanisms. Here, we describe how subtle changes in the hydrophobic core of a model three-helix bundle protein (GM-0) alter its folding energetics. To explore the folding tolerance of GM-0 toward amino acid sequence variability, two mutant proteins (GM-1 and GM-2) were generated. In the mutants, cavities were created in the hydrophobic core of the protein by either singly (GM-1; L35A variant) or doubly (GM-2; L35A/I39A variant) replacing large hydrophobic side chains by smaller Ala residues. The folding of GM-0 is characterized by two partially folded intermediate states exhibiting characteristics of molten globules, as evidenced by pressure-unfolding and pressure-assisted cold denaturation experiments. In contrast, the folding energetics of both mutants, GM-1 and GM-2, exhibit only one folding intermediate. Our results support the view that simple but biologically important folding motifs such as the three-helix bundle can reveal complex folding plasticity, and they point to the role of hydrophobic packing as a determinant of the overall stability and folding thermodynamic of the helix bundle.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Fiocruz MS, Inst Oswaldo Cruz, Dept Fisiol & Farmacodinam, BR-21045900 Rio De Janeiro, Brazil; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Johnson Res Fdn, Philadelphia, PA 19104 USA	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; University of Pennsylvania; University of Pennsylvania	Chapeaurouge, A (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.	henk@ioc.fiocruz.br	Ferreira, Sergio/AAZ-1576-2020	Ferreira, Sergio/0000-0001-7160-9866; , Dahabada/0000-0002-5411-9264	NIGMS NIH HHS [GM65218] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065218] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINO LC, 1991, P NATL ACAD SCI USA, V88, P7715, DOI 10.1073/pnas.88.17.7715; BOCZKO EM, 1995, SCIENCE, V269, P393, DOI 10.1126/science.7618103; Boice JA, 1996, BIOCHEMISTRY-US, V35, P14480, DOI 10.1021/bi961831d; Botelho MM, 2000, EUR J BIOCHEM, V267, P2235, DOI 10.1046/j.1432-1327.2000.01226.x; BRIDGMAN PW, 1931, PHYS HIGH PRESSURE, P233; Capaldi AP, 2001, NAT STRUCT BIOL, V8, P68; Chapeaurouge A, 2002, J BIOL CHEM, V277, P16478, DOI 10.1074/jbc.M105232200; Chapeaurouge A, 2001, J BIOL CHEM, V276, P14861, DOI 10.1074/jbc.M009622200; Eastwood MP, 2001, J CHEM PHYS, V114, P4702, DOI 10.1063/1.1315994; Ferreira ST, 2001, FEBS LETT, V498, P129, DOI 10.1016/S0014-5793(01)02491-7; Frye KJ, 1998, PROTEIN SCI, V7, P2217, DOI 10.1002/pro.5560071020; Godbole S, 1997, BIOCHEMISTRY-US, V36, P119, DOI 10.1021/bi961915m; Gorski SA, 2001, J MOL BIOL, V312, P849, DOI 10.1006/jmbi.2001.5001; Gruebele M, 2002, CURR OPIN STRUC BIOL, V12, P161, DOI 10.1016/S0959-440X(02)00304-4; Hobart SA, 2002, BIOCHEMISTRY-US, V41, P13744, DOI 10.1021/bi0265224; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; Johansson JS, 1998, J AM CHEM SOC, V120, P3881, DOI 10.1021/ja973538m; KAUZMANN W, 1959, ADV PROTEIN CHEM, P1; Khorasanizadeh S, 1996, NAT STRUCT BIOL, V3, P193, DOI 10.1038/nsb0296-193; Lassalle MW, 2003, PROTEIN SCI, V12, P66, DOI 10.1110/ps.0221303; LIM WA, 1992, BIOCHEMISTRY-US, V31, P4324, DOI 10.1021/bi00132a025; Martins SM, 2002, EUR J BIOCHEM, V269, P5484, DOI 10.1046/j.1432-1033.2002.03248.x; MASTERTO.WL, 1968, J PHYS CHEM-US, V72, P4257, DOI 10.1021/j100858a053; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; Nauli S, 2001, NAT STRUCT BIOL, V8, P602, DOI 10.1038/89638; Nguyen H, 2003, P NATL ACAD SCI USA, V100, P3948, DOI 10.1073/pnas.0538054100; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; PTITSYN OB, 1995, TRENDS BIOCHEM SCI, V20, P376, DOI 10.1016/S0968-0004(00)89081-7; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; Sasahara K, 2002, PROTEINS, V49, P472, DOI 10.1002/prot.10215; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; Walsh STR, 2001, J MOL BIOL, V305, P361, DOI 10.1006/jmbi.2000.4184; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; Zhou YQ, 1999, NATURE, V401, P400, DOI 10.1038/43940	35	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10991	10996		10.1074/jbc.M308174200	http://dx.doi.org/10.1074/jbc.M308174200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701847	hybrid			2022-12-25	WOS:000220157600021
J	Tiravanti, E; Samouilov, A; Zweier, JL				Tiravanti, E; Samouilov, A; Zweier, JL			Nitrosyl-heme complexes are formed in the ischemic heart - Evidence of nitrite-derived nitric oxide formation, storage, and signaling in post-ischemic tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; FREE-RADICAL GENERATION; PARAMAGNETIC-RESONANCE; REPERFUSION INJURY; XANTHINE-OXIDASE; BIOLOGICAL-SYSTEMS; REDUCTASE-ACTIVITY; ANOXIC TISSUES; SERUM NITRITE; EPR DETECTION	In addition to the generation from specific nitric-oxide (NO) synthases, NO formation from nitrite occurs in ischemic tissues, such as the heart. Although NO binding to heme-centers is the basis for NO-mediated signaling as occurs through guanylate cyclase, it is not known if this process is triggered with physiologically relevant periods of sublethal ischemia and if nitrite serves as a critical substrate. Therefore electron paramagnetic resonance studies were performed to measure nitrosylheme formation during the time course of myocardial ischemia and reperfusion and the role of nitrite in this process. Rat hearts were either partially nitrite-depleted by nitrite-free buffer perfusion or nitrite-enriched by preinfusion with 50 muM nitrite. Ischemic hearts loaded with nitrite showed prominent spectra of six-coordinate nitrosyl-heme complexes, primarily NO-myoglobin, that increased as a function of ischemic duration, whereas in nonischemic-controls these signals were not seen. Total nitrosyl-heme concentrations within the heart were 6.6 +/- 0.7 muM after 30 min of ischemia. Nitrite-depleted hearts also gave rise to NO-heme signals during ischemia, but levels were 8-fold lower. Nitrite-mediated NO-heme complex formation during ischemia was associated with activation of guanylate cyclase. Upon reperfusion, the levels of NO-heme complexes decreased 3-fold by the first 15 min but remained elevated for over 45 min. The decrease in NO-heme complex levels was paralleled by the formation of nitrate, suggesting the oxidation of heme-bound NO upon reperfusion. Thus, nitrite-mediated NO-heme formation occurs progressively during ischemia, with these complexes serving as a store of NO with concordant activation of NO signaling pathways.	Ohio State Univ, Ctr Biomed EPR Spect & Imaging, Coll Med, Columbus, OH 43210 USA; Ohio State Univ, Davis Heart & Lung Res Inst, Coll Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Cardiovasc Med, Coll Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Zweier, JL (corresponding author), 110G Davis Heart & Lung Res Inst, 473 W 12th Ave, Columbus, OH 43210 USA.	zweier-1@medctr.osu.edu	Samouilov, Alexandre/B-5824-2014; Samouilov, Alexandre/E-4010-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, R01HL063744, R29HL038324, P01HL065608] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38324, HL65608, HL63744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; EVANS T, 1994, J INFECT DIS, V169, P343, DOI 10.1093/infdis/169.2.343; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; GARSIDE C, 1982, MAR CHEM, V11, P159, DOI 10.1016/0304-4203(82)90039-1; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; HAGLER L, 1979, J BIOL CHEM, V254, P6505; HenryYA, 1997, NITRIC OXIDE RES CHE; Hobbs AJ, 1996, METHOD ENZYMOL, V269, P134; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; Kitakaze M, 2001, J MOL CELL CARDIOL, V33, P1727, DOI 10.1006/jmcc.2001.1435; KOMAROV A, 1993, BIOCHEM BIOPH RES CO, V195, P1191, DOI 10.1006/bbrc.1993.2170; KON H, 1968, J BIOL CHEM, V243, P4350; Kozlov AV, 1999, FEBS LETT, V454, P127, DOI 10.1016/S0014-5793(99)00788-7; KUPPUSAMY P, 1995, J CEREBR BLOOD F MET, V15, P899, DOI 10.1038/jcbfm.1995.114; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; Lecour S, 2001, J CARDIOVASC PHARM, V37, P55, DOI 10.1097/00005344-200101000-00007; Lepore DA, 1999, NITRIC OXIDE-BIOL CH, V3, P75, DOI 10.1006/niox.1999.0211; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; Li HT, 2003, BIOCHEMISTRY-US, V42, P1150, DOI 10.1021/bi026385a; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; McKnight GM, 1999, BRIT J NUTR, V81, P349, DOI 10.1017/S000711459900063X; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; Moncada S, 1997, ANN NY ACAD SCI, V811, P60, DOI 10.1111/j.1749-6632.1997.tb51989.x; Nagase S, 1997, BIOCHEM BIOPH RES CO, V233, P150, DOI 10.1006/bbrc.1997.6428; NAVA E, 1992, J CARDIOVASC PHARM, V20, P132; Nohl H, 2000, ACTA BIOCHIM POL, V47, P913, DOI 10.18388/abp.2000_3946; Oldreive C, 2001, FREE RADICAL RES, V35, P215, DOI 10.1080/10715760100300761; Payne WJ, 1997, BIOFACTORS, V6, P47, DOI 10.1002/biof.5520060106; RADI R, 1991, J BIOL CHEM, V266, P4244; Samouilov A, 1998, ANAL BIOCHEM, V258, P322, DOI 10.1006/abio.1998.2609; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; Sastry KVH, 2002, ANAL BIOCHEM, V306, P79, DOI 10.1006/abio.2002.5676; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; Tari A, 2002, DIGEST DIS SCI, V47, P100, DOI 10.1023/A:1013271605493; TOMINAGA T, 1994, J CEREBR BLOOD F MET, V14, P715, DOI 10.1038/jcbfm.1994.92; TOMINAGA T, 1993, BRAIN RES, V614, P342, DOI 10.1016/0006-8993(93)91053-U; TRACEY WR, 1995, J PHARMACOL EXP THER, V272, P1011; VANIN AF, 1993, BIOCHIM BIOPHYS ACTA, V1177, P37, DOI 10.1016/0167-4889(93)90154-H; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; Witting PK, 2001, J BIOL CHEM, V276, P3991, DOI 10.1074/jbc.M005758200; Wunderlich C, 2003, CIRC RES, V92, P1352, DOI 10.1161/01.RES.0000079026.70629.E5; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Yasmin W, 1997, CARDIOVASC RES, V33, P422, DOI 10.1016/S0008-6363(96)00254-4; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; Zhao YD, 1998, BIOCHEMISTRY-US, V37, P12458, DOI 10.1021/bi9811563; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3; ZWEIER JL, 1994, J MAGN RESON SER B, V105, P52, DOI 10.1006/jmrb.1994.1099; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	58	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11065	11073		10.1074/jbc.M311908200	http://dx.doi.org/10.1074/jbc.M311908200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14704151	hybrid			2022-12-25	WOS:000220157600029
J	Basavapathruni, A; Bailey, CM; Anderson, KS				Basavapathruni, A; Bailey, CM; Anderson, KS			Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; IMMUNODEFICIENCY-VIRUS TYPE-1; DEPENDENT PRIMER UNBLOCKING; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; RESISTANCE MUTATIONS; ANTIVIRAL ACTIVITY; INHIBITORS NNRTIS; DNA-POLYMERASE; REPLICATION; DERIVATIVES	Combination therapies treating human immunodeficiency virus type 1 (HIV-1) infection delay the emergence of drug-resistant virus and exhibit synergistic inhibition. This synergy is observed within the two classes of inhibitors that target the essential viral reverse transcriptase (RT): the chain-terminating nucleoside analogs (NRTIs) and the allosteric nonnucleosides (NNR-Tis) that bind in a pocket distinct from the active site. A general mechanism to define the molecular basis for synergy between these two classes remains to be elucidated. Previous mechanistic studies from our laboratory (Spence, R. A., Kati, W. M., Anderson, K. S., and Johnson, K. A. (1995) Science 267, 988-993) have shown that the natural deoxynucleoside triphosphate and the NNRTI can simultaneously bind to their respective sites. This work also suggests communication between the two sites, since the inhibition of RT by NNRTIs is manifested through a remote effect on the chemical step. This interplay between the two sites offers a plausible hypothesis for understanding synergy in which binding of NNRTIs modulates the chain termination by NRTIs. The present study supports this hypothesis by illustrating that the clinically approved NNRTIs, nevirapine and efavirenz, inhibit the ATP-mediated removal of AZTMP, d4TMP, ddCMP, (-)3TCMP, (-)FTCMP, and (+)3TCMP, thereby prolonging the effectiveness of chain termination. This inhibition is mediated through an effect on both the rate of the chemical step and binding of ATP, resulting in an overall decrease in efficiency of removal. This work substantiates communication between the two binding pockets, the sustained use of combination therapy to treat HIV infection, and a molecular basis for understanding synergy.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, SHM B350B,333 Cedar St, New Haven, CT 06520 USA.	karen.anderson@yale.edu		Bailey, Chris/0000-0002-5962-9511	NIGMS NIH HHS [GM49551] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHAUS IW, 1993, J BIOL CHEM, V268, P6119; Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Balzarini J, 1996, MOL PHARMACOL, V50, P394; Borkow G, 1999, ANTIMICROB AGENTS CH, V43, P259, DOI 10.1128/AAC.43.2.259; Carr A, 1996, AIDS, V10, P635, DOI 10.1097/00002030-199606000-00009; CARROLL SS, 1993, J BIOL CHEM, V268, P276; De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; FRANK KB, 1991, J BIOL CHEM, V266, P14232; GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q; HAMME AT, 1994, CHEMTRACTS ORG CHEM, V7, P24; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; King RW, 2002, ANTIMICROB AGENTS CH, V46, P1640, DOI 10.1128/AAC.46.6.1640-1646.2002; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; Merrill DP, 1996, J INFECT DIS, V173, P355, DOI 10.1093/infdis/173.2.355; Meyer PR, 2002, ANTIMICROB AGENTS CH, V46, P1540, DOI 10.1128/AAC.46.5.1540-1545.2002; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Murakami E, 2003, J BIOL CHEM, V278, P36403, DOI 10.1074/jbc.M306236200; Odriozola L, 2003, J BIOL CHEM, V278, P42710, DOI 10.1074/jbc.M212673200; PAUWELS R, 1994, ANTIMICROB AGENTS CH, V38, P2863, DOI 10.1128/AAC.38.12.2863; Ray AS, 2003, BIOCHEMISTRY-US, V42, P8831, DOI 10.1021/bi034435l; Ray AS, 2002, BIOCHEMISTRY-US, V41, P5150, DOI 10.1021/bi0121858; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; Zembower DE, 1997, J MED CHEM, V40, P1005, DOI 10.1021/jm960355m; Zhu QY, 1996, AIDS RES HUM RETROV, V12, P507, DOI 10.1089/aid.1996.12.507	33	45	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6221	6224		10.1074/jbc.C300523200	http://dx.doi.org/10.1074/jbc.C300523200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14722107				2022-12-25	WOS:000188969200005
J	Wang, Y; Lau, SH; Sham, JST; Wu, MC; Wang, T; Guan, XY				Wang, Y; Lau, SH; Sham, JST; Wu, MC; Wang, T; Guan, XY			Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated X gene and hepatocellular carcinogenesis	ONCOGENE			English	Article						hepatitis B virus; integration; X gene; sequence	HEPATITIS-B-VIRUS; HEPATOMA-CELL LINE; TRANSGENIC MICE; TRANSCRIPTION FACTOR; DNA-REPAIR; IN-VIVO; PROTEIN; HEPATOCARCINOGENESIS; EXPRESSION; APOPTOSIS	Although the integration of hepatitis B virus (HBV) into human DNA has been found to be associated with the development of hepatocellular carcinoma (HCC), the molecular mechanism remains unclear. In order to obtain additional insight into the correlation of HBV integration and HCC development, integrated HBV in 14 primary HCC cases was isolated and characterized by sequencing analysis. Our findings in this study showed that: (1) none of the known cellular oncogene or tumor suppressor gene was affected by the HBV integration; (2) although the integration of HBV is random, the integration site was often within or close to human repetitive sequences; (3) integrated HBV may possess the capacity to transpose to another chromosome region through reintegration; (4) rearrangements of HBV sequence were observed in all the 14 integrants, involving (most frequently) X (12/14 integrants), P (8/14), S (7/14), and C (7/14) genes; and (5) 3'-deleted X gene and consequent C-terminal truncated X protein caused by HBV integration was observed in 10 cases. These deletions cause the losses of p53-dependent transcriptional repression binding site, transcription factor Sp1 binding site, and growth-suppressive effect domain, leading to cell proliferation and transformation. This finding suggests that 3'-deleted X gene caused by the HBV integration may play an important role in the HCC development.	Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; Second Mil Med Univ, Eastern Hepatobilliary Surg Hosp, Shanghai, Peoples R China	University of Hong Kong; Naval Medical University	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room 109,Sch Chinese Med Bldg,10 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xyguan@hkucc.hku.hk	Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805				Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; BEASLEY RP, 1981, LANCET, V2, P1129; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; GROZUACIK D, 2001, ONCOGENE, V20, P6233; HANSEN LJ, 1993, MOL CELL BIOL, V13, P659, DOI 10.1128/MCB.13.1.659; JASPERS NGJ, 1995, CURR BIOL, V5, P700, DOI 10.1016/S0960-9822(95)00137-0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Lee H, 1998, J BIOL CHEM, V273, P19786, DOI 10.1074/jbc.273.31.19786; Li J, 2001, J VIROL, V75, P8400, DOI 10.1128/JVI.75.18.8400-8406.2001; Madden CR, 2001, J VIROL, V75, P3851, DOI 10.1128/JVI.75.8.3851-3858.2001; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; NATOLI G, 1994, ONCOGENE, V9, P2837; PETERSON MG, 1991, NATURE, V354, P369; Reifenberg K, 1997, J HEPATOL, V26, P119, DOI 10.1016/S0168-8278(97)80018-9; ROBINSON WS, 1994, ANNU REV MED, V45, P297; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Su TS, 1998, DNA CELL BIOL, V17, P415, DOI 10.1089/dna.1998.17.415; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TOKINO T, 1991, J VIROL, V65, P6761, DOI 10.1128/JVI.65.12.6761-6764.1991; Tu H, 2001, CANCER RES, V61, P7803; URANO Y, 1991, CANCER RES, V51, P1460; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG XW, 1995, CANCER RES, V55, P6012; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P339, DOI 10.1046/j.1440-1746.2000.02166.x; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; ZIEMER M, 1985, J VIROL, V53, P885, DOI 10.1128/JVI.53.3.885-892.1985	32	89	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					142	148		10.1038/sj.onc.1206889	http://dx.doi.org/10.1038/sj.onc.1206889			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712219				2022-12-25	WOS:000187895300015
J	Lombardo, F; Komatsu, D; Hadjiargyrou, M				Lombardo, F; Komatsu, D; Hadjiargyrou, M			Molecular cloning and characterization of Mustang, a novel nuclear protein expressed during skeletal development and regeneration	FASEB JOURNAL			English	Article						fracture; repair; healing; novel; gene	MEDIATED TRANSCRIPTIONAL REPRESSION; FRACTURE REPAIR; GROUCHO; PHOSPHORYLATION; GROWTH; MATRIX	Bone regeneration occurs as a series of events that requires temporal and spatial orchestration of numerous cell types guided by the transcriptional activity of thousands of genes, as recently demonstrated by our laboratory. Using the rat femoral fracture model, bioinformatics, cloning, expression assays, fusion proteins, and transfection, we report on the identification and characterization of one such differentially expressed gene, termed Mustang (musculoskeletal temporally activated novel gene). Mustang encodes for an 82 amino acid nuclear protein with no homology to any known protein family. However, other species homologues (mouse, human, cow) were identified within EST (expressed sequence tag) databases. Nuclear localization was confirmed using a GFP-Mustang fusion protein. Using in situ hybridization, Mustang expression was localized to differentiating periosteal osteogenic cells, proliferating chondrocytes, and osteoblasts of the fracture callus. Unlike adult tissues, developing embryos abundantly express Mustang, especially in mesenchymal condensations of limbs, vertebral perichondrium, and mesenchymal cells of the intervertebral discs. Although the precise function of Mustang is unknown, its unique pattern of expression during bone development and regeneration, absence in adult tissues (except skeletal muscle and tendon), and nuclear localization suggest that Mustang is involved in the development and regeneration of the mammalian musculoskeletal system.	SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Orthopaed, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hadjiargyrou, M (corresponding author), SUNY Stony Brook, Dept Biomed Engn, Psychol A Bldg, Stony Brook, NY 11794 USA.	Michael.Hadjiargyrou@sunysb.edu	Hadjiargyrou, Michael/H-7191-2018	Hadjiargyrou, Michael/0000-0001-8927-2333				BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7; Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925-4773(99)00142-2; Ferguson CM, 1998, ANN NY ACAD SCI, V857, P33, DOI 10.1111/j.1749-6632.1998.tb10105.x; GARMAN R, 2001, ANN BIOMED ENG, V29, pS89; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200; Hadjiargyrou M, 1998, BIOCHEM BIOPH RES CO, V249, P879, DOI 10.1006/bbrc.1998.9167; Hadjiargyrou M, 2001, BONE, V29, P149, DOI 10.1016/S8756-3282(01)00489-6; Hadjiargyrou M, 2000, J BONE MINER RES, V15, P1014, DOI 10.1359/jbmr.2000.15.6.1014; Javed A, 2000, J CELL SCI, V113, P2221; JINGUSHI S, 1992, J BONE MINER RES, V7, P1045; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Nuthall HN, 2002, J BIOL CHEM, V277, P51049, DOI 10.1074/jbc.M111660200; Nuthall HN, 2002, MOL CELL BIOL, V22, P389, DOI 10.1128/MCB.22.2.389-399.2002; SANDBERG MM, 1993, CLIN ORTHOP RELAT R, P292; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7; Zhi J, 2001, J BONE MINER RES, V16, P1994, DOI 10.1359/jbmr.2001.16.11.1994	24	35	38	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					52	61		10.1096/fj.03-0521com	http://dx.doi.org/10.1096/fj.03-0521com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718386				2022-12-25	WOS:000188829300039
J	Watanabe, Y; Yoshida, M				Watanabe, Y; Yoshida, M			Trigonal Dnak-DnaJ complex versus free DnaK and DnaJ - Heat stress converts the former to the latter, and only the latter can do disaggregation in cooperation with ClpB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITES; THERMUS-THERMOPHILUS; CHAPERONE SYSTEM; SACCHAROMYCES-CEREVISIAE; INACTIVATED PROTEINS; MITOCHONDRIAL HSP78; ESCHERICHIA-COLI; HSP104; GRPE; OLIGOMERIZATION	DnaK from Thermus thermophilus (TDnaK) is unique because significant fractions of cellular TDnaK exist as a trigonal K.J complex that consists of three copies each of TDnaK, TDnaJ, and an assembly factor TDafA. Here, chaperone functions of the K.J complex and free TDnaK plus free TDnaJ (K+J) were compared. Substrate proteins were completely denatured at 72-73 degreesC or 89 degreesC in the absence or the presence of K.J complex or K+J and were subsequently incubated at a moderate temperature of 55 degreesC. TGrpE and ATP were always included in the K.J complex and K+J, and TClpB was supplemented at 55 degreesC. At 72-73 degreesC, both the K.J complex and K+J suppressed heat aggregation of substrate proteins. During the next incubation at 55 degreesC, K+J, assisted by TClpB, was able to disaggregate the heat aggregates and efficiently reactivate activities of the proteins, whereas the K.J complex was not; it reactivated only the soluble inactivated proteins. When substrate proteins were heated to 89 degreesC, both the K.J complex and K+J were no longer able to prevent heat aggregation, and because of selective, irreversible denaturation of TDafA the K.J complex dissociated into K+J, which then exhibited disaggregation activity during the next incubation at 55 degreesC. Thus, TClpB-assisted disaggregation activity belongs only to K+J, and TDafA is a potential thermosensor for converting the K.J complex to K+J in response to heat stress.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, R-1,Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp						Beinker P, 2002, J BIOL CHEM, V277, P47160, DOI 10.1074/jbc.M207853200; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Klostermeier D, 1998, J MOL BIOL, V279, P841, DOI 10.1006/jmbi.1998.1816; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; Krzewska J, 2001, J MOL BIOL, V314, P901, DOI 10.1006/jmbi.2001.5190; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; MOTOHASHI K, 1994, J BIOL CHEM, V269, P27074; Motohashi K, 1996, J BIOL CHEM, V271, P17343, DOI 10.1074/jbc.271.29.17343; Motohashi K, 1997, FEBS LETT, V412, P633, DOI 10.1016/S0014-5793(97)00847-8; OKUNO H, 1985, Journal of Applied Biochemistry, V7, P192; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Watanabe YH, 2000, J BIOL CHEM, V275, P12388, DOI 10.1074/jbc.275.17.12388; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; YAMADA T, 1990, J BIOCHEM-TOKYO, V108, P449, DOI 10.1093/oxfordjournals.jbchem.a123220; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	26	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15723	15727		10.1074/jbc.M308782200	http://dx.doi.org/10.1074/jbc.M308782200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14729677	hybrid			2022-12-25	WOS:000220747900005
J	Mashanov, GI; Tacon, D; Peckham, M; Molloy, JE				Mashanov, GI; Tacon, D; Peckham, M; Molloy, JE			The spatial and temporal dynamics of pleckstrin homology domain binding at the plasma membrane measured by Imaging single molecules in live mouse myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL-REFLECTION-FLUORESCENCE; MYOSIN-X; PHOTOBLEACHING RECOVERY; ACTIN DYNAMICS; MICROSCOPY; DIFFUSION; PROTEINS; REGIONS; CELLS	Pleckstrin homology (PH) domains act to target proteins to the plasma membrane and intracellular vesicles by binding to specific phosphoinositol phospholipids. We have investigated the binding kinetics of PH domains found in the tail region of the molecular motor, myosin X. Using total internal reflection fluorescence microscopy, we observed binding and release of individual PH domains fused to green fluorescent protein at the plasma membrane of living cells. Individual spots of light corresponding to single fluorescently tagged molecules were imaged onto a sensitive camera system, and digital image processing was then used to identify each fluorophore and store its trajectory in time and space. The PH domains bound with an apparent on-rate of 0.03 muM(-1) mum(-2) s(-1) and a detachment rate constant of 0.05 s(-1). The average residency time of the domains at the plasma membrane was about 20s. We found very limited movement of the membrane-bound PH domains in the mouse myoblast cells that we studied. This implies that the PH domains must either be attached to the cytoskeleton or corralled in a lipid compartment. Localization of the PH domains together with their rapid detachment rate is probably important in controlling the response of myosin X to signaling events and in regulating its cellular function.	Natl Inst Med Res, MRC, Div Phys Biochem, London NW7 1AA, England; Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	MRC National Institute for Medical Research; University of Leeds	Molloy, JE (corresponding author), Natl Inst Med Res, MRC, Div Phys Biochem, Ridgeway,Mill Hill, London NW7 1AA, England.	jmolloy@nimr.mrc.ac.uk	Peckham, Michelle/J-4991-2015	Peckham, Michelle/0000-0002-3754-2028; Molloy, Justin/0000-0002-8307-2450				Axelrod D, 1992, TOPICS FLUORESCENCE, P289; Berg JS, 2000, J CELL SCI, V113, P3439; Berg JS, 2002, NAT CELL BIOL, V4, P246, DOI 10.1038/ncb762; BURGHARDT TP, 1981, BIOPHYS J, V33, P455, DOI 10.1016/S0006-3495(81)84906-5; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; Cox D, 2002, NAT CELL BIOL, V4, P469, DOI 10.1038/ncb805; Czech MP, 2003, P NATL ACAD SCI USA, V100, P11198, DOI 10.1073/pnas.2135308100; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; Garcia-Parajo MF, 2000, P NATL ACAD SCI USA, V97, P7237, DOI 10.1073/pnas.97.13.7237; Harms GS, 2001, BIOPHYS J, V80, P2396, DOI 10.1016/S0006-3495(01)76209-1; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Mashanov GI, 2003, METHODS, V29, P142, DOI 10.1016/S1046-2023(02)00305-5; Peckham M, 2001, J CELL SCI, V114, P1367; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Sund SE, 2000, BIOPHYS J, V79, P1655, DOI 10.1016/S0006-3495(00)76415-0; THOMPSON NL, 1981, BIOPHYS J, V33, P435, DOI 10.1016/S0006-3495(81)84905-3; van Rheenen J, 2002, MOL BIOL CELL, V13, P3257, DOI 10.1091/mbc.E02-04-0231; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Vrljic M, 2002, BIOPHYS J, V83, P2681, DOI 10.1016/S0006-3495(02)75277-6; Yonezawa S, 2000, BIOCHEM BIOPH RES CO, V271, P526, DOI 10.1006/bbrc.2000.2669; Yonezawa S, 2003, DEV GROWTH DIFFER, V45, P175	25	61	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15274	15280		10.1074/jbc.M312140200	http://dx.doi.org/10.1074/jbc.M312140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14729907	hybrid			2022-12-25	WOS:000220594700095
J	Alvarez, J; Hamplova, J; Hohaus, A; Morano, I; Haase, H; Vassort, G				Alvarez, J; Hamplova, J; Hohaus, A; Morano, I; Haase, H; Vassort, G			Calcium current in rat cardiomyocytes is modulated by the carboxyl-terminal ahnak domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL BETA-SUBUNIT; VOLTAGE-DEPENDENT FACILITATION; CA2+ CHANNEL; PROTEIN-KINASE; MOLECULAR DETERMINANTS; DESMOYOKIN/AHNAK PROTEIN; INACTIVATION; IDENTIFICATION; PHOSPHORYLATION; EXPRESSION	Ahnak, a protein of 5643 amino acids, interacts with the regulatory beta-subunit of cardiac calcium channels and with F-actin. Recently, we defined the binding sites among the protein partners in the carboxyl-terminal domain of ahnak. Here we further narrowed down the beta(2)-interaction sites to the carboxyl-terminal 188 amino acids of ahnak by the recombinant ahnak protein fragments P3 ( amino acids 5456 - 5556) and P4 ( amino acids 5556 - 5643). The effects of these P3 and P4 fragments on the calcium current were investigated under whole-cell patch clamp conditions on rat ventricular cardiomyocytes. P4 but not P3 increased significantly the current amplitude by 22.7 +/- 5% without affecting its voltage dependence. The slow component of calcium current inactivation was slowed down by both P3 and P4, whereas only P3 slowed significantly the fast one. The composite recombinant protein fragment P3 - P4 induced similar modifications to the ones induced by each of the ahnak fragments. In the presence of carboxyl-terminal ahnak protein fragments, isoprenaline induced a similar relative increase in current amplitude and shift in current kinetics. The actin-stabilizing agents, phalloidin and jasplakinolide, did not modify the effects of these ahnak protein fragments on calcium current in control conditions nor in the presence of isoprenaline. Hence, our results suggest that the functional effects of P3, P4, and P3 - P4 on calcium current are mediated by targeting the ahnak-beta(2)-subunit interaction rather than by targeting the ahnak-F-actin interaction. More specifically they suggest that binding of the beta(2)-subunit to the endogenous subsarcolemmal giant ahnak protein re-primes the alpha(1C)/beta(2)-subunit interaction and that the ahnak-derived proteins relieve the beta(2)-subunit from this inhibition.	CHU Arnaud de Villeneuve, INSERM, U390, F-34295 Montpellier 5, France; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Humboldt Univ Charite, Johannes Muller Inst Physiol, D-10117 Berlin, Germany; Inst Cardiol, Havana, Cuba	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Vassort, G (corresponding author), CHU Arnaud de Villeneuve, INSERM, U390, F-34295 Montpellier 5, France.	vassort@montp.inserm.fr						Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Borgonovo B, 2002, NAT CELL BIOL, V4, P955, DOI 10.1038/ncb888; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cens T, 1998, J BIOL CHEM, V273, P18308, DOI 10.1074/jbc.273.29.18308; Cens T, 1996, PFLUG ARCH EUR J PHY, V431, P771, DOI 10.1007/BF02253842; Cens T, 1999, FEBS LETT, V450, P17, DOI 10.1016/S0014-5793(99)00463-9; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; Delgado C, 1999, J MOL CELL CARDIOL, V31, P1783, DOI 10.1006/jmcc.1999.1023; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; Gerhardstein BL, 1999, BIOCHEMISTRY-US, V38, P10361, DOI 10.1021/bi990896o; Guo J, 2003, J PHYSIOL-LONDON, V547, P797, DOI 10.1113/jphysiol.2002.033340; Haase H, 2000, J CELL BIOCHEM, V76, P695, DOI 10.1002/(SICI)1097-4644(20000315)76:4<695::AID-JCB17>3.0.CO;2-Q; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Hering S, 2000, J PHYSIOL-LONDON, V528, P237, DOI 10.1111/j.1469-7793.2000.t01-1-00237.x; Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0855com; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Kamp TJ, 2000, AM J PHYSIOL-HEART C, V278, pH126, DOI 10.1152/ajpheart.2000.278.1.H126; Kamp TJ, 1996, J PHYSIOL-LONDON, V492, P89, DOI 10.1113/jphysiol.1996.sp021291; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; Kingsley PD, 2001, DEV GROWTH DIFFER, V43, P133; Lader AS, 1999, AM J PHYSIOL-CELL PH, V277, pC1277, DOI 10.1152/ajpcell.1999.277.6.C1277; LEE KS, 1987, P NATL ACAD SCI USA, V84, P3941, DOI 10.1073/pnas.84.11.3941; Mitterdorfer J, 1996, BIOCHEMISTRY-US, V35, P9400, DOI 10.1021/bi960683o; Nakamura M, 2000, AM J PHYSIOL-CELL PH, V279, pC480, DOI 10.1152/ajpcell.2000.279.2.C480; Nie ZZ, 2000, J INVEST DERMATOL, V114, P1044, DOI 10.1046/j.1523-1747.2000.00949.x; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; PIETROBON D, 1990, NATURE, V346, P651, DOI 10.1038/346651a0; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1996, AM J PHYSIOL-CELL PH, V271, pC1539, DOI 10.1152/ajpcell.1996.271.5.C1539; Rueckschloss U, 2001, J PHYSIOL-LONDON, V537, P363, DOI 10.1111/j.1469-7793.2001.00363.x; SCULPTOREANU A, 1995, AM J PHYSIOL-CELL PH, V269, pC725, DOI 10.1152/ajpcell.1995.269.3.C725; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; Shi CZ, 2002, J BIOL CHEM, V277, P6813, DOI 10.1074/jbc.M110524200; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Stotz SC, 2000, J BIOL CHEM, V275, P24575, DOI 10.1074/jbc.M000399200; Sussman J, 2001, J CELL BIOL, V154, P1019, DOI 10.1083/jcb.200105121; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; YUAN WL, 1994, AM J PHYSIOL, V267, pH982, DOI 10.1152/ajpheart.1994.267.3.H982	50	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12456	12461		10.1074/jbc.M312177200	http://dx.doi.org/10.1074/jbc.M312177200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722071	hybrid			2022-12-25	WOS:000220334900055
J	Bateman, NW; Tan, DF; Pestell, RG; Black, JD; Black, AR				Bateman, NW; Tan, DF; Pestell, RG; Black, JD; Black, AR			Intestinal tumor progression is associated with altered function of KLF5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; BTEB2 TRANSCRIPTION FACTOR; COLONIC CELL-GROWTH; KINASE-C ISOZYMES; EPITHELIAL-CELLS; PROSTATE-CANCER; FACTOR FAMILY; GENE; EXPRESSION; PROMOTER	Kruppel-like transcription factors have been linked to cell growth regulation and tumorigenesis in a number of systems. In the intestinal epithelium, expression of KLF5 (IKLF/BTEB2) is limited to proliferating crypt cells, indicating a growth-promoting role. Consistent with this role, we demonstrate that expression of KLF5 in non-transformed intestinal epithelial cells ( ileal IEC-18 and Immorto-Min Colon Epithelial (IMCE) cells) enhances colony formation, cyclin D1 transcription, and cell growth. However, in contrast to these effects in non-transformed cells, KLF5 reduced colony number, failed to enhance cyclin D1 transcription, and was negatively correlated with cell growth in colon cancer cell lines. The relationship between tumor progression and KLF5 was further investigated using Ras-mediated transformation of IEC-18 and IMCE cells as syngeneic models. Ras-transformation recapitulated differences in the effects of KLF5 on cell growth and cyclin D1 transcription, providing a direct link between intestinal tumor progression and altered function of KLF5. Ras-transformation also markedly down-regulated KLF5; further analysis indicated that reduced expression of KLF5 mRNA and destabilization of KLF5 protein occur in intestinal tumors. Reduced levels of KLF5 mRNA were also detected in APC(min) mouse and human familial adenomatous polyposis adenomas compared with normal crypt epithelium, indicating that down-regulation of KLF5 is an early event in intestinal tumorigenesis in vivo. Collectively, these data indicate that intestinal tumor progression is associated with a change in the growth-related functions of KLF5 and that intestinal tumors down-regulate KLF5 expression by multiple mechanisms.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; Georgetown Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20057 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Georgetown University	Black, AR (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	adrian.black@roswellpark.org			NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054909, R56DK060632, R01DK060632] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056] Funding Source: Medline; NIDDK NIH HHS [DK 54909, DK 60632] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Black AR, 1996, CANCER RES, V56, P700; Black JD, 2001, GASTROENTEROLOGY, V120, P1868, DOI 10.1053/gast.2001.25287; BRATTAIN MG, 1981, CANCER RES, V41, P1751; Burgess AW, 1998, PHILOS T ROY SOC B, V353, P903, DOI 10.1098/rstb.1998.0254; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen ZY, 2002, J BIOL CHEM, V277, P46831, DOI 10.1074/jbc.M204816200; Clark JA, 2004, J BIOL CHEM, V279, P9233, DOI 10.1074/jbc.M312268200; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; DAbaco GM, 1996, MOL CELL BIOL, V16, P884; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Goodman RH, 2000, GENE DEV, V14, P1553; Hoshino Y, 2000, CIRCULATION, V102, P2528, DOI 10.1161/01.CIR.102.20.2528; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Katz JP, 2002, DEVELOPMENT, V129, P2619; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Muraoka M, 1996, ONCOGENE, V12, P1565; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Ogata T, 2000, TRANSPLANTATION, V70, P1653, DOI 10.1097/00007890-200012150-00019; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Rak J, 2000, CANCER RES, V60, P490; Rozenblum E, 2002, HUM GENET, V110, P111, DOI 10.1007/s00439-001-0646-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Stone CD, 2002, FEBS LETT, V530, P147, DOI 10.1016/S0014-5793(02)03449-X; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Sur I, 2002, EUR J CELL BIOL, V81, P323, DOI 10.1078/0171-9335-00257; Verstovsek G, 1998, GASTROENTEROLOGY, V115, P75, DOI 10.1016/S0016-5085(98)70367-1; WARD JM, 1973, JNCI-J NATL CANCER I, V51, P1997, DOI 10.1093/jnci/51.6.1997; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; Zhang ZP, 2003, NUCLEIC ACIDS RES, V31, P2196, DOI 10.1093/nar/gkg310; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	44	111	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12093	12101		10.1074/jbc.M311532200	http://dx.doi.org/10.1074/jbc.M311532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14726538	hybrid			2022-12-25	WOS:000220334900014
J	Grossman, CE; Qian, YM; Banki, K; Perl, A				Grossman, CE; Qian, YM; Banki, K; Perl, A			ZNF143 mediates basal and tissue-specific expression of human transaldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE TRANSFER-RNA; PENTOSE-PHOSPHATE PATHWAY; TRANSCRIPTION-ACTIVATING FACTOR; SMALL NUCLEAR-RNA; MOUSE MAMMARY-GLAND; ZINC-FINGER; GENE-TRANSCRIPTION; POLYMERASE-III; GLUTATHIONE LEVELS; INDUCED APOPTOSIS	Transaldolase regulates redox-dependent apoptosis through controlling NADPH and ribose 5-phosphate production via the pentose phosphate pathway. The minimal promoter sufficient to drive chloramphenicol acetyltransferase reporter gene activity was mapped to nucleotides - 49 to - 1 relative to the transcription start site of the human transaldolase gene. DNase I footprinting with nuclear extracts of transaldolase-expressing cell lines unveiled protection of nucleotides - 29 to - 16. Electrophoretic mobility shift assays identified a single dominant DNA-protein complex that was abolished by consensus sequence for transcription factor ZNF143/76 or mutation of the ZNF76/143 motif within the transaldolase promoter. Mutation of an AP-2alpha recognition sequence, partially overlapping the ZNF143 motif, increased TAL-H promoter activity in HeLa cells, without significant impact on HepG2 cells, which do not express AP-2alpha. Cooperativity of ZNF143 with AP-2alpha was supported by supershift analysis of HeLa cells where AP-2 may act as cell type-specific repressor of TAL promoter activity. However, overexpression of full-length ZNF143, ZNF76, or dominant-negative DNA-binding domain of ZNF143 enhanced, maintained, or abolished transaldolase promoter activity, respectively, in HepG2 and HeLa cells, suggesting that ZNF143 initiates transcription from the transaldolase core promoter. ZNF143 overexpression also increased transaldolase enzyme activity. ZNF143 and transaldolase expression correlated in 21 different human tissues and were coordinately upregulated 14- and 34-fold, respectively, in lactating mammary glands compared with nonlactating ones. Chromatin immunoprecipitation studies confirm that ZNF143/73 associates with the transaldolase promoter in vivo. Thus, ZNF143 plays a key role in basal and tissue-specific expression of transaldolase and regulation of the metabolic network controlling cell survival and differentiation.	SUNY Syracuse, Coll Med, Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA; SUNY Syracuse, Coll Med, Upstate Med Univ, Dept Microbiol & Immunol, Syracuse, NY 13210 USA; SUNY Syracuse, Coll Med, Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Perl, A (corresponding author), SUNY Syracuse, Coll Med, Upstate Med Univ, Dept Med, 750 E Adams St, Syracuse, NY 13210 USA.	perla@upstate.edu		Qian, Yueming/0000-0001-7340-6421; Perl, Andras/0000-0002-5017-1348	NIDDK NIH HHS [R01 DK 49221] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049221] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi K, 1998, J BIOL CHEM, V273, P8598, DOI 10.1074/jbc.273.15.8598; Adachi K, 1999, ENDOCRINOLOGY, V140, P618, DOI 10.1210/en.140.2.618; ASAHINA T, 1995, DIABETES, V44, P520, DOI 10.2337/diabetes.44.5.520; Banki K, 1998, J BIOL CHEM, V273, P11944, DOI 10.1074/jbc.273.19.11944; BANKI K, 1994, J BIOL CHEM, V269, P2847; Banki K, 1997, GENOMICS, V45, P233, DOI 10.1006/geno.1997.4932; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; BANKI K, 1994, J EXP MED, V180, P1649, DOI 10.1084/jem.180.5.1649; Banki K, 1999, J IMMUNOL, V162, P1466; BAQUER NZ, 1977, DEV MED CHILD NEUROL, V19, P81; Baquer NZ, 1975, NORMAL PATHOLOGICAL, P109; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Benson LQ, 1999, J BIOL CHEM, V274, P28794, DOI 10.1074/jbc.274.40.28794; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BHATNAGAR A, 1990, CIRC RES, V67, P535, DOI 10.1161/01.RES.67.3.535; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOSS GR, 1984, J BIOL CHEM, V259, P2936; BRENOWITZ M, 1986, P NATL ACAD SCI USA, V83, P8462, DOI 10.1073/pnas.83.22.8462; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; Cabezas H, 1999, MOL CELL BIOCHEM, V201, P57, DOI 10.1023/A:1007042531454; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Constantini P., 1996, J BIOL CHEM, V271, P6746; Cooper R.A., 1991, HARRISONS PRINCIPLES, P1531; Cramer C T, 1995, J Biochem Toxicol, V10, P293, DOI 10.1002/jbt.2570100603; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; ESWORTHY RS, 1991, ARCH BIOCHEM BIOPHYS, V286, P330, DOI 10.1016/0003-9861(91)90048-N; Franze A, 1998, FEBS LETT, V437, P313, DOI 10.1016/S0014-5793(98)01259-9; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greene DA, 1999, EUR J PHARMACOL, V375, P217, DOI 10.1016/S0014-2999(99)00356-8; HEINRICH PC, 1976, CANCER RES, V36, P3189; HELD KD, 1993, RADIAT RES, V134, P383, DOI 10.2307/3578201; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Horecker BL, 2002, J BIOL CHEM, V277, P47965, DOI 10.1074/jbc.X200007200; HOTHERSALL JS, 1982, ENZYME, V27, P259, DOI 10.1159/000459058; HUE L, 1974, BIOCHEM BIOPH RES CO, V58, P532, DOI 10.1016/S0006-291X(74)80453-5; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACOBSON S, 1963, J COMP NEUROL, V121, P5, DOI 10.1002/cne.901210103; James H M, 1985, Int J Vitam Nutr Res Suppl, V28, P29; Kashiwagi A., 1996, DIABETES, V45, P84; KAUFFMAN FC, 1977, J NEUROCHEM, V28, P745, DOI 10.1111/j.1471-4159.1977.tb10622.x; KELSO TB, 1989, AM J PHYSIOL, V257, pE885, DOI 10.1152/ajpendo.1989.257.6.E885; Korner K, 1997, NUCLEIC ACIDS RES, V25, P4933, DOI 10.1093/nar/25.24.4933; Kubota H, 2000, J BIOL CHEM, V275, P28641, DOI 10.1074/jbc.M005009200; KUHN E, 1972, BIOCHEMISTRY-US, V11, P1767, DOI 10.1021/bi00760a006; Lachaise F, 2002, GENE, V299, P263, DOI 10.1016/S0378-1119(02)01051-X; Lebeda RA, 1999, BBA-GENE STRUCT EXPR, V1445, P314, DOI 10.1016/S0167-4781(99)00064-0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lowther WJ, 1999, DNA CELL BIOL, V18, P685, DOI 10.1089/104454999314962; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mach CM, 2002, J BIOL CHEM, V277, P4853, DOI 10.1074/jbc.M108308200; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MARTINS RN, 1985, AUST J BIOL SCI, V38, P295; Mayes P., 1993, HARPERS BIOCH, P201; MCDOUGAL DB, 1961, J GEN PHYSIOL, V44, P487, DOI 10.1085/jgp.44.3.487; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; MYSLINSKI E, 1993, J MOL BIOL, V234, P311, DOI 10.1006/jmbi.1993.1588; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; Ni TC, 1996, J BIOL CHEM, V271, P7927, DOI 10.1074/jbc.271.14.7927; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOVELLO F, 1968, BIOCHEM J, V107, P775, DOI 10.1042/bj1070775; Perl A, 2000, J BIOL CHEM, V275, P7261, DOI 10.1074/jbc.275.10.7261; Perl A, 2002, ANTIOXID REDOX SIGN, V4, P427, DOI 10.1089/15230860260196227; PILZ RB, 1984, J BIOL CHEM, V259, P2927; Puskas F, 2000, FASEB J, V14, P1352, DOI 10.1096/fj.14.10.1352; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAGOUSSIS J, 1992, GENOMICS, V14, P673, DOI 10.1016/S0888-7543(05)80167-3; Rincon JC, 1998, NUCLEIC ACIDS RES, V26, P4846, DOI 10.1093/nar/26.21.4846; ROSA LFBPC, 1993, PHYSIOL BEHAV, V53, P651, DOI 10.1016/0031-9384(93)90169-G; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Saur D, 2002, J BIOL CHEM, V277, P25798, DOI 10.1074/jbc.M109802200; Schaub M, 2000, NUCLEIC ACIDS RES, V28, P2114, DOI 10.1093/nar/28.10.2114; Schaub M, 1999, J BIOL CHEM, V274, P24241, DOI 10.1074/jbc.274.34.24241; Schaub M, 1999, J BIOL CHEM, V274, P25042, DOI 10.1074/jbc.274.35.25042; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Schuster C, 1998, MOL CELL BIOL, V18, P2650, DOI 10.1128/MCB.18.5.2650; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; Severin S E, 1980, Adv Enzyme Regul, V19, P235; SPOLARICS Z, 1991, BIOCHEM J, V278, P515, DOI 10.1042/bj2780515; STARK KL, 1989, BIOCHEM PHARMACOL, V38, P2685, DOI 10.1016/0006-2952(89)90555-8; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TAN EL, 1969, COMP BIOCHEM PHYSIOL, V31, P635, DOI 10.1016/0010-406X(69)90064-4; Terzano S, 2000, J BIOL CHEM, V275, P41495, DOI 10.1074/jbc.M006197200; Thom E, 1998, PLANTA, V204, P226, DOI 10.1007/s004250050251; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; URSINI MV, 1993, VIROLOGY, V196, P338, DOI 10.1006/viro.1993.1485; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WOOD T, 1985, PENTOSE PHOSPHATE PA; Wu F, 2002, J CELL BIOCHEM, V84, P699, DOI 10.1002/jcb.10094; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401; Yokota S, 1999, J BIOL CHEM, V274, P37070, DOI 10.1074/jbc.274.52.37070; YOUNG AJ, 1990, P SOC EXP BIOL MED, V193, P274	99	31	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12190	12205		10.1074/jbc.M307039200	http://dx.doi.org/10.1074/jbc.M307039200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14702349	hybrid			2022-12-25	WOS:000220334900025
J	Kajimoto, T; Shirai, Y; Sakai, N; Yamamoto, T; Matsuzaki, H; Kikkawa, U; Saito, N				Kajimoto, T; Shirai, Y; Sakai, N; Yamamoto, T; Matsuzaki, H; Kikkawa, U; Saito, N			Ceramide-induced apoptosis by translocation, phosphorylation, and activation of protein kinase C delta in the Golgi complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; ABL TYROSINE KINASE; SRC FAMILY KINASES; PKC-DELTA; PROTEOLYTIC ACTIVATION; TRANSDUCTION PATHWAY; CELLULAR-RESPONSES; EPSILON; DOMAIN; IDENTIFICATION	Protein kinase C (PKC), a Ca2+/phospholipid-dependent protein kinase, is known as a key enzyme in various cellular responses, including apoptosis. However, the functional role of PKC in apoptosis has not been clarified. In this study, we focused on the involvement of PKCdelta in ceramide-induced apoptosis in HeLa cells and examined the importance of spatiotemporal activation of the specific PKC subtype in apoptotic events. Ceramide-induced apoptosis was inhibited by the PKCdelta-specific inhibitor rottlerin and also was blocked by knockdown of endogenous PKCdelta expression using small interfering RNA. Ceramide induced the translocation of PKCdelta to the Golgi complex and the concomitant activation of PKCdelta via phosphorylation of Tyr(311) and Tyr(332) in the hinge region of the enzyme. Unphosphorylatable PKCdelta (mutants Y311F and Y332F) could translocate to the Golgi complex in response to ceramide, suggesting that tyrosine phosphorylation is not necessary for translocation. However, ceramide failed to activate PKCdelta lacking the C1B domain, which did not translocate to the Golgi complex, but could be activated by tyrosine phosphorylation. These findings suggest that ceramide translocates PKCdelta to the Golgi complex and that PKCdelta is activated by tyrosine phosphorylation in the compartment. Furthermore, we utilized species-specific knockdown of PKCdelta by small interfering RNA to study the significance of phosphorylation of Tyr(311) and Tyr(332) in PKCdelta for ceramide-induced apoptosis and found that phosphorylation of Tyr(311) and Tyr(332) is indispensable for ceramide-induced apoptosis. We demonstrate here that the targeting mechanism of PKCdelta, dual regulation of both its activation and translocation to the Golgi complex, is critical for the ceramide-induced apoptotic event.	Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Kobe, Hyogo 6578501, Japan; Kobe Univ, Biosignal Res Ctr, Biochem Lab, Nada Ku, Kobe, Hyogo 6578501, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol & Pharmacol Neurosci, Minami Ku, Hiroshima 7348551, Japan	Kobe University; Kobe University; Hiroshima University	Saito, N (corresponding author), Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6578501, Japan.	naosaito@kobe-u.ac.jp	Shirai, Yasuhito/O-3255-2018					Bard F, 2002, EUR J CELL BIOL, V81, P26, DOI 10.1078/0171-9335-00217; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Benes C, 2001, AM J PHYSIOL-CELL PH, V280, pC1498, DOI 10.1152/ajpcell.2001.280.6.C1498; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Brugg B, 1996, J NEUROCHEM, V66, P733; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Hamaguchi A, 2003, J BIOL CHEM, V278, P41557, DOI 10.1074/jbc.M305294200; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hu H, 2001, BIOCHEM BIOPH RES CO, V288, P573, DOI 10.1006/bbrc.2001.5814; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Ibitayo AI, 1999, AM J PHYSIOL-GASTR L, V277, pG445, DOI 10.1152/ajpgi.1999.277.2.G445; Ibitayo AI, 1998, AM J PHYSIOL-GASTR L, V275, pG705, DOI 10.1152/ajpgi.1998.275.4.G705; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Sawai H, 1997, J BIOL CHEM, V272, P2452; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	57	86	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12668	12676		10.1074/jbc.M312350200	http://dx.doi.org/10.1074/jbc.M312350200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715667	hybrid			2022-12-25	WOS:000220334900080
J	Lee, S; Roy, F; Galmarini, CM; Accardi, R; Michelon, J; Viller, A; Cros, E; Dumontet, C; Sylla, BS				Lee, S; Roy, F; Galmarini, CM; Accardi, R; Michelon, J; Viller, A; Cros, E; Dumontet, C; Sylla, BS			Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia	ONCOGENE			English	Article						Dok1; chronic lymphocytic leukemia; frameshift mutation; NLS; Lck; tyrosine phosphorylation	RASGAP-BINDING PROTEIN; GTPASE-ACTIVATING PROTEIN; TYROSINE PHOSPHORYLATION; NEGATIVE REGULATION; MOLECULAR-CLONING; DOCKING PROTEIN; P62(DOK) DOK1; V-SRC; KINASE; APOPTOSIS	B-cell chronic lymphocytic leukemia (B-CLL) is a malignant disease characterized by an accumulation of monoclonal CD5+ mature B cells, with a high percentage of cells arrested in the G0/G1 phase of the cell cycle, and a particular resistance toward apoptosis-inducing agents. Dok1 ( downstream of tyrosine kinases) is an abundant Ras-GTPase-activating protein (Ras-GAP)-associated tyrosine kinase substrate, which negatively regulates cell proliferation, downregulates MAP kinase activation and promotes cell migration. The gene encoding Dok1 maps to human chromosome 2p13, a region previously found to be rearranged in B-CLL. We have screened the Dok1 gene for mutations from 46 individuals with B-CLL using heteroduplex analysis. A four-nucleotide GGCC deletion in the coding region was found in the leukemia cells from one patient. This mutation causes a frameshift leading to protein truncation at the carboxyl-terminus, with the acquisition of a novel amino-acid sequence. In contrast to the wild-type Dok1 protein, which has cytoplasmic/membrane localization, the mutant Dok1 is a nuclear protein containing a functional bipartite nuclear localization signal. Whereas overexpression of wild-type Dok1 inhibited PDGF-induced MAP kinase activation, this inhibition was not observed with the mutant Dok1. Furthermore the mutant Dok1 forms heterodimers with Dok1 wild type and the association can be enhanced by Lck-mediated tyrosine-phosphorylation. This is the first example of a Dok1 mutation in B-CLL and the data suggest that Dok1 might play a role in leukemogenesis.	Int Agcy Res Canc, F-69008 Lyon, France; INSERM, U590, F-69008 Lyon, France; Hospices Civils Lyon, F-69008 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon	Sylla, BS (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	sylla@iarc.fr		Galmarini, Carlos Maria/0000-0001-5494-6617; Dumontet, Charles/0000-0003-1875-134X				ABTS H, 1991, LEUKEMIA RES, V15, P987, DOI 10.1016/0145-2126(91)90103-Z; Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cheng GF, 2002, J VIROL, V76, P9434, DOI 10.1128/JVI.76.18.9434-9445.2002; Cong F, 1999, MOL CELL BIOL, V19, P8314; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; ELROUBY S, 1993, BLOOD, V82, P3452; Favre C, 2003, GENES IMMUN, V4, P40, DOI 10.1038/sj.gene.6363891; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hosooka T, 2001, MOL CELL BIOL, V21, P5437, DOI 10.1128/MCB.21.16.5437-5446.2001; Hubert P, 2000, EUR J IMMUNOGENET, V27, P145, DOI 10.1046/j.1365-2370.2000.00203.x; INABA T, 1991, LEUKEMIA, V5, P719; JUCKER M, 1991, LEUKEMIA, V5, P528; Kato I, 2002, J IMMUNOL, V168, P629, DOI 10.4049/jimmunol.168.2.629; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Liang XQ, 2002, J BIOL CHEM, V277, P13732, DOI 10.1074/jbc.M200277200; Martelli MP, 2001, J BIOL CHEM, V276, P45654, DOI 10.1074/jbc.M105777200; Munzert G, 2002, BLOOD, V100, P3749, DOI 10.1182/blood.V100.10.3749; NEET K, 1995, MOL CELL BIOL, V15, P4908; Nelms K, 1998, GENOMICS, V53, P243, DOI 10.1006/geno.1998.5514; Nemorin JG, 2000, J BIOL CHEM, V275, P14590, DOI 10.1074/jbc.275.19.14590; Nemorin JG, 2001, J IMMUNOL, V166, P4408, DOI 10.4049/jimmunol.166.7.4408; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RICHARDSON AL, 1992, ONCOGENE, V7, P961; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Sattler M, 2001, J BIOL CHEM, V276, P2451, DOI 10.1074/jbc.M006250200; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; SCHROEDER HW, 1994, IMMUNOL TODAY, V15, P288, DOI 10.1016/0167-5699(94)90009-4; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; SONNIER JA, 1983, NEW ENGL J MED, V309, P590, DOI 10.1056/NEJM198309083091005; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Sylla BS, 2000, P NATL ACAD SCI USA, V97, P7470, DOI 10.1073/pnas.130193097; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; van Dijk TB, 2000, BLOOD, V96, P3406; VonKnethen A, 1997, LEUKEMIA LYMPHOMA, V26, P551; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wick MJ, 2001, J BIOL CHEM, V276, P42843, DOI 10.1074/jbc.M102116200; Wyatt W, 2000, BLOOD, V96, p367A; Yamakawa N, 2002, EMBO J, V21, P1684, DOI 10.1093/emboj/21.7.1684; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YOFFE G, 1990, J PEDIATR-US, V116, P114, DOI 10.1016/S0022-3476(05)81658-0; Zhao MM, 2001, J EXP MED, V194, P265, DOI 10.1084/jem.194.3.265	52	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2287	2297		10.1038/sj.onc.1207385	http://dx.doi.org/10.1038/sj.onc.1207385			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14730347				2022-12-25	WOS:000220427700002
J	Goren, EN; Reeves, DC; Akabas, MH				Goren, EN; Reeves, DC; Akabas, MH			Loose protein packing around the extracellular half of the GABA(A) receptor beta(1) subunit M2 channel-lining segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; GATED ION-CHANNEL; AMINOBUTYRIC ACID(A) RECEPTORS; MEMBRANE-SPANNING SEGMENT; LIGAND-BINDING DOMAIN; ALPHA-SUBUNIT; 5-HT3 RECEPTOR; SCANNING MUTAGENESIS; CHARGE SELECTIVITY; THREONINE RESIDUE	GABA(A) receptors are ligand-gated ion channels formed by the pseudosymmetrical assembly of five homologous subunits around the central channel axis. The five M2 membrane-spanning segments largely line the channel. In the present work we probed the water surface accessibility of the beta(1) subunit M2 segment using the substituted cysteine accessibility method. We assayed the reaction of the negatively charged sulfhydryl-specific reagent, p-chloromercuribenzenesulfonate (pCMBS(-)), by its effect on subsequent currents elicited by EC50 and saturating GABA concentrations. pCMBS(-), applied with GABA, reacted with 14 of the 19 residues tested. At the M2 cytoplasmic end from 2' to 6' only beta(1)A252C (2') and beta(1)T256C (6') were pCMBS(-) -reactive in the presence of GABA. We infer that the M2 segments are tightly packed in this region. Toward the extracellular half of M2 all residues from beta(1)T262C (12') through beta(1)E270C (20') reacted with pCMBS(-) applied with GABA. We infer that this region is highly mobile and loosely packed against the rest of the protein. Based on differences in pCMBS(-) reaction rates two domains can be distinguished on the putative channel-lining side of M2. A faster reacting domain includes the 2', 9', 12', 13', and 16' residues. The slower reacting face contains the 6', 10', and 14' residues. We hypothesize that these may represent the channel-lining faces in the closed and open states and that gating involves an 80-100degrees rotation of the M2 segments. These results are consistent with the loose packing of the M2 segments inferred from the structure of the homologous Torpedo nicotinic acetylcholine receptor.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Akabas, MH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	makabas@aecom.yu.edu		Akabas, Myles/0000-0001-8781-7846	NIGMS NIH HHS [GM61925] Funding Source: Medline; NINDS NIH HHS [NS30808] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM061925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030808] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Auerbach A, 1996, J PHYSIOL-LONDON, V494, P155, DOI 10.1113/jphysiol.1996.sp021482; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Bianchi MT, 2001, NEUROPHARMACOLOGY, V41, P737, DOI 10.1016/S0028-3908(01)00132-0; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Burkat PM, 2001, J NEUROSCI, V21, P7026, DOI 10.1523/JNEUROSCI.21-18-07026.2001; Chang YC, 1996, J NEUROSCI, V16, P5415; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; Changeux JP, 2001, CURR OPIN NEUROBIOL, V11, P369, DOI 10.1016/S0959-4388(00)00221-X; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; Cymes GD, 2002, BIOCHEMISTRY-US, V41, P5548, DOI 10.1021/bi011864f; Dalziel JE, 2000, MOL PHARMACOL, V57, P875; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; HASINOFF BB, 1971, CAN J BIOCHEM CELL B, V49, P742, DOI 10.1139/o71-105; Horenstein J, 1998, MOL PHARMACOL, V53, P870; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Keramidas A, 2002, J GEN PHYSIOL, V119, P393, DOI 10.1085/jgp.20028552; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Mortensen M, 2003, EUR J PHARMACOL, V476, P17, DOI 10.1016/S0014-2999(03)02125-3; Newell JG, 2003, J BIOL CHEM, V278, P13166, DOI 10.1074/jbc.M211905200; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Reeves DC, 2003, BIOPHYS J, V84, P2338, DOI 10.1016/S0006-3495(03)75039-5; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; Scheller M, 2002, J NEUROSCI, V22, P8411; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; Shan Q, 2002, J BIOL CHEM, V277, P44845, DOI 10.1074/jbc.M208647200; Sine SM, 2002, J BIOL CHEM, V277, P29210, DOI 10.1074/jbc.M203396200; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Thompson SA, 1999, BRIT J PHARMACOL, V127, P1349, DOI 10.1038/sj.bjp.0702687; Tretter V, 1997, J NEUROSCI, V17, P2728; TWYMAN RE, 1990, J PHYSIOL-LONDON, V423, P193, DOI 10.1113/jphysiol.1990.sp018018; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; VANSTEVENINCK J, 1965, J GEN PHYSIOL, V48, P617, DOI 10.1085/jgp.48.4.617; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WHITE BH, 1992, J BIOL CHEM, V267, P15770; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Wotring VE, 2003, J PHYSIOL-LONDON, V548, P527, DOI 10.1113/jphysiol.2002.032045; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	62	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11198	11205		10.1074/jbc.M314050200	http://dx.doi.org/10.1074/jbc.M314050200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14715650	hybrid			2022-12-25	WOS:000220157600045
J	Li, Y; Gazdoiu, S; Pan, ZQ; Fuchs, SY				Li, Y; Gazdoiu, S; Pan, ZQ; Fuchs, SY			Stability of homologue of Slimb F-box protein is regulated by availability of its substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; UBIQUITIN LIGASE COMPLEX; CELL-CYCLE; DEPENDENT DEGRADATION; BETA-TRCP; SCF; NEDD8; HOS; PHOSPHORYLATION; PATHWAY	The homologue of Slimb (HOS) F-box protein is a receptor of the Skp1-Cullin1-F-box protein (SCFHOS) E3 ubiquitin ligase, which mediates ubiquitination and degradation of beta-catenin and the inhibitor of NF-kappaB, IkappaB. We found that HOS itself is an unstable protein that undergoes ubiquitination and degradation in a 26 S proteasome-dependent manner. A HOS mutant lacking the F-box that is deficient in binding to the core SCF components underwent ubiquitination less efficiently and was more stable than the wild type protein. Furthermore, ubiquitination and degradation of HOS was impaired in ts41 cells, in which the activities of Cullin-based ligases were decreased because the NEDD8 pathway was abrogated. Whereas HOS was directly ubiquitinated within the SCFHOS complex in vitro, the addition of phosphorylated IkappaBalpha inhibited this ubiquitination. Increasing cellular levels of HOS substrate ( phosphorylated IkappaBalpha) by activating IkappaB kinase inhibited HOS ubiquitination and led to stabilization of HOS, indicating that interaction between HOS and its substrate might protect HOS from proteolysis. Taken together, our data suggest that proteolysis of HOS depends on its interaction with active components of the SCF complex and that HOS stability is regulated by a bound substrate. These findings may define a mechanism for maintaining activities of specific SCF complexes based on availability of a particular substrate.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	University of Pennsylvania; Icahn School of Medicine at Mount Sinai	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 3800 Spruce St,Rm 161E, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061051] Funding Source: NIH RePORTER; NCI NIH HHS [CA92900] Funding Source: Medline; NIGMS NIH HHS [GM61051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bhatia N, 2002, ONCOGENE, V21, P1501, DOI 10.1038/sj.onc.1205311; Bottero V, 2001, CANCER RES, V61, P7785; Chen YZ, 2000, J BIOL CHEM, V275, P8929, DOI 10.1074/jbc.275.12.8929; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; HERTER JR, 2002, MED SCI MONIT, V8, P283; Kamura T, 2002, J BIOL CHEM, V277, P30388, DOI 10.1074/jbc.M203344200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Mathias N, 1999, MOL CELL BIOL, V19, P1759; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Smothers DB, 2000, MOL CELL BIOL, V20, P7845, DOI 10.1128/MCB.20.21.7845-7852.2000; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	47	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11074	11080		10.1074/jbc.M312301200	http://dx.doi.org/10.1074/jbc.M312301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707120	hybrid			2022-12-25	WOS:000220157600030
J	Mirshahi, T; Logothetis, DE				Mirshahi, T; Logothetis, DE			Molecular determinants responsible for differential cellular distribution of G protein-gated inwardly rectifying K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; RECTIFIER; TRAFFICKING; DOMAINS; GIRK1; HETEROMULTIMER; IDENTIFICATION; LOCALIZATION; SUBUNITS; SIGNALS	Activation of the heteromeric G protein-gated inwardly rectifying K+ channel (GIRK) GIRK1 and GIRK4 subunits gives rise to I-KACh, which controls excitability in atrial tissue. Although homomeric GIRK4 channels localize to the plasma membrane and display moderate function, GIRK1 channels fail to localize to the cell surface and do not exhibit significant function as homomers. Using oocytes to express GFP-tagged GIRK1 and GIRK4 and chimeras between these two proteins, we have identified two regions, one in the proximal C terminus and another in the distal N terminus that are critical for their subcellular localization. Replacement of both of these regions in GIRK1 with corresponding regions from GIRK4 was required for efficient expression of GIRK1 on the plasma membrane. Replacement of either region by itself was ineffective. The distal N terminus and proximal C terminus have been previously suggested to play important roles in ER-export and subunit co-assembly respectively in this family of channels. Our data indicate for the first time that both of these regions need to work in concert to mediate efficient targeting of these channels to the plasma membrane.	Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Logothetis, DE (corresponding author), Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA.	Diomedes.Logothetis@mssm.edu			NHLBI NIH HHS [HL 54185, HL10307] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010307, R01HL054185] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chan KW, 1997, J BIOL CHEM, V272, P6548, DOI 10.1074/jbc.272.10.6548; Deutsch C, 2003, NEURON, V40, P265, DOI 10.1016/S0896-6273(03)00506-3; Deutsch C, 2002, ANNU REV PHYSIOL, V64, P19, DOI 10.1146/annurev.physiol.64.081501.155934; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jones PA, 2001, FEBS LETT, V508, P85, DOI 10.1016/S0014-5793(01)03023-X; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; Konstas AA, 2003, AM J PHYSIOL-CELL PH, V284, pC910, DOI 10.1152/ajpcell.00479.2002; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; Kubo Y, 1996, BIOCHEM BIOPH RES CO, V227, P240, DOI 10.1006/bbrc.1996.1496; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Mirshahi T, 2002, J BIOL CHEM, V277, P7348, DOI 10.1074/jbc.M109999200; Mirshahi T, 2001, METHOD PHARMACOL TOX, P215; Mirshahi Tooraj, 2002, Mol Interv, V2, P289, DOI 10.1124/mi.2.5.289; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Sui JL, 1999, ADV SEC MESS PHOSPH, V33, P179; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Woodward R, 1997, J BIOL CHEM, V272, P10823; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	27	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11890	11897		10.1074/jbc.M313322200	http://dx.doi.org/10.1074/jbc.M313322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14703518	hybrid			2022-12-25	WOS:000220157600126
J	Chandrasekaran, EV; Lakhaman, SS; Chawda, R; Piskorz, CF; Neelamegham, S; Matta, KL				Chandrasekaran, EV; Lakhaman, SS; Chawda, R; Piskorz, CF; Neelamegham, S; Matta, KL			Identification of physiologically relevant substrates for cloned Gal : 3-O-sulfotransferases (Gal3STs) - Distinct high affinity of Gal3ST-2 and LS180 sulfotransferase for the Globo H backbone, Gal3ST-3 for N-glycan multiterminal Gal beta 1,4GlcNAc beta units and 6-sulfoGal beta 1,4GlcNAc beta, and Gal3ST-4 for the mucin core-2 trisaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP T-HAPTEN; L-SELECTIN; MOLECULAR-CLONING; MASS-SPECTROMETRY; LEWIS-TYPE; O-GLYCANS; ALPHA-2,3-SIALYLTRANSFERASE; OLIGOSACCHARIDES; GLYCOPROTEIN; BIOSYNTHESIS	Sulfated glycoconjugates regulate biological processes such as cell adhesion and cancer metastasis. We examined the acceptor specificities and kinetic properties of three cloned Gal: 3-O-sulfotransferases (Gal3STs) ST-2, ST-3, and ST-4 along with a purified Gal3ST from colon carcinoma LS180 cells. Gal3ST-2 was the dominant Gal3ST in LS180. While the mucin core-2 structure Galbeta1,4GlcNAcbeta1,6(3-O-MeGalbeta1,3)GalNAalpha-O-Bn (where Bn is benzyl) and the disaccharide Galbeta1,4GlcNAc served as high affinity acceptors for Gal3ST-2 and Gal3ST-3, 3-O-MeGalbeta1,4GlcNAcbeta1,6(Galbeta1,3)GalNAcalpha-O-Bn and GalX1,3GalNAcalpha-O-Al (where Al is allyl) were efficient acceptors for Gal3ST-4. The activities of Gal3ST-2 and Gal3ST-3 could be distinguished with the Globo H precursor (Galbeta1,3GalNAcbeta1,3Galalpha-O-Me) and fetuin triantennary asialoglycopeptide. Gal3ST-2 acted efficiently on the former, while Gal3ST-3 showed preference for the latter. Gal3ST-4 also acted on the Globo H precursor but not the glycopeptide. In support of the specificity, Gal3ST-2 activity toward the Galbeta1,4GlcNAcbeta unit on mucin core-2 as well as the Globo H precursor could be inhibited competitively by Galbeta1,4GlcNAcbeta1,6(3-O-sulfoGalbeta1,3)GalNAcalpha-O-Bn but not 3-O-sulfoGalbeta1,-4GlcNAcbeta1,6(Galbeta1,3)GalNAcalpha-O-Bn. Remarkably these sulfotransferases were uniquely specific for sulfated substrates: Gal3ST-3 utilized Galbeta1,4(6-O-sulfo)GlcNAcbeta-O-Al as acceptor, Gal3ST-2 acted efficiently on Galbeta1,3(6-O-sulfo)GlcNAcbeta-O-Al, and Gal3ST-4 acted efficiently on Galbeta1,3(6-O-sulfo)GalNAcbeta-O-Al. Mg2+, Mn2+, and Ca2+ stimulated the activities of Gal3ST-2, whereas only Mg2+ augmented Gal3ST-3 activity. Divalent cations did not stimulate Gal3ST-4, although inhibition was noted at high Mn2+ concentrations. The fine substrate specificities of Gal3STs indicate a distinct physiological role for each enzyme.	Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA; SUNY Buffalo, Dept Biol & Chem Engn, Buffalo, NY 14260 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Matta, KL (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Elm & Carlton Sts, Buffalo, NY 14263 USA.	Khushi.Matta@RoswellPark.org		Neelamegham, Sriram/0000-0002-1371-8500	NATIONAL CANCER INSTITUTE [R01CA035329, P30CA016056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063014] Funding Source: NIH RePORTER; NCI NIH HHS [CA35329, CA63213, CA16056] Funding Source: Medline; NHLBI NIH HHS [HL63014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adobati E, 1997, GLYCOBIOLOGY, V7, P173, DOI 10.1093/glycob/7.2.173; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; Chance DL, 1996, CARBOHYD RES, V295, P157, DOI 10.1016/S0008-6215(96)90136-6; Chandrasekaran EV, 2002, GLYCOBIOLOGY, V12, P153, DOI 10.1093/glycob/12.3.153; Chandrasekaran EV, 1997, GLYCOBIOLOGY, V7, P753, DOI 10.1093/glycob/7.6.753; Chandrasekaran EV, 1999, GLYCOCONJUGATE J, V16, P523, DOI 10.1023/A:1007074005371; CHANDRASEKARAN EV, 1994, BIOCHEM BIOPH RES CO, V201, P78, DOI 10.1006/bbrc.1994.1671; CHANDRASEKARAN EV, 1994, BIOCHEM BIOPH RES CO, V198, P350, DOI 10.1006/bbrc.1994.1049; CHANDRASEKARAN EV, 1995, BIOCHEMISTRY-US, V34, P2925, DOI 10.1021/bi00009a024; CHANDRASEKARAN EV, 1995, BIOCHEMISTRY-US, V34, P4748, DOI 10.1021/bi00014a032; de Graffenried CL, 2003, J BIOL CHEM, V278, P40282, DOI 10.1074/jbc.M304928200; El-Fasakhany FM, 2001, J BIOL CHEM, V276, P26988, DOI 10.1074/jbc.M100348200; Fukumoto S, 1999, J BIOL CHEM, V274, P9271, DOI 10.1074/jbc.274.14.9271; Galustian C, 1999, J BIOL CHEM, V274, P18213, DOI 10.1074/jbc.274.26.18213; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Honke K, 1996, J BIOCHEM-TOKYO, V119, P421; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; HOREJSI V, 1978, BIOCHIM BIOPHYS ACTA, V538, P293, DOI 10.1016/0304-4165(78)90357-4; Jain RK, 1998, GLYCOBIOLOGY, V8, P707, DOI 10.1093/glycob/8.7.707; Jain RK, 1998, GLYCOCONJUGATE J, V15, P951, DOI 10.1023/A:1006977607394; JAIN RK, 1993, CARBOHYD RES, V243, P385, DOI 10.1016/0008-6215(93)87042-Q; Jain RK, 1996, CARBOHYD RES, V282, P101, DOI 10.1016/0008-6215(95)00376-2; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; LOGUIDICE JM, 1995, J BIOL CHEM, V270, P27544, DOI 10.1074/jbc.270.46.27544; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Miyamoto D, 1995, BIOCHEM BIOPH RES CO, V217, P852, DOI 10.1006/bbrc.1995.2850; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Sanders WJ, 1999, J BIOL CHEM, V274, P5271, DOI 10.1074/jbc.274.9.5271; Sandhoff R, 2002, J BIOL CHEM, V277, P20386, DOI 10.1074/jbc.M110641200; Seko A, 2001, J BIOL CHEM, V276, P25697, DOI 10.1074/jbc.M101558200; Slovin SF, 1999, P NATL ACAD SCI USA, V96, P5710, DOI 10.1073/pnas.96.10.5710; Sujino K, 2000, GLYCOBIOLOGY, V10, P313, DOI 10.1093/glycob/10.3.313; TADANOARITOMI K, 1995, CARBOHYD RES, V273, P41, DOI 10.1016/0008-6215(95)00106-4; Veerman ECI, 1997, GLYCOBIOLOGY, V7, P37, DOI 10.1093/glycob/7.1.37; Xia J, 2003, SYNLETT, P1291	35	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10032	10041		10.1074/jbc.M311989200	http://dx.doi.org/10.1074/jbc.M311989200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701868	hybrid			2022-12-25	WOS:000220050400047
J	Khosravani, H; Altier, C; Simms, B; Hamming, KS; Snutch, TP; Mezeyova, J; McRory, JE; Zamponi, GW				Khosravani, H; Altier, C; Simms, B; Hamming, KS; Snutch, TP; Mezeyova, J; McRory, JE; Zamponi, GW			Gating effects of mutations in the Ca(v)3.2 T-type calcium channel associated with childhood absence epilepsy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; MOLECULAR CHARACTERIZATION; LOW-THRESHOLD; EXPRESSION; ALPHA(1G); NEURONS; FAMILY; INACTIVATION; SEIZURES; CLONING	Childhood absence epilepsy (CAE) is a type of generalized epilepsy observed in 2 - 10% of epileptic children. In a recent study by Chen et al. ( Chen, Y., Lu, J., Pan, H., Zhang, Y., Wu, H., Xu, K., Liu, X., Jiang, Y., Bao, X., Yao, Z., Ding, K., Lo, W. H., Qiang, B., Chan, P., Shen, Y., and Wu, X. ( 2003) Ann. Neurol. 54, 239 - 243) 12 missense mutations were identified in the CACNA1H (Ca(v)3.2) gene in 14 of 118 patients with CAE but not in 230 control individuals. We have functionally characterized five of these mutations (F161L, E282K, C456S, V831M, and D1463N) using rat Ca(v)3.2 and whole-cell patch clamp recordings in transfected HEK293 cells. Two of the mutations, F161L and E282K, mediated an similar to10-mV hyperpolarizing shift in the half-activation potential. Mutation V831M caused a similar to 50% slowing of inactivation relative to control and shifted half-inactivation potential similar to 10 mV toward more depolarized potentials. Mean time to peak was significantly increased by mutation V831M but was unchanged for all others. No resolvable changes in the parameters of the IV relation or current kinetics were observed with the remaining mutations. The findings suggest that several of the Cav3.2 mutants allow for greater calcium influx during physiological activation and in the case of F161L and E282K can result in channel openings at more hyperpolarized ( close to resting) potentials. This may underlie the propensity for seizures in patients with CAE.	Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; NeuroMed Technol Inc, Vancouver, BC V6T 1Z4, Canada	University of Calgary; University of British Columbia	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	zamponi@ucalgary.ca	Khosravani, Houman/X-2391-2019; Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296; Zamponi, Gerald W./0000-0002-0644-9066				Adams R, 1998, PRINCIPLES NEUROLOGY, V6th; Avoli M, 2001, EPILEPSIA, V42, P445, DOI 10.1046/j.1528-1157.2001.39800.x; Beedle AM, 2002, J MEMBRANE BIOL, V187, P225, DOI 10.1007/s00232-001-0166-2; Chemin J, 2002, J PHYSIOL-LONDON, V540, P3, DOI 10.1113/jphysiol.2001.013269; Chemin J, 2001, BIOPHYS J, V80, P1238, DOI 10.1016/S0006-3495(01)76100-0; Chen YC, 2003, ANN NEUROL, V54, P239, DOI 10.1002/ana.10607; COULTER DA, 1989, ANN NEUROL, V25, P582, DOI 10.1002/ana.410250610; Cribbs LL, 2000, FEBS LETT, V466, P54, DOI 10.1016/S0014-5793(99)01756-1; Crunelli V, 2002, NAT REV NEUROSCI, V3, P371, DOI 10.1038/nrn811; da Silva MRD, 2002, CLIN ENDOCRINOL, V56, P367; Goetz C.G., 1999, TXB CLIN NEUROLOGY; Gomora JC, 2002, BIOPHYS J, V83, P229, DOI 10.1016/S0006-3495(02)75164-3; JASPER HH, 1947, RES PUBL ASS NERV ME, V26, P272; Kim D, 2001, NEURON, V31, P35, DOI 10.1016/S0896-6273(01)00343-9; KOSTYUK PG, 1992, NEUROSCIENCE, V51, P755, DOI 10.1016/0306-4522(92)90515-4; Kozlov AS, 1999, EUR J NEUROSCI, V11, P4149, DOI 10.1046/j.1460-9568.1999.00841.x; Kumar PP, 2002, MOL PHARMACOL, V61, P649, DOI 10.1124/mol.61.3.649; Lee JH, 1999, J NEUROSCI, V19, P1912; Marksteiner R, 2001, J PHYSIOL-LONDON, V537, P27, DOI 10.1111/j.1469-7793.2001.0027k.x; McRory JE, 2001, J BIOL CHEM, V276, P3999, DOI 10.1074/jbc.M008215200; MCRORY JE, 2004, IN PRESS J NEUROSCI, V24; Meeren HKM, 2002, J NEUROSCI, V22, P1480, DOI 10.1523/JNEUROSCI.22-04-01480.2002; Melliti K, 2003, J PHYSIOL-LONDON, V546, P337, DOI 10.1113/jphysiol.2002.026716; Park JY, 2003, FEBS LETT, V547, P37, DOI 10.1016/S0014-5793(03)00665-3; Perez-Reyes E, 1998, J BIOENERG BIOMEMBR, V30, P313, DOI 10.1023/A:1021981420839; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; POLLEN DA, 1963, ELECTROEN CLIN NEURO, V15, P1017, DOI 10.1016/0013-4694(63)90145-7; SONG I, 2001, ANN M SOC NEUR NOV 1; Staes M, 2001, J PHYSIOL-LONDON, V530, P35, DOI 10.1111/j.1469-7793.2001.0035m.x; STERIADE M, 1995, J NEUROSCI, V15, P623; Steriade M, 1998, J NEUROPHYSIOL, V80, P1439, DOI 10.1152/jn.1998.80.3.1439; Stotz SC, 2004, J PHYSIOL-LONDON, V554, P263, DOI 10.1113/jphysiol.2003.047068; Talley EM, 1999, J NEUROSCI, V19, P1895; Talley EM, 2000, MOL BRAIN RES, V75, P159, DOI 10.1016/S0169-328X(99)00307-1	34	139	152	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9681	9684		10.1074/jbc.C400006200	http://dx.doi.org/10.1074/jbc.C400006200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14729682	hybrid			2022-12-25	WOS:000220050400003
J	Mingo-Sion, AM; Marietta, PM; Koller, E; Wolf, DM; Van Den Berg, CL				Mingo-Sion, AM; Marietta, PM; Koller, E; Wolf, DM; Van Den Berg, CL			Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells	ONCOGENE			English	Article						JNK; proliferation; apoptosis; cell cycle; stress signaling	N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; INSULIN-RECEPTOR SUBSTRATE-1; GROWTH SUPPRESSION; CYCLE ARREST; JUN; PHOSPHORYLATION; CHECKPOINT; EXPRESSION; PATHWAY	c-Jun N-terminal kinase (JNK) is activated by diverse cell stimuli, including stress, growth factors, and cytokines. Traditionally, activation of JNK by stress treatment is thought to induce cell death. However, our recent data indicate that JNK's ability to sensitize cells to apoptosis may be, in part, cell cycle dependent. Here, we show that the majority of both paclitaxel- and UV-induced apoptosis can be inhibited by the pharmacological JNK inhibitor, SP600125, in MCF-7 cells. However, inhibition of JNK does little to reverse doxorubicin-induced apoptosis in MCF-7 cells or doxorubicin- and UV-mediated death in MDA MB-231 cells. SP treatment causes G2/M arrest of three breast cancer cell lines and results in the endoreduplication (cellular DNA content >4N) of MCF-7 and MDA MB-231 cells. These effects on cell cycle and apoptosis are not significantly altered by the inhibition of p53, indicating that JNK is functioning independently of p53. Lastly, inhibition of JNK using both SP and antisense oligonucleotides targeted to JNK1 and JNK2 reduced proliferation of all three breast cancer cell lines. Taken together, these results suggest that the activation of JNK is important for the induction of apoptosis following stresses that function at different cell cycle phases, and that basal JNK activity is necessary to promote proliferation and maintain diploidy in breast cancer cells.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80262 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Isis Pharmaceuticals Inc	Van Den Berg, CL (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, 4200 E 9th Ave,Campus Box C238, Denver, CO 80262 USA.	carla.vandenberg@UCHSC.edu						Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; BAND V, 1990, CANCER RES, V50, P7351; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Haq R, 2002, CANCER RES, V62, P5076; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hildesheim J, 2002, CANCER RES, V62, P7305; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; MacCorkle-Chosnek RA, 2001, BIOCHEM BIOPH RES CO, V289, P173, DOI 10.1006/bbrc.2001.5948; Mamay CL, 2003, ONCOGENE, V22, P602, DOI 10.1038/sj.onc.1206186; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Monno S, 2000, ENDOCRINOLOGY, V141, P544, DOI 10.1210/en.141.2.544; Motwani M, 2000, CLIN CANCER RES, V6, P924; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Patel R, 1998, J CELL SCI, V111, P2247; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Woodgett JR, 1996, CANCER SURV, V27, P127; Xue Y, 2003, MOL CARCINOGEN, V36, P38, DOI 10.1002/mc.10096; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200	42	138	143	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					596	604		10.1038/sj.onc.1207147	http://dx.doi.org/10.1038/sj.onc.1207147			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724588				2022-12-25	WOS:000188098300031
J	Versteeg, HH; Spek, CA; Richel, DJ; Peppelenbosch, MP				Versteeg, HH; Spek, CA; Richel, DJ; Peppelenbosch, MP			Coagulation factors VIIa and Xa inhibit apoptosis and anoikis	ONCOGENE			English	Article						apoptosis; anoikis; MAP kinase; PI3 kinase; active-site-blocked FVIIa	FACTOR CYTOPLASMIC DOMAIN; TISSUE FACTOR EXPRESSION; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; KINASE PATHWAY; UP-REGULATION; ACTIVATION; METASTASIS; SURVIVAL	The molecular mechanisms enabling cancer cells to survive loss-of-adhesion-induced apoptosis in the early phases of metastasis remain largely obscure. Interestingly, the overexpression of tissue factor (TF) on tumor cells is associated with successful metastasis and it has now become clear that coagulation factor VIIa (FVIIa), the natural binding partner of TF induces signal transduction in TF-expressing cells. Hence, we investigated the effects of FVIIa-TF interaction on cell survival. We observed that FVIIa, at physiologically relevant concentrations, inhibits cell death and caspase-3 activation induced by serum deprivation and loss of adhesion (lack of integrin signaling) in TF-overexpressing cells, but not in non-TF-expressing cells. This FVIIa effect was not dependent on the formation of the downstream coagulation products FXa or thrombin and was inhibited using an active site-blocked form of FVIIa (FVIIai). FVIIa incubation resulted in the prolonged activation of both the phosphatidylinositide-3-(OH) kinase and p42/p44 MAP kinase pathways, and studies employing pharmacological inhibitors revealed that both the pathways are required for FVIIa-induced cell survival and inhibition of caspase-3 activity. Finally, TF:FVIIa-induced FXa generation dramatically increased cell survival. We propose that FVIIa-induced cell survival may explain why overexpression of TF is associated with successful metastasis.	Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Versteeg, HH (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, G2-105,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	h.h.versteeg@amc.uva.nl	Versteeg, Henri/G-1783-2018; Spek, Arnold/AAC-5866-2019	Versteeg, Henri/0000-0003-4294-175X; Spek, Arnold/0000-0002-2149-4068; Peppelenbosch, Maikel/0000-0001-9112-6028				Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; Hamada K, 1996, CANCER, V77, P1877, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1877::AID-CNCR18>3.0.CO;2-X; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; Seto S, 2000, CANCER, V88, P295, DOI 10.1002/(SICI)1097-0142(20000115)88:2<295::AID-CNCR8>3.0.CO;2-U; Shigemori C, 1998, THROMB HAEMOSTASIS, V80, P894; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; Ueda C, 2001, J GASTROENTEROL, V36, P848, DOI 10.1007/s005350170008; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199; Versteeg HH, 2003, J THROMB HAEMOST, V1, P1012, DOI 10.1046/j.1538-7836.2003.00205.x; Versteeg HH, 2001, THROMB HAEMOSTASIS, V86, P1353; Versteeg HH, 2002, J BIOL CHEM, V277, P27065, DOI 10.1074/jbc.M110325200; Vrana JA, 1996, CANCER RES, V56, P5063; Wang XL, 2002, J BIOL CHEM, V277, P23620, DOI 10.1074/jbc.M202242200	26	88	95	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	2004	23	2					410	417		10.1038/sj.onc.1207066	http://dx.doi.org/10.1038/sj.onc.1207066			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724569				2022-12-25	WOS:000188098300011
J	Kim, S; Zhang, ZM; Upchurch, S; Isern, N; Chen, Y				Kim, S; Zhang, ZM; Upchurch, S; Isern, N; Chen, Y			Structure and DNA-binding sites of the SWI1 AT-rich interaction domain (ARID) suggest determinants for sequence-specific DNA recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAD RINGER GENE; CHEMICAL-SHIFT; NMR; PROTEINS; COMPLEX; DYNAMICS; FAMILY; ASSIGNMENT; MEMBER; C-13	ARID ((A) under barT-(r) under bar ich (i) under bar nteraction (d) under bar omain) is a homologous family of DNA-binding domains that occur in DNA-binding proteins from a wide variety of species, ranging from yeast to nematodes, insects, mammals, and plants. SWI1, a member of the SWI/SNF protein complex that is involved in chromatin remodeling during transcription, contains the ARID motif. The ARID domain of human SWI1 (also known as p270) does not select for a specific DNA sequence from a random sequence pool. The lack of sequence specificity shown by the SWI1 ARID domain stands in contrast to the other characterized ARID domains, which recognize specific AT-rich sequences. We have solved the three-dimensional structure of human SWI1 ARID using solution NMR methods. In addition, we have characterized nonspecific DNA binding by the SWI1 ARID domain. Results from this study indicate that a flexible, long, internal loop in the ARID motif is likely to be important for sequence-specific DNA recognition. The structure of the human SWI1 ARID domain also represents a distinct structural subfamily. Studies of ARID indicate that the boundary of DNA binding structural and functional domains can extend beyond the sequence homologous region in a homologous family of proteins. Structural studies of homologous domains such as the ARID family of DNA-binding domains should provide information to better predict the boundary of structural and functional domains in structural genomic studies.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Grad Sch Biol Sci, Duarte, CA 91010 USA; Pacific NW Natl Lab, William R Wiley Environm Mol Sci Lab, Richland, WA 99352 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Chen, Y (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.			Isern, Nancy/0000-0001-9571-8864	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1994, METHOD ENZYMOL, V239, P79; Burley SK, 2002, ANNU REV GENOM HUM G, V3, P243, DOI 10.1146/annurev.genom.3.022502.103227; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; Iba H, 2003, REV MED VIROL, V13, P99, DOI 10.1002/rmv.378; Iwahara J, 1999, EMBO J, V18, P6084, DOI 10.1093/emboj/18.21.6084; Iwahara J, 2002, EMBO J, V21, P1197, DOI 10.1093/emboj/21.5.1197; Kim S, 2003, J BIOMOL NMR, V27, P277, DOI 10.1023/A:1025434004184; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 2003, BIOINFORMATICS, V19, P315, DOI 10.1093/bioinformatics/19.2.315; Numata S, 1999, CANCER RES, V59, P3741; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Peterson CL, 2002, CURR BIOL, V12, pR245, DOI 10.1016/S0960-9822(02)00782-0; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Rost B, 1996, METHOD ENZYMOL, V266, P525; Shandala T, 1999, DEVELOPMENT, V126, P4341; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Staunton D, 2003, ACCOUNTS CHEM RES, V36, P207, DOI 10.1021/ar010119s; Warren AJ, 2002, CURR OPIN STRUC BIOL, V12, P107, DOI 10.1016/S0959-440X(02)00296-8; Whitson RH, 2003, BIOCHEM BIOPH RES CO, V312, P997, DOI 10.1016/j.bbrc.2003.11.026; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yuan YC, 1998, NAT STRUCT BIOL, V5, P959, DOI 10.1038/2934; Zhu LY, 2001, BIOCHEMISTRY-US, V40, P9142, DOI 10.1021/bi010476a	31	32	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16670	16676		10.1074/jbc.M312115200	http://dx.doi.org/10.1074/jbc.M312115200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14722072	hybrid			2022-12-25	WOS:000220747900119
J	Mahimainathan, L; Choudhury, GG				Mahimainathan, L; Choudhury, GG			Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTORS; MESANGIAL CELL-PROLIFERATION; INDUCED DNA-SYNTHESIS; PDGF-BETA-RECEPTOR; NEGATIVE REGULATION; PROTEIN-KINASE; C-FOS; MICE; AKT; ACTIVATION	PTEN, mutated in a variety of human cancers, is a dual specificity protein phosphatase and also possesses D3-phosphoinositide phosphatase activity on phosphatidylinositol 3,4,5-tris-phosphate (PIP3), a product of phosphatidylinositol 3-kinase. This PIP3 phosphatase activity of PTEN contributes to its tumor suppressor function by inhibition of Akt kinase, a direct target of PIP3. We have recently shown that Akt regulates PDGF-induced DNA synthesis in mesangial cells. In this study, we demonstrate that expression of PTEN in mesangial cells inhibits PDGF-induced Akt activation leading to reduction in PDGF-induced DNA synthesis. As a potential mechanism, we show that PTEN inhibits PDGF-induced protein tyrosine phosphorylation with concomitant dephosphorylation and inactivation of tyrosine phosphorylated and activated PDGF receptor. Recombinant as well as immunopurified PTEN dephosphorylates autophosphorylated PDGF receptor in vitro. Expression of phosphatase deficient mutant of PTEN does not dephosphorylate PDGF-induced tyrosine phosphorylated PDGF receptor. Rather its expression increases tyrosine phosphorylation of PDGF receptor. Furthermore, expression of PTEN attenuated PDGF-induced signal transduction including phosphatidylinositol 3-kinase and Erk1/2 MAPK activities. Our data provide the first evidence that PTEN is physically associated with platelet-derived growth factor (PDGF) receptor and that PDGF causes its dissociation from the receptor. Finally, we show that both the C2 and tail domains of PTEN contribute to binding to the PDGF receptor. These data demonstrate a novel aspect of PTEN function where it acts as an effector for the PDGF receptor function and negatively regulates PDGF receptor activation.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Choudhury, GG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	choudhuryg@uthscsa.edu		/0000-0001-5077-3552	NIDDK NIH HHS [R01 DK 55815, P50 DK 61597] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055815, P50DK061597] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud Hanna E., 1995, P573; ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; BECKMAN SA, 2001, NAT GENET, V29, P396; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cheyney IW, 1999, CANCER RES, V59, P2318; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; Choudhury GG, 2001, BIOCHEM BIOPH RES CO, V286, P1183, DOI 10.1006/bbrc.2001.5483; Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; Davies MA, 1999, CANCER RES, V59, P2551; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; FRAKE TF, 1997, SCIENCE, V275, P665; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Furnari FB, 1998, CANCER RES, V58, P5002; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Gottschalk AR, 2001, CANCER RES, V61, P2105; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Huang H, 1999, DEVELOPMENT, V126, P5365; Huang JH, 2002, ARTERIOSCL THROM VAS, V22, P745, DOI 10.1161/01.ATV.0000016358.05294.8D; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Jefferson JA, 1999, J NEPHROL, V12, P297; JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413; KIYOMOTO H, 1994, FEBS LETT, V353, P217, DOI 10.1016/0014-5793(94)01039-0; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Lokker NA, 2002, CANCER RES, V62, P3729; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; RON D, 1992, BIOTECHNIQUES, V13, P866; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2000, CANCER RES, V60, P3605; STRAWN LM, 1994, J BIOL CHEM, V269, P21215; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Weng LP, 1999, CANCER RES, V59, P5808; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	64	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15258	15268		10.1074/jbc.M314328200	http://dx.doi.org/10.1074/jbc.M314328200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14718524	hybrid			2022-12-25	WOS:000220594700093
J	Zhu, WG; Hileman, T; Ke, Y; Wang, PC; Lu, SL; Duan, WR; Dai, ZY; Tong, TJ; Villalona-Calero, MA; Plass, C; Otterson, GA				Zhu, WG; Hileman, T; Ke, Y; Wang, PC; Lu, SL; Duan, WR; Dai, ZY; Tong, TJ; Villalona-Calero, MA; Plass, C; Otterson, GA			5-aza-2 '-deoxycytidine activates the p53/p21(Waf1/Cip1) pathway to inhibit cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLTRANSFERASE INHIBITION; LUNG-CANCER CELLS; P21(WAF1/CIP1) EXPRESSION; MYELODYSPLASTIC SYNDROME; MAMMALIAN-CELLS; P53; METHYLATION; DAMAGE; GENE; LEUKEMIA	In addition to its demethylating function, 5-aza-2'-deoxycytidine (5-aza-CdR) also plays an important role in inducing cell cycle arrest, differentiation, and cell death. However, the mechanism by which 5-aza-CdR induces antineoplastic activity is not clear. In this study, we found that 5-aza-CdR at limited concentrations (0.01-5 muM) induces inhibition of cell proliferation as well as increased p53/p21(Waf1/Cip1) expression in A549 cells (wild-type p53) but not in H1299 (p53-null) and H719 cells ( p53 mutant). The p53-dependent p21(Waf1/Cip1) expression induced by 5-aza-CdR was not seen in A549 cells transfected with the wild-type human papilloma virus type-16 E6 gene that induces p53 degradation. Furthermore, deletion analysis and site-directed mutagenesis of the p21 promoter reveals that 5-aza-CdR induces p21(Waf1/Cip1) expression through two p53 binding sites in the p21 promoter. Finally, 5-aza-CdR-induced p21(Waf1)/ (Cip1) expression was dependent on DNA damage but not on DNA demethylation as demonstrated by comet assay and bisulfite sequencing, respectively. Our data provide useful clues for judging the therapeutic efficacy of 5-aza-CdR in the treatment of human cancer cells.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Peking Univ, Hlth Sci Ctr, Canc Res Ctr, Beijing 100083, Peoples R China; Ohio State Univ, Dept Internal Med, Div Hematol Oncol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA	Peking University; Peking University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Zhu, WG (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xueyuan Rd, Beijing 100083, Peoples R China.	zhuweiguo@bjmu.edu.cn; otterson-1@medctr.osu.edu	zhu, wei-guo/E-1334-2012; Wang, Pa-Chun/AAD-4094-2019; Plass, Christoph/H-7192-2014	Zhu, Wei-Guo/0000-0001-8385-6581; duan, wenrui/0000-0001-6512-7350	NCI NIH HHS [P30CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahrendt SA, 2003, J NATL CANCER I, V95, P961, DOI 10.1093/jnci/95.13.961; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; ANDERSON D, 1994, MUTAT RES, V307, P261, DOI 10.1016/0027-5107(94)90300-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Blagosklonny MV, 2002, CELL CYCLE, V1, P67, DOI 10.4161/cc.1.1.102; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; COVEY JM, 1986, CANCER RES, V46, P5511; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; DeSimone J, 2002, BLOOD, V99, P3905, DOI 10.1182/blood.V99.11.3905; DINCALCI M, 1985, CANCER RES, V45, P3197; Ding H, 2003, BIOCHEM BIOPH RES CO, V305, P950, DOI 10.1016/S0006-291X(03)00873-8; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fruhwald MC, 2002, MOL GENET METAB, V75, P1, DOI 10.1006/mgme.2001.3265; Fukuoka K, 1997, JPN J CANCER RES, V88, P1009, DOI 10.1111/j.1349-7006.1997.tb00322.x; GLAZER RI, 1984, MOL PHARMACOL, V26, P381; Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koshy M, 2000, BLOOD, V96, P2379, DOI 10.1182/blood.V96.7.2379.h8002379_2379_2384; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LI LH, 1970, CANCER RES, V30, P2760; LIN KT, 1981, J PHARM SCI, V70, P1228, DOI 10.1002/jps.2600701112; Lubbert M, 2000, CURR TOP MICROBIOL, V249, P135; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Momparler RL, 1997, LEUKEMIA, V11, P175, DOI 10.1038/sj.leu.2400550; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Peller S, 1998, GENE CHROMOSOME CANC, V21, P2, DOI 10.1002/(SICI)1098-2264(199801)21:1<2::AID-GCC2>3.0.CO;2-5; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Sacchi S, 1999, CANCER-AM CANCER SOC, V86, P2632, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; VESELY J, 1977, CANCER RES, V37, P3684; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; WILSON VL, 1983, CANCER RES, V43, P3493; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zhu WG, 2001, CANCER RES, V61, P1327	58	126	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15161	15166		10.1074/jbc.M311703200	http://dx.doi.org/10.1074/jbc.M311703200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722112	hybrid			2022-12-25	WOS:000220594700082
J	Hesberg, C; Hansch, R; Mendel, RR; Bittner, F				Hesberg, C; Hansch, R; Mendel, RR; Bittner, F			Tandem orientation of duplicated xanthine dehydrogenase genes from Arabidopsis thaliana - Differential gene expression and enzyme activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR SULFURASE; LEAF SENESCENCE; HYPERSENSITIVE RESPONSE; DROSOPHILA-MELANOGASTER; ASPERGILLUS-NIDULANS; PURINE CATABOLISM; MOLECULAR-OXYGEN; CDNA CLONING; WHEAT LEAVES; OXIDASE TYPE	Xanthine dehydrogenase from the plant Arabidopsis thaliana was analyzed on molecular and biochemical levels. Whereas most other organisms appear to own only one gene for xanthine dehydrogenase A. thaliana possesses two genes in tandem orientation spaced by 704 base pairs. The cDNAs as well as the proteins AtXDH1 and AtXDH2 share an overall identity of 93% and show high homologies to xanthine dehydrogenases from other organisms. Whereas AtXDH2 mRNA is expressed constitutively, alterations of AtXDH1 transcript levels were observed at various stresses like drought, salinity, cold, and natural senescence, but also after abscisic acid treatment. Transcript alteration did not mandatorily result in changes of xanthine dehydrogenase activities. Whereas salt treatment had no effect on xanthine dehydrogenase activities, cold stress caused a decrease, but desiccation and senescence caused a strong increase of activities in leaves. Because AtXDH1 presumably is the more important isoenzyme in A. thaliana it was expressed in Pichia pastoris, purified, and used for biochemical studies. AtXDH1 protein is a homodimer of about 300 kDa consisting of identical subunits of 150 kDa. Like xanthine dehydrogenases from other organisms AtXDH1 uses hypoxanthine and xanthine as main substrates and is strongly inhibited by allopurinol. AtXDH1 could be activated by the purified molybdenum cofactor sulfurase ABA3 that converts inactive desulfo-into active sulfoenzymes. Finally it was found that AtXDH1 is a strict dehydrogenase and not an oxidase, but is able to produce superoxide radicals indicating that besides purine catabolism it might also be involved in response to various stresses that require reactive oxygen species.	Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany	Braunschweig University of Technology	Mendel, RR (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany.	R.Mendel@tu-bs.de		Hansch, Robert/0000-0003-1310-8419				AMAYA Y, 1990, J BIOL CHEM, V265, P14170; BALLOU D, 1969, BIOCHEM BIOPH RES CO, V36, P898, DOI 10.1016/0006-291X(69)90288-5; Berglund L, 1996, J DAIRY SCI, V79, P198, DOI 10.3168/jds.S0022-0302(96)76351-8; Bittner F, 2001, J BIOL CHEM, V276, P40381, DOI 10.1074/jbc.C100472200; BOLAND MJ, 1981, BIOCHEM INT, V2, P567; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUGHLAN MP, 1980, MOLYBDENUM MOLYBDENU, P121; Della Corte E, 1968, FEBS Lett, V2, P83, DOI 10.1016/0014-5793(68)80107-3; Drake R, 1996, PLANT MOL BIOL, V30, P755, DOI 10.1007/BF00019009; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Glatigny A, 1998, J MOL BIOL, V278, P431, DOI 10.1006/jmbi.1998.1707; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; Harris CM, 1997, J BIOL CHEM, V272, P8370, DOI 10.1074/jbc.272.13.8370; HENSEL LL, 1993, PLANT CELL, V5, P553, DOI 10.1105/tpc.5.5.553; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HILLE R, 1995, FASEB J, V9, P995, DOI 10.1096/fasebj.9.11.7649415; HUNT J, 1992, J BIOL CHEM, V267, P21479; KEITH TP, 1987, GENETICS, V116, P67; Koiwai H, 2000, J BIOCHEM-TOKYO, V127, P659, DOI 10.1093/oxfordjournals.jbchem.a022654; Komoto N, 1999, INSECT MOL BIOL, V8, P73, DOI 10.1046/j.1365-2583.1999.810073.x; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LOHMAN KN, 1994, PHYSIOL PLANTARUM, V92, P322, DOI 10.1111/j.1399-3054.1994.tb05343.x; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEHRA RK, 1984, ARCH BIOCHEM BIOPHYS, V229, P585, DOI 10.1016/0003-9861(84)90191-7; MENDEL RR, 1976, BIOCHEM PHYSIOL PFL, V170, P538; MONTALBINI P, 1995, PHYSIOL MOL PLANT P, V46, P275, DOI 10.1006/pmpp.1995.1022; MONTALBINI P, 1992, PLANT SCI, V87, P225, DOI 10.1016/0168-9452(92)90154-E; MONTALBINI P, 1992, J PHYTOPATHOL, V134, P218, DOI 10.1111/j.1439-0434.1992.tb01230.x; Montalbini P, 1996, PHYSIOL MOL PLANT P, V48, P273, DOI 10.1006/pmpp.1996.0023; Montalbini P, 1998, PLANT SCI, V134, P89, DOI 10.1016/S0168-9452(98)00046-6; Montalbini P, 2000, J PLANT PHYSIOL, V156, P3, DOI 10.1016/S0176-1617(00)80266-7; Nishino T, 1997, J BIOL CHEM, V272, P29859, DOI 10.1074/jbc.272.47.29859; NISHINO T, 1989, J BIOL CHEM, V264, P5468; NISHINO T, 1989, J BIOL CHEM, V264, P2518; NISHINO T, 1994, J BIOCHEM, V116, P1; Pastori GM, 1997, PLANT PHYSIOL, V113, P411, DOI 10.1104/pp.113.2.411; PEREZVICENTE R, 1992, BIOCHIM BIOPHYS ACTA, V1117, P159, DOI 10.1016/0304-4165(92)90074-5; ROBINS RK, 1985, J HETEROCYCLIC CHEM, V22, P601, DOI 10.1002/jhet.5570220303; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; RYU SB, 1995, PLANT PHYSIOL, V108, P713, DOI 10.1104/pp.108.2.713; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; Sauer P, 2002, PLANT PHYSIOL BIOCH, V40, P393, DOI 10.1016/S0981-9428(02)01393-1; Schwartz SH, 1997, PLANT PHYSIOL, V114, P161, DOI 10.1104/pp.114.1.161; STIRPE F, 1969, J BIOL CHEM, V244, P3855; TAYLOR CB, 1993, P NATL ACAD SCI USA, V90, P5118, DOI 10.1073/pnas.90.11.5118; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; WAHL RC, 1982, J BIOL CHEM, V257, P3958; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; Xi HL, 2000, J BACTERIOL, V182, P5332, DOI 10.1128/JB.182.19.5332-5341.2000; Xiong LM, 2001, PLANT CELL, V13, P2063, DOI 10.1105/tpc.13.9.2063	53	109	120	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13547	13554		10.1074/jbc.M312929200	http://dx.doi.org/10.1074/jbc.M312929200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726515	hybrid			2022-12-25	WOS:000220478500034
J	Melton, JA; Parker, MW; Rossjohn, J; Buckley, JT; Tweten, RK				Melton, JA; Parker, MW; Rossjohn, J; Buckley, JT; Tweten, RK			The identification and structure of the membrane-spanning domain of the Clostridium septicum alpha toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING TOXIN; ANTHRAX PROTECTIVE ANTIGEN; PROTEIN MODELS; AEROLYSIN; CHANNEL; TRANSMEMBRANE; PROAEROLYSIN; CYTOLYSIN; ENTEROLOBIN; MUTAGENESIS	Alpha toxin (AT) is a pore-forming toxin produced by Clostridium septicum that belongs to the unique aerolysin-like family of pore-forming toxins. The location and structure of the transmembrane domains of these toxins have remained elusive. Using deletion mutagenesis, cysteine-scanning mutagenesis and multiple spectrofluorimetric methods a membrane-spanning amphipathic beta-hairpin of AT has been identified. Spectrofluorimetric analysis of cysteine-substituted residues modified with an environmentally sensitive fluorescent probe via the cysteine sulfydryl showed that the side chains of residues 203 - 232 alternated between the aqueous milieu and the membrane core when the AT oligomer was inserted into membranes, consistent with the formation of an amphipathic transmembrane beta-hairpin. AT derivatives that contained deletions that removed up to 90% of the beta-hairpin did not form a pore but were similar to native toxin in all other aspects of the mechanism. Furthermore, a mutant of AT that contained an engineered disulfide, predicted to restrict the movement of the beta-hairpin, functioned similarly to native toxin except that it did not form a pore unless the disulfide bond was reduced. Together these studies revealed the location and structure of the membrane-spanning domain of AT.	Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Prot Crystallog Unit, Melbourne, Vic 3168, Australia; Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Oklahoma System; University of Oklahoma Health Sciences Center; St. Vincent's Institute of Medical Research; Monash University; University of Victoria	Tweten, RK (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, 940 Stanton L Young Blvd, Oklahoma City, OK 73190 USA.	Rod-Tweten@ouhsc.edu	Rossjohn, Jamie/F-9032-2013; Parker, Michael W/F-9069-2013	Rossjohn, Jamie/0000-0002-2020-7522; Parker, Michael W/0000-0002-3101-1138	NIAID NIH HHS [AI37657, R01 AI032097] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032097, R01AI037657, R37AI037657] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; BALLARD J, 1992, INFECT IMMUN, V60, P784, DOI 10.1128/IAI.60.3.784-790.1992; BALLARD J, 1993, MOL MICROBIOL, V10, P627, DOI 10.1111/j.1365-2958.1993.tb00934.x; Barnham M, 1998, EMERG INFECT DIS, V4, P321, DOI 10.3201/eid0402.980224; Barry R, 2001, J BIOL CHEM, V276, P551, DOI 10.1074/jbc.M008097200; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; Bittencourt SET, 2003, FEBS LETT, V549, P47, DOI 10.1016/S0014-5793(03)00763-4; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; de Sousa M V, 1989, An Acad Bras Cienc, V61, P405; Diep DB, 1999, MOL MICROBIOL, V31, P785, DOI 10.1046/j.1365-2958.1999.01217.x; Diep DB, 1998, MOL MICROBIOL, V30, P341, DOI 10.1046/j.1365-2958.1998.01068.x; Fontes W, 1997, ARCH BIOCHEM BIOPHYS, V347, P201, DOI 10.1006/abbi.1997.0358; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Gordon VM, 1999, J BIOL CHEM, V274, P27274, DOI 10.1074/jbc.274.38.27274; Gordon VM, 1997, INFECT IMMUN, V65, P4130, DOI 10.1128/IAI.65.10.4130-4134.1997; Haugland R., 1996, HDB FLUORESCENT PROB; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; Palmer M, 1996, J BIOL CHEM, V271, P26664, DOI 10.1074/jbc.271.43.26664; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Rossjohn J, 1997, EMBO J, V16, P3426, DOI 10.1093/emboj/16.12.3426; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Rossjohn J, 1998, BIOCHEMISTRY-US, V37, P741, DOI 10.1021/bi9721039; Sellman BR, 1997, MOL MICROBIOL, V25, P429, DOI 10.1046/j.1365-2958.1997.4541820.x; Sellman BR, 1997, MOL MICROBIOL, V23, P551, DOI 10.1046/j.1365-2958.1997.d01-1876.x; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; STEVENS D L, 1990, Reviews of Infectious Diseases, V12, P286; Tsitrin Y, 2002, NAT STRUCT BIOL, V9, P729, DOI 10.1038/nsb839; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; Wichroski MJ, 2002, INFECT IMMUN, V70, P4353, DOI 10.1128/IAI.70.8.4353-4361.2002	41	76	80	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14315	14322		10.1074/jbc.M313758200	http://dx.doi.org/10.1074/jbc.M313758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14715670	hybrid			2022-12-25	WOS:000220478500126
J	Dinadayala, P; Lemassu, A; Granovski, P; Cerantola, S; Winter, N; Daffe, M				Dinadayala, P; Lemassu, A; Granovski, P; Cerantola, S; Winter, N; Daffe, M			Revisiting the structure of the anti-neoplastic Glucans of Mycobacterium bovis Bacille Calmette-Guerin - Structural analysis of the extracellular and boiling water extract-derived glucans of the vaccine substrains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPARATIVE GENOMICS; BLADDER-CANCER; BCG VACCINE; TUBERCULOSIS; POLYSACCHARIDES; SURFACE; IDENTIFICATION; PHTHIOCEROL; LOCATION; POINT	The attenuated strain of Mycobacterium bovis Bacille Calmette-Guerin (BCG), used worldwide to prevent tuberculosis and leprosy, is also clinically used as an immunotherapeutic agent against superficial bladder cancer. An anti-tumor polysaccharide has been isolated from the boiling water extract of the Tice substrain of BCG and tentatively characterized as consisting primarily of repeating units of 6-linked-glucosyl residues. Mycobacterium tuberculosis and other mycobacterial species produce a glycogen-like alpha-glucan composed of repeating units of 4-linked glucosyl residues substituted at some 6 positions by short oligoglucosyl units that also exhibits an anti-tumor activity. Therefore, the impression prevails that mycobacteria synthesize different types of anti-neoplastic glucans or, alternatively, the BCG substrains are singular in producing a unique type of glucan that may confer to them their immunotherapeutic property. The present study addresses this question through the comparative analysis of alpha-glucans purified from the extracellular materials and boiling water extracts of three vaccine substrains. The polysaccharides were purified, and their structural features were established by mono- and two-dimensional NMR spectroscopy and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of the enzymatic and chemical degradation products of the purified compounds. The glucans isolated by the two methods from the three substrains of BCG were shown to exhibit identical structural features shared with the glycogen-like alpha-glucan of M. tuberculosis and other mycobacteria. Incidentally, we observed an occasional release of dextrans from Sephadex columns that may explain the reported occurrence of 6-substituted alpha-glucans in mycobacteria.	CNRS, UMR 5089, Inst Pharmacol & Biol STruct, Dept Mecanismes Mol Infect Mycobacteriennes, F-31077 Toulouse 04, France; Univ Toulouse 3, F-31077 Toulouse 04, France; Inst Pasteur, Unite Genet Mycobacterienne, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Daffe, M (corresponding author), CNRS, UMR 5089, Inst Pharmacol & Biol STruct, Dept Mecanismes Mol Infect Mycobacteriennes, 205 Route Narbonne, F-31077 Toulouse 04, France.	mamadou.daffe@ipbs.fr	Winter, Nathalie/U-2690-2018	Winter, Nathalie/0000-0003-0994-7834; Lemassu, Anne/0000-0002-9323-2497				Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Behr MA, 2000, J BACTERIOL, V182, P3394, DOI 10.1128/JB.182.12.3394-3399.2000; BRADBURY JH, 1984, CARBOHYD RES, V126, P125, DOI 10.1016/0008-6215(84)85131-9; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Cywes C, 1997, INFECT IMMUN, V65, P4258, DOI 10.1128/IAI.65.10.4258-4266.1997; DAFFE M, 1988, BIOCHIM BIOPHYS ACTA, V958, P443, DOI 10.1016/0005-2760(88)90230-5; DAFFE M, 1988, J GEN MICROBIOL, V134, P2049; DAFFE M, 1983, ANN INST PASTEUR MIC, VB134, P241, DOI 10.1016/S0769-2609(83)80037-4; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Dische Z., 1962, METHODS CARBOHYDRATE, V1, P488; Dubnau E, 1998, MOL MICROBIOL, V29, P1526; FINE PEM, 1989, REV INFECT DIS S2, V11, P353; FINNE J, 1980, CARBOHYD RES, V80, P336, DOI 10.1016/S0008-6215(00)84873-9; Garrido JL, 1997, CYTOBIOS, V90, P47; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Jodelet A, 1998, CARBOHYD RES, V312, P139, DOI 10.1016/S0008-6215(98)00241-9; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; Lemassu A, 1996, MICROBIOL-UK, V142, P1513, DOI 10.1099/13500872-142-6-1513; LEMASSU A, 1994, BIOCHEM J, V297, P351, DOI 10.1042/bj2970351; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; MISAKI A, 1966, J BIOCHEM-TOKYO, V59, P511, DOI 10.1093/oxfordjournals.jbchem.a128335; Nseyo UO, 1997, SEMIN SURG ONCOL, V13, P342; ORTALOMAGNE A, 1995, MICROBIOL-UK, V141, P1609, DOI 10.1099/13500872-141-7-1609; OrtaloMagne A, 1996, J BACTERIOL, V178, P456, DOI 10.1128/jb.178.2.456-461.1996; Sauton B, 1912, CR HEBD ACAD SCI, V155, P860; Schwebach JR, 2002, INFECT IMMUN, V70, P2566, DOI 10.1128/IAI.70.5.2566-2575.2002; STEWART TS, 1968, BIOCHEMISTRY-US, V7, P1855, DOI 10.1021/bi00845a033; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; TORREA G, 1995, J CLIN MICROBIOL, V33, P1899, DOI 10.1128/JCM.33.7.1899-1904.1995; WANG RH, 1995, BIOCHEM J, V311, P867, DOI 10.1042/bj3110867; ZANG LH, 1991, CARBOHYD RES, V220, P1, DOI 10.1016/0008-6215(91)80001-4; Zlotta AR, 2000, INT J CANCER, V87, P844, DOI 10.1002/1097-0215(20000915)87:6<844::AID-IJC14>3.0.CO;2-5	33	55	58	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12369	12378		10.1074/jbc.M308908200	http://dx.doi.org/10.1074/jbc.M308908200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715664	Green Published, hybrid			2022-12-25	WOS:000220334900045
J	Hail, N; Konopleva, M; Sporn, M; Lotan, R; Andreeff, M				Hail, N; Konopleva, M; Sporn, M; Lotan, R; Andreeff, M			Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; CERVICAL-CARCINOMA CELLS; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION; N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED APOPTOSIS; 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OIC ACID; ENDOPLASMIC-RETICULUM; LEUKEMIA-CELLS; CANCER CELLS	The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9- dien-28-oic acid ( CDDO) is a novel anticancer agent that induces apoptosis in tumor cells. The cytotoxic stress underpinning CDDO-induced apoptosis has not been established. This study compared and contrasted the effects of CDDO on COLO 16 human skin cancer cells and their respiration-deficient (rho(0)) clones to elucidate the stress signal responsible for initiating apoptosis. CDDO promoted apoptosis in COLO 16 cells in a dose- and time-dependent manner. The rho(0) clones appeared to be more sensitive to CDDO-induced apoptosis implying that the disruption of mitochondrial respiration was not directly associated with triggering cell death. After a 4-h exposure to CDDO, mitochondrial inner transmembrane potential-sensitive dyes revealed mitochondrial hyperpolarization in the COLO 16 cells and mitochondrial depolarization in the rho(0) clones. Electron microscopy illustrated that this exposure also promoted mitochondrial condensation, endoplasmic reticulum dilation, and chromatin condensation in the COLO 16 cells. Endoplasmic reticulum dilation and chromatin condensation were also observed in the rho(0) clones, but the mitochondria in these cells were markedly swollen implying that the disruption of intracellular Ca2+ homeostasis was associated with cell death. A Ca2+-sensitive dye confirmed that CDDO increased cytoplasmic free Ca2+ in the COLO 16 cells, their rho(0) clones, as well as in malignant breast and lung epithelial cells. A cell-permeant Ca2+ chelator reduced the CDDO-induced increase in cytoplasmic free Ca2+, and inhibited caspase activation, the development of apoptotic morphology, and DNA fragmentation in the COLO 16 cells, implying that Ca2+ played a pivotal role in signaling the initiation of apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Sect Mol Hematol & Therapy, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Dartmouth Coll, Dartmouth Med Sch, Dept Pharmacol, Hanover, NH 03755 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Dartmouth College	Andreeff, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Sect Mol Hematol & Therapy, Box 448,1515 Holcombe Blvd, Houston, TX 77030 USA.	mandreef@mdanderson.org			NATIONAL CANCER INSTITUTE [P01CA055164, R01CA089346, P50CA100632, P01CA068233, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [2P30 CA16672, P01 CA55164, 1P50 CA100632-01, P01 CA68233, R01 CA89346, R25 CA57780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gunter TE, 2001, IUBMB LIFE, V52, P197, DOI 10.1080/15216540152846000; Hail N, 2002, JNCI-J NATL CANCER I, V94, P1281, DOI 10.1093/jnci/94.17.1281; Hail N, 2001, J BIOL CHEM, V276, P45614, DOI 10.1074/jbc.M106559200; Hail N, 2001, CANCER RES, V61, P6698; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; Honda T, 1999, BIOORG MED CHEM LETT, V9, P3429, DOI 10.1016/S0960-894X(99)00623-X; Ito Y, 2001, MOL PHARMACOL, V59, P1094, DOI 10.1124/mol.59.5.1094; Ito Y, 2000, CELL GROWTH DIFFER, V11, P261; James AM, 2002, J BIOMED SCI, V9, P475, DOI 10.1007/BF02254975; Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2; Joshi B, 1999, CANCER RES, V59, P4343; Kim JY, 2002, ONCOGENE, V21, P3139, DOI 10.1038/sj.onc.1205406; Kim KB, 2002, MOL CANCER THER, V1, P177; Kindmark H, 2001, J BIOL CHEM, V276, P34530, DOI 10.1074/jbc.M102492200; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lapillonne H, 2003, CANCER RES, V63, P5926; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Macho A, 1999, CELL DEATH DIFFER, V6, P155, DOI 10.1038/sj.cdd.4400465; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729; Muriel MP, 2000, J COMP NEUROL, V426, P297, DOI 10.1002/1096-9861(20001016)426:2<297::AID-CNE10>3.0.CO;2-O; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Pedersen IM, 2002, BLOOD, V100, P2965, DOI 10.1182/blood-2002-04-1174; Poppe M, 2002, J NEUROCHEM, V82, P482, DOI 10.1046/j.1471-4159.2002.01007.x; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sharma RA, 2001, EUR J CANCER, V37, P12, DOI 10.1016/S0959-8049(00)00326-9; SHERER TB, 2003, BIOCHIM BIOPHYS ACTA, V1496, P341; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Stadheim TA, 2002, J BIOL CHEM, V277, P16448, DOI 10.1074/jbc.M108974200; Suh NJ, 1999, CANCER RES, V59, P336; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Swerdlow RH, 1998, EXP NEUROL, V153, P135, DOI 10.1006/exnr.1998.6866; Szabadkai G, 2003, J BIOL CHEM, V278, P15153, DOI 10.1074/jbc.M300180200; Vandecasteele G, 2001, IUBMB LIFE, V52, P213, DOI 10.1080/15216540152846028; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Yie Q, 2002, HEPATOLOGY, V36, P592, DOI 10.1053/jhep.2002.35441; Zell R, 1997, MOL CELL BIOCHEM, V177, P61, DOI 10.1023/A:1006896832582; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	58	42	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11179	11187		10.1074/jbc.M312758200	http://dx.doi.org/10.1074/jbc.M312758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711815	hybrid			2022-12-25	WOS:000220157600043
J	Zahler, AM; Damgaard, CK; Kjems, J; Caputi, M				Zahler, AM; Damgaard, CK; Kjems, J; Caputi, M			SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRE-MESSENGER-RNA; HNRNP A1; SR PROTEINS; IN-VITRO; COOPERATIVE BINDING; SITE SELECTION; INTRON; 3'-SPLICE-SITE; IDENTIFICATION	Splicing of the human immunodeficiency virus, type 1, primary transcript is highly regulated. Maintaining the proper equilibrium among spliced, unspliced, and partially spliced isoforms is essential for the replication of the virus. Here we characterize a complex cis-acting element located in tat exon 2 that is required for the splicing regulation of the upstream intron. An exonic splicing enhancer (ESE) and an exonic splicing silencer (ESS) are both located within the regulatory element. Heterogeneous nuclear ribonucleoprotein ( hnRNP) A/B proteins bind the ESS to repress splicing, whereas the SR protein SC35 binds the ESE to activate it. We show that the SC35 and the hnRNP A1 binding sites overlap within the juxtaposed ESE/ESS. We propose that hnRNP A1 binding to the ESS inhibits splicing of the upstream intron by directly masking the SC35 binding site.	Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA; Univ Calif Santa Cruz, Dept Mol Cellular & Dev Biol, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Ctr Mol Biol RNA, Sinsheimer Labs, Santa Cruz, CA 95064 USA; Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus C, Denmark	State University System of Florida; Florida Atlantic University; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; Aarhus University	Caputi, M (corresponding author), Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA.	mcaputi@fau.edu	Damgaard, Christian K/G-7360-2015; Damgaard, Christian/AAP-3147-2021; Damgaard, Christian/AAR-4075-2020; Kjems, Jorgen/I-3490-2016	Damgaard, Christian/0000-0003-4940-0868; Kjems, Jorgen/0000-0003-4128-9317; Zahler, Alan/0000-0003-0027-1647	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061646] Funding Source: NIH RePORTER; NIAID NIH HHS [5R01AI052820-02] Funding Source: Medline; NIGMS NIH HHS [1R01GM61646] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Damgaard CK, 2002, RNA, V8, P1401, DOI 10.1017/S1355838202023075; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; DYHRMIKKELSEN H, 1995, J BIOL CHEM, V270, P24060, DOI 10.1074/jbc.270.41.24060; GOTTLINGER HG, 1992, VIROLOGY, V189, P618, DOI 10.1016/0042-6822(92)90585-D; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Graveley BR, 1999, CURR BIOL, V9, pR6, DOI 10.1016/S0960-9822(99)80032-3; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Kammler S, 2001, RNA, V7, P421, DOI 10.1017/S1355838201001212; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Mayeda A, 1999, METH MOL B, V118, P309; Nagel RJ, 1998, RNA, V4, P11; OREILLY MM, 1995, VIROLOGY, V213, P6365; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; Rabson AB, 1997, RETROVIRUSES; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Si ZH, 1997, NUCLEIC ACIDS RES, V25, P861, DOI 10.1093/nar/25.4.861; STAFFA A, 1994, J VIROL, V68, P3071, DOI 10.1128/JVI.68.5.3071-3079.1994; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tange TO, 2001, EMBO J, V20, P5748; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Wentz MP, 1997, J VIROL, V71, P8542, DOI 10.1128/JVI.71.11.8542-8551.1997; Zahler AM, 1999, METH MOL B, V118, P419; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	43	110	112	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10077	10084		10.1074/jbc.M312743200	http://dx.doi.org/10.1074/jbc.M312743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14703516	hybrid			2022-12-25	WOS:000220050400052
J	Pennati, M; Binda, M; Colella, G; Zoppe', M; Folini, M; Vignati, S; Valentini, A; Citti, L; De Cesare, M; Pratesi, G; Giacca, M; Daidone, MG; Zaffaroni, N				Pennati, M; Binda, M; Colella, G; Zoppe', M; Folini, M; Vignati, S; Valentini, A; Citti, L; De Cesare, M; Pratesi, G; Giacca, M; Daidone, MG; Zaffaroni, N			Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells	ONCOGENE			English	Article						survivin; ribozyme; prostate cancer; apoptosis; tumorigenicity	HUMAN-MELANOMA CELLS; DOWN-REGULATION; GENE-THERAPY; TUMOR-GROWTH; DEATH; PHOSPHORYLATION; PROGRESSION; RESISTANCE; RECEPTOR; BCL-2	Survivin is a member of the inhibitor of apoptosis protein (IAP) family, which has been implicated in inhibition of apoptosis and control of mitotic progression. The finding that survivin is overexpressed in most human tumors but absent in normal adult tissues has led to the proposal of survivin as a promising therapeutic target for anticancer therapies. We decided to evaluate the effects of a ribozyme-based strategy for survivin inhibition in androgen-independent human prostate cancer cells. We constructed a Moloney-based retroviral vector expressing a ribozyme targeting the 3' end of the CUA(110) triplet in survivin mRNA, encoded as a chimeric RNA within adenoviral VA1 RNA. Polyclonal cell populations obtained by infection with the retroviral vector of two androgen-independent human prostate cancer cell lines (DU145 and PC-3) were selected for the study. Ribozyme-expressing prostate cancer cells were characterized by a significant reduction of survivin expression compared to parental cells transduced with a control ribozyme; the cells became polyploid, underwent caspase-9-dependent apoptosis and showed an altered pattern of gene expression, as detected by oligonucleotide array analysis. Survivin inhibition also increased the susceptibility of prostate cancer cells to cisplatin-induced apoptosis and prevented tumor formation when cells were xenografted in athymic nude mice. These findings suggest that manipulation of the antiapoptotic survivin pathway may provide a novel approach for the treatment of androgen-independent prostate cancer.	Ist Nazl Studio & Cura Tumori, Dipartimento Oncol Sperimentale, I-20133 Milan, Italy; CNR, Ist Fisiol Clin, I-56100 Pisa, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); International Center for Genetic Engineering & Biotechnology (ICGEB)	Zaffaroni, N (corresponding author), Ist Nazl Tumori, Dipartimento Oncol Sperimentale, Unita Operat 10, Via Venezian 1, I-20133 Milan, Italy.	nadia.zaffaroni@istitutotumori.mi.it	Zaffaroni, Nadia/J-8178-2016; Folini, Marco/B-9607-2017; De Cesare, Michelandrea/M-6667-2017; Daidone, Maria Grazia/E-9232-2017; Giacca, Mauro/J-9287-2016; Pennati, Marzia/K-2554-2016	Zaffaroni, Nadia/0000-0002-4669-0890; Folini, Marco/0000-0002-1811-4407; De Cesare, Michelandrea/0000-0001-9687-0753; Daidone, Maria Grazia/0000-0002-4786-1321; Giacca, Mauro/0000-0003-2927-7225; Pennati, Marzia/0000-0002-6181-2681; Colella, Gennaro/0000-0001-9132-8375; ZOPPE', Monica/0000-0003-4590-0718				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x; Cagnon L, 2000, ANTISENSE NUCLEIC A, V10, P251, DOI 10.1089/108729000421439; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Denmeade SR, 1996, PROSTATE, V28, P251; Dennis LK, 2000, PROSTATE, V42, P247; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Giodini A, 2002, CANCER RES, V62, P2462; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Honda T, 2001, ANTICANCER RES, V21, P3141; Howell SB, 2000, MOL UROL, V4, P225; Kore AR, 1998, NUCLEIC ACIDS RES, V26, P4116, DOI 10.1093/nar/26.18.4116; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lewin AS, 2001, TRENDS MOL MED, V7, P221, DOI 10.1016/S1471-4914(01)01965-7; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; McEleny KR, 2002, PROSTATE, V51, P133, DOI 10.1002/pros.10061; Mendoza-Maldonado R, 2002, CANCER GENE THER, V9, P71, DOI 10.1038/sj/cgt/7700410; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Olie RA, 2000, CANCER RES, V60, P2805; Pennati M, 2003, J INVEST DERMATOL, V120, P648, DOI 10.1046/j.1523-1747.2003.12082.x; Pennati M, 2002, J CLIN INVEST, V109, P285; Prislei S, 1997, RNA, V3, P677; Somia NV, 2000, J VIROL, V74, P4420, DOI 10.1128/JVI.74.9.4420-4424.2000; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wall NR, 2003, CANCER RES, V63, P230; Workman P, 1998, BRIT J CANCER, V77, P1; Zaffaroni N, 2002, CELL MOL LIFE SCI, V59, P1406, DOI 10.1007/s00018-002-8518-3	37	77	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					386	394		10.1038/sj.onc.1207071	http://dx.doi.org/10.1038/sj.onc.1207071			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724567				2022-12-25	WOS:000188098300008
J	Vargiu, P; De Abajo, R; Garcia-Ranea, JA; Valencia, A; Santisteban, P; Crespo, P; Bernal, J				Vargiu, P; De Abajo, R; Garcia-Ranea, JA; Valencia, A; Santisteban, P; Crespo, P; Bernal, J			The small GTP-binding protein, Rhes, regulates signal transduction from G protein-coupled receptors	ONCOGENE			English	Article						Ras; thyroid hormone; striatum; adrenergic receptor; PC12 cells	RAS SUPERFAMILY MEMBER; BETA(2)-ADRENERGIC RECEPTOR; ACTIVATION; IDENTIFICATION; DEXRAS1; BLOCKS; CELLS; GENE; DISRUPTION; DEFICIENCY	The Ras homolog enriched in striatum, Rhes, is the product of a thyroid hormone-regulated gene during brain development. Rhes and the dexamethasone-induced Dexras1 define a novel distinct subfamily of proteins within the Ras family, characterized by an extended variable domain in the carboxyl terminal region. We have carried this study because there is a complete lack of knowledge on Rhes signaling. We show that in PC12 cells, Rhes is targeted to the plasma membrane by farnesylation. We demonstrate that about 30% of the native Rhes protein is bound to GTP and this proportion is unaltered by typical Ras family nucleotide exchange factors. However, Rhes is not transforming in murine fibroblasts. We have also examined the role of Rhes in cell signaling. Rhes does not stimulate the ERK pathway. By contrast, it binds to and activates PI3K. On the other hand, we demonstrate that Rhes impairs the activation of the cAMP/PKA pathway by thyroid-stimulating hormone, and by an activated beta2 adrenergic receptor by a mechanism that suggests uncoupling of the receptor to its cognate heterotrimeric complex. Overall, our results provide the initial insights into the role in signal transduction of this novel Ras family member.	CSIC, Inst Invest Biomed Alverto Sols, E-28029 Madrid, Spain; Univ Autonoma Madrid, Madrid 28029, Spain; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Bernal, J (corresponding author), CSIC, Inst Invest Biomed Alverto Sols, Arturo Duperier 4, E-28029 Madrid, Spain.	jbernal@iib.uam.es	Santisteban, Pilar/E-7829-2016; Bernal, Juan/J-6086-2014; Valencia, Alfonso/I-3127-2015; Crespo, Piero/M-3273-2014	Santisteban, Pilar/0000-0002-2758-796X; Bernal, Juan/0000-0002-5867-4951; Valencia, Alfonso/0000-0002-8937-6789; Garcia Ranea, Juan Antonio/0000-0003-0327-1837; Crespo, Piero/0000-0003-2825-7783				Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Bauer B, 1999, J BIOL CHEM, V274, P17763, DOI 10.1074/jbc.274.25.17763; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chan SLF, 2002, BRIT J PHARMACOL, V136, P31, DOI 10.1038/sj.bjp.0704680; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; CLANTON DJ, 1986, P NATL ACAD SCI USA, V83, P5076, DOI 10.1073/pnas.83.14.5076; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DELONG GR, 1985, DEV MED CHILD NEUROL, V27, P317; Falk JD, 1999, J NEUROSCI RES, V57, P782, DOI 10.1002/(SICI)1097-4547(19990915)57:6<782::AID-JNR3>3.0.CO;2-9; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; FARRELL FX, 1993, BIOCHEM J, V289, P349, DOI 10.1042/bj2890349; Foster R, 1996, MOL CELL BIOL, V16, P2689; Graham TE, 2001, ENDOCRINOLOGY, V142, P2631, DOI 10.1210/en.142.6.2631; Graham TE, 2002, J BIOL CHEM, V277, P10876, DOI 10.1074/jbc.M110397200; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Jaffrey SR, 2002, CHEM BIOL, V9, P1329, DOI 10.1016/S1074-5521(02)00293-4; Kemppainen RJ, 1998, J BIOL CHEM, V273, P3129, DOI 10.1074/jbc.273.6.3129; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Mott HR, 1997, BIOCHEMISTRY-US, V36, P3640, DOI 10.1021/bi962790o; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; Park J, 1997, J MOL BIOL, V273, P349, DOI 10.1006/jmbi.1997.1288; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; St Croix B, 2000, SCIENCE, V289, P1197; Takesono A, 2002, J BIOL CHEM, V277, P13827, DOI 10.1074/jbc.M201064200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vargiu P, 2001, MOL BRAIN RES, V94, P1, DOI 10.1016/S0169-328X(01)00140-1; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WITTINGHOFER A, 1995, GUIDEBOOK SMALL GTPA, P20	36	73	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					559	568		10.1038/sj.onc.1207161	http://dx.doi.org/10.1038/sj.onc.1207161			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724584				2022-12-25	WOS:000188098300027
J	Lahortiga, I; Agirre, X; Belloni, E; Vazquez, I; Larrayoz, MJ; Gasparini, P; Coco, FL; Pelicci, PG; Calasanz, MJ; Odero, MD				Lahortiga, I; Agirre, X; Belloni, E; Vazquez, I; Larrayoz, MJ; Gasparini, P; Coco, FL; Pelicci, PG; Calasanz, MJ; Odero, MD			Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells	ONCOGENE			English	Article						PRDM16/MEL1; RPN1; 1p36; 3q21; MDS (RAEB)	ACUTE MYELOID-LEUKEMIA; HEMATOLOGIC MALIGNANCIES; EVI1 EXPRESSION; GENE; 3Q21; IDENTIFICATION; MDS1/EVI1; 1P36.3; METHYLTRANSFERASES; REARRANGEMENTS	Patients with myeloid malignancies and either the 3q21q26 syndrome or t(1;3)(p36;q21) have been reported to share similar clinicopathological features and a common molecular mechanism for leukemogenesis. Overexpression of MDS1/EVI1 (3q26) or MEL1/PRDM16 (1p36), both members of the PR-domain family, has been directly implicated in the malignant transformation of this subset of neoplasias. The breakpoints in both entities are outside the genes, and the 3q21 region, where RPN1 is located, seems to act as an enhancer. MEL1 has been reported to be expressed in leukemia cells with t(1;3) and in the normal uterus and fetal kidney, but neither in bone marrow (BM) nor in other tissues, suggesting that this gene is specific to t(1;3)-positive MDS/AML. We report the molecular characterization of a t(1;3)(p36;q21) in a patient with MDS (RAEB-2). In contrast to previous studies, we demonstrate that MEL1, the PR-containing form, and MEL1S, the PR-lacking form, are widely expressed in normal tissues, including BM. The clinicopathological features and the breakpoint on 1p36 are different from cases previously described, and MEL1 is not overexpressed, suggesting a heterogeneity in myeloid neoplasias with t(1;3).	Univ Navarra, Dept Genet, Pamplona 31008, Spain; FIRC, Inst Mol Oncol, Milan, Italy; European Inst Oncol, Milan, Italy; Univ Tor Vergata, Dipartimento Biopatol & Diagnost Immagini, Rome, Italy	University of Navarra; IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Rome Tor Vergata	Odero, MD (corresponding author), Univ Navarra, Dept Genet, C Irunlarrea S-N, Pamplona 31008, Spain.	modero@unav.es	Gasparini, Patrizia/Q-7626-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Calasanz, MJ/R-5813-2016; Agirre, Xabier/ABE-4110-2020; belloni, elena/H-9909-2013; Odero/ABG-9860-2020	Gasparini, Patrizia/0000-0002-9548-3724; Calasanz, MJ/0000-0002-0374-3008; Odero/0000-0002-8858-2054; Belloni, Elena/0000-0003-3214-0780	Telethon [TGM03Z03, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Du Y, 2001, CANCER RES, V61, P8094; FICHELSON S, 1992, LEUKEMIA, V6, P93; Huang S, 2002, NAT REV CANCER, V2, P469, DOI 10.1038/nrc819; Huang Shi, 1999, Frontiers in Bioscience, V4, pd528, DOI 10.2741/Huang; Langabeer SE, 2001, BRIT J HAEMATOL, V112, P208, DOI 10.1046/j.1365-2141.2001.02569.x; Mochizuki N, 2000, BLOOD, V96, P3209, DOI 10.1182/blood.V96.9.3209.h8003209_3209_3214; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; Nishikata I, 2003, BLOOD, V102, P3323, DOI 10.1182/blood-2002-12-3944; Odero MD, 2001, GENE CHROMOSOME CANC, V31, P134, DOI 10.1002/gcc.1127; Pekarsky Y, 1997, CANCER RES, V57, P3914; Rynditch A, 1997, GENE, V193, P49, DOI 10.1016/S0378-1119(97)00076-0; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; SECKERWALKER LM, 1995, BRIT J HAEMATOL, V91, P490, DOI 10.1111/j.1365-2141.1995.tb05329.x; Shimizu S, 2000, GENE CHROMOSOME CANC, V27, P229, DOI 10.1002/(SICI)1098-2264(200003)27:3<229::AID-GCC2>3.0.CO;2-0; Soderholm J, 1997, LEUKEMIA, V11, P352, DOI 10.1038/sj.leu.2400584; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Vinatzer U, 2003, GENE CHROMOSOME CANC, V36, P80, DOI 10.1002/gcc.10144; Wieser R, 2002, LEUKEMIA LYMPHOMA, V43, P59, DOI 10.1080/10428190210196; Xinh PT, 2003, GENE CHROMOSOME CANC, V36, P313, DOI 10.1002/gcc.10176	19	24	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					311	316		10.1038/sj.onc.1206923	http://dx.doi.org/10.1038/sj.onc.1206923			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712237	Green Published			2022-12-25	WOS:000187895300034
J	Pernot, L; Chesnel, L; Le Gouellec, A; Croize, J; Vernet, T; Dideberg, O; Dessen, A				Pernot, L; Chesnel, L; Le Gouellec, A; Croize, J; Vernet, T; Dideberg, O; Dessen, A			A PBP2x from a clinical isolate of Streptococcus pneumoniae exhibits an alternative mechanism for reduction of susceptibility to beta-lactam antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN 2X; PENICILLIN-RESISTANT; CRYSTAL-STRUCTURE; GENES; KINETICS; 2B; TRANSPEPTIDASE; DEACYLATION; MUTATIONS; DIVERSITY	The human pathogen Streptococcus pneumoniae is one of the main causative agents of respiratory tract infections. At present, clinical isolates of S. pneumoniae often exhibit decreased susceptibility toward beta-lactams, a phenomenon linked to multiple mutations within the penicillin-binding proteins (PBPs). PBP2x, one of the six PBPs of S. pneumoniae, is the first target to be modified under antibiotic pressure. By comparing 89 S. pneumoniae PBP2x sequences from clinical and public data bases, we have identified one major group of sequences from drug-sensitive strains as well as two distinct groups from drug-resistant strains. The first group includes proteins that display high similarity to PBP2x from the well characterized resistant strain Sp328. The second group includes sequences in which a signature mutation, Q552E, is found adjacent to the third catalytic motif. In this work, a PBP2x from a representative strain from the latter group ( S. pneumoniae 5259) was biochemically and structurally characterized. Phenotypical analyses of transformed pneumococci show that the Q552E substitution is responsible for most of the reduction of strain susceptibility toward beta-lactams. The crystal structure of 5259-PBP2x reveals a change in polarity and charge distribution around the active site cavity, as well as rearrangement of strand beta3, emulating structural changes observed for other PBPs that confer drug resistance to Gram-positive pathogens. Interestingly, the active site of 5259-PBP2x is in closed conformation, whereas that of Sp328-PBP2x is open. Consequently, S. pneumoniae has evolved to employ the same protein in two distinct mechanisms of antibiotic resistance.	UJF, CNRS,CEA, Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, F-38027 Grenoble, France; UJF, CNRS,CEA, Inst Biol Struct Jean Pierre Ebel, Lab Ingn Macromol, F-38027 Grenoble, France; CHU Grenoble, Bacteriol Lab, F-38400 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Dessen, A (corresponding author), UJF, CNRS,CEA, Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	dessen@ibs.fr	Le Gouellec, audrey/AAC-3013-2019; le gouellec, audrey/M-6072-2014; Vernet, Thierry/G-1118-2012	Le Gouellec, audrey/0000-0002-4905-3854; chesnel, laurent/0000-0002-4947-5029; Dessen, Andrea/0000-0001-6487-4020				Appelbaum PC, 2002, CLIN INFECT DIS, V34, P1613, DOI 10.1086/340400; Asahi Y, 1999, ANTIMICROB AGENTS CH, V43, P1252, DOI 10.1128/AAC.43.5.1252; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chesnel L, 2003, J BIOL CHEM, V278, P44448, DOI 10.1074/jbc.M305948200; COFFEY TJ, 1991, MOL MICROBIOL, V5, P2255, DOI 10.1111/j.1365-2958.1991.tb02155.x; Dessen A, 2001, J BIOL CHEM, V276, P45106, DOI 10.1074/jbc.M107608200; Di Guilmi AM, 2000, ANAL BIOCHEM, V284, P240, DOI 10.1006/abio.2000.4735; Di Guilmi AM, 2003, J BACTERIOL, V185, P4418, DOI 10.1128/JB.185.15.4418-4423.2003; du Plessis M, 2002, ANTIMICROB AGENTS CH, V46, P2349, DOI 10.1128/AAC.46.8.2349-2357.2002; FRERE JM, 1975, EUR J BIOCHEM, V57, P343, DOI 10.1111/j.1432-1033.1975.tb02307.x; Ghuysen Jean-Marie, 1994, Trends in Microbiology, V2, P372, DOI 10.1016/0966-842X(94)90614-9; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; Gordon E, 2000, J MOL BIOL, V299, P477, DOI 10.1006/jmbi.2000.3740; Grebe T, 1996, ANTIMICROB AGENTS CH, V40, P829, DOI 10.1128/AAC.40.4.829; HAKENBECK R, 1986, EUR J BIOCHEM, V157, P101, DOI 10.1111/j.1432-1033.1986.tb09644.x; Hakenbeck R, 2001, INFECT IMMUN, V69, P2477, DOI 10.1128/IAI.69.4.2477-2486.2001; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; JAMIN M, 1993, BIOCHEM J, V292, P735, DOI 10.1042/bj2920735; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krauss J, 1996, MICROB DRUG RESIST, V2, P183, DOI 10.1089/mdr.1996.2.183; LAIBLE G, 1991, MOL MICROBIOL, V5, P1993, DOI 10.1111/j.1365-2958.1991.tb00821.x; LAIBLE G, 1991, J BACTERIOL, V173, P6986, DOI 10.1128/jb.173.21.6986-6990.1991; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lim D, 2002, NAT STRUCT BIOL, V9, P870, DOI 10.1038/nsb858; Lu WP, 2001, J BIOL CHEM, V276, P31494, DOI 10.1074/jbc.M102499200; McCormick AW, 2003, NAT MED, V9, P424, DOI 10.1038/nm839; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mouz N, 1998, P NATL ACAD SCI USA, V95, P13403, DOI 10.1073/pnas.95.23.13403; Mouz N, 1999, J BIOL CHEM, V274, P19175, DOI 10.1074/jbc.274.27.19175; Nagai K, 2002, ANTIMICROB AGENTS CH, V46, P1273, DOI 10.1128/AAC.46.5.1273-1280.2002; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Pares S, 1996, NAT STRUCT BIOL, V3, P284, DOI 10.1038/nsb0396-284; Sauvage E, 2002, CELL MOL LIFE SCI, V59, P1223, DOI 10.1007/s00018-002-8500-0; Thomas B, 2001, BIOCHEMISTRY-US, V40, P15811, DOI 10.1021/bi011368r; van Heijenoort J, 1998, CELL MOL LIFE SCI, V54, P300, DOI 10.1007/s000180050155; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; Zhao GS, 1997, J BACTERIOL, V179, P4901, DOI 10.1128/jb.179.15.4901-4908.1997	42	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16463	16470		10.1074/jbc.M313492200	http://dx.doi.org/10.1074/jbc.M313492200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14734544	hybrid			2022-12-25	WOS:000220747900094
J	Butler, GS; Tam, EM; Overall, CM				Butler, GS; Tam, EM; Overall, CM			The canonical methionine 392 of matrix metalloproteinase 2 (gelatinase A) is not required for catalytic efficiency or structural integrity - Probing the role of the methionine-turn in the metzincin metalloprotease superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; C-TERMINAL DOMAIN; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; BINDING-PROPERTIES; IV COLLAGENASE; ACTIVATION; TIMP-2; MODULES; IDENTIFICATION	Matrix metalloproteinases (MMPs) are an important family of extracellular proteases that process a variety of biologically significant molecules. MMPs are members of the metzincin superfamily of >770 zinc endopeptidases, which includes astacins, serralysins, adamalysins, leishmanolysins, and snapalysins. Metzincins are characterized by an absolutely conserved methionine residue COOH-terminal to the third histidine in the consensus sequence HEXXHXXGXX(H/D), where the histidine residues chelate a catalytic zinc ion. The canonical methionine is part of a tight 1,4-beta-turn that loops the polypeptide chain beneath the catalytic zinc ion, forming a hydrophobic floor to the Zn2+ ion binding site. The role of this methionine is uncertain, but its absolute conservation indicates an essential catalytic or structural function. To investigate this hypothesis, we replaced Met-392 that forms the Met-turn of human MMP-2 (gelatinase A) by site-directed mutagenesis. The catalytic competence of leucine and serine mutants was assessed. (M392L) MMP-2 and (M392S) MMP-2 cleaved the physiological substrates gelatin, native type I collagen, and the chemokine monocyte chemoattractant protein-3 with similar efficiency to wild-type MMP-2. These mutants also cleaved two quenched fluorescent peptide substrates with a k(cat)/K-m comparable to wild-type MMP-2 and underwent 4-aminophenylmercuric acetate-induced autoactivation with similar kinetics. (M392L) MMP-2 and (M392S) MMP-2 were inhibited by tissue inhibitor of metalloproteinases (TIMP)-1, -2, and -4 and by the zinc chelators 1,10-phenanthroline and a synthetic hydroxamate inhibitor, Batimastat, similar to the wild-type protein, indicating an unaltered active site topography. A tryptic susceptibility assay also suggested that (M392L) MMP-2 and (M392S) MMP-2 were correctly folded. These results challenge the dogma that this methionine residue and the Met-turn, which are absolutely conserved in all of the subfamilies of the metzincins, play an essential role in catalysis or active site structure.	Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Ctr Blood Res, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Overall, CM (corresponding author), Univ British Columbia, Dept Oral Biol & Med Sci, 2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	chris.overall@ubc.ca	Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Bigg HF, 2001, CANCER RES, V61, P3610; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Butler GS, 2002, J BIOL CHEM, V277, P17511, DOI 10.1074/jbc.M201461200; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fingleton B, 2003, EXPERT OPIN THER TAR, V7, P385, DOI 10.1517/14728222.7.3.385; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Hege T, 2001, J MOL BIOL, V314, P181, DOI 10.1006/jmbi.2001.5125; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; PIELAK GJ, 1985, NATURE, V313, P152, DOI 10.1038/313152a0; Pieper M, 1997, J PROTEIN CHEM, V16, P637, DOI 10.1023/A:1026327125333; QORONFLEH MW, 1995, J BIOTECHNOL, V39, P119, DOI 10.1016/0168-1656(94)00149-7; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119	38	36	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15615	15620		10.1074/jbc.M312727200	http://dx.doi.org/10.1074/jbc.M312727200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14732714	hybrid			2022-12-25	WOS:000220594700133
J	Sancenon, V; Puig, S; Mateu-Andres, I; Dorcey, E; Thiele, DJ; Penarrubia, L				Sancenon, V; Puig, S; Mateu-Andres, I; Dorcey, E; Thiele, DJ; Penarrubia, L			The Arabidopsis copper transporter COPT1 functions in root elongation and pollen development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLENE RESPONSE PATHWAY; HORDEUM-VULGARE L.; SACCHAROMYCES-CEREVISIAE; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; TRANSCRIPTION FACTORS; TRANSGENIC TOBACCO; DISEASE PROTEIN; MALE-STERILITY; GENE	Copper plays a dual role in aerobic organisms, as both an essential and a potentially toxic element. To ensure copper availability while avoiding its toxic effects, organisms have developed complex homeostatic networks to control copper uptake, distribution, and utilization. In eukaryotes, including yeasts and mammals, high affinity copper uptake is mediated by the Ctr family of copper transporters. This work is the first report on the physiological function of copper transport in Arabidopsis thaliana. We have studied the expression pattern of COPT1 in transgenic plants expressing a reporter gene under the control of the COPT1 promoter. The reporter gene is highly expressed in embryos, trichomes, stomata, pollen, and root tips. The involvement of COPT1 in copper acquisition was investigated in CaMV35S::COPT1 antisense transgenic plants. Consistent with a decrease in COPT1 expression and the associated copper deprivation, these plants exhibit increased mRNA levels of genes that are down-regulated by copper, decreased rates of Cu-64 uptake by seedlings and reduced steady state levels of copper as measured by atomic absorption spectroscopy in mature leaves. Interestingly, COPT1 antisense plants also display dramatically increased root length, which is completely and specifically reversed by copper addition, and an increased sensitivity to growth inhibition by the copper-specific chelator bathocuproine disulfonic acid. Furthermore, COPT1 antisense plants exhibit pollen development defects that are specifically reversed by copper. Taken together, these studies reveal striking plant growth and development roles for copper acquisition by high affinity copper transporters.	Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Burjassot, Valencia, Spain; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; Univ Valencia, Dept Bot, E-46100 Burjassot, Valencia, Spain	University of Valencia; Duke University; University of Valencia	Penarrubia, L (corresponding author), Univ Valencia, Dept Bioquim & Biol Mol, Ave Dr Moliner 50, E-46100 Burjassot, Valencia, Spain.	penarrub@uv.es	Puig, Sergi/E-4788-2010; Peñarrubia, Lola/ABG-3141-2020	Puig, Sergi/0000-0002-1856-490X; Penarrubia, Lola/0000-0002-4059-2536	NATIONAL CANCER INSTITUTE [R24CA086307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041840] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA86307] Funding Source: Medline; NIGMS NIH HHS [GM41840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acemioglu B, 2001, J COLLOID INTERF SCI, V243, P81, DOI 10.1006/jcis.2001.7873; ALBANI D, 1992, PLANT J, V2, P331; AZOUAOU Z, 1993, SEX PLANT REPROD, V6, P199; Choi YE, 2001, PLANTA, V213, P45, DOI 10.1007/s004250000487; Clemens S, 2001, PLANTA, V212, P475, DOI 10.1007/s004250000458; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DELL B, 1994, PLANT SOIL, V167, P181, DOI 10.1007/BF00007943; FOLEY RC, 1994, PLANT MOL BIOL, V26, P435, DOI 10.1007/BF00039552; Frausto da Silva J.J.R., 1991, BIOL CHEM ELEMENTS I, P388; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; GRAHAM RD, 1975, NATURE, V254, P514, DOI 10.1038/254514a0; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Harris ED, 2000, ANNU REV NUTR, V20, P291, DOI 10.1146/annurev.nutr.20.1.291; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Himelblau E, 2000, CURR OPIN PLANT BIOL, V3, P205, DOI 10.1016/S1369-5266(00)00065-0; Himelblau E, 1998, PLANT PHYSIOL, V117, P1227, DOI 10.1104/pp.117.4.1227; Hirayama T, 1999, CELL, V97, P383, DOI 10.1016/S0092-8674(00)80747-3; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; HUNT LT, 1985, J MOL EVOL, V21, P126, DOI 10.1007/BF02100086; JEFFERSON RA, 1987, EMBO J, V6, P3901; JEWELL AW, 1988, PLANT CELL ENVIRON, V11, P273, DOI 10.1111/j.1365-3040.1988.tb01146.x; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kiegle E, 2000, PLANT J, V21, P225, DOI 10.1046/j.1365-313x.2000.00659.x; Kim SY, 1997, PLANT J, V11, P1237, DOI 10.1046/j.1365-313X.1997.11061237.x; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Marschner H., 1995, MINERAL NUTR HIGHER, V2nd ed.; MCCORMICK S, 1993, PLANT CELL, V5, P1265, DOI 10.1105/tpc.5.10.1265; Mira H, 2001, BIOCHEM J, V357, P545, DOI 10.1042/0264-6021:3570545; Mira H, 2001, PLANT J, V25, P521, DOI 10.1046/j.1365-313x.2001.00985.x; Mira Helena, 2002, P543; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NOBUTAKA M, 2000, PLANT MOL BIOL, V46, P185; Nuutila AM, 2000, PLANT SCI, V151, P85, DOI 10.1016/S0168-9452(99)00202-2; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Plesch G, 2001, PLANT J, V28, P455, DOI 10.1046/j.1365-313X.2001.01166.x; PRESCOTT A, 1987, PLANT MOL BIOL REP, V4, P219, DOI DOI 10.1007/BF02675414; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Rodriguez FI, 1999, SCIENCE, V283, P996, DOI 10.1126/science.283.5404.996; SALT DE, 1995, PLANT PHYSIOL, V109, P1427, DOI 10.1104/pp.109.4.1427; Sancenon V, 2003, PLANT MOL BIOL, V51, P577, DOI 10.1023/A:1022345507112; Scheres B, 1998, CURR OPIN PLANT BIOL, V1, P32, DOI 10.1016/S1369-5266(98)80124-6; Sedbrook JC, 2002, PLANT CELL, V14, P1635, DOI 10.1105/tpc.002360; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; Villanueva MTO, 2001, INT J FOOD SCI NUTR, V52, P243, DOI 10.1080/713671783; WETERINGS K, 1992, PLANT MOL BIOL, V18, P1101, DOI 10.1007/BF00047713; Woeste KE, 2000, PLANT CELL, V12, P443, DOI 10.1105/tpc.12.3.443; Wojnarowiez G, 2002, PLANT SCI, V162, P843, DOI 10.1016/S0168-9452(02)00036-5; WORRALL D, 1992, PLANT CELL, V4, P759, DOI 10.1105/tpc.4.7.759; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787	56	183	197	5	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15348	15355		10.1074/jbc.M313321200	http://dx.doi.org/10.1074/jbc.M313321200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14726516	hybrid			2022-12-25	WOS:000220594700104
J	Surana, NK; Cutter, D; Barenkamp, SJ; St Geme, JW				Surana, NK; Cutter, D; Barenkamp, SJ; St Geme, JW			The Haemophilus influenzae Hia autotransporter contains an unusually short trimeric translocator domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROCOLONY FORMATION; ESCHERICHIA-COLI; MEMBRANE PROTEIN; IDENTIFICATION; PREDICTION; SECRETION; TRANSPORT; DETERMINANTS; ADHERENCE; ADHESIN	Gram-negative bacterial autotransporter proteins are a growing group of virulence factors that are characterized by their ability to cross the outer membrane without the help of accessory proteins. A conserved C-terminal beta-domain is critical for targeting of autotransporters to the outer membrane and for translocation of the N-terminal "passenger" domain to the bacterial surface. We have demonstrated previously that the Haemophilus influenzae Hia adhesin belongs to the autotransporter family, with translocator activity residing in the C-terminal 319 residues. To gain further insight into the mechanism of autotransporter protein translocation, we performed a structure-function analysis on Hia. In initial experiments, we generated a series of in-frame deletions and a set of chimeric proteins containing varying regions of the Hia C terminus fused to a heterologous passenger domain and discovered that the final 76 residues of Hia are both necessary and sufficient for translocation. Analysis by flow cytometry revealed that the region N-terminal to this shortened translocator domain is surface localized, further suggesting that this region is not involved in beta-barrel formation or in translocation of the passenger domain. Western analysis demonstrated that the translocation-competent regions of the C terminus migrated at masses consistent with trimers, suggesting that the Hia C terminus oligomerizes. Furthermore, fusion proteins containing a heterologous passenger domain demonstrated that similarly small C-terminal regions of Yersinia sp. YadA and Neisseria meningitidis NhhA are translocation-competent. These data provide experimental support for a unique subclass of autotransporters characterized by a short trimeric translocator domain.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Pediat, St Louis, MO 63104 USA	Washington University (WUSTL); Washington University (WUSTL); Saint Louis University	St Geme, JW (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,Campus Box 8208, St Louis, MO 63110 USA.	stgeme@borcim.wustl.edu	Barenkamp, Stephen J./I-9390-2019	Barenkamp, Stephen J./0000-0002-3054-8910	NIAID NIH HHS [R01 AI44167, R01 AI48066, T32 AI0717223] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172, R01AI044167, R01AI048066] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON P, 1972, J CLIN INVEST, V51, P31, DOI 10.1172/JCI106793; Barenkamp SJ, 1996, MOL MICROBIOL, V19, P1215, DOI 10.1111/j.1365-2958.1996.tb02467.x; Brandon LD, 2001, J BACTERIOL, V183, P951, DOI 10.1128/JB.183.3.951-958.2001; CARLONE GM, 1986, J CLIN MICROBIOL, V24, P330, DOI 10.1128/JCM.24.3.330-332.1986; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Fink DL, 2003, CELL MICROBIOL, V5, P175, DOI 10.1046/j.1462-5822.2003.00266.x; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; Hendrixson DR, 1998, MOL CELL, V2, P841, DOI 10.1016/S1097-2765(00)80298-1; Hendrixson DR, 1997, MOL MICROBIOL, V26, P505, DOI 10.1046/j.1365-2958.1997.5921965.x; HERRIOTT RM, 1970, J BACTERIOL, V101, P517, DOI 10.1128/JB.101.2.517-524.1970; Hoiczyk E, 2000, EMBO J, V19, P5989, DOI 10.1093/emboj/19.22.5989; KLAUSER T, 1993, J MOL BIOL, V234, P579, DOI 10.1006/jmbi.1993.1613; KLAUSER T, 1992, EMBO J, V11, P2327, DOI 10.1002/j.1460-2075.1992.tb05292.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Laarmann S, 2002, MOL MICROBIOL, V46, P731, DOI 10.1046/j.1365-2958.2002.03189.x; Loveless BJ, 1997, MOL MEMBR BIOL, V14, P113, DOI 10.3109/09687689709048171; Maurer J, 1999, J BACTERIOL, V181, P7014, DOI 10.1128/JB.181.22.7014-7020.1999; Oliver DC, 2003, MOL MICROBIOL, V47, P1367, DOI 10.1046/j.1365-2958.2003.03377.x; Peak IRA, 2000, FEMS IMMUNOL MED MIC, V28, P329, DOI 10.1111/j.1574-695X.2000.tb01494.x; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Roggenkamp A, 2003, J BACTERIOL, V185, P3735, DOI 10.1128/JB.185.13.3735-3744.2003; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J, 2001, MOL CLONING LAB MANU; SCHIRMER T, 1993, PROTEIN SCI, V2, P1361, DOI 10.1002/pro.5560020820; Schulz GE, 2002, BBA-BIOMEMBRANES, V1565, P308, DOI 10.1016/S0005-2736(02)00577-1; Schulz GE, 2000, CURR OPIN STRUC BIOL, V10, P443, DOI 10.1016/S0959-440X(00)00120-2; SETLOW JK, 1968, J BACTERIOL, V95, P546, DOI 10.1128/JB.95.2.546-558.1968; Shannon JL, 1999, J BACTERIOL, V181, P5838, DOI 10.1128/JB.181.18.5838-5842.1999; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; St Geme JW, 1998, INFECT IMMUN, V66, P364; St Geme JW, 2000, J BACTERIOL, V182, P6005, DOI 10.1128/JB.182.21.6005-6013.2000; Stathopoulos C, 2000, MICROBES INFECT, V2, P1061, DOI 10.1016/S1286-4579(00)01260-0; STGEME JW, 1993, P NATL ACAD SCI USA, V90, P2875, DOI 10.1073/pnas.90.7.2875; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Suzuki T, 1995, J BIOL CHEM, V270, P30874, DOI 10.1074/jbc.270.52.30874; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; Veiga E, 1999, MOL MICROBIOL, V33, P1232, DOI 10.1046/j.1365-2958.1999.01571.x; Veiga E, 2002, EMBO J, V21, P2122, DOI 10.1093/emboj/21.9.2122; YEO HJ, 2004, IN PRESS EMBO J	40	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14679	14685		10.1074/jbc.M311496200	http://dx.doi.org/10.1074/jbc.M311496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14726537	hybrid			2022-12-25	WOS:000220594700027
J	Wain, R; Redfield, C; Ferguson, SJ; Smith, LJ				Wain, R; Redfield, C; Ferguson, SJ; Smith, LJ			NMR analysis shows that a b-type variant of Hydrogenobacter thermophilus cytochrome c(552) retains its native structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROME; IN-VITRO FORMATION; CHEMICAL-SHIFTS; HEME; PROTEIN; MATURATION; ASSIGNMENT; BIOGENESIS; CONVERSION; FORMS	Conversion of Hydrogenobacter thermophilus cytochrome c(552) into a b-type cytochrome by mutagenesis of both heme-binding cysteines to alanines significantly reduces the stability of the protein ( Tomlinson, E. J., and Ferguson, S. J. ( 2000) Proc. Natl. Acad. Sci. U. S. A. 97, 5156 - 5160). To understand the effects of this change on the structure and dynamics of the protein, heteronuclear N-15-edited NMR techniques have been used to characterize this b-type variant. The backbone N-15, H-1(N), and H-1(alpha), and H-1(beta) resonances of the protein have been assigned. Analysis of (3)J(HN)alpha coupling constants, nuclear Overhauser enhancement intensities, and chemical shift index data demonstrates that the four alpha-helices present in the wild-type protein are retained in the b-type variant. Comparison of the chemical shifts for the b-type and wild-type proteins indicates that the tertiary structures of the two proteins are closely similar. Some subtle differences are, however, observed for residues in the N-terminal region and in the vicinity of the heme-binding pocket. Hydrogen exchange studies show that there are 25 backbone amide protons that exchange very slowly in the b-type variant and confirm that the fluctuations within the b-type protein are of a similar extent to those in the wild-type protein. These data demonstrate the notable retention of the native secondary structure and tertiary fold despite the absence of covalent linkages between the heme group and the protein.	Univ Oxford, Chem Res Lab, Oxford Ctr Mol Sci, Oxford OX1 3TA, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Smith, LJ (corresponding author), Univ Oxford, Chem Res Lab, Oxford Ctr Mol Sci, Mansfield Rd, Oxford OX1 3TA, England.	lorna.smith@chem.ox.ac.uk		Redfield, Christina/0000-0001-7297-7708				Allen JWA, 2003, J BIOL CHEM, V278, P52075, DOI 10.1074/jbc.M307196200; Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Arnesano F, 2000, BIOCHEMISTRY-US, V39, P1499, DOI 10.1021/bi991831o; AVIRAM I, 1972, BIOPOLYMERS, V11, P2141, DOI 10.1002/bip.1972.360111014; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Case DA, 2000, CURR OPIN STRUC BIOL, V10, P197, DOI 10.1016/S0959-440X(00)00068-3; Clarke J, 1998, CURR OPIN STRUC BIOL, V8, P112, DOI 10.1016/S0959-440X(98)80018-3; Daltrop O, 2003, J BIOL CHEM, V278, P24308, DOI 10.1074/jbc.M301967200; Daltrop O, 2003, J BIOL CHEM, V278, P4404, DOI 10.1074/jbc.M211124200; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; Englander SW, 2000, ANNU REV BIOPH BIOM, V29, P213, DOI 10.1146/annurev.biophys.29.1.213; ENGLANDER SW, 1972, ANNU REV BIOCHEM, V41, P903, DOI 10.1146/annurev.bi.41.070172.004351; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11310, DOI 10.1021/bi9603736; Hasegawa J, 1998, BIOCHEMISTRY-US, V37, P9641, DOI 10.1021/bi9803067; Karan EF, 2002, J BIOL INORG CHEM, V7, P260, DOI 10.1007/s007750100292; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MCLACHLAN SJ, 1986, BIOCHIM BIOPHYS ACTA, V874, P274, DOI 10.1016/0167-4838(86)90026-9; McRee DE, 2001, J BIOL CHEM, V276, P6537, DOI 10.1074/jbc.M008421200; Oldfield E, 2002, ANNU REV PHYS CHEM, V53, P349, DOI 10.1146/annurev.physchem.53.082201.124235; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PETTIGREW GW, 1991, CYTOCHROMES C EVOLUT, P1; REDFIELD C, 1993, NMR MACROMOLECULES P, P71; Rosell FI, 2002, BIOCHEMISTRY-US, V41, P7811, DOI 10.1021/bi016060e; Sambongi Y, 2002, EUR J BIOCHEM, V269, P3355, DOI 10.1046/j.1432-1033.2002.03045.x; Tomlinson EJ, 2000, P NATL ACAD SCI USA, V97, P5156, DOI 10.1073/pnas.090089397; Wain R, 2001, J BIOL CHEM, V276, P45813, DOI 10.1074/jbc.M107572200; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P13	30	17	17	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15177	15182		10.1074/jbc.M311869200	http://dx.doi.org/10.1074/jbc.M311869200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14726539	hybrid			2022-12-25	WOS:000220594700084
J	Lai, KO; Chen, Y; Po, HM; Lok, KC; Gong, K; Ip, NY				Lai, KO; Chen, Y; Po, HM; Lok, KC; Gong, K; Ip, NY			Identification of the Jak/Stat proteins as novel downstream targets of EphA4 signaling in muscle - Implications in the regulation of acetylcholinesterase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; EPIDERMAL-GROWTH-FACTOR; SKELETAL-MUSCLE; NEUROMUSCULAR-JUNCTION; NEURAL DEVELOPMENT; GENE-EXPRESSION; EPHB2 RECEPTOR; JAK FAMILY; ACTIVATION; PHOSPHORYLATION	Eph receptors and their cognate ligands ephrins are important players in axon guidance and neural patterning during development of the nervous system. Much of our knowledge about the signal transduction pathways triggered by Eph receptors has been related to the modulation of actin cytoskeleton, which is fundamental in mediating the cellular responses in growth cone navigation, cell adhesion, and cell migration. In contrast, little was known about whether long term activation of Eph receptor would regulate gene expression. Here we report a novel signaling pathway of EphA4, which involves activation of the tyrosine kinase Jak2 and the transcriptional activator Stat3. Transfection of COS7 cells with EphA4, but not the kinase-dead mutant, induced tyrosine phosphorylation of Jak2, Stat1, and Stat3. Treatment of cultured C2C12 myotubes with ephrin-A1 also induced tyrosine phosphorylation of Stat3, which was abolished by the Jak2 inhibitor AG490. Moreover, Jak2 was co-immunoprecipitated with EphA4 in muscle, and both proteins were concentrated at the neuromuscular junction (NMJ) of adult muscle. By using microarray analysis, we have identified acetylcholinesterase, the critical enzyme that hydrolyzed the neurotransmitter acetylcholine at the NMJ, as a downstream target gene of the Jak/Stat pathway in muscle. More importantly, ephrin-A1 increased the expression of acetylcholinesterase protein in C2C12 myotubes, which was abolished by AG490. In contrast, ephrin-A1 reduced the expression of fibronectin mRNA in C2C12 myotubes independently of Jak2. Finally, the expression level of acetylcholinesterase in limb muscle of EphA4 null mice was significantly reduced compared with the wild-type control. Taken together, these results have identified Jak/Stat proteins as the novel downstream targets of EphA4 signaling. In addition, the present study provides the first demonstration of a potential function of Eph receptors and Jak/Stat proteins at the NMJ.	Hong Kong Univ Sci & Technol, Dept Biochem, Mol Neurosci Ctr, Clear Water Bay, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Clear Water Bay, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Mol Neurosci Ctr, Clear Water Bay, Hong Kong, Peoples R China.	BOIP@UST.HK	Lai, Kwok-On/L-7468-2019; Lai, Kwok-On/E-5182-2011; Lai, Kwok On/ABC-8046-2021	Lai, Kwok-On/0000-0002-4069-054X; Ip, Nancy Yuk-Yu/0000-0002-2763-8907				Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; CHIU AY, 1984, DEV BIOL, V103, P456, DOI 10.1016/0012-1606(84)90333-6; Choi S, 1999, ONCOGENE, V18, P5413, DOI 10.1038/sj.onc.1202917; Coonan JR, 2003, J COMP NEUROL, V458, P98, DOI 10.1002/cne.10571; Coonan JR, 2001, J COMP NEUROL, V436, P248; Cowan CA, 2002, TRENDS CELL BIOL, V12, P339, DOI 10.1016/S0962-8924(02)02317-6; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Ellis C, 1996, ONCOGENE, V12, P1727; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Frost RA, 2002, ENDOCRINOLOGY, V143, P492, DOI 10.1210/en.143.2.492; Fu AKY, 1999, MOL CELL NEUROSCI, V14, P241, DOI 10.1006/mcne.1999.0784; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gerlai R, 1999, J NEUROSCI, V19, P9538; Gerlai R, 2001, NAT REV NEUROSCI, V2, P205, DOI 10.1038/35058582; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; HARPUR AG, 1992, ONCOGENE, V7, P1347; He W, 2002, FEBS LETT, V514, P214, DOI 10.1016/S0014-5793(02)02367-0; Ip FCF, 1996, J NEUROCHEM, V67, P1607; Irie F, 2002, NAT NEUROSCI, V5, P1117, DOI 10.1038/nn964; Kami K, 2002, J HISTOCHEM CYTOCHEM, V50, P1579, DOI 10.1177/002215540205001202; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lai KO, 2003, TRENDS GENET, V19, P395, DOI 10.1016/S0168-9525(03)00147-1; Lai KO, 2001, MOL CELL NEUROSCI, V17, P1034, DOI 10.1006/mcne.2001.0997; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; Megeney LA, 1996, DEV GENET, V19, P139, DOI 10.1002/(SICI)1520-6408(1996)19:2<139::AID-DVG5>3.0.CO;2-A; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; MICHEL RN, 1994, J CELL BIOL, V127, P1061, DOI 10.1083/jcb.127.4.1061; Murai KK, 2002, NEURON, V33, P159, DOI 10.1016/S0896-6273(02)00565-2; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Murata S, 2000, MOL BRAIN RES, V78, P80, DOI 10.1016/S0169-328X(00)00077-2; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Spangenburg EE, 2002, AM J PHYSIOL-CELL PH, V283, pC204, DOI 10.1152/ajpcell.00574.2001; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Yu HH, 2001, ONCOGENE, V20, P3995, DOI 10.1038/sj.onc.1204524; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	55	66	66	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13383	13392		10.1074/jbc.M313356200	http://dx.doi.org/10.1074/jbc.M313356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729671	hybrid			2022-12-25	WOS:000220478500015
J	Prates, MV; Sforca, ML; Regis, WCB; Leite, JRSA; Silva, LP; Pertinhez, TA; Araujo, ALT; Azevedo, RB; Spisni, A; Bloch, C				Prates, MV; Sforca, ML; Regis, WCB; Leite, JRSA; Silva, LP; Pertinhez, TA; Araujo, ALT; Azevedo, RB; Spisni, A; Bloch, C			The NMR-derived solution structure of a new cationic antimicrobial peptide from the skin secretion of the anuran Hyla punctata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-RELAXATION; FROG-SKIN; SPECTROSCOPY; CELLS; KETOCONAZOLE; ANTIBIOTICS; ELUCIDATION; INFECTIONS; PRECURSOR; PROTEINS	Amphibian skin secretions constitute an important source of molecules for antimicrobial drug research in order to combat the increasing resistance of pathogens to conventional antibiotics. Among the various types of substances secreted by the dermal granular amphibian glands, there is a wide range of peptides and proteins, often displaying potent antimicrobial activities and providing an effective defense system against parasite infection. In the present work, we report the NMR solution structure and the biological activity of a cationic 14-residue amphiphilic alpha-helical polypeptide named Hylaseptin P1 ( HSP1), isolated from the skin secretion of the hylid frog Hyla punctata. The peptide antimicrobial activity was verified against Candida albicans, Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, whereas no significant lytic effect was detected toward red or white blood cells.	Embrapa Recursos Genet & Biotecnol, Lab Espectrometria Massa, Brasilia, DF, Brazil; Univ Brasilia, Inst Ciencias Biol, Dept Biol Celular, Brasilia, DF, Brazil; Ctr Biol Mol Estrutural, Lab Nacl Luz Sincrotron, Campinas, SP, Brazil; Univ Estadual Campinas, Inst Biol, Dept Bioquim, Campinas, SP, Brazil; Univ Brasilia, Inst Ciencias Biol, Dept Genet & Morfol, Brasilia, DF, Brazil; Lab SABIN Anal Clin, Brasilia, DF, Brazil; Univ Parma, Dept Expt Med, I-43100 Parma, Italy	Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Universidade de Brasilia; Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade de Brasilia; University of Parma	Bloch, C (corresponding author), Embrapa Recursos Genet & Biotecnol, Lab Espectrometria Massa, Brasilia, DF, Brazil.	cbloch@lnls.br	Bloch, Carlos/S-8375-2019; Azevedo, Ricardo/D-6273-2012; Regis, Wiliam/AAQ-3992-2020; Silva, Luciano Paulino/G-4915-2012; Régis, Wiliam/L-8797-2014; Spisni, Alberto/AAY-7778-2020; Prates, Maura/S-8399-2019; Leite, Jose Roberto/H-9065-2013	Silva, Luciano Paulino/0000-0001-9075-7725; Régis, Wiliam/0000-0002-1462-7440; Prates, Maura/0000-0002-0206-5890; Azevedo, Ricardo/0000-0002-2137-9588; Bloch Jr, Carlos/0000-0003-2799-6883; Sforca, Mauricio/0000-0002-3395-1684; Leite, Jose Roberto/0000-0002-1096-3236				Ali MF, 2002, BBA-PROTEINS PROTEOM, V1601, P55, DOI 10.1016/S1570-9639(02)00432-6; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Arikan S, 2001, CURR PHARM DESIGN, V7, P393, DOI 10.2174/1381612013398031; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; Bok AB, 1999, DRUG SAFETY, V20, P451, DOI 10.2165/00002018-199920050-00005; Brand GD, 2002, J BIOL CHEM, V277, P49332, DOI 10.1074/jbc.M209289200; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULET P, 1991, J BIOL CHEM, V266, P24520; *BYOS TECHN, 1995, INSIGHT II US GUID V; Castano S, 1999, BBA-BIOMEMBRANES, V1416, P161, DOI 10.1016/S0005-2736(98)00219-3; Chen HM, 2001, EUR J BIOCHEM, V268, P1659, DOI 10.1046/j.1432-1033.2001.02039.x; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DORNER K, 1995, CLIN LAB HAEMATOL, V17, P23; Duellman WE., 1994, BIOL AMPHIBIANS; Ellepola A N, 2000, Dent Update, V27, P165; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Giacometti A, 1999, PEPTIDES, V20, P1265, DOI 10.1016/S0196-9781(99)00131-X; Gough M, 1996, INFECT IMMUN, V64, P4922, DOI 10.1128/IAI.64.12.4922-4927.1996; Granier F, 2000, PRESSE MED, V29, P2051; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317, DOI 10.1128/AAC.43.6.1317; Johansen HK, 2002, COCHRANE DB SYST REV, V2; Kieffer AE, 2003, FASEB J, V17, P776, DOI 10.1096/fj.02-0699fje; Kuhn-Nentwig L, 2002, J BIOL CHEM, V277, P11208, DOI 10.1074/jbc.M111099200; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Kumari VK, 2001, J PEPT RES, V58, P433, DOI 10.1034/j.1399-3011.2001.00924.x; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MATSUZAKI K, 1999, BIOCHIM BIOPHYS ACTA, V1426, P1; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MORIKAWA N, 1992, BIOCHEM BIOPH RES CO, V189, P184, DOI 10.1016/0006-291X(92)91542-X; National Committee for Clinical Laboratory Standards, 1995, M27A NAT COMM CLIN L; National Committee for Clinical Laboratory Standars, 1999, M100S9 NCCLS; Ng AWK, 2003, J PHARM PHARM SCI, V6, P67; Oh JE, 1999, BIOORGAN MED CHEM, V7, P2509, DOI 10.1016/S0968-0896(99)00176-5; Park CB, 1996, BIOCHEM BIOPH RES CO, V218, P408, DOI 10.1006/bbrc.1996.0071; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pristovsek P, 2002, J COMPUT CHEM, V23, P335, DOI 10.1002/jcc.10011; Rex JH, 1997, CLIN INFECT DIS, V24, P235, DOI 10.1093/clinids/24.2.235; Simmaco M, 1998, BIOPOLYMERS, V47, P435, DOI 10.1002/(SICI)1097-0282(1998)47:6<435::AID-BIP3>3.3.CO;2-#; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STONE DJM, 1992, J CHEM SOC PERK T 1, P3173, DOI 10.1039/p19920003173; Vanhoye D, 2003, EUR J BIOCHEM, V270, P2068, DOI 10.1046/j.1432-1033.2003.03584.x; Wang YJ, 2002, J CELL BIOCHEM, V87, P147, DOI 10.1002/jcb.10282; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P40; YEAMAN MR, 2002, PHARMACOL REV, V55, P27; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	54	42	54	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13018	13026		10.1074/jbc.M310838200	http://dx.doi.org/10.1074/jbc.M310838200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715660	hybrid			2022-12-25	WOS:000220334900122
J	Sirangelo, I; Malmo, C; Iannuzzi, C; Mezzogiorno, A; Bianco, MR; Papa, M; Irace, G				Sirangelo, I; Malmo, C; Iannuzzi, C; Mezzogiorno, A; Bianco, MR; Papa, M; Irace, G			Fibrillogenesis and cytotoxic activity of the amyloid-forming apomyoglobin mutant W7FW14F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROMIDE MTT REDUCTION; FIBRIL FORMATION; PRION PROTEIN; ALZHEIMERS-DISEASE; MOLTEN GLOBULE; STRUCTURAL-CHARACTERIZATION; FAMILIAL AMYLOIDOSIS; COMMON MECHANISM; ALPHA-SYNUCLEIN; AGGREGATION	The apomyoglobin mutant W7FW14F forms amyloid-like fibrils at physiological pH. We examined the kinetics of fibrillogenesis using three techniques: the time dependence of the fluorescence emission of thioflavin T and 1-anilino-8-naphthalenesulfonate, circular dichroism measurements, and electron microscopy. We found that in the early stage of fibril formation, non-native apomyoglobin molecules containing beta-structure elements aggregate to form a nucleus. Subsequently, more molecules aggregate around the nucleus, thereby resulting in fibril elongation. We evaluated by MTT assay ( 3( 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) the cytotoxicity of these aggregates at the early stage of fibril elongation versus mature fibrils and the wild-type protein. Similar to other amyloid-forming proteins, cell toxicity was not due to insoluble mature fibrils but rather to early pre-fibrillar aggregates. Propidium iodide uptake showed that cell toxicity is the result of altered membrane permeability. Phalloidin staining showed that membrane damage is not associated to an altered cell shape caused by changes in the cytoskeleton.	Seconda Univ Studi Napoli, Dipartimento Biochim & Biofis, I-80138 Naples, Italy; Seconda Univ Studi Napoli, Dipartimento Med Pubbl Anat, I-80138 Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Irace, G (corresponding author), Seconda Univ Studi Napoli, Dipartimento Biochim & Biofis, Via L De Crecchio 7, I-80138 Naples, Italy.	gaetano.irace@unina2.it	Papa, Michele/A-7228-2017; Papa, Michele/AAB-1759-2021	Papa, Michele/0000-0003-4834-7970; Papa, Michele/0000-0002-6609-7453; Sirangelo, Ivana/0000-0002-6408-4990; IANNUZZI, Clara/0000-0003-0092-5997				Abe K, 1998, NEUROSCI RES, V31, P295, DOI 10.1016/S0168-0102(98)00055-8; Bismuto E, 1996, BIOCHEMISTRY-US, V35, P1173, DOI 10.1021/bi951163g; BISMUTO E, 1992, ARCH BIOCHEM BIOPHYS, V298, P624, DOI 10.1016/0003-9861(92)90458-9; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; CAIT E, 2000, J AM CHEM SOC, V122, P12707; Callahan NA, 2001, J BIOL CHEM, V276, P28022, DOI 10.1074/jbc.M103629200; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; Chen CD, 2001, EMBO J, V20, P6277, DOI 10.1093/emboj/20.22.6277; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, J BIOL CHEM, V276, P46714, DOI 10.1074/jbc.M107040200; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; Jacoboni I, 2000, PROTEINS, V41, P535, DOI 10.1002/1097-0134(20001201)41:4<535::AID-PROT100>3.0.CO;2-C; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; Kagan BL, 2002, PEPTIDES, V23, P1311, DOI 10.1016/S0196-9781(02)00067-0; KATAOKA M, 1995, J MOL BIOL, V249, P215, DOI 10.1006/jmbi.1995.0290; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kazmirski SL, 2002, NAT STRUCT BIOL, V9, P112, DOI 10.1038/nsb745; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 1999, BIOCHEMISTRY-US, V38, P13560, DOI 10.1021/bi991021c; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Liu YB, 1998, P NATL ACAD SCI USA, V95, P13266, DOI 10.1073/pnas.95.22.13266; Liu YB, 1997, J NEUROCHEM, V69, P2285; MacPhee CE, 2000, J MOL BIOL, V297, P1203, DOI 10.1006/jmbi.2000.3600; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; Monji A, 2000, NEUROSCI LETT, V278, P81, DOI 10.1016/S0304-3940(99)00899-X; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; NAIKI H, 1991, LAB INVEST, V65, P104; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Pertinhez TA, 2001, FEBS LETT, V495, P184, DOI 10.1016/S0014-5793(01)02384-5; Pillot T, 1999, J NEUROCHEM, V73, P1626, DOI 10.1046/j.1471-4159.1999.0731626.x; Qahwash I, 2003, J BIOL CHEM, V278, P23187, DOI 10.1074/jbc.M213298200; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; Scheibel T, 2001, CURR BIOL, V11, P366, DOI 10.1016/S0960-9822(01)00099-9; Shastry BS, 2003, NEUROCHEM INT, V43, P1, DOI 10.1016/S0197-0186(02)00196-1; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; SHEARMAN MS, 1995, J NEUROCHEM, V65, P218, DOI 10.1046/j.1471-4159.1995.65010218.x; Sirangelo I, 2003, BIOCHEMISTRY-US, V42, P312, DOI 10.1021/bi020447f; Sirangelo I, 2002, J BIOL CHEM, V277, P45887, DOI 10.1074/jbc.M207659200; SIRANGELO I, 1994, FEBS LETT, V338, P11, DOI 10.1016/0014-5793(94)80107-X; Sirangelo I, 2000, EUR J BIOCHEM, V267, P3937, DOI 10.1046/j.1432-1327.2000.01401.x; Sirangelo I, 1998, BBA-PROTEIN STRUCT M, V1385, P69, DOI 10.1016/S0167-4838(98)00038-7; Souillac PO, 2002, J BIOL CHEM, V277, P12666, DOI 10.1074/jbc.M109229200; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Weatherall DJ, 1995, OXFORD TXB MED, V2, P1512; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244; Zurdo J, 2001, J AM CHEM SOC, V123, P8141, DOI 10.1021/ja016229b	73	68	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13183	13189		10.1074/jbc.M308207200	http://dx.doi.org/10.1074/jbc.M308207200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701846	hybrid			2022-12-25	WOS:000220334900140
J	Davoodi-Semiromi, A; Laloraya, M; Kumar, GP; Purohit, S; Jha, RK; She, JX				Davoodi-Semiromi, A; Laloraya, M; Kumar, GP; Purohit, S; Jha, RK; She, JX			A mutant Stat5b with weaker DNA binding affinity defines a key defective pathway in nonobese diabetic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE; JAK-STAT; TRANSCRIPTIONAL RESPONSES; SIGNALING PATHWAYS; T-CELLS; B-CELLS; APOPTOSIS; INTERLEUKIN-2; PROLIFERATION; ERYTHROPOIETIN	A number of cytokines that finely regulate immune response have been implicated in the pathogenesis or protection of type 1 diabetes and other autoimmune diseases. It is, therefore, of pivotal importance to examine a family of proteins that serve as signal transducers and activators of transcription (STATs), which regulate the transcription of a variety of cytokines. We report here a defective gene (Stat5b) located on chromosome 11 within a previously mapped T1D susceptibility interval (Idd4) in the nonobese diabetic ( NOD) mice. Our sequencing analysis revealed a unique mutation C1462A that results in a leucine to methionine (L327M) in Stat5b of NOD mice. Leu(327), the first residue in the DNA binding domain of STAT proteins, is conserved in all identified mammalian STAT proteins. Homology modeling predicted that the mutant Stat5b has a weaker DNA binding, which was confirmed by DNA-protein binding assays. The inapt transcriptional regulation ability of the mutated Stat5b is proved by decreased levels of RNA of Stat5b-regulated genes (IL-2Rbeta and Pim1). Consequently, IL-2Rbeta and Pim1 proteins were shown by Western blotting to have lower levels in NOD compared with normal B6 mice. These proteins have been implicated in immune regulation, apoptosis, activation-induced cell death, and control of autoimmunity. Therefore, the Stat5b pathway is a key molecular defect in NOD mice.	Med Coll Georgia, Ctr Biotechnol & Genom Med, Augusta, GA 30912 USA; Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA; Devi Ahilya Univ, Sch Life Sci, Indore, Madhya Pradesh, India	University System of Georgia; Augusta University; State University System of Florida; University of Florida; Devi Ahilya University	She, JX (corresponding author), Med Coll Georgia, Ctr Biotechnol & Genom Med, 1120 15th St,PV6B108, Augusta, GA 30912 USA.	jshe@mail.mcg.edu	Kumar, Pradeep/GQA-7930-2022; Kumar, Pradeep/Y-4242-2019	Kumar, Pradeep/0000-0001-7603-3579; Purohit, Sharad/0000-0003-0385-3829	NIAID NIH HHS [P01 AI-42288] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI042288] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akashi T, 1997, INT IMMUNOL, V9, P1159, DOI 10.1093/intimm/9.8.1159; Al-Shami A, 1998, J BIOL CHEM, V273, P1058, DOI 10.1074/jbc.273.2.1058; Berns A, 1999, CANCER RES, V59, p1773S; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; CHRISTIANSON SW, 1993, DIABETES, V42, P44, DOI 10.2337/diabetes.42.1.44; Colucci F, 1996, J AUTOIMMUN, V9, P271, DOI 10.1006/jaut.1996.0034; Colucci F, 1997, P NATL ACAD SCI USA, V94, P8670, DOI 10.1073/pnas.94.16.8670; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Denny P, 1997, DIABETES, V46, P695, DOI 10.2337/diabetes.46.4.695; Desbarats L, 1996, EXPERIENTIA, V52, P1123, DOI 10.1007/BF01952111; Eilers M, 1999, MOL CELLS, V9, P1; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; GARCHON HJ, 1994, EUR J IMMUNOL, V24, P380, DOI 10.1002/eji.1830240217; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Goudy K, 2001, P NATL ACAD SCI USA, V98, P13913, DOI 10.1073/pnas.251532298; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Klebb G, 1996, CLIN IMMUNOL IMMUNOP, V81, P282, DOI 10.1006/clin.1996.0190; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; McDuffie M, 2000, CLIN IMMUNOL, V96, P119, DOI 10.1006/clim.2000.4893; Noorchashm H, 1997, DIABETES, V46, P941, DOI 10.2337/diabetes.46.6.941; Peng B, 2002, MOL ENDOCRINOL, V16, P2019, DOI 10.1210/me.2002-0108; Podolin PL, 2000, CYTOKINE, V12, P477, DOI 10.1006/cyto.1999.0609; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Riu E, 1996, P NATL ACAD SCI USA, V93, P2198, DOI 10.1073/pnas.93.5.2198; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Saxena D, 2000, NITRIC OXIDE-BIOL CH, V4, P384, DOI 10.1006/niox.2000.0286; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Serreze DV, 1996, J EXP MED, V184, P2049, DOI 10.1084/jem.184.5.2049; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Storz P, 1999, FEBS LETT, V464, P159, DOI 10.1016/S0014-5793(99)01689-0; Wilson KHS, 2003, DIABETES, V52, P2151, DOI 10.2337/diabetes.52.8.2151; Yoon JW, 2001, ANN NY ACAD SCI, V928, P200; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang YC, 2003, DIABETES, V52, P708, DOI 10.2337/diabetes.52.3.708; Zhou YC, 1999, J BIOL CHEM, V274, P29874, DOI 10.1074/jbc.274.42.29874; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	48	32	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11553	11561		10.1074/jbc.M312110200	http://dx.doi.org/10.1074/jbc.M312110200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701862	hybrid			2022-12-25	WOS:000220157600088
J	Du, LH; Lyle, CS; Obey, TB; Gaarde, WA; Muir, JA; Bennett, BL; Chambers, TC				Du, LH; Lyle, CS; Obey, TB; Gaarde, WA; Muir, JA; Bennett, BL; Chambers, TC			Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity - Evidence that mitotic Bcl-2 phosphorylation is JNK-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; C-JUN; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; MAP KINASES; PATHWAY; APOPTOSIS; GROWTH; REQUIREMENT	The c-Jun NH2-terminal kinase (JNK) subgroup of mitogen-activated protein kinases has been implicated largely in stress responses, but an increasing body of evidence has suggested that JNK also plays a role in cell proliferation and survival. We examined the effect of JNK inhibition, using either SP600125 or specific antisense oligonucleotides, on cell proliferation and cell cycle progression. SP600125 was selective for JNK in vitro and in vivo versus other kinases tested including ERK, p38, cyclin-dependent protein kinase 1 (CDK1), and CDK2. SP600125 inhibited JNK activity and KB- 3 cell proliferation with the same dose dependence, suggesting that inhibition of proliferation was a direct consequence of JNK inhibition. Inhibition of proliferation by SP600125 was associated with an increase in the G(2)-M and apoptotic fractions of cells but was not associated with p53 or p21 induction. Antisense oligonucleotides to JNK2 but not JNK1 caused highly significant inhibition of cell proliferation. Wild-type mouse fibroblasts responded similarly with proliferation inhibition and apoptosis induction, whereas c-jun(-/-) fibroblasts were refractory to the effects of SP600125, suggesting that JNK signaling to c-Jun is required for cell proliferation. Studies in synchronized KB- 3 cells indicated that SP600125 delayed transit time through S and G(2)-M phases. Correspondingly, JNK activity increased in late S phase and peaked in late G(2) phase. During synchronous mitotic progression, cyclin B levels increased concomitant with phosphorylation of c-Jun, H1 histone, and Bcl-2. In the presence of SP600125, mitotic progression was prolonged, and c-Jun phosphorylation was inhibited, but neither H1 nor Bcl-2 phosphorylation was inhibited. However, the CDK inhibitor roscovitine inhibited mitotic Bcl-2 phosphorylation. These results indicate that JNK, and more specifically the JNK2 isoform, plays a key role in cell proliferation and cell cycle progression. In addition, conclusive evidence is presented that a kinase other than JNK, most likely CDK1 or a CDK1-regulated kinase, is responsible for mitotic Bcl-2 phosphorylation.	Univ Arkansas Med Sci Hosp, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; ISIS Pharmaceut Inc, Carlsbad, CA 92008 USA; Celgene, Signal Res Div, San Diego, CA 92121 USA	University of Arkansas System; University of Arkansas Medical Sciences; Isis Pharmaceuticals Inc; Bristol-Myers Squibb; Celgene Corporation	Chambers, TC (corresponding author), Univ Arkansas Med Sci Hosp, Dept Biochem & Mol Biol, Mail Slot 516,4301 W Markham St, Little Rock, AR 72205 USA.	chamberstimothyc@uams.edu			NCI NIH HHS [CA 75577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Fan MY, 2000, CANCER RES, V60, P6403; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Rennefahrt UEE, 2002, J BIOL CHEM, V277, P29510, DOI 10.1074/jbc.M203010200; Rieder C L, 1997, Prog Cell Cycle Res, V3, P301; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	31	128	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11957	11966		10.1074/jbc.M304935200	http://dx.doi.org/10.1074/jbc.M304935200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14704147	hybrid			2022-12-25	WOS:000220157600133
J	MacKenzie, F; Duriez, P; Wong, F; Noseda, M; Karsan, A				MacKenzie, F; Duriez, P; Wong, F; Noseda, M; Karsan, A			Notch4 inhibits endothelial apoptosis via RBP-J kappa-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NOTCH4; TUMOR; FAMILY; GENE; PHOSPHORYLATION; EXPRESSION; RECEPTORS; REGULATOR; REPRESSOR; SURVIVAL	Notch4, a member of the Notch family of transmembrane receptors, is expressed primarily on endothelial cells. Activation of Notch in various cell systems has been shown to regulate cell fate decisions, partly by regulating the propensity of cells to live or die. Various studies have demonstrated a role for Notch1 in modulating apoptosis, either in a positive or negative manner. In this study, we determined that constitutively active Notch4 (Notch4 intracellular domain) inhibited endothelial apoptosis triggered by lipopolysaccharide. Notch signals are transmitted by derepression and coactivation of the transcriptional repressor, RBP-Jkappa, as well as by less well defined mechanisms that are independent of RBP-Jkappa. A Notch mutant lacking the N-terminal RAM domain showed only partial antiapoptotic activity relative to Notch4 intracellular domain but stimulated equivalent RBP-Jkappa-dependent transcriptional activity. Similarly, constitutively active RBP-Jkappa activated a full transcriptional response but only demonstrated partial antiapoptotic activity. Additional studies suggest that Notch4 provides endothelial protection in two ways: inhibition of the JNK-dependent proapoptotic pathway in an RBP-Jkappa-dependent manner and induction of an antiapoptotic pathway through an RBP-Jkappa-independent upregulation of Bcl-2. Our findings demonstrate that Notch4 activation inhibits apoptosis through multiple pathways and provides one mechanism to explain the remarkable capacity of endothelial cells to withstand apoptosis.	Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada; British Columbia Canc Agcy, Dept Med Biophys, Vancouver, BC V5Z 1L3, Canada; British Columbia Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5Z 1L3, Canada	University of British Columbia; British Columbia Cancer Agency; British Columbia Cancer Agency	Karsan, A (corresponding author), British Columbia Canc Res Ctr, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	akarsan@bccrc.ca	Karsan, Aly/K-2067-2015	Noseda, Michela/0000-0002-9553-5029; Duriez, Patrick/0000-0003-1814-2552				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Bray S, 2001, CURR BIOL, V11, pR217, DOI 10.1016/S0960-9822(01)00109-9; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Ear T, 2001, J IMMUNOL METHODS, V257, P41, DOI 10.1016/S0022-1759(01)00445-8; Fleming RJ, 1998, SEMIN CELL DEV BIOL, V9, P599, DOI 10.1006/scdb.1998.0260; Gridley T, 2001, P NATL ACAD SCI USA, V98, P5377, DOI 10.1073/pnas.101138098; Guevara NV, 2001, PHARMACOL RES, V44, P59, DOI 10.1006/phrs.2001.0840; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Hull C, 2002, J IMMUNOL, V169, P2611, DOI 10.4049/jimmunol.169.5.2611; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Jehn BM, 1999, J IMMUNOL, V162, P635; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1997, AM J PATHOL, V151, P1775; KARSAN A, 1999, HEMATOLOGY BASIC PRI, P1770; Krebs LT, 2000, GENE DEV, V14, P1343; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Lee JS, 1999, J VIROL, V73, P5166, DOI 10.1128/JVI.73.6.5166-5171.1999; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; McCright B, 2001, DEVELOPMENT, V128, P491; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Ohishi K, 2000, BLOOD, V95, P2847, DOI 10.1182/blood.V95.9.2847.009k19_2847_2854; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Shutter JR, 2000, GENE DEV, V14, P1313; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200	49	100	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11657	11663		10.1074/jbc.M312102200	http://dx.doi.org/10.1074/jbc.M312102200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701863	hybrid			2022-12-25	WOS:000220157600100
J	Borges, N; Marugg, JD; Empadinhas, N; da Costa, MS; Santos, H				Borges, N; Marugg, JD; Empadinhas, N; da Costa, MS; Santos, H			Specialized roles of the two pathways for the synthesis of mannosylglycerate in osmoadaptation and thermoadaptation of Rhodothermus marinus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTHERMOPHILE ARCHAEOGLOBUS-FULGIDUS; OSMOREGULATORY TREHALOSE SYNTHESIS; SYNTHASE PHOSPHATASE COMPLEX; SP STRAIN PCC-6803; GENETIC-CHARACTERIZATION; THERMUS-THERMOPHILUS; COMPATIBLE SOLUTES; ESCHERICHIA-COLI; SALINITY; PURIFICATION	Rhodothermus marinus responds to fluctuations in the growth temperature and/or salinity by accumulating mannosylglycerate (MG). Two alternative pathways for the synthesis of MG have been identified in this bacterium: a single-step pathway and a two-step pathway. In this work, the genetic and biochemical characterization of the two-step pathway was carried out with the goal of understanding the function of the two pathways and their regulatory mechanisms. Mannosyl-3-phosphoglycerate synthase (MPGS) of the two-step pathway was purified from R. marinus. Sequence information led to the isolation of two contiguous genes, mpgs (encoding MPGS) and mpgp ( encoding mannosyl-3-phosphoglycerate phosphatase). The recombinant MPGS had a low specific activity compared with other homologous MPGSs and contained similar to30 additional residues at the C terminus. Truncation of this extension produced a protein with a 10-fold higher specific activity. Moreover, the activity of the complete MPGS was enhanced upon incubation with R. marinus cell extracts, and protease inhibitors abolished activation. Therefore, the C-terminal peptide of MPGS was identified as a regulatory site for short term control of MG synthesis in R. marinus. The control of gene expression by heat and osmotic stress was also studied; the level of mannosylglycerate synthase involved in the single-step pathway was selectively enhanced by heat stress, whereas MPGS was overproduced in response to osmotic stress. The concomitant changes in the level of MG were assessed as well. We conclude that the two alternative pathways for the synthesis of MG are differently regulated at the level of expression to play specific roles in the adaptation of R. marinus to two different types of aggression. This is the only example of pathway multiplicity being rationalized in terms of the need to respond efficiently to distinct environmental stresses.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Univ Coimbra, Dept Bioquim, P-3000 Coimbra, Portugal; Univ Coimbra, Ctr Neurociencias & Biol Mol, P-3000 Coimbra, Portugal; Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland	Universidade Nova de Lisboa; Universidade de Coimbra; Universidade de Coimbra; Nestle SA	Santos, H (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Rua Quinta Grande 6,Apartado 127, P-2780156 Oeiras, Portugal.	santos@itqb.unl.pt	Borges, Nuno/Q-3515-2019; Empadinhas, Nuno/G-3118-2011; Borges, Nuno/A-1427-2011; Santos, Helena/B-9141-2011	Borges, Nuno/0000-0002-3277-8517; Empadinhas, Nuno/0000-0001-8938-7560; Borges, Nuno/0000-0002-3277-8517; Santos, Helena/0000-0002-8050-9485; Marugg, John/0000-0003-2657-6692; da Costa, Milton/0000-0003-4027-4412				Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; BOCK K, 1974, J CHEM SOC PERK T 2, P293, DOI 10.1039/p29740000293; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Curatti L, 1998, J BACTERIOL, V180, P6776, DOI 10.1128/JB.180.24.6776-6779.1998; De Smet KAL, 2000, MICROBIOL-UK, V146, P199, DOI 10.1099/00221287-146-1-199; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Empadinhas N, 2003, APPL ENVIRON MICROB, V69, P3272, DOI 10.1128/AEM.69.6.3272-3279.2003; Empadinhas N, 2001, J BIOL CHEM, V276, P43580, DOI 10.1074/jbc.M108054200; GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988; Goncalves LG, 2003, FEMS MICROBIOL LETT, V218, P239, DOI 10.1016/S0378-1097(02)01146-1; Hagemann M, 1997, J BACTERIOL, V179, P1727, DOI 10.1128/jb.179.5.1727-1733.1997; Hagemann M, 2001, CURR MICROBIOL, V43, P278, DOI 10.1007/s002840010301; KAASEN I, 1994, GENE, V145, P9, DOI 10.1016/0378-1119(94)90316-6; KOHLE D, 1984, BIOCHIM BIOPHYS ACTA, V799, P59, DOI 10.1016/0304-4165(84)90327-1; Lamosa P, 1998, APPL ENVIRON MICROB, V64, P3591; Lamosa P, 2000, APPL ENVIRON MICROB, V66, P1974, DOI 10.1128/AEM.66.5.1974-1979.2000; LONDESBOROUGH J, 1991, J GEN MICROBIOL, V137, P323, DOI 10.1099/00221287-137-2-323; Marin K, 1998, J BACTERIOL, V180, P4843, DOI 10.1128/JB.180.18.4843-4849.1998; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MARTINS LO, 1995, APPL ENVIRON MICROB, V61, P3299, DOI 10.1128/AEM.61.9.3299-3303.1995; Martins LO, 1999, J BIOL CHEM, V274, P35407, DOI 10.1074/jbc.274.50.35407; NUNES OC, 1992, SYST APPL MICROBIOL, V15, P92, DOI 10.1016/S0723-2020(11)80144-X; NUNES OC, 1995, APPL ENVIRON MICROB, V61, P2351, DOI 10.1128/AEM.61.6.2351-2357.1995; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santos H, 2002, ENVIRON MICROBIOL, V4, P501, DOI 10.1046/j.1462-2920.2002.00335.x; Santos H, 2001, METHOD ENZYMOL, V334, P302; Silva Z, 1999, EXTREMOPHILES, V3, P163, DOI 10.1007/s007920050112; Silva Z, 2003, J BACTERIOL, V185, P5943, DOI 10.1128/JB.185.20.5943-5952.2003; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMSON KS, 1983, BIOCHIM BIOPHYS ACTA, V759, P154, DOI 10.1016/0304-4165(83)90307-0; VICENTESOLER J, 1991, FEMS MICROBIOL LETT, V82, P157; Wolf A, 2003, MOL MICROBIOL, V49, P1119, DOI 10.1046/j.1365-2958.2003.03625.x	33	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9892	9898		10.1074/jbc.M312186200	http://dx.doi.org/10.1074/jbc.M312186200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701859	hybrid			2022-12-25	WOS:000220050400029
J	Ermak, G; Cheadle, C; Becker, KG; Harris, CD; Davies, KJA				Ermak, G; Cheadle, C; Becker, KG; Harris, CD; Davies, KJA			DSCR1 (Adapt78) modulates expression of SOD1	FASEB JOURNAL			English	Article						calcipressin 1; sod 1; oxidative stress; Down's syndrome	CU/ZN-SUPEROXIDE DISMUTASE; SYNDROME CRITICAL REGION; CALCINEURIN A-ALPHA; DOWN-SYNDROME; GENE-EXPRESSION; GLUTATHIONE-PEROXIDASE; OXIDATIVE STRESS; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; INHIBITS CALCINEURIN	DSCR1(Adapt78) is a stress responsive gene that can be induced by multiple stresses. We have previously demonstrated that acute DSCR1(Adapt78) overexpression can transiently protect cells against oxidative stress and calcium-mediated stresses, while its chronic overexpression is associated with neurofibrillary tangles, Alzheimer disease, and Down's syndrome. It seems that a delicate balance of DSCR1(Adapt78) expression is maintained in cells, and this gene can have either protective or damaging effects, depending on both its level and duration of expression. The mechanisms by which DSCR1(Adapt78) can protect or harm cells are poorly understood. Here, we tried to identify pathways and targets affected by the DSCR1(Adapt78) gene using regulated expression of DSCR1(Adapt78) in PC-12 cells, followed by microarray analysis of mRNAs from these cells. We found that DSCR1(Adapt78) expression stimulates SOD1 (intracellular Cu,Zn superoxide dismutase) gene expression and increased sod 1 enzyme activity. Previous studies have indicated that sod 1 can either protect or damage cells, depending on its levels. Our findings suggest that sod 1 may also be involved in both the acute protective and the chronic damaging effects of DSCR1(Adapt78) expression. These data also have importance for our understanding of Down's syndrome, Alzheimer's disease, and other human pathologies.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol & Computat Biol, Los Angeles, CA 90089 USA; NIA, DNA Array Unit, Res Resources Branch, NIH, Baltimore, MD 21224 USA	University of Southern California; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave, Los Angeles, CA 90089 USA.	kelvin@usc.edu		Davies, Kelvin/0000-0001-7790-3003; Becker, Kevin/0000-0002-6794-6656	NIA NIH HHS [AG16256] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG016256] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANNEREN KG, 1987, PEDIATR RES, V21, P88, DOI 10.1203/00006450-198701000-00019; Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; Barrett T, 2001, RESTOR NEUROL NEUROS, V18, P127; BROOKSBANK BWL, 1984, DEV BRAIN RES, V16, P37, DOI 10.1016/0165-3806(84)90060-9; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CEBALLOS I, 1991, FREE RADICAL RES COM, V12-3, P571; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Davies KJA, 2001, BIOFACTORS, V15, P91, DOI 10.1002/biof.5520150208; DEHAAN JB, 1995, BIOCHEM MOL BIOL INT, V35, P1281; deHaan JB, 1996, HUM MOL GENET, V5, P283, DOI 10.1093/hmg/5.2.283; Ermak G, 2002, FASEB J, V16, DOI 10.1096/fj.01-0846com; Ermak G, 2002, DRUG TODAY, V38, P509, DOI 10.1358/dot.2002.38.7.704681; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; GRONER Y, 1994, BIOMED PHARMACOTHER, V48, P231, DOI 10.1016/0753-3322(94)90138-4; Gulesserian T, 2001, J INVEST MED, V49, P41, DOI 10.2310/6650.2001.34089; Honig LS, 2000, AM J MED, V108, P317, DOI 10.1016/S0002-9343(00)00291-6; Hughes SM, 1998, CURR BIOL, V8, pR892, DOI 10.1016/S0960-9822(07)00554-4; Kayyali US, 1997, J NEUROCHEM, V68, P1668; Krebs J, 1998, BIOMETALS, V11, P375, DOI 10.1023/A:1009226316146; Leahy KP, 1999, ARCH BIOCHEM BIOPHYS, V368, P67, DOI 10.1006/abbi.1998.1059; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Mayne M, 2001, J VIROL, V75, P11641, DOI 10.1128/JVI.75.23.11641-11650.2001; Pardo JM, 1998, P NATL ACAD SCI USA, V95, P9681, DOI 10.1073/pnas.95.16.9681; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Strippoli P, 2000, GENOMICS, V64, P252, DOI 10.1006/geno.2000.6127; THASE ME, 1984, BIOL PSYCHIAT, V19, P571; Torsdottir G, 2001, PHARMACOL TOXICOL, V89, P320, DOI 10.1034/j.1600-0773.2001.d01-168.x; Vawter MP, 2001, BRAIN RES BULL, V55, P641, DOI 10.1016/S0361-9230(01)00522-6; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Yang J, 2002, INT FED INFO PROC, V87, P61; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650	43	26	29	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					62	69		10.1096/fj.03-0451com	http://dx.doi.org/10.1096/fj.03-0451com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718387				2022-12-25	WOS:000188829300040
J	Bomgarden, RD; Yean, D; Yee, MC; Cimprich, KA				Bomgarden, RD; Yean, D; Yee, MC; Cimprich, KA			A novel protein activity mediates DNA binding of an ATR-ATRIP complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZING-RADIATION; CELL-CYCLE; DAMAGE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; KINASE; REPLICATION; CHROMATIN; ACTIVATION; MEC1; RPA	The function of the ATR (ataxia-telangiectasia mutated and Rad3-related)-ATRIP (ATR-interacting protein) protein kinase complex is central to the cellular response to replication stress and DNA damage. In order to better understand the function of this complex, we have studied its interaction with DNA. We find that both ATR and ATRIP associate with chromatin in vivo, and they exist as a large molecular weight complex that can bind single-stranded ( ss) DNA cellulose in vitro. Although replication protein A (RPA) is sufficient for the recruitment of ATRIP to ssDNA, we show that a distinct ATR-ATRIP complex is able to bind to DNA with lower affinity in the absence of RPA. In this latter complex, we show that neither ATR nor ATRIP are able to bind DNA individually, nor do they bind DNA in a cooperative manner. However, the addition of HeLa nuclear extract is able to reconstitute the DNA binding of both ATR and ATRIP, suggesting the requirement for an additional protein activity. We also show that ATR is necessary for ATRIP to bind DNA in this low affinity mode and to form a large DNA binding complex. These observations suggest that there are at least two in vitro ATR-ATRIP DNA binding complexes, one which binds DNA with high affinity in an RPA-dependent manner and a second, which binds DNA with lower affinity in an RPA-independent manner but which requires an as of yet unidentified protein.	Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Cimprich, KA (corresponding author), Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA.	cimprich@stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062193] Funding Source: NIH RePORTER; NCI NIH HHS [CA09151] Funding Source: Medline; NIGMS NIH HHS [GM62193] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Melo JA, 2001, GENE DEV, V15, P2809; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Paciotti V, 2000, GENE DEV, V14, P2046; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stokes MP, 2002, J CELL BIOL, V158, P863, DOI 10.1083/jcb.200204127; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wolkow TD, 2003, BMC GENET, V4, DOI 10.1186/1471-2156-4-6; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	35	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13346	13353		10.1074/jbc.M311098200	http://dx.doi.org/10.1074/jbc.M311098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724280	hybrid			2022-12-25	WOS:000220478500011
J	Kasahara, H; Takei, K; Ueda, N; Hishiyama, S; Yamaya, T; Kamiya, Y; Yamaguchi, S; Sakakibara, H				Kasahara, H; Takei, K; Ueda, N; Hishiyama, S; Yamaya, T; Kamiya, Y; Yamaguchi, S; Sakakibara, H			Distinct isoprenoid origins of cis- and trans-zeatin biosyntheses in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKININ BIOSYNTHESIS; ABSCISIC-ACID; PATHWAY; IDENTIFICATION; MEVALONATE; DIPHOSPHATE; METABOLISM; ENCODES; GENE; ISOPENTENYLTRANSFERASE	Plants produce the common isoprenoid precursors isopentenyl diphosphate and dimethylallyl diphosphate ( DMAPP) through the methylerythritol phosphate (MEP) pathway in plastids and the mevalonate (MVA) pathway in the cytosol. To assess which pathways contribute DMAPP for cytokinin biosynthesis, metabolites from each isoprenoid pathway were selectively labeled with C-13 in Arabidopsis seedlings. Efficient C-13 labeling was achieved by blocking the endogenous pathway genetically or chemically during the feed of a C-13 labeled precursor specific to the MEP or MVA pathways. Liquid chromatography-mass spectrometry analysis demonstrated that the prenyl group of trans-zeatin (tZ) and isopentenyladenine is mainly produced through the MEP pathway. In comparison, a large fraction of the prenyl group of cis-zeatin (cZ) derivatives was provided by the MVA pathway. When expressed as fusion proteins with green fluorescent protein in Arabidopsis cells, four adenosine phosphate-isopentenyltransferases (AtIPT1, AtIPT3, AtIPT5, and AtIPT8) were found in plastids, in agreement with the idea that the MEP pathway primarily provides DMAPP to tZ and isopentenyladenine. On the other hand, AtIPT2, a tRNA isopentenyltransferase, was detected in the cytosol. Because the prenylated adenine moiety of tRNA is usually of the cZ type, the formation of cZ in Arabidopsis seedlings might involve the transfer of DMAPP from the MVA pathway to tRNA. Distinct origins of large proportions of DMAPP for tZ and cZ biosynthesis suggest that plants are able to separately modulate the level of these cytokinin species.	RIKEN, Plant Sci Ctr, Lab Commun Mech, Yokohama, Kanagawa 2300045, Japan; RIKEN, Plant Sci Ctr, Lab Cellular Growth & Dev, Yokohama, Kanagawa 2300045, Japan; Forestry & Forest Prod Res Inst, Ibaraki 3058687, Japan	RIKEN; RIKEN; Forestry & Forest Products Research Institute - Japan	Sakakibara, H (corresponding author), RIKEN, Plant Sci Ctr, Lab Commun Mech, Suehiro 1-7-22, Yokohama, Kanagawa 2300045, Japan.	sakaki@postman.riken.go.jp	Yamaguchi, Shinjiro/F-9684-2010; Kasahara, Hiroyuki/F-6445-2012; Sakakibara, Hitoshi/A-6040-2010; Barickman, Thomas/I-6993-2012; Kamiya, Yuji/F-9420-2010	Kasahara, Hiroyuki/0000-0002-4858-0978; Sakakibara, Hitoshi/0000-0001-5449-6492; Kamiya, Yuji/0000-0003-4415-520X				AKIYOSHI DE, 1984, P NATL ACAD SCI-BIOL, V81, P5994, DOI 10.1073/pnas.81.19.5994; Astot C, 2000, P NATL ACAD SCI USA, V97, P14778, DOI 10.1073/pnas.260504097; BARRY GF, 1984, P NATL ACAD SCI-BIOL, V81, P4776, DOI 10.1073/pnas.81.15.4776; CHEN CM, 1969, PHYTOCHEMISTRY, V8, P1687, DOI 10.1016/S0031-9422(00)85955-5; CHEN CM, 1981, PLANT PHYSIOL, V68, P1020, DOI 10.1104/pp.68.5.1020; CHEN CM, 1981, PLANT PHYSIOL, V67, P494, DOI 10.1104/pp.67.3.494; CHEN CM, 1984, PLANT PHYSIOL, V75, P442, DOI 10.1104/pp.75.2.442; Cheng WH, 2002, PLANT CELL, V14, P2723, DOI 10.1105/tpc.006494; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; CROWELL DN, 1992, PLANT PHYSIOL, V100, P2090, DOI 10.1104/pp.100.4.2090; Disch A, 1998, BIOCHEM J, V331, P615, DOI 10.1042/bj3310615; Dobrev PI, 2002, J CHROMATOGR A, V950, P21, DOI 10.1016/S0021-9673(02)00024-9; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Estevez JM, 2000, PLANT PHYSIOL, V124, P95, DOI 10.1104/pp.124.1.95; Giner JL, 1998, TETRAHEDRON LETT, V39, P2479, DOI 10.1016/S0040-4039(98)00310-4; Golovko A, 2002, PLANT MOL BIOL, V49, P161, DOI 10.1023/A:1014958816241; Hecht S, 2001, P NATL ACAD SCI USA, V98, P14837, DOI 10.1073/pnas.201399298; Helliwell CA, 2001, PLANT J, V28, P201, DOI 10.1046/j.1365-313X.2001.01150.x; Hemmerlin A, 2003, J BIOL CHEM, V278, P26666, DOI 10.1074/jbc.M302526200; Hirai N, 2000, BIOSCI BIOTECH BIOCH, V64, P1448, DOI 10.1271/bbb.64.1448; Inoue T, 2001, NATURE, V409, P1060, DOI 10.1038/35059117; Kakimoto T, 2001, PLANT CELL PHYSIOL, V42, P677, DOI 10.1093/pcp/pce112; Kasahara H, 2002, J BIOL CHEM, V277, P45188, DOI 10.1074/jbc.M208659200; Krall L, 2002, FEBS LETT, V527, P315, DOI 10.1016/S0014-5793(02)03258-1; Laureys F, 1998, FEBS LETT, V426, P29, DOI 10.1016/S0014-5793(98)00297-X; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; Mok DWS, 2001, ANNU REV PLANT PHYS, V52, P89, DOI 10.1146/annurev.arplant.52.1.89; Murai N, 1994, CYTOKININS CHEM ACTI, P87; NICANDER B, 1993, PLANTA, V189, P312, DOI 10.1007/BF00194427; Niwa Y, 1999, PLANT J, V18, P455, DOI 10.1046/j.1365-313X.1999.00464.x; Piaggesi A, 1997, PLANT SCI, V129, P131, DOI 10.1016/S0168-9452(97)00186-6; RAUSCHENBACH P, 1974, MESSUNG RADIOAKTIVEN, P360; Rohmer M, 2003, PURE APPL CHEM, V75, P375, DOI 10.1351/pac200375020375; Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c; Sun JQ, 2003, PLANT PHYSIOL, V131, P167, DOI 10.1104/pp.011494; Takei K, 2003, J PLANT RES, V116, P265, DOI 10.1007/s10265-003-0099-1; Takei K, 2001, J BIOL CHEM, V276, P26405, DOI 10.1074/jbc.M102130200; TAYA Y, 1978, NATURE, V271, P545, DOI 10.1038/271545a0; Yamada H, 2001, PLANT CELL PHYSIOL, V42, P1017, DOI 10.1093/pcp/pce127	41	142	153	1	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14049	14054		10.1074/jbc.M314195200	http://dx.doi.org/10.1074/jbc.M314195200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726522	hybrid			2022-12-25	WOS:000220478500094
J	Zhou, J; Schmid, T; Frank, R; Brune, B				Zhou, J; Schmid, T; Frank, R; Brune, B			PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1 alpha from pVHL-independent degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR EXPRESSION; NECROSIS-FACTOR-ALPHA; FACTOR 1-ALPHA; 3-KINASE/AKT PATHWAY; SPOT-SYNTHESIS; NITRIC-OXIDE; HIF-ALPHA; ACTIVATION; HYDROXYLATION; TRANSCRIPTION	Hypoxia inducible factor 1 (HIF-1), a heterodimeric transcription factor composed of HIF-1alpha and HIF-1beta subunits, serves as a key regulator of metabolic adaptation to hypoxia. The amount of HIF-1alpha protein is regulated either by attenuating von Hippel-Lindau protein (pVHL)-dependent ubiquitination and subsequent 26 S proteasomal degradation or by enhancing cap-dependent mRNA translation, presumably involving a phosphatidyinositol 3-kinase (PI3K)/Akt-regulated pathway. In addition, it became apparent that Hsp90 protects HIF-1alpha from oxygen-independent degradation. Here we present evidence that PI3K/Akt is required for heat shock proteins to stabilize HIF-1alpha. In pVHL-deficient renal cell carcinoma cells, PI3K inhibition by LY294002 and wortmannin or transfection of either a dominant negative PI3K or a kinase-dead Akt mutant substantially lowered constitutively expressed HIF-1alpha without altering HIF-1alpha mRNA. Inhibitors of mitogen-activated protein kinase kinase (MAPKK) such as PD98059 or the p38 MAPK inhibitor SB203580 showed no interference. Considering that PI3K inhibitors down-regulated heat shock protein 90 ( Hsp90) as well as Hsp70 expression and moreover attenuated heat- or hypoxia-induced Hsp70 as well as hypoxia-induced Hsp90 up-regulation we conclude that PI3K inhibition promoted degradation of HIF-1alpha indirectly by reducing steady state concentrations of Hsp90 and/or Hsp70. HIF-1alpha co-immunoprecipitated with Hsp90/Hsp70 and direct binding of Hsp70 to the oxygen-dependent degradation domain ( ODD) of HIF-1alpha was proven by a pull-down assay and a peptide array. PI3K-mediated degradation of HIF-1alpha was confirmed in HEK 293 cells under hypoxia, suggesting that heat shock proteins constitute an integral component for HIF-1alpha accumulation. We conclude that PI3K/Akt contributes to HIF-1alpha stabilization by provoking expression of heat shock proteins.	Univ Kaiserslautern, Fac Biol, Dept Cell Biol, D-67663 Kaiserslautern, Germany; German Res Ctr Biotechnol, GBF, Res Grp Mol Recognit, D-38124 Braunschweig, Germany	University of Kaiserslautern; Helmholtz Association; Helmholtz-Center for Infection Research	Brune, B (corresponding author), Univ Kaiserslautern, Fac Biol, Dept Cell Biol, Erwin Schroedinger Str 13-4, D-67663 Kaiserslautern, Germany.	bruene@rhrk.uni-kl.de		Schmid, Tobias/0000-0002-1952-5259				Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Baek SH, 2001, J CELL PHYSIOL, V188, P223, DOI 10.1002/jcp.1117; Blancher C, 2001, CANCER RES, V61, P7349; Bornfeldt KE, 2000, CIRC RES, V86, P1101, DOI 10.1161/01.RES.86.11.1101; Chen EY, 2001, CANCER RES, V61, P2429; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Fujii T, 2002, INT J ONCOL, V20, P955; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Hur E, 2002, MOL PHARMACOL, V62, P975, DOI 10.1124/mol.62.5.975; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kasuno K, 2004, J BIOL CHEM, V279, P2550, DOI 10.1074/jbc.M308197200; Katschinski DM, 2002, J BIOL CHEM, V277, P9262, DOI 10.1074/jbc.M110377200; Kiang JG, 2000, MOL CELL BIOCHEM, V204, P169, DOI 10.1023/A:1007016822939; Kim H, 2001, TOXICOLOGY, V167, P135, DOI 10.1016/S0300-483X(01)00426-7; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee JE, 2001, EXP NEUROL, V170, P129, DOI 10.1006/exnr.2000.7614; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Tomita M, 2000, J RADIAT RES, V41, P93, DOI 10.1269/jrr.41.93; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhong H, 2000, CANCER RES, V60, P1541; Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598	41	195	202	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13506	13513		10.1074/jbc.M310164200	http://dx.doi.org/10.1074/jbc.M310164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726529	hybrid			2022-12-25	WOS:000220478500029
J	Deguchi, H; Yegneswaran, S; Griffin, JH				Deguchi, H; Yegneswaran, S; Griffin, JH			Sphingolipids as bioactive regulators of thrombin generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; SPHINGOSINE 1-PHOSPHATE; GLA DOMAIN; FACTOR-VA; VENOUS THROMBOSIS; FACTOR-X; PROTHROMBIN ACTIVATION; ANTICOAGULANT PROTEIN; FUMONISIN EXPOSURE; ENDOTHELIAL-CELLS	Sphingolipids contribute to modulation of two opposing cell processes, cell growth and apoptotic cell death; ceramide and sphingosine promote the latter and sphingosine-1-phosphate triggers the former. Thrombin, a pro-inflammatory protease that is regulated by the blood coagulation cascade, exerts similar effects depending on cell type. Here we report a new mechanism for cross-talk between sphingolipid metabolism and thrombin generation. Sphingosine and sphinganine, but not ceramide or sphingosine-1-phosphate, down-regulated thrombin generation on platelet surfaces (IC50 = 2.4 and 1.4 muM for sphingosine and sphinganine, respectively) as well as in whole plasma clotting assays. Thrombin generation was also inhibited by glucosylsphingosine, lysosphingomyelin, phytosphingosine, and primary alkylamines with > 10 carbons. Acylation of the amino group ablated anticoagulant activities. Factor Va was required for the anticoagulant property of sphingosine because prothrombin activation was inhibited by sphingosine, sphinganine, and stearylamine in the presence but not in the absence of factor Va. Sphingosine did not inhibit thrombin generation when Gla-domainless factor Xa was used in prothrombinase assays, whereas sphingosine inhibited activation of Gla-domainless prothrombin by factor Xa/factor Va in the absence of phospholipids (IC50 = 0.49 muM). Fluorescence spectroscopy studies showed that sphingosine binds to fluorescein-labeled factor Xa and that this interaction required the Gla domain. These results imply that sphingosine disrupts interactions between factor Va and the Gla domain of factor Xa in the prothrombinase complex. Thus, certain sphingolipids may be bioactive lipid mediators of thrombin generation such that certain sphingolipid metabolites may modulate proteases that affect cell growth and death, blood coagulation, and inflammation.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Griffin, JH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM 180,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jgriffin@scripps.edu		Griffin, John/0000-0002-4302-2547; Deguchi, Hiroshi/0000-0002-7721-1207	NHLBI NIH HHS [R01 HL 21544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; BRANSON HE, 1983, LANCET, V2, P1165; Castegnaro M, 1998, J CHROMATOGR B, V720, P15, DOI 10.1016/S0378-4347(98)00446-0; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Cirino G, 2000, TRENDS PHARMACOL SCI, V21, P170, DOI 10.1016/S0165-6147(00)01469-3; CONKLING PR, 1989, J BIOL CHEM, V264, P18440; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; Deguchi H, 2002, J BIOL CHEM, V277, P8861, DOI 10.1074/jbc.M110252200; Deguchi H, 2001, BLOOD, V97, P1907, DOI 10.1182/blood.V97.7.1907; English D, 2001, CARDIOVASC RES, V49, P588, DOI 10.1016/S0008-6363(00)00230-3; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; Gennero I, 2002, J BIOL CHEM, V277, P12724, DOI 10.1074/jbc.M108933200; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; Griffin J. H., 2001, WILLIAMS HEMATOLOGY, P1435; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Koppaka V, 1996, BIOCHEMISTRY-US, V35, P7482, DOI 10.1021/bi952063d; LECOMPTE MF, 1989, BIOCHIMIE, V71, P175, DOI 10.1016/0300-9084(89)90148-X; MANN KG, 1990, BLOOD, V76, P1; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P5120, DOI 10.1021/bi9626160; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Mizuno H, 2001, P NATL ACAD SCI USA, V98, P7230, DOI 10.1073/pnas.131179698; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; ROSING J, 1988, BIOCHEMISTRY-US, V27, P9048, DOI 10.1021/bi00425a025; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; Shikamoto Y, 2003, J BIOL CHEM, V278, P24090, DOI 10.1074/jbc.M300650200; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; Takeya H, 2003, BLOOD, V102, P1693, DOI 10.1182/blood-2002-11-3607; TANABE S, 1992, THROMB RES, V67, P115, DOI 10.1016/0049-3848(92)90263-A; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; van der Westhuizen L, 1999, FOOD CHEM TOXICOL, V37, P1153, DOI 10.1016/S0278-6915(99)00113-1; Yatomi Y, 2000, BLOOD, V96, P3431; Yegneswaran S, 2003, J BIOL CHEM, V278, P14614, DOI 10.1074/jbc.M206746200; Yegneswaran S, 2002, CHEM BIOL, V9, P485, DOI 10.1016/S1074-5521(02)00132-1	40	36	36	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12036	12042		10.1074/jbc.M302531200	http://dx.doi.org/10.1074/jbc.M302531200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722105	hybrid			2022-12-25	WOS:000220334900006
J	Lindersson, E; Beedholm, R; Hojrup, P; Moos, T; Gai, WP; Hendil, KB; Jensen, PH				Lindersson, E; Beedholm, R; Hojrup, P; Moos, T; Gai, WP; Hendil, KB; Jensen, PH			Proteasomal inhibition by alpha-synuclein filaments and oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; SPORADIC PARKINSONS-DISEASE; LEWY BODIES; IN-VITRO; NEURODEGENERATIVE DISORDERS; CHAPERONE SUPPRESSION; SUBSTANTIA-NIGRA; DROSOPHILA MODEL; 20S PROTEASOME; MUTATION	A unifying feature of many neurodegenerative disorders is the accumulation of polyubiquitinated protein inclusions in dystrophic neurons, e. g. containing alpha- synuclein, which is suggestive of an insufficient proteasomal activity. We demonstrate that alpha- synuclein and 20 S proteasome components co- localize in Lewy bodies and show that subunits from 20 S proteasome particles, in contrast to subunits of the 19 S regulatory complex, bind efficiently to aggregated filamentous but not monomeric alpha- synuclein. Proteasome binding to insoluble alpha- synuclein filaments and soluble alpha- synuclein oligomers results in marked inhibition of its chymotrypsin- like hydrolytic activity through a non- competitive mechanism that is mimicked by model amyloid- Abeta peptide aggregates. Endogenous ligands of aggregated alpha- synuclein like heat shock protein 70 and glyceraldehyde- 6- phosphate dehydrogenase bind filaments and inhibit their anti- proteasomal activity. The inhibitory effect of amyloid aggregates may thus be amenable to modulation by endogenous chaperones and possibly accessible for therapeutic intervention.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Univ So Denmark, Inst Mol Biol, DK-5230 Odense M, Denmark; Univ Copenhagen, Dept Med Anat, DK-2200 Copenhagen, Denmark; Flinders Med Ctr, Dept Physiol, Bedford Pk, SA 5042, Australia; Univ Copenhagen, August Krogh Inst, DK-2100 Copenhagen O, Denmark	Aarhus University; Aarhus University; University of Southern Denmark; University of Copenhagen; Flinders Medical Centre; University of Copenhagen	Jensen, PH (corresponding author), Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark.	phj@biokemi.au.dk	Gai, Wei-Ping/A-3700-2008; Højrup, Peter/ABG-8477-2020	Jensen, Poul Henning/0000-0002-4439-9020; Hojrup, Peter/0000-0002-7838-6180; Moos, Torben/0000-0001-9989-0207				Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Baba M, 1998, AM J PATHOL, V152, P879; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Conconi M, 1999, ARCH BIOCHEM BIOPHYS, V362, P325, DOI 10.1006/abbi.1998.1037; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Elliott SJ, 1998, MOL MICROBIOL, V28, P1, DOI 10.1046/j.1365-2958.1998.00783.x; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fonager J, 2002, EXP GERONTOL, V37, P1223, DOI 10.1016/S0531-5565(02)00128-6; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Gai WP, 1999, J NEUROCHEM, V73, P2093; Gai WP, 2003, EXP NEUROL, V181, P68, DOI 10.1016/S0014-4886(03)00004-9; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hendil KB, 2002, J MOL BIOL, V315, P627, DOI 10.1006/jmbi.2001.5285; HENDIL KB, 1991, J BIOCHEM BIOPH METH, V22, P159, DOI 10.1016/0165-022X(91)90028-U; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; KRISTENSEN P, 1995, BIOCHEM BIOPH RES CO, V207, P1059, DOI 10.1006/bbrc.1995.1294; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Leveugle B, 1996, ACTA NEUROPATHOL, V91, P566, DOI 10.1007/s004010050468; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; McNaught KSP, 2002, NEUROSCI LETT, V326, P155, DOI 10.1016/S0304-3940(02)00296-3; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; Mirza B, 2000, NEUROSCIENCE, V95, P425; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rattan SIS, 1998, BIOCHEM MOL BIOL INT, V45, P753; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; Tatton WG, 2000, ADV RES NEURODEGENER, V8, P77; Tofaris GK, 2003, J BIOL CHEM, V278, P44405, DOI 10.1074/jbc.M308041200; TSUBUKI S, 1994, FEBS LETT, V344, P229, DOI 10.1016/0014-5793(94)00388-2; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398	58	290	301	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12924	12934		10.1074/jbc.M306390200	http://dx.doi.org/10.1074/jbc.M306390200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711827	hybrid			2022-12-25	WOS:000220334900110
J	Street, A; Macdonald, A; Crowder, K; Harris, M				Street, A; Macdonald, A; Crowder, K; Harris, M			The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL PROTEIN; FULL-LENGTH; CDNA-CLONE; PATHWAY; PHOSPHORYLATION; KINASE; TARGET; NEF; TRANSFORMATION; REPLICATION	Hepatitis C virus (HCV) establishes a persistent infection, with up to 80% of infected individuals proceeding to chronic hepatitis, which in many cases may result in liver cirrhosis and hepatocellular carcinoma (HCC); indeed HCV infection is increasingly associated with the development of HCC. The long time period (up to 30 years) between primary infection and the onset of HCC implies that HCV is not directly oncogenic but in some way predisposes patients to develop tumors, though the mechanism for this is unclear as yet. We report here that NS5A binds directly to the Src homology 3 domain of the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K), and this interaction is mediated by a novel (non-proline-rich) motif within NS5A. Coimmunoprecipitation analysis revealed that NS5A bound native heterodimeric PI3K and enhanced the phosphotransferase activity of the catalytic ( p110) subunit both in vitro and in human cell lines harboring a subgenomic HCV replicon or expressing NS5A alone. NS5A-mediated activation of PI3K resulted in increased phosphorylation and activity of Akt/protein kinase B and concomitantly provided protection against the induction of apoptosis in both replicon-harboring cells and cells stably expressing NS5A alone. These data suggest that stimulation of PI3K by NS5A may represent an indirect mechanism for development of HCC in HCV-infected patients and further suggests potential therapeutic strategies to counteract the occurrence of HCV-related HCC.	Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Harris, M (corresponding author), Univ Leeds, Sch Biochem & Microbiol, Mt Preston St, Leeds LS2 9JT, W Yorkshire, England.	mharris@bmb.leeds.ac.uk		Harris, Mark/0000-0002-9821-1003; Macdonald, Andrew/0000-0002-5978-4693				Aoubala M, 2001, J GEN VIROL, V82, P1637, DOI 10.1099/0022-1317-82-7-1637; Bartenschlager R, 1999, J VIRAL HEPATITIS, V6, P165, DOI 10.1046/j.1365-2893.1999.00152.x; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Djordjevic S, 2002, TRENDS BIOCHEM SCI, V27, P426, DOI 10.1016/S0968-0004(02)02136-9; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HARRIS M, 1993, J GEN VIROL, V74, P1581, DOI 10.1099/0022-1317-74-8-1581; He YP, 2003, J GEN VIROL, V84, P535, DOI 10.1099/vir.0.18658-0; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; Honda M, 2000, GASTROENTEROLOGY, V118, P152, DOI 10.1016/S0016-5085(00)70424-0; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kim WR, 2002, HEPATOLOGY, V36, pS30, DOI 10.1053/jhep.2002.36791; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; Linnemann T, 2002, VIROLOGY, V294, P246, DOI 10.1006/viro.2002.1365; Macdonald A, 2004, J GEN VIROL, V85, P721, DOI 10.1099/vir.0.19691-0; Macdonald A, 2003, J BIOL CHEM, V278, P17775, DOI 10.1074/jbc.M210900200; McCormick CJ, 2002, J GEN VIROL, V83, P383, DOI 10.1099/0022-1317-83-2-383; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Sekulic A, 2000, CANCER RES, V60, P3504; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Yanagi M, 1998, VIROLOGY, V244, P161, DOI 10.1006/viro.1998.9092; Yanagi M, 1999, VIROLOGY, V262, P250, DOI 10.1006/viro.1999.9889; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yeung MC, 2002, BIOTECHNIQUES, V33, P734, DOI 10.2144/02334bm03	36	171	183	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12232	12241		10.1074/jbc.M312245200	http://dx.doi.org/10.1074/jbc.M312245200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709551	hybrid			2022-12-25	WOS:000220334900029
J	Tan, L; Qiu, F; Lamport, DTA; Kieliszewski, MJ				Tan, L; Qiu, F; Lamport, DTA; Kieliszewski, MJ			Structure of a hydroxyproline (Hyp)-arabinogalactan polysaccharide from repetitive Ala-Hyp expressed in transgenic Nicotiana tabacum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-GLYCOSYLATION CODES; ARABINOGALACTAN-PROTEINS; CELL-WALL; ACACIA-SENEGAL; EXTRACELLULAR-MATRIX; MASS-SPECTROMETRY; GUM EXUDATE; GLYCOPROTEIN; ARABINOSYLATION; CHLAMYDOMONAS	A synthetic gene encoding the fusion protein (Ala-Hyp) (51)-enhanced green fluorescent protein expressed in Nicotiana tabacum cells produced a fusion glycoprotein with all proline residues hydroxylated and substituted with an arabinogalactan polysaccharide. Alkaline hydrolysis of the fusion glycoprotein yielded a population of hydroxyproline (Hyp)-arabinogalactan polysaccharides ranging in size from 13 to 26 saccharide residues/Hyp, with a median size of 15 - 17 residues. We isolated a 15-residue Hyp-arabinogalactan for structure determination by sugar analyses and one- and two-dimensional nuclear magnetic resonance techniques that provided the assignment of proton and carbon signals of a small polysaccharide O-linked to the hydroxyl group of Hyp. The polysaccharide consisted of a 1,3-linked beta-D-Galp backbone with a single 1,6-linked beta-D-Galp "kink.'' The backbone had two side chains of Galp substituted at position 3 with an arabinose di- or trisaccharide and at position 6 with glucuronic acid or rhamnosyl glucuronic acid. Energy-minimized space-filling molecular models showed hydrogen bonding within polysaccharides attached to repetitive Ala-Hyp and also between polysaccharides and the peptide backbone. Polysaccharides distorted the peptide Ramachandran angles consistent with the circular dichroic spectra of isolated ( Ala-Hyp) 51 and its reversion to a polyproline II-like helix after deglycosylation. This first complete structure of a Hyp-arabinogalactan polysaccharide shows that computer-based molecular modeling of Hyp-rich glycoproteins is now feasible and supports the suggestion that small repetitive subunits comprise larger arabinogalactan polysaccharides.	Ohio Univ, Dept Chem & Biochem, Athens, OH 45701 USA; Oklahoma State Univ, Dept Chem, Stillwater, OK 74078 USA; Univ Sussex, Sch Life Sci, Brighton BN1 9QG, E Sussex, England	University System of Ohio; Ohio University; Oklahoma State University System; Oklahoma State University - Stillwater; University of Sussex	Kieliszewski, MJ (corresponding author), Ohio Univ, Dept Chem & Biochem, Athens, OH 45701 USA.	kielisze@helios.phy.ohiou.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER; NCRR NIH HHS [2P41 RR 05351-06] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKIYAMA Y, 1980, AGR BIOL CHEM TOKYO, V44, P2487, DOI 10.1080/00021369.1980.10864347; AKIYAMA Y, 1981, PHYTOCHEMISTRY, V20, P2507, DOI 10.1016/0031-9422(81)83083-X; ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; BACIC A, 1988, PHYTOCHEMISTRY, V27, P679, DOI 10.1016/0031-9422(88)84074-3; BACIC A, 1987, CARBOHYD RES, V162, P85, DOI 10.1016/0008-6215(87)80203-3; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; CHURMS SC, 1983, CARBOHYD RES, V123, P267, DOI 10.1016/0008-6215(83)88483-3; CHURMS SC, 1984, CARBOHYD RES, V133, P105, DOI 10.1016/0008-6215(84)85187-3; CLARKE AE, 1979, PHYTOCHEMISTRY, V18, P521, DOI 10.1016/S0031-9422(00)84255-7; DEFAYE J, 1986, CARBOHYD RES, V150, P221, DOI 10.1016/0008-6215(86)80018-0; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Du H, 1996, TRENDS CELL BIOL, V6, P411, DOI 10.1016/S0962-8924(96)20036-4; El Khadem H. S., 1988, CARBOHYDRATE CHEM, P1; Ferris PJ, 2001, BIOCHEMISTRY-US, V40, P2978, DOI 10.1021/bi0023605; GAMMON DW, 1986, CARBOHYD RES, V154, P289, DOI 10.1016/S0008-6215(00)90043-0; Gaspar Y, 2001, PLANT MOL BIOL, V47, P161, DOI 10.1023/A:1010683432529; Gens JS, 2000, PROTOPLASMA, V212, P115, DOI 10.1007/BF01279353; GOODENOUGH UW, 1988, J CELL SCI, V90, P717; HAYASHI T, 1984, BIOCHEM J, V217, P719; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Karacsonyi S, 1998, CARBOHYD RES, V307, P271, DOI 10.1016/S0008-6215(98)00052-4; Kawaguchi K, 1996, PLANT J, V9, P777, DOI 10.1046/j.1365-313X.1996.9060777.x; KIELISZEWSKI MJ, 1995, J BIOL CHEM, V270, P2541, DOI 10.1074/jbc.270.6.2541; Kieliszewski MJ, 2001, PHYTOCHEMISTRY, V57, P319, DOI 10.1016/S0031-9422(01)00029-2; KUPCE E, 1995, J MAGN RESON SER A, V115, P273, DOI 10.1006/jmra.1995.1179; Lamport DTA, 2001, CELL MOL LIFE SCI, V58, P1363, DOI 10.1007/PL00000782; Lamport DTA, 1977, RECENT ADV PHYTOCHEM, V11, P79; MERKLE RK, 1994, METHOD ENZYMOL, V230, P1; MILLER DH, 1972, SCIENCE, V176, P918, DOI 10.1126/science.176.4037.918; Nothnagel EA, 1997, INT REV CYTOL, V174, P195, DOI 10.1016/S0074-7696(08)62118-X; Oxley D, 1999, P NATL ACAD SCI USA, V96, P14246, DOI 10.1073/pnas.96.25.14246; Phillips GO, 1996, FOOD HYDROCOLLOID, V10, P11, DOI 10.1016/S0268-005X(96)80048-8; POLLE AY, 2003, J BIOORG CHEM, V27, P45; POPE DG, 1977, PLANT PHYSIOL, V59, P894, DOI 10.1104/pp.59.5.894; QI W, 1991, PLANT PHYSIOL, V96, P848, DOI 10.1104/pp.96.3.848; Roy S, 1998, PLANTA, V204, P450, DOI 10.1007/s004250050279; SAULNIER L, 1995, CARBOHYD POLYM, V26, P279, DOI 10.1016/0144-8617(95)00020-8; SAULNIER L, 1992, CARBOHYD RES, V224, P219, DOI 10.1016/0008-6215(92)84108-5; SERPE MD, 1995, PLANT PHYSIOL, V109, P1007, DOI 10.1104/pp.109.3.1007; SERPE MD, 1994, PLANTA, V193, P542, DOI 10.1007/BF02411560; Sherrier DJ, 1999, ELECTROPHORESIS, V20, P2027, DOI 10.1002/(SICI)1522-2683(19990701)20:10<2027::AID-ELPS2027>3.0.CO;2-A; Shpak E, 1999, P NATL ACAD SCI USA, V96, P14736, DOI 10.1073/pnas.96.26.14736; Shpak E, 2001, J BIOL CHEM, V276, P11272, DOI 10.1074/jbc.M011323200; Stapley BJ, 1999, PROTEIN SCI, V8, P587; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Sumper M, 1998, INT REV CYTOL, V180, P51; Svetek J, 1999, J BIOL CHEM, V274, P14724, DOI 10.1074/jbc.274.21.14724; Tan L, 2003, PLANT PHYSIOL, V132, P1362, DOI 10.1104/pp.103.021766; TAUTVYDAS KJ, 1978, PLANTA, V140, P213, DOI 10.1007/BF00390250; TSUMURAYA Y, 1988, PLANT PHYSIOL, V86, P155, DOI 10.1104/pp.86.1.155; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1; Youl JJ, 1998, P NATL ACAD SCI USA, V95, P7921, DOI 10.1073/pnas.95.14.7921; Zhao ZD, 2002, PLANT J, V31, P431, DOI 10.1046/j.1365-313X.2002.01365.x	53	117	119	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13156	13165		10.1074/jbc.M311864200	http://dx.doi.org/10.1074/jbc.M311864200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14724279	hybrid			2022-12-25	WOS:000220334900137
J	Fiory, F; Oriente, F; Miele, C; Romano, C; Trencia, A; Alberobello, AT; Esposito, I; Valentino, R; Beguinot, F; Formisano, P				Fiory, F; Oriente, F; Miele, C; Romano, C; Trencia, A; Alberobello, AT; Esposito, I; Valentino, R; Beguinot, F; Formisano, P			Protein kinase C-zeta and protein kinase B regulate distinct steps of insulin endocytosis and intracellular sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; SKELETAL-MUSCLE; MEDIATED ENDOCYTOSIS; SIGNAL-TRANSDUCTION; RECEPTOR; PHOSPHORYLATION; INTERNALIZATION; AUTOPHOSPHORYLATION; ACTIVATION	We have investigated the molecular mechanisms regulating insulin internalization and intracellular sorting. Insulin internalization was decreased by 50% upon incubation of the cells with the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY294002. PI3K inhibition also reduced insulin degradation and intact insulin release by 50 and 75%, respectively. Insulin internalization was reduced by antisense inhibition of protein kinase C-zeta(PKCzeta) expression and by overexpression of a dominant negative PKCzeta mutant (DN-PKCzeta). Conversely, overexpression of PKCzeta increased insulin internalization as a function of the PKCzeta levels achieved in the cells. Expression of wild-type protein kinase B (PKB)-alpha or of a constitutively active form (myr-PKB) did not significantly alter insulin internalization and degradation but produced a 100% increase of intact insulin release. Inhibition of PKB by a dominant negative mutant (DN-PKB) or by the pharmacological inhibitor ML-9 reduced intact insulin release by 75% with no effect on internalization and degradation. In addition, overexpression of Rab5 completely rescued the effect of PKCzeta inhibition on insulin internalization but not that of PKB inhibition on intact insulin recycling. Indeed, PKCzeta bound to and activated Rab5. Thus, PI3K controls different steps within the insulin endocytic itinerary. PKCzeta appears to mediate the PI3K effect on insulin internalization in a Rab5-dependent manner, whereas PKB directs intracellular sorting toward intact insulin release.	Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Formisano, P (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Via S Pansini 5, I-80131 Naples, Italy.	fpietro@unina.it	Formisano, Pietro/J-4237-2018; ORIENTE, Francesco/J-6652-2018	ORIENTE, Francesco/0000-0003-4375-4526; Formisano, Pietro/0000-0001-7020-6870	Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Braiman L, 2001, MOL CELL BIOL, V21, P7852, DOI 10.1128/MCB.21.22.7852-7861.2001; Braiman L, 1999, MOL ENDOCRINOL, V13, P2002, DOI 10.1210/me.13.12.2002; Braiman L, 2001, MOL ENDOCRINOL, V15, P565, DOI 10.1210/me.15.4.565; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; Caruso M, 1997, J BIOL CHEM, V272, P7290, DOI 10.1074/jbc.272.11.7290; Caruso M, 2000, DIABETES, V49, P1194, DOI 10.2337/diabetes.49.7.1194; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; Cormont M, 1996, ENDOCRINOLOGY, V137, P3408, DOI 10.1210/en.137.8.3408; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Di Guglielmo GM, 1998, MOL CELL BIOCHEM, V182, P59, DOI 10.1023/A:1006883311233; FAN JY, 1982, P NATL ACAD SCI-BIOL, V79, P7788, DOI 10.1073/pnas.79.24.7788; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; FORMISANO P, 1994, J BIOL CHEM, V269, P16242; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; GEIGER D, 1989, EXP CELL RES, V185, P33, DOI 10.1016/0014-4827(89)90034-7; GOMEZ J, 1995, EUR J IMMUNOL, V25, P2673, DOI 10.1002/eji.1830250941; Gommerman JL, 1997, J BIOL CHEM, V272, P30519, DOI 10.1074/jbc.272.48.30519; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; MARSHALL S, 1987, J BIOL CHEM, V262, P12005; MCCLAIN DA, 1988, DIABETES, V37, P806, DOI 10.2337/diabetes.37.6.806; MCCLAIN DA, 1992, AM J MED SCI, V304, P192, DOI 10.1097/00000441-199209000-00009; Miele C, 1999, J BIOL CHEM, V274, P3094, DOI 10.1074/jbc.274.5.3094; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Smith U, 2000, BIOCHEM BIOPH RES CO, V268, P315, DOI 10.1006/bbrc.2000.2145; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; THIES RS, 1990, J BIOL CHEM, V265, P10132; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Xu JH, 1996, J CELL BIOL, V134, P1301, DOI 10.1083/jcb.134.5.1301	49	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11137	11145		10.1074/jbc.M308751200	http://dx.doi.org/10.1074/jbc.M308751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711831	hybrid			2022-12-25	WOS:000220157600038
J	Katagiri, K; Shimonaka, M; Kinashi, T				Katagiri, K; Shimonaka, M; Kinashi, T			Rap1-mediated lymphocyte function-associated antigen-1 activation by the T cell antigen receptor is dependent on phospholipase C-gamma 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ACTIVATION; RAP1-INDUCED ADHESION; SIGNAL-TRANSDUCTION; SMALL GTPASE; RAP1; MEGAKARYOCYTES; C-GAMMA-1; MIGRATION; RESPONSES; DISTINCT	The small GTPase, Rap1, is a potent activator of leukocyte integrins and enhances the adhesive activity of lymphocyte function-associated antigen-1 (LFA-1) when stimulated by the T cell receptor (TCR) or chemokines. However, the mechanism by which Rap1 is activated remains unclear. Here, we demonstrate that phospholipase C ( PLC)-gamma1 plays a critical role in the signaling pathway leading to Rap1 activation triggered by the TCR. In Jurkat T cells, TCR cross-linking triggered persistent Rap1 activation, and SDF-1 (CXCL12) activated Rap1 transiently. A phospholipase C inhibitor, U73122, abrogated Rap1 activation triggered by both the TCR and SDF-1 ( CXCL12). PLC-gamma1-deficient Jurkat T cells showed a marked reduction of TCR-triggered Rap1 activation and adhesion to intercellular adhesion molecule-1 (ICAM-1) mediated by LFA-1. In contrast, SDF-1-triggered Rap1 activation and adhesion were not affected in these cells. Transfection of these cells with an expression plasmid encoding PLC-gamma1 restored Rap1 activation by the TCR and the ability to adhere to ICAM-1, accompanied by polarized LFA-1 surface clustering colocalized with regulator of adhesion and polarization enriched in lymphoid tissues (RAPL). Furthermore, when expressed in Jurkat cells, CalDAG-GEFI, a calcium and diacylglycerol-responsive Rap1 exchange factor, associated with Rap1, and resulted in enhanced Rap1 activation and adhesion triggered by the TCR. Our results demonstrate that TCR activation of Rap1 depends on PLC-gamma1. This activity is likely to be mediated by CalDAG-GEFI, which is required to activate LFA-1.	Kyoto Univ, Grad Sch Med, Bayer Chair Dept Mol Immunol & Allergy, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Kinashi, T (corresponding author), Kyoto Univ, Grad Sch Med, Bayer Chair Dept Mol Immunol & Allergy, Sakyo Ku, Kyoto 6068501, Japan.	tkinashi@mfour.med.kyoto-u.ac.jp						Abraham RT, 2003, NAT IMMUNOL, V4, P725, DOI 10.1038/ni0803-725; Amsen D, 2000, EUR J IMMUNOL, V30, P2832, DOI 10.1002/1521-4141(200010)30:10<2832::AID-IMMU2832>3.0.CO;2-D; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; de Bruyn KMT, 2003, J BIOL CHEM, V278, P22412, DOI 10.1074/jbc.M212036200; Epler JA, 2000, J IMMUNOL, V165, P4941, DOI 10.4049/jimmunol.165.9.4941; Eto K, 2002, P NATL ACAD SCI USA, V99, P12819, DOI 10.1073/pnas.202380099; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; Krawczyk C, 2002, IMMUNITY, V16, P331, DOI 10.1016/S1074-7613(02)00291-1; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; McLeod S J, 2001, Int Rev Immunol, V20, P763, DOI 10.3109/08830180109045589; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; McLeod SJ, 2002, J IMMUNOL, V169, P1365, DOI 10.4049/jimmunol.169.3.1365; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Sanui T, 2003, IMMUNITY, V19, P119, DOI 10.1016/S1074-7613(03)00169-9; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Tohyama Y, 2003, MOL BIOL CELL, V14, P2570, DOI 10.1091/mbc.E02-09-0615; Woods ML, 2001, EMBO J, V20, P1232, DOI 10.1093/emboj/20.6.1232; Wu DQ, 2000, J CELL SCI, V113, P2935	32	85	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11875	11881		10.1074/jbc.M310717200	http://dx.doi.org/10.1074/jbc.M310717200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14702343	hybrid			2022-12-25	WOS:000220157600124
J	Qiu, Y; Guo, M; Huang, SM; Stein, R				Qiu, Y; Guo, M; Huang, SM; Stein, R			Acetylation of the BETA2 transcription factor by p300-associated factor is important in insulin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING; HISTONE ACETYLATION; HOMEODOMAIN PROTEIN; ENHANCER ACTIVITY; FACTOR GATA-1; P300; DIFFERENTIATION; ACTIVATION; CELLS	The BETA2 transcription factor influences islet beta cell development and function. Activation of insulin gene transcription by this member of the basic helix-loop-elix gene family is mediated by p300 through the ability of this coactivator to form a functional bridge between the basal transcriptional apparatus, BETA2, and PDX-1, another key transcription factor. In this report, we examined whether BETA2-mediated stimulation was also directly influenced by the acetyltransferase activities of p300 or the p300-associated factor. BETA2 was specifically and selectively acetylated by p300-associated factor in beta cells. Sites of BETA2 acetylation were found within the loop region of the basic helix-loop-elix DNA binding/dimerization domain and a more C-erminal region involved in activation. Insulin gene transcription was decreased by blocking acetylation of BETA2 because of effects on DNA binding and activation potential. These findings suggest that acetylation of BETA2 plays a role in controlling the activation state of this islet regulatory factor.	Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37215 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Stein, R (corresponding author), Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37215 USA.	roland.stein@mcmail.vanderbilt.edu		, Yi/0000-0002-3282-6072	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK055091, R01DK050203] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 50203, P60 DK20593, R01 DK55091] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Asahara H, 1999, MOL CELL BIOL, V19, P8219; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chakrabarti SK, 2003, J BIOL CHEM, V278, P23617, DOI 10.1074/jbc.M303423200; Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Eckner R, 1996, BIOL CHEM, V377, P685; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kristinsson SY, 2001, DIABETOLOGIA, V44, P2098, DOI 10.1007/s001250100016; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu M, 2000, P NATL ACAD SCI USA, V97, P865, DOI 10.1073/pnas.97.2.865; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Offield MF, 1996, DEVELOPMENT, V122, P983; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PEYTON M, 1994, J BIOL CHEM, V269, P25936; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; ROBINSON GLWG, 1994, J BIOL CHEM, V269, P2452; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sharma A, 1999, MOL CELL BIOL, V19, P704; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; STEIN R, 2001, HDB PHYSL 7, V2, P25; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1989, MOL CELL BIOL, V9, P4531, DOI 10.1128/MCB.9.10.4531; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang WJ, 2001, MOL CELL BIOL, V21, P2413, DOI 10.1128/MCB.21.7.2413-2422.2001	66	30	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9796	9802		10.1074/jbc.M307577200	http://dx.doi.org/10.1074/jbc.M307577200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701848	hybrid			2022-12-25	WOS:000220050400018
J	Mallette, FA; Goumard, S; Gaumont-Leclerc, MF; Moiseeva, O; Ferbeyre, G				Mallette, FA; Goumard, S; Gaumont-Leclerc, MF; Moiseeva, O; Ferbeyre, G			Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence	ONCOGENE			English	Article						senescence; nuclear bodies; E6; E7; Rb; p53; PML	PAPILLOMAVIRUS TYPE-16 E7; HUMAN-DIPLOID FIBROBLASTS; CELL-CYCLE ARREST; ONCOGENIC RAS; RETINOBLASTOMA PROTEIN; REPLICATIVE SENESCENCE; PREMATURE SENESCENCE; TELOMERASE ACTIVITY; G(1) CONTROL; IMMORTALIZATION	Cellular senescence is a permanent cell cycle arrest that can be triggered by a variety of stresses including short telomeres and activated oncogenes. Promyelocytic leukemia protein (PML) is a central component of the senescence response, and is able to trigger the process when overexpressed in human diploid fibroblasts (HDFs). Senescence induced by PML in HDFs is characterized by a modest increase in p53 levels and activity, the accumulation of hypophosphorylated Rb and a reduced expression of E2F-dependent genes. To dissect the p53 and Rb family requirements for PML-induced senescence, we used the oncoproteins E6 and E7 from human papillomavirus type 16. We found that the coexpression of E6 and E7 inhibited the growth arrest and senescence induced by PML. In addition, these viral oncoproteins blocked the formation of PML bodies and excluded both p53 and Rb from PML bodies. Expression of dominant-negative p53 alone failed to block PML-induced senescence and expression of E6 only delayed the process. On the other hand, expression of E7 was sufficient to block PML-induced senescence, while an E7 mutant unable to bind Rb did not. Together, these data indicate that PML-induced senescence engages the Rb tumor-suppressor pathway predominantly.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Ferbeyre, G (corresponding author), Univ Montreal, Dept Biochim, E-515,CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	g.ferbeyre@umontreal.ca	Moiseeva, Olga/Q-4848-2016; Ferbeyre, Gerardo/A-1569-2010; Mallette, Frédérick A./J-6646-2019	Mallette, Frédérick A./0000-0001-7932-0338				Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ferbeyre G, 2000, GENE DEV, V14, P2015; Franco EL, 2001, CAN MED ASSOC J, V164, P1017; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Haq R, 2002, CANCER RES, V62, P5076; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Heidebrecht HJ, 2001, LAB INVEST, V81, P1163, DOI 10.1038/labinvest.3780328; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Medcalf ASC, 1996, CANCER RES, V56, P4582; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200	53	77	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					91	99		10.1038/sj.onc.1206886	http://dx.doi.org/10.1038/sj.onc.1206886			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712214				2022-12-25	WOS:000187895300010
J	Brown, SE; Cao, AT; Hines, ER; Akhurst, RJ; East, PD				Brown, SE; Cao, AT; Hines, ER; Akhurst, RJ; East, PD			A novel secreted protein toxin from the insect pathogenic bacterium Xenorhabdus nematophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORHABDUS-LUMINESCENS; SEQUENCE-ANALYSIS; BACILLUS-THURINGIENSIS; GENOME SEQUENCE; DELTA-ENDOTOXIN; IDENTIFICATION; GENES; NEMATODES; HETERORHABDITIS; PURIFICATION	The bacterium Xenorhabdus nematophila is an insect pathogen that produces several proteins that enable it to kill insects. Screening of a cosmid library constructed from X. nematophila strain A24 identified a gene that encoded a novel protein that was toxic to insects. The 42-kDa protein encoded by the toxin gene was expressed and purified from a recombinant system, and was shown to kill the larvae of insects such as Galleria mellonella and Helicoverpa armigera when injected at doses of around 30 - 40 ng/g larvae. Sequencing and bioinformatic analysis suggested that the toxin was a novel protein, and that it was likely to be part of a genomic island involved in pathogenicity. When the native bacteria were grown under laboratory conditions, a soluble form of the 42-kDa toxin was secreted only by bacteria in the phase II state. Preliminary histological analysis of larvae injected with recombinant protein suggested that the toxin primarily acted on the midgut of the insect. Finally, some of the common strategies used by the bacterial pathogens of insects, animals, and plants are discussed.	CSIRO Entomol, Acton, ACT 2601, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Brown, SE (corresponding author), CSIRO Entomol, GPO Box 1700, Acton, ACT 2601, Australia.	sue.brown@csiro.au	Brown, Susan/C-3123-2009; East, Peter/C-2352-2009					AKHURST R, 1993, NEMATODES AND THE BIOLOGICAL CONTROL OF INSECT PESTS, P127; Akhurst Raymond J., 1993, P1; AKHURST RJ, 1980, J GEN MICROBIOL, V121, P303; Akhurst RJ, 2003, J ECON ENTOMOL, V96, P1290, DOI 10.1603/0022-0493-96.4.1290; Andrade MA, 1999, BIOINFORMATICS, V15, P391, DOI 10.1093/bioinformatics/15.5.391; Blackburn M, 1998, APPL ENVIRON MICROB, V64, P3036; BOEMARE NE, 1988, J GEN MICROBIOL, V134, P751; Bowen D, 1998, SCIENCE, V280, P2129, DOI 10.1126/science.280.5372.2129; Bowen D, 2000, INSECT BIOCHEM MOLEC, V30, P69, DOI 10.1016/S0965-1748(99)00098-3; Bowen DJ, 1998, APPL ENVIRON MICROB, V64, P3029; BREHELIN M, 1993, J INVERTEBR PATHOL, V61, P188, DOI 10.1006/jipa.1993.1033; Brillard J, 2002, J BACTERIOL, V184, P3871, DOI 10.1128/JB.184.14.3871-3878.2002; Bujnicki JM, 2001, BIOINFORMATICS, V17, P750, DOI 10.1093/bioinformatics/17.8.750; Burnell AM, 2000, NEMATOLOGY, V2, P31, DOI 10.1163/156854100508872; Campbell PM, 2001, INSECT BIOCHEM MOLEC, V31, P513, DOI 10.1016/S0965-1748(01)00035-2; Cao H, 2001, ANNU REV PHYTOPATHOL, V39, P259, DOI 10.1146/annurev.phyto.39.1.259; Collmer A, 2002, TRENDS MICROBIOL, V10, P462, DOI 10.1016/S0966-842X(02)02451-4; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Daborn PJ, 2002, P NATL ACAD SCI USA, V99, P10742, DOI 10.1073/pnas.102068099; Donnenberg MS, 2000, NATURE, V406, P768, DOI 10.1038/35021212; Duchaud E, 2003, NAT BIOTECHNOL, V21, P1307, DOI 10.1038/nbt886; Ffrench-Constant R, 2003, FEMS MICROBIOL REV, V26, P433, DOI 10.1111/j.1574-6976.2003.tb00625.x; Ffrench-Constant RH, 2000, APPL ENVIRON MICROB, V66, P3310, DOI 10.1128/AEM.66.8.3310-3329.2000; Forst S, 1997, ANNU REV MICROBIOL, V51, P47, DOI 10.1146/annurev.micro.51.1.47; Forst S, 1996, MICROBIOL REV, V60, P21, DOI 10.1128/MMBR.60.1.21-43.1996; Guo LN, 1999, J BIOL CHEM, V274, P9836, DOI 10.1074/jbc.274.14.9836; Hacker J, 2000, ANNU REV MICROBIOL, V54, P641, DOI 10.1146/annurev.micro.54.1.641; Haffani YZ, 2001, BIOTECHNOL PROGR, V17, P211, DOI 10.1021/bp000150d; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Heungens K, 2002, MOL MICROBIOL, V45, P1337, DOI 10.1046/j.1365-2958.2002.03100.x; Hilder VA, 1999, CROP PROT, V18, P177, DOI 10.1016/S0261-2194(99)00028-9; Hurst MRH, 2000, J BACTERIOL, V182, P5127, DOI 10.1128/JB.182.18.5127-5138.2000; Karim S, 2000, CURR MICROBIOL, V41, P214, DOI 10.1007/s002840010122; Keen N, 2000, P NATL ACAD SCI USA, V97, P8752, DOI 10.1073/pnas.97.16.8752; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING LAB MANU; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; Morgan JAW, 2001, APPL ENVIRON MICROB, V67, P2062, DOI 10.1128/AEM.67.5.2062-2069.2001; Pan YH, 2002, PROG NAT SCI, V12, P310; Peel MM, 1999, J CLIN MICROBIOL, V37, P3647, DOI 10.1128/JCM.37.11.3647-3653.1999; Ryu K.G., 2000, BIOTECHNOL BIOPROC E, V5, P141, DOI [10.1007/BF02931886, DOI 10.1007/BF02931886]; Shea JE, 2000, CURR OPIN MICROBIOL, V3, P451, DOI 10.1016/S1369-5274(00)00120-X; Silverstein KAT, 2000, BIOINFORMATICS, V16, P1157, DOI 10.1093/bioinformatics/16.12.1157; SMIGIELSKI AJ, 1994, J INVERTEBR PATHOL, V64, P214, DOI 10.1016/S0022-2011(94)90225-9; Thaler JO, 1998, APPL ENVIRON MICROB, V64, P2367; Waterfield NR, 2002, TRENDS MICROBIOL, V10, P541, DOI 10.1016/S0966-842X(02)02463-0; Waterfield NR, 2001, TRENDS MICROBIOL, V9, P185, DOI 10.1016/S0966-842X(01)01978-3; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847	48	47	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14595	14601		10.1074/jbc.M309859200	http://dx.doi.org/10.1074/jbc.M309859200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14707137	hybrid, Green Published			2022-12-25	WOS:000220594700017
J	Munehira, Y; Ohnishi, T; Kawamoto, S; Furuya, A; Shitara, K; Imamura, M; Yokota, T; Takeda, S; Amachi, T; Matsuo, M; Kioka, N; Ueda, K				Munehira, Y; Ohnishi, T; Kawamoto, S; Furuya, A; Shitara, K; Imamura, M; Yokota, T; Takeda, S; Amachi, T; Matsuo, M; Kioka, N; Ueda, K			alpha 1-syntrophin modulates turnover of ABCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER A1; REVERSE CHOLESTEROL TRANSPORT; STEROL REGULATORY ELEMENT; CELLULAR CHOLESTEROL; TANGIER-DISEASE; EXTRACELLULAR DOMAIN; DYSTROPHIN COMPLEX; LIPID EFFLUX; NITRIC-OXIDE; BINDING	ABCA1 (ATP-binding cassette transporter A1) mediates the release of cellular cholesterol and phospholipid to form high density lipoprotein. Functions of ABCA1 are highly regulated at the transcriptional and post-transcriptional levels, and the synthesized ABCA1 protein turns over rapidly with a half-life of 1 - 2 h. To examine whether the functions of ABCA1 are modulated by associated proteins, a yeast two-hybrid library was screened with the C-terminal 120 amino acids of ABCA1. Two PDZ (PSD95-Discs large-ZO1) proteins, alpha1-syntrophin and Lin7, were found to interact with ABCA1. Immunoprecipitation revealed that alpha1-syntrophin interacted with ABCA1 strongly and that the interaction was via the C-terminal three amino acids SYV of ABCA1. Co-expression of alpha1-syntrophin in human embryonic kidney 293 cells retarded degradation of ABCA1 and made the half-life of ABCA1 five times longer than in the cells not expressing alpha1-syntrophin. This effect is not common among PDZ-containing proteins interacting with ABCA1, because Lin7, which was also found to interact with the C terminus region of ABCA1, did not have a significant effect on the half-life of ABCA1. Co-expression of alpha1-syntrophin significantly increased the apoA-I-mediated release of cholesterol. ABCA1 was co-immunoprecipitated with alpha1-syntrophin from mouse brain. These results suggest that alpha1-syntrophin is involved in intracellular signaling, which determines the stability of ABCA1 and modulates cellular cholesterol release.	Kyoto Univ, Lab Cellular Biochem, Div Appl Life Sci, Grad Sch Agr, Kyoto 6068502, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1948533, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo 1878502, Japan	Kyoto University; Kyowa Kirin Ltd; National Center for Neurology & Psychiatry - Japan	Ueda, K (corresponding author), Kyoto Univ, Lab Cellular Biochem, Div Appl Life Sci, Grad Sch Agr, Kyoto 6068502, Japan.	uedak@kais.kyoto-u.ac.ip		Yokota, Toshifumi/0000-0001-7316-3546; Kioka, Noriyuki/0000-0002-2708-537X; , toshifumi/0000-0001-6672-6742; Onishi, Tomohiro/0000-0003-0633-9323; Ueda, Kazumitsu/0000-0003-2980-6078				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Attie AD, 2001, J LIPID RES, V42, P1717; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Buechler C, 2002, BIOCHEM BIOPH RES CO, V293, P759, DOI 10.1016/S0006-291X(02)00303-0; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HARA H, 1991, J BIOL CHEM, V266, P3080; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Kachinsky AM, 1999, J CELL BIOL, V145, P391, DOI 10.1083/jcb.145.2.391; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Ort T, 2001, EMBO J, V20, P4013, DOI 10.1093/emboj/20.15.4013; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Rigot W, 2002, J LIPID RES, V43, P2077, DOI 10.1194/jlr.M200279-JLR200; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Tanaka AR, 2001, BIOCHEM BIOPH RES CO, V283, P1019, DOI 10.1006/bbrc.2001.4891; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	32	97	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15091	15095		10.1074/jbc.M313436200	http://dx.doi.org/10.1074/jbc.M313436200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14722086	hybrid			2022-12-25	WOS:000220594700074
J	Nagano, S; Huang, XD; Moir, RD; Payton, SM; Tanzi, RE; Bush, AI				Nagano, S; Huang, XD; Moir, RD; Payton, SM; Tanzi, RE; Bush, AI			Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links beta-amyloid (A beta) and generates A beta-COX-2 hetero-oligomers that are increased in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MOUSE MODEL; HIPPOCAMPAL-FORMATION; HYDROGEN-PEROXIDE; CLINICAL-TRIAL; METAL-BINDING; PLAQUE CORES; HUMAN BRAIN; PROTEIN; OXIDATION	Oxidative stress is associated with the neuropathology of Alzheimer's disease. We have previously shown that human Abeta has the ability to reduce Fe(III) and Cu(II) and produce hydrogen peroxide coupled with these metals, which is correlated with toxicity against primary neuronal cells. Cyclooxygenase (COX)-2 expression is linked to the progression and severity of pathology in AD. COX is a heme-containing enzyme that produces prostaglandins, and the enzyme also possesses peroxidase activity. Here we investigated the possibility of direct interaction between human Abeta and COX-2 being mediated by the peroxidase activity. Human Abeta formed dimers when it was reacted with COX-2 and hydrogen peroxide. Moreover, the peptide formed a cross-linked complex directly with COX-2. Such cross-linking was not observed with rat Abeta, and the sole tyrosine residue specific for human Abeta might therefore be the site of cross-linking. Similar complexes of Abeta and COX-2 were detected in post-mortem brain samples in greater amounts in AD tissue than in age-matched controls. COX-2-mediated cross-linking may inhibit Abeta catabolism and possibly generate toxic intracellular forms of oligomeric Abeta.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Lab Oxidat Biol, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Charlestown, MA 02129 USA; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Mental Hlth Res Inst Victoria, Oxidat Disorders Lab, Parkville, Vic 3052, Australia	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Melbourne	Bush, AI (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Lab Oxidat Biol, Genet & Aging Res Unit, Bldg 114,16th St, Charlestown, MA 02129 USA.	bush@helix.mgh.harvard.edu	Moir, Robert D./M-7612-2017; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley/Y-2457-2019; Bush, Ashley I/A-1186-2007	Moir, Robert D./0000-0001-5431-3553; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley/0000-0001-8259-9069; Bush, Ashley I/0000-0001-8259-9069	PHS HHS [R01-1912686] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0; Beard CM, 1998, MAYO CLIN PROC, V73, P951, DOI 10.4065/73.10.951; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brzyska M, 2001, EUR J BIOCHEM, V268, P3443, DOI 10.1046/j.1432-1327.2001.02248.x; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Forghani F, 1998, ANAL BIOCHEM, V264, P216, DOI 10.1006/abio.1998.2842; Galeazzi L, 1999, AMYLOID, V6, P7, DOI 10.3109/13506129908993282; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; Head E, 2001, NEUROBIOL DIS, V8, P792, DOI 10.1006/nbdi.2001.0431; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; Hensley K, 1998, J NEUROSCI, V18, P8126; Ho L, 2001, ARCH NEUROL-CHICAGO, V58, P487, DOI 10.1001/archneur.58.3.487; Ho L, 1999, J NEUROSCI RES, V57, P295; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MATTAMMAL MB, 1995, J NEUROCHEM, V64, P1645; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; Miura T, 2001, J MOL STRUCT, V598, P79, DOI 10.1016/S0022-2860(01)00807-9; Oka A, 1997, NEUROREPORT, V8, P1161, DOI 10.1097/00001756-199703240-00020; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Sayre LM, 1997, J NEUROCHEM, V68, P2092; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Thomas T, 2001, NEUROREPORT, V12, P3263, DOI 10.1097/00001756-200110290-00024; Tsai AL, 2000, PROSTAG OTH LIPID M, V62, P231, DOI 10.1016/S0090-6980(00)00083-6; VAUGHAN DW, 1981, J NEUROPATH EXP NEUR, V40, P472, DOI 10.1097/00005072-198107000-00009; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Xiang ZM, 2002, GENE EXPRESSION, V10, P271, DOI 10.3727/000000002783992352; Xiang ZM, 2002, NEUROBIOL AGING, V23, P327, DOI 10.1016/S0197-4580(01)00282-2; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X	53	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14673	14678		10.1074/jbc.M313003200	http://dx.doi.org/10.1074/jbc.M313003200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14724276	hybrid			2022-12-25	WOS:000220594700026
J	Cobine, PA; Ojeda, LD; Rigby, KM; Winge, DR				Cobine, PA; Ojeda, LD; Rigby, KM; Winge, DR			Yeast contain a non-proteinaceous pool of copper in the mitochondrial matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; MANGANESE-SUPEROXIDE DISMUTASE; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; MUTATIONAL ANALYSIS; PHYSIOLOGICAL-ROLE; GENE; METALLOCHAPERONE; SCO1; METALLOTHIONEIN	The yeast mitochondrion is shown to contain a pool of copper that is distinct from that associated with the two known mitochondrial cuproenzymes, superoxide dismutase (Sod1) and cytochrome c oxidase (CcO) and the copper-binding CcO assembly proteins Cox11, Cox17, and Sco1. Only a small fraction of mitochondrial copper is associated with these cuproproteins. The bulk of the remainder is localized within the matrix as a soluble, anionic, low molecular weight complex. The identity of the matrix copper ligand is unknown, but the bulk of the matrix copper fraction is not protein-bound. The mitochondrial copper pool is dynamic, responding to changes in the cytosolic copper level. The addition of copper salts to the growth medium leads to an increase in mitochondrial copper, yet the expansion of this matrix pool does not induce any respiration defects. The matrix copper pool is accessible to a heterologous cuproenzyme. Co-localization of human Sod1 and the metallochaperone CCS within the mitochondrial matrix results in suppression of growth defects of sod2Delta cells. However, in the absence of CCS within the matrix, the activation of human Sod1 can be achieved by the addition of copper salts to the growth medium.	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010; Cobine, Paul/AAH-6619-2020; Cobine, Paul A/G-3107-2011	Cobine, Paul/0000-0001-6012-0985; Cobine, Paul A/0000-0001-6012-0985	NCI NIH HHS [5P30-CA 42014] Funding Source: Medline; NIEHS NIH HHS [ES03817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Balzan R, 1999, BIOCHEM BIOPH RES CO, V256, P63, DOI 10.1006/bbrc.1999.0285; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; El Meskini R, 2003, J BIOL CHEM, V278, P12278, DOI 10.1074/jbc.M211413200; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; Field LS, 2002, J BIOENERG BIOMEMBR, V34, P373, DOI 10.1023/A:1021202119942; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; Gaume B, 1998, EMBO J, V17, P6497, DOI 10.1093/emboj/17.22.6497; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Jensen LT, 1996, J BIOL CHEM, V271, P18514, DOI 10.1074/jbc.271.31.18514; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; KRUMMECK G, 1990, CURR GENET, V18, P13, DOI 10.1007/BF00321109; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Linder MC, 1996, AM J CLIN NUTR, V63, P797; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; Luk E, 2003, P NATL ACAD SCI USA, V100, P10353, DOI 10.1073/pnas.1632471100; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Nobrega MP, 2002, J BIOL CHEM, V277, P40206, DOI 10.1074/jbc.M207348200; Ohlmeier S, 2004, J BIOL CHEM, V279, P3956, DOI 10.1074/jbc.M310160200; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reichert AS, 2002, BBA-MOL CELL RES, V1592, P41, DOI 10.1016/S0167-4889(02)00263-X; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sensi SL, 2002, NEUROBIOL DIS, V10, P100, DOI 10.1006/nbdi.2002.0493; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WRIGHT CF, 1987, J BIOL CHEM, V262, P12912; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	60	163	167	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14447	14455		10.1074/jbc.M312693200	http://dx.doi.org/10.1074/jbc.M312693200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729672	hybrid			2022-12-25	WOS:000220478500141
J	Kakimoto, T; Katoh, H; Negishi, M				Kakimoto, T; Katoh, H; Negishi, M			Identification of splicing variants of rapostlin, a novel Rnd2 effector that interacts with neural Wiskott-Aldrich syndrome protein and induces neurite branching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; GROWTH CONE; ACTIN CYTOSKELETON; PC12 CELLS; BINDING; RAC1; RETRACTION; ACTIVATION; ADHESION; PARTNER	Rho family GTPases regulate neuronal morphology. Rnd subfamily is a new branch of Rho family GTPases. Of these GTPases, Rnd2 is specifically expressed in brain. We recently identified Rapostlin as a novel effector of Rnd2. Rapostlin induces neurite branching in response to Rnd2 in PC12 cells. During the cloning of Rapostlin, we have found two mainly expressed splicing variants of Rapostlin (renamed as RapostlinL), Rapost-linM and RapostlinS, lacking 29 residues and 61 residues within the unique insert region at the center, respectively, and three minor variants, RapostlinLd, RapostlinMd, and RapostlinSd, each with the identical five-amino acid deletion from RapostlinL, RapostlinM, and RapostlinS, respectively. RapostlinL is predominantly expressed in brain, whereas RapostlinS is expressed ubiquitously. In a dot-blot assay, all splicing variants bind to Rnd2 in a GTP-dependent manner. However, RapostlinM and RapostlinS induce less neurite branching when coexpressed with Rnd2 in PC12 cells, indicating that the insert region is important for the branching activity of RapostlinL. All splicing variants bind to N-WASP in vitro and in vivo through the SH3 domain at the carboxyl terminus, and the SH3 domain is essential for branching activity of RapostlinL. In immunoprecipitation experiments, Rnd2 reduces Ra-postlinL-N-WASP interaction, whereas it has little effect on the interaction of RapostlinM or RapostlinS with N-WASP. Therefore, we found that functionally different splicing variants of Rapostlin have different responses to Rnd2 in association with N-WASP.	Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan.	mnegishi@pharm.kyoto-u.ac.jp	kakimoto, tetsuhiro/W-1403-2019	Kakimoto, Tetsuhiro/0000-0003-1349-5690; Katoh, Hironori/0000-0002-8191-8117				Aoki J, 2000, BIOCHEM BIOPH RES CO, V278, P604, DOI 10.1006/bbrc.2000.3842; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Foster R, 1996, MOL CELL BIOL, V16, P2689; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; Fujita H, 2002, J BIOL CHEM, V277, P45428, DOI 10.1074/jbc.M208090200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ishikawa Y, 2003, J NEUROSCI, V23, P11065; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Kalil K, 2000, J NEUROBIOL, V44, P145, DOI 10.1002/1097-4695(200008)44:2<145::AID-NEU5>3.0.CO;2-X; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Katoh H, 2002, MOL CELL BIOL, V22, P2952, DOI 10.1128/MCB.22.9.2952-2964.2002; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Linder S, 2000, J CELL SCI, V113, P4165; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Miki H, 2003, J BIOCHEM, V134, P309, DOI 10.1093/jb/mvg146; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Negishi M, 2002, J BIOCHEM, V132, P157, DOI 10.1093/oxfordjournals.jbchem.a003205; Nishi M, 1999, MOL BRAIN RES, V67, P74, DOI 10.1016/S0169-328X(99)00039-X; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Oinuma I, 2003, J BIOL CHEM, V278, P25671, DOI 10.1074/jbc.M303047200; Riento K, 2003, MOL CELL BIOL, V23, P4219, DOI 10.1128/MCB.23.12.4219-4229.2003; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Szebenyi G, 1998, J NEUROSCI, V18, P7930; Tanaka H, 2002, BIOCHEM J, V365, P349, DOI 10.1042/BJ20020062; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200	33	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14104	14110		10.1074/jbc.M312763200	http://dx.doi.org/10.1074/jbc.M312763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732713	hybrid			2022-12-25	WOS:000220478500100
J	Linke, S; Stojkoski, C; Kewley, RJ; Booker, GW; Whitelaw, ML; Peet, DJ				Linke, S; Stojkoski, C; Kewley, RJ; Booker, GW; Whitelaw, ML; Peet, DJ			Substrate requirements of the oxygen-sensing asparaginyl hydroxylase factor-inhibiting hypoxia-inducible factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTYL-BETA-HYDROXYLASE; VON-HIPPEL-LINDAU; TRANSCRIPTIONAL ACTIVITY; MOLECULAR-DYNAMICS; STRUCTURAL BASIS; HIF-ALPHA; PROLYL; FACTOR-1-ALPHA; HIF-1-ALPHA; PROTEIN	The hypoxia-inducible factor alpha subunits 1 and 2 (HIF-1alpha and HIF-2alpha) are subjected to oxygen-dependent asparaginyl hydroxylation, a modification that represses the carboxyl-terminal transactivation domain (CAD) at normoxia by preventing recruitment of the p300/cAMP-response element-binding protein coactivators. This hydroxylation is performed by the novel asparaginyl hydroxylase, factor-inhibiting HIF-1' (FIH-1), of which HIF-1alpha and HIF-2alpha are the only reported substrates. Here we investigated the substrate requirements of FIH-1 by characterizing its subcellular localization and by examining amino acids within the HIF-1alpha substrate for their importance in recognition and catalysis by FIH-1. Using immunohistochemistry, we showed that both endogenous and transfected FIH-1 are primarily confined to the cytoplasm and remain there under normoxia and following treatment with the hypoxia mimetic, dipyridyl. Individual alanine mutations of seven conserved amino acids flanking the hydroxylated asparagine in HIF-1alpha revealed the importance of the valine (Val-802) adjacent to the targeted asparagine. The HIF-1alpha CAD V802A mutant exhibited a 4-fold lower V-max in enzyme assays, whereas all other mutants were hydroxylated as efficiently as the wild type HIF-1alpha CAD. Furthermore, in cell-based assays the transcriptional activity of V802A was constitutive, suggesting negligible normoxic hydroxylation in HEK293T cells, whereas the wild type and other mutants were repressed under normoxia. Molecular modeling of the HIF-1alpha CAD V802A in complex with FIH-1 predicted an alteration in asparagine positioning compared with the wild type HIF-1alpha CAD, providing an explanation for the impaired catalysis observed and confirming the importance of Val-802 in asparaginyl hydroxylation by FIH-1.	Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Mol Genet Dev, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Peet, DJ (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.	daniel.peet@adelaide.edu.au	Peet, Daniel/AAE-6698-2020	Peet, Daniel/0000-0002-6085-8936; Prior, Robyn/0000-0001-5673-3914				Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Dann CE, 2002, P NATL ACAD SCI USA, V99, P15351, DOI 10.1073/pnas.202614999; Dinchuk JE, 2000, J BIOL CHEM, V275, P39543, DOI 10.1074/jbc.M006753200; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2003, EUR J BIOCHEM, V270, P781, DOI 10.1046/j.1432-1033.2003.03445.x; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee C, 2003, J BIOL CHEM, V278, P7558, DOI 10.1074/jbc.M210385200; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; STENFLO J, 1991, BLOOD, V78, P1637; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; *TRIP INC, 2003, SYBYL VERS 6 9; WANG QP, 1991, J BIOL CHEM, V266, P14004; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200; Zhang JH, 1999, ANAL BIOCHEM, V271, P137, DOI 10.1006/abio.1999.4135; Zhang ZH, 2002, FEBS LETT, V517, P7, DOI 10.1016/S0014-5793(02)02520-6	35	63	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14391	14397		10.1074/jbc.M313614200	http://dx.doi.org/10.1074/jbc.M313614200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734545	hybrid			2022-12-25	WOS:000220478500135
J	Motycka, TA; Bessho, T; Post, SM; Sung, P; Tomkinson, AE				Motycka, TA; Bessho, T; Post, SM; Sung, P; Tomkinson, AE			Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; REPLICATION PROTEIN-A; BREAK-INDUCED RECOMBINATION; YEAST DNA-REPAIR; RAD52 PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE; RAD10; XPF-ERCC1; ERCC1-XPF	The XPF/ERCC1 heterodimer is a DNA structure-specific endonuclease that participates in nucleotide excision repair and homology-dependent recombination reactions, including DNA single strand annealing and gene targeting. Here we show that XPF/ERCC1 is stably associated with hRad52, a recombinational repair protein, in human cell-free extracts and that these factors interact directly via the N-terminal domain of hRad52 and the XPF protein. Complex formation between hRad52 and XPF/ERCC1 concomitantly stimulates the DNA structure-specific endonuclease activity of XPF/ ERCC1 and attenuates the DNA strand annealing activity of hRad52. Our results reveal a novel role for hRad52 as a subunit of a DNA structure-specific endonuclease and are congruent with evidence implicating both hRad52 and XPF/ ERCC1 in a number of homologous recombination reactions. We propose that the ternary complex of hRad52 and XPF/ ERCC1 is the active species that processes recombination intermediates generated during the repair of DNA double strand breaks and in homology-dependent gene targeting events.	Univ Maryland, Dept Radiat Oncol, Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Mol Med Grad Program, San Antonio, TX 78245 USA; Univ Nebraska, Med Ctr, Eppley Inst, Omaha, NE 68198 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	University System of Maryland; University of Maryland Baltimore; University of Texas System; University of Texas Health San Antonio; University of Nebraska System; University of Nebraska Medical Center; Yale University	Tomkinson, AE (corresponding author), Univ Maryland, Dept Radiat Oncol, Radiat Oncol Res Lab, 655 W Baltimore St, Baltimore, MD 21201 USA.	atomkinson@som.umaryland.edu			NCI NIH HHS [P30 CA54174, T32 CA86800, P01 CA81020] Funding Source: Medline; NIEHS NIH HHS [R01 ES07061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA086800, P30CA054174, P01CA081020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adair GR, 2000, EMBO J, V19, P5552, DOI 10.1093/emboj/19.20.5552; AGUILERA A, 1989, GENETICS, V122, P503; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, P3; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BENSON FE, 1998, NATURE, V335, P337; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HOY CA, 1985, CANCER RES, V45, P1737; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; Kagawa W, 2002, MOL CELL, V10, P359, DOI 10.1016/S1097-2765(02)00587-7; Krejci L, 2003, PROG NUCLEIC ACID RE, V74, P159, DOI 10.1016/S0079-6603(03)01013-4; Krejci L, 2002, J BIOL CHEM, V277, P40132, DOI 10.1074/jbc.M206511200; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Niedernhofer LJ, 2001, EMBO J, V20, P6540, DOI 10.1093/emboj/20.22.6540; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Reddy G, 1997, MUTAT RES-FUND MOL M, V377, P53, DOI 10.1016/S0027-5107(97)00057-2; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Rodriguez K, 1996, J BIOL CHEM, V271, P20551, DOI 10.1074/jbc.271.34.20551; RON D, 1992, BIOTECHNIQUES, V13, P866; Sargent RG, 1997, P NATL ACAD SCI USA, V94, P13122, DOI 10.1073/pnas.94.24.13122; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Singleton MR, 2002, P NATL ACAD SCI USA, V99, P13492, DOI 10.1073/pnas.212449899; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; THOMAS BJ, 1989, GENETICS, V123, P725; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	48	70	73	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13634	13639		10.1074/jbc.M313779200	http://dx.doi.org/10.1074/jbc.M313779200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734547	hybrid			2022-12-25	WOS:000220478500044
J	Sorokina, EM; Merlo, JJ; Tsygankov, AY				Sorokina, EM; Merlo, JJ; Tsygankov, AY			Molecular mechanisms of the effect of Herpesvirus saimiri protein StpC on the signaling pathway leading to NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; T-CELL-CLONES; UBIQUITIN-PROTEASOME PATHWAY; RECEPTOR-ASSOCIATED FACTORS; STAT TRANSCRIPTION FACTORS; TYPE-1 TAX PROTEIN; SUBGROUP-C STRAINS; TYROSINE PHOSPHORYLATION; IN-VITRO; LYMPHOCYTE-TRANSFORMATION	Herpesvirus saimiri (Saimiriine herpesvirus-2) causes lethal T lymphoproliferative diseases in the susceptible species and transforms T lymphocytes to continuous growth in vitro. H. saimiri-induced transformation of T cells is becoming an important experimental tool of biomedical research. Two proteins of H. saimiri subgroup C, Tip and StpC, are essential for T cell transformation by this virus. It has been shown previously that StpC transforms fibroblasts, activates NF-kappaB, and binds to tumor necrosis factor (TNF)-receptor-associated factor (TRAF) proteins, but the molecular mechanism of its action remains insufficiently understood. This study further characterized the effect of StpC on NF-kappaB. First, StpC activates NF-kappaB via the consensus pathway involving activation of I-kappaB kinase and subsequent phosphorylation and degradation of I-kappaB in both T lymphoid and epithelial cells. Second, triggering of this pathway by StpC in both T lymphoid and epithelial cells is dependent on the presence of functional NF-kappaB-inducing kinase (NIK). Third, StpC physically interacts with TRAF in epithelial cells, and the effect of StpC on NF-kappaB activity in these cells requires the presence of functional TRAF. Finally the effect of StpC is completely independent of TNF-alpha, a well described stimulus of NF-kappaB activity. Moreover it appears that StpC uncouples stimulation of NF-kappaB activity from TNF-alpha stimulation. Overall these results argue that the effect of StpC on NF-kappaB is similar to the effects of other viral proteins, "usurping" the TRAF/NIK/I-kappaB kinase pathway, and reinforce the notion that the role of StpC in cell transformation by H. saimiri may be mediated by signaling that results in NF-kappaB activation.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	alexander.tsygankov@temple.edu	Tsygankov, Alexander Y/K-6205-2017					Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Broker BM, 1999, MED MICROBIOL IMMUN, V187, P127, DOI 10.1007/s004300050084; BROKER BM, 1993, J IMMUNOL, V151, P1184; Cabanillas JA, 2002, CLIN EXP IMMUNOL, V127, P366, DOI 10.1046/j.1365-2249.2002.01716.x; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Choi JK, 2000, J VIROL, V74, P8102, DOI 10.1128/JVI.74.17.8102-8110.2000; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Damania B, 2001, ADV CANCER RES, V80, P51, DOI 10.1016/S0065-230X(01)80012-9; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Duboise SM, 1998, J VIROL, V72, P1308, DOI 10.1128/JVI.72.2.1308-1313.1998; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fickenscher H, 1997, J VIROL, V71, P2252, DOI 10.1128/JVI.71.3.2252-2263.1997; Fickenscher H, 2001, PHILOS T R SOC B, V356, P545, DOI 10.1098/rstb.2000.0780; Gallego MD, 1997, BLOOD, V90, P3089, DOI 10.1182/blood.V90.8.3089; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hartley DA, 2000, VIROLOGY, V276, P339, DOI 10.1006/viro.2000.0570; Hartley DA, 2000, J BIOL CHEM, V275, P16925, DOI 10.1074/jbc.M000709200; Hartley DK, 1999, J BIOL CHEM, V274, P20056, DOI 10.1074/jbc.274.29.20056; He ZM, 2000, CANCER RES, V60, P1845; Henderson EE, 1999, VIROLOGY, V264, P125, DOI 10.1006/viro.1999.9988; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Isakov N, 2000, EUR J BIOCHEM, V267, P3413, DOI 10.1046/j.1432-1327.2000.01412.x; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JUNG JU, 1994, VIROLOGY, V204, P751, DOI 10.1006/viro.1994.1590; JUNG JU, 1995, J VIROL, V69, P7814, DOI 10.1128/JVI.69.12.7814-7822.1995; JUNG JU, 1995, J BIOL CHEM, V270, P20660, DOI 10.1074/jbc.270.35.20660; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Kjellen P, 2002, VIROLOGY, V297, P281, DOI 10.1006/viro.2002.1419; Lacey SF, 1998, AIDS RES HUM RETROV, V14, P521, DOI 10.1089/aid.1998.14.521; Lee H, 1999, J VIROL, V73, P3913, DOI 10.1128/JVI.73.5.3913-3919.1999; Li XH, 2000, AIDS RES HUM RETROV, V16, P1583, DOI 10.1089/08892220050192994; Lund T, 1997, J VIROL, V71, P378, DOI 10.1128/JVI.71.1.378-382.1997; Lund T, 1996, J VIROL, V70, P600, DOI 10.1128/JVI.70.1.600-606.1996; Lund TC, 1999, J VIROL, V73, P1689, DOI 10.1128/JVI.73.2.1689-1694.1999; Lund TC, 1997, J VIROL, V71, P6677, DOI 10.1128/JVI.71.9.6677-6682.1997; Martin-Villa JM, 1998, TISSUE ANTIGENS, V52, P430, DOI 10.1111/j.1399-0039.1998.tb03069.x; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; MEDVECZKY MM, 1993, VIROLOGY, V196, P402, DOI 10.1006/viro.1993.1495; Meinl E, 2000, J NEUROIMMUNOL, V103, P1, DOI 10.1016/S0165-5728(99)00217-9; Meinl E, 2001, J BIOL CHEM, V276, P36902, DOI 10.1074/jbc.M102668200; Merlo JJ, 1998, ANTICANCER RES, V18, P2389; Merlo JJ, 2001, VIROLOGY, V279, P325, DOI 10.1006/viro.2000.0714; Nakamura H, 2001, J IMMUNOL, V167, P2657, DOI 10.4049/jimmunol.167.5.2657; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Park J, 2002, IMMUNITY, V17, P221, DOI 10.1016/S1074-7613(02)00368-0; Pecher G, 2001, BIOCHEM BIOPH RES CO, V283, P738, DOI 10.1006/bbrc.2001.4846; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Saadawi AM, 1997, TISSUE ANTIGENS, V49, P431, DOI 10.1111/j.1399-0039.1997.tb02775.x; Saha K, 1998, J VIROL, V72, P876, DOI 10.1128/JVI.72.1.876-881.1998; Saha K, 1997, VIROLOGY, V231, P1, DOI 10.1006/viro.1997.8485; Saha K, 1996, NAT MED, V2, P1272, DOI 10.1038/nm1196-1272; Saha K, 1999, J VIROL, V73, P7891, DOI 10.1128/JVI.73.9.7891-7898.1999; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Tsygankov AY, 1999, ANTICANCER RES, V19, P973; Vella C, 2002, AIDS RES HUM RETROV, V18, P933, DOI 10.1089/088922202760265605; Vella C, 1997, J GEN VIROL, V78, P1405, DOI 10.1099/0022-1317-78-6-1405; Wang J, 2001, BIOTECHNIQUES, V31, P722, DOI 10.2144/01314bm01; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; Wiese N, 1996, J BIOL CHEM, V271, P847, DOI 10.1074/jbc.271.2.847; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zheng NN, 2002, J GEN VIROL, V83, P1343, DOI 10.1099/0022-1317-83-6-1343	71	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13469	13477		10.1074/jbc.M305250200	http://dx.doi.org/10.1074/jbc.M305250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14724292	hybrid			2022-12-25	WOS:000220478500025
J	Avrahami, D; Shai, Y				Avrahami, D; Shai, Y			A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICAL ANTIMICROBIAL PEPTIDES; CIRCULAR-DICHROISM SPECTRA; FUNGAL-INFECTIONS; BACILLUS-SUBTILIS; ACYL-CHAIN; IMMUNOCOMPROMISED HOST; SELECTIVE CYTOTOXICITY; PHOSPHOLIPID-MEMBRANES; INFRARED-SPECTROSCOPY; MOLECULAR-BASIS	We report on the synthesis, biological function, and a plausible mode of action of a new group of lipopeptides with potent antifungal and antibacterial activities. These lipopeptides are derived from positively charged peptides containing D- and L-amino acids (diastereomers) that are palmitoylated (PA) at their N terminus. The peptides investigated have the sequence K4X7W, where X designates Gly, Ala, Val, or Leu (designated D-X peptides). The data revealed that PA-D-G and PA-D-A gained potent antibacterial and antifungal activity despite the fact that both parental peptides were completely devoid of any activity toward microorganisms and model phospholipid membranes. In contrast, PA-D-L lost the potent antibacterial activity of the parental peptide but gained and preserved partial antifungal activity. Interestingly, both D- V and its palmitoylated analog were inactive toward bacteria, and only the palmitoylated peptide was highly potent toward yeast. Both PA-D-L and PA-D-V lipopeptides were also endowed with hemolytic activity. Mode of action studies were performed by using tryptophan fluorescence and attenuated total reflectance Fourier transform infrared and circular dichroism spectroscopy as well as transmembrane depolarization assays with bacteria and fungi. The data suggest that the lipopeptides act by increasing the permeability of the cell membrane and that differences in their potency and target specificity are the result of differences in their oligomeric state and ability to dissociate and insert into the cytoplasmic membrane. These results provide insight regarding a new approach of modulating hydrophobicity and the self-assembly of non-membrane interacting peptides in order to endow them with both antibacterial and antifungal activities urgently needed to combat bacterial and fungal infections.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il						Alexander BD, 1997, DRUGS, V54, P657, DOI 10.2165/00003495-199754050-00002; ARIMA K, 1968, BIOCHEM BIOPH RES CO, V31, P488, DOI 10.1016/0006-291X(68)90503-2; Avrahami D, 2002, BIOCHEMISTRY-US, V41, P2254, DOI 10.1021/bi011549t; Avrahami D, 2001, BIOCHEMISTRY-US, V40, P12591, DOI 10.1021/bi0105330; Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; BenMohamed L, 2002, LANCET INFECT DIS, V2, P425, DOI 10.1016/S1473-3099(02)00318-3; BERNHEIMER AW, 1970, J GEN MICROBIOL, V61, P361, DOI 10.1099/00221287-61-3-361; Blondelle SE, 1996, ANTIMICROB AGENTS CH, V40, P1067, DOI 10.1128/AAC.40.5.1067; BRADBURY EM, 1962, J MOL BIOL, V5, P230, DOI 10.1016/S0022-2836(62)80086-2; CAMERON DG, 1980, BIOCHIM BIOPHYS ACTA, V596, P463, DOI 10.1016/0005-2736(80)90135-2; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; de Lucca AJ, 1999, ANTIMICROB AGENTS CH, V43, P1, DOI 10.1093/jac/43.1.1; DENNING DW, 1991, J ANTIMICROB CHEMOTH, V28, P1, DOI 10.1093/jac/28.suppl_B.1; Ellis M, 2000, HOSP MED, V61, P605, DOI 10.12968/hosp.2000.61.9.1415; Frate MC, 2000, EUR J BIOCHEM, V267, P3836, DOI 10.1046/j.1432-1327.2000.01422.x; FREY S, 1991, BIOPHYS J, V60, P922, DOI 10.1016/S0006-3495(91)82126-9; Ghosh JK, 1997, J BIOL CHEM, V272, P31609, DOI 10.1074/jbc.272.50.31609; Goldstein EJC, 2003, ANTIMICROB AGENTS CH, V47, P337, DOI 10.1128/AAC.47.1.337-341.2003; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Groll AH, 1996, J INFECTION, V33, P23, DOI 10.1016/S0163-4453(96)92700-0; Hancock REW, 2002, FEMS MICROBIOL LETT, V206, P143, DOI 10.1016/S0378-1097(01)00480-3; Harrick N.J., 1967, INTERNAL REFLECTION; Heerklotz H, 2001, BIOPHYS J, V81, P1547, DOI 10.1016/S0006-3495(01)75808-0; Hwang PM, 1998, BIOCHEM CELL BIOL, V76, P235, DOI 10.1139/bcb-76-2-3-235; ISHIGURO R, 1993, BIOCHEMISTRY-US, V32, P9792, DOI 10.1021/bi00088a034; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Johnson MD, 2003, EXPERT OPIN PHARMACO, V4, P807, DOI 10.1517/14656566.4.5.807; Kartsonis NA, 2003, DRUG RESIST UPDATE, V6, P197, DOI 10.1016/S1368-7646(03)00064-5; Kontoyiannis DP, 2003, J HOSP INFECT, V53, P243, DOI 10.1053/jhin.2002.1278; Kustanovich I, 2002, J BIOL CHEM, V277, P16941, DOI 10.1074/jbc.M111071200; MAGETDANA R, 1994, TOXICOLOGY, V87, P151, DOI 10.1016/0300-483X(94)90159-7; Majerle A, 2003, J ANTIMICROB CHEMOTH, V51, P1159, DOI 10.1093/jac/dkg219; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; Minamoto GY, 1997, MED CLIN N AM, V81, P381, DOI 10.1016/S0025-7125(05)70523-X; Mukherjee PK, 2003, INFECT IMMUN, V71, P4333, DOI 10.1128/IAI.71.8.4333-4340.2003; Odds FC, 2003, TRENDS MICROBIOL, V11, P272, DOI 10.1016/S0966-842X(03)00117-3; Oren Z, 1998, BIOPOLYMERS, V47, P451; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; Pankuch GA, 2003, J ANTIMICROB CHEMOTH, V51, P443, DOI 10.1093/jac/dkg091; Papo N, 2002, J BIOL CHEM, V277, P33913, DOI 10.1074/jbc.M204928200; ROTHSCHILD KJ, 1979, SCIENCE, V204, P311, DOI 10.1126/science.432645; Sal-Man N, 2002, BIOCHEMISTRY-US, V41, P11921, DOI 10.1021/bi0260482; SAWYER JG, 1988, INFECT IMMUN, V56, P693, DOI 10.1128/IAI.56.3.693-698.1988; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; SHAI Y, 1990, J BIOL CHEM, V265, P20202; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; SHINITZKY M, 1993, J AM CHEM SOC, V115, P12545, DOI 10.1021/ja00079a038; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; STRAHILEVITZ J, 1994, BIOCHEMISTRY-US, V33, P10951, DOI 10.1021/bi00202a014; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; Tossi A, 2000, BIOPOLYMERS, V55, P4; VOGEL H, 1981, FEBS LETT, V134, P37, DOI 10.1016/0014-5793(81)80545-5; Vollenbroich D, 1997, BIOLOGICALS, V25, P289, DOI 10.1006/biol.1997.0099; Walsh TJ, 1996, INFECT DIS CLIN N AM, V10, P365, DOI 10.1016/S0891-5520(05)70303-2; Wiederhold NP, 2003, EXPERT OPIN INV DRUG, V12, P1313, DOI 10.1517/13543784.12.8.1313; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	58	139	143	4	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12277	12285		10.1074/jbc.M312260200	http://dx.doi.org/10.1074/jbc.M312260200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14709550	hybrid			2022-12-25	WOS:000220334900034
J	Bayle, J; Letard, B; Frank, R; Dubreuil, P; De Sepulveda, P				Bayle, J; Letard, B; Frank, R; Dubreuil, P; De Sepulveda, P			Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING SUPPRESSOR; INDUCED STAT INHIBITOR; SOCS-BOX MOTIF; C-KIT; NEGATIVE REGULATION; INSULIN-RECEPTOR; PROTEIN; KINASE; BINDS; ACTIVATION	Suppressor of cytokine signaling (SOCS) proteins are a family of Src homology 2-containing adaptor proteins. Cytokine-inducible Src homology domain 2-containing protein, SOCS1, SOCS2, and SOCS3 have been implicated in the down-regulation of cytokine signaling. The function of SOCS4, 5, 6, and 7 are not known. KIT receptor signaling is regulated by protein tyrosine phosphatases and adaptor proteins. We previously reported that SOCS1 inhibited cell proliferation in response to stem cell factor (SCF). By screening the other members of SOCS family, we identified SOCS6 as a KIT-binding protein. Using KIT mutants and peptides, we demonstrated that SOCS6 bound directly to KIT tyrosine 567 in the juxtamembrane domain. To investigate the function of this interaction, we constitutively expressed SOCS6 in cell lines. Ectopic expression of SOCS6 in Ba/F3-KIT cell line decreased cell proliferation in response to SCF but not SCF-induced chemotaxis. SOCS6 reduced SCF-induced activation of ERK1/2 and p38 but not activation of AKT or STATs in Ba/F3, murine embryonic fibroblast (MEF), or COS-7 cells. SOCS6 did not impair ERK and p38 activation by other stimuli. These results indicate that SOCS6 binds to KIT juxtamembrane region, which affects upstream signaling components leading to MAPK activation. Our results indicate that KIT signaling is regulated by several SOCS proteins and suggest a putative function for SOCS6 as a negative regulator of receptor tyrosine kinases.	INSERM, U119, Lab Hematopoiese Mol & Fonct, F-13009 Marseille, France; German Res Ctr Biotechnol, Res Grp Mol Recognit, D-38124 Braunschweig, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Helmholtz Association; Helmholtz-Center for Infection Research	De Sepulveda, P (corresponding author), INSERM, U119, Lab Hematopoiese Mol & Fonct, 27 Blvd Lei Roure, F-13009 Marseille, France.		dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019; De sepulveda, paulo/K-6043-2015	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; De sepulveda, paulo/0000-0001-8295-5414; LETARD, Sebastien/0000-0002-6508-7376				Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bourette RP, 2001, J BIOL CHEM, V276, P22133, DOI 10.1074/jbc.M101878200; Cunnick JM, 2002, J BIOL CHEM, V277, P9498, DOI 10.1074/jbc.M110547200; De Souza D, 2002, BIOCHEMISTRY-US, V41, P9229, DOI 10.1021/bi0259507; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Frank R, 1996, Methods Mol Biol, V66, P149; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Leung KC, 2003, P NATL ACAD SCI USA, V100, P1016, DOI 10.1073/pnas.0337600100; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; Ueda S, 2002, BLOOD, V99, P3342, DOI 10.1182/blood.V99.9.3342; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Wollberg P, 2003, BIOCHEM J, V370, P1033, DOI 10.1042/BJ20020716; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	43	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12249	12259		10.1074/jbc.M313381200	http://dx.doi.org/10.1074/jbc.M313381200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14707129	hybrid			2022-12-25	WOS:000220334900031
J	Fisher, N; Castleden, CK; Bourges, I; Brasseur, G; Dujardin, G; Meunier, B				Fisher, N; Castleden, CK; Bourges, I; Brasseur, G; Dujardin, G; Meunier, B			Human disease-related mutations in cytochrome b studied in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; SACCHAROMYCES-CEREVISIAE; BC(1) COMPLEX; Q(O) SITE; EXERCISE INTOLERANCE; MISSENSE MUTATION; C-OXIDASE; CENTER-N; GENE; MUTANTS	Several mutations in the mitochondrially encoded cytochrome b have been reported in patients. To characterize their effect, we introduced six " human" mutations, namely G33S, S152P, G252D, Y279C, G291D, and Delta 252 - 259 in the highly similar yeast cytochrome b. G252D showed wild type behavior in standard conditions. However, Asp- 252 may interfere with structural lipid and, in consequence, destabilize the enzyme assembly, which could explain the pathogenicity of the mutation. The mutations G33S, S152P, G291D, and Delta 252 - 259 were clearly pathogenic. They caused a severe decrease of the respiratory function and altered the assembly of the iron- sulfur protein in the bc(1) complex, as observed by immunodetection. Suppressor mutations that partially restored the respiratory function impaired by S152P or G291D were found in or close to the hinge region of the iron- sulfur protein, suggesting that this region may play a role in the stable binding of the subunit to the bc1 complex. Y279C caused a significant decrease of the bc1 function and perturbed the quinol binding. The EPR spectra showed an altered signal, indicative of a lower occupancy of the Q(o) site. The effect of human mutation of residue 279 was confirmed by another change, Y279A, which had a more severe effect on Q(o) site properties. Thus by using yeast as a model system, we identified the molecular basis of the respiratory defect caused by the disease mutations in cytochrome b.	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England; CNRS, Lab Bioenerget & Ingn Prot, F-13402 Marseille 20, France; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	University of London; University College London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Meunier, B (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.	b.meunier@ucl.ac.uk						Andreu AL, 2000, PEDIATR RES, V48, P311, DOI 10.1203/00006450-200009000-00008; Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404; BECKMANN JD, 1989, J BIOL CHEM, V264, P3713; Bonnefoy N, 2001, METHOD CELL BIOL, V65, P381, DOI 10.1016/S0091-679X(01)65022-2; BRASSEUR G, 1995, EUR J BIOCHEM, V230, P1118, DOI 10.1111/j.1432-1033.1995.tb20663.x; Brasseur G, 2001, BBA-BIOENERGETICS, V1506, P89, DOI 10.1016/S0005-2728(01)00186-4; BROWN S, 1993, EUR J BIOCHEM, V213, P137, DOI 10.1111/j.1432-1033.1993.tb17743.x; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; COPPEE JY, 1994, FEBS LETT, V339, P1, DOI 10.1016/0014-5793(94)80373-0; Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5; Ding H, 1995, BIOCHEMISTRY-US, V34, P15997, DOI 10.1021/bi00049a013; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Dumoulin R, 1996, MOL CELL PROBE, V10, P389, DOI 10.1006/mcpr.1996.0053; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P50703, DOI 10.1074/jbc.M208556200; Hill P, 2003, ANTIMICROB AGENTS CH, V47, P2725, DOI 10.1128/AAC.47.9.2725-2731.2003; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Legros F, 2001, EUR J HUM GENET, V9, P510, DOI 10.1038/sj.ejhg.5200678; Meunier B, 2002, BBA-BIOENERGETICS, V1554, P101, DOI 10.1016/S0005-2728(02)00217-7; Meunier B, 2001, BIOCHEM J, V354, P407, DOI 10.1042/0264-6021:3540407; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; Saint-Georges Y, 2002, J BIOL CHEM, V277, P49397, DOI 10.1074/jbc.M207219200; Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x; VANNESTE WH, 1966, BIOCHIM BIOPHYS ACTA, V113, P175, DOI 10.1016/S0926-6593(66)80132-7; Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224	26	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12951	12958		10.1074/jbc.M313866200	http://dx.doi.org/10.1074/jbc.M313866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718526	hybrid			2022-12-25	WOS:000220334900113
J	Fransen, M; Vastiau, I; Brees, C; Brys, V; Mannaerts, GP; Van Veldhoven, PP				Fransen, M; Vastiau, I; Brees, C; Brys, V; Mannaerts, GP; Van Veldhoven, PP			Potential role for Pex19p in assembly of PTS-receptor docking complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL DOCKING; TARGETING SIGNALS; MEMBRANE-PROTEINS; IMPORT; IDENTIFICATION; MULTIPLE; CELLS; LOCALIZATION; BIOGENESIS; MACHINERY	Human Pex19p binds a broad spectrum of peroxisomal membrane proteins (PMPs). It has been proposed that this peroxin may: (i) act as a cycling PMP receptor protein, (ii) facilitate the insertion of newly synthesized PMPs into the peroxisomal membrane, or (iii) function as a chaperone to associate and/or dissociate complexes comprising integral PMPs already in the peroxisomal membrane. We previously demonstrated that human Pex19p binds peroxisomal integral membrane proteins at regions distinct from their sorting sequences. Here we demonstrate that a mutant of Pex13p that fails to bind to Pex19p nevertheless targets to and integrates into the peroxisomal membrane. In addition, through in vitro biochemical analysis, we show that Pex19p competes with Pex5p and Pex13p for binding to Pex14p, supporting a role for this peroxin in regulating assembly/ disassembly of membrane-associated protein complexes. To further examine the molecular mechanism underlying this competition, six evolutionarily conserved amino acids in the Pex5p/Pex13p/Pex19p binding domain of Pex14p were subjected to site-directed mutagenesis and the corresponding mutants functionally analyzed. Our results indicate that the physically overlapping binding sites of Pex14p for Pex5p, Pex13p, and Pex19p are functionally distinct, suggesting that competition occurs through induction of structural changes, rather than through direct competition. Importantly, we also found that amino acid substitutions resulting in a strongly reduced binding affinity for Pex13p affect the peroxisomal localization of Pex14p.	Katholieke Univ Leuven, Fac Geneeskunde, Dept Mol Celbiol, Afdeling Farmacol, B-3000 Louvain, Belgium	KU Leuven	Fransen, M (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Dept Mol Celbiol, Afdeling Farmacol, Campus Gasthuisberg O-N,Herestr 49 O-N, B-3000 Louvain, Belgium.	marc.fransen@med.kuleuven.ac.be	Fransen, Marc/C-6262-2008; Fransen, Marc/ADL-0723-2022; , Van Veldhoven Paul/U-6359-2019	Fransen, Marc/0000-0001-9284-1197; , Van Veldhoven Paul/0000-0002-4478-2564				Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; Biermanns M, 2001, BIOCHEM BIOPH RES CO, V285, P649, DOI 10.1006/bbrc.2001.5220; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Brosius U, 2002, J BIOL CHEM, V277, P774, DOI 10.1074/jbc.M108155200; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Fransen M, 1999, BIOCHEM J, V340, P561, DOI 10.1042/0264-6021:3400561; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Ghys K, 2002, BIOCHEM J, V365, P41, DOI 10.1042/BJ20011432; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gloeckner CJ, 2000, BIOCHEM BIOPH RES CO, V271, P144, DOI 10.1006/bbrc.2000.2572; Hazra PP, 2002, TRAFFIC, V3, P560, DOI 10.1034/j.1600-0854.2002.30806.x; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Lambkin GR, 2001, MOL BIOL CELL, V12, P3353, DOI 10.1091/mbc.12.11.3353; Oliveira MEM, 2002, BBA-BIOMEMBRANES, V1567, P13, DOI 10.1016/S0005-2736(02)00635-1; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Reguenga C, 2001, J BIOL CHEM, V276, P29935, DOI 10.1074/jbc.M104114200; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; Sparkes IA, 2002, MOL MEMBR BIOL, V19, P171, DOI 10.1080/09687680210159422; Stein K, 2002, MOL CELL BIOL, V22, P6056, DOI 10.1128/MCB.22.17.6056-6069.2002; Terlecky SR, 2000, TRAFFIC, V1, P465, DOI 10.1034/j.1600-0854.2000.010604.x; VERHEYDEN K, 1992, BIOCHIM BIOPHYS ACTA, V1109, P48, DOI 10.1016/0005-2736(92)90185-O; Vizeacoumar FJ, 2003, J CELL BIOL, V161, P321, DOI 10.1083/jcb.200210130	31	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12615	12624		10.1074/jbc.M304941200	http://dx.doi.org/10.1074/jbc.M304941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715663	hybrid			2022-12-25	WOS:000220334900075
J	Liu, XQ; De Wulf, P				Liu, XQ; De Wulf, P			Probing the ArcA-P modulon of Escherichia coli by whole genome transcriptional analysis and sequence recognition profiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT REGULATORY SYSTEM; SIGNAL-TRANSDUCTION SYSTEM; SUCCINATE-DEHYDROGENASE; GENE-EXPRESSION; DNA-BINDING; MEDIATING REPRESSION; AEROBIC PATHWAYS; PROMOTER; FNR; OPERON	The ArcB/ArcA two-component signal transduction system of Escherichia coli regulates gene expression in response to the redox conditions of growth. Over the years, genetic screens have lead to the identification of about 30 ArcA-P-controlled operons that are involved in redox metabolism. However, the discovery of 3 targets that are not implicated in respiratory metabolism ( the tra operon for plasmid conjugation, psi site for Xer-based recombination, and oriC site for chromosome replication) suggests that the Arc modulon may comprise additional operons that are involved in a myriad of functions. To identify these operons, we derived the ArcA-P-dependent transcription profile of E. coli using oligonucleotide-based microarray analysis. The findings indicated that 9% of all open reading frames in E. coli are affected either directly or indirectly by ArcA-P. To identify which operons are under the direct control of ArcA-P, we developed the ArcA-P recognition weight matrix from footprinting data and used it to scan the genome, yielding an ArcA-P sequence affinity map. By overlaying both methods, we identified 55 new Arc-regulated operons that are implicated in energy metabolism, transport, survival, catabolism, and transcriptional regulation. The data also suggest that the Arc response pathway, which translates into a net global downscaling of gene expression, overlaps partly with the FNR regulatory network. A conservative but reasonable assessment is that the Arc pathway recruits 100 150 operons to mediate a role in cellular adaptation that is more extensive than hitherto anticipated.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	De Wulf, P (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	dewulf@mit.edu		LIU, XUEQIAO/0000-0001-7652-241X; De Wulf, Peter/0000-0001-9772-5881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Chao GL, 1997, J BACTERIOL, V179, P4299, DOI 10.1128/jb.179.13.4299-4304.1997; Colloms SD, 1998, MOL MICROBIOL, V28, P521, DOI 10.1046/j.1365-2958.1998.00812.x; COTTER PA, 1992, FEMS MICROBIOL LETT, V91, P31; Cunningham L, 1998, FEMS MICROBIOL LETT, V169, P403, DOI 10.1111/j.1574-6968.1998.tb13347.x; De Souza-Hart JA, 2003, INFECT IMMUN, V71, P163, DOI 10.1128/IAI.71.1.163-172.2003; De Wulf P, 2002, J BIOL CHEM, V277, P26652, DOI 10.1074/jbc.M203487200; DRAPAL N, 1995, MOL MICROBIOL, V16, P597, DOI 10.1111/j.1365-2958.1995.tb02422.x; FU HA, 1991, MOL GEN GENET, V226, P209, DOI 10.1007/BF00273605; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; HASSAN HM, 1994, FEMS MICROBIOL REV, V14, P315, DOI 10.1111/j.1574-6976.1994.tb00105.x; IUCHI S, 1989, J BACTERIOL, V171, P868, DOI 10.1128/jb.171.2.868-873.1989; IUCHI S, 1994, J BACTERIOL, V176, P1695, DOI 10.1128/jb.176.6.1695-1701.1994; IUCHI S, 1993, MOL MICROBIOL, V9, P9, DOI 10.1111/j.1365-2958.1993.tb01664.x; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; IUCHI S, 1995, 2 COMPONENT SIGNAL T, P223; Jeon Y, 2001, J BIOL CHEM, V276, P40873, DOI 10.1074/jbc.M104855200; Kim SJ, 1999, IUBMB LIFE, V48, P215, DOI 10.1080/713803496; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Lee YS, 2001, J BIOL CHEM, V276, P9917, DOI 10.1074/jbc.M008629200; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Lynch A. Simon, 1996, P361; Lynch AS, 1996, J BACTERIOL, V178, P6238, DOI 10.1128/JB.178.21.6238-6249.1996; McGuire AM, 1999, MOL MICROBIOL, V32, P219, DOI 10.1046/j.1365-2958.1999.01347.x; Oshima T, 2002, MOL MICROBIOL, V46, P281, DOI 10.1046/j.1365-2958.2002.03170.x; PARK SJ, 1995, MOL MICROBIOL, V15, P473, DOI 10.1111/j.1365-2958.1995.tb02261.x; Pellicer MT, 1999, MOL GEN GENET, V261, P170, DOI 10.1007/s004380050954; Pellicer MT, 1999, J BIOL CHEM, V274, P1745, DOI 10.1074/jbc.274.3.1745; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Robison K, 1998, J MOL BIOL, V284, P241, DOI 10.1006/jmbi.1998.2160; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Sengupta N, 2003, INFECT IMMUN, V71, P5583, DOI 10.1128/IAI.71.10.5583-5589.2003; Shen J, 1997, MOL MICROBIOL, V26, P223, DOI 10.1046/j.1365-2958.1997.5561923.x; Strohmaier H, 1998, J MOL BIOL, V277, P309, DOI 10.1006/jmbi.1997.1598; Tani TH, 2002, P NATL ACAD SCI USA, V99, P13471, DOI 10.1073/pnas.212510999; TARDAT B, 1991, MOL MICROBIOL, V5, P455, DOI 10.1111/j.1365-2958.1991.tb02129.x; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	42	159	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12588	12597		10.1074/jbc.M313454200	http://dx.doi.org/10.1074/jbc.M313454200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711822	hybrid			2022-12-25	WOS:000220334900072
J	Takasaki, K; Shoun, H; Yamaguchi, M; Takeo, K; Nakamura, A; Hoshino, T; Takaya, N				Takasaki, K; Shoun, H; Yamaguchi, M; Takeo, K; Nakamura, A; Hoshino, T; Takaya, N			Fungal ammonia fermentation, a novel metabolic mechanism that couples the dissimilatory and assimilatory pathways of both nitrate and ethanol - Role of acetyl CoA synthetase in anaerobic ATP synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-OXYSPORUM; DENITRIFICATION; GENE; REDUCTION; PURIFICATION; INVOLVEMENT; EXPRESSION; COENZYME; CLONING; ENZYME	Fungal ammonia fermentation is a novel dissimilatory metabolic mechanism that supplies energy under anoxic conditions. The fungus Fusarium oxysporum reduces nitrate to ammonium and simultaneously oxidizes ethanol to acetate to generate ATP (Zhou, Z., Takaya, N., Nakamura, A., Yamaguchi, M., Takeo, K., and Shoun, H. (2002) J. Biol. Chem. 277, 1892-1896). We identified the Aspergillus nidulans genes involved in ammonia fermentation by analyzing fungal mutants. The results showed that assimilatory nitrate and nitrite reductases (the gene products of niaD and niiA) were essential for reducing nitrate and for anaerobic cell growth during ammonia fermentation. We also found that ethanol oxidation is coupled with nitrate reduction and catalyzed by alcohol dehydrogenase, coenzyme A (CoA)-acylating aldehyde dehydrogenase, and acetyl-CoA synthetase (Acs). This is similar to the mechanism suggested in F. oxysporum except A. nidulans uses Acs to produce ATP instead of the ADP-dependent acetate kinase of F. oxysporum. The production of Acs requires a functional facA gene that encodes Acs and that is involved in ethanol assimilation and other metabolic processes. We purified the gene product of facA (FacA) from the fungus to show that the fungus acetylates FacA on its lysine residue(s) specifically under conditions of ammonia fermentation to regulate its substrate affinity. Acetylated FacA had higher affinity for acetyl-CoA than for acetate, whereas non-acetylated FacA had more affinity for acetate. Thus, the acetylated variant of the FacA protein is responsible for ATP synthesis during fungal ammonia fermentation. These results showed that the fungus ferments ammonium via coupled dissimilatory and assimilatory mechanisms.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Chiba Univ, Pathogen Fungi & Microbial Toxicoses Res Ctr, Chiba 2608673, Japan	University of Tsukuba; University of Tokyo; Chiba University	Takaya, N (corresponding author), Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan.	ntakaya@sakura.cc.tsukuba.ac.jp		Nakamura, Akira/0000-0001-7250-7175				BARRATT RW, 1965, GENETICS, V52, P233; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; COVE DJ, 1979, BIOL REV, V54, P291, DOI 10.1111/j.1469-185X.1979.tb01014.x; Felenbok B, 2001, PROG NUCLEIC ACID RE, V69, P149, DOI 10.1016/S0079-6603(01)69047-0; Fujinaga K, 1999, MICROBIOL-SGM, V145, P3377, DOI 10.1099/00221287-145-12-3377; HASAN SM, 1975, J GEN MICROBIOL, V87, P120, DOI 10.1099/00221287-87-1-120; JOHNSTONE LL, 1992, GENE, V111, P149; JOSE MV, 1975, J BIOL CHEM, V250, P7980; Kobayashi M, 1996, J BIOL CHEM, V271, P16263, DOI 10.1074/jbc.271.27.16263; Kurakov AV, 2000, CURR MICROBIOL, V41, P114, DOI 10.1007/s002840010104; Lin JT, 1998, ADV MICROB PHYSIOL, V39, P1; LOCKINGTON RA, 1985, GENE, V33, P137, DOI 10.1016/0378-1119(85)90088-5; Mai XH, 1996, J BACTERIOL, V178, P5897, DOI 10.1128/jb.178.20.5897-5903.1996; MARTINEZBLANCO H, 1992, J BIOL CHEM, V267, P5474; MARZLUF GA, 1993, ANNU REV MICROBIOL, V47, P31, DOI 10.1146/annurev.micro.47.1.31; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; Sanchez LB, 1996, FEBS LETT, V378, P240, DOI 10.1016/0014-5793(95)01463-2; SANDEMAN RA, 1989, MOL GEN GENET, V218, P87, DOI 10.1007/BF00330569; SCHIMPFE.L, 1968, BIOCHIM BIOPHYS ACTA, V151, P317, DOI 10.1016/0005-2744(68)90099-5; SHOUN H, 1992, FEMS MICROBIOL LETT, V94, P277, DOI 10.1111/j.1574-6968.1992.tb05331.x; SHOUN H, 1991, J BIOL CHEM, V266, P11078; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Takaya N, 2000, MOL GEN GENET, V263, P342, DOI 10.1007/s004380051177; Uchimura H, 2002, J BIOCHEM, V131, P579, DOI 10.1093/oxfordjournals.jbchem.a003137; Watsuji T, 2003, BIOSCI BIOTECH BIOCH, V67, P1115, DOI 10.1271/bbb.67.1115; YAMAGUCHI M, 1994, J ELECTRON MICROSC, V43, P386; Zhou ZM, 2002, J BIOL CHEM, V277, P1892, DOI 10.1074/jbc.M109096200; Zhou ZM, 2001, ARCH MICROBIOL, V175, P19, DOI 10.1007/s002030000231; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	31	78	85	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12414	12420		10.1074/jbc.M313761200	http://dx.doi.org/10.1074/jbc.M313761200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722082	hybrid			2022-12-25	WOS:000220334900050
J	Thuahnai, ST; Lund-Katz, S; Dhanasekaran, P; de la Llera-Moya, M; Connelly, MA; Williams, DL; Rothblat, GH; Phillips, MC				Thuahnai, ST; Lund-Katz, S; Dhanasekaran, P; de la Llera-Moya, M; Connelly, MA; Williams, DL; Rothblat, GH; Phillips, MC			Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol - Influence of high density lipoprotein size and structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; SR-BI; BINDING; CELLS; CONFORMATION; PARTICLES; SURFACE; DOMAIN; LIPIDS; SITES	Scavenger receptor (SR)-BI catalyzes the selective uptake of cholesteryl ester (CE) from high density lipoprotein (HDL) by a two-step process that involves the following: 1) binding of HDL to the receptor and 2) diffusion of the CE molecules into the cell plasma membrane. We examined the effects of the size of discoidal HDL particles containing wild-type (WT) apoA-I on selective uptake of CE and efflux of cellular free (unesterified) cholesterol (FC) from COS-7 cells expressing SR-BI to determine the following: 1) the influence of apoA-I conformation on the lipid transfer process, and 2) the contribution of receptor binding-dependent processes to the overall efflux of cellular FC. Large ( 10 nm diameter) reconstituted HDL bound to SR-BI better (B-max similar to420 versus 220 ng of apoA-I/mg cell protein), delivered more CE, and promoted more FC efflux than small ( similar to 8 nm) particles. When normalized to the number of reconstituted HDL particles bound to the receptor, the efficiencies of either CE uptake or FC efflux with these particles were the same indicating that altering the conformation of WT apoA-I modulates binding to the receptor ( step 1) but does not change the efficiency of the subsequent lipid transfer ( step 2); this implies that binding induces an optimal alignment of the WT apoA-I.SR- BI complex so that the efficiency of lipid transfer is always the same. FC efflux to HDL is affected both by binding of HDL to SR-BI and by the ability of the receptor to perturb the packing of FC molecules in the cell plasma membrane.	Univ Penn, Childrens Hosp Philadelphia, Sch Med,Abramson Res Ctr, Div GI Nutr,Lipid Res Grp, Philadelphia, PA 19104 USA; SUNY Stony Brook, Univ Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Phillips, MC (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med,Abramson Res Ctr, Div GI Nutr,Lipid Res Grp, Suite 1102,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	phillipsmi@email.chop.edu		Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, R01HL063768] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63768, HL 22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; de Beer MC, 2001, J LIPID RES, V42, P309; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Liu T, 2002, J BIOL CHEM, V277, P21576, DOI 10.1074/jbc.M112103200; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; ONNELLY MA, 2003, J BIOL CHEM, V278, P25773; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Rothblat GH, 1999, J LIPID RES, V40, P781; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; Thuahnai ST, 2003, J LIPID RES, V44, P1132, DOI 10.1194/jlr.M200429-JLR200; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Tricerri MA, 2002, J LIPID RES, V43, P187; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Williams DL, 1999, CURR OPIN LIPIDOL, V10, P329, DOI 10.1097/00041433-199908000-00007; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200	27	78	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12448	12455		10.1074/jbc.M311718200	http://dx.doi.org/10.1074/jbc.M311718200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718538	hybrid			2022-12-25	WOS:000220334900054
J	Zhao, Q; Boschelli, F; Caplan, AJ; Arndt, KT				Zhao, Q; Boschelli, F; Caplan, AJ; Arndt, KT			Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHYSICAL INTERACTION; MOLECULAR CHAPERONE; STRUCTURAL BASIS; PROTEIN-KINASES; P50(CDC37); HSP90; RECEPTOR; CDC28; PHOSPHORYLATION	Cdc37 is a molecular chaperone that is important for the stability and activity of several protein kinases, including Cdk4 and Raf1. We first determined, using in vitro assays, that Cdc37 binds to the amino-terminal lobe of Cdk4. Subsequent mutagenesis revealed that Gly-15 (G15A) and Gly-18 (G18A) were critical for Cdc37-Cdk4 complex formation. Gly-15 and Gly-18 of Cdk4 are within the conserved Gly-X-Gly-X-X-Gly motif that is required for ATP binding to the kinase. Mutation of either glycine at the equivalent positions of Raf1 (G358A and G361A) also inhibited Cdc37 binding to Raf1. Replacing another conserved residue critical for ATP binding and kinase activity, Lys-35 (K35A), reduced Cdc37-Cdk4 complex formation but to a lesser extent. The interaction of Cdk4 with Cdc37 in vitro was not sensitive to changes in ATP levels. Cell-based assays indicated that Cdk4(G15A) and Cdk4(G18A) were present at the same level as wild type Cdk4. Equivalent amounts of p16 bound to Cdk4G15A and Cdk4(G18A) relative to wild type Cdk4, suggesting that Cdk4(G15A) and Cdk4(G18A) adopt significant tertiary structure. However, in contrast to wild type Cdk4, Cdk4(G15A), and Cdk4(G18A) had greatly reduced binding of cyclin D1, Cdc37, and Hsp90. Importantly, overexpression of Cdc37 not only stimulated cyclin D1 binding to wild type Cdk4 but also restored its binding to Cdk4(G15A). Under the same conditions, p16 binding to wild type Cdk4 was suppressed. Our findings show that the interaction of Cdc37 with its client protein kinases requires amino acid residues within a motif that is present in many protein kinases.	Wyeth Res, Dept Oncol, Pearl River, NY 10965 USA; Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Pfizer; Icahn School of Medicine at Mount Sinai	Arndt, KT (corresponding author), Wyeth Res, Dept Oncol, 401 N Middletown Rd, Pearl River, NY 10965 USA.	arndtk1@wyeth.com	Caplan, Avrom/GPT-0824-2022					Abbas-Terki T, 2000, FEBS LETT, V467, P111, DOI 10.1016/S0014-5793(00)01134-0; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; BRUGGE JS, 1982, NATURE, V295, P250, DOI 10.1038/295250a0; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Dey B, 1996, MOL BIOL CELL, V7, P1405, DOI 10.1091/mbc.7.9.1405; Farrell A, 2000, MOL CELL BIOL, V20, P749, DOI 10.1128/MCB.20.3.749-754.2000; FERGUSON J, 1986, NUCLEIC ACIDS RES, V14, P6681, DOI 10.1093/nar/14.16.6681; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; Konstantinidis AK, 1998, J BIOL CHEM, V273, P26506, DOI 10.1074/jbc.273.41.26506; Kumar R, 2001, J BIOL CHEM, V276, P11371, DOI 10.1074/jbc.M010480200; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Lange BMH, 2002, EMBO J, V21, P5364, DOI 10.1093/emboj/cdf531; Lee P, 2002, J CELL BIOL, V159, P1051, DOI 10.1083/jcb.200210121; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Mort-Bontemps-Soret M, 2002, MOL GENET GENOMICS, V267, P447, DOI 10.1007/s00438-002-0676-3; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rao J, 2001, J BIOL CHEM, V276, P5814, DOI 10.1074/jbc.M007385200; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Scholz G, 2000, MOL CELL BIOL, V20, P6984, DOI 10.1128/MCB.20.18.6984-6995.2000; Schulze-Gahmen U, 2002, NAT STRUCT BIOL, V9, P177, DOI 10.1038/nsb756; Schutz AR, 1997, J CELL BIOL, V136, P969, DOI 10.1083/jcb.136.5.969; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang XT, 2002, J BIOL CHEM, V277, P24361, DOI 10.1074/jbc.M202198200	42	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12560	12564		10.1074/jbc.M308242200	http://dx.doi.org/10.1074/jbc.M308242200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701845	hybrid			2022-12-25	WOS:000220334900068
J	Yanamandra, N; Gumidyala, KV; Waldron, KG; Gujrati, M; Olivero, WC; Dinh, D; Rao, JS; Mohanam, S				Yanamandra, N; Gumidyala, KV; Waldron, KG; Gujrati, M; Olivero, WC; Dinh, D; Rao, JS; Mohanam, S			Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis	ONCOGENE			English	Article						cathepsin B; angiogenesis; glioblastoma; antisense	ENDOTHELIAL GROWTH-FACTOR; SQUAMOUS CARCINOMA-CELLS; HUMAN BRAIN-TUMORS; IN-VITRO; CYSTEINE PROTEINASES; INVASIVE PROPERTIES; VEGF EXPRESSION; DOWN-REGULATION; ENZYME-ACTIVITY; IV COLLAGENASE	The cysteine proteinase cathepsin B has been implicated in tumor progression by virtue of its increased mRNA and protein levels, as well as its localization at the invading front of the tumor. In this study, we examined whether blocking cathepsin B expression in human glioblastoma SNB19 cells affects angiogenesis. Stable transfectants of human glioblastoma cells with a plasmid containing antisense cathepsin B cDNA showed decreased migration rates in wound- and spheroid- migration assays. Analysis showed a reduction in VEGF protein and MMP- 9 activity in the cathepsin B antisense cDNA- transfected cells. Regarding angiogenesis in vitro, we found that the conditioned medium of glioblastoma cells with downregulated cathepsin B expression reduced cell - cell interaction of human microvascular endothelial cells, resulting in the disruption of capillary- like network formation. Furthermore, a marked reduction in microvasculature development was seen in an in vivo dorsal air sac assay of glioblastoma cells with downregulated cathepsin B expression. Taken together, these results provide evidence that inhibition of cathepsin B expression can suppress glioblastoma- induced neovascularization.	Univ Illinois, Coll Med, Program Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Mohanam, S (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, 1 Illini Dr,Box 1649, Peoria, IL 61656 USA.	smohanam@uic.edu			NATIONAL CANCER INSTITUTE [R01CA076350, R01CA075557, R01CA085216, R01CA092393] Funding Source: NIH RePORTER; NCI NIH HHS [CA76350, CA75557, CA92393, CA85216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CAO LQ, 1994, GENE, V139, P163, DOI 10.1016/0378-1119(94)90750-1; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; Chandrasekar N, 2000, CLIN EXP METASTAS, V18, P337, DOI 10.1023/A:1010833730407; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Creemers LB, 1998, MATRIX BIOL, V16, P575, DOI 10.1016/S0945-053X(98)90068-3; Demchik LL, 1999, INT J DEV NEUROSCI, V17, P483, DOI 10.1016/S0736-5748(99)00011-8; GARRIDO T, 1995, BRIT J CANCER, V71, P770, DOI 10.1038/bjc.1995.149; GUINEC N, 1993, BIOL CHEM H-S, V374, P1135, DOI 10.1515/bchm3.1993.374.7-12.1135; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; Hizel C, 1998, ONCOL REP, V5, P31; Hughes SJ, 1998, P NATL ACAD SCI USA, V95, P12410, DOI 10.1073/pnas.95.21.12410; IacobuzioDonahue CA, 1997, J BIOL CHEM, V272, P29190, DOI 10.1074/jbc.272.46.29190; Kachra Z, 1999, CLIN EXP METASTAS, V17, P555, DOI 10.1023/A:1006760632766; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Kruger S, 1999, CANCER RES, V59, P6010; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Lopes MBS, 2003, MICROSC RES TECHNIQ, V60, P225, DOI 10.1002/jemt.10260; Lorenzo K, 2000, CANCER RES, V60, P4070; Machein MR, 2000, J NEURO-ONCOL, V50, P109, DOI 10.1023/A:1006416003964; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Miyoshi C, 2001, IN VIVO, V15, P233; Mohanam S, 2001, ONCOGENE, V20, P3665, DOI 10.1038/sj.onc.1204480; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; NAKAO H, 1989, INT J BIOCHEM, V21, P739; Nirmala C, 2000, INT J CANCER, V88, P766, DOI 10.1002/1097-0215(20001201)88:5<766::AID-IJC13>3.0.CO;2-Y; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RAO JS, 1993, CANCER RES, V53, P2208; Sameni Mansoureh, 1995, Pathol Oncol Res, V1, P43; SLOANE BF, 1994, J CELL SCI, V107, P373; SPIESS E, 1994, J HISTOCHEM CYTOCHEM, V42, P917, DOI 10.1177/42.7.8014475; Strojnik T, 1999, CLIN CANCER RES, V5, P559; Szpaderska AM, 2001, CANCER RES, V61, P3493; Venetsanakos E, 2002, EXP CELL RES, V273, P21, DOI 10.1006/excr.2001.5424; Virgintino D, 2003, HISTOCHEM CELL BIOL, V119, P227, DOI 10.1007/s00418-003-0510-y; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wesseling P, 1997, J NEURO-ONCOL, V32, P253, DOI 10.1023/A:1005746320099	43	72	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2224	2230		10.1038/sj.onc.1207338	http://dx.doi.org/10.1038/sj.onc.1207338			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14730346				2022-12-25	WOS:000220280900012
J	Wu, MC; Ho, SM				Wu, MC; Ho, SM			PMP24, a gene identified by MSRF, undergoes DNA hypermethylation-associated gene silencing during cancer progression in an LNCaP model	ONCOGENE			English	Article						peroxisome; androgen independency; prostate neoplasm; epigenetic regulation of gene expression; 5-aza-2 '-deoxycytidine; bisulfite genomic sequencing	HUMAN PROSTATE-CANCER; ARBITRARILY PRIMED-PCR; HUMAN TUMOR-CELLS; CPG ISLAND; METHYLATION DIFFERENCES; EPIGENETIC REGULATION; EPITHELIAL-CELLS; MEMBRANE-PROTEIN; SUPPRESSOR GENE; RECEPTOR GENE	Transcriptional silencing of antitumor genes via CpG island methylation could be a mechanism mediating prostate cancer (PCa) progression from an androgen-sensitive (AS) to an androgen-insensitive (AI) state. We have used the (m) under bar ethylation-(s) under bar ensitive (r) under bar estriction (f) under bar ingerprinting (MSRF) technique to identify novel CpG-rich sequences that are differentially methylated between the genome of the AS PCa cell line LNCaP and that of an AI subline LNCaPCS generated by maintaining LNCaP in medium with charcoal-stripped (CS) serum for over 30 passages. One such sequence identified was located on a 5' CpG island that was found to span part of the promoter, exon 1, and part of intron 1 of the (p) under bar eroxisomal (m) under bar embrane (p) under bar rotein 24 kDa (PMP24) gene. Using semiquantitative RT-PCR and bisulfite genomic sequencing, we established an inverse relationship between mRNA expression and methylation of the 5' CpG island of PMP24. PMP24 mRNA was absent in LNCaPCS and the androgen receptor-negative PC-3 cell line; both exhibited dense methylation in the said CpG island. In contrast, PMP24 mRNA was expressed in LNCaP and normal prostatic epithelial cells (NPrECs) whose PMP24 5' CpG island remained unmethylated. Treatment of LNCaPCS and PC-3 with the demethylating agent 5-aza-2'-deoxycytidine (5-AZAdC) reactivated PMP24 mRNA expression. Transient transfection of PMP24 into LNCaPCS and PC-3 cells induced a significant reduction in cell growth and soft-agar colony formation potential, suggesting that PMP24 gene product has antitumor properties. These results demonstrate the utility of MSRF in the identification of novel, differentially methylated DNA sequences in the genome and suggest that hypermethylation-mediated silencing of PMP24 is an epigenetic event involved in PCa progression to androgen independence.	Univ Massachusetts, Sch Med, Dept Surg, Div Urol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Interdisciplinary Grad Program, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Div Urol, Rm 504,Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	Shuk-Mei.Ho@umassmed.edu			NCI NIH HHS [CA94221, CA62269] Funding Source: Medline; NIDDK NIH HHS [DK61084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094221, R01CA062269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BRYANT DD, 1995, BIOCHEM MOL MED, V55, P22, DOI 10.1006/bmme.1995.1027; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Davies Catherine S, 2002, Methods Mol Biol, V200, P43; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; El Yaagoubi M, 1998, BIOCHEM MOL BIOL INT, V46, P321; Esteller M, 2000, CANCER RES, V60, P129; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gonzalgo ML, 1997, CANCER RES, V57, P594; GRAFF JR, 1995, CANCER RES, V55, P5195; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; HAYATSU H, 1970, J AM CHEM SOC, V92, P724, DOI 10.1021/ja00706a062; Huang THM, 1997, CANCER RES, V57, P1030; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jarrard DF, 1997, CLIN CANCER RES, V3, P2121; Jarrard DF, 1998, CANCER RES, V58, P5310; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; Johnson TL, 2001, PLANT PHYSIOL, V127, P731, DOI 10.1104/pp.010262; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kibel AS, 2001, PROSTATE, V48, P248, DOI 10.1002/pros.1104; Kohno T, 1998, HUM GENET, V102, P258, DOI 10.1007/s004390050689; Kuzmin I, 2002, CANCER RES, V62, P3498; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lau KM, 2000, CANCER RES, V60, P3175; Lauer C, 1999, CARCINOGENESIS, V20, P985, DOI 10.1093/carcin/20.6.985; Liang G, 1998, GENOMICS, V53, P260, DOI 10.1006/geno.1998.5502; Liang GG, 2002, METHODS, V27, P150, DOI 10.1016/S1046-2023(02)00068-3; Liang GN, 2000, CANCER RES, V60, P4907; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Lou W, 1999, CANCER RES, V59, P2329; MARSHALL KG, 1995, JAMA-J AM MED ASSOC, V274, P607, DOI 10.1001/jama.1995.03530080023020; Masters C, 1998, MOL CELL BIOCHEM, V187, P85, DOI 10.1023/A:1006863123068; Mobley JA, 2003, CANCER EPIDEM BIOMAR, V12, P775; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190; Nelson JB, 1997, CANCER RES, V57, P35; Newling DWW, 1996, EUR UROL, V29, P69; Reguenga C, 1999, BBA-GENE STRUCT EXPR, V1445, P337, DOI 10.1016/S0167-4781(99)00061-5; Robbins SE, 1996, PROSTATE, V29, P362; Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X; SALMON SE, 1978, NEW ENGL J MED, V298, P1321, DOI 10.1056/NEJM197806152982401; SCHER HI, 1995, UROLOGY, V46, P142, DOI 10.1016/S0090-4295(99)80182-4; Schmitt JF, 2002, MOL ENDOCRINOL, V16, P213, DOI 10.1210/me.16.2.213; Singal R, 2001, CANCER RES, V61, P4820; Singh S, 2003, CANCER RES, V63, P2306; Syed V, 2001, CANCER RES, V61, P6768; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Taplin ME, 2001, J CLIN ENDOCR METAB, V86, P3467, DOI 10.1210/jc.86.8.3467; Tekur S, 2001, MOL CARCINOGEN, V30, P1, DOI 10.1002/1098-2744(200101)30:1<1::AID-MC1008>3.0.CO;2-X; Toyota M, 1999, CANCER RES, V59, P2307; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Verkaik NS, 1999, INT J CANCER, V80, P439; WANG RYH, 1980, NUCLEIC ACIDS RES, V8, P4777, DOI 10.1093/nar/8.20.4777; Zheng SL, 2001, HUM GENET, V108, P430, DOI 10.1007/s004390100513	58	28	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					250	259		10.1038/sj.onc.1207076	http://dx.doi.org/10.1038/sj.onc.1207076			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712230				2022-12-25	WOS:000187895300026
J	Chen, WJ; Lin, JK				Chen, WJ; Lin, JK			Induction of G(1) arrest and apoptosis in human Jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27(Kip1), p21(Cip1/WAF1), and Bax proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED DEGRADATION; CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; BETA-D-GLUCOSE; DOWN-REGULATION; CALPAIN INHIBITOR; IN-VITRO; 20 S; ACTIVATION; PATHWAY	Pentagalloylglucose, which is found in many medicinal plants, can arrest the cell cycle at G(1) phase through down-regulation of cyclin-dependent kinases 2 and 4 and up-regulation of the cyclin-dependent kinase inhibitors p27(Kip1) and p21(Cip1/WAF1) in human breast cancer cells. Pentagalloylglucose also induces apoptosis in human leukemic cells. However, the mechanisms by which pentagalloylglucose induces these effects is unclear. We now show that pentagalloylglucose inhibits the activities of purified 20 and 26 S proteasomes in vitro, the 26 S proteasome in Jurkat T cell lysates, and chymotrypsin-like activity of the 26 S proteasome in intact Jurkat T cells. The turnover of p27(Kip1) and p21(Cip1/WAF1), which is necessary for cell cycle progression mediated by proteasome degradation, was disrupted by treatment of human Jurkat T cells with pentagalloylglucose. This was shown by cycloheximide treatment and in vivo pulse-chase labeling experiments, and this effect correlated with the arrest of proliferation of Jurkat T cells at G(1). Inhibition of the proteasome by pentagalloylglucose and by the proteasome inhibitor MG132 caused accumulation of ubiquitin-tagged proteins in Jurkat T cells. The addition of pentagalloylglucose to Jurkat T cells enhanced the stability of the proteasome substrate Bax and increased cytochrome c release and apoptosis. Our findings suggest a mechanism for the effect of pentagalloylglucose on the cell cycle in human leukemic cells: that pentagalloylglucose down-regulates proteasome-mediated pathways because it is a proteasome inhibitor.	Natl Taiwan Univ, Coll Med, Inst Biochem & Cell Biol, Taipei, Taiwan	National Taiwan University	Lin, JK (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem & Cell Biol, No 1,Sect 1,Jen Ai Rd, Taipei, Taiwan.	jklin@ha.mc.ntu.edu.tw						ADACHI H, 1989, CHEM PHARM BULL, V37, P1341; Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Adams J, 1998, BIOORG MED CHEM LETT, V8, P333, DOI 10.1016/S0960-894X(98)00029-8; Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; CANNELL RJP, 1998, BIOCHEM J, V255, P937; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHEN WJ, BIOCH PHARM, V65, P1777; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dawson S, 2002, J BIOL CHEM, V277, P10893, DOI 10.1074/jbc.M107313200; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Feldman KS, 2001, BIOORG MED CHEM LETT, V11, P1813, DOI 10.1016/S0960-894X(01)00332-8; Gardner RC, 2000, BIOCHEM J, V346, P447, DOI 10.1042/0264-6021:3460447; Goto H, 1996, PLANTA MED, V62, P436, DOI 10.1055/s-2006-957934; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAYASHI T, 1989, J NAT PROD, V52, P210, DOI 10.1021/np50061a035; Hideshima T, 2001, CANCER RES, V61, P3071; Ho LL, 2002, EUR J PHARMACOL, V453, P149, DOI 10.1016/S0014-2999(02)02340-3; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Ikebe T, 1998, INT J CANCER, V77, P578; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Konishi K, 1999, BIOL PHARM BULL, V22, P240, DOI 10.1248/bpb.22.240; KONISHI K, 1990, CHEM PHARM BULL, V38, P474, DOI 10.1248/cpb.38.474; KONISHI K, 1993, BIOL PHARM BULL, V16, P716; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; LIN JH, 1990, CHEM PHARM BULL, V38, P1218, DOI 10.1248/cpb.38.1218; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009.abs; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Nam S, 2001, CANCER EPIDEM BIOMAR, V10, P1083; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Niedermann G, 1999, IMMUNOL REV, V172, P29, DOI 10.1111/j.1600-065X.1999.tb01354.x; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Oikawa T, 1998, BIOCHEM BIOPH RES CO, V246, P243, DOI 10.1006/bbrc.1998.8604; Ono K, 2000, CLIN CHIM ACTA, V290, P159, DOI 10.1016/S0009-8981(99)00184-9; Orlowski M, 2000, ARCH BIOCHEM BIOPHYS, V383, P1, DOI 10.1006/abbi.2000.2036; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pan MH, 2000, BIOCHEM PHARMACOL, V59, P357, DOI 10.1016/S0006-2952(99)00335-4; Pan MH, 1999, EUR J PHARMACOL, V381, P171, DOI 10.1016/S0014-2999(99)00549-X; Pan MH, 2001, J AGR FOOD CHEM, V49, P1464, DOI 10.1021/jf001129v; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PINTER M, 1994, NEUROSCI LETT, V170, P91, DOI 10.1016/0304-3940(94)90246-1; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; SUGAYA A, 1991, J ETHNOPHARMACOL, V33, P159, DOI 10.1016/0378-8741(91)90174-C; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; Wang IK, 1999, EUR J CANCER, V35, P1517, DOI 10.1016/S0959-8049(99)00168-9; Wang IK, 2000, PHARMACOL TOXICOL, V86, P83, DOI 10.1034/j.1600-0773.2000.d01-16.x	62	49	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13496	13505		10.1074/jbc.M212390200	http://dx.doi.org/10.1074/jbc.M212390200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726525	hybrid			2022-12-25	WOS:000220478500028
J	Murray, DS; Schumacher, MA; Brennan, RG				Murray, DS; Schumacher, MA; Brennan, RG			Crystal structures of QacR-diamidine complexes reveal additional multidrug-binding modes and a novel mechanism of drug charge neutralization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; EFFLUX PUMP; DNA-BINDING; PROTEIN; RECOGNITION; RESISTANCE; CHEMISTRY; RESIDUES	The Staphylococcus aureus multidrug-binding protein QacR represses transcription of the plasmid-encoded membrane protein QacA, a multidrug efflux transporter. QacR is induced by multiple structurally dissimilar monovalent and bivalent cationic lipophilic compounds, many of which are effluxed from the cell by QacA via the proton motive force. The multidrug-binding pocket of QacR has been shown to be quite extensive and features several glutamates and multiple aromatic residues. To date, the structure of only one QacR-bivalent cationic drug complex ( that of QacR bound to dequalinium) has been determined, and how other longer or shorter bivalent cationic compounds bind is unknown. Here we report the crystal structures of QacR bound to two cytotoxic bivalent diamidines, pentamidine and hexamidine. These compounds are structurally similar, differing by only one methylene carbon in the alkyl chain linker. However, this small difference results in very dissimilar binding modes. Similar to dequalinium, hexamidine spans the multidrug-binding pocket, and its positively charged benzamidine groups are neutralized by residues Glu-57 and Glu-120. Pentamidine binds QacR in a novel fashion whereby one of its benzamidine groups interacts with residue Glu-63, and the other is neutralized by carbonyl and side chain oxygen atoms. Thus, these structures demonstrate that a formal negative charge is not a prerequisite for binding positively charged drugs and underscore the versatility of the QacR and, likely, all multidrug-binding pockets.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Brennan, RG (corresponding author), 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	brennanr@ohsu.edu		Brennan, Richard/0000-0001-7647-485X	NIAID NIH HHS [AI48593] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048593] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aramaki H, 1995, PROTEIN ENG, V8, P1259, DOI 10.1093/protein/8.12.1259; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brown MH, 2001, J MOL MICROB BIOTECH, V3, P163; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casewell M, 2003, J ANTIMICROB CHEMOTH, V52, P159, DOI 10.1093/jac/dkg313; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Grkovic S, 2001, J BACTERIOL, V183, P7102, DOI 10.1128/JB.183.24.7102-7109.2001; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hiramatsu K, 2002, CURR OPIN INFECT DIS, V15, P407, DOI 10.1097/00001432-200208000-00009; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Levy SB, 2001, CLIN INFECT DIS, V33, pS124, DOI 10.1086/321837; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; LITTLEJOHN TG, 1992, FEMS MICROBIOL LETT, V95, P259; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McKeegan KS, 2003, TRENDS MICROBIOL, V11, P21, DOI 10.1016/S0966-842X(02)00010-0; Mitchell BA, 1998, ANTIMICROB AGENTS CH, V42, P475; Neyfakh AA, 2002, MOL MICROBIOL, V44, P1123, DOI 10.1046/j.1365-2958.2002.02965.x; Rayment I, 1997, METHOD ENZYMOL, V276, P171, DOI 10.1016/S0076-6879(97)76058-0; Saier MH, 1998, FASEB J, V12, P265, DOI 10.1096/fasebj.12.3.265; Schumacher MA, 2002, EMBO J, V21, P1210, DOI 10.1093/emboj/21.5.1210; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2002, MOL MICROBIOL, V45, P885, DOI 10.1046/j.1365-2958.2002.03039.x; Tegoni M, 2000, BBA-PROTEIN STRUCT M, V1482, P229, DOI 10.1016/S0167-4838(00)00167-9; Tsuzuki S, 2000, J AM CHEM SOC, V122, P11450, DOI 10.1021/ja001901a; Vincent F, 2000, J MOL BIOL, V300, P127, DOI 10.1006/jmbi.2000.3820; Yu EW, 2003, J BACTERIOL, V185, P5657, DOI 10.1128/JB.185.19.5657-5664.2003; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6; ZHELEZNOVAHELDW.EE, 2001, NATURE, V409, P378; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	33	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14365	14371		10.1074/jbc.M313870200	http://dx.doi.org/10.1074/jbc.M313870200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726520	hybrid			2022-12-25	WOS:000220478500132
J	Natale, P; Swaving, J; van der Does, C; de Keyzer, J; Driessen, AJM				Natale, P; Swaving, J; van der Does, C; de Keyzer, J; Driessen, AJM			Binding of SecA to the SecYEG complex accelerates the rate of nucleotide exchange on SecA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCASE SUBUNIT SECA; COLI PLASMA-MEMBRANE; DISTINCT ATP-BINDING; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; PREPROTEIN TRANSLOCASE; BACILLUS-SUBTILIS; ACIDIC PHOSPHOLIPIDS; PRECURSOR PROTEINS; CATALYTIC CYCLE	SecYEG translocase mediates the transport of preproteins across the inner membrane of Escherichia coli. SecA binds the membrane-embedded SecYEG protein-conducting channel with high affinity and then drives the stepwise translocation of preproteins across the membrane through multiple cycles of ATP binding and hydrolysis. We have investigated the kinetics of nucleotide binding to SecA while associated with the SecYEG complex. Lipid-bound SecA was separated from Se-cYEG-bound SecA by sedimentation of the proteoliposomes through a glycerol cushion, which maintains the SecA native state and effectively removes the lipid-bound SecA fraction. Nucleotide binding was assessed by means of fluorescence resonance energy transfer using fluorescent ATP analogues as acceptors of the intrinsic SecA tryptophan fluorescence in the presence of a tryptophanless variant of the SecYEG complex. Binding of SecA to the SecYEG complex elevated the rate of nucleotide exchange at SecA independently of the presence of preprotein. This defines a novel pretranslocation activated state of SecA that is primed for ATP hydrolysis upon preprotein interaction.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Microbiol, NL-9750 AA Haren, Netherlands	University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Microbiol, NL-9750 AA Haren, Netherlands.	a.j.m.driessen@biol.rug.nl	Natale, Paolo/E-9326-2012; Driessen, Arnold J.M./D-1876-2012	Natale, Paolo/0000-0002-4759-0816; Driessen, Arnold J.M./0000-0001-9258-9104				AHN T, 1994, BIOCHEM BIOPH RES CO, V203, P326, DOI 10.1006/bbrc.1994.2185; Benach J, 2003, J BIOL CHEM, V278, P3628, DOI 10.1074/jbc.M205992200; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; Bu ZM, 2003, J MOL BIOL, V332, P23, DOI 10.1016/S0022-2836(03)00840-4; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; de Keyzer J, 2002, J BIOL CHEM, V277, P46059, DOI 10.1074/jbc.M208449200; de Keyzer J, 2002, FEBS LETT, V510, P17, DOI 10.1016/S0014-5793(01)03213-6; den Blaauwen T, 1999, FEBS LETT, V458, P145, DOI 10.1016/S0014-5793(99)01139-4; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; Ding HY, 2003, BIOCHEMISTRY-US, V42, P8729, DOI 10.1021/bi0342057; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; Kourtz L, 2000, MOL MICROBIOL, V37, P1342, DOI 10.1046/j.1365-2958.2000.02078.x; Lakowicz J R, 1999, PRINCIPLES FLUORESCE, P367, DOI 10.1007/978-1-4757-3061-6; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Nishiyama K, 1999, EMBO J, V18, P1049, DOI 10.1093/emboj/18.4.1049; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; PERSHT A, 1999, STRUCTURE MECH PROTE, P143; Scheffers DJ, 2000, MOL MICROBIOL, V35, P1211, DOI 10.1046/j.1365-2958.2000.01791.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Schmidt M, 2000, J BIOL CHEM, V275, P15440, DOI 10.1074/jbc.M000605200; Sharma V, 2003, P NATL ACAD SCI USA, V100, P2243, DOI 10.1073/pnas.0538077100; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; Weinkauf S, 2001, ACTA CRYSTALLOGR D, V57, P559, DOI 10.1107/S0907444901001202; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134	45	21	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13769	13777		10.1074/jbc.M312892200	http://dx.doi.org/10.1074/jbc.M312892200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14722060	hybrid, Green Published			2022-12-25	WOS:000220478500061
J	Sprague, ER; Martin, WL; Bjorkman, PJ				Sprague, ER; Martin, WL; Bjorkman, PJ			pH dependence and stoichiometry of binding to the Fc region of IgG by the herpes simplex virus Fc receptor gE-gI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARICELLA-ZOSTER-VIRUS; TRANS-GOLGI NETWORK; I-RELATED RECEPTOR; PLASMON RESONANCE BIOSENSORS; IMMUNOGLOBULIN-G IGG; PSEUDORABIES VIRUS; VIRAL GLYCOPROTEINS; CRYSTAL-STRUCTURE; CYTOPLASMIC TAIL; INFECTED-CELLS	Herpes simplex virus type 1 encodes two glycoproteins, gE and gI, that form a heterodimer on the surface of virions and infected cells. The gE-gI heterodimer has been implicated in cell-to-cell spread of virus and is a receptor for the Fc fragment of IgG. Previous studies localized the gE-gI-binding site on human IgG to a region near the interface between the C(H)2 and C(H)3 domains of Fc, which also serves as the binding site for bacterial and mammalian Fc receptors. Although there are two potential gE-gI-binding sites per Fc homodimer, only one gE-gI heterodimer binds per IgG in gel filtration experiments. Here we report production of recombinant human Fc molecules that contain zero, one, or two potential gE-gI-binding sites and use them in analytical ultracentrifugation experiments to show that two gE-gI heterodimers can bind to each Fc. Further characterization of the gE-gI interaction with Fc reveals a sharp pH dependence of binding, with K-D values of similar to 340 and similar to 930 nM for the first and second binding events, respectively, at the slightly basic pH of the cell surface (pH 7.4), but undetectable binding at pH 6.0. This strongly pH-dependent interaction suggests a physiological role for gE-gI dissociation from IgG within acidic intracellular compartments, consistent with a mechanism whereby herpes simplex virus promotes intracellular degradation of anti-viral antibodies.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Bjorkman, PJ (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	bjorkman@caltech.edu		Sprague, Elizabeth/0000-0002-1603-3750				ADLER R, 1978, INFECT IMMUN, V21, P442, DOI 10.1128/IAI.21.2.442-447.1978; Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; Alconada A, 1999, J VIROL, V73, P377, DOI 10.1128/JVI.73.1.377-387.1999; Bebbington C. R., 1987, DNA CLONING PRACTICA, P163; BROWN VI, 1991, DNA CELL BIOL, V10, P399, DOI 10.1089/dna.1991.10.399; Chapman TL, 1999, J BIOL CHEM, V274, P6911, DOI 10.1074/jbc.274.11.6911; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; DOWLER KW, 1984, J MED VIROL, V13, P251, DOI 10.1002/jmv.1890130307; DUBIN G, 1991, J VIROL, V65, P7046, DOI 10.1128/JVI.65.12.7046-7050.1991; DUBIN G, 1990, J VIROL, V64, P2725, DOI 10.1128/JVI.64.6.2725-2731.1990; Favoreel HW, 2000, VIROLOGY, V267, P151, DOI 10.1006/viro.1999.0132; Favoreel HW, 1997, J VIROL, V71, P8254, DOI 10.1128/JVI.71.11.8254-8261.1997; FRANK I, 1989, J VIROL, V63, P4479, DOI 10.1128/JVI.63.11.4479-4488.1989; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; Ghetie V, 1997, IMMUNOL TODAY, V18, P592, DOI 10.1016/S0167-5699(97)01172-9; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; GHIRLANDO R, 1995, BIOCHEMISTRY-US, V34, P13320, DOI 10.1021/bi00041a007; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Herr AB, 2003, NATURE, V423, P614, DOI 10.1038/nature01685; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; JOHANSSON PJH, 1994, IMMUNOLOGY, V83, P631; JOHANSSON PJH, 1984, J VIROL, V50, P796, DOI 10.1128/JVI.50.3.796-804.1984; JOHANSSON PJH, 1989, IMMUNOLOGY, V66, P8; JOHANSSON PJH, 1985, J VIROL, V56, P489, DOI 10.1128/JVI.56.2.489-494.1985; JOHANSSON PJH, 1986, IMMUNOLOGY, V58, P251; JOHNSON DC, 1987, J VIROL, V61, P2208, DOI 10.1128/JVI.61.7.2208-2216.1987; JOHNSON DC, 1988, J VIROL, V62, P1347, DOI 10.1128/JVI.62.4.1347-1354.1988; Junghans RP, 1997, IMMUNOL RES, V16, P29, DOI 10.1007/BF02786322; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; LITWIN V, 1992, J VIROL, V66, P3643, DOI 10.1128/JVI.66.6.3643-3651.1992; Martin WL, 1999, BIOCHEMISTRY-US, V38, P12639, DOI 10.1021/bi9913505; Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Nagashunmugam T, 1998, J VIROL, V72, P5351, DOI 10.1128/JVI.72.7.5351-5359.1998; Olson JK, 1997, J VIROL, V71, P4042, DOI 10.1128/JVI.71.5.4042-4054.1997; Olson JK, 1998, J VIROL, V72, P1542, DOI 10.1128/JVI.72.2.1542-1551.1998; Olson JK, 1997, J VIROL, V71, P110, DOI 10.1128/JVI.71.1.110-119.1997; Pasieka TJ, 2003, J VIROL, V77, P4191, DOI 10.1128/JVI.77.7.4191-4204.2003; Popov S, 1996, MOL IMMUNOL, V33, P521, DOI 10.1016/0161-5890(96)00004-1; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; Rizvi SM, 2001, J VIROL, V75, P11897, DOI 10.1128/JVI.75.23.11897-11901.2001; Sanchez LM, 1999, BIOCHEMISTRY-US, V38, P9471, DOI 10.1021/bi9907330; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SIMISTER NE, 1989, COLD SPRING HARB SYM, V54, P571, DOI 10.1101/SQB.1989.054.01.068; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; Simister NE, 1997, BIOCHEM SOC T, V25, P481, DOI 10.1042/bst0250481; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Stryer L., 1988, BIOCHEMISTRY-US, P21; Tirabassi RS, 1998, J VIROL, V72, P4571, DOI 10.1128/JVI.72.6.4571-4579.1998; Tirabassi RS, 1999, J VIROL, V73, P2717, DOI 10.1128/JVI.73.4.2717-2728.1999; Van de Walle GR, 2003, J GEN VIROL, V84, P939, DOI 10.1099/vir.0.18663-0; VANVLIET KE, 1992, IMMUNOLOGY, V77, P109; Vaughn DE, 1997, J MOL BIOL, V274, P597, DOI 10.1006/jmbi.1997.1388; WESTMORELAND D, 1974, J GEN VIROL, V24, P167, DOI 10.1099/0022-1317-24-1-167; Whitbeck JC, 1996, J VIROL, V70, P7878, DOI 10.1128/JVI.70.11.7878-7884.1996; WIGER D, 1985, IMMUNOLOGY, V54, P565; YAO ZB, 1993, J VIROL, V67, P305, DOI 10.1128/JVI.67.1.305-314.1993; Zhu ZL, 1996, J VIROL, V70, P6563, DOI 10.1128/JVI.70.10.6563-6575.1996; ZHU ZL, 1995, J VIROL, V69, P7951, DOI 10.1128/JVI.69.12.7951-7959.1995; ZUCKERMANN FA, 1988, J VIROL, V62, P4622, DOI 10.1128/JVI.62.12.4622-4626.1988	68	36	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14184	14193		10.1074/jbc.M313281200	http://dx.doi.org/10.1074/jbc.M313281200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734541	hybrid, Green Accepted			2022-12-25	WOS:000220478500110
J	Valadez, JG; Guengerich, FP				Valadez, JG; Guengerich, FP			S-(2-chloroethyl)glutathione-generated p53 mutation spectra are influenced by differential repair rates more than sites of initial DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOSE-DEPENDENT DIFFERENCES; LIGATION-MEDIATED PCR; GUANINE PHOSPHORIBOSYLTRANSFERASE GENE; BENZO<A>PYRENE DIOL EPOXIDE; UV-INDUCED MUTAGENESIS; FUNCTIONAL ASSAY; ALKYLATING-AGENTS; SKIN-CANCER; TRANSVERSION MUTATIONS; MOLECULAR EPIDEMIOLOGY	Several steps occur between the reaction of a chemical with DNA and a mutation, and each may influence the resulting mutation spectrum, i.e. nucleotides at which the mutations occur. The half-mustard S-(2-bromoethyl) glutathione is the reactive conjugate implicated in ethylene dibromide-induced mutagenesis attributed to the glutathione-dependent pathway. A human p53-driven Ade reporter system in yeast was used to study the factors involved in producing mutations. The synthetic analog S-(2-chloroethyl) glutathione was used to produce DNA damage; the damage to the p53 exons was analyzed using a new fluorescence-based modification of ligation-mediated polymerase chain reaction and an automated sequencer. The mutation spectrum was strongly dominated by the G to A transition mutations seen in other organisms with S-(2-chloroethyl) glutathione or ethylene dibromide. The mutation spectrum clearly differed from the spontaneous spectrum or that derived from N-ethyl,N-nitrosourea. Distinct differences were seen between patterns of modification of p53 DNA exposed to the mutagen in vitro versus in vivo. In the four p53 exons in which mutants were analyzed, the major sites of mutation matched the sites with long half-lives of repair much better than the sites of initial damage. However, not all slowly repaired sites yielded mutations in part because of the lack of effect of mutations on phenotype. We conclude that the rate of DNA repair at individual nucleotides is a major factor in influencing the mutation spectra in this system. The results are consistent with a role of N-7-guanyl adducts in mutagenesis.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; IPN, Ctr Invest & Estudios Avanzados, Dept Biotecnol & Bioingn, Mexico City 07360, DF, Mexico	Vanderbilt University; Vanderbilt University; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NIEHS NIH HHS [P30 ES00267, R01 ES10546] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010546, P30ES000267] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMBROSE BJB, 1988, ANAL BIOCHEM, V169, P151, DOI 10.1016/0003-2697(88)90266-7; AMBROSE BJB, 1985, BIOCHEMISTRY-US, V24, P6194, DOI 10.1021/bi00343a025; AMES BN, 1979, SCIENCE, V204, P587, DOI 10.1126/science.373122; Bailey EA, 1996, P NATL ACAD SCI USA, V93, P1535, DOI 10.1073/pnas.93.4.1535; BALLERING LAP, 1994, CARCINOGENESIS, V15, P869, DOI 10.1093/carcin/15.5.869; Bauer KH, 1928, MUTATIONSTHEORIE GES; BENASUTTI M, 1988, BIOCHEMISTRY-US, V27, P472, DOI 10.1021/bi00401a068; BENZER S, 1961, P NATL ACAD SCI USA, V47, P403, DOI 10.1073/pnas.47.3.403; Cariello NF, 1998, NUCLEIC ACIDS RES, V26, P198, DOI 10.1093/nar/26.1.198; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; Cloutier JF, 2001, J MOL BIOL, V306, P169, DOI 10.1006/jmbi.2000.4371; CMARIK JL, 1992, J BIOL CHEM, V267, P6672; Colominas C, 1996, J AM CHEM SOC, V118, P6811, DOI 10.1021/ja954293l; Dai SM, 2000, NAT BIOTECHNOL, V18, P1108, DOI 10.1038/80323; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1998, ONCOGENE, V16, P1241, DOI 10.1038/sj.onc.1201647; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FOSTER PL, 1988, MUTAT RES, V194, P171, DOI 10.1016/0167-8817(88)90019-3; Fronza G, 2000, MUTAT RES-REV MUTAT, V462, P293, DOI 10.1016/S1383-5742(00)00011-9; Graves RJ, 1996, MUTAGENESIS, V11, P229, DOI 10.1093/mutage/11.3.229; GROOPMAN JD, 1981, P NATL ACAD SCI-BIOL, V78, P5445, DOI 10.1073/pnas.78.9.5445; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hatahet Z, 1998, P NATL ACAD SCI USA, V95, P8556, DOI 10.1073/pnas.95.15.8556; HEIDELBERGER C, 1975, ANNU REV BIOCHEM, V44, P79, DOI 10.1146/annurev.bi.44.070175.000455; Holmquist GP, 1997, MUTAT RES-REV MUTAT, V386, P69, DOI 10.1016/S1383-5742(96)00045-2; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; Hu WW, 2003, BIOCHEMISTRY-US, V42, P10012, DOI 10.1021/bi034631s; HUMPHREYS WG, 1990, BIOCHEMISTRY-US, V29, P10342, DOI 10.1021/bi00497a008; HURLEY LH, 1986, ACCOUNTS CHEM RES, V19, P230, DOI 10.1021/ar00128a001; INSKEEP PB, 1986, CANCER RES, V46, P2839; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; KIERDASZUK B, 1993, BIOPHYS CHEM, V46, P207, DOI 10.1016/0301-4622(93)80014-A; KIM DH, 1990, CHEM RES TOXICOL, V3, P587, DOI 10.1021/tx00018a015; Kim MS, 1998, CHEM RES TOXICOL, V11, P311, DOI 10.1021/tx970206m; KOGA N, 1986, BIOCHEMISTRY-US, V25, P2192, DOI 10.1021/bi00356a051; KOHN KW, 1987, NUCLEIC ACIDS RES, V15, P10531, DOI 10.1093/nar/15.24.10531; Lawley P. D., 1984, CHEM CARCINOGENS, P324; LAWLEY PD, 1961, NATURE, V192, P1081, DOI 10.1038/1921081b0; LEE GSF, 1992, J MOL BIOL, V223, P617, DOI 10.1016/0022-2836(92)90978-S; Liu LP, 2002, J BIOL CHEM, V277, P37920, DOI 10.1074/jbc.M205548200; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Moore DD, 1995, GLOB MOB SURV; Moshinsky DJ, 2000, ENVIRON MOL MUTAGEN, V35, P31, DOI 10.1002/(SICI)1098-2280(2000)35:1<31::AID-EM5>3.0.CO;2-S; Moshinsky DJ, 1997, P NATL ACAD SCI USA, V94, P2266, DOI 10.1073/pnas.94.6.2266; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; OLSON WA, 1973, JNCI-J NATL CANCER I, V51, P1993, DOI 10.1093/jnci/51.6.1993; OZAWA N, 1983, P NATL ACAD SCI-BIOL, V80, P5266, DOI 10.1073/pnas.80.17.5266; PERSMARK M, 1994, BIOCHEMISTRY-US, V33, P8662, DOI 10.1021/bi00195a006; PETERSON LA, 1988, J AM CHEM SOC, V110, P3284, DOI 10.1021/ja00218a045; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P155, DOI 10.1016/S0027-5107(00)00022-1; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P1, DOI 10.1016/S0027-5107(00)00012-9; PFEIFER GP, 1993, MUTAT RES, V288, P39, DOI 10.1016/0027-5107(93)90206-U; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; Pfeifer GP, 1997, BBA-REV CANCER, V1333, pM1, DOI 10.1016/S0304-419X(97)00004-8; Pfeifer GP, 1998, ENVIRON MOL MUTAGEN, V31, P197, DOI 10.1002/(SICI)1098-2280(1998)31:3<197::AID-EM1>3.0.CO;2-I; RANNUG U, 1980, MUTAT RES, V76, P269, DOI 10.1016/0165-1110(80)90020-2; RICHARDSON FC, 1990, MUTAT RES, V233, P127, DOI 10.1016/0027-5107(90)90157-Y; Rogozin IB, 2003, MUTAT RES-REV MUTAT, V544, P65, DOI 10.1016/S1383-5742(03)00032-2; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SAID B, 1991, NUCLEIC ACIDS RES, V19, P1311, DOI 10.1093/nar/19.6.1311; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Schiltz M, 1999, CARCINOGENESIS, V20, P2279, DOI 10.1093/carcin/20.12.2279; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; Suen W, 1999, P NATL ACAD SCI USA, V96, P4500, DOI 10.1073/pnas.96.8.4500; SUN M, 1984, SCIENCE, V223, P464, DOI 10.1126/science.6362008; Suo ZC, 1998, J BIOL CHEM, V273, P27259, DOI 10.1074/jbc.273.42.27259; Szabo Piroska E., 1996, P343; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Tretyakova NY, 1999, CHEM RES TOXICOL, V12, P459, DOI 10.1021/tx980235c; Vaisman A, 2003, DNA REPAIR, V2, P991, DOI 10.1016/S1568-7864(03)00094-6; WATSON JD, 1953, NATURE, V171, P964, DOI 10.1038/171964b0; Wei SJC, 1996, CANCER RES, V56, P3695; WEI SJC, 1993, CANCER RES, V53, P3294; WEI SJC, 1991, P NATL ACAD SCI USA, V88, P11227, DOI 10.1073/pnas.88.24.11227; WURDEMAN RL, 1989, J AM CHEM SOC, V111, P6408, DOI 10.1021/ja00198a064; Yoon JH, 2000, J MOL BIOL, V299, P681, DOI 10.1006/jmbi.2000.3771; Yoon JH, 2003, CARCINOGENESIS, V24, P113, DOI 10.1093/carcin/24.1.113; Yoon JH, 2001, CANCER RES, V61, P7110; You YH, 2001, J MOL BIOL, V305, P389, DOI 10.1006/jmbi.2000.4322; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	84	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13435	13446		10.1074/jbc.M312358200	http://dx.doi.org/10.1074/jbc.M312358200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14715658	hybrid			2022-12-25	WOS:000220478500021
J	Sah, JF; Balasubramanian, S; Eckert, RL; Rorke, EA				Sah, JF; Balasubramanian, S; Eckert, RL; Rorke, EA			Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway - Evidence for direct inhibition of ERK1/2 and AKT kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECTOCERVICAL EPITHELIAL-CELLS; FORKHEAD TRANSCRIPTION FACTOR; ACTIVATED PROTEIN-KINASES; BREAST-CANCER CELLS; CARCINOMA-CELLS; HUMAN-PAPILLOMAVIRUS; CERVICAL-CANCER; MESSENGER-RNA; RETINOIC ACID; TEA	Epidermal growth factor receptor (EGFR) activation is absolutely required for cervical cell proliferation. This suggests that EGFR-inhibitory agents may be of therapeutic value. In the present study, we investigated the effects of epigallocatechin-3-gallate (EGCG), a bioactive green tea polyphenol, on EGFR signaling in cervical cells. EGCG inhibits epidermal growth factor-dependent activation of EGFR, and EGFR-dependent activation of the mitogen-activated protein kinases ERK1/2. EGCG also inhibits EGFR-dependent AKT activity. The EGCG-dependent reduction in ERK and AKT activity is associated with reduced phosphorylation of downstream substrates, including p90RSK, FKHR, and BAD. These changes are associated with increased p53, p21(WAF-1), and p27(KIP-1) levels, reduced cyclin E level, and reduced CDK2 kinase activity. Consistent with these findings, flow cytometry and TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling) staining revealed EGCG-dependent G(1) arrest. Moreover, sustained EGCG treatment caused apoptotic cell death. In addition to inhibiting EGFR, cell-free studies demonstrated that EGCG directly inhibits ERK1/2 and AKT, suggesting that EGCG acts simultaneously at multiple levels to inhibit EGF-dependent signaling. Importantly, the EGCG inhibition is selective, as EGCG does not effect the EGFR-dependent activation of JNK. These results suggest that EGCG acts to selectively inhibit multiple EGF-dependent kinases to inhibit cell proliferation.	Case Western Reserve Univ, Sch Med, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Rorke, EA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Environm Hlth Sci, Cleveland, OH 44106 USA.	ear4@po.cwru.edu		Sah, Jerome/0000-0001-9478-7155	NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009126] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA134274] Funding Source: Medline; NIEHS NIH HHS [ES 009126] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmad N, 2000, BIOCHEM BIOPH RES CO, V275, P328, DOI 10.1006/bbrc.2000.3297; Akerman GS, 2001, CANCER RES, V61, P3837; Annabi B, 2002, BBA-MOL CELL RES, V1542, P209, DOI 10.1016/S0167-4889(01)00187-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; GULLICK WJ, 1986, CANCER RES, V46, P285; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hernaez JF, 1998, MUTAT RES-FUND MOL M, V402, P299, DOI 10.1016/S0027-5107(97)00309-6; Howley P M, 1991, Princess Takamatsu Symp, V22, P239; JACOBBERGER JW, 1995, EXP CELL RES, V220, P390, DOI 10.1006/excr.1995.1330; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Katiyar SK, 2001, INT J ONCOL, V18, P1307; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liang YC, 1999, J CELL BIOCHEM, V75, P1; Liang YC, 1997, J CELL BIOCHEM, V67, P55, DOI 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Masuda M, 2001, CLIN CANCER RES, V7, P4220; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Murthy NS, 2000, EUR J CANCER PREV, V9, P5, DOI 10.1097/00008469-200002000-00002; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Ngan HYS, 2001, TUMOR BIOL, V22, P176, DOI 10.1159/000050613; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Otsuka T, 1998, LIFE SCI, V63, P1397, DOI 10.1016/S0024-3205(98)00406-8; Page C, 2000, INT J ONCOL, V17, P23; Pianetti S, 2002, CANCER RES, V62, P652; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Rorke EA, 2000, EXP CELL RES, V259, P149, DOI 10.1006/excr.2000.4953; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; SIZEMORE N, 1993, CANCER RES, V53, P4511; Sizemore N, 1998, EXP CELL RES, V244, P349, DOI 10.1006/excr.1998.4179; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Ueda M, 1992, Nihon Sanka Fujinka Gakkai Zasshi, V44, P1165; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang ZQ, 2003, J BIOL CHEM, V278, P11138, DOI 10.1074/jbc.M209108200; Yeh PY, 2002, BIOCHEM PHARMACOL, V63, P1423, DOI 10.1016/S0006-2952(02)00908-5; Zhu XF, 2001, CANCER LETT, V169, P27, DOI 10.1016/S0304-3835(01)00547-X; ZUR HH, 1996, BIOCHIM BIOPHYS ACTA, V1288, pF55	54	206	227	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12755	12762		10.1074/jbc.M312333200	http://dx.doi.org/10.1074/jbc.M312333200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701854	hybrid			2022-12-25	WOS:000220334900089
J	Sayer, NM; Cubin, M; Rhie, A; Bullock, M; Tahiri-Alaoui, A; James, W				Sayer, NM; Cubin, M; Rhie, A; Bullock, M; Tahiri-Alaoui, A; James, W			Structural determinants of conformationally selective, prion-binding aptamers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGIFORM ENCEPHALOPATHY; RNA LIGANDS; PROTEIN; SCRAPIE; DISEASE; MICE; INFECTIVITY; POLYMERASE; CONVERSION; RESISTANT	We have recently described the isolation of 2'-fluoropyrimidine-substituted RNA aptamers that bind selectively to disease-associated beta-sheet-rich forms of the prion protein, PrP, from a number of mammalian species. These aptamers inhibit the accumulation of protease-resistant forms of PrP in a prion-seeded, in vitro conversion assay. Here we identify the minimal portions of two of these aptamers that retain binding specificity. We determine their secondary structures by a combination of modeling and solution probing. Finally, we identify an internal site for biotinylation of a minimized, synthetic aptamer and use the resultant reagent in the detection of abnormal forms of PrP in vitro.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	James, W (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	William.james@path.ox.ac.uk	james, william/H-4289-2013	james, william/0000-0002-2506-1198				AURUP H, 1992, BIOCHEMISTRY-US, V31, P9636, DOI 10.1021/bi00155a016; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Bieschke J, 2000, P NATL ACAD SCI USA, V97, P5468, DOI 10.1073/pnas.97.10.5468; Brown P, 1999, TRANSFUSION, V39, P1169, DOI 10.1046/j.1537-2995.1999.39111169.x; Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; HEIDENREICH O, 1995, NUCLEIC ACIDS RES, V23, P2223, DOI 10.1093/nar/23.12.2223; Hur K, 2002, MECH AGEING DEV, V123, P1637, DOI 10.1016/S0047-6374(02)00099-4; Ingrosso L, 2002, TRENDS MOL MED, V8, P273, DOI 10.1016/S1471-4914(02)02358-4; James William, 2001, Current Opinion in Pharmacology, V1, P540, DOI 10.1016/S1471-4892(01)00093-5; Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003; Kraus E, 1998, J IMMUNOL, V160, P5209; Nguyen DH, 2002, J AM CHEM SOC, V124, P15081, DOI 10.1021/ja027635d; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200; Rubenstein R, 1998, BIOCHEM BIOPH RES CO, V246, P100, DOI 10.1006/bbrc.1998.8542; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Safar JG, 2002, NAT BIOTECHNOL, V20, P1147, DOI 10.1038/nbt748; Sayer N, 2002, BIOCHEM BIOPH RES CO, V293, P924, DOI 10.1016/S0006-291X(02)00308-X; Shaked GM, 2001, J BIOL CHEM, V276, P31479, DOI 10.1074/jbc.C100278200; TAHIRIALAOUI A, 2002, NUCLEIC ACIDS RES, V30, P1; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	29	88	93	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13102	13109		10.1074/jbc.M310928200	http://dx.doi.org/10.1074/jbc.M310928200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14711834	hybrid			2022-12-25	WOS:000220334900131
J	Shi, SL; Grothe, S; Zhang, YP; O'Connor-McCourt, MD; Poole, AR; Roughley, PJ; Mort, JS				Shi, SL; Grothe, S; Zhang, YP; O'Connor-McCourt, MD; Poole, AR; Roughley, PJ; Mort, JS			Link protein has greater affinity for versican than aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE AGGREGATING PROTEOGLYCAN; BOVINE ARTICULAR-CARTILAGE; HYALURONIC-ACID; EQUILIBRIUM-BINDING; CDNA CLONING; SULFATE; DOMAIN; BRAIN; MONOMERS; ABSENCE	The function of link protein in stabilizing the interaction between aggrecan and hyaluronan to form aggrecan aggregates, via the binding of link protein to the aggrecan G1 domain and hyaluronan, is well established. However, it is not known whether link protein can function with similar avidity with versican, another member of the large hyaluronan-binding proteoglycan family that also binds to hyaluronan via its G1 domain. To address this issue, we have compared the interaction of the versican and aggrecan G1 domains with link protein and hyaluronan using recombinant proteins expressed in insect cells and BIAcore analysis. The results showed that link protein could significantly improve the binding of both G1 domains to hyaluronan and that its interaction with VG1 is of a higher affinity than that with AG1. These observations suggest that link protein may function as a stabilizer of the interaction, not only between aggrecan and hyaluronan in cartilage, but also between versican and hyaluronan in many tissues.	Shriners Hosp Children, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada; Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada; Natl Res Council Canada, Receptor Signalling & Prote Grp, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	McGill University; McGill University; McGill University; McGill University; National Research Council Canada	Mort, JS (corresponding author), Shriners Hosp Children, Joint Dis Lab, 1529 Cedar Ave, Montreal, PQ H3G 1A6, Canada.	jmort@shriners.mcgill.ca						BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKWALTER JA, 1984, J BIOL CHEM, V259, P5361; CATERSON B, 1978, BIOCHEM BIOPH RES CO, V80, P496, DOI 10.1016/0006-291X(78)91596-6; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DUDHIA J, 1990, NUCLEIC ACIDS RES, V18, P2214, DOI 10.1093/nar/18.8.2214; FOSANG AJ, 1991, BIOCHEM J, V273, P369, DOI 10.1042/bj2730369; FRANZEN A, 1981, BIOCHEM J, V197, P669, DOI 10.1042/bj1970669; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HASCALL VC, 1977, J SUPRAMOL STR CELL, V7, P101, DOI 10.1002/jss.400070110; HEINEGARD D, 1977, J BIOL CHEM, V252, P1980; Hirakawa S, 2000, BIOCHEM BIOPH RES CO, V276, P982, DOI 10.1006/bbrc.2000.3583; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; LYON M, 1983, BIOCHEM J, V213, P445, DOI 10.1042/bj2130445; Matsumoto K, 2003, J BIOL CHEM, V278, P41205, DOI 10.1074/jbc.M305060200; Melrose J, 1998, ANAL BIOCHEM, V256, P149, DOI 10.1006/abio.1997.2509; MORGELIN M, 1988, BIOCHEM J, V253, P175; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; NGUYEN Q, 1989, BIOCHEM J, V259, P61, DOI 10.1042/bj2590061; NIEDUSZYNSKI IA, 1980, BIOCHEM J, V185, P107, DOI 10.1042/bj1850107; ROSENBERG L, 1991, J BIOL CHEM, V266, P7016; ROSENBERG L, 1988, J BIOL CHEM, V263, P18071; Shi SL, 2003, ARTHRITIS RHEUM-US, V48, P2903, DOI 10.1002/art.11270; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Spicer AP, 2003, J BIOL CHEM, V278, P21083, DOI 10.1074/jbc.M213100200; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	32	37	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12060	12066		10.1074/jbc.M310091200	http://dx.doi.org/10.1074/jbc.M310091200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14724283	hybrid			2022-12-25	WOS:000220334900009
J	Swiatek, W; Tsai, IC; Klimowski, L; Pepler, A; Barnette, J; Yost, HJ; Virshup, DM				Swiatek, W; Tsai, IC; Klimowski, L; Pepler, A; Barnette, J; Yost, HJ; Virshup, DM			Regulation of casein kinase I epsilon activity by Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; CATENIN DEGRADATION COMPLEX; POLYPOSIS-COLI GENE; BETA-CATENIN; PHOSPHORYLATION; AXIN; PATHWAY; SUBUNIT; FAMILY; DELTA	The Wnt/beta- catenin signaling pathway is important in both development and cancer. Casein kinase Iepsilon (CKIepsilon) is a positive regulator of the canonical Wnt pathway. CKIepsilon itself can be regulated in vitro by inhibitory autophosphorylation, and recent data suggest that in vivo kinase activity can be regulated by extracellular stimuli. We show here that the phosphorylation state and kinase activity of CKIepsilon are directly regulated by Wnt signaling. Coexpression of XWnt- 8 or addition of soluble Wnt- 3a ligand led to a significant and rapid increase in the activity of endogenous CKIepsilon. The increase in CKIepsilon activity is the result of decreased inhibitory autophosphorylation because it is abolished by preincubation of immunoprecipitated kinase with ATP. Furthermore, mutation of CKIepsilon inhibitory autophosphorylation sites creates a kinase termed CKIepsilon ( MM2) that is significantly more active than CKIepsilon and is not activated further upon Wnt stimulation. Autoinhibition of CKIepsilon is biologically relevant because CKIepsilon ( MM2) is more effective than CKIepsilon at activating transcription from a Lef1- dependent promoter. Finally, CKIepsilon ( MM2) expression in Xenopus embryos induces both axis duplication and additional developmental abnormalities. The data suggest that Wnt signaling activates CKIepsilon by causing transient dephosphorylation of critical inhibitory sites present in the carboxyl- terminal domain of the kinase. Activation of the Wnt pathway may therefore stimulate a cellular phosphatase to dephosphorylate and activate CKIepsilon.	Univ Utah, Huntsman Canc Inst, Ctr Children, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pediat, Div Hematol Oncol, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Virshup, DM (corresponding author), Univ Utah, Huntsman Canc Inst, Ctr Children, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	David.Virshup@hci.utah.edu	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NCI NIH HHS [R01 CA 80809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu F, 2002, J BIOL CHEM, V277, P45393, DOI 10.1074/jbc.M204499200; McKay RM, 2001, DEV BIOL, V235, P378, DOI 10.1006/dbio.2001.0307; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shibamoto S, 1998, GENES CELLS, V3, P659; Sillibourne JE, 2002, J MOL BIOL, V322, P785, DOI 10.1016/S0022-2836(02)00857-4; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zilian O, 1999, DEVELOPMENT, V126, P5409	43	92	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13011	13017		10.1074/jbc.M304682200	http://dx.doi.org/10.1074/jbc.M304682200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722104	hybrid			2022-12-25	WOS:000220334900121
J	Uekita, T; Gotoh, I; Kinoshita, T; Itoh, Y; Sato, H; Shiomi, T; Okada, Y; Seiki, M				Uekita, T; Gotoh, I; Kinoshita, T; Itoh, Y; Sato, H; Shiomi, T; Okada, Y; Seiki, M			Membrane-type 1 matrix metalloproteinase cytoplasmic tail-binding protein-1 is a new member of the Cupin superfamily - A possible multifunctional protein acting as an invasion suppressor down-regulated in tumors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SALVAGE PATHWAY; KLEBSIELLA-PNEUMONIAE; CELL INVASION; MT1-MMP; HEMOPEXIN; CLEAVAGE; SURFACE; DOMAIN; OLIGOMERIZATION; PROTEOLYSIS	Membrane-type 1 matrix metalloproteinase (MT1MMP/MMP-14) is an enzyme that promotes tumor cell invasion in tissues. Although the proteolytic activity of MT1-MMP is indispensable for invasion, it is also regulated by functions of the cytoplasmic tail. In this study we obtained a new human gene whose product binds to the tail sequence in yeast. The product, MTCBP-1, is a 19-kDa protein that belongs to the newly proposed Cupin superfamily composed of proteins with diverse functions. MTCBP-1 expressed in cells formed a complex with MT1-MMP and co-localized at the membrane. It was also detected in both the cytoplasm and nucleus, where MT1-MMP does not exist. In human tumor cell lines MTCBP-1 expression was significantly low compared with non-transformed fibroblasts, and enforced expression of MTCBP-1 inhibited the activity of MT1-MMP in promoting cell migration and invasion. MTCBP-1 showed significant homology to the bacterial aci-reductone dioxygenase, which is an enzyme in methionine metabolism. The C-terminal part of MTCBP-1 is identical to Sip-L, which is reported to be important for human hepatitis C virus replication. Thus, MTCBP-1 may have multiple functions other than the regulation of MT1-MMP, which presumably depends on the subcellular compartment.	Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo 1088639, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan; Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan	University of Tokyo; Kanazawa University; Keio University	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.	mseiki@ims.u-tokyo.ac.jp	Okada, Yasunori/B-5550-2014; Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015; KINOSHITA, Takeshi/D-8436-2015; Shiomi, Takayuki/A-2228-2014	Okada, Yasunori/0000-0001-9208-4755; Shiomi, Takayuki/0000-0002-4250-1204; Itoh, Yoshifumi/0000-0002-2128-2823				Dai Y, 1999, J BIOL CHEM, V274, P1193, DOI 10.1074/jbc.274.3.1193; Dai Y, 2001, BIOCHEMISTRY-US, V40, P6379, DOI 10.1021/bi010110y; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; MYERS RW, 1993, J BIOL CHEM, V268, P24785; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Pochapsky TC, 2002, NAT STRUCT BIOL, V9, P966, DOI 10.1038/nsb863; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; WRAY JW, 1993, J BIOL CHEM, V268, P21466; Yeh CT, 2001, J VIROL, V75, P11017, DOI 10.1128/JVI.75.22.11017-11024.2001	26	61	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12734	12743		10.1074/jbc.M309957200	http://dx.doi.org/10.1074/jbc.M309957200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14718544	hybrid			2022-12-25	WOS:000220334900087
J	Cui, WW; Tomarev, SI; Piatigorsky, J; Chepelinsky, AB; Duncan, MK				Cui, WW; Tomarev, SI; Piatigorsky, J; Chepelinsky, AB; Duncan, MK			Mafs, Prox1, and Pax6 can regulate chicken beta B1-crystallin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CRYSTALLIN GENE; LENS DEVELOPMENT; C-MAF; TRANSCRIPTION FACTORS; HOMEOBOX GENE; TRANSGENIC MICE; MOUSE LENS; MOLECULAR-FEATURES; RESPONSIVE ELEMENT; DELTA-CRYSTALLIN	During lens fiber cell differentiation, the regulation of crystallin gene expression is coupled with dramatic morphological changes. Here we report that Mafs, Prox1, and Pax6, which are essential transcription factors for normal lens development, bind to three functionally important cis elements, PL1, PL2, and OL2, in the chicken betaB1-crystallin promoter and may cooperatively direct the transcription of this lens fiber cell preferred gene. Gel shift assays demonstrated that Mafs bind to the MARE-like sequences in the PL1 and PL2 elements, whereas Prox1, a sequence-specific DNA-binding protein like its Drosophila homolog Prospero, interacts with the OL2 element. Furthermore, Pax6, a known repressor of the chicken betaB1-crystallin promoter, binds to all three of these cis elements. In transfection assays, Mafs and Prox1 activated the chicken betaB1-crystallin promoter; however, their transactivation ability was repressed when co-transfected with Pax6. Taken together with the known spatiotemporal expression patterns of Mafs, Prox1, and Pax6 in the developing lens, we propose that Pax6 occupies and represses the chicken betaB1-crystallin promoter in lens epithelial cells, and is displaced by Prox1 and Mafs, which activate the promoter, in differentiating cortical fiber cells.	Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA; NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	University of Delaware; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Duncan, MK (corresponding author), Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA.	duncanm@udel.edu		Duncan, Melinda/0000-0003-1570-322X	NATIONAL EYE INSTITUTE [R01EY012221, Z01EY000126, Z01EY000311, Z01EY000253] Funding Source: NIH RePORTER; NEI NIH HHS [EY12221] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ashery-Padan R, 2000, GENE DEV, V14, P2701, DOI 10.1101/gad.184000; BeleckyAdams T, 1997, INVEST OPHTH VIS SCI, V38, P1293; BRAHMA SK, 1988, EXP EYE RES, V47, P507, DOI 10.1016/0014-4835(88)90060-7; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Chen Q, 2002, J BIOL CHEM, V277, P24081, DOI 10.1074/jbc.M201821200; Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255; Chow RL, 1999, DEVELOPMENT, V126, P4213; Civil A, 2002, NUCLEIC ACIDS RES, V30, P975, DOI 10.1093/nar/30.4.975; Collinson JM, 2001, P NATL ACAD SCI USA, V98, P9688, DOI 10.1073/pnas.161144098; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; CVEKL A, 1995, MOL CELL BIOL, V15, P653; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; DUNCAN MK, 1995, BBA-GENE STRUCT EXPR, V1261, P68, DOI 10.1016/0167-4781(94)00223-P; Duncan MK, 1996, MECH DEVELOP, V57, P79, DOI 10.1016/0925-4773(96)00533-3; Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579; Duncan MK, 2002, MECH DEVELOP, V112, P195, DOI 10.1016/S0925-4773(01)00645-1; Gehring WJ, 2002, INT J DEV BIOL, V46, P65; Gehring WJ, 1999, TRENDS GENET, V15, P371, DOI 10.1016/S0168-9525(99)01776-X; GopalSrivastava R, 1996, J BIOL CHEM, V271, P23029, DOI 10.1074/jbc.271.38.23029; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; Hassan B, 1997, P NATL ACAD SCI USA, V94, P10991, DOI 10.1073/pnas.94.20.10991; Haynes JI, 1996, DEV DYNAM, V207, P75, DOI 10.1002/(SICI)1097-0177(199609)207:1<75::AID-AJA8>3.3.CO;2-O; HEJTMANCIK JF, 1985, DEV BIOL, V109, P72, DOI 10.1016/0012-1606(85)90347-1; Huang WD, 2002, J BIOL CHEM, V277, P50668, DOI 10.1074/jbc.M206544200; Ilagan JG, 1999, J BIOL CHEM, V274, P19973, DOI 10.1074/jbc.274.28.19973; Ishibashi S, 2001, MECH DEVELOP, V101, P155, DOI 10.1016/S0925-4773(00)00585-2; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; Kondoh H, 1999, CURR OPIN GENET DEV, V9, P301, DOI 10.1016/S0959-437X(99)80045-8; Koroma BM, 1997, INVEST OPHTH VIS SCI, V38, P108; Kralova J, 2002, GENE, V286, P271, DOI 10.1016/S0378-1119(02)00425-0; Krausz E, 1996, INVEST OPHTH VIS SCI, V37, P2120; Lengler J, 2001, NUCLEIC ACIDS RES, V29, P515, DOI 10.1093/nar/29.2.515; Liu YW, 2003, MOL CELL BIOL, V23, P7243, DOI 10.1128/MCB.23.20.7243-7255.2003; Muta M, 2002, GENES CELLS, V7, P791, DOI 10.1046/j.1365-2443.2002.00560.x; Ogino H, 2000, DEV GROWTH DIFFER, V42, P437; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Piatigorsky Joram, 2003, Journal of Structural and Functional Genomics, V3, P131; Planque N, 2001, J BIOL CHEM, V276, P35751, DOI 10.1074/jbc.M104523200; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; Ring BZ, 2000, DEVELOPMENT, V127, P307; ROTH HJ, 1991, MOL CELL BIOL, V11, P1488, DOI 10.1128/MCB.11.3.1488; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; Sharon-Friling R, 1998, MOL CELL BIOL, V18, P2067, DOI 10.1128/MCB.18.4.2067; Taube JR, 2002, TRANSGENIC RES, V11, P397, DOI 10.1023/A:1016364001095; Tomarev SI, 1996, DEV DYNAM, V206, P354, DOI 10.1002/(SICI)1097-0177(199608)206:4<354::AID-AJA2>3.0.CO;2-H; TOMAREV SI, 1994, J MOL EVOL, V39, P134; Ueda Y, 2002, INVEST OPHTH VIS SCI, V43, P205; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Wistow G, 2002, MOL VIS, V8, P171; Wride MA, 1996, DIFFERENTIATION, V61, P77, DOI 10.1046/j.1432-0436.1996.6120077.x; Yoshida K, 1997, INVEST OPHTH VIS SCI, V38, P2679; Yoshida T, 2002, GENES CELLS, V7, P693, DOI 10.1046/j.1365-2443.2002.00548.x	60	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11088	11095		10.1074/jbc.M312414200	http://dx.doi.org/10.1074/jbc.M312414200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707122	hybrid			2022-12-25	WOS:000220157600032
J	Monte, M; Benetti, R; Collavin, L; Marchionni, L; Del Sal, G; Schneider, C				Monte, M; Benetti, R; Collavin, L; Marchionni, L; Del Sal, G; Schneider, C			hGTSE-1 expression stimulates cytoplasmic localization of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; WILD-TYPE P53; DAMAGE-INDUCED PHOSPHORYLATION; RING-FINGER DOMAIN; CELL-CYCLE; DNA-DAMAGE; TERMINAL DOMAIN; ENDOGENOUS P53; PROTEIN; MDM2	hGTSE-1 (human G(2) and S phase-expressed-1) is a cell cycle-regulated protein mainly localized in the cytoplasm and apparently associated with the microtubules. hGTSE-1 is able to down-regulate levels and activity of the p53 tumor suppressor protein: it binds the C-terminal region of p53 and represses its ability to induce apoptosis after DNA damage. Here we report that, after DNA damage, hGTSE-1 becomes stabilized in a p53-independent way and accumulated in the nucleus. Further characterization of hGTSE-1 localization revealed increased nuclear staining in unstressed cells after treatment with the nuclear export inhibitor leptomycin B, or when a nuclear export signal (NES) located in its C-terminal region was mutated. Finally, we provide evidence that hGTSE-1 ectopic expression, in addition to p53 protein levels down-regulation, is able to enhance cytoplasmic localization of p53. Interestingly, NES-mutated hGTSE-1 accumulates in the nucleus, binds p53 but looses its ability to enhance cytoplasmic redistribution of p53 and to regulate p53 protein levels. Similarly, when wild type hGTSE-1 functions on p53 were analyzed in cells lacking Mdm2, it failed in regulating both p53 localization and protein levels, thus indicating that hGTSE-1 requires an intact NES and functional Mdm2 for the regulation of p53. Our results provide new insights into the mechanism of hGTSE-1 function, whereby its characterized nucleo-cytoplasmic shuttling ability is required to regulate p53.	Lab Nazl Consorzio Interuniv Biotechnol, I-34012 Trieste, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34100 Trieste, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	University of Trieste; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotechnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.	schneide@sci.area.trieste.it	Marchionni, Luigi/S-6774-2017; Collavin, Licio/A-5312-2010	Marchionni, Luigi/0000-0002-7336-8071; Collavin, Licio/0000-0001-6815-5381; DEL SAL, GIANNINO/0000-0003-2185-6003; Monte, Martin/0000-0002-5068-563X; BENETTI, Roberta/0000-0001-8863-0821				Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Collavin L, 2000, FEBS LETT, V481, P57, DOI 10.1016/S0014-5793(00)01969-4; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; Mathur M, 2003, ONCOGENE, V22, P5031, DOI 10.1038/sj.onc.1206643; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Monte M, 2000, GENE, V254, P229, DOI 10.1016/S0378-1119(00)00260-2; Monte M, 2003, J BIOL CHEM, V278, P30356, DOI 10.1074/jbc.M302902200; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; VIKHANSKAYA F, 1994, NUCLEIC ACIDS RES, V22, P1012, DOI 10.1093/nar/22.6.1012; Wadhwa R, 2002, EXP CELL RES, V274, P246, DOI 10.1006/excr.2002.5468; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	45	40	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11744	11752		10.1074/jbc.M311123200	http://dx.doi.org/10.1074/jbc.M311123200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707141	hybrid			2022-12-25	WOS:000220157600111
J	Arimura, N; Horiba, T; Imagawa, M; Shimizu, M; Sato, R				Arimura, N; Horiba, T; Imagawa, M; Shimizu, M; Sato, R			The peroxisome proliferator-activated receptor gamma regulates expression of the perilipin gene in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; A-MEDIATED LIPOLYSIS; PPAR-GAMMA; ALPHA; DIFFERENTIATION; PROMOTER; ADIPOGENESIS; ORGANIZATION; STORAGE; FAMILY	Recent studies have shown that lipid droplets are covered with a proteinaceous coat, although the functions and identities of the component proteins have not yet been well elucidated. The first identified lipid droplet-specific proteins are the perilipins, a family of proteins coating the surfaces of lipid droplets of adipocytes. The generation of perilipin-null mice has revealed that although they consume more food than control mice, they have normal body weight and are resistant to diet-induced obesity. In one study (Martinez-Botas, J., Anderson, J. B., Tessier, D., Lapillonne, A., Chang, B. H. J., Quast, M. J., Gorenstein, D., Chen, K. H., and Chan, L. ( 2000) Nat. Genet. 26, 474-479) it was reported that in an animal model obesity was reversible by breeding perilipin -/- alleles into Lepr db/db obese mice, ostensibly by increasing the metabolic rate of the mice. To understand the exact mechanisms that drive the exclusive expression of the perilipin gene in adipocytes, we analyzed the 5'-flanking region of the mouse gene. Treatment of differentiating 3T3-L1 adipocytes with an agonist of proliferator-activated receptor ( PPAR) gamma, the putative "master regulator" of adipocyte differentiation, significantly augmented perilipin gene expression. Reporter assays using the -2.0-kb promoter revealed that this region contains a functional PPARgamma-responsive element. Gel mobility shift and chromatin immunoprecipitation assays showed that endogenous PPARgamma protein binds to the perilipin promoter. PPARgamma2, an isoform exclusively expressed in adipocytes, was found to be the most potent regulator from among the PPAR family members including PPARalpha and PPARgamma1. These results make evident the fact that perilipin gene expression in differentiating adipocytes is crucially regulated by PPARgamma2, providing new insights into the adipogenic action of PPARgamma2 and adipose-specific gene expression, as well as potential anti-obesity pharmaceutical agents targeted to a reduction of the perilipin gene product.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Aichi 4678603, Japan; Basic Res Act Innovat Biosci, Tokyo 1050001, Japan	University of Tokyo; Nagoya City University	Sato, R (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan.	aroysato@mail.ecc.u-tokyo.ac.jp						BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Camp HS, 1999, FEBS LETT, V447, P186, DOI 10.1016/S0014-5793(99)00268-9; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Inoue J, 2001, BIOCHEM BIOPH RES CO, V283, P1157, DOI 10.1006/bbrc.2001.4915; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Misawa K, 2003, J BIOL CHEM, V278, P36176, DOI 10.1074/jbc.M302387200; Mueller E, 2002, J BIOL CHEM, V277, P41925, DOI 10.1074/jbc.M206950200; Nakahara M, 2002, J BIOL CHEM, V277, P37229, DOI 10.1074/jbc.M206749200; Okuno M, 2002, FEBS LETT, V519, P108, DOI 10.1016/S0014-5793(02)02720-5; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	31	162	181	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10070	10076		10.1074/jbc.M308522200	http://dx.doi.org/10.1074/jbc.M308522200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14704148	hybrid			2022-12-25	WOS:000220050400051
J	Arakawa, R; Hayashi, M; Remaley, AT; Brewer, BH; Yamauchi, Y; Yokoyama, S				Arakawa, R; Hayashi, M; Remaley, AT; Brewer, BH; Yamauchi, Y; Yokoyama, S			Phosphorylation and stabilization of ATP binding cassette transporter a1 by synthetic Amphiphilic helical peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CELLULAR CHOLESTEROL; TANGIER-DISEASE; APOLIPOPROTEINS; EFFLUX; MECHANISM; RELEASE; MICE; DEGRADATION; DEFICIENCY	To investigate structural requirement of helical apolipoprotein to phosphorylate and stabilize ATP-binding cassette transporter A1 (ABCA1), synthetic peptides (Remaley, A. T., Thomas, F., Stonik, J. A., Demosky, S. J., Bark, S. E., Neufeld, E. B., Bocharov, A. V., Vishnyakova, T. G., Patterson, A. P., Eggerman, T. L., Santamarina-Fojo, S., and Brewer, H. B. (2003) J. Lipid Res. 44, 828 836) were examined for these activities. L37pA, an L amino acid peptide that contains two class-A amphiphilic helices, and D37pA, the same peptide with all D amino acids, both removed cholesterol and phospholipid from differentiated THP-1 cells more than apolipoproteins (apos) A-I, A-II, and E. Both peptides also mediated lipid release from human fibroblasts WI-38 similar to apoA-I. L2D37pA, an L-peptide whose valine and tyrosine were replaced with D amino acids also promoted lipid release from WI-38 but less so with THP-1, whereas L3D37pA, in which alanine, lysine, and asparatic acid were replaced with D amino acids was ineffective in lipid release for both cell lines. ABCA1 protein in THP-1 and WT-38 was stabilized against proteolytic degradation by apoA-I, apoA-II, and apoE and by all the peptides tested except for L3D37pA, and ABCA1 phosphorylation closely correlated with its stabilization. The analysis of the relationship among these parameters indicated that removal of phospholipid triggers signals for phosphorylation and stabilization of AECA1. We thus concluded that an amphiphilic helical motif is the minimum structural requirement for a protein to stabilize AECA1 against proteolytic degradation.	Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan; Grelan Pharmaceut Co Ltd, Div Res & Dev, Tokyo 2050002, Japan; NHLBI, NIH, Mol Dis Branch, Bethesda, MD 20892 USA	Nagoya City University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Yokoyama, S (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan.	syokoyam@med.nagoya-cu.ac.jp	Yamauchi, Yoshio/I-7539-2014	Yamauchi, Yoshio/0000-0001-5559-4596				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; JACKSON RL, 1986, METHOD ENZYMOL, V128, P223; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; OHNISHI T, 1993, BIOCHEMISTRY-US, V32, P5029, DOI 10.1021/bi00070a009; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; TAJIMA S, 1983, J BIOL CHEM, V258, P73; Tsujita M, 2000, BBA-MOL CELL BIOL L, V1485, P199, DOI 10.1016/S1388-1981(00)00061-5; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200; Yamauchi Y, 2002, BBA-MOL CELL BIOL L, V1585, P1, DOI 10.1016/S1388-1981(02)00304-9; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	20	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6217	6220		10.1074/jbc.C300553200	http://dx.doi.org/10.1074/jbc.C300553200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14701850	hybrid			2022-12-25	WOS:000188969200004
J	Zou, WG; Luo, CX; Zhang, ZL; Liu, J; Gu, JF; Pei, ZF; Qian, C; Liu, XY				Zou, WG; Luo, CX; Zhang, ZL; Liu, J; Gu, JF; Pei, ZF; Qian, C; Liu, XY			A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent	ONCOGENE			English	Article						oncolytic adenovirus; E1A gene; hTERT promoter; telomerase; cancer	REPLICATION-COMPETENT ADENOVIRUS; SUICIDE GENE-THERAPY; EXPRESSING BACTERIAL NITROREDUCTASE; REVERSE-TRANSCRIPTASE PROMOTER; CATALYTIC SUBUNIT HTERT; HUMAN CANCER-CELLS; HUMAN BONE-MARROW; PROSTATE-CANCER; HEPATOCELLULAR-CARCINOMA; BAX GENE	Telomerase is a therapeutic target for cancer. Human telomerase reverse transcriptase (hTERT), the catalytic subunit of the telomerase, is transcriptionaly upregulated exclusively in about 90#37; of cancer cells. Previous studies have demonstrated that hTERT promoter can control the expression of exogenous genes to the telomerase-positive cancer cells, thus hTERT promoter is an excellent candidate for generating cancer-specific oncolytic adenovirus. In this study, we devised a novel oncolytic adenovirus (Ad.TERT) by replacing the normal E1A regulatory elements with hTERT promoter. Ad.TERT displays cancer-specific E1A expression, virus replication and cytolysis in in vitro experiments. In animal experiments, intratumoral administration of Ad.TERT demonstrates potent antitumoral efficacy at least in two xenograft models (Bcap37 and BEL7404). Ad.TERT was targeted by the telomerase activity in cancer cells and has potent antitumoral efficacy in vivo, and since telomerase activity is a wide-ranged tumor marker, Ad.TERT could be a powerful therapeutic agent for a variety of cancers.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Univ Navarra, Sch Med, Dept Med, E-31080 Pamplona, Spain	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Navarra	Liu, XY (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	xyliu@sibs.ac.cn	zhang, zl/D-9716-2012					Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; Bilsland AE, 2003, ONCOGENE, V22, P370, DOI 10.1038/sj.onc.1206168; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Curiel DT, 2000, CLIN CANCER RES, V6, P3395; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323; Gu J, 2000, CANCER RES, V60, P5359; Gu J, 2002, ONCOGENE, V21, P4757, DOI 10.1038/sj.onc.1205582; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Hernandez-Alcoceba R, 2002, HUM GENE THER, V13, P1737, DOI 10.1089/104303402760293574; HORWITZ MS, 1996, FIELDS VIROLOGY, P2149; Ichikawa T, 2001, CANCER RES, V61, P5336; Jakubczak JL, 2003, CANCER RES, V63, P1490; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirch HC, 2002, ONCOGENE, V21, P7991, DOI 10.1038/sj.onc.1205965; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Komata T, 2002, ONCOGENE, V21, P656, DOI 10.1038/sj.onc.1205072; Kruyt FAE, 2002, HUM GENE THER, V13, P485, DOI 10.1089/10430340252809784; Kurihara T, 2000, J CLIN INVEST, V106, P763, DOI 10.1172/JCI9180; Li YH, 2001, CANCER RES, V61, P6428; Lin TY, 2002, ONCOGENE, V21, P8020, DOI 10.1038/sj.onc.1205926; Liu J, 2002, INT J ONCOL, V21, P661; Matsubara S, 2001, CANCER RES, V61, P6012; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Motoi F, 2000, HUM GENE THER, V11, P223, DOI 10.1089/10430340050015978; Nakamura Y, 1999, MOL CARCINOGEN, V26, P312, DOI 10.1002/(SICI)1098-2744(199912)26:4<312::AID-MC10>3.3.CO;2-1; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; Plumb JA, 2001, ONCOGENE, V20, P7797, DOI 10.1038/sj.onc.1204954; Post DE, 2003, ONCOGENE, V22, P2065, DOI 10.1038/sj.onc.1206464; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; Rodriguez R, 1997, CANCER RES, V57, P2559; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Takakura M, 1999, CANCER RES, V59, P551; Tsukuda K, 2002, CANCER RES, V62, P3438; Wang JH, 2002, BIOCHEM BIOPH RES CO, V290, P1454, DOI 10.1006/bbrc.2002.6373; Watanabe T, 1996, BLOOD, V87, P5032, DOI 10.1182/blood.V87.12.5032.bloodjournal87125032; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Wildner O, 1999, GENE THER, V6, P57, DOI 10.1038/sj.gt.3300810; Yasumoto S, 1996, ONCOGENE, V13, P433; Yu DC, 1999, CANCER RES, V59, P4200; Yu DC, 2001, CANCER RES, V61, P517	46	53	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					457	464		10.1038/sj.onc.1207033	http://dx.doi.org/10.1038/sj.onc.1207033			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724574				2022-12-25	WOS:000188098300016
J	Cencig, S; Nanbru, C; Le, SY; Gueydan, C; Huez, G; Kruys, V				Cencig, S; Nanbru, C; Le, SY; Gueydan, C; Huez, G; Kruys, V			Mapping and characterization of the minimal internal ribosome entry segment in the human c-myc mRNA 5 ' untranslated region	ONCOGENE			English	Article						translation; IRES; proto-oncogene; c-myc	SITE-MEDIATED TRANSLATION; 5' UNTRANSLATED REGION; GROWTH-FACTOR; CELL-CYCLE; ALTERNATIVE TRANSLATION; PROTEIN-SYNTHESIS; INITIATION; TRANSCRIPTION; BINDING; IDENTIFICATION	The human c-myc proto-oncogene is transcribed from four alternative promoters generating transcripts with 5' untranslated regions of various lengths. These transcripts encode two proteins, c-Myc1 and c-Myc2, from two initiation codons, CUG and AUG, respectively. We and others have previously demonstrated that the region of c-myc transcripts between nucleotides (nt) -363 and -94 upstream from the CUG start codon contained an internal ribosome entry site leading to the cap-independent translation of c-myc open reading frames (ORFs). Here, we mapped a 50-nt sequence (-143 -94), which is sufficient to promote internal translation initiation of c-myc ORFs. Interestingly, this 50-nt element can be further dissected into two segments of 14 nt, each capable of activating internal translation initiation. We also demonstrate that this 50-nt element acts as the ribosome landing site from which the preinitiation ribosomal complex scans the mRNA until the CUG or AUG start codons.	Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; NCI, Lab Expt & Computat Biol, Ctr Canc Res, NIH, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kruys, V (corresponding author), Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, Rue Profs Jeener & Brachet 12, B-6041 Gosselies, Belgium.	vkruys@ulb.ac.be	Kruys, Veronique I/N-6613-2018	Kruys, Veronique/0000-0002-3144-5403; Gueydan, Cyril/0000-0003-3097-7667				Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu MCY, 1999, P NATL ACAD SCI USA, V96, P1339, DOI 10.1073/pnas.96.4.1339; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; Jackson RJ, 1995, RNA, V1, P985; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; Kim JH, 2003, MOL CELL BIOL, V23, P708, DOI 10.1128/MCB.23.2.708-720.2003; KRUYS V, 1993, J EXP MED, V177, P1383, DOI 10.1084/jem.177.5.1383; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Le SY, 1996, VIRUS GENES, V12, P135, DOI 10.1007/BF00572952; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Nanbru C, 2001, ONCOGENE, V20, P4270, DOI 10.1038/sj.onc.1204548; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Owens GC, 2001, P NATL ACAD SCI USA, V98, P1471, DOI 10.1073/pnas.98.4.1471; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sella O, 1999, MOL CELL BIOL, V19, P5429; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2	48	16	18	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					267	277		10.1038/sj.onc.1207017	http://dx.doi.org/10.1038/sj.onc.1207017			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712232				2022-12-25	WOS:000187895300028
J	Kim, B; van Golen, CM; Feldman, EL				Kim, B; van Golen, CM; Feldman, EL			Insulin-like growth factor-I signaling in human neuroblastoma cells	ONCOGENE			English	Article						insulin-like growth factor I; neuroblastoma; Shc; insulin receptor substrate; FAK; paxillin	FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; NEURAL CREST; DIFFERENTIAL REGULATION; HEMATOPOIETIC-CELLS; PREVENTS APOPTOSIS; MEDIATED SURVIVAL; BREAST-CANCER	Neuroblastoma is a heterogeneous tumor consisting of N (neuronal) and S (stromal) cells. We report that more tumorigenic and motile N cells express higher levels of IGF-I receptor (IGF-IR) than less tumorigenic, more adherent S cells. Shc, one of the two major docking partners of IGF-IR, is equally expressed in N and S cell lines. IGF-I treatment phosphorylates Shc in N cells, but only weakly activates Shc in S cells. Expression of the second partner, insulin receptor substrate (IRS), is cell type specific. S cells exclusively express IRS-1 that undergoes sustained phosphorylation by IGF-I. In contrast, N cells express IRS-2 that is transiently phosphorylated by IGF-I. Downstream of IRS-2 and Shc, IGF-I treatment results in strong activation of Akt and MAPK in N cells and activation of both pathways is required for IGF-I-mediated differentiation. Only IGF-IR activation of phosphatidylinositol-3 kinase is required for tumor edge ruffling in N and S cells, with stimulation of focal adhesion kinase (FAK) and paxillin. This detailed understanding of the 'biochemical signature' of N and S cells provides the background needed to target and disrupt specific IGF signaling pathways in an attempt to develop more effective therapies.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kim, B (corresponding author), Univ Michigan, Dept Neurol, 4414 Kresge III,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	bhumsoo@umich.edu		Feldman, Eva/0000-0002-9162-2694	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038849, R01NS036778] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36778, NS38849] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BASERGA R, 1995, CANCER RES, V55, P249; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; CICCARONE V, 1989, CANCER RES, V49, P219; Corvi R, 1997, J NEURO-ONCOL, V31, P25, DOI 10.1023/A:1005721027709; DECLERCK YA, 1987, CANCER RES, V47, P6505; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Encinas M, 1999, J NEUROCHEM, V73, P1409, DOI 10.1046/j.1471-4159.1999.0731409.x; FAVROT MC, 1991, INT J CANCER, V49, P347, DOI 10.1002/ijc.2910490306; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; FLICKINGER KS, 1994, EXP CELL RES, V213, P156, DOI 10.1006/excr.1994.1185; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frappaz D, 2000, J CLIN ONCOL, V18, P468, DOI 10.1200/JCO.2000.18.3.468; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Guo HB, 2002, CANCER RES, V62, P6837; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Ivankovic-Dikic I, 2000, NAT CELL BIOL, V2, P574, DOI 10.1038/35023515; Judware R, 1995, ONCOGENE, V11, P2599; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; Kim BS, 1998, J NEUROCHEM, V71, P1333; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; Kurihara S, 2000, ENDOCR J, V47, P739, DOI 10.1507/endocrj.47.739; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Liu XD, 1998, CANCER RES, V58, P5432; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Miller TM, 1997, J BIOL CHEM, V272, P9847; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; RETTIG WJ, 1987, CANCER RES, V47, P1383; ROSS RA, 1985, CANCER RES, V45, P1628; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Russell JW, 1998, J NEUROBIOL, V36, P455, DOI 10.1002/(SICI)1097-4695(19980915)36:4<455::AID-NEU1>3.0.CO;2-V; Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schmidt ML, 2000, J CLIN ONCOL, V18, P1260, DOI 10.1200/JCO.2000.18.6.1260; Scibelli A, 2003, VET RES, V34, P193, DOI 10.1051/vetres:2002066; Seiler AEM, 2001, J NEUROCHEM, V76, P573, DOI 10.1046/j.1471-4159.2001.00025.x; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Singleton JR, 1996, CANCER RES, V56, P4522; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; Van Golen CM, 2000, J CELL PHYSIOL, V182, P24, DOI 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; Yee D, 2002, SEMIN ONCOL, V29, P86, DOI 10.1053/sonc.2002.34060; YOSHIHARA T, 1992, INT J CANCER, V51, P620, DOI 10.1002/ijc.2910510419; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Zumkeller W, 1999, HORM METAB RES, V31, P138, DOI 10.1055/s-2007-978711	77	69	69	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					130	141		10.1038/sj.onc.1206924	http://dx.doi.org/10.1038/sj.onc.1206924			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712218				2022-12-25	WOS:000187895300014
J	Fadeel, B; Orrenius, S; Pervaiz, S				Fadeel, B; Orrenius, S; Pervaiz, S			Buried alive: a novel approach to cancer treatment	FASEB JOURNAL			English	Article						cancer cells; apoptosis; scavenger receptors; phagocytosis; cell clearance	CELL-DEATH; CLEARANCE; PHOSPHATIDYLSERINE; APOPTOSIS; AUTOANTIGENS; PHAGOCYTOSIS; STRESS	The heightened interest in the development of novel anti-cancer drugs that trigger apoptotic death in cancer cells stems from the fact that immediately upon execution of the death signal, the corpse is efficiently removed via specific recruitment of phagocytic cells. This prevents spilling of cellular contents and the associated inflammatory response, a likely scenario during necrotic death. Recent evidence has established that phagocytic removal of apoptotic cells is a function of ligand-receptor interaction, whereby the ligand(s) for the scavenger receptor(s) of phagocytic cells is/are specifically expressed on apoptosing cells. Therefore, by implication, enhancing this ligand-receptor interaction could be an alternate means for removing unwanted cells. Here we present a provocative hypothesis that circumvents the need for chemotherapy-induced apoptosis in cancer cells. According to our model, cancer cells need not die in order to be removed by scavenger cells, but could still be effectively phagocytosed provided the cell surface expression of specific molecules that strongly engage phagocytic cells is sufficiently enhanced. In other words, inducing the expression of "eat me" signals on cancer cells could be a novel approach to "bury alive" these unwanted cells without the untoward effects of chemotherapy-induced apoptosis.	Natl Univ Singapore, Fac Med, Dept Physiol, NUS Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore; Karolinska Inst, Inst Environm Med, Div Toxicol, S-10401 Stockholm, Sweden	National University of Singapore; Karolinska Institutet	Pervaiz, S (corresponding author), Natl Univ Singapore, Fac Med, Dept Physiol, NUS Grad Sch Integrat Sci & Engn, MD9 03-06, Singapore 117548, Singapore.	phssp@nus.edu.sg	Pervaiz, Shazib/C-4188-2015					Bergsmedh A, 2001, P NATL ACAD SCI USA, V98, P6407, DOI 10.1073/pnas.101129998; Brown S, 2002, NATURE, V418, P200, DOI 10.1038/nature00811; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; FADEEL B, 2003, IN PRESS CELL MOL LI; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Pervaiz S, 2002, CURR PHARM DESIGN, V8, P1723, DOI 10.2174/1381612023394025; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SCHROIT AJ, 1985, J BIOL CHEM, V260, P5131	18	14	18	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					1	4		10.1096/fj.03-0510hyp	http://dx.doi.org/10.1096/fj.03-0510hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718381				2022-12-25	WOS:000188829300034
J	Le Bras, S; Foucault, I; Foussat, A; Brignone, C; Acuto, O; Deckert, M				Le Bras, S; Foucault, I; Foussat, A; Brignone, C; Acuto, O; Deckert, M			Recruitment of the actin-binding protein HIP-55 to the immunological synapse regulates T cell receptor signaling and endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE ANTIGEN RECEPTORS; NEGATIVE REGULATION; ADAPTER PROTEINS; FUNCTIONAL-ANALYSIS; DOWN-MODULATION; LINKER PROTEIN; C-CBL; ACTIVATION; CYTOSKELETON; TRANSDUCTION	Actin cytoskeleton dynamics critically regulate T cell activation. We found that the cytoplasmic adaptor HIP-55, a Src/Syk-kinases substrate and member of the drebrin/ Abp1 family of actin-binding proteins, localized to the T cell-antigen-presenting cell (APC) contact site in an antigen-dependent manner. Using green fluorescent protein fusion proteins, both Src homology 3 (SH3) and actin binding domains were found necessary for recruitment at the T cell-APC interface. HIP-55 was not implicated in conjugate formation and actin polymerization but regulated distal signaling events through binding and activation of hematopoietic progenitor kinase 1 (HPK1), a germinal center kinase (GCK) family kinase involved in negative signaling in T cells. Using RNA interference and overexpression experiments, the HIP-55- HPK1 complex was found to negatively regulate nuclear factor of activated T cell ( NFAT) activation by the T cell antigen receptor. Moreover, we show that HIP-55, which partly co-localized with early endocytic compartments, promoted both basal and ligand-dependent T cell receptor (TCR) down-modulation, resulting in a decreased TCR expression. SH3 and actin-depolymerizing factor homology domains were required for this function. As controls, the expression of CD28 and the glycosylphosphatidylinositol-linked protein CD59 was not affected by HIP-55 overexpression. These results suggest that, in addition to binding to HPK1, HIP-55 might negatively regulate TCR signaling through down-regulation of TCR expression. Our findings show that HIP-55 is a key novel component of the immunological synapse that modulates T cell activation by connecting actin cytoskeleton and TCRs to gene activation and endocytic processes.	INSERM, U576, Hop Archet, F-06202 Nice 3, France; Inst Pasteur, CNRS, URA 1961, Unite Immunol Mol, F-75015 Paris, France	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Deckert, M (corresponding author), INSERM, U576, Hop Archet, F-06202 Nice 3, France.	deckert@unice.fr	Deckert, Marcel/T-3566-2019; Deckert, Marcel/M-4998-2016	Deckert, Marcel/0000-0003-2094-559X; 				Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; CALLEWAERT DM, 1991, CYTOMETRY, V12, P666, DOI 10.1002/cyto.990120711; Cannon JL, 2001, IMMUNITY, V15, P249, DOI 10.1016/S1074-7613(01)00178-9; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; Egen JG, 2002, IMMUNITY, V16, P23, DOI 10.1016/S1074-7613(01)00259-X; Ensenat D, 1999, J BIOL CHEM, V274, P33945, DOI 10.1074/jbc.274.48.33945; Fazi B, 2002, J BIOL CHEM, V277, P5290, DOI 10.1074/jbc.M109848200; Fuller CL, 2003, IMMUNOL REV, V191, P220, DOI 10.1034/j.1600-065X.2003.00004.x; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; ISHIKAWA R, 1994, J BIOL CHEM, V269, P29928; Jang IK, 2003, CURR OPIN IMMUNOL, V15, P315, DOI 10.1016/S0952-7915(03)00048-7; Kessels MM, 2000, MOL BIOL CELL, V11, P393, DOI 10.1091/mbc.11.1.393; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Koretzky GA, 2001, NAT REV IMMUNOL, V1, P95, DOI 10.1038/35100523; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Lanzavecchia A, 2001, NAT IMMUNOL, V2, P487, DOI 10.1038/88678; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; Larbolette O, 1999, MOL CELL BIOL, V19, P1539; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu HY, 2000, IMMUNITY, V13, P665, DOI 10.1016/S1074-7613(00)00066-2; Loreto MP, 2002, MOL CELL BIOL, V22, P4241, DOI 10.1128/MCB.22.12.4241-4255.2002; Mise-Omata S, 2003, BIOCHEM BIOPH RES CO, V301, P704, DOI 10.1016/S0006-291X(02)02972-8; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Olazabal IM, 2001, J CELL BIOL, V154, P679, DOI 10.1083/jcb.200105061; Putnam MA, 2003, J IMMUNOL, V170, P905, DOI 10.4049/jimmunol.170.2.905; Ramjaun AR, 2001, J BIOL CHEM, V276, P28913, DOI 10.1074/jbc.M103198200; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; van der Merwe PA, 2002, CURR OPIN IMMUNOL, V14, P293, DOI 10.1016/S0952-7915(02)00350-3; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266	47	67	73	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15550	15560		10.1074/jbc.M312659200	http://dx.doi.org/10.1074/jbc.M312659200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14729663	hybrid			2022-12-25	WOS:000220594700127
J	Surguladze, N; Thompson, KM; Beard, JL; Connor, JR; Fried, MG				Surguladze, N; Thompson, KM; Beard, JL; Connor, JR; Fried, MG			Interactions and reactions of ferritin with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEAL EPITHELIAL-CELLS; GLOBIN GENE-EXPRESSION; IRON-SULFUR CENTER; RAT-LIVER NUCLEI; GEL-ELECTROPHORESIS; RIBONUCLEOTIDE REDUCTASE; LIPID-PEROXIDATION; PROTECTS DNA; K562 CELLS; BINDING	Ferritin, normally considered a cytoplasmic iron-storage protein, is also found in the nuclei of some cells. There is no current agreement about its function(s) in this environment. Proposals include DNA protection, provision of iron to nuclear enzymes, and regulation of transcription initiation, but evidence for these functions is scanty. We have shown previously that H-ferritin subunits can be cross-linked to chromosomal DNA in vivo (Thompson, K. J., Fried, M. G., Ye, Z., Boyer, P., and Connor, J. R. ( 2002) J. Cell Sci. 115, 2165 - 2177). Here we describe systematic analyses of DNA binding and the covalent stability of DNA in the presence of ferritins from several different sources. Our data show that the H-subunit of human ferritin binds DNA, whereas neither the L-subunit nor the ferroxidase-deficient 222-mutant of the H-subunit has detectable binding activity. DNA binding is without significant preference for base composition, sequence, or the nature of DNA ends. Hand L-ferritins and ferritins of mixed subunit composition stimulate the conversion of superhelical plasmid DNA to the relaxed form. The sensitivity of this conversion to glycerol suggests that DNA is nicked by a free radical mechanism. The rate of nicking correlates with the iron content of the ferritin and is strongly inhibited by chelators. Ferritin-dependent nicking is characterized by a kinetic lag that is not seen in control reactions containing free iron species. These results suggest that the release of iron from ferritin is an important part of the nicking mechanism. The potential role of ferritin as a protector of the genome is discussed in the context of these results.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA; Penn State Univ, Dept Nutr Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Fried, MG (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.	mfried@psu.edu			NIDDK NIH HHS [DK54289] Funding Source: Medline; NIGMS NIH HHS [R01 GM070662, R01 GM070662-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070662] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRONIKASHVILI EL, 1974, CANCER RES, V34, P271; BAUER WR, 1978, ANNU REV BIOPHYS BIO, V7, P287, DOI 10.1146/annurev.bb.07.060178.001443; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; BRODERSEN R, 1987, EUR J BIOCHEM, V169, P487, DOI 10.1111/j.1432-1033.1987.tb13636.x; Broyles RH, 2001, P NATL ACAD SCI USA, V98, P9145, DOI 10.1073/pnas.151147098; BROYLES RH, 1995, COLLOQ INSE, V234, P43; Cai CX, 1997, J BIOL CHEM, V272, P12831, DOI 10.1074/jbc.272.19.12831; Cai CX, 2001, J CELL SCI, V114, P2327; Cai CX, 1998, MOL BIOL CELL, V9, P1037, DOI 10.1091/mbc.9.5.1037; CHASTEEN ND, 1994, ADV EXP MED BIOL, V356, P23; Cheepsunthorn P, 2001, J COMP NEUROL, V431, P382, DOI 10.1002/1096-9861(20010319)431:4<382::AID-CNE1077>3.0.CO;2-#; Erikson KM, 1997, J NUTR, V127, P2030, DOI 10.1093/jn/127.10.2030; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; Fried MG, 1997, ELECTROPHORESIS, V18, P6, DOI 10.1002/elps.1150180103; Fried MG, 1998, ELECTROPHORESIS, V19, P1247, DOI 10.1002/elps.1150190804; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; Gurgueira SA, 1996, J BIOL CHEM, V271, P13616, DOI 10.1074/jbc.271.23.13616; Gutfreund H, 1995, KINETICS LIFE SCI, P103; HADDOW A, 1960, J NATL CANCER I, V24, P109; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HILL TL, 1986, INTRO STAT THERMODYN, P59; HURTA RAR, 1991, BIOCHEM CELL BIOL, V69, P635, DOI 10.1139/o91-094; IANCU TC, 1985, J HEPATOL, V1, P261, DOI 10.1016/S0168-8278(85)80054-4; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; Kurien BT, 1997, ANAL BIOCHEM, V245, P123, DOI 10.1006/abio.1996.9971; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Orino K, 2002, BIOMETALS, V15, P59, DOI 10.1023/A:1013102012234; Pountney D, 1999, J CELL SCI, V112, P825; PRINCE RC, 1993, TRENDS BIOCHEM SCI, V18, P153; *PROM CORP, 2000, PROM TECHN B, V33; REIF DW, 1988, ARCH BIOCHEM BIOPHYS, V264, P238, DOI 10.1016/0003-9861(88)90590-5; REIF DW, 1992, FREE RADICAL BIO MED, V12, P417, DOI 10.1016/0891-5849(92)90091-T; Romeo AM, 2001, J BIOL CHEM, V276, P24301, DOI 10.1074/jbc.M010806200; SAMOKYSZYN VM, 1988, DRUG METAB REV, V19, P283, DOI 10.3109/03602538808994137; SHIRES TK, 1982, BIOCHEM J, V205, P321, DOI 10.1042/bj2050321; SMITH AG, 1990, HEPATOLOGY, V12, P1399, DOI 10.1002/hep.1840120622; SPRAGUE ED, 1980, ANAL BIOCHEM, V101, P175, DOI 10.1016/0003-2697(80)90057-3; TACHON P, 1989, FREE RADICAL RES COM, V7, P1, DOI 10.3109/10715768909088155; Theil EC, 2003, J NUTR, V133, p1549S, DOI 10.1093/jn/133.5.1549S; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THEIL EC, 1990, ADV ENZYMOL RAMB, V63, P421; Thompson KJ, 2002, J CELL SCI, V115, P2165; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; VACA CE, 1989, BIOCHIM BIOPHYS ACTA, V1001, P35, DOI 10.1016/0005-2760(89)90304-4; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WHITING RF, 1981, CANCER RES, V41, P1628; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285; WU YJ, 1991, J BIOL CHEM, V266, P17566; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	54	58	61	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14694	14702		10.1074/jbc.M313348200	http://dx.doi.org/10.1074/jbc.M313348200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14734543	hybrid			2022-12-25	WOS:000220594700029
J	Grosset, C; Boniface, R; Duchez, P; Solanilla, A; Cosson, B; Ripoche, J				Grosset, C; Boniface, R; Duchez, P; Solanilla, A; Cosson, B; Ripoche, J			In vivo studies of translational repression mediated by the granulocyte-macrophage colony-stimulating factor AU-rich element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; POLY(A) TAIL; POLY(A)-BINDING PROTEIN; UNTRANSLATED REGION; BINDING-PROTEIN; C-FOS; TURNOVER; DECAY; INITIATION; EUKARYOTES	The AU-rich element (ARE) controls the turnover of many unstable mRNAs and their translation. The granulocyte-macrophage colony-stimulating factor (GMCSF) ARE is known to be a destabilizing element, but its role in translation remains unclear. Here we studied in vivo the role of the GM-CSF ARE on the mRNA and protein expressions of an enhanced green fluorescent protein reporter gene. The GM-CSF ARE had a repressor effect on translation independently of its effect on mRNA levels. In the context of an internal ribosome entry site, the GM-CSF ARE still repressed translation but was no longer functional as a destabilizing element. Gel retardation assays showed that poly(A)-binding protein is displaced from the poly(A) tail when the ARE is present in the 3'-untranslated region. These data suggest that the GM-CSF ARE controls translation and mRNA decay by interfering with poly(A)-binding protein-mediated mRNA circularization.	Univ Bordeaux 2, CNRS, FRE 2617, F-33076 Bordeaux, France; Univ Rennes 1, CNRS, UMR 6061, F-35043 Rennes, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Grosset, C (corresponding author), Univ Bordeaux 2, CNRS, FRE 2617, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	christophe.grosset@umr5540.u-bordeaux2.fr	Grosset, Christophe/I-5059-2016; Grosset, Christophe/P-9864-2019	Grosset, Christophe/0000-0002-0479-6291; Grosset, Christophe/0000-0002-0479-6291; DUCHEZ, PASCALE/0000-0003-1474-3764; Cosson, Bertrand/0000-0003-3401-7137				BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; Bollig F, 2003, BIOCHEM BIOPH RES CO, V301, P665, DOI 10.1016/S0006-291X(03)00015-9; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; D'Orso I, 2002, J BIOL CHEM, V277, P50520, DOI 10.1074/jbc.M209092200; Dreyfus M, 2002, CELL, V111, P611, DOI 10.1016/S0092-8674(02)01137-6; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Houzet L, 2001, BLOOD, V98, P1281, DOI 10.1182/blood.V98.5.1281; Jarzembowski JA, 1999, NUCLEIC ACIDS RES, V27, P3660, DOI 10.1093/nar/27.18.3660; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Laroia G, 2002, P NATL ACAD SCI USA, V99, P1842, DOI 10.1073/pnas.042575699; Mazumder B, 2001, MOL CELL BIOL, V21, P6440, DOI 10.1128/MCB.21.19.6440-6449.2001; Metcalf D, 1997, CIBA F SYMP, V204, P40; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Mitchell P, 2001, CURR OPIN CELL BIOL, V13, P320, DOI 10.1016/S0955-0674(00)00214-3; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Svitkin YV, 2001, RNA, V7, P1743; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; Voeltz GK, 2001, GENE DEV, V15, P774, DOI 10.1101/gad.872201; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wiklund L, 2002, J BIOL CHEM, V277, P40462, DOI 10.1074/jbc.M205929200; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; Xu NH, 2001, MOL CELL BIOL, V21, P6960, DOI 10.1128/MCB.21.20.6960-6971.2001	35	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13354	13362		10.1074/jbc.M308003200	http://dx.doi.org/10.1074/jbc.M308003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726527	hybrid			2022-12-25	WOS:000220478500012
J	Kramer, G; Patzelt, H; Rauch, T; Kurz, TA; Vorderwulbecke, S; Bukau, B; Deuerling, E				Kramer, G; Patzelt, H; Rauch, T; Kurz, TA; Vorderwulbecke, S; Bukau, B; Deuerling, E			Trigger factor peptidyl-prolyl cis/trans isomerase activity is not essential for the folding of cytosolic proteins in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NASCENT POLYPEPTIDES; ENZYMATIC CATALYSIS; MUTATIONAL ANALYSIS; DNAK; DOMAIN; SUBSTRATE; BINDING; SITE; IDENTIFICATION; ISOMERIZATION	The ribosome-associated Trigger Factor (TF) cooperates with the DnaK system to assist the folding of newly synthesized polypeptides in Escherichia coli. TF unifies two functions in one to promote proper protein folding in vitro. First, as a chaperone it binds to unfolded protein substrates, thereby preventing aggregation and supporting productive folding. Second, TF catalyzes the cis/trans isomerization of peptidyl-prolyl bonds, which can be a rate-limiting step in protein folding. Here, we investigated whether the peptidyl-prolyl cis/trans isomerase ( PPIase) function is essential for the folding activity of TF in vitro and in vivo by separating these two TF activities through site-directed mutagenesis of the PPIase catalytic center. Of the four different TF variants carrying point mutations in the PPIase domain, only the exchange of the conserved residue Phe-198 to Ala (TF F198A) abolished the PPIase activity of TF toward both a tetrapeptide and the model protein substrate RNase T1 in vitro. In contrast, all other activities of TF F198A tested were comparable with wild type TF. TF F198A retained a similar binding specificity toward membrane-bound peptides, assisted the refolding of denatured D-glyceraldehyde-3-phosphate dehydrogenase in vitro, and associated with nascent polypeptides in an in vitro transcription/translation system. Importantly, expression of the TF F198A encoding gene complemented the synthetic lethality of DeltatigDeltadnaK cells and prevented global protein misfolding at temperatures between 20 and 34 degreesC in these cells. We conclude that the PPIase activity is not required for the function of TF in folding of newly synthesized proteins.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Deuerling, E (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	e.deuerling@zmbh.uni-heidelberg.de		Patzelt, Holger/0000-0001-9886-8374; Bukau, Bernd/0000-0003-0521-7199; Kramer, Gunter/0000-0001-7552-8393				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; Behrens S, 2001, EMBO J, V20, P285, DOI 10.1093/emboj/20.1.285; CALLEBAUT I, 1995, FEBS LETT, V374, P211, DOI 10.1016/0014-5793(95)01109-R; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DeCenzo MT, 1996, PROTEIN ENG, V9, P173, DOI 10.1093/protein/9.2.173; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; FISCHER G, 1992, MOL MICROBIOL, V6, P1375, DOI 10.1111/j.1365-2958.1992.tb00858.x; GUTHRIE B, 1990, J BACTERIOL, V172, P5555, DOI 10.1128/jb.172.10.5555-5562.1990; Hesterkamp T, 1996, FEBS LETT, V385, P67, DOI 10.1016/0014-5793(96)00351-1; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Huang GC, 2000, PROTEIN SCI, V9, P1254, DOI 10.1110/ps.9.6.1254; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lyon WR, 2003, J BACTERIOL, V185, P3661, DOI 10.1128/JB.185.12.3661-3667.2003; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; MUCKE M, 1992, BIOCHEMISTRY-US, V31, P7848; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Pirkl F, 2001, J BIOL CHEM, V276, P37034, DOI 10.1074/jbc.M102595200; Ramm K, 2001, J MOL BIOL, V310, P485, DOI 10.1006/jmbi.2001.4747; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Schaffitzel E, 2001, BIOL CHEM, V382, P1235, DOI 10.1515/BC.2001.154; Schiene-Fischer C, 2002, BIOL CHEM, V383, P1865, DOI 10.1515/BC.2002.210; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; Scholz C, 1997, FEBS LETT, V414, P69, DOI 10.1016/S0014-5793(97)00979-4; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; Stoller G, 1996, FEBS LETT, V384, P117, DOI 10.1016/0014-5793(96)00282-7; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x	33	81	83	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14165	14170		10.1074/jbc.M313635200	http://dx.doi.org/10.1074/jbc.M313635200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729669	Green Published, hybrid			2022-12-25	WOS:000220478500107
J	Moorefield, KS; Fry, SJ; Horowitz, JM				Moorefield, KS; Fry, SJ; Horowitz, JM			Sp2 DNA binding activity and trans-activation are negatively regulated in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; RETINOBLASTOMA RB PROTEIN; TRANSCRIPTION FACTOR SP1; KRUPPEL-LIKE FACTOR; GENE-EXPRESSION; AMINO-TERMINUS; GROWTH SUPPRESSION; SP-FAMILY; PROMOTER; RECEPTOR	Previous studies have indicated that Sp2 binds poorly to GC-rich sequences bound by Sp1 and Sp3, and further functional analyses of Sp2 have been limited. To study Sp2-mediated transcription, we employed a PCR-based protocol to determine the Sp2 consensus DNA-binding sequence (5'-GGGCGGGAC-3') and performed kinetic experiments to show that Sp2 binds this consensus sequence with high affinity (225 pM) in vitro. To determine the functional consequence of Sp2 interaction with this sequence in vivo, we transformed well characterized Sp-binding sites within the dihydrofolate reductase (DHFR) promoter to consensus Sp2-binding sites. Incorporation of Sp2-binding sites within the DHFR promoter increased Sp2-mediated trans-activation in transient co-transfection experiments but also revealed Sp2 to be a relatively weak trans-activator with little or no capacity for additive or synergistic trans-activation. Using chimeric molecules prepared with portions of Sp1 and Sp2 and the human prostate-specific antigen promoter, we show that Sp2 DNA binding activity and trans-activation are negatively regulated in mammalian cells. Taken together, our data indicate that Sp2 is functionally distinct relative to other Sp family members and suggest that Sp2 may play a unique role in cell physiology.	N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27606 USA; N Carolina State Univ, Grad Program Genom Sci, Raleigh, NC 27606 USA	University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University	Horowitz, JM (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, 4700 Hillsborough St, Raleigh, NC 27606 USA.	jon_horowitz@ncsu.edu			NATIONAL CANCER INSTITUTE [R01CA053248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065405] Funding Source: NIH RePORTER; NCI NIH HHS [CA53248] Funding Source: Medline; NIGMS NIH HHS [GM065405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajuh PM, 2000, NUCLEIC ACIDS RES, V28, P678, DOI 10.1093/nar/28.3.678; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Bakovic M, 2000, J LIPID RES, V41, P583; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Chen H, 2002, CANCER RES, V62, P338; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Geng Y, 1999, BIOCHEM BIOPH RES CO, V263, P366, DOI 10.1006/bbrc.1999.1374; Gollner H, 2001, MECH DEVELOP, V106, P77, DOI 10.1016/S0925-4773(01)00420-8; Gollner H, 2001, GENES CELLS, V6, P689, DOI 10.1046/j.1365-2443.2001.00455.x; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Gurova KV, 2002, ONCOGENE, V21, P153, DOI 10.1038/sj.onc.1205001; Halim AB, 2001, J BIOL CHEM, V276, P9784, DOI 10.1074/jbc.M002347200; Hong YL, 1999, J BIOL CHEM, V274, P12967, DOI 10.1074/jbc.274.19.12967; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kennett SB, 2002, J BIOL CHEM, V277, P9780, DOI 10.1074/jbc.M108661200; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kimura N, 2001, ENDOCRINOLOGY, V142, P1427, DOI 10.1210/en.142.4.1427; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; MURATA Y, 1994, J BIOL CHEM, V269, P20674; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Peters CS, 2001, J BIOL CHEM, V276, P13718, DOI 10.1074/jbc.M011562200; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; SHI YG, 1995, CHEM BIOL, V2, P83, DOI 10.1016/1074-5521(95)90280-5; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shimizu C, 2001, BIOCHEM BIOPH RES CO, V284, P763, DOI 10.1006/bbrc.2001.5032; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; Sterner JM, 1996, CELL GROWTH DIFFER, V7, P53; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869	52	32	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13911	13924		10.1074/jbc.M313589200	http://dx.doi.org/10.1074/jbc.M313589200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726517	hybrid			2022-12-25	WOS:000220478500078
J	Schneider, M; Nesheim, M				Schneider, M; Nesheim, M			A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCARBOXYPEPTIDASE-B; PROTEOLYTIC CLEAVAGE; THERMAL-STABILITY; ACTIVATION; KINETICS; BINDING; TAFI; PROTEASE; ALPHA(2)-ANTIPLASMIN; ALPHA-2-ANTIPLASMIN	Previous work using soluble fibrin surrogates or very dilute fibrin indicate that inhibition of plasmin by antiplasmin is attenuated by fibrin surrogates; however, this phenomenon has not been quantified within intact fibrin clots. Therefore, a novel system was designed to measure plasmin inhibition by antiplasmin in real time within an intact clot during fibrinolysis. This was accomplished by including the plasmin substrate S2251 and a recombinant fluorescent derivative of plasminogen (S741C-fluorescein) into clots formed from purified components. Steady state plasmin levels were estimated from the rates of S2251 hydrolysis, the rates of plasminogen activation were estimated by fluorescence decrease over time, and residual antiplasmin was deduced from residual fluorescence. From these measurements, the second order rate constant could be inferred at any time during fibrinolysis. Immediately after clot formation, the rate constant for inhibition decreased 3-fold from 9.6 x 10(6) M-1 s(-1) measured in a soluble buffer system to 3.2 x 10(6) M-1 s(-1) in an intact fibrin clot. As the clot continued to lyse, the rate constant for inhibition continued to decrease by 38-fold at maximum. To determine whether this protection was the result of plasmin exposure of carboxyl-terminal lysine residues, clots were formed in the presence of activated thrombin-activatable fibrinolysis inhibitor (TAFIa). In the presence of TAFIa, the initial protective effect associated with clot formation occurred; however, the secondary protective effect associated with lysine residue exposure was delayed in a TAFIa concentration-dependent manner. This latter effect represents another mechanism whereby TAFIa attenuates fibrinolysis.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Nesheim, M (corresponding author), Queens Univ, Dept Biochem, Rm A212,Botterell Hall, Kingston, ON K7L 3N6, Canada.	nesheimm@post.queensu.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46703-6] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANONICK PK, 1991, BIOCHEM J, V275, P53, DOI 10.1042/bj2750053; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; Christensen U, 1996, FEBS LETT, V387, P58, DOI 10.1016/0014-5793(96)00429-2; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; EATON DL, 1991, J BIOL CHEM, V266, P21833; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KOLEV K, 1994, J BIOL CHEM, V269, P17030; Lee AYY, 2001, THROMB HAEMOSTASIS, V85, P502, DOI 10.1055/s-0037-1615612; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; Mao SS, 1999, J BIOL CHEM, V274, P35046, DOI 10.1074/jbc.274.49.35046; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; Schneider M, 2002, J BIOL CHEM, V277, P1021, DOI 10.1074/jbc.M104444200; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; Wang HY, 2003, EUR J BIOCHEM, V270, P2023, DOI 10.1046/j.1432-1033.2003.03578.x; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WANG W, 1994, J BIOL CHEM, V269, P15937; WIMAN B, 1978, EUR J BIOCHEM, V87, P143, DOI 10.1111/j.1432-1033.1978.tb12360.x; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x	28	55	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13333	13339		10.1074/jbc.M313164200	http://dx.doi.org/10.1074/jbc.M313164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14715655	hybrid			2022-12-25	WOS:000220478500009
J	Sounni, NE; Roghi, C; Chabottaux, V; Janssen, M; Munaut, C; Maquoi, E; Galvez, BG; Gilles, C; Frankenne, F; Murphy, G; Foidart, JM; Noel, AS				Sounni, NE; Roghi, C; Chabottaux, V; Janssen, M; Munaut, C; Maquoi, E; Galvez, BG; Gilles, C; Frankenne, F; Murphy, G; Foidart, JM; Noel, AS			Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; FACTOR GENE-EXPRESSION; TISSUE INHIBITOR; TUMOR-GROWTH; INTEGRIN ALPHA-V-BETA-3; MAMMARY-CARCINOMA; ANGIOGENIC SWITCH; DOWN-REGULATION; CANCER-CELLS; C-SRC	Membrane-type 1 matrix metalloproteinase (MT1-MMP) and vascular endothelial growth factor ( VEGF) are two key molecules involved in pericellular proteolysis and cell proliferation during tumor growth and angiogenesis. Our previous data showed that MT1-MMP overexpression in human breast carcinoma MCF7 cells induced an up-regulation of VEGF expression. This effect was associated in vivo with accelerated tumor growth and angiogenesis. We now provide evidence that MT1-MMP overexpression specifically affected VEGF-A production and failed to influence that of other VEGF family members ( VEGF, B, C, D, or PlGF) or their receptors. The up-regulation of VEGF-A by MT1-MMP was related to an increased transcriptional activation rather than to a modification of mRNA stability. It was blocked by synthetic MMP inhibitors, TIMP2, but not TIMP-1 and abolished by a partial deletion of the catalytic domain or the cytoplasmic tail of MT1-MMP. Analysis of the signal transduction mechanisms demonstrated that MT1-MMP acts through a signaling pathway involving Src tyrosine kinases. Thus, our results provide new insight into the mechanisms of action of MT1-MMP during angiogenesis and suggest that the full enzymatic activity of MT1-MMP is required for a specific up-regulation of VEGF-A through an activation of Src tyrosine kinase pathways.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Univ Cambridge, Cambridge Inst Med Res, Dept Oncol, Cambridge CB2 2XY, England; Hosp Princesa, Dept Inmunol, Madrid 28006, Spain	University of Liege; University of Cambridge; Hospital de La Princesa	Noel, AS (corresponding author), Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium.	agnes.noel@ulg.ac.be	Munaut, Carine/K-8138-2019; Sounni, Nor Eddine/AAY-8766-2021; Gálvez, Beatriz G./H-1644-2015; Roghi, Christian/F-3228-2012	Sounni, Nor Eddine/0000-0001-9962-9236; Gálvez, Beatriz G./0000-0002-8082-9323; Roghi, Christian/0000-0002-4109-6382; Noel, Agnes/0000-0002-7670-6179				Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21-3-337; Arlt M, 2002, CANCER RES, V62, P5543; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baramova EN, 1997, FEBS LETT, V405, P157, DOI 10.1016/S0014-5793(97)00175-0; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Eccles SA, 1996, CANCER RES, V56, P2815; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802; Fukuda R, 2003, CANCER RES, V63, P2330; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Goffin F, 2003, BIOL REPROD, V69, P976, DOI 10.1095/biolreprod.103.015933; Grams F, 2001, BIOL CHEM, V382, P1277, DOI 10.1515/BC.2001.159; Hajitou A, 2001, CANCER RES, V61, P3450; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Lafleur MA, 2002, J CELL SCI, V115, P3427; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Llano E, 1999, CANCER RES, V59, P2570; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Munaut C, 2003, INT J CANCER, V106, P848, DOI 10.1002/ijc.11313; Nuttall RK, 2003, MOL CANCER RES, V1, P333; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Sounni NE, 2003, MATRIX BIOL, V22, P55, DOI 10.1016/S0945-053X(03)00003-9; Sounni NE, 2002, INT J CANCER, V98, P23, DOI 10.1002/ijc.10134; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Velasco G, 2000, CANCER RES, V60, P877; Wang YH, 1999, J BIOL CHEM, V274, P33043, DOI 10.1074/jbc.274.46.33043; Yana I, 2002, CLIN EXP METASTAS, V19, P209, DOI 10.1023/A:1015527220537; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yoshiji H, 1998, INT J CANCER, V75, P81, DOI 10.1002/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.3.CO;2-J; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	55	121	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13564	13574		10.1074/jbc.M307688200	http://dx.doi.org/10.1074/jbc.M307688200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729679	hybrid, Green Submitted, Green Published			2022-12-25	WOS:000220478500036
J	Brown, C; Gaspar, J; Pettit, A; Lee, R; Gu, XS; Wang, H; Manning, C; Voland, C; Goldring, SR; Goldring, MB; Libermann, TA; Gravallese, EM; Oettgen, P				Brown, C; Gaspar, J; Pettit, A; Lee, R; Gu, XS; Wang, H; Manning, C; Voland, C; Goldring, SR; Goldring, MB; Libermann, TA; Gravallese, EM; Oettgen, P			ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; RHEUMATOID-ARTHRITIS; FACTOR-ALPHA; SYNOVIAL FIBROBLASTS; BINDING-SITES; DNA-BINDING; ETS FAMILY; ANGIOGENESIS	Angiogenesis is a critical component of the inflammatory response associated with a number of conditions. Angiopoietin-1 (Ang-1) is an angiogenic growth factor that promotes the chemotaxis of endothelial cells and facilitates the maturation of new blood vessels. Ang-1 expression is up-regulated in response to tumor necrosis factor-alpha (TNF-alpha). To begin to elucidate the underlying molecular mechanisms by which Ang-1 gene expression is regulated during inflammation, we isolated 3.2 kb of the Ang-1 promoter that contain regulatory elements sufficient to mediate induction of the promoter in response to TNF-alpha, interleukin-1beta, and endotoxin. Surprisingly, sequence analysis of this promoter failed to reveal binding sites for transcription factors that are frequently associated with mediating inflammatory responses, such as NF-kappaB, STAT, NFAT, or C/EBP. However, putative binding sites for ETS and AP-1 transcription factor family members were identified. Interestingly, among a panel of ETS factors tested in a transient transfection assay, only the ETS factor ESE-1 was capable of transactivating the Ang-1 promoter. ESE-1 binds to specific ETS sites within the Ang-1 promoter that are functionally important for transactivation by ESE-1. ESE-1 and Ang-1 are induced in synovial fibroblasts in response to inflammatory cytokines, with ESE-1 induction slightly preceding that of Ang-1. Mutation of a high-affinity ESE-1 binding site leads to a marked reduction in Ang-1 transactivation by ESE-1, inducibility by inflammatory cytokines, and DNA binding to the ESE-1 protein. Transcriptional profiling of cells transiently transfected with an ESE-1 expression vector demonstrates that the endogenous Ang-1 gene is directly inducible by ESE-1. Finally, Ang-1 and ESE-1 exhibit a similar and strong expression pattern in the synovium of patients with rheumatoid arthritis. Our results support a novel paradigm for the ETS factor ESE-1 as a transcriptional mediator of angiogenesis in the setting of inflammation.	Harvard Inst Med, Beth Israel Deaconess Med Ctr, Dept Med, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; New England Baptist Hospital	Oettgen, P (corresponding author), Harvard Inst Med, Beth Israel Deaconess Med Ctr, Dept Med, New England Baptist Bone & Joint Inst, 4 Blackfan Circle, Boston, MA 02115 USA.	joettgen@caregroup.harvard.edu	Wang, Hong/H-6298-2012; Pettit, Allison/O-4462-2019; Libermann, Towia/F-9866-2010; Oettgen, Peter/AAF-5026-2021	Pettit, Allison/0000-0003-4707-7892; Libermann, Towia/0000-0002-4006-8179	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045378, R01AR047952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022021, R56AG022021] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 67219] Funding Source: Medline; NIAID NIH HHS [AI 49527] Funding Source: Medline; NIAMS NIH HHS [AR 47952, AR 45378] Funding Source: Medline; NIA NIH HHS [AG 22021] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; ELVERT G, 2002, J BIOL CHEM; Erman B, 1998, MOL CELL BIOL, V18, P1322, DOI 10.1128/MCB.18.3.1322; Escoubet-Lozach L, 2002, J ALLERGY CLIN IMMUN, V110, P553, DOI 10.1067/mai.2002.128076; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; FITZGERALD O, 1991, ANN RHEUM DIS, V50, P792, DOI 10.1136/ard.50.11.792; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Goetze S, 2001, ATHEROSCLEROSIS, V159, P93, DOI 10.1016/S0021-9150(01)00497-X; Grall F, 2003, ARTHRITIS RHEUM, V48, P1249, DOI 10.1002/art.10942; Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P; Gravallese EM, 2003, ANN RHEUM DIS, V62, P100, DOI 10.1136/ard.62.2.100; Gu XS, 2001, J BIOL CHEM, V276, P9421, DOI 10.1074/jbc.M010070200; Hanada T, 2002, CYTOKINE GROWTH F R, V13, P413, DOI 10.1016/S1359-6101(02)00026-6; Huang XL, 1999, BIOCHEM BIOPH RES CO, V264, P133, DOI 10.1006/bbrc.1999.1472; Itaya H, 2001, THROMB HAEMOSTASIS, V85, P171, DOI 10.1055/s-0037-1612921; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D; KOCH AE, 1994, J IMMUNOL, V152, P4149; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Niini T, 2002, LEUKEMIA, V16, P2213, DOI 10.1038/sj.leu.2402685; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; Paleolog EM, 1998, ARTHRITIS RHEUM, V41, P1258, DOI 10.1002/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1; Rudders S, 2001, J BIOL CHEM, V276, P3302, DOI 10.1074/jbc.M006507200; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Scott BB, 2002, J RHEUMATOL, V29, P230; Senger DR, 1996, AM J PATHOL, V149, P293; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shahrara S, 2002, ARTHRITIS RES, V4, P201, DOI 10.1186/ar407; STEVENS CR, 1991, ARTHRITIS RHEUM, V34, P1508; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Walsh DA, 1999, RHEUMATOLOGY, V38, P103, DOI 10.1093/rheumatology/38.2.103; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015	51	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12794	12803		10.1074/jbc.M308593200	http://dx.doi.org/10.1074/jbc.M308593200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14715662	hybrid			2022-12-25	WOS:000220334900094
J	Fu, DX; Kobayashi, M; Lin, L				Fu, DX; Kobayashi, M; Lin, L			A p105-based inhibitor broadly represses NF-kappa B activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SKIN CARCINOGENESIS; INDUCED P105 PROTEOLYSIS; ALPHA-INDUCED APOPTOSIS; GLYCINE-RICH REGION; PRECURSOR P105; DNA-BINDING; SPLENIC MICROARCHITECTURE; NF-KAPPA-B1 P105; 65-KD SUBUNIT; HUMAN CANCER	An IkappaBalpha-based NF-kappaB super repressor (sr) has been used widely for studying genes regulated by NF-kappaB transcription factors. Repression of NF-kappaB by IkappaBalpha(sr) also facilitates tumor necrosis factor alpha-induced apoptosis in the cell. However, IkappaBalpha primarily targets RelA and c-Rel-containing complexes, leaving other NF-kappaB/Rel protein complexes, such as p50 and p52 homodimers, and RelB heterodimers uninhibited. Because these atypical NF-kappaB complexes also contribute to gene regulation and are activated in pathological conditions, broad inhibition of all NF-kappaB species is of significant pharmacological and clinical interests. We have designed, generated, and tested a p105-based NF-kappaB super repressor. We showed that p105(sr), which no longer generates p50 and undergoes signal-induced degradation, effectively inhibits all NF-kappaB activities. In addition, we also demonstrated that p105(sr) significantly enhances tumor necrosis factor alpha-mediated killing of MT1/2 skin papilloma cells where p50 homodimer activity is elevated. Our results suggest that p105(sr) is a broader range and effective NF-kappaB super repressor and can potentially be used in cells where a noncanonical NF-kappaB activity is dominant or multiple NF-kappaB activities are activated.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Lin, L (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	llin3@jhmi.edu			NATIONAL CANCER INSTITUTE [P50CA098252] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA 98252] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Beinke S, 2002, J BIOL CHEM, V277, P24162, DOI 10.1074/jbc.M201576200; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; ERNST MK, 1995, MOL CELL BIOL, V15, P872; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; Kurland JF, 2003, J BIOL CHEM, V278, P32465, DOI 10.1074/jbc.M212919200; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; La E, 1999, MOL CARCINOGEN, V24, P276, DOI 10.1002/(SICI)1098-2744(199904)24:4<276::AID-MC5>3.0.CO;2-#; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Moorthy AK, 2003, J BIOL CHEM, V278, P556, DOI 10.1074/jbc.M207515200; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Orian A, 1999, MOL CELL BIOL, V19, P3664; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Spiegelman VS, 1997, MOL CARCINOGEN, V20, P99, DOI 10.1002/(SICI)1098-2744(199709)20:1<99::AID-MC11>3.0.CO;2-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tang GL, 2001, MOL CELL, V8, P1005, DOI 10.1016/S1097-2765(01)00380-X; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784	54	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12819	12826		10.1074/jbc.M312572200	http://dx.doi.org/10.1074/jbc.M312572200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14703515	hybrid			2022-12-25	WOS:000220334900097
J	Hiniker, A; Bardwell, JCA				Hiniker, A; Bardwell, JCA			In vivo substrate specificity of periplasmic disulfide oxidoreductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-BINDING PROTEIN; BOND FORMATION INVIVO; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GENE-EXPRESSION; SHIGELLA-FLEXNERI; RIBONUCLEASE-I; DSBA; TRANSPORT; VITRO	In Escherichia coli, a family of periplasmic disulfide oxidoreductases catalyzes correct disulfide bond formation in periplasmic and secreted proteins. Despite the importance of native disulfide bonds in the folding and function of many proteins, a systematic investigation of the in vivo substrates of E. coli periplasmic disulfide oxidoreductases, including the well characterized oxidase DsbA, has not yet been performed. We combined a modified osmotic shock periplasmic extract and two-dimensional gel electrophoresis to identify substrates of the periplasmic oxidoreductases DsbA, DsbC, and DsbG. We found 10 cysteine- containing periplasmic proteins that are substrates of the disulfide oxidase DsbA, including PhoA and FlgI, previously established DsbA substrates. This technique did not detect any in vivo substrates of DsbG, but did identify two substrates of DsbC, RNase I and MepA. We confirmed that RNase I is a substrate of DsbC both in vivo and in vitro. This is the first time that DsbC has been shown to affect the in vivo function of a native E. coli protein, and the results strongly suggest that DsbC acts as a disulfide isomerase in vivo. We also demonstrate that DsbC, but not DsbG, is critical for the in vivo activity of RNase I, indicating that DsbC and DsbG do not function identically in vivo. The absence of substrates for DsbG suggests either that the in vivo substrate specificity of DsbG is more limited than that of DsbC or that DsbG is not active under the growth conditions tested. Our work represents one of the first times the in vivo substrate specificity of a folding catalyst system has been systematically investigated. Because our methodology is based on the simple assumption that the absence of a folding catalyst should cause its substrates to be present at decreased steady- state levels, this technique should be useful in analyzing the substrate specificity of any folding catalyst or chaperone for which mutations are available.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Sci Training Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Bardwell, JCA (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu			NIGMS NIH HHS [GM 57039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057039] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Bader MW, 2001, EMBO J, V20, P1555, DOI 10.1093/emboj/20.7.1555; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Bohin JP, 2000, FEMS MICROBIOL LETT, V186, P11, DOI 10.1016/S0378-1097(00)00110-5; Chilcott GS, 2000, MICROBIOL MOL BIOL R, V64, P694, DOI 10.1128/MMBR.64.4.694-708.2000; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Debarbieux L, 1998, P NATL ACAD SCI USA, V95, P10751, DOI 10.1073/pnas.95.18.10751; FORST S, 1987, J BIOL CHEM, V262, P16433; GESTELAND RF, 1966, J MOL BIOL, V16, P67, DOI 10.1016/S0022-2836(66)80263-2; Hiniker A, 2003, BIOCHEMISTRY-US, V42, P1179, DOI 10.1021/bi027141t; JACOBDUBUISSON F, 1994, P NATL ACAD SCI USA, V91, P11552, DOI 10.1073/pnas.91.24.11552; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; KANG CH, 1991, J BIOL CHEM, V266, P23893; Katzen F, 2000, CELL, V103, P769, DOI 10.1016/S0092-8674(00)00180-X; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; Kreimer DI, 2000, EUR J BIOCHEM, V267, P4242; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Li MS, 2001, BIOCHEM BIOPH RES CO, V288, P91, DOI 10.1006/bbrc.2001.5734; LOUBENS I, 1993, MOL MICROBIOL, V10, P329, DOI 10.1111/j.1365-2958.1993.tb01959.x; MEYER SE, 1990, J BACTERIOL, V172, P5501, DOI 10.1128/jb.172.9.5501-5502.1990; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NEU HC, 1965, J BIOL CHEM, V240, P3685; Nickitenko AV, 1995, BIOCHEMISTRY-US, V34, P16585, DOI 10.1021/bi00051a006; OXENDER DL, 1980, P NATL ACAD SCI-BIOL, V77, P1412, DOI 10.1073/pnas.77.3.1412; Padmanabhan S, 2001, ARCH BIOCHEM BIOPHYS, V390, P42, DOI 10.1006/abbi.2001.2359; Page F, 2001, J BACTERIOL, V183, P3134, DOI 10.1128/JB.183.10.3134-3141.2001; Pittman MS, 2002, J BIOL CHEM, V277, P49841, DOI 10.1074/jbc.M205615200; PUGSLEY AP, 1993, MOL GEN GENET, V237, P407, DOI 10.1007/BF00279445; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SCHIRMER T, 1993, PROTEIN SCI, V2, P1361, DOI 10.1002/pro.5560020820; Skorko-Glonek J, 2003, BBA-PROTEINS PROTEOM, V1649, P171, DOI 10.1016/S1570-9639(03)00170-5; Sone M, 1997, J BIOL CHEM, V272, P10349; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Tanaka N, 2000, J MOL BIOL, V298, P859, DOI 10.1006/jmbi.2000.3707; Waheed A, 1997, PROTEIN EXPRES PURIF, V9, P279, DOI 10.1006/prep.1996.0691; Waller PRH, 1996, J BACTERIOL, V178, P1146, DOI 10.1128/jb.178.4.1146-1153.1996; WATARAI M, 1995, P NATL ACAD SCI USA, V92, P4927, DOI 10.1073/pnas.92.11.4927; WURTZEL ET, 1982, J BIOL CHEM, V257, P13685; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004; YIM HH, 1992, J BACTERIOL, V174, P3637, DOI 10.1128/JB.174.11.3637-3644.1992; ZANIEWSKI R, 1984, J BIOL CHEM, V259, P1651; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; Zhao Z, 2003, J BIOL CHEM, V278, P43292, DOI 10.1074/jbc.M306945200	54	134	136	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12967	12973		10.1074/jbc.M311391200	http://dx.doi.org/10.1074/jbc.M311391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14726535	hybrid			2022-12-25	WOS:000220334900115
J	Timchenko, NA; Patel, R; Iakova, P; Cai, ZJ; Quan, L; Timchenko, LT				Timchenko, NA; Patel, R; Iakova, P; Cai, ZJ; Quan, L; Timchenko, LT			Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY REGION; MUSCLE DIFFERENTIATION; TRANSCRIPTION FACTOR; TRANSGENIC MICE; MESSENGER-RNA; CTG REPEATS; EXPRESSION; MEF2; ACTIVATION; MUTATION	Accumulation of RNA CUG repeats in myotonic dystrophy type 1 (DM1) patients leads to the induction of a CUG-binding protein, CUGBP1, which increases translation of several proteins that are required for myogenesis. In this paper, we examine the role of overexpression of CUGBP1 in DM1 muscle pathology using transgenic mice that overexpress CUGBP1 in skeletal muscle. Our data demonstrate that the elevation of CUGBP1 in skeletal muscle causes overexpression of MEF2A and p21 to levels that are significantly higher than those in skeletal muscle of wild type animals. A similar induction of these proteins is observed in skeletal muscle of DM1 patients with increased levels of CUGBP1. Immunohistological analysis showed that the skeletal muscle from mice overexpressing CUGBP1 is characterized by a developmental delay, muscular dystrophy, and myofiber-type switch: increase of slow/oxidative fibers and the reduction of fast fibers. Examination of molecular mechanisms by which CUGBP1 up-regulates MEF2A shows that CUGBP1 increases translation of MEF2A via direct interaction with GCN repeats located within MEF2A mRNA. Our data suggest that CUGBP1-ediated overexpression of MEF2A and p21 inhibits myogenesis and contributes to the development of muscle deficiency in DM1 patients.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Physiol & Mol Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Timchenko, LT (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza, Houston, TX 77030 USA.	lubovt@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA100070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049222, R01AR044387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG020752] Funding Source: NIH RePORTER; NCI NIH HHS [CA 100070] Funding Source: Medline; NIAMS NIH HHS [AR 49222, AR 44387] Funding Source: Medline; NIA NIH HHS [AG 20752] Funding Source: Medline; NIGMS NIH HHS [GM 55188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amack JD, 1999, HUM MOL GENET, V8, P1975, DOI 10.1093/hmg/8.11.1975; ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; Berul CI, 1999, J CLIN INVEST, V103, pR1, DOI 10.1172/JCI5346; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1997, MOL CELL BIOL, V17, P2756, DOI 10.1128/MCB.17.5.2756; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GUNDERSEN K, 1995, MOL CELL BIOL, V15, P7127; Gunthorpe D, 1999, DEV BIOL, V215, P130, DOI 10.1006/dbio.1999.9449; Harper P., 1995, METABOLIC MOL BASES, P4227; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Klesert TR, 2000, NAT GENET, V25, P105, DOI 10.1038/75490; Lu XH, 1999, HUM MOL GENET, V8, P53, DOI 10.1093/hmg/8.1.53; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Monckton DG, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P181; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; SAHGAL V, 1983, J NEUROL SCI, V59, P47, DOI 10.1016/0022-510X(83)90080-1; Sarkar PS, 2000, NAT GENET, V25, P110, DOI 10.1038/75500; Savkur RS, 2001, NAT GENET, V29, P40, DOI 10.1038/ng704; Seznec H, 2001, HUM MOL GENET, V10, P2717, DOI 10.1093/hmg/10.23.2717; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; Timchenko LT, 1999, AM J HUM GENET, V64, P360, DOI 10.1086/302268; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 2001, J BIOL CHEM, V276, P7820, DOI 10.1074/jbc.M005960200; Timchenko NA, 2001, MOL CELL BIOL, V21, P6927, DOI 10.1128/MCB.21.20.6927-6938.2001; Wu H, 2002, J CLIN INVEST, V109, P1327, DOI 10.1172/JCI200215417; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	36	157	160	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13129	13139		10.1074/jbc.M312923200	http://dx.doi.org/10.1074/jbc.M312923200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14722059	hybrid			2022-12-25	WOS:000220334900134
J	Chen, W; Yazicioglu, M; Cobb, MH				Chen, W; Yazicioglu, M; Cobb, MH			Characterization of OSR1, a member of the mammalian Ste20p/germinal center kinase subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL CENTER KINASE; N-TERMINAL KINASE; HEMATOPOIETIC PROGENITOR KINASE; RICH STE20-RELATED KINASE; STE20-LIKE PROTEIN-KINASE; P21-ACTIVATED KINASE; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; ACTIVATION; PATHWAY	In examining the protein kinase components of mitogen-activated protein ( MAP) kinase ( MAPK) cascades that regulate the c-Jun N-terminal kinase (JNK) in Drosophila S2 cells, we previously found that distinct upstream kinases were involved in responses to sorbitol and lipopolysaccharide. Here we have extended that analysis to the possible MAPK kinase kinase kinases (MAP4Ks) in the JNK pathway. Fray, a putative Drosophila MAP4K, provided a major contribution to JNK activation by sorbitol. To explore the possible link to JNK in mammalian cells, we isolated and characterized OSR1 ( oxidative stress-responsive 1), one of two human Fray homologs. OSR1 is a 58-kDa protein of 527 amino acids that is widely expressed in mammalian tissues and cell lines. Of potential regulators surveyed, endogenous OSR1 is activated only by osmotic stresses, notably sorbitol and to a lesser extent NaCl. However, OSR1 did not increase the activity of coexpressed JNK, nor did it activate three other MAPKs, p38, ERK2, and ERK5. A two-hybrid screen implicated another Ste20p family member, the p21-activated protein kinase PAK1, as an OSR1 target. OSR1 phosphorylated threonine 84 in the N-terminal regulatory domain of PAK1. Replacement of threonine 84 with glutamate reduced the activation of PAK1 by an active form of the small G protein Cdc42, suggesting that phosphorylation by OSR1 modulates the G protein sensitivity of PAK isoforms.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mcobb@mednet.swmed.edu		Cobb, Melanie/0000-0003-0833-5473	NIGMS NIH HHS [GM53032] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Dan I, 2002, J BIOL CHEM, V277, P5929, DOI 10.1074/jbc.M110882200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Dowd BFX, 2003, J BIOL CHEM, V278, P27347, DOI 10.1074/jbc.M301899200; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; FROST JA, 1998, J BIOL CHEM, V273, P28253; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Harden N, 1996, MOL CELL BIOL, V16, P1896; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Johnston AM, 2000, ONCOGENE, V19, P4290, DOI 10.1038/sj.onc.1203784; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Leiserson WM, 2000, NEURON, V28, P793, DOI 10.1016/S0896-6273(00)00154-9; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Ling P, 1999, MOL CELL BIOL, V19, P1359; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; Nishigaki K, 2003, J BIOL CHEM, V278, P13520, DOI 10.1074/jbc.M208601200; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Pandey A, 2002, ONCOGENE, V21, P3939, DOI 10.1038/sj.onc.1205478; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Qian ZJ, 2001, J BIOL CHEM, V276, P22439, DOI 10.1074/jbc.M009323200; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tamari M, 1999, J HUM GENET, V44, P116, DOI 10.1007/s100380050121; Tsutsumi T, 2000, J BIOL CHEM, V275, P9157, DOI 10.1074/jbc.275.13.9157; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Walter SA, 2003, J BIOL CHEM, V278, P18221, DOI 10.1074/jbc.M212556200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	55	67	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11129	11136		10.1074/jbc.M313562200	http://dx.doi.org/10.1074/jbc.M313562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14707132	hybrid			2022-12-25	WOS:000220157600037
J	Levinthal, DJ; DeFranco, DB				Levinthal, DJ; DeFranco, DB			Transient phosphatidylinositol 3-kinase inhibition protects immature primary cortical neurons from oxidative toxicity via suppression of extracellular signal-regulated kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; INDEPENDENT CA2+ CHANNELS; CELL-DEATH; PHOSPHOINOSITIDE 3-KINASE; GROWTH-FACTOR; NEURODEGENERATIVE DISORDERS; HIPPOCAMPAL-NEURONS; IN-VITRO; PATHWAY; PHOSPHORYLATION	Oxidative stress has been shown to underlie a diverse range of neuropathological conditions. Glutamate-induced oxidative toxicity is a well described model of oxidative stress-induced neurodegeneration that relies upon the ability of extracellular glutamate to inhibit a glutamate/ cystine antiporter, which results in a depletion of intracellular cysteine and the blockade of continued glutathione synthesis. Glutathione depletion leads to a gradual toxic accumulation of reactive oxygen species. We have previously determined that glutamate-induced oxidative toxicity is accompanied by a robust increase in activation of the mitogen-activated protein kinase (MAPK) member extracellular-signal regulated kinase (ERK) and that this activation is essential for neuronal cell death. This study demonstrates that delayed ERK activation is dependent upon the activity of phosphoinositol-3 kinase (PI3K) and that transient but not sustained PI3K inhibition leads to significant protection of neurons from oxidative stress-induced neurodegeneration. Furthermore, we show that transient PI3K inhibition prevents the delayed activation of MEK-1, a direct activator of ERK, during oxidative stress. Thus, this study is the first to demonstrate a novel level of cross-talk between the PI3K and ERK pathways in cultured immature cortical neuronal cultures that contributes to the unfolding of a cell death program. The PI3K pathway, therefore, may serve opposing roles during the progression of oxidative stress in neurons, acting at distinct kinetic phases to either promote or limit a slowly developing program of cell death.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Ctr Neurosci, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	DeFranco, DB (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, E1352 BST, Pittsburgh, PA 15261 USA.	dod1@pitt.edu	Levinthal, David/AAJ-6606-2021	Levinthal, David/0000-0001-8453-8382	NINDS NIH HHS [R01 NS38319, T32 NS07433, F30 NS43824] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS043824, T32NS007433, R01NS038319] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Blair LAC, 1999, J NEUROSCI, V19, P1940; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Du S, 2002, J NEUROSCI, V22, P7408; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Henshall DC, 2002, J NEUROSCI, V22, P8458; Hsieh HJ, 1998, J CELL PHYSIOL, V175, P156, DOI 10.1002/(SICI)1097-4652(199805)175:2<156::AID-JCP5>3.0.CO;2-N; Kansra V, 2001, J BIOL CHEM, V276, P31831, DOI 10.1074/jbc.M009374200; Kawanabe Y, 2003, MOL PHARMACOL, V63, P808, DOI 10.1124/mol.63.4.808; Kawanabe Y, 2002, MOL PHARMACOL, V62, P756, DOI 10.1124/mol.62.3.756; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luo HR, 2003, P NATL ACAD SCI USA, V100, P11712, DOI 10.1073/pnas.1634990100; Mattson MP, 2001, APOPTOSIS, V6, P69, DOI 10.1023/A:1009676112184; Mizuta I, 1998, CELL MOL LIFE SCI, V54, P721, DOI 10.1007/s000180050199; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, J NEUROSCI, V22, P7923; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; Perkinton MS, 1999, J NEUROSCI, V19, P5861, DOI 10.1523/JNEUROSCI.19-14-05861.1999; RATAN RR, 1994, J NEUROCHEM, V62, P376; Sanna PP, 2002, J NEUROSCI, V22, P3359; Seki T, 1999, PFLUG ARCH EUR J PHY, V437, P317, DOI 10.1007/s004240050785; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225; Zhu Y, 2002, J NEUROSCI, V22, P3898, DOI 10.1523/JNEUROSCI.22-10-03898.2002; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	53	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11206	11213		10.1074/jbc.M314261200	http://dx.doi.org/10.1074/jbc.M314261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14715649	hybrid			2022-12-25	WOS:000220157600046
J	Ohkawa, K; Ishida, H; Nakanishi, F; Hosui, A; Ueda, K; Takehara, T; Hori, M; Hayashi, N				Ohkawa, K; Ishida, H; Nakanishi, F; Hosui, A; Ueda, K; Takehara, T; Hori, M; Hayashi, N			Hepatitis C virus core functions as a suppressor of cyclin-dependent kinase-activating kinase and impairs cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; PROTEIN INTERACTS; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY; TRANSGENIC MICE; CDK INHIBITORS; PHOSPHORYLATION; APOPTOSIS; RECEPTOR	We investigated how the hepatitis C virus (HCV) core protein affects the cell cycle profile and cell cycle-related molecules by using the HCV core-expressing stable transfectant. Analysis of the cell cycle profile showed that HCV core impaired G(1) to S transition. The E2F-mediated transcription, phosphorylation of the retinoblastoma protein, and cyclin-dependent kinase (CDK) 4 and CDK2 activities were suppressed in HCV core-expressing cells. The expression levels of G(1) phase-related CDKs/cyclins and various CDK inhibitors were not substantially affected by expression of HCV core. When influences of HCV core on CDK-activating kinase (CAK) were examined, the expression levels of the CAK components, CDK7, cyclin H, and MAT1, were not affected. However, formation of the ternary CAK complex, CAK activity, and the CDK2 level with activating phosphorylation were inhibited by expression of the HCV core. The direct effect of HCV core on CAK was further assessed in the cell-free system by adding the in vitro translated HCV core protein to the anti-CDK7 immunoprecipitate from the cell. The results showed that HCV core led to dissociation of MAT1 from the CAK complex and suppressed the CAK activity. Furthermore, the binding assay revealed that the HCV core was directed against CDK7. Their interaction occurred mainly in the nucleus by the immunostaining. In conclusion, the HCV core protein interacts with CAK and functions as an extrinsic suppressor of CAK. This may be the molecular basis of HCV core-mediated suppression of cell cycle progression. Our findings suggest a novel mechanism concerning HCV core-mediated alteration in the cell cycle machinery.	Osaka Univ, Grad Sch Med, Dept Mol Therapeut, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Microbiol, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Hayashi, N (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Therapeut, 2-2 Yamadaoka, Osaka 5650871, Japan.	hayashin@moltx.med.osaka-u.ac.jp	Hosui, Atsushi/AAC-1771-2020	Hosui, Atsushi/0000-0003-0777-8045				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HIRAMATSU N, 1992, HEPATOLOGY, V16, P306, DOI 10.1002/hep.1840160205; Honda M, 2000, HEPATOLOGY, V31, P1351, DOI 10.1053/jhep.2000.7985; Hosui A, 2003, J BIOL CHEM, V278, P28562, DOI 10.1074/jbc.M210485200; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; Ishida H, 2000, J VIROL, V74, P1241, DOI 10.1128/JVI.74.3.1241-1251.2000; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Machida K, 2001, J BIOL CHEM, V276, P12140, DOI 10.1074/jbc.M010137200; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Ohkawa K, 2003, HEPATOL RES, V25, P396, DOI 10.1016/S1386-6346(03)00017-2; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; PATEK PQ, 1978, NATURE, V276, P510, DOI 10.1038/276510a0; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tokushige K, 1997, J VIROL METHODS, V64, P73, DOI 10.1016/S0166-0934(96)02143-X; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; Tsutsumi T, 2002, HEPATOLOGY, V35, P937, DOI 10.1053/jhep.2002.32470; Wagner S, 1997, GASTROENTEROLOGY, V113, P1836, DOI 10.1016/S0016-5085(97)70003-9; Wang F, 2000, BIOCHEM BIOPH RES CO, V273, P479, DOI 10.1006/bbrc.2000.2970; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; YI S, 1993, INT J CANCER, V55, P952, DOI 10.1002/ijc.2910550613; Yoshida H, 2001, J BIOL CHEM, V276, P16399, DOI 10.1074/jbc.M006671200; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197	54	27	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11719	11726		10.1074/jbc.M308560200	http://dx.doi.org/10.1074/jbc.M308560200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14711830	hybrid			2022-12-25	WOS:000220157600108
J	Rizhsky, L; Davletova, S; Liang, HJ; Mittler, R				Rizhsky, L; Davletova, S; Liang, HJ; Mittler, R			The zinc finger protein Zat12 is required for cytosolic ascorbate peroxidase 1 expression during oxidative stress in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; ABIOTIC STRESS; DROUGHT STRESS; CELL-DEATH; PATHWAYS; TOLERANCE; THALIANA; PATHOGEN; TOBACCO	Cytosolic ascorbate peroxidase 1 (Apx1) is a key H2O2 removal enzyme in plants. Microarray analysis of Apx1-deficient Arabidopsis plants revealed that the expression of two zinc finger proteins (Zat12 and Zat7) and a WRKY transcription factor (WRKY25) is elevated in knock-out Apx1 plants grown under controlled conditions. Because mutants lacking Apx1 accumulate H2O2, we examined the correlation between H2O2 and the expression of Zat12, Zat7, WRKY25, and Apx1. The expression of Zat12, Zat7, and WRKY25 was simultaneously elevated in cells in response to oxidative stress (i.e. H2O2 or paraquat application), heat shock, or wounding. In contrast, light or osmotic stress did not enhance the expression of these putative transcription factors. All stresses tested enhanced the expression of Apx1. Transgenic plants expressing Zat12 or Zat7 could tolerate oxidative stress. In contrast, transgenic plants expressing WRKY25 could not. Although the expression of Zat12, Zat7, or WRKY25 in transgenic plants did not enhance the expression of Apx1 under controlled conditions, Zat12-deficient plants were unable to enhance the expression of Apx1, Zat7, or WRKY25 in response to H2O2 or paraquat application. Zat12-deficient plants were also more sensitive than wild type plants to H2O2 application as revealed by a higher level of H2O2-induced protein oxidation detected in these plants by protein blots. Our results suggest that Zat12 is an important component of the oxidative stress response signal transduction network of Arabidopsis required for Zat7, WRKY25, and Apx1 expression during oxidative stress.	Univ Nevada, Dept Biochem, Reno, NV 89557 USA; Iowa State Univ Sci & Technol, Dept Bot, Inst Plant Sci, Ames, IA 50011 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Iowa State University	Mittler, R (corresponding author), Univ Nevada, Dept Biochem, Mail Stop 330, Reno, NV 89557 USA.	ronm@unr.edu	Rizshsky, Ludmila/D-3133-2011; Mittler, Ron/ABE-6496-2020; Davletova, Sholpan/K-5764-2015	Davletova, Sholpan/0000-0003-4759-3256; Rizhsky, Ludmila/0000-0003-2323-8225				BENT AF, 2000, PLANT MOL BIOL MANUA; Chen WQ, 2002, PLANT CELL, V14, P559, DOI 10.1105/tpc.010410; Cheong YH, 2002, PLANT PHYSIOL, V129, P661, DOI 10.1104/pp.002857; Desikan R, 2001, PLANT PHYSIOL, V127, P159, DOI 10.1104/pp.127.1.159; Epple P, 2003, P NATL ACAD SCI USA, V100, P6831, DOI 10.1073/pnas.1130421100; Eulgem T, 2000, TRENDS PLANT SCI, V5, P199, DOI 10.1016/S1360-1385(00)01600-9; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; Fowler S, 2002, PLANT CELL, V14, P1675, DOI 10.1105/tpc.003483; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kazuoka T, 2000, PLANT J, V24, P191, DOI 10.1046/j.1365-313x.2000.00864.x; Klok EJ, 2002, PLANT CELL, V14, P2481, DOI 10.1105/tpc.004747; Knight H, 2001, TRENDS PLANT SCI, V6, P262, DOI 10.1016/S1360-1385(01)01946-X; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Kreps JA, 2002, PLANT PHYSIOL, V130, P2129, DOI 10.1104/pp.008532; MEHTA RA, 1992, J BIOL CHEM, V267, P2810; Mittler R, 1998, PLANT CELL, V10, P461, DOI 10.1105/tpc.10.3.461; MITTLER R, 1994, PLANT J, V5, P397, DOI 10.1111/j.1365-313X.1994.00397.x; Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9; Neill S, 2002, CURR OPIN PLANT BIOL, V5, P388, DOI 10.1016/S1369-5266(02)00282-0; Nover L, 2001, CELL STRESS CHAPERON, V6, P177, DOI 10.1379/1466-1268(2001)006<0177:AATHST>2.0.CO;2; Panchuk II, 2002, PLANT PHYSIOL, V129, P838, DOI 10.1104/pp.001362; Pastori GM, 2002, PLANT PHYSIOL, V129, P460, DOI 10.1104/pp.011021; Pnueli L, 2003, PLANT J, V34, P187, DOI 10.1046/j.1365-313X.2003.01715.x; Rizhsky L, 2003, J BIOL CHEM, V278, P38921, DOI 10.1074/jbc.M304987200; Rizhsky L, 2001, PLANT MOL BIOL, V46, P313, DOI 10.1023/A:1010617220067; Stracke R, 2001, CURR OPIN PLANT BIOL, V4, P447, DOI 10.1016/S1369-5266(00)00199-0; Torres MA, 2002, P NATL ACAD SCI USA, V99, P517, DOI 10.1073/pnas.012452499; Vranova E, 2002, J EXP BOT, V53, P1227, DOI 10.1093/jexbot/53.372.1227; Vranova E, 2002, P NATL ACAD SCI USA, V99, P10870, DOI 10.1073/pnas.152337999; Zhang JZ, 2003, CURR OPIN PLANT BIOL, V6, P430, DOI 10.1016/S1369-5266(03)00081-5; Zhu JK, 2002, ANNU REV PLANT BIOL, V53, P247, DOI 10.1146/annurev.arplant.53.091401.143329	31	326	385	3	59	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11736	11743		10.1074/jbc.M313350200	http://dx.doi.org/10.1074/jbc.M313350200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14722088	hybrid			2022-12-25	WOS:000220157600110
J	Mori, M; Yoneyama, M; Ito, T; Takahashi, K; Inagaki, F; Fujita, T				Mori, M; Yoneyama, M; Ito, T; Takahashi, K; Inagaki, F; Fujita, T			Identification of Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that determines activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CREB-BINDING PROTEIN/P300; NF-KAPPA-B; VIRUS-INFECTION; TRANSCRIPTION FACTORS; POSITIVE FEEDBACK; IN-VIVO; IRF-3; INDUCTION; INVOLVEMENT	Interferon regulatory factor (IRF)-3 is a critical transcription factor regulating innate immune responses against viral and bacterial infections. Signals activated by various pathogens are integrated by IRF-3 kinase, resulting in the specific phosphorylation of IRF-3 in the cytoplasm. This phosphorylation induces dimerization and association with the coactivators CREB-binding protein/p300, and the resultant complex activates the target genes in the nucleus. However, the phosphorylation sites that determine the active/inactive status of IRF-3 have been a source of controversy. In this study, we generated an antibody that specifically detects the phosphorylation of Ser-386 and used it as a probe. We found: 1) viral infection specifically induces phosphorylation of the Ser-386; 2) recently identified IRF-3 kinases (IKK-i/epsilon and TBK-1) phosphorylate Ser-386 and induce its dimerization; 3) phosphorylation of Ser-386 is exclusively observed with the dimer; 4) mutation at Ser-386 abolishes the dimerization potential; 5) a constitutively active 5D mutant designed to mimic phosphorylation of Ser/Thr residues other than Ser-385 and - 386 is secondarily phosphorylated at Ser-386, presumably by an irrelevant kinase. These results strongly suggest that Ser-386 is the target of the IRF-3 kinase and critical determinant for the activation of IRF-3.	Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Nagasaki Univ, Sch Med, Dept Biochem, Nagasaki 8528523, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan	Tokyo Metropolitan Institute of Medical Science; Nagasaki University; Hokkaido University	Fujita, T (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	fujita@rinshoken.or.jp	Yoneyama, Mitsutoshi/D-8244-2017	Yoneyama, Mitsutoshi/0000-0001-9512-0408				De Maeyer E, 1998, Int Rev Immunol, V17, P53, DOI 10.3109/08830189809084487; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Nomura F, 2000, GENES CELLS, V5, P191; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; SEN GC, 1992, J BIOL CHEM, V267, P5017; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shinobu N, 2002, FEBS LETT, V517, P251, DOI 10.1016/S0014-5793(02)02636-4; Suhara W, 2000, J BIOCHEM-TOKYO, V128, P301, DOI 10.1093/oxfordjournals.jbchem.a022753; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Takahasi K, 2003, NAT STRUCT BIOL, V10, P922, DOI 10.1038/nsb1001; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yang HM, 2002, EUR J BIOCHEM, V269, P6142, DOI 10.1046/j.1432-1033.2002.03330.x; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	25	162	168	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9698	9702		10.1074/jbc.M310616200	http://dx.doi.org/10.1074/jbc.M310616200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14703513	hybrid			2022-12-25	WOS:000220050400007
J	Lamalice, L; Houle, F; Jourdan, G; Huot, J				Lamalice, L; Houle, F; Jourdan, G; Huot, J			Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38	ONCOGENE			English	Article						VEGF; VEGFR2; SAPK2/p38; Cdc42	ENDOTHELIAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE PATHWAYS; FOCAL ADHESION KINASE; ACTIN-BASED MOTILITY; CELL-MIGRATION; DNA-SYNTHESIS; PAF SYNTHESIS; P38 MAPK; RECEPTOR	Activation of the tyrosine kinase receptor vascular endothelial growth factor receptor 2 (VEGFR2) by VEGF leads to the activation of stress-activated protein kinase (SAPK)2/p38 and then to actin polymerization and reorganization into stress fibers in endothelial cells. In turn, this triggers endothelial cell migration. Yet, nothing is known about the molecular mechanisms that couple VEGFR2 to SAPK2/p38. Here, we found that VEGF increased by twofold the activity of the small GTPase Cdc42 and that the expression of two different constitutively active forms of Cdc42 (Cdc42 V12 and Cdc42 L61) led to a marked increase in the formation of stress fibers that was sensitive to SAPK/p38 inhibition by SB203580. Moreover, the expression of a dominant-negative form of Cdc42 (Cdc42 N17) inhibited the activation of SAPK2/p38 and of its direct target MAP kinase-activated protein kinase 2. These results indicate that Cdc42 is upstream of SAPK2/p38 in response to the activation of VEGFR2 by VEGF. In contrast, we found that neither RhoA nor Rac was involved in the SAPK2/p38-mediated actin reorganization induced by VEGF. Using a site-specific mutant of the major autophosphorylation site Y1214 on VEGFR2, we found that the mutant Y1214F inhibited the activation of both Cdc42 and SAPK2/p38 in response to VEGF. We conclude that phosphorylation of Y1214 on VEGFR2 is required to trigger the sequential activation of Cdc42 and SAPK2/p38 and to drive the SAPK2/p38-mediated actin remodeling in stress fibers in endothelial cells exposed to VEGF.	Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada	Laval University	Huot, J (corresponding author), Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, 9 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	Jacques.Huot@phc.ulaval.ca						Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Barleon B, 1997, CANCER RES, V57, P5421; BARRY ST, 1994, J CELL SCI, V107, P2033; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P1253, DOI 10.1038/sj.bjp.0704367; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Dechert MA, 2001, AM J PHYSIOL-CELL PH, V281, pC123, DOI 10.1152/ajpcell.2001.281.1.C123; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Ferrara N, 1996, Curr Opin Nephrol Hypertens, V5, P35, DOI 10.1097/00041552-199601000-00008; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kroll J, 2000, Z KARDIOL, V89, P206, DOI 10.1007/s003920050472; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Li XD, 2002, J BIOL CHEM, V277, P15207, DOI 10.1074/jbc.M109913200; Masson-Gadais B, 2003, CELL STRESS CHAPERON, V8, P37, DOI 10.1379/1466-1268(2003)8<37:IVRFVA>2.0.CO;2; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; Nakamura M, 2002, PATHOL INT, V52, P331, DOI 10.1046/j.1440-1827.2002.01367.x; Pai KS, 2002, J NEUROCHEM, V80, P715, DOI 10.1046/j.0022-3042.2001.00761.x; Pai KS, 2001, J BIOL CHEM, V276, P32642, DOI 10.1074/jbc.M104212200; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Polverini Peter J, 2002, J Dent Educ, V66, P962; Ratcliffe KE, 2002, ONCOGENE, V21, P6307, DOI 10.1038/sj.onc.1205781; Renkema GH, 2002, MOL CELL BIOL, V22, P6719, DOI 10.1128/MCB.22.19.6719-6725.2002; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; Ridley AJ, 1999, NAT CELL BIOL, V1, pE64, DOI 10.1038/11034; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Sato Y, 2000, ANN NY ACAD SCI, V902, P201; SEETHARAM L, 1995, ONCOGENE, V10, P135; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Van Trappen PO, 2002, BRIT J CANCER, V87, P537, DOI 10.1038/sj.bjc.6600471; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; ZENG H, 2002, J BIOL CHEM, V19, P19; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	166	171	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					434	445		10.1038/sj.onc.1207034	http://dx.doi.org/10.1038/sj.onc.1207034			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724572				2022-12-25	WOS:000188098300014
J	Meadows, KN; Bryant, P; Vincent, PA; Pumiglia, KM				Meadows, KN; Bryant, P; Vincent, PA; Pumiglia, KM			Activated Ras induces a proangiogenic phenotype in primary endothelial cells	ONCOGENE			English	Article						angiogenesis; VEGF; Erk; migration; PI3K; proliferation; Ras	THYROID EPITHELIAL-CELLS; WILD-TYPE P53; GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CYCLE ARREST; TUMOR ANGIOGENESIS; COOPERATING ONCOGENES; ACTIN REORGANIZATION; NEURITE OUTGROWTH	Angiogenic factors alter endothelial cell phenotype to promote the formation of new blood vessels, a process critical for a number of normal and pathological conditions. Ras is required for the induction of the angiogenic phenotype in response to vascular endothelial growth factor (VEGF). However, VEGF generates many signals, several of which are not dependent upon Ras activation. Our current study investigates the sufficiency of Ras activation for driving angiogenic responses. An activated Ras(V12) mutant induces prominent membrane ruffling, branching morphogenesis on three-dimensional collagen, DNA synthesis, and cell migration in primary endothelial cells. An upregulation of PI3K/AKT, Erk, and Jnk signaling pathways accompany these phenotypic changes. The inhibition of Erk blocked cell proliferation, but only partially attenuated migration. Blocking PI3K had no effect on DNA synthesis, but caused a modest reduction in cell migration. Lastly, Jnk played a significant role in both the proliferation and migration response. These effects of Ras(V12) are not the result of increased autocrine secretion of VEGF. These data suggest that the acquisition of activating Ras mutations can lead to a proangiogenic conversion in the phenotype of primary endothelial cells. Furthermore, these data raise the possibility that chronic Ras activation in endothelial cells may be sufficient to promote angiogenesis and the development of vascular anomalies.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA	Albany Medical College; Albany Medical College	Pumiglia, KM (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	pumiglk@mail.amc.edu		Pumiglia, Kevin/0000-0003-4655-0334	NCI NIH HHS [R01 CA081419, R01-CA-81419] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081419] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FOX PL, 1994, ONCOGENE, V9, P3519; Fox SB, 1996, J PATHOL, V179, P232, DOI 10.1002/(SICI)1096-9896(199607)179:3<232::AID-PATH505>3.0.CO;2-A; Ghosh PK, 2002, NAT CELL BIOL, V4, P894, DOI 10.1038/ncb873; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gitler AD, 2003, NAT GENET, V33, P75, DOI 10.1038/ng1059; Goi T, 1999, MOL CELL BIOL, V19, P1731; Goncharova EA, 2002, AM J PHYSIOL-LUNG C, V283, pL354, DOI 10.1152/ajplung.00010.2002; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Hong HHL, 2000, TOXICOL PATHOL, V28, P529, DOI 10.1177/019262330002800404; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MacKenzie KL, 2002, ONCOGENE, V21, P4200, DOI 10.1038/sj.onc.1205425; MARION MJ, 1991, MOL CARCINOGEN, V4, P450, DOI 10.1002/mc.2940040607; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03; Pal S, 2001, CANCER RES, V61, P6952; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Rak J, 2000, CANCER RES, V60, P490; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Soga N, 2001, CELL COMMUN ADHES, V8, P1, DOI 10.3109/15419060109080703; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; Spyridopoulos I, 2002, BASIC RES CARDIOL, V97, P117, DOI 10.1007/s003950200001; Suzuki E, 2002, HYPERTENS RES, V25, P773; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; TAKESHITA S, 1995, AM J PATHOL, V147, P1649; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zhang LL, 2000, CANCER RES, V60, P3655; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	64	75	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					192	200		10.1038/sj.onc.1206921	http://dx.doi.org/10.1038/sj.onc.1206921			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712224				2022-12-25	WOS:000187895300020
